<?xml version="1.0" encoding="utf-8"?>
<items><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Short stature  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0349588"&gt;&lt;i&gt;C0349588&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Finding (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0349588&amp;amp;tui=T033"&gt;&lt;i&gt;T033&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD9&lt;/td&gt;
                &lt;td&gt;783.43&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD10&lt;/td&gt;
                &lt;td&gt;R62.52&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;206930002, 158283003, 237836003, 277266007&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;STATURE SHORTNESS, SHORT STATURE, Short stature, [D]Short stature (context-dependent category), Stature Short, [D]Short stature, short stature, short stature (physical finding), [D]Short stature (situation), short stature was noted, Stature short, Short stature NOS, Short;stature, stature short, small stature, Small stature, SS - Short stature, short; stature, stature; short, Short stature (finding), Short;growth&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;korte gestalte, kleine gestalte, gestalte; klein, klein; gestalte&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Petite taille, Insuffisance staturale, Petite stature&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;untersetzte Statur, kleine Statur&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Bassa statura, Statura bassa&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Estatura baixa, Estatura pequena&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;Corta estatura, Pequeña estatura, Estatura disminuida, [D]baja estatura (categoría dependiente del contexto), [D]Short stature, talla baja, [D]baja estatura, [D]baja estatura (situación), baja estatura (hallazgo), baja estatura, estatura pequeña, trastorno con baja estatura (trastorno), trastorno con baja estatura, trastorno con talla baja&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;低身長, ﾃｲｼﾝﾁｮｳ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;Malý vzrůst, Malá postava&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;Alacsony termet, Termet alacsony, Kis termet&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Short stature  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Short Stature</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Growth Disorders</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;See Also&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Peds/FlrTThrv.htm" class="LinkPage"&gt;Failure to Thrive&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Evaluation: Algorithm&lt;ol&gt;&lt;li&gt;Determine if growth is truly delayed&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Endo/Exam/MdprntlHght.htm" class="LinkPage"&gt;Calculation of Growth Delay&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Determine when growth delay began (in-utero, perinatal or childhood)&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Endo/Growth/GrwthDlyOnstDtrmntn.htm" class="LinkPage"&gt;Growth Delay Onset Determination&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Exam: General&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Exam/WghtMsrmntInChldrn.htm" class="LinkPage"&gt;Weight Measurement in Children&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Exam/HghtMsrmntInChldrn.htm" class="LinkPage"&gt;Height Measurement in Children&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Exam/BdyMsIndx.htm" class="LinkPage"&gt;Body Mass Index&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Exam/WghtFrHghtAg.htm" class="LinkPage"&gt;Weight for Height Age&lt;/a&gt;&lt;/li&gt;&lt;li&gt;See &lt;a href="../../Endo/Exam/DysmrphcFtrsInCngntlDysrdrs.htm" class="LinkPage"&gt;Dysmorphic features in Congenital Dysorders&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Exam: Findings suggestive of collagen bone disease&lt;ol&gt;&lt;li&gt;Examples&lt;ol&gt;&lt;li&gt;Osteochondrodysplasia&lt;/li&gt;&lt;li&gt;Metaphyseal dysostosis&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Extremely Short&lt;ol&gt;&lt;li&gt;Disproportionate shortness ("Dwarf")&lt;ol&gt;&lt;li&gt;Arms and legs short compared with trunk&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Proportionate shortness&lt;ol&gt;&lt;li&gt;"China Doll" Shortness&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Abnormal measurements&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Exam/LnrGrwthVlcty.htm" class="LinkPage"&gt;Linear Growth Velocity&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Exam/SxlDvlpmnt.htm" class="LinkPage"&gt;Tanner Staging&lt;/a&gt; (See &lt;a href="../../Endo/Exam/SxlDvlpmnt.htm" class="LinkPage"&gt;Tanner Staging&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Exam/ArmSpn.htm" class="LinkPage"&gt;Arm Span&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Exam/UprTLwrSgmntRt.htm" class="LinkPage"&gt;Upper to Lower Segment Ratio&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Exam: Term Newborn&lt;ol&gt;&lt;li&gt;Micropenis (size &amp;lt;2.8 cm stretched)&lt;ol&gt;&lt;li&gt;Assess for &lt;a href="../../Endo/Lab/LtnzngHrmn.htm" class="LinkPage"&gt;Luteinizing hormone&lt;/a&gt; deficiency&lt;/li&gt;&lt;li&gt;Associated with panhypopituitarism&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Congenital &lt;a href="../../Neuro/Exam/Nystgms.htm" class="LinkPage"&gt;Nystagmus&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Assess for  septo-optic dysplasia&lt;/li&gt;&lt;li&gt;Associated with &lt;a href="../../Endo/Pharm/HmnGrwthHrmn.htm" class="LinkPage"&gt;Growth Hormone&lt;/a&gt; deficiency&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Diagnostics&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Rad/BnAgFlm.htm" class="LinkPage"&gt;Bone Age Film&lt;/a&gt;s&lt;/li&gt;&lt;li&gt;Formal dental exam for dental age&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Labs: Routine&lt;ol&gt;&lt;li&gt;&lt;a href="../../Uro/Lab/Urnlys.htm" class="LinkPage"&gt;Urinalysis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../HemeOnc/Lab/CmpltBldCnt.htm" class="LinkPage"&gt;Complete Blood Count&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../HemeOnc/Lab/ErythrcytSdmntnRt.htm" class="LinkPage"&gt;Erythrocyte Sedimentation Rate&lt;/a&gt; (ESR)&lt;/li&gt;&lt;li&gt;Chemistry panel (Chem8)&lt;/li&gt;&lt;li&gt;&lt;a href="../../GI/Lab/LvrFnctnTst.htm" class="LinkPage"&gt;Liver Function Test&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../HemeOnc/Lab/SrmIrn.htm" class="LinkPage"&gt;Serum Iron&lt;/a&gt; and &lt;a href="../../HemeOnc/Lab/SrmFrtn.htm" class="LinkPage"&gt;Ferritin&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Differential Diagnosis (with specific related evaluation)&lt;ol&gt;&lt;li&gt;Normal tests, evaluation and &lt;a href="../../Endo/Rad/BnAgFlm.htm" class="LinkPage"&gt;Bone Age Film&lt;/a&gt;s&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Growth/FmlShrtStr.htm" class="LinkPage"&gt;Familial Short Stature&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Normal tests and evaluation with a minimally delayed &lt;a href="../../Endo/Rad/BnAgFlm.htm" class="LinkPage"&gt;Bone Age Film&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Growth/CnsttnlShrtStr.htm" class="LinkPage"&gt;Constitutional Short Stature&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Abnormal tests or evaluation with a normal &lt;a href="../../Endo/Rad/BnAgFlm.htm" class="LinkPage"&gt;Bone Age Film&lt;/a&gt; (requires further evaluation)&lt;ol&gt;&lt;li&gt;&lt;a href="../../HemeOnc/Anemia/IrnDfcncyAnm.htm" class="LinkPage"&gt;Iron Deficiency Anemia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Inflammatory conditions&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Dysmorphic features present - Refer to geneticist and endocrinologist&lt;ol&gt;&lt;li&gt;&lt;a href="../../Neuro/Disability/DwnSyndrm.htm" class="LinkPage"&gt;Down Syndrome&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Noonan Syndrome&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Peds/PrdrWlSyndrm.htm" class="LinkPage"&gt;Prader-Willi Syndrome&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Russell-Silver Syndrome&lt;/li&gt;&lt;li&gt;Skeletal Dysplasia&lt;/li&gt;&lt;li&gt;Turner Syndrome&lt;/li&gt;&lt;li&gt;&lt;a href="../../Neuro/Disability/FtlAlchlSyndrm.htm" class="LinkPage"&gt;Fetal Alcohol Syndrome&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Abnormal labs or evaluation with delayed bone age imaging&lt;ol&gt;&lt;li&gt;Gluten-sensitive &lt;a href="../../GI/IBD/IntstnlEntrpthy.htm" class="LinkPage"&gt;Enteropathy&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Tissue transglutaminase antibodies&lt;/li&gt;&lt;li&gt;Antiendomysial &lt;a href="../../ID/Exam/Imnglbln.htm" class="LinkPage"&gt;Antibody&lt;/a&gt; titers&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Lung/Peds/CystcFbrs.htm" class="LinkPage"&gt;Cystic Fibrosis&lt;/a&gt; (typically age &amp;lt;2 at diagnosis)&lt;ol&gt;&lt;li&gt;&lt;a href="../../Lung/Lab/SwtChlrd.htm" class="LinkPage"&gt;Sweat Chloride&lt;/a&gt; testing&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Cushing Disease&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/FrUrnCrtsl.htm" class="LinkPage"&gt;24 hour Urine Cortisol&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/HmnGrwthHrmn.htm" class="LinkPage"&gt;Growth Hormone&lt;/a&gt; deficiency&lt;ol&gt;&lt;li&gt;IGF-1&lt;/li&gt;&lt;li&gt;IGF-binding protein #3&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/Hypthyrdsm.htm" class="LinkPage"&gt;Hypothyroidism&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/ThyrdStmltngHrmn.htm" class="LinkPage"&gt;Thyroid Stimulating Hormone&lt;/a&gt; (TSH)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/Thyrxn.htm" class="LinkPage"&gt;Free T4&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Pharm/Vitamins/VtmnDDfcncy.htm" class="LinkPage"&gt;Vitamin D Deficiency&lt;/a&gt; (&lt;a href="../../Rheum/Peds/Rckts1.htm" class="LinkPage"&gt;Rickets&lt;/a&gt;)&lt;ol&gt;&lt;li&gt;25-hydroxyvitamin D&lt;/li&gt;&lt;li&gt;1,25-dihydroxyvitamin D&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/PrthyrdHrmn.htm" class="LinkPage"&gt;Parathyroid Hormone&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Nwosu%20%20%5BAU%5D%20AND%202008%20%5BDP%5D%20AND%20%20Am%20Fam%20Physician%20%20%5BTA%5D" class="LinkRef"&gt;Nwosu (2008) Am Fam Physician 78(5): 597-4&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0349588</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Growth/ShrtStr.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Short Stature, Delayed Linear Growth, Delayed Growth</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Growth/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees></FP_UMLS_Trees><FP_Condition_name_check></FP_Condition_name_check><FP_Condition_name><value>Postprandial Hypoglycemia</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Hypoglycemic Disorders</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Causes&lt;ol&gt;&lt;li&gt;Post-surgical conditions with rapid gastric emptying&lt;ol&gt;&lt;li&gt;Gastrectomy&lt;/li&gt;&lt;li&gt;Gastrojejunostomy&lt;/li&gt;&lt;li&gt;Pyloroplasty&lt;/li&gt;&lt;li&gt;Vagotomy&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Fructose Intolerance&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Metabolism/Glctsm.htm" class="LinkPage"&gt;Galactosemia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Leucine sensitivity&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Pathophysiology&lt;ol&gt;&lt;li&gt;Excessive &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; following rapid &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; absorption&lt;/li&gt;&lt;li&gt;Results from post-surgical rapid gastric emptying&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Management&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Endo/Hypoglycemia/Hypglycm.htm" class="LinkPage"&gt;Hypoglycemia&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Hypoglycemia/PstprndlHypglycm.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Postprandial Hypoglycemia, Reactive Hypoglycemia</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Hypoglycemia/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees></FP_UMLS_Trees><FP_Condition_name_check></FP_Condition_name_check><FP_Condition_name><value>Unintentional Weight Loss Causes</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Geriatric Medicine</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;See Also&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Geri/UntntnlWghtLs.htm" class="LinkPage"&gt;Unintentional Weight Loss&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/MdctnsAsctdWthUntntnlWghtLs.htm" class="LinkPage"&gt;Medications Associated with Unintentional Weight Loss&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Causes: "Meals on Wheels" Mnemonic&lt;ol&gt;&lt;li&gt;Medication Effects&lt;/li&gt;&lt;li&gt;Emotional Problems (&lt;a href="../../Psych/Depress/MjrDprsn.htm" class="LinkPage"&gt;Major Depression&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Psych/Eating/AnrxNrvs.htm" class="LinkPage"&gt;Anorexia Nervosa&lt;/a&gt; or &lt;a href="../../Psych/CD/AlchlAbs.htm" class="LinkPage"&gt;Alcoholism&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Late-life paranoia&lt;/li&gt;&lt;li&gt;Swallowing disorders (See &lt;a href="../../Neuro/Exam/Dysphg.htm" class="LinkPage"&gt;Dysphagia&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;Oral factors (e.g. Poorly fitting dentures)&lt;/li&gt;&lt;li&gt;No Money&lt;/li&gt;&lt;li&gt;Wandering (&lt;a href="../../Neuro/Cognitive/Dmnt.htm" class="LinkPage"&gt;Dementia&lt;/a&gt; related behavior)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/Hyprthyrdsm1.htm" class="LinkPage"&gt;Hyperthyroidism&lt;/a&gt;, Hyperparaythyroidism, Hypoadrenalism&lt;/li&gt;&lt;li&gt;Enteric problems (e.g. Malabsorption)&lt;/li&gt;&lt;li&gt;Eating problems (e.g. difficult self-feeding)&lt;/li&gt;&lt;li&gt;Low salt diet or low &lt;a href="../../CV/Lab/Lpd.htm" class="LinkPage"&gt;Cholesterol&lt;/a&gt; diet&lt;/li&gt;&lt;li&gt;Stones (&lt;a href="../../Surgery/GI/ActChlcysts.htm" class="LinkPage"&gt;Cholecystitis&lt;/a&gt;) or social problems (isolation)&lt;/li&gt;&lt;li&gt;References&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Morley%20%20%5BAU%5D%20AND%201995%20%5BDP%5D%20AND%20%20Ann%20Intern%20Med%20%20%5BTA%5D" class="LinkRef"&gt;Morley (1995) Ann Intern Med 123:850-9&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Causes: Common&lt;ol&gt;&lt;li&gt;Idiopathic in one quarter of cases&lt;/li&gt;&lt;li&gt;&lt;a href="../../Psych/Depress/MjrDprsn.htm" class="LinkPage"&gt;Major Depression&lt;/a&gt; and other mental illness (18%)&lt;/li&gt;&lt;li&gt;&lt;a href="../../HemeOnc/Endo/CchxInCncr.htm" class="LinkPage"&gt;Cachexia in Cancer&lt;/a&gt; (16%)&lt;ol&gt;&lt;li&gt;&lt;a href="../../GI/Anatomy/StmchAntmy.htm" class="LinkPage"&gt;Stomach&lt;/a&gt; carcinoma&lt;/li&gt;&lt;li&gt;&lt;a href="../../GI/HemeOnc/PncrtcCncr.htm" class="LinkPage"&gt;Pancreatic Cancer&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../GI/HemeOnc/ClrctlCncr.htm" class="LinkPage"&gt;Colon Cancer&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Other cancers (e.g. &lt;a href="../../Gyn/HemeOnc/BrstCncr.htm" class="LinkPage"&gt;Breast Cancer&lt;/a&gt;)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Non-malignant Gastrointestinal Causes (14%)&lt;ol&gt;&lt;li&gt;&lt;a href="../../Surgery/GI/ActChlcysts.htm" class="LinkPage"&gt;Cholecystitis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../GI/PUD/PptcUlcrDs.htm" class="LinkPage"&gt;Peptic Ulcer Disease&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../GI/Esophagus/GstrsphglRflx.htm" class="LinkPage"&gt;Gastroesophageal Reflux&lt;/a&gt; Disease&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/CHF/CngstvHrtFlr.htm" class="LinkPage"&gt;Congestive Heart Failure&lt;/a&gt; (5-10%)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Psych/CD/AlchlAbs.htm" class="LinkPage"&gt;Alcoholism&lt;/a&gt; or other &lt;a href="../../Psych/CD/ChmclDpndncy.htm" class="LinkPage"&gt;Drug Abuse&lt;/a&gt; (5-10%)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Lung/COPD/ChrncObstrctvPlmnryDs.htm" class="LinkPage"&gt;Chronic Obstructive Pulmonary Disease&lt;/a&gt; (5-10%)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Causes: Other Causes&lt;ol&gt;&lt;li&gt;Endocrine Conditions&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/DM/DbtsMlts.htm" class="LinkPage"&gt;Diabetes Mellitus&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/Hyprthyrdsm1.htm" class="LinkPage"&gt;Hyperthyroidism&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/Hypthyrdsm.htm" class="LinkPage"&gt;Hypothyroidism&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Connective Tissue Disease&lt;ol&gt;&lt;li&gt;&lt;a href="../../Lung/ILD/Srcds.htm" class="LinkPage"&gt;Sarcoidosis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Rheum/R_2/RhmtdArthrts.htm" class="LinkPage"&gt;Rheumatoid Arthritis&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Medication adverse effects&lt;ol&gt;&lt;li&gt;&lt;a href="../../Geri/Pharm/Plyphrmcy.htm" class="LinkPage"&gt;Polypharmacy&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/MdctnsAsctdWthUntntnlWghtLs.htm" class="LinkPage"&gt;Medications Associated with Unintentional Weight Loss&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Neurologic Diseases&lt;ol&gt;&lt;li&gt;&lt;a href="../../Neuro/Motor/MsclrDystrphy.htm" class="LinkPage"&gt;Muscular Dystrophy&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Bulbar Palsy&lt;/li&gt;&lt;li&gt;&lt;a href="../../Neuro/CV/IschmcStrk.htm" class="LinkPage"&gt;Cerebrovascular Accident&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Neuro/Motor/MysthnGrvs.htm" class="LinkPage"&gt;Myasthenia Gravis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Neuro/Tremor/PrknsnsDs.htm" class="LinkPage"&gt;Parkinson's Disease&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Neuro/Cognitive/Dmnt.htm" class="LinkPage"&gt;Dementia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Neuro/Cognitive/Dlrm.htm" class="LinkPage"&gt;Delirium&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Psych/Eating/AnrxNrvs.htm" class="LinkPage"&gt;Anorexia Nervosa&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Chronic Infection&lt;ol&gt;&lt;li&gt;&lt;a href="../../HIV/Exam/HmnImndfcncyVrs.htm" class="LinkPage"&gt;HIV Infection&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Lung/Tb/Tbrcls.htm" class="LinkPage"&gt;Tuberculosis&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../ID/Exam/Fvr.htm" class="LinkPage"&gt;Fever&lt;/a&gt; (See also &lt;a href="../../ID/Exam/Fvr.htm" class="LinkPage"&gt;Fever&lt;/a&gt; of Unkown Origin)&lt;ol&gt;&lt;li&gt;Basal metabolic rate increases 7% per degree F&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Malabsorption&lt;ol&gt;&lt;li&gt;Pancreatic Insufficiency&lt;/li&gt;&lt;li&gt;&lt;a href="../../GI/Malabsorption/GltnEntrpthy.htm" class="LinkPage"&gt;Celiac Sprue&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;Heizer in Dornbrand (1992) Ambulatory Care, p. 15-18&lt;/li&gt;&lt;li&gt;Karsh in Friedman (1991) Medical Diagnosis, p. 13-16&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Grazewood%20%20%5BAU%5D%20AND%201998%20%5BDP%5D%20AND%20%20J%20Fam%20Pract%20%20%5BTA%5D" class="LinkRef"&gt;Grazewood (1998) J Fam Pract 47(1): 19-25&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Huffman%20%20%5BAU%5D%20AND%202002%20%5BDP%5D%20AND%20%20Am%20Fam%20Physician%20%20%5BTA%5D" class="LinkRef"&gt;Huffman (2002) Am Fam Physician 65(4):640-50&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Morley%20%20%5BAU%5D%20AND%201995%20%5BDP%5D%20AND%20%20Ann%20Intern%20Med%20%20%5BTA%5D" class="LinkRef"&gt;Morley (1995) Ann Intern Med 123:850-9&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=White%20%20%5BAU%5D%20AND%201991%20%5BDP%5D%20AND%20%20Am%20Fam%20Physician%20%20%5BTA%5D" class="LinkRef"&gt;White (1991) Am Fam Physician 44(6): 2087-97&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Zawada%20%20%5BAU%5D%20AND%201996%20%5BDP%5D%20AND%20%20Postgrad%20Med%20%20%5BTA%5D" class="LinkRef"&gt;Zawada (1996) Postgrad Med 100(1):207-25&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Geri/UntntnlWghtLsCs.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Unintentional Weight Loss Causes, Meals on Wheels Mnemonic</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Geri/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees></FP_UMLS_Trees><FP_Condition_name_check></FP_Condition_name_check><FP_Condition_name><value>Diabetes Resources</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Diabetes Mellitus</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;General Resources&lt;ol&gt;&lt;li&gt;American Diabetes Association&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.diabetes.org" class="LinkWebExt"&gt;http://www.diabetes.org&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Includes annual recommendations and algorithms&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;American Association of Diabetes Educators&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.aadenet.org" class="LinkWebExt"&gt;http://www.aadenet.org&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;CDC's Diabetes and Public Health Resource&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.cdc.gov/diabetes/" class="LinkWebExt"&gt;http://www.cdc.gov/diabetes/&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Take Charge of Your Diabetes&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.cdc.gov/diabetes/pubs/tcoyd.htm" class="LinkWebExt"&gt;http://www.cdc.gov/diabetes/pubs/tcoyd.htm&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;National Diabetes Education Program&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ndep.nih.gov" class="LinkWebExt"&gt;http://www.ndep.nih.gov&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Juvenile Diabetes Research Foundation International&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.jdrf.org" class="LinkWebExt"&gt;http://www.jdrf.org&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;AIDA Diabetes Simulation&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.2aida.org/online" class="LinkWebExt"&gt;http://www.2aida.org/online&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Rick Mendosa's Diabetes Directory&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.mendosa.com/diabetes.htm" class="LinkWebExt"&gt;http://www.mendosa.com/diabetes.htm&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/DM/DbtsRsrcs.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Diabetes Resources</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/DM/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees></FP_UMLS_Trees><FP_Condition_name_check></FP_Condition_name_check><FP_Condition_name><value>Endocrinology Worksheets</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: General</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Body Habitus Calculations&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.fpnotebook.com/_media/CalcsHabitus.htm" class="LinkWebInt"&gt;CalcsHabitus.htm&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Gen/EndcrnlgyWrkshts.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Endocrinology Worksheets</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Gen/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Endocrine system  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0014136"&gt;&lt;i&gt;C0014136&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A system of glands and cells that make hormones that are released directly into the blood and travel to tissues and organs all over the body. The endocrine system controls growth, sexual development, sleep, hunger, and the way the body uses food.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;The system of glands that release their secretions (hormones) directly into the circulatory system. In addition to the ENDOCRINE GLANDS, included are the CHROMAFFIN SYSTEM and the NEUROSECRETORY SYSTEMS.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;Collective designation for those tissues capable of secreting hormones.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CSP)&lt;/td&gt;
                &lt;td&gt;ductless glands that secrete substances which are released directly into the circulation and which influence metabolism and other body functions.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Body System (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0014136&amp;amp;tui=T022"&gt;&lt;i&gt;T022&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D004703&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;113331007&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Endocrine System, ENDOCRINE SYSTEM, ENDOCRINE SYSTEM: GENERAL TERMS, Endocrine Systems, System, Endocrine, Systems, Endocrine, Endocrine structure (body structure), Endocrine structure, Structure of endocrine system, Structure of endocrine system (body structure), Endocrine System in General, SECTION B ENDOCRINE SYSTEM, B0 ENDOCRINE SYSTEM: GENERAL TERMS, Systema endocrinum, Endocrine, endocrine systems, endocrine glands system, endocrine gland/system, endocrine system, Endocrine system structure, Endocrine system, Body System, Endocrine/Metabolic, Endocrine/Metabolic Body System, Hormonal System, Organ System, Endocrine/Metabolic, Endocrine/Metabolic Organ System, Metabolic/Endocrine Body System&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Endokrina systemet&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;endokrinní systém&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Umpieritysjärjestelmä&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;ENDOKRINNAIA SISTEMA, ЭНДОКРИННАЯ СИСТЕМА&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Croatian&lt;/td&gt;
                &lt;td&gt;ENDOKRINI SUSTAV&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Latvian&lt;/td&gt;
                &lt;td&gt;Endokrīnā sistēma&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Układ wewnątrzwydzielniczy&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;estructura del sistema endocrino (estructura corporal), estructura del sistema endocrino, sistema endocrino, Sistema Endocrino&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Système endocrine, Système endocrinien&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Endokrines System&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Sistema endocrino&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;Endocrien systeem, Systeem, endocrien&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Sistema Endócrino&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Endocrine system  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Endocrine Anatomy</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Anatomy</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Components&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Anatomy/AdrnlAntmy.htm" class="LinkPage"&gt;Adrenal Anatomy&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Anatomy/ThyrdAntmy.htm" class="LinkPage"&gt;Thyroid Anatomy&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Anatomy/PrthyrdAntmy.htm" class="LinkPage"&gt;Parathyroid Anatomy&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Neuro/Anatomy/PtryAntmy.htm" class="LinkPage"&gt;Pituitary Anatomy&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Uro/Anatomy/Tstcl.htm" class="LinkPage"&gt;Testes&lt;/a&gt; Anatomy&lt;/li&gt;&lt;li&gt;&lt;a href="../../Gyn/Anatomy/AdnxlAntmy.htm" class="LinkPage"&gt;Ovary&lt;/a&gt; Anatomy&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0014136</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Anatomy/EndcrnAntmy.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Endocrine Anatomy</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Anatomy/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees></FP_UMLS_Trees><FP_Condition_name_check></FP_Condition_name_check><FP_Condition_name><value>Thyroid Eye Disease</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Ophthalmology</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;See Also&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/Hyprthyrdsm1.htm" class="LinkPage"&gt;Hyperthyroidism&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/GrvsDs.htm" class="LinkPage"&gt;Grave's Disease&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Epidemiology&lt;ol&gt;&lt;li&gt;Eye complications occur in 25-50% of &lt;a href="../../Endo/Thyroid/GrvsDs.htm" class="LinkPage"&gt;Grave's Disease&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Pathophysiology&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/GrvsDs.htm" class="LinkPage"&gt;Grave's Disease&lt;/a&gt; induced eye changes&lt;ol&gt;&lt;li&gt;Sensitized orbital tissue-specific &lt;a href="../../HemeOnc/Lab/LymphcytCnt.htm" class="LinkPage"&gt;T-Lymphocyte&lt;/a&gt;s&lt;/li&gt;&lt;li&gt;Local inflammatory cellular infiltration of eye&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Orbital fibroblasts mediate changes&lt;ol&gt;&lt;li&gt;Adipose hypertrophy&lt;/li&gt;&lt;li&gt;Glycosaminoglycan accumulates&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Residual scarring may cause irreversible &lt;a href="../../Eye/Sx/Prpts.htm" class="LinkPage"&gt;Proptosis&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Risk Factors&lt;ol&gt;&lt;li&gt;&lt;a href="../../Psych/CD/Cgrt.htm" class="LinkPage"&gt;Tobacco&lt;/a&gt; abuse (relative risk 4)&lt;/li&gt;&lt;li&gt;Older men appear to have more severe cases&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Rdn.htm" class="LinkPage"&gt;Radioiodine&lt;/a&gt; therapy may cause flare in eye disease&lt;ol&gt;&lt;li&gt;Prednisone used to prevent flare&lt;ol&gt;&lt;li&gt;Dose: 40 to 80 mg daily&lt;/li&gt;&lt;li&gt;Taper off over 3 months&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Symptoms&lt;ol&gt;&lt;li&gt;Ocular pain&lt;ol&gt;&lt;li&gt;Pressure sensation on or behind globe&lt;/li&gt;&lt;li&gt;Worse with &lt;a href="../../Eye/Anatomy/ExtrclrMvmnt.htm" class="LinkPage"&gt;Extraocular Movement&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Photophobia&lt;/li&gt;&lt;li&gt;&lt;a href="../../Eye/Conjunctiva/Chms.htm" class="LinkPage"&gt;Chemosis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Eye/Sx/Dplp.htm" class="LinkPage"&gt;Diplopia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Eye/Sx/Prpts.htm" class="LinkPage"&gt;Exophthalmos&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Eye irritation (gritty sensation)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Signs&lt;ol&gt;&lt;li&gt;&lt;a href="../../Eye/Sx/Prpts.htm" class="LinkPage"&gt;Proptosis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Eye/Anatomy/LdAntmy.htm" class="LinkPage"&gt;Eyelid&lt;/a&gt; and &lt;a href="../../Eye/Anatomy/EyAntmy.htm" class="LinkPage"&gt;Conjunctiva&lt;/a&gt; edema and redness&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Radiology&lt;ol&gt;&lt;li&gt;MRI or CT of orbits&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Management&lt;ol&gt;&lt;li&gt;Manage &lt;a href="../../Endo/Thyroid/GrvsDs.htm" class="LinkPage"&gt;Grave's Disease&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Refer all cases to ophthalmology&lt;/li&gt;&lt;li&gt;Treatment used by ophthalmology in mod. to severe cases&lt;ol&gt;&lt;li&gt;High dose &lt;a href="../../Endo/Pharm/SystmcCrtcstrd.htm" class="LinkPage"&gt;Corticosteroid&lt;/a&gt;s&lt;/li&gt;&lt;li&gt;Orbital decompression&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Course&lt;ol&gt;&lt;li&gt;Clinical findings may persist after &lt;a href="../../Endo/Anatomy/ThyrdAntmy.htm" class="LinkPage"&gt;Thyroid&lt;/a&gt; treated&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Cawood%20%20%5BAU%5D%20AND%202004%20%5BDP%5D%20AND%20%20BMJ%20%20%5BTA%5D" class="LinkRef"&gt;Cawood (2004) BMJ 329:385-90&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Eye/ThyrdEyDs.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Thyroid Eye Disease, Hyperthyroidism Related Infiltrative Ophthalmopathy, Ophthalmoplegia Due to Grave's Disease, Grave's Ophthalmoplegia</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Eye/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Pheochromocytoma  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0031511"&gt;&lt;i&gt;C0031511&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CHV)&lt;/td&gt;
                &lt;td&gt;A usually benign, well-encapsulated, lobular, vascular tumor of chromaffin tissue of the ADRENAL MEDULLA&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CHV)&lt;/td&gt;
                &lt;td&gt;A usually benign, well-encapsulated, lobular, vascular tumor of chromaffin tissue of the ADRENAL MEDULLA&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CHV)&lt;/td&gt;
                &lt;td&gt;A usually benign, well-encapsulated, lobular, vascular tumor of chromaffin tissue of the ADRENAL MEDULLA&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CHV)&lt;/td&gt;
                &lt;td&gt;A usually benign, well-encapsulated, lobular, vascular tumor of chromaffin tissue of the ADRENAL MEDULLA&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CHV)&lt;/td&gt;
                &lt;td&gt;A usually benign, well-encapsulated, lobular, vascular tumor of chromaffin tissue of the ADRENAL MEDULLA&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MEDLINEPLUS)&lt;/td&gt;
                &lt;td&gt;
                  &lt;span&gt;
                    &lt;p&gt;Pheochromocytoma is a rare tumor that usually starts in the cells of one of your adrenal glands. Although they are usually &lt;a href="http://www.nlm.nih.gov/medlineplus/benigntumors.html"&gt;benign&lt;/a&gt;, pheochromocytomas often cause the adrenal gland to make too many hormones. This can lead to high blood pressure and cause  symptoms such as &lt;/p&gt;
                    &lt;ul&gt;&lt;li&gt;	Headaches&lt;/li&gt;
                      &lt;li&gt;	Sweating&lt;/li&gt;
                      &lt;li&gt;	Pounding of the heart&lt;/li&gt;
                      &lt;li&gt;	Chest pain&lt;/li&gt;
                      &lt;li&gt;	A feeling of anxiety&lt;/li&gt;
                    &lt;/ul&gt;&lt;p&gt;Sometimes pheochromocytoma is part of another condition called multiple endocrine neoplasia syndrome (MEN). People with MEN often have other cancers and other problems involving hormones. &lt;/p&gt;
                    &lt;p&gt;Surgery is the most common treatment.  Other options include radiation therapy and chemotherapy.&lt;/p&gt;
                    &lt;p style="font-weight:bold;font-style:italic;"&gt;NIH: National Cancer Institute&lt;/p&gt;
                  &lt;/span&gt;
                &lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;Tumor that forms in the center of the adrenal gland (gland located above the kidney) that causes it to make too much adrenaline. Pheochromocytomas are usually benign (not cancer) but can cause high blood pressure, pounding headaches, heart palpitations, flushing of the face, nausea, and vomiting.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;A usually benign, well-encapsulated, lobular, vascular tumor of chromaffin tissue of the ADRENAL MEDULLA or sympathetic paraganglia. The cardinal symptom, reflecting the increased secretion of EPINEPHRINE and NOREPINEPHRINE, is HYPERTENSION, which may be persistent or intermittent. During severe attacks, there may be HEADACHE; SWEATING, palpitation, apprehension, TREMOR; PALLOR or FLUSHING of the face, NAUSEA and VOMITING, pain in the CHEST and ABDOMEN, and paresthesias of the extremities. The incidence of malignancy is as low as 5% but the pathologic distinction between benign and malignant pheochromocytomas is not clear. (Dorland, 27th ed; DeVita Jr et al., Cancer: Principles &amp;amp; Practice of Oncology, 3d ed, p1298)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CSP)&lt;/td&gt;
                &lt;td&gt;usually benign, well-encapsulated, lobular, vascular tumor of chromaffin tissue of the adrenal medulla or sympathetic paraganglia; the cardinal symptom, reflecting the increased secretion of epinephrine and norepinephrine, is hypertension, which may be persistent or intermittent.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A benign or malignant neuroendocrine neoplasm of the sympathetic nervous system that secretes catecholamines. It arises from the chromaffin cells of the adrenal medulla. Clinical presentation includes headaches, palpitations, chest and abdominal pain, hypertension, fever, and tremor. Microscopically, a characteristic nesting (zellballen) growth pattern is usually seen. Other growth patterns including trabecular pattern may also be present.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Neoplastic Process (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0031511&amp;amp;tui=T191"&gt;&lt;i&gt;T191&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D010673&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD10&lt;/td&gt;
                &lt;td&gt;M8700/0&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;302835009, 85583005, 399343007, 360335004, 360332001, 154555009, 188337000, 269615000&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Pheochromocytomas, CHROMAFFINOMA, MEDULLARY, PARAGANGLIOMA, MEDULLARY, PHAEOCHROMOCYTOMA, Pheochromocytoma, NOS, Phaeochromocytoma, NOS, Adrenal Medullary Paraganglioma, Adrenal Medullary Pheochromocytoma, Adrenal Pheochromocytoma, Intraadrenal Paraganglioma, Chromaffin Paraganglioma of the Adrenal Gland, Adrenal Gland Chromaffin Paraganglioma, Adrenal Gland Chromaffinoma, Adrenal Gland Paraganglioma, Adrenal Gland Pheochromocytoma, PHEOCHROMOCYTOMA, Pheochromocytoma, adrenal, Pheochromocytoma syndrome, [M]Pheochromocytoma NOS, Phaeochromocytoma NOS, Pheochromocytoma NOS, chromaffinoma, Pheochromocytoma [Disease/Finding], chromaffin tumor, pheochromocytoma syndrome, pheochromocytomas, phaeochromocytoma, Chromaffin paraganglioma, Chromaffin tumor, Chromaffinoma, Chromaffin tumour, Phaeochromocytoma, [M]Phaeochromocytoma NOS, Chromaffinoma (disorder), Adrenal medullary paraganglioma, Pheochromocytoma (disorder), Pheochromocytoma (morphologic abnormality), pheochromocytoma, Chromaffin paraganglioma (disorder), Phaeochromocytoma (disorder), Phaeochromocytoma [Ambiguous], Pheochromocytoma, PCC&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;PHEOCHROMOCYTOME, Chromaffinome, Phéochromocytome&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;FEOCROMOCITOMA, Feocromocitoma, Feocromocitoma Extra-Adrenal&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;FEOCROMOCITOMA, Pheochromocytoma, Phaeochromocytoma, cromafinoma (trastorno), cromafinoma, feocromocitoma (anomalía morfológica), feocromocitoma (trastorno), feocromocitoma, SAI, feocromocitoma, paraganglioma cromafín, paraganglioma de células argentafines (trastorno), paraganglioma de células argentafines, paraganglioma de células cromafines, tumor cromafín, tumor de células cromafines, Feocromocitoma&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;PHAEOCHROMOZYTOM, Phaeochromozytom, Phäochromozytom&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Feokromocytom&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;ｶｯｼｮｸｻｲﾎﾞｳｼｭ, 褐色細胞腫, かっ色細胞腫, クロム親和細胞腫, クロム親和性細胞腫, 髄質細胞腫, 好クロム性細胞腫&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;feochromocytom, Feochromocytom&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Feokromosytooma&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;FEOKHROMOBLASTOMA, OPUKHOL' KHROMAFINNAIA, KHROMAFFINOMA, FEOKHROMOTSITOMA, ОПУХОЛЬ ХРОМАФИННАЯ, ФЕОХРОМОБЛАСТОМА, ФЕОХРОМОЦИТОМА, ХРОМАФФИНОМА&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Croatian&lt;/td&gt;
                &lt;td&gt;FEOKROMOCITOM&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Przyzwojak chromochłonny, Guz chromochłonny nadnerczy, Pheochromocytoma, Barwiak&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;Phaeochromocytoma, Phaeocromocytoma&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;feochromocytoom, Feochromocytoom&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Feocromocitoma&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Paroxysmal hypertension  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0221154"&gt;&lt;i&gt;C0221154&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Sign or Symptom (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0221154&amp;amp;tui=T184"&gt;&lt;i&gt;T184&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;23130000&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;HYPERTENSION, PAROXYSMAL, Hypertension, paroxysmal, paroxysmal hypertension (physical finding), paroxysmal hypertension, paroxysmal hypertension was observed, Hypertension paroxysmal, Paroxysmal hypertension, Paroxysmal hypertension (disorder), Paroxysmal Hypertension&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;paroxysmale hypertensie&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Hypertension paroxystique&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Hypertonie, paroxysmal&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Ipertensione parossistica&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Hipertensão paroxística&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;Hipertensión paroxística, hipertensión arterial paroxística (trastorno), hipertensión arterial paroxística&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;発作性高血圧, ﾎｯｻｾｲｺｳｹﾂｱﾂ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;Paroxysmální hypertenze&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;Paroxysmalis hypertonia&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Pheochromocytoma  (</value><value>)
</value><value>Paroxysmal hypertension  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Pheochromocytoma</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Adrenal Disease</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Definition&lt;ol&gt;&lt;li&gt;&lt;a href="../../Neuro/Pharm/AdrnrgcRcptr.htm" class="LinkPage"&gt;Catecholamine&lt;/a&gt; secreting tumor of the &lt;a href="../../Endo/Anatomy/AdrnlAntmy.htm" class="LinkPage"&gt;Adrenal Gland&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Epidemiology&lt;ol&gt;&lt;li&gt;&lt;a href="../../Prevent/Epi/DsIncdncRt.htm" class="LinkPage"&gt;Incidence&lt;/a&gt;: Rare&lt;/li&gt;&lt;li&gt;Peak ages: 30-60 years&lt;/li&gt;&lt;li&gt;&lt;a href="../../Pharm/Nutrition/NnNtrtvSwtnr.htm" class="LinkPage"&gt;Equal&lt;/a&gt; male and female predominance&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Presentation: Classic Episodes&lt;ol&gt;&lt;li&gt;Predominant Symptoms&lt;ol&gt;&lt;li&gt;&lt;a href="../../Neuro/Sx/Hdch.htm" class="LinkPage"&gt;Headache&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Diaphoresis or Sweating&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Sx/Plptn.htm" class="LinkPage"&gt;Palpitation&lt;/a&gt;s&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Associated Symptoms&lt;ol&gt;&lt;li&gt;Anxiety&lt;/li&gt;&lt;li&gt;&lt;a href="../../Neuro/Tremor/Trmr.htm" class="LinkPage"&gt;Tremor&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Pallor&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Sx/ChstPn.htm" class="LinkPage"&gt;Chest Pain&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Surgery/GI/EpgstrcPn.htm" class="LinkPage"&gt;Epigastric Pain&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Gyn/Sx/VsmtrSymptmsOfMnps.htm" class="LinkPage"&gt;Flushing&lt;/a&gt; (rare)&lt;/li&gt;&lt;li&gt;Painless &lt;a href="../../Uro/Urine/HmtrInAdlts.htm" class="LinkPage"&gt;Hematuria&lt;/a&gt; (rare)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Timing of episodes&lt;ol&gt;&lt;li&gt;Duration: One hour or less&lt;/li&gt;&lt;li&gt;Frequency: daily to once every few months&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Presentation: Other&lt;ol&gt;&lt;li&gt;Hyperadrenergic spells (see classic episodes above)&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Htn/RstntHyprtnsn.htm" class="LinkPage"&gt;Resistant Hypertension&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Malignant or intra-operative &lt;a href="../../CV/Htn/Hyprtnsn.htm" class="LinkPage"&gt;Hypertension&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Prevent/HME/FmlyHstry.htm" class="LinkPage"&gt;Family History&lt;/a&gt; of Pheochromocytoma or predisposing syndromes (e.g. MEN 2, NF1, VHL. SDH)&lt;/li&gt;&lt;li&gt;Premature &lt;a href="../../CV/Htn/Hyprtnsn.htm" class="LinkPage"&gt;Hypertension&lt;/a&gt; (age under 20 years)&lt;/li&gt;&lt;li&gt;Idiopathic &lt;a href="../../CV/CHF/SystlcDysfnctn.htm" class="LinkPage"&gt;Dilated Cardiomyopathy&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Diagnostic Clues&lt;ol&gt;&lt;li&gt;Six "H's"&lt;ol&gt;&lt;li&gt;&lt;a href="../../CV/Htn/Hyprtnsn.htm" class="LinkPage"&gt;Hypertension&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Neuro/Sx/Hdch.htm" class="LinkPage"&gt;Headache&lt;/a&gt; - throbbing (90%)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Derm/Sweat/Hyprhdrs.htm" class="LinkPage"&gt;Hyperhidrosis&lt;/a&gt; or excessive sweating (69%)&lt;/li&gt;&lt;li&gt;Heart consciousness or &lt;a href="../../CV/Sx/Plptn.htm" class="LinkPage"&gt;Palpitation&lt;/a&gt;s (73%)&lt;/li&gt;&lt;li&gt;Hypermetabolism&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Hyperglycemia&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Rule of 10&lt;ol&gt;&lt;li&gt;Familial (10%)&lt;/li&gt;&lt;li&gt;Malignant (10%)&lt;/li&gt;&lt;li&gt;Multiple or Bilateral (10%)&lt;/li&gt;&lt;li&gt;Extra-adrenal (10%)&lt;/li&gt;&lt;li&gt;Childhood onset (10%)&lt;/li&gt;&lt;li&gt;Recurrence after Surgery (10%)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Differential Diagnosis&lt;ol&gt;&lt;li&gt;Primary &lt;a href="../../Endo/Adrenal/Hyprldstrnsm.htm" class="LinkPage"&gt;Aldosteronism&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../GI/HemeOnc/CrcndTmr.htm" class="LinkPage"&gt;Carcinoid&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Accelerated or &lt;a href="../../CV/Htn/HyprtnsnMngmntFrSpcfcEmrgncs.htm" class="LinkPage"&gt;Malignant Hypertension&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Illicit, OTC or prescribed &lt;a href="../../Neuro/Pharm/AdrnrgcRcptr.htm" class="LinkPage"&gt;Sympathomimetic&lt;/a&gt; medications&lt;/li&gt;&lt;li&gt;&lt;a href="../../ENT/HemeOnc/Chmdctm.htm" class="LinkPage"&gt;Chemodectoma&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Neuro/Anatomy/GnglnAntmy.htm" class="LinkPage"&gt;Ganglion&lt;/a&gt;euroma&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/Hyprthyrdsm1.htm" class="LinkPage"&gt;Thyrotoxicosis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Gyn/Endo/Mnps.htm" class="LinkPage"&gt;Menopause&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Psych/Anxiety/PncDsrdr.htm" class="LinkPage"&gt;Panic Disorder&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Antihypertensive withdrawal (e.g. &lt;a href="../../CV/Pharm/AlphAdrnrgcCntrlAgnst.htm" class="LinkPage"&gt;Clonidine&lt;/a&gt; withdrawal)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Labs: Preparation&lt;ol&gt;&lt;li&gt;Stop any interfering medications&lt;ol&gt;&lt;li&gt;&lt;a href="../../CV/Pharm/Lbtl.htm" class="LinkPage"&gt;Labetalol&lt;/a&gt; (stop for 1 week)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Psych/Pharm/TrcyclcAntdprsnt.htm" class="LinkPage"&gt;Tricyclic Antidepressant&lt;/a&gt; (stop for 2 weeks)&lt;/li&gt;&lt;li&gt;Psychoactive medications (stop for weeks)&lt;/li&gt;&lt;li&gt;Levodopa or &lt;a href="../../CV/Pharm/AlphAdrnrgcCntrlAgnst.htm" class="LinkPage"&gt;Methyldopa&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../ENT/Pharm/Dcngstnt.htm" class="LinkPage"&gt;Decongestant&lt;/a&gt;s&lt;/li&gt;&lt;li&gt;&lt;a href="../../Psych/Pharm/Bnzdzpn.htm" class="LinkPage"&gt;Benzodiazepine&lt;/a&gt;s&lt;/li&gt;&lt;li&gt;Muscle relaxants (mephenasin, &lt;a href="../../Rheum/Pharm/SkltlMsclRlxnt.htm" class="LinkPage"&gt;Methocarbamol&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;Avoid &lt;a href="../../Pharm/Analgesic/Actmnphn.htm" class="LinkPage"&gt;Tylenol&lt;/a&gt; for 48 hours&lt;/li&gt;&lt;li&gt;Avoid &lt;a href="../../Pharm/Analgesic/Asprn.htm" class="LinkPage"&gt;Aspirin&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Stop other interfering agents&lt;ol&gt;&lt;li&gt;No &lt;a href="../../Pharm/Nutrition/Cfn.htm" class="LinkPage"&gt;Caffeine&lt;/a&gt;, &lt;a href="../../Psych/Pharm/Alchl.htm" class="LinkPage"&gt;Alcohol&lt;/a&gt; or &lt;a href="../../Psych/CD/Cgrt.htm" class="LinkPage"&gt;Tobacco&lt;/a&gt; for 4 hours&lt;/li&gt;&lt;li&gt;Tomatoes&lt;/li&gt;&lt;li&gt;Walnuts&lt;/li&gt;&lt;li&gt;Pineapple&lt;/li&gt;&lt;li&gt;Banana&lt;/li&gt;&lt;li&gt;Eggplant&lt;/li&gt;&lt;li&gt;Avocado&lt;/li&gt;&lt;li&gt;Plums&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Labs: Available Tests&lt;ol&gt;&lt;li&gt;Best studies&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/UrnMtnphrn.htm" class="LinkPage"&gt;Urine Metanephrine&lt;/a&gt;s (24 hour collections)&lt;ol&gt;&lt;li&gt;Use as first line screening&lt;/li&gt;&lt;li&gt;&lt;a href="../../Prevent/Epi/TstSnstvty.htm" class="LinkPage"&gt;Test Sensitivity&lt;/a&gt;: 76%&lt;/li&gt;&lt;li&gt;&lt;a href="../../Prevent/Epi/TstSpcfcty.htm" class="LinkPage"&gt;Test Specificity&lt;/a&gt;: 94%&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Plasma Free Metanephrines&lt;ol&gt;&lt;li&gt;Very high false positive rate (Pheochromocytoma is rare)&lt;/li&gt;&lt;li&gt;Use only for confirmation, not for screening&lt;/li&gt;&lt;li&gt;&lt;a href="../../Prevent/Epi/TstSnstvty.htm" class="LinkPage"&gt;Test Sensitivity&lt;/a&gt;: 99%&lt;/li&gt;&lt;li&gt;&lt;a href="../../Prevent/Epi/TstSpcfcty.htm" class="LinkPage"&gt;Test Specificity&lt;/a&gt;: 89%&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Tests with lower efficacy&lt;ol&gt;&lt;li&gt;Urinary VMA&lt;ol&gt;&lt;li&gt;Normal value under 6.5 mg/day&lt;/li&gt;&lt;li&gt;Imprecise test&lt;/li&gt;&lt;li&gt;Drugs and food interfere with test&lt;/li&gt;&lt;li&gt;&lt;a href="../../Prevent/Epi/TstSnstvty.htm" class="LinkPage"&gt;Test Sensitivity&lt;/a&gt;: 63%&lt;/li&gt;&lt;li&gt;&lt;a href="../../Prevent/Epi/TstSpcfcty.htm" class="LinkPage"&gt;Test Specificity&lt;/a&gt;: 94%&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Plasma &lt;a href="../../Neuro/Pharm/AdrnrgcRcptr.htm" class="LinkPage"&gt;Catecholamine&lt;/a&gt;s (&lt;a href="../../CV/Pharm/Nrpnphrn.htm" class="LinkPage"&gt;Norepinephrine&lt;/a&gt;, &lt;a href="../../CV/Pharm/Epnphrn.htm" class="LinkPage"&gt;Epinephrine&lt;/a&gt;)&lt;ol&gt;&lt;li&gt;&lt;a href="../../Prevent/Epi/TstSnstvty.htm" class="LinkPage"&gt;Test Sensitivity&lt;/a&gt;: 85%&lt;/li&gt;&lt;li&gt;&lt;a href="../../Prevent/Epi/TstSpcfcty.htm" class="LinkPage"&gt;Test Specificity&lt;/a&gt;: 80%&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Labs: Protocol&lt;ol&gt;&lt;li&gt;First: &lt;a href="../../Endo/Lab/UrnMtnphrn.htm" class="LinkPage"&gt;24-hour Urine Metanephrine&lt;/a&gt; and &lt;a href="../../Endo/Lab/UrnVnlylmndlcAcd.htm" class="LinkPage"&gt;Urine VMA&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Next: Plasma Free Metanephrines&lt;/li&gt;&lt;li&gt;Next: Plasma &lt;a href="../../Neuro/Pharm/AdrnrgcRcptr.htm" class="LinkPage"&gt;Catecholamine&lt;/a&gt;s (equivocal metanephrines)&lt;/li&gt;&lt;li&gt;Final: &lt;a href="../../Endo/Lab/ClndnSprsnTst.htm" class="LinkPage"&gt;Clonidine Suppression&lt;/a&gt; (positive &lt;a href="../../Neuro/Pharm/AdrnrgcRcptr.htm" class="LinkPage"&gt;Catecholamine&lt;/a&gt;s)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Radiology: Tumor localization&lt;ol&gt;&lt;li&gt;Adrenal CT or Adrenal MRI&lt;ol&gt;&lt;li&gt;&lt;a href="../../Prevent/Epi/TstSnstvty.htm" class="LinkPage"&gt;Test Sensitivity&lt;/a&gt;: 93 to 100%&lt;/li&gt;&lt;li&gt;&lt;a href="../../Prevent/Epi/TstSpcfcty.htm" class="LinkPage"&gt;Test Specificity&lt;/a&gt;: 70%&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;MIGB Scan (metaiodobenzyl-guanidine)&lt;ol&gt;&lt;li&gt;&lt;a href="../../Prevent/Epi/TstSnstvty.htm" class="LinkPage"&gt;Test Sensitivity&lt;/a&gt;: 77 to 90%&lt;/li&gt;&lt;li&gt;&lt;a href="../../Prevent/Epi/TstSpcfcty.htm" class="LinkPage"&gt;Test Specificity&lt;/a&gt;: 95 to 100%&lt;/li&gt;&lt;li&gt;Good for looking for tumors in unusual places&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Management&lt;ol&gt;&lt;li&gt;Preoperative Medical Management&lt;ol&gt;&lt;li&gt;&lt;a href="../../Neuro/Pharm/AlphAdrnrgcRcptr.htm" class="LinkPage"&gt;Alpha Adrenergic Receptor&lt;/a&gt; antagonist (2 weeks pre-op)&lt;ol&gt;&lt;li&gt;Phenoxybenzamine PO bid&lt;/li&gt;&lt;li&gt;Phentolamine IV prn&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Pharm/BtBlckr.htm" class="LinkPage"&gt;Beta Blocker&lt;/a&gt; (only start after alpha blockade)&lt;ol&gt;&lt;li&gt;&lt;a href="../../CV/Pharm/Prprnl.htm" class="LinkPage"&gt;Propranolol&lt;/a&gt; PO qid&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Surgical Management&lt;ol&gt;&lt;li&gt;Laparoscopic adrenalectomy Indications&lt;ol&gt;&lt;li&gt;Single, small adrenal tumors&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Htn/Hyprtnsn.htm" class="LinkPage"&gt;Hypertension&lt;/a&gt; controlled&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Open Adrenalectomy&lt;ol&gt;&lt;li&gt;Adrenal tumor size over 7 cm&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Intra-Operative Management&lt;ol&gt;&lt;li&gt;Continuous Arterial-line &lt;a href="../../CV/Exam/BldPrsr.htm" class="LinkPage"&gt;Blood Pressure&lt;/a&gt; Monitoring&lt;/li&gt;&lt;li&gt;Treat &lt;a href="../../CV/Exam/Hyptnsn.htm" class="LinkPage"&gt;Hypotension&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Fluid management&lt;/li&gt;&lt;li&gt;Consider pressor support&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Treat &lt;a href="../../CV/Htn/Hyprtnsn.htm" class="LinkPage"&gt;Hypertension&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Phentolamine&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Pharm/Ntrprsd.htm" class="LinkPage"&gt;Nitroprusside&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Treat &lt;a href="../../CV/EKG/Tchycrd.htm" class="LinkPage"&gt;Tachycardia&lt;/a&gt; or ectopy&lt;ol&gt;&lt;li&gt;&lt;a href="../../CV/Pharm/BtBlckr.htm" class="LinkPage"&gt;Beta Blocker&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Adjunctive treatment for malignant Pheochromocytoma&lt;ol&gt;&lt;li&gt;&lt;a href="../../HemeOnc/Pharm/Chmthrpy.htm" class="LinkPage"&gt;Chemotherapy&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Cyclophosphamide&lt;/li&gt;&lt;li&gt;Dacarbazine&lt;/li&gt;&lt;li&gt;Vincristine&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;MIGB (metaiodobenzyl-guanidine &lt;a href="../../Endo/Pharm/Rdn.htm" class="LinkPage"&gt;I-131&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;Metyrosine 1 gram every 6 hours&lt;ol&gt;&lt;li&gt;Depletes tumor &lt;a href="../../Neuro/Pharm/AdrnrgcRcptr.htm" class="LinkPage"&gt;Catecholamine&lt;/a&gt; stores&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Course&lt;ol&gt;&lt;li&gt;Persistent &lt;a href="../../CV/Htn/Hyprtnsn.htm" class="LinkPage"&gt;Hypertension&lt;/a&gt; in 25% of treated patients&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Monitoring&lt;ol&gt;&lt;li&gt;Screen &lt;a href="../../Endo/Lab/UrnMtnphrn.htm" class="LinkPage"&gt;Urine Metanephrine&lt;/a&gt;s annually&lt;/li&gt;&lt;li&gt;Screen Urine &lt;a href="../../Neuro/Pharm/AdrnrgcRcptr.htm" class="LinkPage"&gt;Catecholamine&lt;/a&gt;s annually&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;Bailey (2001) CMEA Medicine Lecture, San Diego&lt;/li&gt;&lt;li&gt;(Feb 2001) Ann Intern Med&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0031511</value><value>C0221154</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Adrenal/Phchrmcytm.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Pheochromocytoma, Paroxysmal Hypertension</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Adrenal/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees></FP_UMLS_Trees><FP_Condition_name_check></FP_Condition_name_check><FP_Condition_name><value>Skin Conditions in Diabetes Mellitus</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Dermatology</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Skin conditions associated with &lt;a href="../../Endo/DM/DbtsMlts.htm" class="LinkPage"&gt;Diabetes Mellitus&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Derm/AcnthsNgrcns.htm" class="LinkPage"&gt;Acanthosis Nigricans&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Derm/NcrbsLpdc.htm" class="LinkPage"&gt;Necrobiosis Lipoidica diabeticorum&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Derm/DbtcDrmpthy.htm" class="LinkPage"&gt;Diabetic Dermopathy&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Derm/GrnlmAnlr.htm" class="LinkPage"&gt;Granuloma Annulare&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Xanthoma diabeticorum&lt;ol&gt;&lt;li&gt;Xanthomas suggest &lt;a href="../../CV/Lipid/Hyprchlstrlm.htm" class="LinkPage"&gt;Hyperlipidemia&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Bullosis Diabeticorum (rare)&lt;ol&gt;&lt;li&gt;&lt;a href="../../Derm/Exam/Blstr.htm" class="LinkPage"&gt;Bulla&lt;/a&gt;e on extremities (especially feet)&lt;/li&gt;&lt;li&gt;Usually heel without scarring&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Diabetic Ulcer&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Derm/SknCndtnsInDbtsMlts.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Skin Conditions in Diabetes Mellitus, Diabetic Skin Disorders</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Derm/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees></FP_UMLS_Trees><FP_Condition_name_check></FP_Condition_name_check><FP_Condition_name><value>Gastrointestinal Manifestations of Diabetes Mellitus</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Gastroenterology</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Associated Conditions: Esophagus, &lt;a href="../../GI/Anatomy/StmchAntmy.htm" class="LinkPage"&gt;Stomach&lt;/a&gt; and &lt;a href="../../GI/Anatomy/BwlAntmy.htm" class="LinkPage"&gt;Bowel&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Esophageal Reflux&lt;/li&gt;&lt;li&gt;&lt;a href="../../GI/Stomach/Gstrprs.htm" class="LinkPage"&gt;Gastroparesis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/GI/DbtsRltdIntstnlEntrpthy.htm" class="LinkPage"&gt;Diabetes Related Intestinal Enteropathy&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Associated Conditions: &lt;a href="../../GI/Anatomy/LvrAntmy.htm" class="LinkPage"&gt;Liver&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../GI/Lvr/NnlchlcFtyLvr.htm" class="LinkPage"&gt;Nonalcoholic Fatty Liver&lt;/a&gt; Disease&lt;/li&gt;&lt;li&gt;&lt;a href="../../GI/Lvr/HptsC.htm" class="LinkPage"&gt;Hepatitis C&lt;/a&gt; (higher rate of comorbidity)&lt;/li&gt;&lt;li&gt;&lt;a href="../../GI/HemeOnc/Hmchrmts.htm" class="LinkPage"&gt;Hemochromatosis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../GI/Lvr/Crhs.htm" class="LinkPage"&gt;Cirrhosis&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Prevention&lt;ol&gt;&lt;li&gt;Optimize &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; control&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/GI/GstrntstnlMnfstnsOfDbtsMlts.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Gastrointestinal Manifestations of Diabetes Mellitus, Diabetes Related Gastrointestinal Conditions</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/GI/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees></FP_UMLS_Trees><FP_Condition_name_check></FP_Condition_name_check><FP_Condition_name><value>Thyroid Carcinoma</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Hematology and Oncology</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;See Also&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/HemeOnc/ThyrdAdnm.htm" class="LinkPage"&gt;Thyroid Nodule&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Epidemiology&lt;ol&gt;&lt;li&gt;&lt;a href="../../Prevent/Epi/DsIncdncRt.htm" class="LinkPage"&gt;Incidence&lt;/a&gt; of Thyroid Carcinoma US: 20,000/year&lt;/li&gt;&lt;li&gt;&lt;a href="../../Prevent/Epi/DsIncdncRt.htm" class="LinkPage"&gt;Incidence&lt;/a&gt; by &lt;a href="../../Derm/Exam/Ndl1.htm" class="LinkPage"&gt;Nodule&lt;/a&gt; type&lt;ol&gt;&lt;li&gt;Single &lt;a href="../../Derm/Exam/Ndl1.htm" class="LinkPage"&gt;Nodule&lt;/a&gt;s: 5-10% are carcinoma&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/MltndlrGtr.htm" class="LinkPage"&gt;Multinodular Goiter&lt;/a&gt;: &amp;lt;5% are carcinoma&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Types of Thyroid Carcinoma&lt;ol&gt;&lt;li&gt;Papillary carcinoma (up to 80%)&lt;ol&gt;&lt;li&gt;Insidious growth&lt;/li&gt;&lt;li&gt;May go undiagnosed until metastases&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Follicular Carcinoma (10-25%)&lt;ol&gt;&lt;li&gt;Female &amp;gt; Male&lt;/li&gt;&lt;li&gt;Peaks at age 50-60 years&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Neuro/Anatomy/MdlOblngt.htm" class="LinkPage"&gt;Medulla&lt;/a&gt;ry Carcinoma (5-10%)&lt;ol&gt;&lt;li&gt;Secretes multiple substances including &lt;a href="../../Rheum/Pharm/Clctn.htm" class="LinkPage"&gt;Calcitonin&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Associated with Multiple Endocrine Neoplasia&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Parathyroid/MltplEndcrnNplsTyp1.htm" class="LinkPage"&gt;MEN II&lt;/a&gt;a (&lt;a href="../../Endo/Parathyroid/MltplEndcrnNplsTyp1.htm" class="LinkPage"&gt;Sipple's Syndrome&lt;/a&gt;)&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Adrenal/Phchrmcytm.htm" class="LinkPage"&gt;Pheochromocytoma&lt;/a&gt; and &lt;a href="../../Endo/Anatomy/PrthyrdAntmy.htm" class="LinkPage"&gt;Parathyroid&lt;/a&gt; hyperplasia&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Parathyroid/MltplEndcrnNplsTyp1.htm" class="LinkPage"&gt;MEN II&lt;/a&gt;b&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Adrenal/Phchrmcytm.htm" class="LinkPage"&gt;Pheochromocytoma&lt;/a&gt; and mucosal neuroma&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Undifferentiated Carcinoma (5-10%)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Anatomy/ThyrdAntmy.htm" class="LinkPage"&gt;Thyroid&lt;/a&gt;&lt;a href="../../HemeOnc/Lymph/Lymphm.htm" class="LinkPage"&gt;Lymphoma&lt;/a&gt; (5%)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Risk Factors and Red Flags&lt;ol&gt;&lt;li&gt;Male gender (especially under age 40 years)&lt;/li&gt;&lt;li&gt;Age extremes (under age 20 and over age 65)&lt;/li&gt;&lt;li&gt;Rapid painless growth of &lt;a href="../../Endo/HemeOnc/ThyrdAdnm.htm" class="LinkPage"&gt;Thyroid Nodule&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Local symptoms consistent with invasion&lt;ol&gt;&lt;li&gt;&lt;a href="../../Neuro/Exam/Dysphg.htm" class="LinkPage"&gt;Dysphagia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Ortho/Sx/ChrncNckPn.htm" class="LinkPage"&gt;Neck Pain&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../ENT/Sx/Hrsns.htm" class="LinkPage"&gt;Hoarseness&lt;/a&gt; or raspy voice&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Head and neck radiation history&lt;/li&gt;&lt;li&gt;&lt;a href="../../Prevent/HME/FmlyHstry.htm" class="LinkPage"&gt;Family History&lt;/a&gt; of &lt;a href="../../Endo/Anatomy/ThyrdAntmy.htm" class="LinkPage"&gt;Thyroid&lt;/a&gt; malignancy&lt;ol&gt;&lt;li&gt;Thyroid Cancer&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Anatomy/ThyrdAntmy.htm" class="LinkPage"&gt;Thyroid&lt;/a&gt; polyposis (Gardner's Syndrome)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Anatomy/ThyrdAntmy.htm" class="LinkPage"&gt;Thyroid&lt;/a&gt; fixation to skin or trachea&lt;/li&gt;&lt;li&gt;Hard &lt;a href="../../Derm/Exam/Ndl1.htm" class="LinkPage"&gt;Nodule&lt;/a&gt; on palpation&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Evaluation&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Endo/HemeOnc/ThyrdAdnm.htm" class="LinkPage"&gt;Thyroid Nodule&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Prognosis&lt;ol&gt;&lt;li&gt;Papillary carcinoma&lt;ol&gt;&lt;li&gt;Best prognosis of Thyroid Cancer&lt;/li&gt;&lt;li&gt;Ten year survival: 70-80%&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Follicular Carcinoma&lt;ol&gt;&lt;li&gt;Five year survival: 30%&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Neuro/Anatomy/MdlOblngt.htm" class="LinkPage"&gt;Medulla&lt;/a&gt;ry Carcinoma&lt;ol&gt;&lt;li&gt;Variable prognosis&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/HemeOnc/ThyrdCrcnm.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Thyroid Carcinoma, Thyroid Cancer</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/HemeOnc/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees></FP_UMLS_Trees><FP_Condition_name_check></FP_Condition_name_check><FP_Condition_name><value>Obesity Resources</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Obesity</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;General Resources&lt;ol&gt;&lt;li&gt;Shape Up America&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.shapeup.org" class="LinkWebExt"&gt;http://www.shapeup.org&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Weight Control Information Network (WIN)&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.niddk.nih.gov/health/nutrit/nutrit.htm" class="LinkWebExt"&gt;http://www.niddk.nih.gov/health/nutrit/nutrit.htm&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Phone: 877-946-4627&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;The North American Association for the study of &lt;a href="../../Endo/Obesity/Obsty.htm" class="LinkPage"&gt;Obesity&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.naaso.org" class="LinkWebExt"&gt;http://www.naaso.org&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Weight Loss Groups&lt;ol&gt;&lt;li&gt;Weight Watchers&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.weightwatchers.com" class="LinkWebExt"&gt;http://www.weightwatchers.com&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;TOPS (Take Off Pounds Sensibly)&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.tops.org" class="LinkWebExt"&gt;http://www.tops.org&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Advocacy, Support and Lobby Groups&lt;ol&gt;&lt;li&gt;National Association to Advance Fat Acceptance&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.naafa.org" class="LinkWebExt"&gt;http://www.naafa.org&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Phone: 916-558-6880&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Council on Size and Weight Discrimination&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.cswd.org" class="LinkWebExt"&gt;http://www.cswd.org&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Phone: 845-679-1209&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;American &lt;a href="../../Endo/Obesity/Obsty.htm" class="LinkPage"&gt;Obesity&lt;/a&gt; Association&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.obesity.org" class="LinkWebExt"&gt;http://www.obesity.org&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Phone: 800-98-OBESE&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Medical Supplies for Obese Patients&lt;ol&gt;&lt;li&gt;Amplestuff: Make your world fit you&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.amplestuff.com" class="LinkWebExt"&gt;http://www.amplestuff.com&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Phone: 845-679-3316&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Size Wise&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.sizewise.com" class="LinkWebExt"&gt;http://www.sizewise.com&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Phone: 800-238-0658&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Obesity/ObstyRsrcs.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Obesity Resources</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Obesity/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Postpartum Thyroiditis  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0271815"&gt;&lt;i&gt;C0271815&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;Transient autoimmune thyroiditis occurring in the POSTPARTUM PERIOD. It is characterized by the presence of high titers of AUTOANTIBODIES against THYROID PEROXIDASE and THYROGLOBULIN. Clinical signs include the triphasic thyroid hormone pattern: beginning with THYROTOXICOSIS, followed with HYPOTHYROIDISM, then return to euthyroid state by 1 year postpartum.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Disease or Syndrome (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0271815&amp;amp;tui=T047"&gt;&lt;i&gt;T047&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D050032&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD10&lt;/td&gt;
                &lt;td&gt;O90.5&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;199241008, 52772002&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Postpartumtyreoidit&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;thyreoiditis poporodní, tyreoiditida poporodní&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;Postpartum thyroiditis, tiroiditis posparto, tiroiditis postparto (trastorno), tiroiditis postparto, Tiroiditis Posparto&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Synnytyksenjälkeinen kilpirauhastulehdus&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;TIREOIDIT POSLERODOVOI, ТИРЕОИДИТ ПОСЛЕРОДОВОЙ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;postpartum thyroiditis (diagnosis), postpartum thyroiditis, Postpartum Thyroiditis [Disease/Finding], thyroiditis postpartum, Postpartum thyroiditis, Postpartum thyroiditis (disorder), postpartum; thyroiditis, thyroiditis; postpartum, Post partum Thyroiditis, Post-partum Thyroiditides, Post-partum Thyroiditis, Postpartum Thyroiditides, Postpartum Thyroiditis, Thyroiditides, Post-partum, Thyroiditides, Postpartum, Thyroiditis, Post-partum, Thyroiditis, Postpartum&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;出産後自己免疫性甲状腺症候群, 甲状腺炎-出産後, 分娩後一過性甲状腺中毒症, 甲状腺炎-分娩後, 分娩後甲状腺炎, 出産後甲状腺炎&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Korean&lt;/td&gt;
                &lt;td&gt;분만후 갑상샘염&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Thyroïdite du post-partum, Thyroïdite du postpartum&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Tireoidite Pós-Parto&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Zapalenie tarczycy poporodowe&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;post partum; thyroïditis, thyroïditis; post partum, Thyroïditis post partum&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Postpartale Thyreoiditis, Thyreoiditis, postpartale&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Tiroidite postpartum&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Postpartum Thyroiditis  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Postpartum Thyroiditis</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Obstetrics</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;See also&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/Hypthyrdsm.htm" class="LinkPage"&gt;Hypothyroidism&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/Hyprthyrdsm1.htm" class="LinkPage"&gt;Hyperthyroidism&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/HshmtsThyrdts.htm" class="LinkPage"&gt;Hashimoto's Thyroiditis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/Thyrdts.htm" class="LinkPage"&gt;Painless Thyroiditis&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Definition&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/Thyrdts.htm" class="LinkPage"&gt;Painless Thyroiditis&lt;/a&gt; following pregnancy&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Epidemiology&lt;ol&gt;&lt;li&gt;Occurs in 5-10% of postpartum patients&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Pathophysiology&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/Thyrdts.htm" class="LinkPage"&gt;Painless Thyroiditis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Similar pathophysiology to &lt;a href="../../Endo/Thyroid/HshmtsThyrdts.htm" class="LinkPage"&gt;Hashimoto's Thyroiditis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Associated with HLA-DRB, HLA-DR4 and HLA-DR5&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Risk Factors&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/AnthyrdAntbdy.htm" class="LinkPage"&gt;Antithyroid Peroxidase Antibody&lt;/a&gt; positive (25% risk)&lt;ol&gt;&lt;li&gt;Associated with &lt;a href="../../Endo/Thyroid/Thyrdts.htm" class="LinkPage"&gt;Thyroiditis&lt;/a&gt; risk, even if euthyroid&lt;/li&gt;&lt;li&gt;Predicts recurrent &lt;a href="../../Endo/Thyroid/Thyrdts.htm" class="LinkPage"&gt;Thyroiditis&lt;/a&gt; in future pregnancies&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/DM/TypDbtsMlts.htm" class="LinkPage"&gt;Type I Diabetes Mellitus&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Psych/OB/PstprtmMjrDprsn.htm" class="LinkPage"&gt;Postpartum Depression&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Prevent/HME/FmlyHstry.htm" class="LinkPage"&gt;Family History&lt;/a&gt; of autoimmune &lt;a href="../../Endo/Thyroid/Thyrdts.htm" class="LinkPage"&gt;Thyroiditis&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Types: Postpartum Thyroiditis&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/Hypthyrdsm.htm" class="LinkPage"&gt;Hypothyroidism&lt;/a&gt; (40%)&lt;ol&gt;&lt;li&gt;Occurs within one year of delivery (mean: 6 months)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/Hyprthyrdsm1.htm" class="LinkPage"&gt;Hyperthyroidism&lt;/a&gt; (30%)&lt;ol&gt;&lt;li&gt;Occurs within 10 months of delivery (mean: 3 months)&lt;/li&gt;&lt;li&gt;Resolves spontaneously within 2-3 months of onset&lt;/li&gt;&lt;li&gt;Asymptomatic in one third of patients&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Initial &lt;a href="../../Endo/Thyroid/Hyprthyrdsm1.htm" class="LinkPage"&gt;Hyperthyroidism&lt;/a&gt;, then &lt;a href="../../Endo/Thyroid/Hypthyrdsm.htm" class="LinkPage"&gt;Hypothyroidism&lt;/a&gt; (25%)&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/Hyprthyrdsm1.htm" class="LinkPage"&gt;Hyperthyroidism&lt;/a&gt; phase: 2-4 months postpartum&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/Hypthyrdsm.htm" class="LinkPage"&gt;Hypothyroidism&lt;/a&gt; phase: 4-8 months postpartum&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Complications: Persistent &lt;a href="../../Endo/Thyroid/Hypthyrdsm.htm" class="LinkPage"&gt;Hypothyroidism&lt;/a&gt; (30-50%)&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/Hypthyrdsm.htm" class="LinkPage"&gt;Hypothyroidism&lt;/a&gt; persists or recurs within 9 years&lt;/li&gt;&lt;li&gt;Risk factors for longterm hypothyrodism&lt;ol&gt;&lt;li&gt;Initial &lt;a href="../../Endo/Thyroid/Hypthyrdsm.htm" class="LinkPage"&gt;Hypothyroidism&lt;/a&gt; at onset of thyoriditis&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/AnthyrdAntbdy.htm" class="LinkPage"&gt;Antithyroid Microsomal Antibody&lt;/a&gt; at high titer&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Anatomy/ThyrdAntmy.htm" class="LinkPage"&gt;Thyroid&lt;/a&gt;&lt;a href="../../Rad/Ultrasound/Ultrsnd.htm" class="LinkPage"&gt;Ultrasound&lt;/a&gt; with hypoechogenic pattern&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Differential Diagnosis&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Endo/Thyroid/Thyrdts.htm" class="LinkPage"&gt;Painless Thyroiditis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/HshmtsThyrdts.htm" class="LinkPage"&gt;Hashimoto's Thyroiditis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/GrvsDs.htm" class="LinkPage"&gt;Grave's Disease&lt;/a&gt; (very important to differentiate)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Labs&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/AnthyrdAntbdy.htm" class="LinkPage"&gt;Antithyroid Peroxidase Antibody&lt;/a&gt; positive (80%)&lt;ol&gt;&lt;li&gt;Similar to &lt;a href="../../Endo/Thyroid/HshmtsThyrdts.htm" class="LinkPage"&gt;Hashimoto's Thyroiditis&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../HemeOnc/Lab/ErythrcytSdmntnRt.htm" class="LinkPage"&gt;Erythrocyte Sedimentation Rate&lt;/a&gt; (ESR) normal&lt;ol&gt;&lt;li&gt;Contrast to &lt;a href="../../Endo/Thyroid/HshmtsThyrdts.htm" class="LinkPage"&gt;Hashimoto's Thyroiditis&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Anatomy/ThyrdAntmy.htm" class="LinkPage"&gt;Thyroid&lt;/a&gt; stimulating &lt;a href="../../ID/Exam/Imnglbln.htm" class="LinkPage"&gt;Antibody&lt;/a&gt; negative&lt;ol&gt;&lt;li&gt;Contrast with &lt;a href="../../Endo/Thyroid/GrvsDs.htm" class="LinkPage"&gt;Grave's Disease&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Imaging&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Rad/RdctvIdnUptkScn.htm" class="LinkPage"&gt;Radioiodine Uptake&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Suppressed uptake (Contrast with &lt;a href="../../Endo/Thyroid/GrvsDs.htm" class="LinkPage"&gt;Grave's Disease&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;Do not perform if &lt;a href="../../OB/Lactation/BrstFdng.htm" class="LinkPage"&gt;Breast Feeding&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Anatomy/ThyrdAntmy.htm" class="LinkPage"&gt;Thyroid&lt;/a&gt;&lt;a href="../../Rad/Ultrasound/Ultrsnd.htm" class="LinkPage"&gt;Ultrasound&lt;/a&gt; with doppler&lt;ol&gt;&lt;li&gt;No increased blood flow (Contrast with Grave's)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Management&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/Hyprthyrdsm1.htm" class="LinkPage"&gt;Hyperthyroidism&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../CV/Pharm/BtBlckr.htm" class="LinkPage"&gt;Beta Blocker&lt;/a&gt;s if symptomatic (caution in &lt;a href="../../OB/Lactation/BrstFdng.htm" class="LinkPage"&gt;Lactation&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;No effect with &lt;a href="../../Endo/Pharm/AnthyrdDrg.htm" class="LinkPage"&gt;Propylthiouracil&lt;/a&gt; or &lt;a href="../../Endo/Pharm/AnthyrdDrg.htm" class="LinkPage"&gt;Methimazole&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Follow TSH and T4 Free&lt;ol&gt;&lt;li&gt;Anticipate resolution within 2-3 months&lt;/li&gt;&lt;li&gt;May be followed by &lt;a href="../../Endo/Thyroid/Hypthyrdsm.htm" class="LinkPage"&gt;Hypothyroidism&lt;/a&gt; (see types above)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/Hypthyrdsm.htm" class="LinkPage"&gt;Hypothyroidism&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/ThyrdHrmnRplcmnt.htm" class="LinkPage"&gt;Levothyroxine&lt;/a&gt; for symptomatic &lt;a href="../../Endo/Thyroid/Hypthyrdsm.htm" class="LinkPage"&gt;Hypothyroidism&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Follow TSH&lt;ol&gt;&lt;li&gt;Anticipate &lt;a href="../../Endo/Anatomy/ThyrdAntmy.htm" class="LinkPage"&gt;Thyroid&lt;/a&gt; normalizing by 6-9 months in 80%&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Prevention&lt;ol&gt;&lt;li&gt;Screen pregnant women with risk factors (see above)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Bindra%20%20%5BAU%5D%20AND%202006%20%5BDP%5D%20AND%20%20Am%20Fam%20Physician%20%20%5BTA%5D" class="LinkRef"&gt;Bindra (2006) Am Fam Physician 73(10):1769-76&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Stagnaro-Green%20%20%5BAU%5D%20AND%202002%20%5BDP%5D%20AND%20%20J%20Clin%20Endocrinol%20Metab%20%20%5BTA%5D" class="LinkRef"&gt;Stagnaro-Green (2002) J Clin Endocrinol Metab 87:4042-7&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0271815</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/OB/PstprtmThyrdts.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Postpartum Thyroiditis</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/OB/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Tanner Scale  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C2826146"&gt;&lt;i&gt;C2826146&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A scale of physical development in children, adolescents and adults based on external primary and secondary sex characteristics, such as the size of the breasts, genitalia, and development of pubic hair. (Tanner JM. Growth at adolescence. 2d ed. Oxford: Blackwell, 1962)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Intellectual Product (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C2826146&amp;amp;tui=T170"&gt;&lt;i&gt;T170&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Tanner Scale, Tanner Stages&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Adrenarche  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0686792"&gt;&lt;i&gt;C0686792&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;A stage of development at which the ADRENAL GLANDS undergo maturation leading to the capability of producing increasing amounts of adrenal androgens, DEHYDROEPIANDROSTERONE and ANDROSTENEDIONE. Adrenarche usually begins at about 7 or 8 years of age before the signs of PUBERTY and continues throughout puberty.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Biologically Active Substance (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0686792&amp;amp;tui=T123"&gt;&lt;i&gt;T123&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D050499&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;103020000&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;adrenarche&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Adrenarke&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;ADRENARKHE, АДРЕНАРХЕ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Adrenarke&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;adrenarche, Adrenarche (finding), Adrenarche&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Adrenarche&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;adrenarca (hallazgo), adrenarca, Adrenarquia&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Adrenarca&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Adrenarche&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Adrenarca&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Adrénarche, Puberté surrénalienne&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Endocrine disorder related to puberty  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0271522"&gt;&lt;i&gt;C0271522&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Disease or Syndrome (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0271522&amp;amp;tui=T047"&gt;&lt;i&gt;T047&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;4900002&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Endocrine disorder related to puberty, NOS, Endocrine disorder related to puberty (disorder), Endocrine disorder related to puberty&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;enfermedad endocrina relacionada con la pubertad (trastorno), enfermedad endocrina relacionada con la pubertad&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Tanner Scale  (</value><value>)
</value><value>Adrenarche  (</value><value>)
</value><value>Endocrine disorder related to puberty  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Sexual Development</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Examination</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Definitions&lt;ol&gt;&lt;li&gt;Adrenarche: Increased adrenal androgen secretion&lt;ol&gt;&lt;li&gt;Occurs between ages 6 to 8 years&lt;/li&gt;&lt;li&gt;Transient growth spurt&lt;/li&gt;&lt;li&gt;Some children develop axillary and pubic &lt;a href="../../Derm/Anatomy/Hr.htm" class="LinkPage"&gt;Hair Growth&lt;/a&gt;&lt;/li&gt;&lt;li&gt;No Sexual Development occurs&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Gonadarche: GnRH released&lt;ol&gt;&lt;li&gt;Boys&lt;ol&gt;&lt;li&gt;LH stimulates Testosterone production&lt;/li&gt;&lt;li&gt;FSH stimulates sperm maturation&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Girls&lt;ol&gt;&lt;li&gt;FSH stimulates &lt;a href="../../Gyn/Pharm/Estrgn.htm" class="LinkPage"&gt;Estrogen&lt;/a&gt; and follicle formation&lt;/li&gt;&lt;li&gt;LH stimulates corpus luteum after &lt;a href="../../Gyn/Exam/Ovltn.htm" class="LinkPage"&gt;Ovulation&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Exam: Normal Development&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Exam/MlTnrStg.htm" class="LinkPage"&gt;Male Tanner Stage&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Exam/FmlTnrStg.htm" class="LinkPage"&gt;Female Tanner Stage&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Exam: Abnormal Development&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Sex/PrcsPbrty.htm" class="LinkPage"&gt;Precocious Puberty&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Sex/PbrtlDly.htm" class="LinkPage"&gt;Delayed Puberty&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C2826146</value><value>C0686792</value><value>C0271522</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Exam/SxlDvlpmnt.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Sexual Development, Puberty, Pubertal Milestone, Adrenarche, Gonadarche, Tanner Staging, Tanner Scale</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Exam/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Multiple Endocrine Neoplasia Type 2a  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0025268"&gt;&lt;i&gt;C0025268&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;Multiple endocrine neoplasia caused by mutation of the RET gene. Patients develop medullary thyroid carcinomas, and may also develop pheochromocytomas and parathyroid gland hyperplasia.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;A form of multiple endocrine neoplasia characterized by the presence of medullary carcinoma (CARCINOMA, MEDULLARY) of the THYROID GLAND, and usually with the co-occurrence of PHEOCHROMOCYTOMA, producing CALCITONIN and ADRENALINE, respectively. Less frequently, it can occur with hyperplasia or adenoma of the PARATHYROID GLANDS. This disease is due to gain-of-function mutations of the MEN2 gene on CHROMOSOME 10 (Locus: 10q11.2), also known as the RET proto-oncogene that encodes a RECEPTOR PROTEIN-TYROSINE KINASE. It is an autosomal dominant inherited disease.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Neoplastic Process (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0025268&amp;amp;tui=T191"&gt;&lt;i&gt;T191&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D018813&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD9&lt;/td&gt;
                &lt;td&gt;258.02&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD10&lt;/td&gt;
                &lt;td&gt;E31.22&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;61808009&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Multiple endocrine adenomatosis, type IIa, MEA syndrome, type IIa, MEA II, MEN II, Sipple Syndrome, MEA 2a, MEA IIa, MEN 2, MEN 2a, MEN IIa, MEN2a, MULTIPLE ENDOCRINE NEOPLASIA TYPE II, Multiple Endocrine Neoplasia Type 2a, Multiple Endocrine Neoplasms Type 2a, Neoplasia, Multiple Endocrine Type 2a, Neoplasms, Multiple Endocrine Type 2a, MEN syndrome type 2A, Multiple endoc neoplas type 2A, MULTIPLE ENDOCRINE NEOPLASIA, TYPE IIA, MEN2A, PHEOCHROMOCYTOMA AND AMYLOID-PRODUCING MEDULLARY THYROID CARCINOMA, SIPPLE SYNDROME, PTC SYNDROME, MULTIPLE ENDOCRINE NEOPL TYPE 2A, MEN 002 A, NEOPLASIA MULTIPLE ENDOCRINE TYPE 002 A, NEOPLASMS MULTIPLE ENDOCRINE TYPE 002 A, MEN 002, NEOPL MULTIPLE ENDOCRINE TYPE 2A, type II multiple endocrine neoplasia, multiple endocrine neoplasia, type 2 (diagnosis), multiple endocrine neoplasia, type 2, type II multiple endocrine neoplasia (diagnosis), type IIa multiple endocrine neoplasia (diagnosis), type IIa multiple endocrine neoplasia, Multiple Endocrine Neoplasia Type 2A, MEN 2A, Multiple Endocrine Neoplasia, Type II, Multiple endocrine adenomatosis Type II, Multiple endocrine neoplasia Type II, MEN Type II, MEA Type II, Mult endo neop type IIA, Multiple endocrine neoplasia [MEN] type IIA, Multiple Endocrine Neoplasia Type 2a [Disease/Finding], MEN 2A Syndrome, MEN-2A Syndromes, MEN-2A Syndrome, sipple syndrome, multiple endocrine neoplasia type 2A (MEN 2A), men type 2, men type ii, sipple's syndrome, Multiple endocrine adenomatosis Type IIa, Sipple's syndrome, Familial chromaffinomatosis, MEA, type 2, MEN, type 2, Multiple endocrine adenomatosis, type 2, Multiple endocrine neoplasia, type 2, PTC syndrome, Sipple syndrome, MEN 2A - Multiple endocrine neoplasia syndrome type 2A, MEN 2A syndrome, Multiple endocrine neoplasia syndrome type 2A, Multiple endocrine neoplasia, type 2 (disorder), MEA Type 2a, MEN Type 2a, Multiple Endocrine Adenomatosis Type 2A, Multiple Endocrine Adenomatosis Type 2a, Multiple Endocrine Adenomatosis Type II, Multiple Endocrine Adenomatosis, Type II, Multiple Endocrine Neoplasia Type II, Multiple Endocrine Neoplasia Type 2&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Adenomatosi endocrina multipla tipo II, Neoplasia endocrina multipla tipo II, Adenomatosi endocrina multipla tipo IIa, Neoplasia endocrina multipla tipo 2&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;MEN type II, multipele endocriene neoplasie type II, multipele endocriene adenomatosis type IIa, MEA type II, multipele endocriene adenomatosis type II, MEN 2, MEN 2a, Multipele-endocriene-neoplasiesyndroom type 2a, Neoplasie type 2a, multipele endocriene, Neoplasmata type 2a, multipele endocriene, Sipple-syndroom, Syndroom type 2a, Multipele-endocriene-neoplasie-&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Polyadénomatose endocrinienne type IIa, AEM de type II, MEN (adénomatose polyendocrinienne) de type II, Adénomatose polyendocrinienne de type II, Apudomatose de type IIa, Adénomatose endocrine multiple type II, Syndrome de Sipple, Néoplasie endocrinienne multiple de type 2a, Polyadénomatose endocrinienne de type 2A, Adénomatose endocrinienne multiple de type 2a, NEM 2a, NEM IIa, NEM2a&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;MEA Typ II, multiple endokrine Neoplasie Typ II, multiple endokrine Adenomatose Typ IIa, MEN Typ II, MEN 002, MEN 002 A, TUMOREN MULTIPLE ENDOKRINE TYP 002 A, NEOPLASIE MULTIPLE ENDOKRINE TYP 002 A, multiple endokrine Adenomatose Typ II, MEN 2a, MEN 2, Multiple endokrine Neoplasie Typ 2a, Neoplasie, multiple endokrine, Typ 2a, Sipple-Syndrom, Tumoren, multiple endokrine, Typ 2a&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Adenomatose endócrina múltipla tipo IIa, Neoplasia endócrina múltipla tipo II, Adenomatose endócrina múltipla tipo II, MEN 2, MEN 2a, Neoplasia Endócrina Múltipla Tipo 2a, Síndrome de Sipple, Neoplasias Endócrinas Múltiplas Tipo 2a&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;Adenomatosis endocrina múltiple tipo IIa, NEM de tipo II, AEM de tipo II, Neoplasia endocrina múltiple de tipo II, NEM, tipo 2, adenomatosis endocrina múltiple, tipo 2, cromafinomatosis familiar, neoplasia endocrina múltiple, tipo 2 (trastorno), neoplasia endocrina múltiple, tipo 2, síndrome de PTC, síndrome de Sipple, Adenomatosis endocrina múltiple de tipo II, MEN 2, MEN 2a, Neoplasia Endocrina Múltiple Tipo 2a, Neoplasia Múltiple Endocrina Tipo 2a, Síndrome de Sipple, Neoplasia Endocrina Multiple Tipo 2a, Neoplasia Multiple Endocrina Tipo 2a, Sindrome de Sipple, Neoplasias Multiples Endocrinas Tipo 2a, Neoplasias Múltiples Endocrinas Tipo 2a&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;多発性内分泌腺腫症２型, 多発性内分泌腫症２型, 多発性内分泌腺腫症２ａ型, ﾀﾊﾂｾｲﾅｲﾌﾞﾝﾋﾟｾﾝｼｭｼｮｳ2ｶﾞﾀ, ﾀﾊﾂｾｲﾅｲﾌﾞﾝﾋﾟﾂｾﾝｼｭｼｮｳ2aｶﾞﾀ, ﾀﾊﾂｾｲﾅｲﾌﾞﾝﾋﾟﾂｼｭｼｮｳ2ｶﾞﾀ, ﾀﾊﾂｾｲﾅｲﾌﾞﾝﾋﾟﾂｾﾝｼｭｼｮｳ2ｶﾞﾀ, ﾀﾊﾂｾｲﾅｲﾌﾞﾝﾋﾟｼｭｼｮｳ2ｶﾞﾀ, ﾀﾊﾂｾｲﾅｲﾌﾞﾝﾋﾟｾﾝｼｭｼｮｳ2aｶﾞﾀ, MEN2A型, 多発性内分泌腫瘍2型, Sipple症候群, シップル症候群, 多内分泌腫瘍2A, 多内分泌腫瘍2, 多発性内分泌腫瘍2A型, 多発性内分泌腺腫症2A, 多発性内分泌腺腫症2, 腫瘍-多発性内分泌2A型&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Multipla hormonella tumörer typ 2a&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;nádory mnohočetné endokrinní typ 2a, Mnohočetná endokrinní adenomatóza Typ II, Mnohočetná endokrinní neoplazie Typ II, MEA Typ II, MEN Typ II, Mnohočetná endokrinní adenomatóza Typ IIa&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;MEN 2A -oireyhtymä&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;MEN 2A, ENDOKRINNAIA NEOPLAZIIA MNOZHESTVENNAIA TIPA 2A, SIPPLA SINDROM, MEN 2, NOVOOBRAZOVANIIA ENDOKRINNYE MNOZHESTVENNYE TIPA 2A, ENDOKRINNYKH ZHELEZ NOVOOBRAZOVANIIA TIPA 2A MNOZHESTVENNYE, NEOPLAZIIA ENDOKRINNAIA MNOZHESTVENNAIA TIPA 2A, МЭН 2A, МЭН 2, НЕОПЛАЗИЯ ЭНДОКРИННАЯ МНОЖЕСТВЕННАЯ ТИПА 2A, НОВООБРАЗОВАНИЯ ЭНДОКРИННЫЕ МНОЖЕСТВЕННЫЕ ТИПА 2A, СИППЛА СИНДРОМ, ЭНДОКРИННАЯ НЕОПЛАЗИЯ МНОЖЕСТВЕННАЯ ТИПА 2A, ЭНДОКРИННЫХ ЖЕЛЕЗ НОВООБРАЗОВАНИЯ ТИПА 2A МНОЖЕСТВЕННЫЕ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;MEN 2, MEN 2a, Gruczolakowatość wewnątrzwydzielnicza typu 2a&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;Multiplex endocrin adenomatosis II. típus, MEA típus II, Ember típus II, Többszörös endocrin neoplasia típus II, Többszörös endocrin adenomatosis típus iia&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Multiple Endocrine Neoplasia Type 2a  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Multiple Endocrine Neoplasia Type 2</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Parathyroid Disease</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Conditions&lt;ol&gt;&lt;li&gt;Familial &lt;a href="../../Endo/Parathyroid/Hyprprthyrdsm.htm" class="LinkPage"&gt;Primary Hyperparathyroidism&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Adrenal/Phchrmcytm.htm" class="LinkPage"&gt;Pheochromocytoma&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Neuro/Anatomy/MdlOblngt.htm" class="LinkPage"&gt;Medulla&lt;/a&gt;ry &lt;a href="../../Endo/HemeOnc/ThyrdCrcnm.htm" class="LinkPage"&gt;Thyroid Carcinoma&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0025268</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Parathyroid/MltplEndcrnNplsTyp1.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Multiple Endocrine Neoplasia Type 2, Multiple Endocrine Neoplasia Type II, Sipple's Syndrome, MEN II</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Parathyroid/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Obesity Adverse Event  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C1963185"&gt;&lt;i&gt;C1963185&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Finding (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C1963185&amp;amp;tui=T033"&gt;&lt;i&gt;T033&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Obesity, Obesity Adverse Event&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Obesity  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0028754"&gt;&lt;i&gt;C0028754&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;Having a high amount of body fat (body mass index [BMI] of 30 or more).&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A disorder characterized by having a high amount of body fat.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MEDLINEPLUS)&lt;/td&gt;
                &lt;td&gt;
                  &lt;span&gt;
                    &lt;p&gt;Obesity means having too much body fat. It is different from being overweight, which means weighing too much.  The weight may come from muscle, bone, fat and/or body water.  Both terms mean that a person's weight is greater than what's considered healthy for his or her height. &lt;/p&gt;
                    &lt;p&gt;Obesity occurs over time when you eat more calories than you use. The balance between calories-in and calories-out differs for each person. Factors that might tip the balance include your genetic makeup, overeating, eating high-fat foods and not being physically active. &lt;/p&gt;
                    &lt;p&gt;Being obese increases your risk of diabetes, heart disease, stroke, arthritis and some cancers. If you are obese, losing even 5 to 10 percent of your weight can delay or prevent some of these diseases.&lt;/p&gt;
                    &lt;p style="font-weight:bold;font-style:italic;"&gt;NIH: National Institute of Diabetes and Digestive and Kidney Diseases&lt;/p&gt;
                  &lt;/span&gt;
                &lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A condition marked by an abnormally high, unhealthy amount of body fat.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CSP)&lt;/td&gt;
                &lt;td&gt;excessively high accumulation of body fat or adipose tissue in relation to lean body mass; the amount of body fat (or adiposity) includes concern for both the distribution of fat throughout the body and the size of the adipose tissue deposits; individuals are usually at high clinical risk because of excess amount of body fat (BMI greater than 30).&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;A status with BODY WEIGHT that is grossly above the acceptable or desirable weight, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Disease or Syndrome (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0028754&amp;amp;tui=T047"&gt;&lt;i&gt;T047&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D009765&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD9&lt;/td&gt;
                &lt;td&gt;278.00&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD10&lt;/td&gt;
                &lt;td&gt;E66, E66.9&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;5476005, 154776002, 190963004, 414916001, 414915002&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Adiposity, Obesities, Obesity, OBESE, OBESITY, Obesity, NOS, Obesity, unspecified, obesity (diagnosis), obesity, Obesity NOS, Obesity [Disease/Finding], obese, adiposity, Obesity [Ambiguous], Obese, Obese (finding), Obesity (disorder)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;OBESITE, Obésité, non précisée, Obésité&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;OBESIDADE, Obesidade NE, Obesidade&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;OBESIDAD, Obesidad no especificada, Obesity [Ambiguous], Obesity, obesidad (trastorno), obesidad, obeso (hallazgo), obeso, Obesidad&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;obesitas niet-gespecificeerd, Vetzucht, niet gespecificeerd, zwaarlijvigheid, Adipositas, Vetzucht&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Fettleibigkeit, unspezifisch, ADIPOSITAS, Adipositas, nicht naeher bezeichnet, Adipositas, Fettsucht, Obesitas&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Obesità, non specificata, Obesità&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;肥満, 肥満、詳細不明, ﾋﾏﾝ, ﾋﾏﾝｼｮｳｻｲﾌﾒｲ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Fetma&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;obezita, Obezita, blíže neurčená, Obezita&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Lihavuus&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;OZHIRENIE, ОЖИРЕНИЕ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Korean&lt;/td&gt;
                &lt;td&gt;상세불명의 비만, 비만&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Croatian&lt;/td&gt;
                &lt;td&gt;GOJAZNOST&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Otyłość&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;Obesitas, nem meghatározott, Obesitas&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Obesity Adverse Event  (</value><value>)
</value><value>Obesity  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Obesity Risk</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Obesity</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Indications&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Obesity/ObstyEvltn.htm" class="LinkPage"&gt;Obesity Evaluation&lt;/a&gt; for Management Strategy based on&lt;ol&gt;&lt;li&gt;Comorbid conditions&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Exam/BdyMsIndx.htm" class="LinkPage"&gt;Body Mass Index&lt;/a&gt; (BMI)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Evaluation: Health Risk Stratification&lt;ol&gt;&lt;li&gt;Minimal to Low Risk&lt;ol&gt;&lt;li&gt;BMI &amp;lt;27 if no additional health risk factors&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Moderate Risk&lt;ol&gt;&lt;li&gt;BMI &amp;gt;27 (or &amp;gt;25 if other risk factors present)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;High Risk&lt;ol&gt;&lt;li&gt;BMI &amp;gt;30 (Or &amp;gt;27 if other risk factors present)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Very High Risk&lt;ol&gt;&lt;li&gt;BMI &amp;gt;35 (Or &amp;gt;30 if other risk factors present)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Extremely High Risk&lt;ol&gt;&lt;li&gt;BMI &amp;gt;40 (Or &amp;gt;35 if other risk factors present)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Evaluation: Comorbid Conditions&lt;ol&gt;&lt;li&gt;Cardiovascular Disease: Nurses' Health Study&lt;ol&gt;&lt;li&gt;Studied 115,818 nurses ages 30-55&lt;/li&gt;&lt;li&gt;Over 14 years of study, 1292 nurses developed CAD&lt;/li&gt;&lt;li&gt;Relative Risk (RR) of CAD increased with BMI&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Exam/BdyMsIndx.htm" class="LinkPage"&gt;Body Mass Index&lt;/a&gt; (BMI) &amp;lt; 21: RR = 1&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Exam/BdyMsIndx.htm" class="LinkPage"&gt;Body Mass Index&lt;/a&gt; (BMI) &amp;lt; 23: RR = 1.2&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Exam/BdyMsIndx.htm" class="LinkPage"&gt;Body Mass Index&lt;/a&gt; (BMI) &amp;lt; 25: RR = 1.48&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Exam/BdyMsIndx.htm" class="LinkPage"&gt;Body Mass Index&lt;/a&gt; (BMI) &amp;lt; 29: RR = 2.08&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Exam/BdyMsIndx.htm" class="LinkPage"&gt;Body Mass Index&lt;/a&gt; (BMI) &amp;gt; 29: RR = 3.53&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Reference&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Willett%20%20%5BAU%5D%20AND%201995%20%5BDP%5D%20AND%20%20%20%5BTA%5D" class="LinkRef"&gt;Willett (1995) 273:461-5&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Htn/Hyprtnsn.htm" class="LinkPage"&gt;Hypertension&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Systolic &lt;a href="../../CV/Exam/BldPrsr.htm" class="LinkPage"&gt;Blood Pressure&lt;/a&gt; increase 6.5mm per 10% weight&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Dyslipidemia&lt;ol&gt;&lt;li&gt;&lt;a href="../../CV/Lab/Lpd.htm" class="LinkPage"&gt;Total Cholesterol&lt;/a&gt; increases 12 mg/dl per 10% weight&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Lab/Trglycrd.htm" class="LinkPage"&gt;Triglyceride&lt;/a&gt;s increase with weight&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Lab/LdlChlstrl.htm" class="LinkPage"&gt;LDL Cholesterol&lt;/a&gt; increases with weight&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Lab/HdlChlstrl.htm" class="LinkPage"&gt;HDL Cholesterol&lt;/a&gt; falls with increasing weight&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/DM/DbtsMlts.htm" class="LinkPage"&gt;Diabetes Mellitus&lt;/a&gt; (&lt;a href="../../Endo/DM/TypDbtsMlts1.htm" class="LinkPage"&gt;Type II Diabetes&lt;/a&gt;)&lt;ol&gt;&lt;li&gt;Fasting &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Sugar&lt;/a&gt; increases 2 mg/dl per 10% weight&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Obesity/Obsty.htm" class="LinkPage"&gt;Obesity&lt;/a&gt; present in 80% of &lt;a href="../../Endo/DM/TypDbtsMlts1.htm" class="LinkPage"&gt;Type II Diabetes Mellitus&lt;/a&gt;&lt;/li&gt;&lt;li&gt;BMI &amp;gt;35 confers 8-30x risk over normal weight&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Respiratory&lt;ol&gt;&lt;li&gt;&lt;a href="../../Lung/Apnea/SlpApn.htm" class="LinkPage"&gt;Sleep Apnea&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Pickwickian Hypoventilation&lt;/li&gt;&lt;li&gt;Muscular work of breathing increased with weight&lt;/li&gt;&lt;li&gt;&lt;a href="../../Lung/Asthma/Asthm.htm" class="LinkPage"&gt;Asthma&lt;/a&gt; worse at increased weight&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Lung/PlmnryHyprtnsn.htm" class="LinkPage"&gt;Pulmonary Hypertension&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Cardiomegaly&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/CHF/CngstvHrtFlr.htm" class="LinkPage"&gt;Congestive Heart Failure&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Gastrointestinal Disease&lt;ol&gt;&lt;li&gt;&lt;a href="../../GI/Anatomy/GlBldr.htm" class="LinkPage"&gt;Gall Bladder&lt;/a&gt; Disease (&lt;a href="../../Surgery/GI/ActChlcysts.htm" class="LinkPage"&gt;Cholecystitis&lt;/a&gt;, &lt;a href="../../Surgery/GI/Glstn.htm" class="LinkPage"&gt;Cholelithiasis&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;&lt;a href="../../GI/Lvr/NnlchlcFtyLvr.htm" class="LinkPage"&gt;Nonalcoholic Steatohepatitis&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Joint Disease&lt;ol&gt;&lt;li&gt;&lt;a href="../../Rheum/OA/Ostrthrts.htm" class="LinkPage"&gt;Osteoarthritis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Rheum/OA/Ostrthrts.htm" class="LinkPage"&gt;Degenerative Joint Disease&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Rheum/joint/GtyArthrts.htm" class="LinkPage"&gt;Gouty Arthritis&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Miscellaneous Conditions&lt;ol&gt;&lt;li&gt;Menstrual irregularities&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Malignancy&lt;ol&gt;&lt;li&gt;Obese Women&lt;ol&gt;&lt;li&gt;&lt;a href="../../Gyn/HemeOnc/EndmtrlCncr.htm" class="LinkPage"&gt;Endometrial Cancer&lt;/a&gt; Relative Risk: 5&lt;/li&gt;&lt;li&gt;&lt;a href="../../Gyn/HemeOnc/BrstCncr.htm" class="LinkPage"&gt;Breast Cancer&lt;/a&gt; risk increased&lt;/li&gt;&lt;li&gt;&lt;a href="../../Gyn/HemeOnc/CrvclCncr.htm" class="LinkPage"&gt;Cervical Cancer&lt;/a&gt; risk increased&lt;/li&gt;&lt;li&gt;&lt;a href="../../Gyn/HemeOnc/OvrnCncr.htm" class="LinkPage"&gt;Ovarian Cancer&lt;/a&gt; risk increased&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Obese Men&lt;ol&gt;&lt;li&gt;&lt;a href="../../GI/HemeOnc/ClrctlCncr.htm" class="LinkPage"&gt;Colorectal Cancer&lt;/a&gt; risk increased&lt;/li&gt;&lt;li&gt;&lt;a href="../../Uro/HemeOnc/PrstCncr.htm" class="LinkPage"&gt;Prostate Cancer&lt;/a&gt; risk increased&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Evaluation: Risks for further weight gain&lt;ol&gt;&lt;li&gt;Progressive weight gain since adolescence&lt;/li&gt;&lt;li&gt;&lt;a href="../../Prevent/HME/FmlyHstry.htm" class="LinkPage"&gt;Family History&lt;/a&gt; of &lt;a href="../../Endo/Obesity/Obsty.htm" class="LinkPage"&gt;Obesity&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Psych/Eating/BlmNrvs.htm" class="LinkPage"&gt;Bulimia&lt;/a&gt; or &lt;a href="../../Psych/Eating/BngEtngDsrdr.htm" class="LinkPage"&gt;Binge Eating&lt;/a&gt; disorder&lt;/li&gt;&lt;li&gt;Depression, Anxiety or emotional Stress&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/MdctnsAsctdWthWghtGn.htm" class="LinkPage"&gt;Medications Associated with Weight Gain&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Related Medical conditions&lt;ol&gt;&lt;li&gt;Hyperinsulinemia (&lt;a href="../../Endo/DM/TypDbtsMlts1.htm" class="LinkPage"&gt;Type II Diabetes Mellitus&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Gyn/HemeOnc/BrstCncr.htm" class="LinkPage"&gt;Breast Cancer&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../GI/HemeOnc/ClrctlCncr.htm" class="LinkPage"&gt;Colon Cancer&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Gyn/HemeOnc/EndmtrlCncr.htm" class="LinkPage"&gt;Endometrial Cancer&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Gyn/Endo/Mnps.htm" class="LinkPage"&gt;Menopause&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Physical inactivity&lt;/li&gt;&lt;li&gt;&lt;a href="../../Psych/CD/TbcCstn.htm" class="LinkPage"&gt;Smoking Cessation&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Frank%20%20%5BAU%5D%20AND%201998%20%5BDP%5D%20AND%20%20J%20Am%20Diet%20Assoc%20%20%5BTA%5D" class="LinkRef"&gt;Frank (1998) J Am Diet Assoc 98:S44-48&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Hakala%20%20%5BAU%5D%20AND%202000%20%5BDP%5D%20AND%20%20Chest%20%20%5BTA%5D" class="LinkRef"&gt;Hakala (2000) Chest 118:1315-21&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Lyznicki%20%20%5BAU%5D%20AND%202001%20%5BDP%5D%20AND%20%20Am%20Fam%20Physician%20%20%5BTA%5D" class="LinkRef"&gt;Lyznicki (2001) Am Fam Physician 63(11):2185-96&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Rippe%20%20%5BAU%5D%20AND%201998%20%5BDP%5D%20AND%20%20J%20Am%20Diet%20Assoc%20%20%5BTA%5D" class="LinkRef"&gt;Rippe (1998) J Am Diet Assoc 98:S9-15&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Speer%20%20%5BAU%5D%20AND%201997%20%5BDP%5D%20AND%20%20Phys%20Sportsmed%20%20%5BTA%5D" class="LinkRef"&gt;Speer (1997) Phys Sportsmed 25:94-107&lt;/a&gt;&lt;/li&gt;&lt;li&gt;(1998) AOA Treatment Adult &lt;a href="../../Endo/Obesity/Obsty.htm" class="LinkPage"&gt;Obesity&lt;/a&gt;, 2nd edition&lt;/li&gt;&lt;li&gt;(1998) &lt;a href="../../Endo/Obesity/Obsty.htm" class="LinkPage"&gt;Obesity&lt;/a&gt; Res 6(suppl 2):51S-209S&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C1963185</value><value>C0028754</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Obesity/ObstyRsk.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Obesity Risk, Obesity Comorbid Conditions</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Obesity/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Triiodothyronine  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0041014"&gt;&lt;i&gt;C0041014&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A thyroid hormone.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;A T3 thyroid hormone normally synthesized and secreted by the thyroid gland in much smaller quantities than thyroxine (T4). Most T3 is derived from peripheral monodeiodination of T4 at the 5' position of the outer ring of the iodothyronine nucleus. The hormone finally delivered and used by the tissues is mainly T3.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CSP)&lt;/td&gt;
                &lt;td&gt;one of the thyroid hormones; an organic iodine containing compound secreted in small amounts by the thyroid gland; most circulating triiodothyroinine is produced by the deiodination of thyroxine in the peripheral tissues.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A thyroid hormone containing 3 iodine atoms generally synthesized from levothyroxine, and has greater biological activity.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A thyroid hormone. Also called triiodothyronine or liothyronine sodium.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (PDQ)&lt;/td&gt;
                &lt;td&gt;A therapeutic formulation of the primary physiologically active form of endogenous thyroid hormone. In vivo, triiodothyronine enters the nucleus and binds to nuclear thyroid hormone receptors that subsequently bind to thyroid response elements (TREs) located in target genes. Receptor binding by triiodothyronine in combination with recruited coactivators results in maximal transcriptional activation after binding to TREs; in general, binding of thyroid hormone receptor alone to TREs leads to repression of gene transcription. Check for "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=470233&amp;amp;idtype=1" active clinical trials or "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=470233&amp;amp;idtype=1&amp;amp;closed=1" closed clinical trials using this agent. ("http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;amp;code=C907" NCI Thesaurus)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A therapeutic formulation of the primary physiologically active form of endogenous thyroid hormone. In vivo, triiodothyronine enters the nucleus and binds to nuclear thyroid hormone receptors that subsequently bind to thyroid response elements (TREs) located in target genes. Receptor binding by triiodothyronine in combination with recruited coactivators results in maximal transcriptional activation after binding to TREs; in general, binding of thyroid hormone receptor alone to TREs leads to repression of gene transcription (NCI04)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Amino Acid, Peptide, or Protein (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0041014&amp;amp;tui=T116"&gt;&lt;i&gt;T116&lt;/i&gt;&lt;/a&gt;)
, Pharmacologic Substance (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0041014&amp;amp;tui=T121"&gt;&lt;i&gt;T121&lt;/i&gt;&lt;/a&gt;)
, Hormone (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0041014&amp;amp;tui=T125"&gt;&lt;i&gt;T125&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D014284&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;61275002, 350358003, 74495008, 36437009&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Liothyronine, Triiodothyronine, L-Tyrosine, O-(4-hydroxy-3-iodophenyl)-3,5-diiodo-, liothyronine, Triiodothyronine preparation, triiodothyronine, T-3, 3,3',5-triiodo-L-thyronine, T3, T&amp;lt;sub&amp;gt;3&amp;lt;/sub&amp;gt;, Triiodothyronine (T3), L-triiodothyronine preparation, T&amp;gt;3&amp;lt; preparation, T&amp;lt;sub&amp;gt;3&amp;lt;/sub&amp;gt; preparation, T3 preparation, Triiodothyronine preparation (product), therapeutic triiodothyronine, L-Triiodothyronine, T AAA THYROID HORMONE 003, Triiodothyronine [Chemical/Ingredient], t3 thyroid hormone, t3, LIOTHYRONINE, T3 Thyroid Hormone, Thyroid Hormone, T3, 3,5,3' Triiodothyronine, T3 - Liothyronine, Tri-iodothyronine product, T3 - Triiodothyronine, Total triiodothyronine, T&amp;gt;3&amp;lt;, Liothyronine (product), Triiodothyronine (substance), Liothyronine (substance), Triiodothyronine preparation (substance), Therapeutic T3&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Trijodtyronin&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;preparado con triyodotironina (producto), liotironina, preparado con T&amp;gt;3&amp;lt;, liotironina (producto), preparado de L-triyodotironina, preparado con triyodotironina, tri-iodotironina, producto (producto), tri-iodotironina, producto, preparado de T3, preparado con T3, preparado de T&amp;lt;sub&amp;gt;3&amp;lt;/sub&amp;gt;, preparado con T&amp;lt;sub&amp;gt;3&amp;lt;/sub&amp;gt;, T3, 3, 5, 3' triyodotironina, preparado de T&amp;gt;3&amp;lt;, preparado de triyodotironina (producto), preparado de triyodotironina (sustancia), preparado de triyodotironina, tri-iodotironina, producto (sustancia), triyodotironina (sustancia), triyodotironina, Triyodotironina, Hormona Tiroidea T3, Liotironina&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;hormon T3, trijodthyronin&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Trijodotyroniini&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;T3 (Hormone thyroïdienne), Tri-iodothyronine, Hormone thyroïdienne T3, Triiodothyronine, 3,5,3'-triiodothyronine, Liothyronine&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;TRIIODTIRONIN, LIOTIRONIN, ЛИОТИРОНИН, ТРИИОДТИРОНИН&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;リオチロニン, フリーT3, リオサイロニン, トリヨードチロニン, トリヨードサイロニン, L-トリヨードチロニン&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;T AAA SCHILDDRÜSENHORMON 003, Liothyronin, Triiodthyronin, T3-Schilddrüsenhormon&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Croatian&lt;/td&gt;
                &lt;td&gt;TRIJODTIRONIN&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;T3, Hormônio T3 da Tireóide, Hormônio Tireóideo T3, Liotironina, Triiodotironina&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Trójjodotyronina, T3, Trijodotyronina&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Triiodotironina&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Triiodothyronine  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Triiodothyronine</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Pathology and Laboratory Medicine</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;See Also&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Lthyrn.htm" class="LinkPage"&gt;Triiodothyronine Replacement&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/Hypthyrdsm.htm" class="LinkPage"&gt;Hypothyroidism&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/Hyprthyrdsm1.htm" class="LinkPage"&gt;Hyperthyroidism&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Normal Levels&lt;ol&gt;&lt;li&gt;Triiodothyronine (T3): 80-180 ng/dl&lt;/li&gt;&lt;li&gt;Free T3: 230-619 pg/dl&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Measurement&lt;ol&gt;&lt;li&gt;T3 radioimmunoassay measures bound and Free T3&lt;ol&gt;&lt;li&gt;Affected by TBG levels as well as other factors&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Free Triiodothyronine (Free T3) measures only active T3&lt;ol&gt;&lt;li&gt;Not affected by &lt;a href="../../Endo/Lab/ThyrxnBndngGlbln.htm" class="LinkPage"&gt;Thyroid Binding Globulin&lt;/a&gt; (TBG)&lt;/li&gt;&lt;li&gt;Represents 0.3% of total T3&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;False &lt;a href="../../Endo/Thyroid/Hypthyrdsm.htm" class="LinkPage"&gt;Hypothyroidism&lt;/a&gt; if impaired T4 to T3 conversion&lt;ol&gt;&lt;li&gt;Systemic illness&lt;/li&gt;&lt;li&gt;Fasting&lt;/li&gt;&lt;li&gt;Surgical stress&lt;/li&gt;&lt;li&gt;Drugs&lt;ol&gt;&lt;li&gt;Prednisone&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/AnthyrdDrg.htm" class="LinkPage"&gt;Propylthiouracil&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Pharm/Amdrn.htm" class="LinkPage"&gt;Amiodarone&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Radiopaque contrast&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Pharm/Prprnl.htm" class="LinkPage"&gt;Propranolol&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0041014</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Lab/Trdthyrn.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Triiodothyronine, T3, Free T3</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Lab/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Hurthle Cells  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0949667"&gt;&lt;i&gt;C0949667&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;Oxyphil cells in the thyroid gland are known as Hurthle cells and Askenazy cells.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A large, granular eosinophilic cell derived from thyroid follicular epithelium by accumulation of mitochondria&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Cell (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0949667&amp;amp;tui=T025"&gt;&lt;i&gt;T025&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D024862&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Hurthle Cell, Oxyphil cell of thyroid, Thyroid gland oxyphil cell, hurthle cells, hurthle cell, cells hurthles, Askenazy Cells, Cells, Askenazy, Cells, Hurthle, Thyroid Gland Oxyphil Cell, Thyroid Gland Oxyphilic Cell, Hurthle Cells&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Cellule de Hürthle, Cellules de Hürthle&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;Hürthleovy buňky&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Células de Hürthle&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;Celulas de Hurthle, Células de Hürthle&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Hürthle-Zellen&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;Hurthle-cellen&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Hashimoto Disease  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0677607"&gt;&lt;i&gt;C0677607&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;An inflammatory disorder that affects the thyroid gland. It is characterized by the infiltration of the thyroid parenchyma by lymphocytes. It includes Hashimoto thyroiditis and subacute lymphocytic thyroiditis.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CSP)&lt;/td&gt;
                &lt;td&gt;progressive enlargement of the thyroid gland, often associated with hypothyroidism.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;Chronic autoimmune thyroiditis, characterized by the presence of high serum thyroid AUTOANTIBODIES; GOITER; and HYPOTHYROIDISM.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Disease or Syndrome (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0677607&amp;amp;tui=T047"&gt;&lt;i&gt;T047&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D050031, C535842&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD9&lt;/td&gt;
                &lt;td&gt;245.2&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD10&lt;/td&gt;
                &lt;td&gt;E06.3&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;237537002, 237534009, 21983002, 190297000, 154667002, 267466008&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Hashimoto's struma, Struma lymphomatosum, THYROIDITIS, HASHIMOTO, HASHIMOTO DISEASE, STRUMA LYMPHOMATOSA, THYROIDITIS, CHRONIC LYMPHADENOID, THYROIDITIS, LYMPHOID, Hashimoto's Thyroiditis, Chron lymphocytic thyroiditis, THYROIDITIS CHRONIC LYMPHOCYTIC &amp;lt;HASHIMOTOS&amp;gt;, HASHIMOTO THYROIDITIS, HASHIMOTO STRUMA, lymphomatous thyroiditis, HT, HASHIMOTOS DIS, HASHIMOTO DIS, hashimoto's thyroiditis, Struma lymphomatosis (disorder), Hashimoto's thyroiditis (disorder), Hashimoto's thyroiditis (diagnosis), THYROIDITIS HASHIMOTO, THYROIDITIS CHRONIC LYMPHOCYTIC HASHIMOTOS, Chr lymphocyt thyroidit, Hashimoto's Syndrome, Hashimoto's Syndromes, Hashimotos Syndrome, Syndromes, Hashimoto's, Hashimoto Syndrome, Syndrome, Hashimoto's, Hashimoto Disease [Disease/Finding], Hashimoto's Struma, hashimoto's disease, chronic thyroiditis, Disease;Hashimotos, chronic lymphocytic thyroiditis, hashimoto disease, autoimmune thyroiditides, hashimoto thyroiditis, lymphocytic thyroiditis, autoimmune thyroiditis, hashimoto's struma, Hashimoto's thyroiditis, Lymphocytic thyroiditis, Chronic lymphocytic thyroiditis, Autoimmune lymphocytic chronic thyroiditis, Hashimoto thyroiditis, Struma lymphomatosa, Hashimoto's disease, Struma lymphomatosis, Hashimoto thyroiditis (disorder), Hashimoto; thyroiditis, Hashimoto, chronic; thyroiditis, lymphadenoid, lymphocytic; thyroiditis, lymphoid; thyroiditis, lymphomatosa; goiter, lymphomatous; thyroiditis, struma; lymphomatosa, thyroiditis; Hashimoto, thyroiditis; chronic, lymphadenoid, thyroiditis; lymphocytic, thyroiditis; lymphoid, thyroiditis; lymphomatous, Lymphocytic Thyroiditis, Disease, Hashimoto, Hashimoto's Disease, Hashimotos Disease, Disease, Hashimoto's, Chronic Lymphocytic Thyroiditis, Chronic Lymphocytic Thyroiditides, Hashimoto Thyroiditides, Hashimoto Thyroiditis, Lymphocytic Thyroiditides, Chronic, Lymphocytic Thyroiditis, Chronic, Thyroiditides, Chronic Lymphocytic, Thyroiditides, Hashimoto, Thyroiditis, Chronic Lymphocytic, Thyroiditis, Hashimoto, Hashimoto Disease, Hashimotos disease&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;ziekte van Hashimoto, chronische lymfocytische thyreoïditis, Hashimoto-thyreoïditis, lymfocytische thyreoïditis, Hashimoto; thyroïditis, chronisch; thyroïditis, lymfadenoïd, lymfocytair; thyroïditis, lymfomateus; thyroïditis, lymfoïd; thyroïditis, lymphomatosa; struma, struma; lymphomatosa, thyroïditis; Hashimoto, thyroïditis; chronisch, lymfadenoïd, thyroïditis; lymfocytair, thyroïditis; lymfomateus, thyroïditis; lymfoïd&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Thyroïdite chronique de Hashimoto, Thyroïdite lymphocytique, Thyroïdite lymphocytique chronique, Maladie d'Hashimoto, Maladie de Hashimoto, Thyroidite lymphocytaire de Hashimoto, Thyroïdite chronique lymphocytaire, Thyroïdite d'Hashimoto, Thyroïdite de Hashimoto&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;chronische lymphozytische Thyroiditis, lymphozytische Thyroiditis, Hashimoto-Thyroiditis, Hashimoto-Krankheit, Chronische lymphyzytäre Thyreoiditis, Hashimoto-Thyreoiditis, Thyreoiditis, chronische lymphozytäre&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Tiroidite linfocitica, Tiroidite linfocitaria cronica, Malattia di Hashimoto, Tiroidite di Hashimoto&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Tiroidite linfocítica crónica, Tiroidite de Hashimoto, Tiroidite linfocítica, Doença de Hashimoto&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;Tiroiditis linfocítica, Toroiditis linfocítica crónica, Struma lymphomatosis, Hashimoto's disease, Hashimoto's thyroiditis, enfermedad de Hashimoto, estruma linfomatoso, tiroiditis crónica linfocitaria autoinmune, tiroiditis de Hashimoto (trastorno), tiroiditis de Hashimoto, tiroiditis linfocítica, Enfermedad de Hashimoto, Tiroiditis de Hashimoto&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;リンパ球性甲状腺炎, 慢性リンパ球性甲状腺炎, ﾘﾝﾊﾟｷｭｳｾｲｺｳｼﾞｮｳｾﾝｴﾝ, ﾊｼﾓﾄﾋﾞｮｳ, ﾏﾝｾｲﾘﾝﾊﾟｷｭｳｾｲｺｳｼﾞｮｳｾﾝｴﾝ, 橋本甲状腺炎, Hashimoto甲状腺炎, 橋本病&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Hashimotos sjukdom&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;chronická lymfocytární tyreoiditida, Hashimotova nemoc, Lymfocytická tyreoiditida, Chronická lymfocytická tyreoiditida, Hashimotova choroba, Hashimotova tyreoiditida&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Hashimoton tauti&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;KHASHIMOTO BOLEZN', HASHIMOTO BOLEZN', HASHIMOTO БОЛЕЗНЬ, ХАШИМОТО БОЛЕЗНЬ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Wole Hashimoto, Choroba Hashimoto&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;Lymphocytás thyreoiditis, Hashimoto-betegség, Chronicus lymphocytás thyreoiditis, Hashimoto-thyreoiditis&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Hurthle Cells  (</value><value>)
</value><value>Hashimoto Disease  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Hashimoto's Thyroiditis</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Thyroid Disease</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;See Also&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/Hypthyrdsm.htm" class="LinkPage"&gt;Hypothyroidism&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/Thyrdts.htm" class="LinkPage"&gt;Thyroiditis&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Epidemiology&lt;ol&gt;&lt;li&gt;More common in women than men by 3-7 fold&lt;/li&gt;&lt;li&gt;Age of onset peaks at 40-60 years&lt;/li&gt;&lt;li&gt;&lt;a href="../../Prevent/Epi/DsPrvlncRt.htm" class="LinkPage"&gt;Prevalence&lt;/a&gt; of &lt;a href="../../Endo/Lab/AnthyrdAntbdy.htm" class="LinkPage"&gt;Antithyroid Antibody&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Total population: 3-4%&lt;/li&gt;&lt;li&gt;Euthyroid asymptomatic adolescents: 1.4%&lt;/li&gt;&lt;li&gt;Middle aged to elderly women: 30-40%&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Pathophysiology&lt;ol&gt;&lt;li&gt;Chronic autoimmune &lt;a href="../../Endo/Anatomy/ThyrdAntmy.htm" class="LinkPage"&gt;Thyroid&lt;/a&gt; inflammation&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Anatomy/ThyrdAntmy.htm" class="LinkPage"&gt;Thyroid&lt;/a&gt; infiltration by &lt;a href="../../HemeOnc/Lab/LymphcytCnt.htm" class="LinkPage"&gt;Lymphocyte&lt;/a&gt;s&lt;/li&gt;&lt;li&gt;Results in formation of Askanazy cells (Hurthle Cells)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Risk Factors: Hashimoto's with &lt;a href="../../Endo/Thyroid/Hypthyrdsm.htm" class="LinkPage"&gt;Hypothyroidism&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Excess Iodide intake&lt;/li&gt;&lt;li&gt;&lt;a href="../../Psych/CD/Cgrt.htm" class="LinkPage"&gt;Tobacco&lt;/a&gt; abuse (thiocyanate exposure)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Symptoms&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Endo/Thyroid/Hypthyrdsm.htm" class="LinkPage"&gt;Hypothyroidism&lt;/a&gt;&lt;ol&gt;&lt;li&gt;May initially experience &lt;a href="../../Endo/Thyroid/Hyprthyrdsm1.htm" class="LinkPage"&gt;Hyperthyroidism&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Painless &lt;a href="../../Endo/Thyroid/Gtr.htm" class="LinkPage"&gt;Goiter&lt;/a&gt; (painful in rare cases)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Signs&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/Hypthyrdsm.htm" class="LinkPage"&gt;Hypothyroidism&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Anatomy/ThyrdAntmy.htm" class="LinkPage"&gt;Thyroid&lt;/a&gt;&lt;a href="../../Endo/Thyroid/Gtr.htm" class="LinkPage"&gt;Goiter&lt;/a&gt; (90% of cases)&lt;ol&gt;&lt;li&gt;Symmetric, diffusely enlarged &lt;a href="../../Endo/Anatomy/ThyrdAntmy.htm" class="LinkPage"&gt;Thyroid&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Firm, irregular &lt;a href="../../Endo/Anatomy/ThyrdAntmy.htm" class="LinkPage"&gt;Thyroid&lt;/a&gt; surface&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Labs&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/AnthyrdAntbdy.htm" class="LinkPage"&gt;Antithyroid Antibody&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/AnthyrdAntbdy.htm" class="LinkPage"&gt;Antithyroid Microsomal Antibody&lt;/a&gt; (Peroxidase &lt;a href="../../ID/Exam/Imnglbln.htm" class="LinkPage"&gt;Antibody&lt;/a&gt;)&lt;ol&gt;&lt;li&gt;Present in up to 95% of Hashimoto cases&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/AnthyrdAntbdy.htm" class="LinkPage"&gt;Antithyroglobulin Antibody&lt;/a&gt; may be present&lt;/li&gt;&lt;li&gt;TSH-receptor blocking &lt;a href="../../ID/Exam/Imnglbln.htm" class="LinkPage"&gt;Antibody&lt;/a&gt; may be present&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Anatomy/ThyrdAntmy.htm" class="LinkPage"&gt;Thyroid&lt;/a&gt; function stepwise change&lt;ol&gt;&lt;li&gt;First: TSH rises&lt;/li&gt;&lt;li&gt;Next: T4 declines&lt;/li&gt;&lt;li&gt;Next: T3 decline&lt;/li&gt;&lt;li&gt;Last: Symptomatic &lt;a href="../../Endo/Thyroid/Hypthyrdsm.htm" class="LinkPage"&gt;Hypothyroidism&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Associated conditions&lt;ol&gt;&lt;li&gt;&lt;a href="../../HemeOnc/Anemia/VtmnBDfcncy.htm" class="LinkPage"&gt;Pernicious Anemia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Rheum/Diffuse/SjgrnsSyndrm.htm" class="LinkPage"&gt;Sjogren's Syndrome&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Chronic hepatitis&lt;/li&gt;&lt;li&gt;&lt;a href="../../Rheum/Diffuse/SystmcLpsErythmts.htm" class="LinkPage"&gt;Systemic Lupus Erythematosus&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Rheum/R_2/RhmtdArthrts.htm" class="LinkPage"&gt;Rheumatoid Arthritis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Adrenal/AdsnsDs.htm" class="LinkPage"&gt;Adrenal Insufficiency&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/DM/DbtsMlts.htm" class="LinkPage"&gt;Diabetes Mellitus&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Derm/Pigment/Vtlg.htm" class="LinkPage"&gt;Vitiligo&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Management&lt;ol&gt;&lt;li&gt;TSH &amp;gt;10 mU/L&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/ThyrdHrmnRplcmnt.htm" class="LinkPage"&gt;Levothyroxine&lt;/a&gt; in all patients&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;TSH 4.5 to 10 mU/L&lt;ol&gt;&lt;li&gt;Pregnancy: &lt;a href="../../Endo/Pharm/ThyrdHrmnRplcmnt.htm" class="LinkPage"&gt;Levothyroxine&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Other: Variable recommendations on whether to treat&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Course&lt;ol&gt;&lt;li&gt;Initially metabolically normal&lt;/li&gt;&lt;li&gt;Later &lt;a href="../../Endo/Anatomy/ThyrdAntmy.htm" class="LinkPage"&gt;Thyroid&lt;/a&gt; failure usually ensues&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Complications: &lt;a href="../../Endo/HemeOnc/ThyrdCrcnm.htm" class="LinkPage"&gt;Thyroid Cancer&lt;/a&gt;s&lt;ol&gt;&lt;li&gt;Primary &lt;a href="../../Endo/Anatomy/ThyrdAntmy.htm" class="LinkPage"&gt;Thyroid&lt;/a&gt;&lt;a href="../../HemeOnc/Lymph/Lymphm.htm" class="LinkPage"&gt;Lymphoma&lt;/a&gt; (80 fold increased risk)&lt;ol&gt;&lt;li&gt;Presents as rapidly growing &lt;a href="../../Endo/HemeOnc/ThyrdAdnm.htm" class="LinkPage"&gt;Thyroid Nodule&lt;/a&gt;&lt;/li&gt;&lt;li&gt;FNA &lt;a href="../../Endo/HemeOnc/ThyrdAdnm.htm" class="LinkPage"&gt;Thyroid Nodule&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Papillary Carcinoma&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Bindra%20%20%5BAU%5D%20AND%202006%20%5BDP%5D%20AND%20%20Am%20Fam%20Physician%20%20%5BTA%5D" class="LinkRef"&gt;Bindra (2006) Am Fam Physician 73:1769-76&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Dayan%20%20%5BAU%5D%20AND%201996%20%5BDP%5D%20AND%20%20N%20Engl%20J%20Med%20%20%5BTA%5D" class="LinkRef"&gt;Dayan (1996) N Engl J Med 335:99-107&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0949667</value><value>C0677607</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Thyroid/HshmtsThyrdts.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Hashimoto's Thyroiditis, Hashimoto's Disease, Chronic Lymphocytic Thyroiditis, Chronic Autoimmune Thyroiditis, Askenazy Cell, Hurthle Cell</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Thyroid/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Anti-Obesity Agents  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0376607"&gt;&lt;i&gt;C0376607&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;Agents that increase energy expenditure and weight loss by neural and chemical regulation. Beta-adrenergic agents and serotoninergic drugs have been experimentally used in patients with non-insulin dependent diabetes mellitus (NIDDM) to treat obesity.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Pharmacologic Substance (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0376607&amp;amp;tui=T121"&gt;&lt;i&gt;T121&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D019440&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Agents, Anti-Obesity, Agents, Antiobesity, Anti Obesity Agents, Anti Obesity Drugs, Anti-Obesity Agents, Anti-Obesity Drugs, Antiobesity Agents, Antiobesity Drugs, Drugs, Anti-Obesity, Drugs, Antiobesity, ANTIOBESITY AGENTS, anti-obesity agents (medication), anti-obesity agents, anti obesity drug, antiobesity drug, anti obesity drugs, antiobesity drugs, anti-obesity drugs&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Pilules antiobésité, Médicaments anti-obésité, Médicaments antiobésité, Pilules anti-obésité, Médicaments contre l'obésité, Agents antiobésité, Agents anti-obésité&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Fetma, medel mot&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;látky proti obezitě&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Laihdutuslääkkeet&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;OZHIRENIE, LEKARSTVENNYE SREDSTVA, VES-PONIZHAIUSHCHIE SREDSTVA, ВЕС-ПОНИЖАЮЩИЕ СРЕДСТВА, ОЖИРЕНИЕ, ЛЕКАРСТВЕННЫЕ СРЕДСТВА&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;痩せ薬, やせ薬, 抗肥満薬, 減量薬, 抗肥満剤&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Leki przeciw otyłości, Środki obniżające wagę&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Antiadiposita&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Agentes Anti-Obesidade&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Farmaci contro l'obesità&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;Agentes Anti Obesidad&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Appetite Depressants  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0003620"&gt;&lt;i&gt;C0003620&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;Agents that are used to suppress appetite.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CSP)&lt;/td&gt;
                &lt;td&gt;class of drugs which suppress appetite, used for weight control.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;Any substance that induces loss of appetite to prevent weight gain and achieve weight loss.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Pharmacologic Substance (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0003620&amp;amp;tui=T121"&gt;&lt;i&gt;T121&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D001067&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;371141007, 108374003&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Anorectics, Appetite Depressants, Appetite Suppressants, Depressants, Appetite, Suppressants, Appetite, anorexic agent, Appetite depressants, Anorexigenic Drugs, Appetite-Depressing Drugs, Drugs, Anorexigenic, Drugs, Appetite-Depressing, APPETITE DEPRESS, APPETITE SUPPRESSANTS, Anorexic Agent, Anorexics, anorexigenic drug, appetite depressant, Anorexic Drugs, Drugs, Anorexic, Appetite Suppressant Drugs, Appetite-Suppressant Drugs, Drugs, Appetite-Suppressant, anorectic agents, anorexiants, appetite depressants, appetite suppressants, anorexics (medication), anorexics, Anorexiant product, Appetite Suppressant, [GA750] APPETITE SUPPRESSANTS, Anorexic drugs, Anorectic Agents, Agents, Anorectic, anorectics, anorexiant, agents anorexic, appetite suppressant, appetite drugs suppressants, anorexic drugs, anorectic agent, appetite suppressant drugs, Anorexiant (substance), Anorexiant product (product), Anorexiant, Appetite Depressing Drugs&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Anorexigènes, Agents anorexigènes, Suppresseurs de l'appétit, Médicaments anorexigènes, Coupe-faim, Modérateurs de l'appétit&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Aptitdämpande medel&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;anorexika, anorektika&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Ruokahalua hillitsevät lääkkeet&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;ANOREKSIGENNYE SREDSTVA, LEKARSTVENNYE SREDSTVA, SNIZHAIUSHCHIE APPETIT, АНОРЕКСИГЕННЫЕ СРЕДСТВА, ЛЕКАРСТВЕННЫЕ СРЕДСТВА, СНИЖАЮЩИЕ АППЕТИТ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Leki zmniejszające łaknienie&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;食欲減退薬, 食欲抑制剤, 食欲抑制薬&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;anorexígeno (sustancia), anorexígeno, producto anorexígeno (producto), producto anorexígeno, Anorexicos, Depresores del Apetito, Supresores del Apetito&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Anorektika, Appetithemmer, Appetitzügler&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Anoressizanti&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Anorexígenos, Depressores do Apetite, Supressores do Apetite&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Anti-Obesity Agents  (</value><value>)
</value><value>Appetite Depressants  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Obesity Medication</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Obesity</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Indications (Follow these strictly!!)&lt;ol&gt;&lt;li&gt;Morbid &lt;a href="../../Endo/Obesity/Obsty.htm" class="LinkPage"&gt;Obesity&lt;/a&gt; (BMI&amp;gt;30)&lt;/li&gt;&lt;li&gt;Moderate &lt;a href="../../Endo/Obesity/Obsty.htm" class="LinkPage"&gt;Obesity&lt;/a&gt; (BMI 27) with comorbidity&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Management: Medications (most are DEA Controlled agents)&lt;ol&gt;&lt;li&gt;FDA Schedule 4 Medications&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Phntrmn.htm" class="LinkPage"&gt;Phentermine&lt;/a&gt; (Fastin, Adipex-P, Lonamin)&lt;/li&gt;&lt;li&gt;Diethylpropion (Tenuate)&lt;/li&gt;&lt;li&gt;Lorcaserin (Belviq)&lt;ol&gt;&lt;li&gt;Anticipated to be available in late 2012&lt;/li&gt;&lt;li&gt;Weight loss is 7 pounds more than &lt;a href="../../Pharm/Psych/PlcbEfct.htm" class="LinkPage"&gt;Placebo&lt;/a&gt; in one year&lt;/li&gt;&lt;li&gt;&lt;a href="../../Psych/Neuro/Srtn.htm" class="LinkPage"&gt;Serotonin&lt;/a&gt; 2C agonist that increases satiety&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Fidler%20%20%5BAU%5D%20AND%202011%20%5BDP%5D%20AND%20%20J%20Clin%20Endocrinol%20Metab%20%20%5BTA%5D" class="LinkRef"&gt;Fidler (2011) J Clin Endocrinol Metab 96:3067-3077&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;FDA Schedule 3 Medications&lt;ol&gt;&lt;li&gt;Benzphetamine (Didrex)&lt;/li&gt;&lt;li&gt;Phendimetrazine (Bontril)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Non-FDA-Scheduled medications&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Orlst.htm" class="LinkPage"&gt;Orlistat&lt;/a&gt; (&lt;a href="../../Endo/Pharm/Orlst.htm" class="LinkPage"&gt;Xenical&lt;/a&gt;)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Management: Combination Protocols&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Phntrmn.htm" class="LinkPage"&gt;Phentermine&lt;/a&gt; and &lt;a href="../../Psych/Pharm/Flxtn.htm" class="LinkPage"&gt;Prozac&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Phntrmn.htm" class="LinkPage"&gt;Phentermine&lt;/a&gt; 30 mg PO qd&lt;/li&gt;&lt;li&gt;&lt;a href="../../Psych/Pharm/Flxtn.htm" class="LinkPage"&gt;Prozac&lt;/a&gt; 20 mg PO qd&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Phntrmn.htm" class="LinkPage"&gt;Phentermine&lt;/a&gt; and &lt;a href="../../Neuro/Pharm/Tprmt.htm" class="LinkPage"&gt;Topiramate&lt;/a&gt; (Qsymia, previously Qnexa)&lt;ol&gt;&lt;li&gt;Anticipated to be available in late 2012&lt;/li&gt;&lt;li&gt;Weight loss is promising at 24 pounds in one year or 10% of body weight&lt;/li&gt;&lt;li&gt;Adverse effects&lt;ol&gt;&lt;li&gt;&lt;a href="../../OB/Fetus/TrtgnExpsr.htm" class="LinkPage"&gt;Teratogen&lt;/a&gt;ic (&lt;a href="../../Neuro/Pharm/Tprmt.htm" class="LinkPage"&gt;Topiramate&lt;/a&gt;)&lt;ol&gt;&lt;li&gt;Precautions to avoid pregnancy while on Qsymia are paramount&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/EKG/Tchycrd.htm" class="LinkPage"&gt;Tachycardia&lt;/a&gt; and &lt;a href="../../CV/Htn/Hyprtnsn.htm" class="LinkPage"&gt;Hypertension&lt;/a&gt; (&lt;a href="../../Endo/Pharm/Phntrmn.htm" class="LinkPage"&gt;Phentermine&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;Impaired memory and concentration (&lt;a href="../../Neuro/Pharm/Tprmt.htm" class="LinkPage"&gt;Topiramate&lt;/a&gt;)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;References&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Garvery%20%20%5BAU%5D%20AND%202012%20%5BDP%5D%20AND%20%20Am%20J%20Clin%20Nutr%20%20%5BTA%5D" class="LinkRef"&gt;Garvery (2012) Am J Clin Nutr 95:297–308&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Management: Dietary Supplements&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Endo/Obesity/DtrySplmntsInObsty.htm" class="LinkPage"&gt;Dietary Supplements in Obesity&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Contraindications: Noradrenergic agents (all agents other than &lt;a href="../../Endo/Pharm/Orlst.htm" class="LinkPage"&gt;Orlistat&lt;/a&gt;)&lt;ol&gt;&lt;li&gt;&lt;a href="../../CV/Htn/Hyprtnsn.htm" class="LinkPage"&gt;Hypertension&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Advanced cardiovascular disease&lt;ol&gt;&lt;li&gt;&lt;a href="../../CV/CAD/ActCrnrySyndrm.htm" class="LinkPage"&gt;Coronary Artery Disease&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/CHF/CngstvHrtFlr.htm" class="LinkPage"&gt;Congestive Heart Failure&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Arrhythmias&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/Hyprthyrdsm1.htm" class="LinkPage"&gt;Hyperthyroidism&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Narrow-Angle &lt;a href="../../Eye/Glaucoma/Glcm.htm" class="LinkPage"&gt;Glaucoma&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Psych/CD/ChmclDpndncy.htm" class="LinkPage"&gt;Substance Abuse&lt;/a&gt; history&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Drug Interactions&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Orlst.htm" class="LinkPage"&gt;Orlistat&lt;/a&gt; interferes only with Cyclosporine&lt;/li&gt;&lt;li&gt;Noradrenergic agents (all except &lt;a href="../../Endo/Pharm/Orlst.htm" class="LinkPage"&gt;Orlistat&lt;/a&gt;)&lt;ol&gt;&lt;li&gt;&lt;a href="../../Psych/Pharm/MnmnOxdsInhbtr.htm" class="LinkPage"&gt;MAO inhibitor&lt;/a&gt;s&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Pharm/PrphrlActngAdrnrgcAntgnst.htm" class="LinkPage"&gt;Guanethidine&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Psych/Pharm/TrcyclcAntdprsnt.htm" class="LinkPage"&gt;Tricyclic Antidepressant&lt;/a&gt;s&lt;/li&gt;&lt;li&gt;&lt;a href="../../Psych/Pharm/Alchl.htm" class="LinkPage"&gt;Alcohol&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Centrally acting stimulants or anorexiants&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Adjunctive Therapies&lt;ol&gt;&lt;li&gt;&lt;a href="../../Surgery/Pharm/BlAcdOrlDsltnThrpy.htm" class="LinkPage"&gt;Ursodeoxycholic Acid&lt;/a&gt; 600mg qd&lt;ol&gt;&lt;li&gt;Prevention of &lt;a href="../../Surgery/GI/Glstn.htm" class="LinkPage"&gt;Gallstone&lt;/a&gt;s in dieting obese patients&lt;/li&gt;&lt;li&gt;Reference&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Shiffman%20%20%5BAU%5D%20AND%201995%20%5BDP%5D%20AND%20%20Ann%20Intern%20Med%20%20%5BTA%5D" class="LinkRef"&gt;Shiffman (1995) Ann Intern Med 122:899-905&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Preparations: Pharmacologic Therapies recalled by FDA for CV effects&lt;ol&gt;&lt;li&gt;Fenfluramine&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Dxfnflrmn.htm" class="LinkPage"&gt;Dexfenfluramine&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Sbtrmn.htm" class="LinkPage"&gt;Sibutramine&lt;/a&gt; (&lt;a href="../../Endo/Pharm/Sbtrmn.htm" class="LinkPage"&gt;Meridia&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;Phenylpropanolamine (over-the-counter)&lt;ol&gt;&lt;li&gt;&lt;a href="../../ENT/Pharm/Dcngstnt.htm" class="LinkPage"&gt;Decongestant&lt;/a&gt; that stimulates &lt;a href="../../Neuro/Pharm/AdrnrgcRcptr.htm" class="LinkPage"&gt;Adrenergic Receptor&lt;/a&gt;s&lt;/li&gt;&lt;li&gt;Elevates &lt;a href="../../CV/Exam/BldPrsr.htm" class="LinkPage"&gt;Blood Pressure&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Preparations: Research Drugs (not approved)&lt;ol&gt;&lt;li&gt;Selective Cannabinoid Type I Blocker&lt;ol&gt;&lt;li&gt;Acomplia (Rimonabant) is first in class&lt;/li&gt;&lt;li&gt;Decreases appetite by blocking cannabinoid receptors&lt;/li&gt;&lt;li&gt;May also be effective in &lt;a href="../../Psych/CD/TbcCstn.htm" class="LinkPage"&gt;Tobacco Cessation&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Fernandez%20%20%5BAU%5D%20AND%202004%20%5BDP%5D%20AND%20%20Curr%20Opin%20Investig%20Drugs%20%20%5BTA%5D" class="LinkRef"&gt;Fernandez (2004) Curr Opin Investig Drugs 5:430-5&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/HmnGrwthHrmn.htm" class="LinkPage"&gt;Growth Hormone&lt;/a&gt;&lt;ol&gt;&lt;li&gt;No change in body weight&lt;/li&gt;&lt;li&gt;Decreases Body fat 9.2%&lt;/li&gt;&lt;li&gt;Decreased visceral fat 18%&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Johanssen%20%20%5BAU%5D%20AND%201997%20%5BDP%5D%20AND%20%20J%20Clin%20Endocrinol%20Metab%20%20%5BTA%5D" class="LinkRef"&gt;Johanssen (1997) J Clin Endocrinol Metab 82: 727&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;(1998) AOA Treatment Adult &lt;a href="../../Endo/Obesity/Obsty.htm" class="LinkPage"&gt;Obesity&lt;/a&gt;, 2nd edition&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Frank%20%20%5BAU%5D%20AND%201998%20%5BDP%5D%20AND%20%20J%20Am%20Diet%20Assoc%20%20%5BTA%5D" class="LinkRef"&gt;Frank (1998) J Am Diet Assoc 98:S44-48&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Lyznicki%20%20%5BAU%5D%20AND%202001%20%5BDP%5D%20AND%20%20Am%20Fam%20Physician%20%20%5BTA%5D" class="LinkRef"&gt;Lyznicki (2001) Am Fam Physician 63(11):2185-96&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Rippe%20%20%5BAU%5D%20AND%201998%20%5BDP%5D%20AND%20%20J%20Am%20Diet%20Assoc%20%20%5BTA%5D" class="LinkRef"&gt;Rippe (1998) J Am Diet Assoc 98:S9-15&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Speer%20%20%5BAU%5D%20AND%201997%20%5BDP%5D%20AND%20%20Phys%20Sportsmed%20%20%5BTA%5D" class="LinkRef"&gt;Speer (1997) Phys Sportsmed 25:94-107&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Yanovski%20%20%5BAU%5D%20AND%202002%20%5BDP%5D%20AND%20%20N%20Engl%20J%20Med%20%20%5BTA%5D" class="LinkRef"&gt;Yanovski (2002) N Engl J Med 346:593&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0376607</value><value>C0003620</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Obesity/ObstyMdctn.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Obesity Medication, Appetite Suppressants, Appetite Depressants, Anti-Obesity Agents</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Obesity/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Obesity  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0028754"&gt;&lt;i&gt;C0028754&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;Having a high amount of body fat (body mass index [BMI] of 30 or more).&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A disorder characterized by having a high amount of body fat.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MEDLINEPLUS)&lt;/td&gt;
                &lt;td&gt;
                  &lt;span&gt;
                    &lt;p&gt;Obesity means having too much body fat. It is different from being overweight, which means weighing too much.  The weight may come from muscle, bone, fat and/or body water.  Both terms mean that a person's weight is greater than what's considered healthy for his or her height. &lt;/p&gt;
                    &lt;p&gt;Obesity occurs over time when you eat more calories than you use. The balance between calories-in and calories-out differs for each person. Factors that might tip the balance include your genetic makeup, overeating, eating high-fat foods and not being physically active. &lt;/p&gt;
                    &lt;p&gt;Being obese increases your risk of diabetes, heart disease, stroke, arthritis and some cancers. If you are obese, losing even 5 to 10 percent of your weight can delay or prevent some of these diseases.&lt;/p&gt;
                    &lt;p style="font-weight:bold;font-style:italic;"&gt;NIH: National Institute of Diabetes and Digestive and Kidney Diseases&lt;/p&gt;
                  &lt;/span&gt;
                &lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A condition marked by an abnormally high, unhealthy amount of body fat.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CSP)&lt;/td&gt;
                &lt;td&gt;excessively high accumulation of body fat or adipose tissue in relation to lean body mass; the amount of body fat (or adiposity) includes concern for both the distribution of fat throughout the body and the size of the adipose tissue deposits; individuals are usually at high clinical risk because of excess amount of body fat (BMI greater than 30).&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;A status with BODY WEIGHT that is grossly above the acceptable or desirable weight, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Disease or Syndrome (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0028754&amp;amp;tui=T047"&gt;&lt;i&gt;T047&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D009765&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD9&lt;/td&gt;
                &lt;td&gt;278.00&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD10&lt;/td&gt;
                &lt;td&gt;E66, E66.9&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;5476005, 154776002, 190963004, 414916001, 414915002&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Adiposity, Obesities, Obesity, OBESE, OBESITY, Obesity, NOS, Obesity, unspecified, obesity (diagnosis), obesity, Obesity NOS, Obesity [Disease/Finding], obese, adiposity, Obesity [Ambiguous], Obese, Obese (finding), Obesity (disorder)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;OBESITE, Obésité, non précisée, Obésité&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;OBESIDADE, Obesidade NE, Obesidade&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;OBESIDAD, Obesidad no especificada, Obesity [Ambiguous], Obesity, obesidad (trastorno), obesidad, obeso (hallazgo), obeso, Obesidad&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;obesitas niet-gespecificeerd, Vetzucht, niet gespecificeerd, zwaarlijvigheid, Adipositas, Vetzucht&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Fettleibigkeit, unspezifisch, ADIPOSITAS, Adipositas, nicht naeher bezeichnet, Adipositas, Fettsucht, Obesitas&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Obesità, non specificata, Obesità&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;肥満, 肥満、詳細不明, ﾋﾏﾝ, ﾋﾏﾝｼｮｳｻｲﾌﾒｲ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Fetma&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;obezita, Obezita, blíže neurčená, Obezita&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Lihavuus&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;OZHIRENIE, ОЖИРЕНИЕ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Korean&lt;/td&gt;
                &lt;td&gt;상세불명의 비만, 비만&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Croatian&lt;/td&gt;
                &lt;td&gt;GOJAZNOST&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Otyłość&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;Obesitas, nem meghatározott, Obesitas&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Obesity  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Obesity Evaluation</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Obesity</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;See Also&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Obesity/Obsty.htm" class="LinkPage"&gt;Obesity&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Contraindications: &lt;a href="../../Endo/Obesity/ObstyMngmnt.htm" class="LinkPage"&gt;Weight Reduction&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Temporary Exclusions&lt;ol&gt;&lt;li&gt;Pregnancy (&lt;a href="../../OB/Lactation/BrstFdng.htm" class="LinkPage"&gt;Lactation&lt;/a&gt; allowed if milk established)&lt;/li&gt;&lt;li&gt;Unstable mental or medical illness&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Possible Exclusions&lt;ol&gt;&lt;li&gt;&lt;a href="../../Surgery/GI/Glstn.htm" class="LinkPage"&gt;Cholelithiasis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Rheum/Bone/Ostprs.htm" class="LinkPage"&gt;Osteoporosis&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Permanent Exclusions&lt;ol&gt;&lt;li&gt;&lt;a href="../../Psych/Eating/AnrxNrvs.htm" class="LinkPage"&gt;Anorexia Nervosa&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Terminal illness&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Approach&lt;ol&gt;&lt;li&gt;Determine &lt;a href="../../Endo/Obesity/ObstyMsrmnt.htm" class="LinkPage"&gt;Obesity Measurement&lt;/a&gt;s&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Exam/BdyMsIndx.htm" class="LinkPage"&gt;Body Mass Index&lt;/a&gt; (BMI)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Exam/WstTHpRt.htm" class="LinkPage"&gt;Waist-to-Hip Ratio&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Exam/WstTHpRt.htm" class="LinkPage"&gt;Waist Circumference&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Evaluate Comorbid &lt;a href="../../Endo/Obesity/ObstyRsk.htm" class="LinkPage"&gt;Obesity Risk&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Is Patient Ready and Able to lose weight?&lt;ol&gt;&lt;li&gt;Yes: &lt;a href="../../Endo/Obesity/ObstyMngmnt.htm" class="LinkPage"&gt;Weight Reduction&lt;/a&gt; Protocol&lt;/li&gt;&lt;li&gt;No: Prevention of Weight Gain Protocol&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Labs&lt;ol&gt;&lt;li&gt;Fasting &lt;a href="../../CV/Lab/Lpd.htm" class="LinkPage"&gt;Lipid&lt;/a&gt; profile&lt;/li&gt;&lt;li&gt;Chemistry panel (including fasting &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Serum Glucose&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/ThyrdStmltngHrmn.htm" class="LinkPage"&gt;Thyroid Stimulating Hormone&lt;/a&gt; (TSH)&lt;ol&gt;&lt;li&gt;Rarely the cause for weight gain&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Resources&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Frank%20%20%5BAU%5D%20AND%201998%20%5BDP%5D%20AND%20%20J%20Am%20Diet%20Assoc%20%20%5BTA%5D" class="LinkRef"&gt;Frank (1998) J Am Diet Assoc 98:S44-48&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Lyznicki%20%20%5BAU%5D%20AND%202001%20%5BDP%5D%20AND%20%20Am%20Fam%20Physician%20%20%5BTA%5D" class="LinkRef"&gt;Lyznicki (2001) Am Fam Physician 63(11):2185-96&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Rippe%20%20%5BAU%5D%20AND%201998%20%5BDP%5D%20AND%20%20J%20Am%20Diet%20Assoc%20%20%5BTA%5D" class="LinkRef"&gt;Rippe (1998) J Am Diet Assoc 98:S9-15&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Speer%20%20%5BAU%5D%20AND%201997%20%5BDP%5D%20AND%20%20Phys%20Sportsmed%20%20%5BTA%5D" class="LinkRef"&gt;Speer (1997) Phys Sportsmed 25:94-107&lt;/a&gt;&lt;/li&gt;&lt;li&gt;(1998) AOA Treatment Adult &lt;a href="../../Endo/Obesity/Obsty.htm" class="LinkPage"&gt;Obesity&lt;/a&gt;, 2nd edition&lt;/li&gt;&lt;li&gt;(1998) &lt;a href="../../Endo/Obesity/Obsty.htm" class="LinkPage"&gt;Obesity&lt;/a&gt; Res 6(suppl 2):51S-209S&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0028754</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Obesity/ObstyEvltn.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Obesity Evaluation</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Obesity/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Overweight  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0497406"&gt;&lt;i&gt;C0497406&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CHV)&lt;/td&gt;
                &lt;td&gt;BMI 25&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CHV)&lt;/td&gt;
                &lt;td&gt;BMI 25&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;Being too heavy for one's height. Excess body weight can come from fat, muscle, bone, and/or water retention. Being overweight does not always mean being obese.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;A status with BODY WEIGHT that is above certain standard of acceptable or desirable weight. In the scale of BODY MASS INDEX, overweight is defined as having a BMI of 25.0-29.9 kg/m2. Overweight may or may not be due to increases in body fat (ADIPOSE TISSUE), hence overweight does not equal "over fat".&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Sign or Symptom (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0497406&amp;amp;tui=T184"&gt;&lt;i&gt;T184&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D050177&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD9&lt;/td&gt;
                &lt;td&gt;278.02&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD10&lt;/td&gt;
                &lt;td&gt;E66.3&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;238131007, 23495001&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;OVERWEIGHT, OVER WEIGHT, Overweight (BMI &amp;lt;30), overweight (diagnosis), overweight (physical finding), overweight, Overweight [Disease/Finding], clinical overweight, Patient overweight, Overweight (finding), Overweight, overweight (BMI&amp;lt;30), Overweight (BMI 25-30)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;過体重, ｶﾀｲｼﾞｭｳ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Övervikt, OVERVIKT (BMI &amp;lt;30)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;nadváha, Nadváha&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Ylipaino, YLIPAINO (BMI &amp;lt; 30)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Surplus de poids, Excédent de poids, Excès de poids, Exces de poids (IMC &amp;lt;30), Surcharge pondérale, Surpoids&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;VES IZBYTOCHNYI, ВЕС ИЗБЫТОЧНЫЙ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Excesso de peso (IMC &amp;lt;30), Excesso de peso, Sobrepeso&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Norwegian&lt;/td&gt;
                &lt;td&gt;OVERVEKT BMI&amp;lt;30&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;Overgewicht (BMI &amp;lt;30), Overgewicht, overgewicht&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Danish&lt;/td&gt;
                &lt;td&gt;Overvaegt (BMI &amp;lt;30)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;Sobrepeso (I.M.C. &amp;lt;30), paciente con peso alto, paciente con sobrepeso, sobrepeso (hallazgo), sobrepeso, Sobrepeso&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Sovrappeso(BMI &amp;lt;30), Sovrappeso&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Uebergewicht(Koerper-Massen-Index&amp;lt;30), Uebergewicht, Übergewicht&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;koverseg (BMI &amp;lt; 30), Túlsúly&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Croatian&lt;/td&gt;
                &lt;td&gt;Not Translated[Overweight]&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Basque&lt;/td&gt;
                &lt;td&gt;GEHIEGIZKO PISUA(BMI&amp;lt;30)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Nadwaga&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Obesity  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0028754"&gt;&lt;i&gt;C0028754&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;Having a high amount of body fat (body mass index [BMI] of 30 or more).&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A disorder characterized by having a high amount of body fat.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MEDLINEPLUS)&lt;/td&gt;
                &lt;td&gt;
                  &lt;span&gt;
                    &lt;p&gt;Obesity means having too much body fat. It is different from being overweight, which means weighing too much.  The weight may come from muscle, bone, fat and/or body water.  Both terms mean that a person's weight is greater than what's considered healthy for his or her height. &lt;/p&gt;
                    &lt;p&gt;Obesity occurs over time when you eat more calories than you use. The balance between calories-in and calories-out differs for each person. Factors that might tip the balance include your genetic makeup, overeating, eating high-fat foods and not being physically active. &lt;/p&gt;
                    &lt;p&gt;Being obese increases your risk of diabetes, heart disease, stroke, arthritis and some cancers. If you are obese, losing even 5 to 10 percent of your weight can delay or prevent some of these diseases.&lt;/p&gt;
                    &lt;p style="font-weight:bold;font-style:italic;"&gt;NIH: National Institute of Diabetes and Digestive and Kidney Diseases&lt;/p&gt;
                  &lt;/span&gt;
                &lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A condition marked by an abnormally high, unhealthy amount of body fat.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CSP)&lt;/td&gt;
                &lt;td&gt;excessively high accumulation of body fat or adipose tissue in relation to lean body mass; the amount of body fat (or adiposity) includes concern for both the distribution of fat throughout the body and the size of the adipose tissue deposits; individuals are usually at high clinical risk because of excess amount of body fat (BMI greater than 30).&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;A status with BODY WEIGHT that is grossly above the acceptable or desirable weight, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Disease or Syndrome (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0028754&amp;amp;tui=T047"&gt;&lt;i&gt;T047&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D009765&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD9&lt;/td&gt;
                &lt;td&gt;278.00&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD10&lt;/td&gt;
                &lt;td&gt;E66, E66.9&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;5476005, 154776002, 190963004, 414916001, 414915002&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Adiposity, Obesities, Obesity, OBESE, OBESITY, Obesity, NOS, Obesity, unspecified, obesity (diagnosis), obesity, Obesity NOS, Obesity [Disease/Finding], obese, adiposity, Obesity [Ambiguous], Obese, Obese (finding), Obesity (disorder)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;OBESITE, Obésité, non précisée, Obésité&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;OBESIDADE, Obesidade NE, Obesidade&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;OBESIDAD, Obesidad no especificada, Obesity [Ambiguous], Obesity, obesidad (trastorno), obesidad, obeso (hallazgo), obeso, Obesidad&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;obesitas niet-gespecificeerd, Vetzucht, niet gespecificeerd, zwaarlijvigheid, Adipositas, Vetzucht&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Fettleibigkeit, unspezifisch, ADIPOSITAS, Adipositas, nicht naeher bezeichnet, Adipositas, Fettsucht, Obesitas&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Obesità, non specificata, Obesità&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;肥満, 肥満、詳細不明, ﾋﾏﾝ, ﾋﾏﾝｼｮｳｻｲﾌﾒｲ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Fetma&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;obezita, Obezita, blíže neurčená, Obezita&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Lihavuus&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;OZHIRENIE, ОЖИРЕНИЕ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Korean&lt;/td&gt;
                &lt;td&gt;상세불명의 비만, 비만&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Croatian&lt;/td&gt;
                &lt;td&gt;GOJAZNOST&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Otyłość&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;Obesitas, nem meghatározott, Obesitas&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Overweight  (</value><value>)
</value><value>Obesity  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Obesity</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Obesity</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;See Also&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Peds/ObstyInChldrn.htm" class="LinkPage"&gt;Obesity in Children&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Epidemiology&lt;ol&gt;&lt;li&gt;&lt;a href="../../Prevent/Epi/DsPrvlncRt.htm" class="LinkPage"&gt;Prevalence&lt;/a&gt;: 33% US adults age 20 to 74 are obese&lt;/li&gt;&lt;li&gt;Trends&lt;ol&gt;&lt;li&gt;Obesity &lt;a href="../../Prevent/Epi/DsPrvlncRt.htm" class="LinkPage"&gt;Prevalence&lt;/a&gt; has increased 8% since 1980&lt;/li&gt;&lt;li&gt;Obesity &lt;a href="../../Prevent/Epi/DsPrvlncRt.htm" class="LinkPage"&gt;Prevalence&lt;/a&gt; has increased 54% ages 6-11 years&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Patients gain 1 pound per year after age 25&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Pathophysiology: Fat expands in 2 ways&lt;ol&gt;&lt;li&gt;Fat Cell Number&lt;ol&gt;&lt;li&gt;Fat cell number does not decrease with weight loss&lt;/li&gt;&lt;li&gt;Increases 5 fold until age 22 years&lt;/li&gt;&lt;li&gt;Increase continues with nutritional excess&lt;/li&gt;&lt;li&gt;Non-obese person has 25-30 billion fat cells&lt;/li&gt;&lt;li&gt;Obese person has 260 billion cells&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Fat Cell Size&lt;ol&gt;&lt;li&gt;Fat cell size reduces with weight loss&lt;/li&gt;&lt;li&gt;Adults fill existing fat cells when they over eat&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Evaluation&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Endo/Obesity/ObstyEvltn.htm" class="LinkPage"&gt;Obesity Evaluation&lt;/a&gt;&lt;/li&gt;&lt;li&gt;See &lt;a href="../../Endo/Obesity/ObstyMsrmnt.htm" class="LinkPage"&gt;Obesity Measurement&lt;/a&gt;&lt;/li&gt;&lt;li&gt;See &lt;a href="../../Endo/Obesity/ObstyRsk.htm" class="LinkPage"&gt;Obesity Risk&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Diagnosis: Obesity&lt;ol&gt;&lt;li&gt;Men: 20% over estimated &lt;a href="../../Endo/Exam/IdlWghtInAdlts.htm" class="LinkPage"&gt;Ideal Weight&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Women: 30% over estimated &lt;a href="../../Endo/Exam/IdlWghtInAdlts.htm" class="LinkPage"&gt;Ideal Weight&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Management&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Endo/Obesity/ObstyMngmnt.htm" class="LinkPage"&gt;Obesity Management&lt;/a&gt;&lt;/li&gt;&lt;li&gt;See &lt;a href="../../Endo/Obesity/ObstyMdctn.htm" class="LinkPage"&gt;Obesity Medication&lt;/a&gt;s&lt;/li&gt;&lt;li&gt;See &lt;a href="../../Endo/Obesity/ObstyRsrcs.htm" class="LinkPage"&gt;Obesity Resources&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Worksheets&lt;ol&gt;&lt;li&gt;Dietician in the Box&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.fpnotebook.com/_media/PreventEdWeightLoss2Sjm.htm" class="LinkWebInt"&gt;PreventEdWeightLoss2Sjm.htm&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Research: Obesity Gene (ob)&lt;ol&gt;&lt;li&gt;Ob expression&lt;ol&gt;&lt;li&gt;Feeding turns on rat adipocytes via &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Inhibit Neuropeptide Y synthesis at appetite center&lt;/li&gt;&lt;li&gt;Neuropeptide Y&lt;ol&gt;&lt;li&gt;Decreases thermogenesis&lt;/li&gt;&lt;li&gt;Increases &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; and appetite&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Ob gene function: Produces Leptin (protein)&lt;ol&gt;&lt;li&gt;Leptin uppresses appetite in rats&lt;/li&gt;&lt;li&gt;Leptin increases thermogenesis in rats&lt;/li&gt;&lt;li&gt;Leptin decreases &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; levels in rats&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;References&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Saladin%20%20%5BAU%5D%20AND%201995%20%5BDP%5D%20AND%20%20Nature%20%20%5BTA%5D" class="LinkRef"&gt;Saladin (1995) Nature 377:527-9&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Stephens%20%20%5BAU%5D%20AND%201995%20%5BDP%5D%20AND%20%20Nature%20%20%5BTA%5D" class="LinkRef"&gt;Stephens (1995) Nature 377:530-2&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Pelleymounter%20(1995)%20Science,%20269%20%5BAU%5D%20AND%205223%20%5BDP%5D%20AND%20:%20%5BTA%5D" class="LinkRef"&gt;Pelleymounter (1995) Science, 269(5223):540-3&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0497406</value><value>C0028754</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Obesity/Obsty.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Obesity, Overweight</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Obesity/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Obesity screen  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0740216"&gt;&lt;i&gt;C0740216&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Therapeutic or Preventive Procedure (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0740216&amp;amp;tui=T061"&gt;&lt;i&gt;T061&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;171192001, 148407009, 268551005&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Obesity screen, Weight screen (&amp;amp; [obesity]) (procedure), screening obesity, obesity screening, Obesity screening (procedure), Obesity screening, Weight screen, Weight screen (&amp;amp; [obesity])&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;Weight screen (&amp;amp; [obesity]), cribado para obesidad, detección selectiva de obesidad (procedimiento), screening de obesidad, cribaje para obesidad, pesquisa para obesidad, rastreo para obesidad, detección selectiva para obesidad, screening para obesidad, tamizaje de obesidad, cribado para la detección de obesidad, tamizaje para obesidad, Weight screen, cribado de obesidad, cribado para la detección de obesidad (procedimiento), pesquisa de obesidad, Obesity screen, detección selectiva de obesidad&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Obesity  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0028754"&gt;&lt;i&gt;C0028754&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;Having a high amount of body fat (body mass index [BMI] of 30 or more).&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A disorder characterized by having a high amount of body fat.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MEDLINEPLUS)&lt;/td&gt;
                &lt;td&gt;
                  &lt;span&gt;
                    &lt;p&gt;Obesity means having too much body fat. It is different from being overweight, which means weighing too much.  The weight may come from muscle, bone, fat and/or body water.  Both terms mean that a person's weight is greater than what's considered healthy for his or her height. &lt;/p&gt;
                    &lt;p&gt;Obesity occurs over time when you eat more calories than you use. The balance between calories-in and calories-out differs for each person. Factors that might tip the balance include your genetic makeup, overeating, eating high-fat foods and not being physically active. &lt;/p&gt;
                    &lt;p&gt;Being obese increases your risk of diabetes, heart disease, stroke, arthritis and some cancers. If you are obese, losing even 5 to 10 percent of your weight can delay or prevent some of these diseases.&lt;/p&gt;
                    &lt;p style="font-weight:bold;font-style:italic;"&gt;NIH: National Institute of Diabetes and Digestive and Kidney Diseases&lt;/p&gt;
                  &lt;/span&gt;
                &lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A condition marked by an abnormally high, unhealthy amount of body fat.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CSP)&lt;/td&gt;
                &lt;td&gt;excessively high accumulation of body fat or adipose tissue in relation to lean body mass; the amount of body fat (or adiposity) includes concern for both the distribution of fat throughout the body and the size of the adipose tissue deposits; individuals are usually at high clinical risk because of excess amount of body fat (BMI greater than 30).&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;A status with BODY WEIGHT that is grossly above the acceptable or desirable weight, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Disease or Syndrome (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0028754&amp;amp;tui=T047"&gt;&lt;i&gt;T047&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D009765&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD9&lt;/td&gt;
                &lt;td&gt;278.00&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD10&lt;/td&gt;
                &lt;td&gt;E66, E66.9&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;5476005, 154776002, 190963004, 414916001, 414915002&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Adiposity, Obesities, Obesity, OBESE, OBESITY, Obesity, NOS, Obesity, unspecified, obesity (diagnosis), obesity, Obesity NOS, Obesity [Disease/Finding], obese, adiposity, Obesity [Ambiguous], Obese, Obese (finding), Obesity (disorder)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;OBESITE, Obésité, non précisée, Obésité&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;OBESIDADE, Obesidade NE, Obesidade&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;OBESIDAD, Obesidad no especificada, Obesity [Ambiguous], Obesity, obesidad (trastorno), obesidad, obeso (hallazgo), obeso, Obesidad&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;obesitas niet-gespecificeerd, Vetzucht, niet gespecificeerd, zwaarlijvigheid, Adipositas, Vetzucht&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Fettleibigkeit, unspezifisch, ADIPOSITAS, Adipositas, nicht naeher bezeichnet, Adipositas, Fettsucht, Obesitas&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Obesità, non specificata, Obesità&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;肥満, 肥満、詳細不明, ﾋﾏﾝ, ﾋﾏﾝｼｮｳｻｲﾌﾒｲ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Fetma&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;obezita, Obezita, blíže neurčená, Obezita&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Lihavuus&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;OZHIRENIE, ОЖИРЕНИЕ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Korean&lt;/td&gt;
                &lt;td&gt;상세불명의 비만, 비만&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Croatian&lt;/td&gt;
                &lt;td&gt;GOJAZNOST&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Otyłość&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;Obesitas, nem meghatározott, Obesitas&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Obesity screen  (</value><value>)
</value><value>Obesity  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Obesity Measurement</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Obesity</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Exam: Most useful Measurements&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Exam/BdyMsIndx.htm" class="LinkPage"&gt;Body Mass Index&lt;/a&gt; (BMI)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Exam/WstTHpRt.htm" class="LinkPage"&gt;Anthropometry&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Exam/WstTHpRt.htm" class="LinkPage"&gt;Waist-to-Hip Ratio&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Exam/WstTHpRt.htm" class="LinkPage"&gt;Waist Circumference&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Exam: Other Measurements&lt;ol&gt;&lt;li&gt;Skin-fold measurement&lt;ol&gt;&lt;li&gt;Very operator dependent&lt;/li&gt;&lt;li&gt;Normal subcutaneous fat&lt;ol&gt;&lt;li&gt;Men: 11%&lt;/li&gt;&lt;li&gt;Women: 18%&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Underwater weighing&lt;ol&gt;&lt;li&gt;Gold standard&lt;/li&gt;&lt;li&gt;Dependent on bone density&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Bioelectrical impedance&lt;ol&gt;&lt;li&gt;Safe, noninvasive, fairly reliable&lt;/li&gt;&lt;li&gt;Dependent on hydration&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Resources&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Frank%20%20%5BAU%5D%20AND%201998%20%5BDP%5D%20AND%20%20J%20Am%20Diet%20Assoc%20%20%5BTA%5D" class="LinkRef"&gt;Frank (1998) J Am Diet Assoc 98:S44-48&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Lyznicki%20%20%5BAU%5D%20AND%202001%20%5BDP%5D%20AND%20%20Am%20Fam%20Physician%20%20%5BTA%5D" class="LinkRef"&gt;Lyznicki (2001) Am Fam Physician 63(11):2185-96&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Rippe%20%20%5BAU%5D%20AND%201998%20%5BDP%5D%20AND%20%20J%20Am%20Diet%20Assoc%20%20%5BTA%5D" class="LinkRef"&gt;Rippe (1998) J Am Diet Assoc 98:S9-15&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Speer%20%20%5BAU%5D%20AND%201997%20%5BDP%5D%20AND%20%20Phys%20Sportsmed%20%20%5BTA%5D" class="LinkRef"&gt;Speer (1997) Phys Sportsmed 25:94-107&lt;/a&gt;&lt;/li&gt;&lt;li&gt;(1998) AOA Treatment Adult &lt;a href="../../Endo/Obesity/Obsty.htm" class="LinkPage"&gt;Obesity&lt;/a&gt;, 2nd edition&lt;/li&gt;&lt;li&gt;(1998) &lt;a href="../../Endo/Obesity/Obsty.htm" class="LinkPage"&gt;Obesity&lt;/a&gt; Res 6(suppl 2):51S-209S&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0740216</value><value>C0028754</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Obesity/ObstyMsrmnt.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Obesity Measurement, Obesity Screening</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Obesity/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Weight maintenance regimen  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0920298"&gt;&lt;i&gt;C0920298&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MEDLINEPLUS)&lt;/td&gt;
                &lt;td&gt;
                  &lt;span&gt;
                    &lt;p&gt;If you are overweight, you are not alone.  Sixty-six percent of adults in the U.S. are overweight or &lt;a href="http://www.nlm.nih.gov/medlineplus/obesity.html"&gt;obese&lt;/a&gt;.   Achieving a healthy weight can help you control your cholesterol, blood pressure and blood sugar. It might also help you prevent weight-related diseases, such as heart disease, diabetes, arthritis and some cancers. &lt;/p&gt;
                    &lt;p&gt;Eating too much or not being physically active enough will make you overweight. To maintain your weight, the calories you eat must equal the energy you burn. To lose weight, you must use more calories than you eat. A weight-control strategy might include&lt;/p&gt;
                    &lt;ul&gt;&lt;li&gt;Choosing low-fat, low-calorie foods&lt;/li&gt;
                      &lt;li&gt;Eating smaller portions&lt;/li&gt;
                      &lt;li&gt;Drinking water instead of sugary drinks&lt;/li&gt;
                      &lt;li&gt;Being physically active&lt;/li&gt;
                    &lt;/ul&gt;&lt;p style="font-weight:bold;font-style:italic;"&gt;NIH: National Institute of Diabetes and Digestive and Kidney Diseases&lt;/p&gt;
                  &lt;/span&gt;
                &lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (HHC)&lt;/td&gt;
                &lt;td&gt;Actions performed to control obesity or debilitation.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CSP)&lt;/td&gt;
                &lt;td&gt;therapy to regulate body weight.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (PSY)&lt;/td&gt;
                &lt;td&gt;Deliberate regulation of one's weight through diet, exercise, or other means. Also, the relative weight change resulting from such regulation practices. Used for human populations only.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NIC)&lt;/td&gt;
                &lt;td&gt;Facilitating maintenance of optimal body weight and percent body fat&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NOC)&lt;/td&gt;
                &lt;td&gt;Personal actions to achieve and maintain optimum body weight&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Therapeutic or Preventive Procedure (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0920298&amp;amp;tui=T061"&gt;&lt;i&gt;T061&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;388962008&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Weight Control, Weight maintenance diet, Weight Management, Weight maintenance regimen or diet, weight control (history), weight control, rnrx weight control, rnrx weight control (treatment), controling weight, Weight control, Weight maintenance regimen (regime/therapy), Weight management, Weight maintenance regimen, weight management&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Controllo del peso&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;体重管理, ﾀｲｼﾞｭｳｶﾝﾘ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;Kontrola hmotnosti&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;Testsúlykontrol&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;dieta para mantenimiento de peso (régimen/tratamiento), dieta para mantenimiento de peso, Control del peso&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Controlo de peso&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;gewichtscontrole&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Contrôle du poids&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Gewichtskontrolle&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Obesity Adverse Event  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C1963185"&gt;&lt;i&gt;C1963185&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Finding (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C1963185&amp;amp;tui=T033"&gt;&lt;i&gt;T033&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Obesity, Obesity Adverse Event&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Obesity monitoring status  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0421268"&gt;&lt;i&gt;C0421268&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Finding (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0421268&amp;amp;tui=T033"&gt;&lt;i&gt;T033&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;243862009&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Obesity monitoring status, Obesity monitoring status (finding)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;situación del control de la obesidad, situación del monitoreo de la obesidad (hallazgo), situación del monitoreo de la obesidad&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Weight maintenance regimen  (</value><value>)
</value><value>Obesity Adverse Event  (</value><value>)
</value><value>Obesity monitoring status  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Obesity Management</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Obesity</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;See Also&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Sports/ExrcsInObsty.htm" class="LinkPage"&gt;Exercise in Obesity&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Management: Select appropriate target weight loss&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Exam/BdyMsIndx.htm" class="LinkPage"&gt;Body Mass Index&lt;/a&gt; (BMI) &amp;gt; 30: Current BMI - 2&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Exam/BdyMsIndx.htm" class="LinkPage"&gt;Body Mass Index&lt;/a&gt; (BMI) &amp;lt;= 30: Lose 10% of current weight&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Management: Establish basic weight loss program&lt;ol&gt;&lt;li&gt;Healthy eating and reduced caloric intake&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Endo/Exam/EnrgyDfctClcltn.htm" class="LinkPage"&gt;Energy Deficit Calculation&lt;/a&gt;&lt;/li&gt;&lt;li&gt;See &lt;a href="../../Pharm/Nutrition/NtrtnGdlns.htm" class="LinkPage"&gt;Food Pyramid&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Eat a minimum of 3 times daily (esp. eat breakfast daily)&lt;ol&gt;&lt;li&gt;Stop &lt;a href="../../Psych/Eating/BngEtngDsrdr.htm" class="LinkPage"&gt;Binge Eating&lt;/a&gt; at bedtime&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Drink non-sugar, non-&lt;a href="../../Pharm/Nutrition/Cfn.htm" class="LinkPage"&gt;Caffeine&lt;/a&gt; fluid &amp;gt;64 ounces/day&lt;/li&gt;&lt;li&gt;Observe serving size and ingredients closely&lt;ol&gt;&lt;li&gt;Super-sized meals dramatically increases calories&lt;/li&gt;&lt;li&gt;One 8 ounce soda contains 15 teaspoons of sugar&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Write down everything you eat&lt;ol&gt;&lt;li&gt;Weight watchers&lt;/li&gt;&lt;li&gt;Handheld log&lt;ol&gt;&lt;li&gt;Balance Log&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.healthetech.com" class="LinkWebExt"&gt;http://www.healthetech.com&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Vivonic&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.vivonic.com" class="LinkWebExt"&gt;http://www.vivonic.com&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Calorie Chart&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.caloriechart.org" class="LinkWebExt"&gt;http://www.caloriechart.org&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Lose It!&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.apptism.com/apps/lose-it" class="LinkWebExt"&gt;http://www.apptism.com/apps/lose-it&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Use high bulk, low density foods&lt;ol&gt;&lt;li&gt;Eat Foods with high water, fiber, and lean protein&lt;/li&gt;&lt;li&gt;Fruit: 3/4 pound grapes = 1.5 ounces chocolate cals&lt;/li&gt;&lt;li&gt;Vegetables: 1 pound carrots = 1 ounce peanuts cals&lt;/li&gt;&lt;li&gt;Reference&lt;ol&gt;&lt;li&gt;Thompson (2005) Mayo Reviews Lecture, Rochester&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Choose dietary management for the longterm&lt;ol&gt;&lt;li&gt;Diets are equally effective in weight loss&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Dansinger%20%20%5BAU%5D%20AND%202005%20%5BDP%5D%20AND%20%20JAMA%20%20%5BTA%5D" class="LinkRef"&gt;Dansinger (2005) JAMA 293:43-53&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Increase &lt;a href="../../Sports/Exercise/Exrcs.htm" class="LinkPage"&gt;Physical Activity&lt;/a&gt;&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Endo/Sports/ExrcsInObsty.htm" class="LinkPage"&gt;Exercise in Obesity&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Start with 10 minutes everyday and build&lt;/li&gt;&lt;li&gt;&lt;a href="../../Sports/Exercise/Exrcs.htm" class="LinkPage"&gt;Exercise&lt;/a&gt; is key in a weight loss&lt;ol&gt;&lt;li&gt;However &lt;a href="../../Sports/Exercise/Exrcs.htm" class="LinkPage"&gt;Exercise&lt;/a&gt; without dietary change does not result in weight loss&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Wing%20%20%5BAU%5D%20AND%201999%20%5BDP%5D%20AND%20%20Med%20Sci%20Sports%20Exerc%20%20%5BTA%5D" class="LinkRef"&gt;Wing (1999) Med Sci Sports Exerc 31:S547&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Incorporate Lifestyle change strategies&lt;/li&gt;&lt;li&gt;Consider changing from &lt;a href="../../Endo/Pharm/MdctnsAsctdWthWghtGn.htm" class="LinkPage"&gt;Medications Associated with Weight Gain&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Consider organized weight loss program&lt;ol&gt;&lt;li&gt;Weight Watchers&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.weightwatchers.com" class="LinkWebExt"&gt;http://www.weightwatchers.com&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;TOPS (Take Off Pounds Sensibly)&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.tops.org" class="LinkWebExt"&gt;http://www.tops.org&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Management: Modify weight loss program based on &lt;a href="../../Endo/Obesity/ObstyRsk.htm" class="LinkPage"&gt;Obesity Risk&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Moderate Risk&lt;ol&gt;&lt;li&gt;Basic weight loss program&lt;/li&gt;&lt;li&gt;Consider low calorie diet&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;High and very high risk&lt;ol&gt;&lt;li&gt;Basic weight loss program&lt;/li&gt;&lt;li&gt;Consider very low calorie diet&lt;/li&gt;&lt;li&gt;Consider &lt;a href="../../Endo/Obesity/ObstyMdctn.htm" class="LinkPage"&gt;Obesity Medication&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Extremely high risk&lt;ol&gt;&lt;li&gt;Basic weight loss program&lt;/li&gt;&lt;li&gt;Consider very low calorie diet&lt;/li&gt;&lt;li&gt;Consider &lt;a href="../../Endo/Obesity/ObstyMdctn.htm" class="LinkPage"&gt;Obesity Medication&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Consider surgical intervention&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Frank%20%20%5BAU%5D%20AND%201998%20%5BDP%5D%20AND%20%20J%20Am%20Diet%20Assoc%20%20%5BTA%5D" class="LinkRef"&gt;Frank (1998) J Am Diet Assoc 98:S44-48&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Lyznicki%20%20%5BAU%5D%20AND%202001%20%5BDP%5D%20AND%20%20Am%20Fam%20Physician%20%20%5BTA%5D" class="LinkRef"&gt;Lyznicki (2001) Am Fam Physician 63(11):2185-96&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Rippe%20%20%5BAU%5D%20AND%201998%20%5BDP%5D%20AND%20%20J%20Am%20Diet%20Assoc%20%20%5BTA%5D" class="LinkRef"&gt;Rippe (1998) J Am Diet Assoc 98:S9-15&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Speer%20%20%5BAU%5D%20AND%201997%20%5BDP%5D%20AND%20%20Phys%20Sportsmed%20%20%5BTA%5D" class="LinkRef"&gt;Speer (1997) Phys Sportsmed 25:94-107&lt;/a&gt;&lt;/li&gt;&lt;li&gt;(1998) AOA Treatment Adult &lt;a href="../../Endo/Obesity/Obsty.htm" class="LinkPage"&gt;Obesity&lt;/a&gt;, 2nd edition&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0920298</value><value>C1963185</value><value>C0421268</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Obesity/ObstyMngmnt.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Obesity Management, Weight Reduction, Obesity Monitoring</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Obesity/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Thyroxine  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0040165"&gt;&lt;i&gt;C0040165&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CHV)&lt;/td&gt;
                &lt;td&gt;thyroid hormone&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CHV)&lt;/td&gt;
                &lt;td&gt;thyroid hormone&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CHV)&lt;/td&gt;
                &lt;td&gt;thyroid hormone&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CHV)&lt;/td&gt;
                &lt;td&gt;thyroid hormone&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CHV)&lt;/td&gt;
                &lt;td&gt;thyroid hormone&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CHV)&lt;/td&gt;
                &lt;td&gt;thyroid hormone&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A hormone that is made by the thyroid gland and contains iodine. T4 increases the rate of chemical reactions in cells and helps control growth and development. T4 can also be made in the laboratory and is used to treat thyroid disorders.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;The major hormone derived from the thyroid gland. Thyroxine is synthesized via the iodination of tyrosines (MONOIODOTYROSINE) and the coupling of iodotyrosines (DIIODOTYROSINE) in the THYROGLOBULIN. Thyroxine is released from thyroglobulin by proteolysis and secreted into the blood. Thyroxine is peripherally deiodinated to form TRIIODOTHYRONINE which exerts a broad spectrum of stimulatory effects on cell metabolism.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CSP)&lt;/td&gt;
                &lt;td&gt;tetraiodothyronine (T4); major hormone elaborated by the thyroid gland follicular cells; increases the rate of cell metabolism, essential for central nervous system maturation, and regulates a number of other functions.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A hormone synthesized and secreted by the thyroid gland containing four iodine atoms and is converted to triiodothyronine (T3) in the body, influencing metabolism and organ function.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (PDQ)&lt;/td&gt;
                &lt;td&gt;A hormone synthesized and secreted by the thyroid gland containing four iodine atoms and is converted to triiodothyronine (T3) in the body, influencing metabolism and organ function. Check for "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=528273&amp;amp;idtype=1" active clinical trials or "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=528273&amp;amp;idtype=1&amp;amp;closed=1" closed clinical trials using this agent. ("http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;amp;code=C2302" NCI Thesaurus)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Amino Acid, Peptide, or Protein (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0040165&amp;amp;tui=T116"&gt;&lt;i&gt;T116&lt;/i&gt;&lt;/a&gt;)
, Pharmacologic Substance (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0040165&amp;amp;tui=T121"&gt;&lt;i&gt;T121&lt;/i&gt;&lt;/a&gt;)
, Hormone (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0040165&amp;amp;tui=T125"&gt;&lt;i&gt;T125&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D013974&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;73187006, 38076006&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;3,5,3',5'-Tetraiodothyronine, L Thyroxine, L-3,5,3',5'-Tetraiodothyronine, L-Thyroxine, Levothyroxine, Thyroxin, Thyroxine, O-(4-Hydroxy-3,5-diiodophenyl) 3,5-diiodo-L-tyrosine, O-(4-Hydroxy-3,5-diiodophenyl)-3,5-diiodotyrosine, Tyrosine, O-(4-hydroxy-3,5-diiodophenyl)-3,5-diiodo-, levothyroxine, T4, T4 preparation, T&amp;lt;sub&amp;gt;4&amp;lt;/sub&amp;gt; preparation, T&amp;lt;sub&amp;gt;4&amp;lt;/sub&amp;gt;, thyroxine, T AAB THYROID HORMONE 004, THROXINE L, Thyroxine [Chemical/Ingredient], l-thyroxine, thyroxine (T4), l thyroxine, LEVOTHYROXINE, thyroxin, L-3,5,5'-tetraiodothyronine, T4 Thyroid Hormone, Thyroid Hormone, T4, 3,5,3'5' Tetraiodothyronine, Tetraiodothyronine preparation, Thyroxine preparation, Thyroxine product, T4 - Thyroxine, Total thyroxine, TT4 - Total thyroxine, T&amp;gt;4&amp;lt; preparation, T&amp;gt;4&amp;lt;, Tetraiodothyronine preparation (product), Thyroxine (substance), Tetraiodothyronine preparation (substance)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;L-Tireoxina, Levotireoxina, Tetraiodotironina, Tireotoxina, Levotiroxina, Tirotoxina, Tireoxina, T4, Tiroxina, Hormônio T4 da Tireóide, Hormônio Tireóideo T4&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Tyroxin&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;thyroxin, hormon T4, tyroxin&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Tyroksiini&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;T4 (Hormone thyroïdienne), Lévothyroxine, L-Thyroxine, 3,5,3',5'-Tétraiodothyronine, Hormone thyroïdienne T4, Tétra-iodothyronine, Tétraiodothyronine, Thyroxine&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;L-3,5,3',5'-TETRAIODTIRONIN, L-TIROKSIN, TIROKSIN, LEVOTIROKSIN, L-3,5,3',5'-ТЕТРАИОДТИРОНИН, L-ТИРОКСИН, ЛЕВОТИРОКСИН, ТИРОКСИН&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;サイロキシン, テトラヨードチロニン, レボチロキシンナトリウム水和物, L-チロキシン, チラージンS, レボチロキシンナトリウム, チラーヂンS, フリーT4, チロキシン, レボサイロキシン, レボチロキシン, L-3,5,3',5'-テトラヨードチロニン&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;T4, preparado con tetrayodotironina (producto), tetrayodotironina, preparado de tiroxina, tetrayodotironina (producto), preparado con tetrayodotironina, 3, 5, 3'5' tetrayodotironina, preparado de T&amp;gt;4, preparado de tetrayodotironina (producto), preparado de tetrayodotironina (sustancia), preparado de tetrayodotironina, tiroxina (sustancia), tiroxina, Tiroxina, Hormona Tiroidea T4, Levotiroxina, Tiroxina-L&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;T AAB SCHILDDRÜSENHORMON 004, THYROXIN A L, L-Thyroxin, Laevothyroxin, Levothyroxin, Thyroxin, T4-Schilddrüsenhormon&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Croatian&lt;/td&gt;
                &lt;td&gt;TIROKSIN&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;L-tyroksyna, Tyroksyna, Sól sodowa lewotyroksyny, Lewotyroksyna&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Tiroxina&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Thyroxine  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Thyroxine</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Pathology and Laboratory Medicine</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;See Also&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/ThyrdHrmnRplcmnt.htm" class="LinkPage"&gt;Thyroxine Replacement&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/Hypthyrdsm.htm" class="LinkPage"&gt;Hypothyroidism&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/Hyprthyrdsm1.htm" class="LinkPage"&gt;Hyperthyroidism&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Indication&lt;ol&gt;&lt;li&gt;Evaluation of &lt;a href="../../Endo/Anatomy/ThyrdAntmy.htm" class="LinkPage"&gt;Thyroid&lt;/a&gt; Function&lt;/li&gt;&lt;li&gt;Combined with &lt;a href="../../Endo/Lab/ThyrdStmltngHrmn.htm" class="LinkPage"&gt;Thyroid Stimulating Hormone&lt;/a&gt; (TSH)&lt;ol&gt;&lt;li&gt;Together most accurate assessment of &lt;a href="../../Endo/Anatomy/ThyrdAntmy.htm" class="LinkPage"&gt;Thyroid&lt;/a&gt; status&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Normal&lt;ol&gt;&lt;li&gt;Thyroxine (T4): 4-12 ug/dl&lt;/li&gt;&lt;li&gt;Free Thyroxine (Free T4): 0.7 - 1.9 ng/dl&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Measurement&lt;ol&gt;&lt;li&gt;Radioimmunoassay measures bound serum Thyroxine (T4)&lt;/li&gt;&lt;li&gt;Free Thyroxine (Free T4) measures only active T4&lt;ol&gt;&lt;li&gt;Not affected by &lt;a href="../../Endo/Lab/ThyrxnBndngGlbln.htm" class="LinkPage"&gt;Thyroid Binding Globulin&lt;/a&gt; (TBG)&lt;/li&gt;&lt;li&gt;Free Thyroxine (Free T4) represents 0.03% of total T4&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Increased Thyroxine or Free T4&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/GrvsDs.htm" class="LinkPage"&gt;Grave's Disease&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/MltndlrGtr.htm" class="LinkPage"&gt;Toxic Multinodular Goiter&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Toxic adenoma&lt;/li&gt;&lt;li&gt;Iatrogenic/factitious&lt;/li&gt;&lt;li&gt;Transient &lt;a href="../../Endo/Thyroid/Hyprthyrdsm1.htm" class="LinkPage"&gt;Hyperthyroidism&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/ID/SbctGrnlmtsThyrdts.htm" class="LinkPage"&gt;Subacute Thyroiditis&lt;/a&gt;,&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/HshmtsThyrdts.htm" class="LinkPage"&gt;Hashimoto's Thyroiditis&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Rarely&lt;ol&gt;&lt;li&gt;Hyperthyroid secondary to pituitary disease&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/HemeOnc/ThyrdCrcnm.htm" class="LinkPage"&gt;Thyroid Cancer&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Pharm/Amdrn.htm" class="LinkPage"&gt;Amiodarone&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Decreased Thyroxine or Free T4&lt;ol&gt;&lt;li&gt;Primary &lt;a href="../../Endo/Thyroid/Hypthyrdsm.htm" class="LinkPage"&gt;Hypothyroidism&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/HshmtsThyrdts.htm" class="LinkPage"&gt;Hashimoto's Thyroiditis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Idiopathic &lt;a href="../../Endo/Thyroid/Hypthyrdsm.htm" class="LinkPage"&gt;Myxedema&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Previous treatment of &lt;a href="../../Endo/Thyroid/Hyprthyrdsm1.htm" class="LinkPage"&gt;Hyperthyroidism&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/ID/SbctGrnlmtsThyrdts.htm" class="LinkPage"&gt;Subacute Thyroiditis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Prior neck radiotherapy&lt;/li&gt;&lt;li&gt;Iodine deficiency or excess&lt;/li&gt;&lt;li&gt;Congenital&lt;/li&gt;&lt;li&gt;Medications&lt;ol&gt;&lt;li&gt;&lt;a href="../../Psych/Pharm/LthmCrbnt.htm" class="LinkPage"&gt;Lithium&lt;/a&gt;&lt;/li&gt;&lt;li&gt;PAS&lt;/li&gt;&lt;li&gt;&lt;a href="../../ID/Pharm/Slfnmd.htm" class="LinkPage"&gt;Sulfonamide&lt;/a&gt;s&lt;/li&gt;&lt;li&gt;Phenylbutazone&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Pharm/Amdrn.htm" class="LinkPage"&gt;Amiodarone&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Thiourea&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Secondary &lt;a href="../../Endo/Thyroid/Hypthyrdsm.htm" class="LinkPage"&gt;Hypothyroidism&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Pituitary dysfunction&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Tertiary &lt;a href="../../Endo/Thyroid/Hypthyrdsm.htm" class="LinkPage"&gt;Hypothyroidism&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Hypothalamic disease&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Very rare&lt;ol&gt;&lt;li&gt;Tissue resistance to &lt;a href="../../Endo/Anatomy/ThyrdAntmy.htm" class="LinkPage"&gt;Thyroid&lt;/a&gt; hormone&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0040165</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Lab/Thyrxn.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Thyroxine, Free T4, T4</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Lab/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Thyrotropin  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0040160"&gt;&lt;i&gt;C0040160&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;A glycoprotein hormone secreted by the adenohypophysis (PITUITARY GLAND, ANTERIOR). Thyrotropin stimulates THYROID GLAND by increasing the iodide transport, synthesis and release of thyroid hormones (THYROXINE and TRIIODOTHYRONINE). Thyrotropin consists of two noncovalently linked subunits, alpha and beta. Within a species, the alpha subunit is common in the pituitary glycoprotein hormones (TSH; LUTEINIZING HORMONE and FSH), but the beta subunit is unique and confers its biological specificity.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A peptide hormone secreted by the anterior pituitary. It promotes the growth of the thyroid gland and stimulates the synthesis of thyroid hormones and the release of thyroxine by the thyroid gland.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CSP)&lt;/td&gt;
                &lt;td&gt;glycoprotein hormone of the anterior pituitary that promotes the growth of, sustains, and stimulates hormonal secretion of the thyroid gland.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A hormone produced by the pituitary gland. TSH stimulates the release of thyroid hormone from thyroglobulin. It also stimulates the growth of thyroid follicular cells. An abnormal TSH level may mean that the thyroid hormonal regulation system is out of control, usually as a result of a benign condition (hyperthyroidism or hypothyroidism).&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Amino Acid, Peptide, or Protein (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0040160&amp;amp;tui=T116"&gt;&lt;i&gt;T116&lt;/i&gt;&lt;/a&gt;)
, Pharmacologic Substance (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0040160&amp;amp;tui=T121"&gt;&lt;i&gt;T121&lt;/i&gt;&lt;/a&gt;)
, Hormone (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0040160&amp;amp;tui=T125"&gt;&lt;i&gt;T125&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D013972&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;65428006, 326013007, 24096000&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Thyroid stimulating hormone (TSH), Hormone, Thyroid-Stimulating, Thyreotropin, Thyroid-Stimulating Hormone, Thyrotrophin, Thyrotropin, thyrotropin, TSH preparation, Thyrotrophic hormone product, Thyrotropic hormone preparation, thyroid-stimulating hormone, TSH - Thyroid stimulating hormone, TSH-Thyroid stim horm, Thyroid Stimulating Hormone [EPC], Thyrotropin [Chemical/Ingredient], Thyroid Stimulating Hormone, thyroid stimulating hormone (TSH), thyrotropic hormone, thyroid stimulating hormone, TSH (Thyroid Stimulating Hormone), TSH, Thyroid stimulating hormone, Thyrotrophin product, Thyroid stimulating hormone (substance), Thyrotrophin product (product), Thyrotrophin product (substance), Thyrotropic hormone preparation (product), Thyrotropic hormone preparation (substance), Thyrotropic Hormone&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Hormônio Tireoestimulante, Tirotropina, Tireotropina, Tireotrofina, Hormônio Estimulante da Glândula Tireóide, Hormônio Estimulante da Tireóide, Tirotrofina&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Tyreotropin&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;tyreoideu stimulující hormon, TSH, tyreotropin, thyreotropin&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Tyreotropiini&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;TSH (Thyroid-stimulating hormone), Thyréotrophine, Thyréostimuline, Thyréotropine, Thyrotropine, Thyrotrophine, Hormone thyréotrope&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;TIREOTROPNYI GORMON, SHCHITOVIDNUIU ZHELEZU STIMULIRUIUSHCHII GORMON, TIROTROPIN, SHCHITOVIDNOI ZHELEZY STIMULIRUIUSHCHII GORMON, TIREOSTIMULIRUIUSHCHII GIPOFIZARNYI GORMON, TIREOTROPIN, TSH, ТИРЕОСТИМУЛИРУЮЩИЙ ГИПОФИЗАРНЫЙ ГОРМОН, ТИРЕОТРОПИН, ТИРЕОТРОПНЫЙ ГОРМОН, ТИРОТРОПИН, ЩИТОВИДНОЙ ЖЕЛЕЗЫ СТИМУЛИРУЮЩИЙ ГОРМОН, ЩИТОВИДНУЮ ЖЕЛЕЗУ СТИМУЛИРУЮЩИЙ ГОРМОН&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;甲状腺刺激ホルモン, チトロパール, チロトロピン, サイロトロピン&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;tirotrofina, producto (producto), tirotrofina (producto), tirotrofina, producto, hormona estimulante tiroidea, hormona tiroideoestimulante, preparado de TSH, preparado de hormona tirotrófica (producto), preparado de hormona tirotrófica (sustancia), preparado de hormona tirotrófica, preparado de hormona tirotrópica, preparado de tirotrofina, tirotrofina (sustancia), tirotrofina, tirotropina, Tirotropina, Hormona Estimulante de la Tiroides&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Tireotropina, TSH (Ormone stimolante la tiroide), Ormone stimolante la tiroide, Tirotropina&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Croatian&lt;/td&gt;
                &lt;td&gt;TIREOTROPIN, TIROTROPIN&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Tyreotropina, Hormon tyreotropowy, TSH&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Thyreoidea-stimulierendes Hormon, Thyreotropin, TSH (Thyreoidea-stimulierendes Hormon)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Thyrotropin  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Thyroid Stimulating Hormone</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Pathology and Laboratory Medicine</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Physiology&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Endo/Anatomy/ThyrdAntmy.htm" class="LinkPage"&gt;Thyroid Physiology&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Variation&lt;ol&gt;&lt;li&gt;TSH levels follow a circadian rhythm&lt;ol&gt;&lt;li&gt;TSH will vary as much as 1-2 uIU/ml over the course of the day&lt;/li&gt;&lt;li&gt;Consider drawing TSH at the same time of day for longterm serial measurements&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;TSH levels increase with normal aging in euthyroid patients&lt;ol&gt;&lt;li&gt;Consider using age-adjusted TSH interpretation&lt;/li&gt;&lt;li&gt;Age 20-29: 3.56 mIU/ml is 97th percentile&lt;/li&gt;&lt;li&gt;Age &amp;gt;80: 7.49 mIU/ml is 97th percentile&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Surks%20%20%5BAU%5D%20AND%202007%20%5BDP%5D%20AND%20%20JCEM%20%20%5BTA%5D" class="LinkRef"&gt;Surks (2007) JCEM 92: 4575&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;TSH levels are suppressed in pregnancy (due to high level HCG activity at TSH receptors)&lt;ol&gt;&lt;li&gt;Newly diagnosed &lt;a href="../../Endo/Thyroid/Hypthyrdsm.htm" class="LinkPage"&gt;Hypothyroidism&lt;/a&gt; in pregnancy&lt;ol&gt;&lt;li&gt;Obtain euthyroid state as soon as possible&lt;/li&gt;&lt;li&gt;Recheck TSH 30-40 days after &lt;a href="../../Endo/Pharm/ThyrdHrmnRplcmnt.htm" class="LinkPage"&gt;Levothyroxine&lt;/a&gt; dose start and dose change&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Follow &lt;a href="../../Endo/Anatomy/ThyrdAntmy.htm" class="LinkPage"&gt;Thyroid&lt;/a&gt; function closely&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/ThyrdHrmnRplcmnt.htm" class="LinkPage"&gt;Levothyroxine&lt;/a&gt; dose typically requires up to 30% increase in pregnancy&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Preconception&lt;ol&gt;&lt;li&gt;Goal TSH &amp;lt;2.5 mIU/ml&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Trimester 1&lt;ol&gt;&lt;li&gt;Goal TSH &amp;lt;2.5 mIU/ml&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Trimester 2-3&lt;ol&gt;&lt;li&gt;Goal TSH &amp;lt;3.0 mIU/ml&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;References&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=2007%20%5BDP%5D%20AND%20%20JCEM%20%20%5BTA%5D%20AND%2092%20%5BVI%5D%20AND%20%20S1%20%5BPG%5D" class="LinkRef"&gt;(2007) JCEM 92: S1-47&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Euthyroid individuals still have considerable variation in TSH levels over time&lt;/li&gt;&lt;li&gt;Populations of euthyroid individuals also have considerable variation in TSH levels&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Regulation&lt;ol&gt;&lt;li&gt;Negative feedback&lt;ol&gt;&lt;li&gt;Unbound &lt;a href="../../Endo/Lab/Thyrxn.htm" class="LinkPage"&gt;Thyroxine&lt;/a&gt; (&lt;a href="../../Endo/Lab/Thyrxn.htm" class="LinkPage"&gt;Free T4&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;Unbound &lt;a href="../../Endo/Lab/Trdthyrn.htm" class="LinkPage"&gt;Triiodothyronine&lt;/a&gt; (&lt;a href="../../Endo/Lab/Trdthyrn.htm" class="LinkPage"&gt;Free T3&lt;/a&gt;)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Positive Stimulation&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/ThyrdRlsngHrmn.htm" class="LinkPage"&gt;Thyroid Releasing Hormone&lt;/a&gt; (TRH)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Interpretation&lt;ol&gt;&lt;li&gt;Normal&lt;ol&gt;&lt;li&gt;Random: 0.3 - 5.0 uIU/ml&lt;/li&gt;&lt;li&gt;Following &lt;a href="../../Endo/Lab/ThyrdRlsngHrmn.htm" class="LinkPage"&gt;Thyroid Releasing Hormone&lt;/a&gt; (TRH) stimulation&lt;ol&gt;&lt;li&gt;TSH: 9-30 uIU/ml at 20-30 min&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Borderline Increased: 5-10 uIU/ml&lt;/li&gt;&lt;li&gt;High: &amp;gt;10 uIU/ml&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Causes: Increased TSH&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/Hypthyrdsm.htm" class="LinkPage"&gt;Hypothyroidism&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Drugs&lt;ol&gt;&lt;li&gt;&lt;a href="../../Psych/Pharm/Hlprdl.htm" class="LinkPage"&gt;Haloperidol&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Chlorpromazine&lt;/li&gt;&lt;li&gt;Metoclopramide&lt;/li&gt;&lt;li&gt;Domperidone&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;TSH antibodies&lt;/li&gt;&lt;li&gt;Pituitary resistance&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Causes: Decreased TSH&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/Hyprthyrdsm1.htm" class="LinkPage"&gt;Hyperthyroidism&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/SbclnclHypthyrdsm.htm" class="LinkPage"&gt;Euthyroid Sick Syndrome&lt;/a&gt; (associated with acute illness)&lt;/li&gt;&lt;li&gt;Pituitary disease causing TSH deficiency&lt;/li&gt;&lt;li&gt;&lt;a href="../../Renal/Sodium/Hypntrm.htm" class="LinkPage"&gt;Hyponatremia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Malnutrition&lt;/li&gt;&lt;li&gt;&lt;a href="../../Psych/Exam/MdDsrdr.htm" class="LinkPage"&gt;Mood Disorder&lt;/a&gt;s&lt;/li&gt;&lt;li&gt;Medications&lt;ol&gt;&lt;li&gt;&lt;a href="../../CV/Pharm/Dpmn.htm" class="LinkPage"&gt;Dopamine&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/SystmcCrtcstrd.htm" class="LinkPage"&gt;Corticosteroid&lt;/a&gt;s&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/DpmnAgnst.htm" class="LinkPage"&gt;Bromocriptine&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Levodopa&lt;/li&gt;&lt;li&gt;&lt;a href="../../Pharm/Vitamins/VtmnB6.htm" class="LinkPage"&gt;Pyridoxine&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0040160</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Lab/ThyrdStmltngHrmn.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Thyroid Stimulating Hormone, TSH, Serum TSH</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Lab/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Diabetic Neuropathies  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0011882"&gt;&lt;i&gt;C0011882&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;Peripheral, autonomic, and cranial nerve disorders that are associated with DIABETES MELLITUS. These conditions usually result from diabetic microvascular injury involving small blood vessels that supply nerves (VASA NERVORUM). Relatively common conditions which may be associated with diabetic neuropathy include third nerve palsy (see OCULOMOTOR NERVE DISEASES); MONONEUROPATHY; mononeuropathy multiplex; diabetic amyotrophy; a painful POLYNEUROPATHY; autonomic neuropathy; and thoracoabdominal neuropathy. (From Adams et al., Principles of Neurology, 6th ed, p1325)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CSP)&lt;/td&gt;
                &lt;td&gt;common complication of diabetes mellitus in which nerves are damaged as a result of hyperglycemia (high blood sugar levels).&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Disease or Syndrome (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0011882&amp;amp;tui=T047"&gt;&lt;i&gt;T047&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D003929&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD9&lt;/td&gt;
                &lt;td&gt;250.6&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;866003, 190353001, 230572002, 154683002, 193182005, 267472008, 190349003&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Neuropathy, diabetic, DIABETIC NEUROPATHY, Neuropathies, Diabetic, Diabetic neuropathies, NEUROPATHY, DIABETIC, Neuropathy, Diabetic, Diab.mell. with neuropathy, NEUROPATHY DIABETIC, Diabetes mellitus NOS with neurological manifestation (disorder), Diabetes mellitus NOS with neurological manifestation, Diabetic Neuropathies [Disease/Finding], Neuropathy;diabetic, diabetic nerve damage, diabetic neuropathies, Diabetic neuropathy, Diabetes mellitus with neuropathy, Diabetic neuropathy (disorder), neuropathy; diabetes (manifestation), Diabetes mellitus with neurological manifestation, Diabetes + neuropathy, Diabetic neuropathy (disorder) [Ambiguous], Neuropathy - diabetic, Diabetic Neuropathies, Diabetic Neuropathy, Diabetes with neurological manifestations, diabetic neuropathy&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Neuropatia diabetica, Neuropatie diabetiche&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Diabetesneuropatier&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;diabetické neuropatie, Diabetická neuropatie&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;Diabetic neuropathy, Diabetes + neuropathy, Neuropathy - diabetic, diabetes mellitus con neuropatía, diabetes mellitus, SAI con manifestaciones neurológicas (trastorno), diabetes mellitus, SAI con manifestaciones neurológicas, diabetes sacarina con neuropatía, neuropatía diabética (concepto no activo), neuropatía diabética (trastorno), neuropatía diabética, Neuropatía diabética, Acropatia Diabetica Ulcero-Mutilante, Neuropatías Diabéticas, Acropatía Diabética Úlcero-Mutilante, Neuropatias Diabeticas&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Diabeettiset neuropatiat&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;DIABETICHESKIE NEVROPATII, DIABETICHESKAIA POLINEVROPATIIA, DIABETICHESKAIA AMIOTROFIIA, DIABETICHESKAIA NEVRALGIIA, DIABETICHESKAIA NEVROPATIIA AVTONOMNAIA, ДИАБЕТИЧЕСКАЯ АМИОТРОФИЯ, ДИАБЕТИЧЕСКАЯ НЕВРАЛГИЯ, ДИАБЕТИЧЕСКАЯ НЕВРОПАТИЯ АВТОНОМНАЯ, ДИАБЕТИЧЕСКАЯ ПОЛИНЕВРОПАТИЯ, ДИАБЕТИЧЕСКИЕ НЕВРОПАТИИ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;ﾄｳﾆｮｳﾋﾞｮｳｾｲﾆｭｰﾛﾊﾟﾁｰ, 糖尿病性ニューロパチー, 糖尿病性ニューロパシー, 糖尿病ニューロパシー, 糖尿病神経障害, 神経障害-糖尿病性, 糖尿病性神経障害&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Croatian&lt;/td&gt;
                &lt;td&gt;DIJABETIČNE NEUROPATIJE&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Neuropatie cukrzycowe&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;Diabeteses neuropathia&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;neuropathie; diabetes, diabetische neuropathie, Diabetische neuropathie, Neuropathie, diabetische&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Neuropatia diabética, Acropatia Diabética Úlcero-Mutilante, Neuropatias Diabéticas&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Neuropathie diabétique, Neuropathies diabétiques&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Diabetische Neuropathie, Diabetische Neuropathien&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Diabetic Neuropathies  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Diabetic Neuropathy</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Neurology</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Epidemiology&lt;ol&gt;&lt;li&gt;Occurs in Type I and &lt;a href="../../Endo/DM/TypDbtsMlts1.htm" class="LinkPage"&gt;Type II Diabetes Mellitus&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Occurs in 42% of &lt;a href="../../Endo/DM/TypDbtsMlts1.htm" class="LinkPage"&gt;Type II Diabetes Mellitus&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Onset within 10 years of disease&lt;/li&gt;&lt;li&gt;Higher risk with higher &lt;a href="../../Endo/Lab/HmglbnAc.htm" class="LinkPage"&gt;Glycosylated Hemoglobin&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Partanen%20%20%5BAU%5D%20AND%201995%20%5BDP%5D%20AND%20%20N%20Engl%20J%20Med%20%20%5BTA%5D" class="LinkRef"&gt;Partanen (1995) N Engl J Med 333:89-94&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Types&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Neuro/BltrlPrphrlPlynrpthyInDbts.htm" class="LinkPage"&gt;Bilateral Peripheral Polyneuropathy in Diabetes&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Neuro/MnrpthyInDbts.htm" class="LinkPage"&gt;Diabetic Focal Neuropathy&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Neuro/DbtcAtnmcNrpthy.htm" class="LinkPage"&gt;Diabetic Autonomic Neuropathy&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Diagnosis&lt;ol&gt;&lt;li&gt;See also &lt;a href="../../Neuro/Exam/DbtcNrpthyTstng.htm" class="LinkPage"&gt;Peripheral Neuropathy Testing&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Differential Diagnosis&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Ortho/Sx/LgPn.htm" class="LinkPage"&gt;Leg Pain&lt;/a&gt;&lt;/li&gt;&lt;li&gt;See &lt;a href="../../Neuro/Autonomic/AtnmcDysfnctn.htm" class="LinkPage"&gt;Autonomic Neuropathy&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Peripheral &lt;a href="../../Neuro/Sx/SymtrcPrphrlNrpthy.htm" class="LinkPage"&gt;Polyneuropathy&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../HemeOnc/Anemia/VtmnBDfcncy.htm" class="LinkPage"&gt;Vitamin B12 Deficiency&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Especially when using &lt;a href="../../Endo/Pharm/Glcphg.htm" class="LinkPage"&gt;Metformin&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Pharm/Vitamins/FlcAcd.htm" class="LinkPage"&gt;Folic Acid&lt;/a&gt; deficiency&lt;/li&gt;&lt;li&gt;&lt;a href="../../HemeOnc/Anemia/IrnDfcncyAnm.htm" class="LinkPage"&gt;Iron Deficiency Anemia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/Hypthyrdsm.htm" class="LinkPage"&gt;Hypothyroidism&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Renal/Failure/ActRnlFlr.htm" class="LinkPage"&gt;Uremia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../ER/Toxin/ChmclTxn.htm" class="LinkPage"&gt;Chemical Toxin&lt;/a&gt; exposure (heavy metal toxicity)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Psych/CD/AlchlAbs.htm" class="LinkPage"&gt;Alcohol Abuse&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Lung/ILD/Srcds.htm" class="LinkPage"&gt;Sarcoidosis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../ID/Bacteria/Lprsy.htm" class="LinkPage"&gt;Leprosy&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Periarteritis nodosum&lt;/li&gt;&lt;li&gt;&lt;a href="../../Rheum/Diffuse/SystmcLpsErythmts.htm" class="LinkPage"&gt;Systemic Lupus Erythematosus&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../HemeOnc/Leukemia/Lkm.htm" class="LinkPage"&gt;Leukemia&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Other important causes of &lt;a href="../../Ortho/Sx/LgPn.htm" class="LinkPage"&gt;Leg Pain&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../Ortho/L-Spine/LmbrDscHrntn.htm" class="LinkPage"&gt;Lumbar Disc Disease&lt;/a&gt; with radiculopathy&lt;/li&gt;&lt;li&gt;Lumbar central spinal stenosis&lt;/li&gt;&lt;li&gt;&lt;a href="../../Surgery/CV/PrphrlArtrlOclsvDs.htm" class="LinkPage"&gt;Claudication&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Ortho/Sx/NctrnlLgCrmp.htm" class="LinkPage"&gt;Night Cramp&lt;/a&gt;s&lt;/li&gt;&lt;li&gt;&lt;a href="../../Neuro/Motor/RstlsLgSyndrm.htm" class="LinkPage"&gt;Restless Leg Syndrome&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Rheum/OA/Ostrthrts.htm" class="LinkPage"&gt;Degenerative Joint Disease&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Hip &lt;a href="../../Rheum/OA/Ostrthrts.htm" class="LinkPage"&gt;Osteoarthritis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Rheum/OA/KnOstrthrts.htm" class="LinkPage"&gt;Knee Osteoarthritis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Ortho/Anatomy/AnklAntmy.htm" class="LinkPage"&gt;Ankle&lt;/a&gt;&lt;a href="../../Rheum/OA/Ostrthrts.htm" class="LinkPage"&gt;Osteoarthritis&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Complications (of distal symmetric &lt;a href="../../Neuro/Sx/SymtrcPrphrlNrpthy.htm" class="LinkPage"&gt;Polyneuropathy&lt;/a&gt;)&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Rheum/Neuro/ChrctFt.htm" class="LinkPage"&gt;Charcot Foot&lt;/a&gt;&lt;/li&gt;&lt;li&gt;See &lt;a href="../../Surgery/Derm/FtWnd.htm" class="LinkPage"&gt;Foot Wound&lt;/a&gt;&lt;/li&gt;&lt;li&gt;See &lt;a href="../../Ortho/ID/DbtcFtOstmylts.htm" class="LinkPage"&gt;Suspected Osteomyelitis in Diabetes Mellitus&lt;/a&gt;&lt;/li&gt;&lt;li&gt;See &lt;a href="../../Neuro/Tremor/PrphrlNrpthyTrmr.htm" class="LinkPage"&gt;Peripheral Neuropathy Tremor&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Management: Approach&lt;ol&gt;&lt;li&gt;See dosing regimens in next section&lt;/li&gt;&lt;li&gt;Step 1&lt;ol&gt;&lt;li&gt;See prevention below for diabetes care optimization&lt;/li&gt;&lt;li&gt;Evaluate for other causes of &lt;a href="../../Neuro/Sx/PrphrlNrpthy.htm" class="LinkPage"&gt;Peripheral Neuropathy&lt;/a&gt; (see differential diagnosis above)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Step 2&lt;ol&gt;&lt;li&gt;&lt;a href="../../Psych/Pharm/TrcyclcAntdprsnt.htm" class="LinkPage"&gt;Tricyclic Antidepressant&lt;/a&gt;s (&lt;a href="../../Psych/Pharm/Amtrptyln.htm" class="LinkPage"&gt;Amitriptyline&lt;/a&gt;, &lt;a href="../../Psych/Pharm/Nrtrptyln.htm" class="LinkPage"&gt;Nortriptyline&lt;/a&gt;)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Step 3&lt;ol&gt;&lt;li&gt;Anticonvulsants&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Step 4&lt;ol&gt;&lt;li&gt;&lt;a href="../../Psych/Neuro/Srtn.htm" class="LinkPage"&gt;Serotonin&lt;/a&gt;-&lt;a href="../../CV/Pharm/Nrpnphrn.htm" class="LinkPage"&gt;Norepinephrine&lt;/a&gt; reuptake inhibitors&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Step 5&lt;ol&gt;&lt;li&gt;Reconsider differential diagnosis&lt;/li&gt;&lt;li&gt;Chronic &lt;a href="../../Pharm/Analgesic/Anlgsc.htm" class="LinkPage"&gt;Analgesic&lt;/a&gt;s (&lt;a href="../../Pharm/Analgesic/NrctcAnlgsc.htm" class="LinkPage"&gt;Opioid&lt;/a&gt;s, &lt;a href="../../Pharm/Analgesic/Trmdl.htm" class="LinkPage"&gt;Tramadol&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;Consider pain management referral&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Adjuncts (add at any point)&lt;ol&gt;&lt;li&gt;Topical &lt;a href="../../CV/Pharm/Ldcn.htm" class="LinkPage"&gt;Lidocaine&lt;/a&gt; (Lidoderm)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Pharm/Analgesic/Cpscn.htm" class="LinkPage"&gt;Capsaicin&lt;/a&gt; cream&lt;/li&gt;&lt;li&gt;&lt;a href="../../Pharm/Procedure/Acpnctr.htm" class="LinkPage"&gt;Acupuncture&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Management: Medications for Painful &lt;a href="../../Neuro/Sx/PrphrlNrpthy.htm" class="LinkPage"&gt;Peripheral Neuropathy&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../Psych/Pharm/TrcyclcAntdprsnt.htm" class="LinkPage"&gt;Tricyclic Antidepressant&lt;/a&gt;s&lt;ol&gt;&lt;li&gt;May be more effective in burning, steady pain&lt;/li&gt;&lt;li&gt;&lt;a href="../../Psych/Pharm/Amtrptyln.htm" class="LinkPage"&gt;Amitriptyline&lt;/a&gt; (&lt;a href="../../Psych/Pharm/Amtrptyln.htm" class="LinkPage"&gt;Elavil&lt;/a&gt;) started at 10-30 mg at bedtime and increased to 50-75 mg (maximum 150 mg) at bedtime&lt;/li&gt;&lt;li&gt;&lt;a href="../../Psych/Pharm/Nrtrptyln.htm" class="LinkPage"&gt;Nortriptyline&lt;/a&gt; (&lt;a href="../../Psych/Pharm/Nrtrptyln.htm" class="LinkPage"&gt;Pamelor&lt;/a&gt;) started at 10-30 mg at bedtime and increased to 50-75 mg (maximum 150 mg) at bedtime&lt;/li&gt;&lt;li&gt;&lt;a href="../../Psych/Pharm/Nrprmn.htm" class="LinkPage"&gt;Desipramine&lt;/a&gt; (&lt;a href="../../Psych/Pharm/Nrprmn.htm" class="LinkPage"&gt;Norpramin&lt;/a&gt;) starting at 25 mg at bedtime&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Anticonvulsants&lt;ol&gt;&lt;li&gt;May be more effective in sharp lancinating pain&lt;/li&gt;&lt;li&gt;&lt;a href="../../Neuro/Pharm/Gbpntn.htm" class="LinkPage"&gt;Gabapentin&lt;/a&gt; (&lt;a href="../../Neuro/Pharm/Gbpntn.htm" class="LinkPage"&gt;Neurontin&lt;/a&gt;)&lt;ol&gt;&lt;li&gt;Start at 100 mg at bedtime to 100 mg orally three time daily&lt;/li&gt;&lt;li&gt;Advance to 300 orally three times daily (maximum 1200 mg three times daily)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Neuro/Pharm/Prgbln.htm" class="LinkPage"&gt;Pregabalin&lt;/a&gt; (&lt;a href="../../Neuro/Pharm/Prgbln.htm" class="LinkPage"&gt;Lyrica&lt;/a&gt;)&lt;ol&gt;&lt;li&gt;Very similar to &lt;a href="../../Neuro/Pharm/Gbpntn.htm" class="LinkPage"&gt;Gabapentin&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Start at 50 mg orally two to three times daily&lt;/li&gt;&lt;li&gt;Titrate to 100 mg orally three times daily or 150 mg twice daily (maximum 300 mg twice daily)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Neuro/Pharm/Crbmzpn.htm" class="LinkPage"&gt;Carbamazepine&lt;/a&gt; (&lt;a href="../../Neuro/Pharm/Crbmzpn.htm" class="LinkPage"&gt;Tegretol&lt;/a&gt;)&lt;ol&gt;&lt;li&gt;Start at 100 mg orally twice daily&lt;/li&gt;&lt;li&gt;Advance to 200 mg orally twice daily as tolerated (maximum 600 mg twice daily)&lt;/li&gt;&lt;li&gt;Requires &lt;a href="../../HemeOnc/Lab/CmpltBldCnt.htm" class="LinkPage"&gt;Complete Blood Count&lt;/a&gt; monitoring&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Psych/Neuro/Srtn.htm" class="LinkPage"&gt;Serotonin&lt;/a&gt;-&lt;a href="../../CV/Pharm/Nrpnphrn.htm" class="LinkPage"&gt;Norepinephrine&lt;/a&gt; Reuptake Inhibitors&lt;ol&gt;&lt;li&gt;&lt;a href="../../Psych/Pharm/Dlxtn.htm" class="LinkPage"&gt;Duloxetine&lt;/a&gt; (&lt;a href="../../Psych/Pharm/Dlxtn.htm" class="LinkPage"&gt;Cymbalta&lt;/a&gt;)&lt;ol&gt;&lt;li&gt;Start at 20 mg twice daily&lt;/li&gt;&lt;li&gt;Advance to 60 mg daily (or divided 30 mg twice daily)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Psych/Pharm/Vnlfxn.htm" class="LinkPage"&gt;Venlafaxine&lt;/a&gt; (&lt;a href="../../Psych/Pharm/Vnlfxn.htm" class="LinkPage"&gt;Effexor&lt;/a&gt;)&lt;ol&gt;&lt;li&gt;Extended release (preferred): &lt;a href="../../Psych/Pharm/Vnlfxn.htm" class="LinkPage"&gt;Venlafaxine&lt;/a&gt; XR 37.5 mg daily (titrate to 225 mg daily)&lt;/li&gt;&lt;li&gt;Regular (generic): &lt;a href="../../Psych/Pharm/Vnlfxn.htm" class="LinkPage"&gt;Venlafaxine&lt;/a&gt; 37.5 mg twice daily (titrate to 225 mg divided twice daily)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Topical pain management&lt;ol&gt;&lt;li&gt;&lt;a href="../../Sports/Pharm/ElctrclStmltnThrpy.htm" class="LinkPage"&gt;TENS&lt;/a&gt; Unit&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Pharm/Ldcn.htm" class="LinkPage"&gt;Lidocaine&lt;/a&gt; 5% patch (Lidoderm) up to 3 patches applied daily to affected area (applied for no more than 12 hours daily)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Pharm/Analgesic/Cpscn.htm" class="LinkPage"&gt;Capsaicin&lt;/a&gt; 0.075% cream applied to affected area twice daily (start with small amount and slowly increase)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Pharm/Analgesic/Anlgsc.htm" class="LinkPage"&gt;Analgesic&lt;/a&gt;s&lt;ol&gt;&lt;li&gt;&lt;a href="../../Pharm/Analgesic/NnstrdlAntInflmtry.htm" class="LinkPage"&gt;NSAID&lt;/a&gt;S are not typically recommended in &lt;a href="../../Endo/DM/DbtsMlts.htm" class="LinkPage"&gt;Diabetes Mellitus&lt;/a&gt; due to renal, gastrointestinal and cardiovascular risks&lt;/li&gt;&lt;li&gt;&lt;a href="../../Pharm/Analgesic/Trmdl.htm" class="LinkPage"&gt;Tramadol&lt;/a&gt; (&lt;a href="../../Pharm/Analgesic/Trmdl.htm" class="LinkPage"&gt;Ultram&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Pharm/Analgesic/NrctcAnlgsc.htm" class="LinkPage"&gt;Opioid&lt;/a&gt;s (avoid unless no other option available)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Prevention&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Endo/Prevent/DbtcFtCr.htm" class="LinkPage"&gt;Diabetic Foot Care&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Optimize &lt;a href="../../Endo/DM/DbtsMlts.htm" class="LinkPage"&gt;Diabetes Mellitus&lt;/a&gt; management (&lt;a href="../../Endo/Lab/HmglbnAc.htm" class="LinkPage"&gt;Hemoglobin A1C&lt;/a&gt; &amp;lt;7-8%)&lt;/li&gt;&lt;li&gt;Optimize &lt;a href="../../CV/Htn/Hyprtnsn.htm" class="LinkPage"&gt;Hypertension&lt;/a&gt; and &lt;a href="../../CV/Lipid/Anthyprlpdmc.htm" class="LinkPage"&gt;Hyperlipidemia Management&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Aring%20%20%5BAU%5D%20AND%202005%20%5BDP%5D%20AND%20%20Am%20Fam%20Physician%20%20%5BTA%5D" class="LinkRef"&gt;Aring (2005) Am Fam Physician 71:2123-30&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Backonja%20%20%5BAU%5D%20AND%201998%20%5BDP%5D%20AND%20%20JAMA%20%20%5BTA%5D" class="LinkRef"&gt;Backonja (1998) JAMA 280:1831-36&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Kochar%20%20%5BAU%5D%20AND%202004%20%5BDP%5D%20AND%20%20QJM%20%20%5BTA%5D" class="LinkRef"&gt;Kochar (2004) QJM 97:33-8&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Lindsay%20%20%5BAU%5D%20AND%202010%20%5BDP%5D%20AND%20%20Am%20Fam%20Physician%20%20%5BTA%5D" class="LinkRef"&gt;Lindsay (2010) Am Fam Physician 82(2): 151-8&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Lipnick%20%20%5BAU%5D%20AND%201996%20%5BDP%5D%20AND%20%20Am%20Fam%20Physician%20%20%5BTA%5D" class="LinkRef"&gt;Lipnick (1996) Am Fam Physician 54(8):2478-84&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=McQuay%20%20%5BAU%5D%20AND%201996%20%5BDP%5D%20AND%20%20Pain%20%20%5BTA%5D" class="LinkRef"&gt;McQuay (1996) Pain 68:217-27&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Simmons%20%20%5BAU%5D%20AND%202000%20%5BDP%5D%20AND%20%20Clinical%20Diabetes%20%20%5BTA%5D" class="LinkRef"&gt;Simmons (2000) Clinical Diabetes 18:116-7&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Sindrup%20%20%5BAU%5D%20AND%201990%20%5BDP%5D%20AND%20%20Pain%20%20%5BTA%5D" class="LinkRef"&gt;Sindrup (1990) Pain 42:135-44&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Veves%20%20%5BAU%5D%20AND%202008%20%5BDP%5D%20AND%20%20Pain%20Med%20%20%5BTA%5D" class="LinkRef"&gt;Veves (2008) Pain Med 9(6): 660-74&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Wong%20(2007)%20BMJ%20335%20%5BAU%5D%20AND%207610%20%5BDP%5D%20AND%20:%20%20%5BTA%5D" class="LinkRef"&gt;Wong (2007) BMJ 335(7610): 87&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0011882</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Neuro/DbtcNrpthy.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Diabetic Neuropathy, Peripheral Neuropathy in Diabetes Mellitus</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Neuro/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Dietary Supplements  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0242295"&gt;&lt;i&gt;C0242295&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MEDLINEPLUS)&lt;/td&gt;
                &lt;td&gt;
                  &lt;span&gt;
                    &lt;p&gt;Dietary supplements are vitamins, minerals, herbs and other substances meant to improve your diet. They can come as pills, capsules, powders and liquids. Supplements do not have to go through the testing that drugs do. &lt;/p&gt;
                    &lt;p&gt;Some supplements can play an important role in health. For example, pregnant women can take the vitamin folic acid to prevent certain birth defects in their babies. Taking supplements can also be a type of &lt;a href="http://www.nlm.nih.gov/medlineplus/complementaryandalternativemedicine.html"&gt;complementary or alternative  medicine&lt;/a&gt; (CAM).&lt;/p&gt;
                    &lt;p&gt;To take a supplement as safely as possible&lt;/p&gt;
                    &lt;ul&gt;&lt;li&gt;	Tell your doctor about any dietary supplements you use&lt;/li&gt;
                      &lt;li&gt;	Do not take a bigger dose than the label recommends&lt;/li&gt;
                      &lt;li&gt;	Stop taking it if you have side effects&lt;/li&gt;
                      &lt;li&gt;	Read trustworthy information about the supplement &lt;/li&gt;
                    &lt;/ul&gt;&lt;p style="font-weight:bold;font-style:italic;"&gt;NIH: National Center for Complementary and Alternative Medicine&lt;/p&gt;
                  &lt;/span&gt;
                &lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A product that is added to the diet. A dietary supplement is taken by mouth, and usually contains one or more dietary ingredient (such as vitamin, mineral, herb, amino acid, and enzyme).&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CSP)&lt;/td&gt;
                &lt;td&gt;something that completes a diet, offsets a dietary deficiency or strengthens the diet.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;Products in capsule, tablet or liquid form that provide essential nutrients, such as a vitamin, an essential mineral, a protein, an herb, or similar nutritional substance. (FDA Backgrounder, June 15, 1993, p2)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (PSY)&lt;/td&gt;
                &lt;td&gt;Orally ingested products intended as supplements to the diet, including vitamins, herbs, amino acids, and concentrates, metabolites, and extracts of these substances.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;Oral preparations containing dietary ingredient(s) intended to supplement the diet. Dietary ingredients include vitamins, minerals, herbs, amino acids, extracts and metabolites.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Food (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0242295&amp;amp;tui=T168"&gt;&lt;i&gt;T168&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D019587&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;373689005, 226279009, 108961000, 373453009&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Supplement, Dietary, Supplements, Dietary, Dietary Supplement, Nutritional Supplement, Supplement, dietary supplements, dietary supplements (medication), Dietary supplement, nutritional supplementation, nutrient supplementation, dietary supplement, nutritional supplement, Nutrient supplementation, Nutritional supplementation, Nutrient supplementation (product), Nutritional supplement (product), Nutritional supplement (substance), Nutritional supplement, Dietary Supplements, Nutrient supplementation (substance), Nutritional Supplements, nutritional supplements&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Nahrungsergänzungsmittel&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Kosttillskott&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;potravní doplňky&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;suplemento de nutrientes (sustancia), suplemento de nutrientes, Alimentos Nutracéuticos, Alimentos Nutraceuticos, complemento nutricional (producto), complemento nutricional (sustancia), complemento nutricional, suplemento con nutrientes (producto), suplemento con nutrientes, suplemento nutricional (producto), suplemento nutricional (sustancia), suplemento nutricional, Suplementos Dieteticos, Suplementos Dietéticos&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Ravinnonkorvikkeet&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;PITATEL'NUIU TSENNOST' POVYSHAIUSHCHIE VESHCHESTVA, ПИТАТЕЛЬНУЮ ЦЕННОСТЬ ПОВЫШАЮЩИЕ ВЕЩЕСТВА&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;栄養補充食品, ダイエタリーサプリメント, 食品-補充, 補充食品, ダイエタリー･サプリメント, 食品-栄養補助, ダイエタリー･サプルメント, サプリメント食品, 栄養補助食品, 栄養補給食品&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Alimentos Nutracêuticos, Suplementos Nutricionais, Suplementos Dietéticos&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Croatian&lt;/td&gt;
                &lt;td&gt;DODACI PREHRANI&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Suplementy żywności, Suplementy diety, Wzbogacanie żywności&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Compléments alimentaires&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Integratori alimentari&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;Voedingssupplement, Voedingssupplementen&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Dietary Supplements  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Dietary Supplements in Obesity</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Obesity</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;See Also&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Obesity/Obsty.htm" class="LinkPage"&gt;Obesity&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Obesity/ObstyMngmnt.htm" class="LinkPage"&gt;Obesity Management&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Obesity/ObstyMdctn.htm" class="LinkPage"&gt;Obesity Medication&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;General&lt;ol&gt;&lt;li&gt;Most studies on these agents are too short duration&lt;/li&gt;&lt;li&gt;Most studies have also been of low power&lt;/li&gt;&lt;li&gt;No strong evidence that any supplements are effective&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Preparations: Ineffective Agents (Avoid these)&lt;ol&gt;&lt;li&gt;Chitosan&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Pittler%20%20%5BAU%5D%20AND%201999%20%5BDP%5D%20AND%20%20Eur%20J%20Clin%20Nutr%20%20%5BTA%5D" class="LinkRef"&gt;Pittler (1999) Eur J Clin Nutr 53:379-81&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Conjugated &lt;a href="../../Pharm/Nutrition/Omg6FtyAcd.htm" class="LinkPage"&gt;Linoleic Acid&lt;/a&gt; (CLA)&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Blankson%20%20%5BAU%5D%20AND%202000%20%5BDP%5D%20AND%20%20J%20Nutr%20%20%5BTA%5D" class="LinkRef"&gt;Blankson (2000) J Nutr 130:2943-8&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/ChrmPclnt.htm" class="LinkPage"&gt;Chromium Picolinate&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Ineffective with risk of &lt;a href="../../Renal/Failure/Rhbdmylys.htm" class="LinkPage"&gt;Rhabdomyolysis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Vincent%20%20%5BAU%5D%20AND%202003%20%5BDP%5D%20AND%20%20Sports%20Med%20%20%5BTA%5D" class="LinkRef"&gt;Vincent (2003) Sports Med 33:213-30&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Human chorionic &lt;a href="../../Endo/Pharm/HmnGrwthHrmn.htm" class="LinkPage"&gt;Growth Hormone&lt;/a&gt; (HCG)&lt;ol&gt;&lt;li&gt;Pulled from U.S. market by FDA in 2012&lt;/li&gt;&lt;li&gt;Ineffective for weight loss despite which use continues by some weight loss clinics and someOTC manufacturers&lt;/li&gt;&lt;li&gt;Risk of &lt;a href="../../HemeOnc/CV/DpVnThrmbs.htm" class="LinkPage"&gt;Venous Thromboembolism&lt;/a&gt;, &lt;a href="../../Psych/Depress/MjrDprsn.htm" class="LinkPage"&gt;Major Depression&lt;/a&gt;, cardiovascular events&lt;/li&gt;&lt;li&gt;FDA Consumer Update&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm281333.htm" class="LinkWebExt"&gt;http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm281333.htm&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Pharm/Nutrition/Fbr.htm" class="LinkPage"&gt;Fiber&lt;/a&gt; (guar gum, &lt;a href="../../Pharm/Nutrition/Fbr.htm" class="LinkPage"&gt;Psyllium&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;Yerba mate&lt;/li&gt;&lt;li&gt;Licorice&lt;/li&gt;&lt;li&gt;Vitamin B5&lt;/li&gt;&lt;li&gt;L-Carnitine&lt;/li&gt;&lt;li&gt;Dandelion (&lt;a href="../../CV/Pharm/Drtc.htm" class="LinkPage"&gt;Diuretic&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;&lt;a href="../../GI/Pharm/StmlntLxtv.htm" class="LinkPage"&gt;Cascara&lt;/a&gt; (&lt;a href="../../GI/Pharm/Lxtv.htm" class="LinkPage"&gt;Laxative&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Pharm/Alternative/StJhnsWrt.htm" class="LinkPage"&gt;St. John's Wort&lt;/a&gt; (no effect on weight loss)&lt;/li&gt;&lt;li&gt;&lt;a href="../../OB/Procedure/LmnrInsrtn.htm" class="LinkPage"&gt;Laminaria&lt;/a&gt; (kelp)&lt;/li&gt;&lt;li&gt;Spirulina (blue green algae)&lt;/li&gt;&lt;li&gt;Goggul (myrrh tree extract)&lt;/li&gt;&lt;li&gt;Apple cider vinegar&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Preparations: Agents with inconsistent results or weak evidence&lt;ol&gt;&lt;li&gt;Garcinia cambogia (hydroxycitric acid)&lt;ol&gt;&lt;li&gt;Trials have shown conflicting results&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Glucomannan (&lt;a href="../../Pharm/Nutrition/Fbr.htm" class="LinkPage"&gt;Dietary Fiber&lt;/a&gt; source)&lt;ol&gt;&lt;li&gt;Modest weight loss in small trials&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Hydroxymethylbutyrate or Pyruvate&lt;ol&gt;&lt;li&gt;May increase &lt;a href="../../Endo/Exam/IdlWghtInAdlts.htm" class="LinkPage"&gt;Lean Body Mass&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Uro/Pharm/Yhmbn.htm" class="LinkPage"&gt;Yohimbine&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Pharm/Alternative/Gnsng.htm" class="LinkPage"&gt;Ginseng&lt;/a&gt;&lt;ol&gt;&lt;li&gt;No evidence to date supporting weight loss role&lt;/li&gt;&lt;li&gt;May improve &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; tolerance in diabetics&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Sotaniemi%20%20%5BAU%5D%20AND%201995%20%5BDP%5D%20AND%20%20Diabetes%20Care%20%20%5BTA%5D" class="LinkRef"&gt;Sotaniemi (1995) Diabetes Care 18:1373-5&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Pharm/Alternative/GrnT.htm" class="LinkPage"&gt;Green Tea&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Pyruvate&lt;/li&gt;&lt;li&gt;Raspberry Ketone&lt;ol&gt;&lt;li&gt;Artificially synthesized to flavor food or as perfume in cosmetics&lt;/li&gt;&lt;li&gt;Animal studies may show benefit in lipid metabolism&lt;ol&gt;&lt;li&gt;No human studies to demonstrate benefit in weight loss&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;No safety data for doses or frequency used for weight loss&lt;ol&gt;&lt;li&gt;&lt;a href="../../CV/Sx/Plptn.htm" class="LinkPage"&gt;Palpitation&lt;/a&gt;s have been reported&lt;/li&gt;&lt;li&gt;&lt;a href="../../HemeOnc/Pharm/Wrfrn.htm" class="LinkPage"&gt;Warfarin&lt;/a&gt; drug interaction reported (reduced &lt;a href="../../HemeOnc/Pharm/Wrfrn.htm" class="LinkPage"&gt;Warfarin&lt;/a&gt; effect)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;References&lt;ol&gt;&lt;li&gt;(2012) Presc Lett 19(5): 29&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Dihydroepiandrosterone (&lt;a href="../../Sports/Pharm/Andrstndn.htm" class="LinkPage"&gt;DHEA&lt;/a&gt;)&lt;ol&gt;&lt;li&gt;Sex hormone precursor (Testosterone, &lt;a href="../../Gyn/Pharm/Estrgn.htm" class="LinkPage"&gt;Estrogen&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;May reduce abdominal fat&lt;/li&gt;&lt;li&gt;May increase &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; sensitivity&lt;/li&gt;&lt;li&gt;Long-term safety unclear&lt;ol&gt;&lt;li&gt;Risk of &lt;a href="../../Gyn/HemeOnc/BrstCncr.htm" class="LinkPage"&gt;Breast Cancer&lt;/a&gt; and &lt;a href="../../Uro/HemeOnc/PrstCncr.htm" class="LinkPage"&gt;Prostate Cancer&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;References&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=2004%20%5BDP%5D%20AND%20%20JAMA%20%20%5BTA%5D%20AND%20292%20%5BVI%5D%20AND%202243%20%5BPG%5D" class="LinkRef"&gt;(2004) JAMA 292:2243&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Preparations: Agents with significant safety concerns (do not use)&lt;ol&gt;&lt;li&gt;Avoid &lt;a href="../../Pharm/Alternative/Ephdrn.htm" class="LinkPage"&gt;Ephedra&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Significant adverse effects (see &lt;a href="../../Pharm/Alternative/Ephdrn.htm" class="LinkPage"&gt;Ephedra&lt;/a&gt; for risks)&lt;/li&gt;&lt;li&gt;Marginal benefit in weight loss (1 kg)&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Shekelle%20%20%5BAU%5D%20AND%202003%20%5BDP%5D%20AND%20%20JAMA%20%20%5BTA%5D" class="LinkRef"&gt;Shekelle (2003) JAMA 289:1537-45&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Resources&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Pharm/Alternative/HrblRsrcs.htm" class="LinkPage"&gt;Dietary Supplement Resources&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Prittler%20%20%5BAU%5D%20AND%202004%20%5BDP%5D%20AND%20%20Am%20J%20Clin%20Nutr%20%20%5BTA%5D" class="LinkRef"&gt;Prittler (2004) Am J Clin Nutr 79:529-36&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Saper%20%20%5BAU%5D%20AND%202004%20%5BDP%5D%20AND%20%20Am%20Fam%20Physician%20%20%5BTA%5D" class="LinkRef"&gt;Saper (2004) Am Fam Physician 70:1731-38&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0242295</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Obesity/DtrySplmntsInObsty.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Dietary Supplements in Obesity, Obesity Management with Dietary Supplements</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Obesity/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Thyroxine-Binding Globulin  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0087090"&gt;&lt;i&gt;C0087090&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;A thyroid hormone transport protein found in serum. It binds about 75% of circulating THYROXINE and 70% of circulating TRIIODOTHYRONINE.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Amino Acid, Peptide, or Protein (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0087090&amp;amp;tui=T116"&gt;&lt;i&gt;T116&lt;/i&gt;&lt;/a&gt;)
, Immunologic Factor (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0087090&amp;amp;tui=T129"&gt;&lt;i&gt;T129&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D056825&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;123338002, 143682007, 166320009, 166334009, 415720002, 88181004&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Thyroxine-Binding Globulin, TBG - Thyroxine binding globulin, TBG-Thyroxine binding globulin, Thyroxin binding globulin (TBG), Serpin A7, Thyroxine Binding Globulin, Thyropexin, Thyroxine-Binding Globulin [Chemical/Ingredient], tbg, thyroxine binding globulin (TBG), thyroxine binding globulin, Thyroxine binding glob., Thyroxine binding globulin -RETIRED-, Thyroxine binding globulin-TBG, TBG, Thyroxine binding globulin, Thyroxin-binding globulin, Thyroxine binding globulin (substance)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;globulina fijadora de T4, Thyroxine binding glob., TBG - Thyroxine binding globulin, Thyroxine binding globulin, Thyroxine binding globulin-TBG, Globulina de Unión a Tiroxina, Globulina de Union a Tiroxina, globulina fijadora de tiroxina - RETIRADO - (concepto no activo), globulina fijadora de tiroxina - RETIRADO -, globulina fijadora de tiroxina, globulina fijadora de tiroxina (sustancia)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Globuline liant la thyroxine, Globuline fixant la thyroxine, Globuline se liant à la thyroxine, TBG (Thyroxine-Binding Globulin), Globuline de liaison à la thyroxine&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Thyroxinbindendes Globulin&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Globulina Ligada a Tiroxina, Globulina Ligante de Tireoxina, Globulina Ligante de Tiroxina, Globulina Ligada a Tireoxina&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;ТИРОКСИН-СВЯЗЫВАЮЩИЙ ГЛОБУЛИН, TIROKSIN-SVIAZYVAIUSHCHII GLOBULIN, ТИРОПЕКСИН, SERPIN A7, TIROPEKSIN, СЕРПИН A7&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Tyroxinbindande globulin&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;thyropexin, serpin A7, globulin vázající thyroxin&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Globulina legante la tiroxina&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Globulina wiążąca tyroksynę&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;チロキシン結合グロブリン, サイロキシン結合グロブリン&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Thyroxine-Binding Globulin  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Thyroxine Binding Globulin</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Pathology and Laboratory Medicine</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Physiology&lt;ol&gt;&lt;li&gt;Radioimmunoassay of major storage of &lt;a href="../../Endo/Anatomy/ThyrdAntmy.htm" class="LinkPage"&gt;Thyroid&lt;/a&gt; hormone&lt;/li&gt;&lt;li&gt;TBG binds &lt;a href="../../Endo/Anatomy/ThyrdAntmy.htm" class="LinkPage"&gt;Thyroid&lt;/a&gt; hormone in circulation&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/Thyrxn.htm" class="LinkPage"&gt;Thyroxine&lt;/a&gt; (T4) is 99.97% protein bound&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/Trdthyrn.htm" class="LinkPage"&gt;Triiodothyronine&lt;/a&gt; (T3) is 99.7% protein bound&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Interpretation&lt;ol&gt;&lt;li&gt;TBG effects measurement of total T4 and T3&lt;ol&gt;&lt;li&gt;Increased TBG increases total T4 and T3 measurements&lt;ol&gt;&lt;li&gt;Decreased percent &lt;a href="../../Endo/Lab/Thyrxn.htm" class="LinkPage"&gt;Free T4&lt;/a&gt; and T3&lt;/li&gt;&lt;li&gt;No change in &lt;a href="../../Endo/Lab/Thyrxn.htm" class="LinkPage"&gt;Free T4&lt;/a&gt; and &lt;a href="../../Endo/Lab/Trdthyrn.htm" class="LinkPage"&gt;Free T3&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Decreased TBG decreases total T4 and T3 measurements&lt;ol&gt;&lt;li&gt;Increased percent &lt;a href="../../Endo/Lab/Thyrxn.htm" class="LinkPage"&gt;Free T4&lt;/a&gt; and T3&lt;/li&gt;&lt;li&gt;No change in &lt;a href="../../Endo/Lab/Thyrxn.htm" class="LinkPage"&gt;Free T4&lt;/a&gt; and &lt;a href="../../Endo/Lab/Trdthyrn.htm" class="LinkPage"&gt;Free T3&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Labs unaffected by Thyroid Binding Globulin (TBG)&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/FrThyrxnIndx.htm" class="LinkPage"&gt;Free Thyroxine Index&lt;/a&gt; (FTI)&lt;ol&gt;&lt;li&gt;Calculation based on &lt;a href="../../Endo/Lab/T3RsnUptk.htm" class="LinkPage"&gt;T3 Resin Uptake&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Free &lt;a href="../../Endo/Lab/Thyrxn.htm" class="LinkPage"&gt;Thyroxine&lt;/a&gt; (&lt;a href="../../Endo/Lab/Thyrxn.htm" class="LinkPage"&gt;Free T4&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;Free &lt;a href="../../Endo/Lab/Trdthyrn.htm" class="LinkPage"&gt;Triiodothyronine&lt;/a&gt; (&lt;a href="../../Endo/Lab/Trdthyrn.htm" class="LinkPage"&gt;Free T3&lt;/a&gt;)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Increased TBG (Reduces total T4 and T3 measurements)&lt;ol&gt;&lt;li&gt;Pregnancy&lt;/li&gt;&lt;li&gt;Newborn state&lt;/li&gt;&lt;li&gt;Chronic Active Hepatitis&lt;/li&gt;&lt;li&gt;Biliary &lt;a href="../../GI/Lvr/Crhs.htm" class="LinkPage"&gt;Cirrhosis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Infection&lt;/li&gt;&lt;li&gt;Acute intermittent porphyria&lt;/li&gt;&lt;li&gt;Familial hyperthyroxinemia&lt;/li&gt;&lt;li&gt;Drugs&lt;ol&gt;&lt;li&gt;&lt;a href="../../Gyn/Pharm/OrlCntrcptv.htm" class="LinkPage"&gt;Oral Contraceptive&lt;/a&gt;s&lt;/li&gt;&lt;li&gt;&lt;a href="../../Gyn/Pharm/Estrgn.htm" class="LinkPage"&gt;Estrogen&lt;/a&gt;s&lt;/li&gt;&lt;li&gt;&lt;a href="../../Gyn/Pharm/Tmxfn.htm" class="LinkPage"&gt;Tamoxifen&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Pharm/Analgesic/MthdnInChrncPn.htm" class="LinkPage"&gt;Methadone&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Psych/CD/OpdAbs.htm" class="LinkPage"&gt;Heroin&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Perphenazine&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Decreased TBG (Elevates total T4 and T3 measurements)&lt;ol&gt;&lt;li&gt;&lt;a href="../../GI/Prevent/PrvntnOfLvrDsPrgrsn.htm" class="LinkPage"&gt;Chronic Liver Disease&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../GI/Lab/DrctBlrbn.htm" class="LinkPage"&gt;Obstructive Jaundice&lt;/a&gt; or &lt;a href="../../GI/Lvr/Crhs.htm" class="LinkPage"&gt;Cirrhosis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Severe systemic illness&lt;/li&gt;&lt;li&gt;Active &lt;a href="../../Endo/Pituitary/Acrmgly.htm" class="LinkPage"&gt;Acromegaly&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Renal/Glomerulus/NphrtcSyndrm.htm" class="LinkPage"&gt;Nephrotic Syndrome&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Surgical Stress&lt;/li&gt;&lt;li&gt;Medications&lt;ol&gt;&lt;li&gt;Androgens&lt;/li&gt;&lt;li&gt;&lt;a href="../../Pharm/Analgesic/Slcylt.htm" class="LinkPage"&gt;Salicylate&lt;/a&gt;s&lt;/li&gt;&lt;li&gt;L-asparaginase&lt;/li&gt;&lt;li&gt;Large doses of glucocorticoids (Prednisone)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0087090</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Lab/ThyrxnBndngGlbln.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Thyroxine Binding Globulin, Thyroid Binding Globulin, TBG</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Lab/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees></FP_UMLS_Trees><FP_Condition_name_check></FP_Condition_name_check><FP_Condition_name><value>Bilateral Peripheral Polyneuropathy in Diabetes</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Neurology</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Epidemiology&lt;ol&gt;&lt;li&gt;Most common &lt;a href="../../Endo/Neuro/DbtcNrpthy.htm" class="LinkPage"&gt;Diabetic Neuropathy&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Symptoms&lt;ol&gt;&lt;li&gt;Distal &lt;a href="../../Neuro/Sensory/Prsths.htm" class="LinkPage"&gt;Paresthesia&lt;/a&gt;s, hyperesthesias or numbness&lt;/li&gt;&lt;li&gt;Symptoms worse at night&lt;/li&gt;&lt;li&gt;"Stocking &amp;amp; Glove" &lt;a href="../../Neuro/Sx/PrphrlNrpthy.htm" class="LinkPage"&gt;Neuropathy&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Related to longest axons affected first&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Rheum/Sx/MsclWkns.htm" class="LinkPage"&gt;Muscle Weakness&lt;/a&gt; and atrophy may be noted&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Signs: Specific nerve functions affected&lt;ol&gt;&lt;li&gt;Vibration and position sense&lt;ol&gt;&lt;li&gt;Achilles and &lt;a href="../../Ortho/Anatomy/Ptl.htm" class="LinkPage"&gt;Patella&lt;/a&gt;r tendon &lt;a href="../../Neuro/Exam/RflxExm.htm" class="LinkPage"&gt;Deep Tendon Reflex&lt;/a&gt;es&lt;/li&gt;&lt;li&gt;&lt;a href="../../Neuro/Exam/Gt.htm" class="LinkPage"&gt;Gait&lt;/a&gt; ataxia&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Sharp-dull discrimination&lt;/li&gt;&lt;li&gt;&lt;a href="../../Neuro/Exam/TwPntDscrmntn.htm" class="LinkPage"&gt;Two Point Discrimination&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Decreased "protective sensation"&lt;ol&gt;&lt;li&gt;10 g Monofilament Test&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Neuro/Exam/MtrExm.htm" class="LinkPage"&gt;Muscle Strength&lt;/a&gt; may also be affected&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Differential Diagnosis&lt;ol&gt;&lt;li&gt;&lt;a href="../../Neuro/Sx/SymtrcPrphrlNrpthy.htm" class="LinkPage"&gt;Polyneuropathy&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Neuro/BltrlPrphrlPlynrpthyInDbts.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Bilateral Peripheral Polyneuropathy in Diabetes, Diabetic Distal Symmetric Polyneuropathy</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Neuro/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees></FP_UMLS_Trees><FP_Condition_name_check></FP_Condition_name_check><FP_Condition_name><value>Diabetic Autonomic Neuropathy</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Neurology</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Background&lt;ol&gt;&lt;li&gt;Subtype of &lt;a href="../../Endo/Neuro/DbtcNrpthy.htm" class="LinkPage"&gt;Diabetic Neuropathy&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Affects sympathetic, parasympathetic and enteric nerves&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Epidemiology&lt;ol&gt;&lt;li&gt;Most common in &amp;gt;20 years of poor glycemic control&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Cardiovascular &lt;a href="../../Neuro/Autonomic/AtnmcDysfnctn.htm" class="LinkPage"&gt;Autonomic Neuropathy&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../CV/Exam/OrthstcHyptnsn.htm" class="LinkPage"&gt;Orthostatic Hypotension&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Sports/Exercise/Exrcs.htm" class="LinkPage"&gt;Exercise&lt;/a&gt; intolerance&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Sx/Syncp.htm" class="LinkPage"&gt;Syncope&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Exam/QtIntrvl.htm" class="LinkPage"&gt;Prolonged QT&lt;/a&gt; interval on &lt;a href="../../CV/Exam/Elctrcrdgrm.htm" class="LinkPage"&gt;Electrocardiogram&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Evaluate &lt;a href="../../CV/Exam/HrtRt.htm" class="LinkPage"&gt;Heart Rate&lt;/a&gt; variability and stress test&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Gastrointestinal &lt;a href="../../Neuro/Autonomic/AtnmcDysfnctn.htm" class="LinkPage"&gt;Autonomic Neuropathy&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Altered bowel habits (&lt;a href="../../GI/Diarrhea/ActDrh.htm" class="LinkPage"&gt;Diarrhea&lt;/a&gt; or &lt;a href="../../GI/Constipation/CnstptnInAdlts.htm" class="LinkPage"&gt;Constipation&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;Gastric atony (&lt;a href="../../Neuro/Exam/Dysphg.htm" class="LinkPage"&gt;Dysphagia&lt;/a&gt;, bloating, &lt;a href="../../GI/Sx/Vmtng.htm" class="LinkPage"&gt;Nausea&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;&lt;a href="../../GI/Rectum/FclIncntnc.htm" class="LinkPage"&gt;Fecal Incontinence&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Genitourinary &lt;a href="../../Neuro/Autonomic/AtnmcDysfnctn.htm" class="LinkPage"&gt;Autonomic Dysfunction&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../Uro/Anatomy/BldrAntmy.htm" class="LinkPage"&gt;Bladder&lt;/a&gt; dysfunction&lt;ol&gt;&lt;li&gt;&lt;a href="../../Uro/Incontinence/UrnryIncntnc.htm" class="LinkPage"&gt;Urinary Incontinence&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Urinary frequency&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Sexual dysfunction&lt;ol&gt;&lt;li&gt;&lt;a href="../../Uro/Impotence/ErctlDysfnctn.htm" class="LinkPage"&gt;Erectile Dysfunction&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Loss of libido&lt;/li&gt;&lt;li&gt;Anorgasmia&lt;/li&gt;&lt;li&gt;&lt;a href="../../Gyn/Sx/PnflIntrcrs.htm" class="LinkPage"&gt;Dyspareunia&lt;/a&gt; (associated with vaginal dryness)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Miscellaneous autonomic symptoms&lt;ol&gt;&lt;li&gt;Unaware of hypoglycemic episodes&lt;/li&gt;&lt;li&gt;Abnormal pupil function&lt;/li&gt;&lt;li&gt;Sudomotor &lt;a href="../../Neuro/Sx/PrphrlNrpthy.htm" class="LinkPage"&gt;Neuropathy&lt;/a&gt; (&lt;a href="../../Derm/Anatomy/SwtGlnd.htm" class="LinkPage"&gt;Sweat Gland&lt;/a&gt; dysfunction)&lt;ol&gt;&lt;li&gt;Dry, pruritic skin&lt;ol&gt;&lt;li&gt;Extremity &lt;a href="../../Derm/Hair/Alpc.htm" class="LinkPage"&gt;Hair Loss&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Differential Diagnosis&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Neuro/Autonomic/AtnmcDysfnctn.htm" class="LinkPage"&gt;Autonomic Neuropathy&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Vinik%20%20%5BAU%5D%20AND%202003%20%5BDP%5D%20AND%20%20Diabetes%20Care%20%20%5BTA%5D" class="LinkRef"&gt;Vinik (2003) Diabetes Care 26:1153-79&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Neuro/DbtcAtnmcNrpthy.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Diabetic Autonomic Neuropathy, Autonomic Neuropathy in Diabetes</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Neuro/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Thyrotropin-Releasing Hormone  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0040162"&gt;&lt;i&gt;C0040162&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;Expressed (highest) in the medial hypothalamic paraventricular nuclei and median eminence by human TRH Gene, 242-aa 27-kDa (precursor) (prepro-)Thyrotropin-Releasing Hormone is a major regulator of TSH biosynthesis and release in the anterior pituitary gland and neurotransmitter/neuromodulator in the central and peripheral nervous systems. (NCI)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CSP)&lt;/td&gt;
                &lt;td&gt;tripeptide hormone elaborated by the median eminence of the hypothalamus which stimulates release of thyrotropin from the anterior pituitary gland.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;A tripeptide that stimulates the release of THYROTROPIN and PROLACTIN. It is synthesized by the neurons in the PARAVENTRICULAR NUCLEUS of the HYPOTHALAMUS. After being released into the pituitary portal circulation, TRH (was called TRF) stimulates the release of TSH and PRL from the ANTERIOR PITUITARY GLAND.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Amino Acid, Peptide, or Protein (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0040162&amp;amp;tui=T116"&gt;&lt;i&gt;T116&lt;/i&gt;&lt;/a&gt;)
, Pharmacologic Substance (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0040162&amp;amp;tui=T121"&gt;&lt;i&gt;T121&lt;/i&gt;&lt;/a&gt;)
, Hormone (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0040162&amp;amp;tui=T125"&gt;&lt;i&gt;T125&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D013973&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;29361008, 73805002, 10534002, 412495007, 412496008, 412494006&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Thyrotropin-Releasing Hormone, Protirelin preparation, TRF - Protirelin, TRH - Protirelin, Thyrotropin Releasing Factor, Thyrotropin-Releasing Factor, pyroGlu-His-Pro-NH2 (or 5-oxo-L-prolyl-L-histidyl-L-prolinamide), TRH-Thyrotrophin rel horm, Thyrotropin releasing factor (TRF), thyrotropin releasing hormone, protirelin, protirelin (discontinued) (medication), protirelin (discontinued), thyrotropin-releasing hormone, thyrotropin RH, hormones protirelin (discontinued), Protirelin preparation (product), Thyrotropin-releasing factor, Thyrotropin-Releasing Hormone [Chemical/Ingredient], thyrotrophin releasing hormone, trh, thyrotropin releasing hormone (TRH), Thyrotropin releasing hormone preparation, TRF, TRH, Thyrotrophin-releasing hormone, Thyrotropin releasing factor, Thyrotropin releasing hormone, TRH - Thyrotrophin releasing hormone, Thyrotrophin releasing hormone, Thyrotropin releasing factor (substance), Thyrotropin releasing hormone preparation (product), Protirelin preparation -RETIRED-, Thyrotropin releasing hormone preparation (substance), Protirelin (product), Protirelin (substance), Thyrotropin releasing factor agent (substance), Thyrotropin releasing factor agent, Thyrotropin Releasing Hormone, Protirelin, PROTIRELIN&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Hormônio Liberador de Tireotropina, Hormônio Liberador de Tirotropina, Hormônio Liberador de Tirotrofina, Protirelina&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Thyreotropin-Releasing-Hormon, Prolactin-Releasing-Hormon, Protirelin, Thyreotropin-Releasing-Faktor, TRH (Thyreotropin-Releasing-Hormon), Thyreotropin-Releasing Hormon&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Thyrolibérine, Hormone de libération de la thyrotropine, Hormone de libération de la thyréostimuline, Facteur de libération de la thyrotropine, Facteur de libération de la thyréostimuline, Hormone de libération de la thyréotropine, TRF (Thyrotropin-Releasing Factor), Thyréolibérine, Protireline, Protyreline, Pyr-His-ProNH2, TRH (Thyrotropin-Releasing Hormone)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Tyreotropinfrisättande hormon&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;hormon uvolňující thyreotropin, hormon uvolňující tyreotropin, protirelin, tyreoliberin, thyreoliberin&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Tyreoliberiini&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;TIROLIBERIN, TIROTROPIN-RILIZING-GORMON, TIREOTROPIN-RILIZING-GORMON, PROTIRELIN, TIREOTROPNYI GORMON-OSVOBOZHDAIUSHCHII FAKTOR, ПРОТИРЕЛИН, ТИРЕОТРОПИН-РИЛИЗИНГ-ГОРМОН, ТИРЕОТРОПНЫЙ ГОРМОН-ОСВОБОЖДАЮЩИЙ ФАКТОР, ТИРОЛИБЕРИН, ТИРОТРОПИН-РИЛИЗИНГ-ГОРМОН&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;オリストン, チロリベリン, 酒石酸プロチレリン, ボグニン, プロチレリン酒石酸塩, シンプロチン, ヒシダリン, ヒルロック, 甲状腺刺激ホルモン放出因子, プロチレリン酒石酸塩水和物, プロチレリン, ヒルトニン, アルヒルト, 甲状腺刺激ホルモン放出ホルモン, チロトロピン放出ホルモン, サイロトロピン放出ホルモン&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;hormona liberadora de tirotrofina, hormona liberadora de tirotrofina (producto), preparado de hormona liberadora de tirotrofina (producto), preparado de hormona liberadora de tirotrofina, preparado de protirrelina, factor liberador de TSH, factor liberador de tirotrofina (sustancia), factor liberador de tirotrofina, hormona liberadora de TSH, preparado de TRH, preparado de hormona liberadora de tirotrofina (sustancia), preparado de protirrelina-RETIRADO- (concepto no activo), preparado de protirrelina-RETIRADO-, preparado de tiroliberina, agente con factor liberador de tirotrofina (sustancia), agente con factor liberador de tirotrofina, protirelina (producto), protirelina (sustancia), protirelina, Hormona Liberadora de Tirotropina, Protirelina&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Tiroliberina, Protirelina, Ormone di rilascio della tirotropina, Ormone rilasciante la tirotropina&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Croatian&lt;/td&gt;
                &lt;td&gt;HORMON KOJI OSLOBAĐA TIREOTROPIN&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Tyreoliberyna, Hormon uwalniający tyreotropinę&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Thyrotropin-Releasing Hormone  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Thyroid Releasing Hormone</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Pathology and Laboratory Medicine</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Measurement&lt;ol&gt;&lt;li&gt;Measures responsiveness of pituitary to TRH&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Protocol&lt;ol&gt;&lt;li&gt;Administer TRH 500 ug&lt;/li&gt;&lt;li&gt;Measure &lt;a href="../../Endo/Lab/ThyrdStmltngHrmn.htm" class="LinkPage"&gt;Thyroid Stimulating Hormone&lt;/a&gt; (TSH) at 30-60 min&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Interpretation of TSH&lt;ol&gt;&lt;li&gt;Normal Response&lt;ol&gt;&lt;li&gt;TSH rises 2-4x baseline&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/Hyprthyrdsm1.htm" class="LinkPage"&gt;Hyperthyroidism&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Low TSH with suppressed response to TRH&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/Hypthyrdsm.htm" class="LinkPage"&gt;Hypothyroidism&lt;/a&gt;&lt;ol&gt;&lt;li&gt;High TSH with exaggerated TRH response&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0040162</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Lab/ThyrdRlsngHrmn.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Thyroid Releasing Hormone, TRH</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Lab/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees></FP_UMLS_Trees><FP_Condition_name_check></FP_Condition_name_check><FP_Condition_name><value>Diabetic Amyotrophy</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Neurology</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Epidemiology&lt;ol&gt;&lt;li&gt;Subtype of &lt;a href="../../Endo/Neuro/DbtcNrpthy.htm" class="LinkPage"&gt;Diabetic Neuropathy&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Most often in older males with &lt;a href="../../Endo/DM/TypDbtsMlts1.htm" class="LinkPage"&gt;Type II Diabetes&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Symptoms&lt;ol&gt;&lt;li&gt;Disabling and bilateral thigh &lt;a href="../../Rheum/Sx/MsclWkns.htm" class="LinkPage"&gt;Muscle Weakness&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Weight loss&lt;/li&gt;&lt;li&gt;Myalgias may be present&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Signs&lt;ol&gt;&lt;li&gt;&lt;a href="../../Ortho/Anatomy/ThghAntmy.htm" class="LinkPage"&gt;Thigh&lt;/a&gt; muscle atrophy&lt;ol&gt;&lt;li&gt;Iliopsoas weakness&lt;/li&gt;&lt;li&gt;Quadriceps weakness&lt;/li&gt;&lt;li&gt;Adductor &lt;a href="../../Rheum/Sx/MsclWkns.htm" class="LinkPage"&gt;Muscle Weakness&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Ortho/Anatomy/Ptl.htm" class="LinkPage"&gt;Patella&lt;/a&gt;r &lt;a href="../../Neuro/Exam/RflxExm.htm" class="LinkPage"&gt;Deep Tendon Reflex&lt;/a&gt; loss&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Neuro/DbtcAmytrphy.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Diabetic Amyotrophy, Femoral Neuropathy of Diabetes, Proximal Motor Neuropathy of Diabetes Mellitus</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Neuro/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees></FP_UMLS_Trees><FP_Condition_name_check></FP_Condition_name_check><FP_Condition_name><value>Mononeuropathy in Diabetes</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Neurology</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Background&lt;ol&gt;&lt;li&gt;Subtype of &lt;a href="../../Endo/Neuro/DbtcNrpthy.htm" class="LinkPage"&gt;Diabetic Neuropathy&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Sudden onset large nerve involvement&lt;/li&gt;&lt;li&gt;Associated with nerve infarction&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Distribution: Common areas effected&lt;ol&gt;&lt;li&gt;&lt;a href="../../Ortho/Anatomy/WrstAntmy.htm" class="LinkPage"&gt;Wrist&lt;/a&gt; drop (&lt;a href="../../Ortho/Anatomy/HndAntmy.htm" class="LinkPage"&gt;Radial Nerve&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;Loss of finger flexion and grip (&lt;a href="../../Ortho/Anatomy/HndAntmy.htm" class="LinkPage"&gt;Median Nerve&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Ortho/Anatomy/FtAntmy.htm" class="LinkPage"&gt;Foot&lt;/a&gt; drop (deep peroneal nerve, L4-L5)&lt;/li&gt;&lt;li&gt;Recurrent laryngeal nerve&lt;/li&gt;&lt;li&gt;&lt;a href="../../Neuro/Anatomy/CrnlNrv.htm" class="LinkPage"&gt;Cranial Nerve&lt;/a&gt; palsy (&lt;a href="../../Neuro/Anatomy/CrnlNrv3.htm" class="LinkPage"&gt;CN 3&lt;/a&gt;, &lt;a href="../../Neuro/Anatomy/CrnlNrv4.htm" class="LinkPage"&gt;CN 4&lt;/a&gt;, &lt;a href="../../Neuro/Anatomy/CrnlNrv6.htm" class="LinkPage"&gt;CN 6&lt;/a&gt;)&lt;ol&gt;&lt;li&gt;Ophthalmoplegia, &lt;a href="../../Eye/Lid/Pts.htm" class="LinkPage"&gt;Ptosis&lt;/a&gt;, &lt;a href="../../Eye/Sx/Dplp.htm" class="LinkPage"&gt;Diplopia&lt;/a&gt; yet PERRLA (&lt;a href="../../Neuro/Anatomy/CrnlNrv3.htm" class="LinkPage"&gt;CN 3&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;Affected eye slightly more elevated (&lt;a href="../../Neuro/Anatomy/CrnlNrv4.htm" class="LinkPage"&gt;CN 4&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;Affected eye deviated medially (&lt;a href="../../Neuro/Anatomy/CrnlNrv6.htm" class="LinkPage"&gt;CN 6&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Neuro/CN/BlsPlsy.htm" class="LinkPage"&gt;Bell's Palsy&lt;/a&gt; (&lt;a href="../../Neuro/Anatomy/CrnlNrv7.htm" class="LinkPage"&gt;CN 7&lt;/a&gt;)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Course&lt;ol&gt;&lt;li&gt;Often resolves spontaneously in 3-12 months&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Variant: &lt;a href="../../Neuro/Sx/AsymtrcPrphrlNrpthy.htm" class="LinkPage"&gt;Mononeuropathy Multiplex&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Multiple nerves affected&lt;/li&gt;&lt;li&gt;Consider &lt;a href="../../Rheum/CV/Vsclts.htm" class="LinkPage"&gt;Vasculitis&lt;/a&gt; as cause&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Differential Diagnosis&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Neuro/Sx/AsymtrcPrphrlNrpthy.htm" class="LinkPage"&gt;Mononeuropathy&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Neuro/MnrpthyInDbts.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Mononeuropathy in Diabetes, Diabetic Focal Neuropathy</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Neuro/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;T3 uptake measurement  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0202224"&gt;&lt;i&gt;C0202224&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;The determination of the binding of triiodothyonine to thyroxine binding globulin protein in a sample.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A measurement of the binding of triiodothyonine to thyroxine binding globulin protein in a biological specimen.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Laboratory Procedure (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0202224&amp;amp;tui=T059"&gt;&lt;i&gt;T059&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;143695002, 166340002, 250669007, 17130003, 275756004&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;T3RU, Triiodothyronine uptake (procedure), Tri-iodothyronine uptake, T3 uptake, T3U, Triiodothyronine Uptake Measurement, T3UP, Triiodothyronine Uptake, triiodothyronine uptake measurement (lab test), triiodothyronine uptake measurement, T3 resin uptake, resin t3 uptake, t3 uptake, t3u, t3 uptake test, t3 resin uptake, Tri-iodothyronine resin uptake measurement, T3U measurement, T3 - Triiodothyronine uptake, T3 uptake test, T3 uptake measurement (procedure), T3 uptake test (procedure), Triiodothyronine uptake, T3 uptake measurement&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Captazione di triiodotironina, Captazione di T3&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;T3-opname, T3 opname, trijoodthyronineopname&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;T3-Aufnahme, T3U, Trijodthyronin-Aufnahme&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Captação de T3, Captação de tri-iodotironina&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;Captación de T3, T3 uptake test, Triiodothyronine uptake, medición de T3U, medición de captación de T3 (procedimiento), medición de captación de T3, medición de la captación de resina de triyodotironina, prueba de captación de T3, prueba de captación de triyodotironina (procedimiento), prueba de captación de triyodotironina, Captación de triyodotironina&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;トリヨードチロニン摂取, Ｔ３摂取, Ｔ３摂取Ｕ, ﾄﾘﾖｰﾄﾞﾁﾛﾆﾝｾｯｼｭ, T3ｾｯｼｭU, T3ｾｯｼｭ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Test d'Hamolsky, Test d'Ham, Fixation de tri-iodothyronine&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;Vychytávání trijodtyroninu, T3U (vychytávání T3), Vychytávání T3&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;T3U (T3 felvétel), T3 felvétel, Tri-jód-tironin felvétel&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>T3 uptake measurement  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>T3 Resin Uptake</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Pathology and Laboratory Medicine</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Indications&lt;ol&gt;&lt;li&gt;Used to calculate &lt;a href="../../Endo/Lab/FrThyrxnIndx.htm" class="LinkPage"&gt;Free Thyroxine Index&lt;/a&gt; (FTI)&lt;ol&gt;&lt;li&gt;Interpret in conjunction with Total T4 or Total T3&lt;/li&gt;&lt;li&gt;Corrects for abnormal &lt;a href="../../Endo/Lab/ThyrxnBndngGlbln.htm" class="LinkPage"&gt;Thyroid Binding Globulin&lt;/a&gt; (TBG)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/Thyrxn.htm" class="LinkPage"&gt;Free T4&lt;/a&gt; also corrects for &lt;a href="../../Endo/Lab/ThyrxnBndngGlbln.htm" class="LinkPage"&gt;Thyroid Binding Globulin&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/Thyrxn.htm" class="LinkPage"&gt;Free T4&lt;/a&gt; is preferred over FTI (and T3RU)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Measurement&lt;ol&gt;&lt;li&gt;Unbound &lt;a href="../../Endo/Lab/ThyrxnBndngGlbln.htm" class="LinkPage"&gt;Thyroid Binding Globulin&lt;/a&gt; filled with T3&lt;/li&gt;&lt;li&gt;Remaining unbound &lt;a href="../../Endo/Lab/Trdthyrn.htm" class="LinkPage"&gt;Triiodothyronine&lt;/a&gt; (T3) is measured&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Increased T3 Resin Uptake&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/Hyprthyrdsm1.htm" class="LinkPage"&gt;Hyperthyroidism&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Systemic illness&lt;/li&gt;&lt;li&gt;&lt;a href="../../GI/Lvr/Crhs.htm" class="LinkPage"&gt;Cirrhosis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Renal/Glomerulus/NphrtcSyndrm.htm" class="LinkPage"&gt;Nephrotic Syndrome&lt;/a&gt;&lt;/li&gt;&lt;li&gt;X-linked decreased &lt;a href="../../Endo/Lab/ThyrxnBndngGlbln.htm" class="LinkPage"&gt;Thyroid Binding Globulin&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Adrenal/CshngsDs.htm" class="LinkPage"&gt;Cushing's Disease&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pituitary/Acrmgly.htm" class="LinkPage"&gt;Acromegaly&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/DM/DbtcKtcds.htm" class="LinkPage"&gt;Diabetic Ketoacidosis&lt;/a&gt; (DKA)&lt;/li&gt;&lt;li&gt;Drugs&lt;ol&gt;&lt;li&gt;Prednisone&lt;/li&gt;&lt;li&gt;Androgen&lt;/li&gt;&lt;li&gt;&lt;a href="../../Pharm/Analgesic/Slcylt.htm" class="LinkPage"&gt;Salicylate&lt;/a&gt;s&lt;/li&gt;&lt;li&gt;&lt;a href="../../Sports/Pharm/AnblcStrd.htm" class="LinkPage"&gt;Anabolic Steroid&lt;/a&gt;s&lt;/li&gt;&lt;li&gt;Asparaginase&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Decreased T3 Resin Uptake&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/Hypthyrdsm.htm" class="LinkPage"&gt;Hypothyroidism&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Pregnancy&lt;/li&gt;&lt;li&gt;Hepatitis&lt;/li&gt;&lt;li&gt;Porphyria&lt;/li&gt;&lt;li&gt;X-Linked increased &lt;a href="../../Endo/Lab/ThyrxnBndngGlbln.htm" class="LinkPage"&gt;Thyroid Binding Globulin&lt;/a&gt; (TBG)&lt;/li&gt;&lt;li&gt;Primary Biliary &lt;a href="../../GI/Lvr/Crhs.htm" class="LinkPage"&gt;Cirrhosis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Malnutrition&lt;/li&gt;&lt;li&gt;Drugs&lt;ol&gt;&lt;li&gt;&lt;a href="../../Gyn/Pharm/Estrgn.htm" class="LinkPage"&gt;Estrogen&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Gyn/Pharm/OrlCntrcptv.htm" class="LinkPage"&gt;Oral Contraceptive&lt;/a&gt;s&lt;/li&gt;&lt;li&gt;Perphenazine&lt;/li&gt;&lt;li&gt;Fluorouracil&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Pharm/FbrcAcd.htm" class="LinkPage"&gt;Clofibrate&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0202224</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Lab/T3RsnUptk.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: T3 Resin Uptake, T3 Binding Ratio, T3RU</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Lab/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees></FP_UMLS_Trees><FP_Condition_name_check></FP_Condition_name_check><FP_Condition_name><value>Thyroid Function Test</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Pathology and Laboratory Medicine</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;General&lt;ol&gt;&lt;li&gt;TSH alone is sufficiently sensitive and specific&lt;/li&gt;&lt;li&gt;TSH is a good single screening outpatient test&lt;/li&gt;&lt;li&gt;References&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Bauer%20%20%5BAU%5D%20AND%201996%20%5BDP%5D%20AND%20%20Arch%20Intern%20Med%20%20%5BTA%5D" class="LinkRef"&gt;Bauer (1996) Arch Intern Med 156:2333-7&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Normal &lt;a href="../../Endo/Lab/ThyrdStmltngHrmn.htm" class="LinkPage"&gt;Thyroid Stimulating Hormone&lt;/a&gt; (TSH): 0.3 to 5.0 mU/L&lt;ol&gt;&lt;li&gt;Normal &lt;a href="../../Endo/Lab/FrThyrxnIndx.htm" class="LinkPage"&gt;Free Thyroxine Index&lt;/a&gt; or &lt;a href="../../Endo/Lab/Thyrxn.htm" class="LinkPage"&gt;Free T4&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Diagnosis: Euthyroid&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Low &lt;a href="../../Endo/Lab/FrThyrxnIndx.htm" class="LinkPage"&gt;Free Thyroxine Index&lt;/a&gt; or &lt;a href="../../Endo/Lab/Thyrxn.htm" class="LinkPage"&gt;Free T4&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Diagnosis: Secondary &lt;a href="../../Endo/Thyroid/Hypthyrdsm.htm" class="LinkPage"&gt;Hypothyroidism&lt;/a&gt; (Central)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;High &lt;a href="../../Endo/Lab/ThyrdStmltngHrmn.htm" class="LinkPage"&gt;Thyroid Stimulating Hormone&lt;/a&gt; (TSH): &amp;gt;5-20 mU/L&lt;ol&gt;&lt;li&gt;Normal &lt;a href="../../Endo/Lab/FrThyrxnIndx.htm" class="LinkPage"&gt;Free Thyroxine Index&lt;/a&gt; or &lt;a href="../../Endo/Lab/Thyrxn.htm" class="LinkPage"&gt;Free T4&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Diagnosis: &lt;a href="../../Endo/Thyroid/SbclnclHypthyrdsm.htm" class="LinkPage"&gt;Subclinical Hypothyroidism&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Management&lt;ol&gt;&lt;li&gt;Non-specific Symptoms: Consider &lt;a href="../../Endo/Pharm/ThyrdHrmnRplcmnt.htm" class="LinkPage"&gt;Levothyroxine&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/Gtr.htm" class="LinkPage"&gt;Goiter&lt;/a&gt; OR Microsomal Antibodies exceed 1:1600&lt;ol&gt;&lt;li&gt;Positive: &lt;a href="../../Endo/Pharm/ThyrdHrmnRplcmnt.htm" class="LinkPage"&gt;Levothyroxine&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Negative: Follow clinically&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Low &lt;a href="../../Endo/Lab/FrThyrxnIndx.htm" class="LinkPage"&gt;Free Thyroxine Index&lt;/a&gt; or &lt;a href="../../Endo/Lab/Thyrxn.htm" class="LinkPage"&gt;Free T4&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Diagnosis: &lt;a href="../../Endo/Thyroid/Hypthyrdsm.htm" class="LinkPage"&gt;Hypothyroidism&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Management: &lt;a href="../../Endo/Pharm/ThyrdHrmnRplcmnt.htm" class="LinkPage"&gt;Levothyroxine&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Low &lt;a href="../../Endo/Lab/ThyrdStmltngHrmn.htm" class="LinkPage"&gt;Thyroid Stimulating Hormone&lt;/a&gt; (TSH): &amp;lt;0.3 mU/L&lt;ol&gt;&lt;li&gt;Normal &lt;a href="../../Endo/Lab/FrThyrxnIndx.htm" class="LinkPage"&gt;Free Thyroxine Index&lt;/a&gt; or &lt;a href="../../Endo/Lab/Thyrxn.htm" class="LinkPage"&gt;Free T4&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Normal &lt;a href="../../Endo/Lab/Trdthyrn.htm" class="LinkPage"&gt;Triiodothyronine&lt;/a&gt; (T3)&lt;ol&gt;&lt;li&gt;Diagnosis: &lt;a href="../../Endo/Thyroid/SbclnclHyprthyrdsm.htm" class="LinkPage"&gt;Subclinical Hyperthyroidism&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Management&lt;ol&gt;&lt;li&gt;Consider following clinically&lt;/li&gt;&lt;li&gt;Age over 60 years&lt;ol&gt;&lt;li&gt;Risk of &lt;a href="../../CV/EKG/AtrlFbrltn.htm" class="LinkPage"&gt;Atrial Fibrillation&lt;/a&gt; or &lt;a href="../../Rheum/Bone/Ostprs.htm" class="LinkPage"&gt;Osteoporosis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Consider definitive treatment&lt;/li&gt;&lt;li&gt;Observe closely&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;High &lt;a href="../../Endo/Lab/Trdthyrn.htm" class="LinkPage"&gt;Triiodothyronine&lt;/a&gt; (T3)&lt;ol&gt;&lt;li&gt;Diagnosis: T3 Toxicosis&lt;/li&gt;&lt;li&gt;Management: Treat &lt;a href="../../Endo/Thyroid/Hyprthyrdsm1.htm" class="LinkPage"&gt;Hyperthyroidism&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;High &lt;a href="../../Endo/Lab/FrThyrxnIndx.htm" class="LinkPage"&gt;Free Thyroxine Index&lt;/a&gt; or &lt;a href="../../Endo/Lab/Thyrxn.htm" class="LinkPage"&gt;Free T4&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Diagnosis: &lt;a href="../../Endo/Thyroid/Hyprthyrdsm1.htm" class="LinkPage"&gt;Hyperthyroidism&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Rad/RdctvIdnUptkScn.htm" class="LinkPage"&gt;Radioiodine Uptake&lt;/a&gt; scan Elevated:&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/GrvsDs.htm" class="LinkPage"&gt;Grave's Disease&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Toxic nodular &lt;a href="../../Endo/Thyroid/Gtr.htm" class="LinkPage"&gt;Goiter&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Toxic &lt;a href="../../Endo/HemeOnc/ThyrdAdnm.htm" class="LinkPage"&gt;Thyroid Adenoma&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Rad/RdctvIdnUptkScn.htm" class="LinkPage"&gt;Radioiodine Uptake&lt;/a&gt; scan Low or Absent:&lt;ol&gt;&lt;li&gt;Acute viral &lt;a href="../../Endo/Thyroid/Thyrdts.htm" class="LinkPage"&gt;Thyroiditis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Silent &lt;a href="../../Endo/Thyroid/Thyrdts.htm" class="LinkPage"&gt;Thyroiditis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Struma ovarii&lt;/li&gt;&lt;li&gt;Excessive &lt;a href="../../Endo/Pharm/ThyrdHrmnRplcmnt.htm" class="LinkPage"&gt;Levothyroxine&lt;/a&gt; ingestion&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Costa%20%20%5BAU%5D%20AND%201995%20%5BDP%5D%20AND%20%20Am%20Fam%20Physician%20%20%5BTA%5D" class="LinkRef"&gt;Costa (1995) Am Fam Physician 52(8):2325-30&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Pittman%20%20%5BAU%5D%20AND%201996%20%5BDP%5D%20AND%20%20Am%20Fam%20Physician%20%20%5BTA%5D" class="LinkRef"&gt;Pittman (1996) Am Fam Physician 54(3):961-6&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Lab/ThyrdFnctnTst.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Thyroid Function Test</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Lab/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Reverse Triiodothyronine  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0041017"&gt;&lt;i&gt;C0041017&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;A metabolite of THYROXINE, formed by the peripheral enzymatic monodeiodination of T4 at the 5 position of the inner ring of the iodothyronine nucleus.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Amino Acid, Peptide, or Protein (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0041017&amp;amp;tui=T116"&gt;&lt;i&gt;T116&lt;/i&gt;&lt;/a&gt;)
, Pharmacologic Substance (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0041017&amp;amp;tui=T121"&gt;&lt;i&gt;T121&lt;/i&gt;&lt;/a&gt;)
, Hormone (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0041017&amp;amp;tui=T125"&gt;&lt;i&gt;T125&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D014285&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;60760000&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;3,3',5'-Triiodothyronine, 3,3,5 Triiodothyronine, 3,3,5-Triiodothyronine, Triiodothyronine, Reverse, L-Tyrosine, O-(4-hydroxy-3,5-diiodophenyl)-3-iodo-, Reverse T3, r T3, Reverse T3 (substance), Reverse T&amp;lt;sub&amp;gt;3&amp;lt;/sub&amp;gt; (substance), Reverse T&amp;lt;sub&amp;gt;3&amp;lt;/sub&amp;gt;, r T&amp;lt;sub&amp;gt;3&amp;lt;/sub&amp;gt;, TRIIODOTHYRONINE A 03 03 05, REVERSE T 03 THYROID HORMONE, REVERSE T3, RT3 - Reverse triiodothyronine, Triiodothyronine, Reverse [Chemical/Ingredient], Triiodothyronine.reverse, reverse triiodothyronine, reverse t3, Reverse T3 Thyroid hormone, Reverse Triiodothyronine, 3,3' 5 Triiodothyronine, Reverse triiodothyronine, rT3 - Reverse triiodothyronine, r T&amp;gt;3&amp;lt;, Reverse T&amp;gt;3&amp;lt;, Reverse T&amp;gt;3&amp;lt; (substance)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Trijodtyronin, omvänt&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;trijodthyronin reverzní&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Käänteistrijodityroniini&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;rT3 (reverse Triiodothyronine), Triiodothyronine inverse, Tri-iodothyronine inverse, 3,3',5'-triiodothyronine&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;TRIIODTIRONIN REVERSIVNYI, 3',3',5'-TRIIODTIRONIN, REVERSIVNYI TRIIODTIRONIN, 3',3',5'-ТРИИОДТИРОНИН, РЕВЕРСИВНЫЙ ТРИИОДТИРОНИН, ТРИИОДТИРОНИН РЕВЕРСИВНЫЙ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;T3 reversa (sustancia), T&amp;lt;sub&amp;gt;3&amp;lt;/sub&amp;gt; reversa (sustancia), T3 reversa, T&amp;lt;sub&amp;gt;3&amp;lt;/sub&amp;gt; reversa, Triyodotironina Inversa, Hormona Tiroidea T3 Inversa, 3, 3' 5 triyodotironina, T&amp;gt;3&amp;lt; reversa (sustancia), T&amp;gt;3&amp;lt; reversa, 3,3',5'-Triyodotironina&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;REVERSES T 03 SCHILDDRÜSENHORMON, TRIIODOTHYRONIN A 03 03 05, 3,3',5'-Triiodthyronin, Reverses Triiodthyronin, Triiodthyronin, reverses, Reverses T3-Schilddrüsenhormon&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;T3 Invertido, 3,3',5'-Triiodotironina, Hormônio Tireóideo T3 Reverso, Triiodotironina Reversa&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Trójjodotyronina odwrócona, Trijodotyronina odwrócona&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;トリヨードチロニン-リバース, 3,3',5'-トリヨードチロニン, トリヨードサイロニン-リバース, リバースT3, リバーストリヨードサイロニン, リバーストリヨードチロニン&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Triiodotironina reverse&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Reverse Triiodothyronine  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Reverse T3</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Pathology and Laboratory Medicine</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Measurement&lt;ol&gt;&lt;li&gt;Radioimmunoassay for inactive isomer of T3&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0041017</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Lab/RvrsT3.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Reverse T3, rT3</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Lab/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees></FP_UMLS_Trees><FP_Condition_name_check></FP_Condition_name_check><FP_Condition_name><value>Thyroid Function Summary</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Pathology and Laboratory Medicine</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;
              &lt;a href="../../Endo/Thyroid/Hyprthyrdsm1.htm" class="LinkPage"&gt;Hyperthyroidism&lt;/a&gt;
              &lt;ol&gt;&lt;li&gt;Increased&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/Thyrxn.htm" class="LinkPage"&gt;Thyroxine&lt;/a&gt; (T4) and &lt;a href="../../Endo/Lab/Trdthyrn.htm" class="LinkPage"&gt;Triiodothyronine&lt;/a&gt; (T3)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/Thyrxn.htm" class="LinkPage"&gt;Free T4&lt;/a&gt; (fT4) and &lt;a href="../../Endo/Lab/Trdthyrn.htm" class="LinkPage"&gt;Free T3&lt;/a&gt; (fT3)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/T3RsnUptk.htm" class="LinkPage"&gt;T3 Resin Uptake&lt;/a&gt; (&lt;a href="../../Endo/Lab/T3RsnUptk.htm" class="LinkPage"&gt;T3RU&lt;/a&gt;) and &lt;a href="../../Endo/Lab/FrThyrxnIndx.htm" class="LinkPage"&gt;Free Thyroxine Index&lt;/a&gt; (FTI)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/RvrsT3.htm" class="LinkPage"&gt;Reverse T3&lt;/a&gt; (rT3)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
                &lt;li&gt;Decreased&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/ThyrdStmltngHrmn.htm" class="LinkPage"&gt;Thyroid Stimulating Hormone&lt;/a&gt; (TSH)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/ThyrdRlsngHrmn.htm" class="LinkPage"&gt;Thyroid Releasing Hormone&lt;/a&gt; (TRH)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
              &lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;
              &lt;a href="../../Endo/Thyroid/Hypthyrdsm.htm" class="LinkPage"&gt;Hypothyroidism&lt;/a&gt;
              &lt;ol&gt;&lt;li&gt;Increased&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/ThyrdStmltngHrmn.htm" class="LinkPage"&gt;Thyroid Stimulating Hormone&lt;/a&gt; (TSH)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/ThyrdRlsngHrmn.htm" class="LinkPage"&gt;Thyroid Releasing Hormone&lt;/a&gt; (TRH)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
                &lt;li&gt;Decreased&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/Thyrxn.htm" class="LinkPage"&gt;Thyroxine&lt;/a&gt; (T4) and &lt;a href="../../Endo/Lab/Trdthyrn.htm" class="LinkPage"&gt;Triiodothyronine&lt;/a&gt; (T3)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/Thyrxn.htm" class="LinkPage"&gt;Free T4&lt;/a&gt; (fT4) and &lt;a href="../../Endo/Lab/Trdthyrn.htm" class="LinkPage"&gt;Free T3&lt;/a&gt; (fT3)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/T3RsnUptk.htm" class="LinkPage"&gt;T3 Resin Uptake&lt;/a&gt; (&lt;a href="../../Endo/Lab/T3RsnUptk.htm" class="LinkPage"&gt;T3RU&lt;/a&gt;) and &lt;a href="../../Endo/Lab/FrThyrxnIndx.htm" class="LinkPage"&gt;Free Thyroxine Index&lt;/a&gt; (FTI)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/RvrsT3.htm" class="LinkPage"&gt;Reverse T3&lt;/a&gt; (rT3)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
              &lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Costa%20%20%5BAU%5D%20AND%201995%20%5BDP%5D%20AND%20%20Am%20Fam%20Physician%20%20%5BTA%5D" class="LinkRef"&gt;Costa (1995) Am Fam Physician 52(8):2325-30&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Pittman%20%20%5BAU%5D%20AND%201996%20%5BDP%5D%20AND%20%20Am%20Fam%20Physician%20%20%5BTA%5D" class="LinkRef"&gt;Pittman (1996) Am Fam Physician 54(3):961-6&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Lab/ThyrdFnctnSmry.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Thyroid Function Summary</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Lab/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees></FP_UMLS_Trees><FP_Condition_name_check></FP_Condition_name_check><FP_Condition_name><value>Serum Dehydroepiandrosterone</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Pathology and Laboratory Medicine</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Normal Levels&lt;ol&gt;&lt;li&gt;Male: 143 to 486 ug/dl&lt;/li&gt;&lt;li&gt;Female: 40 to 410 ug/dl&lt;/li&gt;&lt;li&gt;Postmenopausal: &amp;lt;100 ug/dl&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Lab/SrmDhydrpndrstrn.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Serum Dehydroepiandrosterone, Serum DHEA</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Lab/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Sex Hormone-Binding Globulin  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0036883"&gt;&lt;i&gt;C0036883&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;A glycoprotein migrating as a beta-globulin. Its molecular weight, 52,000 or 95,000-115,000, indicates that it exists as a dimer. The protein binds testosterone, dihydrotestosterone, and estradiol in the plasma. Sex hormone-binding protein has the same amino acid sequence as ANDROGEN-BINDING PROTEIN. They differ by their sites of synthesis and post-translational oligosaccharide modifications.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;Expressed as 2 alternative isoforms in Sertoli cells and liver by human SHBG Gene, 402-aa 44-kDa (precursor) homodimeric Sex Hormone-Binding Globulin is a secreted beta-globulin plasma glycoprotein containing 2 laminin G-like domains that specifically bind 5-alpha-dihydrotestosterone, testosterone, or 17-beta-estradiol. An androgen transport protein, SHBG regulates the plasma metabolic clearance rate of steroid hormones by controlling plasma concentration and may be involved in receptor-mediated processes as well. (NCI)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Amino Acid, Peptide, or Protein (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0036883&amp;amp;tui=T116"&gt;&lt;i&gt;T116&lt;/i&gt;&lt;/a&gt;)
, Biologically Active Substance (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0036883&amp;amp;tui=T123"&gt;&lt;i&gt;T123&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D012738&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;55503002&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Binding Globulin, Testosterone-Estradiol, Globulin, Sex Hormone-Binding, Globulin, Testosterone-Estradiol Binding, Hormone-Binding Globulin, Sex, Sex Hormone Binding Globulin, Sex Hormone-Binding Globulin, Sex Steroid Binding Protein, Sex Steroid-Binding Protein, Steroid-Binding Protein, Sex, Testosterone-Estradiol Binding Globulin, SHBG- Sex horm bind globulin, Sex Hormone-Binding Globulin [Chemical/Ingredient], sex hormone binding globulin, sex hormone-binding globulin, sex hormone binding globulin (SHBG), shbg, GBG, Sex hormone binding globulin, Sex steroid binding globulin, SHBG - Sex hormone binding globulin, Sex steroid binding globulin (substance), Testosterone Estradiol Binding Globulin, SHBG, Testis-Specific Androgen-Binding Protein&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Könshormonbindande globulin&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;globulin vážící pohlavní hormony&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Sukupuolihormoneja sitova globuliini&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;TESTOSTERON-ESTRADIOL-SVIAZYVAIUSHCHII GLOBULIN, POLOVOI GORMON-SVIAZYVAIUSHCHII GLOBULIN, ESTRADIOL-SVIAZYVAIUSHCHII GLOBULIN, TESTOSTERON-SVIAZYVAIUSHCHII GLOBULIN, ПОЛОВОЙ ГОРМОН-СВЯЗЫВАЮЩИЙ ГЛОБУЛИН, ТЕСТОСТЕРОН-СВЯЗЫВАЮЩИЙ ГЛОБУЛИН, ТЕСТОСТЕРОН-ЭСТРАДИОЛ-СВЯЗЫВАЮЩИЙ ГЛОБУЛИН, ЭСТРАДИОЛ-СВЯЗЫВАЮЩИЙ ГЛОБУЛИН&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Globuline fixant les hormones sexuelles, Globuline de transport des hormones sexuelles, SBP (Sex Steroid-Binding Protein), Globuline de fixation des hormones sexuelles, Globuline de liaison des hormones sexuelles, Globuline liant les hormones sexuelles, Globuline se liant aux hormones sexuelles, Protéine de transport des hormones sexuelles, Globuline de liaison aux hormones sexuelles, Protéine de liaison aux hormones stéroïdes sexuelles&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Globulina legante testosterone-estradiolo, Proteina legante ormoni sessuali steroidei, Globulina legante ormoni sessuali&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Globulina de Ligação a Testosterona e a Estradiol, Globulina de Ligação a Hormônio Sexual, Proteína de Ligação a Esteróide Sexual&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Globuliny wiążące hormony płciowe&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;性ステロイド結合蛋白質, 性ホルモン結合グロブリン, テストステロンエストラジオール結合グロブリン, 性ホルモン結合性グロブリン&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;proteína fijadora de esteroides sexuales (sustancia), proteína fijadora de esteroides sexuales, Globulina de Union a Estradiol Testosterona, Globulina de Union a Hormona Sexual, Globulina de Unión a Estradiol Testosterona, Globulina de Unión a Hormona Sexual, Proteina de Union a Esteroide Sexual, Proteína de Unión a Esteroide Sexual&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Geschlechtshormonbindendes Globulin, Sexualhormonbindendes Globulin, Sexualsteroidbindendes Globulin, Testosteron-Estradiol-bindendes Globulin, Estradiol-bindendes Globulin, Globulin, Estradiol-bindendes, Globulin, Testosteron-bindendes, Testosteron-bindendes Globulin&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Sex Hormone-Binding Globulin  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Sex Hormone Binding Globulin</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Pathology and Laboratory Medicine</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Normal Levels&lt;ol&gt;&lt;li&gt;Male: 0.4 to 1.3 ug DHT/100 ml&lt;/li&gt;&lt;li&gt;Female: 0.4 to 3.5 ug DHT/100 ml&lt;/li&gt;&lt;li&gt;Pregnancy: 6.5 to 9.7 ug DHT/100 ml&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0036883</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Lab/SxHrmnBndngGlbln.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Sex Hormone Binding Globulin, SHBG</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Lab/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Prolactin  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0033371"&gt;&lt;i&gt;C0033371&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CHV)&lt;/td&gt;
                &lt;td&gt;milk producing hormone&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CHV)&lt;/td&gt;
                &lt;td&gt;milk producing hormone&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CHV)&lt;/td&gt;
                &lt;td&gt;milk producing hormone&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CHV)&lt;/td&gt;
                &lt;td&gt;milk producing hormone&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CHV)&lt;/td&gt;
                &lt;td&gt;milk producing hormone&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A hormone that is made by the pituitary gland (a pea-sized organ in the center of the brain). Prolactin causes a woman's breasts to make milk during and after pregnancy, and has many other effects in the body.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;A lactogenic hormone secreted by the adenohypophysis (PITUITARY GLAND, ANTERIOR). It is a polypeptide of approximately 23 kD. Besides its major action on lactation, in some species prolactin exerts effects on reproduction, maternal behavior, fat metabolism, immunomodulation and osmoregulation. Prolactin receptors are present in the mammary gland, hypothalamus, liver, ovary, testis, and prostate.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CSP)&lt;/td&gt;
                &lt;td&gt;glycoprotein hormone secreted by the anterior pituitary; in mammals it stimulates the production of milk and assists in maintaining the corpus luteum.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;Human prolactin (227 aa, 26 kDa precursor) is encoded by the human prolactin (PIT1) gene. This secreted lactogenic glycoprotein is expressed in both anterior pituitary lactotropes and the decidual endometrium. It acts primarily on the mammary gland and, in synergy with estrogen, induces progesterone release by corpus luteum cells to render the uterine mucosa suitable for implantation.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Amino Acid, Peptide, or Protein (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0033371&amp;amp;tui=T116"&gt;&lt;i&gt;T116&lt;/i&gt;&lt;/a&gt;)
, Pharmacologic Substance (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0033371&amp;amp;tui=T121"&gt;&lt;i&gt;T121&lt;/i&gt;&lt;/a&gt;)
, Hormone (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0033371&amp;amp;tui=T125"&gt;&lt;i&gt;T125&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D011388&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;70454002, 82166002&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Hormone, Pituitary Lactogenic, Hormone, Pituitary Mammotropic, Lactogenic Hormone, Pituitary, Luteotropin, Mammotropic Hormone, Pituitary, Mammotropin, Pituitary Lactogenic Hormone, Pituitary Mammotropic Hormone, Prolactin, luteotropin, LTH (luteotropic hormone), lactogenic hormone, luteotropic hormone, mammary stimulating hormone, Lactogenic hormone, PROLACTIN, Prolactin [Chemical/Ingredient], lth, prolactins, prolactine, prolactin, LTH, PRL (Prolactin), Prl - Prolactin, Prolactin preparation, Prolactin (substance), Prolactin preparation (product), Prolactin preparation (substance), PRL&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Prolaktin&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;prolaktin&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Prolaktiini&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Lactostimuline, Mammotropine, Mammotrophine, PRL (Prolactin), Hormone galactogène, Prolactine&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;PRL (Prolattina), Ormone pituitario lattogenico, Mammotropina, Ormone pituitario della mammotropina, Prolattina&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;LAKTOGENNYI GORMON GIPOFIZA, LIUTEOTROPIN, LAKTIKOTROPNYI GORMON, PROLAKTIN, MAMMOTROPIN, MAMMOTROPNYI GORMON GIPOFIZA, ЛАКТИКОТРОПНЫЙ ГОРМОН, ЛАКТОГЕННЫЙ ГОРМОН ГИПОФИЗА, ЛЮТЕОТРОПИН, МАММОТРОПИН, МАММОТРОПНЫЙ ГОРМОН ГИПОФИЗА, ПРОЛАКТИН&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;ラクトトロピン, 乳腺刺激ホルモン-下垂体性, 黄体刺激ホルモン, プロラクチン, ルテオトロピン, 下垂体性乳腺刺激ホルモン, 下垂体性泌乳刺激ホルモン, 乳汁分泌ホルモン, 乳腺刺激ホルモン, 催乳ホルモン, マンモトロピン&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;prolactina (producto), preparado de PL, preparado de prolactina (producto), preparado de prolactina, preparado de prolactina (sustancia), prolactina (sustancia), prolactina, Prolactina, Hormona-Lactogeno Pituitaria, Hormona Mamotropica Pituitaria, Hormona Mamotropico-Pituitaria, Mamotropina, Hormona Mamotrópica Pituitaria, Hormona Mamotrópico-Pituitaria, Hormona-Lactógeno Pituitaria&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Croatian&lt;/td&gt;
                &lt;td&gt;PROLAKTIN&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Prolaktyna, Laktotropina, Hormon laktotropowy&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Mammotropin, Prolactin, Lactogene Hormone, hypophysäre, Mammotrope Hormone, hypophysäre&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Hormônio Lactogênico Pituitário, Hormônio Mamotrófico Pituitário, Hormônio Mamotrópico Pituitário, Mamotrofina, Mamotropina, Prolactina&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Prolactin  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Prolactin</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Pathology and Laboratory Medicine</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Physiology&lt;ol&gt;&lt;li&gt;Prolactin is synthesized and secreted by lactotrophs in the anterior pituitary&lt;ol&gt;&lt;li&gt;Stimulation (releasing factors)&lt;ol&gt;&lt;li&gt;Vasoactive intestinal polypeptide (VIP)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/ThyrdRlsngHrmn.htm" class="LinkPage"&gt;Thyroid Releasing Hormone&lt;/a&gt; (TRH, short-term factor only)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Gyn/Pharm/Estrgn.htm" class="LinkPage"&gt;Estrogen&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Inhibition&lt;ol&gt;&lt;li&gt;Hypothalamic &lt;a href="../../CV/Pharm/Dpmn.htm" class="LinkPage"&gt;Dopamine&lt;/a&gt; (Prolactin Inhibiting Factor or PIF)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Prolactin Characteristics&lt;ol&gt;&lt;li&gt;Polypeptide hormone with 198 amino acids&lt;/li&gt;&lt;li&gt;Resembles &lt;a href="../../Endo/Pharm/HmnGrwthHrmn.htm" class="LinkPage"&gt;Human Growth Hormone&lt;/a&gt; (hCG)&lt;/li&gt;&lt;li&gt;Resembles Human Placental lactogen (hPL)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Prolactin increases with infant &lt;a href="../../OB/Lactation/BrstFdng.htm" class="LinkPage"&gt;Breast Feeding&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Increases with each &lt;a href="../../OB/Lactation/BrstFdng.htm" class="LinkPage"&gt;Breast Feeding&lt;/a&gt; episode&lt;/li&gt;&lt;li&gt;Prolactin levels gradually level off after the first few months of regularly &lt;a href="../../OB/Lactation/BrstFdng.htm" class="LinkPage"&gt;Breast Feeding&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Prolactin decreases to normal within 1-2 months of stopping &lt;a href="../../OB/Lactation/BrstFdng.htm" class="LinkPage"&gt;Breast Feeding&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Preparation&lt;ol&gt;&lt;li&gt;Fasting level drawn before noon&lt;/li&gt;&lt;li&gt;No &lt;a href="../../Gyn/Anatomy/BrstAntmy.htm" class="LinkPage"&gt;Breast&lt;/a&gt; stimulation in last 48 hours&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Interpretation: Normal Levels&lt;ol&gt;&lt;li&gt;Adult: &amp;lt;20 ng/ml&lt;/li&gt;&lt;li&gt;Newborn: 100 to 300 (falls below 20 after 6 weeks)&lt;/li&gt;&lt;li&gt;Pregnancy&lt;ol&gt;&lt;li&gt;First Trimester: &amp;lt;80 ng/ml&lt;/li&gt;&lt;li&gt;Second trimester: &amp;lt;160 ng/ml&lt;/li&gt;&lt;li&gt;Third Trimester: &amp;lt;400 ng/ml&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../OB/Lactation/BrstFdng.htm" class="LinkPage"&gt;Lactation&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Initially (&amp;lt;3 months postpartum)&lt;ol&gt;&lt;li&gt;First week: 100 ng/ml basal level&lt;/li&gt;&lt;li&gt;First 1-2 months: 50 ng/ml basal level&lt;/li&gt;&lt;li&gt;Suckling raises Prolactin 10-20 fold above basal&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Later (3-6 months postpartum)&lt;ol&gt;&lt;li&gt;Basal rates approach non-pregnant levels&lt;/li&gt;&lt;li&gt;Suckling may double basal level&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;References&lt;ol&gt;&lt;li&gt;Bakerman (1984) ABCs of Lab Data, p. 342&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Interpretation: Increased Prolactin &amp;gt; 20 ng/ml&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Endo/Pituitary/Hyprprlctnm.htm" class="LinkPage"&gt;Hyperprolactinemia&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0033371</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Lab/Prlctn.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Prolactin, Serum Prolactin</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Lab/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Free thyroxine index test  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0202024"&gt;&lt;i&gt;C0202024&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Laboratory Procedure (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0202024&amp;amp;tui=T059"&gt;&lt;i&gt;T059&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;143690007, 166333003, 39700003&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Indice di tiroxina libera&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;遊離サイロキシンインデックス, ﾕｳﾘｻｲﾛｷｼﾝｲﾝﾃﾞｯｸｽ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;Free thyroxine index, Free thyroxine index (&amp;amp; level), índice de FT4, índice de tiroxina libre (procedimiento), índice de tiroxina libre, Índice de tiroxina libre&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;free thyroxine index (lab test), free thyroxine index, Free thyroxine index (&amp;amp; level) (procedure), Free thyroxine index test, FTI (free T4 index), FTI (free thyroxine index), free T4 index, free thyroxine index test, Free thyroxine index, FT4 index, FTI, FT4I, FTI - Free thyroxine index, Free thyroxine index level, Free thyroxine index (procedure), Free thyroxine index (&amp;amp; level)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;Index volného tyroxinu&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;Szabad tiroxin index&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Índice de tiroxina livre&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;vrij-thyroxine-index&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Index de thyroxine libre&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Freies Thyroxin-Index&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Free thyroxine index test  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Free Thyroxine Index</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Pathology and Laboratory Medicine</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Normal&lt;ol&gt;&lt;li&gt;Free Thyroxine Index: 4-11&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Indications&lt;ol&gt;&lt;li&gt;Corrects for abnormal &lt;a href="../../Endo/Lab/ThyrxnBndngGlbln.htm" class="LinkPage"&gt;Thyroid Binding Globulin&lt;/a&gt; (TBG)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/Thyrxn.htm" class="LinkPage"&gt;Free T4&lt;/a&gt; also corrects for &lt;a href="../../Endo/Lab/ThyrxnBndngGlbln.htm" class="LinkPage"&gt;Thyroid Binding Globulin&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/Thyrxn.htm" class="LinkPage"&gt;Free T4&lt;/a&gt; is preferred over FTI&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Measurement&lt;ol&gt;&lt;li&gt;Calculated: T4 x &lt;a href="../../Endo/Lab/T3RsnUptk.htm" class="LinkPage"&gt;T3 Binding Ratio&lt;/a&gt; (&lt;a href="../../Endo/Lab/T3RsnUptk.htm" class="LinkPage"&gt;T3RU&lt;/a&gt;)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0202024</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Lab/FrThyrxnIndx.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Free Thyroxine Index, Free T4 Index, FTI, FT4I</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Lab/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees></FP_UMLS_Trees><FP_Condition_name_check></FP_Condition_name_check><FP_Condition_name><value>Luteinizing hormone</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Pathology and Laboratory Medicine</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Normal Serum Levels&lt;ol&gt;&lt;li&gt;Male: &amp;lt;15 mIU/ml&lt;/li&gt;&lt;li&gt;Female: &amp;lt;30 mIU/ml (higher in mid-cycle surge)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Gyn/Endo/Mnps.htm" class="LinkPage"&gt;Menopause&lt;/a&gt;: 30 to 200 mIU/ml&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Detection: Urine LH&lt;ol&gt;&lt;li&gt;Urine LH dip-stick kit used to detect &lt;a href="../../Gyn/Exam/Ovltn.htm" class="LinkPage"&gt;Ovulation&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Urine LH consistently surges 72 hours before &lt;a href="../../Gyn/Exam/Ovltn.htm" class="LinkPage"&gt;Ovulation&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Most accurate kits (prescribed)&lt;ol&gt;&lt;li&gt;OvuQuick&lt;/li&gt;&lt;li&gt;Clear Plan Easy&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;References&lt;ol&gt;&lt;li&gt;Stewart (2003) AAFP Board Review, Seattle&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Guermandi%20%20%5BAU%5D%20AND%202001%20%5BDP%5D%20AND%20%20Obstet%20Gynecol%20%20%5BTA%5D" class="LinkRef"&gt;Guermandi (2001) Obstet Gynecol 97:92-6&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Lab/LtnzngHrmn.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Luteinizing hormone, Serum LH, Urine LH, Ovulation kit</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Lab/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;buccal smear biopsy procedure  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0581714"&gt;&lt;i&gt;C0581714&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Diagnostic Procedure (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0581714&amp;amp;tui=T060"&gt;&lt;i&gt;T060&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;31402005, 303995001&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Striscio orale, Striscio buccale&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;uitstrijkje wangslijmvlies, wangslijmvliesuitstrijkje&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;頬部スミア, ﾎﾎﾌﾞｽﾐｱ, ｷｮｳﾌﾞｽﾐｱ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Buccal smear for Barr bodies (procedure), Smear buccal, buccal smears, buccal smear, Buccal smear, Buccal smear procedure, Buccal smear procedure (procedure), Buccal smear for Barr bodies, Buccal smear for Barr bodies (procedure) [Ambiguous], buccal smear biopsy procedure&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;Stěr z bukální sliznice&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;Buccalis kenet&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;extendido bucal para detección de corpúsculos de Barr (concepto no activo), extendido bucal para detección de corpúsculos de Barr (procedimiento), extendido bucal para detección de corpúsculos de Barr, frotis bucal, procedimiento de extendido de material del carrillo, procedimiento de extendido yugal (procedimiento), procedimiento de extendido yugal, procedimiento de frotis yugal, Frotis bucal&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Esfregaço bucal&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Frottis buccal&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Mundabstrich&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Sex Chromatin  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0036867"&gt;&lt;i&gt;C0036867&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSHFRE)&lt;/td&gt;
                &lt;td&gt;Dans le noyau à l'interphase, masse condensée de chromatine représentant un chromosome X inactif. Normalement, seul un chromosome X est actif dans une cellule quelque soit le nombre total de chromosomes X. Chaque chromosome X, plus un, forme la chromatine sexuelle (corpuscule de Barr). Le nombre de corpuscule de Barr présents donne une indication du nombre de chromosomes X de la cellule : Nombre de chromosomes X = nombre de corpuscules + 1.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;The inactive, condensed X chromosome in a female somatic cell.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;In the interphase nucleus, a condensed mass of chromatin representing an inactivated X chromosome. Each X CHROMOSOME, in excess of one, forms sex chromatin (Barr body) in the mammalian nucleus. (from King &amp;amp; Stansfield, A Dictionary of Genetics, 4th ed)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (GO)&lt;/td&gt;
                &lt;td&gt;A structure found in a female mammalian cell containing an unpaired X chromosome that has become densely heterochromatic, silenced and localized at the nuclear periphery. [GOC:hjd]&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (GO)&lt;/td&gt;
                &lt;td&gt;A condensed mass of compacted chromatin that represents an inactivated X chromosome. [ISBN:0198506732 "Oxford Dictionary of Biochemistry and Molecular Biology"]&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Cell Component (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0036867&amp;amp;tui=T026"&gt;&lt;i&gt;T026&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D012728&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;58348001&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Barr Bodies, Bodies, Barr, Chromatin, Sex, Chromatins, Sex, Sex Chromatin, Sex Chromatins, sex chromatin, Barr chromatin body, Barr bodies, barr bodies, chromatin sex, barr body, Barr body, Sex chromatin, Sex chromatin (substance), Barr Body&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Corpuscules de Barr, Chromatine sexuelle&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Könskromatin&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;sexchromatin&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Barrin kappale&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;X-KHROMATIN, KHROMATIN POLOVOI, Y-KHROMATIN, BARRA TEL'TSA, POLOVOI KHROMATIN, X-ХРОМАТИН, Y-ХРОМАТИН, БАРРА ТЕЛЬЦА, ПОЛОВОЙ ХРОМАТИН, ХРОМАТИН ПОЛОВОЙ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Corpi di Barr, Cromatina sessuale&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Latvian&lt;/td&gt;
                &lt;td&gt;Dzimumhromatīns&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Ciałko Barra, Chromatyna płciowa&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;クロマチン-性, 性クロマチン, バール小体, 性染色質, 染色質-性&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;cromatina sexual (sustancia), cromatina sexual, cuerpo de cromatina de Barr, Corpusculos de Barr, Cromatina Sexual&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Chromatin, Geschlechts-, Geschlechtschromatin, Barr-Körperchen&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;Barr-lichaampjes, Chromatine, sekse-, Seksechromatine&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Corpos de Barr, Cromatina Sexual&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>buccal smear biopsy procedure  (</value><value>)
</value><value>Sex Chromatin  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Buccal Smear</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Pathology and Laboratory Medicine</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Definitions&lt;ol&gt;&lt;li&gt;Buccal Smear (or Sex Chromatin Test)&lt;ol&gt;&lt;li&gt;Microscopy of cheek cell scraping&lt;/li&gt;&lt;li&gt;Presence of barr bodies suggests 2 X-chromosomes&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Barr Body&lt;ol&gt;&lt;li&gt;Inactivated X-Chromosome in each cell of a female&lt;/li&gt;&lt;li&gt;Seen as an intracellular dark spot on microscopy&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;History&lt;ol&gt;&lt;li&gt;Barr Body first identified by Dr. Murray Barr in 1949&lt;/li&gt;&lt;li&gt;Mary Lyon suggested etiology and named it Barr Body&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Physiology&lt;ol&gt;&lt;li&gt;All cells in female, turn off 1 of 2 X-Chromosomes&lt;/li&gt;&lt;li&gt;Occurs on day 16 of &lt;a href="../../OB/Rad/FrstTrmstrUltrsnd.htm" class="LinkPage"&gt;Embryo&lt;/a&gt;nic development&lt;/li&gt;&lt;li&gt;Each cell child inherits same inactivated X-Chromosome&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Indications&lt;ol&gt;&lt;li&gt;Replaced by karyotype for full chromosomal mapping&lt;/li&gt;&lt;li&gt;Previously used to evaluate abnormal &lt;a href="../../Endo/Exam/SxlDvlpmnt.htm" class="LinkPage"&gt;Sexual Development&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../Gyn/Menses/PrmryAmnrh.htm" class="LinkPage"&gt;Delayed Menarche&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Sex/PbrtlDly.htm" class="LinkPage"&gt;Delayed Puberty&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Procedure&lt;ol&gt;&lt;li&gt;Gently scrape inside of cheek&lt;ol&gt;&lt;li&gt;May use wooden &lt;a href="../../ENT/Anatomy/Tng.htm" class="LinkPage"&gt;Tongue&lt;/a&gt; blade or toothpick&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Spread sample onto slide into drop of saline&lt;/li&gt;&lt;li&gt;Dry slide and stain with methylene blue 0.3%&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Interpretation&lt;ol&gt;&lt;li&gt;Barr Body: Crumpled dark chromosome seen in cell&lt;ol&gt;&lt;li&gt;Suggests normal female karyotype 46XX&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0581714</value><value>C0036867</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Lab/BclSmr.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Buccal Smear, Sex Chromatin Test, Barr Body</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Lab/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees></FP_UMLS_Trees><FP_Condition_name_check></FP_Condition_name_check><FP_Condition_name><value>Antithyroid Antibody</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Pathology and Laboratory Medicine</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Measurement&lt;ol&gt;&lt;li&gt;Bioassay&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Thyroid Stimulating Immunoglobulin (TSH receptor ab)&lt;ol&gt;&lt;li&gt;Binds and activates TSH receptor in &lt;a href="../../Endo/Anatomy/ThyrdAntmy.htm" class="LinkPage"&gt;Thyroid&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Seen in &lt;a href="../../Endo/Thyroid/Hyprthyrdsm1.htm" class="LinkPage"&gt;Hyperthyroidism&lt;/a&gt;: &lt;a href="../../Endo/Thyroid/GrvsDs.htm" class="LinkPage"&gt;Grave's Disease&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Linked with ophthalmopathy&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Antithyroid Microsomal Antibody (TMAb)&lt;ol&gt;&lt;li&gt;Antithyroid Peroxidase Antibody&lt;/li&gt;&lt;li&gt;Seen in &lt;a href="../../Endo/Thyroid/Hypthyrdsm.htm" class="LinkPage"&gt;Hypothyroidism&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/HshmtsThyrdts.htm" class="LinkPage"&gt;Hashimoto's Thyroiditis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/SbclnclHypthyrdsm.htm" class="LinkPage"&gt;Subclinical Hypothyroidism&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Antithyroglobulin Antibody (TgAb)&lt;ol&gt;&lt;li&gt;Seen in &lt;a href="../../Endo/Thyroid/HshmtsThyrdts.htm" class="LinkPage"&gt;Hashimoto's Thyroiditis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Less commonly elevated compared with TMAb&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Lab/AnthyrdAntbdy.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Antithyroid Antibody, TSH Receptor Antibody, Thyroid Stimulating Immunoglobulin, Antithyroid Microsomal Antibody, Antithyroid Peroxidase Antibody, Antithyroglobulin Antibody</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Lab/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees></FP_UMLS_Trees><FP_Condition_name_check></FP_Condition_name_check><FP_Condition_name><value>GnRH Stimulation Test</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Pathology and Laboratory Medicine</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Indications&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Sex/PrcsPbrty.htm" class="LinkPage"&gt;Precocious Puberty&lt;/a&gt; (suspect pathologic central cause)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Sex/PbrtlDly.htm" class="LinkPage"&gt;Delayed Puberty&lt;/a&gt; (suspect hormonal cause)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Technique&lt;ol&gt;&lt;li&gt;Patient fasts overnight&lt;/li&gt;&lt;li&gt;Administer 100 ug GnRH IV or SC&lt;/li&gt;&lt;li&gt;Obtain Serum Gonadotropin Levels&lt;ol&gt;&lt;li&gt;Labs&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/FlclStmltngHrmn.htm" class="LinkPage"&gt;Follicle Stimulating Hormone&lt;/a&gt; (FSH)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/LtnzngHrmn.htm" class="LinkPage"&gt;Luteinizing hormone&lt;/a&gt; (LH)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Timing&lt;ol&gt;&lt;li&gt;Baseline prior to GnRH administration&lt;/li&gt;&lt;li&gt;After injection at 15, 30, 45, and 60 minutes&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Interpretation&lt;ol&gt;&lt;li&gt;Central &lt;a href="../../Endo/Sex/PrcsPbrty.htm" class="LinkPage"&gt;Precocious Puberty&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Two fold or higher increase in FSH and LH&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Reiter%20%20%5BAU%5D%20AND%201975%20%5BDP%5D%20AND%20%20Pediatr%20Res%20%20%5BTA%5D" class="LinkRef"&gt;Reiter (1975) Pediatr Res 9:111-6&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Lab/GnrhStmltnTst.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: GnRH Stimulation Test</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Lab/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees></FP_UMLS_Trees><FP_Condition_name_check></FP_Condition_name_check><FP_Condition_name><value>Follicle Stimulating Hormone</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Pathology and Laboratory Medicine</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Normal Levels&lt;ol&gt;&lt;li&gt;Male: &amp;lt;20 mIU/ml&lt;/li&gt;&lt;li&gt;Female: &amp;lt;25 mIU/ml (Higher in mid-cycle surge)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Gyn/Endo/Mnps.htm" class="LinkPage"&gt;Menopause&lt;/a&gt;: 30 to 250 mIU/ml&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Indications&lt;ol&gt;&lt;li&gt;Not necessary to confirm &lt;a href="../../Gyn/Endo/Mnps.htm" class="LinkPage"&gt;Menopause&lt;/a&gt; diagnosis&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Lab/FlclStmltngHrmn.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Follicle Stimulating Hormone, Serum FSH</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Lab/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Parathyroid Hormone  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0030520"&gt;&lt;i&gt;C0030520&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;A polypeptide hormone (84 amino acid residues) secreted by the PARATHYROID GLANDS which performs the essential role of maintaining intracellular CALCIUM levels in the body. Parathyroid hormone increases intracellular calcium by promoting the release of CALCIUM from BONE, increases the intestinal absorption of calcium, increases the renal tubular reabsorption of calcium, and increases the renal excretion of phosphates.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CSP)&lt;/td&gt;
                &lt;td&gt;polypeptide hormone secreted by the parathyroid glands which maintains intracellular calcium levels in the body; parathyroid hormone increases intracellular calcium by promoting the release of calcium from bone, increases the intestinal absorption of calcium, increases the renal tubular reabsorption of calcium, and increases the renal excretion of phosphates.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (PDQ)&lt;/td&gt;
                &lt;td&gt;Encoded by human PTH Gene (Parathyroid Hormone Family), secreted (parathyroid cells) 115-aa 13-kDa (precursor) Parathyroid Hormone elevates blood Ca2+ levels by dissolving the salts in bone and preventing renal excretion. PTH defects cause familial isolated hypoparathyroidism. (NCI) Check for "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=489119&amp;amp;idtype=1" active clinical trials or "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=489119&amp;amp;idtype=1&amp;amp;closed=1" closed clinical trials using this agent. ("http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;amp;code=C41027" NCI Thesaurus)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Amino Acid, Peptide, or Protein (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0030520&amp;amp;tui=T116"&gt;&lt;i&gt;T116&lt;/i&gt;&lt;/a&gt;)
, Pharmacologic Substance (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0030520&amp;amp;tui=T121"&gt;&lt;i&gt;T121&lt;/i&gt;&lt;/a&gt;)
, Hormone (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0030520&amp;amp;tui=T125"&gt;&lt;i&gt;T125&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D010281&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;27518004, 68136009, 4076007, 373752003&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Hormone, Parathyroid, Parathormone, Parathyrin, Parathyroid Hormone (1-84), PTH (1-84), PARATHYROID HORMONE PREPARATIONS, PARATHYROID HORMONES, Parathormone preparation, NOS, Parathormone, NOS, Parathyroid extract, NOS, Parathyroid hormone preparation, NOS, Parathyroid hormone, NOS, PTH, parathyroid hormone, parathormone, parathyrin, PARATHYROID, parathyroid (medication), parathyroid, A1A PARATHYROID HORMONE PREPARATIONS, B34 PARATHYROID HORMONES, Parathormone (substance), Parathyroid Hormone, Parathyroid Hormone [Chemical/Ingredient], Parathyroid-class Hormone, [HS600] PARATHYROID, Parathyroid Hormone [EPC], Parathyroid hormones, parathyroid hormones, Parathyroid Hormones, Parathyroid hormone, PTH - Parathyroid hormone, Parathyroid hormone preparation, Parathormone preparation, Parathyroid extract, Parathyroid hormone agent (substance), Parathyroid hormone agent, Parathyroid hormone preparation (product), Parathyroid hormone preparation (substance), Parathyroid, Parathyroid hormone (substance), Intact parathyroid hormone (substance)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;hormona paratiroidea intacta, preparado con PTH, preparado con hormona paratiroidea (producto), hormona paratiroidea (producto), preparado con hormona paratiroidea, agente con hormona paratiroidea (sustancia), agente con hormona paratiroidea, extracto paratiroideo, hormona paratiroidea (sustancia), hormona paratiroidea, parathormona (concepto no activo), parathormona, preparado con paratohormona, preparado de PTH, preparado de hormona paratiroidea (producto), preparado de hormona paratiroidea (sustancia), preparado de hormona paratiroidea, preparado de paratohormona, Hormona Paratiroidea&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Bisköldkörtelhormoner&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;parathormon, parathyroidní hormon&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Lisäkilpirauhashormoni&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Parathyrine, PTH (Parathyroid hormone), PTH (1-84), Hormone parathyroïdienne, Parathormone&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;PTH (1-84), Parathyrin, Parathormon, Nebenschilddrüsenhormone&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;GORMONY PARASHCHITOVIDNOI ZHELEZY, PARAT-GORMON, PARATGORMON, PARASHCHITOVIDNOI ZHELEZY GORMON, OKOLOSHCHITOVIDNOI ZHELEZY GORMONY, PARATIREOIDNYI GORMON, ГОРМОНЫ ПАРАЩИТОВИДНОЙ ЖЕЛЕЗЫ, ОКОЛОЩИТОВИДНОЙ ЖЕЛЕЗЫ ГОРМОНЫ, ПАРАТ-ГОРМОН, ПАРАТГОРМОН, ПАРАТИРЕОИДНЫЙ ГОРМОН, ПАРАЩИТОВИДНОЙ ЖЕЛЕЗЫ ГОРМОН&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;上皮小体ホルモン, パラソルモン, 副甲状腺ホルモン&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;PTH (1-84), Paratormoni, Ormoni paratiroidei (1-84), Paratirine, Ormoni paratiroidei&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Croatian&lt;/td&gt;
                &lt;td&gt;PARATIREOIDNI HORMON&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Hormon przytarczyc, Parathormon, Paratyreoidyna, Hormon gruczołów przytarczycznych&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Hormônio Paratireóideo, Hormônio Paratireoidiano&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Parathyroid Hormone  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Parathyroid Hormone</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Pathology and Laboratory Medicine</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Physiology: Parathyroid Hormone (PTH)&lt;ol&gt;&lt;li&gt;PTH is released by &lt;a href="../../Endo/Anatomy/PrthyrdAntmy.htm" class="LinkPage"&gt;Parathyroid Gland&lt;/a&gt;s in neck&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Anatomy/PrthyrdAntmy.htm" class="LinkPage"&gt;Parathyroid&lt;/a&gt;s increase PTH when calcium is low&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Anatomy/PrthyrdAntmy.htm" class="LinkPage"&gt;Parathyroid&lt;/a&gt;s decrease PTH when calcium is high&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Pharmacokinetics&lt;ol&gt;&lt;li&gt;PTH is 84 amino-acid peptide&lt;/li&gt;&lt;li&gt;Circulating half-life: 2-5 minutes&lt;/li&gt;&lt;li&gt;Metabolized by liver and &lt;a href="../../Renal/Anatomy/RnlAntmy.htm" class="LinkPage"&gt;Kidney&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Mechanism&lt;ol&gt;&lt;li&gt;PTH stimulates &lt;a href="../../Rheum/Exam/BnPhyslgy.htm" class="LinkPage"&gt;Osteoclast&lt;/a&gt;s in bone&lt;ol&gt;&lt;li&gt;&lt;a href="../../Rheum/Exam/BnPhyslgy.htm" class="LinkPage"&gt;Osteoclast&lt;/a&gt;s mobilize bone calcium&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;PTH acts at &lt;a href="../../Renal/Anatomy/RnlAntmy.htm" class="LinkPage"&gt;Kidney&lt;/a&gt;s to increase &lt;a href="../../Renal/Lab/SrmClcm.htm" class="LinkPage"&gt;Serum Calcium&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Increases calcium reabsorption&lt;/li&gt;&lt;li&gt;&lt;a href="../../Renal/Anatomy/RnlAntmy.htm" class="LinkPage"&gt;Kidney&lt;/a&gt; activates 25-hydroxyVitamin D&lt;ol&gt;&lt;li&gt;Converts it to 1,25-dihydroxyVitamin D3&lt;/li&gt;&lt;li&gt;Increases intestinal calcium absorption&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Testing&lt;ol&gt;&lt;li&gt;Tests to avoid&lt;ol&gt;&lt;li&gt;C-Terminal PTH&lt;/li&gt;&lt;li&gt;N-Terminal PTH&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Recommended Test&lt;ol&gt;&lt;li&gt;Whole Molecule PTH by IRMA (Mid-region or Intact PTH)&lt;ol&gt;&lt;li&gt;Measures C-Terminal and N-Terminal PTH&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Interpretation: Normal &lt;a href="../../Renal/Lab/SrmClcm.htm" class="LinkPage"&gt;Serum Calcium&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Parathyroid Hormone: 10 to 66 pg/ml&lt;ol&gt;&lt;li&gt;Normal &lt;a href="../../Endo/Anatomy/PrthyrdAntmy.htm" class="LinkPage"&gt;Parathyroid&lt;/a&gt; Function&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Interpretation: &lt;a href="../../Renal/Calcium/Hyprclcm.htm" class="LinkPage"&gt;High Serum Calcium&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Parathyroid Hormone &amp;gt;66 pg/ml&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Parathyroid/Hyprprthyrdsm.htm" class="LinkPage"&gt;Primary Hyperparathyroidism&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Consider &lt;a href="../../Endo/Parathyroid/MltplEndcrnNplsTyp.htm" class="LinkPage"&gt;MEN I&lt;/a&gt; or &lt;a href="../../Endo/Parathyroid/MltplEndcrnNplsTyp1.htm" class="LinkPage"&gt;MEN II&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Parathyroid Hormone 10-66 pg/ml&lt;ol&gt;&lt;li&gt;Familial Hypocalciuric &lt;a href="../../Renal/Calcium/Hyprclcm.htm" class="LinkPage"&gt;Hypercalcemia&lt;/a&gt;&lt;ol&gt;&lt;li&gt;24 hour &lt;a href="../../Renal/Lab/UrnClcm.htm" class="LinkPage"&gt;Urine Calcium&lt;/a&gt; to &lt;a href="../../Sports/Pharm/Crtn1.htm" class="LinkPage"&gt;Creatine&lt;/a&gt; clearance &amp;lt;0.01&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Parathyroid Hormone &amp;lt;10 pg/ml&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Anatomy/PrthyrdAntmy.htm" class="LinkPage"&gt;Parathyroid&lt;/a&gt; Cancer&lt;/li&gt;&lt;li&gt;Granulomatous Disease&lt;/li&gt;&lt;li&gt;&lt;a href="../../Renal/Calcium/MlkAlklSyndrm.htm" class="LinkPage"&gt;Milk-Alkali Syndrome&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Adrenal/AdsnsDs.htm" class="LinkPage"&gt;Adrenal Insufficiency&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/Hyprthyrdsm1.htm" class="LinkPage"&gt;Hyperthyroidism&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Prolonged immobilization&lt;/li&gt;&lt;li&gt;Medication related&lt;ol&gt;&lt;li&gt;&lt;a href="../../Psych/Pharm/LthmCrbnt.htm" class="LinkPage"&gt;Lithium&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Theophylline&lt;/li&gt;&lt;li&gt;&lt;a href="../../Gyn/Pharm/Tmxfn.htm" class="LinkPage"&gt;Tamoxifen&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Interpretation: &lt;a href="../../Renal/Calcium/Hypclcm.htm" class="LinkPage"&gt;Low Serum Calcium&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Parathyroid Hormone &amp;gt;66 pg/ml&lt;ol&gt;&lt;li&gt;Secondary &lt;a href="../../Endo/Parathyroid/Hyprprthyrdsm.htm" class="LinkPage"&gt;Hyperparathyroidism&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../Renal/Failure/ActRnlFlr.htm" class="LinkPage"&gt;Renal Failure&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Gastrointestinal malabsorption&lt;/li&gt;&lt;li&gt;&lt;a href="../../Renal/Magnesium/Hypmgnsm.htm" class="LinkPage"&gt;Hypomagnesemia&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Parathyroid Hormone 10 to 66 pg/ml&lt;ol&gt;&lt;li&gt;Pseudohypoparathyroidism&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Parathyroid Hormone &amp;lt;10 pg/ml&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Parathyroid/Hyprthyrdsm.htm" class="LinkPage"&gt;Hypoparathyroidism&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;Bakerman (1984) ABCs of Lab Data, ILD, Greenville, NC&lt;/li&gt;&lt;li&gt;Einhorn (2001) CMEA Medicine Lecture, San Diego&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Taniegra%20%20%5BAU%5D%20AND%202004%20%5BDP%5D%20AND%20%20Am%20Fam%20Physician%20%20%5BTA%5D" class="LinkRef"&gt;Taniegra (2004) Am Fam Physician 69(2):333-40&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0030520</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Lab/PrthyrdHrmn.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Parathyroid Hormone, C-Terminal PTH, N-Terminal PTH, Whole Molecule PTH, Intact PTH, Mid-Region PTH, PTH</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Lab/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Hemoglobin, Glycosylated  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0017853"&gt;&lt;i&gt;C0017853&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Amino Acid, Peptide, or Protein (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0017853&amp;amp;tui=T116"&gt;&lt;i&gt;T116&lt;/i&gt;&lt;/a&gt;)
, Biologically Active Substance (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0017853&amp;amp;tui=T123"&gt;&lt;i&gt;T123&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D006442&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;259689004, 143080000, 165678002&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Glycated Hemoglobins, Glycosylated Hemoglobin, Hemoglobin, Glycosylated, Hemoglobins, Glycated, Hemoglobin.glycated, glycosylated hemoglobin, glycosylate hemoglobin, glycosylate haemoglobin, glycosylated hemoglobins, glycated haemoglobin, glycosylated hb, glycated hemoglobin, glycosylated haemoglobin, hemoglobin glycated, Glycated haemoglobin, Glycated hemoglobin, Glycosylated Hb, Glycosylated haemoglobin, Glycosylated hemoglobin, Glycosylated hemoglobin (substance)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;Glycated hemoglobin, Glycated haemoglobin, Glycosylated Hb, glucohemoglobina (sustancia), glucohemoglobina&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Hémoglobine glyquée, Hémoglobine glycosylée, Glycohémoglobine&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Glycosylated hemoglobin A  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0019018"&gt;&lt;i&gt;C0019018&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;Minor hemoglobin components of human erythrocytes designated A1a, A1b, and A1c. Hemoglobin A1c is most important since its sugar moiety is glucose covalently bound to the terminal amino acid of the beta chain. Since normal glycohemoglobin concentrations exclude marked blood glucose fluctuations over the preceding three to four weeks, the concentration of glycosylated hemoglobin A is a more reliable index of the blood sugar average over a long period of time.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Amino Acid, Peptide, or Protein (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0019018&amp;amp;tui=T116"&gt;&lt;i&gt;T116&lt;/i&gt;&lt;/a&gt;)
, Biologically Active Substance (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0019018&amp;amp;tui=T123"&gt;&lt;i&gt;T123&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D006442&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;103232008, 33601001, 259689004&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Glycohemoglobin A, Glycosylated Hemoglobin A, Hb A1, Hb A1a+b, Hb A1c, HbA1, Hemoglobin A(1), Hemoglobin A, Glycosylated, Glycosylated hemoglobin A, HBA GLYCOSYLATED, HBA 01, HEMOGLOBIN AA 01, HB AC 01, HbA&amp;lt;sub&amp;gt;1c&amp;lt;/sub&amp;gt; (substance), Haemoglobin A1c, HbA&amp;gt;1c&amp;lt; (substance), HbA1c, HbA1c (substance), HbA&amp;gt;1c&amp;lt;, Hemoglobin A1c, HbA&amp;lt;sub&amp;gt;1c&amp;lt;/sub&amp;gt;, Hemoglobin A, Glycosylated [Chemical/Ingredient], hemoglobin a1c, hba1, hemoglobin a 1, glycosylated hemoglobin a, hb a1, hba1c, haemoglobin a1c, HbA1 - Glycated haemoglobin, HbA1 - Glycated hemoglobin, Glycosylated haemoglobin A, Glycosylated hemoglobin A (substance)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Hemoglobin A, glykosylerat&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;HbA&amp;gt;1c&amp;lt; (sustancia), hemoglobina glucosilada (sustancia), hemoglobina glicosilada A, hemoglobina glucosilada, HbA&amp;gt;1c&amp;lt;, HbA1c, hemoglobina A1c, HbA&amp;lt;sub&amp;gt;1c&amp;lt;/sub&amp;gt;, HbA1c (sustancia), HbA&amp;lt;sub&amp;gt;1c&amp;lt;/sub&amp;gt; (sustancia), hemoglobina A glucosilada (sustancia), hemoglobina A glucosilada, Glucohemoglobina A, Hb A1c, HbA1, Hemoglobina A(1), Hemoglobina A Glicosilada, Hemoglobina A Glucosilada&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;HbA1, hemoglobin A glykosylovaný&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Hemoglobiini A1c&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Hb A1, HbA1, Hémoglobine A(1), Hémoglobine A1c, Hb A1c, Hb A1a+b, Hémoglobine A glycosylée, Glycohémoglobine A, Hémoglobine glycosylée A1c, Hémoglobine A1&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Hb A1a+b, Emoglobina A(1), Hb A1c, HbA1, Glicoemoglobina A, Hb A1, Emoglobina A glicosilata&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;GLIKOGEMOGLOBIN A, GEMOGLOBIN A GLIKOZILIROVANNYI, GLIKOZILIROVANNYI GEMOGLOBIN A, GEMOGLOBIN A(1), HB A1C, HBA1, ГЕМОГЛОБИН A(1), ГЕМОГЛОБИН A ГЛИКОЗИЛИРОВАННЫЙ, ГЛИКОГЕМОГЛОБИН A, ГЛИКОЗИЛИРОВАННЫЙ ГЕМОГЛОБИН A&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;HBA 01, HB AC 01, HÄMOGLOBIN A 01, Hb A1c, HbA1, Glycohämoglobin A, Glycosyliertes Hämoglobin A, Hämoglobin A(1), Hämoglobin A, glycosyliertes&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Hemoglobina A glikozylowana, Glikohemoglobina A&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;HbA糖化, グリコシルヘモグロビンA, グリコシル化ヘモグロビンA, グリコヘモグロビンA, ヘモグロビンA1, 糖化血色素A, 血色素A-糖化, グリコヘモグロビン, ヘモグロビンA1c, 糖化HbA, 糖化ヘモグロビンA&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Glicohemoglobina A, Hb A1c, HbA1, Hemoglobina A(1), Hemoglobina A Glicosilada&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Hemoglobin, Glycosylated  (</value><value>)
</value><value>Glycosylated hemoglobin A  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Hemoglobin A1C</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Pathology and Laboratory Medicine</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Epidemiology&lt;ol&gt;&lt;li&gt;Hemoglobin A1C may be important measure in non-diabetic&lt;/li&gt;&lt;li&gt;Hemoglobin A1C associated mortality (contrast with &amp;lt;5)&lt;ol&gt;&lt;li&gt;Relative risk of Hemoglobin A1C 5.0 to 5.4&lt;ol&gt;&lt;li&gt;All cause mortality: 1.41&lt;/li&gt;&lt;li&gt;Cardiovascular mortality: 2.53&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Relative risk of Hemoglobin A1C 5.4 to 6.9&lt;ol&gt;&lt;li&gt;All cause mortality: 2.07&lt;/li&gt;&lt;li&gt;Cardiovascular mortality: 2.46&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Relative risk of Hemoglobin A1C 7.0 or higher&lt;ol&gt;&lt;li&gt;All cause mortality: 2.64&lt;/li&gt;&lt;li&gt;Cardiovascular mortality: 5.04&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;References&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Khaw%20%20%5BAU%5D%20AND%202001%20%5BDP%5D%20AND%20%20BMJ%20%20%5BTA%5D" class="LinkRef"&gt;Khaw (2001) BMJ 322:15-8&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Background&lt;ol&gt;&lt;li&gt;Glycosylated Hemoglobin is not equivalent to A1C&lt;ol&gt;&lt;li&gt;Hemoglobin A1C is 70% total Glycosylated Hemoglobin&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Approximating &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Serum Glucose&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Hemoglobin A1C of 6% represents mean &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; of 130&lt;/li&gt;&lt;li&gt;Each 1% increase in A1C, &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; increases 30&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Interpretation: Correlation to Mean &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Serum Glucose&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Hemoglobin A1C: 5.5% represents mean &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; of 100&lt;/li&gt;&lt;li&gt;Hemoglobin A1C: 7.0% represents mean &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; of 150&lt;/li&gt;&lt;li&gt;Hemoglobin A1C: 8.0% represents mean &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; of 180&lt;/li&gt;&lt;li&gt;Hemoglobin A1C: 9.0% represents mean &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; of 220&lt;/li&gt;&lt;li&gt;Hemoglobin A1C: 10.0% represents mean &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; of 250&lt;/li&gt;&lt;li&gt;Hemoglobin A1C: 11.5% represents mean &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; of 300&lt;/li&gt;&lt;li&gt;Hemoglobin A1C: 13.0% represents mean &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; of 350&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Interpretation: Fasting vs post-prandial &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Hyperglycemia&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Hemoglobin A1C &amp;lt;7.3%:&lt;ol&gt;&lt;li&gt;Postprandial &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt;: 30%&lt;/li&gt;&lt;li&gt;Fasting &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt;: 70%&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Hemoglobin A1C 7.3-8.4%&lt;ol&gt;&lt;li&gt;Postprandial &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt;: 50%&lt;/li&gt;&lt;li&gt;Fasting &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt;: 50%&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Hemoglobin A1C 8.5-9.2%&lt;ol&gt;&lt;li&gt;Postprandial &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt;: 55%&lt;/li&gt;&lt;li&gt;Fasting &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt;: 45%&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Hemoglobin A1C 9.3-10.2%&lt;ol&gt;&lt;li&gt;Postprandial &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt;: 60%&lt;/li&gt;&lt;li&gt;Fasting &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt;: 40%&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Hemoglobin A1C &amp;gt;10.2%&lt;ol&gt;&lt;li&gt;Postprandial &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt;: 70%&lt;/li&gt;&lt;li&gt;Fasting &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt;: 30%&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;References&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Monnler%20%20%5BAU%5D%20AND%202003%20%5BDP%5D%20AND%20%20Diabetes%20Care%20%20%5BTA%5D" class="LinkRef"&gt;Monnler (2003) Diabetes Care 26:881-5&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Interpretation: Diagnosis of &lt;a href="../../Endo/DM/DbtsMlts.htm" class="LinkPage"&gt;Diabetes Mellitus&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Hemoglobin A1C &amp;lt;5.2%: No &lt;a href="../../Endo/DM/DbtsMlts.htm" class="LinkPage"&gt;Diabetes Mellitus&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../Prevent/Epi/TstSnstvty.htm" class="LinkPage"&gt;Test Sensitivity&lt;/a&gt;: 100%&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Hemoglobin A1C &amp;gt;6%: &lt;a href="../../Endo/DM/DbtsMlts.htm" class="LinkPage"&gt;Diabetes Mellitus&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../Prevent/Epi/TstSpcfcty.htm" class="LinkPage"&gt;Test Specificity&lt;/a&gt;: 100%&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0017853</value><value>C0019018</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Lab/HmglbnAc.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Hemoglobin A1C, Glycosylated Hemoglobin, HBA1C, HgbA1c</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Lab/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Measurement of glucose 3 hours after glucose challenge for glucose tolerance test  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0202050"&gt;&lt;i&gt;C0202050&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (ALT)&lt;/td&gt;
                &lt;td&gt;Analyzing a client/patient's blood sample to determine his or her blood glucose levels. Use DEABZ in conjunction with DEACS or DEACT. For a 4-hour test, use DEACU or DEACV. Service is billed per test.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Laboratory Procedure (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0202050&amp;amp;tui=T059"&gt;&lt;i&gt;T059&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;13165004&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Glucose tolerance test, 3 hours, Measurement of glucose 3 hours after glucose challenge for glucose tolerance test (procedure), Measurement of glucose 3 hours after glucose challenge for glucose tolerance test, Glucose tolerance test, 3 hours (procedure), 3 hour glucose tolerance test, 3 hours glucose tolerance test, 3 glucose hour testing tolerance, Glucose tolerance 3-hour test each test, GTT 3-hour tst ea.tst&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;medición de glucosa 3 horas después de la administración de glucosa para la prueba de tolerancia a la glucosa, prueba de tolerancia a la glucosa, 3 horas, medición de glucosa 3 horas después de la administración de glucosa para la prueba de tolerancia a la glucosa (procedimiento), prueba de tolerancia a la glucosa, 3 horas (procedimiento)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Measurement of glucose 3 hours after glucose challenge for glucose tolerance test  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Glucose Tolerance Test 3 hour</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Pathology and Laboratory Medicine</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Indications&lt;ol&gt;&lt;li&gt;Diagnosis of &lt;a href="../../Endo/OB/GstnlDbts.htm" class="LinkPage"&gt;Gestational Diabetes&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Failed &lt;a href="../../Endo/Lab/GlcsChlngTst.htm" class="LinkPage"&gt;Glucose Challenge Test&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Protocol&lt;ol&gt;&lt;li&gt;Fasting patient ingests 100 gram Glucola Drink&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Glucose&lt;/a&gt; measured at 4 times&lt;ol&gt;&lt;li&gt;Fasting baseline before Glucola&lt;/li&gt;&lt;li&gt;Hour 1 after Glucola&lt;/li&gt;&lt;li&gt;Hour 2 after Glucola&lt;/li&gt;&lt;li&gt;Hour 3 after Glucola&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Interpretation&lt;ol&gt;&lt;li&gt;Diagnosis suggestive of &lt;a href="../../Endo/OB/GstnlDbts.htm" class="LinkPage"&gt;Gestational Diabetes&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Two or more values below are abnormal&lt;/li&gt;&lt;li&gt;Carpenter and Coustan guidelines are the standard of care now&lt;ol&gt;&lt;li&gt;Replaces the NDDG guidelines which were 10 points higher than these&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Carpenter and Coustan Abnormal Value cut-offs&lt;ol&gt;&lt;li&gt;Fasting &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; &amp;gt; 95 mg/dl&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; at 1 hour &amp;gt; 180 mg/dl&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; at 2 hours &amp;gt; 155 mg/dl&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; at 3 hours &amp;gt; 140 mg/dl&lt;/li&gt;&lt;li&gt;References&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Carpenter%20%20%5BAU%5D%20AND%201982%20%5BDP%5D%20AND%20%20Am%20J%20Obstet%20Gynecol%20%20%5BTA%5D" class="LinkRef"&gt;Carpenter (1982) Am J Obstet Gynecol 144:768-73&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0202050</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Lab/GlcsTlrncTst3Hr.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Glucose Tolerance Test 3 hour, Glucose Tolerance Test, Three Hour Glucose Tolerance Test</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Lab/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees></FP_UMLS_Trees><FP_Condition_name_check></FP_Condition_name_check><FP_Condition_name><value>Urine Metanephrine</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Pathology and Laboratory Medicine</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Preparation&lt;ol&gt;&lt;li&gt;Stop agents altering metanephrines before checking&lt;/li&gt;&lt;li&gt;See &lt;a href="../../Endo/Adrenal/Phchrmcytm.htm" class="LinkPage"&gt;Pheochromocytoma&lt;/a&gt; for agents to avoid before test&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Normal&lt;ol&gt;&lt;li&gt;Urine Metanephrines: 0 to 2.0 mg per 24 hours&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Increased&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Adrenal/Phchrmcytm.htm" class="LinkPage"&gt;Pheochromocytoma&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Neuroblastoma&lt;/li&gt;&lt;li&gt;Stress&lt;/li&gt;&lt;li&gt;Drugs or medications&lt;ol&gt;&lt;li&gt;&lt;a href="../../Pharm/Nutrition/Cfn.htm" class="LinkPage"&gt;Caffeine&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Phenothiazines&lt;/li&gt;&lt;li&gt;&lt;a href="../../Psych/Pharm/MnmnOxdsInhbtr.htm" class="LinkPage"&gt;MAO inhibitor&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Alternative options&lt;ol&gt;&lt;li&gt;Serum Metanephrines&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Lab/UrnMtnphrn.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Urine Metanephrine, 24-hour Urine Metanephrine</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Lab/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Measurement of glucose 2 hours after glucose challenge for glucose tolerance test  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0202049"&gt;&lt;i&gt;C0202049&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (ALT)&lt;/td&gt;
                &lt;td&gt;Analyzing a client/patient's blood sample to determine his or her blood glucose levels. Use DEABZ in conjunction with DEACS. For additional time, use DEACT. For a 4-hour test, use DEACU or DEACV. Service is billed per test.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Laboratory Procedure (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0202049&amp;amp;tui=T059"&gt;&lt;i&gt;T059&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;49167009&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Glucose tolerance test, 2 hours, Measurement of glucose 2 hours after glucose challenge for glucose tolerance test (procedure), Glucose tolerance test, 2 hours (procedure), Measurement of glucose 2 hours after glucose challenge for glucose tolerance test, Glucose tolerance 2-hour test each test, GTT 2-h tst ea.tst&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;medición de glucosa 2 horas después de la administración de glucosa para la prueba de tolerancia a la glucosa (procedimiento), prueba de tolerancia a la glucosa, 2 horas (procedimiento), prueba de tolerancia a la glucosa, 2 horas, medición de glucosa 2 horas después de la administración de glucosa para la prueba de tolerancia a la glucosa&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Measurement of glucose 2 hours after glucose challenge for glucose tolerance test  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Glucose Tolerance Test 2 hour</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Pathology and Laboratory Medicine</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Indications (rarely indicated)&lt;ol&gt;&lt;li&gt;Diagnosis of &lt;a href="../../Endo/DM/DbtsMlts.htm" class="LinkPage"&gt;Diabetes Mellitus&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Replaced by fasting &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Serum Glucose&lt;/a&gt; &amp;gt;126 mg/dl&lt;/li&gt;&lt;li&gt;May be useful in &lt;a href="../../Endo/DM/InslnRstncSyndrm.htm" class="LinkPage"&gt;Insulin Resistance&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Protocol&lt;ol&gt;&lt;li&gt;Administer 75 grams Glucola drink&lt;/li&gt;&lt;li&gt;Measure &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Serum Glucose&lt;/a&gt; over 2 hour period&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Interpretation&lt;ol&gt;&lt;li&gt;Positive if 2 values exceed 200 mg/dl&lt;/li&gt;&lt;li&gt;Elevated values must include 2 hour &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0202049</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Lab/GlcsTlrncTstHr.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Glucose Tolerance Test 2 hour, Two hour Glucose Tolerance Test</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Lab/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Urine VMA measurement  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0428375"&gt;&lt;i&gt;C0428375&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Laboratory Procedure (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0428375&amp;amp;tui=T059"&gt;&lt;i&gt;T059&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;144639000, 167410009, 271253003&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;CPT&lt;/td&gt;
                &lt;td&gt;84585&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Vanillylmandelic acid (VMA), urine, VANILLYLMANDELIC ACID (VMA), URINE, urine vanillylmandelic acid measurement (lab test), urine vanillylmandelic acid, urine vanillylmandelic acid measurement, Urine VMA (&amp;amp; level) (procedure), urine VMA measurement, Measurement of vanillylmandelic acid in urine specimen (procedure), Measurement of vanillylmandelic acid in urine specimen, Urine VMA level, Urine VMA measurement (procedure), Urine VMA, ASSAY OF URINE VMA, Assay of urine vma, Urine VMA (&amp;amp; level), VMA - urine, Urine VMA measurement, VANILLYLMANDELIC ACID URINE&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;medición urinaria de ácido vainillíl mandélico, Urine VMA (&amp;amp; level), VMA - urine, Urine VMA, medición urinaria de ácido vainillilmandélico, medición de ácido vainillilmandélico en espécimen de orina (procedimiento), determinación de nivel urinario de ácido vainillilmandélico, medición de ácido vainillilmandélico en espécimen de orina, medición urinaria de VMA, medición urinaria de ácido vainillilmandélico (procedimiento), medición de ácido vainillilmandélico en muestra de orina, Vainililmandelico, acido (VMA), en orina, medición urinaria de ácido vainillíl mandélico (procedimiento), medición urinaria de ácido vanilmandélico, nivel urinario de VMA, nivel urinario de ácido vainillín mandélico&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Urine VMA measurement  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Urine Vanillylmandelic Acid</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Pathology and Laboratory Medicine</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Physiology&lt;ol&gt;&lt;li&gt;VMA is a &lt;a href="../../Neuro/Pharm/AdrnrgcRcptr.htm" class="LinkPage"&gt;Catecholamine&lt;/a&gt; metabolite&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Indications&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Adrenal/Phchrmcytm.htm" class="LinkPage"&gt;Pheochromocytoma&lt;/a&gt; (other tests used more often)&lt;/li&gt;&lt;li&gt;Neuroblastoma diagnosis or monitoring&lt;/li&gt;&lt;li&gt;Suspected Multiple endocrine adenomatosis&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Anatomy/ThyrdAntmy.htm" class="LinkPage"&gt;Thyroid&lt;/a&gt;&lt;a href="../../Neuro/Anatomy/MdlOblngt.htm" class="LinkPage"&gt;Medulla&lt;/a&gt;ry Carcinoma&lt;ol&gt;&lt;li&gt;Evaluation for coexisting &lt;a href="../../Endo/Adrenal/Phchrmcytm.htm" class="LinkPage"&gt;Pheochromocytoma&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Normal Levels&lt;ol&gt;&lt;li&gt;Age 3-8 years: less than 2.3 mg per day&lt;/li&gt;&lt;li&gt;Age 9-12 years: less than 3.4 mg per day&lt;/li&gt;&lt;li&gt;Age 13-17 years: less than 3.9 mg per day&lt;/li&gt;&lt;li&gt;Adults: less than 6.7 mg per day&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Causes of Increased Levels&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Adrenal/Phchrmcytm.htm" class="LinkPage"&gt;Pheochromocytoma&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Neuroblastoma&lt;/li&gt;&lt;li&gt;Ganglioma&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0428375</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Lab/UrnVnlylmndlcAcd.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Urine Vanillylmandelic Acid, Urine VMA</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Lab/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Blood Glucose  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0005802"&gt;&lt;i&gt;C0005802&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;Glucose (a type of sugar) found in the blood.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;Glucose in blood.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CSP)&lt;/td&gt;
                &lt;td&gt;levels of glucose found in the blood.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Carbohydrate (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0005802&amp;amp;tui=T118"&gt;&lt;i&gt;T118&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D001786&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Blood Glucose, Blood Sugar, Glucose, Blood, Sugar, Blood, Blood sugar, blood glucose, Blood Glucose [Chemical/Ingredient], bloods sugar, glucose blood, sugar blood, blood sugars, blood sugar, glycemia&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Blodsocker&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;glykémie, krevní glukosa, krevní cukr&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Verensokeri&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;GLIUKOZA KROVI, SAKHAR KROVI, KROVI SAKHAR, ГЛЮКОЗА КРОВИ, КРОВИ САХАР, САХАР КРОВИ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Croatian&lt;/td&gt;
                &lt;td&gt;GLUKOZA U KRVI&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;Glucosa Sanguínea, Azucar en la Sangre, Azucar de la Sangre, Azúcar en la Sangre, Glucosa Sanguinea, Glucemia, Glucosa de la Sangre, Azúcar de la Sangre, Glucosa en la Sangre&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Glucose no Sangue, Glucemia, Glucose do Sangue, Açúcar do Sangue, Açúcar no Sangue, Glicemia, Glucose Sanguínea&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Glukoza we krwi, Glikemia, Cukier we krwi&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;血糖, 血中グルコース&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Glycémie&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Blutglucose, Blutzucker, Glucose, Blut-&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Glicemia&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Hyperglycemia  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0020456"&gt;&lt;i&gt;C0020456&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;Abnormally high BLOOD GLUCOSE level.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A high level of blood sugar. It is usually an indication of diabetes mellitus.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A disorder characterized by laboratory test results that indicate an elevation in the concentration of blood sugar. It is usually an indication of diabetes mellitus or glucose intolerance.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;Higher than normal amount of glucose (a type of sugar) in the blood. Hyperglycemia can be a sign of diabetes or other conditions.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CSP)&lt;/td&gt;
                &lt;td&gt;abnormally high blood glucose level.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Disease or Syndrome (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0020456&amp;amp;tui=T047"&gt;&lt;i&gt;T047&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D006943&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD10&lt;/td&gt;
                &lt;td&gt;R73.9&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;315299009, 390730002, 154719004, 207643008, 80394007, 144187006, 270004003, 207289007&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Hyperglycemias, HYPERGLYCAEMIA, HYPERGLYCEMIA, Hyperglycemia, NOS, [D]Hyperglycaemia, [D]Hyperglycemia, Hyperglycaemia, NOS, Hyperglycaemia, unspecified, Hyperglycemia, unspecified, [D]Hyperglycemia (context-dependent category), Hyperglycemia NOS, [X]Hyperglycaemia, unspecified, [X]Hyperglycemia, unspecified, hyperglycemia, hyperglycemia (diagnosis), elevated blood sugar, elevated glucose, [D]Hyperglycaemia (situation), Hyperglycaemia (disorder), Hyperglycaemia NOS, [X]Hyperglycemia, unspecified (finding), [D]Hyperglycemia (situation), Hyperglycemia, BLOOD GLUCOSE, HIGH, GLUCOSE, HIGH BLOOD, HIGH BLOOD GLUCOSE, Hyperglycemia [Disease/Finding], hyperglycaemia, high blood sugar level, high blood sugar, Hyperglycaemia, Hyperglycemia (disorder), blood sugar; high, blood; sugar, high, high; blood sugar, sugar; blood, high, [X]Hyperglycemia, unspecified (context-dependent category)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;HYPERGLYCEMIE, Hyperglycémie SAI, Hyperglycémie&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;HIPERGLICEMIA, Hiperglicemia NE, Hiperglucemia Pós-Prandial, Hiperglicemia, Hiperglucemia&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;HYPERGLYKAEMIE, Hyperglykaemie NNB, Hyperglykaemie, nicht naeher bezeichnet, Hyperglykaemie, Hyperglykämie&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;hyperglykemie NAO, bloed; suiker, hoog, bloedsuiker; hoog, hoog; bloedsuiker, suiker; bloed, hoog, Hyperglykemie, niet gespecificeerd, hyperglykemie, Glykemie, hyper-, Hyperglykemie&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Iperglicemia NAS, Iperglicemia&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;Hiperglucemia NEOM, [D]hiperglucemia (categoría dependiente del contexto), [X]hiperglucemia, no especificada (categoría dependiente del contexto), Hyperglycaemia, [D]Hyperglycemia, Hyperglycemia, [D]Hyperglycaemia, HIPERGLUCEMIA, Hiperglucemia Postprandial, [X]hiperglucemia, no especificada (hallazgo), [X]hiperglucemia, no especificada, [D]hiperglucemia (situación), [D]hiperglucemia, Hiperglicemia, hiperglicemia, hiperglucemia (trastorno), hiperglucemia, Hiperglucemia&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;高血糖ＮＯＳ, ｺｳｹｯﾄｳ, ｺｳｹｯﾄｳNOS, 過血糖, 高血糖症, 高血糖, 過血糖症&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Hyperglykemi&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;hyperglykémie, Hyperglykemie, Hyperglykemie NOS, Hypeglykemie&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Hyperglykemia&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;GIPERGLIKEMIIA, ГИПЕРГЛИКЕМИЯ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Korean&lt;/td&gt;
                &lt;td&gt;상세불명의 과혈당&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Croatian&lt;/td&gt;
                &lt;td&gt;HIPERGLIKEMIJA&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Hiperglikemia&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;Hyperglycaemia k.m.n., Hyperglycaemia&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Glucose  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0017725"&gt;&lt;i&gt;C0017725&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A hexose with an aldehyde group; in which each of the 5 remaining carbons other than the aldehyde group has one hydroxyl group in the R,S,R, and R configuration counting from the first hydroxyl containing carbon next to the aldehyde in the straight chain (Fisher) projection; otherwise all carbons have exclusively hydrogens. Occurs mostly as pyran (6-membered oxygen containing ring or oxane) and rarely as furan (5-membered oxygen containing ring) or straight chain. When glucose forms a ring an additional ""anomeric"" asymmetric carbon is created which is denoted as ""alpha"" or ""beta"". For isomers see http://en.wikipedia.org/wiki/Glucose.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;A primary source of energy for living organisms. It is naturally occurring and is found in fruits and other parts of plants in its free state. It is used therapeutically in fluid and nutrient replacement.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CSP)&lt;/td&gt;
                &lt;td&gt;aldohexose occurring as the D form and found as a free monosaccharide in fruits and other parts of plants and in the normal blood of all animals; the end product of carbohydrate metabolism and the chief source of energy for most living organisms.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A type of sugar; the chief source of energy for living organisms.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A simple sugar monosaccharide having two isoforms, alpha and beta, with a chemical structure of C6H12O6 that acts as an energy source for both plants and animals by reacting with oxygen, generating carbon dioxide and water, and releasing energy.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Carbohydrate (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0017725&amp;amp;tui=T118"&gt;&lt;i&gt;T118&lt;/i&gt;&lt;/a&gt;)
, Pharmacologic Substance (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0017725&amp;amp;tui=T121"&gt;&lt;i&gt;T121&lt;/i&gt;&lt;/a&gt;)
, Biologically Active Substance (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0017725&amp;amp;tui=T123"&gt;&lt;i&gt;T123&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D005947&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;387370006, 67079006, 325307004, 111138002, 66611007, 386987008&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;D Glucose, D-Glucose, Dextrose, Glucose, glucose, D-glucopyranose monohydrate preparation, D-glucose preparation, Glucose [endocrine], Glucose, NOS, d-Glucose preparation, Dextrose (substance), D-glucose, Glucose [endocrine] (product), foods dextrose, glucose (dextrose), glucose (dextrose) (medication), foods glucose (dextrose), dextrose (medication), Dextrose preparation, Dextrose preparation (product), 6-(hydroxymethyl)oxane-2,3,4,5-tetrol, DEXTROSE, Glucose [Chemical/Ingredient], endocrine glucose, glucose preparations, d-glucose, glucoses, dextrose, Dextrose product, Glucose preparation, Glucose product, Glucose (substance), Glucose preparation (product), Dextrose preparation (substance), Glucose [endocrine] (substance), Glucose preparation (substance), GLUCOSE&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Glukos&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;preparado de dextrosa, dextrosa, D-glucosa, dextrosa (sustancia), glucosa [uso endocrinológico] (producto), glucosa [uso endocrinológico], preparado con D-glucosa, preparado con monohidrato de D-glucopiranosa, preparado con dextrosa, preparado con glucosa (producto), preparado con dextrosa (producto), glucosa (producto), preparado con glucosa, glucosa (sustancia), glucosa [endocrina] (producto), glucosa [endocrina], glucosa, preparado de D-glucosa, preparado de dextrosa (producto), preparado de dextrosa (sustancia), preparado de glucosa (producto), preparado de glucosa (sustancia), preparado de glucosa, preparado de monohidrato de D-glucopiranosa, Glucosa, Dextrosa&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;glukosa&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Glukoosi&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Destrosio, D-glucosio, Glucosio&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;DEKSTROZA, GLIUKOZA, ГЛЮКОЗА, ДЕКСТРОЗА&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;グルコース, デキストロース, ブドウ糖, 葡萄糖&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Croatian&lt;/td&gt;
                &lt;td&gt;GLUKOZA&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Glikoza, Dekstroza, Glukoza&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Dextrose, Glucose&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Dextrose, Glucose, Glukose&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Destrose, Glicose, Glucose&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Glucose measurement, serum  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0202041"&gt;&lt;i&gt;C0202041&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A quantitative measurement of the amount of glucose present in a sample of serum.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Laboratory Procedure (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0202041&amp;amp;tui=T059"&gt;&lt;i&gt;T059&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;22569008&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;serum glucose, Serum Glucose, Glucose, serum, measurement, Serum Glucose Measurement, Serum glucose, glucose serum tests, glucose serum test, serum glucose test, glucose serum, Serum Glucose Test, Glucose measurement, serum, Glucose measurement, serum (procedure)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;serum glucose&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Glucose sérique&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Glukose im Serum&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Glucosio sierico&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Glucose sérica&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;Glucosa sérica, medición de glucosa en suero (procedimiento), medición de glucosa en suero&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;血清ブドウ糖, ｹｯｾｲﾌﾞﾄﾞｳﾄｳ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;Hladina glukózy v séru&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;Szérum glükóz&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Blood Glucose  (</value><value>)
</value><value>Hyperglycemia  (</value><value>)
</value><value>Glucose  (</value><value>)
</value><value>Glucose measurement, serum  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Serum Glucose</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Pathology and Laboratory Medicine</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;See Also&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/MdctnCsOfHyprglycm.htm" class="LinkPage"&gt;Medication Causes of Hyperglycemia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/DM/DbtsMlts.htm" class="LinkPage"&gt;Diabetes Mellitus&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/GlcsChlngTst.htm" class="LinkPage"&gt;Glucose Challenge Test&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/GlcsTlrncTstHr.htm" class="LinkPage"&gt;Two hour Glucose Tolerance Test&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/GlcsTlrncTst3Hr.htm" class="LinkPage"&gt;Three Hour Glucose Tolerance Test&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/HmglbnAc.htm" class="LinkPage"&gt;Hemoglobin A1C&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Precautions&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Endo/DM/DbtsMlts.htm" class="LinkPage"&gt;Diabetes Mellitus&lt;/a&gt; for evaluation and management of initial evaluation and management of Hyperglycemia&lt;/li&gt;&lt;li&gt;Serum Glucose &amp;gt;250 mg/dl may be associated with &lt;a href="../../Renal/Lab/SrmPtsm.htm" class="LinkPage"&gt;Serum K&lt;/a&gt;etone production&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Normal&lt;ol&gt;&lt;li&gt;Fasting Blood Sugar: &amp;lt;100 mg/dl&lt;ol&gt;&lt;li&gt;Reflects &lt;a href="../../Endo/DM/InslnRstncSyndrm.htm" class="LinkPage"&gt;Insulin Resistance&lt;/a&gt;, hepatic production and overnight Glucose secretion&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Postprandial 2 hours: &amp;lt;140 mg/dl&lt;ol&gt;&lt;li&gt;Reflects pancreatic islet cell response to a meal (endogenous &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; secretion)&lt;/li&gt;&lt;li&gt;Blood Glucose may in some cases rise as high as 160 mg/dl after a large meal in a non-diabetic patient&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Stress response&lt;ol&gt;&lt;li&gt;Typically Serum Glucose &amp;lt;200 mg/dl&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Causes: &lt;a href="../../Endo/Hypoglycemia/Hypglycm.htm" class="LinkPage"&gt;Hypoglycemia&lt;/a&gt;&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Endo/Hypoglycemia/Hypglycm.htm" class="LinkPage"&gt;Hypoglycemia&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Causes: Hyperglycemia&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Endo/Pharm/MdctnCsOfHyprglycm.htm" class="LinkPage"&gt;Medication Causes of Hyperglycemia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Endocrine&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/DM/DbtsMlts.htm" class="LinkPage"&gt;Diabetes Mellitus&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Pituitary or adrenal disease&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Anatomy/ThyrdAntmy.htm" class="LinkPage"&gt;Thyroid&lt;/a&gt; disease&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Non-Endocrine&lt;ol&gt;&lt;li&gt;&lt;a href="../../GI/Anatomy/LvrAntmy.htm" class="LinkPage"&gt;Liver&lt;/a&gt; disease&lt;/li&gt;&lt;li&gt;CNS disease&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0005802</value><value>C0020456</value><value>C0017725</value><value>C0202041</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Lab/SrmGlcs.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Serum Glucose, Blood Glucose, Blood Sugar, Glucose, Hyperglycemia</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Lab/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees></FP_UMLS_Trees><FP_Condition_name_check></FP_Condition_name_check><FP_Condition_name><value>Glucose to Insulin Ratio</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Pathology and Laboratory Medicine</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Indications&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/DM/InslnRstncSyndrm.htm" class="LinkPage"&gt;Insulin Resistance&lt;/a&gt; in &lt;a href="../../Gyn/Endo/PlycystcOvryDs.htm" class="LinkPage"&gt;Polycystic Ovary Syndrome&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Efficacy in &lt;a href="../../Endo/DM/InslnRstncSyndrm.htm" class="LinkPage"&gt;Insulin Resistance&lt;/a&gt; Diagnosis in &lt;a href="../../Gyn/Endo/PlycystcOvryDs.htm" class="LinkPage"&gt;PCOS&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Normalized for non-Hispanic white &lt;a href="../../Gyn/Endo/PlycystcOvryDs.htm" class="LinkPage"&gt;PCOS&lt;/a&gt; women&lt;/li&gt;&lt;li&gt;&lt;a href="../../Prevent/Epi/TstSnstvty.htm" class="LinkPage"&gt;Test Sensitivity&lt;/a&gt;: 95%&lt;/li&gt;&lt;li&gt;&lt;a href="../../Prevent/Epi/TstSpcfcty.htm" class="LinkPage"&gt;Test Specificity&lt;/a&gt;: 84%&lt;/li&gt;&lt;li&gt;&lt;a href="../../Prevent/Epi/PstvPrdctvVl.htm" class="LinkPage"&gt;Positive Predictive Value&lt;/a&gt;: 87%&lt;/li&gt;&lt;li&gt;&lt;a href="../../Prevent/Epi/NgtvPrdctvVl.htm" class="LinkPage"&gt;Negative Predictive Value&lt;/a&gt;: 94%&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Interpretation&lt;ol&gt;&lt;li&gt;G:I Ratio &amp;lt;4.5 considered abnormal&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Legro%20%20%5BAU%5D%20AND%201998%20%5BDP%5D%20AND%20%20J%20Clin%20Endocrinol%20Metab%20%20%5BTA%5D" class="LinkRef"&gt;Legro (1998) J Clin Endocrinol Metab 83:2694-8&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Lab/GlcsTInslnRt.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Glucose to Insulin Ratio, G:I Ratio</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Lab/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees></FP_UMLS_Trees><FP_Condition_name_check></FP_Condition_name_check><FP_Condition_name><value>Serum Cortisol</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Pathology and Laboratory Medicine</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Normal&lt;ol&gt;&lt;li&gt;Cortisol 8 am: 4-19&lt;/li&gt;&lt;li&gt;Cortisol 4 pm: 2-15&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Increased&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Adrenal/CshngsDs.htm" class="LinkPage"&gt;Cushing's Disease&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Ectopic ACTH production&lt;ol&gt;&lt;li&gt;Small-cell &lt;a href="../../Lung/HemeOnc/LngCncr.htm" class="LinkPage"&gt;Lung Cancer&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Renal/Failure/ChrncRnlFlr.htm" class="LinkPage"&gt;Chronic Renal Failure&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Pregnancy&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Decreased&lt;ol&gt;&lt;li&gt;Primary or Secondary adrenocortical insufficiency&lt;/li&gt;&lt;li&gt;Anterior pituitary dysfunction&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Lab/SrmCrtsl.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Serum Cortisol</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Lab/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees></FP_UMLS_Trees><FP_Condition_name_check></FP_Condition_name_check><FP_Condition_name><value>Free Urine Cortisol</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Pathology and Laboratory Medicine</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Indication&lt;ol&gt;&lt;li&gt;Screening for &lt;a href="../../Endo/Adrenal/CshngsDs.htm" class="LinkPage"&gt;Cushing's Disease&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Normal&lt;ol&gt;&lt;li&gt;Free Urine Cortisol: 10-110 ug/24 hr&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Increased&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Endo/Lab/SrmCrtsl.htm" class="LinkPage"&gt;Serum Cortisol&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Lab/FrUrnCrtsl.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Free Urine Cortisol, 24-hour Urinary free cortisol level, 24 hour Urine Cortisol, Urine 17-Ketosteroid excretion, Urine 17-Hydroxysteroid excretion</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Lab/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Dexamethasone suppression test  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0430115"&gt;&lt;i&gt;C0430115&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (PSY)&lt;/td&gt;
                &lt;td&gt;Laboratory analysis of hypersecretion of cortisol and the body's failure to suppress cortisol after the administration of dexamethasone. Used primarily for diagnosis of major depressive disorders.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CSP)&lt;/td&gt;
                &lt;td&gt;injection of dexamethasone causes serum cortisol to fall; this can be correlated with behavioral measures of depression, but the test is not reliable enough for diagnostic use.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Laboratory Procedure (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0430115&amp;amp;tui=T059"&gt;&lt;i&gt;T059&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;392884002, 393839005, 252190006&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Test di soppressione con desametasone&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;デキサメサゾン抑制試験, ﾃﾞｷｻﾒｻｿﾞﾝﾖｸｾｲｼｹﾝ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;dexamethasone suppression test, Dexamethasone suppression test, DST, dexamethasone suppression tests, dst, Dexamethasone suppression test (procedure), Dexamethasone Suppression Test&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;Dexamethasone suppression test, prueba de supresión con dexametasona (procedimiento), prueba de supresión con dexametasona, Prueba de supresión con dexametasona&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;Dexametazonový supresní test&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;Dexamethason suppressziós vizsgálat&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Exame de supressão de dexametasona&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;dexamethason-suppressietest&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Épreuve de freinage à la dexaméthasone&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Dexamethason-Suppressionstest&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Dexamethasone suppression test  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Dexamethasone Suppression Test</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Pathology and Laboratory Medicine</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Background&lt;ol&gt;&lt;li&gt;Two stage testing described below will miss cases&lt;/li&gt;&lt;li&gt;The low dose (1 mg) test is not adequately sensitive&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Indications: &lt;a href="../../Endo/Adrenal/CshngsDs.htm" class="LinkPage"&gt;Cushing's Disease&lt;/a&gt; Screening&lt;ol&gt;&lt;li&gt;Second line test&lt;/li&gt;&lt;li&gt;Start with &lt;a href="../../Endo/Lab/FrUrnCrtsl.htm" class="LinkPage"&gt;24-hour Urinary free cortisol level&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Mechanism&lt;ol&gt;&lt;li&gt;Test measures &lt;a href="../../Endo/Anatomy/AdrnlAntmy.htm" class="LinkPage"&gt;Adrenal Gland&lt;/a&gt; response to ACTH&lt;/li&gt;&lt;li&gt;ACTH should decrease in response to &lt;a href="../../Endo/Pharm/SystmcCrtcstrd.htm" class="LinkPage"&gt;Dexamethasone&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Decreased ACTH should result in decreased Cortisol&lt;/li&gt;&lt;li&gt;Failure for cortisol to suppress suggests 2 causes&lt;ol&gt;&lt;li&gt;&lt;a href="../../Neuro/Anatomy/PtryAntmy.htm" class="LinkPage"&gt;Pituitary Gland&lt;/a&gt; ACTH over-produced or&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Anatomy/AdrnlAntmy.htm" class="LinkPage"&gt;Adrenal Gland&lt;/a&gt; cortisol over-produced&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Protocol&lt;ol&gt;&lt;li&gt;Step 1: Draw &lt;a href="../../Endo/Lab/SrmCrtsl.htm" class="LinkPage"&gt;Serum Cortisol&lt;/a&gt; at 4 pm on day 1&lt;/li&gt;&lt;li&gt;Step 2: Patient takes &lt;a href="../../Endo/Pharm/SystmcCrtcstrd.htm" class="LinkPage"&gt;Dexamethasone&lt;/a&gt; 1 mg at 11 pm day 1&lt;/li&gt;&lt;li&gt;Step 3: Draw &lt;a href="../../Endo/Lab/SrmCrtsl.htm" class="LinkPage"&gt;Serum Cortisol&lt;/a&gt; at 8-9 am on day 2&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Interpretation (Based on &lt;a href="../../Endo/Lab/SrmCrtsl.htm" class="LinkPage"&gt;Serum Cortisol&lt;/a&gt; on day 2, 8 am)&lt;ol&gt;&lt;li&gt;AM &lt;a href="../../Endo/Lab/SrmCrtsl.htm" class="LinkPage"&gt;Serum Cortisol&lt;/a&gt; &amp;lt;5 mcg/dl (especially if &amp;lt;2)&lt;ol&gt;&lt;li&gt;Normal response (Suppresses)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;AM &lt;a href="../../Endo/Lab/SrmCrtsl.htm" class="LinkPage"&gt;Serum Cortisol&lt;/a&gt; &amp;gt;5 mcg/dl&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Adrenal/CshngsDs.htm" class="LinkPage"&gt;Cushing's Disease&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Repeating with &lt;a href="../../Endo/Pharm/SystmcCrtcstrd.htm" class="LinkPage"&gt;Dexamethasone&lt;/a&gt; 8 mg determines site&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Anatomy/AdrnlAntmy.htm" class="LinkPage"&gt;Adrenal Gland&lt;/a&gt; source will not suppress&lt;/li&gt;&lt;li&gt;Pituitary source will suppress&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0430115</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Lab/DxmthsnSprsnTst.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Dexamethasone Suppression Test</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Lab/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees></FP_UMLS_Trees><FP_Condition_name_check></FP_Condition_name_check><FP_Condition_name><value>Glucose Challenge Test</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Pathology and Laboratory Medicine</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Indication: &lt;a href="../../Endo/OB/GstnlDbts.htm" class="LinkPage"&gt;Gestational Diabetes&lt;/a&gt;&lt;a href="../../Prevent/Epi/ScrngTst.htm" class="LinkPage"&gt;Screening Test&lt;/a&gt;&lt;ol&gt;&lt;li&gt;All pregnant patients at 24-28 weeks gestation&lt;/li&gt;&lt;li&gt;Test with initial &lt;a href="../../OB/Lab/PrntlLb.htm" class="LinkPage"&gt;Prenatal Lab&lt;/a&gt;s if indicated below&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Obesity/Obsty.htm" class="LinkPage"&gt;Overweight&lt;/a&gt; patient&lt;/li&gt;&lt;li&gt;&lt;a href="../../Prevent/HME/FmlyHstry.htm" class="LinkPage"&gt;Family History&lt;/a&gt; of &lt;a href="../../Endo/DM/DbtsMlts.htm" class="LinkPage"&gt;Diabetes Mellitus&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Age over 30 years&lt;/li&gt;&lt;li&gt;Prior history of &lt;a href="../../Endo/DM/InslnRstncSyndrm.htm" class="LinkPage"&gt;Glucose Intolerance&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Prior pregnancy complication&lt;ol&gt;&lt;li&gt;&lt;a href="../../OB/Fetus/FtlMcrsm.htm" class="LinkPage"&gt;Fetal Macrosomia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../OB/Antepartum/LtPrgncyLs.htm" class="LinkPage"&gt;Intrauterine Fetal Demise&lt;/a&gt; (&lt;a href="../../OB/Antepartum/LtPrgncyLs.htm" class="LinkPage"&gt;Stillborn&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/OB/HyprtnsvDsrdrsOfPrgncy.htm" class="LinkPage"&gt;Pregnancy Induced Hypertension&lt;/a&gt; (PIH)&lt;/li&gt;&lt;li&gt;Polyhydramnios&lt;/li&gt;&lt;li&gt;Congenital defect&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Protocol&lt;ol&gt;&lt;li&gt;Patient ingests 50 gram Glucola Drink&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Serum Glucose&lt;/a&gt; measured after 1 hour&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Interpretation&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Serum Glucose&lt;/a&gt; &amp;gt;130 mg/dl suggests gestation diabetes&lt;/li&gt;&lt;li&gt;Obtain &lt;a href="../../Endo/Lab/GlcsTlrncTst3Hr.htm" class="LinkPage"&gt;Glucose Tolerance Test 3 hour&lt;/a&gt; if positive&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Efficacy&lt;ol&gt;&lt;li&gt;&lt;a href="../../Prevent/Epi/TstSnstvty.htm" class="LinkPage"&gt;Test Sensitivity&lt;/a&gt;: 90% (80% if 140 mg/dl cut-off used)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Prevent/Epi/TstSpcfcty.htm" class="LinkPage"&gt;Test Specificity&lt;/a&gt;: 87%&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=2001%20%5BDP%5D%20AND%20%20Obstet%20Gynecol%20%20%5BTA%5D%20AND%2098%20%5BVI%5D%20AND%20525%20%5BPG%5D" class="LinkRef"&gt;(2001) Obstet Gynecol 98:525-38&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Lab/GlcsChlngTst.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Glucose Challenge Test</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Lab/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Tanner girls breast development stage  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0429602"&gt;&lt;i&gt;C0429602&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Finding (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0429602&amp;amp;tui=T033"&gt;&lt;i&gt;T033&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;251811005&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Tanner girl breast development, breast development Tanner stage, Tanner girls breast development (physical finding), girls development breast, breast development girls, girl breast development, tanner girls breast development stage, B - Breast stage, Girls breast development, Tanner girls breast development, Tanner girls breast development stage (observable entity), Tanner girls breast development stage&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;estadio de desarrollo mamario en las niñas según escala de Tanner (entidad observable), estadio de desarrollo mamario en las niñas según escala de Tanner&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Tanner girls pubic hair  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C2197575"&gt;&lt;i&gt;C2197575&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Finding (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C2197575&amp;amp;tui=T033"&gt;&lt;i&gt;T033&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;female pubic hair Tanner stage, Tanner girls pubic hair (physical finding), Tanner girls pubic hair&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Tanner girls breast development stage  (</value><value>)
</value><value>Tanner girls pubic hair  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Female Tanner Stage</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Examination</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Stage: Tanner 1 (Prepubertal)&lt;ol&gt;&lt;li&gt;Height increases at basal rate: 5-6 cm/year&lt;/li&gt;&lt;li&gt;&lt;a href="../../Gyn/Anatomy/BrstAntmy.htm" class="LinkPage"&gt;Breast&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Papilla elevation only&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Pubic &lt;a href="../../Derm/Anatomy/Hr.htm" class="LinkPage"&gt;Hair&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Villus hair only&lt;/li&gt;&lt;li&gt;No coarse, pigmented hair&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Stage: Tanner 2&lt;ol&gt;&lt;li&gt;Height increases at accelerated rate: 7-8 cm/year&lt;/li&gt;&lt;li&gt;&lt;a href="../../Gyn/Anatomy/BrstAntmy.htm" class="LinkPage"&gt;Breast&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../Gyn/Anatomy/BrstAntmy.htm" class="LinkPage"&gt;Breast&lt;/a&gt; buds palpable and areolae enlarge&lt;/li&gt;&lt;li&gt;Age 10.9 years (8.9-12.9 years)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Pubic &lt;a href="../../Derm/Anatomy/Hr.htm" class="LinkPage"&gt;Hair&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Minimal coarse, pigmented hair mainly on labia&lt;/li&gt;&lt;li&gt;Age 11.2 years (9.0-13.4 years)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Modifications based on increasingly earlier &lt;a href="../../Endo/Exam/SxlDvlpmnt.htm" class="LinkPage"&gt;Puberty&lt;/a&gt;&lt;ol&gt;&lt;li&gt;White: Stage 2 changes may appear one year earlier&lt;/li&gt;&lt;li&gt;Black: Stage 2 changes may appear two years earlier&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Stage: Tanner 3&lt;ol&gt;&lt;li&gt;Height increases at peak rate: 8 cm/year (age 12.5)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Gyn/Anatomy/BrstAntmy.htm" class="LinkPage"&gt;Breast&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Elevation of &lt;a href="../../Gyn/Anatomy/BrstAntmy.htm" class="LinkPage"&gt;Breast&lt;/a&gt; contour; areolae enlarge&lt;/li&gt;&lt;li&gt;Age 11.9 years (9.9-13.9 years)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Pubic &lt;a href="../../Derm/Anatomy/Hr.htm" class="LinkPage"&gt;Hair&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Dark, coarse, curly hair spreads over mons pubis&lt;/li&gt;&lt;li&gt;Age 11.9 years (9.6-14.1 years)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Other changes&lt;ol&gt;&lt;li&gt;Axillary hair develops (13.1 years)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Derm/Acne/AcnVlgrs.htm" class="LinkPage"&gt;Acne Vulgaris&lt;/a&gt; develops (13.2 years)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Stage: Tanner 4&lt;ol&gt;&lt;li&gt;Height increases at 7 cm/year&lt;/li&gt;&lt;li&gt;&lt;a href="../../Gyn/Anatomy/BrstAntmy.htm" class="LinkPage"&gt;Breast&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Areolae forms secondary mound on the &lt;a href="../../Gyn/Anatomy/BrstAntmy.htm" class="LinkPage"&gt;Breast&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Age: 12.9 years (10.5-15.3 years)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Pubic &lt;a href="../../Derm/Anatomy/Hr.htm" class="LinkPage"&gt;Hair&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../Derm/Anatomy/Hr.htm" class="LinkPage"&gt;Hair&lt;/a&gt; of adult quality&lt;/li&gt;&lt;li&gt;No spread to junction of medial thigh with perineum&lt;/li&gt;&lt;li&gt;Age: 12.6 years (10.4-14.8 years)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Stage: Tanner 5&lt;ol&gt;&lt;li&gt;No further height increases after age 16 years&lt;/li&gt;&lt;li&gt;&lt;a href="../../Gyn/Anatomy/BrstAntmy.htm" class="LinkPage"&gt;Breast&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Adult &lt;a href="../../Gyn/Anatomy/BrstAntmy.htm" class="LinkPage"&gt;Breast&lt;/a&gt; contour&lt;/li&gt;&lt;li&gt;Areola recesses to general contour of &lt;a href="../../Gyn/Anatomy/BrstAntmy.htm" class="LinkPage"&gt;Breast&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Pubic hair&lt;ol&gt;&lt;li&gt;Adult distribution of hair&lt;/li&gt;&lt;li&gt;Pubic hair spreads to medial thigh&lt;/li&gt;&lt;li&gt;Pubic hair does not extend up linea alba&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Exam: Other Milestones&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Exam/SxlDvlpmnt.htm" class="LinkPage"&gt;Adrenarche&lt;/a&gt;: Age 6 to 8 years&lt;/li&gt;&lt;li&gt;&lt;a href="../../Gyn/Exam/MnstrlBldng.htm" class="LinkPage"&gt;Menarche&lt;/a&gt;: Age 12.7 years (10.8-14.5 years)&lt;ol&gt;&lt;li&gt;Delayed &amp;gt;1 year if low body fat (e.g. athlete)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Exam: Growth in Girls&lt;ol&gt;&lt;li&gt;Peak height velocity: 11.5 years (9.7-13.3 years)&lt;/li&gt;&lt;li&gt;Basal growth occurs up until Tanner Stage 2&lt;ol&gt;&lt;li&gt;Basal Growth rate: 5.0 to 6.0 cm per year&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Pubertal Growth&lt;ol&gt;&lt;li&gt;Girls who mature average time: 8.3 (6.1-10.4) cm/yr&lt;/li&gt;&lt;li&gt;Girls who mature early: 9.0 (7.0-11.0) cm/yr&lt;/li&gt;&lt;li&gt;Girls who mature late: 7.5 (5.4-9.6) cm/yr&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Tanner%20%20%5BAU%5D%20AND%201985%20%5BDP%5D%20AND%20%20J%20Pediatr%20%20%5BTA%5D" class="LinkRef"&gt;Tanner (1985) J Pediatr 107(3):317&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Tanner (1966) Growth at Adolescence, Appleton&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0429602</value><value>C2197575</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Exam/FmlTnrStg.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Female Tanner Stage, Female Sexual Development, Female Tanner Staging, Tanner Girls Pubic Hair, Tanner Girls Breast Development Stage</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Exam/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Android obesity  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0342940"&gt;&lt;i&gt;C0342940&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Disease or Syndrome (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0342940&amp;amp;tui=T047"&gt;&lt;i&gt;T047&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;238132000&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;obesity android, android obesity, Android obesity, Android obesity (disorder)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;obesidad androide (trastorno), obesidad androide&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Anthropometry  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0003188"&gt;&lt;i&gt;C0003188&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;The technique that deals with the measurement of the size, weight, and proportions of the human or other primate body.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CSP)&lt;/td&gt;
                &lt;td&gt;measurement of the physical dimensions of the human or other primate body characteristics such as size, breadth, girth, weight, proportion and distance between anatomical points; also includes segment masses, the centers of gravity of body segments, and the ranges of joint motion, which are used in biomechanical analyses of work postures; in anthropology it is used to refer to different body sizes and proportions of individuals belonging to different populations.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Research Activity (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0003188&amp;amp;tui=T062"&gt;&lt;i&gt;T062&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D000886&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Anthropometry, anthropometry&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Antropometri&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;antropometrie&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Antropometria&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;ANTROPOMETRIIA, АНТРОПОМЕТРИЯ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Croatian&lt;/td&gt;
                &lt;td&gt;ANTROPOMETRIJA&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Antropometria&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Anthropométrie&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Anthropometrie&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Antropometria&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;Antropometrie&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Antropometria&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;Antropometria, Antropometría&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Android obesity  (</value><value>)
</value><value>Anthropometry  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Waist-to-Hip Ratio</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Examination</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Technique&lt;ol&gt;&lt;li&gt;General&lt;ol&gt;&lt;li&gt;Use non-stretchable measuring tape&lt;/li&gt;&lt;li&gt;Tape should touch skin, but not compress soft tissue&lt;/li&gt;&lt;li&gt;Avoid twists in the tape&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Waist Circumference&lt;ol&gt;&lt;li&gt;Do not measure within 1 hour of large meal&lt;/li&gt;&lt;li&gt;Measure patient while supine&lt;ol&gt;&lt;li&gt;Measuring tape may fall in standing position&lt;/li&gt;&lt;li&gt;Panniculus shifts downward in standing position&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Williamson%20%20%5BAU%5D%20AND%201993%20%5BDP%5D%20AND%20%20Am%20J%20Hum%20Biol%20%20%5BTA%5D" class="LinkRef"&gt;Williamson (1993) Am J Hum Biol 15:159-67&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Measure at natural waist, midway between:&lt;ol&gt;&lt;li&gt;Palpated iliac crest&lt;/li&gt;&lt;li&gt;Palpated lowest rib margin at mid axillary line&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Hip Circumference&lt;ol&gt;&lt;li&gt;Patient stands erect&lt;ol&gt;&lt;li&gt;Arms at side&lt;/li&gt;&lt;li&gt;Feet together&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Measure hips at maximum circumference over buttocks&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Interpretation of Higher &lt;a href="../../Endo/Obesity/ObstyRsk.htm" class="LinkPage"&gt;Obesity Risk&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Waist-to-Hip Ratio&lt;ol&gt;&lt;li&gt;Measures fat distribution&lt;ol&gt;&lt;li&gt;Pear Obesity (Gynoid Obesity)&lt;/li&gt;&lt;li&gt;Apple Obesity (Android Obesity, Beer Belly)&lt;ol&gt;&lt;li&gt;Higher cardiovascular disease risk&lt;/li&gt;&lt;li&gt;Higher risk of &lt;a href="../../Endo/DM/InslnRstncSyndrm.htm" class="LinkPage"&gt;Insulin Resistance&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Values suggestive of Apple Obesity&lt;ol&gt;&lt;li&gt;Males &amp;gt; 1.0 confers increased risk&lt;/li&gt;&lt;li&gt;Females &amp;gt; 0.9 confers increased risk&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Waist Circumference&lt;ol&gt;&lt;li&gt;Males &amp;gt;= 40 inches (102 cm) confers increased risk&lt;/li&gt;&lt;li&gt;Females &amp;gt;= 35 inches (88 cm) confers increased risk&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;Flier in Wilson (1998) Williams Endocrinology, p. 1063&lt;/li&gt;&lt;li&gt;(1998) Treatment of Adult &lt;a href="../../Endo/Obesity/Obsty.htm" class="LinkPage"&gt;Obesity&lt;/a&gt;, AOA, p. 63-4&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.shapeup.org" class="LinkWebExt"&gt;http://www.shapeup.org&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0342940</value><value>C0003188</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Exam/WstTHpRt.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Waist-to-Hip Ratio, Waist Circumference, Anthropometry, Android Obesity, Apple Obesity, Beer Belly, Gynoid Obesity, Pear Obesity</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Exam/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees></FP_UMLS_Trees><FP_Condition_name_check></FP_Condition_name_check><FP_Condition_name><value>Clonidine Suppression Test</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Pathology and Laboratory Medicine</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Indications&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Adrenal/Phchrmcytm.htm" class="LinkPage"&gt;Pheochromocytoma&lt;/a&gt; evaluation&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Technique&lt;ol&gt;&lt;li&gt;Obtain initial plasma &lt;a href="../../Neuro/Pharm/AdrnrgcRcptr.htm" class="LinkPage"&gt;Catecholamine&lt;/a&gt;s&lt;/li&gt;&lt;li&gt;Administer oral &lt;a href="../../CV/Pharm/AlphAdrnrgcCntrlAgnst.htm" class="LinkPage"&gt;Clonidine&lt;/a&gt; dose&lt;/li&gt;&lt;li&gt;Recheck plasma &lt;a href="../../Neuro/Pharm/AdrnrgcRcptr.htm" class="LinkPage"&gt;Catecholamine&lt;/a&gt;s after &lt;a href="../../CV/Pharm/AlphAdrnrgcCntrlAgnst.htm" class="LinkPage"&gt;Clonidine&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Interpretation&lt;ol&gt;&lt;li&gt;&lt;a href="../../Neuro/Pharm/AdrnrgcRcptr.htm" class="LinkPage"&gt;Catecholamine&lt;/a&gt;s normally suppressed after &lt;a href="../../CV/Pharm/AlphAdrnrgcCntrlAgnst.htm" class="LinkPage"&gt;Clonidine&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Neuro/Pharm/AdrnrgcRcptr.htm" class="LinkPage"&gt;Catecholamine&lt;/a&gt;s not suppressed in &lt;a href="../../Endo/Adrenal/Phchrmcytm.htm" class="LinkPage"&gt;Pheochromocytoma&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Lab/ClndnSprsnTst.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Clonidine Suppression Test, Clonidine Suppression</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Lab/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Body mass index procedure  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0005893"&gt;&lt;i&gt;C0005893&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;An indicator of body density as determined by the relationship of BODY WEIGHT to BODY HEIGHT. BMI=weight (kg)/height squared (m2). BMI correlates with body fat (ADIPOSE TISSUE). Their relationship varies with age and gender. For adults, BMI falls into these categories: below 18.5 (underweight); 18.5-24.9 (normal); 25.0-29.9 (overweight); 30.0 and above (obese). (National Center for Health Statistics, Centers for Disease Control and Prevention)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Diagnostic Procedure (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0005893&amp;amp;tui=T060"&gt;&lt;i&gt;T060&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D015992&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Body Mass Index, Index, Body Mass, Quetelets Index, Body mass index, BMI, body mass index (BMI), quetelet index, body mass index, Body mass index procedure, Quetelet Index, Quetelet's Index, Index, Quetelet&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;ボディ・マス・インデックス, ﾎﾞﾃﾞｨﾏｽｲﾝﾃﾞｯｸｽ, Quetelet指数, ケトレー指数, 体重指数&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Kroppsmasseindex&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;BMI, index tělesné hmotnosti, Body mass index&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Painoindeksi&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Index de Quetelet, IMC (Indice de Masse Corporelle), Indice de masse corporelle, Indice de Quetelet, Index de masse corporelle&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;TELA MASSY INDEKS, KVETELETA INDEKS, КВЕТЕЛЕТА ИНДЕКС, ТЕЛА МАССЫ ИНДЕКС&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Indice di Quetelet, Indice di massa corporea&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Croatian&lt;/td&gt;
                &lt;td&gt;INDEKS TJELESNE MASE&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Wskaźnik masy ciała, BMI&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;Testtömeg index&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Índice de massa corporal, Índice de Massa Corporal, IMC, Índice de Quetelet&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;Índice de masa corporal, Indice de Masa Corporal, Indice de Quetelet, Índice de Masa Corporal, Índice de Quetelet&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Koerpermassenindex, Quetelet-Index, Körpermasse-Index&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;BMI, Body-mass index, Quetelet-index&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Body mass index  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C1305855"&gt;&lt;i&gt;C1305855&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A general indicator of the body fat an individual is carrying based upon the ratio of weight to height. (NCI)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A measure that relates body weight to height. BMI is sometimes used to measure total body fat and whether a person is a healthy weight. Excess body fat is linked to an increased risk of some diseases including heart disease and some cancers.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A general indicator of the body fat an individual is carrying based upon the ratio of weight to height.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Clinical Attribute (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C1305855&amp;amp;tui=T201"&gt;&lt;i&gt;T201&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;248359001, 60621009, 162859006, 363807006, 140075008&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Body mass index, NOS, Quetelet index, Quetelet index (observable entity), BODY MASS INDEX, Quetelet Index, body mass index (physical finding), body mass index, BMI, quetelet index, body mass index (BMI), Body mass index (observable entity), BMI - Body mass index, Body mass index, Body mass index - observation, Body mass index [dup] (observable entity), Body Mass Index&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;índice de Quetelet, índice de Quetelet (entidad observable), Body mass index, IMC, índice de masa corporal (entidad observable), índice de masa corporal, BMI&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Body mass index procedure  (</value><value>)
</value><value>Body mass index  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Body Mass Index</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Examination</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;See Also&lt;ol&gt;&lt;li&gt;Endocrine Calculations&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Indication&lt;ol&gt;&lt;li&gt;Used in evaluation of &lt;a href="../../Endo/Obesity/Obsty.htm" class="LinkPage"&gt;Obesity&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Advantages&lt;ol&gt;&lt;li&gt;Highly correlated to body fat&lt;/li&gt;&lt;li&gt;May be best method available&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Disadvantages&lt;ol&gt;&lt;li&gt;Not accurate in muscular patients (athletes)&lt;/li&gt;&lt;li&gt;Not accurate in pregnancy or &lt;a href="../../OB/Lactation/BrstFdng.htm" class="LinkPage"&gt;Lactation&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Calculation&lt;ol&gt;&lt;li&gt;BMI = (weight in kilograms) / (height in Meters)^2&lt;/li&gt;&lt;li&gt;BMI = (weight in lbs x 700) / (height in Inches)^2&lt;/li&gt;&lt;li&gt;Approximating the weight at which BMI=27 (&lt;a href="../../Endo/Obesity/Obsty.htm" class="LinkPage"&gt;Obesity&lt;/a&gt;)&lt;ol&gt;&lt;li&gt;Start with 100 pounds&lt;/li&gt;&lt;li&gt;Add 5 pounds for every inch over 5 feet tall&lt;/li&gt;&lt;li&gt;Add 40 pounds&lt;/li&gt;&lt;li&gt;Example: What weight is BMI=27 for 66 inch person?&lt;/li&gt;&lt;li&gt;Answer: 100 + (6x5) + 40 = 170 pounds&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Interpretation: Adults&lt;ol&gt;&lt;li&gt;BMI &amp;lt;18.5: Underweight&lt;/li&gt;&lt;li&gt;BMI &amp;lt;20: Underweight or endurance athlete&lt;/li&gt;&lt;li&gt;BMI 20 to 22: &lt;a href="../../Endo/Exam/IdlWghtInAdlts.htm" class="LinkPage"&gt;Ideal Weight&lt;/a&gt;&lt;/li&gt;&lt;li&gt;BMI 22 to 25: Healthy Weight&lt;/li&gt;&lt;li&gt;BMI 25: Mild &lt;a href="../../Endo/Obesity/Obsty.htm" class="LinkPage"&gt;Obesity&lt;/a&gt; (WHO Grade 1, 110% &lt;a href="../../Endo/Exam/IdlWghtInAdlts.htm" class="LinkPage"&gt;Ideal Weight&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;BMI 27: Moderate &lt;a href="../../Endo/Obesity/Obsty.htm" class="LinkPage"&gt;Obesity&lt;/a&gt; (120% of &lt;a href="../../Endo/Exam/IdlWghtInAdlts.htm" class="LinkPage"&gt;Ideal Weight&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;BMI 30: Severe &lt;a href="../../Endo/Obesity/Obsty.htm" class="LinkPage"&gt;Obesity&lt;/a&gt; (WHO Grade 2, 130% &lt;a href="../../Endo/Exam/IdlWghtInAdlts.htm" class="LinkPage"&gt;Ideal Weight&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;BMI 40: Morbid &lt;a href="../../Endo/Obesity/Obsty.htm" class="LinkPage"&gt;Obesity&lt;/a&gt; (WHO Grade 3)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Interpretation: Boys (Derived from CDC BMI charts)&lt;ol&gt;&lt;li&gt;Approximation&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Obesity/Obsty.htm" class="LinkPage"&gt;Overweight&lt;/a&gt; BMI = (Age in years) + 14&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Age 10&lt;ol&gt;&lt;li&gt;Mean BMI (50%): 17&lt;/li&gt;&lt;li&gt;At Risk BMI (&amp;gt;85%): 20&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Obesity/Obsty.htm" class="LinkPage"&gt;Overweight&lt;/a&gt; BMI (&amp;gt;95%): 23.5&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Age 12&lt;ol&gt;&lt;li&gt;Mean BMI (50%): 18&lt;/li&gt;&lt;li&gt;At Risk BMI (&amp;gt;85%): 22&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Obesity/Obsty.htm" class="LinkPage"&gt;Overweight&lt;/a&gt; BMI (&amp;gt;95%): 25&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Age 14&lt;ol&gt;&lt;li&gt;Mean BMI (50%): 19&lt;/li&gt;&lt;li&gt;At Risk BMI (&amp;gt;85%): 23&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Obesity/Obsty.htm" class="LinkPage"&gt;Overweight&lt;/a&gt; BMI (&amp;gt;95%): 27&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Age 16&lt;ol&gt;&lt;li&gt;Mean BMI (50%): 20&lt;/li&gt;&lt;li&gt;At Risk BMI (&amp;gt;85%): 25&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Obesity/Obsty.htm" class="LinkPage"&gt;Overweight&lt;/a&gt; BMI (&amp;gt;95%): 29&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Interpretation: Girls (Derived from CDC BMI charts)&lt;ol&gt;&lt;li&gt;Approximation&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Obesity/Obsty.htm" class="LinkPage"&gt;Overweight&lt;/a&gt; BMI = (Age in years) + 13&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Age 10&lt;ol&gt;&lt;li&gt;Mean BMI (50%): 17&lt;/li&gt;&lt;li&gt;At Risk BMI (&amp;gt;85%): 20&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Obesity/Obsty.htm" class="LinkPage"&gt;Overweight&lt;/a&gt; BMI (&amp;gt;95%): 23&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Age 12&lt;ol&gt;&lt;li&gt;Mean BMI (50%): 18&lt;/li&gt;&lt;li&gt;At Risk BMI (&amp;gt;85%): 22&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Obesity/Obsty.htm" class="LinkPage"&gt;Overweight&lt;/a&gt; BMI (&amp;gt;95%): 26&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Age 14&lt;ol&gt;&lt;li&gt;Mean BMI (50%): 19&lt;/li&gt;&lt;li&gt;At Risk BMI (&amp;gt;85%): 24&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Obesity/Obsty.htm" class="LinkPage"&gt;Overweight&lt;/a&gt; BMI (&amp;gt;95%): 28&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Age 16&lt;ol&gt;&lt;li&gt;Mean BMI (50%): 20&lt;/li&gt;&lt;li&gt;At Risk BMI (&amp;gt;85%): 25&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Obesity/Obsty.htm" class="LinkPage"&gt;Overweight&lt;/a&gt; BMI (&amp;gt;95%): 29&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Resources&lt;ol&gt;&lt;li&gt;NIH &lt;a href="../../Endo/Obesity/Obsty.htm" class="LinkPage"&gt;Obesity&lt;/a&gt; Education Initiative BMI Calculator&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.nhlbisupport.com/bmi/bmicalc.htm" class="LinkWebExt"&gt;http://www.nhlbisupport.com/bmi/bmicalc.htm&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;CDC Growth Charts (source for childhood BMIs above)&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.cdc.gov/growthcharts" class="LinkWebExt"&gt;http://www.cdc.gov/growthcharts&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;CDC Body Mass Index Information&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.cdc.gov/nccdphp/dnpa/obesity/bmi.htm" class="LinkWebExt"&gt;http://www.cdc.gov/nccdphp/dnpa/obesity/bmi.htm&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;Green (1994) Bright Futures, NCEMCH, p. 266&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0005893</value><value>C1305855</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Exam/BdyMsIndx.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Body Mass Index, BMI, Body Mass Index Calculation</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Exam/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Tanner boys genital development stage  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0429596"&gt;&lt;i&gt;C0429596&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Finding (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0429596&amp;amp;tui=T033"&gt;&lt;i&gt;T033&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;251805007&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Tanner boy genital development, male genital development Tanner stage, Tanner boys genital development (physical finding), Boys genital development, Tanner boys genital development, G - Genitalia stage, Tanner boys genital development stage (observable entity), Tanner boys genital development stage&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;estadio de desarrollo genital del varón según escala de Tanner (entidad observable), estadio de desarrollo genital del varón según escala de Tanner&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Tanner boys genital development stage  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Male Tanner Stage</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Examination</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Stage: Tanner 1 (Prepubertal)&lt;ol&gt;&lt;li&gt;Height increases at basal rate: 5-6 cm/year&lt;/li&gt;&lt;li&gt;&lt;a href="../../Uro/Anatomy/Tstcl.htm" class="LinkPage"&gt;Testes&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Smaller than 4 ml or long axis &amp;lt;2.5 cm&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Pubic &lt;a href="../../Derm/Anatomy/Hr.htm" class="LinkPage"&gt;Hair&lt;/a&gt;&lt;ol&gt;&lt;li&gt;No coarse, pigmented hair&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Uro/Anatomy/AntmyOfThPns.htm" class="LinkPage"&gt;Penis&lt;/a&gt; Stage&lt;ol&gt;&lt;li&gt;No growth&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Stage: Tanner 2&lt;ol&gt;&lt;li&gt;Height increases at basal rate: 5-6 cm/year&lt;/li&gt;&lt;li&gt;&lt;a href="../../Uro/Anatomy/Tstcl.htm" class="LinkPage"&gt;Testes&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Size 4 ml or long axis 2.5 to 3.2 cm&lt;/li&gt;&lt;li&gt;Age 11.5 years (age 9.5 to 13.5 years)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Pubic &lt;a href="../../Derm/Anatomy/Hr.htm" class="LinkPage"&gt;Hair&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Minimal coarse, pigmented hair at base of penis&lt;/li&gt;&lt;li&gt;Age 12.0 years (age 9.9 to 14.0 years)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Uro/Anatomy/AntmyOfThPns.htm" class="LinkPage"&gt;Penis&lt;/a&gt; Stage&lt;ol&gt;&lt;li&gt;Earliest increased length and width&lt;/li&gt;&lt;li&gt;Age 11.5 years (age 10.5-14.5 years)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Stage: Tanner 3&lt;ol&gt;&lt;li&gt;Height increases at accelerated rate: 7-8 cm/year&lt;/li&gt;&lt;li&gt;&lt;a href="../../Uro/Anatomy/Tstcl.htm" class="LinkPage"&gt;Testes&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Size 12 ml or long axis 3.6 cm&lt;/li&gt;&lt;li&gt;Age 14.0 years (11.5-16.5 years)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Pubic &lt;a href="../../Derm/Anatomy/Hr.htm" class="LinkPage"&gt;Hair&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Coarse, dark curly hair spread over the pubis&lt;/li&gt;&lt;li&gt;Age 13.1 years (11.2-15.0 years)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Uro/Anatomy/AntmyOfThPns.htm" class="LinkPage"&gt;Penis&lt;/a&gt; Stage&lt;ol&gt;&lt;li&gt;Increased length and width&lt;/li&gt;&lt;li&gt;Age 12.4 years (10.1-14.6 years)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Other Changes&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Sx/Gyncmst.htm" class="LinkPage"&gt;Gynecomastia&lt;/a&gt; may occur (age 13.2 years)&lt;/li&gt;&lt;li&gt;Voice breaks (age 13.5 years)&lt;/li&gt;&lt;li&gt;Muscle mass increases&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Stage: Tanner 4&lt;ol&gt;&lt;li&gt;Height increases at peak rate: 10 cm/year (age 13.8)&lt;/li&gt;&lt;li&gt;Pubic &lt;a href="../../Derm/Anatomy/Hr.htm" class="LinkPage"&gt;Hair&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../Derm/Anatomy/Hr.htm" class="LinkPage"&gt;Hair&lt;/a&gt; of adult quality&lt;/li&gt;&lt;li&gt;Not spread to junction of medial thigh with perineum&lt;/li&gt;&lt;li&gt;Age 13.9 years (12.0-15.8 years)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Uro/Anatomy/AntmyOfThPns.htm" class="LinkPage"&gt;Penis&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Continued growth in length and width&lt;/li&gt;&lt;li&gt;Age 13.2 years (11.2-15.3 years)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Uro/Anatomy/Tstcl.htm" class="LinkPage"&gt;Testes&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Length 4.1 to 4.5 cm&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Other Changes&lt;ol&gt;&lt;li&gt;Axillary hair (age 14.0 years)&lt;/li&gt;&lt;li&gt;Voice changes (age 14.1 years)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Derm/Acne/AcnVlgrs.htm" class="LinkPage"&gt;Acne Vulgaris&lt;/a&gt; (age 14.3 years)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Stage: Tanner 5&lt;ol&gt;&lt;li&gt;No further height increases after age 17 years&lt;/li&gt;&lt;li&gt;Pubic &lt;a href="../../Derm/Anatomy/Hr.htm" class="LinkPage"&gt;Hair&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Adult pubic hair distribution (15.3 years)&lt;/li&gt;&lt;li&gt;Pubic hair spreads to medial thigh&lt;/li&gt;&lt;li&gt;No hair spread to linea alba&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Uro/Anatomy/AntmyOfThPns.htm" class="LinkPage"&gt;Penis&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Mature genital size by 16.5 years&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Uro/Anatomy/Tstcl.htm" class="LinkPage"&gt;Testes&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Length &amp;gt;4.5 cm&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Secondary sexual characteristics&lt;ol&gt;&lt;li&gt;Facial hair present on sides&lt;/li&gt;&lt;li&gt;Mature male physique&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Sx/Gyncmst.htm" class="LinkPage"&gt;Gynecomastia&lt;/a&gt; disappears&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Exam: Testicle Size (typical ranges)&lt;ol&gt;&lt;li&gt;Birth to 6 months&lt;ol&gt;&lt;li&gt;Size: 1.5 cm long and 1.0 cm wide&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Child &amp;lt;6 years&lt;ol&gt;&lt;li&gt;Size 2 cm long and 1.2 cm wide&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Adult:&lt;ol&gt;&lt;li&gt;Size 4-5 cm long and 3.0 cm wide and 3.0 cm deep (AP)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Uro/Anatomy/Tstcl.htm" class="LinkPage"&gt;Testicle&lt;/a&gt; length &amp;lt;3.5 cm is considered small for an adult&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Exam: Growth in Boys&lt;ol&gt;&lt;li&gt;Peak height velocity: Age 13.5 (11.7-15.3 years)&lt;/li&gt;&lt;li&gt;Basal growth occurs up until Tanner Stage 3&lt;ol&gt;&lt;li&gt;Basal Growth rate: 5.0 to 6.0 cm per year&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Pubertal Growth&lt;ol&gt;&lt;li&gt;Boys who mature average time: 9.5 (7.1-11.9) cm/yr&lt;/li&gt;&lt;li&gt;Boys who mature early: 10.3 (7.9-12.5) cm/yr&lt;/li&gt;&lt;li&gt;Boys who mature late:  8.5 (6.3-10.7) cm/yr&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Reference&lt;ol&gt;&lt;li&gt;Tanner (1966) Growth at Adolescence, Appleton&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Marshall%20%20%5BAU%5D%20AND%201970%20%5BDP%5D%20AND%20%20Arch%20Dis%20Child%20%20%5BTA%5D" class="LinkRef"&gt;Marshall (1970) Arch Dis Child 45:13-23&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Tanner%20%20%5BAU%5D%20AND%201985%20%5BDP%5D%20AND%20%20J%20Pediatr%20%20%5BTA%5D" class="LinkRef"&gt;Tanner (1985) J Pediatr 107(3):317&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0429596</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Exam/MlTnrStg.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Male Tanner Stage, Male Sexual Development, Male Tanner Staging, Testicle Size, Tanner Boys Genital Development Stage</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Exam/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees></FP_UMLS_Trees><FP_Condition_name_check></FP_Condition_name_check><FP_Condition_name><value>Steroid Hormone Pathway</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Examination</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Physiology&lt;ol&gt;&lt;li&gt;&lt;a href="../../CV/Lab/Lpd.htm" class="LinkPage"&gt;Cholesterol&lt;/a&gt; is precursor for 5 steroid hormone classes&lt;ol&gt;&lt;li&gt;Progestagens (e.g. &lt;a href="../../Gyn/Pharm/Prgstrn.htm" class="LinkPage"&gt;Progesterone&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;Glucocorticoids (e.g. Cortisol)&lt;/li&gt;&lt;li&gt;Mineralcorticoids (e.g. Aldosterone)&lt;/li&gt;&lt;li&gt;Androgens (e.g. Testosterone)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Gyn/Pharm/Estrgn.htm" class="LinkPage"&gt;Estrogen&lt;/a&gt;s&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Synthesis sites&lt;ol&gt;&lt;li&gt;Adrenal cortex: Glucocorticoids, Mineralcorticoids&lt;/li&gt;&lt;li&gt;Women&lt;ol&gt;&lt;li&gt;Corpus luteum: Progestagens&lt;/li&gt;&lt;li&gt;&lt;a href="../../Gyn/Anatomy/AdnxlAntmy.htm" class="LinkPage"&gt;Ovary&lt;/a&gt;: &lt;a href="../../Gyn/Pharm/Estrgn.htm" class="LinkPage"&gt;Estrogen&lt;/a&gt;s&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Men&lt;ol&gt;&lt;li&gt;&lt;a href="../../Uro/Anatomy/Tstcl.htm" class="LinkPage"&gt;Testis&lt;/a&gt;: Testosterone&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Conditions related to enzyme deficiencies&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Adrenal/CngntlAdrnlHyprpls.htm" class="LinkPage"&gt;Congenital Adrenal Hyperplasia&lt;/a&gt;&lt;ol&gt;&lt;li&gt;21-Hydroxylase deficiency is most common&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Step 1: Steroid Synthesis - &lt;a href="../../CV/Lab/Lpd.htm" class="LinkPage"&gt;Cholesterol&lt;/a&gt; to Precursors&lt;ol&gt;&lt;li&gt;&lt;a href="../../CV/Lab/Lpd.htm" class="LinkPage"&gt;Cholesterol&lt;/a&gt; converted to Pregnenolone&lt;ol&gt;&lt;li&gt;Stimulated by ACTH release from anterior pituitary&lt;/li&gt;&lt;li&gt;Key enzyme: Desmolase&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Pregnenolone converted to &lt;a href="../../Gyn/Pharm/Prgstrn.htm" class="LinkPage"&gt;Progesterone&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Pregnenolone is precursor of all steroids&lt;/li&gt;&lt;li&gt;Key enzyme: 3-B-Hydroxysteroid Dehydrogenase&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Gyn/Pharm/Prgstrn.htm" class="LinkPage"&gt;Progesterone&lt;/a&gt; converted to 17-a-hydroxyprogesterone&lt;ol&gt;&lt;li&gt;Key enzyme: 17-Hydroxylase&lt;/li&gt;&lt;li&gt;17-a-hydroxyprogesterone is precursor&lt;ol&gt;&lt;li&gt;Cortisol Synthesis (Go to step 2)&lt;/li&gt;&lt;li&gt;Aldosterone Synthesis (Go to Step 4)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;17-a-hydroxyprogesterone converted to &lt;a href="../../Sports/Pharm/Andrstndn.htm" class="LinkPage"&gt;Androstenedione&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Key enzyme: 3-B-Hydroxysteroid Dehydrogenase&lt;/li&gt;&lt;li&gt;&lt;a href="../../Sports/Pharm/Andrstndn.htm" class="LinkPage"&gt;Androstenedione&lt;/a&gt; is sex hormone precursor (see Step 3)&lt;ol&gt;&lt;li&gt;Estrone&lt;/li&gt;&lt;li&gt;Testosterone&lt;/li&gt;&lt;li&gt;Estradiol&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Step 2: Cortisol Synthesis from 17-a-hydroxyprogesterone&lt;ol&gt;&lt;li&gt;17-a-hydroxyprogesterone converted to 11-Deoxycortisol&lt;ol&gt;&lt;li&gt;Key enzyme: 21-Hydroxylase&lt;/li&gt;&lt;li&gt;Most common enzyme deficiency in steroid synthesis&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Adrenal/CngntlAdrnlHyprpls.htm" class="LinkPage"&gt;Congenital Adrenal Hyperplasia&lt;/a&gt; (with virilization)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;11-Deoxycortisol converted to Cortisol&lt;ol&gt;&lt;li&gt;Key enzyme: 11-Hydroxylase&lt;/li&gt;&lt;li&gt;Enzyme deficiency related condition&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Adrenal/CngntlAdrnlHyprpls.htm" class="LinkPage"&gt;Congenital Adrenal Hyperplasia&lt;/a&gt; (with virilization)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Cortisol&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Step 3: Sex Hormones from &lt;a href="../../Sports/Pharm/Andrstndn.htm" class="LinkPage"&gt;Androstenedione&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../Sports/Pharm/Andrstndn.htm" class="LinkPage"&gt;Androstenedione&lt;/a&gt; converted to Estrone or&lt;/li&gt;&lt;li&gt;&lt;a href="../../Sports/Pharm/Andrstndn.htm" class="LinkPage"&gt;Androstenedione&lt;/a&gt; converted to Testosterone&lt;ol&gt;&lt;li&gt;Testosterone converted to Estradiol&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Step 4: Aldosterone from &lt;a href="../../Gyn/Pharm/Prgstrn.htm" class="LinkPage"&gt;Progesterone&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../Gyn/Pharm/Prgstrn.htm" class="LinkPage"&gt;Progesterone&lt;/a&gt; converted to 11-Deoxycorticosterone&lt;ol&gt;&lt;li&gt;Key enzyme: 21-Hydroxylase&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;11-Deoxycorticosterone converted to Cortisosterone&lt;ol&gt;&lt;li&gt;Key enzyme: 11-Hydroxylase&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Corticosterone converted to Aldosterone&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Exam/StrdHrmnPthwy.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Steroid Hormone Pathway, Sex Hormone Synthesis, Cortisol Synthesis, Aldosterone Synthesis</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Exam/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees></FP_UMLS_Trees><FP_Condition_name_check></FP_Condition_name_check><FP_Condition_name><value>Oral Manifestations of Diabetes</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Examination</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Associated Conditions&lt;ol&gt;&lt;li&gt;&lt;a href="../../Dental/Gingiva/Prdnts.htm" class="LinkPage"&gt;Periodontitis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../ENT/Mouth/Thrsh.htm" class="LinkPage"&gt;Oral Candidiasis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../ENT/Sx/SlvryGlndEnlrgmnt.htm" class="LinkPage"&gt;Sialadenosis&lt;/a&gt; (&lt;a href="../../ENT/Anatomy/PrtdGlnd.htm" class="LinkPage"&gt;Parotid Gland&lt;/a&gt; enlargement)&lt;/li&gt;&lt;li&gt;&lt;a href="../../ENT/Tongue/AtrphcGlsts.htm" class="LinkPage"&gt;Atrophic Glossitis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../ENT/Sx/TstSnstn.htm" class="LinkPage"&gt;Taste Dysfunction&lt;/a&gt; (&lt;a href="../../ENT/Sx/TstSnstn.htm" class="LinkPage"&gt;Dysgeusia&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;&lt;a href="../../ENT/Sx/BrngMthSyndrm.htm" class="LinkPage"&gt;Burning Mouth Syndrome&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Exam/OrlMnfstnsOfDbts.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Oral Manifestations of Diabetes, Mouth Conditions in Diabetes Mellitus, Diabetes Associated Oral Conditions</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Exam/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees></FP_UMLS_Trees><FP_Condition_name_check></FP_Condition_name_check><FP_Condition_name><value>Weight for Height Age</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Examination</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;See Also&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Exam/WghtMsrmntInChldrn.htm" class="LinkPage"&gt;Weight Measurement in Children&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Exam/WghtFrLngth.htm" class="LinkPage"&gt;Weight for Length&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Indication&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Growth/GrwthAssmnt.htm" class="LinkPage"&gt;Growth Assessment&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Peds/FlrTThrv.htm" class="LinkPage"&gt;Failure to Thrive&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Definition&lt;ol&gt;&lt;li&gt;Assesses percent of target weight based on age and length&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Calculation&lt;ol&gt;&lt;li&gt;Step 1: Define height age&lt;ol&gt;&lt;li&gt;Determine age when 50% children reach patient's height&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Step 2: Define target weight&lt;ol&gt;&lt;li&gt;Locate 50th percentile Weight for Height Age (Step 1)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Step 3: Calculate Weight for Height Age&lt;ol&gt;&lt;li&gt;Calculation = (Actual weight)/(Target weight) x 100&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Interpretation&lt;ol&gt;&lt;li&gt;Normal Weight for Height Age: 80-120% of target weight&lt;ol&gt;&lt;li&gt;Endocrine disease will also have a normal result&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Low Weight for Height Age: &amp;lt;80%&lt;ol&gt;&lt;li&gt;Suggests Protein Calorie malnutrition&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;High Weight for Height Age: &amp;gt;120%&lt;ol&gt;&lt;li&gt;Suggests &lt;a href="../../Endo/Obesity/Obsty.htm" class="LinkPage"&gt;Obesity&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Exam/WghtFrHghtAg.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Weight for Height Age</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Exam/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees></FP_UMLS_Trees><FP_Condition_name_check></FP_Condition_name_check><FP_Condition_name><value>Daily Energy Allowance</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Examination</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Indications&lt;ol&gt;&lt;li&gt;Estimates average Daily Energy Allowances&lt;/li&gt;&lt;li&gt;Assumptions&lt;ol&gt;&lt;li&gt;Light to moderate &lt;a href="../../Sports/Exercise/Exrcs.htm" class="LinkPage"&gt;Physical Activity&lt;/a&gt;&lt;/li&gt;&lt;li&gt;No underlying medical conditions&lt;/li&gt;&lt;li&gt;Women who are not lactating and not pregnant&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Interpretation&lt;ol&gt;&lt;li&gt;RDAs grossly overestimate caloric needs&lt;/li&gt;&lt;li&gt;Continuation at these intakes will result in &lt;a href="../../Endo/Obesity/Obsty.htm" class="LinkPage"&gt;Obesity&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Protocol: Recommended average Daily Energy Allowances in Children&lt;ol&gt;&lt;li&gt;Age 1 to 3 years: 102 kcal/kg&lt;/li&gt;&lt;li&gt;Age 4 to 6 years: 90 kcal/kg&lt;/li&gt;&lt;li&gt;Age 7 to 10 years: 70 kcal/kg&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Protocol: Recommended average Daily Energy Allowances in Men&lt;ol&gt;&lt;li&gt;Age 11 to 14 years: 55 kcal/kg&lt;/li&gt;&lt;li&gt;Age 15 to 18 years: 45 kcal/kg&lt;/li&gt;&lt;li&gt;Age 19 to 24 years: 40 kcal/kg&lt;/li&gt;&lt;li&gt;Age 25 to 50 years: 37 kcal/kg&lt;/li&gt;&lt;li&gt;Age over 51 years: 30 kcal/kg&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Protocol: Recommended average Daily Energy Allowances in Women&lt;ol&gt;&lt;li&gt;Age 11 to 14 years: 47 kcal/kg&lt;/li&gt;&lt;li&gt;Age 15 to 18 years: 40 kcal/kg&lt;/li&gt;&lt;li&gt;Age 19 to 24 years: 38 kcal/kg&lt;/li&gt;&lt;li&gt;Age 25 to 50 years: 36 kcal/kg&lt;/li&gt;&lt;li&gt;Age over 51 years: 30 kcal/kg&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;(1989) RDA's 10th Edition, National Academy Press&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Exam/DlyEnrgyAlwnc.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Daily Energy Allowance</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Exam/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;glucose metabolism  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0596620"&gt;&lt;i&gt;C0596620&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CSP)&lt;/td&gt;
                &lt;td&gt;sum of chemical changes that occur within the tissues of an organism consisting of anabolism (biosynthesis) and catabolism of glucose; the buildup and breakdown of glucose for utilization by the organism.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (GO)&lt;/td&gt;
                &lt;td&gt;The chemical reactions and pathways involving glucose, the aldohexose gluco-hexose. D-glucose is dextrorotatory and is sometimes known as dextrose; it is an important source of energy for living organisms and is found free as well as combined in homo- and hetero-oligosaccharides and polysaccharides. [ISBN:0198506732 "Oxford Dictionary of Biochemistry and Molecular Biology"]&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Molecular Function (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0596620&amp;amp;tui=T044"&gt;&lt;i&gt;T044&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;glucose metabolic process, glucose metabolism, cellular glucose metabolic process, Glucose Metabolism&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>glucose metabolism  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Glucose Metabolism</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Examination</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Physiology&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Glucose&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Released from hepatic stores between meals&lt;/li&gt;&lt;li&gt;Derived from ingested carbohydrates&lt;ol&gt;&lt;li&gt;Postprandial &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; &amp;gt;20 fold over hepatic release&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt;&lt;ol&gt;&lt;li&gt;General&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; produced by pancreatic beta cells&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; release stimulated by &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Glucose&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; response to &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; is linear&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; response is based on &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; sensitivity&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; sensitivity depends on &lt;a href="../../Psych/Pharm/Zlpdm.htm" class="LinkPage"&gt;Ambien&lt;/a&gt;t &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Normal: Rapid &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; release with a meal&lt;/li&gt;&lt;li&gt;Fasting: Steeper rate of &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; release&lt;/li&gt;&lt;li&gt;Prolonged &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Hyperglycemia&lt;/a&gt;: Flattened response&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Phase 1 &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; Release&lt;ol&gt;&lt;li&gt;Duration: 10 minutes&lt;/li&gt;&lt;li&gt;Suppresses hepatic &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; release&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Phase 2 &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; Release&lt;ol&gt;&lt;li&gt;Duration: 2 years&lt;/li&gt;&lt;li&gt;Controls mealtime carbohydrates&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Basal &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; Release&lt;ol&gt;&lt;li&gt;Low continuous &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; level&lt;/li&gt;&lt;li&gt;Covers metabolic needs between meals&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Pathophysiology: &lt;a href="../../Endo/DM/TypDbtsMlts1.htm" class="LinkPage"&gt;Type II Diabetes Mellitus&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Loss of &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; sensitivity (see above)&lt;ol&gt;&lt;li&gt;Loss of phase 1 &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; response&lt;/li&gt;&lt;li&gt;Insufficient phase 2 &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; response&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; production by beta cell&lt;ol&gt;&lt;li&gt;First: &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; increases to overcome &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; toxicity&lt;/li&gt;&lt;li&gt;Results in beta-cell exhaustion (&lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; Toxicity)&lt;ol&gt;&lt;li&gt;Initially reversible beta cell exhaustion&lt;/li&gt;&lt;li&gt;Permanent later as amyloid replaces beta cells&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; levels decrease as beta cells fail&lt;ol&gt;&lt;li&gt;Beta-cell function reduced to &amp;lt;50% by DM diagnosis&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Impaired incretin action&lt;ol&gt;&lt;li&gt;Incretins manage postprandial &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; levels&lt;ol&gt;&lt;li&gt;Incretin released from GI tract following meals&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Endogenous Incretin effects&lt;ol&gt;&lt;li&gt;Increases &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; dependent &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; secretion&lt;/li&gt;&lt;li&gt;Delays gastric emptying&lt;/li&gt;&lt;li&gt;Decreases food intake (improves satiety)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Progressive incretin reduced activity&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/IncrtnMmtc.htm" class="LinkPage"&gt;Glucagon-Like Peptide 1&lt;/a&gt; (&lt;a href="../../Endo/Pharm/IncrtnMmtc.htm" class="LinkPage"&gt;GLP-1&lt;/a&gt;) activity decreases&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Medications&lt;ol&gt;&lt;li&gt;Increase &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; sensitivity&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Glcphg.htm" class="LinkPage"&gt;Metformin&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Thzldndn.htm" class="LinkPage"&gt;Thiazolidinedione&lt;/a&gt;s&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Stimulate &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; release from beta cells&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/NnSlfnylrInslnScrtgs.htm" class="LinkPage"&gt;Meglitinide&lt;/a&gt;s (act on phase 1 release)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Slfnylr.htm" class="LinkPage"&gt;Sulfonylurea&lt;/a&gt;s (act on phase 2 release)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Replace &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt;&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Increase incretin levels (&lt;a href="../../Endo/Pharm/IncrtnMmtc.htm" class="LinkPage"&gt;GLP-1&lt;/a&gt;)&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/IncrtnMmtc.htm" class="LinkPage"&gt;Exenatide&lt;/a&gt; (&lt;a href="../../Endo/Pharm/IncrtnMmtc.htm" class="LinkPage"&gt;Byetta&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Stglptn.htm" class="LinkPage"&gt;Sitagliptin&lt;/a&gt; (&lt;a href="../../Endo/Pharm/Stglptn.htm" class="LinkPage"&gt;Januvia&lt;/a&gt;)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0596620</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Exam/GlcsMtblsm.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Glucose Metabolism</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Exam/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees></FP_UMLS_Trees><FP_Condition_name_check></FP_Condition_name_check><FP_Condition_name><value>Weight Velocity</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Examination</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Definition&lt;ol&gt;&lt;li&gt;Child's weight change in grams over 1-2 months is compared to cohort of children of the same age&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Interpretation&lt;ol&gt;&lt;li&gt;Weight change &amp;lt;5th percentile suggests &lt;a href="../../Endo/Peds/FlrTThrv.htm" class="LinkPage"&gt;Failure to Thrive&lt;/a&gt; Risk&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Resources&lt;ol&gt;&lt;li&gt;WHO Weight Velocity Charts&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.who.int/childgrowth/standards/w_velocity/en/" class="LinkWebExt"&gt;http://www.who.int/childgrowth/standards/w_velocity/en/&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Exam/WghtVlcty.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Weight Velocity</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Exam/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees></FP_UMLS_Trees><FP_Condition_name_check></FP_Condition_name_check><FP_Condition_name><value>Energy Deficit Calculation</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Examination</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Step 1: Estimate Resting Energy Expenditure (REE)&lt;ol&gt;&lt;li&gt;Based on Mifflin-St Jeor Equation&lt;/li&gt;&lt;li&gt;Males Resting Energy Expenditure&lt;ol&gt;&lt;li&gt;Start: 10 x (Weight in kilograms) + 5&lt;/li&gt;&lt;li&gt;Add: 6.25 x (Height in centimeters)&lt;/li&gt;&lt;li&gt;Subtract: 5 x (Age in years)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Females Resting Energy Expenditure&lt;ol&gt;&lt;li&gt;Start: 10 x (Weight in kilograms) - 161&lt;/li&gt;&lt;li&gt;Add: 6.25 x (Height in centimeters)&lt;/li&gt;&lt;li&gt;Subtract: 5 x (Age in years)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Step 2: Estimate Daily caloric need&lt;ol&gt;&lt;li&gt;Consider Activity factor (AF) of 1.0&lt;ol&gt;&lt;li&gt;AF &amp;gt;1.0 grossly overestimates caloric needs&lt;/li&gt;&lt;li&gt;Using activity factor of 1.0 may be weight neutral&lt;ol&gt;&lt;li&gt;Mucha (2007) HP Primary Care Medicine, Lecture&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Bezera%20%20%5BAU%5D%20AND%202001%20%5BDP%5D%20AND%20%20J%20Amer%20Dietetic%20Assoc%20%20%5BTA%5D" class="LinkRef"&gt;Bezera (2001) J Amer Dietetic Assoc 101&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Determine Daily caloric need&lt;ol&gt;&lt;li&gt;Resting Energy Expenditure x Activity Factor&lt;/li&gt;&lt;li&gt;See also &lt;a href="../../Endo/Exam/DlyEnrgyAlwnc.htm" class="LinkPage"&gt;Daily Energy Allowance&lt;/a&gt;s&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Step 3: Calculate Adjusted caloric intake&lt;ol&gt;&lt;li&gt;Determine daily caloric deficit (Usually 500 kcals/day)&lt;ol&gt;&lt;li&gt;Deficit of 500 Kcals/day = 3500/week (1 pound/week)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Determine Adjusted caloric intake&lt;ol&gt;&lt;li&gt;Daily caloric need - Daily caloric Deficit (500)&lt;/li&gt;&lt;li&gt;Do not lower intake below 1000 Kcals/day&lt;/li&gt;&lt;li&gt;Consider using REE x0.8 for weight loss program&lt;ol&gt;&lt;li&gt;Mucha (2007) HP Primary Care Medicine, Lecture&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Bezera%20%20%5BAU%5D%20AND%202001%20%5BDP%5D%20AND%20%20J%20Amer%20Dietetic%20Assoc%20%20%5BTA%5D" class="LinkRef"&gt;Bezera (2001) J Amer Dietetic Assoc 101&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Consider calorie intake goal based on body weight range&lt;ol&gt;&lt;li&gt;Body weight &amp;lt;200 pounds: 1000 Kcals/day (500 kcal deficit per day)&lt;/li&gt;&lt;li&gt;Body weight 200-249 pounds: 1200 Kcals/day (750 kcal deficit per day)&lt;/li&gt;&lt;li&gt;Body weight 250-299 pounds: 1500 Kcals/day (1000 kcal deficit per day)&lt;/li&gt;&lt;li&gt;Body weight 300-349 pounds: 1800 Kcals/day (1250 kcal deficit per day)&lt;/li&gt;&lt;li&gt;Body weight &amp;gt;350 pounds: 2000 Kcals/day (1500 kcal deficit per day)&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Klein%20%20%5BAU%5D%20AND%202002%20%5BDP%5D%20AND%20%20%20%5BTA%5D" class="LinkRef"&gt;Klein (2002) 123(3): 882-932&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Frank%20%20%5BAU%5D%20AND%201998%20%5BDP%5D%20AND%20%20J%20Am%20Diet%20Assoc%20%20%5BTA%5D" class="LinkRef"&gt;Frank (1998) J Am Diet Assoc 98:S44-48&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Lyznicki%20%20%5BAU%5D%20AND%202001%20%5BDP%5D%20AND%20%20Am%20Fam%20Physician%20%20%5BTA%5D" class="LinkRef"&gt;Lyznicki (2001) Am Fam Physician 63(11):2185-96&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Rippe%20%20%5BAU%5D%20AND%201998%20%5BDP%5D%20AND%20%20J%20Am%20Diet%20Assoc%20%20%5BTA%5D" class="LinkRef"&gt;Rippe (1998) J Am Diet Assoc 98:S9-15&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Speer%20%20%5BAU%5D%20AND%201997%20%5BDP%5D%20AND%20%20Phys%20Sportsmed%20%20%5BTA%5D" class="LinkRef"&gt;Speer (1997) Phys Sportsmed 25:94-107&lt;/a&gt;&lt;/li&gt;&lt;li&gt;(1998) AOA Treatment Adult &lt;a href="../../Endo/Obesity/Obsty.htm" class="LinkPage"&gt;Obesity&lt;/a&gt;, 2nd edition&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Exam/EnrgyDfctClcltn.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Energy Deficit Calculation, Resting Energy Expenditure, Daily caloric need, Adjusted caloric intake</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Exam/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees></FP_UMLS_Trees><FP_Condition_name_check></FP_Condition_name_check><FP_Condition_name><value>Upper to Lower Segment Ratio</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Examination</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Indications&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Growth/GrwthAssmnt.htm" class="LinkPage"&gt;Growth Assessment&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Differentiates collagen bone disease (skeletal dysplasia) from primary spine (e.g. &lt;a href="../../Ortho/T-Spine/Scls.htm" class="LinkPage"&gt;Scoliosis&lt;/a&gt;)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Technique: Measurement&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Endo/Exam/StngHght.htm" class="LinkPage"&gt;Sitting Height&lt;/a&gt; for an alternative method of calculating segment heights&lt;/li&gt;&lt;li&gt;Lower segment: Top of pubic symphysis to floor&lt;/li&gt;&lt;li&gt;Upper segment: Top of head to top of pubic symphysis&lt;ol&gt;&lt;li&gt;Calculation: TotalHeight - LowerSegmentHeight&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Interpretation: Normal upper to lower ratio&lt;ol&gt;&lt;li&gt;Birth upper to lower ratio: 1.70 (Greatest ratio)&lt;/li&gt;&lt;li&gt;Postpuberty upper to lower ratio: 0.89 - 0.95&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Exam/UprTLwrSgmntRt.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Upper to Lower Segment Ratio</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Exam/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees></FP_UMLS_Trees><FP_Condition_name_check></FP_Condition_name_check><FP_Condition_name><value>Linear Growth Velocity</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Examination</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Indications&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Growth/GrwthAssmnt.htm" class="LinkPage"&gt;Growth Assessment&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Assessment for collagen bone disease&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Efficacy&lt;ol&gt;&lt;li&gt;Single most important &lt;a href="../../Endo/Growth/GrwthAssmnt.htm" class="LinkPage"&gt;Growth Assessment&lt;/a&gt; screening tool&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Normal height increase&lt;ol&gt;&lt;li&gt;Age &amp;lt;1 year: 10.0 inches (25 cm) growth/year&lt;ol&gt;&lt;li&gt;Age &amp;lt;6 months: 16 to 17 cm growth/year&lt;/li&gt;&lt;li&gt;Age 6-12 months: 8 cm growth/year&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Age 1 to 2 years: 4.0 inches (10 cm) growth/year&lt;/li&gt;&lt;li&gt;Age 2 to 3 years: 3.2 inches (8 cm) growth/year&lt;/li&gt;&lt;li&gt;Age 3 to 4 years: 2.8 inches (7 cm) growth/year&lt;/li&gt;&lt;li&gt;Age 4 to 10 years: 2.0-2.4 inches (5-6 cm) growth/year&lt;/li&gt;&lt;li&gt;Prepuberty Nadir&lt;ol&gt;&lt;li&gt;Age 10 year old girl: 2.2 inches (5.5 cm) growth/year&lt;/li&gt;&lt;li&gt;Age 12 year old boy: 1.9 inches (4.9 cm) growth/year&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Pubertal Acceleration&lt;ol&gt;&lt;li&gt;Girls: 3.33 inches (8.5 cm) growth/year&lt;/li&gt;&lt;li&gt;Boys:  3.75 inches (9.5 cm) growth/year&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Interpretation: Abnormal Growth&lt;ol&gt;&lt;li&gt;Growth/Year: &amp;lt;1.75 inches (4.5 cm) age 3 to &lt;a href="../../Endo/Exam/SxlDvlpmnt.htm" class="LinkPage"&gt;Puberty&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Minimum time interval between assessments&lt;ol&gt;&lt;li&gt;Age &amp;lt;3 years: minimum 4 month interval&lt;/li&gt;&lt;li&gt;Age &amp;gt;3 years: minimum 6 month interval&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Exam/LnrGrwthVlcty.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Linear Growth Velocity</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Exam/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees></FP_UMLS_Trees><FP_Condition_name_check></FP_Condition_name_check><FP_Condition_name><value>Weight for Length</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Examination</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;See Also&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Exam/WghtMsrmntInChldrn.htm" class="LinkPage"&gt;Weight Measurement in Children&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Exam/WghtFrHghtAg.htm" class="LinkPage"&gt;Weight for Height Age&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Indication&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Growth/GrwthAssmnt.htm" class="LinkPage"&gt;Growth Assessment&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Peds/FlrTThrv.htm" class="LinkPage"&gt;Failure to Thrive&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Efficacy&lt;ol&gt;&lt;li&gt;Weight for Length is a better indicator than weight alone for determining &lt;a href="../../Endo/Peds/FlrTThrv.htm" class="LinkPage"&gt;Failure to Thrive&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Definition&lt;ol&gt;&lt;li&gt;Assesses percentile of a given Weight for Length (or height) ratio when comparing children in the same age cohort&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Interpretation&lt;ol&gt;&lt;li&gt;Criteria for severe malnutrition (may warrant inpatient management for &lt;a href="../../Endo/Peds/FlrTThrv.htm" class="LinkPage"&gt;Failure to Thrive&lt;/a&gt;)&lt;ol&gt;&lt;li&gt;Weight &amp;lt;70% of the 50th percentile Weight for Length&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Bern%20%20%5BAU%5D%20AND%201997%20%5BDP%5D%20AND%20%20Bull%20World%20Health%20Organ%20%20%5BTA%5D" class="LinkRef"&gt;Bern (1997) Bull World Health Organ 75(suppl 1): 87-96&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Exam/WghtFrLngth.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Weight for Length</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Exam/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees></FP_UMLS_Trees><FP_Condition_name_check></FP_Condition_name_check><FP_Condition_name><value>Weight Measurement in Children</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Examination</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;See Also&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Exam/HghtMsrmntInChldrn.htm" class="LinkPage"&gt;Height Measurement in Children&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Growth/GrwthAssmnt.htm" class="LinkPage"&gt;Growth Assessment&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Physiology&lt;ol&gt;&lt;li&gt;Weight is best assessment of nutrition and growth&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Normal Weight Increases&lt;ol&gt;&lt;li&gt;Birth Weight&lt;ol&gt;&lt;li&gt;Weight doubles by 4-5 months of age&lt;/li&gt;&lt;li&gt;Weight triples by 1 year of age&lt;/li&gt;&lt;li&gt;Weight quadruples by 2 years of age&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Annual increase (Ages 2-9): 5 lb/year (2.25 kg/year)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Normal Weight in boys (range: 3% to 97%)&lt;ol&gt;&lt;li&gt;Age 1 year: 21-32 lbs, mean: 10 kg (22 lb)&lt;/li&gt;&lt;li&gt;Age 2 years: 23-35 lbs, mean: 13 kg (28 lb)&lt;/li&gt;&lt;li&gt;Age 3 years: 27-39 lbs, mean: 15 kg (33 lb)&lt;/li&gt;&lt;li&gt;Age 4 years: 30-43 lbs, mean: 17 kg (37 lb)&lt;/li&gt;&lt;li&gt;Age 5 years: 34-52 lbs, mean: 19 kg (42 lb)&lt;/li&gt;&lt;li&gt;Age 6 years: 39-61 lbs, mean: 21 kg (46 lb)&lt;/li&gt;&lt;li&gt;Age 7 years: 43-70 lbs, mean: 23 kg (51 lb)&lt;/li&gt;&lt;li&gt;Age 8 years: 48-79 lbs, mean: 25 kg (55 lb)&lt;/li&gt;&lt;li&gt;Age 9 years: 53-90 lbs, mean: 28 kg (62 lb)&lt;/li&gt;&lt;li&gt;Age 10 years: 57-100 lbs, mean: 31 kg (68 lb)&lt;/li&gt;&lt;li&gt;Age 11 years: 62-112 lbs, mean: 35 kg (77 lb)&lt;/li&gt;&lt;li&gt;Age 12 years: 67-124 lbs, mean: 40 kg (88 lb)&lt;/li&gt;&lt;li&gt;Age 13 years: 72-138 lbs, mean: 45 kg (99 lb)&lt;/li&gt;&lt;li&gt;Age 14 years: 80-151 lbs, mean: 51 kg (112 lb)&lt;/li&gt;&lt;li&gt;Age 15 years: 91-162 lbs, mean: 57 kg (125 lb)&lt;/li&gt;&lt;li&gt;Age 16 years: 103-171 lbs, mean: 62 kg (136 lb)&lt;/li&gt;&lt;li&gt;Age 17 years: 111-176 lbs, mean: 136 lbs&lt;/li&gt;&lt;li&gt;Age 18 years: 69 kg (152 lb)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Normal Weight in Girls (range: 3% to 97%)&lt;ol&gt;&lt;li&gt;Birth: 5.8-9.4 lbs, mean: 3 kg (7 lb)&lt;/li&gt;&lt;li&gt;Age 1 year: 17-27 lbs, mean: 10 kg (22 lb)&lt;/li&gt;&lt;li&gt;Age 2 years: 22-34 lbs, mean: 12 kg (27 lb)&lt;/li&gt;&lt;li&gt;Age 3 years: 26-42 lbs, mean: 15 kg (32 lb)&lt;/li&gt;&lt;li&gt;Age 4 years: 29-48 lbs, mean: 16 kg (36 lb)&lt;/li&gt;&lt;li&gt;Age 5 years: 33-52 lbs, mean: 19 kg (41 lb)&lt;/li&gt;&lt;li&gt;Age 6 years: 37-59 lbs, mean: 21 kg (47 lb)&lt;/li&gt;&lt;li&gt;Age 7 years: 41-67 lbs, mean: 24 kg (52 lb)&lt;/li&gt;&lt;li&gt;Age 8 years: 45-79 lbs, mean: 26 kg (58 lb)&lt;/li&gt;&lt;li&gt;Age 9 years: 49-90 lbs, mean: 29 kg (64 lb)&lt;/li&gt;&lt;li&gt;Age 10 years: 53-102 lbs, mean: 32 kg (70 lb)&lt;/li&gt;&lt;li&gt;Age 11 years: 58-113 lbs, mean: 36 kg (79 lb)&lt;/li&gt;&lt;li&gt;Age 12 years: 64-128 lbs, mean: 40 kg (88 lb)&lt;/li&gt;&lt;li&gt;Age 13 years: 72-142 lbs, mean: 45 kg (99 lb)&lt;/li&gt;&lt;li&gt;Age 14 years: 83-151 lbs, mean: 49 kg (108 lb)&lt;/li&gt;&lt;li&gt;Age 15 years: 89-155 lbs, mean: 52 kg (114 lb)&lt;/li&gt;&lt;li&gt;Age 16 years: 92-158 lbs, mean: 53 kg (117 lb)&lt;/li&gt;&lt;li&gt;Age 17 years: 94-160 lbs, mean: 54 kg (119 lb)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Resources&lt;ol&gt;&lt;li&gt;WHO updated growth charts (predominantly &lt;a href="../../Gyn/Anatomy/BrstAntmy.htm" class="LinkPage"&gt;Breast&lt;/a&gt; fed infants, data from 6 countries)&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.who.int/childgrowth" class="LinkWebExt"&gt;http://www.who.int/childgrowth&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;New CDC Growth Charts reflecting &lt;a href="../../Endo/Exam/BdyMsIndx.htm" class="LinkPage"&gt;Body Mass Index&lt;/a&gt; (typically heavier than WHO cohorts)&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.cdc.gov/growthcharts" class="LinkWebExt"&gt;http://www.cdc.gov/growthcharts&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Exam/WghtMsrmntInChldrn.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Weight Measurement in Children</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Exam/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees></FP_UMLS_Trees><FP_Condition_name_check></FP_Condition_name_check><FP_Condition_name><value>Growth Physiology</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Examination</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;See Also&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Growth/ShrtStr.htm" class="LinkPage"&gt;Delayed Growth&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Peds/FlrTThrv.htm" class="LinkPage"&gt;Failure to Thrive&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Physiology: Nutrition, Intake, and Absorption Requirements for Growth&lt;ol&gt;&lt;li&gt;Adequate Total Calorie Intake&lt;/li&gt;&lt;li&gt;Amount and Quality of Protein (Essential Amino Acids)&lt;/li&gt;&lt;li&gt;Minerals (growth regulation)&lt;ol&gt;&lt;li&gt;Calcium&lt;/li&gt;&lt;li&gt;&lt;a href="../../Pharm/Minerals/Znc.htm" class="LinkPage"&gt;Zinc&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Copper&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Adequate Gastrointestinal function&lt;ol&gt;&lt;li&gt;Adequate gastrointestinal mucosal surface&lt;/li&gt;&lt;li&gt;Adequate gastrointestinal motility&lt;/li&gt;&lt;li&gt;Adequate digestive enzymes&lt;ol&gt;&lt;li&gt;&lt;a href="../../GI/Anatomy/StmchAntmy.htm" class="LinkPage"&gt;Stomach&lt;/a&gt; and duodenum&lt;/li&gt;&lt;li&gt;&lt;a href="../../GI/Anatomy/PncrsAntmy.htm" class="LinkPage"&gt;Pancreas&lt;/a&gt; enzymes&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Adequate bile salts for fat absorption&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Physiology: Hormonal factors related to Growth&lt;ol&gt;&lt;li&gt;Pituitary &lt;a href="../../Endo/Pharm/HmnGrwthHrmn.htm" class="LinkPage"&gt;Growth Hormone&lt;/a&gt; (GH)&lt;ol&gt;&lt;li&gt;Regulated by Hypothalamus&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Anatomy/ThyrdAntmy.htm" class="LinkPage"&gt;Thyroid&lt;/a&gt; Hormone critical for &lt;a href="../../Endo/Pharm/HmnGrwthHrmn.htm" class="LinkPage"&gt;Growth Hormone&lt;/a&gt; secretion&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/HmnGrwthHrmn.htm" class="LinkPage"&gt;Growth Hormone&lt;/a&gt; action&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/HmnGrwthHrmn.htm" class="LinkPage"&gt;Growth Hormone&lt;/a&gt; released from pituitary&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/HmnGrwthHrmn.htm" class="LinkPage"&gt;Growth Hormone&lt;/a&gt; reaches liver and other tissues&lt;/li&gt;&lt;li&gt;IGF-I synthesized&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt;-like Growth Factor or &lt;a href="../../Rheum/Pharm/SkltlMsclRlxnt.htm" class="LinkPage"&gt;Soma&lt;/a&gt;tomedin C&lt;/li&gt;&lt;li&gt;IGF-I stimulates cartilage proliferation&lt;/li&gt;&lt;li&gt;Affects growth plate long bones&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Requires adequate caloric intake and &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Pharm/Vitamins/VtmnD.htm" class="LinkPage"&gt;Vitamin D&lt;/a&gt; (ingested or produced)&lt;ol&gt;&lt;li&gt;Metabolized in liver and &lt;a href="../../Renal/Anatomy/RnlAntmy.htm" class="LinkPage"&gt;Kidney&lt;/a&gt; to active form&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Sex Hormones&lt;ol&gt;&lt;li&gt;Initially stimulate growth&lt;/li&gt;&lt;li&gt;Later halt growth&lt;ol&gt;&lt;li&gt;Fuses epiphysis to diaphysis of long bones&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Physiology: Genetic factors related to growth&lt;ol&gt;&lt;li&gt;Chromosomal abnormalities&lt;/li&gt;&lt;li&gt;Osteochondrodystophies&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Exam/GrwthPhyslgy.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Growth Physiology</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Exam/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees></FP_UMLS_Trees><FP_Condition_name_check></FP_Condition_name_check><FP_Condition_name><value>Ideal Weight in Adults</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Examination</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;See Also&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Exam/WghtMsrmntInChldrn.htm" class="LinkPage"&gt;Weight Measurement in Children&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Exam/BdyMsIndx.htm" class="LinkPage"&gt;Body Mass Index&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Calculation: Male&lt;ol&gt;&lt;li&gt;Ideal Weight&lt;ol&gt;&lt;li&gt;Weight = 50 + 2.3 x (height in inches - 60)&lt;/li&gt;&lt;li&gt;Weight = 50 + 0.91 x (height in centimeters - 152.4)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Lean Body Mass&lt;ol&gt;&lt;li&gt;Weight = (1.10 x WtKg)-128x(WtKg^2)/(100 x Htm^2)&lt;/li&gt;&lt;li&gt;Where WtKg: Weight in Kg, and HtM: Height in meters&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Calculations: Female&lt;ol&gt;&lt;li&gt;Ideal Weight&lt;ol&gt;&lt;li&gt;Weight = 45 + 2.3 x (height in inches - 60)&lt;/li&gt;&lt;li&gt;Weight = 45.5 + 0.91 x (height in centimeter - 152.4)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Lean Body Mass&lt;ol&gt;&lt;li&gt;Weight = (1.07 x WtKg)-148x(WtKg^2)/(100 x Htm^2)&lt;/li&gt;&lt;li&gt;Where WtKg: Weight in Kg, and HtM: Height in meters&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Approximate Predicted Weight estimate&lt;ol&gt;&lt;li&gt;Male: 106 + (height in inches over 60) x 6&lt;/li&gt;&lt;li&gt;Female: 100 + (height in inches over 60) x 5&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Exam/IdlWghtInAdlts.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Ideal Weight in Adults, Ideal Weight, Predicted Weight, Lean Body Mass, Lean Body Weight</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Exam/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees></FP_UMLS_Trees><FP_Condition_name_check></FP_Condition_name_check><FP_Condition_name><value>Arm Span</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Examination</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Indication&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Growth/GrwthAssmnt.htm" class="LinkPage"&gt;Growth Assessment&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Measurement&lt;ol&gt;&lt;li&gt;Extend both hands outward (each arm abducted to 90)&lt;/li&gt;&lt;li&gt;Measure finger tip to Finger tip&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Normal results&lt;ol&gt;&lt;li&gt;Children: Arm Span is 1 cm shorter than height&lt;/li&gt;&lt;li&gt;Adolescent: Arm Span is same length as height&lt;/li&gt;&lt;li&gt;Adult: Arm Span exceeds height by more than 5 cm&lt;/li&gt;&lt;li&gt;Longer Arm Spans&lt;ol&gt;&lt;li&gt;Boys&lt;/li&gt;&lt;li&gt;African american descent&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Exam/ArmSpn.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Arm Span</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Exam/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees></FP_UMLS_Trees><FP_Condition_name_check></FP_Condition_name_check><FP_Condition_name><value>Height Measurement in Children</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Examination</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;See Also&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Exam/WghtMsrmntInChldrn.htm" class="LinkPage"&gt;Weight Measurement in Children&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Growth/GrwthAssmnt.htm" class="LinkPage"&gt;Growth Assessment&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Physiology&lt;ol&gt;&lt;li&gt;Birth length reflects maternal genetics and nutrition&lt;/li&gt;&lt;li&gt;Age 6-18 month length reflects paternal genetics&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Technique: Accurate length measurement&lt;ol&gt;&lt;li&gt;Precaution: Do not plot standing height on a supine chart (birth to 3 years)&lt;ol&gt;&lt;li&gt;Standing height is always shorter than supine height&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Measure horizontally (lying) if child under age 2 years&lt;/li&gt;&lt;li&gt;Measure vertically (standing) if child older than 2 years old&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Interpretation&lt;ol&gt;&lt;li&gt;Age &amp;lt;2 years&lt;ol&gt;&lt;li&gt;Shifts across height growth chart lines are normal&lt;/li&gt;&lt;li&gt;Reflects shift from maternal to paternal genetics&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Age 2-13 years&lt;ol&gt;&lt;li&gt;Shifts across 2 growth chart lines are abnormal&lt;/li&gt;&lt;li&gt;Growth should at least parallel the 3rd percentile line&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Exam: Normal Height increases per year (&lt;a href="../../Endo/Exam/LnrGrwthVlcty.htm" class="LinkPage"&gt;Linear Growth Velocity&lt;/a&gt;)&lt;ol&gt;&lt;li&gt;Birth length&lt;ol&gt;&lt;li&gt;Average: birth length: 20 inches (50 cm)&lt;/li&gt;&lt;li&gt;Length doubles by age 4 years&lt;/li&gt;&lt;li&gt;Length triples by age 13 years&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;First year growth: 9-11 inches (23-27 cm)&lt;/li&gt;&lt;li&gt;Second year growth: 4-6 inches (10-14 cm)&lt;/li&gt;&lt;li&gt;Third year growth: 3-4 inches (7.5 - 10 cm)&lt;/li&gt;&lt;li&gt;Annual growth until &lt;a href="../../Endo/Exam/SxlDvlpmnt.htm" class="LinkPage"&gt;Puberty&lt;/a&gt;: 2-3 inches (6-7 cm)&lt;/li&gt;&lt;li&gt;Prepuberty growth: 2 inches (5 cm)&lt;/li&gt;&lt;li&gt;Pubertal growth&lt;ol&gt;&lt;li&gt;Boys: 4-6 inches (10-14 cm)&lt;/li&gt;&lt;li&gt;Girls: 3-5 inches (8-12 cm)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Normal Heights for boys (range: 3% to 97%)&lt;ol&gt;&lt;li&gt;Age 1 year: 28-32 inches, mean: 76 cm (30 in)&lt;/li&gt;&lt;li&gt;Age 2 years: 33-37 inches, mean: 88 cm (35 in)&lt;/li&gt;&lt;li&gt;Age 3 years: 36-41 inches, mean: 95 cm (38 in)&lt;/li&gt;&lt;li&gt;Age 4 years: 38-44 inches, mean: 103 cm (41 in)&lt;/li&gt;&lt;li&gt;Age 5 years: 40-47 inches, mean: 110 cm (44 in)&lt;/li&gt;&lt;li&gt;Age 6 years: 43-50 inches, mean: 116 cm (46 in)&lt;/li&gt;&lt;li&gt;Age 7 years: 45-53 inches, mean: 121 cm (48 in)&lt;/li&gt;&lt;li&gt;Age 8 years: 47-55 inches, mean: 127 cm (51 in)&lt;/li&gt;&lt;li&gt;Age 9 years: 49-57 inches, mean: 132 cm (53 in)&lt;/li&gt;&lt;li&gt;Age 10 years: 51-59 inches, mean: 137 cm (55 in)&lt;/li&gt;&lt;li&gt;Age 11 years: 53-61 inches, mean: 143 cm (57 in)&lt;/li&gt;&lt;li&gt;Age 12 years: 54-64 inches, mean: 150 cm (60 in)&lt;/li&gt;&lt;li&gt;Age 13 years: 56-67 inches, mean: 156 cm (62 in)&lt;/li&gt;&lt;li&gt;Age 14 years: 57-70 inches, mean: 163 cm (65 in)&lt;/li&gt;&lt;li&gt;Age 15 years: 60-72 inches, mean: 169 cm (68 in)&lt;/li&gt;&lt;li&gt;Age 16 years: 62-73 inches, mean: 173 cm (69 in)&lt;/li&gt;&lt;li&gt;Age 17 years: 63-74 inches, mean: 68 inches&lt;/li&gt;&lt;li&gt;Age 18 years: 177 cm (71 in)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Normal Height for Girls (range: 3% to 97%)&lt;ol&gt;&lt;li&gt;Birth: 18.5-21.1 inches, mean: 50 cm (20 in)&lt;/li&gt;&lt;li&gt;Age 1 years: 27-31 inches, mean: 73 cm (29 in)&lt;/li&gt;&lt;li&gt;Age 2 years: 32-37 inches, mean: 85 cm (34 in)&lt;/li&gt;&lt;li&gt;Age 3 years: 35-40 inches, mean: 95 cm (38 in)&lt;/li&gt;&lt;li&gt;Age 4 years: 38-44 inches, mean: 103 cm (41 in)&lt;/li&gt;&lt;li&gt;Age 5 years: 40-47 inches, mean: 108 cm (43 in)&lt;/li&gt;&lt;li&gt;Age 6 years: 43-49 inches, mean: 115 cm (46 in)&lt;/li&gt;&lt;li&gt;Age 7 years: 45-52 inches, mean: 120 cm (48 in)&lt;/li&gt;&lt;li&gt;Age 8 years: 47-54 inches, mean: 125 cm (50 in)&lt;/li&gt;&lt;li&gt;Age 9 years: 49-56 inches, mean: 130 cm (52 in)&lt;/li&gt;&lt;li&gt;Age 10 years: 50-59 inches, mean: 138 cm (55 in)&lt;/li&gt;&lt;li&gt;Age 11 years: 52-62 inches, mean: 143 cm (57 in)&lt;/li&gt;&lt;li&gt;Age 12 years: 54-65 inches, mean: 150 cm (60 in)&lt;/li&gt;&lt;li&gt;Age 13 years: 57-66 inches, mean: 155 cm (62 in)&lt;/li&gt;&lt;li&gt;Age 14 years: 58-67 inches, mean: 158 cm (63 in)&lt;/li&gt;&lt;li&gt;Age 15 years: 59-68 inches, mean: 158 cm (63 in)&lt;/li&gt;&lt;li&gt;Age 16 years: 59-68 inches, mean: 159 cm (64 in)&lt;/li&gt;&lt;li&gt;Age 17 years: 60-68 inches, mean: 160 cm (64 in)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Exam/HghtMsrmntInChldrn.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Height Measurement in Children, Length Measurement in Children</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Exam/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees></FP_UMLS_Trees><FP_Condition_name_check></FP_Condition_name_check><FP_Condition_name><value>Sitting Height</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Examination</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Indications&lt;ol&gt;&lt;li&gt;Growth velocity to determine growth spurt&lt;/li&gt;&lt;li&gt;Used in &lt;a href="../../Ortho/T-Spine/Scls.htm" class="LinkPage"&gt;Scoliosis&lt;/a&gt; assessment&lt;/li&gt;&lt;li&gt;Alternative to the &lt;a href="../../Endo/Exam/UprTLwrSgmntRt.htm" class="LinkPage"&gt;Upper to Lower Segment Ratio&lt;/a&gt; in Growth Delay evaluation&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Technique&lt;ol&gt;&lt;li&gt;Measure standing height&lt;/li&gt;&lt;li&gt;Measure Sitting Height&lt;ol&gt;&lt;li&gt;Measure height in standard chair&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Determine Truncal Height (upper segment height)&lt;ol&gt;&lt;li&gt;Subtract height of seat from Sitting Height&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Determine leg height (lower segment height)&lt;ol&gt;&lt;li&gt;Subtract Truncal Height (upper segment height) from standing height&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Interpretation: &lt;a href="../../Ortho/T-Spine/Scls.htm" class="LinkPage"&gt;Scoliosis&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Measure every 3-4 months during expected growth spurt&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Interpretation: Growth Delay Evaluation&lt;ol&gt;&lt;li&gt;Use truncal to leg heights calculated above in the &lt;a href="../../Endo/Exam/UprTLwrSgmntRt.htm" class="LinkPage"&gt;Upper to Lower Segment Ratio&lt;/a&gt; calculation&lt;/li&gt;&lt;li&gt;This may be more accurate than the method described in &lt;a href="../../Endo/Exam/UprTLwrSgmntRt.htm" class="LinkPage"&gt;Upper to Lower Segment Ratio&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Exam/StngHght.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Sitting Height, Truncal Height</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Exam/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees></FP_UMLS_Trees><FP_Condition_name_check></FP_Condition_name_check><FP_Condition_name><value>Dysmorphic features in Congenital Dysorders</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Examination</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Findings: Body Habitus&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Obesity/Obsty.htm" class="LinkPage"&gt;Obesity&lt;/a&gt; in &lt;a href="../../Endo/Peds/PrdrWlSyndrm.htm" class="LinkPage"&gt;Prader-Willi Syndrome&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Short and stocky girl in Turner Syndrome&lt;/li&gt;&lt;li&gt;Newborn macrosomia in Beckwith-Wiedemann Syndrome&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Findings: &lt;a href="../../Endo/Growth/ShrtStr.htm" class="LinkPage"&gt;Short Stature&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../Neuro/Disability/DwnSyndrm.htm" class="LinkPage"&gt;Down Syndrome&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Noonan Syndrome&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Peds/PrdrWlSyndrm.htm" class="LinkPage"&gt;Prader-Willi Syndrome&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Russell-Silver Syndrome&lt;/li&gt;&lt;li&gt;Skeletal Dysplasia&lt;/li&gt;&lt;li&gt;Turner Syndrome&lt;/li&gt;&lt;li&gt;&lt;a href="../../Neuro/Disability/FtlAlchlSyndrm.htm" class="LinkPage"&gt;Fetal Alcohol Syndrome&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Gluten-sensitive &lt;a href="../../GI/IBD/IntstnlEntrpthy.htm" class="LinkPage"&gt;Enteropathy&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Lung/Peds/CystcFbrs.htm" class="LinkPage"&gt;Cystic Fibrosis&lt;/a&gt; (typically age &amp;lt;2 at diagnosis)&lt;/li&gt;&lt;li&gt;Cushing Disease&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/HmnGrwthHrmn.htm" class="LinkPage"&gt;Growth Hormone&lt;/a&gt; deficiency&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/Hypthyrdsm.htm" class="LinkPage"&gt;Hypothyroidism&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Pharm/Vitamins/VtmnDDfcncy.htm" class="LinkPage"&gt;Vitamin D Deficiency&lt;/a&gt; (&lt;a href="../../Rheum/Peds/Rckts1.htm" class="LinkPage"&gt;Rickets&lt;/a&gt;)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Findings: &lt;a href="../../Endo/Growth/TlStr.htm" class="LinkPage"&gt;Tall Stature&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/HmnGrwthHrmn.htm" class="LinkPage"&gt;Growth Hormone&lt;/a&gt; secreting tumors (&lt;a href="../../Endo/Pituitary/Ggntsm.htm" class="LinkPage"&gt;Gigantism&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/Hyprthyrdsm1.htm" class="LinkPage"&gt;Thyrotoxicosis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Growth/MrfnsSyndrm.htm" class="LinkPage"&gt;Marfan Syndrome&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Metabolism/Hmcystnr.htm" class="LinkPage"&gt;Homocystinuria&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Growth/CrbrlGgntsm.htm" class="LinkPage"&gt;Cerebral Gigantism&lt;/a&gt; (&lt;a href="../../Endo/Growth/CrbrlGgntsm.htm" class="LinkPage"&gt;Soto Syndrome&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;Beckwith-Wiedemann Syndrome&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Adrenal/CngntlAdrnlHyprpls.htm" class="LinkPage"&gt;Congenital Adrenal Hyperplasia&lt;/a&gt; (Untreated, pubertal)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Sex/KlnfltrSyndrm.htm" class="LinkPage"&gt;Klinefelter Syndrome&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Obesity/Obsty.htm" class="LinkPage"&gt;Obesity&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Sex/PrcsPbrty.htm" class="LinkPage"&gt;Precocious Puberty&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Findings: &lt;a href="../../Neuro/Anatomy/SklAntmy.htm" class="LinkPage"&gt;Skull&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../NICU/Neuro/Crnsynsts.htm" class="LinkPage"&gt;Craniosynostosis&lt;/a&gt; in Skeletal Dysplasia&lt;/li&gt;&lt;li&gt;&lt;a href="../../Rheum/Exam/Crntbs.htm" class="LinkPage"&gt;Craniotabes&lt;/a&gt; (softening of posterior skull bone, ping-ping ball feel)&lt;ol&gt;&lt;li&gt;&lt;a href="../../Pharm/Vitamins/VtmnDDfcncy.htm" class="LinkPage"&gt;Vitamin D Deficiency&lt;/a&gt; (&lt;a href="../../Rheum/Peds/Rckts1.htm" class="LinkPage"&gt;Rickets&lt;/a&gt;)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Frontal bossing (prominent frontal forehead) in Sotos Syndrome&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Findings: Head&lt;ol&gt;&lt;li&gt;Disproportionately large head in Skeletal Dysplasia&lt;/li&gt;&lt;li&gt;Low posterior hairline in Turner Syndrome&lt;/li&gt;&lt;li&gt;&lt;a href="../../NICU/Exam/HdCrcmfrnc.htm" class="LinkPage"&gt;Microcephaly&lt;/a&gt; in &lt;a href="../../Neuro/Disability/FtlAlchlSyndrm.htm" class="LinkPage"&gt;Fetal Alcohol Syndrome&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Findings: Ears&lt;ol&gt;&lt;li&gt;Dysplastic or folded in &lt;a href="../../Neuro/Disability/DwnSyndrm.htm" class="LinkPage"&gt;Down Syndrome&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Low set in Noonan Syndrome&lt;/li&gt;&lt;li&gt;Thick helix in Noonan Syndrome&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Findings: Face&lt;ol&gt;&lt;li&gt;Triangular-shaped face in Noonan syndrome, Russell-Silver Syndrome&lt;/li&gt;&lt;li&gt;Midface hypoplasia in hypopituitarism&lt;/li&gt;&lt;li&gt;Moon facies in Cushing Syndrome&lt;/li&gt;&lt;li&gt;Craniofacial abnormalities in Weaver Syndrome&lt;/li&gt;&lt;li&gt;Facial &lt;a href="../../Gyn/Sx/VsmtrSymptmsOfMnps.htm" class="LinkPage"&gt;Flushing&lt;/a&gt; in Sotos Syndrome&lt;/li&gt;&lt;li&gt;Long narrow face in Sotos Syndrome&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Findings: Eyes&lt;ol&gt;&lt;li&gt;Palpebral fissures (distance between upper and lower &lt;a href="../../Eye/Anatomy/LdAntmy.htm" class="LinkPage"&gt;Eyelid&lt;/a&gt;s)&lt;ol&gt;&lt;li&gt;Upward slanted in &lt;a href="../../Neuro/Disability/DwnSyndrm.htm" class="LinkPage"&gt;Down Syndrome&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Downward slanted in Noonan Syndrome, Sotos Syndrome&lt;/li&gt;&lt;li&gt;Narrow in &lt;a href="../../Neuro/Disability/FtlAlchlSyndrm.htm" class="LinkPage"&gt;Fetal Alcohol Syndrome&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Epicanthal folds&lt;ol&gt;&lt;li&gt;Normal in some ethnicity (e.g. asian descent)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Neuro/Disability/FtlAlchlSyndrm.htm" class="LinkPage"&gt;Fetal Alcohol Syndrome&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Eye/Lid/Pts.htm" class="LinkPage"&gt;Ptosis&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Noonan Syndrome&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Eye/Exam/Sclr.htm" class="LinkPage"&gt;Sclera&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Blue &lt;a href="../../Eye/Exam/Sclr.htm" class="LinkPage"&gt;Sclera&lt;/a&gt; in Russell-Silver Syndrome&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Eye/Peds/CngntlCtrct.htm" class="LinkPage"&gt;Congenital Cataract&lt;/a&gt;s in Skeletal Dysplasia&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Findings: Nose&lt;ol&gt;&lt;li&gt;Flat nasal bridge in &lt;a href="../../Neuro/Disability/DwnSyndrm.htm" class="LinkPage"&gt;Down Syndrome&lt;/a&gt;, &lt;a href="../../Neuro/Disability/FtlAlchlSyndrm.htm" class="LinkPage"&gt;Fetal Alcohol Syndrome&lt;/a&gt;&lt;/li&gt;&lt;li&gt;High or prominent nasal bridge in Noonan Syndrome, Russell-Silver Syndrome&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Findings: Mouth&lt;ol&gt;&lt;li&gt;Downward turned in Russell-Silver Syndrome&lt;/li&gt;&lt;li&gt;Thin upper lip in &lt;a href="../../Neuro/Disability/FtlAlchlSyndrm.htm" class="LinkPage"&gt;Fetal Alcohol Syndrome&lt;/a&gt;&lt;/li&gt;&lt;li&gt;High arched &lt;a href="../../Dental/Anatomy/PltAntmy.htm" class="LinkPage"&gt;Palate&lt;/a&gt; in Turner Syndrome&lt;/li&gt;&lt;li&gt;Smooth philtrum (depression between nose and mouth) in &lt;a href="../../Neuro/Disability/FtlAlchlSyndrm.htm" class="LinkPage"&gt;Fetal Alcohol Syndrome&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../ENT/Sx/TngEnlrgmnt.htm" class="LinkPage"&gt;Macroglossia&lt;/a&gt; in Beckwith-Wiedemann Syndrome&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Findings: Jaw&lt;ol&gt;&lt;li&gt;Micrognathia in Russell-Silver Syndrome&lt;/li&gt;&lt;li&gt;Prominent, narrow jaw in Sotos Syndrome&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Findings: Neck&lt;ol&gt;&lt;li&gt;Webbed neck in Turner Syndrome&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Findings: Long bones&lt;ol&gt;&lt;li&gt;&lt;a href="../../Ortho/Fracture/Frctr.htm" class="LinkPage"&gt;Fracture&lt;/a&gt;s in Skeletal Dysplasia&lt;/li&gt;&lt;li&gt;Extremity bowing in &lt;a href="../../Rheum/Peds/Rckts1.htm" class="LinkPage"&gt;Rickets&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Findings: Arms&lt;ol&gt;&lt;li&gt;Increased &lt;a href="../../Endo/Exam/ArmSpn.htm" class="LinkPage"&gt;Arm Span&lt;/a&gt; in &lt;a href="../../Endo/Sex/KlnfltrSyndrm.htm" class="LinkPage"&gt;Klinefelter Syndrome&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Findings: Hands&lt;ol&gt;&lt;li&gt;Bulbous wrists in &lt;a href="../../Rheum/Peds/Rckts1.htm" class="LinkPage"&gt;Rickets&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Transverse palmar crease (simian crease) in &lt;a href="../../Neuro/Disability/DwnSyndrm.htm" class="LinkPage"&gt;Down Syndrome&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Short &lt;a href="../../Ortho/Anatomy/MtcrplBn.htm" class="LinkPage"&gt;Fourth Metacarpal&lt;/a&gt; in Turner Syndrome&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Findings: Nails&lt;ol&gt;&lt;li&gt;Hypoplastic nails in Skeletal Dysplasia&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Findings: Feet&lt;ol&gt;&lt;li&gt;&lt;a href="../../Ortho/Peds/Clbft.htm" class="LinkPage"&gt;Clubfoot&lt;/a&gt; in Skeletal Dysplasia&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Findings: &lt;a href="../../Lung/Anatomy/ChstAntmy.htm" class="LinkPage"&gt;Chest&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../Lung/Exam/PctsExcvtm.htm" class="LinkPage"&gt;Pectus Excavatum&lt;/a&gt; in Noonan Syndrome&lt;/li&gt;&lt;li&gt;Shield-shaped chest in Turner Syndrome&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Findings: &lt;a href="../../GI/Anatomy/AbdmnlAntmy.htm" class="LinkPage"&gt;Abdomen&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Violaceous striae in Cushing Syndrome&lt;/li&gt;&lt;li&gt;&lt;a href="../../NICU/Surgery/Omphlcl.htm" class="LinkPage"&gt;Omphalocele&lt;/a&gt; in Beckwith-Wiedemann Syndrome&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Findings: &lt;a href="../../Gyn/Anatomy/BrstAntmy.htm" class="LinkPage"&gt;Breast&lt;/a&gt;s&lt;ol&gt;&lt;li&gt;Widely-spaced nipples in Turner Syndrome&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Findings: Genitourinary&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Sex/Hypgndsm.htm" class="LinkPage"&gt;Hypogonadism&lt;/a&gt; in &lt;a href="../../Endo/Peds/PrdrWlSyndrm.htm" class="LinkPage"&gt;Prader-Willi Syndrome&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Micropenis in hypopituitarism&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Findings: Endocrine&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Hypoglycemia/Hypglycm.htm" class="LinkPage"&gt;Hypoglycemia&lt;/a&gt; in Beckwith-Wiedemann Syndrome&lt;/li&gt;&lt;li&gt;Feminization&lt;ol&gt;&lt;li&gt;Sparse facial and body hair in &lt;a href="../../Endo/Sex/KlnfltrSyndrm.htm" class="LinkPage"&gt;Klinefelter Syndrome&lt;/a&gt;&lt;/li&gt;&lt;li&gt;High pitched voice in &lt;a href="../../Endo/Sex/KlnfltrSyndrm.htm" class="LinkPage"&gt;Klinefelter Syndrome&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Exam/DysmrphcFtrsInCngntlDysrdrs.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Dysmorphic features in Congenital Dysorders</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Exam/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees></FP_UMLS_Trees><FP_Condition_name_check></FP_Condition_name_check><FP_Condition_name><value>Midparental Height</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Examination</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;See Also&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Growth/GrwthAssmnt.htm" class="LinkPage"&gt;Growth Assessment&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Peds/FlrTThrv.htm" class="LinkPage"&gt;Failure to Thrive&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Growth/ShrtStr.htm" class="LinkPage"&gt;Short Stature&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Growth/TlStr.htm" class="LinkPage"&gt;Tall Stature&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Step 1: Calculate Final Height prediction (mid-parental height)&lt;ol&gt;&lt;li&gt;Boy&lt;ol&gt;&lt;li&gt;In: (Father's Height + Mother's Height + 5) / 2&lt;/li&gt;&lt;li&gt;Cm: (Father's Height + Mother's Height + 13) / 2&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Girl&lt;ol&gt;&lt;li&gt;In: (Father's Height - 5 + Mother's Height) / 2&lt;/li&gt;&lt;li&gt;Cm: (Father's Height - 13 + Mother's Height) / 2&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Step 2: Identify Predicted Growth Percentile&lt;ol&gt;&lt;li&gt;Use above predicted mean height to mark growth chart&lt;ol&gt;&lt;li&gt;Mark chart at 18-20 year old mark&lt;/li&gt;&lt;li&gt;Mark &lt;a href="../../Prevent/Epi/StstclSgnfcnc.htm" class="LinkPage"&gt;Confidence Interval&lt;/a&gt;s&lt;ol&gt;&lt;li&gt;Mean Height in inches +/- 2 inches (some use 3.3 inches)&lt;/li&gt;&lt;li&gt;Mean Height in centimeters +/- 5 centimeters (some use 8.3 cm)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Identify growth percentiles for the predicted height&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Step 3: Indications for growth evaluation&lt;ol&gt;&lt;li&gt;Child over age 24 months should fall into above percentiles&lt;ol&gt;&lt;li&gt;Growth should at least parallel the 3rd or 97th percentile line&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Pursue growth evaluation for any child below minimum or above maximum&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Exam/MdprntlHght.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Midparental Height, Calculation of Growth Delay, Calculation of Growth Excess</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Exam/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees></FP_UMLS_Trees><FP_Condition_name_check></FP_Condition_name_check><FP_Condition_name><value>Gestational Diabetes Perinatal Mortality</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Obstetrics</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Epidemiology&lt;ol&gt;&lt;li&gt;Overall Gestation Diabetes Perinatal Mortality: 16.3%&lt;/li&gt;&lt;li&gt;Gestational DKA confers 50-80% perinatal mortality&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;
              &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; Control related to perinatal mortality&lt;ol&gt;&lt;li&gt;American Study (1972)&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; &amp;lt;100: Perinatal mortality 3.4%&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; 101-150: Perinatal mortality 16%&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; &amp;gt;150: Perinatal mortality 24%&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;British Study (1965)&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; &amp;lt;150: Perinatal mortality 7.6%&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; 151-200: Perinatal mortality 21%&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; &amp;gt;200: Perinatal mortality 38%&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;White's Classification of Diabetes (Mortality 1946-72)&lt;ol&gt;&lt;li&gt;Class A (5% Mortality)&lt;ol&gt;&lt;li&gt;Definition&lt;ol&gt;&lt;li&gt;Abnormal &lt;a href="../../Endo/Lab/GlcsTlrncTst3Hr.htm" class="LinkPage"&gt;Glucose Tolerance Test&lt;/a&gt;&lt;/li&gt;&lt;li&gt;No clinical signs of &lt;a href="../../Endo/DM/DbtsMlts.htm" class="LinkPage"&gt;Diabetes Mellitus&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Sub-classification&lt;ol&gt;&lt;li&gt;A1 Diabetic: diet controlled&lt;/li&gt;&lt;li&gt;A2 Diabetic: &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; controlled&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Class B (13.9% Mortality)&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/DM/DbtsMlts.htm" class="LinkPage"&gt;Diabetes Mellitus&lt;/a&gt; diagnosed after age 20 years or&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/DM/DbtsMlts.htm" class="LinkPage"&gt;Diabetes Mellitus&lt;/a&gt; present less than 10 years and&lt;/li&gt;&lt;li&gt;No &lt;a href="../../Surgery/CV/PrphrlArtrlOclsvDs.htm" class="LinkPage"&gt;Peripheral Vascular Disease&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Class C (18.1% Mortality)&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/DM/DbtsMlts.htm" class="LinkPage"&gt;Diabetes Mellitus&lt;/a&gt; diagnosed age 10 to 19 years or&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/DM/DbtsMlts.htm" class="LinkPage"&gt;Diabetes Mellitus&lt;/a&gt; present 10-19 years and&lt;/li&gt;&lt;li&gt;No &lt;a href="../../Surgery/CV/PrphrlArtrlOclsvDs.htm" class="LinkPage"&gt;Peripheral Vascular Disease&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Class D (17.9% Mortality)&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/DM/DbtsMlts.htm" class="LinkPage"&gt;Diabetes Mellitus&lt;/a&gt; diagnosed under age 10 years or&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/DM/DbtsMlts.htm" class="LinkPage"&gt;Diabetes Mellitus&lt;/a&gt; present more than 20 years or&lt;/li&gt;&lt;li&gt;&lt;a href="../../Surgery/CV/PrphrlArtrlOclsvDs.htm" class="LinkPage"&gt;Peripheral Vascular Disease&lt;/a&gt; or&lt;/li&gt;&lt;li&gt;Retinopthy&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Class F (35.4% Mortality)&lt;ol&gt;&lt;li&gt;Nephropathy&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Class H&lt;ol&gt;&lt;li&gt;Cardiac Disease&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Class R&lt;ol&gt;&lt;li&gt;Proliferative Retinopathy&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Class T&lt;ol&gt;&lt;li&gt;History of Transplant&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/OB/GstnlDbtsPrntlMrtlty.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Gestational Diabetes Perinatal Mortality</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/OB/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees></FP_UMLS_Trees><FP_Condition_name_check></FP_Condition_name_check><FP_Condition_name><value>Gestational Diabetes Management</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Obstetrics</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Indications: &lt;a href="../../Endo/OB/GstnlDbts.htm" class="LinkPage"&gt;Gestational Diabetes&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Abnormal &lt;a href="../../Endo/Lab/GlcsTlrncTst3Hr.htm" class="LinkPage"&gt;Glucose Tolerance Test 3 hour&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Preexisting &lt;a href="../../Endo/DM/DbtsMlts.htm" class="LinkPage"&gt;Diabetes Mellitus&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Monitoring: &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Glucose&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Frequency of &lt;a href="../../Endo/DM/DbtsMltsGlcsMngmnt.htm" class="LinkPage"&gt;Blood Glucose Monitoring&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; therapy: qid &lt;a href="../../Endo/DM/DbtsMltsGlcsMngmnt.htm" class="LinkPage"&gt;Blood Sugar Monitoring&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Diet control: 4 &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Sugar&lt;/a&gt;s on 2 days per week&lt;ol&gt;&lt;li&gt;Increase monitoring if 2 values/week abnormal&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Target Levels&lt;ol&gt;&lt;li&gt;Before Breakfast or early morning (2-6 am): 60 to 96 mg/dl&lt;/li&gt;&lt;li&gt;Before Lunch,Dinner: 60 to 115 mg/dl&lt;/li&gt;&lt;li&gt;One hour post prandial goal: under 140 mg/dl&lt;/li&gt;&lt;li&gt;Two hour post prandial goal: under 120 mg/dl&lt;/li&gt;&lt;li&gt;Check &lt;a href="../../Uro/Lab/UrnKtn.htm" class="LinkPage"&gt;Urine Ketone&lt;/a&gt;s in early morning&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Preferred monitoring: Postprandial &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Glucose&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Post-prandial &lt;a href="../../Endo/DM/DbtsMltsGlcsMngmnt.htm" class="LinkPage"&gt;Blood Glucose Monitoring&lt;/a&gt; preferred&lt;/li&gt;&lt;li&gt;Associated with improved outcomes&lt;ol&gt;&lt;li&gt;Lower &lt;a href="../../Endo/Lab/HmglbnAc.htm" class="LinkPage"&gt;Hemoglobin A1C&lt;/a&gt; levels&lt;/li&gt;&lt;li&gt;Lower birth weights&lt;/li&gt;&lt;li&gt;Fewer cesarean sections&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;References&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=De%20Veciana%20%20%5BAU%5D%20AND%201995%20%5BDP%5D%20AND%20%20N%20Engl%20J%20Med%20%20%5BTA%5D" class="LinkRef"&gt;De Veciana (1995) N Engl J Med 333:1237-41&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Evaluation: Initial&lt;ol&gt;&lt;li&gt;Diabetic diet&lt;/li&gt;&lt;li&gt;Diabetic nurse consultation&lt;/li&gt;&lt;li&gt;Initiate home &lt;a href="../../Endo/DM/DbtsMltsGlcsMngmnt.htm" class="LinkPage"&gt;Blood Sugar Monitoring&lt;/a&gt;&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Endo/DM/DbtsMltsGlcsMngmnt.htm" class="LinkPage"&gt;Blood Glucose Monitoring&lt;/a&gt; above&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Management: Diet controlled management&lt;ol&gt;&lt;li&gt;Indications&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Sugar&lt;/a&gt;s within target range (see above)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Monitoring&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Endo/DM/DbtsMltsGlcsMngmnt.htm" class="LinkPage"&gt;Blood Glucose Monitoring&lt;/a&gt; above&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Dietary recommendations&lt;ol&gt;&lt;li&gt;Restrict carbohydrates to &amp;lt;40% of daily calories&lt;/li&gt;&lt;li&gt;Caloric restriction if BMI &amp;gt; 30 kg/m2&lt;ol&gt;&lt;li&gt;Limit to 25 KCal/kg of actual weight per day&lt;/li&gt;&lt;li&gt;Avoid severe caloric restriction&lt;ol&gt;&lt;li&gt;Ketonemia associated with psychomotor delay&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Rizzo%20%20%5BAU%5D%20AND%201995%20%5BDP%5D%20AND%20%20Am%20J%20Obstet%20Gynecol%20%20%5BTA%5D" class="LinkRef"&gt;Rizzo (1995) Am J Obstet Gynecol 173:1753-8&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Sports/Exercise/Exrcs.htm" class="LinkPage"&gt;Exercise&lt;/a&gt; recommendations&lt;ol&gt;&lt;li&gt;Regular aerobic &lt;a href="../../Sports/Exercise/Exrcs.htm" class="LinkPage"&gt;Exercise&lt;/a&gt; improves glycemic control&lt;/li&gt;&lt;li&gt;Circuit &lt;a href="../../Sports/Exercise/StrngthTrng.htm" class="LinkPage"&gt;Resistance Training&lt;/a&gt; improves glycemic control&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Brankston%20%20%5BAU%5D%20AND%202004%20%5BDP%5D%20AND%20%20Am%20J%20Obstet%20%20%5BTA%5D" class="LinkRef"&gt;Brankston (2004) Am J Obstet 190:188-93&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Management: &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Indications&lt;ol&gt;&lt;li&gt;Failed diet control (see above)&lt;ol&gt;&lt;li&gt;Fasting &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Glucose&lt;/a&gt; &amp;gt; 95 mg/dl or&lt;/li&gt;&lt;li&gt;Two hour postprandial &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Glucose&lt;/a&gt; &amp;gt;120 mg/dl&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Preexisting &lt;a href="../../Endo/DM/TypDbtsMlts.htm" class="LinkPage"&gt;Insulin Dependent Diabetes Mellitus&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Protocol&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Endo/OB/GstnlDbtsInslnMngmnt.htm" class="LinkPage"&gt;Insulin Management in Pregnancy&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Endocrine consult as needed for &lt;a href="../../Endo/Pharm/InslnDsng.htm" class="LinkPage"&gt;Insulin Dosing&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Protocols: Experimental  (not to be used in practice)&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/ScndGnrtnSlfnylr.htm" class="LinkPage"&gt;Glyburide&lt;/a&gt; is only hypoglycemic not contraindicated&lt;ol&gt;&lt;li&gt;ACOG and ADA do not recommend use until further RCT&lt;/li&gt;&lt;li&gt;Unclear whether &lt;a href="../../Endo/Pharm/ScndGnrtnSlfnylr.htm" class="LinkPage"&gt;Glyburide&lt;/a&gt; crosses the placenta&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Jacobson%20%20%5BAU%5D%20AND%202005%20%5BDP%5D%20AND%20%20Am%20J%20Obstet%20Gynecol%20%20%5BTA%5D" class="LinkRef"&gt;Jacobson (2005) Am J Obstet Gynecol 193(1): 118-24&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Glcphg.htm" class="LinkPage"&gt;Glucophage&lt;/a&gt; is also being studied in pregnancy&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Rowan%20%20%5BAU%5D%20AND%202008%20%5BDP%5D%20AND%20%20N%20Engl%20J%20Med%20%20%5BTA%5D" class="LinkRef"&gt;Rowan (2008) N Engl J Med 358(19):2003-15&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Glueck%20%20%5BAU%5D%20AND%202002%20%5BDP%5D%20AND%20%20Hum%20Reprod%20%20%5BTA%5D" class="LinkRef"&gt;Glueck (2002) Hum Reprod 17:2858-64&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Pregnancy in &lt;a href="../../Endo/DM/InslnRstncSyndrm.htm" class="LinkPage"&gt;Metabolic Syndrome&lt;/a&gt; on &lt;a href="../../Endo/Pharm/Glcphg.htm" class="LinkPage"&gt;Metformin&lt;/a&gt;: 42%&lt;ol&gt;&lt;li&gt;If occurs on &lt;a href="../../Endo/Pharm/Glcphg.htm" class="LinkPage"&gt;Metformin&lt;/a&gt;, continue for first 20 weeks&lt;/li&gt;&lt;li&gt;Prevents &lt;a href="../../Endo/Pharm/SmgyPhnmn.htm" class="LinkPage"&gt;Rebound Hyperglycemia&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/ScndGnrtnSlfnylr.htm" class="LinkPage"&gt;Second Generation Sulfonylurea&lt;/a&gt;s experimentally used&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Sugar&lt;/a&gt; controlled as well as &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Markedly reduced &lt;a href="../../Endo/Hypoglycemia/Hypglycm.htm" class="LinkPage"&gt;Hypoglycemia&lt;/a&gt; with &lt;a href="../../Endo/Pharm/OrlHypglycmc.htm" class="LinkPage"&gt;Oral Hypoglycemic&lt;/a&gt;&lt;/li&gt;&lt;li&gt;No increased fetal anomaly or perinatal death&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;References&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Greene%20%20%5BAU%5D%20AND%202000%20%5BDP%5D%20AND%20%20N%20Engl%20J%20Med%20%20%5BTA%5D" class="LinkRef"&gt;Greene (2000) N Engl J Med 343:1178-9&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Langer%20%20%5BAU%5D%20AND%202000%20%5BDP%5D%20AND%20%20N%20Engl%20J%20Med%20%20%5BTA%5D" class="LinkRef"&gt;Langer (2000) N Engl J Med 343:1134-8&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Monitoring: Antepartum aggressive monitoring for complications&lt;ol&gt;&lt;li&gt;Monitoring starting at 32 weeks gestation&lt;ol&gt;&lt;li&gt;Weekly &lt;a href="../../OB/Fetus/NnStrsTst.htm" class="LinkPage"&gt;Non-Stress Test&lt;/a&gt; (biweekly if on &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; or poor control)&lt;/li&gt;&lt;li&gt;Amniotic fluid weekly if on &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; or poor control&lt;/li&gt;&lt;li&gt;Some protocols include &lt;a href="../../OB/Fetus/BphysclPrfl.htm" class="LinkPage"&gt;Biophysical Profile&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Daily &lt;a href="../../OB/Fetus/FtlMvmntCnt.htm" class="LinkPage"&gt;Fetal Kick Count&lt;/a&gt;s starting at 34 weeks gestation&lt;/li&gt;&lt;li&gt;&lt;a href="../../OB/Rad/ObstrcUltrsnd.htm" class="LinkPage"&gt;Obstetric Ultrasound&lt;/a&gt; monthly&lt;ol&gt;&lt;li&gt;Assess &lt;a href="../../OB/Fetus/FtlGrwth.htm" class="LinkPage"&gt;Fetal Growth&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../OB/Exam/RtnObstrcVst.htm" class="LinkPage"&gt;Prenatal Visit&lt;/a&gt; frequency and monitoring based on &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Sugar&lt;/a&gt; control&lt;/li&gt;&lt;li&gt;Plan &lt;a href="../../OB/Ld/LbrIndctn.htm" class="LinkPage"&gt;Labor Induction&lt;/a&gt; by 39-40 weeks&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Management: Intrapartum&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Endo/OB/GstnlDbtsInslnMngmntIntrprtm.htm" class="LinkPage"&gt;Insulin Management in Labor&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Timing of delivery&lt;ol&gt;&lt;li&gt;Consider offering Cesarean section for EFW &amp;gt; 4500 g&lt;/li&gt;&lt;li&gt;Delivery prior to 40 weeks not indicated unless&lt;ol&gt;&lt;li&gt;Poor glycemic control&lt;/li&gt;&lt;li&gt;Other fetal or maternal complications&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Management: Postpartum Care&lt;ol&gt;&lt;li&gt;Consider &lt;a href="../../Endo/Lab/GlcsTlrncTstHr.htm" class="LinkPage"&gt;Glucose Tolerance Test 2 hour&lt;/a&gt; (75 g Glucola)&lt;ol&gt;&lt;li&gt;Non-Lactating: Schedule at 6 weeks to 3 months&lt;/li&gt;&lt;li&gt;&lt;a href="../../OB/Lactation/BrstFdng.htm" class="LinkPage"&gt;Breast Feeding&lt;/a&gt;: Schedule at 6 months&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Maintain ideal body weight&lt;/li&gt;&lt;li&gt;Moderate intensity &lt;a href="../../Sports/Exercise/Exrcs.htm" class="LinkPage"&gt;Exercise&lt;/a&gt; for 150 minutes per week&lt;/li&gt;&lt;li&gt;Fasting &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Glucose&lt;/a&gt; yearly&lt;ol&gt;&lt;li&gt;Risk of developing &lt;a href="../../Endo/DM/TypDbtsMlts1.htm" class="LinkPage"&gt;Type II Diabetes Mellitus&lt;/a&gt; within 10 years: 50%&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Serlin%20%20%5BAU%5D%20AND%202009%20%5BDP%5D%20AND%20%20Am%20Fam%20Physician%20%20%5BTA%5D" class="LinkRef"&gt;Serlin (2009) Am Fam Physician 80(1):57-62&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Turok%20%20%5BAU%5D%20AND%202003%20%5BDP%5D%20AND%20%20Am%20Fam%20Physician%20%20%5BTA%5D" class="LinkRef"&gt;Turok (2003) Am Fam Physician 68(9):1767-72&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/OB/GstnlDbtsMngmnt.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Gestational Diabetes Management</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/OB/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees></FP_UMLS_Trees><FP_Condition_name_check></FP_Condition_name_check><FP_Condition_name><value>Gestational Diabetes Insulin Management</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Obstetrics</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;See Also&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/InslnDsng.htm" class="LinkPage"&gt;Insulin Dosing&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/OB/GstnlDbtsInslnMngmntIntrprtm.htm" class="LinkPage"&gt;Gestational Diabetes Insulin Management Intrapartum&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Indication&lt;ol&gt;&lt;li&gt;Failed Gastational Diabetes Diet Management&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Protocol: Calculate Ideal Body Weight&lt;ol&gt;&lt;li&gt;Start with 100 pounds + 5 pounds per inch over 5 feet&lt;/li&gt;&lt;li&gt;Add 30 pounds for pregnancy&lt;/li&gt;&lt;li&gt;Convert to Kilograms: Pounds / 2.2&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Protocol: Calculate Total Daily Calories&lt;ol&gt;&lt;li&gt;Option 1&lt;ol&gt;&lt;li&gt;Calories/day = &lt;a href="../../Endo/Exam/IdlWghtInAdlts.htm" class="LinkPage"&gt;Ideal Weight&lt;/a&gt; (in kg) x 35 KCal/kg&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Option 2 (if BMI &amp;gt; 30 kg/m2)&lt;ol&gt;&lt;li&gt;Calories/day = actual weight (in kg) x 25 Kcal/kg&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Protocol: Calculate Daily &lt;a href="../../Endo/Pharm/InslnDsng.htm" class="LinkPage"&gt;Insulin Dosing&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; types&lt;ol&gt;&lt;li&gt;Short acting: Regular or &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Lispro&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Long acting: NPH or &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Ultralente&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Note that &lt;a href="../../Endo/Pharm/AnlgBslInsln.htm" class="LinkPage"&gt;Lantus&lt;/a&gt; and &lt;a href="../../Endo/Pharm/AnlgBslInsln.htm" class="LinkPage"&gt;Levemir&lt;/a&gt; are not recommended due to lack of data in pregnancy&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; per day (based on pre-pregnancy weight)&lt;ol&gt;&lt;li&gt;Some providers use start of 0.7 u/kg/day&lt;/li&gt;&lt;li&gt;First half of pregnancy: 0.6 u/kg/day&lt;/li&gt;&lt;li&gt;Second half of pregnancy: 0.9 u/kg/day&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Divide &lt;a href="../../Endo/Pharm/InslnDsng.htm" class="LinkPage"&gt;Insulin Dosing&lt;/a&gt; over course of day&lt;ol&gt;&lt;li&gt;Morning: 2/3 of &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;NPH Insulin&lt;/a&gt;: 2/3&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Regular Insulin&lt;/a&gt;: 1/3&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Evening: 1/3 pf &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;NPH Insulin&lt;/a&gt;: 1/2&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Regular Insulin&lt;/a&gt;: 1/2&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/OB/GstnlDbtsInslnMngmnt.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Gestational Diabetes Insulin Management, Insulin Management in Pregnancy</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/OB/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees></FP_UMLS_Trees><FP_Condition_name_check></FP_Condition_name_check><FP_Condition_name><value>Gestational Diabetes Insulin Management Intrapartum</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Obstetrics</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Indication&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/OB/GstnlDbtsInslnMngmnt.htm" class="LinkPage"&gt;Gestational Diabetes Insulin Management&lt;/a&gt; in Labor&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Preparation of &lt;a href="../../Endo/Pharm/VrblRtInslnInfsn.htm" class="LinkPage"&gt;Insulin Drip&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Dilute 25 units &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Humulin&lt;/a&gt; Regular in 250 cc Normal Saline&lt;/li&gt;&lt;li&gt;Coadminister maintenance fluids at 125 cc/hour&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Monitoring&lt;ol&gt;&lt;li&gt;Intrapartum&lt;ol&gt;&lt;li&gt;Fingerstick &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Sugar&lt;/a&gt; every 1 to 2 hours&lt;/li&gt;&lt;li&gt;Target &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Sugar&lt;/a&gt;s between 80 to 110 mg/dl&lt;/li&gt;&lt;li&gt;Check &lt;a href="../../Uro/Lab/UrnKtn.htm" class="LinkPage"&gt;Urine Ketone&lt;/a&gt;s with each Void&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Postpartum&lt;ol&gt;&lt;li&gt;Discontinue &lt;a href="../../Endo/Pharm/VrblRtInslnInfsn.htm" class="LinkPage"&gt;Insulin Drip&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Check Fingerstick &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Sugar&lt;/a&gt; hourly for 2-4 hours&lt;/li&gt;&lt;li&gt;Fingerstick &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Sugar&lt;/a&gt; before meals and at bedtime&lt;/li&gt;&lt;li&gt;Decrease monitoring to a fasting morning &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Sugar&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;
              &lt;a href="../../Endo/Pharm/VrblRtInslnInfsn.htm" class="LinkPage"&gt;Insulin Drip&lt;/a&gt; Protocol (based on &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Sugar&lt;/a&gt; q1-2 hours)&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Sugar&lt;/a&gt; &amp;lt;100 mg/dl&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/VrblRtInslnInfsn.htm" class="LinkPage"&gt;Insulin Drip&lt;/a&gt; 0.5 units/hour in D5LR or D5NS&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Sugar&lt;/a&gt; 100 to 140 mg/dl&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/VrblRtInslnInfsn.htm" class="LinkPage"&gt;Insulin Drip&lt;/a&gt; 1.0 units/hour in NS&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Sugar&lt;/a&gt; 141 to 180 mg/dl&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/VrblRtInslnInfsn.htm" class="LinkPage"&gt;Insulin Drip&lt;/a&gt; 1.5 units/hour in NS&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Sugar&lt;/a&gt; 181 to 220 mg/dl&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/VrblRtInslnInfsn.htm" class="LinkPage"&gt;Insulin Drip&lt;/a&gt; 2.0 units/hour in NS&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Sugar&lt;/a&gt; &amp;gt;220 mg/dl&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/VrblRtInslnInfsn.htm" class="LinkPage"&gt;Insulin Drip&lt;/a&gt; 2.5 units/hour in NS&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/OB/GstnlDbtsInslnMngmntIntrprtm.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Gestational Diabetes Insulin Management Intrapartum, Insulin Management in Labor</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/OB/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees></FP_UMLS_Trees><FP_Condition_name_check></FP_Condition_name_check><FP_Condition_name><value>Gestational Diabetes</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Obstetrics</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Epidemiology: &lt;a href="../../Prevent/Epi/DsPrvlncRt.htm" class="LinkPage"&gt;Prevalence&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Overall: 2-5% of pregnant women in U.S.&lt;/li&gt;&lt;li&gt;High risk groups (see below): 14%&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Risk Factors&lt;ol&gt;&lt;li&gt;Maternal Age &amp;gt; 30 years&lt;/li&gt;&lt;li&gt;&lt;a href="../../Prevent/HME/FmlyHstry.htm" class="LinkPage"&gt;Family History&lt;/a&gt; of &lt;a href="../../Endo/DM/DbtsMlts.htm" class="LinkPage"&gt;Diabetes Mellitus&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Personal History of &lt;a href="../../Endo/DM/DbtsMlts.htm" class="LinkPage"&gt;Diabetes Mellitus&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Previous abnormal lab testing&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/GlcsChlngTst.htm" class="LinkPage"&gt;Glucose Challenge Test&lt;/a&gt; (GCT)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/GlcsTlrncTst3Hr.htm" class="LinkPage"&gt;Glucose Tolerance Test&lt;/a&gt; (GTT)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Uro/Lab/UrnGlcs.htm" class="LinkPage"&gt;Glycosuria&lt;/a&gt; (&lt;a href="../../Uro/Lab/UrnGlcs.htm" class="LinkPage"&gt;Urine Glucose&lt;/a&gt; positive)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Symptoms of &lt;a href="../../Endo/DM/DbtsMlts.htm" class="LinkPage"&gt;Diabetes Mellitus&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Polyuria (pre-pregnant)&lt;/li&gt;&lt;li&gt;Polydypsia&lt;/li&gt;&lt;li&gt;Blurred vision&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Prior Pregnancy Complication&lt;ol&gt;&lt;li&gt;History of infant with Macrosomia&lt;ol&gt;&lt;li&gt;Weight exceeds 4000 grams or 9 pounds&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;History of infant with congenital anomaly&lt;/li&gt;&lt;li&gt;Prior &lt;a href="../../OB/Antepartum/LtPrgncyLs.htm" class="LinkPage"&gt;Stillbirth&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Habitual Abortions&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/OB/HyprtnsvDsrdrsOfPrgncy.htm" class="LinkPage"&gt;Preeclampsia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Polyhydramnios&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Obesity/Obsty.htm" class="LinkPage"&gt;Obesity&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Htn/Hyprtnsn.htm" class="LinkPage"&gt;Hypertension&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Uro/ID/RcrntCysts.htm" class="LinkPage"&gt;Recurrent Urinary Tract Infection&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Recurrent &lt;a href="../../Gyn/Vagina/Vgnts.htm" class="LinkPage"&gt;Vaginitis&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Labs: Screening&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/GlcsChlngTst.htm" class="LinkPage"&gt;Glucose Challenge Test&lt;/a&gt; (GCT)&lt;ol&gt;&lt;li&gt;Non-fasting patient drinks 50 grams of &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; and has &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Serum Glucose&lt;/a&gt; drawn at 1 hour&lt;/li&gt;&lt;li&gt;Abnormal if &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Serum Glucose&lt;/a&gt; exceeds 130 mg/dl&lt;/li&gt;&lt;li&gt;Timing of Test&lt;ol&gt;&lt;li&gt;High Risk (See Risk Factors above)&lt;ol&gt;&lt;li&gt;Perform GCT at initial antepartum visit&lt;/li&gt;&lt;li&gt;Rescreen GCT at 24-28 weeks if initially negative&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Low Risk&lt;ol&gt;&lt;li&gt;Perform GCT at 24-28 weeks&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/GlcsTlrncTst3Hr.htm" class="LinkPage"&gt;Glucose Tolerance Test&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Indicated for abnormal &lt;a href="../../Endo/Lab/GlcsChlngTst.htm" class="LinkPage"&gt;Glucose Challenge Test&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Fasting patient drinks 100 grams of &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; and has &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Serum Glucose&lt;/a&gt; drawn fasting, 1,2, 3 hours&lt;/li&gt;&lt;li&gt;Interpretation&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Endo/Lab/GlcsTlrncTst3Hr.htm" class="LinkPage"&gt;Glucose Tolerance Test&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Abnormal if 2 or more readings over respective cut-offs (95, 180,155, and 140 mg/dl)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Complications: Fetal&lt;ol&gt;&lt;li&gt;&lt;a href="../../OB/Fetus/FtlMcrsm.htm" class="LinkPage"&gt;Fetal Macrosomia&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Operative delivery risk (Ceserean section)&lt;/li&gt;&lt;li&gt;&lt;a href="../../NICU/Birth/NwbrnInjry.htm" class="LinkPage"&gt;Birth Trauma&lt;/a&gt; risk&lt;/li&gt;&lt;li&gt;&lt;a href="../../OB/Ld/ShldrDystc.htm" class="LinkPage"&gt;Shoulder Dystocia&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Hypoglycemia/Hypglycm.htm" class="LinkPage"&gt;Hypoglycemia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../ER/Environ/Hypthrm.htm" class="LinkPage"&gt;Hypothermia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../GI/Lab/Blrbn.htm" class="LinkPage"&gt;Hyperbilirubinemia&lt;/a&gt;,&lt;/li&gt;&lt;li&gt;&lt;a href="../../Renal/Calcium/Hypclcm.htm" class="LinkPage"&gt;Hypocalcemia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Premature birth&lt;/li&gt;&lt;li&gt;Respiratory distress syndrome&lt;/li&gt;&lt;li&gt;&lt;a href="../../HemeOnc/Marrow/PlycythmRbrVr.htm" class="LinkPage"&gt;Polycythemia Vera&lt;/a&gt; (plethora)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Obesity/Obsty.htm" class="LinkPage"&gt;Obesity&lt;/a&gt; during childhood&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Complications: Maternal&lt;ol&gt;&lt;li&gt;Longterm risk of developing &lt;a href="../../Endo/DM/DbtsMlts.htm" class="LinkPage"&gt;Diabetes Mellitus&lt;/a&gt;: 50%&lt;ol&gt;&lt;li&gt;Consider &lt;a href="../../Endo/Prevent/DbtsScrng.htm" class="LinkPage"&gt;Diabetes Screening&lt;/a&gt; annually&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Htn/Hyprtnsn.htm" class="LinkPage"&gt;Hypertension&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/OB/HyprtnsvDsrdrsOfPrgncy.htm" class="LinkPage"&gt;Preeclampsia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Ceserean Section&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Prognosis&lt;ol&gt;&lt;li&gt;See Gestational Diabates perinatal mortality&lt;/li&gt;&lt;li&gt;Maternal and fetal outcomes are significantly improved with good &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Sugar&lt;/a&gt; control&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Crowther%20%20%5BAU%5D%20AND%202005%20%5BDP%5D%20AND%20%20N%20Engl%20J%20Med%20%20%5BTA%5D" class="LinkRef"&gt;Crowther (2005) N Engl J Med 352(24): 2477-86&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Metzger%20%20%5BAU%5D%20AND%202008%20%5BDP%5D%20AND%20%20N%20Engl%20J%20Med%20%20%5BTA%5D" class="LinkRef"&gt;Metzger (2008) N Engl J Med 358(19): 1991-2002&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=2001%20%5BDP%5D%20AND%20%20Obstet%20Gynecol%20%20%5BTA%5D%20AND%2098%20%5BVI%5D%20AND%20525%20%5BPG%5D" class="LinkRef"&gt;(2001) Obstet Gynecol 98:525-38&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/OB/GstnlDbts.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Gestational Diabetes</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/OB/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Acute thyroiditis  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0001360"&gt;&lt;i&gt;C0001360&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Disease or Syndrome (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0001360&amp;amp;tui=T047"&gt;&lt;i&gt;T047&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD9&lt;/td&gt;
                &lt;td&gt;245.0&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD10&lt;/td&gt;
                &lt;td&gt;E06.0&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;154665005, 190295008, 190293001&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Acute Thyroiditis, Acute thyroiditis NOS, acute thyroiditis, acute thyroiditis (diagnosis), Thyroiditis acute, THYROIDITIS ACUTE, Acute thyroiditis NOS (disorder), thyroiditis acute, Acute thyroiditis, Acute thyroiditis (disorder), acute; thyroiditis, thyroiditis; acute&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Tiroidite acuta&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;acute thyreoïditis, acuut; thyroïditis, thyroïditis; acuut, Acute thyroïditis, thyreoïditis acuut&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;akute Thyreoiditis, Akute Thyreoiditis, Thyreoiditis akut&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;急性甲状腺炎, ｷｭｳｾｲｺｳｼﾞｮｳｾﾝｴﾝ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;Acute thyroiditis, tiroiditis aguda (trastorno), tiroiditis aguda, SAI (trastorno), tiroiditis aguda, SAI, tiroiditis aguda, Tiroiditis aguda&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;Akutní zánět štítné žlázy, Akutní tyreoiditida&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Korean&lt;/td&gt;
                &lt;td&gt;급성 갑상샘염&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;Acut thyreoiditis, Heveny pajzsmirigy-gyulladás&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Tiroidite aguda&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Thyroïdite aiguë&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Thyroiditis  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0040147"&gt;&lt;i&gt;C0040147&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CHV)&lt;/td&gt;
                &lt;td&gt;inflammation of the thyroid gland&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CHV)&lt;/td&gt;
                &lt;td&gt;inflammation of the thyroid gland&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;Inflammation of the thyroid gland. Thyroiditis may be an autoimmune disease that affects the thyroid gland over time, causing hypothyroidism (too little thyroid hormone). A temporary form of thyroiditis may also occur after the birth of a baby, or when viral or bacterial infections spread to the thyroid.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CSP)&lt;/td&gt;
                &lt;td&gt;inflammation of the thyroid gland.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;Inflammatory diseases of the THYROID GLAND. Thyroiditis can be classified into acute (THYROIDITIS, SUPPURATIVE), subacute (granulomatous and lymphocytic), chronic fibrous (Riedel's), chronic lymphocytic (HASHIMOTO DISEASE), transient (POSTPARTUM THYROIDITIS), and other AUTOIMMUNE THYROIDITIS subtypes.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Disease or Syndrome (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0040147&amp;amp;tui=T047"&gt;&lt;i&gt;T047&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D013966&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD9&lt;/td&gt;
                &lt;td&gt;245.9, 245&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD10&lt;/td&gt;
                &lt;td&gt;E06, E06.9&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;154664009, 154668007, 190301009, 82119001&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Thyroiditides, THYROIDITIS, Thyroiditis, NOS, Thyroiditis NOS, Thyroiditis, unspecified, Thyroiditis, thyroiditis, thyroiditis (diagnosis), Thyroiditis NOS (disorder), Thyroiditis [Disease/Finding], unspecified thyroiditis, Thyroiditis (disorder)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;THYROIDITE, Thyroïdite SAI, Thyroïdite, non précisée, Thyroïdite&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;TIROIDITIS, Tiroiditis NEOM, Tiroiditis no especificada, Thyroiditis, Thyroiditis NOS, tiroiditis (trastorno), tiroiditis, SAI (trastorno), tiroiditis, SAI, tiroiditis, Tiroiditis&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;THYREOIDITIS, Thyreoiditis, unspezifisch, Thyreoiditis NNB, Thyreoiditis, nicht naeher bezeichnet, Thyroiditis, Thyreoiditis&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;thyreoïditis NAO, thyreoïditis, niet-gespecificeerd, Thyroïditis, niet gespecificeerd, thyreoïditis, Thyreoiditis, Thyroïditis&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Tiroidite NAS, Tiroidite non specificata, Tiroidite&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Tiroidite NE, Tiroidite, TIROIDITE, Tireóide, Tireoidite&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;甲状腺炎、詳細不明, 甲状腺炎, 甲状腺炎ＮＯＳ, ｺｳｼﾞｮｳｾﾝｴﾝｼｮｳｻｲﾌﾒｲ, ｺｳｼﾞｮｳｾﾝｴﾝ, ｺｳｼﾞｮｳｾﾝｴﾝNOS&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Sköldkörtelinflammation&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;tyreoiditida, štítná žláza - zánět, Zánět štítné žlázy, Tyreoiditida NOS, Tyreoiditida, blíže neurčená&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Kilpirauhastulehdus&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;TIREOIDIT, ТИРЕОИДИТ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Korean&lt;/td&gt;
                &lt;td&gt;상세불명의 갑상샘염, 갑상샘염&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Croatian&lt;/td&gt;
                &lt;td&gt;TIREOIDITIS&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Zapalenie tarczycy&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;Thyreoiditis, Thyreoiditis, nem meghatározott, Thyreoiditis k.m.n.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Acute thyroiditis  (</value><value>)
</value><value>Thyroiditis  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Thyroiditis</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Thyroid Disease</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Definition&lt;ol&gt;&lt;li&gt;Acute &lt;a href="../../Endo/Anatomy/ThyrdAntmy.htm" class="LinkPage"&gt;Thyroid&lt;/a&gt; Inflammation&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Causes: Painful Thyroiditis&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/ID/SbctGrnlmtsThyrdts.htm" class="LinkPage"&gt;Subacute Granulomatous Thyroiditis&lt;/a&gt; (uncommon)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/ID/SprtvThyrdts.htm" class="LinkPage"&gt;Suppurative Thyroiditis&lt;/a&gt; (rare)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/RdtnIndcdThyrdts.htm" class="LinkPage"&gt;Radiation-Induced Thyroiditis&lt;/a&gt; (1% of I131 patients)&lt;/li&gt;&lt;li&gt;Traumatic Thyroiditis (rare)&lt;ol&gt;&lt;li&gt;Self-limited Thyroiditis due to local trauma&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Causes: Painless Thyroiditis&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/HshmtsThyrdts.htm" class="LinkPage"&gt;Hashimoto's Thyroiditis&lt;/a&gt; (5-10% of cases)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/OB/PstprtmThyrdts.htm" class="LinkPage"&gt;Postpartum Thyroiditis&lt;/a&gt; (5% of cases)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/SbctLymphcytcThyrdts.htm" class="LinkPage"&gt;Subacute Lymphocytic Thyroiditis&lt;/a&gt; (uncommon)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/MdctnsAfctngThyrdFnctn.htm" class="LinkPage"&gt;Drug-Induced Thyroiditis&lt;/a&gt; (10% of cases)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/RdlsThyrdts.htm" class="LinkPage"&gt;Riedel's Thyroiditis&lt;/a&gt; (uncommon)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Bindra%20%20%5BAU%5D%20AND%202006%20%5BDP%5D%20AND%20%20Am%20Fam%20Physician%20%20%5BTA%5D" class="LinkRef"&gt;Bindra (2006) Am Fam Physician 73:1769-76&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0001360</value><value>C0040147</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Thyroid/Thyrdts.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Thyroiditis, Acute Thyroiditis, Painful Thyroiditis, Painless Thyroiditis</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Thyroid/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Subacute lymphocytic thyroiditis  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C1306804"&gt;&lt;i&gt;C1306804&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Disease or Syndrome (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C1306804&amp;amp;tui=T047"&gt;&lt;i&gt;T047&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;361126006, 18018005&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Subacute lymphocytic thyroiditis, Subacute lymphocytic thyroiditis (disorder), Subacute Lymphocytic Thyroiditis&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;tiroiditis linfocítica subaguda (trastorno), tiroiditis linfocítica subaguda&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Subacute lymphocytic thyroiditis  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Subacute Lymphocytic Thyroiditis</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Thyroid Disease</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Pathophysiology&lt;ol&gt;&lt;li&gt;Autoimmune lymphocytic infiltrate&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Epidemiology&lt;ol&gt;&lt;li&gt;More common in women by 4 fold&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Signs&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/Gtr.htm" class="LinkPage"&gt;Goiter&lt;/a&gt; (50%)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/Hyprthyrdsm1.htm" class="LinkPage"&gt;Hyperthyroidism&lt;/a&gt; (up tp 20%)&lt;ol&gt;&lt;li&gt;Duration: Typically &amp;lt;4 months&lt;/li&gt;&lt;li&gt;Followed by &lt;a href="../../Endo/Thyroid/Hypthyrdsm.htm" class="LinkPage"&gt;Hypothyroidism&lt;/a&gt; and then euthyroid&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Differential Diagnosis&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/OB/PstprtmThyrdts.htm" class="LinkPage"&gt;Postpartum Thyroiditis&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Nearly identical, except limited to postpartum period&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/HshmtsThyrdts.htm" class="LinkPage"&gt;Hashimoto's Thyroiditis&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Similar, except pathology (Fibrosis, &lt;a href="../../Endo/Thyroid/HshmtsThyrdts.htm" class="LinkPage"&gt;Hurthle Cell&lt;/a&gt;s)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/GrvsDs.htm" class="LinkPage"&gt;Grave's Disease&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Presents with pretibial edema, &lt;a href="../../Eye/Sx/Prpts.htm" class="LinkPage"&gt;Proptosis&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/ID/SbctGrnlmtsThyrdts.htm" class="LinkPage"&gt;Subacute Thyroiditis&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/Thyrdts.htm" class="LinkPage"&gt;Painful Thyroiditis&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Labs&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/ThyrdFnctnTst.htm" class="LinkPage"&gt;Thyroid Function Test&lt;/a&gt;s (T4 Free and TSH)&lt;/li&gt;&lt;li&gt;Antibodies&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/AnthyrdAntbdy.htm" class="LinkPage"&gt;Antithyroid Peroxidase Antibody&lt;/a&gt; (positive in 50%)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/AnthyrdAntbdy.htm" class="LinkPage"&gt;Thyroid Stimulating Immunoglobulin&lt;/a&gt;s absent&lt;ol&gt;&lt;li&gt;Contrast with &lt;a href="../../Endo/Thyroid/GrvsDs.htm" class="LinkPage"&gt;Grave's Disease&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Imaging&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Rad/RdctvIdnUptkScn.htm" class="LinkPage"&gt;Radioiodine Uptake&lt;/a&gt; (&lt;a href="../../Endo/Anatomy/ThyrdAntmy.htm" class="LinkPage"&gt;Thyroid&lt;/a&gt; uptake and scan)&lt;ol&gt;&lt;li&gt;Low uptake (contrast with &lt;a href="../../Endo/Thyroid/GrvsDs.htm" class="LinkPage"&gt;Grave's Disease&lt;/a&gt;)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Course&lt;ol&gt;&lt;li&gt;Resolves within 1 year in most cases&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Bindra%20%20%5BAU%5D%20AND%202006%20%5BDP%5D%20AND%20%20Am%20Fam%20Physician%20%20%5BTA%5D" class="LinkRef"&gt;Bindra (2006) Am Fam Physician 73(10):1769-76&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C1306804</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Thyroid/SbctLymphcytcThyrdts.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Subacute Lymphocytic Thyroiditis, Silent Sporadic Thyroiditis, Painless Sporadic Thyroiditis</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Thyroid/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees></FP_UMLS_Trees><FP_Condition_name_check></FP_Condition_name_check><FP_Condition_name><value>Endocrine Medications in Pregnancy</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Obstetrics</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;See Also&lt;ol&gt;&lt;li&gt;&lt;a href="../../OB/Pharm/MdctnsInPrgncy.htm" class="LinkPage"&gt;Medications in Pregnancy&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/OB/GstnlDbts.htm" class="LinkPage"&gt;Gestational Diabetes&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Class A: No risk in controlled human studies&lt;ol&gt;&lt;li&gt;Dessicated &lt;a href="../../Endo/Anatomy/ThyrdAntmy.htm" class="LinkPage"&gt;Thyroid&lt;/a&gt; (Armour &lt;a href="../../Endo/Anatomy/ThyrdAntmy.htm" class="LinkPage"&gt;Thyroid&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/ThyrdHrmnRplcmnt.htm" class="LinkPage"&gt;Levothyroxine&lt;/a&gt; (T4 or &lt;a href="../../Endo/Pharm/ThyrdHrmnRplcmnt.htm" class="LinkPage"&gt;Synthroid&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Lthyrn.htm" class="LinkPage"&gt;Liothyronine&lt;/a&gt; (T3 or &lt;a href="../../Endo/Pharm/Lthyrn.htm" class="LinkPage"&gt;Cytomel&lt;/a&gt;)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Class B: No risk in controlled animal studies&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/AlphGlcsdsInhbtr.htm" class="LinkPage"&gt;Acarbose&lt;/a&gt; (&lt;a href="../../Endo/Pharm/AlphGlcsdsInhbtr.htm" class="LinkPage"&gt;Precose&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Rheum/Pharm/Clctn.htm" class="LinkPage"&gt;Calcitonin&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Glcphg.htm" class="LinkPage"&gt;Metformin&lt;/a&gt; (&lt;a href="../../Endo/Pharm/Glcphg.htm" class="LinkPage"&gt;Glucophage&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;Prednisone&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/SystmcCrtcstrd.htm" class="LinkPage"&gt;Prednisolone&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Class C: Small risk in controlled animal studies&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/FrstGnrtnSlfnylr.htm" class="LinkPage"&gt;Acetohexamide&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Beclomethasone&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/SystmcCrtcstrd.htm" class="LinkPage"&gt;Betamethasone&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/DpmnAgnst.htm" class="LinkPage"&gt;Bromocriptine&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/FrstGnrtnSlfnylr.htm" class="LinkPage"&gt;Chlorpropamide&lt;/a&gt; (Diabinase)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/SystmcCrtcstrd.htm" class="LinkPage"&gt;Dexamethasone&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/ScndGnrtnSlfnylr.htm" class="LinkPage"&gt;Glipizide&lt;/a&gt; (Glucotrol)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/ScndGnrtnSlfnylr.htm" class="LinkPage"&gt;Glyburide&lt;/a&gt; (Micronase or DiaBeta)&lt;/li&gt;&lt;li&gt;Triamcinolone&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Class D: Strong evidence of risk to the human fetus&lt;ol&gt;&lt;li&gt;Lynestrenol&lt;/li&gt;&lt;li&gt;&lt;a href="../../Gyn/Pharm/Prvr.htm" class="LinkPage"&gt;Medroxyprogesterone&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/AnthyrdDrg.htm" class="LinkPage"&gt;Methimazole&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/AnthyrdDrg.htm" class="LinkPage"&gt;Propylthiouracil&lt;/a&gt; (preferred over &lt;a href="../../Endo/Pharm/AnthyrdDrg.htm" class="LinkPage"&gt;Methimazole&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Gyn/Pharm/Tmxfn.htm" class="LinkPage"&gt;Tamoxifen&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/FrstGnrtnSlfnylr.htm" class="LinkPage"&gt;Tolbutamide&lt;/a&gt; (Orinase)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Class X: Very high risk to the human fetus&lt;ol&gt;&lt;li&gt;Clomiphene (&lt;a href="../../Gyn/Pharm/Clmd.htm" class="LinkPage"&gt;Clomid&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Gyn/Pharm/Dnzl.htm" class="LinkPage"&gt;Danazol&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Diethylstilbesterol (DES)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Gyn/Pharm/Estrgn.htm" class="LinkPage"&gt;Estrogen&lt;/a&gt;s (all)&lt;/li&gt;&lt;li&gt;Iodide &lt;a href="../../Endo/Pharm/Rdn.htm" class="LinkPage"&gt;I-131&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Leuprolide (Leupron)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Gyn/Pharm/FrstGnrtnPrgstn.htm" class="LinkPage"&gt;Norethindrone&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Gyn/Pharm/FrstGnrtnPrgstn.htm" class="LinkPage"&gt;Norethynodrel&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Gyn/Pharm/ThrdGnrtnPrgstn.htm" class="LinkPage"&gt;Norgestrel&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Gyn/Pharm/OrlCntrcptv.htm" class="LinkPage"&gt;Oral Contraceptive&lt;/a&gt;s&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;Briggs (1998) Drugs in Pregnancy and &lt;a href="../../OB/Lactation/BrstFdng.htm" class="LinkPage"&gt;Lactation&lt;/a&gt;, 5th ed&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Larimore%20%20%5BAU%5D%20AND%202000%20%5BDP%5D%20AND%20%20Prim%20Care%20%20%5BTA%5D" class="LinkRef"&gt;Larimore (2000) Prim Care 27(1):35-53&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/OB/EndcrnMdctnsInPrgncy.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Endocrine Medications in Pregnancy</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/OB/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Riedel's thyroiditis  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0154162"&gt;&lt;i&gt;C0154162&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Disease or Syndrome (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0154162&amp;amp;tui=T047"&gt;&lt;i&gt;T047&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD10&lt;/td&gt;
                &lt;td&gt;E06.5&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;89024000, 237540002, 190298005&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;REIDEL STRUMA, RIEDEL STRUMA, THYROIDITIS, INVASIVE, THYROIDITIS, LIGNEOUS, THYROIDITIS, RIEDEL, THYROIDITIS, WOODY, THYROIDITIS CHRONIC &amp;lt;RIEDELS&amp;gt;, Reidel's thyroiditis, Ligneous thyroiditis (disorder), Riedel's thyroiditis (diagnosis), THYROIDITIS CHRONIC RIEDELS, Riedel thyroiditis, reidel struma, riedel thyroiditis, invasive fibrous thyroiditis, riedels thyroiditis, riedel's thyroiditis, Invasive thyroiditis, Ligneous thyroiditis, Riedel's thyroiditis, Invasive fibrous thyroiditis, Struma fibrosa thyroid, Woody thyroiditis, Riedel's thyroiditis (disorder), Riedel; struma, Riedel; thyroiditis, ligneous; thyroiditis, struma; Riedel, thyroiditis; Riedel, thyroiditis; ligneous, thyroiditis; woody, woody; thyroiditis&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;invasieve thyroïditis, Riedel thyreoïditis, Reidel's thyroïditis, Riedel; struma, Riedel; thyroïditis, houtachtig; thyroïditis, lignosa; thyroïditis, struma; Riedel, thyroïditis; Riedel, thyroïditis; houtachtig, thyroïditis; lignosa&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Thyroïdite de Riedel, Thyroïdite ligneuse, Thyroïdite invasive&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;invasive Thyreoiditis, Ligneous Thyroiditis, Riedel-Thyroiditis&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Tiroidite invasiva, Tiroidite lignea, Tiroidite di Riedel&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Tiroidite invasiva, Tiroidite de Riedel, Tiroidite lenhosa&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;Tiroiditis invasiva, Tiroiditis leñosa, Tiroiditis de Riedel, Ligneous thyroiditis, Riedel's thyroiditis, tiroiditis de Riedel (trastorno), tiroiditis de Riedel, tiroiditis fibrosa invasiva, tiroiditis leñosa, tiroiditis por estruma fibroso&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;木様甲状腺炎, リーデル甲状腺炎, 侵入性甲状腺炎, ﾘｰﾃﾞﾙｺｳｼﾞｮｳｾﾝｴﾝ, ﾓｸﾖｳｺｳｼﾞｮｳｾﾝｴﾝ, ｼﾝﾆｭｳｾｲｺｳｼﾞｮｳｾﾝｴﾝ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;Thyroiditis lignea, Riedlova tyreoiditida, Invazivní tyreoiditida&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;Riedel-thyreoiditis, Invasiv thyreoiditis, Thyreoiditis ligneosa&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Fibrous autoimmune thyroiditis  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0271813"&gt;&lt;i&gt;C0271813&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Pathologic Function (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0271813&amp;amp;tui=T046"&gt;&lt;i&gt;T046&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD9&lt;/td&gt;
                &lt;td&gt;245.3&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD10&lt;/td&gt;
                &lt;td&gt;E06.5&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;84362007, 190298005&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Chronic fibrous thyroiditis, THYROIDITIS, CHRONIC FIBROUS, chronic fibrous thyroiditis, chronic fibrous thyroiditis (diagnosis), Thyroiditis fibrous chronic, Chr fibrous thyroiditis, Chronic thyroiditis, fibrous variant, Fibrous autoimmune thyroiditis, Hashimoto thyroiditis, fibrous variant, Noninvasive fibrous thyroiditis, Fibrous autoimmune thyroiditis (disorder), chronic; thyroiditis, fibrous, thyroiditis; chronic, fibrous&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Tiroidite fibrosa cronica&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;chronische fibreuze thyreoïditis, chronisch; thyroïditis, fibreus, thyroïditis; chronisch, fibreus, thyreoïditis fibreus chronisch&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;chronische fibroese Thyreoiditis, Thyreoiditis fibroes chronisch&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;慢性線維性甲状腺炎, ﾏﾝｾｲｾﾝｲｾｲｺｳｼﾞｮｳｾﾝｴﾝ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;Chronic fibrous thyroiditis, tiroiditis crónica, variante fibrosa, tiroiditis de Hashimoto, variante fibrosa (trastorno), tiroiditis de Hashimoto, variante fibrosa, tiroiditis fibrosa autoinmune, Tiroiditis fibrosa crónica&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;Chronický fibrózní zánět štítné žlázy, Chronická fibrózní tyreoiditida&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;Chronikus fibrosus thyreoiditis&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Tiroidite fibrosa crónica&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Thyroïdite fibreuse chronique&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Riedel's thyroiditis  (</value><value>)
</value><value>Fibrous autoimmune thyroiditis  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Riedel's Thyroiditis</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Thyroid Disease</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Pathophysiology&lt;ol&gt;&lt;li&gt;Idiopathic fibrosis of &lt;a href="../../Endo/Anatomy/ThyrdAntmy.htm" class="LinkPage"&gt;Thyroid&lt;/a&gt; and adjacent neck&lt;/li&gt;&lt;li&gt;May be associated with mor generalized fibrosis&lt;ol&gt;&lt;li&gt;Idiopathic Multifocal Fibrosclerosis&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Epidemiology&lt;ol&gt;&lt;li&gt;Onset age 30 to 60 years&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Symptoms&lt;ol&gt;&lt;li&gt;Symptoms related to compression on esophagus, trachea&lt;ol&gt;&lt;li&gt;&lt;a href="../../Lung/Sx/Strdr.htm" class="LinkPage"&gt;Stridor&lt;/a&gt; or &lt;a href="../../Lung/Sx/ActDyspn.htm" class="LinkPage"&gt;Dyspnea&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Neuro/Exam/Dysphg.htm" class="LinkPage"&gt;Dysphagia&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Signs&lt;ol&gt;&lt;li&gt;Very firm (rock or wood-like) &lt;a href="../../Endo/Anatomy/ThyrdAntmy.htm" class="LinkPage"&gt;Thyroid&lt;/a&gt; swelling&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/Hypthyrdsm.htm" class="LinkPage"&gt;Hypothyroidism&lt;/a&gt; (30%)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Labs&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/ThyrdFnctnTst.htm" class="LinkPage"&gt;Thyroid Function Test&lt;/a&gt;s (T4 Free and TSH)&lt;/li&gt;&lt;li&gt;Antithyroid peroxidase antibodies (&amp;gt;60%)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Imaging&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Rad/RdctvIdnUptkScn.htm" class="LinkPage"&gt;Radioiodine Uptake&lt;/a&gt; (&lt;a href="../../Endo/Anatomy/ThyrdAntmy.htm" class="LinkPage"&gt;Thyroid&lt;/a&gt; uptake and scan)&lt;ol&gt;&lt;li&gt;Low uptake (contrast with &lt;a href="../../Endo/Thyroid/GrvsDs.htm" class="LinkPage"&gt;Grave's Disease&lt;/a&gt;)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Diagnosis&lt;ol&gt;&lt;li&gt;Open &lt;a href="../../Endo/Anatomy/ThyrdAntmy.htm" class="LinkPage"&gt;Thyroid&lt;/a&gt; biopsy&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Management: Tracheal or esophageal compression&lt;ol&gt;&lt;li&gt;First-line&lt;ol&gt;&lt;li&gt;Surgical decompression&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Other agents&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/SystmcCrtcstrd.htm" class="LinkPage"&gt;Corticosteroid&lt;/a&gt;s&lt;/li&gt;&lt;li&gt;&lt;a href="../../Rheum/Pharm/Mthtrxt.htm" class="LinkPage"&gt;Methotrexate&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Gyn/Pharm/Tmxfn.htm" class="LinkPage"&gt;Tamoxifen&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Bindra%20%20%5BAU%5D%20AND%202006%20%5BDP%5D%20AND%20%20Am%20Fam%20Physician%20%20%5BTA%5D" class="LinkRef"&gt;Bindra (2006) Am Fam Physician 73(10):1769-76&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0154162</value><value>C0271813</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Thyroid/RdlsThyrdts.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Riedel's Thyroiditis, Fibrous Thyroiditis</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Thyroid/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Myxedema  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0027145"&gt;&lt;i&gt;C0027145&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CSP)&lt;/td&gt;
                &lt;td&gt;condition characterized by a dry, waxy type of swelling with abnormal deposits of mucin in the skin and other tissues; it is produced by a functional insufficiency of the thyroid gland, resulting in deficiency of thyroid hormone.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;A condition characterized by a dry, waxy type of swelling (EDEMA) with abnormal deposits of MUCOPOLYSACCHARIDES in the SKIN and other tissues. It is caused by a deficiency of THYROID HORMONES. The skin becomes puffy around the eyes and on the cheeks. The face is dull and expressionless with thickened nose and lips.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Disease or Syndrome (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0027145&amp;amp;tui=T047"&gt;&lt;i&gt;T047&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D009230&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD10&lt;/td&gt;
                &lt;td&gt;E03.9&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;43153006, 154660000, 190274003, 267465007&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Myxedema, Myxedemas, MYXOEDEMA, Myxedema, NOS, Hypothyroidism/myxedema, Myxoedema, NOS, MYXEDEMA, myxedema, myxedema (diagnosis), Myxedema NOS, Myxedema [Disease/Finding], Myxoedema, Myxedema (disorder), Hypothyroidism/myxoedema, myxoedema&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;MYXOEDEME, Hypothyroidie/myxoedeme, Myxoedème&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;MIXEDEMA, Hipotiroidismo/mixedema, Mixedema&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;MIXEDEMA, Myxedema, Myxoedema, Hipotiroidismo/mixedema, Mixoedema, mixedema (trastorno), mixedema, Mixedema&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;MYXOEDEM, Hypothyreose/Myxoedem, Myxoedem, Myxödem&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Myxödem, HYPOTYREOIDISM/MYXODEM&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;myxedém, Myxedém&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Myksedeema, KILPIRAUHASEN VAJAATOIMINTA/MYXODEMA&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;MIKSEDEMA, МИКСЕДЕМА&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Norwegian&lt;/td&gt;
                &lt;td&gt;HYPOTYREOSE/MYKSODEM/KRETINISME&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;Hypothyreoidie/myxoedeem, myxoedeem, Hypothyreoàdie/myxoedeem, Myxoedeem&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Danish&lt;/td&gt;
                &lt;td&gt;Hypotyreose/myksodem&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Ipotiroidismo/mixedema, Mixedema&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;hypothyreosis/myxoedema, Myxoedema&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;ﾈﾝｴｷｽｲｼｭ, 粘液水腫&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Croatian&lt;/td&gt;
                &lt;td&gt;MIKSEDEM&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Basque&lt;/td&gt;
                &lt;td&gt;HIPOTIROIDISMOA/MISOEDEMA&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hebrew&lt;/td&gt;
                &lt;td&gt;hipotiroidizm&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Obrzęk śluzowaty&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Hypothyroidism  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0020676"&gt;&lt;i&gt;C0020676&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A condition in which the production of thyroid hormone by the thyroid gland is diminished. Signs and symptoms of hypothyroidism include low metabolic rate, tendency to weight gain, somnolence and sometimes myxedema. In the United States, the most common cause of hypothyroidism is Hashimoto's thyroiditis, an autoimmune disorder.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A disorder characterized by a decrease in production of thyroid hormone by the thyroid gland.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;Too little thyroid hormone. Symptoms include weight gain, constipation, dry skin, and sensitivity to the cold.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CSP)&lt;/td&gt;
                &lt;td&gt;deficiency of thyroid gland activity; characterized by decreased basal metabolic rate, fatigue and lethargy, sensitivity to cold, and menstrual disturbances; untreated it progresses to myxedema; in infants severe hypothyroidism leads to cretinism.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;A syndrome that results from abnormally low secretion of THYROID HORMONES from the THYROID GLAND, leading to a decrease in BASAL METABOLIC RATE. In its most severe form, there is accumulation of MUCOPOLYSACCHARIDES in the SKIN and EDEMA, known as MYXEDEMA.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Disease or Syndrome (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0020676&amp;amp;tui=T047"&gt;&lt;i&gt;T047&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D007037&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD9&lt;/td&gt;
                &lt;td&gt;244.9&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD10&lt;/td&gt;
                &lt;td&gt;E03.9&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;237572004, 267377003, 40930008, 154660000, 190274003, 267465007, 190290003&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Hypothyroidism, Hypothyroidisms, Unspecified hypothyroidism, HYPOTHYROIDISM, THYROID ACTIVITY DECREASED, Hypothyroidism, NOS, Hypothyroidism NOS, Hypothyroidism, unspecified, hypothyroidism, hypothyroidism (diagnosis), Thyroid activity decreased, HYPOTHYROID, Hypothyroidism NOS (disorder), Hypothyroidism [Disease/Finding], hypothyroidisms, hypothyroid, Underactive Thyroid, underactive thyroid, Hypothyroid, Hypothyroidism (disorder), deficiency; thyroid, insufficiency; thyroid, subthyroidism, thyroid; deficiency, thyroid; insufficiency, Thyroid insufficiency, Hypothyroidism [Ambiguous], Thyroid deficiency&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;HYPOTHYROIDIE, Hypothyroïdisme non précisé, Activité thyroïdienne diminuée, DIMINUTION ACTIVITE THYROIDIENNE, Hypothyréose, Hypothyroïdie, Hypothyroïdisme&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;HIPOTIROIDISMO, Hipotiroidismo no especificado, Actividad del tiroides disminuida, Thyroid deficiency, Hypothyroidism, Thyroid insufficiency, Hypothyroidism NOS, Hypothyroidism [Ambiguous], TIROIDES, ACTIVIDAD DISMINUIDA, hipotiroidismo (trastorno), hipotiroidismo, SAI (trastorno), hipotiroidismo, SAI, hipotiroidismo, Hipotiroidismo&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;HYPOTHYREOSE, Schilddruesenaktivitaet erniedrigt, unspezifische Hypothyreose, Hypothyreose, nicht naeher bezeichnet, SCHILDDRUESENAKTIVITAET VERMINDER, Hypothyreose, Hypothyreoidismus&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;verlaagde schildklieractiviteit, niet-gespecificeerde hypothyroïdie, deficiëntie; schildklier, insufficiëntie; schildklier, schildklier; deficiëntie, schildklier; insufficiëntie, Hypothyroïdie, niet gespecificeerd, hypothyroïdie, Hypothyreose, Hypothyreoïdie, Thyreoïdie, hypo-&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Attività tiroidea diminuita, Ipotiroidismo non specificato, Ipotiroidismo&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Hipotiroidismo NE, Actividade tiroideia diminuída, DIMINUICAO DA ACTIVIDADE TIROIDEI, HIPOTIROIDISMO, Hipotiroidismo, Hipotireoidismo&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;詳細不明の甲状腺機能低下症, 甲状腺機能低下症, 甲状腺機能低下, ｺｳｼﾞｮｳｾﾝｷﾉｳﾃｲｶ, ｺｳｼﾞｮｳｾﾝｷﾉｳﾃｲｶｼｮｳ, ｼｮｳｻｲﾌﾒｲﾉｺｳｼﾞｮｳｾﾝｷﾉｳﾃｲｶｼｮｳ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Hypotyreos&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;hypotyreoidismus, Blíže neurčená hypotyreóza, Hypotyreóza, Snížená činnost štítné žlázy&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Kilpirauhasen vajaatoiminta&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;GIPOTIREOIDIZM, GALLA BOLEZN', GIPOTIREOZ, ГАЛЛА БОЛЕЗНЬ, ГИПОТИРЕОЗ, ГИПОТИРЕОИДИЗМ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Korean&lt;/td&gt;
                &lt;td&gt;상세불명의 갑상샘 기능저하증&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Croatian&lt;/td&gt;
                &lt;td&gt;HIPOTIREOZA&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Niedoczynność tarczycy&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;Hypothyreosis, Pajzsmirigy aktivitás csökkenése, Nem meghatározott hypothyreosis&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Myxedema  (</value><value>)
</value><value>Hypothyroidism  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Hypothyroidism</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Thyroid Disease</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Epidemiology: &lt;a href="../../Prevent/Epi/DsPrvlncRt.htm" class="LinkPage"&gt;Prevalence&lt;/a&gt; (US)&lt;ol&gt;&lt;li&gt;Congenital: 1 in 4000 newborns&lt;/li&gt;&lt;li&gt;Adults:&lt;ol&gt;&lt;li&gt;Age over 65 years: 2-4% (especially older women)&lt;/li&gt;&lt;li&gt;Overall in U.S.: 0.3-1.0%&lt;/li&gt;&lt;li&gt;Undiagnosed cases: 13 Million estimated in U.S.&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Causes&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/HshmtsThyrdts.htm" class="LinkPage"&gt;Hashimoto's Thyroiditis&lt;/a&gt; (Most common cause)&lt;/li&gt;&lt;li&gt;Congenital Hypothyroidism (&lt;a href="../../Endo/NICU/InfntlHypthyrdsm.htm" class="LinkPage"&gt;Cretinism&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Anatomy/ThyrdAntmy.htm" class="LinkPage"&gt;Thyroid&lt;/a&gt; ablation&lt;ol&gt;&lt;li&gt;Graves' Disease Management&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Rdn.htm" class="LinkPage"&gt;Radioactive Iodine&lt;/a&gt; (&lt;a href="../../Endo/Pharm/Rdn.htm" class="LinkPage"&gt;I-131&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Anatomy/ThyrdAntmy.htm" class="LinkPage"&gt;Thyroid&lt;/a&gt;ectomy&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Neck radiation in cancer treatment&lt;ol&gt;&lt;li&gt;&lt;a href="../../HemeOnc/Lymph/HdgknDs.htm" class="LinkPage"&gt;Hodgkin's Lymphoma&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Laryngeal Cancer&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Medications&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Endo/Pharm/MdctnsAfctngThyrdFnctn.htm" class="LinkPage"&gt;Medications Affecting Thyroid Function&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Secondary Hypothyroidism (Central causes, only 5% of cases)&lt;ol&gt;&lt;li&gt;Congenital Hypopituitarism&lt;/li&gt;&lt;li&gt;Pituitary necrosis (Sheehan's Syndrome)&lt;/li&gt;&lt;li&gt;Pituitary or Hypothalamic lesion&lt;/li&gt;&lt;li&gt;&lt;a href="../../HIV/Exam/HmnImndfcncyVrs.htm" class="LinkPage"&gt;HIV Infection&lt;/a&gt; on highly active &lt;a href="../../HIV/Pharm/AntRtrvrlThrpy.htm" class="LinkPage"&gt;Antiretroviral&lt;/a&gt;s&lt;ol&gt;&lt;li&gt;Also associated with low &lt;a href="../../HIV/Lab/Cd4ClCnt.htm" class="LinkPage"&gt;CD4 Count&lt;/a&gt;s&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Beltran%20%20%5BAU%5D%20AND%202003%20%5BDP%5D%20AND%20%20Clin%20Infect%20Dis%20%20%5BTA%5D" class="LinkRef"&gt;Beltran (2003) Clin Infect Dis 37:579-83&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Transient Hypothyroidism&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/OB/PstprtmThyrdts.htm" class="LinkPage"&gt;Postpartum Thyroiditis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/ID/SbctGrnlmtsThyrdts.htm" class="LinkPage"&gt;Subacute Thyroiditis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Silent &lt;a href="../../Endo/Thyroid/Thyrdts.htm" class="LinkPage"&gt;Thyroiditis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;TSH receptor blocking &lt;a href="../../ID/Exam/Imnglbln.htm" class="LinkPage"&gt;Antibody&lt;/a&gt; associated &lt;a href="../../Endo/Thyroid/Thyrdts.htm" class="LinkPage"&gt;Thyroiditis&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Symptoms&lt;ol&gt;&lt;li&gt;Generalized&lt;ol&gt;&lt;li&gt;&lt;a href="../../Rheum/Sx/Ftg.htm" class="LinkPage"&gt;Fatigue&lt;/a&gt; or weakness (99%)&lt;/li&gt;&lt;li&gt;Lethargy (91%)&lt;/li&gt;&lt;li&gt;Cold intolerance (89%)&lt;/li&gt;&lt;li&gt;Weight gain despite diminished food intake&lt;/li&gt;&lt;li&gt;&lt;a href="../../Renal/Edema/Edm.htm" class="LinkPage"&gt;Edema&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Arthralgias&lt;/li&gt;&lt;li&gt;Myalgias&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Neuropsychiatric&lt;ol&gt;&lt;li&gt;Diminished libido&lt;/li&gt;&lt;li&gt;&lt;a href="../../Neuro/Sx/Hdch.htm" class="LinkPage"&gt;Headache&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../ENT/Sx/Hrsns.htm" class="LinkPage"&gt;Hoarseness&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Slow thinking&lt;/li&gt;&lt;li&gt;Forgetfulness (66%)&lt;/li&gt;&lt;li&gt;Slow speech (91%)&lt;/li&gt;&lt;li&gt;Depressed Mood&lt;/li&gt;&lt;li&gt;Difficult Concentration&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Gastrointestinal&lt;ol&gt;&lt;li&gt;&lt;a href="../../GI/Constipation/CnstptnInAdlts.htm" class="LinkPage"&gt;Constipation&lt;/a&gt; (61%)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Dermatologic&lt;ol&gt;&lt;li&gt;Dry or coarse skin (97%)&lt;/li&gt;&lt;li&gt;Decreased sweating (89%)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Derm/Hair/Alpc.htm" class="LinkPage"&gt;Hair Loss&lt;/a&gt; (especially outer third of eyebrows)&lt;/li&gt;&lt;li&gt;Broken nails&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Gynecologic&lt;ol&gt;&lt;li&gt;&lt;a href="../../Gyn/Sx/Amnrh.htm" class="LinkPage"&gt;Amenorrhea&lt;/a&gt; or &lt;a href="../../Gyn/Menses/OvltryBldng.htm" class="LinkPage"&gt;Menorrhagia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Gyn/Endo/FmlInfrtlty.htm" class="LinkPage"&gt;Infertility&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Symptoms: Presentations&lt;ol&gt;&lt;li&gt;Most specific symptoms for Hypothyroidism&lt;ol&gt;&lt;li&gt;&lt;a href="../../GI/Constipation/CnstptnInAdlts.htm" class="LinkPage"&gt;Constipation&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Cold Intolerance&lt;/li&gt;&lt;li&gt;&lt;a href="../../Derm/Dry/DrySkn.htm" class="LinkPage"&gt;Dry Skin&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Proximal &lt;a href="../../Rheum/Sx/MsclWkns.htm" class="LinkPage"&gt;Muscle Weakness&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Derm/Anatomy/Hr.htm" class="LinkPage"&gt;Hair&lt;/a&gt; thinning or &lt;a href="../../Derm/Hair/Alpc.htm" class="LinkPage"&gt;Hair Loss&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Infants and children&lt;ol&gt;&lt;li&gt;Lethargy&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Peds/FlrTThrv.htm" class="LinkPage"&gt;Failure to Thrive&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Women&lt;ol&gt;&lt;li&gt;Irregular &lt;a href="../../Gyn/Exam/MnstrlBldng.htm" class="LinkPage"&gt;Menses&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Gyn/Endo/FmlInfrtlty.htm" class="LinkPage"&gt;Infertility&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Older patients&lt;ol&gt;&lt;li&gt;Cognitive decline&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Signs&lt;ol&gt;&lt;li&gt;General&lt;ol&gt;&lt;li&gt;Round puffy face or other facial edema (79%)&lt;/li&gt;&lt;li&gt;Periorbital or &lt;a href="../../Eye/Anatomy/LdAntmy.htm" class="LinkPage"&gt;Eyelid&lt;/a&gt; edema (90%)&lt;/li&gt;&lt;li&gt;Large, thick &lt;a href="../../ENT/Anatomy/Tng.htm" class="LinkPage"&gt;Tongue&lt;/a&gt; or &lt;a href="../../ENT/Sx/TngEnlrgmnt.htm" class="LinkPage"&gt;Macroglossia&lt;/a&gt; (82%)&lt;/li&gt;&lt;li&gt;Non-pitting ankle edema&lt;/li&gt;&lt;li&gt;&lt;a href="../../ER/Environ/Hypthrm.htm" class="LinkPage"&gt;Hypothermia&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Neuropsychiatric&lt;ol&gt;&lt;li&gt;Slow speech&lt;/li&gt;&lt;li&gt;Hoarse voice&lt;/li&gt;&lt;li&gt;Hypokinesia&lt;/li&gt;&lt;li&gt;Generalized &lt;a href="../../Rheum/Sx/MsclWkns.htm" class="LinkPage"&gt;Muscle Weakness&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Delayed relaxation of &lt;a href="../../Neuro/Exam/RflxExm.htm" class="LinkPage"&gt;Deep Tendon Reflex&lt;/a&gt;es&lt;ol&gt;&lt;li&gt;&lt;a href="../../Neuro/Exam/RflxExm.htm" class="LinkPage"&gt;Patellar Reflex&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Neuro/Exam/RflxExm.htm" class="LinkPage"&gt;Ankle Jerk&lt;/a&gt; reflex&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Dermatologic&lt;ol&gt;&lt;li&gt;Cold, dry, thick &lt;a href="../../Derm/Exam/Dsqmtn.htm" class="LinkPage"&gt;Scaling&lt;/a&gt; skin&lt;ol&gt;&lt;li&gt;Affects palms, soles, elbows and knees&lt;/li&gt;&lt;li&gt;Skin may show yellow-orange discoloration&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Dry coarse brittle hair (76%)&lt;/li&gt;&lt;li&gt;Dry, longitudinally ridged nails&lt;/li&gt;&lt;li&gt;Lateral eyebrow thinning&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Cardiopulmonary&lt;ol&gt;&lt;li&gt;Faint cardiac impulse&lt;/li&gt;&lt;li&gt;Indistinct heart tones&lt;/li&gt;&lt;li&gt;Cardiac enlargement&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/EKG/Brdycrd.htm" class="LinkPage"&gt;Bradycardia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Pericardium/PrcrdlEfsn.htm" class="LinkPage"&gt;Pericardial Effusion&lt;/a&gt; (severe Hypothyroidism)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Lung/Pleura/PlrlEfsn.htm" class="LinkPage"&gt;Pleural Effusion&lt;/a&gt; (severe Hypothyroidism)&lt;/li&gt;&lt;li&gt;Variable effect on &lt;a href="../../CV/Exam/BldPrsr.htm" class="LinkPage"&gt;Blood Pressure&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../CV/Exam/Hyptnsn.htm" class="LinkPage"&gt;Hypotension&lt;/a&gt; may be present&lt;/li&gt;&lt;li&gt;Diastolic &lt;a href="../../CV/Htn/Hyprtnsn.htm" class="LinkPage"&gt;Hypertension&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Dernellis%20%20%5BAU%5D%20AND%202002%20%5BDP%5D%20AND%20%20Am%20Heart%20J%20%20%5BTA%5D" class="LinkRef"&gt;Dernellis (2002) Am Heart J 143:718-24&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Gastrointestinal&lt;ol&gt;&lt;li&gt;&lt;a href="../../GI/Exam/Ascts.htm" class="LinkPage"&gt;Ascites&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Pearls: TSH Screening Indications&lt;ol&gt;&lt;li&gt;All elderly with depression&lt;/li&gt;&lt;li&gt;All elderly entering long term care&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Labs: &lt;a href="../../Endo/Lab/ThyrdFnctnTst.htm" class="LinkPage"&gt;Thyroid Function Test&lt;/a&gt;s&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Endo/Lab/ThyrdFnctnTst.htm" class="LinkPage"&gt;Thyroid Function Test&lt;/a&gt;ing&lt;/li&gt;&lt;li&gt;TSH is the primary screening and monitoring test&lt;ol&gt;&lt;li&gt;Most sensitive marker for &lt;a href="../../Endo/Anatomy/ThyrdAntmy.htm" class="LinkPage"&gt;Thyroid&lt;/a&gt; function&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Protocol&lt;ol&gt;&lt;li&gt;Screening: TSH with reflex to &lt;a href="../../Endo/Lab/Thyrxn.htm" class="LinkPage"&gt;Free T4&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Monitoring after diagnosis: TSH alone is sufficient&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Interpretation&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/ThyrdStmltngHrmn.htm" class="LinkPage"&gt;Serum TSH&lt;/a&gt; increased&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/Thyrxn.htm" class="LinkPage"&gt;Free T4&lt;/a&gt; low&lt;ol&gt;&lt;li&gt;Primary Hypothyroidism&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/Thyrxn.htm" class="LinkPage"&gt;Free T4&lt;/a&gt; normal&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/SbclnclHypthyrdsm.htm" class="LinkPage"&gt;Subclinical Hypothyroidism&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Overt Hypothyroidism unlikely if &lt;a href="../../Endo/Lab/ThyrdStmltngHrmn.htm" class="LinkPage"&gt;Serum TSH&lt;/a&gt; 6-10&lt;/li&gt;&lt;li&gt;Consider checking &lt;a href="../../Endo/Lab/Trdthyrn.htm" class="LinkPage"&gt;Free T3&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/Trdthyrn.htm" class="LinkPage"&gt;Free T3&lt;/a&gt; is low in congenital absence of T4 to T3 converting enzyme&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/Trdthyrn.htm" class="LinkPage"&gt;Free T3&lt;/a&gt; may also be low due to &lt;a href="../../CV/Pharm/Amdrn.htm" class="LinkPage"&gt;Amiodarone&lt;/a&gt; blocking T4 to T3 conversion&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/ThyrdStmltngHrmn.htm" class="LinkPage"&gt;Serum TSH&lt;/a&gt; decreased&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/Thyrxn.htm" class="LinkPage"&gt;Free T4&lt;/a&gt; low&lt;ol&gt;&lt;li&gt;Central Hypothyroidism (secondary Hypothyroidism)&lt;ol&gt;&lt;li&gt;Urgent endocrinology consultation&lt;/li&gt;&lt;li&gt;Obtain head imaging (MRI Brain) with attention toward sella turcica&lt;/li&gt;&lt;li&gt;Obtain other pituitary-related hormone levels&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/FlclStmltngHrmn.htm" class="LinkPage"&gt;Serum FSH&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/LtnzngHrmn.htm" class="LinkPage"&gt;Serum LH&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/Prlctn.htm" class="LinkPage"&gt;Serum Prolactin&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/SrmCrtsl.htm" class="LinkPage"&gt;Serum Cortisol&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Uro/Lab/TtlTststrn.htm" class="LinkPage"&gt;Serum Testosterone&lt;/a&gt; (males)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/Thyrxn.htm" class="LinkPage"&gt;Free T4&lt;/a&gt; high&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/Hyprthyrdsm1.htm" class="LinkPage"&gt;Hyperthyroidism&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Labs: Other&lt;ol&gt;&lt;li&gt;&lt;a href="../../CV/Lab/Lpd.htm" class="LinkPage"&gt;Lipid&lt;/a&gt; profile&lt;ol&gt;&lt;li&gt;&lt;a href="../../CV/Lab/LdlChlstrl.htm" class="LinkPage"&gt;LDL Cholesterol&lt;/a&gt; elevated&lt;/li&gt;&lt;li&gt;Serum &lt;a href="../../CV/Lab/Trglycrd.htm" class="LinkPage"&gt;Triglyceride&lt;/a&gt; elevated&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Serum labs&lt;ol&gt;&lt;li&gt;&lt;a href="../../CV/Lab/CrtnPhsphkns.htm" class="LinkPage"&gt;Creatine Phosphokinase&lt;/a&gt; (CPK) elevated&lt;/li&gt;&lt;li&gt;&lt;a href="../../GI/Lab/Ldh.htm" class="LinkPage"&gt;Lactate Dehydrogenase&lt;/a&gt; (LDH) elevated&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/Prlctn.htm" class="LinkPage"&gt;Serum Prolactin&lt;/a&gt; increased (see &lt;a href="../../Endo/Pituitary/Hyprprlctnm.htm" class="LinkPage"&gt;Hyperprolactinemia&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Renal/Lab/SrmSdm.htm" class="LinkPage"&gt;Serum Sodium&lt;/a&gt; decreased (see &lt;a href="../../Renal/Sodium/Hypntrm.htm" class="LinkPage"&gt;Hyponatremia&lt;/a&gt;)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Blood count and acute phase reactants&lt;ol&gt;&lt;li&gt;&lt;a href="../../HemeOnc/Lab/CmpltBldCnt.htm" class="LinkPage"&gt;Complete Blood Count&lt;/a&gt; (CBC)&lt;ol&gt;&lt;li&gt;Refractory &lt;a href="../../HemeOnc/Anemia/McrcytcAnm.htm" class="LinkPage"&gt;Macrocytic Anemia&lt;/a&gt; or &lt;a href="../../HemeOnc/Anemia/NrmcytcAnm.htm" class="LinkPage"&gt;Normocytic Anemia&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../HemeOnc/Lab/CRctvPrtn.htm" class="LinkPage"&gt;C-Reactive Protein&lt;/a&gt; (C-RP) increased&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Uro/Lab/Urnlys.htm" class="LinkPage"&gt;Urinalysis&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../Uro/Urine/PrtnrInAdlts.htm" class="LinkPage"&gt;Proteinuria&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Diagnostics: &lt;a href="../../CV/Exam/Elctrcrdgrm.htm" class="LinkPage"&gt;Electrocardiogram&lt;/a&gt; (EKG)&lt;ol&gt;&lt;li&gt;&lt;a href="../../CV/EKG/Brdycrd.htm" class="LinkPage"&gt;Bradycardia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Low amplitude &lt;a href="../../CV/Exam/QrsCmplx.htm" class="LinkPage"&gt;QRS Complex&lt;/a&gt;es&lt;/li&gt;&lt;li&gt;Flattened or inverted &lt;a href="../../CV/Exam/TWv.htm" class="LinkPage"&gt;T Wave&lt;/a&gt;s&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Imaging&lt;ol&gt;&lt;li&gt;Retarded bone growth&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Complications&lt;ol&gt;&lt;li&gt;&lt;a href="../../CV/Lipid/Hyprchlstrlm.htm" class="LinkPage"&gt;Hyperlipidemia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Htn/Hyprtnsn.htm" class="LinkPage"&gt;Hypertension&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Gyn/Endo/FmlInfrtlty.htm" class="LinkPage"&gt;Infertility&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Neuromuscular dysfunction&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/MyxdmCm.htm" class="LinkPage"&gt;Myxedema Coma&lt;/a&gt; (rare, 0.22 per million persons)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Management&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Endo/Pharm/ThyrdHrmnRplcmnt.htm" class="LinkPage"&gt;Thyroid Replacement&lt;/a&gt; (&lt;a href="../../Endo/Pharm/ThyrdHrmnRplcmnt.htm" class="LinkPage"&gt;Levothyroxine&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;See &lt;a href="../../Endo/Thyroid/SbclnclHypthyrdsm.htm" class="LinkPage"&gt;Subclinical Hypothyroidism&lt;/a&gt; for treatment indications&lt;/li&gt;&lt;li&gt;Elderly: Consider withdrawing &lt;a href="../../Endo/Pharm/ThyrdHrmnRplcmnt.htm" class="LinkPage"&gt;Thyroid Replacement&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Indication: Elderly in Community and nursing-home&lt;/li&gt;&lt;li&gt;May have been diagnosed prior to sensitive TSH&lt;/li&gt;&lt;li&gt;Trial at decreased dose or off for 6 weeks&lt;/li&gt;&lt;li&gt;Recheck TSH after trial&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Pregnancy: Avoidance of Hypothyroidism is critical&lt;ol&gt;&lt;li&gt;Obtain endocrinology consultation&lt;/li&gt;&lt;li&gt;Check &lt;a href="../../Endo/Lab/ThyrdStmltngHrmn.htm" class="LinkPage"&gt;Thyroid Stimulating Hormone&lt;/a&gt; (TSH) at earliest pregnancy diagnosis&lt;/li&gt;&lt;li&gt;See &lt;a href="../../Endo/Pharm/ThyrdHrmnRplcmnt.htm" class="LinkPage"&gt;Levothyroxine&lt;/a&gt; for dosing protocol&lt;ol&gt;&lt;li&gt;Increased dose required from earliest diagnosis of pregnancy until delivery&lt;/li&gt;&lt;li&gt;Decrease dose to baseline immediately after delivery, and recheck TSH in 6-8 weeks&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Recheck TSH every trimester at minimum&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Management: Endocrinology referral indications&lt;ol&gt;&lt;li&gt;Age &amp;lt;18 years old&lt;/li&gt;&lt;li&gt;Cardiac disorders&lt;/li&gt;&lt;li&gt;Concurrent other endocrine disorders&lt;/li&gt;&lt;li&gt;Pregnancy&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Anatomy/ThyrdAntmy.htm" class="LinkPage"&gt;Thyroid Gland&lt;/a&gt; structural abnormality (e.g. &lt;a href="../../Endo/Thyroid/Gtr.htm" class="LinkPage"&gt;Goiter&lt;/a&gt; or thryoid &lt;a href="../../Derm/Exam/Ndl1.htm" class="LinkPage"&gt;Nodule&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;Poor response to &lt;a href="../../Endo/Pharm/ThyrdHrmnRplcmnt.htm" class="LinkPage"&gt;Thyroid Replacement&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Management: Persistent Symptoms despite normal range TSH&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Rheum/Sx/Ftg.htm" class="LinkPage"&gt;Fatigue&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Consider drug interaction with &lt;a href="../../Endo/Pharm/ThyrdHrmnRplcmnt.htm" class="LinkPage"&gt;Levothyroxine&lt;/a&gt;&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Endo/Pharm/ThyrdHrmnRplcmnt.htm" class="LinkPage"&gt;Levothyroxine&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Consider other causes&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Adrenal/AdsnsDs.htm" class="LinkPage"&gt;Adrenal Insufficiency&lt;/a&gt; (rare)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Renal/Failure/ChrncRnlFlr.htm" class="LinkPage"&gt;Chronic Kidney Disease&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../GI/Anatomy/LvrAntmy.htm" class="LinkPage"&gt;Liver&lt;/a&gt; disease&lt;/li&gt;&lt;li&gt;&lt;a href="../../Lung/Apnea/SlpApn.htm" class="LinkPage"&gt;Sleep Apnea&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Psych/Exam/MdDsrdr.htm" class="LinkPage"&gt;Mood Disorder&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../Psych/Depress/MjrDprsn.htm" class="LinkPage"&gt;Major Depression&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Psych/Anxiety/AnxtyDsrdr.htm" class="LinkPage"&gt;Anxiety Disorder&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Pharm/Vitamins/VtmnDfcncy.htm" class="LinkPage"&gt;Vitamin Deficiency&lt;/a&gt; or &lt;a href="../../HemeOnc/Anemia/Anm.htm" class="LinkPage"&gt;Anemia&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../HemeOnc/Anemia/VtmnBDfcncy.htm" class="LinkPage"&gt;Vitamin B12 Deficiency&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../HemeOnc/Anemia/IrnDfcncyAnm.htm" class="LinkPage"&gt;Iron Deficiency Anemia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Pharm/Vitamins/VtmnDDfcncy.htm" class="LinkPage"&gt;Vitamin D Deficiency&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Infection&lt;ol&gt;&lt;li&gt;&lt;a href="../../ID/Virus/Mncls.htm" class="LinkPage"&gt;Mononucleosis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../ID/Vector/LymDs.htm" class="LinkPage"&gt;Lyme Disease&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../HIV/Exam/HmnImndfcncyVrs.htm" class="LinkPage"&gt;HIV Infection&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Alternative replacement strategies are not typically recommended&lt;ol&gt;&lt;li&gt;Dessicated &lt;a href="../../Endo/Anatomy/ThyrdAntmy.htm" class="LinkPage"&gt;Thyroid&lt;/a&gt; hormone or Armour &lt;a href="../../Endo/Anatomy/ThyrdAntmy.htm" class="LinkPage"&gt;Thyroid&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Not recommended by American Association of Endocrinology&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Combination T3 (&lt;a href="../../Endo/Pharm/Lthyrn.htm" class="LinkPage"&gt;Liothyronine&lt;/a&gt;, &lt;a href="../../Endo/Pharm/Lthyrn.htm" class="LinkPage"&gt;Cytomel&lt;/a&gt;) and T4 (&lt;a href="../../Endo/Pharm/ThyrdHrmnRplcmnt.htm" class="LinkPage"&gt;Levothyroxine&lt;/a&gt;) Therapy&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Endo/Pharm/Lthyrn.htm" class="LinkPage"&gt;Liothyronine&lt;/a&gt; (&lt;a href="../../Endo/Pharm/Lthyrn.htm" class="LinkPage"&gt;Cytomel&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;Adding T3 to T4 was initially found to improve neuropsychiatric symptoms&lt;/li&gt;&lt;li&gt;Most studies suggest no benefit and are often associated with iatrogenic &lt;a href="../../Endo/Thyroid/Hyprthyrdsm1.htm" class="LinkPage"&gt;Hyperthyroidism&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Clyde%20%20%5BAU%5D%20AND%202003%20%5BDP%5D%20AND%20%20JAMA%20%20%5BTA%5D" class="LinkRef"&gt;Clyde (2003) JAMA 290:2952-8&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Escobar-Morreale%20%20%5BAU%5D%20AND%202005%20%5BDP%5D%20AND%20%20J%20Clin%20Endocrinol%20Metab%20%20%5BTA%5D" class="LinkRef"&gt;Escobar-Morreale (2005) J Clin Endocrinol Metab 90(8):4946-54&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Management: Abnormal TSH despite previously stable dose&lt;ol&gt;&lt;li&gt;Non-compliance with &lt;a href="../../Endo/Pharm/ThyrdHrmnRplcmnt.htm" class="LinkPage"&gt;Thyroid Replacement&lt;/a&gt; (missed doses)&lt;/li&gt;&lt;li&gt;Change in formulation (e.g. manufacturer change, or generic to brand name)&lt;ol&gt;&lt;li&gt;Avoid changes in formulation and recheck TSH 4-6 weeks after such changes occur&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Hormonal changes&lt;ol&gt;&lt;li&gt;Pregnancy (maintaining euthyroid state in pregnancy is critical)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Gyn/Pharm/OrlCntrcptv.htm" class="LinkPage"&gt;Oral Contraceptive&lt;/a&gt;s or &lt;a href="../../Gyn/Pharm/EstrgnRplcmnt.htm" class="LinkPage"&gt;Estrogen Replacement&lt;/a&gt; started or stopped&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Decreased &lt;a href="../../Endo/Pharm/ThyrdHrmnRplcmnt.htm" class="LinkPage"&gt;Levothyroxine&lt;/a&gt; absorption or drug interaction&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Endo/Pharm/ThyrdHrmnRplcmnt.htm" class="LinkPage"&gt;Levothyroxine&lt;/a&gt; for drug interactions and &lt;a href="../../Pharm/Adverse/FdIntrctns.htm" class="LinkPage"&gt;Food Interactions&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/ThyrdHrmnRplcmnt.htm" class="LinkPage"&gt;Levothyroxine&lt;/a&gt; taken with meals&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Coll%20%20%5BAU%5D%20AND%202000%20%5BDP%5D%20AND%20%20J%20Am%20Board%20Fam%20Pract%20%20%5BTA%5D" class="LinkRef"&gt;Coll (2000) J Am Board Fam Pract 13:403-7&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Gaitonde%20%20%5BAU%5D%20AND%202012%20%5BDP%5D%20AND%20%20Am%20Fam%20Physician%20%20%5BTA%5D" class="LinkRef"&gt;Gaitonde (2012) Am Fam Physician 86(3): 244-51&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Hueston%20%20%5BAU%5D%20AND%202001%20%5BDP%5D%20AND%20%20Am%20Fam%20Physician%20%20%5BTA%5D" class="LinkRef"&gt;Hueston (2001) Am Fam Physician 64(10):1717-24&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Singer%20%20%5BAU%5D%20AND%201995%20%5BDP%5D%20AND%20%20JAMA%20%20%5BTA%5D" class="LinkRef"&gt;Singer (1995) JAMA 273(10):808-12&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0027145</value><value>C0020676</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Thyroid/Hypthyrdsm.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Hypothyroidism, Myxedema</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Thyroid/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Thyroid Crisis  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0040127"&gt;&lt;i&gt;C0040127&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;A dangerous life-threatening hypermetabolic condition characterized by high FEVER and dysfunction of the cardiovascular, the nervous, and the gastrointestinal systems.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Disease or Syndrome (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0040127&amp;amp;tui=T047"&gt;&lt;i&gt;T047&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D013958&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD10&lt;/td&gt;
                &lt;td&gt;E05.5&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;190262002, 29028009&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Crisis, Thyrotoxic, Storm, Thyrotoxic, Thyroid Crisis, Thyroid Storm, Thyrotoxic Crisis, Thyrotoxic Storm, CRISIS THYROID, Crisis, Thyroid, Storm, Thyroid, THYROID CRISIS, THYROID STORM, THYROTOXIC CRISIS, THYROTOXIC STORM, Hyperthyroidism with Storm, Thyroid crisis or storm, thyroid storm, THYROTOX STORM, THYROTOX CRISIS, CRISIS THYROTOX, Thyroid crisis (disorder), thyrotoxic crisis (diagnosis), thyrotoxic crisis, thyroid crisis (storm), thyrotoxic storm, Crisis thyroid, Thyroid Crisis [Disease/Finding], storm thyroid, crisis thyroid, thyrotoxic crises, thyroid crisis, thyroid storms, Thyroid storm, Thyrotoxic crisis, Thyroid crisis, Thyrotoxic crisis (disorder), crisis; thyroid, crisis; thyrotoxic, storm; thyrotoxic, thyroid; crisis, thyrotoxic; crisis, thyrotoxic; storm&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;HYPERTHYROIDIE, Crise thyroïdienne aiguë, Basedowisme aigu, Crise thyréotoxique, Crise thyrotoxique&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;CRISIS TIROIDEA, Tormenta tiroidea, Crisis tiroidea, Tempestad Tiroidea, Tempestad Tirotóxica, Tormenta Tiroidea, Tempestad Tirotoxica, Tormenta Tirotóxica, Tormenta Tirotoxica, Thyroid crisis, crisis tiroidea, crisis tirotóxica (trastorno), crisis tirotóxica, tormenta tiroidea, Crisis tirotóxica, Crisis Tiroidea, Crisis Tirotóxica, Crisis Tirotoxica&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Crisi tireotossica, Crisi tirotossica, Tempesta tireotossica, Tempesta tiroidea, Crisi tiroidea&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;schildkliercrisis, crisis schildklier, thyreoïdstorm, crisis; schildklier, crisis; thyrotoxisch, schildklier; crisis, storm; thyrotoxisch, thyrotoxisch; crisis, thyrotoxisch; storm, Thyrotoxische crisis of storm, thyreotoxische crisis, Crisis, thyrotoxische, Thyreotoxicose, Thyreotoxische crisis, Thyreotoxische storm, Thyrotoxicose, Thyrotoxische crisis, Thyrotoxische storm&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;thyreotoxischen Krise, Krise thyreotoxisch, SCHILDDRUESENHORMNE MASSIV ERHOEH, thyreotoxische Krise, Hyperthyreote Krise, Thyreoidale Krise, Thyreotoxische Krise&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Crise tiroideia, Tempestade tiroideia, TEMPESTADE TIROIDEIA, Crise tirotóxica, Crise Tireóidea, Crise Tireotóxica, Tempestade Tireóidea, Tempestade Tireotóxica&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Tyreotoxisk kris&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;ｺｳｼﾞｮｳｾﾝｸﾘｰｾﾞ, ｺｳｼﾞｮｳｾﾝﾁｭｳﾄﾞｸｸﾘｰｾﾞ, 甲状腺ストーム, ｺｳｼﾞｮｳｾﾝｽﾄｰﾑ, クリーゼ-甲状腺, 甲状腺急性発症, 甲状腺クリーゼ, 甲状腺中毒クリーゼ, 甲状腺中毒急性発作, 甲状腺中毒発症, 甲状腺急性発作, 甲状腺発症&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;tyreotoxická krize, Tyreoidní bouře, Tyreotoxická krize, Tyreoidní krize&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Hypertyreoottinen kriisi&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;TIREOTOKSICHESKII SHKVAL, TIREOTOKSICHESKII KRIZ, TIREOIDNYI SHTORM, ТИРЕОИДНЫЙ ШТОРМ, ТИРЕОТОКСИЧЕСКИЙ КРИЗ, ТИРЕОТОКСИЧЕСКИЙ ШКВАЛ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Korean&lt;/td&gt;
                &lt;td&gt;갑상샘 중독발증 또는 급성발작&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Przełom tarczycowy&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;Pajzsmirigy crisis, Hyperthyreosisos crisis, Hyperthyreotikus crisis&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Thyroid Crisis  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Thyroid Storm</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Thyroid Disease</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Definition&lt;ol&gt;&lt;li&gt;Severe &lt;a href="../../Endo/Thyroid/Hyprthyrdsm1.htm" class="LinkPage"&gt;Thyrotoxicosis&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Management&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/AnthyrdDrg.htm" class="LinkPage"&gt;Propylthiouracil&lt;/a&gt; (PTU)&lt;ol&gt;&lt;li&gt;Load: 1 g load&lt;/li&gt;&lt;li&gt;Maintenance: 300 mg q6h&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/SystmcCrtcstrd.htm" class="LinkPage"&gt;Dexamethasone&lt;/a&gt; 2 mg PO or IV every 6 hours&lt;/li&gt;&lt;li&gt;Potassium iodide (SSKI)&lt;ol&gt;&lt;li&gt;Dose: 4-5 drops every 6 hours for 2 days&lt;/li&gt;&lt;li&gt;Initiate after PTU loading dose&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Pharm/Prprnl.htm" class="LinkPage"&gt;Propranolol&lt;/a&gt; 10-20 mg IV or PO every 6 hours&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0040127</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Thyroid/ThyrdStrm.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Thyroid Storm, Thyroid Crisis</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Thyroid/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Euthyroid Sick Syndromes  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0015190"&gt;&lt;i&gt;C0015190&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;Conditions of abnormal THYROID HORMONES release in patients with apparently normal THYROID GLAND during severe systemic illness, physical TRAUMA, and psychiatric disturbances. It can be caused by the loss of endogenous hypothalamic input or by exogenous drug effects. The most common abnormality results in low T3 THYROID HORMONE with progressive decrease in THYROXINE; (T4) and TSH. Elevated T4 with normal T3 may be seen in diseases in which THYROXINE-BINDING GLOBULIN synthesis and release are increased.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Disease or Syndrome (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0015190&amp;amp;tui=T047"&gt;&lt;i&gt;T047&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D005067&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD9&lt;/td&gt;
                &lt;td&gt;790.94&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD10&lt;/td&gt;
                &lt;td&gt;E07.81&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;237542005&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Euthyroid Sick Syndrome, Euthyroid Sick Syndromes, EUTHYROID SICK SYNDROME &amp;lt;LOW T3/ LOW T4 SYNDROME&amp;gt;, Euthyroid sick syndrome, euthyroid sick syndrome, euthyroid sick syndrome (diagnosis), SICK EUTHYROID SYNDROME, EUTHYROID SICK SYNDROME LOW T3 LOW T4 SYNDROME, Euthyroid sick-syndrome, Euthyroid Sick Syndromes [Disease/Finding], sick euthyroid syndrome, Sick-euthyroid syndrome, Sick-euthyroid syndrome (disorder), sick-euthyroid; syndrome, syndrome; sick-euthyroid, Non Thyroidal Illness Syndrome, Non-Thyroidal Illness Syndrome, Sick Euthyroid Syndrome, Syndrome, Non-Thyroidal Illness, Syndrome, Sick Euthyroid, Syndromes, Non-Thyroidal Illness&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Sindrome tireopatica eutiroidea, Sindrome del malato non-tiroideo, Sick Euthyroid Syndrome, Euthyroid Sick Sindromes&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;甲状腺機能正常症候群, ｺｳｼﾞｮｳｾﾝｷﾉｳｾｲｼﾞｮｳｼｮｳｺｳｸﾞﾝ, 低T3状態, 甲状腺機能正常な病的症候群, 低T3T4症候群, 低T3症候群, トリヨードサイロニン低下状態, 高テトラヨードサイロニン症候群, 高T4症候群, 甲状腺機能正常患者症候群&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Euthyroid-sick syndromes&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;eutyreoidální 'sick' syndromy, Eutyreoidní sick syndrom&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Korkea T4 -oireyhtymä&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;VYSOKOGO POKAZATELIA T4 SINDROM, EUTIREOIDNYE SINDROMY, NIZKOGO POKAZATELIA T3 I T4 SINDROM, NIZKOGO POKAZATELIA T3 SINDROM, ВЫСОКОГО ПОКАЗАТЕЛЯ T4 СИНДРОМ, НИЗКОГО ПОКАЗАТЕЛЯ T3 И T4 СИНДРОМ, НИЗКОГО ПОКАЗАТЕЛЯ T3 СИНДРОМ, ЭУТИРЕОИДНЫЕ СИНДРОМЫ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Zespoły z nieprawidłowym poziomem hormonów tarczycy, Nieprawidłowy poziom T3 i T4 w eutyreozie&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;Euthyroid betegség syndroma&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;sick-euthyroid; syndroom, syndroom; sick-euthyroid, euthyroid sick syndrome, Syndroom, sick euthyroid&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;síndrome del enfermo eutiroideo (trastorno), síndrome del enfermo eutiroideo, Síndrome del enfermo eutiroideo, Sindromes de Eutiroidismo Enfermo, Síndromes del Eutiroideo Enfermo, Síndromes de Eutiroidismo Enfermo, Sindromes del Eutiroideo Enfermo&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Síndrome de doença eutiróide, Síndromes do Eutireóideo-Doente&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Syndrome des maladies générales chez un euthyroïdien, Syndrome euthyroïdien, Syndrome normothyroïdien&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Euthyroid Sick Syndrom, Euthyroid-Sick-Syndrome&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Euthyroid Sick Syndromes  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Subclinical Hypothyroidism</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Thyroid Disease</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;See Also&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/Hypthyrdsm.htm" class="LinkPage"&gt;Hypothyroidism&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Definition&lt;ol&gt;&lt;li&gt;Elevated TSH with normal &lt;a href="../../Endo/Lab/Thyrxn.htm" class="LinkPage"&gt;Free T4&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Epidemiology&lt;ol&gt;&lt;li&gt;&lt;a href="../../Prevent/Epi/DsIncdncRt.htm" class="LinkPage"&gt;Incidence&lt;/a&gt; Older Men: 2-8%&lt;/li&gt;&lt;li&gt;&lt;a href="../../Prevent/Epi/DsIncdncRt.htm" class="LinkPage"&gt;Incidence&lt;/a&gt; Older Women: 5-10%&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Precautions&lt;ol&gt;&lt;li&gt;Normal TSH range increases with age up to 7.5 mIU/L for an 80 year old patient (see TSH)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Indications: Treatment&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/ThyrdStmltngHrmn.htm" class="LinkPage"&gt;Thyroid Stimulating Hormone&lt;/a&gt; (TSH) &amp;gt; 10 mU/ml or&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Anatomy/ThyrdAntmy.htm" class="LinkPage"&gt;Thyroid&lt;/a&gt; peroxidase &lt;a href="../../ID/Exam/Imnglbln.htm" class="LinkPage"&gt;Antibody&lt;/a&gt; positive or&lt;/li&gt;&lt;li&gt;Symptoms with persistent mildly elevatad TSH&lt;ol&gt;&lt;li&gt;Depression&lt;/li&gt;&lt;li&gt;&lt;a href="../../Rheum/Sx/Ftg.htm" class="LinkPage"&gt;Fatigue&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Lipid/Hyprchlstrlm.htm" class="LinkPage"&gt;Hyperlipidemia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/Gtr.htm" class="LinkPage"&gt;Goiter&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Prevent/Hmcystn.htm" class="LinkPage"&gt;Hyperhomocysteinemia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/CAD/ActCrnrySyndrm.htm" class="LinkPage"&gt;Coronary Artery Disease&lt;/a&gt; or &lt;a href="../../CV/Prevent/CrdcRsk.htm" class="LinkPage"&gt;Cardiac Risk Factor&lt;/a&gt;s&lt;/li&gt;&lt;li&gt;Pregnancy or expected pregnancy&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Complications&lt;ol&gt;&lt;li&gt;&lt;a href="../../CV/CAD/ActCrnrySyndrm.htm" class="LinkPage"&gt;Coronary Artery Disease&lt;/a&gt; (increased risk in elderly)&lt;ol&gt;&lt;li&gt;Treating patients with Subclinical Hypothyroidism may lower cardiovascular disease risk&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Biondi%20%20%5BAU%5D%20AND%202002%20%5BDP%5D%20AND%20%20Ann%20Intern%20Med%20%5BTA%5D" class="LinkRef"&gt;Biondi (2002) Ann Intern Med&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Management&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Endo/Thyroid/Hypthyrdsm.htm" class="LinkPage"&gt;Hypothyroidism&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/ThyrdHrmnRplcmnt.htm" class="LinkPage"&gt;Levothyroxine&lt;/a&gt;&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Endo/Pharm/ThyrdHrmnRplcmnt.htm" class="LinkPage"&gt;Levothyroxine&lt;/a&gt; for standard dosing protocol if TSH &amp;gt;10 mIU/L&lt;/li&gt;&lt;li&gt;Dosing (indicated for TSH &amp;lt;10 mIU/L and indications listed above)&lt;ol&gt;&lt;li&gt;Younger than age 50 years&lt;ol&gt;&lt;li&gt;Start at 50 mcg daily and increase by 25 mcg every 6 weeks until goals met&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Over age 50 years&lt;ol&gt;&lt;li&gt;Start at 12.5 to 25 mcg daily and increase by 12.5 to 25 mcg every 6 weeks until goals met&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Goals for treating Subclinical Hypothyroidism&lt;ol&gt;&lt;li&gt;&lt;a href="../../CV/Lab/LdlChlstrl.htm" class="LinkPage"&gt;LDL Cholesterol&lt;/a&gt; falls&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/Hypthyrdsm.htm" class="LinkPage"&gt;Hypothyroidism&lt;/a&gt; symptoms improve&lt;/li&gt;&lt;li&gt;TSH normalizes &amp;lt;4.0&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Precautions: Avoid overtreatment with excessive &lt;a href="../../Endo/Pharm/ThyrdHrmnRplcmnt.htm" class="LinkPage"&gt;Levothyroxine&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Risk of &lt;a href="../../Rheum/Bone/Ostprs.htm" class="LinkPage"&gt;Osteoporosis&lt;/a&gt; worsening, &lt;a href="../../CV/EKG/AtrlFbrltn.htm" class="LinkPage"&gt;Atrial Fibrillation&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Monitoring&lt;ol&gt;&lt;li&gt;Aim to lower &lt;a href="../../Endo/Lab/ThyrdStmltngHrmn.htm" class="LinkPage"&gt;Serum TSH&lt;/a&gt; to mid-normal: 1 to 3 mU/ml&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Course: Risk of longterm progression to overt &lt;a href="../../Endo/Thyroid/Hypthyrdsm.htm" class="LinkPage"&gt;Hypothyroidism&lt;/a&gt;&lt;ol&gt;&lt;li&gt;TSH 4-6 mU/ml: No increased risk of future &lt;a href="../../Endo/Thyroid/Hypthyrdsm.htm" class="LinkPage"&gt;Hypothyroidism&lt;/a&gt;&lt;/li&gt;&lt;li&gt;TSH &amp;gt;6 mU/ml: 27-42% risk of future &lt;a href="../../Endo/Thyroid/Hypthyrdsm.htm" class="LinkPage"&gt;Hypothyroidism&lt;/a&gt;&lt;/li&gt;&lt;li&gt;TSH &amp;gt;6 mU/ml and &lt;a href="../../Endo/Anatomy/ThyrdAntmy.htm" class="LinkPage"&gt;Thyroid&lt;/a&gt; Peroxidase &lt;a href="../../ID/Exam/Imnglbln.htm" class="LinkPage"&gt;Antibody&lt;/a&gt; positive: &amp;gt;55% risk of future &lt;a href="../../Endo/Thyroid/Hypthyrdsm.htm" class="LinkPage"&gt;Hypothyroidism&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;(2012) Presc Lett 19(6): 34&lt;/li&gt;&lt;li&gt;Svec (2001) CMEA Medicine Lecture, San Diego&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Hueston%20%20%5BAU%5D%20AND%202001%20%5BDP%5D%20AND%20%20Am%20Fam%20Physician%20%20%5BTA%5D" class="LinkRef"&gt;Hueston (2001) Am Fam Physician 64(10):1717-24&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Adlin%20%20%5BAU%5D%20AND%201998%20%5BDP%5D%20AND%20%20Am%20Fam%20Physician%20%20%5BTA%5D" class="LinkRef"&gt;Adlin (1998) Am Fam Physician 57(4):776-80&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Vanderpump%20%20%5BAU%5D%20AND%201995%20%5BDP%5D%20AND%20%20Clin%20Endocrinol%20%20%5BTA%5D" class="LinkRef"&gt;Vanderpump (1995) Clin Endocrinol 43:55&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0015190</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Thyroid/SbclnclHypthyrdsm.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Subclinical Hypothyroidism, Sick Euthyroid Syndrome, Euthyroid Sick Syndrome</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Thyroid/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees></FP_UMLS_Trees><FP_Condition_name_check></FP_Condition_name_check><FP_Condition_name><value>Diabetes Mellitus Preconception Counseling</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Obstetrics</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Contraindications to Pregnancy&lt;ol&gt;&lt;li&gt;Renal disease&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Htn/HyprtnsnMngmntFrSpcfcEmrgncs.htm" class="LinkPage"&gt;Uncontrolled Hypertension&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/CAD/AngnPctrs.htm" class="LinkPage"&gt;Ischemic Heart Disease&lt;/a&gt; (&lt;a href="../../CV/CAD/ActCrnrySyndrm.htm" class="LinkPage"&gt;Coronary Artery Disease&lt;/a&gt;)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Preconception &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Sugar&lt;/a&gt; Goals&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/HmglbnAc.htm" class="LinkPage"&gt;Glycosylated Hemoglobin&lt;/a&gt; (&lt;a href="../../Endo/Lab/HmglbnAc.htm" class="LinkPage"&gt;Hemoglobin A1C&lt;/a&gt;): &amp;lt;8.0%&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Sugar&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Fasting &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Sugar&lt;/a&gt;: 60-100 mg/dl&lt;/li&gt;&lt;li&gt;Two hour Postprandial &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Sugar&lt;/a&gt;: 100-120 mg/dl&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Labs: Preconception Evaluation&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/HmglbnAc.htm" class="LinkPage"&gt;Glycosylated Hemoglobin&lt;/a&gt; (&lt;a href="../../Endo/Lab/HmglbnAc.htm" class="LinkPage"&gt;Hemoglobin A1C&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Lab/Lpd.htm" class="LinkPage"&gt;Lipid&lt;/a&gt; profile&lt;/li&gt;&lt;li&gt;Urine 24 hour collection&lt;ol&gt;&lt;li&gt;&lt;a href="../../Uro/Lab/4HrUrnPrtn.htm" class="LinkPage"&gt;24 Hour Urine Protein&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Renal/Lab/CrtnClrnc.htm" class="LinkPage"&gt;Creatinine Clearance&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Ophthalmologic examination&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Exam/Elctrcrdgrm.htm" class="LinkPage"&gt;Electrocardiogram&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Indicated for &lt;a href="../../Endo/DM/DbtsMlts.htm" class="LinkPage"&gt;Diabetes Mellitus&lt;/a&gt; more than 10 years&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Complications: Fetal&lt;ol&gt;&lt;li&gt;Congenital Malformations: 6-10% &lt;a href="../../Prevent/Epi/DsIncdncRt.htm" class="LinkPage"&gt;Incidence&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Organs that develop in first 7-8 weeks gestation&lt;ol&gt;&lt;li&gt;&lt;a href="../../CV/Peds/VntrclrSptlDfct.htm" class="LinkPage"&gt;Ventricular Septal Defect&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../NICU/Neuro/Dysrphsm.htm" class="LinkPage"&gt;Neural Tube Defect&lt;/a&gt; (e.g. &lt;a href="../../NICU/Neuro/SpnlDysrphsm.htm" class="LinkPage"&gt;Spina bifida&lt;/a&gt; or &lt;a href="../../NICU/Neuro/CrnlDysrphsm.htm" class="LinkPage"&gt;Anencephaly&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;Caudal regression syndrome&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../OB/Fetus/FtlMcrsm.htm" class="LinkPage"&gt;Fetal Macrosomia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Fetal relative risk of developing &lt;a href="../../Endo/DM/DbtsMlts.htm" class="LinkPage"&gt;Diabetes Mellitus&lt;/a&gt;: 3&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Complications: Maternal&lt;ol&gt;&lt;li&gt;&lt;a href="../../CV/OB/HyprtnsvDsrdrsOfPrgncy.htm" class="LinkPage"&gt;Pregnancy Induced Hypertension&lt;/a&gt; (PIH)&lt;/li&gt;&lt;li&gt;Complicated &lt;a href="../../Uro/ID/UrnryTrctInfctn.htm" class="LinkPage"&gt;Urinary Tract Infection&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/OB/DbtsMltsPrcncptnCnslng.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Diabetes Mellitus Preconception Counseling</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/OB/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Graves Disease  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0018213"&gt;&lt;i&gt;C0018213&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CHV)&lt;/td&gt;
                &lt;td&gt;a condition usually caused by excessive production of thyroid hormone and characterized by an enlarged thyroid gland&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CHV)&lt;/td&gt;
                &lt;td&gt;a condition usually caused by excessive production of thyroid hormone and characterized by an enlarged thyroid gland&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CHV)&lt;/td&gt;
                &lt;td&gt;a condition usually caused by excessive production of thyroid hormone and characterized by an enlarged thyroid gland&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CHV)&lt;/td&gt;
                &lt;td&gt;a condition usually caused by excessive production of thyroid hormone and characterized by an enlarged thyroid gland&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CHV)&lt;/td&gt;
                &lt;td&gt;a condition usually caused by excessive production of thyroid hormone and characterized by an enlarged thyroid gland&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CHV)&lt;/td&gt;
                &lt;td&gt;a condition usually caused by excessive production of thyroid hormone and characterized by an enlarged thyroid gland&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CHV)&lt;/td&gt;
                &lt;td&gt;a condition usually caused by excessive production of thyroid hormone and characterized by an enlarged thyroid gland&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CHV)&lt;/td&gt;
                &lt;td&gt;a condition usually caused by excessive production of thyroid hormone and characterized by an enlarged thyroid gland&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CHV)&lt;/td&gt;
                &lt;td&gt;a condition usually caused by excessive production of thyroid hormone and characterized by an enlarged thyroid gland&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;Hyperthyroidism associated with diffuse hyperplasia of the thyroid gland (goiter), resulting from production of antibodies that are directed against the thyrotropin receptor complex of the follicular epithelial cells. As a result, the thyroid gland enlarges and secrets increased amounts of thyroid hormones. --2004&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CSP)&lt;/td&gt;
                &lt;td&gt;exophthalmos occurring in association with goiter; hyperthyroidism with protrusion of the eyeballs.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;A common form of hyperthyroidism with a diffuse hyperplastic GOITER. It is an autoimmune disorder that produces antibodies against the THYROID STIMULATING HORMONE RECEPTOR. These autoantibodies activate the TSH receptor, thereby stimulating the THYROID GLAND and hypersecretion of THYROID HORMONES. These autoantibodies can also affect the eyes (GRAVES OPHTHALMOPATHY) and the skin (Graves dermopathy).&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Disease or Syndrome (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0018213&amp;amp;tui=T047"&gt;&lt;i&gt;T047&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D006111&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD10&lt;/td&gt;
                &lt;td&gt;E05.0&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;237823003, 367367004, 237510004, 353295004, 55807009, 190240002, 38591003, 154655004, 267464006, 367449005&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Basedow Disease, Basedow's Disease, Basedows Disease, Disease, Basedow, Exophthalmic Goiter, Exophthalmic Goiters, Goiter, Exophthalmic, Goiters, Exophthalmic, Disease, Basedow's, Disease, Graves', BASEDOW DISEASE, DISEASE GRAVES', EXOPHTHALMIC GOITER, EXOPHTHALMIC GOITRE, FLAJANI DISEASE, GOITER, EXOPHTHALMIC, GRAVES' DISEASE, GOITER EXOPHTHALMIC, HYPERTHYROIDISM &amp;lt;GRAVES DISEASE&amp;gt;, HYPERTHYROIDISM, AUTOIMMUNE, GRD, GRAVES DISEASE, BASEDOW DIS, BASEDOWS DIS, GRAVES DIS, Graves' disease (diagnosis), Grave's disease, Graves' disease (diffuse toxic goiter), grave's disease, Autoimmune hyperthyroidism, Disease Graves', Goiter exophthalmic, GRAVE DISEASE, HYPERTHYROIDISM GRAVES DISEASE, Graves Disease, Basedow disease, Graves Disease [Disease/Finding], Disease;Basedows, basedows disease, hyperthyroidism graves disease, Disease;Graves, disease graves, basedow's disease, graves' disease, graves disease, basedow disease, diseases graves, Basedow's disease, Graves' disease, Graves' disease with exophthalmos, Toxic diffuse goiter with exophthalmos, Exophthalmic goiter, Exophthalmic goitre, Toxic diffuse goitre with exophthalmos, Graves' disease (disorder), Toxic diffuse goiter with exophthalmos (disorder), Basedow's disease (disorder), Flajani, Graves, Basedow, exophthalmic; goiter, exophthalmos; goiter (etiology), exophthalmos; goiter (manifestation), goiter; exophthalmos (etiology), goiter; exophthalmos (manifestation), struma; exophthalmic, Graves' disease [Ambiguous], exophthalmic goiter, Graves' Disease, Disease, Graves, Graves disease, Basedows disease, Graves-Basedow disease&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;GOITRE EXOPHTALMIQUE, MALADIE DE GRAVES-BASEDOW, Hyperthyroïdie autoimmune, Goitre exophtalmique, Maladie de Basedow, Goitre toxique diffus, Maladie de Graves-Basedow, Maladie de Graves&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;ENFERMEDAD DE GRAVES, BOCIO EXOFTALMICO, Bocio exoftálmico, Enfermedad de Graves-Basedow, Graves disease, Graves' disease [Ambiguous], Graves' disease, Basedow's disease, Hipertiroidismo autoinmune, Enfermedad de Graves, Enfermedad de Graves (trastorno), bocio difuso tóxico con exoftalmos, enfermedad de Basedow (trastorno), enfermedad de Basedow, enfermedad de Graves (concepto no activo), enfermedad de Graves (trastorno), enfermedad de Graves con exoftalmos (trastorno), enfermedad de Graves con exoftalmos, enfermedad de Graves, Enfermedad de Basedow, Bocio Exoftálmico, Bocio Exoftalmico&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;BOCIO EXOFTALMICO, Doença de Graves-Basedow, Bócio exoftálmico, DOENCA DE GRAVES-BASEDOW, Hipertiroidismo autoimune, Bócio Exoftalmico, Doença de Basedow, Doença de Graves&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;ziekte van Graves-Basedow, struma exoftalmisch, exoftalmische struma, exoftalmisch struma, ziekte van Graves, auto-immune hyperthyreoïdie, exoftalmie; struma, struma; exoftalmie, ziekte van Basedow, Basedow, ziekte van, Exoftalmisch struma, Struma, exoftalmisch, Ziekte van Graves&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Krankheit Basedow, Krankheit Graves, Graves-Basedow Krankheit, autoimmune Schilddruesenueberfunktion, BASEDOWSCHE KRANKHEIT, MORBUS BASEDOW, Basedow-Krankheit, Basedow-Struma, Exophthalmus mit Struma, Graves-Krankheit&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Malattia di Graves-Basedow, Malattia di Graves, Ipertiroidismo autoimmunitario, Gozzo esoftalmico, Morbo di Basedow, Morbo di Basedow-Graves, Malattia di Flajani-Basedow-Graves, Morbo di Graves&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;グレーブス・バセドウ病, ﾊﾞｾﾄﾞｳﾋﾞｮｳ, ｸﾞﾚｰﾌﾞｽﾋﾞｮｳ, ｸﾞﾚｰﾌﾞｽﾊﾞｾﾄﾞｳﾋﾞｮｳ, ｼﾞｺﾒﾝｴｷｾｲｺｳｼﾞｮｳｾﾝｷﾉｳｺｳｼﾝｼｮｳ, 自己免疫性甲状腺機能亢進症, ｶﾞﾝｷｭｳﾄｯｼｭﾂｾｲｺｳｼﾞｮｳｾﾝｼｭ, Graves氏病, グレーヴス病, グレーヴズ病, バセドウ病, 眼球突出性甲状腺腫, グレーブス病, 浸潤性眼障害, バーゼドー病, バセドー病, 眼障害-浸潤性, 甲状腺腫-眼球突出性, Basedow病, Graves病&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Giftstruma&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;Gravesova nemoc, Basedowova nemoc, Exoftalmická struma, Autoimunní hypertyroidismus, Basedowova choroba, Gravesova choroba, Graves-Basedowova choroba&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Basedowin tauti&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;BAZEDOVA BOLEZN', EKZOFTAL'MICHESKII ZOB, GREIVSA BOLEZN', ZOB EKZOFTAL'MICHESKII, ZOB DIFFUZNYI TOKSICHESKII, БАЗЕДОВА БОЛЕЗНЬ, ГРЕЙВСА БОЛЕЗНЬ, ЗОБ ДИФФУЗНЫЙ ТОКСИЧЕСКИЙ, ЗОБ ЭКЗОФТАЛЬМИЧЕСКИЙ, ЭКЗОФТАЛЬМИЧЕСКИЙ ЗОБ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Croatian&lt;/td&gt;
                &lt;td&gt;GRAVESOVA BOLEST&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Choroba Gravesa-Basedowa, Wole nadczynne&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;Graves-kór, Autoimmun hyperthyreosis, Graves betegség, Graves-Basedow-kór, Basedow-kór, Exophthalmikus struma&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Graves Disease  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Grave's Disease</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Thyroid Disease</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;See Also&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Eye/ThyrdEyDs.htm" class="LinkPage"&gt;Thyroid Eye Disease&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/Hyprthyrdsm1.htm" class="LinkPage"&gt;Hyperthyroidism&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Epidemiology&lt;ol&gt;&lt;li&gt;Most common cause of &lt;a href="../../Endo/Thyroid/Hyprthyrdsm1.htm" class="LinkPage"&gt;Thyrotoxicosis&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Signs: Specific to Grave's Disease&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Endo/Thyroid/Hyprthyrdsm1.htm" class="LinkPage"&gt;Hyperthyroidism&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Diffuse &lt;a href="../../Endo/Thyroid/Gtr.htm" class="LinkPage"&gt;Goiter&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Audible bruit over &lt;a href="../../Endo/Anatomy/ThyrdAntmy.htm" class="LinkPage"&gt;Thyroid&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Infiltrative ophthalmopathy (&lt;a href="../../Endo/Eye/ThyrdEyDs.htm" class="LinkPage"&gt;Thyroid Eye Disease&lt;/a&gt;)&lt;ol&gt;&lt;li&gt;Ophthalmoplegia&lt;/li&gt;&lt;li&gt;&lt;a href="../../Eye/Sx/Prpts.htm" class="LinkPage"&gt;Proptosis&lt;/a&gt; (&lt;a href="../../Eye/Sx/Prpts.htm" class="LinkPage"&gt;Exophthalmos&lt;/a&gt;) in 50% of cases&lt;/li&gt;&lt;li&gt;Periorbital swelling&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Dermopathy&lt;ol&gt;&lt;li&gt;Pretibial &lt;a href="../../Endo/Thyroid/Hypthyrdsm.htm" class="LinkPage"&gt;Myxedema&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Lab&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/AnthyrdAntbdy.htm" class="LinkPage"&gt;Thyroid Stimulating Immunoglobulin&lt;/a&gt; (TSH receptor ab)&lt;ol&gt;&lt;li&gt;Specific to Grave's Disease&lt;/li&gt;&lt;li&gt;Linked with ophthalmopathy&lt;/li&gt;&lt;li&gt;Usually not needed for diagnosis&lt;/li&gt;&lt;li&gt;May be used to monitor effects of treatment&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/AnthyrdAntbdy.htm" class="LinkPage"&gt;Antithyroid Peroxidase Antibody&lt;/a&gt; negative&lt;ol&gt;&lt;li&gt;Contrast with positive in &lt;a href="../../Endo/Thyroid/HshmtsThyrdts.htm" class="LinkPage"&gt;Hashimoto's Thyroiditis&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Imaging&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Anatomy/ThyrdAntmy.htm" class="LinkPage"&gt;Thyroid&lt;/a&gt;&lt;a href="../../Rad/Ultrasound/Ultrsnd.htm" class="LinkPage"&gt;Ultrasound&lt;/a&gt; with doppler&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Anatomy/ThyrdAntmy.htm" class="LinkPage"&gt;Thyroid&lt;/a&gt; hypervascularity with increased flow&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Anatomy/ThyrdAntmy.htm" class="LinkPage"&gt;Thyroid&lt;/a&gt; uptake and scan&lt;ol&gt;&lt;li&gt;High uptake on scan&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Management&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Endo/Thyroid/HyprthyrdsmMngmnt.htm" class="LinkPage"&gt;Hyperthyroidism Management&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Referral to ophthalmology for ocular involvement&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0018213</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Thyroid/GrvsDs.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Grave's Disease, Basedows Disease, Exophthalmic Goiter</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Thyroid/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Hyperthyroidism  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0020550"&gt;&lt;i&gt;C0020550&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;Overactivity of the thyroid gland resulting in overproduction of thyroid hormone and increased metabolic rate. Causes include diffuse hyperplasia of the thyroid gland (Graves' disease), single nodule in the thyroid gland, and thyroiditis. The symptoms are related to the increased metabolic rate and include weight loss, fatigue, heat intolerance, excessive sweating, diarrhea, tachycardia, insomnia, muscle weakness, and tremor.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A disorder characterized by excessive levels of thyroid hormone in the body. Common causes include an overactive thyroid gland or thyroid hormone overdose.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CSP)&lt;/td&gt;
                &lt;td&gt;excessive functional activity of the thyroid gland.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;Hypersecretion of THYROID HORMONES from the THYROID GLAND. Elevated levels of thyroid hormones increase BASAL METABOLIC RATE.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;Too much thyroid hormone. Symptoms include weight loss, chest pain, cramps, diarrhea, and nervousness.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Disease or Syndrome (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0020550&amp;amp;tui=T047"&gt;&lt;i&gt;T047&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D006980&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD10&lt;/td&gt;
                &lt;td&gt;E05.9&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;34486009, 154655004, 190239004, 267464006&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Hyperthyroidism, HYPERTHYROIDISM, Hyperthyroidism, NOS, overactive thyroid, hyperthyroidism, hyperthyroidism (diagnosis), Hyperthyroidism NOS, Hyperthyroidism [Disease/Finding], Primary Hyperthyroidism, Primary Hyperthyroidisms, Hyperthyroidism, Primary, hyperthyroidism nos, Hyperthyroidism (disorder), Overactive Thyroid&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;HYPERTHYROIDIE, Hyperthyréose, Hyperthyroïdie, Hyperthyroïdisme&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;HIPERTIROIDISMO, Hyperthyroidism, hipertiroidismo (trastorno), hipertiroidismo, Hipertiroidismo&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;HYPERTHYREOSE, Hyperthyroidismus, Hyperthyreoidismus, Hyperthyreose&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;甲状腺機能亢進症, ｺｳｼﾞｮｳｾﾝｷﾉｳｺｳｼﾝｼｮｳ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Hypertyreos&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;hypertyreoidismus, Hypertyreóza&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Kilpirauhasen liikatoiminta&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;GIPERTIREOIDIZM, GIPERTIREOZ, ГИПЕРТИРЕОЗ, ГИПЕРТИРЕОИДИЗМ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;HIPERTIROIDISMO, Hipertiroidismo, Hipertireoidismo&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Croatian&lt;/td&gt;
                &lt;td&gt;HIPERTIREOZA&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Nadczynność tarczycy&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;Hyperthyreosis&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;hyperthyroïdie, Basedow, ziekte van, Hyperthyreose, Hyperthyreoïdie, Hyperthyroïdie, Thyreoïdie, hyper-&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Ipertiroidismo&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Hyperthyroidism  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Hyperthyroidism Management</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Thyroid Disease</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;See Also&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/ThyrdStrm.htm" class="LinkPage"&gt;Thyroid Storm&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/Hyprthyrdsm1.htm" class="LinkPage"&gt;Hyperthyroidism&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/GrvsDs.htm" class="LinkPage"&gt;Grave's Disease&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/SbclnclHyprthyrdsm.htm" class="LinkPage"&gt;Subclinical Hyperthyroidism&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Medications: Antiadrenergic Medications&lt;ol&gt;&lt;li&gt;Indications&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/Thyrdts.htm" class="LinkPage"&gt;Thyroiditis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Concurrent initially with ablation, PTU/MTZ, surgery&lt;/li&gt;&lt;li&gt;Symptomatic control&lt;ol&gt;&lt;li&gt;Controls &lt;a href="../../Neuro/Tremor/Trmr.htm" class="LinkPage"&gt;Tremor&lt;/a&gt;, &lt;a href="../../CV/Sx/Plptn.htm" class="LinkPage"&gt;Palpitation&lt;/a&gt;s, nervousness&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Pharm/BtBlckr.htm" class="LinkPage"&gt;Beta Blocker&lt;/a&gt;s (non-selective preferred)&lt;ol&gt;&lt;li&gt;&lt;a href="../../CV/Pharm/Prprnl.htm" class="LinkPage"&gt;Propranolol&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Start: 10-20 mg PO q6 hours&lt;/li&gt;&lt;li&gt;Advance to 20 to 80 mg PO q6 hours&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Pharm/Dltzm.htm" class="LinkPage"&gt;Diltiazem&lt;/a&gt; (&lt;a href="../../CV/Pharm/Dltzm.htm" class="LinkPage"&gt;Cardizem&lt;/a&gt;)&lt;ol&gt;&lt;li&gt;Alternative if &lt;a href="../../CV/Pharm/BtBlckr.htm" class="LinkPage"&gt;Beta Blocker&lt;/a&gt;s not tolerated&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Medications: Antithyroid Medications&lt;ol&gt;&lt;li&gt;Indications&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/Hyprthyrdsm1.htm" class="LinkPage"&gt;Hyperthyroidism&lt;/a&gt; in children and adolescents&lt;/li&gt;&lt;li&gt;Pregnancy (PTU)&lt;/li&gt;&lt;li&gt;Severe &lt;a href="../../Endo/Thyroid/GrvsDs.htm" class="LinkPage"&gt;Grave's Disease&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Antithyroid Medications&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/AnthyrdDrg.htm" class="LinkPage"&gt;Methimazole&lt;/a&gt; 15-30 mg per day&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/AnthyrdDrg.htm" class="LinkPage"&gt;Propylthiouracil&lt;/a&gt; (PTU) 100-200 mg PO tid&lt;ol&gt;&lt;li&gt;Indicated in pregnancy&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Monitoring&lt;ol&gt;&lt;li&gt;See Antithyroid Medications&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Management: Ablation&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Rdn.htm" class="LinkPage"&gt;Radioactive Iodine&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Management of choice for &lt;a href="../../Endo/Thyroid/GrvsDs.htm" class="LinkPage"&gt;Grave's Disease&lt;/a&gt; of all ages&lt;/li&gt;&lt;li&gt;Recurrent &lt;a href="../../Endo/Thyroid/Hyprthyrdsm1.htm" class="LinkPage"&gt;Hyperthyroidism&lt;/a&gt; after &lt;a href="../../Endo/Pharm/AnthyrdDrg.htm" class="LinkPage"&gt;Antithyroid Drug&lt;/a&gt;s&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/MltndlrGtr.htm" class="LinkPage"&gt;Toxic Multinodular Goiter&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Toxic &lt;a href="../../Derm/Exam/Ndl1.htm" class="LinkPage"&gt;Nodule&lt;/a&gt; in patient over age 40 years&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Subtotal &lt;a href="../../Endo/Anatomy/ThyrdAntmy.htm" class="LinkPage"&gt;Thyroid&lt;/a&gt;ectomy&lt;ol&gt;&lt;li&gt;Pregnancy&lt;/li&gt;&lt;li&gt;Children intollerant to antithyroid medications&lt;/li&gt;&lt;li&gt;Toxic &lt;a href="../../Derm/Exam/Ndl1.htm" class="LinkPage"&gt;Nodule&lt;/a&gt; under age 40 years&lt;/li&gt;&lt;li&gt;Large &lt;a href="../../Endo/Anatomy/ThyrdAntmy.htm" class="LinkPage"&gt;Thyroid&lt;/a&gt;&lt;a href="../../Endo/Thyroid/Gtr.htm" class="LinkPage"&gt;Goiter&lt;/a&gt; causing local compression&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Monitoring after ablation&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/ThyrdStmltngHrmn.htm" class="LinkPage"&gt;Thyroid Stimulating Hormone&lt;/a&gt; may not be accurate&lt;/li&gt;&lt;li&gt;Follow &lt;a href="../../Endo/Lab/Thyrxn.htm" class="LinkPage"&gt;Free T4&lt;/a&gt;, &lt;a href="../../Endo/Lab/Trdthyrn.htm" class="LinkPage"&gt;Free T3&lt;/a&gt; to base &lt;a href="../../Endo/Pharm/ThyrdHrmnRplcmnt.htm" class="LinkPage"&gt;Thyroid Replacement&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Ginsberg%20%20%5BAU%5D%20AND%202003%20%5BDP%5D%20AND%20%20CMAJ%20%20%5BTA%5D" class="LinkRef"&gt;Ginsberg (2003) CMAJ 168:575-85&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Reid%20%20%5BAU%5D%20AND%202005%20%5BDP%5D%20AND%20%20Am%20Fam%20Physician%20%20%5BTA%5D" class="LinkRef"&gt;Reid (2005) Am Fam Physician 72:623-36&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0020550</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Thyroid/HyprthyrdsmMngmnt.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Hyperthyroidism Management</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Thyroid/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Myxedema coma  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0238298"&gt;&lt;i&gt;C0238298&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Disease or Syndrome (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0238298&amp;amp;tui=T047"&gt;&lt;i&gt;T047&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD10&lt;/td&gt;
                &lt;td&gt;E03.5&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;190292006, 21263006&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;MYXEDEMA COMA, Myxoedema coma (disorder), myxedema coma, myxedema coma (diagnosis), Myxedema coma, Hypothyroid coma, Myxoedema coma, Myxedema coma (disorder), coma; myxedema, myxedema; coma&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Coma da mixedema&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Coma de myxoedème, Coma myxoedèmateux&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Coma de mixedema, Coma mixedematoso&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;Coma por mixedema, Myxoedema coma, Myxedema coma, coma hipotiroideo (trastorno), coma hipotiroideo, coma mixedematoso, Coma mixedematoso&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;粘液水腫性昏睡, ﾈﾝｴｷｽｲｼｭｾｲｺﾝｽｲ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;Myxedémové kóma&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Korean&lt;/td&gt;
                &lt;td&gt;점액수종 혼수&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;Mixödemás kóma, Mixödémás kóma&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;coma; myxoedeem, myxoedeem; coma, Myxoedeemcoma, myxoedeem coma&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Myxoedemkoma&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Myxedema coma  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Myxedema Coma</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Thyroid Disease</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;See Also&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/Hypthyrdsm.htm" class="LinkPage"&gt;Hypothyroidism&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Epidemiology&lt;ol&gt;&lt;li&gt;&lt;a href="../../Prevent/Epi/DsIncdncRt.htm" class="LinkPage"&gt;Incidence&lt;/a&gt;: Rare (0.22 per Million persons in U.S.)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Pathophysiology&lt;ol&gt;&lt;li&gt;Severe &lt;a href="../../Endo/Thyroid/Hypthyrdsm.htm" class="LinkPage"&gt;Hypothyroidism&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Predisposing factors&lt;ol&gt;&lt;li&gt;Cold exposure&lt;/li&gt;&lt;li&gt;Trauma&lt;/li&gt;&lt;li&gt;Infection&lt;/li&gt;&lt;li&gt;&lt;a href="../../Pharm/Analgesic/NrctcAnlgsc.htm" class="LinkPage"&gt;Narcotic&lt;/a&gt;s&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Signs&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Endo/Thyroid/Hypthyrdsm.htm" class="LinkPage"&gt;Hypothyroidism&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Hypothermic stuporous state&lt;/li&gt;&lt;li&gt;Respiratory depression with hypercarbia&lt;/li&gt;&lt;li&gt;&lt;a href="../../Lung/Pleura/PlrlEfsn.htm" class="LinkPage"&gt;Pleural Effusion&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Percardial effusion&lt;/li&gt;&lt;li&gt;&lt;a href="../../GI/Bowel/Mgcln.htm" class="LinkPage"&gt;Megacolon&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Hemodynamic instability&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Labs&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Endo/Thyroid/Hypthyrdsm.htm" class="LinkPage"&gt;Hypothyroidism&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Management&lt;ol&gt;&lt;li&gt;Medical emergency with high mortality&lt;/li&gt;&lt;li&gt;Endocrinology consultation&lt;/li&gt;&lt;li&gt;ICU admission&lt;/li&gt;&lt;li&gt;&lt;a href="../../Lung/Procedure/MchnclVntltn.htm" class="LinkPage"&gt;Ventilator&lt;/a&gt;y and hemodynamic support&lt;/li&gt;&lt;li&gt;Anticipate electrolyte abnormalities (e.g. &lt;a href="../../Renal/Sodium/Hypntrm.htm" class="LinkPage"&gt;Hyponatremia&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;Consider &lt;a href="../../Endo/Pharm/SystmcCrtcstrd.htm" class="LinkPage"&gt;Corticosteroid&lt;/a&gt;s&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Wartofsky%20%20%5BAU%5D%20AND%202006%20%5BDP%5D%20AND%20%20Endocrinol%20Metab%20Clin%20North%20Am%20%20%5BTA%5D" class="LinkRef"&gt;Wartofsky (2006) Endocrinol Metab Clin North Am 35(4): 687-98&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0238298</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Thyroid/MyxdmCm.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Myxedema Coma</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Thyroid/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Decreased thyroid stimulating hormone level  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C1295607"&gt;&lt;i&gt;C1295607&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Finding (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C1295607&amp;amp;tui=T033"&gt;&lt;i&gt;T033&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;124773007, 131017004&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Decreased thyroid stimulating hormone level -RETIRED-, Decreased thyroid stimulating hormone level (biological function) (finding), Decreased thyroid stimulating hormone level (finding), Decreased thyroid stimulating hormone level, Decreased thyroid stimulating hormone level (biological function)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;disminución del nivel de tirotropina, nivel de tirotropina disminuido (hallazgo), disminución del nivel de tirotropina (hallazgo), nivel de tirotropina disminuido, disminución del nivel de tirotropina (función biológica), disminución del nivel de tirotropina - RETIRADO - (concepto no activo), disminución del nivel de tirotropina - RETIRADO -&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Decreased thyroid stimulating hormone level  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Subclinical Hyperthyroidism</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Thyroid Disease</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Definition&lt;ol&gt;&lt;li&gt;Euthyroid patient with TSH suppression&lt;ol&gt;&lt;li&gt;Low but detectable TSH: 0.1 to 0.4 mIU/L&lt;/li&gt;&lt;li&gt;Suppressed TSH: &amp;lt;0.1 mIU/L&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Epidemiology&lt;ol&gt;&lt;li&gt;&lt;a href="../../Prevent/Epi/DsPrvlncRt.htm" class="LinkPage"&gt;Prevalence&lt;/a&gt; in U.S. (study included patients over age 12 years old)&lt;ol&gt;&lt;li&gt;TSH &amp;lt;0.4 mIU/L: 3.2%&lt;/li&gt;&lt;li&gt;TSH &amp;lt;0.1 mIU/L: 0.7%&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Hollowell%20%20%5BAU%5D%20AND%202002%20%5BDP%5D%20AND%20%20J%20Clin%20Endocrinol%20Metab%20%20%5BTA%5D" class="LinkRef"&gt;Hollowell (2002) J Clin Endocrinol Metab 87(2): 489-99&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;More common in the elderly&lt;ol&gt;&lt;li&gt;Prevalance in age over 70 years approaches 15% in iodine deficient regions&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Aghini%20%20%5BAU%5D%20AND%201999%20%5BDP%5D%20AND%20%20J%20Clin%20Endocrinol%20Metab%20%20%5BTA%5D" class="LinkRef"&gt;Aghini (1999) J Clin Endocrinol Metab 84(2): 561-6&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Causes&lt;ol&gt;&lt;li&gt;Over-treatment of &lt;a href="../../Endo/Thyroid/Hypthyrdsm.htm" class="LinkPage"&gt;Hypothyroidism&lt;/a&gt; (excessive &lt;a href="../../Endo/Pharm/ThyrdHrmnRplcmnt.htm" class="LinkPage"&gt;Thyroid Replacement&lt;/a&gt;)&lt;ol&gt;&lt;li&gt;&lt;a href="../../Prevent/Epi/DsPrvlncRt.htm" class="LinkPage"&gt;Prevalence&lt;/a&gt; approaches 20%&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/MltndlrGtr.htm" class="LinkPage"&gt;Multinodular Goiter&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Silent &lt;a href="../../Endo/Thyroid/Thyrdts.htm" class="LinkPage"&gt;Thyroiditis&lt;/a&gt; (TSH normalizes within months)&lt;/li&gt;&lt;li&gt;Pituitary abnormalities (&lt;a href="../../Endo/Lab/Thyrxn.htm" class="LinkPage"&gt;Free T4&lt;/a&gt; also suppressed)&lt;/li&gt;&lt;li&gt;Early &lt;a href="../../Endo/Thyroid/Hyprthyrdsm1.htm" class="LinkPage"&gt;Hyperthyroidism&lt;/a&gt; in transition&lt;/li&gt;&lt;li&gt;Partially treated &lt;a href="../../Endo/Thyroid/Hyprthyrdsm1.htm" class="LinkPage"&gt;Hyperthyroidism&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Iodine&lt;ol&gt;&lt;li&gt;Recent radiocontrast administration (e.g. IVP)&lt;/li&gt;&lt;li&gt;Other excessive iodine intake&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Medications&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/SystmcCrtcstrd.htm" class="LinkPage"&gt;Corticosteroid&lt;/a&gt;s&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Pharm/Dpmn.htm" class="LinkPage"&gt;Dopamine&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Symptoms&lt;ol&gt;&lt;li&gt;Significant &lt;a href="../../Endo/Thyroid/Hyprthyrdsm1.htm" class="LinkPage"&gt;Hyperthyroidism&lt;/a&gt; symptoms absent&lt;/li&gt;&lt;li&gt;Nonspecific symptoms may be present&lt;ol&gt;&lt;li&gt;Malaise&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/EKG/Tchycrd.htm" class="LinkPage"&gt;Tachycardia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Nervousness or anxiety&lt;/li&gt;&lt;li&gt;&lt;a href="../../Rheum/Sx/MsclWkns.htm" class="LinkPage"&gt;Muscle Weakness&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Differential Diagnosis&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Endo/Thyroid/Hyprthyrdsm1.htm" class="LinkPage"&gt;Hyperthyroidism&lt;/a&gt;&lt;/li&gt;&lt;li&gt;See &lt;a href="../../Endo/Lab/ThyrdStmltngHrmn.htm" class="LinkPage"&gt;Thyroid Stimulating Hormone&lt;/a&gt; (TSH)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Complications&lt;ol&gt;&lt;li&gt;Overt &lt;a href="../../Endo/Thyroid/Hyprthyrdsm1.htm" class="LinkPage"&gt;Hyperthyroidism&lt;/a&gt;&lt;ol&gt;&lt;li&gt;TSH 0.1 to 0.4 mIU/L: 1-3% risk per year (in age over 60 years)&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Rosario%20%20%5BAU%5D%20AND%202010%20%5BDP%5D%20AND%20%20Clin%20Endocrinol%20%20%5BTA%5D" class="LinkRef"&gt;Rosario (2010) Clin Endocrinol 72(5): 685-8&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;TSH &amp;lt;0.1 mIU/L: 27% 27% risk in 2 years (in age over 65 years)&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Rosario%20%20%5BAU%5D%20AND%202008%20%5BDP%5D%20AND%20%20Clin%20Endocrinol%20%20%5BTA%5D" class="LinkRef"&gt;Rosario (2008) Clin Endocrinol 68(3): 491-2&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Cause of Subclinical Hyperthyroidism impacts risk of progression&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/MltndlrGtr.htm" class="LinkPage"&gt;Multinodular Goiter&lt;/a&gt; is typically stable without progression&lt;/li&gt;&lt;li&gt;Graves Disease is more unpredictable in terms of course&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Cardiovascular effects&lt;ol&gt;&lt;li&gt;&lt;a href="../../CV/EKG/AtrlFbrltn.htm" class="LinkPage"&gt;Atrial Fibrillation&lt;/a&gt; (relative risk: 3-5 in age &amp;gt; 60)&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Auer%20%20%5BAU%5D%20AND%202001%20%5BDP%5D%20AND%20%20Am%20Heart%20J%20%20%5BTA%5D" class="LinkRef"&gt;Auer (2001) Am Heart J 142(5):838-42&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Sawin%20%20%5BAU%5D%20AND%201994%20%5BDP%5D%20AND%20%20N%20Engl%20J%20Med%20%20%5BTA%5D" class="LinkRef"&gt;Sawin (1994) N Engl J Med 331(19): 1249-52&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Increased left ventricular mass&lt;/li&gt;&lt;li&gt;Decreased &lt;a href="../../CV/Exam/HrtRt.htm" class="LinkPage"&gt;Heart Rate&lt;/a&gt; variability&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Increased Mortality in older patients&lt;ol&gt;&lt;li&gt;Mortality increased by 20% over 10 years (especially if TSH persistently &amp;lt;0.1)&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Haentjens%20%20%5BAU%5D%20AND%202008%20%5BDP%5D%20AND%20%20Eur%20J%20Endocrinol%20%20%5BTA%5D" class="LinkRef"&gt;Haentjens (2008) Eur J Endocrinol 159(3): 329-41&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Sgarbi%20%20%5BAU%5D%20AND%202010%20%5BDP%5D%20AND%20%20Eur%20J%20Endocrinol%20%20%5BTA%5D" class="LinkRef"&gt;Sgarbi (2010) Eur J Endocrinol 162(3): 569-77&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Increased &lt;a href="../../Rheum/Bone/Ostprs.htm" class="LinkPage"&gt;Osteoporosis&lt;/a&gt; risk in postmenopausal women&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Rosario%20%20%5BAU%5D%20AND%202008%20%5BDP%5D%20AND%20%20Arq%20Bras%20Endocrinol%20Metabol%20%20%5BTA%5D" class="LinkRef"&gt;Rosario (2008) Arq Bras Endocrinol Metabol 52(9):1448-51&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Uzzan%20%20%5BAU%5D%20AND%201996%20%5BDP%5D%20AND%20%20J%20Clin%20Endocrinol%20Metab%20%20%5BTA%5D" class="LinkRef"&gt;Uzzan (1996) J Clin Endocrinol Metab 81(12): 4278-89&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Increased &lt;a href="../../Rheum/Sx/MsclWkns.htm" class="LinkPage"&gt;Muscle Weakness&lt;/a&gt; and atrophy risk&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Labs&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/ThyrdStmltngHrmn.htm" class="LinkPage"&gt;Thyroid Stimulating Hormone&lt;/a&gt; (TSH) decreased&lt;/li&gt;&lt;li&gt;Serum Free &lt;a href="../../Endo/Lab/Thyrxn.htm" class="LinkPage"&gt;Thyroxine&lt;/a&gt; (&lt;a href="../../Endo/Lab/Thyrxn.htm" class="LinkPage"&gt;Free T4&lt;/a&gt;) normal&lt;/li&gt;&lt;li&gt;Serum Free &lt;a href="../../Endo/Lab/Trdthyrn.htm" class="LinkPage"&gt;Triiodothyronine&lt;/a&gt; (&lt;a href="../../Endo/Lab/Trdthyrn.htm" class="LinkPage"&gt;Free T3&lt;/a&gt;) nornal&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Imaging: 24 hour &lt;a href="../../Endo/Rad/RdctvIdnUptkScn.htm" class="LinkPage"&gt;Radioactive Iodine Uptake Scan&lt;/a&gt; (&lt;a href="../../Endo/Rad/RdctvIdnUptkScn.htm" class="LinkPage"&gt;RAIU&lt;/a&gt;)&lt;ol&gt;&lt;li&gt;Increased &amp;gt;30% at 24 hours&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/GrvsDs.htm" class="LinkPage"&gt;Grave's Disease&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/MltndlrGtr.htm" class="LinkPage"&gt;Multinodular Goiter&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Autonomous &lt;a href="../../Endo/HemeOnc/ThyrdAdnm.htm" class="LinkPage"&gt;Thyroid Nodule&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Decreased &amp;lt;5% at 24 hours&lt;ol&gt;&lt;li&gt;Silent &lt;a href="../../Endo/Thyroid/Thyrdts.htm" class="LinkPage"&gt;Thyroiditis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/OB/PstprtmThyrdts.htm" class="LinkPage"&gt;Postpartum Thyroiditis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Exogenous &lt;a href="../../Endo/Anatomy/ThyrdAntmy.htm" class="LinkPage"&gt;Thyroid&lt;/a&gt; hormone intake&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Evaluation&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Endo/Thyroid/Hyprthyrdsm1.htm" class="LinkPage"&gt;Hyperthyroidism&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Initial lab testing&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/ThyrdStmltngHrmn.htm" class="LinkPage"&gt;Thyroid Stimulating Hormone&lt;/a&gt; (TSH)&lt;/li&gt;&lt;li&gt;Serum &lt;a href="../../Endo/Lab/Thyrxn.htm" class="LinkPage"&gt;Free T4&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Serum &lt;a href="../../Endo/Lab/Trdthyrn.htm" class="LinkPage"&gt;Free T3&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../HemeOnc/Lab/CmpltBldCnt.htm" class="LinkPage"&gt;Complete Blood Count&lt;/a&gt; (CBC)&lt;/li&gt;&lt;li&gt;Chemistry panel&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Subsequent monthly testing for 3 months&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/ThyrdStmltngHrmn.htm" class="LinkPage"&gt;Thyroid Stimulating Hormone&lt;/a&gt; (TSH)&lt;/li&gt;&lt;li&gt;Serum &lt;a href="../../Endo/Lab/Thyrxn.htm" class="LinkPage"&gt;Free T4&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Serum &lt;a href="../../Endo/Lab/Trdthyrn.htm" class="LinkPage"&gt;Free T3&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Three month assessment&lt;ol&gt;&lt;li&gt;Overt &lt;a href="../../Endo/Thyroid/Hyprthyrdsm1.htm" class="LinkPage"&gt;Hyperthyroidism&lt;/a&gt; (increased &lt;a href="../../Endo/Lab/Thyrxn.htm" class="LinkPage"&gt;Free T4&lt;/a&gt; or &lt;a href="../../Endo/Lab/Trdthyrn.htm" class="LinkPage"&gt;Free T3&lt;/a&gt;)&lt;ol&gt;&lt;li&gt;Evaluate as &lt;a href="../../Endo/Thyroid/Hyprthyrdsm1.htm" class="LinkPage"&gt;Hyperthyroidism&lt;/a&gt; (including &lt;a href="../../Endo/Rad/RdctvIdnUptkScn.htm" class="LinkPage"&gt;RAIU&lt;/a&gt; Scan)&lt;/li&gt;&lt;li&gt;See &lt;a href="../../Endo/Thyroid/HyprthyrdsmMngmnt.htm" class="LinkPage"&gt;Hyperthyroidism Management&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;TSH below 0.1 with normal &lt;a href="../../Endo/Lab/Thyrxn.htm" class="LinkPage"&gt;Free T4&lt;/a&gt;, &lt;a href="../../Endo/Lab/Trdthyrn.htm" class="LinkPage"&gt;Free T3&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Obtain 24 hour &lt;a href="../../Endo/Rad/RdctvIdnUptkScn.htm" class="LinkPage"&gt;Radioactive Iodine Uptake Scan&lt;/a&gt; (&lt;a href="../../Endo/Rad/RdctvIdnUptkScn.htm" class="LinkPage"&gt;RAIU&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;Consider &lt;a href="../../Endo/Thyroid/HyprthyrdsmMngmnt.htm" class="LinkPage"&gt;Hyperthyroidism Management&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Symptomatic or&lt;/li&gt;&lt;li&gt;Over age 65 years or&lt;/li&gt;&lt;li&gt;Cardiovascular disease or significant risk factors or&lt;/li&gt;&lt;li&gt;&lt;a href="../../Rheum/Bone/Ostprs.htm" class="LinkPage"&gt;Osteoporosis&lt;/a&gt; or &lt;a href="../../Rheum/Bone/Ostprs.htm" class="LinkPage"&gt;Osteopenia&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;TSH between 0.1 to 0.45 with normal &lt;a href="../../Endo/Lab/Thyrxn.htm" class="LinkPage"&gt;Free T4&lt;/a&gt;, &lt;a href="../../Endo/Lab/Trdthyrn.htm" class="LinkPage"&gt;Free T3&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Obtain 24 hour &lt;a href="../../Endo/Rad/RdctvIdnUptkScn.htm" class="LinkPage"&gt;Radioactive Iodine Uptake Scan&lt;/a&gt; (&lt;a href="../../Endo/Rad/RdctvIdnUptkScn.htm" class="LinkPage"&gt;RAIU&lt;/a&gt;)&lt;ol&gt;&lt;li&gt;Evaluate for endogenous disease (e.g. Destructive &lt;a href="../../Endo/Thyroid/Thyrdts.htm" class="LinkPage"&gt;Thyroiditis&lt;/a&gt;, &lt;a href="../../Endo/Thyroid/GrvsDs.htm" class="LinkPage"&gt;Grave's Disease&lt;/a&gt;)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Periodic re-evaluation of TSH every 3-12 months&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Donangelo%20%20%5BAU%5D%20AND%202011%20%5BDP%5D%20AND%20%20Am%20Fam%20Physician%20%20%5BTA%5D" class="LinkRef"&gt;Donangelo (2011) Am Fam Physician 83(8): 933-8&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Marqusee%20%20%5BAU%5D%20AND%201998%20%5BDP%5D%20AND%20%20Endocrinol%20Metab%20Clin%20North%20Am%20%20%5BTA%5D" class="LinkRef"&gt;Marqusee (1998) Endocrinol Metab Clin North Am 27:37-49&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Shrier%20%20%5BAU%5D%20AND%202002%20%5BDP%5D%20AND%20%20Am%20Fam%20Physician%20%20%5BTA%5D" class="LinkRef"&gt;Shrier (2002) Am Fam Physician 65(3):431-8&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Surks%20%20%5BAU%5D%20AND%202004%20%5BDP%5D%20AND%20%20JAMA%20%20%5BTA%5D" class="LinkRef"&gt;Surks (2004) JAMA 291:228-38&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Woeber%20%20%5BAU%5D%20AND%201997%20%5BDP%5D%20AND%20%20Arch%20Intern%20Med%20%20%5BTA%5D" class="LinkRef"&gt;Woeber (1997) Arch Intern Med 157:1065-8&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C1295607</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Thyroid/SbclnclHyprthyrdsm.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Subclinical Hyperthyroidism</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Thyroid/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Toxic multinodular goiter  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0154143"&gt;&lt;i&gt;C0154143&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Disease or Syndrome (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0154143&amp;amp;tui=T047"&gt;&lt;i&gt;T047&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD9&lt;/td&gt;
                &lt;td&gt;242.2&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD10&lt;/td&gt;
                &lt;td&gt;E05.2&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;154658002, 190249001, 26389007&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;MULTINODULAR TOXIC GOITER, PARRY DISEASE, Thyrotox + tox multinod goiter, Thyrotox + tox multinod goitre, Thyrotoxic - multinodul goiter, Thyrotoxic - multinodul goitre, Toxic multinodular goiter NOS, Toxic multinodular goitre NOS, toxic multinodular goiter, toxic multinodular goiter (diagnosis), Toxic multinodular goitre (disorder), THYROID GOITER TOXIC MULTINODULAR, Toxic multinodular goiter NOS (disorder), parry disease, multinodular toxic goiter, Goitre;multinodular;toxic, multinodular toxic goitre, Toxic multinodular goiter, Secondary thyroid hyperplasia, Thyrotoxicosis due to multinodular goiter, Thyrotoxicosis due to multinodular goitre, Thyrotoxicosis with toxic multinodular goiter, Thyrotoxicosis with toxic multinodular goitre, Toxic multinodular goitre, Toxic multinodular goiter (disorder), Parry, goiter; thyrotoxicosis, multinodular, multinodular; goiter, toxic or with hyperthyroidism, nodular; goiter, with thyrotoxicosis, struma; multinodular, toxic or with hyperthyroidism, struma; nodular, with thyrotoxicosis, struma; thyrotoxicosis, nodular, struma; toxic, multinodular, thyrotoxicosis; goiter, multinodular, thyrotoxicosis; goiter, nodular, toxic; goiter, multinodular, Goiter;multinodular;toxic, toxic multinodular goitre&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;toxisch multinodulair struma, multinodulair; struma, toxisch of met hyperthyroïdie, nodulair; struma, met thyrotoxicose, struma; multinodulair, toxisch of met hyperthyroïdie, struma; nodulair, met thyrotoxicose, struma; thyrotoxicose, multinodulair, struma; thyrotoxicose, nodulair, struma; toxisch, multinodulair, thyrotoxicose; struma, multinodulair, thyrotoxicose; struma, nodulair, toxisch; struma, multinodulair, Thyrotoxicose met toxische multinodulaire struma&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Goitre multinodulaire toxique&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;toxische multi-nodulaere Struma, Hyperthyreose mit toxischer mehrknotiger Struma&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Gozzo multinodulare tossico&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Bócio multinodular tóxico&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;Bocio multinodular tóxico, Toxic multinodular goitre, Toxic multinodular goiter, bocio multinodular tóxico (trastorno), bocio multinodular tóxico, bocio tóxico multinodular, SAI (trastorno), bocio tóxico multinodular, SAI, hiperplasia tiroidea secundaria&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;ﾁｭｳﾄﾞｸｾｲﾀｹｯｾﾂｾｲｺｳｼﾞｮｳｾﾝｼｭ, 中毒性多結節性甲状腺腫&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;Toxická mnohouzlová struma&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Korean&lt;/td&gt;
                &lt;td&gt;중독성 다결절성 갑상샘종을 동반한 갑상샘중독증&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;Toxikus multinodularis struma&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Multinodular goiter  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0342208"&gt;&lt;i&gt;C0342208&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Disease or Syndrome (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0342208&amp;amp;tui=T047"&gt;&lt;i&gt;T047&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;237570007&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;MULTINODULAR THYROID, MULTINODULAR GOITER, multinodular goiter, the thyroid had multiple nodules, Multinodular goiter, THYROID GOITER MULTINODULAR, multiple nodules of thyroid, multiple nodules of thyroid (physical finding), multinodular goitre, struma; multinodular, thyroid multinodular, goiters multinodular, multinodular thyroid, multiple nodules thyroid, multinodular; goiter, Multinodular goiter (disorder), Multiple thyroid nodules, Multinodular goitre&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;struma; multinodulair, multinodulair; struma&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;bocio multinodular (trastorno), bocio multinodular, nódulos tiroideos múltiples&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Non-toxic multinodular goiter  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0271761"&gt;&lt;i&gt;C0271761&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Disease or Syndrome (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0271761&amp;amp;tui=T047"&gt;&lt;i&gt;T047&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD9&lt;/td&gt;
                &lt;td&gt;241.1&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD10&lt;/td&gt;
                &lt;td&gt;E04.2&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;154653006, 36241006&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Nontoxic multinodular goiter, Nontoxic multinodular goitre, nontoxic multinodular goiter (diagnosis), nontoxic multinodular goiter, Non-toxic multinodular goitre (disorder), Nontox multinodul goiter, Goitre;multinodular;non toxic, Multinodular non-toxic goiter, Non-toxic multinodular goiter, Multinodular non-toxic goitre, Non-toxic multinodular goitre, Non-toxic multinodular goiter (disorder), nontoxic; goiter, multinodular, struma; nontoxic, multinodular, Goiter;multinodular;non toxic, non toxic multinodular goiter, non toxic multinodular goitre&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;niet-toxische multinodulaire struma, niet-toxisch multinodulair struma, niet-toxisch; struma, multinodulair, struma; niet-toxisch, multinodulair, Niet-toxische multinodulaire struma&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Goitre multinodulaire non toxique&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;nicht-toxische multi-nodulaere Struma, Nichttoxische mehrknotige Struma&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Gozzo multinodulare non tossico&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Bócio multinodular não tóxico&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;Bocio multinodular no tóxico, Non-toxic multinodular goiter, Non-toxic multinodular goitre, bocio multinodular no tóxico (trastorno), bocio multinodular no tóxico, bocio no tóxico multinodular&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;非中毒性多結節性甲状腺腫, ﾋﾁｭｳﾄﾞｸｾｲﾀｹｯｾﾂｾｲｺｳｼﾞｮｳｾﾝｼｭ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;Netoxická mnohouzlová struma&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Korean&lt;/td&gt;
                &lt;td&gt;비중독성 다결절성 갑상샘종&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;Nem-toxikus multinodularis struma&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Toxic multinodular goiter  (</value><value>)
</value><value>Multinodular goiter  (</value><value>)
</value><value>Non-toxic multinodular goiter  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Multinodular Goiter</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Thyroid Disease</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Causes&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/Gtr.htm" class="LinkPage"&gt;Simple Goiter&lt;/a&gt; develops into Multinodular Goiter&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Types&lt;ol&gt;&lt;li&gt;Non-Toxic Multinodular Goiter&lt;/li&gt;&lt;li&gt;Toxic Multinodular Goiter (50%)&lt;ol&gt;&lt;li&gt;Results in &lt;a href="../../Endo/Thyroid/Hyprthyrdsm1.htm" class="LinkPage"&gt;Thyrotoxicosis&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Differential Diagnosis&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/HemeOnc/ThyrdCrcnm.htm" class="LinkPage"&gt;Thyroid Cancer&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Symptoms&lt;ol&gt;&lt;li&gt;&lt;a href="../../Neuro/Exam/Dysphg.htm" class="LinkPage"&gt;Dysphagia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Lung/Airway/FrgnBdyAsprtn.htm" class="LinkPage"&gt;Choking&lt;/a&gt; sensation&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Signs&lt;ol&gt;&lt;li&gt;Markedly enlarged nodular &lt;a href="../../Endo/Anatomy/ThyrdAntmy.htm" class="LinkPage"&gt;Thyroid&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Lung/Sx/Strdr.htm" class="LinkPage"&gt;Stridor&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Complications&lt;ol&gt;&lt;li&gt;Toxic Multinodular Goiter (&lt;a href="../../Endo/Thyroid/Hyprthyrdsm1.htm" class="LinkPage"&gt;Thyrotoxicosis&lt;/a&gt;)&lt;ol&gt;&lt;li&gt;Cardiovascular complications&lt;ol&gt;&lt;li&gt;&lt;a href="../../CV/EKG/AtrlFbrltn.htm" class="LinkPage"&gt;Atrial Fibrillation&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/EKG/Tchycrd.htm" class="LinkPage"&gt;Tachycardia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/CHF/CngstvHrtFlr.htm" class="LinkPage"&gt;Congestive Heart Failure&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;No Ophthalmopathy (&lt;a href="../../Eye/Sx/Prpts.htm" class="LinkPage"&gt;Proptosis&lt;/a&gt; and stare)&lt;/li&gt;&lt;li&gt;No Dermopathy&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Both Toxic and Non-Toxic Multinodular Goiter&lt;ol&gt;&lt;li&gt;&lt;a href="../../CV/Vessel/SprVnCvObstrctn.htm" class="LinkPage"&gt;Superior Vena Cava Syndrome&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Results from thoracic outlet obstruction&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0154143</value><value>C0342208</value><value>C0271761</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Thyroid/MltndlrGtr.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Multinodular Goiter, Toxic Multinodular Goiter, Non-Toxic Multinodular Goiter</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Thyroid/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Colloid goiter  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0221268"&gt;&lt;i&gt;C0221268&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Disease or Syndrome (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0221268&amp;amp;tui=T047"&gt;&lt;i&gt;T047&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD10&lt;/td&gt;
                &lt;td&gt;E04.0&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;61037007, 190234009&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;GOITER, COLLOID, Goiter, colloid, Non-tox diffus colloid goiter, Non-tox diffus colloid goitre, Diffuse (colloid) nontoxic goiter, colloid goitre, colloid goiter, goiter colloid, Colloid goiter, Colloid goitre, Non-toxic diffuse colloid goiter, Non-toxic diffuse colloid goitre, Non-toxic colloid goiter, Non-toxic colloid goitre, Colloid goiter (disorder), nontoxic; goiter, diffuse (colloid), struma; nontoxic, diffuse (colloid)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;Colloid goiter, Colloid goitre, bocio coloide (trastorno), bocio coloide&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;niet-toxisch; struma, diffuus (colloïd), struma; niet-toxisch, diffuus (colloïd)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Goiter  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0018021"&gt;&lt;i&gt;C0018021&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;Enlargement of the thyroid gland usually caused by lack of iodine in the diet, hyperthyroidism, or thyroid nodules. Symptoms include difficulty in breathing and swallowing.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;Enlargement of the THYROID GLAND that may increase from about 20 grams to hundreds of grams in human adults. Goiter is observed in individuals with normal thyroid function (euthyroidism), thyroid deficiency (HYPOTHYROIDISM), or hormone overproduction (HYPERTHYROIDISM). Goiter may be congenital or acquired, sporadic or endemic (GOITER, ENDEMIC).&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CSP)&lt;/td&gt;
                &lt;td&gt;enlargement of the thyroid gland.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;An enlarged thyroid. It may be caused by too little iodine in the diet or by other conditions. Most goiters are not cancer.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Disease or Syndrome (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0018021&amp;amp;tui=T047"&gt;&lt;i&gt;T047&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D006042&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD9&lt;/td&gt;
                &lt;td&gt;240.9&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD10&lt;/td&gt;
                &lt;td&gt;E04.9&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;237568003, 267370001, 3716002, 190235005, 190232008&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Enlarged thyroid gland, GOITER, GOITRE, THYROID ENLARGED, THYROID ENLARGEMENT, THYROMEGALY, Goiter, NOS, Goitre, NOS, Goiter NOS, Goiter, unspecified, Goitre NOS, Goiter (excl T85 T86), Goiter (excluding T85 T86), thyromegaly, Goitre (disorder), enlargement under Adam's apple (symptom), enlargement under Adam's apple, goiter, Goiter, Enlarged thyroid, Thyroid enlarged, Goitre, unspecified, THYROID GOITER, Goiter NOS (disorder), Goiter [Disease/Finding], enlargement of thyroid, swelling thyroid gland, Enlarged;thyroid, Enlargement;thyroid, goiter thyroid, thyroid goiter, Struma, enlarged thyroid gland, goitres, goiters, thyroid gland swelling, Thyromegaly, Enlargement of thyroid, Struma of thyroid, Goitre, Struma - goiter, Struma - goitre, Swelling of thyroid gland, Thyroid enlargement, Goiter (disorder), enlargement; thyroid, struma, thyroid; enlargement, Goiters, enlarged thyroid, goitre, thyroid enlargement&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;GOITRE, Goitre, non précisé, Hypertrophie thyroïdienne, Goitre non précisé, Thyromégalie, AUGMENTATION VOLUME THYROIDE, Goitre (SF T85 T86), Goitre&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;BOCIO, Bócio NE, Tiroideia aumentada de volume, Tiromegalia, AUMENTO DE VOLUME DA TIROIDE, Bocio (excl T85 T86), Bócio&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;BOCIO, Bocio no especificado, Tiromegalia, Hipertrofia del tiroides, Tiroides agrandado, Thyroid enlargement, Struma - goitre, Goitre, Goiter NOS, Struma - goiter, Goitre NOS, Goiter, Bocio/nodulo (ex T85 T86), TIROIDES AUMENTADO, agrandamiento de la tiroides, bocio (trastorno), bocio, SAI (trastorno), bocio, SAI, bocio, estruma tiroideo, Bocio&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;STRUMA, Struma, unspezifisch, vergroesserte Schilddruese, Schilddruesenvergroesserung, Schilddruese vergroessert, SCHILDDRUESENVERGROESSERG, Struma (ex T85 T86), Kropf, Struma&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;struma, niet-gespecificeerd, thyromegaly, vergroot thyroïd, vergrote schildklier, Struma (ex T85 T86), schildklier; vergroting, vergroting; schildklier, struma, Goitre, Krop, Struma&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Gozzo non specificato, Tiroide ingrandita, Tiromegalia, Gozzo(escl T85 T86), Gozzo&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;甲状腺腫、詳細不明, 甲状腺腫大, 甲状腺腫, ｺｳｼﾞｮｳｾﾝｼｭｼｮｳｻｲﾌﾒｲ, ｺｳｼﾞｮｳｾﾝｼｭﾀﾞｲ, ｺｳｼﾞｮｳｾﾝｼｭ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Struma, STRUMA&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;struma, Struma, blíže neurčená, Zvětšená štítná žláza, Tyromegalie, Struma&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Struuma, STRUUMA (PL T85,T86)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;ZOB, ЗОБ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Norwegian&lt;/td&gt;
                &lt;td&gt;STRUMA/THYR KNUTE U/HYPERTYREOSE&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Danish&lt;/td&gt;
                &lt;td&gt;Struma/knude tyreoidea (ex T85 T86)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;golyva (kiv. T85, T86), Struma, Struma, nem meghatározott, Pajzsmirigy megnagyobbodása, Pajzsmirigy-megnagyobbodás, Megnagyobbodott pajzsmirigy&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Croatian&lt;/td&gt;
                &lt;td&gt;STRUMA&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Basque&lt;/td&gt;
                &lt;td&gt;BOZIOA,TIROTOSIKOSI GABEKO NODULO TIROIDEA&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hebrew&lt;/td&gt;
                &lt;td&gt;hagdalat hatiroid, goiter lelo yeter peilut&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Wole&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Endemic goiter  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0018022"&gt;&lt;i&gt;C0018022&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;A form of IODINE deficiency disorders characterized by an enlargement of the THYROID GLAND in a significantly large fraction of a POPULATION GROUP. Endemic goiter is common in mountainous and iodine-deficient areas of the world where the DIET contains insufficient amount of iodine.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Disease or Syndrome (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0018022&amp;amp;tui=T047"&gt;&lt;i&gt;T047&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D006043&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD9&lt;/td&gt;
                &lt;td&gt;240.0&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD10&lt;/td&gt;
                &lt;td&gt;E01.2, E01.0&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;190319000, 190316007, 191043000, 267369002, 56805008, 271949009, 190234009&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Endemic Goiters, Goiter, Endemic, Goiters, Endemic, Goiter, specified as simple, GOITER ENDEMIC, Goiter, endemic, Iodine goiter, Endemic goiter, Endemic goiter - iodine defic, Endemic goitre - iodine defic, Iod-def-rel (endm) goit,uns, Iod-def-reltd df(endemic)goitr, Iodine-deficiency-related (endemic) goiter, unspecified, Iodine-deficiency-related (endemic) goitre, unspecified, [X]Iod-def-rel (endm) goit,uns, [X]Iodine-deficiency-related (endemic) goiter, unspecified, [X]Iodine-deficiency-related (endemic) goitre, unspecified, simple goiter (diagnosis), iodine deficient endemic goiter, iodine deficient endemic goiter (diagnosis), simple goiter, [X]Iodine-deficiency-related (endemic) goitre, unspecified (disorder), Iodine-deficiency-related endemic goitre (disorder), Goitre, specified as simple, [X]Iodine-deficiency-related (endemic) goiter, unspecified (disorder), Endemic goiter NOS, Iodine-deficiency related diffuse (endemic) goiter, Iodine-deficiency related (endemic) goiter, unspecified, Goiter, Endemic [Disease/Finding], endemic goiter, goiters iodine, iodine goiter, endemic goitre, Simple goiter, Simple iodine deficiency goiter, Endemic goitre, Iodine-deficiency-related diffuse (endemic) goiter, Iodine-deficiency-related diffuse (endemic) goitre, Simple goitre, Simple iodine deficiency goitre, Iodine-deficiency-related endemic goiter, Iodine-deficiency-related endemic goitre, Endemic goiter (disorder), Iodine-deficiency-related endemic goiter (disorder), Simple goiter (disorder), endemic; goiter, iodine-deficiency; goiter (endemic), simple; goiter, struma; endemic, struma; iodine-deficiency (endemic), struma; simple, Simple Goiter, Endemic Goiter&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;struma, gespecificeerd als enkelvoudig, enkelvoudige struma, endemisch struma, endemisch; struma, jodiumdeficiëntie; struma (endemisch), simplex; struma, struma; endemisch, struma; jodiumdeficiëntie (endemisch), struma; simplex, Diffuse (endemische) struma samenhangend met jodiumdeficiëntie, Struma (endemisch) samenhangend met jodiumdeficiëntie, niet gespecificeerd, Endemische struma, Struma, endemisch&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Goitre, précisé simple, Goitre simple, Goitre endémique&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Struma, als einfach bezeichnet, einfache Struma, Jodmangelbedingte Struma (endemisch), nicht naeher bezeichnet, Jodmangelbedingte diffuse Struma (endemisch), endemischer Kropf, Struma, endemische&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Gozzo specificato come semplice, Gozzo semplice, Gozzo endemico&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Bócio especificado como simples, Bócio simples, Bócio endémico, Bócio Endêmico&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;Bocio especificado como simple, Bocio simple, [X]Iodine-deficiency-related (endemic) goitre, unspecified, Iodine-deficiency-related endemic goiter, Iodine-deficiency-related endemic goitre, [X]Iodine-deficiency-related (endemic) goiter, unspecified, Simple goiter, Simple goitre, [X]bocio relacionado con la deficiencia de iodo (endémico), no especificado, [X]bocio relacionado con la deficiencia de yodo (endémico), no especificado, [X]bocio relacionado con la deficiencia de yodo (endémico), no especificado (trastorno), Bocio endémico, bocio endémico (trastorno), bocio endémico relacionado con deficiencia de yodo (trastorno), bocio endémico relacionado con deficiencia de yodo, bocio endémico, bocio simple (trastorno), bocio simple por deficiencia de yodo, bocio simple, Bocio Endémico, Bocio Endemico&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;単純性甲状腺腫, ﾀﾝｼﾞｭﾝｾｲｺｳｼﾞｮｳｾﾝｼｭ, 甲状腺腫-地方病性, ﾁﾎｳﾋﾞｮｳｾｲｺｳｼﾞｮｳｾﾝｼｭ, 地方性甲状腺腫, 地方病性甲状腺腫&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Struma, endemisk&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;struma endemická, Struma, určená jako prostá, Prostá struma, Endemická struma&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Endeeminen struuma&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;ZOB ENDEMICHESKII, ЗОБ ЭНДЕМИЧЕСКИЙ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Korean&lt;/td&gt;
                &lt;td&gt;요오드결핍과 관련된 미만성(풍토성) 갑상샘종, 요오드결핍과 관련된(풍토성) 상세불명의 갑상샘종&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Croatian&lt;/td&gt;
                &lt;td&gt;STRUMA, ENDEMSKA&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Wole endemiczne&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;Struma, egyszerűnek meghatározott, Endemiás struma, Egyszerű struma&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Colloid goiter  (</value><value>)
</value><value>Goiter  (</value><value>)
</value><value>Endemic goiter  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Goiter</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Thyroid Disease</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Epidemiology&lt;ol&gt;&lt;li&gt;Endemic in areas distant from sea (e.g. mountains)&lt;ol&gt;&lt;li&gt;Common sites: Alps, Andes, and Himalayas&lt;/li&gt;&lt;li&gt;Related to deficient iodine intake&lt;/li&gt;&lt;li&gt;Often occurs before &lt;a href="../../Endo/Exam/SxlDvlpmnt.htm" class="LinkPage"&gt;Puberty&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Sporadic form much more common in women (8:1)&lt;ol&gt;&lt;li&gt;Adolescent girls&lt;/li&gt;&lt;li&gt;Pregnant, Lactating or Menopausal women&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Criteria&lt;ol&gt;&lt;li&gt;Diffuse &lt;a href="../../Endo/Anatomy/ThyrdAntmy.htm" class="LinkPage"&gt;Thyroid&lt;/a&gt; enlargement without nodularity&lt;/li&gt;&lt;li&gt;Euthyroid function&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Causes&lt;ol&gt;&lt;li&gt;Idiopathic (Sporadic)&lt;/li&gt;&lt;li&gt;Iodine Deficiency (Endemic Goiter)&lt;/li&gt;&lt;li&gt;Goitrogens (&lt;a href="../../Endo/Anatomy/ThyrdAntmy.htm" class="LinkPage"&gt;Thyroid&lt;/a&gt; suppressants)&lt;ol&gt;&lt;li&gt;Calcium and fluorides in water&lt;/li&gt;&lt;li&gt;Cabbage&lt;/li&gt;&lt;li&gt;Cassava&lt;/li&gt;&lt;li&gt;Cauliflower&lt;/li&gt;&lt;li&gt;Brussels sprouts&lt;/li&gt;&lt;li&gt;Turnips&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Symptoms&lt;ol&gt;&lt;li&gt;Often asymptomatic&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Anatomy/ThyrdAntmy.htm" class="LinkPage"&gt;Thyroid&lt;/a&gt; sensitive to touch&lt;/li&gt;&lt;li&gt;&lt;a href="../../Lung/Sx/ActDyspn.htm" class="LinkPage"&gt;Dyspnea&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Neuro/Exam/Dysphg.htm" class="LinkPage"&gt;Dysphagia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Lung/Sx/Cgh.htm" class="LinkPage"&gt;Cough&lt;/a&gt; with large glands&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Signs&lt;ol&gt;&lt;li&gt;Palpable diffuse &lt;a href="../../Endo/Anatomy/ThyrdAntmy.htm" class="LinkPage"&gt;Thyroid&lt;/a&gt; enlargement&lt;/li&gt;&lt;li&gt;No &lt;a href="../../Endo/Anatomy/ThyrdAntmy.htm" class="LinkPage"&gt;Thyroid&lt;/a&gt; nodularity&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Management&lt;ol&gt;&lt;li&gt;Early Goiter&lt;ol&gt;&lt;li&gt;Iodine replacement results in Goiter regression&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Late Goiter&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/ThyrdHrmnRplcmnt.htm" class="LinkPage"&gt;Thyroid Replacement&lt;/a&gt; required&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Prevention&lt;ol&gt;&lt;li&gt;Iodized salt in diet&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Course&lt;ol&gt;&lt;li&gt;If untreated, develops into &lt;a href="../../Endo/Thyroid/MltndlrGtr.htm" class="LinkPage"&gt;Multinodular Goiter&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Rifat%20%20%5BAU%5D%20AND%201994%20%5BDP%5D%20AND%20%20Am%20Fam%20Physician%20%20%5BTA%5D" class="LinkRef"&gt;Rifat (1994) Am Fam Physician 50(4):785-90&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Siminoski%20%20%5BAU%5D%20AND%201995%20%5BDP%5D%20AND%20%20JAMA%20%20%5BTA%5D" class="LinkRef"&gt;Siminoski (1995) JAMA 273(10):813-7&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0221268</value><value>C0018021</value><value>C0018022</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Thyroid/Gtr.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Goiter, Simple Goiter, Endemic Goiter, Colloid Goiter</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Thyroid/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Granuloma Annulare  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0085074"&gt;&lt;i&gt;C0085074&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A localized or generalized inflammatory skin disorder characterized by the formation of papules and ring-shaped plaques in the skin. Morphologically these lesions are granulomatous inflammatory processes with central necrosis surrounded by palisading histiocytes.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;Benign granulomatous disease of unknown etiology characterized by a ring of localized or disseminated papules or nodules on the skin and palisading histiocytes surrounding necrobiotic tissue resulting from altered collagen structures.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Disease or Syndrome (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0085074&amp;amp;tui=T047"&gt;&lt;i&gt;T047&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D016460&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD10&lt;/td&gt;
                &lt;td&gt;L92.0&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;65508009, 156368000, 200953005, 267850001&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;GRANULOME ANNULAIRE, Granulome annulaire&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;GRANULOMA ANNULARE, granuloma annulare (diagnosis), granuloma annulare, Granuloma Annulare [Disease/Finding], annulares granuloma, annulare granuloma, Granuloma annulare, GA - Granuloma annulare, Granuloma annulare (disorder), granuloma; annulare, annulare; granuloma, Granulome annulare, Granuloma Annulare&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;GRANULOMA ANULAR, Granuloma anular, Granuloma Anular&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;GRANULOMA ANULAR, Granulome annulare, Granuloma annulare, granuloma anular (trastorno), granuloma anular, Granuloma anular, Granuloma Anular&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;環状肉芽腫, ｶﾝｼﾞｮｳﾆｸｹﾞｼｭ, ｶﾝｼﾞｮｳﾆｸｶﾞｼｭ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Granuloma annulare&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;granulom anulární, Granuloma annulare&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Rengasgranulooma&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;GRANULOMA KOL'TSEVIDNAIA, GRANULEMA KOL'TSEVIDNAIA, ГРАНУЛЕМА КОЛЬЦЕВИДНАЯ, ГРАНУЛОМА КОЛЬЦЕВИДНАЯ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;GRANULOMA ANULARE, Granuloma anulare, Granuloma annulare&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Korean&lt;/td&gt;
                &lt;td&gt;환상육아종&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Ziarniniak obrączkowaty&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;Granuloma annulare&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;annulare; granuloom, granuloom; annulare, granuloma annulare, Granuloma annulare&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Granuloma anulare&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Granuloma Annulare  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Granuloma Annulare</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Dermatology</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Definition&lt;ol&gt;&lt;li&gt;Benign, self-limited annular rash in age &amp;lt;30 years&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Epidemiology&lt;ol&gt;&lt;li&gt;Occurs most commonly in young women&lt;/li&gt;&lt;li&gt;Most patients are under age 30 years&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Associated Conditions&lt;ol&gt;&lt;li&gt;Most cases occur without underlying condition&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/DM/DbtsMlts.htm" class="LinkPage"&gt;Diabetes Mellitus&lt;/a&gt; (up to 12% of cases)&lt;/li&gt;&lt;li&gt;Post-&lt;a href="../../ER/Derm/SknTrm.htm" class="LinkPage"&gt;Skin Trauma&lt;/a&gt; (e.g. &lt;a href="../../ER/Derm/InsctBt.htm" class="LinkPage"&gt;Insect Bite&lt;/a&gt;s)&lt;/li&gt;&lt;li&gt;Following &lt;a href="../../Lung/Lab/TbrclnSknTst.htm" class="LinkPage"&gt;Tuberculin Skin Test&lt;/a&gt;s&lt;/li&gt;&lt;li&gt;Malignancy: &lt;a href="../../HemeOnc/Lymph/Lymphm.htm" class="LinkPage"&gt;Lymphoma&lt;/a&gt; (usually), &lt;a href="../../Uro/HemeOnc/PrstCncr.htm" class="LinkPage"&gt;Prostate Cancer&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Viral infections&lt;ol&gt;&lt;li&gt;&lt;a href="../../ID/Virus/Mncls.htm" class="LinkPage"&gt;Epstein Barr Virus&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../ID/Virus/HrpsZstr.htm" class="LinkPage"&gt;Herpes Zoster&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../HIV/Exam/HmnImndfcncyVrs.htm" class="LinkPage"&gt;HIV Infection&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Symptoms&lt;ol&gt;&lt;li&gt;Asymptomatic or mild &lt;a href="../../Derm/Sx/PrtcCndtn.htm" class="LinkPage"&gt;Pruritus&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Signs&lt;ol&gt;&lt;li&gt;Characteristics&lt;ol&gt;&lt;li&gt;Initial&lt;ol&gt;&lt;li&gt;Flesh-colored &lt;a href="../../Derm/Exam/Ppl.htm" class="LinkPage"&gt;Papule&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Derm/Exam/Ppl.htm" class="LinkPage"&gt;Papule&lt;/a&gt; involutes centrally&lt;/li&gt;&lt;li&gt;Forms &lt;a href="../../Derm/Exam/AnlrLsn.htm" class="LinkPage"&gt;Annular Lesion&lt;/a&gt; (ring shape)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Later&lt;ol&gt;&lt;li&gt;Ring of &lt;a href="../../Derm/Exam/Ppl.htm" class="LinkPage"&gt;Papule&lt;/a&gt;s enlarges up to 5 cm diameter&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Distribution&lt;ol&gt;&lt;li&gt;Dorsolateral feet and ankles (most common)&lt;/li&gt;&lt;li&gt;Dorsolateral hands and wrists&lt;/li&gt;&lt;li&gt;Less commonly may occur anywhere&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Other distinguishing features&lt;ol&gt;&lt;li&gt;Palms, Scalp and Plantar surfaces spared&lt;/li&gt;&lt;li&gt;No scale&lt;/li&gt;&lt;li&gt;No associated &lt;a href="../../Derm/Exam/Blstr.htm" class="LinkPage"&gt;Vesicle&lt;/a&gt;s or &lt;a href="../../Derm/Exam/Ppl.htm" class="LinkPage"&gt;Papule&lt;/a&gt;s&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Types&lt;ol&gt;&lt;li&gt;Localized Granuloma Annulare (75% of cases)&lt;ol&gt;&lt;li&gt;Typical distribution as above&lt;/li&gt;&lt;li&gt;Spontaneous resolution by 2 years in 50% of cases&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Disseminated Granuloma Annulare&lt;ol&gt;&lt;li&gt;Ten or more lesions with widespread involvement&lt;/li&gt;&lt;li&gt;Increased association with &lt;a href="../../Endo/DM/DbtsMlts.htm" class="LinkPage"&gt;Diabetes Mellitus&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Lesions may persist for &amp;gt;4 years&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Generalized perforating Granuloma Annulare (rare)&lt;ol&gt;&lt;li&gt;Small umbilicated 1-4 mm &lt;a href="../../Derm/Exam/Ppl.htm" class="LinkPage"&gt;Papule&lt;/a&gt;s&lt;/li&gt;&lt;li&gt;Seen in children and young adults&lt;/li&gt;&lt;li&gt;Distribution&lt;ol&gt;&lt;li&gt;Localized form: arms, &lt;a href="../../GI/Anatomy/PlvcAntmy.htm" class="LinkPage"&gt;Pelvis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Generalized form: Trunk, &lt;a href="../../GI/Anatomy/AbdmnlAntmy.htm" class="LinkPage"&gt;Abdomen&lt;/a&gt;, arms, legs&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Subcutaneous Granuloma Annulare&lt;ol&gt;&lt;li&gt;Large, deep &lt;a href="../../Derm/Exam/SknLsnSldSknClrd.htm" class="LinkPage"&gt;Skin-Colored Nodule&lt;/a&gt;s&lt;/li&gt;&lt;li&gt;Young children (Age 2-5 years)&lt;/li&gt;&lt;li&gt;Distribution&lt;ol&gt;&lt;li&gt;Hands and fingers&lt;/li&gt;&lt;li&gt;Scalp&lt;/li&gt;&lt;li&gt;Buttocks&lt;/li&gt;&lt;li&gt;&lt;a href="../../Ortho/Anatomy/ElbwAntmy.htm" class="LinkPage"&gt;Elbow&lt;/a&gt;s and knees&lt;/li&gt;&lt;li&gt;Perioral&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;May occur in clusters&lt;/li&gt;&lt;li&gt;No associated underlying conditions&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Actinic Granuloma Annulare&lt;ol&gt;&lt;li&gt;Sun-exposed skin involvement&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Differential Diagnosis&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Derm/Exam/AnlrLsn.htm" class="LinkPage"&gt;Annular Lesion&lt;/a&gt;s&lt;/li&gt;&lt;li&gt;Distinguishing features of Granuloma Annulare&lt;ol&gt;&lt;li&gt;Smooth skin surface&lt;/li&gt;&lt;li&gt;No overlying scale&lt;/li&gt;&lt;li&gt;No associated &lt;a href="../../Derm/Exam/Blstr.htm" class="LinkPage"&gt;Vesicle&lt;/a&gt;s or &lt;a href="../../Derm/Exam/Pstl.htm" class="LinkPage"&gt;Pustule&lt;/a&gt;s&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Similar appearing lesions&lt;ol&gt;&lt;li&gt;&lt;a href="../../Derm/Fungus/CtnsFnglInfctn.htm" class="LinkPage"&gt;Tinea&lt;/a&gt; manus or &lt;a href="../../Derm/Fungus/TnCrprs.htm" class="LinkPage"&gt;Tinea Corporis&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Scale, &lt;a href="../../Derm/Exam/Ppl.htm" class="LinkPage"&gt;Papule&lt;/a&gt;s or &lt;a href="../../Derm/Exam/Blstr.htm" class="LinkPage"&gt;Vesicle&lt;/a&gt;s present&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../ID/Derm/ErythmChrncmMgrns.htm" class="LinkPage"&gt;Erythema Migrans&lt;/a&gt; (&lt;a href="../../ID/Vector/LymDs.htm" class="LinkPage"&gt;Lyme Disease&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;&lt;a href="../../ID/STD/TrtrySyphls.htm" class="LinkPage"&gt;Tertiary Syphilis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Nummular eczema&lt;/li&gt;&lt;li&gt;&lt;a href="../../Derm/Hyperplasia/Psrs.htm" class="LinkPage"&gt;Psoriasis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Erythema annulare centrifigum&lt;/li&gt;&lt;li&gt;&lt;a href="../../Rheum/Derm/CtnsLpsErythmts.htm" class="LinkPage"&gt;Discoid Lupus&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Lung/ILD/Srcds.htm" class="LinkPage"&gt;Sarcoidosis&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Labs&lt;ol&gt;&lt;li&gt;Fasting &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/DM/InslnRstncSyndrm.htm" class="LinkPage"&gt;Glucose Intolerance&lt;/a&gt; common&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Biopsy&lt;ol&gt;&lt;li&gt;May appear similar to &lt;a href="../../Endo/Derm/NcrbsLpdc.htm" class="LinkPage"&gt;Necrobiosis Lipoidica&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Characteristic findings&lt;ol&gt;&lt;li&gt;Epithelioid histiocytes surround anuclear &lt;a href="../../Derm/Anatomy/SknAntmy.htm" class="LinkPage"&gt;Dermis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Mucin deposition&lt;/li&gt;&lt;li&gt;May be reported as focal collagen degeneration&lt;ol&gt;&lt;li&gt;With reactive inflammation and fibrosis&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Management&lt;ol&gt;&lt;li&gt;Most lesions do not require treatment&lt;/li&gt;&lt;li&gt;All treatments risk scarring&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/SystmcCrtcstrd.htm" class="LinkPage"&gt;Corticosteroid&lt;/a&gt;s&lt;ol&gt;&lt;li&gt;Intralesional &lt;a href="../../Endo/Pharm/SystmcCrtcstrd.htm" class="LinkPage"&gt;Corticosteroid&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../Derm/Pharm/TpclCrtcstrd.htm" class="LinkPage"&gt;Kenalog&lt;/a&gt; 2.5 to 5 mg/ml injected into raised border&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Derm/Pharm/TpclCrtcstrd.htm" class="LinkPage"&gt;Topical Corticosteroid&lt;/a&gt;s under &lt;a href="../../Derm/Pharm/OclsvDrsng.htm" class="LinkPage"&gt;Occlusion&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Derm/Procedure/Crythrpy.htm" class="LinkPage"&gt;Cryotherapy&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Treatments for refractory cases (by Dermatologists)&lt;ol&gt;&lt;li&gt;All based on case reports of &amp;lt;10 patients per study&lt;/li&gt;&lt;li&gt;Toxicity limits use in primary care&lt;/li&gt;&lt;li&gt;Include: &lt;a href="../../Lung/Pharm/Dpsn.htm" class="LinkPage"&gt;Dapsone&lt;/a&gt;, &lt;a href="../../Derm/Pharm/Istrtn.htm" class="LinkPage"&gt;Accutane&lt;/a&gt;, Fumaric acid esters&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Course&lt;ol&gt;&lt;li&gt;Resolution without treatment within months to 2 years&lt;/li&gt;&lt;li&gt;Recurrence occurs in 40% of children&lt;/li&gt;&lt;li&gt;Types associated with slower and incomplete resolution&lt;ol&gt;&lt;li&gt;Disseminated Granuloma Annulare&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;Habif (1996) Clinical Dermatology, Mosby, p. 786&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Cyr%20%20%5BAU%5D%20AND%202006%20%5BDP%5D%20AND%20%20Am%20Fam%20Physician%20%20%5BTA%5D" class="LinkRef"&gt;Cyr (2006) Am Fam Physician 74:1729-34&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Hsu%20%20%5BAU%5D%20AND%202001%20%5BDP%5D%20AND%20%20Am%20Fam%20Physician%20%20%5BTA%5D" class="LinkRef"&gt;Hsu (2001) Am Fam Physician 64(22): 289-96&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Smith%20%20%5BAU%5D%20AND%201997%20%5BDP%5D%20AND%20%20Int%20J%20Dermatol%20%20%5BTA%5D" class="LinkRef"&gt;Smith (1997) Int J Dermatol 36:326-33&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0085074</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Derm/GrnlmAnlr.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Granuloma Annulare</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Derm/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Acanthosis Nigricans  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0000889"&gt;&lt;i&gt;C0000889&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A melanotic cutaneous lesion that develops in the axilla and other body folds. It may be idiopathic, drug-induced, or it may be associated with the presence of an endocrine disorder or malignancy.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;A circumscribed melanosis consisting of a brown-pigmented, velvety verrucosity or fine papillomatosis appearing in the axillae and other body folds. It occurs in association with endocrine disorders, underlying malignancy, administration of certain drugs, or as in inherited disorder.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CSP)&lt;/td&gt;
                &lt;td&gt;circumscribed melanosis consisting of a brown pigmented, velvety verrucosity or fine papillomatosis appearing in the axillae and other body folds; occurs in association with endocrine disorders, underlying malignancy, administration of certain drugs, or as in inherited disorder.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Disease or Syndrome (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0000889&amp;amp;tui=T047"&gt;&lt;i&gt;T047&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D000052&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD10&lt;/td&gt;
                &lt;td&gt;L83&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;402599005, 72129000&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;KERATOSIS NIGRICANS, ACANTHOSIS NIGRICANS, keratosis nigricans, acanthosis nigricans (diagnosis), acanthosis nigricans, Acanthosis Nigricans [Disease/Finding], acanthosis nigrican, Acanthosis nigricans, Keratosis nigricans, AN - Acanthosis nigricans, Acanthosis nigricans (disorder), keratosis; nigricans, nigricans; keratosis, Acanthosis Nigricans&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Acantosis nigricans, Acantosi nigricans&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;黒色表皮腫, ｺｸｼｮｸﾋｮｳﾋｼｭ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Acanthosis nigricans&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;Acanthosis nigricans&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Acanthosis nigricans&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Korean&lt;/td&gt;
                &lt;td&gt;흑색 가시세포증(극세포증)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Croatian&lt;/td&gt;
                &lt;td&gt;ACANTHOSIS NIGRICANS&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Rogowacenie ciemne&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;Acanthosis nigricans&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;keratose; nigricans, nigricans; keratose, acanthosis nigricans, Acanthosis nigricans&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;acantosis nigricans (trastorno), acantosis nigricans, queratosis nigricans, Acanthosis nigricans, Acantosis Nigricans&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Acantose nigricans, Acantose Nigricans&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Acanthosis nigricans&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Acanthosis nigricans&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;ACANTHOSIS NIGRICANS&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Acanthosis Nigricans  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Acanthosis Nigricans</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Dermatology</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Classification and Causes&lt;ol&gt;&lt;li&gt;Type 1: Hereditary Benign Acanthosis Nigricans&lt;ol&gt;&lt;li&gt;Idiopathic onset during childhood or &lt;a href="../../Endo/Exam/SxlDvlpmnt.htm" class="LinkPage"&gt;Puberty&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Type 2: Benign Acanthosis due to &lt;a href="../../Endo/DM/InslnRstncSyndrm.htm" class="LinkPage"&gt;Insulin Resistance&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/DM/DbtsMlts.htm" class="LinkPage"&gt;Diabetes Mellitus&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Gyn/Endo/Hyprndrgnsm.htm" class="LinkPage"&gt;Androgen Excess&lt;/a&gt; (&lt;a href="../../Gyn/Endo/Hyprndrgnsm.htm" class="LinkPage"&gt;Hyperandrogenism&lt;/a&gt;)&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pituitary/Acrmgly.htm" class="LinkPage"&gt;Acromegaly&lt;/a&gt; (&lt;a href="../../Endo/Pituitary/Ggntsm.htm" class="LinkPage"&gt;Gigantism&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Adrenal/CshngsDs.htm" class="LinkPage"&gt;Cushing's Syndrome&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Gyn/Endo/HrAnSyndrm.htm" class="LinkPage"&gt;HAIR-AN Syndrome&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Sex/Hypgndsm.htm" class="LinkPage"&gt;Hypogonadism&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Adrenal/AdsnsDs.htm" class="LinkPage"&gt;Addison's Disease&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/Hypthyrdsm.htm" class="LinkPage"&gt;Hypothyroidism&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Type 3: Pseudo-Acanthosis Nigricans&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Obesity/Obsty.htm" class="LinkPage"&gt;Obesity&lt;/a&gt; resulting in &lt;a href="../../Endo/DM/InslnRstncSyndrm.htm" class="LinkPage"&gt;Insulin Resistance&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Seen in patients with darker pigmentation&lt;/li&gt;&lt;li&gt;Specific findings&lt;ol&gt;&lt;li&gt;Numerous &lt;a href="../../Derm/Hyperplasia/SknTg.htm" class="LinkPage"&gt;Skin Tag&lt;/a&gt;s in axilla and groin&lt;/li&gt;&lt;li&gt;Velvety patch at inner upper thigh areas of chafing&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Type 4: Drug-induced Acanthosis Nigricans&lt;ol&gt;&lt;li&gt;&lt;a href="../../CV/Pharm/Ncn.htm" class="LinkPage"&gt;Nicotinic Acid&lt;/a&gt; (high dose)&lt;/li&gt;&lt;li&gt;Glucocorticoids&lt;/li&gt;&lt;li&gt;&lt;a href="../../Gyn/Pharm/DthylstlbstrlExpsr.htm" class="LinkPage"&gt;Diethylstilbestrol&lt;/a&gt; (DES)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Gyn/Pharm/OrlCntrcptv.htm" class="LinkPage"&gt;Oral Contraceptive&lt;/a&gt;s (androgenic &lt;a href="../../Gyn/Pharm/Prgstrn.htm" class="LinkPage"&gt;Progesterone&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/HmnGrwthHrmn.htm" class="LinkPage"&gt;Growth Hormone&lt;/a&gt; therapy&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Type 5: Malignant Acanthosis Nigricans&lt;ol&gt;&lt;li&gt;Causes&lt;ol&gt;&lt;li&gt;Paraneoplastic tumors (Adenocarcinoma)&lt;/li&gt;&lt;li&gt;&lt;a href="../../HemeOnc/Lymph/Lymphm.htm" class="LinkPage"&gt;Lymphoma&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Specific findings&lt;ol&gt;&lt;li&gt;Palm and sole hyperkeratosis&lt;/li&gt;&lt;li&gt;Lip vermilion border and &lt;a href="../../Dental/Exam/LblMcs.htm" class="LinkPage"&gt;Oral Mucosa&lt;/a&gt; involved&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Signs&lt;ol&gt;&lt;li&gt;Characteristics&lt;ol&gt;&lt;li&gt;&lt;a href="../../Derm/Pigment/Hyprpgmntn.htm" class="LinkPage"&gt;Hyperpigmentation&lt;/a&gt; patches (dirty-appearing)&lt;/li&gt;&lt;li&gt;Velvety feel and appearance develops over time&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Distribution&lt;ol&gt;&lt;li&gt;Nape of neck&lt;/li&gt;&lt;li&gt;Axillae&lt;/li&gt;&lt;li&gt;Groin&lt;/li&gt;&lt;li&gt;&lt;a href="../../Gyn/Anatomy/VlvrAntmy.htm" class="LinkPage"&gt;Vulva&lt;/a&gt; and Perineum&lt;/li&gt;&lt;li&gt;Antecubital fossa&lt;/li&gt;&lt;li&gt;Knuckles&lt;/li&gt;&lt;li&gt;Submammary region&lt;/li&gt;&lt;li&gt;&lt;a href="../../NICU/GI/UmblclCrd.htm" class="LinkPage"&gt;Umbilicus&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Evaluation&lt;ol&gt;&lt;li&gt;Consider malignancy&lt;ol&gt;&lt;li&gt;Onset over age 35 years&lt;/li&gt;&lt;li&gt;Non-obese patient&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Evaluate for cause of &lt;a href="../../Endo/DM/InslnRstncSyndrm.htm" class="LinkPage"&gt;Insulin Resistance&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Evaluate for &lt;a href="../../Gyn/Endo/Hyprndrgnsm.htm" class="LinkPage"&gt;Hyperandrogenism&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Elmer%20%20%5BAU%5D%20AND%202001%20%5BDP%5D%20AND%20%20Am%20Fam%20Physician%20%20%5BTA%5D" class="LinkRef"&gt;Elmer (2001) Am Fam Physician 63(12):2385-90&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Fitzpatrick (1992) Atlas Dermatology, McGraw, p.732-3&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Hacker%20%20%5BAU%5D%20AND%201996%20%5BDP%5D%20AND%20%20Postgrad%20Med%20%20%5BTA%5D" class="LinkRef"&gt;Hacker (1996) Postgrad Med 99(6):177-86&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0000889</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Derm/AcnthsNgrcns.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Acanthosis Nigricans</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Derm/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees></FP_UMLS_Trees><FP_Condition_name_check></FP_Condition_name_check><FP_Condition_name><value>Thyroid Adenoma</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Hematology and Oncology</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;See Also&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/MltndlrGtr.htm" class="LinkPage"&gt;Multinodular Goiter&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Epidemiology&lt;ol&gt;&lt;li&gt;&lt;a href="../../Prevent/Epi/DsIncdncRt.htm" class="LinkPage"&gt;Incidence&lt;/a&gt; of Thyroid Nodules US: 9 Million per year&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/HemeOnc/ThyrdCrcnm.htm" class="LinkPage"&gt;Thyroid Carcinoma&lt;/a&gt; occurs in 5-10% of palpable &lt;a href="../../Derm/Exam/Ndl1.htm" class="LinkPage"&gt;Nodule&lt;/a&gt;s&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Prevent/Epi/DsPrvlncRt.htm" class="LinkPage"&gt;Prevalence&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Women: 7-8% lifetime &lt;a href="../../Prevent/Epi/DsPrvlncRt.htm" class="LinkPage"&gt;Prevalence&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Men: 2% lifetime &lt;a href="../../Prevent/Epi/DsPrvlncRt.htm" class="LinkPage"&gt;Prevalence&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Present on autopsy in 50% of cases&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Signs&lt;ol&gt;&lt;li&gt;Discrete palpable Thyroid Nodules&lt;ol&gt;&lt;li&gt;Small, less than 4 cm&lt;/li&gt;&lt;li&gt;Usually solitary&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Usually cold &lt;a href="../../Derm/Exam/Ndl1.htm" class="LinkPage"&gt;Nodule&lt;/a&gt; on &lt;a href="../../Endo/Anatomy/ThyrdAntmy.htm" class="LinkPage"&gt;Thyroid&lt;/a&gt; scan&lt;ol&gt;&lt;li&gt;Only 1% are active &lt;a href="../../Derm/Exam/Ndl1.htm" class="LinkPage"&gt;Nodule&lt;/a&gt;s (&lt;a href="../../Endo/Thyroid/Hyprthyrdsm1.htm" class="LinkPage"&gt;Hyperthyroidism&lt;/a&gt;)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Evaluation&lt;ol&gt;&lt;li&gt;Step 1: Identify palpable &lt;a href="../../Derm/Exam/Ndl1.htm" class="LinkPage"&gt;Nodule&lt;/a&gt; on exam&lt;/li&gt;&lt;li&gt;Step 2: Obtain TSH&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/Hyprthyrdsm1.htm" class="LinkPage"&gt;Hyperthyroidism&lt;/a&gt;: Go to Step 3&lt;/li&gt;&lt;li&gt;Euthyroid: Go to Step 4&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Step 3: Obtain Radioactive &lt;a href="../../Endo/Anatomy/ThyrdAntmy.htm" class="LinkPage"&gt;Thyroid&lt;/a&gt; Scan&lt;ol&gt;&lt;li&gt;Hot &lt;a href="../../Derm/Exam/Ndl1.htm" class="LinkPage"&gt;Nodule&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Euthyroid: No further testing&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/Hyprthyrdsm1.htm" class="LinkPage"&gt;Hyperthyroidism&lt;/a&gt;: Consider &lt;a href="../../Endo/Pharm/Rdn.htm" class="LinkPage"&gt;Radioactive Iodine&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Cold &lt;a href="../../Derm/Exam/Ndl1.htm" class="LinkPage"&gt;Nodule&lt;/a&gt;&lt;ol&gt;&lt;li&gt;More likely to be malignant (5-15% of cases)&lt;/li&gt;&lt;li&gt;Go to Step 4&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Step 4: &lt;a href="../../Endo/Anatomy/ThyrdAntmy.htm" class="LinkPage"&gt;Thyroid&lt;/a&gt;&lt;a href="../../Rad/Ultrasound/Ultrsnd.htm" class="LinkPage"&gt;Ultrasound&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Benign appearing &lt;a href="../../Derm/Exam/Ndl1.htm" class="LinkPage"&gt;Nodule&lt;/a&gt; &amp;lt;1 cm with negative clinical history&lt;ol&gt;&lt;li&gt;Observe and follow&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Derm/Exam/Ndl1.htm" class="LinkPage"&gt;Nodule&lt;/a&gt; &amp;gt;1 cm&lt;ol&gt;&lt;li&gt;&lt;a href="../../Derm/Exam/Cyst.htm" class="LinkPage"&gt;Cyst&lt;/a&gt;ic lesion&lt;ol&gt;&lt;li&gt;Simple drainage&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Solid Lesion&lt;ol&gt;&lt;li&gt;Go to Step 5 (FNA)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Step 5: Fine needle aspiration (FNA)&lt;ol&gt;&lt;li&gt;Consider &lt;a href="../../Rad/Ultrasound/Ultrsnd.htm" class="LinkPage"&gt;Ultrasound&lt;/a&gt; guided FNA&lt;/li&gt;&lt;li&gt;Benign&lt;ol&gt;&lt;li&gt;Consider repeating FNA in 6 months&lt;/li&gt;&lt;li&gt;Consider repeat &lt;a href="../../Endo/Anatomy/ThyrdAntmy.htm" class="LinkPage"&gt;Thyroid&lt;/a&gt;&lt;a href="../../Rad/Ultrasound/Ultrsnd.htm" class="LinkPage"&gt;Ultrasound&lt;/a&gt; every 1-2 years&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Suspicious: Frozen section&lt;ol&gt;&lt;li&gt;Consider &lt;a href="../../Endo/Anatomy/ThyrdAntmy.htm" class="LinkPage"&gt;Thyroid&lt;/a&gt; lobectomy if still inconclusive&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Malignant: &lt;a href="../../Endo/Anatomy/ThyrdAntmy.htm" class="LinkPage"&gt;Thyroid&lt;/a&gt;ectomy&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Differential Diagnosis&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/HemeOnc/ThyrdCrcnm.htm" class="LinkPage"&gt;Thyroid Carcinoma&lt;/a&gt; (5-10% in adults, 14-40% in children)&lt;/li&gt;&lt;li&gt;Dominant follicle in &lt;a href="../../Endo/Thyroid/MltndlrGtr.htm" class="LinkPage"&gt;Multinodular Goiter&lt;/a&gt; (23%)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Anatomy/ThyrdAntmy.htm" class="LinkPage"&gt;Thyroid&lt;/a&gt; cyst (simple or mixed)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/Thyrdts.htm" class="LinkPage"&gt;Thyroiditis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Thyroid Adenoma&lt;ol&gt;&lt;li&gt;Simple or colloid Macrofollicular Adenoma&lt;ol&gt;&lt;li&gt;Most common type&lt;/li&gt;&lt;li&gt;Follicles of normal size&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../OB/Rad/FrstTrmstrUltrsnd.htm" class="LinkPage"&gt;Embryo&lt;/a&gt;nal (Trabecular) adenoma&lt;ol&gt;&lt;li&gt;Mostly stroma and minimal follicles&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Fetal Microfollicular Adenoma&lt;ol&gt;&lt;li&gt;Small follicles with minimal colloid&lt;/li&gt;&lt;li&gt;Follicular cancer found in 5% of cases&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/HshmtsThyrdts.htm" class="LinkPage"&gt;Hurthle Cell&lt;/a&gt; Adenoma (uncommon)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Monitoring&lt;ol&gt;&lt;li&gt;Slow serial growth of benign Thyroid Nodules&lt;ol&gt;&lt;li&gt;Unlikely to be malignant if initial FNA negative&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Alexander%20%20%5BAU%5D%20AND%202003%20%5BDP%5D%20AND%20%20Ann%20Intern%20Med%20%20%5BTA%5D" class="LinkRef"&gt;Alexander (2003) Ann Intern Med 138:315-8&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Boigon%20%20%5BAU%5D%20AND%201995%20%5BDP%5D%20AND%20%20Postgrad%20Med%20%20%5BTA%5D" class="LinkRef"&gt;Boigon (1995) Postgrad Med 98(2):73-80&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Giuffrida%20%20%5BAU%5D%20AND%201995%20%5BDP%5D%20AND%20%20Am%20J%20Med%20%20%5BTA%5D" class="LinkRef"&gt;Giuffrida (1995) Am J Med 99(6):642-50&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Mazzaferri%20%20%5BAU%5D%20AND%201993%20%5BDP%5D%20AND%20%20N%20Engl%20J%20Med%20%20%5BTA%5D" class="LinkRef"&gt;Mazzaferri (1993) N Engl J Med 328:553-9&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Walsh%20%20%5BAU%5D%20AND%201999%20%5BDP%5D%20AND%20%20Clin%20Otolaryngol%20%20%5BTA%5D" class="LinkRef"&gt;Walsh (1999) Clin Otolaryngol 24:388-97&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Welker%20%20%5BAU%5D%20AND%202003%20%5BDP%5D%20AND%20%20Am%20Fam%20Physician%20%20%5BTA%5D" class="LinkRef"&gt;Welker (2003) Am Fam Physician 67(3):559-74&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/HemeOnc/ThyrdAdnm.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Thyroid Adenoma, Thyroid Nodule</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/HemeOnc/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;insulinoma  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0021670"&gt;&lt;i&gt;C0021670&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;An insulin-producing neuroendocrine neoplasm arising from the beta cells of the pancreas. Patients exhibit symptoms related to hypoglycemia due to inappropriate secretion of insulin.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;An insulin-producing neuroendocrine neoplasm arising from the beta cells of the pancreas. It may or may not be associated with inappropriate secretion of insulin and an associated clinical syndrome.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;An abnormal mass that grows in the beta cells of the pancreas that make insulin. Beta cell neoplasms are usually benign (not cancer). They secrete insulin and are the most common cause of low blood sugar caused by having too much insulin in the body.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;An abnormal mass that grows in the beta cells of the pancreas that make insulin. Beta cell neoplasms are usually benign (not cancer). They secrete insulin and are the most common cause of low blood sugar caused by having too much insulin in the body.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;A benign tumor of the PANCREATIC BETA CELLS. Insulinoma secretes excess INSULIN resulting in HYPOGLYCEMIA.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Neoplastic Process (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0021670&amp;amp;tui=T191"&gt;&lt;i&gt;T191&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D007340&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD10&lt;/td&gt;
                &lt;td&gt;M8151/0&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;134154009, 25324008, 302822000&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Beta-cell adenoma, beta Cell Tumor, beta-Cell Tumor, beta-Cell Tumors, Insulinoma, Insulinomas, Insuloma, Insulomas, Tumor, beta-Cell, Tumors, beta-Cell, Adenoma, beta-Cell, Adenoma, beta Cell, Adenomas, beta-Cell, beta-Cell Adenomas, INSULINOMA, INSULOMA, PANCREAS, ISLET-CELL TUMOR, INSULIN-PRODUCING, beta-Cell Adenoma, Insulinoma, NOS, Pancreatic Insulin Producing Neoplasm, Insulinoma syndrome, Insulinoma NOS, [M]Insulinoma NOS, [M]Insulinoma NOS (morphologic abnormality), Insulinoma [Disease/Finding], insuloma, insulinomas, Pancreatic Insulinoma, beta cell tumor of the pancreas, pancreatic insulin-producing tumor, beta cell neoplasm, Pancreatic Insulin Producing Tumor, Pancreatic Insulin Producing Neuroendocrine Tumor, Pancreatic Insulin Producing NET, Beta cell adenoma, Insulinoma (disorder), Insulinoma (morphologic abnormality), islet cell insulinoma, pancreatic insulinoma, beta-cell; adenoma, pancreas, beta-cell; tumor, pancreas, beta-cell; tumor, unspecified site, insulinoma; pancreas, insulinoma; unspecified site, adenoma; beta-cell, pancreas, pancreas; adenoma, beta-cell, pancreas; beta-cell tumor, pancreas; insulinoma, pancreas; tumor, beta-cell, tumor; beta-cell, pancreas, tumor; beta-cell, unspecified site, Insulin-Producing Islet Cell Neoplasm, Insulin-Producing Islet Cell Tumor, Insulin-Producing Neoplasm of Islet Cells, Insulin-Producing Neoplasm of the Islet Cells, Insulin-Producing Tumor of Islet Cells, Insulin-Producing Tumor of the Islet Cells, Pancreatic Beta Cell Tumor, Beta Cell Neoplasm of Pancreas, Beta Cell Neoplasm of the Pancreas, Beta Cell Neoplasm, Beta Cell Tumor of Pancreas, Beta Cell Tumor of the Pancreas, Beta Cell Tumor, insulinoma&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Insulinom&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;ｲﾝｽﾘﾉｰﾏ, インスリノーマ, インシュリノーマ, インスリン分泌性島細胞腫, ベータ細胞腫瘍, ベータ細胞腺腫, インスリン分泌性膵島細胞腫, 腺腫-ベータ細胞, 膵島細胞腫-インスリン分泌性&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;insulinom, Inzulinom&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Insulinooma&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;NOVOOBRAZOVANIE IZ BETA-KLETOK, BETA-KLETOCHNOE NOVOOBRAZOVANIE, INSULINOMA, OPUKHOL' IZ BETA-KLETOK, INSULOMA, БЕТА-КЛЕТОЧНОЕ НОВООБРАЗОВАНИЕ, ИНСУЛИНОМА, ИНСУЛОМА, НОВООБРАЗОВАНИЕ ИЗ БЕТА-КЛЕТОК, ОПУХОЛЬ ИЗ БЕТА-КЛЕТОК&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Tumore delle cellule beta, Adenoma delle cellule beta, Insuloma, Insulinoma&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;[M] insulinoma SAI, [M] insulinoma SAI (anomalía morfológica), adenoma de células beta, adenoma insular de células beta, insulinoma (anomalía morfológica), insulinoma (trastorno), insulinoma, Insulinoma, Adenoma de Células beta, Insuloma, Tumor de Células beta, Adenoma de Celulas beta, Tumor de Celulas beta&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Nowotwór komórek beta trzustki, Insulinoma&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;Insulinoma&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;adenoom; bèta-cel, pancreas, bèta-cel; adenoom, pancreas, bèta-cel; tumor, niet gespecificeerde lokalisatie, bèta-cel; tumor, pancreas, insulinoom; niet gespecificeerde lokalisatie, insulinoom; pancreas, pancreas; adenoom, bèta-cel, pancreas; bèta-celtumor, pancreas; insulinoom, pancreas; tumor, bèta-cel, tumor; bèta-cel, niet gespecificeerde lokalisatie, tumor; bèta-cel, pancreas, insulinoom, Insulinoom, Adenoom, bètacel-, Bètaceltumor&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Insulinome, Tumeur bêta-langerhansienne insulino-sécrétante, Tumeur bêta-langerhansienne insulinosécrétante, Tumeur bêta-langerhansienne&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Adenom, Beta-Zell-, Beta-Zell-Tumor, Insulinom, Isulinom&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Insulinoma, Adenoma de Células-beta, Insuloma, Tumor de Células-beta&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Islet Cell Tumor  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0242363"&gt;&lt;i&gt;C0242363&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A neoplasm with neuroendocrine differentiation that arises from the pancreas. It includes neuroendocrine tumors (low and intermediate grade) and neuroendocrine carcinomas (high grade).&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Neoplastic Process (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0242363&amp;amp;tui=T191"&gt;&lt;i&gt;T191&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D007516&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD10&lt;/td&gt;
                &lt;td&gt;D13.7&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;261713004, 76345009, 128878003, 237596009, 399528006, 126864006, 154609001, 269636003, 188855000&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Island Cell Tumor, Island Cell Tumors, Islet Cell Tumors, Nesidioblastoma, Tumor, Island Cell, Tumor, Islet Cell, Tumors, Island Cell, Tumors, Islet Cell, NESIDIOBLASTOMA, Pancreatic Endocrine Neoplasm, Pancreatic neuroendocrine tumour, Pancreatic neuroendocrine tumor, neoplasm of islets of Langerhans (diagnosis), neoplasm of islets of Langerhans, islet cell tumors, islet cell tumour, endocrine pancreas tumors, islet cell tumor, endocrine pancreas tumor, endocrine pancreatic tumors, islet cell adenoma, pancreatic endocrine tumor, nesidioblastoma, Pancreatic Neuroendocrine Neoplasm, Islet Cell Tumor, Islet cell tumor, Islet cell tumour, Pancreatic endocrine tumor, Pancreatic endocrine tumour, Tumor of endocrine pancreas, Tumour of endocrine pancreas, Islet cell neoplasm (morphologic abnormality), Islet cell neoplasm, Islet cell tumor (morphologic abnormality), Neoplasm of islets of Langerhans (disorder), Neoplasm of islets of Langerhans, Tumor of endocrine pancreas (disorder), islet cell tumor; pancreas, islet cell; tumor, pancreas, nesidioblastoma; pancreas, nesidioblastoma; unspecified site, pancreas; islet cell tumor, pancreas; nesidioblastoma, pancreas; tumor, islet cell, tumor; islet cell, pancreas, Endocrine tumor of pancreas, Endocrine tumour of pancreas&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;neoplasia de células de los islotes pancreáticos, Pancreatic endocrine tumor, Islet cell tumour, Endocrine tumor of pancreas, Islet cell tumor, Pancreatic endocrine tumour, Endocrine tumour of pancreas, Tumor pancreático neuroendocrino, Tumor de Celulas de los Islotes Pancreaticos, Tumor de Células de los Islotes Pancreáticos, neoplasia de células de los islotes pancreáticos (anomalía morfológica), neoplasia de islote celular (anomalía morfológica), neoplasia de islote celular, neoplasia de los islotes de Langerhans (trastorno), neoplasia de los islotes de Langerhans, nesidioblastoma, tumor de células de los islotes (anomalía morfológica), tumor de células de los islotes, tumor de células insulares, tumor del células del islote pancreático, tumor del páncreas endócrino (trastorno), tumor del páncreas endócrino, Nesidioblastoma&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Tumor de Células das Ilhotas Pancreáticas, Tumor neuroendócrino pancreático, Nesidioblastoma&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Tumeur neuroendocrinienne pancréatique, Nésidioblastome&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;neuro-endocriene tumor in de pancreas, eilandcel; tumor, pancreas, eilandceltumor; pancreas, nesidioblastoom; niet gespecificeerde lokalisatie, nesidioblastoom; pancreas, pancreas; eilandceltumor, pancreas; nesidioblastoom, pancreas; tumor, eilandcel, tumor; eilandcel, pancreas, Eilandceltumor, Nesidioblastoom&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;neuroendokriner Pankreastumor, Inselzelltumor&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Tumore neuroendocrino pancreatico&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;膵神経内分泌腫瘍, ｽｲｼﾝｹｲﾅｲﾌﾞﾝﾋﾟｼｭﾖｳ, ｽｲｼﾝｹｲﾅｲﾌﾞﾝﾋﾟﾂｼｭﾖｳ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;Pankreatický neuroendokrinní nádor&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;Hasnyálmirigy neuroendocrin tumor&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>insulinoma  (</value><value>)
</value><value>Islet Cell Tumor  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Insulinoma</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Hematology and Oncology</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Symptoms and Signs&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Endo/Hypoglycemia/Hypglycm.htm" class="LinkPage"&gt;Hypoglycemia&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Radiology (Localize tumor)&lt;ol&gt;&lt;li&gt;CT &lt;a href="../../GI/Anatomy/AbdmnlAntmy.htm" class="LinkPage"&gt;Abdomen&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Rad/Ultrasound/Ultrsnd.htm" class="LinkPage"&gt;Ultrasound&lt;/a&gt;&lt;a href="../../GI/Anatomy/PncrsAntmy.htm" class="LinkPage"&gt;Pancreas&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Management&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Endo/Hypoglycemia/Hypglycm.htm" class="LinkPage"&gt;Hypoglycemia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Surgical excision&lt;/li&gt;&lt;li&gt;Medical Therapy (If surgery delayed or ineffective)&lt;ol&gt;&lt;li&gt;&lt;a href="../../CV/Pharm/DrctActngVsdltr.htm" class="LinkPage"&gt;Diazoxide&lt;/a&gt; 300-1200 mg/day IV/PO PLUS a &lt;a href="../../CV/Pharm/Drtc.htm" class="LinkPage"&gt;Diuretic&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Octreotide 150-150 ug/day divided doses SC&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0021670</value><value>C0242363</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/HemeOnc/Inslnm.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Insulinoma, Pancreatic Islet Cell Tumor</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/HemeOnc/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees></FP_UMLS_Trees><FP_Condition_name_check></FP_Condition_name_check><FP_Condition_name><value>Diabetic Dermopathy</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Dermatology</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Epidemiology&lt;ol&gt;&lt;li&gt;Most common skin finding in &lt;a href="../../Endo/DM/DbtsMlts.htm" class="LinkPage"&gt;Diabetes Mellitus&lt;/a&gt;&lt;ol&gt;&lt;li&gt;More common if comorbid &lt;a href="../../Endo/Neuro/DbtcNrpthy.htm" class="LinkPage"&gt;Diabetic Neuropathy&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;More common in men&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Pathophysiology&lt;ol&gt;&lt;li&gt;Skin &lt;a href="../../Derm/Pigment/Hyprpgmntn.htm" class="LinkPage"&gt;Hyperpigmentation&lt;/a&gt; due to hemosiderin deposition&lt;/li&gt;&lt;li&gt;May be associated with trauma&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Symptoms&lt;ol&gt;&lt;li&gt;None&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Signs&lt;ol&gt;&lt;li&gt;Round hyperpigmented areas&lt;ol&gt;&lt;li&gt;Initial: flat-topped, red and scaly &lt;a href="../../Derm/Exam/Ppl.htm" class="LinkPage"&gt;Papule&lt;/a&gt;s&lt;/li&gt;&lt;li&gt;Later: Depressed below skin level&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Distribution&lt;ol&gt;&lt;li&gt;Bilateral shins (most common)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Ortho/Anatomy/FrmAntmy.htm" class="LinkPage"&gt;Forearm&lt;/a&gt;s&lt;/li&gt;&lt;li&gt;Anterior thighs&lt;/li&gt;&lt;li&gt;Lateral feet&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Course&lt;ol&gt;&lt;li&gt;Heal spontaneously&lt;/li&gt;&lt;li&gt;May leave preciously involved skin with altered pigment&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;Habif (1996) Dermatology, p. 624&lt;/li&gt;&lt;li&gt;Marx (2002) Rosen's Emergency Medicine, 1759-60&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Derm/DbtcDrmpthy.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Diabetic Dermopathy, Skin Spots</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Derm/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees></FP_UMLS_Trees><FP_Condition_name_check></FP_Condition_name_check><FP_Condition_name><value>Necrobiosis Lipoidica</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Dermatology</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Epidemiology&lt;ol&gt;&lt;li&gt;Age of onset&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/DM/TypDbtsMlts.htm" class="LinkPage"&gt;Type I Diabetes Mellitus&lt;/a&gt;: 22 (mean age of onset)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/DM/TypDbtsMlts1.htm" class="LinkPage"&gt;Type II Diabetes Mellitus&lt;/a&gt;: 30 to 50 years&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Most common in women by 3 fold&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Pathophysiology&lt;ol&gt;&lt;li&gt;Unknown etiology&lt;/li&gt;&lt;li&gt;Appears related to microvascular changes&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Associated Conditions: &lt;a href="../../Endo/DM/DbtsMlts.htm" class="LinkPage"&gt;Diabetes Mellitus&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Necrobiosis patients with comorbid diabetes: 11-65%&lt;/li&gt;&lt;li&gt;&lt;a href="../../Prevent/Epi/DsPrvlncRt.htm" class="LinkPage"&gt;Prevalence&lt;/a&gt; of necrobiosis in Diabetes: 0.3 to 1.6%&lt;/li&gt;&lt;li&gt;Necrobiosis predicts of future diabetes development&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Symptoms&lt;ol&gt;&lt;li&gt;Lesions are painless in most cases&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Signs&lt;ol&gt;&lt;li&gt;Slowly growing oval atrophic &lt;a href="../../Derm/Exam/Plq.htm" class="LinkPage"&gt;Plaque&lt;/a&gt;s&lt;ol&gt;&lt;li&gt;May be several centimeters in size&lt;/li&gt;&lt;li&gt;Initial&lt;ol&gt;&lt;li&gt;Erythematous &lt;a href="../../Derm/Exam/Plq.htm" class="LinkPage"&gt;Plaque&lt;/a&gt; with raised irregular border&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Later&lt;ol&gt;&lt;li&gt;Yellow brown waxy central atrophic area&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Distribution&lt;ol&gt;&lt;li&gt;Classic (Diabetes): Bilateral shins, medial malleolus&lt;/li&gt;&lt;li&gt;Other less-commonly involved locations&lt;ol&gt;&lt;li&gt;Hands and &lt;a href="../../Ortho/Anatomy/FrmAntmy.htm" class="LinkPage"&gt;Forearm&lt;/a&gt;s&lt;/li&gt;&lt;li&gt;Face and scalp&lt;/li&gt;&lt;li&gt;&lt;a href="../../GI/Anatomy/AbdmnlAntmy.htm" class="LinkPage"&gt;Abdomen&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Telangiectases (subcutaneous vessels)&lt;/li&gt;&lt;li&gt;Lesions may ulcerate with trauma (risk of infection)&lt;/li&gt;&lt;li&gt;Associated &lt;a href="../../Neuro/Sx/PrphrlNrpthy.htm" class="LinkPage"&gt;Neuropathy&lt;/a&gt; in 50% of patients&lt;ol&gt;&lt;li&gt;Decreased pinprick and fine &lt;a href="../../Neuro/Exam/SnsryExm.htm" class="LinkPage"&gt;Touch Sensation&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Labs: Biopsy (often not needed)&lt;ol&gt;&lt;li&gt;Necrobiosis of collagen&lt;/li&gt;&lt;li&gt;Histiocytes and &lt;a href="../../HemeOnc/Lab/LymphcytCnt.htm" class="LinkPage"&gt;Lymphocyte&lt;/a&gt;s surround collagen&lt;/li&gt;&lt;li&gt;Inflammation around blood vessels&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Differential Diagnosis&lt;ol&gt;&lt;li&gt;Dermatopathology&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Derm/GrnlmAnlr.htm" class="LinkPage"&gt;Granuloma Annulare&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Clinical&lt;ol&gt;&lt;li&gt;Rheumatoid &lt;a href="../../Derm/Exam/Ndl1.htm" class="LinkPage"&gt;Nodule&lt;/a&gt;s in &lt;a href="../../Rheum/R_2/RhmtdArthrts.htm" class="LinkPage"&gt;Rheumatoid Arthritis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../ENT/Derm/ErythmNdsm.htm" class="LinkPage"&gt;Erythema Nodosum&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Management&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/SystmcCrtcstrd.htm" class="LinkPage"&gt;Corticosteroid&lt;/a&gt;s&lt;ol&gt;&lt;li&gt;&lt;a href="../../Derm/Pharm/TpclCrtcstrd.htm" class="LinkPage"&gt;Clobetasol Propionate&lt;/a&gt; under &lt;a href="../../Derm/Pharm/OclsvDrsng.htm" class="LinkPage"&gt;Occlusion&lt;/a&gt; for 6 weeks&lt;/li&gt;&lt;li&gt;Intralesional &lt;a href="../../Derm/Pharm/TpclCrtcstrd.htm" class="LinkPage"&gt;Kenalog&lt;/a&gt; 10 mg/ml (dilute to 2.5 mg/ml)&lt;/li&gt;&lt;li&gt;Oral prednisone for 5 weeks&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Topical Psoralen with &lt;a href="../../Derm/Environ/SnExpsr.htm" class="LinkPage"&gt;Ultraviolet A&lt;/a&gt; Exposure (PUVA)&lt;/li&gt;&lt;li&gt;Inhibition of Platelet aggregation&lt;ol&gt;&lt;li&gt;Pentoxifylline (Trental) 400 mg PO tid for 4-8 weeks&lt;/li&gt;&lt;li&gt;&lt;a href="../../Pharm/Analgesic/Asprn.htm" class="LinkPage"&gt;Aspirin&lt;/a&gt; 325 mg PO qd for 3 to 7 months&lt;/li&gt;&lt;li&gt;&lt;a href="../../HemeOnc/Pharm/Dpyrdml.htm" class="LinkPage"&gt;Dipyridamole&lt;/a&gt; (&lt;a href="../../HemeOnc/Pharm/Dpyrdml.htm" class="LinkPage"&gt;Persantine&lt;/a&gt;) 150-200 mg PO divided qid&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Skin Grafting or local excision&lt;ol&gt;&lt;li&gt;Not recommended due to high recurrence rate&lt;/li&gt;&lt;li&gt;Extensive skin involvement refractory to above&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Other treatment modalities&lt;ol&gt;&lt;li&gt;Laser treatment for telangiectasias&lt;/li&gt;&lt;li&gt;&lt;a href="../../Derm/Pharm/BnzylPrxd.htm" class="LinkPage"&gt;Benzoyl Peroxide&lt;/a&gt; for ulcerated lesions&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Course&lt;ol&gt;&lt;li&gt;Gradually resolves over 6-12 year period&lt;/li&gt;&lt;li&gt;Residual atrophy persists after resolution&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;Habif (1996) Clinical Dermatology, Mosby, p. 784-5&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Ferringer%20%20%5BAU%5D%20AND%202002%20%5BDP%5D%20AND%20%20Dermatol%20Clin%20%20%5BTA%5D" class="LinkRef"&gt;Ferringer (2002) Dermatol Clin 20(3):483&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Lowitt%20%20%5BAU%5D%20AND%201991%20%5BDP%5D%20AND%20%20J%20Am%20Acad%20Dermatol%20%20%5BTA%5D" class="LinkRef"&gt;Lowitt (1991) J Am Acad Dermatol 25:735-48&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Paron%20%20%5BAU%5D%20AND%202000%20%5BDP%5D%20AND%20%20Prim%20Care%20%20%5BTA%5D" class="LinkRef"&gt;Paron (2000) Prim Care 27(2):371-83&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Derm/NcrbsLpdc.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Necrobiosis Lipoidica, Necrobiosis Lipoidica diabeticorum</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Derm/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees></FP_UMLS_Trees><FP_Condition_name_check></FP_Condition_name_check><FP_Condition_name><value>Diabetes Related Intestinal Enteropathy</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Gastroenterology</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;See Also&lt;ol&gt;&lt;li&gt;&lt;a href="../../GI/IBD/IntstnlEntrpthy.htm" class="LinkPage"&gt;Intestinal Enteropathy&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Pathophysiology&lt;ol&gt;&lt;li&gt;&lt;a href="../../GI/Diarrhea/ActDrh.htm" class="LinkPage"&gt;Diarrhea&lt;/a&gt; causes&lt;ol&gt;&lt;li&gt;Stasis syndrome due to impaired &lt;a href="../../GI/Anatomy/SmlBwlAntmy.htm" class="LinkPage"&gt;Small Bowel&lt;/a&gt; motility&lt;/li&gt;&lt;li&gt;Hypermotility due to unmitigated sympathetic activity&lt;/li&gt;&lt;li&gt;Pancreatic insufficiency&lt;/li&gt;&lt;li&gt;Bile salt malabsorption&lt;/li&gt;&lt;li&gt;Steatorrhea&lt;/li&gt;&lt;li&gt;Drug-induced causes (e.g. &lt;a href="../../Endo/Pharm/Glcphg.htm" class="LinkPage"&gt;Metformin&lt;/a&gt;)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../GI/Constipation/CnstptnCs.htm" class="LinkPage"&gt;Constipation Causes&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../GI/Anatomy/LrgBwlAntmy.htm" class="LinkPage"&gt;Large Bowel&lt;/a&gt; dysfunction due to &lt;a href="../../Neuro/Sx/PrphrlNrpthy.htm" class="LinkPage"&gt;Neuropathy&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Impaired gastrocolic reflex&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../GI/Rectum/FclIncntnc.htm" class="LinkPage"&gt;Fecal Incontinence&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Anal sphincter dysfunction related to &lt;a href="../../Neuro/Sx/PrphrlNrpthy.htm" class="LinkPage"&gt;Neuropathy&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Symptoms&lt;ol&gt;&lt;li&gt;&lt;a href="../../GI/Diarrhea/ActDrh.htm" class="LinkPage"&gt;Diarrhea&lt;/a&gt; (occurs in up to 22% of patients with diabetes)&lt;/li&gt;&lt;li&gt;&lt;a href="../../GI/Constipation/CnstptnInAdlts.htm" class="LinkPage"&gt;Constipation&lt;/a&gt; (occurs in up to 44% of patients with diabetes)&lt;/li&gt;&lt;li&gt;&lt;a href="../../GI/Rectum/FclIncntnc.htm" class="LinkPage"&gt;Fecal Incontinence&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Labs&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/ThyrdStmltngHrmn.htm" class="LinkPage"&gt;Thyroid Stimulating Hormone&lt;/a&gt; (TSH)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Management: &lt;a href="../../GI/Diarrhea/ActDrh.htm" class="LinkPage"&gt;Diarrhea&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Maintain adequate hydration, electrolyte replacement, and nutritional maintenance&lt;/li&gt;&lt;li&gt;Symptomatic relief with antidiarrheal agents&lt;ol&gt;&lt;li&gt;Avoid over-use due to &lt;a href="../../GI/Bowel/Mgcln.htm" class="LinkPage"&gt;Megacolon&lt;/a&gt; risk&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Bacterial overgrowth treatment&lt;ol&gt;&lt;li&gt;Trial used &lt;a href="../../ID/Pharm/Amnpnclns.htm" class="LinkPage"&gt;Augmentin&lt;/a&gt; for 10 days in patients with positive hydrogen breath tests&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Virally-Monod%20%20%5BAU%5D%20AND%201998%20%5BDP%5D%20AND%20%20Diabetes%20Metab%20%20%5BTA%5D" class="LinkRef"&gt;Virally-Monod (1998) Diabetes Metab 24:530-6&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Management: &lt;a href="../../GI/Constipation/CnstptnInAdlts.htm" class="LinkPage"&gt;Constipation&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Eliminate &lt;a href="../../GI/Pharm/MdctnCsOfCnstptn.htm" class="LinkPage"&gt;Medication Causes of Constipation&lt;/a&gt;&lt;/li&gt;&lt;li&gt;See &lt;a href="../../GI/Constipation/ChrncCnstptn.htm" class="LinkPage"&gt;Constipation Management&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Maleki%20%20%5BAU%5D%20AND%201998%20%5BDP%5D%20AND%20%20Dig%20Dis%20Sci%20%20%5BTA%5D" class="LinkRef"&gt;Maleki (1998) Dig Dis Sci 43: 2373-8&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Shakil%20%20%5BAU%5D%20AND%202008%20%5BDP%5D%20AND%20%20Am%20Fam%20Physician%20%20%5BTA%5D" class="LinkRef"&gt;Shakil (2008) Am Fam Physician 77: 1697-704&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/GI/DbtsRltdIntstnlEntrpthy.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Diabetes Related Intestinal Enteropathy</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/GI/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Diabetic Retinopathy  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0011884"&gt;&lt;i&gt;C0011884&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;Disease of the RETINA as a complication of DIABETES MELLITUS. It is characterized by the progressive microvascular complications, such as ANEURYSM, interretinal EDEMA, and intraocular PATHOLOGIC NEOVASCULARIZATION.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CSP)&lt;/td&gt;
                &lt;td&gt;retinal changes occurring in diabetes mellitus, marked by microaneurysms, exudates, and hemorrhages, and sometimes by neovascularization.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Disease or Syndrome (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0011884&amp;amp;tui=T047"&gt;&lt;i&gt;T047&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D003930&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD9&lt;/td&gt;
                &lt;td&gt;362.0&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD10&lt;/td&gt;
                &lt;td&gt;H36.0&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;4855003, 163997001, 141196007, 155107006, 193353002, 154678005, 267471001, 309595004&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Retinopathy, diabetic, Diabetic Retinopathies, Retinopathies, Diabetic, DIABETIC RETINOPATHY, Retinopathy, Diabetic, Diabetic retinopathy, NOS, Diabetic retinopathy NOS, DR - Diabetic retinopathy, DR, diabetic retinopathy (diagnosis), diabetic retinopathy, Retina abnormal - diabet-relat, Retinopathy diabetic, Diabetic retinopathy NOS (disorder), Diabetic Retinopathy [Disease/Finding], Retinopathy;diabetic, Diabetic retinopathy, Retinal abnormality - diabetes-related, Diabetic retinopathy (disorder), Diabetic Retinopathy, Retinal abnormality - diabetes-related (disorder), Retinopathy - diabetic&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;retinopathie diabetisch, diabetische retinopathie, Diabetische retinopathie, Retinopathie, diabetische&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Retinopathie diabetisch, Retinopathia diabetica, diabetische Retinopathia, Diabetische Retinopathie&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Diabetisk näthinnesjukdom&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;diabetická retinopatie, Diabetická retinopatie&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;Retinopathy - diabetic, Diabetic retinopathy, Retinal abnormality - diabetes-related, anomalía retiniana relacionada con diabetes (trastorno), anomalía retiniana relacionada con diabetes, retinopatía diabética (trastorno), retinopatía diabética, SAI (trastorno), retinopatía diabética, SAI, retinopatía diabética, Retinopatía diabética, Retinopatía Diabética, Retinopatia Diabetica&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Diabeettinen retinopatia&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;DIABETICHESKAIA RETINOPATIIA, ДИАБЕТИЧЕСКАЯ РЕТИНОПАТИЯ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Korean&lt;/td&gt;
                &lt;td&gt;당뇨 망막병증&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Croatian&lt;/td&gt;
                &lt;td&gt;DIJABETIČNA RETINOPATIJA&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Retinopatia cukrzycowa&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;糖尿病網膜症, ﾄｳﾆｮｳﾋﾞｮｳﾓｳﾏｸｼｮｳ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;Diabeteses retinopathia&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Retinopatia diabética, Retinopatia Diabética&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Rétinopathie diabétique&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Retinopatia diabetica&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Diabetic Retinopathy  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Diabetic Retinopathy</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Ophthalmology</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;See Also&lt;ol&gt;&lt;li&gt;Diabetes Complications&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Epidemiology&lt;ol&gt;&lt;li&gt;Occurs in 20% of patients with &lt;a href="../../Endo/DM/DbtsMlts.htm" class="LinkPage"&gt;Diabetes Mellitus&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Occurs equally in Type I and &lt;a href="../../Endo/DM/TypDbtsMlts1.htm" class="LinkPage"&gt;Type II Diabetes Mellitus&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Risk Factors&lt;ol&gt;&lt;li&gt;Longer duration of &lt;a href="../../Endo/DM/DbtsMlts.htm" class="LinkPage"&gt;Diabetes Mellitus&lt;/a&gt; (&amp;gt;72 months)&lt;/li&gt;&lt;li&gt;Poor &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Glucose&lt;/a&gt; control (Hgb A1C &amp;gt; 8.0)&lt;/li&gt;&lt;li&gt;Increased &lt;a href="../../Uro/Lab/UrnMcrlbmn.htm" class="LinkPage"&gt;Microalbuminuria&lt;/a&gt; levels (&amp;gt;9.5)&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Saum%20%20%5BAU%5D%20AND%202002%20%5BDP%5D%20AND%20%20Br%20J%20Gen%20Pract%20%20%5BTA%5D" class="LinkRef"&gt;Saum (2002) Br J Gen Pract 52:214-6&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Types&lt;ol&gt;&lt;li&gt;Nonproliferative Retinopathy&lt;ol&gt;&lt;li&gt;&lt;a href="../../Eye/Anatomy/RtnlAntmy.htm" class="LinkPage"&gt;Retina&lt;/a&gt;l veins dilated&lt;/li&gt;&lt;li&gt;Cotton Wool exudates or spots&lt;/li&gt;&lt;li&gt;Hard exudates&lt;/li&gt;&lt;li&gt;Macular edema&lt;/li&gt;&lt;li&gt;Intraretinal &lt;a href="../../ER/FEN/HmrhgcShck.htm" class="LinkPage"&gt;Hemorrhage&lt;/a&gt;s&lt;/li&gt;&lt;li&gt;Microaneurysms&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Proliferative Retinopathy&lt;ol&gt;&lt;li&gt;Neovascularization&lt;/li&gt;&lt;li&gt;Preretinal &lt;a href="../../ER/FEN/HmrhgcShck.htm" class="LinkPage"&gt;Hemorrhage&lt;/a&gt;s&lt;/li&gt;&lt;li&gt;&lt;a href="../../Eye/Retina/VtrsHmrhg.htm" class="LinkPage"&gt;Vitreous Hemorrhage&lt;/a&gt;s&lt;/li&gt;&lt;li&gt;Vascular fibrosis&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Protocol: Ophthalmology Exam Intervals with no &lt;a href="../../Eye/Anatomy/RtnlAntmy.htm" class="LinkPage"&gt;Retina&lt;/a&gt;l disease&lt;ol&gt;&lt;li&gt;Children with Diabetes&lt;ol&gt;&lt;li&gt;Initial Exam: Age 10 years (or after 3-5 years of &lt;a href="../../Endo/DM/DbtsMlts.htm" class="LinkPage"&gt;Diabetes Mellitus&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;Subsequent Exams: Annually&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Adults with Type 2 Diabetes&lt;ol&gt;&lt;li&gt;Initial Exam: At diagnosis&lt;/li&gt;&lt;li&gt;Subsequent Exams: Annually&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Protocol: Ophthalmology Exam Intervals for those with &lt;a href="../../Eye/Anatomy/RtnlAntmy.htm" class="LinkPage"&gt;Retina&lt;/a&gt;l disease&lt;ol&gt;&lt;li&gt;Mild to moderate nonproliferative Diabetic Retinopathy&lt;ol&gt;&lt;li&gt;No macular edema: Exams every 6-12 months&lt;/li&gt;&lt;li&gt;Macular edema present: Consider laser photocoagulation&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Severe nonproliferative Diabetic Retinopathy&lt;ol&gt;&lt;li&gt;Eye examinations every 2-4 months&lt;/li&gt;&lt;li&gt;Consider laser photocoagulation&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Proliferative Diabetic Retinopathy&lt;ol&gt;&lt;li&gt;Consider laser photocoagulation&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Resources&lt;ol&gt;&lt;li&gt;AAO Practice Guideline&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.aao.org/education/guidelines/ppp/dr_new.cfm" class="LinkWebExt"&gt;http://www.aao.org/education/guidelines/ppp/dr_new.cfm&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0011884</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Eye/DbtcRtnpthy.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Diabetic Retinopathy</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Eye/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Multiple Endocrine Neoplasia Type 1  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0025267"&gt;&lt;i&gt;C0025267&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;Multiple endocrine neoplasia caused by inactivation of the tumor suppressor gene MEN-1. Patients may develop hyperparathyroidism and parathyroid gland adenomas, pituitary gland adenomas, pancreatic islet cell neoplasms, and carcinoid tumors.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A rare, inherited disorder that affects the endocrine glands and can cause tumors in the parathyroid and pituitary glands and the pancreas. These tumors are usually benign (not cancer). They cause the glands to secrete high levels of hormones, which can lead to other medical problems, such as kidney stones, fertility problems, and severe ulcers. In some cases, tumors inside the pancreas can become malignant (cancer).&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;A form of multiple endocrine neoplasia that is characterized by the combined occurrence of tumors in the PARATHYROID GLANDS, the PITUITARY GLAND, and the PANCREATIC ISLETS. The resulting clinical signs include HYPERPARATHYROIDISM; HYPERCALCEMIA; HYPERPROLACTINEMIA; CUSHING DISEASE; GASTRINOMA; and ZOLLINGER-ELLISON SYNDROME. This disease is due to loss-of-function of the MEN1 gene, a tumor suppressor gene (GENES, TUMOR SUPPRESSOR) on CHROMOSOME 11 (Locus: 11q13).&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Neoplastic Process (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0025267&amp;amp;tui=T191"&gt;&lt;i&gt;T191&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D018761&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD9&lt;/td&gt;
                &lt;td&gt;258.01&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD10&lt;/td&gt;
                &lt;td&gt;E31.21&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;30664006, 190566000&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Multiple endocrine adenomatosis, type I, Wermer's syndrome, MEA syndrome, type I, MEA I, MEN I, Wermer Syndrome, ADENOMATOSIS, POLYGLANDULAR, ENDOCRINE ADENOMA PEPTIC ULCER COMPLEX, MEA 1, MEN 1, MEN1, MULTIPLE ENDOCRINE NEOPLASIA TYPE 1, MULTIPLE ENDOCRINE NEOPLASIA TYPE I, Multiple Endocrine Neoplasia Type 1, Multiple Endocrine Neoplasia Type I, Multiple Endocrine Neoplasms Type 1, Neoplasia, Multiple Endocrine Type 1, Neoplasms, Multiple Endocrine Type 1, Neoplasms, Multiple Endocrine Type I, MEN syndrome type 1, Multiple endoc neoplas type 1, Wermer's Syndrome, MULTIPLE ENDOCRINE NEOPLASIA, TYPE I, ENDOCRINE ADENOMATOSIS, MULTIPLE, WERMER SYNDROME, NEOPL MULTIPLE ENDOCRINE TYPE 1, MEN 001, NEOPLASIA MULTIPLE ENDOCRINE TYPE 001, NEOPLASMS MULTIPLE ENDOCRINE TYPE 001, MULTIPLE ENDOCRINE NEOPL TYPE 1, type I multiple endocrine neoplasia (diagnosis), type I multiple endocrine neoplasia, Multiple endocrine adenomatosis Type I, Multiple endocrine neoplasia Type I, MEN Type I, MEA Type I, Mult endo neoplas type I, Multiple endocrine neoplasia [MEN] type I, Multiple Endocrine Neoplasia Type 1 [Disease/Finding], wermer syndrome, men 1 syndrome, wermer's syndrome, men type 1, multiple endocrine neoplasia type 1 (MEN1), men type i, multiple endocrine neoplasia type 1 syndrome, MEN1 syndrome, MEA, type 1, MEN, type 1, Multiple endocrine adenomatosis, type 1, Multiple endocrine neoplasia, type 1, Wermer syndrome, MEN 1 - Multiple endocrine neoplasia syndrome type 1, MEN 1 syndrome, Multiple endocrine neoplasia syndrome type 1, Multiple endocrine neoplasia, type 1 (disorder), MEA Type 1, MEN Type 1, Multiple Endocrine Adenomatosis Type 1, Multiple Endocrine Adenomatosis Type I, Multiple Endocrine Adenomatosis, Type I, Multiple Endocrine Neoplasia, Type I&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Adenomatosi endocrina multipla tipo I, Neoplasia endocrina multipla tipo I, Sindrome di Wermer, MEA 1, MEN 1, MEN I, MEA I, Neoplasia endocrina multipla tipo 1&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;multipele endocriene neoplasie type I, MEA type I, MEN type I, multipele endocriene adenomatosis type I, MEN 1, Multipele-endocriene-neoplasiesyndroom type 1, Neoplasie type 1, multipele endocriene, Neoplasmata type 1, mutipele endocriene, Syndroom type 1, multipele-endocriene-neoplasie-, Wermer-syndroom&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Adénomatose polyendocrinienne de type I, AEM de type I, Apudomatose de type I, Adénomatose endocrine multiple type I, Syndrome de Wermer, Néoplasie endocrinienne multiple de type 1, Polyadénomatose endocrinienne de type 1, Adénomatose endocrinienne multiple de type 1, NEM 1, NEM I, NEM1&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;MEA Typ I, multiple endokrine Neoplasie Typ I, MEN Typ I, NEOPLASIE MULTIPLE ENDOKRINE TYP 001, TUMOREN MULTIPLE ENDOKRINE TYP 001, MEN 001, multiple endokrine Adenomatose Typ I, MEN 1, Multiple endokrine Neoplasie Typ 1, Neoplasie, multiple endokrine, Typ 1, Tumoren, multiple endokrine, Typ 1, Wermer-Syndrom&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Neoplasia endócrina múltipla tipo I, Adenomatose endócrina múltipla tipo I, MEN 1, Neoplasia Endócrina Múltipla Tipo 1, Síndrome de Wermer, Neoplasias Endócrinas Múltiplas Tipo 1&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;AEM de tipo I, NEM de tipo I, Neoplasia endocrina múltiple de tipo I, Wermer's syndrome, NEM, tipo 1, adenomatosis endocrina múltiple, tipo 1, neoplasia endocrina múltiple, tipo 1 (trastorno), neoplasia endocrina múltiple, tipo 1, síndrome de Wermer, Adenomatosis endocrina múltiple de tipo I, MEN 1, Neoplasia Endocrina Múltiple Tipo 1, Neoplasia Múltiple Endocrina Tipo 1, Síndrome de Wermer, Neoplasia Endocrina Multiple Tipo 1, Neoplasia Multiple Endocrina Tipo 1, Sindrome de Wermer, Neoplasias Multiples Endocrinas Tipo 1, Neoplasias Múltiples Endocrinas Tipo 1&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;多発性内分泌腺腫症１型, 多発性内分泌腫症１型, ﾀﾊﾂｾｲﾅｲﾌﾞﾝﾋﾟｾﾝｼｭｼｮｳ1ｶﾞﾀ, ﾀﾊﾂｾｲﾅｲﾌﾞﾝﾋﾟｼｭｼｮｳ1ｶﾞﾀ, ﾀﾊﾂｾｲﾅｲﾌﾞﾝﾋﾟﾂｼｭｼｮｳ1ｶﾞﾀ, ﾀﾊﾂｾｲﾅｲﾌﾞﾝﾋﾟﾂｾﾝｼｭｼｮｳ1ｶﾞﾀ, 多発性内分泌腫瘍1型, MEN1型, Wermer症候群, ウェルマー症候群, 多内分泌腫瘍1, 多内分泌腫瘍1型, 多発性内分泌腺腫症1, 腫瘍-多発性内分泌1型&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Multipla hormonella tumörer typ 1&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;nádory mnohočetné endokrinní typ 1, Mnohočetná endokrinní adenomatóza Typ I, Mnohočetná endokrinní neoplazie typu I, MEN Typ I, MEA Typ I&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Multippeli endokriininen neoplasia tyyppi 1&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;NOVOOBRAZOVANIIA ENDOKRINNYE MNOZHESTVENNYE TIPA 1, VERMERA SINDROM, ENDOKRINNAIA NEOPLAZIIA MNOZHESTVENNAIA TIPA 1, NEOPLAZIIA ENDOKRINNAIA MNOZHESTVENNAIA TIPA 1, ENDOKRINNYKH ZHELEZ NOVOOBRAZOVANIIA TIPA 1 MNOZHESTVENNYE, MEN 1, ВЕРМЕРА СИНДРОМ, МЭН 1, НЕОПЛАЗИЯ ЭНДОКРИННАЯ МНОЖЕСТВЕННАЯ ТИПА 1, НОВООБРАЗОВАНИЯ ЭНДОКРИННЫЕ МНОЖЕСТВЕННЫЕ ТИПА 1, ЭНДОКРИННАЯ НЕОПЛАЗИЯ МНОЖЕСТВЕННАЯ ТИПА 1, ЭНДОКРИННЫХ ЖЕЛЕЗ НОВООБРАЗОВАНИЯ ТИПА 1 МНОЖЕСТВЕННЫЕ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Gruczolakowatość wewnątrzwydzielnicza typu 1, Nowotwory mnogie hormonalne typ I, Zespół Wermera, MEN 1&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;MEA típus I, Multiplex endocrin adenomatosis I. típus, Ember típus I, Többszörös endocrin neoplasia típus I&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Multiple Endocrine Neoplasia Type 1  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Multiple Endocrine Neoplasia Type 1</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Parathyroid Disease</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Conditions&lt;ol&gt;&lt;li&gt;Familial &lt;a href="../../Endo/Parathyroid/Hyprprthyrdsm.htm" class="LinkPage"&gt;Primary Hyperparathyroidism&lt;/a&gt; (95% of cases)&lt;/li&gt;&lt;li&gt;Pituitary adenoma&lt;/li&gt;&lt;li&gt;Pancreatic islet tumors&lt;/li&gt;&lt;li&gt;Zollinger-Ellison Syndrome&lt;ol&gt;&lt;li&gt;Hypergastrinemia&lt;/li&gt;&lt;li&gt;&lt;a href="../../GI/PUD/PptcUlcrDs.htm" class="LinkPage"&gt;Peptic Ulcer Disease&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0025267</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Parathyroid/MltplEndcrnNplsTyp.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Multiple Endocrine Neoplasia Type 1, Multiple Endocrine Neoplasia Type I, Werner's Syndrome, MEN I</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Parathyroid/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Hyperparathyroidism  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0020502"&gt;&lt;i&gt;C0020502&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;Hyperfunction of the parathyroid glands resulting in the overproduction of parathyroid hormone. It may be primary or secondary; primary hyperparathyroidism is caused by parathyroid adenoma, parathyroid hyperplasia, parathyroid carcinoma, and multiple endocrine neoplasia. It is associated with hypercalcemia and hypophosphatemia. Signs and symptoms include weakness, fatigue, nausea, vomiting, constipation, depression, bone pain, osteoporosis, cystic bone lesions, and kidney stones. Secondary hyperparathyroidism is caused by the chronic stimulation of the parathyroid glands in patients with chronic renal failure, rickets, and malabsorption syndromes.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A disorder characterized by an increase in production of parathyroid hormone by the parathyroid glands. This results in hypercalcemia (abnormally high levels of calcium in the blood).&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A condition in which the parathyroid gland (one of four pea-sized organs found on the thyroid) makes too much parathyroid hormone. This causes a loss of calcium from the bones and an increased level of calcium in the blood. Symptoms include bone pain and kidney problems.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (AIR)&lt;/td&gt;
                &lt;td&gt;WHAT: Hyperparathyroidism.	Hyperparathyroidism: a condition due to an increase in the secretion of the parathyroids, causing generalized osteitis fibrosa cystica, elevated serum calcium, decreased serum phosphorus, and increased excretion of both calcium and phosphorus.	WHY:	Several rheumatological disorders are associated with hyperpara- thyroidism. First, hyperuricemia and gouty arthritis (which may mimic hyperparathyroidism with renal stone formation and colic) have an increased incidence in patients with hyperparathyroidism. Second, patients with primary hyperparathyroidism show an increased incidence of chondrocalcinosis with episodes of calcium pyrophosphate crystal induced synovitis. Approximately 25% of patients with hyperparathyroidism will show radiographic evidence of calcification of articular cartilage and joint capsules. Finally, there can be a synovial and cartilaginous lesion ("osteogenic synovitis") in patients with hyperparathyroidism which may mimic other primary rheumatic diseases such as rheumatoid arthritis. In osteogenic synovitis there is softening and collapse of subchondral bone. Eventually the cartilage overlying this area erodes and is replaced by an irregular fibrocartilage. Eventually the articular surface of the joint is destroyed and secondary degenerative arthritis may develop.	REFS:	1) Zvaifler, NJ; Reefe, WE and Black, RL: Articular manifestations in primary hyperparathyroidism. Arthritis Rheum 5:237, 1962. 2) Scott, JT; Dixon, ASJ and Bywaters, EGL: Association of hyperuricemia and gout with hyperparathyroidism. Br Med J 1:1070, 1964. 3) Bywaters, EGL and Scott, JT : Joint lesions of hyperparathyroidism. Ann Rheum Dis 22:171-87, 1963.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CSP)&lt;/td&gt;
                &lt;td&gt;abnormally increased activity of the parathyroid glands, which may be primary or secondary; primary hyperparathyroidism is associated with neoplasia or hyperplasia; excess of parathyroid hormone leads to alteration in function of bone, renal tubules, and gastrointestinal mucosa.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;A condition of abnormally elevated output of PARATHYROID HORMONE (or PTH) triggering responses that increase blood CALCIUM. It is characterized by HYPERCALCEMIA and BONE RESORPTION, eventually leading to bone diseases. PRIMARY HYPERPARATHYROIDISM is caused by parathyroid HYPERPLASIA or PARATHYROID NEOPLASMS. SECONDARY HYPERPARATHYROIDISM is increased PTH secretion in response to HYPOCALCEMIA, usually caused by chronic KIDNEY DISEASES.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Disease or Syndrome (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0020502&amp;amp;tui=T047"&gt;&lt;i&gt;T047&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D006961&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD9&lt;/td&gt;
                &lt;td&gt;252.00, 252.0&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD10&lt;/td&gt;
                &lt;td&gt;E21.3&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;154696001, 66999008, 190451000&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Hyperparathyroidism, HYPERPARATHYROIDISM, PARATHYROID, HYPERFUNCTION, Hyperparathyroidism, NOS, Hyperparathyroidism, unspecified, hyperparathyroidism (diagnosis), hyperparathyroidism, hyperpth, Hyperparathyroidism NOS, Hyperparathyroidism [Disease/Finding], HPTH - Hyperparathyroidism, Hyperparathyroidism (disorder), hyperfunction; parathyroid, parathyroid; hyperfunction&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;HYPERPARATHYROIDIE, Hyperparathyroïdie SAI, Hyperparathyroïdie, Hyperparathyroïdisme&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;HIPERPARATIROIDISMO, Hiperparatiroidismo NEOM, Hyperparathyroidism, hiperparatiroidismo (trastorno), hiperparatiroidismo, Hiperparatiroidismo&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;HYPERPARATHYREOIDISMUS, Hyperparathyreoidismus NNB, Hyperparathyreoidismus, nicht naeher bezeichnet, Hyperparathyreoidismus&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;hyperparathyroïdie NAO, bijschildklier; hyperfunctie, hyperfunctie; bijschildklier, Hyperparathyroïdie, niet gespecificeerd, hyperparathyroïdie, Parathyreotoxicose, Parathyrotoxicose, Hyperparathyreoïdie, Hyperparathyroïdie, Parathyroïdie, hyper-&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Iperparatiroidismo NAS, Iperparatiroidismo&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Hiperparatiroidismo NE, HIPERPARATIROIDISMO, Hiperparatireoidismo&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;副甲状腺機能亢進症ＮＯＳ, 副甲状腺機能亢進症, ﾌｸｺｳｼﾞｮｳｾﾝｷﾉｳｺｳｼﾝｼｮｳ, ﾌｸｺｳｼﾞｮｳｾﾝｷﾉｳｺｳｼﾝｼｮｳNOS&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Hyperparatyreos&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;hyperparatyreoidismus, Hyperparatyreóza, Hyperparatyreóza NOS&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Hyperparatyreoosi&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;GIPERPARATIREOIDIZM, GIPERPARATIREOZ, ГИПЕРПАРАТИРЕОЗ, ГИПЕРПАРАТИРЕОИДИЗМ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Korean&lt;/td&gt;
                &lt;td&gt;상세불명의 부갑상샘 기능항진증&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Croatian&lt;/td&gt;
                &lt;td&gt;HIPERPARATIREOIDIZAM&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Nadczynność przytarczyc&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;Hyperparathyreosis k.m.n., Hyperparathyreosis&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Hyperparathyroidism, Primary  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0221002"&gt;&lt;i&gt;C0221002&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;Hyperfunction of the parathyroid glands resulting in the overproduction of parathyroid hormone. It is caused by parathyroid adenoma, parathyroid hyperplasia, parathyroid carcinoma, and multiple endocrine neoplasia. It is associated with hypercalcemia and hypophosphatemia. Signs and symptoms include weakness, fatigue, nausea, vomiting, constipation, depression, bone pain, osteoporosis, cystic bone lesions, and kidney stones.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;A condition of abnormally elevated output of PARATHYROID HORMONE due to parathyroid HYPERPLASIA or PARATHYROID NEOPLASMS. It is characterized by the combination of HYPERCALCEMIA, phosphaturia, elevated renal 1,25-DIHYDROXYVITAMIN D3 synthesis, and increased BONE RESORPTION.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Disease or Syndrome (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0221002&amp;amp;tui=T047"&gt;&lt;i&gt;T047&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D049950&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD9&lt;/td&gt;
                &lt;td&gt;252.01&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD10&lt;/td&gt;
                &lt;td&gt;E21.0&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;190452007, 36348003&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;HYPERPARATHYROIDISM, PRIMARY, Hyperparathyroidism, primary, HYPERPARATHYROIDISM PRIMARY, primary hyperparathyroidism, Hyperparathyroidism primary, HYPERPARATHYROID PRIMARY, Primary hyperparathyroid, Hyperparathyroidism, Primary [Disease/Finding], Primary hyperparathyroidism, Primary hyperparathyroidism (disorder), hyperparathyroidism; primary, primary; hyperparathyroidism, Hyperparathyroidism, Primary, Hyperparathyroidisms, Primary, Primary Hyperparathyroidisms, Primary Hyperparathyroidism&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;primaire hyperparathyroïdie, hyperparathyroïdie; primair, primair; hyperparathyroïdie, Primaire hyperparathyroïdie, hyperparathyroïdie primair&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;primaerer Hyperparathyreoidismus, Primaerer Hyperparathyreoidismus, Hyperparathyreoidismus primaer, Hyperparathyreoidismus, primärer, Primärer Hyperparathyreoidismus&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Iperparatiroidismo primitivo, Iperparatiroidismo primario&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Hyperparatyreos, primär&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;ｹﾞﾝﾊﾟﾂｾｲﾌｸｺｳｼﾞｮｳｾﾝｷﾉｳｺｳｼﾝｼｮｳ, 原発性上皮小体機能亢進症, 副甲状腺機能亢進症-原発性, 原発性上皮小体亢進症, 原発性副甲状腺機能亢進症, 原発性上皮小体亢進, 原発性上皮小体機能亢進, 上皮小体機能亢進症-原発性&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;hyperparatyreoidismus primární, Primární hyperparatyreóza&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;Primary hyperparathyroidism, hiperparatiroidismo primario (trastorno), hiperparatiroidismo primario, Hiperparatiroidismo primario, Hiperparatiroidismo Primario&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Primaarinen lisäkilpirauhasten liikatoiminta&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;GIPERPARATIREOZ PERVICHNYI, ГИПЕРПАРАТИРЕОЗ ПЕРВИЧНЫЙ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Korean&lt;/td&gt;
                &lt;td&gt;원발성 부갑상샘 기능항진증&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Nadczynność przytarczyc pierwotna&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;Primaer hyperparathyreosis, Primaer hyperparathyreoidismus&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Hiperparatiroidismo primário, Hiperparatireoidismo Primário&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Hyperparathyroïdie primaire, Hyperparathyroïdie primitive, Hyperparathyroïdisme primaire, Hyperparathyroïdisme primitif&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Hyperparathyroidism  (</value><value>)
</value><value>Hyperparathyroidism, Primary  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Hyperparathyroidism</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Parathyroid Disease</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Pathophysiology&lt;ol&gt;&lt;li&gt;Overactive &lt;a href="../../Endo/Anatomy/PrthyrdAntmy.htm" class="LinkPage"&gt;Parathyroid Gland&lt;/a&gt;s (&amp;gt;=1 of 4 glands)&lt;/li&gt;&lt;li&gt;Produce excessive &lt;a href="../../Endo/Lab/PrthyrdHrmn.htm" class="LinkPage"&gt;Parathyroid Hormone&lt;/a&gt; (PTH)&lt;/li&gt;&lt;li&gt;Results in disorder of bone metabolism&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Epidemiology&lt;ol&gt;&lt;li&gt;&lt;a href="../../Prevent/Epi/DsIncdncRt.htm" class="LinkPage"&gt;Incidence&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Women: 2-3 cases per 1000 women over age 65 years&lt;/li&gt;&lt;li&gt;Men: 1 case per 1000 men over age 65 years&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Ages&lt;ol&gt;&lt;li&gt;Range: 40-70 years old&lt;/li&gt;&lt;li&gt;Mean: 55 years old&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Etiology&lt;ol&gt;&lt;li&gt;Single &lt;a href="../../Endo/Anatomy/PrthyrdAntmy.htm" class="LinkPage"&gt;Parathyroid&lt;/a&gt; Adenoma (82 to 85%)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Anatomy/PrthyrdAntmy.htm" class="LinkPage"&gt;Parathyroid Gland&lt;/a&gt; Hyperplasia or hypertrophy (15%)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Anatomy/PrthyrdAntmy.htm" class="LinkPage"&gt;Parathyroid&lt;/a&gt; Malignancy (0.5 to 3%)&lt;/li&gt;&lt;li&gt;Familial Hyperparathyroidism (10-20%): Younger patients&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Parathyroid/MltplEndcrnNplsTyp.htm" class="LinkPage"&gt;Multiple Endocrine Neoplasia Type I&lt;/a&gt; (&lt;a href="../../Endo/Parathyroid/MltplEndcrnNplsTyp.htm" class="LinkPage"&gt;MEN I&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Parathyroid/MltplEndcrnNplsTyp.htm" class="LinkPage"&gt;Multiple Endocrine Neoplasia Type I&lt;/a&gt; (&lt;a href="../../Endo/Parathyroid/MltplEndcrnNplsTyp1.htm" class="LinkPage"&gt;MEN II&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;Familial Hypocalciuric &lt;a href="../../Renal/Calcium/Hyprclcm.htm" class="LinkPage"&gt;Hypercalcemia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Hyperparathyroidism-Jaw Tumor Syndrome&lt;/li&gt;&lt;li&gt;Neonatal severe Primary Hyperparathyroidism&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Other &lt;a href="../../Endo/Anatomy/PrthyrdAntmy.htm" class="LinkPage"&gt;Parathyroid&lt;/a&gt; related causes&lt;ol&gt;&lt;li&gt;&lt;a href="../../Psych/Pharm/LthmCrbnt.htm" class="LinkPage"&gt;Lithium&lt;/a&gt; Therapy&lt;/li&gt;&lt;li&gt;External neck radiation exposure&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Non-primary causes of Hyperparathyroidism&lt;ol&gt;&lt;li&gt;Secondary Hyperparathyroidism in &lt;a href="../../Renal/Calcium/Hypclcm.htm" class="LinkPage"&gt;Hypocalcemia&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../Pharm/Vitamins/VtmnDDfcncy.htm" class="LinkPage"&gt;Vitamin D Deficiency&lt;/a&gt; (renal insufficiency)&lt;/li&gt;&lt;li&gt;Decreased calcium intake&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Tertiary Hyperparathyroidism&lt;ol&gt;&lt;li&gt;Accelerated response to chronic &lt;a href="../../Renal/Calcium/Hypclcm.htm" class="LinkPage"&gt;Hypocalcemia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Anatomy/PrthyrdAntmy.htm" class="LinkPage"&gt;Parathyroid&lt;/a&gt; over-produces PTH causing &lt;a href="../../Renal/Calcium/Hyprclcm.htm" class="LinkPage"&gt;Hypercalcemia&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Symptoms and signs&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Renal/Calcium/Hyprclcm.htm" class="LinkPage"&gt;Hypercalcemia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Asymptomatic &lt;a href="../../Renal/Calcium/Hyprclcm.htm" class="LinkPage"&gt;Hypercalcemia&lt;/a&gt; (up to 80% of cases)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Diagnosis&lt;ol&gt;&lt;li&gt;Mnemonic (classic presentation is uncommon)&lt;ol&gt;&lt;li&gt;Stones&lt;/li&gt;&lt;li&gt;Bones&lt;/li&gt;&lt;li&gt;Abdominal groans&lt;/li&gt;&lt;li&gt;Psychic moans&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Constellation of findings&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Renal/Calcium/Hyprclcm.htm" class="LinkPage"&gt;Hypercalcemia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Calcium oxalate renal stones (&lt;a href="../../Uro/Renal/Nphrlths.htm" class="LinkPage"&gt;Nephrolithiasis&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;Bony changes&lt;ol&gt;&lt;li&gt;Osteitis fibrosa&lt;/li&gt;&lt;li&gt;Salt and pepper skull&lt;/li&gt;&lt;li&gt;Bone resorption&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../GI/Pancreas/ActPncrts.htm" class="LinkPage"&gt;Acute Pancreatitis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Psych/Psychosis/Psychs.htm" class="LinkPage"&gt;Psychosis&lt;/a&gt; and depression&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Labs&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/PrthyrdHrmn.htm" class="LinkPage"&gt;Parathyroid Hormone&lt;/a&gt; (PTH) Level elevated&lt;ol&gt;&lt;li&gt;Measure &lt;a href="../../Endo/Lab/PrthyrdHrmn.htm" class="LinkPage"&gt;Intact PTH&lt;/a&gt;&lt;/li&gt;&lt;li&gt;See &lt;a href="../../Endo/Lab/PrthyrdHrmn.htm" class="LinkPage"&gt;Parathyroid Hormone&lt;/a&gt; for algorithm&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Serum Electrolyte abnormalities&lt;ol&gt;&lt;li&gt;&lt;a href="../../Renal/Calcium/Hyprclcm.htm" class="LinkPage"&gt;Hypercalcemia&lt;/a&gt; (Use &lt;a href="../../Renal/Lab/SrmClcm.htm" class="LinkPage"&gt;Corrected Serum Calcium&lt;/a&gt;)&lt;ol&gt;&lt;li&gt;Draw fasting with minimal &lt;a href="../../Derm/Pharm/OclsvDrsng.htm" class="LinkPage"&gt;Occlusion&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Discontinue &lt;a href="../../CV/Pharm/ThzdDrtc.htm" class="LinkPage"&gt;Thiazide Diuretic&lt;/a&gt;s for 2 weeks before&lt;/li&gt;&lt;li&gt;Repeat serum testing in 2 weeks if normal&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Renal/Chloride/Hyprchlrm.htm" class="LinkPage"&gt;Hyperchloremia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Renal/Phosphorus/Hyphsphtm.htm" class="LinkPage"&gt;Hypophosphatemia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Renal/Potassium/Hypklm.htm" class="LinkPage"&gt;Hypokalemia&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Miscellaneous&lt;ol&gt;&lt;li&gt;1,25 Dihydroxyvitamin D3&lt;ol&gt;&lt;li&gt;Indicated if &lt;a href="../../Renal/Lab/SrmClcm.htm" class="LinkPage"&gt;Serum Calcium&lt;/a&gt; low&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Renal/Lab/UrnClcm.htm" class="LinkPage"&gt;Urine Calcium&lt;/a&gt; and Phosphate&lt;ol&gt;&lt;li&gt;&lt;a href="../../Renal/Lab/UrnClcm.htm" class="LinkPage"&gt;Hypercalciuria&lt;/a&gt; (24 hour &lt;a href="../../Renal/Lab/UrnClcm.htm" class="LinkPage"&gt;Urine Calcium&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;Hyperphosphaturia&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Renal/Lab/ArtrlBldGs.htm" class="LinkPage"&gt;Arterial Blood Gas&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../Renal/AcidBase/MtblcAcds.htm" class="LinkPage"&gt;Non-Anion Gap Metabolic Acidosis&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Renal/Lab/RnlFnctn.htm" class="LinkPage"&gt;Renal Function&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../Renal/Lab/CrtnClrnc.htm" class="LinkPage"&gt;Creatinine Clearance&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Radiology&lt;ol&gt;&lt;li&gt;Classic XRay Findings&lt;ol&gt;&lt;li&gt;&lt;a href="../../Neuro/Rad/SklXry.htm" class="LinkPage"&gt;Skull XRay&lt;/a&gt;&lt;ol&gt;&lt;li&gt;"Salt and pepper" skull&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Lung/Rad/ChstXry.htm" class="LinkPage"&gt;Chest XRay&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Distal Clavicle resorption&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Hand XRay&lt;ol&gt;&lt;li&gt;Second and third middle phalange bone resorption&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Dental XRay&lt;ol&gt;&lt;li&gt;Bone resorption of Lamina dura around teeth&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Sestamibi Technetium Tc 99mParathyroid Scan&lt;ol&gt;&lt;li&gt;&lt;a href="../../Prevent/Epi/TstSnstvty.htm" class="LinkPage"&gt;Test Sensitivity&lt;/a&gt; for localizing adenoma: 95%&lt;/li&gt;&lt;li&gt;Causes of non-localizing scan&lt;ol&gt;&lt;li&gt;Ectopic PTH production&lt;/li&gt;&lt;li&gt;Diagnostic error&lt;/li&gt;&lt;li&gt;Four-gland hyperplasia&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;End-organ evaluation&lt;ol&gt;&lt;li&gt;Renal &lt;a href="../../Rad/Ultrasound/Ultrsnd.htm" class="LinkPage"&gt;Ultrasound&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Rheum/Rad/BnMnrlDnsty.htm" class="LinkPage"&gt;Bone Densitometry&lt;/a&gt; (&lt;a href="../../Rheum/Rad/DlEnrgyXryAbsrptmtry.htm" class="LinkPage"&gt;DEXA Scan&lt;/a&gt;)&lt;ol&gt;&lt;li&gt;Lumbar spine&lt;/li&gt;&lt;li&gt;Hip&lt;/li&gt;&lt;li&gt;&lt;a href="../../Ortho/Anatomy/FrmAntmy.htm" class="LinkPage"&gt;Forearm&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Differential Diagnosis&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Renal/Calcium/Hyprclcm.htm" class="LinkPage"&gt;Hypercalcemia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Renal/Calcium/FmlBngnHypclcrcHyprclcm.htm" class="LinkPage"&gt;Familial benign hypocalciuric hypercalcemia&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Does not improve with surgery, unlike primary disease&lt;/li&gt;&lt;li&gt;Calcium to &lt;a href="../../Renal/Lab/SrmCrtn.htm" class="LinkPage"&gt;Creatinine&lt;/a&gt; ratio &amp;lt;0.01&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Management: Medical Monitoring&lt;ol&gt;&lt;li&gt;Indications&lt;ol&gt;&lt;li&gt;Asymptomatic patients without surgical indications&lt;/li&gt;&lt;li&gt;&lt;a href="../../Renal/Lab/SrmClcm.htm" class="LinkPage"&gt;Serum Calcium&lt;/a&gt; level only mildly increased&lt;/li&gt;&lt;li&gt;No priot life-threatening &lt;a href="../../Renal/Calcium/Hyprclcm.htm" class="LinkPage"&gt;Hypercalcemia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Normal &lt;a href="../../Renal/Lab/RnlFnctn.htm" class="LinkPage"&gt;Renal Function&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../Renal/Lab/CrtnClrnc.htm" class="LinkPage"&gt;Creatinine Clearance&lt;/a&gt; &amp;gt;70%&lt;/li&gt;&lt;li&gt;No &lt;a href="../../Uro/Renal/Nphrlths.htm" class="LinkPage"&gt;Nephrolithiasis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;No Nephrocalcinosis&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Normal &lt;a href="../../Rheum/Rad/BnMnrlDnsty.htm" class="LinkPage"&gt;Bone Mineral Density&lt;/a&gt; (&lt;a href="../../Rheum/Bone/Ostprs.htm" class="LinkPage"&gt;Osteopenia&lt;/a&gt; or better)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Avoid provocative factors&lt;ol&gt;&lt;li&gt;&lt;a href="../../CV/Pharm/ThzdDrtc.htm" class="LinkPage"&gt;Thiazide Diuretic&lt;/a&gt;s and &lt;a href="../../Psych/Pharm/LthmCrbnt.htm" class="LinkPage"&gt;Lithium&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Avoid Volume depletion (maintain hydration)&lt;/li&gt;&lt;li&gt;Avoid prolonged bedrest or inactivity&lt;/li&gt;&lt;li&gt;Avoid High Calcium diet&lt;/li&gt;&lt;li&gt;Avoid &lt;a href="../../Pharm/Vitamins/VtmnD.htm" class="LinkPage"&gt;Vitamin D&lt;/a&gt; supplementation&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Encourage moderate &lt;a href="../../Sports/Exercise/Exrcs.htm" class="LinkPage"&gt;Physical Activity&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Minimize bone resorption&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Encourage 64 ounces non-caffeinated fluid per day&lt;ol&gt;&lt;li&gt;Minimize risk of &lt;a href="../../Uro/Renal/Nphrlths.htm" class="LinkPage"&gt;Nephrolithiasis&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Encourage moderate calcium intake (1000 mg/day)&lt;ol&gt;&lt;li&gt;Low Calcium diet may surge &lt;a href="../../Endo/Lab/PrthyrdHrmn.htm" class="LinkPage"&gt;Parathyroid Hormone&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Medications&lt;ol&gt;&lt;li&gt;Calcium Lowering Therapy&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Renal/Calcium/Hyprclcm.htm" class="LinkPage"&gt;Hypercalcemia&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Pharmacologic Measures: Reduce bone resorption&lt;ol&gt;&lt;li&gt;&lt;a href="../../Gyn/Pharm/EstrgnRplcmnt.htm" class="LinkPage"&gt;Estrogen Replacement Therapy&lt;/a&gt; (Postmenopausal)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Rheum/Pharm/Bsphsphnts.htm" class="LinkPage"&gt;Bisphosphonates&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Management: Surgery&lt;ol&gt;&lt;li&gt;Indications in Primary Hyperparathyroidism&lt;ol&gt;&lt;li&gt;&lt;a href="../../Renal/Lab/SrmClcm.htm" class="LinkPage"&gt;Serum Calcium&lt;/a&gt; &amp;gt;12 mg/dl&lt;/li&gt;&lt;li&gt;Hypercalcemic crisis (&lt;a href="../../Renal/Lab/SrmClcm.htm" class="LinkPage"&gt;Serum Calcium&lt;/a&gt; &amp;gt;14 mg/dl)&lt;/li&gt;&lt;li&gt;24 hour &lt;a href="../../Renal/Lab/UrnClcm.htm" class="LinkPage"&gt;Urine Calcium&lt;/a&gt; &amp;gt;400 mg/day&lt;/li&gt;&lt;li&gt;&lt;a href="../../Rheum/Bone/Ostprs.htm" class="LinkPage"&gt;Osteoporosis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Osteitis fibrosa cystica&lt;/li&gt;&lt;li&gt;&lt;a href="../../Uro/Renal/Nphrlths.htm" class="LinkPage"&gt;Nephrolithiasis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Nephrocalcinosis&lt;/li&gt;&lt;li&gt;Young patient age (e.g. age &amp;lt;50 years)&lt;/li&gt;&lt;li&gt;Exacerbating factors&lt;ol&gt;&lt;li&gt;Dehydration&lt;/li&gt;&lt;li&gt;Immobile patient&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Renal/Lab/CrtnClrnc.htm" class="LinkPage"&gt;Creatinine Clearance&lt;/a&gt; 30% below age-matched peers&lt;/li&gt;&lt;li&gt;Persistent &lt;a href="../../Renal/Calcium/Hyprclcm.htm" class="LinkPage"&gt;Hypercalcemia&lt;/a&gt; symptoms (esp neuromuscular)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Efficacy&lt;ol&gt;&lt;li&gt;Successful in up to 95% of cases&lt;/li&gt;&lt;li&gt;Few complications&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Single &lt;a href="../../Endo/Anatomy/PrthyrdAntmy.htm" class="LinkPage"&gt;Parathyroid&lt;/a&gt; Adenoma&lt;ol&gt;&lt;li&gt;Surgery to locate and remove adenoma&lt;/li&gt;&lt;li&gt;Biopsy a second gland to rule out atrophy&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Anatomy/PrthyrdAntmy.htm" class="LinkPage"&gt;Parathyroid&lt;/a&gt; hyperplasia or hypertrophy&lt;ol&gt;&lt;li&gt;Remove 3.5 glands&lt;/li&gt;&lt;li&gt;Autotransplant tissue into arm muscle&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Monitoring of medically managed patients&lt;ol&gt;&lt;li&gt;Every 6 month labs&lt;ol&gt;&lt;li&gt;&lt;a href="../../Renal/Lab/SrmClcm.htm" class="LinkPage"&gt;Serum Calcium&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Every 12 month labs&lt;ol&gt;&lt;li&gt;&lt;a href="../../Renal/Lab/SrmCrtn.htm" class="LinkPage"&gt;Serum Creatinine&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Urinary Calcium Excretion&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Every 6-12 month labs for women&lt;ol&gt;&lt;li&gt;Bone Density (&lt;a href="../../Rheum/Rad/DlEnrgyXryAbsrptmtry.htm" class="LinkPage"&gt;DEXA Scan&lt;/a&gt;)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;Spiegel in Goldman (2000) Cecil Medicine, p. 1402-5&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=1991%20%5BDP%5D%20AND%20%20Ann%20Intern%20Med%20%20%5BTA%5D%20AND%20114%20%5BVI%5D%20AND%20593%20%5BPG%5D" class="LinkRef"&gt;(1991) Ann Intern Med 114:593-7&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Bilezikian%20%20%5BAU%5D%20AND%202002%20%5BDP%5D%20AND%20%20J%20Clin%20Endocrinol%20Metab%20%20%5BTA%5D" class="LinkRef"&gt;Bilezikian (2002) J Clin Endocrinol Metab 87:5353-61&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Taniegra%20%20%5BAU%5D%20AND%202004%20%5BDP%5D%20AND%20%20Am%20Fam%20Physician%20%20%5BTA%5D" class="LinkRef"&gt;Taniegra (2004) Am Fam Physician 69(2):333-40&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0020502</value><value>C0221002</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Parathyroid/Hyprprthyrdsm.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Hyperparathyroidism, Primary Hyperparathyroidism</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Parathyroid/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Hyperthyroidism  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0020550"&gt;&lt;i&gt;C0020550&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;Overactivity of the thyroid gland resulting in overproduction of thyroid hormone and increased metabolic rate. Causes include diffuse hyperplasia of the thyroid gland (Graves' disease), single nodule in the thyroid gland, and thyroiditis. The symptoms are related to the increased metabolic rate and include weight loss, fatigue, heat intolerance, excessive sweating, diarrhea, tachycardia, insomnia, muscle weakness, and tremor.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A disorder characterized by excessive levels of thyroid hormone in the body. Common causes include an overactive thyroid gland or thyroid hormone overdose.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CSP)&lt;/td&gt;
                &lt;td&gt;excessive functional activity of the thyroid gland.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;Hypersecretion of THYROID HORMONES from the THYROID GLAND. Elevated levels of thyroid hormones increase BASAL METABOLIC RATE.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;Too much thyroid hormone. Symptoms include weight loss, chest pain, cramps, diarrhea, and nervousness.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Disease or Syndrome (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0020550&amp;amp;tui=T047"&gt;&lt;i&gt;T047&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D006980&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD10&lt;/td&gt;
                &lt;td&gt;E05.9&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;34486009, 154655004, 190239004, 267464006&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Hyperthyroidism, HYPERTHYROIDISM, Hyperthyroidism, NOS, overactive thyroid, hyperthyroidism, hyperthyroidism (diagnosis), Hyperthyroidism NOS, Hyperthyroidism [Disease/Finding], Primary Hyperthyroidism, Primary Hyperthyroidisms, Hyperthyroidism, Primary, hyperthyroidism nos, Hyperthyroidism (disorder), Overactive Thyroid&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;HYPERTHYROIDIE, Hyperthyréose, Hyperthyroïdie, Hyperthyroïdisme&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;HIPERTIROIDISMO, Hyperthyroidism, hipertiroidismo (trastorno), hipertiroidismo, Hipertiroidismo&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;HYPERTHYREOSE, Hyperthyroidismus, Hyperthyreoidismus, Hyperthyreose&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;甲状腺機能亢進症, ｺｳｼﾞｮｳｾﾝｷﾉｳｺｳｼﾝｼｮｳ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Hypertyreos&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;hypertyreoidismus, Hypertyreóza&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Kilpirauhasen liikatoiminta&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;GIPERTIREOIDIZM, GIPERTIREOZ, ГИПЕРТИРЕОЗ, ГИПЕРТИРЕОИДИЗМ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;HIPERTIROIDISMO, Hipertiroidismo, Hipertireoidismo&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Croatian&lt;/td&gt;
                &lt;td&gt;HIPERTIREOZA&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Nadczynność tarczycy&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;Hyperthyreosis&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;hyperthyroïdie, Basedow, ziekte van, Hyperthyreose, Hyperthyreoïdie, Hyperthyroïdie, Thyreoïdie, hyper-&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Ipertiroidismo&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Thyrotoxicosis  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0040156"&gt;&lt;i&gt;C0040156&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A hypermetabolic syndrome caused by the elevation of thyroid hormone levels in the serum. Signs and symptoms include tachycardia, palpitations, tremor, weight loss, warm weather intolerance, and moist skin. Causes include Graves disease, toxic nodular goiter, toxic thyroid nodule, and lymphocytic thyroiditis.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;A hypermetabolic syndrome caused by excess THYROID HORMONES which may come from endogenous or exogenous sources. The endogenous source of hormone may be thyroid HYPERPLASIA; THYROID NEOPLASMS; or hormone-producing extrathyroidal tissue. Thyrotoxicosis is characterized by NERVOUSNESS; TACHYCARDIA; FATIGUE; WEIGHT LOSS; heat intolerance; and excessive SWEATING.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Disease or Syndrome (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0040156&amp;amp;tui=T047"&gt;&lt;i&gt;T047&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D013971&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD9&lt;/td&gt;
                &lt;td&gt;242&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD10&lt;/td&gt;
                &lt;td&gt;E05.9&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;267373004, 154659005, 190267008, 90739004, 286909009, 154655004, 190239004, 267464006&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Thyrotoxicoses, THYROTOXICOSIS, Thyrotoxicosis, NOS, Thyrotoxicosis NOS, Thyrotoxicosis, unspecified, Thyrotoxicosis, Thyrotoxicosis +/- goiter, Thyrotoxicosis +/- goitre, thyrotoxicosis with or without goiter, thyrotoxicosis with or without goiter (diagnosis), Thyrotoxicosis NOS (disorder), Thyrotoxicosis [Disease/Finding], Thyrotoxicosis with or without goiter, Thyrotoxicosis with or without goitre, Thyrotoxicosis (disorder), Thyrotoxicosis with or without goiter (disorder), thyrotoxicosis, thyroid; toxic, toxic; thyroid, Thyrotoxicosis [Ambiguous]&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;TIROTOXICOSE, Tirotoxicose com ou sem bócio, Tirotoxicose, Tireotoxicose&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;TIROTOXICOSIS, Tirotoxicosis con o sin bocio, Thyrotoxicosis +/- goitre, Thyrotoxicosis, Thyrotoxicosis +/- goiter, Thyrotoxicosis [Ambiguous], Thyrotoxicosis NOS, hipertiroidismo con o sin bocio (trastorno), hipertiroidismo con o sin bocio, hipertiroidismo, SAI (trastorno), hipertiroidismo, SAI, tirotoxicosis (trastorno), tirotoxicosis con o sin bocio (trastorno), tirotoxicosis con o sin bocio, tirotoxicosis, SAI (trastorno), tirotoxicosis, SAI, tirotoxicosis, Tirotoxicosis&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;THYREOTOXIKOSE, Thyreotoxikose mit oder ohne Struma, Hyperthyreose, nicht naeher bezeichnet, Thyreotoxikose&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;thyreotoxicose met of zonder struma, thyreotoxicose, schildklier; toxisch, toxisch; schildklier, Thyrotoxicose, niet gespecificeerd, Hyperthyreoidie, Thyreotoxicose, Thyrotoxicose, Toxicose, thyreo-, Hyperthyroïdie&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Thyrotoxicose avec ou sans goitre, THYREOTOXICOSE, Thyrotoxicose, Thyréotoxicose&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Tireotossicosi con o senza gozzo, Tireotossicosi&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;甲状腺中毒症, 甲状腺腫を伴うまたは伴わない甲状腺中毒症, ｺｳｼﾞｮｳｾﾝｼｭｦﾄﾓﾅｳﾏﾀﾊﾄﾓﾅﾜﾅｲｺｳｼﾞｮｳｾﾝﾁｭｳﾄﾞｸｼｮｳ, ｺｳｼﾞｮｳｾﾝﾁｭｳﾄﾞｸｼｮｳ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Tyreotoxikos&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;tyreotoxikóza, Tyreotoxikóza se strumou nebo bez strumy, Tyreotoxikóza&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Tyreotoksikoosi&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;TIREOTOKSIKOZ, ТИРЕОТОКСИКОЗ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Korean&lt;/td&gt;
                &lt;td&gt;상세불명의 갑상샘중독증&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Tyreotoksykoza&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;Hyperthyreosis strumával vagy anélkül, Thyreotoxicosis&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Hyperthyroidism  (</value><value>)
</value><value>Thyrotoxicosis  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Hyperthyroidism</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Thyroid Disease</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;See Also&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/SbclnclHyprthyrdsm.htm" class="LinkPage"&gt;Subclinical Hyperthyroidism&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/GrvsDs.htm" class="LinkPage"&gt;Grave's Disease&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/ThyrdStrm.htm" class="LinkPage"&gt;Thyroid Storm&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Epidemiology&lt;ol&gt;&lt;li&gt;Lifetime &lt;a href="../../Prevent/Epi/DsPrvlncRt.htm" class="LinkPage"&gt;Prevalence&lt;/a&gt; (US): 0.5%&lt;ol&gt;&lt;li&gt;Women: 2%&lt;/li&gt;&lt;li&gt;Men 0.2%&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Turnbridge%20%20%5BAU%5D%20AND%201977%20%5BDP%5D%20AND%20%20Clin%20Endocrinol%20%20%5BTA%5D" class="LinkRef"&gt;Turnbridge (1977) Clin Endocrinol 7:481-93&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Causes&lt;ol&gt;&lt;li&gt;Stimulatory Causes (positive &lt;a href="../../Endo/Pharm/Rdn.htm" class="LinkPage"&gt;Radioactive Iodine&lt;/a&gt; scan)&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/GrvsDs.htm" class="LinkPage"&gt;Grave's Disease&lt;/a&gt; (60-80% of Hyperthyroidism cases)&lt;/li&gt;&lt;li&gt;&lt;a href="../../OB/HemeOnc/Chrcrcnm.htm" class="LinkPage"&gt;Trophoblastic Tumor&lt;/a&gt;s activate TSH receptors via HCG (&lt;a href="../../OB/HemeOnc/Chrcrcnm.htm" class="LinkPage"&gt;Choriocarcinoma&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;Pituitary TSH-secreting tumor&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Non-Stimulatory Causes&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/MltndlrGtr.htm" class="LinkPage"&gt;Toxic Multinodular Goiter&lt;/a&gt; (5%)&lt;/li&gt;&lt;li&gt;Toxic &lt;a href="../../Endo/HemeOnc/ThyrdAdnm.htm" class="LinkPage"&gt;Thyroid Adenoma&lt;/a&gt; (Plummer's Disease)&lt;/li&gt;&lt;li&gt;Exogenous &lt;a href="../../Endo/Anatomy/ThyrdAntmy.htm" class="LinkPage"&gt;Thyroid&lt;/a&gt; hormone source&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/Thyrdts.htm" class="LinkPage"&gt;Thyroiditis&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/ID/SbctGrnlmtsThyrdts.htm" class="LinkPage"&gt;Subacute Thyroiditis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/Thyrdts.htm" class="LinkPage"&gt;Acute Thyroiditis&lt;/a&gt; (Bacterial infection)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/OB/PstprtmThyrdts.htm" class="LinkPage"&gt;Postpartum Thyroiditis&lt;/a&gt; (lymphocytic &lt;a href="../../Endo/Thyroid/Thyrdts.htm" class="LinkPage"&gt;Thyroiditis&lt;/a&gt;)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Tumors (rare)&lt;ol&gt;&lt;li&gt;Metastatic follicular &lt;a href="../../Endo/HemeOnc/ThyrdCrcnm.htm" class="LinkPage"&gt;Thyroid Cancer&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Gyn/HemeOnc/OvrnCncr.htm" class="LinkPage"&gt;Ovarian Cancer&lt;/a&gt; producing &lt;a href="../../Endo/Lab/Thyrxn.htm" class="LinkPage"&gt;Thyroxine&lt;/a&gt; (struma ovarii)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Medication-Induced Hyperthyroidism&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Endo/Pharm/MdctnsAfctngThyrdFnctn.htm" class="LinkPage"&gt;Medications Affecting Thyroid Function&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Combined Stimulatory and Non-Stimulatory Causes (positive &lt;a href="../../Endo/Pharm/Rdn.htm" class="LinkPage"&gt;Radioactive Iodine&lt;/a&gt; scan)&lt;ol&gt;&lt;li&gt;Nodular &lt;a href="../../Endo/Thyroid/Gtr.htm" class="LinkPage"&gt;Goiter&lt;/a&gt; with superimposed stimulation&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Symptoms&lt;ol&gt;&lt;li&gt;Nervousness or alertness&lt;/li&gt;&lt;li&gt;Emotional lability (Anxiety, Irritability)&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Sx/Plptn.htm" class="LinkPage"&gt;Palpitation&lt;/a&gt;s&lt;/li&gt;&lt;li&gt;&lt;a href="../../Psych/Sleep/Insmn.htm" class="LinkPage"&gt;Insomnia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Neuro/Tremor/Trmr.htm" class="LinkPage"&gt;Tremor&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Rheum/Sx/MsclWkns.htm" class="LinkPage"&gt;Muscle Weakness&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Frequent &lt;a href="../../GI/Exam/Dfctn.htm" class="LinkPage"&gt;Bowel Movement&lt;/a&gt;s, &lt;a href="../../GI/Diarrhea/ActDrh.htm" class="LinkPage"&gt;Diarrhea&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Excessive Sweating&lt;/li&gt;&lt;li&gt;Weight loss despite increased appetite&lt;/li&gt;&lt;li&gt;Heat intolerance&lt;/li&gt;&lt;li&gt;Oligomenorrhea or &lt;a href="../../Gyn/Sx/Amnrh.htm" class="LinkPage"&gt;Amenorrhea&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Signs&lt;ol&gt;&lt;li&gt;Anxious, restless, fidgeting patient&lt;/li&gt;&lt;li&gt;Dermatologic&lt;ol&gt;&lt;li&gt;Warm, moist and velvety&lt;/li&gt;&lt;li&gt;Palmar erythema&lt;/li&gt;&lt;li&gt;&lt;a href="../../Derm/Anatomy/Hr.htm" class="LinkPage"&gt;Hair&lt;/a&gt; fine and silky&lt;/li&gt;&lt;li&gt;&lt;a href="../../Derm/Anatomy/NlAntmy.htm" class="LinkPage"&gt;Fingernail&lt;/a&gt;s&lt;ol&gt;&lt;li&gt;&lt;a href="../../Derm/Nails/Onychlys.htm" class="LinkPage"&gt;Onycholysis&lt;/a&gt; (Plummer's Nails)&lt;/li&gt;&lt;li&gt;Brown &lt;a href="../../Derm/Nails/NlDsclrtn.htm" class="LinkPage"&gt;Nail Discoloration&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Neuromuscular&lt;ol&gt;&lt;li&gt;Fine &lt;a href="../../Neuro/Tremor/Trmr.htm" class="LinkPage"&gt;Tremor&lt;/a&gt; of fingers, &lt;a href="../../ENT/Anatomy/Tng.htm" class="LinkPage"&gt;Tongue&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Hyperkinesia&lt;/li&gt;&lt;li&gt;Rapid speech&lt;/li&gt;&lt;li&gt;Quadriceps weakness&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Eye changes&lt;ol&gt;&lt;li&gt;Stare&lt;/li&gt;&lt;li&gt;Widened palpebral fissures&lt;/li&gt;&lt;li&gt;Infrequent blinking&lt;/li&gt;&lt;li&gt;&lt;a href="../../Eye/Conjunctiva/Chms.htm" class="LinkPage"&gt;Chemosis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Lid lag&lt;/li&gt;&lt;li&gt;&lt;a href="../../Eye/Sx/Prpts.htm" class="LinkPage"&gt;Proptosis&lt;/a&gt; (&lt;a href="../../Eye/Sx/Prpts.htm" class="LinkPage"&gt;Exophthalmos&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;Periorbital edema&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Cardiovascular&lt;ol&gt;&lt;li&gt;Increased &lt;a href="../../CV/Exam/BldPrsr.htm" class="LinkPage"&gt;Blood Pressure&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Systolic &lt;a href="../../CV/Htn/Hyprtnsn.htm" class="LinkPage"&gt;Hypertension&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Wide &lt;a href="../../CV/Exam/PlsPrsr.htm" class="LinkPage"&gt;Pulse Pressure&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Arrhythmia&lt;ol&gt;&lt;li&gt;&lt;a href="../../CV/EKG/AtrlFbrltn.htm" class="LinkPage"&gt;Atrial Fibrillation&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/EKG/Tchycrd.htm" class="LinkPage"&gt;Tachycardia&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Auscultation&lt;ol&gt;&lt;li&gt;Loud &lt;a href="../../CV/Exam/SHrtSnd.htm" class="LinkPage"&gt;S1 Heart Sound&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Loud &lt;a href="../../CV/Exam/SHrtSnd1.htm" class="LinkPage"&gt;S2 Heart Sound&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Exam/SystlcMrmr.htm" class="LinkPage"&gt;Systolic Murmur&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Cardiac hypertrophy&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Labs&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Endo/Lab/ThyrdFnctnTst.htm" class="LinkPage"&gt;Thyroid Function Test&lt;/a&gt;ing&lt;/li&gt;&lt;li&gt;Serum &lt;a href="../../Endo/Lab/ThyrdStmltngHrmn.htm" class="LinkPage"&gt;Thyroid Stimulating Hormone&lt;/a&gt; (TSH) suppressed&lt;/li&gt;&lt;li&gt;Serum Free &lt;a href="../../Endo/Lab/Thyrxn.htm" class="LinkPage"&gt;Thyroxine&lt;/a&gt; (&lt;a href="../../Endo/Lab/Thyrxn.htm" class="LinkPage"&gt;Free T4&lt;/a&gt;) elevated&lt;/li&gt;&lt;li&gt;Non-specific lab changes (variably present)&lt;ol&gt;&lt;li&gt;&lt;a href="../../HemeOnc/Lab/CmpltBldCnt.htm" class="LinkPage"&gt;Complete Blood Count&lt;/a&gt; (CBC)&lt;ol&gt;&lt;li&gt;&lt;a href="../../HemeOnc/Anemia/Anm.htm" class="LinkPage"&gt;Anemia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Granulocytosis and &lt;a href="../../HemeOnc/Lab/LymphcytCnt.htm" class="LinkPage"&gt;Lymphocytosis&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Electrolytes&lt;ol&gt;&lt;li&gt;&lt;a href="../../Renal/Calcium/Hyprclcm.htm" class="LinkPage"&gt;Hypercalcemia&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../GI/Lab/LvrFnctnTst.htm" class="LinkPage"&gt;Liver Function Test&lt;/a&gt;s&lt;ol&gt;&lt;li&gt;&lt;a href="../../GI/Anatomy/LvrAntmy.htm" class="LinkPage"&gt;Liver&lt;/a&gt; transaminases (AST,ALT) increased&lt;/li&gt;&lt;li&gt;&lt;a href="../../GI/Lab/AlklnPhsphts.htm" class="LinkPage"&gt;Alkaline Phosphatase&lt;/a&gt; increased&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Diagnostics&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Anatomy/ThyrdAntmy.htm" class="LinkPage"&gt;Thyroid&lt;/a&gt; Uptake Scan&lt;ol&gt;&lt;li&gt;Differentiate Hyperthyroidism causes&lt;/li&gt;&lt;li&gt;Identify hot and cold &lt;a href="../../Derm/Exam/Ndl1.htm" class="LinkPage"&gt;Nodule&lt;/a&gt;s&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Anatomy/ThyrdAntmy.htm" class="LinkPage"&gt;Thyroid&lt;/a&gt;&lt;a href="../../Rad/Ultrasound/Ultrsnd.htm" class="LinkPage"&gt;Ultrasound&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Differentiate solid from cystic &lt;a href="../../Derm/Exam/Ndl1.htm" class="LinkPage"&gt;Nodule&lt;/a&gt;s&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;If solid cold &lt;a href="../../Derm/Exam/Ndl1.htm" class="LinkPage"&gt;Nodule&lt;/a&gt;:&lt;ol&gt;&lt;li&gt;Fine needle biopsy&lt;/li&gt;&lt;li&gt;&lt;a href="../../Neuro/Rad/CtHd.htm" class="LinkPage"&gt;CT Head&lt;/a&gt; &amp;amp; Neck (evaluate for metestatic disease)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Evaluation&lt;ol&gt;&lt;li&gt;Step 1: Check TSH&lt;ol&gt;&lt;li&gt;TSH Normal: No Hyperthyroidism&lt;/li&gt;&lt;li&gt;TSH Suppressed: Go to Step 2 below&lt;/li&gt;&lt;li&gt;TSH Increased: Check &lt;a href="../../Endo/Lab/Thyrxn.htm" class="LinkPage"&gt;Free T4&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Normal or Low: Consider &lt;a href="../../Endo/Thyroid/Hypthyrdsm.htm" class="LinkPage"&gt;Hypothyroidism&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/Thyrxn.htm" class="LinkPage"&gt;Free T4&lt;/a&gt; High: Secondary Hyperthyroidism (rare)&lt;ol&gt;&lt;li&gt;Obtain MRI or CT of &lt;a href="../../Neuro/Anatomy/PtryAntmy.htm" class="LinkPage"&gt;Pituitary Gland&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Step 2: Check &lt;a href="../../Endo/Lab/Thyrxn.htm" class="LinkPage"&gt;Free T4&lt;/a&gt; (for suppressed TSH)&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/Thyrxn.htm" class="LinkPage"&gt;Free T4&lt;/a&gt; High: Go to Step 3&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/Thyrxn.htm" class="LinkPage"&gt;Free T4&lt;/a&gt; Normal: Measure serum &lt;a href="../../Endo/Lab/Trdthyrn.htm" class="LinkPage"&gt;Free T3&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Normal T3: Follow for transient cause resolution&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/Trdthyrn.htm" class="LinkPage"&gt;Free T3&lt;/a&gt; high: Go to Step 3&lt;ol&gt;&lt;li&gt;T3 toxicosis (seen in 10-15% cases)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Step 3: &lt;a href="../../Endo/Anatomy/ThyrdAntmy.htm" class="LinkPage"&gt;Thyroid&lt;/a&gt; Uptake Scan (Primary &lt;a href="../../Endo/Thyroid/Hypthyrdsm.htm" class="LinkPage"&gt;Hypothyroidism&lt;/a&gt;)&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Anatomy/ThyrdAntmy.htm" class="LinkPage"&gt;Thyroid&lt;/a&gt; Uptake Scan with low uptake&lt;ol&gt;&lt;li&gt;Single "Cold" &lt;a href="../../Derm/Exam/Ndl1.htm" class="LinkPage"&gt;Nodule&lt;/a&gt;: Possible &lt;a href="../../Endo/HemeOnc/ThyrdCrcnm.htm" class="LinkPage"&gt;Thyroid Cancer&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Diffusely low uptake: Go to Step 4&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Anatomy/ThyrdAntmy.htm" class="LinkPage"&gt;Thyroid&lt;/a&gt; Uptake Scan with high uptake&lt;ol&gt;&lt;li&gt;Diffusely high uptake: &lt;a href="../../Endo/Thyroid/GrvsDs.htm" class="LinkPage"&gt;Grave's Disease&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Single "Hot" &lt;a href="../../Derm/Exam/Ndl1.htm" class="LinkPage"&gt;Nodule&lt;/a&gt;: Toxic &lt;a href="../../Endo/HemeOnc/ThyrdAdnm.htm" class="LinkPage"&gt;Thyroid Adenoma&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Multiple "Hot" &lt;a href="../../Derm/Exam/Ndl1.htm" class="LinkPage"&gt;Nodule&lt;/a&gt;s: &lt;a href="../../Endo/Thyroid/MltndlrGtr.htm" class="LinkPage"&gt;Toxic Multinodular Goiter&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Step 4: Check Thyroglobulin (scan with low uptake)&lt;ol&gt;&lt;li&gt;Thyroglobulin Low: Exogenous hormone source&lt;/li&gt;&lt;li&gt;Thyroglobulin High&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/Thyrdts.htm" class="LinkPage"&gt;Thyroiditis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Ectopic &lt;a href="../../Endo/Anatomy/ThyrdAntmy.htm" class="LinkPage"&gt;Thyroid&lt;/a&gt; hormone production (e.g. ovary)&lt;/li&gt;&lt;li&gt;Excess iodide exposure&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Management&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Endo/Thyroid/HyprthyrdsmMngmnt.htm" class="LinkPage"&gt;Hyperthyroidism Management&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Haddard%20%20%5BAU%5D%20AND%201998%20%5BDP%5D%20AND%20%20Postgrad%20Med%20%20%5BTA%5D" class="LinkRef"&gt;Haddard (1998) Postgrad Med 104(1):42-59&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Hennessey%20%20%5BAU%5D%20AND%201996%20%5BDP%5D%20AND%20%20Am%20Fam%20Physician%20%20%5BTA%5D" class="LinkRef"&gt;Hennessey (1996) Am Fam Physician 54(4):1315-24&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Reid%20%20%5BAU%5D%20AND%202005%20%5BDP%5D%20AND%20%20Am%20Fam%20Physician%20%20%5BTA%5D" class="LinkRef"&gt;Reid (2005) Am Fam Physician 72:623-36&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Singer%20%20%5BAU%5D%20AND%201995%20%5BDP%5D%20AND%20%20JAMA%20%20%5BTA%5D" class="LinkRef"&gt;Singer (1995) JAMA 273(10):808-12&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Slatosky%20%20%5BAU%5D%20AND%202000%20%5BDP%5D%20AND%20%20Am%20Fam%20Physician%20%20%5BTA%5D" class="LinkRef"&gt;Slatosky (2000) Am Fam Physician 61(4):1047-52&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0020550</value><value>C0040156</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Thyroid/Hyprthyrdsm1.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Hyperthyroidism, Thyrotoxicosis</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Thyroid/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Thyroid Diseases  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0040128"&gt;&lt;i&gt;C0040128&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MEDLINEPLUS)&lt;/td&gt;
                &lt;td&gt;
                  &lt;span&gt;
                    &lt;p&gt;Your thyroid is a butterfly-shaped gland in your neck, just above your collarbone.  It is one of your endocrine glands, which make hormones.  The thyroid helps set your metabolism - how your body gets energy from the foods you eat.&lt;/p&gt;
                    &lt;p&gt;Millions of people in the U.S. have thyroid diseases.  Most of them are women.  If you have a thyroid disease, your body uses energy more slowly or quickly than it should.  A thyroid gland that is not active enough, called hypothyroidism, is far more common.  It can make you gain weight, feel fatigued and have difficulty dealing with cold temperatures.  If your thyroid is too active, it makes more thyroid hormones than your body needs.  That condition is hyperthyroidism.  Too much thyroid hormone can make you lose weight, speed up your heart rate and make you very sensitive to heat. &lt;/p&gt;
                    &lt;p&gt;There are many causes for both conditions.  Treatment involves trying to reset your body's metabolism to a normal rate.&lt;/p&gt;
                  &lt;/span&gt;
                &lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CSP)&lt;/td&gt;
                &lt;td&gt;condition in which there is a deviation from or interruption of the normal structure or function of the thyroid gland, which is a highly vascular endocrine gland that produces the thyroid hormones which are concerned in regulating the metabolic rate of the body.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;Pathological processes involving the THYROID GLAND.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Disease or Syndrome (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0040128&amp;amp;tui=T047"&gt;&lt;i&gt;T047&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D013959&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD9&lt;/td&gt;
                &lt;td&gt;246.9, 240-246.99&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD10&lt;/td&gt;
                &lt;td&gt;E00-E07.9, E07.9, E00-E07&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;14304000, 191036006, 154649009, 190311002, 190232008&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Disease, Thyroid, Diseases, Thyroid, Thyroid Diseases, Unspecified disorder of thyroid, THYROID DISEASE, THYROID DISORDER, Disorders of thyroid gland, THYROID DISEASE, NOS, DISORDER THYROID, Thyroid, Thyroid Disease, DISEASES OF THE THYROID GLAND, Disease of thyroid gland, Disease of thyroid gland, NOS, Diseases of Thyroid Gland, Disorder of thyroid gland, NOS, HYPOTHYROIDISM, HYPERTHYROIDISM AND OTHER DISORDERS, Thyroid disorder NOS, Disorder of thyroid, unspecified, Thyroid disorder, NOS, THYROID DIS, SECTION B-8 DISEASES OF THE THYROID GLAND, B-80 HYPOTHYROIDISM, HYPERTHYROIDISM AND OTHER DISORDERS, thyroid disorder, thyroid disorder (diagnosis), Thyroid gland disorders, Disorder thyroid, THYROID ABNORMAL, Disorder of thyroid NOS, Thyroid disorder NOS (disorder), Thyroid disorders, Thyroid Diseases [Disease/Finding], thyroid gland disease, thyroid gland diseases, abnormal thyroid, diseases of the thyroid gland, thyroid disease, thyroid diseases, thyroid gland disorder, thyroid disorders, thyroid abnormal, thyroid gland disorders, Disorders of thyroid gland (E00-E07), Thyroid disease, Thyroid disorder, disease (or disorder); thyroid, thyroid; disorder, Disorder of thyroid gland, Disease of thyroid gland (disorder), Disorder of thyroid gland (disorder), Thyroid Disorders, Thyroid Gland Diseases, Thyroid Gland Disease, Thyroid Gland Disorders, Thyroid Gland Disorder, DISORDERS OF THYROID GLAND&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Patologia della tiroide, Patologie della ghiandola tiroidea, Disturbo della tiroide, Patologia della tiroide NAS, Disturbo non specificato della tiroide, Malattie tiroidee&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;schildklieraandoening NAO, aandoening schildklier, niet-gespecificeerde schildklieraandoening, aandoening; schildklier, schildklier; aandoening, Schildklieraandoening, niet gespecificeerd, schildklieraandoeningen, thyroïdaandoening, Schildklieraandoening, Schildklierziekte, Schildklierziekten, Ziekte, schildklier-&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Trouble de la thyroïde non précisé, Trouble thyroïdien SAI, TROUBLE THYROIDIEN, Trouble thyroïdien, Troubles de la glande thyroïde, Maladies thyroidiennes, Maladies de la thyroïde&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;unspezifische Funktionsstoerung der Schilddruese, Erkrankungen der Schilddruese NNB, Erkrankung der Schilddruese, Krankheit der Schilddruese, nicht naeher bezeichnet, SCHILDDRUESENSTOERUNG, Erkrankungen der Schilddruese, Schilddruesenerkrankung, Schilddrüsenkrankheiten&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Doença da tiroideia NE, Afecção NE da tiroideia, Afecção da tiroideia, ALTERACAO TIROIDEIA, Anomalia da tireóide, Doenças da tiroideia, Doenças da Glândula Tireóide, Doenças da Tireóide&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;Trastorno no especificado del tiroides, Trastorno de tiroides NEOM, enfermedad de la glándula tiroides (trastorno), Disorders of thyroid gland, Disorder of thyroid gland, TIROIDES, TRASTORNO, trastorno tiroideo, SAI (trastorno), trastorno tiroideo, SAI, trastorno tiroideo, Trastorno de tiroides, Trastornos de la glándula tiroides, trastorno de la glándula tiroides, trastorno de la glándula tiroides (trastorno), enfermedad de la glándula tiroides, Enfermedades de la Tiroides, Enfermedades Tiroideas, Enfermedades de la Glandula Tiroides, Enfermedades de la Glándula Tiroides&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;甲状腺障害, 甲状腺障害ＮＯＳ, 詳細不明の甲状腺障害, ｺｳｼﾞｮｳｾﾝｼｮｳｶﾞｲNOS, ｺｳｼﾞｮｳｾﾝｼｮｳｶﾞｲ, ｼｮｳｻｲﾌﾒｲﾉｺｳｼﾞｮｳｾﾝｼｮｳｶﾞｲ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Sköldkörtelsjukdomar&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;tyreoidea - nemoci, Porucha štítné žlázy, Porucha štítné žlázy NOS, Poruchy štítné žlázy, Blíže neurčená porucha štítné žlázy, thyreoidea - nemoci&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Kilpirauhasen sairaudet&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;SHCHITOVIDNOI ZHELEZY BOLEZNI, ЩИТОВИДНОЙ ЖЕЛЕЗЫ БОЛЕЗНИ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Korean&lt;/td&gt;
                &lt;td&gt;상세불명의 갑상샘의 장애&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Croatian&lt;/td&gt;
                &lt;td&gt;TIREOIDNE BOLESTI, BOLESTI ŠTITNJAČE, TIROIDNE BOLESTI&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Choroby tarczycy&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;Pajzsmirigy nem meghatározott betegsége, Pajzsmirigy betegségek, Pajzsmirigy betegség k.m.n., Pajzsmirigy betegség&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Thyroid Gland  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0040132"&gt;&lt;i&gt;C0040132&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;An endocrine gland located at the base of the neck that produces and secretes thyroxine and other hormones. Thyroxine is important for metabolic control.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (FMA)&lt;/td&gt;
                &lt;td&gt;Lobular organ the parenchyma of which consists of ductless, glandular follicles filled with colloid. Examples: thyroid gland proper, accessory thyroid gland, lingual thyroid gland.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;An endocrine gland located at the base of the neck that produces and secretes thyroxine and other hormones. Thyroxine is important for metabolic control. (NCI)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A gland located beneath the larynx (voice box) that makes thyroid hormone and calcitonin. The thyroid gland helps regulate growth and metabolism.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (UWDA)&lt;/td&gt;
                &lt;td&gt;Lobular organ the parenchyma of which consists of ductless, glandular follicles filled with colloid. Examples: thyroid gland proper, accessory thyroid gland, lingual thyroid gland.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;A highly vascularized endocrine gland consisting of two lobes joined by a thin band of tissue with one lobe on each side of the TRACHEA. It secretes THYROID HORMONES from the follicular cells and CALCITONIN from the parafollicular cells thereby regulating METABOLISM and CALCIUM level in blood, respectively.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CSP)&lt;/td&gt;
                &lt;td&gt;endocrine gland normally situated in the lower part of the front of the neck; secretes, stores and releases the iodine dependent thyroid hormones thyroxine and triiodothyroine which play major endocrine roles in regulating metabolic rate; also secretes thyrocalcitonin.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Body Part, Organ, or Organ Component (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0040132&amp;amp;tui=T023"&gt;&lt;i&gt;T023&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D013961&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;69748006&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;HL7&lt;/td&gt;
                &lt;td&gt;THYRD&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Gland, Thyroid, Glands, Thyroid, Thyroid Gland, Thyroid Glands, Thyroid gland, NOS, THYROID GLAND, Thyroid, Thyroids, thyroid gland, thyroid, Thyroid, NOS, B6 THYROID GLAND, Glandula thyroidea, THYROID, thyroid glands, thyroids, Thyroid gland, Thyroid structure, Thyroid structure (body structure), Head and Neck, Thyroid&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Corps thyroïde, Glande thyroide, Thyroïde&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Sköldkörtel&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;štítná žláza, tyreoidea, glandula thyreoidea, thyreoidea&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Kilpirauhanen&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;SHCHITOVIDNAIA ZHELEZA, ЩИТОВИДНАЯ ЖЕЛЕЗА&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;甲状腺&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Glândula Tiróide, Tiróide, Glândula Tireóide, Tireóide&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Latvian&lt;/td&gt;
                &lt;td&gt;Vairogdziedzeris&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Tarczyca, Gruczoł tarczowy&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Croatian&lt;/td&gt;
                &lt;td&gt;ŠTITNA ŽLIJEZDA, ŠTITNJAČA, TIREOIDEJA&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;estructura de la glándula tiroides (estructura corporal), estructura de la glándula tiroides, glándula tiroides, Glándula Tiroides, Glandula Tiroides&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Glandula thyreoidea, Schilddrüse&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Tiroide&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;Glandula thyreoidea, Schildklier&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Thyroid Diseases  (</value><value>)
</value><value>Thyroid Gland  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Thyroid Anatomy</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Anatomy</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;See Also&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Anatomy/PrthyrdAntmy.htm" class="LinkPage"&gt;Parathyroid Anatomy&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Anatomy/EndcrnAntmy.htm" class="LinkPage"&gt;Endocrine Anatomy&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../ENT/Anatomy/HdAndNckAntmy.htm" class="LinkPage"&gt;Head and Neck Anatomy&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;
              &lt;a href="../../OB/Fetus/Embrylgy.htm" class="LinkPage"&gt;Embryology&lt;/a&gt;
              &lt;ol&gt;&lt;li&gt;Develops from &lt;a href="../../ENT/Anatomy/Tng.htm" class="LinkPage"&gt;Tongue&lt;/a&gt; root (foramen cecum)&lt;/li&gt;
                &lt;li&gt;Formed by 5th-6th week of development&lt;/li&gt;
              &lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Anatomy&lt;ol&gt;&lt;li&gt;Images&lt;ol&gt;&lt;li class="thumb"&gt;&lt;a href="http://www.fpnotebook.com/_media/ThyroidAnterior.gif" class="LinkGraphic"&gt;&lt;img src="http://www.fpnotebook.com/_thumb/ThyroidAnterior_t.gif" alt="ThyroidAnterior.gif" border="0"&gt;&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Normal Adult Thyroid weighs 20-25g&lt;/li&gt;&lt;li&gt;Components&lt;ol&gt;&lt;li&gt;Two Lateral lobes&lt;/li&gt;&lt;li&gt;Isthmus centrally connects the lobes&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Near structures&lt;ol&gt;&lt;li&gt;Recurrent laryngeal nerve&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Anatomy/PrthyrdAntmy.htm" class="LinkPage"&gt;Parathyroid Gland&lt;/a&gt;s&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Physiology&lt;ol&gt;&lt;li&gt;Stressors stimulate increased Thyroid function&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Exam/SxlDvlpmnt.htm" class="LinkPage"&gt;Puberty&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Pregnancy&lt;/li&gt;&lt;li&gt;Physiologic stress&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Hypothalamus&lt;ol&gt;&lt;li&gt;Thyrotropin Releasing Hormone (TRH) released&lt;/li&gt;&lt;li&gt;TRH passes down pituitary stalk to pituitary&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Anterior Pituitary&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/ThyrdStmltngHrmn.htm" class="LinkPage"&gt;Thyroid Stimulating Hormone&lt;/a&gt; (TSH) released&lt;/li&gt;&lt;li&gt;TSH passes into circulation to Thyroid&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Thyroid&lt;ol&gt;&lt;li&gt;Iodine is absorbed from circulation&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/Thyrxn.htm" class="LinkPage"&gt;Thyroxine&lt;/a&gt; (T4) released into circulation&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Peripheral Tissues&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/Trdthyrn.htm" class="LinkPage"&gt;Triiodothyronine&lt;/a&gt; (T3) produced from T4 deiodination&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Circulation&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/ThyrxnBndngGlbln.htm" class="LinkPage"&gt;Thyroid Binding Globulin&lt;/a&gt; (TBG) binds T4 and T3&lt;ol&gt;&lt;li&gt;T4 is 99.96% bound&lt;/li&gt;&lt;li&gt;T3 is 99.7% bound&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;T4 and T3 stimulate all metabolic processes&lt;ol&gt;&lt;li&gt;T3 is several times more potent than T4&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Feedback Loop&lt;ol&gt;&lt;li&gt;Increased T4 and T3 levels suppress TRH and TSH&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0040128</value><value>C0040132</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Anatomy/ThyrdAntmy.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Thyroid Anatomy, Thyroid Physiology, Thyroid, Thyroid Gland</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Anatomy/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Adrenal Glands  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0001625"&gt;&lt;i&gt;C0001625&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A flattened, roughly triangular body resting upon the upper end of each kidney; it is one of the ductless glands furnishing internal secretions (epinephrine and norepinephrine from the medulla and steroid hormones from the cortex).&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;Suprarenal gland. A flattened, roughly triangular body resting upon the upper end of each kidney; it is one of the ductless glands furnishing internal secretions (epinephrine and norepinephrine from the medulla and steroid hormones from the cortex). (NCI)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A small gland that makes steroid hormones, adrenaline, and noradrenaline. These hormones help control heart rate, blood pressure, and other important body functions. There are two adrenal glands, one on top of each kidney.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;A pair of glands located at the cranial pole of each of the two KIDNEYS. Each adrenal gland is composed of two distinct endocrine tissues with separate embryonic origins, the ADRENAL CORTEX producing STEROIDS and the ADRENAL MEDULLA producing NEUROTRANSMITTERS.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CSP)&lt;/td&gt;
                &lt;td&gt;paired glands situated in the retroperitoneal tissues at the superior pole of each kidney.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Body Part, Organ, or Organ Component (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0001625&amp;amp;tui=T023"&gt;&lt;i&gt;T023&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D000311&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;23451007&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;HL7&lt;/td&gt;
                &lt;td&gt;ADR&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Adrenal Glands, Gland, Adrenal, Glands, Adrenal, ADRENAL GLANDS, Adrenal gland, NOS, Adrenal glands, Suprarenal gland, B3 ADRENAL GLANDS, Glandula suprarenalis, Set of adrenal glands, ADRENAL GLAND, adrenals glands, adrenal glands, both adrenal glands, bilateral adrenal gland, suprarenal gland, adrenal gland, Adrenal gland, Adrenal structure, Adrenal structure (body structure), Adrenal Gland, Adrenals, Adrenal&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Binjurar&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;nadledviny&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Lisämunuaiset&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;NADPOCHECHNIKI, НАДПОЧЕЧНИКИ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;estructura suprarrenal (estructura corporal), estructura de la glándula suprarrenal (estructura corporal), estructura de la glándula suprarrenal, estructura suprarrenal, glándula adrenal, glándula suprarrenal, Glándulas Suprarrenales, Glandulas Suprarrenales&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Croatian&lt;/td&gt;
                &lt;td&gt;NADBUBREŽNE ŽLIJEZDE&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Latvian&lt;/td&gt;
                &lt;td&gt;Virsnieres, Virsnieru dziedzeri&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Gruczoły nadnerczowe, Nadnercza, Nadnercze&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Glandes surrénales, Surrénales, Surrénale, Glande surrénale&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Glandula suprarenalis, Nebennieren, Glandulae suprarenales&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Ghiandole surrenali&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;Bijnier, Bijnieren, Glandula suprarenalis&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Glândulas Supra-Renais, Glândulas Adrenais&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Adrenal Glands  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Adrenal Anatomy</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Anatomy</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;See Also&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Anatomy/EndcrnAntmy.htm" class="LinkPage"&gt;Endocrine Anatomy&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../GI/Anatomy/AbdmnlAntmy.htm" class="LinkPage"&gt;Abdominal Anatomy&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Anatomy: Images&lt;ol&gt;&lt;li class="thumb"&gt;&lt;a href="http://www.fpnotebook.com/_media/giAdrenalGrayBB1183.gif" class="LinkGraphic"&gt;&lt;img src="http://www.fpnotebook.com/_thumb/giAdrenalGrayBB1183_t.gif" alt="giAdrenalGrayBB1183.gif" border="0"&gt;&lt;/a&gt;&lt;small&gt;&lt;span&gt;Lewis (1918) Gray's Anatomy 20th ed &lt;/span&gt;(in &lt;a href="http://fpnotebook.com/about.htm#images"&gt;public domain&lt;/a&gt; at &lt;a href="http://education.yahoo.com/reference/gray/illustrations/figure?id=1183"&gt;Yahoo&lt;/a&gt; or &lt;a href="http://bartleby.com/107/illus1183.html"&gt;BartleBy&lt;/a&gt;)&lt;/small&gt;&lt;/li&gt;&lt;li class="thumb"&gt;&lt;a href="http://www.fpnotebook.com/_media/giAdrenalGrayBB1184.gif" class="LinkGraphic"&gt;&lt;img src="http://www.fpnotebook.com/_thumb/giAdrenalGrayBB1184_t.gif" alt="giAdrenalGrayBB1184.gif" border="0"&gt;&lt;/a&gt;&lt;small&gt;&lt;span&gt;Lewis (1918) Gray's Anatomy 20th ed &lt;/span&gt;(in &lt;a href="http://fpnotebook.com/about.htm#images"&gt;public domain&lt;/a&gt; at &lt;a href="http://education.yahoo.com/reference/gray/illustrations/figure?id=1184"&gt;Yahoo&lt;/a&gt; or &lt;a href="http://bartleby.com/107/illus1184.html"&gt;BartleBy&lt;/a&gt;)&lt;/small&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0001625</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Anatomy/AdrnlAntmy.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Adrenal Anatomy, Adrenal Gland</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Anatomy/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees></FP_UMLS_Trees><FP_Condition_name_check></FP_Condition_name_check><FP_Condition_name><value>Endocrinology Resources</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: General</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Patient Library Recommendations&lt;ol&gt;&lt;li&gt;Chase (2002) Understanding &lt;a href="../../Endo/DM/TypDbtsMlts.htm" class="LinkPage"&gt;IDDM&lt;/a&gt; (for children)&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.amazon.com/exec/obidos/ASIN/%200967539838/familypracticeno" class="LinkBookStore"&gt;Paid link to Amazon.com (ISBN  0967539838)&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Heller (1998) Carbohydrate Addicted Kids&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.amazon.com/exec/obidos/ASIN/%200060929502/familypracticeno" class="LinkBookStore"&gt;Paid link to Amazon.com (ISBN  0060929502)&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Other Books&lt;ol&gt;&lt;li&gt;Becker (2001) Endocrinology, Lippincott&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.amazon.com/exec/obidos/ASIN/%200781717507/familypracticeno" class="LinkBookStore"&gt;Paid link to Amazon.com (ISBN  0781717507)&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Wilson (1998) Williams Endocrinology, Saunders&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.amazon.com/exec/obidos/ASIN/%200721661521/familypracticeno" class="LinkBookStore"&gt;Paid link to Amazon.com (ISBN  0721661521)&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Gen/EndcrnlgyRsrcs.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Endocrinology Resources</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Gen/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees></FP_UMLS_Trees><FP_Condition_name_check></FP_Condition_name_check><FP_Condition_name><value>Patient Education in Endocrinology</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: General</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Endocrine and Metabolic Disease Education (NIDDK)&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.niddk.nih.gov/health/endo/endo.htm" class="LinkWebExt"&gt;http://www.niddk.nih.gov/health/endo/endo.htm&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Gen/PtntEdctnInEndcrnlgy.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Patient Education in Endocrinology, Endocrine Disease Patient Education</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Gen/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees></FP_UMLS_Trees><FP_Condition_name_check></FP_Condition_name_check><FP_Condition_name><value>Endocrinology Links</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: General</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;See Also&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/DM/DbtsMlts.htm" class="LinkPage"&gt;Diabetes Mellitus&lt;/a&gt; Resources&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Obesity/ObstyRsrcs.htm" class="LinkPage"&gt;Obesity Resources&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;
              &lt;a href="../../Endo/DM/DbtsMlts.htm" class="LinkPage"&gt;Diabetes Mellitus&lt;/a&gt;
              &lt;ol&gt;&lt;li&gt;American Diabetes Association&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.diabetes.org" class="LinkWebExt"&gt;http://www.diabetes.org&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
                &lt;li&gt;CDC's Diabetes and Public Health Resource&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.cdc.gov/diabetes/" class="LinkWebExt"&gt;http://www.cdc.gov/diabetes/&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
                &lt;li&gt;AIDA Diabetes &lt;a href="../../Endo/Pharm/InslnSmltn.htm" class="LinkPage"&gt;Insulin Simulation&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.2aida.org/online" class="LinkWebExt"&gt;http://www.2aida.org/online&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
                &lt;li&gt;Rick Mendosa's Diabetes Directory&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.mendosa.com/diabetes.htm" class="LinkWebExt"&gt;http://www.mendosa.com/diabetes.htm&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
              &lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Nutrition&lt;ol&gt;&lt;li&gt;Nutrition Facts and Calorie Counter&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.nutritiondata.com" class="LinkWebExt"&gt;http://www.nutritiondata.com&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;General Endocrine Resources&lt;ol&gt;&lt;li&gt;National Institute Diabetes, Digestive, &lt;a href="../../Renal/Anatomy/RnlAntmy.htm" class="LinkPage"&gt;Kidney&lt;/a&gt; Disease&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.niddk.nih.gov/health/health.htm" class="LinkWebExt"&gt;http://www.niddk.nih.gov/health/health.htm&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;American Association of Clinical Endocrinologists&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.aace.com" class="LinkWebExt"&gt;http://www.aace.com&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;The Endocrine Society&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.endo-society.org/index.htm" class="LinkWebExt"&gt;http://www.endo-society.org/index.htm&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Gen/EndcrnlgyLnks.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Endocrinology Links</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Gen/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Hypoparathyroidism  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0020626"&gt;&lt;i&gt;C0020626&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;An endocrine disorder characterized by decreased production of parathyroid hormone by the parathyroid glands. It is usually caused by damage of the parathyroid glands during head and neck surgery. Signs and symptoms include muscle cramps, abdominal pain, dry skin, brittle nails, cataracts, tetany, and convulsions.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;A condition caused by a deficiency of PARATHYROID HORMONE (or PTH). It is characterized by HYPOCALCEMIA and hyperphosphatemia. Hypocalcemia leads to TETANY. The acquired form is due to removal or injuries to the PARATHYROID GLANDS. The congenital form is due to mutations of genes, such as TBX1; (see DIGEORGE SYNDROME); CASR encoding CALCIUM-SENSING RECEPTOR; or PTH encoding parathyroid hormone.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A disorder characterized by a decrease in production of parathyroid hormone by the parathyroid glands.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CSP)&lt;/td&gt;
                &lt;td&gt;condition produced by greatly reduced function of the parathyroids possibly due to autoimmune disease or genetic factors, or by the removal of those bodies; lack of parathyroid hormone leads to a fall in plasma calcium level, which may result in increase neuromuscular excitability and ultimately tetany followed by a rise in plasma phosphate level.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Disease or Syndrome (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0020626&amp;amp;tui=T047"&gt;&lt;i&gt;T047&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D007011&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD9&lt;/td&gt;
                &lt;td&gt;252.1&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD10&lt;/td&gt;
                &lt;td&gt;E20, E20.9&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;190457001, 36976004, 154697005, 267479004&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;HYPOPARATHYROIDIE, Hypoparathyroïdie, Insuffisance parathyroïdienne, Hypoparathyroïdisme&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;HYPOPARATHYROIDISM, Hypoparathyroidism, NOS, Hypoparathyroidism NOS, Hypoparathyroidism, unspecified, hypoparathyroidism (diagnosis), hypoparathyroidism, HYPOPARATHYROID, Hypoparathyroidism NOS (disorder), Hypoparathyroidism [Disease/Finding], hypoparathyroid, Deficiency of PTH, Deficiency of parathyrin, Deficiency of parathyroid hormone, Hypoparathyroidism (disorder), deficiency; parathyroid, insufficiency; parathyroid, parathyroid; deficiency, parathyroid; insufficiency, Hypoparathyroidism&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;HIPOPARATIROIDISMO, Hypoparathyroidism, deficiencia de PTH, deficiencia de hormona paratiroidea, deficiencia de paratohormona, déficit de PTH, déficit de hormona paratiroidea, hipoparatiroidismo (trastorno), hipoparatiroidismo, SAI (trastorno), hipoparatiroidismo, SAI, hipoparatiroidismo, Hipoparatiroidismo&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Hypoparatyreos&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;ﾌｸｺｳｼﾞｮｳｾﾝｷﾉｳﾃｲｶｼｮｳ, 上皮小体機能低下, 上皮小体機能低下症, 上皮小体低下, 上皮小体低下症, 副甲状腺機能低下症, 副甲状腺機能低下&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;hypoparatyreoidismus, Hypoparatyreóza&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Hypoparatyreoosi&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;GIPOPARATIREOZ, GIPOPARATIREOIDIZM, ГИПОПАРАТИРЕОЗ, ГИПОПАРАТИРЕОИДИЗМ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;HIPOPARATIROIDISMO, Hipoparatiroidismo, Hipoparatireoidismo&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;HYPOPARATHYROIDISMUS, Hypoparathyreoidismus, nicht naeher bezeichnet, Hypoparathyreoidismus&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Korean&lt;/td&gt;
                &lt;td&gt;상세불명의 부갑상샘 기능저하증, 부갑상샘 기능저하증&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Niedoczynność przytarczyc&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;Hypoparathyreosis&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;bijschildklier; deficiëntie, bijschildklier; insufficiëntie, deficiëntie; bijschildklier, insufficiëntie; bijschildklier, Hypoparathyroïdie, niet gespecificeerd, hypoparathyroïdie, Hypoparathyreosis, Hypoparathyreoïdie, Hypoparathyroïdie, Parathyroïdie, hypo-&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Ipoparatiroidismo&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Hypoparathyroidism  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Hypoparathyroidism</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Parathyroid Disease</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Causes&lt;ol&gt;&lt;li&gt;Hereditary&lt;ol&gt;&lt;li&gt;Idiopathic Hypoparathyroidism&lt;/li&gt;&lt;li&gt;DiGeorge Syndrome&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Acquired&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Anatomy/ThyrdAntmy.htm" class="LinkPage"&gt;Thyroid&lt;/a&gt;ectomy with operative &lt;a href="../../Endo/Anatomy/PrthyrdAntmy.htm" class="LinkPage"&gt;Parathyroid&lt;/a&gt; removal&lt;/li&gt;&lt;li&gt;Radiation&lt;/li&gt;&lt;li&gt;&lt;a href="../../GI/HemeOnc/Hmchrmts.htm" class="LinkPage"&gt;Hemochromatosis&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Autoimmune Syndrome&lt;ol&gt;&lt;li&gt;Adrenal, Ovarian and &lt;a href="../../Endo/Anatomy/PrthyrdAntmy.htm" class="LinkPage"&gt;Parathyroid&lt;/a&gt; failure&lt;/li&gt;&lt;li&gt;Mucocutaneous &lt;a href="../../ID/Fungus/Cnds.htm" class="LinkPage"&gt;Candidiasis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Derm/Hair/Alpc.htm" class="LinkPage"&gt;Alopecia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Derm/Pigment/Vtlg.htm" class="LinkPage"&gt;Vitiligo&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../HemeOnc/Anemia/VtmnBDfcncy.htm" class="LinkPage"&gt;Pernicious Anemia&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Symptoms and signs&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Renal/Calcium/Hypclcm.htm" class="LinkPage"&gt;Hypocalcemia&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Labs&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Renal/Calcium/Hypclcm.htm" class="LinkPage"&gt;Hypocalcemia&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;
              &lt;a href="../../Renal/Pharm/ClcmPrntrlAdmnstrtn.htm" class="LinkPage"&gt;Calcium Replacement&lt;/a&gt;
              &lt;ol&gt;&lt;li&gt;General&lt;ol&gt;&lt;li&gt;Adjust dosing to &lt;a href="../../Renal/Lab/SrmClcm.htm" class="LinkPage"&gt;Serum Calcium&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Avoid &lt;a href="../../Renal/Lab/UrnClcm.htm" class="LinkPage"&gt;Hypercalciuria&lt;/a&gt; (risk of &lt;a href="../../Uro/Renal/Nphrlths.htm" class="LinkPage"&gt;Nephrolithiasis&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;Check for &lt;a href="../../Renal/Magnesium/Hypmgnsm.htm" class="LinkPage"&gt;Hypomagnesemia&lt;/a&gt; and replace if low&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
                &lt;li&gt;Preparations&lt;ol&gt;&lt;li&gt;&lt;a href="../../Renal/Pharm/OrlClcm.htm" class="LinkPage"&gt;Calcium Citrate&lt;/a&gt; 950 mg 2 tabs po tid&lt;/li&gt;&lt;li&gt;Calcitriol (&lt;a href="../../Pharm/Vitamins/VtmnD.htm" class="LinkPage"&gt;Vitamin D&lt;/a&gt;) 0.5 ug/day&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
              &lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0020626</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Parathyroid/Hyprthyrdsm.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Hypoparathyroidism</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Parathyroid/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Diabetic education  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0204935"&gt;&lt;i&gt;C0204935&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Health Care Activity (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0204935&amp;amp;tui=T058"&gt;&lt;i&gt;T058&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;6143009&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Diabetic patient education, diabetic patient education, Diabetic patient education (procedure), Diabetic patient education (regime/therapy), Diabetic education (procedure), Diabetic education&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;educación del paciente diabético (procedimiento), educación del paciente diabético (régimen/tratamiento), educación del paciente diabético&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Diabetic education  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Diabetic Education</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Diabetes Mellitus</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Approach: Employ a Pediatric Diabetes Team (Essential)&lt;ol&gt;&lt;li&gt;Physician&lt;/li&gt;&lt;li&gt;Nurse or Nurse Practitioner&lt;/li&gt;&lt;li&gt;Diabetes Educator&lt;/li&gt;&lt;li&gt;Nutritionist or Dietician&lt;/li&gt;&lt;li&gt;Social Worker&lt;/li&gt;&lt;li&gt;Psychologist&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Approach: Initial Education&lt;ol&gt;&lt;li&gt;Describe &lt;a href="../../Endo/DM/DbtsMlts.htm" class="LinkPage"&gt;Diabetes Mellitus&lt;/a&gt; pathophysiology&lt;/li&gt;&lt;li&gt;Management principles&lt;ol&gt;&lt;li&gt;Taking &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; (when prescribed) is non-negotiable&lt;/li&gt;&lt;li&gt;Other issues are negotiable&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; action and use&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/DM/DbtsMltsGlcsMngmnt.htm" class="LinkPage"&gt;Blood Glucose Monitoring&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Uro/Lab/UrnKtn.htm" class="LinkPage"&gt;Urine Ketone&lt;/a&gt; testing&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Hypoglycemia/Hypglycm.htm" class="LinkPage"&gt;Hypoglycemia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Sports/ExrcsInDbtsMlts.htm" class="LinkPage"&gt;Exercise in Diabetes Mellitus&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Prevent/NtrtnInDbtsMlts.htm" class="LinkPage"&gt;Nutrition in Diabetes Mellitus&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Psychological Issues&lt;/li&gt;&lt;li&gt;Home Treatment&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Approach: Ongoing Education&lt;ol&gt;&lt;li&gt;Should occur at every visit&lt;/li&gt;&lt;li&gt;Must be age and education-level appropriate&lt;ol&gt;&lt;li&gt;Include children age 5 and older in discussion&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Include skill review&lt;/li&gt;&lt;li&gt;Prevention&lt;ol&gt;&lt;li&gt;Seasonal illness prevention&lt;/li&gt;&lt;li&gt;&lt;a href="../../ID/Immunize/AdltVcntn.htm" class="LinkPage"&gt;Immunization&lt;/a&gt;s: &lt;a href="../../ID/Immunize/InflnzVcn.htm" class="LinkPage"&gt;Influenza Vaccine&lt;/a&gt;&lt;/li&gt;&lt;li&gt;See &lt;a href="../../Endo/Prevent/DbtcFtCr.htm" class="LinkPage"&gt;Diabetic Foot Care&lt;/a&gt;&lt;/li&gt;&lt;li&gt;See &lt;a href="../../Endo/Sports/ExrcsInDbtsMlts.htm" class="LinkPage"&gt;Exercise in Diabetes Mellitus&lt;/a&gt;&lt;/li&gt;&lt;li&gt;See &lt;a href="../../Endo/Prevent/NtrtnInDbtsMlts.htm" class="LinkPage"&gt;Nutrition in Diabetes Mellitus&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Emergencies&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Hypoglycemia/Hypglycm.htm" class="LinkPage"&gt;Hypoglycemia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/DM/TypDbtsMlts.htm" class="LinkPage"&gt;Type I Diabetes Mellitus&lt;/a&gt;&lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Hyperglycemia&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/DM/DbtcKtcds.htm" class="LinkPage"&gt;Diabetic Ketoacidosis&lt;/a&gt; (DKA)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/DM/TypDbtsMlts1.htm" class="LinkPage"&gt;Type II Diabetes Mellitus&lt;/a&gt;&lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Hyperglycemia&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/DM/HyprsmlrHyprglycmcSt.htm" class="LinkPage"&gt;Hyperosmolar Hyperglycemic Nonketotic Coma&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Chronic Complications&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Eye/DbtcRtnpthy.htm" class="LinkPage"&gt;Diabetic Retinopathy&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Renal/DbtcNphrpthy.htm" class="LinkPage"&gt;Diabetic Nephropathy&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Neuro/DbtcNrpthy.htm" class="LinkPage"&gt;Diabetic Neuropathy&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/CAD/ActCrnrySyndrm.htm" class="LinkPage"&gt;Coronary Artery Disease&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0204935</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/DM/DbtcEdctn.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Diabetic Education, Diabetes Mellitus Education</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/DM/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Other specified disorders of parathyroid gland  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0154195"&gt;&lt;i&gt;C0154195&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Disease or Syndrome (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0154195&amp;amp;tui=T047"&gt;&lt;i&gt;T047&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD9&lt;/td&gt;
                &lt;td&gt;252.8&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD10&lt;/td&gt;
                &lt;td&gt;E21.4&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;191055006&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Other specified disorders of parathyroid gland, Oth spc diso/parathyrd glnd, [X]Oth spc diso/parathyrd glnd, [X]Other specified disorders of parathyroid gland, [X]Other specified disorders of parathyroid gland (disorder), Parathyroid disorder NEC&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;andere gespecificeerde aandoeningen van parathyroïd, Overige gespecificeerde aandoeningen van bijschildklier&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Autres troubles précisés de la parathyroïde&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;sonstige spezifische Erkrankungen der Nebenschilddruese, Sonstige naeher bezeichnete Krankheiten der Nebenschilddruese&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Altri disturbi specificati della ghiandola paratiroide&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Outras afecções especificadas da paratiroideia&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;Otros trastornos especificados de la glándula paratiroides, [X]otros trastornos especificados de glándula paratiroides (trastorno), [X]otros trastornos especificados de glándula paratiroides&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;Jiné určené poruchy příštítných tělísek&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Korean&lt;/td&gt;
                &lt;td&gt;부갑상샘의 기타 명시된 장애&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;Mellékpajzsmirigy egyéb meghatározott betegségei&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Parathyroid gland  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0030518"&gt;&lt;i&gt;C0030518&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CSP)&lt;/td&gt;
                &lt;td&gt;small paired endocrine glands in the region of the thyroid gland which secrete parathyroid hormone and are concerned with the metabolism of calcium and phosphorus.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;Two pairs of small oval-shaped glands located in the front and the base of the NECK and adjacent to the two lobes of THYROID GLAND. They secrete PARATHYROID HORMONE that regulates the balance of CALCIUM; PHOSPHORUS; and MAGNESIUM in the body.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;One of two small paired endocrine glands, superior and inferior, usually found embedded in the connective tissue capsule on the posterior surface of the thyroid gland; these glands secrete parathyroid hormone that regulates the metabolism of calcium and phosphorus. The parenchyma is composed of chief and oxyphilic cells arranged in anastomosing cords.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Body Part, Organ, or Organ Component (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0030518&amp;amp;tui=T023"&gt;&lt;i&gt;T023&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D010280&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;111002, 181121007&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Parathyroid gland, Gland, Parathyroid, Glands, Parathyroid, Parathyroid Glands, PARATHYROID GLANDS, Parathyroid gland, NOS, Parathyroid glands, parathyroid, Parathyroid, NOS, B7 PARATHYROID GLANDS, Glandula parathyroidea, parathyroid glands, parathyroids, parathyroid gland, Parathyroid, Parathyroid structure, Parathyroid structure (body structure), Parathyroid Gland, Head and Neck, Parathyroid&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Bisköldkörtlar&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;paratyreoidea, příštítná tělíska, příštítná žláza&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Lisäkilpirauhaset&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;OKOLOSHCHITOVIDNYE ZHELEZY, PARATIREOIDNYE ZHELEZY, PARASHCHITOVIDNYE ZHELEZY, ОКОЛОЩИТОВИДНЫЕ ЖЕЛЕЗЫ, ПАРАТИРЕОИДНЫЕ ЖЕЛЕЗЫ, ПАРАЩИТОВИДНЫЕ ЖЕЛЕЗЫ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Croatian&lt;/td&gt;
                &lt;td&gt;PARATIREOIDEJA&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Latvian&lt;/td&gt;
                &lt;td&gt;Vairogdziedzera blakusķermenīši&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Gruczoły przytarczyczne, Przytarczyce&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;estructura de la glándula paratiroides (estructura corporal), estructura de la glándula paratiroides, glándula paratiroides, Glándulas Paratiroides, Glandulas Paratiroides&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Glande parathyroïde, Parathyroïde, Glandes parathyroïdes, Parathyroïdes&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Parathyreoidea, Nebenschilddrüsen&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Ghiandole paratiroidi&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;Bijschildklier, Bijschildklieren, Glandula parathyroidea&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Glândulas Paratireóides&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Other specified disorders of parathyroid gland  (</value><value>)
</value><value>Parathyroid gland  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Parathyroid Anatomy</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Anatomy</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;See Also&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Anatomy/EndcrnAntmy.htm" class="LinkPage"&gt;Endocrine Anatomy&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../ENT/Anatomy/HdAndNckAntmy.htm" class="LinkPage"&gt;Head and Neck Anatomy&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Anatomy/ThyrdAntmy.htm" class="LinkPage"&gt;Thyroid Anatomy&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Anatomy&lt;ol&gt;&lt;li&gt;Images&lt;ol&gt;&lt;li class="thumb"&gt;&lt;a href="http://www.fpnotebook.com/_media/entParathyroidGrayBB1177.gif" class="LinkGraphic"&gt;&lt;img src="http://www.fpnotebook.com/_thumb/entParathyroidGrayBB1177_t.gif" alt="entParathyroidGrayBB1177.gif" border="0"&gt;&lt;/a&gt;&lt;small&gt;&lt;span&gt;Lewis (1918) Gray's Anatomy 20th ed &lt;/span&gt;(in &lt;a href="http://fpnotebook.com/about.htm#images"&gt;public domain&lt;/a&gt; at &lt;a href="http://education.yahoo.com/reference/gray/illustrations/figure?id=1177"&gt;Yahoo&lt;/a&gt; or &lt;a href="http://bartleby.com/107/illus1177.html"&gt;BartleBy&lt;/a&gt;)&lt;/small&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Four Parathyroid Glands in neck&lt;/li&gt;&lt;li&gt;One gland positioned behind each of &lt;a href="../../Endo/Anatomy/ThyrdAntmy.htm" class="LinkPage"&gt;Thyroid&lt;/a&gt; poles&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Physiology&lt;ol&gt;&lt;li&gt;Parathyroid Gland regulates extracellular calcium&lt;ol&gt;&lt;li&gt;Parathyroid synthesizes &lt;a href="../../Endo/Lab/PrthyrdHrmn.htm" class="LinkPage"&gt;Parathyroid Hormone&lt;/a&gt; (PTH)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Parathyroid increases PTH release when calcium falls&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Endo/Lab/PrthyrdHrmn.htm" class="LinkPage"&gt;Parathyroid Hormone&lt;/a&gt; for PTH physiology&lt;/li&gt;&lt;li&gt;PTH rises when calcium falls, and increases calcium&lt;/li&gt;&lt;li&gt;PTH falls when calcium rises, and decreases calcium&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Pathophysiology&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Endo/Parathyroid/Hyprprthyrdsm.htm" class="LinkPage"&gt;Hyperparathyroidism&lt;/a&gt;&lt;/li&gt;&lt;li&gt;See &lt;a href="../../Endo/Parathyroid/Hyprthyrdsm.htm" class="LinkPage"&gt;Hypoparathyroidism&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0154195</value><value>C0030518</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Anatomy/PrthyrdAntmy.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Parathyroid Anatomy, Parathyroid Gland, Parathyroid</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Anatomy/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees></FP_UMLS_Trees><FP_Condition_name_check></FP_Condition_name_check><FP_Condition_name><value>Diabetes Mellitus Glucose Management</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Diabetes Mellitus</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;History: &lt;a href="../../Endo/DM/DbtsMlts.htm" class="LinkPage"&gt;Diabetes Mellitus&lt;/a&gt; Pharmacology&lt;ol&gt;&lt;li&gt;1922: Crude &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; Extracts by Banting and Best&lt;/li&gt;&lt;li&gt;1940: &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;NPH Insulin&lt;/a&gt; developed&lt;/li&gt;&lt;li&gt;1950: &lt;a href="../../Endo/Pharm/Slfnylr.htm" class="LinkPage"&gt;Sulfonylurea&lt;/a&gt;s developed&lt;/li&gt;&lt;li&gt;1960: &lt;a href="../../Endo/Pharm/Glcphg.htm" class="LinkPage"&gt;Biguanide&lt;/a&gt;s off market&lt;/li&gt;&lt;li&gt;1970: &lt;a href="../../Endo/Pharm/ScndGnrtnSlfnylr.htm" class="LinkPage"&gt;Second Generation Sulfonylurea&lt;/a&gt;s&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Protocol: Blood Glucose Monitoring Goals&lt;ol&gt;&lt;li&gt;Target &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Glucose&lt;/a&gt; (&amp;gt;50% of readings in range)&lt;ol&gt;&lt;li&gt;Children under age 6&lt;ol&gt;&lt;li&gt;Before meals: 100-180 mg/dl&lt;/li&gt;&lt;li&gt;Bedtime and overnight: 110-200 mg/dl&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Children age 6 to 12&lt;ol&gt;&lt;li&gt;Before meals: 90-180 mg/dl&lt;/li&gt;&lt;li&gt;Bedtime and overnight: 100-180 mg/dl&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Children age 13 to 19&lt;ol&gt;&lt;li&gt;Before meals: 90-130 mg/dl&lt;/li&gt;&lt;li&gt;Bedtime and overnight: 90-150 mg/dl&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Adult&lt;ol&gt;&lt;li&gt;Fasting (before breakfast): &amp;lt;105 mg/dl&lt;/li&gt;&lt;li&gt;Before Meals:  70-120 mg/dl&lt;/li&gt;&lt;li&gt;Two hour post-prandial &amp;lt;160 mg/dl&lt;/li&gt;&lt;li&gt;Before bedtime: 100-160 mg/dl&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Adjust target to &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Glucose&lt;/a&gt; 100-160 mg/dl before meals IF&lt;ol&gt;&lt;li&gt;Recurrent &lt;a href="../../Endo/Hypoglycemia/Hypglycm.htm" class="LinkPage"&gt;Hypoglycemia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Decreased Life expectancy&lt;ol&gt;&lt;li&gt;Frail elderly&lt;/li&gt;&lt;li&gt;Cognitive disorder&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Serious comorbid medical condition&lt;ol&gt;&lt;li&gt;&lt;a href="../../CV/CAD/ActCrnrySyndrm.htm" class="LinkPage"&gt;Coronary Artery Disease&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Neuro/CV/IschmcStrk.htm" class="LinkPage"&gt;Cerebrovascular Accident&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Renal/Failure/ChrncRnlFlr.htm" class="LinkPage"&gt;End Stage Renal Disease&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Hypoglycemia/Hypglycm.htm" class="LinkPage"&gt;Hypoglycemia&lt;/a&gt; unaware&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Target &lt;a href="../../Endo/Lab/HmglbnAc.htm" class="LinkPage"&gt;Hemoglobin A1C&lt;/a&gt; (check 3-4 times per year)&lt;ol&gt;&lt;li&gt;Under age 6 years: 7.5 to 8.5%&lt;/li&gt;&lt;li&gt;Age 6 to 12: &amp;lt;8.0%&lt;/li&gt;&lt;li&gt;Age 13-19: &amp;lt;7.5%&lt;/li&gt;&lt;li&gt;Age 20 and older: &amp;lt;7.0%&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Additional Monitoring&lt;ol&gt;&lt;li&gt;&lt;a href="../../Uro/Lab/UrnKtn.htm" class="LinkPage"&gt;Urine Ketone&lt;/a&gt; Indication (&lt;a href="../../Endo/DM/TypDbtsMlts.htm" class="LinkPage"&gt;Type I Diabetes Mellitus&lt;/a&gt;)&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Glucose&lt;/a&gt; exceeds 240 for 2 values&lt;/li&gt;&lt;li&gt;Concurrent illness or infection&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Protocol: Scheduled Blood Glucose Monitoring&lt;ol&gt;&lt;li&gt;Individualized and negotiated&lt;/li&gt;&lt;li&gt;Minimum monitoring routine&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/DM/TypDbtsMlts.htm" class="LinkPage"&gt;Type I Diabetes Mellitus&lt;/a&gt;: At least three times daily&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/DM/TypDbtsMlts1.htm" class="LinkPage"&gt;Type II Diabetes Mellitus&lt;/a&gt;: At least once daily&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Karter%20%20%5BAU%5D%20AND%202001%20%5BDP%5D%20AND%20%20Am%20J%20Med%20%20%5BTA%5D" class="LinkRef"&gt;Karter (2001) Am J Med 111:1-9&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Ideal monitoring routine&lt;ol&gt;&lt;li&gt;Before meals (qAC)&lt;/li&gt;&lt;li&gt;After meals (2 hours post-prandial)&lt;/li&gt;&lt;li&gt;Bedtime (qHS)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Monitoring in Special Circumstances&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Sugar&lt;/a&gt; at 3 am&lt;ol&gt;&lt;li&gt;Obtain prior to adjusting overnight &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Obtain if morning &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Hyperglycemia&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Hyperglycemia&lt;/a&gt; (&lt;a href="../../Endo/Pharm/DwnPhnmn.htm" class="LinkPage"&gt;Dawn Phenomena&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;Nocturnal &lt;a href="../../Endo/Hypoglycemia/Hypglycm.htm" class="LinkPage"&gt;Hypoglycemia&lt;/a&gt; (&lt;a href="../../Endo/Pharm/SmgyPhnmn.htm" class="LinkPage"&gt;Somogyi Phenomena&lt;/a&gt;)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Sports/ExrcsInDbtsMlts.htm" class="LinkPage"&gt;Exercise in Diabetes Mellitus&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Check &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; before and after &lt;a href="../../Sports/Exercise/Exrcs.htm" class="LinkPage"&gt;Exercise&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Consider 2 hour post-prandial &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; (PPG) weekly&lt;ol&gt;&lt;li&gt;PPG is earliest detectable glycemic abnormality&lt;/li&gt;&lt;li&gt;PPG correlates best with &lt;a href="../../Endo/Lab/HmglbnAc.htm" class="LinkPage"&gt;Hemoglobin A1C&lt;/a&gt;&lt;/li&gt;&lt;li&gt;PPG correlates with vascular complications&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Protocol: &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Glucose&lt;/a&gt; data utilization&lt;ol&gt;&lt;li&gt;Imperative to review &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Sugar&lt;/a&gt; logs frequently&lt;/li&gt;&lt;li&gt;Certain monitors can download stored values to PC&lt;ol&gt;&lt;li&gt;Calculates &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; ranges, median, and means&lt;/li&gt;&lt;li&gt;Plots &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; trends overall and by time of day&lt;/li&gt;&lt;li&gt;Shows pie chart of high, low, and ideal &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Correlate &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Sugar&lt;/a&gt; readings with &lt;a href="../../Endo/Lab/HmglbnAc.htm" class="LinkPage"&gt;Hemoglobin A1C&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Review &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Sugar&lt;/a&gt; trends between clinic visits&lt;/li&gt;&lt;li&gt;If &lt;a href="../../Endo/Lab/HmglbnAc.htm" class="LinkPage"&gt;Hemoglobin A1C&lt;/a&gt; does not correlate with &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Check meter accuracy&lt;/li&gt;&lt;li&gt;Assess patient finger stick &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Sugar&lt;/a&gt; skills&lt;/li&gt;&lt;li&gt;Monitor &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Glucose&lt;/a&gt; more frequently&lt;/li&gt;&lt;li&gt;Refer for diabetes education&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Adjust Management if&lt;ol&gt;&lt;li&gt;Hypoglycemic Episodes (treat these first)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Glucose&lt;/a&gt; or &lt;a href="../../Endo/Lab/HmglbnAc.htm" class="LinkPage"&gt;Hemoglobin A1C&lt;/a&gt; target goals per age not met&lt;/li&gt;&lt;li&gt;Example of adult indications for adjusted medications&lt;ol&gt;&lt;li&gt;Fasting or pre-meal &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Serum Glucose&lt;/a&gt; exceeds 140 (&amp;gt;50% of readings)&lt;/li&gt;&lt;li&gt;Bedtime &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; exceeds 160 (&amp;gt;50% of readings)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/HmglbnAc.htm" class="LinkPage"&gt;Hemoglobin A1C&lt;/a&gt; exceeds 7.0%&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Efficacy: Intensive &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; lowering effects (on average goal of Hgb A1c &amp;lt;7.0%)&lt;ol&gt;&lt;li&gt;DCCT results&lt;ol&gt;&lt;li&gt;Retinopathy reduced by 63%&lt;/li&gt;&lt;li&gt;&lt;a href="../../Neuro/Sx/PrphrlNrpthy.htm" class="LinkPage"&gt;Neuropathy&lt;/a&gt; reduced by 60%&lt;/li&gt;&lt;li&gt;Nephropathy reduced by 54%&lt;/li&gt;&lt;li&gt;Complication-free living increased by &amp;gt;15 years&lt;/li&gt;&lt;li&gt;Life expectancy extended by &amp;gt;5 years&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=1993%20%5BDP%5D%20AND%20%20N%20Engl%20J%20Med%20%20%5BTA%5D%20AND%20329%20%5BVI%5D%20AND%20977%20%5BPG%5D" class="LinkRef"&gt;(1993) N Engl J Med 329:977-86&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=1996%20%5BDP%5D%20AND%20%20JAMA%20%20%5BTA%5D%20AND%20276%20%5BVI%5D%20AND%201409%20%5BPG%5D" class="LinkRef"&gt;(1996) JAMA 276:1409-15&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Combined study results&lt;ol&gt;&lt;li&gt;Microvascular Disease&lt;ol&gt;&lt;li&gt;Improved outcomes in UGDP, UKPDS, DCCT/EDIC, ADVANCE&lt;/li&gt;&lt;li&gt;No difference for outicomes n ACCORD and VADT&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Macrovascular Disease&lt;ol&gt;&lt;li&gt;Improved outcomes in UKPDS, DCCT/EDIC&lt;/li&gt;&lt;li&gt;No difference for outcomes in UGDP, ADVANCE, ACCORD and VADT&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Overall Mortality&lt;ol&gt;&lt;li&gt;No difference in mortality UGDP, UKPDS, DCCT/EDIC, ADVANCE, VADT&lt;/li&gt;&lt;li&gt;Increased mortality with ACCORD&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Summary&lt;ol&gt;&lt;li&gt;Only one study showed increased mortality with intensive &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; control (ACCORD)&lt;/li&gt;&lt;li&gt;All other studies showed improved outcomes or no difference&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Studies&lt;ol&gt;&lt;li&gt;ACCORD&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=2008%20%5BDP%5D%20AND%20%20N%20Engl%20J%20Med%20%20%5BTA%5D%20AND%20358%20%5BVI%5D%20AND%20%202545%20%5BPG%5D" class="LinkRef"&gt;(2008) N Engl J Med 358: 2545-59&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;ADVANCE&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=2008%20%5BDP%5D%20AND%20%20N%20Engl%20J%20Med%20%20%5BTA%5D%20AND%20358%20%5BVI%5D%20AND%20%202560%20%5BPG%5D" class="LinkRef"&gt;(2008) N Engl J Med 358: 2560-72&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;DCCT/EDIC&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=2005%20%5BDP%5D%20AND%20%20N%20Engl%20J%20Med%20%20%5BTA%5D%20AND%20353%20%5BVI%5D%20AND%20%202643%20%5BPG%5D" class="LinkRef"&gt;(2005) N Engl J Med 353: 2643-53&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;UKPDS&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=1998%20%5BDP%5D%20AND%20%20Lancet%20%20%5BTA%5D%20AND%20352%20%5BVI%5D%20AND%20%20837%20%5BPG%5D" class="LinkRef"&gt;(1998) Lancet 352: 837-53&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;References&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Kendall%20%20%5BAU%5D%20AND%202008%20%5BDP%5D%20AND%20%20Park%20Nicollet%20Primary%20Care%20Update%20Lecture,%20St%20Louis%20Park,%20MN%20%5BTA%5D" class="LinkRef"&gt;Kendall (2008) Park Nicollet Primary Care Update Lecture, St Louis Park, MN&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/DM/DbtsMltsGlcsMngmnt.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Diabetes Mellitus Glucose Management, Blood Glucose Monitoring Goals, Blood Glucose Monitoring Schedule, Blood Glucose Monitoring, Blood Sugar Monitoring</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/DM/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees></FP_UMLS_Trees><FP_Condition_name_check></FP_Condition_name_check><FP_Condition_name><value>Diabetes Mellitus Control in Hospital</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Diabetes Mellitus</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;See Also&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/InslnSldngScl.htm" class="LinkPage"&gt;Insulin Sliding Scale&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/HrlySbctnsInsln.htm" class="LinkPage"&gt;Hourly Subcutaneous Insulin Lispro&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/VrblRtInslnInfsn.htm" class="LinkPage"&gt;Insulin Infusion&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Complications: Uncontrolled &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Glucose&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Decreased survival&lt;/li&gt;&lt;li&gt;Increased cardiac or &lt;a href="../../Neuro/CV/IschmcStrk.htm" class="LinkPage"&gt;Cerebral Infarction&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Increased infectious disease&lt;/li&gt;&lt;li&gt;Post-surgical &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Hyperglycemia&lt;/a&gt; correlates to complications&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/DM/DbtsMlts.htm" class="LinkPage"&gt;Diabetes Mellitus&lt;/a&gt; confers 2 relatve risk complication&lt;/li&gt;&lt;li&gt;BG &amp;gt;200 mg/dl confers &amp;gt;3 relative risk complication&lt;/li&gt;&lt;li&gt;BG &amp;gt;250 mg/dl confers &amp;gt;12 relative risk complication&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=2002%20%5BDP%5D%20AND%20%20Amer%20J%20Cardiol%20%5BTA%5D" class="LinkRef"&gt;(2002) Amer J Cardiol&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Approach&lt;ol&gt;&lt;li&gt;Evaluate status on hospitalization&lt;ol&gt;&lt;li&gt;Check fasting &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Glucose&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/HmglbnAc.htm" class="LinkPage"&gt;Hemoglobin A1C&lt;/a&gt; on admission&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Hospitalized &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Glucose&lt;/a&gt; control in non-ICU patients&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; monitoring&lt;ol&gt;&lt;li&gt;Oral medications: once daily &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Glucose&lt;/a&gt; (random &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; is acceptable)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt;: At meals and at bedtime (4 times daily)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Non-ICU &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Glucose&lt;/a&gt; goal: &amp;lt;180 mg/dl (&amp;lt;140 mg/dl preprandial)&lt;ol&gt;&lt;li&gt;Modify protocol immediately if &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Glucose&lt;/a&gt; below 70 mg/dl&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Continue home &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; management protocol if possible&lt;ol&gt;&lt;li&gt;Avoid &lt;a href="../../Endo/Pharm/Thzldndn.htm" class="LinkPage"&gt;Thiazolidinedione&lt;/a&gt;s in cardiovascular disease (especially if part of admission indications)&lt;/li&gt;&lt;li&gt;Avoid &lt;a href="../../Endo/Pharm/Glcphg.htm" class="LinkPage"&gt;Metformin&lt;/a&gt; in declining &lt;a href="../../Renal/Lab/RnlFnctn.htm" class="LinkPage"&gt;Renal Function&lt;/a&gt;, if &lt;a href="../../Rad/Pharm/RdgrphcCntrstMd.htm" class="LinkPage"&gt;Intravenous Contrast&lt;/a&gt; dye used, or if &lt;a href="../../Derm/Pharm/AlphHydrxyAcd.htm" class="LinkPage"&gt;Lactic Acid&lt;/a&gt;osis&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Hospitalized &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Glucose&lt;/a&gt; control in ICU&lt;ol&gt;&lt;li&gt;Very tight &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; control in critically ill patients is associated with worse outcomes&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Finfer%20%20%5BAU%5D%20AND%202009%20%5BDP%5D%20AND%20%20N%20Engl%20J%20Med%20%20%5BTA%5D" class="LinkRef"&gt;Finfer (2009) N Engl J Med 360(13): 1283-97&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Monitor &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Glucose&lt;/a&gt; every 4 hours depending on status&lt;ol&gt;&lt;li&gt;For patients who are eating meals, following the non-ICU protocol above&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;ICU goal &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Glucose&lt;/a&gt;: 140-180 mg/dl&lt;ol&gt;&lt;li&gt;Modify protocol immediately if &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Glucose&lt;/a&gt; below 70 mg/dl&lt;/li&gt;&lt;li&gt;Treat &lt;a href="../../Endo/Hypoglycemia/Hypglycm.htm" class="LinkPage"&gt;Hypoglycemia&lt;/a&gt; with D50 IV&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Protocol: Complete &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; Orders&lt;ol&gt;&lt;li&gt;Basal &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt;: Long acting &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; (e.g. &lt;a href="../../Endo/Pharm/AnlgBslInsln.htm" class="LinkPage"&gt;Lantus&lt;/a&gt;, NPH)&lt;ol&gt;&lt;li&gt;Do not adjust &lt;a href="../../Endo/Pharm/AnlgBslInsln.htm" class="LinkPage"&gt;Lantus&lt;/a&gt; for oral intake&lt;/li&gt;&lt;li&gt;NPH may require adjustment if covering mealtime&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Bolus &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt;: &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Lispro&lt;/a&gt;, &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Aspart&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Cover meals, snacks with units per carbohydrate&lt;/li&gt;&lt;li&gt;See &lt;a href="../../Endo/Pharm/CrbhydrtCntInInslnDsng.htm" class="LinkPage"&gt;Insulin Adjustment with Carbohydrate Counting&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Hypoglycemia/HypglycmMngmnt.htm" class="LinkPage"&gt;Hypoglycemia Management&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Hyperglycemia&lt;/a&gt; coverage: Sliding scale coverage&lt;ol&gt;&lt;li&gt;Cover as units per &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; 50 mg/dl over 150 mg/dl&lt;/li&gt;&lt;li&gt;Adjust per condition (low dose scale versus high dose scale)&lt;/li&gt;&lt;li&gt;See &lt;a href="../../Endo/Pharm/InslnSldngScl.htm" class="LinkPage"&gt;Correctional Insulin Dosing&lt;/a&gt; (&lt;a href="../../Endo/Pharm/InslnSldngScl.htm" class="LinkPage"&gt;Insulin Sliding Scale&lt;/a&gt;)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Sawin%20%20%5BAU%5D%20AND%202010%20%5BDP%5D%20AND%20%20Am%20Fam%20Physician%20%20%5BTA%5D" class="LinkRef"&gt;Sawin (2010) Am Fam Physician 81(9): 1121-4&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Moghissi%20%20%5BAU%5D%20AND%202009%20%5BDP%5D%20AND%20%20Diabetes%20Care%20%20%5BTA%5D" class="LinkRef"&gt;Moghissi (2009) Diabetes Care 32(6): 1119-31&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Maynard%20%20%5BAU%5D%20AND%202009%20%5BDP%5D%20AND%20%20J%20Hosp%20Med%20%20%5BTA%5D" class="LinkRef"&gt;Maynard (2009) J Hosp Med 4(1): 3-15&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/DM/DbtsMltsCntrlInHsptl.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Diabetes Mellitus Control in Hospital</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/DM/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees></FP_UMLS_Trees><FP_Condition_name_check></FP_Condition_name_check><FP_Condition_name><value>Hyperosmolar Hyperglycemic State</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Diabetes Mellitus</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Pathophysiology&lt;ol&gt;&lt;li&gt;Diuresis secondary to glucosuria&lt;/li&gt;&lt;li&gt;Water loss exceeds sodium loss&lt;ol&gt;&lt;li&gt;Results in hyperosomality and &lt;a href="../../Renal/Sodium/Hyprntrm.htm" class="LinkPage"&gt;Hypernatremia&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Predisposing Factors&lt;ol&gt;&lt;li&gt;Uncontrolled of undiagnosed &lt;a href="../../Endo/DM/TypDbtsMlts1.htm" class="LinkPage"&gt;Type II Diabetes Mellitus&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Advanced age&lt;/li&gt;&lt;li&gt;Infection (&lt;a href="../../Lung/ID/Pnmn.htm" class="LinkPage"&gt;Pneumonia&lt;/a&gt;, UTI, &lt;a href="../../ID/Fever/Sps1.htm" class="LinkPage"&gt;Sepsis&lt;/a&gt;, &lt;a href="../../Derm/Bacteria/Cllts.htm" class="LinkPage"&gt;Cellulitis&lt;/a&gt;)&lt;ol&gt;&lt;li&gt;Causes more than 50% of hyperosmolar &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Hyperglycemia&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Medications&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Endo/Pharm/MdctnCsOfHyprglycm.htm" class="LinkPage"&gt;Medication Causes of Hyperglycemia&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Vascular event&lt;ol&gt;&lt;li&gt;&lt;a href="../../Neuro/CV/IschmcStrk.htm" class="LinkPage"&gt;Cerebrovascular Accident&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Lung/CV/PlmnryEmblsm.htm" class="LinkPage"&gt;Pulmonary Embolism&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/CAD/ActCrnrySyndrm.htm" class="LinkPage"&gt;Myocardial Infarction&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Mesenteric thrombosis&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Endocrine Disease&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pituitary/Acrmgly.htm" class="LinkPage"&gt;Acromegaly&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Adrenal/CshngsDs.htm" class="LinkPage"&gt;Cushing's Disease&lt;/a&gt; or ACTH producing tumors&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/Hyprthyrdsm1.htm" class="LinkPage"&gt;Thyrotoxicosis&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Comorbid illness&lt;ol&gt;&lt;li&gt;&lt;a href="../../Neuro/CV/SbdrlHmtm.htm" class="LinkPage"&gt;Subdural Hematoma&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../GI/Pancreas/ActPncrts.htm" class="LinkPage"&gt;Acute Pancreatitis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Severe &lt;a href="../../ER/Environ/BrnInjry.htm" class="LinkPage"&gt;Burn Injury&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Psych/CD/ChmclDpndncy.htm" class="LinkPage"&gt;Substance Abuse&lt;/a&gt; (&lt;a href="../../Psych/CD/AlchlAbs.htm" class="LinkPage"&gt;Alcohol Abuse&lt;/a&gt; or &lt;a href="../../Psych/CD/Ccn.htm" class="LinkPage"&gt;Cocaine&lt;/a&gt; use)&lt;/li&gt;&lt;li&gt;Renal Insufficiency&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Symptoms&lt;ol&gt;&lt;li&gt;Insidious onset of symptoms over days to weeks&lt;/li&gt;&lt;li&gt;Symptoms related to &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Hyperglycemia&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Polyuria&lt;/li&gt;&lt;li&gt;Polydipsia&lt;/li&gt;&lt;li&gt;Weight loss&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Symptoms common at presentation&lt;ol&gt;&lt;li&gt;Weakness&lt;/li&gt;&lt;li&gt;Visual changes&lt;/li&gt;&lt;li&gt;&lt;a href="../../Ortho/Sx/NctrnlLgCrmp.htm" class="LinkPage"&gt;Leg Cramp&lt;/a&gt;s&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Neurologic changes occur later&lt;ol&gt;&lt;li&gt;Progressive &lt;a href="../../Neuro/LOC/AltrdLvlOfCnscsns.htm" class="LinkPage"&gt;Decreased Level of Consciousness&lt;/a&gt; (50%)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Neuro/Seizure/Szr.htm" class="LinkPage"&gt;Seizure&lt;/a&gt;s (5%)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Signs&lt;ol&gt;&lt;li&gt;&lt;a href="../../ID/Exam/Fvr.htm" class="LinkPage"&gt;Fever&lt;/a&gt; (low grade)&lt;/li&gt;&lt;li&gt;Severe dehydration&lt;/li&gt;&lt;li&gt;Neurologic deficit (related to hyperosmolality)&lt;ol&gt;&lt;li&gt;&lt;a href="../../Neuro/LOC/AltrdLvlOfCnscsns.htm" class="LinkPage"&gt;Decreased Level of Consciousness&lt;/a&gt; (&lt;a href="../../Neuro/LOC/Cm2.htm" class="LinkPage"&gt;Coma&lt;/a&gt; in 30%)&lt;/li&gt;&lt;li&gt;Transient &lt;a href="../../Neuro/Exam/Hmplg.htm" class="LinkPage"&gt;Hemiparesis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Hyperreflexia or areflexia&lt;/li&gt;&lt;li&gt;&lt;a href="../../Neuro/Seizure/Szr.htm" class="LinkPage"&gt;Seizure&lt;/a&gt;s occur in 25%&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Differential Diagnosis&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/DM/DbtcKtcds.htm" class="LinkPage"&gt;Diabetic Ketoacidosis&lt;/a&gt; (arterial pH &amp;lt;7.30 with ketosis)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Diagnosis&lt;ol&gt;&lt;li&gt;Severe dehydration with &lt;a href="../../Renal/Lab/SrmOsmlty.htm" class="LinkPage"&gt;Serum Osmolality&lt;/a&gt; &amp;gt;320&lt;/li&gt;&lt;li&gt;&lt;a href="../../Neuro/LOC/AltrdLvlOfCnscsns.htm" class="LinkPage"&gt;Altered Level of Consciousness&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Hyperglycemia&lt;/a&gt; with &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Serum Glucose&lt;/a&gt; &amp;gt;600&lt;/li&gt;&lt;li&gt;Minimal to no ketosis&lt;ol&gt;&lt;li&gt;Minimal to acidosis (arterial pH &amp;gt;7.30)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Labs&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Glucose&lt;/a&gt; 600-2000 mg/dl&lt;/li&gt;&lt;li&gt;Serum Osmolarity &amp;gt;320 mOsm&lt;ol&gt;&lt;li&gt;Often &amp;gt; 350 mOsm/liter&lt;/li&gt;&lt;li&gt;&lt;a href="../../Neuro/LOC/Cm2.htm" class="LinkPage"&gt;Coma&lt;/a&gt; seen if Osms exceed 340 mOsm/liter&lt;/li&gt;&lt;li&gt;Water deficit 100-200 ml/kg&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;BUN markedly elevated (70-90 mg/dl)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Renal/Lab/SrmPtsm.htm" class="LinkPage"&gt;Serum K&lt;/a&gt;etones not detected&lt;/li&gt;&lt;li&gt;No &lt;a href="../../Renal/AcidBase/MtblcAcds.htm" class="LinkPage"&gt;Metabolic Acidosis&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../Renal/Lab/ArtrlBldGs.htm" class="LinkPage"&gt;Arterial Blood Gas&lt;/a&gt; with arterial pH &amp;gt; 7.30&lt;/li&gt;&lt;li&gt;Serum bicarbonate &amp;gt;15 meq/L&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Electrolytes&lt;ol&gt;&lt;li&gt;Sodium deficit: 7-13 meq/kg&lt;ol&gt;&lt;li&gt;Usually elevated&lt;ol&gt;&lt;li&gt;Lowered 1.6 meq/L each 100 mg/dl &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; rise&lt;/li&gt;&lt;li&gt;See corrected &lt;a href="../../Renal/Lab/SrmSdm.htm" class="LinkPage"&gt;Serum Sodium&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Potassium deficit: 5-15 meq/kg&lt;/li&gt;&lt;li&gt;Calcium deficit 50-100 meq/kg&lt;/li&gt;&lt;li&gt;&lt;a href="../../Pharm/Minerals/Mgnsm.htm" class="LinkPage"&gt;Magnesium&lt;/a&gt; deficit 50-100 meq/kg&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Monitoring&lt;ol&gt;&lt;li&gt;Bedside fingerstick &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; every 30-60 minutes&lt;/li&gt;&lt;li&gt;Recheck labs every 2-4 hours until stable&lt;ol&gt;&lt;li&gt;Electrolytes&lt;/li&gt;&lt;li&gt;&lt;a href="../../Renal/Lab/BldUrNtrgn.htm" class="LinkPage"&gt;Blood Urea Nitrogen&lt;/a&gt; and &lt;a href="../../Renal/Lab/SrmCrtn.htm" class="LinkPage"&gt;Serum Creatinine&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Serum Glucose&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Management: Fluid Replacement&lt;ol&gt;&lt;li&gt;Initial&lt;ol&gt;&lt;li&gt;Normal saline 1 Liter/hour&lt;/li&gt;&lt;li&gt;Run normal saline until stable vitals and urine&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Later&lt;ol&gt;&lt;li&gt;Fluid&lt;ol&gt;&lt;li&gt;&lt;a href="../../Renal/Sodium/Hyprntrm.htm" class="LinkPage"&gt;Hypernatremia&lt;/a&gt;: 1/2NS&lt;/li&gt;&lt;li&gt;&lt;a href="../../Renal/Sodium/Hypntrm.htm" class="LinkPage"&gt;Hyponatremia&lt;/a&gt; (uncommon): NS&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Rate&lt;ol&gt;&lt;li&gt;Estimate: 150 to 500 cc/hour&lt;/li&gt;&lt;li&gt;Calculation: 4-14 cc/kg/hour&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Overall&lt;ol&gt;&lt;li&gt;50% of loss replaced in first 12 hours&lt;/li&gt;&lt;li&gt;50% of loss replaced over next 24 hours&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Management: &lt;a href="../../Renal/Lab/SrmPtsm.htm" class="LinkPage"&gt;Serum Potassium&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../Renal/Lab/SrmPtsm.htm" class="LinkPage"&gt;Serum Potassium&lt;/a&gt; &amp;lt;3.3&lt;ol&gt;&lt;li&gt;Hold &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; until &lt;a href="../../Renal/Lab/SrmPtsm.htm" class="LinkPage"&gt;Serum Potassium&lt;/a&gt; &amp;gt;3.3&lt;/li&gt;&lt;li&gt;Replace potassium with 40 meq&lt;ol&gt;&lt;li&gt;Potassium Chloride 27 meq&lt;/li&gt;&lt;li&gt;Potassium Phosphate 13 meq&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Renal/Lab/SrmPtsm.htm" class="LinkPage"&gt;Serum Potassium&lt;/a&gt; &amp;gt;5.0&lt;ol&gt;&lt;li&gt;Hold &lt;a href="../../Renal/Pharm/PtsmRplcmnt.htm" class="LinkPage"&gt;Potassium Replacement&lt;/a&gt; in IV Fluids&lt;/li&gt;&lt;li&gt;Recheck &lt;a href="../../Renal/Lab/SrmPtsm.htm" class="LinkPage"&gt;Serum Potassium&lt;/a&gt; every 2 hours&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Renal/Lab/SrmPtsm.htm" class="LinkPage"&gt;Serum Potassium&lt;/a&gt; &amp;gt;3.3 and &amp;lt;5.0&lt;ol&gt;&lt;li&gt;Keep &lt;a href="../../Renal/Lab/SrmPtsm.htm" class="LinkPage"&gt;Serum Potassium&lt;/a&gt; &amp;gt;4.0 and &amp;lt;5.0&lt;/li&gt;&lt;li&gt;Add 30 meq of potassium to each liter of IV fluid&lt;ol&gt;&lt;li&gt;Potassium chloride 20 meq/Liter&lt;/li&gt;&lt;li&gt;Potassium phosphate 10 meq/Liter&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Management: Phase 3 - &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Glucose&lt;/a&gt; Control&lt;ol&gt;&lt;li&gt;Precautions&lt;ol&gt;&lt;li&gt;&lt;a href="../../Renal/Potassium/Hypklm.htm" class="LinkPage"&gt;Hypokalemia&lt;/a&gt; must be corrected prior to &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Hold &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; until &lt;a href="../../Renal/Lab/SrmPtsm.htm" class="LinkPage"&gt;Serum Potassium&lt;/a&gt; &amp;gt;3.3&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Adult IV &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; administration&lt;ol&gt;&lt;li&gt;Initial&lt;ol&gt;&lt;li&gt;Give IV bolus of 0.15 units/kg&lt;/li&gt;&lt;li&gt;Start 0.1 units/kg/hour &lt;a href="../../Endo/Pharm/VrblRtInslnInfsn.htm" class="LinkPage"&gt;Insulin Drip&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Maintenance&lt;ol&gt;&lt;li&gt;Anticipate &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Serum Glucose&lt;/a&gt; drop of 50-70 mg/dl/hour&lt;ol&gt;&lt;li&gt;If inadequate drop, then increase drip&lt;ol&gt;&lt;li&gt;Increase &lt;a href="../../Endo/Pharm/VrblRtInslnInfsn.htm" class="LinkPage"&gt;Insulin Infusion&lt;/a&gt; rate by 50-100%&lt;/li&gt;&lt;li&gt;Continue at increased rate until adequate&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;When &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Serum Glucose&lt;/a&gt; &amp;lt;300 mg/dl&lt;ol&gt;&lt;li&gt;Keep &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Serum Glucose&lt;/a&gt; at 250 to 300 mg/dl until&lt;ol&gt;&lt;li&gt;&lt;a href="../../Renal/Lab/SrmOsmlty.htm" class="LinkPage"&gt;Serum Osmolality&lt;/a&gt; &amp;lt;315 mOsm/kg&lt;/li&gt;&lt;li&gt;Alert mental status&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Decrease rate by 50% (to 0.05 units/kg) or&lt;/li&gt;&lt;li&gt;Discontinue &lt;a href="../../Endo/Pharm/VrblRtInslnInfsn.htm" class="LinkPage"&gt;Insulin Drip&lt;/a&gt; and start SC dosing&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; monitoring&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; monitoring every 30 minutes to 1 hour&lt;/li&gt;&lt;li&gt;Target &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; decrease 50-70 mg/dl/hour&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Dextrose Administration&lt;ol&gt;&lt;li&gt;Add 5% Dextrose to fluids when &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; &amp;lt; 300 mg/dl&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Complications&lt;ol&gt;&lt;li&gt;Mortality (10-40%): Significantly higher than DKA&lt;/li&gt;&lt;li&gt;&lt;a href="../../Neuro/Seizure/Szr.htm" class="LinkPage"&gt;Seizure&lt;/a&gt;s&lt;/li&gt;&lt;li&gt;&lt;a href="../../HemeOnc/CV/DpVnThrmbs.htm" class="LinkPage"&gt;Deep Vein Thrombosis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Lung/CV/PlmnryEmblsm.htm" class="LinkPage"&gt;Pulmonary Embolus&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../GI/Pancreas/ActPncrts.htm" class="LinkPage"&gt;Pancreatitis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Renal/Failure/ActRnlFlr.htm" class="LinkPage"&gt;Renal Failure&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Prevention&lt;ol&gt;&lt;li&gt;Maximize &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; control and compliance&lt;/li&gt;&lt;li&gt;Ensure adequate hydration&lt;/li&gt;&lt;li&gt;Monitor for dehydration, infection, and &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Hyperglycemia&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Chiasson%20%20%5BAU%5D%20AND%202003%20%5BDP%5D%20AND%20%20CMAJ%20%20%5BTA%5D" class="LinkRef"&gt;Chiasson (2003) CMAJ 168:859-66&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Stoner%20%20%5BAU%5D%20AND%202005%20%5BDP%5D%20AND%20%20Am%20Fam%20Physician%20%20%5BTA%5D" class="LinkRef"&gt;Stoner (2005) Am Fam Physician 71:1723-30&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Trence%20%20%5BAU%5D%20AND%202001%20%5BDP%5D%20AND%20%20Endocrinol%20Metab%20Clin%20North%20Am%20%20%5BTA%5D" class="LinkRef"&gt;Trence (2001) Endocrinol Metab Clin North Am 30:817-31&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/DM/HyprsmlrHyprglycmcSt.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Hyperosmolar Hyperglycemic State, Hyperosmolar Hyperglycemic Nonketotic Coma, Hyperglycemic Dehydration Syndrome, Hyperosmolar Nonketotic Diabetic Syndrome</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/DM/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees></FP_UMLS_Trees><FP_Condition_name_check></FP_Condition_name_check><FP_Condition_name><value>Diabetic Ketoacidosis Management in Adults</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Diabetes Mellitus</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;See Also&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/DM/DbtcKtcds.htm" class="LinkPage"&gt;Diabetic Ketoacidosis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/DM/DbtcKtcdsMngmntInChldrn.htm" class="LinkPage"&gt;Diabetic Ketoacidosis Management in Children&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Management: Phase 1 - Fluids in Adults (Emergent)&lt;ol&gt;&lt;li&gt;Stabilize shock and &lt;a href="../../Neuro/LOC/Cm2.htm" class="LinkPage"&gt;Coma&lt;/a&gt; states first!&lt;/li&gt;&lt;li&gt;Correct Volume Deficit&lt;ol&gt;&lt;li&gt;Initial&lt;ol&gt;&lt;li&gt;Give 1 liter NS bolus over first 45 minutes&lt;/li&gt;&lt;li&gt;Repeat fluid bolus until shock corrected&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Next&lt;ol&gt;&lt;li&gt;Protocol 1 (standard protocol)&lt;ol&gt;&lt;li&gt;Replace first 50% volume deficit in first 8 hours&lt;ol&gt;&lt;li&gt;Use Normal Saline or Lactated Ringers&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Replace remaining 50% deficit over next 16 hours&lt;ol&gt;&lt;li&gt;Use D5 1/2 NS at 150-250 ml per hour&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Protocol 2&lt;ol&gt;&lt;li&gt;NS at 10 cc/kg/hr (+/- 5 cc/kg/hr)&lt;ol&gt;&lt;li&gt;Until &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Serum Glucose&lt;/a&gt; &amp;lt;250 mg/dl&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Then D5 1/2NS with 20 kcl&lt;ol&gt;&lt;li&gt;Give 150-250 cc/hour&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Protocol 3 (new protocol)&lt;ol&gt;&lt;li&gt;Protocol uses 0.675% saline&lt;/li&gt;&lt;li&gt;Administer 2.5 x maintenance rate&lt;ol&gt;&lt;li&gt;Continue for 24 hours or until no acidosis&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Then administer 1 to 1.5 x maintenance rate&lt;/li&gt;&lt;li&gt;Efficacy in children (compared with Protocol 1)&lt;ol&gt;&lt;li&gt;Reduces fluid rate&lt;ol&gt;&lt;li&gt;May decrease risk of cerebral edema&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Resulted in cost savings &amp;gt;$1000/patient&lt;/li&gt;&lt;li&gt;Faster acidosis resolution&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Felner%20%20%5BAU%5D%20AND%202001%20%5BDP%5D%20AND%20%20Pediatrics%20%20%5BTA%5D" class="LinkRef"&gt;Felner (2001) Pediatrics 108:735-40&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Precautions&lt;ol&gt;&lt;li&gt;Do not drop &lt;a href="../../Renal/Lab/SrmOsmlty.htm" class="LinkPage"&gt;Serum Osmolality&lt;/a&gt; (calc) &amp;gt;3 mOsms/hour&lt;ol&gt;&lt;li&gt;Risk of cerebral edema&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Slow replacement if &lt;a href="../../Renal/Edema/Edm.htm" class="LinkPage"&gt;Fluid Overload&lt;/a&gt; risk&lt;ol&gt;&lt;li&gt;&lt;a href="../../CV/CHF/CngstvHrtFlr.htm" class="LinkPage"&gt;Congestive Heart Failure&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Renal/Failure/ChrncRnlFlr.htm" class="LinkPage"&gt;Chronic Renal Insufficiency&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/CAD/ActCrnrySyndrm.htm" class="LinkPage"&gt;Myocardial Infarction&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Follow Intake and output closely&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Management: Phase 2 - Acidosis, electrolytes in Adults&lt;ol&gt;&lt;li&gt;&lt;a href="../../Renal/Pharm/PtsmRplcmnt.htm" class="LinkPage"&gt;Potassium Replacement&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Precautions&lt;ol&gt;&lt;li&gt;&lt;a href="../../Renal/Potassium/Hypklm.htm" class="LinkPage"&gt;Hypokalemia&lt;/a&gt; must be corrected prior to &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Hold &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; until potassium &amp;gt;3.3 meq/L in adults&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Prerequisites&lt;ol&gt;&lt;li&gt;&lt;a href="../../CV/Exam/Elctrcrdgrm.htm" class="LinkPage"&gt;Electrocardiogram&lt;/a&gt; without signs of &lt;a href="../../Renal/Potassium/Hyprklm.htm" class="LinkPage"&gt;Hyperkalemia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Adequate urine output&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Administration: Adults&lt;ol&gt;&lt;li&gt;&lt;a href="../../Renal/Lab/SrmPtsm.htm" class="LinkPage"&gt;Serum Potassium&lt;/a&gt; &amp;lt;3.3 meq/L&lt;ol&gt;&lt;li&gt;Do not administer &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; until potassium &amp;gt;3.3&lt;/li&gt;&lt;li&gt;Give KCl 40 meq/hour IV until corrects&lt;ol&gt;&lt;li&gt;Requires hourly recheck of &lt;a href="../../Renal/Lab/SrmPtsm.htm" class="LinkPage"&gt;Serum Potassium&lt;/a&gt;&lt;/li&gt;&lt;li&gt;This is maximum IV potassium rate!&lt;/li&gt;&lt;li&gt;Requires cardiac monitoring&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Renal/Lab/SrmPtsm.htm" class="LinkPage"&gt;Serum Potassium&lt;/a&gt; 3.3 to 5.0 meq/L&lt;ol&gt;&lt;li&gt;Standard replacement: 20-30 meq per liter&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Renal/Lab/SrmPtsm.htm" class="LinkPage"&gt;Serum Potassium&lt;/a&gt; &amp;gt;5.0 meq/L&lt;ol&gt;&lt;li&gt;Do not administer any potassium&lt;/li&gt;&lt;li&gt;Monitor every 2 hours until &amp;lt;5.0&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Renal/Pharm/PhsphrsRplcmnt.htm" class="LinkPage"&gt;Phosphate Replacement&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Indications&lt;ol&gt;&lt;li&gt;&lt;a href="../../Renal/Lab/SrmPhsphrs.htm" class="LinkPage"&gt;Serum Phosphorus&lt;/a&gt; &amp;lt; 0.5-1.0 mg/dl (Severe Depletion)&lt;/li&gt;&lt;li&gt;Controversial - May not be required&lt;/li&gt;&lt;li&gt;Patient may experience &lt;a href="../../Rheum/Sx/MsclWkns.htm" class="LinkPage"&gt;Muscle Weakness&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Consider if cardiopulmonary adverse affects&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Contraindications&lt;ol&gt;&lt;li&gt;Renal Insufficiency&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Administration&lt;ol&gt;&lt;li&gt;Determine &lt;a href="../../Renal/Pharm/PtsmRplcmnt.htm" class="LinkPage"&gt;Potassium Replacement&lt;/a&gt; as above&lt;/li&gt;&lt;li&gt;Replace part of potassium with potassium phosphate&lt;ol&gt;&lt;li&gt;Potassium Phosphate: Replace one third potassium&lt;/li&gt;&lt;li&gt;Potassium Chloride: Replace two thirds potassium&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Renal/Pharm/MgnsmSlft.htm" class="LinkPage"&gt;Magnesium Replacement&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Indications&lt;ol&gt;&lt;li&gt;Symptomatic &lt;a href="../../Renal/Magnesium/Hypmgnsm.htm" class="LinkPage"&gt;Hypomagnesemia&lt;/a&gt; (&lt;a href="../../Pharm/Minerals/Mgnsm.htm" class="LinkPage"&gt;Magnesium&lt;/a&gt; &amp;lt;1 meq/L)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Administration&lt;ol&gt;&lt;li&gt;MgSO4 50%: 2.5-5.0 ml (20-40 meq) IM&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Renal/Pharm/SdmBcrbnt.htm" class="LinkPage"&gt;Sodium Bicarbonate&lt;/a&gt; Replacement&lt;ol&gt;&lt;li&gt;Indications&lt;ol&gt;&lt;li&gt;ABG pH &amp;lt; 6.9 to 7.0 after initial hour of hydration&lt;/li&gt;&lt;li&gt;Other contributing factors&lt;ol&gt;&lt;li&gt;&lt;a href="../../CV/Exam/Hyptnsn.htm" class="LinkPage"&gt;Shock&lt;/a&gt; or &lt;a href="../../Neuro/LOC/Cm2.htm" class="LinkPage"&gt;Coma&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Severe &lt;a href="../../Renal/Potassium/Hyprklm.htm" class="LinkPage"&gt;Hyperkalemia&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Administration&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Renal/Pharm/SdmBcrbntInSvrMtblcAcds.htm" class="LinkPage"&gt;Sodium Bicarbonate in Severe Metabolic Acidosis&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Management: Phase 3 - &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Glucose&lt;/a&gt; Control&lt;ol&gt;&lt;li&gt;Precautions&lt;ol&gt;&lt;li&gt;&lt;a href="../../Renal/Potassium/Hypklm.htm" class="LinkPage"&gt;Hypokalemia&lt;/a&gt; must be corrected prior to &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Adult &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; protocol&lt;ol&gt;&lt;li&gt;IV &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; administration&lt;ol&gt;&lt;li&gt;Initial&lt;ol&gt;&lt;li&gt;Give IV bolus of 0.15 units/kg&lt;/li&gt;&lt;li&gt;Start 0.1 units/kg/hour &lt;a href="../../Endo/Pharm/VrblRtInslnInfsn.htm" class="LinkPage"&gt;Insulin Drip&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Maintenance&lt;ol&gt;&lt;li&gt;Anticipate &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Serum Glucose&lt;/a&gt; drop of 50-70 mg/dl/hour&lt;ol&gt;&lt;li&gt;If inadequate drop, then increase drip&lt;ol&gt;&lt;li&gt;Increase &lt;a href="../../Endo/Pharm/VrblRtInslnInfsn.htm" class="LinkPage"&gt;Insulin Infusion&lt;/a&gt; rate by 50-100%&lt;/li&gt;&lt;li&gt;Continue at increased rate until adequate&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;When &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Serum Glucose&lt;/a&gt; &amp;lt;200-250 mg/dl&lt;ol&gt;&lt;li&gt;Keep &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Serum Glucose&lt;/a&gt; at 150 to 200 mg/dl&lt;/li&gt;&lt;li&gt;Decrease rate by 50% (to 0.05 units/kg) or&lt;/li&gt;&lt;li&gt;Discontinue &lt;a href="../../Endo/Pharm/VrblRtInslnInfsn.htm" class="LinkPage"&gt;Insulin Drip&lt;/a&gt; and start SC dosing&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;IM or SC &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; administration&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Endo/Pharm/HrlySbctnsInsln.htm" class="LinkPage"&gt;Hourly Subcutaneous Insulin Lispro&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; monitoring&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; monitoring every 30 minutes to 1 hour&lt;/li&gt;&lt;li&gt;Target &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; decrease 50-70 mg/dl/h&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Dextrose Administration&lt;ol&gt;&lt;li&gt;Add 5% Dextrose to fluids when &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; &amp;lt; 250 mg/dl&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Chiasson%20%20%5BAU%5D%20AND%202003%20%5BDP%5D%20AND%20%20CMAJ%20%20%5BTA%5D" class="LinkRef"&gt;Chiasson (2003) CMAJ 168:859-66&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Orland in Stine (1994) Emergency Med, p. 204-5&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Kitabchi%20%20%5BAU%5D%20AND%202001%20%5BDP%5D%20AND%20%20Diabetes%20Care%20%20%5BTA%5D" class="LinkRef"&gt;Kitabchi (2001) Diabetes Care 24:131-53&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Trachtenbarg%20%20%5BAU%5D%20AND%202005%20%5BDP%5D%20AND%20%20Am%20Fam%20Physician%20%20%5BTA%5D" class="LinkRef"&gt;Trachtenbarg (2005) Am Fam Physician 71(9): 1705-22&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Trence%20%20%5BAU%5D%20AND%202001%20%5BDP%5D%20AND%20%20Endocrinol%20Metab%20Clin%20North%20Am%20%20%5BTA%5D" class="LinkRef"&gt;Trence (2001) Endocrinol Metab Clin North Am 30:817-31&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/DM/DbtcKtcdsMngmntInAdlts.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Diabetic Ketoacidosis Management in Adults, DKA Management</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/DM/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Diabetes Mellitus, Insulin-Dependent  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0011854"&gt;&lt;i&gt;C0011854&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;Diabetes mellitus characterized by insulin deficiency, sudden onset, severe hyperglycemia, rapid progression to ketoacidosis, and death unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MEDLINEPLUS)&lt;/td&gt;
                &lt;td&gt;
                  &lt;span&gt;
                    &lt;p&gt;
                      &lt;a href="http://www.nlm.nih.gov/medlineplus/diabetes.html"&gt;Diabetes&lt;/a&gt; means your blood glucose, or blood sugar, is too high.  With Type 1 diabetes, your pancreas does not make insulin. Insulin is a hormone that helps glucose get into your cells to give them energy. Without insulin, too much glucose stays in your blood.  Over time, high blood glucose can lead to &lt;a href="http://www.nlm.nih.gov/medlineplus/diabetescomplications.html"&gt;serious problems&lt;/a&gt; with your heart, eyes, kidneys, nerves, and gums and teeth. &lt;/p&gt;
                    &lt;p&gt;Type 1 diabetes happens most often in children and young adults but can appear at any age. Symptoms may include&lt;/p&gt;
                    &lt;ul&gt;&lt;li&gt;	Being very thirsty &lt;/li&gt;
                      &lt;li&gt;	Urinating often &lt;/li&gt;
                      &lt;li&gt;	Feeling very hungry or tired &lt;/li&gt;
                      &lt;li&gt;	Losing weight without trying &lt;/li&gt;
                      &lt;li&gt;	Having sores that heal slowly &lt;/li&gt;
                      &lt;li&gt;	Having dry, itchy skin &lt;/li&gt;
                      &lt;li&gt;	Losing the feeling in your feet or having tingling in your feet &lt;/li&gt;
                      &lt;li&gt;	Having blurry eyesight &lt;/li&gt;
                    &lt;/ul&gt;&lt;p&gt;A blood test can show if you have diabetes. If you do, you will need to take &lt;a href="http://www.nlm.nih.gov/medlineplus/diabetesmedicines.html"&gt;insulin&lt;/a&gt; for the rest of your life.&lt;/p&gt;
                    &lt;p style="font-weight:bold;font-style:italic;"&gt;NIH: National Institute of Diabetes and Digestive and Kidney Diseases&lt;/p&gt;
                  &lt;/span&gt;
                &lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CSP)&lt;/td&gt;
                &lt;td&gt;subtype of diabetes mellitus that is characterized by insulin deficiency; it is manifested by the sudden onset of severe hyperglycemia, rapid progression to diabetic ketoacidosis, and death unless treated with insulin; the disease may occur at any age, but is most common in childhood or adolescence.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Disease or Syndrome (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0011854&amp;amp;tui=T047"&gt;&lt;i&gt;T047&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D003922&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD10&lt;/td&gt;
                &lt;td&gt;E10&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;154673001, 190362004, 267469001, 46635009, 190322003&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Brittle Diabetes Mellitus, Diabetes Mellitus, Brittle, Diabetes Mellitus, Insulin-Dependent, Diabetes Mellitus, Juvenile Onset, Diabetes Mellitus, Juvenile-Onset, Diabetes Mellitus, Ketosis Prone, Diabetes Mellitus, Ketosis-Prone, IDDM, Juvenile-Onset Diabetes Mellitus, Ketosis-Prone Diabetes Mellitus, DIABETES MELLITUS, INSULIN DEPENDENT, DIABETES MELLITUS, TYPE 1, Diabetes Mellitus, Insulin Dependent, Diabetes mellitus, type I, JUVENILE ONSET DIABETES MELLITUS, insulin dependent diabetes mellitus, DIABETES MELLITUS (JUVENILE ONSET), DIABETES MELLITUS INSULIN DEPENDENT, Insulin depend diabetes mellit, Juvenile onset diabet mellitis, Diabetes Mellitus, Sudden Onset, Diabetes Mellitus, Sudden-Onset, Mellitus, Sudden-Onset Diabetes, Sudden-Onset Diabetes Mellitus, Diabetes mellitus, growth onset type, Diabetes mellitus, juvenile onset type, DIABETES MELLITUS, INSULIN-DEPENDENT, DIABETES MELLITUS, TYPE I, JOD, IDDM1, INSULIN-DEPENDENT DIABETES MELLITUS 1, JUVENILE-ONSET DIABETES, Diabetes mellitus, insulin-dependent, DIABETES MELLITUS, INSULIN-DEPENDENT, 1, DIABETES MELLITUS TYPE 01, juvenile diabetes mellitus, ketosis prone diabetes, IDD, Juvenile diabetes, Diabetes mellitus juvenile onset, Diabetes mellitus insulin-dependent, Ketosis-prone diabetes mellitus, Insulin dependent diabetic, type I diabetes, insulin-dependent diabetes mellitus, juvenile-onset diabetes mellitus, type I diabetes mellitus (diagnosis), type I diabetes mellitus, iddm, juvenile onset diabetes mellitus, diabetes, type i, jodm, diabetes type i, Diabetes mellitus: [juvenile] or [insulin dependent] (disorder), Type I diabetes mellitus (disorder), Type 1 Diabetes, Insulin Dependent Diabetes Mellitus, Type I Diabetes, Insulin Dependent Diabetes, Type I Diabetes Mellitus, Juvenile Diabetes, IDDM-Insulin-depend diab mell, Insulin-depend diabet mellitus, Insulin-dependent diabetes, Diabetes Type 1, Insulin-Dependent Diabetes Mellitus, DIABETES MELLITUS, KETOSIS-PRONE, Type 1 diabetes, Diabetes mellitus, type 1, KPD, brittle diabetes (mellitus), juvenile onset diabetes (mellitus), ketosis-prone diabetes (mellitus), Diabetes Mellitus, Type 1 [Disease/Finding], Diabetes;Type 1, diabetes type 1, Diabetes;insulin dependent, Diabetes;juvenile onset, type i diabetes, type 1 diabetes mellitus, diabetes mellitus type i, diabetes mellitus type 1, type i diabetes mellitus, Insulin dependent diabetes mellitus, Diabetes mellitus type I, Juvenile onset diabetes mellitus, Type 1 diabetes mellitus, Insulin-dependent diabetes mellitus, IDDM - Insulin-dependent diabetes mellitus, Type I diabetes mellitus, Diabetes mellitus type 1 (disorder), Diabetes mellitus type 1, Diabetes insulin dependent, diabetes; insulin-dependent, diabetes; juvenile-onset, diabetes; ketosis-prone, diabetes; type I, insulin-dependent; diabetes, juvenile-onset; diabetes, ketosis, prone; diabetes, type I; diabetes, Diabetes mellitus - juvenile, Diabetes mellitus: [juvenile] or [insulin dependent], Insulin dependent diabetes mel, Diabetes Mellitus, Type I, Diabetes Mellitus, Type 1, Type 1 Diabetes Mellitus, insulin dependent diabetes, type 1 diabetes, juvenile onset of diabetes&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Typ 1-diabetes&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;diabetes mellitus se sklonem ke ketóze, diabetes mellitus insulin dependentní, diabetes mellitus náhle vzniklý, diabetes mellitus labilní, diabetes mellitus 1. typu, diabetes mellitus juvenilní, Inzulindependentní diabetes mellitus, Diabetes mellitus se sklonem k ketoacidóze, Diabetes mellitus typu 1, Juvenilní diabetes mellitus, Juvenilní diabetes, Inzulindependentní diabetes, Diabetes mellitus I.typu&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;Insulin dependent diabetes mel, Insulin dependent diabetes mellitus, Type I diabetes mellitus, Diabetes mellitus: [juvenile] or [insulin dependent], Diabetes mellitus - juvenile, Diabetes mellitus de comienzo juvenil, Diabetes mellitus insulinodependiente, Diabetes mellitus con riesgo de cetosis, Diabetes mellitus dependiente de insulina, DMID, Diabetes insulinodependiente, Diabetes juvenil, Diabetes mellitus tipo 1, Diabetes mellitus tipo I, diabetes mellitus dependiente de insulina (trastorno), diabetes mellitus dependiente de insulina, diabetes mellitus insulino - dependiente, diabetes mellitus tipo I, Diabetes Mellitus con Propensión a la Cetosis, Diabetes Mellitus de Inicio Súbito, Diabetes Mellitus Insulino-Dependiente, Diabetes Mellitus Juvenil Inicial, Diabetes Mellitus Tipo 1, Dmid, Diabetes Mellitus Inestable, Diabetes Mellitus con Propension a la Cetosis, Diabetes Mellitus de Inicio Subito&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Diabète insulino-dépendant, Diabétique insulino-dépendant, Apparition juvénile de diabète sucré, Diabète sucré de type I, DID, DID1, Diabète de type I, Diabète insulinodépendant, Diabète juvénile, Diabète de type 1, DSID (Diabète Sucré InsulinoDépendant), DSID, Diabète instable, Diabète sucré de type 1, Diabète sucré insulino-dépendant, Diabète sucré insulinodépendant&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;diabetes mellitus insuline-afhankelijk, juveniele diabetes, type I diabetes mellitus, diabetes mellitus, juveniel, type 1 diabetes mellitus, IADM, insuline-afhankelijke diabeet, ketosis-geneigde diabetes mellitus, insuline-afhankelijke diabetes mellitus, Insuline-afhankelijke diabetes, diabetes; insuline-afhankelijk, diabetes; juvenile-onset, diabetes; neiging tot ketose, diabetes; type I, insuline-afhankelijk; diabetes, juvenile-onset; diabetes, ketose, neiging tot; diabetes, type I; diabetes, Diabetes mellitus type 1, Diabetes mellitus, 'sudden-onset', Diabetes mellitus, brittle, Diabetes mellitus, insuline-afhankelijke, Diabetes mellitus, juveniele, Diabetes mellitus, ketose-gevoelige, IDDM ("Insulin-Dependent Diabetes Mellitus"), Insuline-afhankelijke diabetes mellitus, Mellitus, insuline-afhankelijke diabetes&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Diabetes mellitus insulinodependente, Diabético insulinodependente, Diabetes mellitus com início na juventude, Diabetes mellitus com tendência para cetose, Dibetes mellitus tipo I, Diabetes juvenil, Diabetes Mellitus com Tendência à Cetose, Diabetes Mellitus de Início na Juventude, Diabetes Mellitus de Início Súbito, Diabetes Mellitus Instável, Diabetes Mellitus Insulino-Dependente, Diabetes Mellitus Tipo 1, Dmid, Diabetes Mellitus Dependente de Insulina&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Diabetes mellitus insulinpflichtig, Diabetes mellitus, Einsetzen im jugendlichen Alter, insulinabhaengiger Diabetes mellitus, Diabetes mellitus Typ 1, Typ I Diabetes mellitus, Ketose-anfaelliger Diabetes mellitus, insulinpflichtiger Diabetiker, juveniler Diabetes, Primaer insulinabhaengiger Diabetes mellitus [Typ-I-Diabetes], Brittle-Diabetes, Diabetes mellitus, Brittle-, Diabetes mellitus, Typ I, Diabetes mellitus, juveniler Typ, Diabetes mellitus, mit Ketoseneigung, IDDM, Diabetes mellitus, insulinabhängiger, Diabetes mellitus, plötzlicher Beginn, Diabetes mellitus, Typ 1, Typ-1-Diabetes mellitus, Typ-I-Diabetes mellitus&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Diabete mellito ad esordio giovanile, Diabete giovanile, Diabete mellito tendente alla acidosi, Diabetico insulino-dipendente, Diabete mellito di tipo 1, Diabete mellito insulino-dipendente, Chetosi incline al diabete mellito, Diabete mellito a insorgenza giovanile, IDDM, Diabete mellito a insorgenza improvvisa, Diabete mellito instabile, Diabete mellito di tipo I&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;１型糖尿病, 1ｶﾞﾀﾄｳﾆｮｳﾋﾞｮｳ, ｹﾄｰｼｽｹｲｺｳﾄｳﾆｮｳﾋﾞｮｳ, ｲﾝｽﾘﾝｲｿﾞﾝｾｲﾄｳﾆｮｳﾋﾞｮｳ, ｼﾞｬｸﾈﾝﾊｯｼｮｳﾄｳﾆｮｳﾋﾞｮｳ, 若年性糖尿病, ｼﾞｬｸﾈﾝｾｲﾄｳﾆｮｳﾋﾞｮｳ, インシュリン依存性糖尿病, 若年発症糖尿病, 糖尿病-若年発症型, I型糖尿病, 自己免疫性糖尿病, 糖尿病-インスリン依存型, 糖尿病-ケトーシス傾向, 糖尿病-不安定型, ケトーシス傾向糖尿病, 糖尿病-若年発症, インスリン依存性糖尿病, 若年発症型糖尿病, 糖尿病-インスリン依存性, インシュリン依存型糖尿病, インスリン依存型糖尿病, 若年糖尿病, 不安定型糖尿病, 糖尿病-インシュリン依存型, 糖尿病-自己免疫性, 糖尿病1型, 1型糖尿病, 糖尿病-1型&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Tyypin 1 diabetes&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;DIABET SAKHARNYI NESTABIL'NYI, SAKHARNYI DIABET INSULINZAVISIMYI, DIABET AUTOIMMUNNYI, DIABET SAKHARNYI LABIL'NYI, DIABET SAKHARNYI S VNEZAPNYM NACHALOM, DIABET SAKHARNYI, TIP 1, DIABET SAKHARNYI IUNOSHESKII, DIABET SAKHARNYI, SKLONNOST' K KETOATSIDOZU, DIABET SAKHARNYI INSULINZAVISIMYI, DIABET SAKHARNYI, TIP I, ДИАБЕТ АУТОИММУННЫЙ, ДИАБЕТ САХАРНЫЙ ИНСУЛИНЗАВИСИМЫЙ, ДИАБЕТ САХАРНЫЙ ЛАБИЛЬНЫЙ, ДИАБЕТ САХАРНЫЙ НЕСТАБИЛЬНЫЙ, ДИАБЕТ САХАРНЫЙ С ВНЕЗАПНЫМ НАЧАЛОМ, ДИАБЕТ САХАРНЫЙ, СКЛОННОСТЬ К КЕТОАЦИДОЗУ, ДИАБЕТ САХАРНЫЙ, ТИП I, ДИАБЕТ САХАРНЫЙ ЮНОШЕСКИЙ, САХАРНЫЙ ДИАБЕТ ИНСУЛИНЗАВИСИМЫЙ, ДИАБЕТ САХАРНЫЙ, ТИП 1&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Korean&lt;/td&gt;
                &lt;td&gt;인슐린-의존 당뇨병&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Croatian&lt;/td&gt;
                &lt;td&gt;DIJABETES MELITUS, TIP 1&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Cukrzyca typu 1, Cukrzyca młodzieńcza&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;Fiatalkori diabetes mellitus, Insulin-dependens diabetes mellitus, I típusú cukorbetegség, IDDM, Insulindependens diabetes mellitus, 1. típusú cukorbetegség, Ketosisra hajlamosító diabetes mellitus, Insulin dependens diabeteses, Fiatalkori diabetes&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Diabetes Mellitus, Insulin-Dependent  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Type 1 Diabetes Mellitus</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Diabetes Mellitus</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;See Also&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/DM/DbtsMlts.htm" class="LinkPage"&gt;Diabetes Mellitus&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Epidemiology&lt;ol&gt;&lt;li&gt;Typically onset before age 30 years&lt;/li&gt;&lt;li&gt;Non-obese patients&lt;/li&gt;&lt;li&gt;&lt;a href="../../Prevent/Epi/DsPrvlncRt.htm" class="LinkPage"&gt;Prevalence&lt;/a&gt;: 5-10% of total &lt;a href="../../Endo/DM/DbtsMlts.htm" class="LinkPage"&gt;Diabetes Mellitus&lt;/a&gt; patients (3 million cases in United States)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Etiology&lt;ol&gt;&lt;li&gt;Type 1A&lt;ol&gt;&lt;li&gt;Environmental and genetic factors&lt;/li&gt;&lt;li&gt;HLA-DR4 association&lt;/li&gt;&lt;li&gt;Cell mediated pancreatic beta cell destruction&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Type 1B (uncommon)&lt;ol&gt;&lt;li&gt;Primary autoimmune condition&lt;/li&gt;&lt;li&gt;Associated with other &lt;a href="../../ENT/Allergy/Atmnty.htm" class="LinkPage"&gt;Autoimmune Conditions&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/HshmtsThyrdts.htm" class="LinkPage"&gt;Hashimoto's Thyroiditis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/GrvsDs.htm" class="LinkPage"&gt;Grave's Disease&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Neuro/Motor/MysthnGrvs.htm" class="LinkPage"&gt;Myasthenia Gravis&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;HLA-DR3 association&lt;/li&gt;&lt;li&gt;&lt;a href="../../Prevent/Epi/DsIncdncRt.htm" class="LinkPage"&gt;Incidence&lt;/a&gt; highest in 30-50 year olds&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Secondary &lt;a href="../../Endo/DM/DbtsMlts.htm" class="LinkPage"&gt;Diabetes Mellitus&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../Lung/Peds/CystcFbrs.htm" class="LinkPage"&gt;Cystic Fibrosis&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Environmental Factors&lt;ol&gt;&lt;li&gt;Medications&lt;ol&gt;&lt;li&gt;Streptozocin&lt;/li&gt;&lt;li&gt;&lt;a href="../../ID/Pharm/Pntmdn.htm" class="LinkPage"&gt;Pentamidine&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../ID/Virus/Vrs.htm" class="LinkPage"&gt;Virus&lt;/a&gt;es&lt;ol&gt;&lt;li&gt;&lt;a href="../../ID/Virus/Mmps.htm" class="LinkPage"&gt;Mumps&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Coxsackie&lt;ol&gt;&lt;li&gt;Enterovirus IgM linked to IDDM in adolescents&lt;ol&gt;&lt;li&gt;Studied 128 children with new onset IDDM&lt;/li&gt;&lt;li&gt;Non-specific to subtype (coxsackie, echovirus)&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Helfand%20%20%5BAU%5D%20AND%201995%20%5BDP%5D%20AND%20%20J%20Infect%20Dis%20%20%5BTA%5D" class="LinkRef"&gt;Helfand (1995) J Infect Dis 172:1206-11&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Congenital &lt;a href="../../ID/Virus/Rbl1.htm" class="LinkPage"&gt;Rubella&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Late Type I Diabetes Mellitus develops in 40%&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../ID/Virus/Cytmglvrs.htm" class="LinkPage"&gt;Cytomegalovirus&lt;/a&gt; (CMV)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Symptoms and Signs&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Endo/DM/DbtsMlts.htm" class="LinkPage"&gt;Diabetes Mellitus&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Common Presentations&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/DM/DbtcKtcds.htm" class="LinkPage"&gt;Diabetic Ketoacidosis&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Major presenting syndrome in 25% of cases&lt;/li&gt;&lt;li&gt;More common in under 3 years and adolescence&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Incidental glucosuria or &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Hyperglycemia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Surgery/GI/ActAbdmnlPn.htm" class="LinkPage"&gt;Acute Abdominal Pain&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../ID/Virus/Inflnz.htm" class="LinkPage"&gt;Influenza&lt;/a&gt;-like illness&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Diagnosis&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Endo/DM/DbtsMlts.htm" class="LinkPage"&gt;Diabetes Mellitus&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Oral &lt;a href="../../Endo/Lab/GlcsTlrncTst3Hr.htm" class="LinkPage"&gt;Glucose Tolerance Test&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Fasting &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Glucose&lt;/a&gt; or Random &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Glucose&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Two hour post-prandial &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Intravenous &lt;a href="../../Endo/Lab/GlcsTlrncTst3Hr.htm" class="LinkPage"&gt;Glucose Tolerance Test&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Labs&lt;ol&gt;&lt;li&gt;Initial studies&lt;ol&gt;&lt;li&gt;&lt;a href="../../Uro/Lab/Urnlys.htm" class="LinkPage"&gt;Urinalysis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Glucose&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Electrolytes&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/HmglbnAc.htm" class="LinkPage"&gt;Glycosylated Hemoglobin&lt;/a&gt; (&lt;a href="../../Endo/Lab/HmglbnAc.htm" class="LinkPage"&gt;Hemoglobin A1C&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/ThyrdStmltngHrmn.htm" class="LinkPage"&gt;Thyroid Stimulating Hormone&lt;/a&gt; (TSH)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Diagnostics in Atypical Presentation&lt;ol&gt;&lt;li&gt;Anti-Glutamic Acid Decarboxylase &lt;a href="../../ID/Exam/Imnglbln.htm" class="LinkPage"&gt;Antibody&lt;/a&gt; (Anti-GAD65 &lt;a href="../../ID/Exam/Imnglbln.htm" class="LinkPage"&gt;Antibody&lt;/a&gt;) - most useful of markers&lt;ol&gt;&lt;li&gt;&lt;a href="../../Prevent/Epi/TstSnstvty.htm" class="LinkPage"&gt;Test Sensitivity&lt;/a&gt; in Type I Diabetes: 60% in adults (60-73% in children)&lt;/li&gt;&lt;li&gt;Not specific, also found in 7-34% in adults and children with &lt;a href="../../Endo/DM/TypDbtsMlts1.htm" class="LinkPage"&gt;Type II Diabetes&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Absence of &lt;a href="../../ID/Exam/Imnglbln.htm" class="LinkPage"&gt;Antibody&lt;/a&gt; makes requring inulin withn 6 years in adults unlikely (NPV 94%)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Anti-islet cell surface &lt;a href="../../ID/Exam/Imnglbln.htm" class="LinkPage"&gt;Antibody&lt;/a&gt; (ICA)&lt;ol&gt;&lt;li&gt;&lt;a href="../../Prevent/Epi/TstSnstvty.htm" class="LinkPage"&gt;Test Sensitivity&lt;/a&gt; in Type I Diabetes: 75-85% in adults and children&lt;/li&gt;&lt;li&gt;Not specific for Type I Diabetes (seen in up to 21% of &lt;a href="../../Endo/DM/TypDbtsMlts1.htm" class="LinkPage"&gt;Type II Diabetes&lt;/a&gt; adults)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Anti-&lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt;&lt;a href="../../ID/Exam/Imnglbln.htm" class="LinkPage"&gt;Antibody&lt;/a&gt; (IA-2a and IA-2b)&lt;ol&gt;&lt;li&gt;&lt;a href="../../Prevent/Epi/TstSnstvty.htm" class="LinkPage"&gt;Test Sensitivity&lt;/a&gt; in Type I Diabetes: 40% in adults and 40-86% in children&lt;/li&gt;&lt;li&gt;More specific for Type I Diabetes (only present in ~2% of &lt;a href="../../Endo/DM/TypDbtsMlts1.htm" class="LinkPage"&gt;Type II Diabetes&lt;/a&gt;)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;C-peptide low or absent (&amp;lt;1.51 ng)&lt;ol&gt;&lt;li&gt;Consider after Sustacal challenge&lt;/li&gt;&lt;li&gt;Not specific for Type I Diabetes Mellitus (also seen in Type II)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;References&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Patel%20%20%5BAU%5D%20AND%202010%20%5BDP%5D%20AND%20%20Am%20Fam%20Physician%20%20%5BTA%5D" class="LinkRef"&gt;Patel (2010) Am Fam Physician 81(7): 863-70&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Management: Initial&lt;ol&gt;&lt;li&gt;Treat acute problems (includes non-diabetic issues)&lt;/li&gt;&lt;li&gt;Set initial goals and targets&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Endo/DM/DbtsMltsGlcsMngmnt.htm" class="LinkPage"&gt;Diabetes Mellitus Glucose Management&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Initiate &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; therapy&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Endo/Pharm/InslnDsng.htm" class="LinkPage"&gt;Insulin Dosing&lt;/a&gt;&lt;/li&gt;&lt;li&gt;If atypical presentation, then base on ketones&lt;ol&gt;&lt;li&gt;Ketones positive: Start &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Ketones negative: Consider treating as Type II&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Education&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Endo/DM/DbtcEdctn.htm" class="LinkPage"&gt;Diabetes Mellitus Education&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Teach survival skills&lt;/li&gt;&lt;li&gt;Establish plan for ongoing care and education&lt;/li&gt;&lt;li&gt;Review importance of intensive therapy (compared with conventional care)&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Endo/DM/DbtsMltsGlcsMngmnt.htm" class="LinkPage"&gt;Diabetes Mellitus Glucose Management&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Management: Follow-up&lt;ol&gt;&lt;li&gt;Initial&lt;ol&gt;&lt;li&gt;Daily phone contact for first 3 days&lt;/li&gt;&lt;li&gt;Office visit within 2 weeks&lt;/li&gt;&lt;li&gt;Emergency 24 hour phone number given&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Adjustment phase&lt;ol&gt;&lt;li&gt;Consider weekly phone call&lt;/li&gt;&lt;li&gt;Monthly office visit&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Maintenance Phase&lt;ol&gt;&lt;li&gt;Office visit every 3-4 months&lt;/li&gt;&lt;li&gt;Review &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Sugar&lt;/a&gt; Log&lt;ol&gt;&lt;li&gt;Hypoglycemic Episodes&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Hyperglycemia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Ketones&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Review food plan&lt;/li&gt;&lt;li&gt;Review &lt;a href="../../Sports/Exercise/Exrcs.htm" class="LinkPage"&gt;Exercise&lt;/a&gt; program&lt;/li&gt;&lt;li&gt;Review Medications&lt;/li&gt;&lt;li&gt;Exam&lt;ol&gt;&lt;li&gt;Height and Weight&lt;/li&gt;&lt;li&gt;Growth rate (pediatric &lt;a href="../../Endo/DM/DbtsMlts.htm" class="LinkPage"&gt;Diabetes Mellitus&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Exam/BldPrsr.htm" class="LinkPage"&gt;Blood Pressure&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Labs&lt;ol&gt;&lt;li&gt;Check &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; Meter against &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Serum Glucose&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/HmglbnAc.htm" class="LinkPage"&gt;Hemoglobin A1C&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Education&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Prevent/NtrtnInDbtsMlts.htm" class="LinkPage"&gt;Nutrition in Diabetes Mellitus&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Sports/ExrcsInDbtsMlts.htm" class="LinkPage"&gt;Exercise in Diabetes Mellitus&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Yearly Exam&lt;ol&gt;&lt;li&gt;Health Maintenance Exam&lt;/li&gt;&lt;li&gt;Fasting lipid profile within 6 months of diagnosis&lt;ol&gt;&lt;li&gt;&lt;a href="../../CV/Lab/Trglycrd.htm" class="LinkPage"&gt;Triglyceride&lt;/a&gt;s commonly elevated&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Neuro/Exam/NrlgcExm.htm" class="LinkPage"&gt;Neurologic Exam&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Dental exam&lt;/li&gt;&lt;li&gt;Optometry or Ophthalmology Exam&lt;ol&gt;&lt;li&gt;Age over 12 years or &lt;a href="../../Endo/DM/DbtsMlts.htm" class="LinkPage"&gt;Diabetes Mellitus&lt;/a&gt; for 5 years&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Uro/Lab/UrnMcrlbmn.htm" class="LinkPage"&gt;Urine Microalbumin&lt;/a&gt; yearly&lt;ol&gt;&lt;li&gt;Age over 12 years or &lt;a href="../../Endo/DM/DbtsMlts.htm" class="LinkPage"&gt;Diabetes Mellitus&lt;/a&gt; for 5 years&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Management: New Tools&lt;ol&gt;&lt;li&gt;Monitoring&lt;ol&gt;&lt;li&gt;Continuous &lt;a href="../../Endo/DM/DbtsMltsGlcsMngmnt.htm" class="LinkPage"&gt;Blood Sugar Monitoring&lt;/a&gt; (24 hour)&lt;/li&gt;&lt;li&gt;Transcutaneous &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Serum Glucose&lt;/a&gt; monitoring (watch)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Treatment options&lt;ol&gt;&lt;li&gt;Islet Cell Transplants (high efficacy in trials)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/InslnPmp.htm" class="LinkPage"&gt;Insulin Pump&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0011854</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/DM/TypDbtsMlts.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Type 1 Diabetes Mellitus, Type I Diabetes Mellitus, Insulin Dependent Diabetes Mellitus, IDDM, Type I Diabetes</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/DM/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees></FP_UMLS_Trees><FP_Condition_name_check></FP_Condition_name_check><FP_Condition_name><value>Diabetes Mellitus Complications</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Diabetes Mellitus</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Prevention&lt;ol&gt;&lt;li&gt;Better glycemic control yields lower complication risk&lt;/li&gt;&lt;li&gt;Most patients with diabetes die of cardiovascular disease complications&lt;ol&gt;&lt;li&gt;&lt;a href="../../CV/Htn/Hyprtnsn.htm" class="LinkPage"&gt;Hypertension&lt;/a&gt; control has greater benefit in reducing stroke risk&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Lipid/Hyprchlstrlm.htm" class="LinkPage"&gt;Hyperlipidemia&lt;/a&gt; control has greater benefit in reducing coronary disease risk&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Complications reduced 60% if &lt;a href="../../Endo/Lab/HmglbnAc.htm" class="LinkPage"&gt;Hemoglobin A1C&lt;/a&gt; &amp;lt;7.2%&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=1995%20%5BDP%5D%20AND%20%20N%20Engl%20J%20Med%20%20%5BTA%5D%20AND%20332%20%5BVI%5D%20AND%201251%20%5BPG%5D" class="LinkRef"&gt;(1995) N Engl J Med 332:1251-5&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Complications: Macrovascular&lt;ol&gt;&lt;li&gt;&lt;a href="../../CV/CAD/ActCrnrySyndrm.htm" class="LinkPage"&gt;Atherosclerotic Heart Disease&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/CAD/ActCrnrySyndrm.htm" class="LinkPage"&gt;Myocardial Infarction&lt;/a&gt; and Sudden Death&lt;/li&gt;&lt;li&gt;&lt;a href="../../Surgery/CV/PrphrlArtrlOclsvDs.htm" class="LinkPage"&gt;Peripheral Vascular Disease&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Neuro/CV/IschmcStrk.htm" class="LinkPage"&gt;Cerebrovascular Disease&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Renal/CV/RnlArtryStns.htm" class="LinkPage"&gt;Renal Artery Stenosis&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Complications: Microvascular&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Eye/DbtcRtnpthy.htm" class="LinkPage"&gt;Diabetic Retinopathy&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Renal/DbtcNphrpthy.htm" class="LinkPage"&gt;Diabetic Nephropathy&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Occurs in 40% of &lt;a href="../../Endo/DM/TypDbtsMlts.htm" class="LinkPage"&gt;Type I Diabetes Mellitus&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Occurs in 20% of &lt;a href="../../Endo/DM/TypDbtsMlts1.htm" class="LinkPage"&gt;Type II Diabetes Mellitus&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Neuro/Sx/PrphrlNrpthy.htm" class="LinkPage"&gt;Peripheral Neuropathy&lt;/a&gt;&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Endo/Neuro/DbtcNrpthy.htm" class="LinkPage"&gt;Diabetic Neuropathy&lt;/a&gt;&lt;/li&gt;&lt;li&gt;See also &lt;a href="../../Neuro/Exam/DbtcNrpthyTstng.htm" class="LinkPage"&gt;Peripheral Neuropathy Testing&lt;/a&gt;&lt;/li&gt;&lt;li&gt;See &lt;a href="../../Rheum/Neuro/ChrctFt.htm" class="LinkPage"&gt;Charcot Foot&lt;/a&gt;&lt;/li&gt;&lt;li&gt;See &lt;a href="../../Surgery/Derm/FtWnd.htm" class="LinkPage"&gt;Foot Ulcer&lt;/a&gt; and &lt;a href="../../Endo/Prevent/DbtcFtCr.htm" class="LinkPage"&gt;Diabetic Foot Care&lt;/a&gt;&lt;/li&gt;&lt;li&gt;See &lt;a href="../../Ortho/ID/DbtcFtOstmylts.htm" class="LinkPage"&gt;Suspected Osteomyelitis in Diabetes Mellitus&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Neuro/Autonomic/AtnmcDysfnctn.htm" class="LinkPage"&gt;Autonomic Neuropathy&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../GI/Stomach/Gstrprs.htm" class="LinkPage"&gt;Gastroparesis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Uro/Impotence/ErctlDysfnctn.htm" class="LinkPage"&gt;Impotence&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/DM/DbtsMltsCmplctns.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Diabetes Mellitus Complications</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/DM/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees></FP_UMLS_Trees><FP_Condition_name_check></FP_Condition_name_check><FP_Condition_name><value>Diabetic Ketoacidosis Management in Children</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Diabetes Mellitus</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;See Also&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/DM/DbtcKtcds.htm" class="LinkPage"&gt;Diabetic Ketoacidosis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/DM/DbtcKtcdsMngmntInAdlts.htm" class="LinkPage"&gt;Diabetic Ketoacidosis Management in Adults&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Management: Phase 1 in Children (Emergent)&lt;ol&gt;&lt;li&gt;Stabilize shock and &lt;a href="../../Neuro/LOC/Cm2.htm" class="LinkPage"&gt;Coma&lt;/a&gt; states first!&lt;/li&gt;&lt;li&gt;Correct Volume Deficit&lt;ol&gt;&lt;li&gt;Initial&lt;ol&gt;&lt;li&gt;Give 20 cc/kg NS bolus over first 45 minutes&lt;/li&gt;&lt;li&gt;Repeat fluid bolus until shock corrected&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Next&lt;ol&gt;&lt;li&gt;Protocol 1 (standard protocol)&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Peds/FEN/PdtrcDhydrtnMngmnt.htm" class="LinkPage"&gt;Pediatric Dehydration Management&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Replace first 50% volume deficit in first 8 hours&lt;/li&gt;&lt;li&gt;Replace remaining 50% deficit over next 16 hours&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Protocol 2&lt;ol&gt;&lt;li&gt;NS at 10 cc/kg/hr (+/- 5 cc/kg/hr)&lt;ol&gt;&lt;li&gt;Until &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Serum Glucose&lt;/a&gt; &amp;lt;250 mg/dl&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Then D5 1/2NS with 20 kcl&lt;ol&gt;&lt;li&gt;Use 1 to 1.5 x maintenance rate&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Protocol 3 (new protocol)&lt;ol&gt;&lt;li&gt;Protocol uses 0.675% saline&lt;/li&gt;&lt;li&gt;Administer 2.5 x maintenance rate&lt;ol&gt;&lt;li&gt;Continue for 24 hours or until no acidosis&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Then administer 1 to 1.5 x maintenance rate&lt;/li&gt;&lt;li&gt;Efficacy in children (compared with Protocol 1)&lt;ol&gt;&lt;li&gt;Reduces fluid rate&lt;ol&gt;&lt;li&gt;May decrease risk of cerebral edema&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Resulted in cost savings &amp;gt;$1000/patient&lt;/li&gt;&lt;li&gt;Faster acidosis resolution&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Felner%20%20%5BAU%5D%20AND%202001%20%5BDP%5D%20AND%20%20Pediatrics%20%20%5BTA%5D" class="LinkRef"&gt;Felner (2001) Pediatrics 108:735-40&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Precautions&lt;ol&gt;&lt;li&gt;Do not drop &lt;a href="../../Renal/Lab/SrmOsmlty.htm" class="LinkPage"&gt;Serum Osmolality&lt;/a&gt; (calc) &amp;gt;3 mOsms/hour&lt;ol&gt;&lt;li&gt;Risk of cerebral edema&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Slow replacement if &lt;a href="../../Renal/Edema/Edm.htm" class="LinkPage"&gt;Fluid Overload&lt;/a&gt; risk&lt;ol&gt;&lt;li&gt;&lt;a href="../../CV/CHF/CngstvHrtFlr.htm" class="LinkPage"&gt;Congestive Heart Failure&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Renal/Failure/ChrncRnlFlr.htm" class="LinkPage"&gt;Chronic Renal Insufficiency&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Follow Intake and output closely&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Management: Phase 2 - Acidosis, electrolytes in children&lt;ol&gt;&lt;li&gt;&lt;a href="../../Renal/Pharm/PtsmRplcmnt.htm" class="LinkPage"&gt;Potassium Replacement&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Precautions&lt;ol&gt;&lt;li&gt;&lt;a href="../../Renal/Potassium/Hypklm.htm" class="LinkPage"&gt;Hypokalemia&lt;/a&gt; must be corrected prior to &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Hold &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; until potassium &amp;gt;2.5 meq/L in children&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Prerequisites&lt;ol&gt;&lt;li&gt;&lt;a href="../../CV/Exam/Elctrcrdgrm.htm" class="LinkPage"&gt;Electrocardiogram&lt;/a&gt; without signs of &lt;a href="../../Renal/Potassium/Hyprklm.htm" class="LinkPage"&gt;Hyperkalemia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Adequate urine output&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Administration: Children&lt;ol&gt;&lt;li&gt;&lt;a href="../../Renal/Lab/SrmPtsm.htm" class="LinkPage"&gt;Serum Potassium&lt;/a&gt; &amp;lt;2.5 meq/L&lt;ol&gt;&lt;li&gt;Do not administer &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; until potassium &amp;gt;2.5&lt;/li&gt;&lt;li&gt;KCl 1 meq/kg (to 40 meq) IV over 1 hour, recheck&lt;ol&gt;&lt;li&gt;This is maximum IV potassium rate!&lt;/li&gt;&lt;li&gt;Requires cardiac monitoring&lt;/li&gt;&lt;li&gt;Requires hourly recheck of &lt;a href="../../Renal/Lab/SrmPtsm.htm" class="LinkPage"&gt;Serum Potassium&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Renal/Lab/SrmPtsm.htm" class="LinkPage"&gt;Serum Potassium&lt;/a&gt; 2.5 to 3.5 meq/L&lt;ol&gt;&lt;li&gt;Give 40-60 meq/L in IV solution&lt;/li&gt;&lt;li&gt;Recheck &lt;a href="../../Renal/Lab/SrmPtsm.htm" class="LinkPage"&gt;Serum Potassium&lt;/a&gt; hourly&lt;/li&gt;&lt;li&gt;Continue replacement until potassium &amp;gt;3.5 meq/L&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Renal/Lab/SrmPtsm.htm" class="LinkPage"&gt;Serum Potassium&lt;/a&gt; 3.5 to 5.0 meq/L&lt;ol&gt;&lt;li&gt;Replace 30-40 meq per liter&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Renal/Lab/SrmPtsm.htm" class="LinkPage"&gt;Serum Potassium&lt;/a&gt; &amp;gt;5.0 meq/L&lt;ol&gt;&lt;li&gt;Do not administer any potassium&lt;/li&gt;&lt;li&gt;Monitor every 1 hour until &amp;lt;5.0&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Renal/Pharm/PhsphrsRplcmnt.htm" class="LinkPage"&gt;Phosphate Replacement&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Indications&lt;ol&gt;&lt;li&gt;&lt;a href="../../Renal/Lab/SrmPhsphrs.htm" class="LinkPage"&gt;Serum Phosphorus&lt;/a&gt; &amp;lt; 0.5-1.0 mg/dl (Severe Depletion)&lt;/li&gt;&lt;li&gt;Controversial - May not be required&lt;/li&gt;&lt;li&gt;Consider if cardiopulmonary adverse affects&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Contraindications&lt;ol&gt;&lt;li&gt;Renal Insufficiency&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Administration&lt;ol&gt;&lt;li&gt;Determine &lt;a href="../../Renal/Pharm/PtsmRplcmnt.htm" class="LinkPage"&gt;Potassium Replacement&lt;/a&gt; as above&lt;/li&gt;&lt;li&gt;Replace part of potassium with potassium phosphate&lt;ol&gt;&lt;li&gt;Potassium Phosphate: Replace one third potassium&lt;/li&gt;&lt;li&gt;Potassium Chloride: Replace two thirds potassium&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Renal/Pharm/MgnsmSlft.htm" class="LinkPage"&gt;Magnesium Replacement&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Indications&lt;ol&gt;&lt;li&gt;Symptomatic &lt;a href="../../Renal/Magnesium/Hypmgnsm.htm" class="LinkPage"&gt;Hypomagnesemia&lt;/a&gt; (&lt;a href="../../Pharm/Minerals/Mgnsm.htm" class="LinkPage"&gt;Magnesium&lt;/a&gt; &amp;lt;1 meq/L)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Administration&lt;ol&gt;&lt;li&gt;MgSO4 50%: 0.2 ml/kg/day IM divide in 3 doses&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Renal/Pharm/SdmBcrbnt.htm" class="LinkPage"&gt;Sodium Bicarbonate&lt;/a&gt; Replacement&lt;ol&gt;&lt;li&gt;Indications&lt;ol&gt;&lt;li&gt;ABG pH &amp;lt; 7.0 after initial hour of hydration&lt;/li&gt;&lt;li&gt;Other contributing factors&lt;ol&gt;&lt;li&gt;&lt;a href="../../CV/Exam/Hyptnsn.htm" class="LinkPage"&gt;Shock&lt;/a&gt; or &lt;a href="../../Neuro/LOC/Cm2.htm" class="LinkPage"&gt;Coma&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Severe &lt;a href="../../Renal/Potassium/Hyprklm.htm" class="LinkPage"&gt;Hyperkalemia&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Administration&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Renal/Pharm/SdmBcrbntInSvrMtblcAcds.htm" class="LinkPage"&gt;Sodium Bicarbonate in Severe Metabolic Acidosis&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Management: Phase 3 - &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; control in children&lt;ol&gt;&lt;li&gt;Initial &lt;a href="../../Endo/Pharm/InslnDsng.htm" class="LinkPage"&gt;Insulin Dosing&lt;/a&gt;&lt;ol&gt;&lt;li&gt;IV &lt;a href="../../Endo/Pharm/VrblRtInslnInfsn.htm" class="LinkPage"&gt;Insulin Drip&lt;/a&gt; starting at 0.1 unit/kg/hour&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Maintenance&lt;ol&gt;&lt;li&gt;Continue &lt;a href="../../Endo/Pharm/VrblRtInslnInfsn.htm" class="LinkPage"&gt;Insulin Infusion&lt;/a&gt; until acidosis resolves&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;When pH&amp;gt;7.3 and serum bicarbonate &amp;gt;15&lt;ol&gt;&lt;li&gt;Decrease &lt;a href="../../Endo/Pharm/VrblRtInslnInfsn.htm" class="LinkPage"&gt;Insulin Infusion&lt;/a&gt; to 0.05 units/kg/hour&lt;/li&gt;&lt;li&gt;Continue &lt;a href="../../Endo/Pharm/VrblRtInslnInfsn.htm" class="LinkPage"&gt;Insulin Infusion&lt;/a&gt; until SC &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; started&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; and electolyte monitoring&lt;ol&gt;&lt;li&gt;Check bedside &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; every 1/2-2 hours until stable&lt;/li&gt;&lt;li&gt;Recheck chem8 q2-4 hours until stable&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Initiate SC dosing&lt;ol&gt;&lt;li&gt;Known diabetic&lt;ol&gt;&lt;li&gt;Restart prior program and readjust &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;New patient: Determine &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; requirements&lt;ol&gt;&lt;li&gt;Regular 0.1 to 0.25 units per kg every 6-8 hours&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Brink%20%20%5BAU%5D%20AND%201999%20%5BDP%5D%20AND%20%20Diabetes%20Nutr%20Metab%20%20%5BTA%5D" class="LinkRef"&gt;Brink (1999) Diabetes Nutr Metab 12:122-35&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Kitabchi%20%20%5BAU%5D%20AND%202001%20%5BDP%5D%20AND%20%20Diabetes%20Care%20%20%5BTA%5D" class="LinkRef"&gt;Kitabchi (2001) Diabetes Care 24:131-53&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Trachtenbarg%20%20%5BAU%5D%20AND%202005%20%5BDP%5D%20AND%20%20Am%20Fam%20Physician%20%20%5BTA%5D" class="LinkRef"&gt;Trachtenbarg (2005) Am Fam Physician 71: 1705-22&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/DM/DbtcKtcdsMngmntInChldrn.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Diabetic Ketoacidosis Management in Children, Pediatric DKA Treatment</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/DM/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Diabetic Ketoacidosis  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0011880"&gt;&lt;i&gt;C0011880&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A type of metabolic acidosis produced by accumulation of ketone bodies resulting from uncontrolled diabetes mellitus.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;A life-threatening complication of diabetes mellitus, primarily of TYPE 1 DIABETES MELLITUS with severe INSULIN deficiency and extreme HYPERGLYCEMIA. It is characterized by KETOSIS; DEHYDRATION; and depressed consciousness leading to COMA.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CHV)&lt;/td&gt;
                &lt;td&gt;a serious complication of diabetes mellitus&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CHV)&lt;/td&gt;
                &lt;td&gt;a serious complication of diabetes mellitus&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CHV)&lt;/td&gt;
                &lt;td&gt;a serious complication of diabetes mellitus&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CSP)&lt;/td&gt;
                &lt;td&gt;complication of diabetes resulting from severe insulin deficiency coupled with an absolute or relative increase in glucagon concentration; metabolic acidosis is caused by the breakdown of adipose stores and resulting increased levels of free fatty acids; glucagon accelerates the oxidation of the free fatty acids producing excess ketone bodies (ketosis).&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;The metabolic condition resulted from uncontrolled diabetes mellitus, in which the shift of acid-base status of the body toward the acid side because of loss of base or retention of acids other than carbonic acid is accompanied by the accumulation of ketone bodies in body tissues and fluids.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Disease or Syndrome (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0011880&amp;amp;tui=T047"&gt;&lt;i&gt;T047&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D016883&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD9&lt;/td&gt;
                &lt;td&gt;250.1&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;24927004, 420422005, 154671004, 267467004, 190328004&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Diabetic keto-acidosis, Acidoses, Diabetic, Acidosis, Diabetic, Diabetic Acidoses, Diabetic Acidosis, Diabetic Ketoacidoses, Ketoacidoses, Diabetic, Ketoacidosis, Diabetic, Diabetes with ketoacidosis, ACIDOSIS DIABETIC, ACIDOSIS, DIABETIC, DIABETIC ACIDOSIS, DIABETIC KETOACIDOSIS, DKA, diabetic acidosis, Diabetes Mellitus with Ketoacidosis, Diabetic acidosis without coma, Diabetic ketosis without coma, DKA - Diabetic ketoacidosis, Diab.mell.+ketoacid -onset NOS, Diabetes mellitus NOS with ketoacidosis, Diabetic acidosis, NOS, Diabetic ketoacidosis, Diabetes mellitus with ketoacidosis, Diabetic acidosis, Diabetes with ketoacidosis (disorder), Ketoacidosis in diabetes mellitus (disorder), Ketoacidosis in diabetes mellitus, Diab.mell.with ketoacidosis, diabetes with ketoacidosis, diabetes mellitus with ketoacidosis, diabetes mellitus with ketoacidosis (diagnosis), Diabetes mellitus (&amp;amp; [ketoacidosis]) (disorder), Acidosis diabetic, Ketoacidosis (diabetic), Diabetic ketosis, KETOACIDOSIS DIABETIC, Diabetes mellitus NOS with ketoacidosis (disorder), KETOACIDOSIS, DIABETIC, Diabetic Ketoacidosis [Disease/Finding], diabetic ketoacidosis, diabetic ketoacidoses, diabetic ketosis, diabetic ketoses, Diabetes mellitus (&amp;amp; [ketoacidosis]), Ketoacidosis - diabetic, Diabetic Ketoses, Diabetic Ketosis, Ketoses, Diabetic, Ketosis, Diabetic, Diabetic Ketoacidosis&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;ACIDOCETOSE DIABETIQUE, Diabète sucré avec kétoacidose, Kétoacidose (diabétique), Diabète avec kétoacidose, Acidocétose diabétique, Acidose diabétique, Cétose diabétique, Acido-cétose diabétique&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;CETOACIDOSE DIABETICA, Acidose diabética, Diabetes com cetacidose, Cetacidose diabética, Diabetes mellitus com cetacidose, Cetose diabética, Cetoacidose diabética, Acidose Diabética, Cetoacidose Diabética, Cetose Diabética&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;CETOACIDOSIS DIABETICA, diabetes mellitus con cetoacidosis, cetoacidosis diabética, cetoacidosis en diabetes mellitus, cetoacidosis en diabetes mellitus (trastorno), Diabetes mellitus con cetoacidosis, Acidosis diabética, Cetosis diabética, Cetoacidosis (diabética), Diabetes con cetoacidosis, acidosis diabética, diabetes con cetoacidosis, cetoacidosis diabética (trastorno), Diabetic ketoacidosis, Ketoacidosis - diabetic, Diabetes mellitus (&amp;amp; [ketoacidosis]), diabetes mellitus, SAI con cetoacidosis (trastorno), diabetes mellitus, SAI con cetoacidosis, Cetoacidosis diabética, Acidosis Diabética, Cetoacidosis Diabética, Cetosis Diabética, Acidosis Diabetica, Cetoacidosis Diabetica, Cetosis Diabetica&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;DIABETISCHE KETOAZIDOSE, Diabetes mellitus mit Ketoazidose, Azidose, diabetisch, Ketoazidose (diabetisch), diabetische Azidose, diabetische Ketose, Diabetes mit Ketoazidose, diabetische Ketoazidose, Azidose, diabetische, Diabetische Azidose, Diabetische Ketoazidose, Ketoazidose, diabetische&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;diabetes mellitus met ketoacidose, diabetische ketose, diabetes met ketoacidose, diabetische acidose, ketoacidose (diabetisch), acidose diabetisch, diabetische ketoacidose, Acidose, diabetische, Diabetische acidose, Diabetische ketoacidose, Diabetische ketose, Ketoacidose, diabetische, Ketose, diabetische&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Diabete mellito con chetoacidosi, Chetoacidosi (diabetica), Diabete con chetoacidosi, Chetosi diabetica, Acidosi diabetica, Chetoacidosi diabetica&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;ケトアシドーシスを伴う糖尿病, ケトアシドーシス（糖尿病性）, ｹﾄｱｼﾄﾞｰｼｽﾄｳﾆｮｳﾋﾞｮｳｾｲ, ﾄｳﾆｮｳﾋﾞｮｳｾｲｱｼﾄﾞｰｼｽ, ｹﾄｱｼﾄﾞｰｼｽｦﾄﾓﾅｳﾄｳﾆｮｳﾋﾞｮｳ, ﾄｳﾆｮｳﾋﾞｮｳｾｲｹﾄｱｼﾄﾞｰｼｽ, ﾄｳﾆｮｳﾋﾞｮｳｾｲｹﾄｰｼｽ, 糖尿病性アシドーシス, 糖尿病性ケトーシス, ケトーシス-糖尿病性, 糖尿病ケトアシドーシス, ケトアシドーシス-糖尿病性, アシドーシス-糖尿病性, 糖尿病性ケトアシドーシス&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Diabetesketoacidos&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;diabetická ketoacidóza, diabetická ketóza, Diabetes mellitus s ketoacidózou, Diabetická ketóza, Diabetická ketoacidóza, Diabetická acidóza, Diabetes s ketoacidózou, Ketoacidóza (diabetická)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Diabeettinen ketoasidoosi&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;DIABETICHESKII ATSIDOZ, ATSIDOZ DIABETICHESKII, DIABETICHESKII KETOATSIDOZ, DIABETICHESKII KETOZ, KETOATSIDOZ DIABETICHESKII, KETOZ DIABETICHESKII, АЦИДОЗ ДИАБЕТИЧЕСКИЙ, ДИАБЕТИЧЕСКИЙ АЦИДОЗ, ДИАБЕТИЧЕСКИЙ КЕТОАЦИДОЗ, ДИАБЕТИЧЕСКИЙ КЕТОЗ, КЕТОАЦИДОЗ ДИАБЕТИЧЕСКИЙ, КЕТОЗ ДИАБЕТИЧЕСКИЙ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Croatian&lt;/td&gt;
                &lt;td&gt;DIJABETIČNA KETOACIDOZA&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Kwasica cukrzycowa, Ketoza cukrzycowa, Kwasica ketonowa cukrzycowa&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;Diabéteszes acidózis, Diabetes mellitus ketoacidosissal, Diabetes ketoacidosissal, Diabeteses acidosis, Diabeteses ketosis, Diabeteses ketoacidosis, Ketoacidosis (diabeteses)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Diabetic Ketoacidosis  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Diabetic Ketoacidosis</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Diabetes Mellitus</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;See Also&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/DM/DbtcKtcdsMngmntInAdlts.htm" class="LinkPage"&gt;Diabetic Ketoacidosis Management in Adults&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/DM/DbtcKtcdsMngmntInChldrn.htm" class="LinkPage"&gt;Diabetic Ketoacidosis Management in Children&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Precipitating Factors&lt;ol&gt;&lt;li&gt;Uncontrolled or new onset &lt;a href="../../Endo/DM/DbtsMlts.htm" class="LinkPage"&gt;Diabetes Mellitus&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/CAD/ActCrnrySyndrm.htm" class="LinkPage"&gt;Myocardial Infarction&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Pregnancy&lt;/li&gt;&lt;li&gt;Infection&lt;ol&gt;&lt;li&gt;&lt;a href="../../ID/Fever/Sps1.htm" class="LinkPage"&gt;Septic Shock&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Uro/ID/UrnryTrctInfctn.htm" class="LinkPage"&gt;Urinary Tract Infection&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Lung/ID/Pnmn.htm" class="LinkPage"&gt;Pneumonia&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Symptoms&lt;ol&gt;&lt;li&gt;Rapid onset of symptoms&lt;/li&gt;&lt;li&gt;Weakness&lt;/li&gt;&lt;li&gt;&lt;a href="../../GI/Sx/Vmtng.htm" class="LinkPage"&gt;Nausea&lt;/a&gt; and &lt;a href="../../GI/Sx/Vmtng.htm" class="LinkPage"&gt;Vomiting&lt;/a&gt; (50-80% of cases)&lt;/li&gt;&lt;li&gt;Lethargy&lt;/li&gt;&lt;li&gt;&lt;a href="../../Surgery/GI/ActAbdmnlPn.htm" class="LinkPage"&gt;Abdominal Pain&lt;/a&gt; (30% of patients)&lt;ol&gt;&lt;li&gt;May present as a vague &lt;a href="../../Surgery/GI/ActAbdmnlPn.htm" class="LinkPage"&gt;Abdominal Pain&lt;/a&gt; with minimal tenderness on exam&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Signs&lt;ol&gt;&lt;li&gt;Mental clouding&lt;/li&gt;&lt;li&gt;Kussmaul breathing&lt;/li&gt;&lt;li&gt;Acetone on breath&lt;/li&gt;&lt;li&gt;Dehydration (often &amp;gt;10% dehydrated)&lt;ol&gt;&lt;li&gt;&lt;a href="../../Derm/Dry/DrySkn.htm" class="LinkPage"&gt;Dry Skin&lt;/a&gt; with loss of &lt;a href="../../ER/Exam/SknTrgr.htm" class="LinkPage"&gt;Skin Turgor&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Eyes sunken&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/EKG/Tchycrd.htm" class="LinkPage"&gt;Tachycardia&lt;/a&gt; and possibly &lt;a href="../../CV/Exam/Hyptnsn.htm" class="LinkPage"&gt;Hypotension&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Temperature below normal&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Labs&lt;ol&gt;&lt;li&gt;Bedside &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Uro/Lab/Urnlys.htm" class="LinkPage"&gt;Urinalysis&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Glucosuria&lt;/li&gt;&lt;li&gt;Ketonuria&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Uro/Lab/UrnKtn.htm" class="LinkPage"&gt;Urine Ketone&lt;/a&gt;s&lt;/li&gt;&lt;li&gt;Highly sensitive for Diabetic Ketoacidosis&lt;ol&gt;&lt;li&gt;High &lt;a href="../../Prevent/Epi/NgtvPrdctvVl.htm" class="LinkPage"&gt;Negative Predictive Value&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Negative &lt;a href="../../Uro/Lab/UrnKtn.htm" class="LinkPage"&gt;Urine Ketone&lt;/a&gt; excludes DKA diagnosis&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Schwab%20%20%5BAU%5D%20AND%201999%20%5BDP%5D%20AND%20%20Ann%20Emerg%20Med%20%20%5BTA%5D" class="LinkRef"&gt;Schwab (1999) Ann Emerg Med 34:342-6&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Poor &lt;a href="../../Prevent/Epi/TstSpcfcty.htm" class="LinkPage"&gt;Specificity&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Confirm with serum beta hydroxybutyrate&lt;ol&gt;&lt;li&gt;Beta hydroxybutyrate is converted to acetoacetate which is then detected on the &lt;a href="../../Uro/Lab/Urnlys.htm" class="LinkPage"&gt;Urine Dipstick&lt;/a&gt; as ketones&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Normal serum bicarbonate and &lt;a href="../../Renal/Lab/AnGp.htm" class="LinkPage"&gt;Anion Gap&lt;/a&gt; suggests resolving DKA or false positive ketonuria&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Chemistry Panel (Chem8)&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Serum Glucose&lt;/a&gt; increased (&lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Hyperglycemia&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Renal/Lab/SrmSdm.htm" class="LinkPage"&gt;Serum Sodium&lt;/a&gt; decreased (&lt;a href="../../Renal/Sodium/Hypntrm.htm" class="LinkPage"&gt;Hyponatremia&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Renal/Lab/SrmChlrd.htm" class="LinkPage"&gt;Serum Chloride&lt;/a&gt; depressed (&lt;a href="../../Renal/Chloride/Hypchlrm.htm" class="LinkPage"&gt;Hypochloremia&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;Serum Bicarbonate depressed&lt;/li&gt;&lt;li&gt;&lt;a href="../../Renal/Lab/AnGp.htm" class="LinkPage"&gt;Anion Gap&lt;/a&gt; elevated (&amp;gt;10 to 12)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Renal/Lab/SrmPhsphrs.htm" class="LinkPage"&gt;Serum Phosphorus&lt;/a&gt; decreased (&lt;a href="../../Renal/Phosphorus/Hyphsphtm.htm" class="LinkPage"&gt;Hypophosphatemia&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Renal/Lab/SrmMgnsm.htm" class="LinkPage"&gt;Serum Magnesium&lt;/a&gt; decreased (&lt;a href="../../Renal/Magnesium/Hypmgnsm.htm" class="LinkPage"&gt;Hypomagnesemia&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Renal/Lab/SrmOsmlty.htm" class="LinkPage"&gt;Serum Osmolality&lt;/a&gt; (calculate and measure if available)&lt;ol&gt;&lt;li&gt;Should be &amp;gt;320 mOsm/kg if DKA present&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Renal/Lab/ArtrlBldGs.htm" class="LinkPage"&gt;Arterial Blood Gas&lt;/a&gt; (ABG)&lt;ol&gt;&lt;li&gt;&lt;a href="../../Renal/AcidBase/MtblcAcds.htm" class="LinkPage"&gt;Metabolic Acidosis&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Beta hydroxybutyrate (or &lt;a href="../../Renal/Lab/SrmPtsm.htm" class="LinkPage"&gt;Serum K&lt;/a&gt;etones)&lt;ol&gt;&lt;li&gt;Beta hydroxybytyrate is the most important ketone in Diabetic Ketoacidosis&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Precipitating factor evaluation&lt;ol&gt;&lt;li&gt;&lt;a href="../../HemeOnc/Lab/CmpltBldCnt.htm" class="LinkPage"&gt;Complete Blood Count&lt;/a&gt; with differential&lt;/li&gt;&lt;li&gt;&lt;a href="../../ID/Lab/BldCltr.htm" class="LinkPage"&gt;Blood Culture&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Uro/Lab/UrnCltr.htm" class="LinkPage"&gt;Urine Culture&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Lung/Rad/ChstXry.htm" class="LinkPage"&gt;Chest XRay&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Exam/Elctrcrdgrm.htm" class="LinkPage"&gt;Electrocardiogram&lt;/a&gt; (EKG)&lt;ol&gt;&lt;li&gt;Indicated over age 40 or over 10 years of Diabetes&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Evaluation of Diabetes and Endocrine Status&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/HmglbnAc.htm" class="LinkPage"&gt;Hemoglobin A1C&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Anti-GAD65 &lt;a href="../../ID/Exam/Imnglbln.htm" class="LinkPage"&gt;Antibody&lt;/a&gt; (identifies Type I diabetics)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/ThyrdStmltngHrmn.htm" class="LinkPage"&gt;Thyroid Stimulating Hormone&lt;/a&gt; (TSH)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Diagnostic Criteria: &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Hyperglycemia&lt;/a&gt;, Ketosis, Acidosis&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Glucose&lt;/a&gt; exceeds 250 mg/dl&lt;/li&gt;&lt;li&gt;&lt;a href="../../Renal/AcidBase/MtblcAcds.htm" class="LinkPage"&gt;Metabolic Acidosis&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Serum pH &amp;lt; 7.30&lt;/li&gt;&lt;li&gt;Serum Bicarbonate &amp;lt; 15 meq/L&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Moderate Ketonuria or Ketonemia&lt;ol&gt;&lt;li&gt;&lt;a href="../../Renal/Lab/SrmPtsm.htm" class="LinkPage"&gt;Serum K&lt;/a&gt;etones exceed 1:2 dilution&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Renal/Lab/AnGp.htm" class="LinkPage"&gt;Anion Gap&lt;/a&gt; elevated&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Evaluation: Severity&lt;ol&gt;&lt;li&gt;Arterial pH&lt;ol&gt;&lt;li&gt;Mild: 7.25 to 7.30&lt;/li&gt;&lt;li&gt;Moderate: 7.00 to 7.24&lt;/li&gt;&lt;li&gt;Severe: &amp;lt; 7.00&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Serum bicarbonate&lt;ol&gt;&lt;li&gt;Mild: 15-18&lt;/li&gt;&lt;li&gt;Moderate: 10 to 14&lt;/li&gt;&lt;li&gt;Severe: &amp;lt; 10&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Mental status&lt;ol&gt;&lt;li&gt;Mild: Alert&lt;/li&gt;&lt;li&gt;Moderate: Drowsy&lt;/li&gt;&lt;li&gt;Severe: Stupor&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Indications for home management&lt;ol&gt;&lt;li&gt;Mild Diabetic Ketoacidosis and&lt;/li&gt;&lt;li&gt;Alert mental status and&lt;/li&gt;&lt;li&gt;Taking oral fluids&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Management&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Endo/DM/DbtcKtcdsMngmntInAdlts.htm" class="LinkPage"&gt;Diabetic Ketoacidosis Management in Adults&lt;/a&gt;&lt;/li&gt;&lt;li&gt;See &lt;a href="../../Endo/DM/DbtcKtcdsMngmntInChldrn.htm" class="LinkPage"&gt;Diabetic Ketoacidosis Management in Children&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Complications&lt;ol&gt;&lt;li&gt;Metabolic Complications&lt;ol&gt;&lt;li&gt;Severe &lt;a href="../../Renal/AcidBase/MtblcAcds.htm" class="LinkPage"&gt;Metabolic Acidosis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Renal/Potassium/Hypklm.htm" class="LinkPage"&gt;Hypokalemia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Hypoglycemia/Hypglycm.htm" class="LinkPage"&gt;Hypoglycemia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Renal/Calcium/Hypclcm.htm" class="LinkPage"&gt;Hypocalcemia&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Non-metabolic Complications&lt;ol&gt;&lt;li&gt;&lt;a href="../../ID/Fever/Sps1.htm" class="LinkPage"&gt;Septic Shock&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Hypovolemic &lt;a href="../../CV/Exam/Hyptnsn.htm" class="LinkPage"&gt;Shock&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Vascular Thrombosis&lt;/li&gt;&lt;li&gt;Pulmonary edema (aggressive rehydration)&lt;/li&gt;&lt;li&gt;Cerebral edema&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Prevention of Diabetic Ketoacidosis&lt;ol&gt;&lt;li&gt;Diabetic action plan based on &lt;a href="../../Endo/DM/DbtsMltsGlcsMngmnt.htm" class="LinkPage"&gt;Blood Glucose Monitoring&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Home monitoring of beta hydroxybutyrate or ketones&lt;/li&gt;&lt;li&gt;Plan for supplementing short acting &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Sick day &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; coverage&lt;/li&gt;&lt;li&gt;Liquid diets when sick&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Case management&lt;ol&gt;&lt;li&gt;Diabetic educator&lt;/li&gt;&lt;li&gt;Frequent phone contact&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Consider &lt;a href="../../Endo/Pharm/InslnPmp.htm" class="LinkPage"&gt;Insulin Pump&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;Orland in Stine (1994) Emergency Med, p. 204-5&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Chiasson%20%20%5BAU%5D%20AND%202003%20%5BDP%5D%20AND%20%20CMAJ%20%20%5BTA%5D" class="LinkRef"&gt;Chiasson (2003) CMAJ 168:859-66&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Kitabchi%20%20%5BAU%5D%20AND%202001%20%5BDP%5D%20AND%20%20Diabetes%20Care%20%20%5BTA%5D" class="LinkRef"&gt;Kitabchi (2001) Diabetes Care 24:131-53&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Trachtenbarg%20%20%5BAU%5D%20AND%202005%20%5BDP%5D%20AND%20%20Am%20Fam%20Physician%20%20%5BTA%5D" class="LinkRef"&gt;Trachtenbarg (2005) Am Fam Physician 71(9): 1705-22&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Trence%20%20%5BAU%5D%20AND%202001%20%5BDP%5D%20AND%20%20Endocrinol%20Metab%20Clin%20North%20Am%20%20%5BTA%5D" class="LinkRef"&gt;Trence (2001) Endocrinol Metab Clin North Am 30:817-31&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0011880</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/DM/DbtcKtcds.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Diabetic Ketoacidosis, DKA</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/DM/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees></FP_UMLS_Trees><FP_Condition_name_check></FP_Condition_name_check><FP_Condition_name><value>Growth Delay Onset Determination</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Growth Disorders</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Causes: &lt;a href="../../OB/Fetus/IntrtrnGrwthRtrdtn.htm" class="LinkPage"&gt;Intrauterine Growth Retardation&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Genetic or chromosomal abnormality&lt;/li&gt;&lt;li&gt;Transplacental infectious disease (&lt;a href="../../OB/ID/TrchInfctn.htm" class="LinkPage"&gt;TORCH Virus&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;Malnutrition&lt;/li&gt;&lt;li&gt;&lt;a href="../../Renal/Lab/Hypx.htm" class="LinkPage"&gt;Hypoxia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Toxins&lt;ol&gt;&lt;li&gt;&lt;a href="../../Psych/Pharm/Alchl.htm" class="LinkPage"&gt;Alcohol&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Nicotine&lt;/li&gt;&lt;li&gt;&lt;a href="../../Psych/CD/ChmclDpndncy.htm" class="LinkPage"&gt;Substance Abuse&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Medications&lt;ol&gt;&lt;li&gt;&lt;a href="../../Neuro/Pharm/Phnytn.htm" class="LinkPage"&gt;Phenytoin&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Causes: Birth&lt;ol&gt;&lt;li&gt;&lt;a href="../../OB/Ld/NnrsrngFtlSts.htm" class="LinkPage"&gt;Birth Asphyxia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../NICU/Birth/NwbrnInjry.htm" class="LinkPage"&gt;Birth Trauma&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Hypoglycemia/Hypglycm.htm" class="LinkPage"&gt;Hypoglycemia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Prolonged &lt;a href="../../NICU/GI/JndcInNwbrns.htm" class="LinkPage"&gt;Neonatal Jaundice&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Panhypopituitarism&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Causes: Childhood&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Endo/Peds/FlrTThrvCs.htm" class="LinkPage"&gt;Failure to Thrive Causes&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Growth/GrwthDlyOnstDtrmntn.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Growth Delay Onset Determination</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Growth/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Diabetes Mellitus, Non-Insulin-Dependent  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0011860"&gt;&lt;i&gt;C0011860&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A type of diabetes mellitus that is characterized by insulin resistance or desensitization and increased blood glucose levels. This is a chronic disease that can develop gradually over the life of a patient and can be linked to both environmental factors and heredity.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CSP)&lt;/td&gt;
                &lt;td&gt;subclass of diabetes mellitus that is not insulin responsive or dependent; characterized initially by insulin resistance and hyperinsulinemia and eventually by glucose intolerance, hyperglycemia, and overt diabetes; type II diabetes mellitus is no longer considered a disease exclusively found in adults; patients seldom develop ketosis but often exhibit obesity.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Disease or Syndrome (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0011860&amp;amp;tui=T047"&gt;&lt;i&gt;T047&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D003924&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD10&lt;/td&gt;
                &lt;td&gt;E11&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;190384004, 154672006, 267468009, 44054006, 190323008&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Noninsulin dependent diabetes mellitus, Adult-Onset Diabetes Mellitus, Diabetes Mellitus, Adult Onset, Diabetes Mellitus, Adult-Onset, Diabetes Mellitus, Ketosis Resistant, Diabetes Mellitus, Ketosis-Resistant, Diabetes Mellitus, Non Insulin Dependent, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Noninsulin Dependent, Diabetes Mellitus, Stable, Ketosis-Resistant Diabetes Mellitus, NIDDM, Non-Insulin-Dependent Diabetes Mellitus, Stable Diabetes Mellitus, DIABETES MELLITUS, NON-INSULIN DEPENDENT, ADULT ONSET DIABETES MELLITUS, DIABETES MELLITUS, TYPE 2, DIABETES, ADULT ONSET, DIABETES, KETOSIS RESISTANT, DIABETES, MATURITY ONSET, Diabetes Mellitus, Maturity Onset, Diabetes Mellitus, Maturity-Onset, Diabetes mellitus, type II, MOD, MODY, Maturity Onset Diabetes Mellitus, Maturity-Onset Diabetes Mellitus, noninsulin dependent diabetes mellitus, DIABETES MELLITUS (ADULT ONSET), NCDMM, Maturity onset diabetes mellit, NIDDM-Non-ins dep diabetes mel, Diabetes Mellitus, Slow Onset, Diabetes Mellitus, Slow-Onset, Slow-Onset Diabetes Mellitus, Diabetes mellitus, adult onset type, Noninsulin-dependent diabetes mellitus, NONINSULIN-DEPENDENT DIABETES MELLITUS, Diabetes mellitus, noninsulin-dependent, DIABETES MELLITUS, NONINSULIN-DEPENDENT, MATURITY-ONSET DIABETES, DIABETES MELLITUS, TYPE II, DIABETES MELLITUS NON INSULIN-DEP, DIABETES MELLITUS TYPE 02, adult onset diabetes mellitus, ketosis resistant diabetes, Diabetes mellitus non insulin-dep, Diabetes mellitus maturity onset, Diabetes mellitus non-insulin-dependent, Maturity onset diabetes, type II diabetes mellitus, AODM, type II diabetes mellitus (diagnosis), type 2 diabetes, non-insulin dependent diabetes mellitus, aodm, niddm, diabetes type ii, diabetes, type ii, Type II diabetes mellitus (disorder), Diabetes mellitus: [adult onset] or [noninsulin dependent] (disorder), Diabetes mellitus - adult ons, Type 2 Diabetes, Type II Diabetes Mellitus, Non-Insulin Dependent Diabetes Mellitus, Adult-Onset Diabetes, Type 2 Diabetes Mellitus Non-Insulin Dependent, Type II Diabetes, Non-ins-dep diabetes mellitus, DIABETES MELLITUS NON INSULIN DEPENDENT, DIABETES MELLITUS NOS LATE ONSET, Type II diabetes, T2D, T2DM - Type 2 Diabetes mellitus, Diabetes, Type 2, Diabetes Mellitus, Type 2 [Disease/Finding], diabetes mellitus type ii, Diabetes;Type 2, Diabetes;adult onset, Diabetes;non insulin depend, type II diabetes, type ii diabetes mellitus, diabetes type 2, diabete type 2, late onset diabetes, maturity onset diabetes, diabetes mellitus type 2, non-insulin dependent diabetes, type 2 diabetes mellitus, Diabetes mellitus type II, Non-insulin dependent diabetes mellitus, Maturity onset diabetes mellitus, NIDDM - Non-insulin dependent diabetes mellitus, Type 2 diabetes mellitus, Non-insulin-dependent diabetes mellitus, Diabetes mellitus - adult onset, Type II diabetes mellitus, Diabetes mellitus type 2 (disorder), Diabetes mellitus type 2, Diabetes non-insulin dependent, diabetes, NIDDM; diabetes, diabetes; NIDDM, diabetes; adult-onset, diabetes; maturity-onset, diabetes; non-insulin-dependent, diabetes; nonketotic, diabetes; type II, maturity-onset; diabetes, non-insulin-dependent; diabetes, nonketotic; diabetes, adult-onset; diabetes, type II; diabetes, Diabetes mellitus -adult onset, Diabetes mellitus: [adult onset] or [noninsulin dependent], Noninsulin dependent diab.mell, Diabetes Mellitus, Type II, Diabetes Mellitus, Type 2, Type 2 Diabetes Mellitus, Non-Insulin Dependent Diabetes, non insulin dependent diabetes, adult onset diabetes&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Typ 2-diabetes&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;diabetes mellitus non insulin dependentní, MODY, diabetes mellitus 2. typu, diabetes mellitus bez ketolátek, diabetes mellitus vzniklý v dospělosti, diabetes mellitus stabilizovaný, diabetes mellitus - slow-onset, Inzulin nondependentní diabetes mellitus, Diabetes mellitus s manifestací v dospělosti, Diabetes mellitus typu 2, Diabetes s manifestací v dospělosti, Diabetes mellitus II.typu, monogenní diabetes mellitus&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;Noninsulin dependent diab.mell, Maturity onset diabetes mellitus, Maturity onset diabetes, Non-insulin dependent diabetes mellitus, Type II diabetes mellitus, Diabetes mellitus -adult onset, Diabetes mellitus: [adult onset] or [noninsulin dependent], Diabetes mellitus tipo II, Diabetes mellitus no dependiente de insulina, Diabetes mellitus no insulinodependiente, Diabetes mellitus de comienzo en la edad adulta, Diabetes mellitus tipo 2, Diabetes de aparición en la madurez, DIABETES MELLITUS NO-INSULINO DEP, diabetes mellitus no dependiente de insulina (trastorno), diabetes mellitus no dependiente de insulina, diabetes mellitus no insulino - dependiente, diabetes mellitus tipo II, DMIM, DMNID, Diabetes Mellitus de Inicio Adulto, Diabetes Mellitus de Inicio en la Madurez, Diabetes Mellitus de Inicio Lento, Diabetes Mellitus Estable, Diabetes Mellitus no Insulino-Dependiente, Diabetes Mellitus Resistente a la Cetosis, Diabetes Mellitus Tipo 2&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Diabète sucré non dépendant d'insuline, Diabète sucré de la maturité, Diabète sucré non insulino-dépendant, Diabète sucré non insulino dép, Diabète sucré de type II, DIABETE NON INSULINO-DEPENDANT, DID2, Diabète avec insulinorésistance, Diabète avec intolérance au glucose, Diabète de la maturité, Diabète de type II, Diabète gras, Diabète non insulinodépendant, DNID, Diabète de type 2, DSNID, Diabète sucré de type 2&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;type II diabetes mellitus, type 2 diabetes mellitus, ouderdomsdiabetes, diabetes mellitus, ouderdoms, NIADM, diabetes mellitus insuline-onafhankelijk, niet-insuline-afhankelijke diabetes mellitus, Niet insuline-afhankelijke diabetes, NIDDM; diabetes, adult-onset; diabetes, diabetes; NIDDM, diabetes; adult-onset, diabetes; maturity-onset, diabetes; niet-insuline-afhankelijk, diabetes; niet-ketotisch, diabetes; type II, maturity-onset; diabetes, niet-insuline-afhankelijk; diabetes, niet-ketotisch; diabetes, type II; diabetes, Niet-insuline-afhankelijke diabetes mellitus, 'Maturity-onset' diabetes mellitus, Diabetes mellitus type 2, Diabetes mellitus, 'adult-onset', Diabetes mellitus, 'maturity-onset', Diabetes mellitus, 'slow-onset', Diabetes mellitus, ketose-resistente, Diabetes mellitus, niet-insulineafhankelijke, Diabetes mellitus, stabiele, MODY ("maturity-onset diabetes of the young"), Mellitus, niet-insulineafhankelijke diabetes, NIDDM ("Non-Insulin-Dependent Diabetes Mellitus"), Niet-insulineafhankelijke diabetes mellitus&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Diabetes mellitus não insulinodependente, Dibetes mellitus tipo II, Diabetes mellitus com início na idade adulta, Diabetes do adulto, DIABETES MELLITUS NAO INSULINODEP, DMNID, MODY, Diabetes Mellitus de Início Gradativo, Diabetes Mellitus de Início na Maturidade, Diabetes Mellitus de Início no Adulto, Diabetes Mellitus Estável, Diabetes Mellitus não Insulino-Dependente, Diabetes Mellitus Resistente a Cetose, Diabetes Mellitus Tipo 2, Diabetes Mellitus não Dependente de Insulina&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Diabetes mellitus Typ 2, Diabetes mellitus mit Maturity-onset, Maturity-onset-Diabetes, nicht-insulinpflichtiger Diabetes mellitus, Typ II Diabetes mellitus, Diabetes mellitus nicht insulinpflichtig, DIABETES MELLITUS, NICHT INSULINA, Nicht primaer insulinabhaengiger Diabetes mellitus [Typ-II-Diabetes], Altersdiabetes, Diabetes mellitus im Alter, Diabetes mellitus, Erwachsenen-, Diabetes mellitus, Typ II, Diabetes mellitus, ketoazidoseresistenter, Diabetes mellitus, langsamer Beginn, Diabetes mellitus, nichtinsulinpflichtiger, Diabetes mellitus, stabiler, MODY, NIDDM&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Diabete mellito di tipo 2, Diabete dell'adulto, Diabete mellito ad esordio in età matura, Diabete mellito non insulinodipendente, Diabete mellito a insorgenza in età matura, NIDDM, Diabete mellito non insulino-dipendente, Diabete mellito resistente alla chetosi, Diabete mellito stabile, Diabete mellito a insorgenza in età adulta, Diabete mellito a insorgenza lenta, Diabete mellito ad insorgenza lenta, Diabete mellito di tipo II&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;2ｶﾞﾀﾄｳﾆｮｳﾋﾞｮｳ, ２型糖尿病, ｲﾝｽﾘﾝﾋｲｿﾞﾝｾｲﾄｳﾆｮｳﾋﾞｮｳ, ｾｲｼﾞﾝﾊｯｼｮｳｶﾞﾀﾄｳﾆｮｳﾋﾞｮｳ, 糖尿病-インスリン非依存性, 安定型糖尿病, 2型糖尿病, インシュリン非依存型糖尿病, インスリン非依存型糖尿病, インスリン非依存性糖尿病, ケトーシス抵抗性糖尿病, 成人発症型糖尿病, 糖尿病-2型, 糖尿病-成人発症, 非インシュリン依存型糖尿病, II型糖尿病, インスリン非依存糖尿病, 成人型糖尿病, 成人発症糖尿病, 糖尿病-インシュリン非依存型, 糖尿病-インスリン非依存型, 糖尿病-ケトーシス抵抗性, 糖尿病-安定型, 糖尿病-成人発症型, 糖尿病2型&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Tyypin 2 diabetes&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;DIABET SAKHARNYI S MEDLENNYM NACHALOM, DIABET SAKHARNYI ZRELOGO VOZRASTA, DIABET SAKHARNYI, TIP II, DIABET SAKHARNYI, TIP 2, DIABET SAKHARNYI STABIL'NYI, DIABET SAKHARNYI INSULINNEZAVISIMYI, DIABET SAKHARNYI KETOZOREZISTENTNYI, SAKHARNYI DIABET INSULINNEZAVISIMYI, ДИАБЕТ САХАРНЫЙ ЗРЕЛОГО ВОЗРАСТА, ДИАБЕТ САХАРНЫЙ ИНСУЛИННЕЗАВИСИМЫЙ, ДИАБЕТ САХАРНЫЙ КЕТОЗОРЕЗИСТЕНТНЫЙ, ДИАБЕТ САХАРНЫЙ С МЕДЛЕННЫМ НАЧАЛОМ, ДИАБЕТ САХАРНЫЙ СТАБИЛЬНЫЙ, ДИАБЕТ САХАРНЫЙ, ТИП II, САХАРНЫЙ ДИАБЕТ ИНСУЛИННЕЗАВИСИМЫЙ, ДИАБЕТ САХАРНЫЙ, ТИП 2&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Korean&lt;/td&gt;
                &lt;td&gt;인슐린-비의존 당뇨병&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Croatian&lt;/td&gt;
                &lt;td&gt;DIJABETES MELITUS, TIP 2&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Cukrzyca nie zależna od insuliny, Cukrzyca typu 2, Cukrzyca dorosłych&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;NIDDM, Időskori diabetes, II típusú cukorbetegség, 2. típusú cukorbetegség, Időskori diabetes mellitus, Nem-insulinfüggő diabetes mellitus, Nem-insulindependens cukorbetegség&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Diabetes Mellitus, Non-Insulin-Dependent  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Type 2 Diabetes Mellitus</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Diabetes Mellitus</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;See Also&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/DM/DbtsMlts.htm" class="LinkPage"&gt;Diabetes Mellitus&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Epidemiology&lt;ol&gt;&lt;li&gt;Represents 90% of all &lt;a href="../../Endo/DM/DbtsMlts.htm" class="LinkPage"&gt;Diabetes Mellitus&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Typically occurs over age 40 years in obese patients&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Pathophysiology&lt;ol&gt;&lt;li&gt;Triad of factors contributing to &lt;a href="../../Endo/DM/DbtsMlts.htm" class="LinkPage"&gt;Diabetes Mellitus&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../Sports/Disability/Dsblty.htm" class="LinkPage"&gt;Impairment&lt;/a&gt; of pancreatic beta-cell function&lt;ol&gt;&lt;li&gt;Decreased beta cell response to &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Abnormal &lt;a href="../../Endo/Pharm/Glcgn.htm" class="LinkPage"&gt;Glucagon&lt;/a&gt; secretion&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Rheum/Diffuse/Amylds.htm" class="LinkPage"&gt;Amyloidosis&lt;/a&gt; of islet cells (40% of patients)&lt;/li&gt;&lt;li&gt;Pancreatic fibrosis (66% of patients)&lt;ol&gt;&lt;li&gt;Associated fatty infiltration, vessel sclerosis&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Decreased &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; sensitivity (60-80% of patients)&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Endo/DM/InslnRstncSyndrm.htm" class="LinkPage"&gt;Insulin Resistance&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Obesity/Obsty.htm" class="LinkPage"&gt;Obesity&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Incretin Deficiency&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Course&lt;ol&gt;&lt;li&gt;12 years before diagnosis: &lt;a href="../../Endo/DM/InslnRstncSyndrm.htm" class="LinkPage"&gt;Impaired Glucose Tolerance&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/DM/InslnRstncSyndrm.htm" class="LinkPage"&gt;Insulin Resistance&lt;/a&gt; starts&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; levels start to rise&lt;/li&gt;&lt;li&gt;Fasting and post-meal &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; normal&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;8 years before diagnosis: Postprandial &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Hyperglycemia&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Beta cell function at 75%&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; levels increase to 150% of normal&lt;/li&gt;&lt;li&gt;Fasting and post-meal &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; normal&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;2 years before diagnosis: Type 2 diabetes phase I&lt;ol&gt;&lt;li&gt;Beta cell function at 50%&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; levels increase to 200% of normal (peak)&lt;/li&gt;&lt;li&gt;Post-prandial &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; 150-200 mg/dl&lt;/li&gt;&lt;li&gt;Normal fasting &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;2 years after diagnosis: Type 2 diabetes phase II&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; levels fall to 150% of normal&lt;/li&gt;&lt;li&gt;Post-prandial &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; 200 mg/dl&lt;/li&gt;&lt;li&gt;Fasting &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; &amp;gt;140-150 mg/dl&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;8 years after diagnosis: Type 2 diabetes phase III&lt;ol&gt;&lt;li&gt;Beta cell function at 25%&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; levels fall to 100% of normal&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;14 years after diagnosis&lt;ol&gt;&lt;li&gt;Beta cell function approaches 0%&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; levels fall below 50% and approach 0&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Etiology&lt;ol&gt;&lt;li&gt;Autosomal Recessive&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Risk Factors:&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Obesity/Obsty.htm" class="LinkPage"&gt;Obesity&lt;/a&gt; (especially &lt;a href="../../Endo/Exam/WstTHpRt.htm" class="LinkPage"&gt;Apple Obesity&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;Previous &lt;a href="../../Endo/OB/GstnlDbts.htm" class="LinkPage"&gt;Gestational Diabetes&lt;/a&gt; (GDM)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Prevent/HME/FmlyHstry.htm" class="LinkPage"&gt;Family History&lt;/a&gt; of Type II Diabetes Mellitus&lt;/li&gt;&lt;li&gt;Age over 40 years (risk increases with age)&lt;ol&gt;&lt;li&gt;Type II Diabetes Mellitus does occur in children&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Sedentary lifestyle (decreased &lt;a href="../../Sports/Exercise/Exrcs.htm" class="LinkPage"&gt;Physical Activity&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;Previously &lt;a href="../../Endo/DM/InslnRstncSyndrm.htm" class="LinkPage"&gt;Impaired Glucose Tolerance&lt;/a&gt; (IGT)&lt;/li&gt;&lt;li&gt;Western diet&lt;ol&gt;&lt;li&gt;Red meats and processed meats&lt;/li&gt;&lt;li&gt;High fat foods (french fries, high fat dairy, eggs)&lt;/li&gt;&lt;li&gt;High sugar foods, desserts and drinks&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Van%20Dam%20%20%5BAU%5D%20AND%202002%20%5BDP%5D%20AND%20%20Ann%20Intern%20Med%20%20%5BTA%5D" class="LinkRef"&gt;Van Dam (2002) Ann Intern Med 136:201-9&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Ethnicity&lt;ol&gt;&lt;li&gt;Native American&lt;/li&gt;&lt;li&gt;African American or Black&lt;/li&gt;&lt;li&gt;Asian Type II Diabetics may be thin&lt;/li&gt;&lt;li&gt;Hispanic&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Psych/CD/Cgrt.htm" class="LinkPage"&gt;Cigarette&lt;/a&gt; smoking decreases &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; sensitivity&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Targher%20%20%5BAU%5D%20AND%201997%20%5BDP%5D%20AND%20%20Clin%20Endocrinol%20Metab%20%20%5BTA%5D" class="LinkRef"&gt;Targher (1997) Clin Endocrinol Metab 82:3619-23&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Protective Factors (based on initial study findings)&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Endo/DM/InslnRstncSyndrm.htm" class="LinkPage"&gt;Insulin Resistance&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Symptoms and Signs&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Endo/DM/DbtsMlts.htm" class="LinkPage"&gt;Diabetes Mellitus&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Diagnostic Criteria&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Endo/DM/DbtsMlts.htm" class="LinkPage"&gt;Diabetes Mellitus&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Associated Conditions&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Endo/DM/InslnRstncSyndrm.htm" class="LinkPage"&gt;Insulin Resistance&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Derm/AcnthsNgrcns.htm" class="LinkPage"&gt;Acanthosis Nigricans&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Labs&lt;ol&gt;&lt;li&gt;&lt;a href="../../Uro/Lab/UrnKtn.htm" class="LinkPage"&gt;Urine Ketone&lt;/a&gt;s: Usually negative&lt;ol&gt;&lt;li&gt;Exception: Children with Type II Diabetes&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;See &lt;a href="../../Endo/DM/DbtsMlts.htm" class="LinkPage"&gt;Diabetes Mellitus&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Precautions: Accord Trial&lt;ol&gt;&lt;li&gt;Suggests higher risk of aggressively lowering &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Glucose&lt;/a&gt; in Type II Diabetes&lt;/li&gt;&lt;li&gt;Risk increased with &lt;a href="../../Endo/Lab/HmglbnAc.htm" class="LinkPage"&gt;Hemoglobin A1C&lt;/a&gt; of 6.4% compared with 7.5%&lt;/li&gt;&lt;li&gt;Mortality was higher in the 6.4% A1C group by 3 per thousand patients&lt;/li&gt;&lt;li&gt;Endocrinologists still recommend goal of &amp;lt;7.0% and await larger trial (Advance)&lt;/li&gt;&lt;li&gt;References: NHLBI Questions and Answers regarding Accord Study&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.nhlbi.nih.gov/health/prof/heart/other/accord/q_a.htm" class="LinkWebExt"&gt;http://www.nhlbi.nih.gov/health/prof/heart/other/accord/q_a.htm&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Management: Summary&lt;ol&gt;&lt;li&gt;Medical nutrition therapy&lt;ol&gt;&lt;li&gt;Indications to start at presentation&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/HmglbnAc.htm" class="LinkPage"&gt;Hemoglobin A1C&lt;/a&gt; &amp;lt;8%, Fasting BG &amp;lt;200, Random BG &amp;lt;250&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Efficacy: A1C decrease 1%&lt;/li&gt;&lt;li&gt;Protocol&lt;ol&gt;&lt;li&gt;Obese patients (Fasting &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; high)&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/DM/InslnRstncSyndrm.htm" class="LinkPage"&gt;Insulin Resistance&lt;/a&gt; primary problem in early phase&lt;/li&gt;&lt;li&gt;Focus on weight loss and activity&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Lean patients (Postprandial &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; high)&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; deficiency is primary problem&lt;/li&gt;&lt;li&gt;Focus on &lt;a href="../../Endo/Prevent/CrbhydrtCnt.htm" class="LinkPage"&gt;Carbohydrate Counting&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Oral agents&lt;ol&gt;&lt;li&gt;Indications to start at presentation&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/HmglbnAc.htm" class="LinkPage"&gt;Hemoglobin A1C&lt;/a&gt; 8-8.9%&lt;/li&gt;&lt;li&gt;Fasting BG 200-250 mg/dl&lt;/li&gt;&lt;li&gt;Random or casual BG 250-300 mg/dl&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Efficacy: A1C decrease 1-2% (combined with above)&lt;/li&gt;&lt;li&gt;Protocol&lt;ol&gt;&lt;li&gt;Obese patients (Fasting &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; high)&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Glcphg.htm" class="LinkPage"&gt;Metformin&lt;/a&gt; (&lt;a href="../../Endo/Pharm/Glcphg.htm" class="LinkPage"&gt;Glucophage&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Thzldndn.htm" class="LinkPage"&gt;Glitazone&lt;/a&gt; (e.g. &lt;a href="../../Endo/Pharm/Thzldndn.htm" class="LinkPage"&gt;Pioglitazone&lt;/a&gt;, &lt;a href="../../Endo/Pharm/Thzldndn.htm" class="LinkPage"&gt;Rosiglitazone&lt;/a&gt;)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Lean patients (Postprandial &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; high)&lt;ol&gt;&lt;li&gt;Oral secretagogue (e.g. &lt;a href="../../Endo/Pharm/Slfnylr.htm" class="LinkPage"&gt;Sulfonylurea&lt;/a&gt;)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Combination therapy&lt;ol&gt;&lt;li&gt;Indications to start at presentation&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/HmglbnAc.htm" class="LinkPage"&gt;Hemoglobin A1C&lt;/a&gt; 9-11%&lt;/li&gt;&lt;li&gt;Fasting BG 251-300 mg/dl&lt;/li&gt;&lt;li&gt;Random or casual BG 301-350 mg/dl&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Efficacy: A1C decrease 2-4% (combined with above)&lt;/li&gt;&lt;li&gt;Protocol: Options&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Glcphg.htm" class="LinkPage"&gt;Glucophage&lt;/a&gt; with &lt;a href="../../Endo/Pharm/Thzldndn.htm" class="LinkPage"&gt;Glitazone&lt;/a&gt; (esp. obese patients)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Slfnylr.htm" class="LinkPage"&gt;Insulin Secretagogue&lt;/a&gt; with &lt;a href="../../Endo/Pharm/Thzldndn.htm" class="LinkPage"&gt;Glitazone&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Slfnylr.htm" class="LinkPage"&gt;Insulin Secretagogue&lt;/a&gt; with &lt;a href="../../Endo/Pharm/Glcphg.htm" class="LinkPage"&gt;Glucophage&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Incretin with Sulfnylurea (use caution)&lt;/li&gt;&lt;li&gt;Incretin with &lt;a href="../../Endo/Pharm/Glcphg.htm" class="LinkPage"&gt;Glucophage&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; Therapy&lt;ol&gt;&lt;li&gt;Indications to start at presentation&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/HmglbnAc.htm" class="LinkPage"&gt;Hemoglobin A1C&lt;/a&gt; &amp;gt;11%&lt;/li&gt;&lt;li&gt;Fasting BG &amp;gt;300 mg/dl&lt;/li&gt;&lt;li&gt;Random or casual BG &amp;gt;350 mg/dl&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Protocol: Options&lt;ol&gt;&lt;li&gt;Basal &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Basal with bolus &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Mixed &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Management: General&lt;ol&gt;&lt;li&gt;Intensive &lt;a href="../../Endo/DM/DbtcEdctn.htm" class="LinkPage"&gt;Diabetic Education&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Goal &lt;a href="../../Endo/Lab/HmglbnAc.htm" class="LinkPage"&gt;Hemoglobin A1C&lt;/a&gt; &amp;lt;7.0 to 8.0&lt;ol&gt;&lt;li&gt;Goal relaxed to 8% in 2009 based on ACCORD and ADVANCE results&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Fasting plasma &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt;: 70 to 140 mg/dl (ideal &amp;lt;105)&lt;ol&gt;&lt;li&gt;New guidelines may suggest 70 to 120 mg/dl&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;2 hour postprandial &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt;: &amp;lt;160 mg/dl (ideal &amp;lt;135)&lt;ol&gt;&lt;li&gt;Ideally, only 20-40 mg/dl rise over pre-meal&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Bedtime &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt;: 100-140 mg/dl&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Weight loss if &lt;a href="../../Endo/Obesity/Obsty.htm" class="LinkPage"&gt;Overweight&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Recommend 10-20 pound weight loss&lt;/li&gt;&lt;li&gt;Lower caloric intake by 250-500 calories per day&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Cardiovascular Disease Prevention&lt;ol&gt;&lt;li&gt;Lower &lt;a href="../../CV/Lab/LdlChlstrl.htm" class="LinkPage"&gt;LDL Cholesterol&lt;/a&gt; &amp;lt;80-100 (&lt;a href="../../CV/Pharm/HmgCRdctsInhbtr.htm" class="LinkPage"&gt;Statin&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;Lower &lt;a href="../../CV/Exam/BldPrsr.htm" class="LinkPage"&gt;Blood Pressure&lt;/a&gt; &amp;lt;130/80 (&lt;a href="../../CV/Pharm/AcInhbtr.htm" class="LinkPage"&gt;ACE Inhibitor&lt;/a&gt; or ARB as first line medication)&lt;ol&gt;&lt;li&gt;Keep systolic &lt;a href="../../CV/Exam/BldPrsr.htm" class="LinkPage"&gt;Blood Pressure&lt;/a&gt; between 120 and 130 mmHg&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Pharm/Analgesic/Asprn.htm" class="LinkPage"&gt;Aspirin&lt;/a&gt; 81-160 mg PO qd&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Pharm/AcInhbtr.htm" class="LinkPage"&gt;ACE Inhibitor&lt;/a&gt; (Indicated in &lt;a href="../../Uro/Urine/PrtnrInAdlts.htm" class="LinkPage"&gt;Proteinuria&lt;/a&gt;)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Management: Medications in children with Type II Diabetes&lt;ol&gt;&lt;li&gt;First-line agents&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Glcphg.htm" class="LinkPage"&gt;Metformin&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Start with basal &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Consider pre-mixed &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; (e.g. 70/30) for postprandial &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Hyperglycemia&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Second-line agents&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Slfnylr.htm" class="LinkPage"&gt;Sulfonylurea&lt;/a&gt;s (risk of &lt;a href="../../Endo/Hypoglycemia/Hypglycm.htm" class="LinkPage"&gt;Hypoglycemia&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/AlphGlcsdsInhbtr.htm" class="LinkPage"&gt;Acarbose&lt;/a&gt; or &lt;a href="../../CV/Pharm/BlBndngRsn.htm" class="LinkPage"&gt;Colesevelam&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Agents with unknown safety in children&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Thzldndn.htm" class="LinkPage"&gt;Actos&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Stglptn.htm" class="LinkPage"&gt;Januvia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/IncrtnMmtc.htm" class="LinkPage"&gt;Byetta&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;References&lt;ol&gt;&lt;li&gt;(2012) Presc Lett 19(7): 40&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Management: Medications&lt;ol&gt;&lt;li&gt;First-line &lt;a href="../../Endo/Pharm/OrlHypglycmc.htm" class="LinkPage"&gt;Oral Hypoglycemic&lt;/a&gt;s&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Endo/Pharm/OrlHypglycmc.htm" class="LinkPage"&gt;Oral Hypoglycemic&lt;/a&gt; agents&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Glcphg.htm" class="LinkPage"&gt;Glucophage&lt;/a&gt; (&lt;a href="../../Endo/Pharm/Glcphg.htm" class="LinkPage"&gt;Metformin&lt;/a&gt;) or&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Thzldndn.htm" class="LinkPage"&gt;Thiazolidinedione&lt;/a&gt; (if &lt;a href="../../Endo/Pharm/Glcphg.htm" class="LinkPage"&gt;Glucophage&lt;/a&gt; contraindicated)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Indications&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; toxicity&lt;ol&gt;&lt;li&gt;Fasting &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Glucose&lt;/a&gt; &amp;gt;250 mg/dl and&lt;/li&gt;&lt;li&gt;Ketosis or weight loss&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/HmglbnAc.htm" class="LinkPage"&gt;Hemoglobin A1C&lt;/a&gt; &amp;gt; 10% or random &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Glucose&lt;/a&gt; consistently &amp;gt;300 mg/dl&lt;/li&gt;&lt;li&gt;Inadequate &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Sugar&lt;/a&gt; control on oral agents and &lt;a href="../../Endo/Lab/HmglbnAc.htm" class="LinkPage"&gt;Hemoglobin A1C&lt;/a&gt; &amp;gt;9%&lt;/li&gt;&lt;li&gt;Late stage Type II Diabetes (&amp;gt;5-10 years)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Surgery/PrprtvDbtsMngmnt.htm" class="LinkPage"&gt;Perioperative Diabetes Management&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Renal/Failure/ChrncRnlFlr.htm" class="LinkPage"&gt;Chronic Renal Failure&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Pregnancy&lt;/li&gt;&lt;li&gt;Acute illness&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Protocol&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Endo/Pharm/InslnDsng.htm" class="LinkPage"&gt;Insulin Dosing&lt;/a&gt;&lt;/li&gt;&lt;li&gt;See &lt;a href="../../Endo/Pharm/InslnDsngInTypDbts1.htm" class="LinkPage"&gt;Insulin Dosing in Type II Diabetes&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Option 1: &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; augmentation&lt;ol&gt;&lt;li&gt;Start Dose: 0.15 to 0.20 units/kg daily (10-14 units/day)&lt;/li&gt;&lt;li&gt;Titrate Dose: Increase by 2 units every 3 days&lt;/li&gt;&lt;li&gt;Preparations&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/AnlgBslInsln.htm" class="LinkPage"&gt;Insulin Glargine&lt;/a&gt; (&lt;a href="../../Endo/Pharm/AnlgBslInsln.htm" class="LinkPage"&gt;Lantus&lt;/a&gt;) daily or&lt;/li&gt;&lt;li&gt;NPH (&lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Novolin&lt;/a&gt; N, &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Humulin&lt;/a&gt; N) at bedtime or twice daily&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Option 2: &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; replacement&lt;ol&gt;&lt;li&gt;Titrate dose up to 0.5 units/kg daily&lt;/li&gt;&lt;li&gt;Long-acting basal &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; (NPH or &lt;a href="../../Endo/Pharm/AnlgBslInsln.htm" class="LinkPage"&gt;Lantus&lt;/a&gt;) and&lt;/li&gt;&lt;li&gt;Short-acting bolus &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; (&lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Lispro&lt;/a&gt;, &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Aspart&lt;/a&gt;, Reg)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Efficacy&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; therapy does not reduce quality of life&lt;/li&gt;&lt;li&gt;No increase in hypoglycemic episodes&lt;/li&gt;&lt;li&gt;Significant improvement in glycemic control&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=De%20Grauw%20%20%5BAU%5D%20AND%202001%20%5BDP%5D%20AND%20%20Br%20J%20Gen%20Pract%20%20%5BTA%5D" class="LinkRef"&gt;De Grauw (2001) Br J Gen Pract 51:527-32&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Management: Initial&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Endo/DM/DbtsMltsGlcsMngmnt.htm" class="LinkPage"&gt;Diabetes Mellitus Glucose Management&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Sample Initial Protocol&lt;ol&gt;&lt;li&gt;Fasting &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Sugar&lt;/a&gt; &amp;lt;200 or random &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; &amp;lt;250&lt;ol&gt;&lt;li&gt;Consider trial of diet and &lt;a href="../../Sports/Exercise/Exrcs.htm" class="LinkPage"&gt;Exercise&lt;/a&gt; for 1-2 months&lt;/li&gt;&lt;li&gt;Strongly consider concurrent &lt;a href="../../Endo/Pharm/OrlHypglycmc.htm" class="LinkPage"&gt;Oral Hypoglycemic&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Fasting &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Sugar&lt;/a&gt; &amp;lt;300 or random &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; &amp;lt;350&lt;ol&gt;&lt;li&gt;Start &lt;a href="../../Endo/Pharm/OrlHypglycmc.htm" class="LinkPage"&gt;Oral Hypoglycemic&lt;/a&gt; agent (see above)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Fasting &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Glucose&lt;/a&gt; &amp;gt;250 mg/dl and &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; toxicity&lt;ol&gt;&lt;li&gt;Start &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; replacement protocol (see above)&lt;/li&gt;&lt;li&gt;Concurrently start &lt;a href="../../Endo/Pharm/OrlHypglycmc.htm" class="LinkPage"&gt;Oral Hypoglycemic&lt;/a&gt; (&lt;a href="../../Endo/Pharm/Glcphg.htm" class="LinkPage"&gt;Metformin&lt;/a&gt;)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Fasting &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Sugar&lt;/a&gt; &amp;gt;300 or random &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; &amp;gt;350&lt;ol&gt;&lt;li&gt;Start &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; replacement protocol (see above)&lt;/li&gt;&lt;li&gt;Concurrently start &lt;a href="../../Endo/Pharm/OrlHypglycmc.htm" class="LinkPage"&gt;Oral Hypoglycemic&lt;/a&gt; (&lt;a href="../../Endo/Pharm/Glcphg.htm" class="LinkPage"&gt;Metformin&lt;/a&gt;)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Management: Follow-up Adjustment Phase&lt;ol&gt;&lt;li&gt;Weekly phone call to review &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Glucose&lt;/a&gt; log&lt;/li&gt;&lt;li&gt;Monthly clinic visits&lt;/li&gt;&lt;li&gt;Dietician or nutritionist every 2-4 weeks&lt;/li&gt;&lt;li&gt;Goal &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Glucose&lt;/a&gt; not met (&lt;a href="../../Endo/Lab/HmglbnAc.htm" class="LinkPage"&gt;Hemoglobin A1C&lt;/a&gt; &amp;gt;7.0)&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/OrlHypglycmc.htm" class="LinkPage"&gt;Oral Hypoglycemic&lt;/a&gt; agents not maximized&lt;ol&gt;&lt;li&gt;Maximize dosing of current agents&lt;/li&gt;&lt;li&gt;Add &lt;a href="../../Endo/Pharm/Slfnylr.htm" class="LinkPage"&gt;Sulfonylurea&lt;/a&gt; to &lt;a href="../../Endo/Pharm/Glcphg.htm" class="LinkPage"&gt;Glucophage&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Add &lt;a href="../../Endo/Pharm/Thzldndn.htm" class="LinkPage"&gt;Thiazolidinedione&lt;/a&gt; if not already added&lt;/li&gt;&lt;li&gt;Add Incretin (&lt;a href="../../Endo/Pharm/IncrtnMmtc.htm" class="LinkPage"&gt;GLP-1 Analog&lt;/a&gt; or &lt;a href="../../Endo/Pharm/Stglptn.htm" class="LinkPage"&gt;DPP-4 Inhibitor&lt;/a&gt;)&lt;ol&gt;&lt;li&gt;Avoid using 2 Incretins in combination (raises cost, risk of &lt;a href="../../GI/Pancreas/ActPncrts.htm" class="LinkPage"&gt;Pancreatitis&lt;/a&gt; without significant benefit)&lt;/li&gt;&lt;li&gt;(2012) Presc Lett 19(8): 45&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/OrlHypglycmc.htm" class="LinkPage"&gt;Oral Hypoglycemic&lt;/a&gt;s maximized or contraindicated&lt;ol&gt;&lt;li&gt;Start &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; augmentation (see above)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; augmentation has already been started&lt;ol&gt;&lt;li&gt;Start &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; replacement (see above)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Management: Follow-up Maintenance Phase&lt;ol&gt;&lt;li&gt;Clinic visits every 3-4 months&lt;ol&gt;&lt;li&gt;Review &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Sugar&lt;/a&gt; log and Hypoglycemic episodes&lt;/li&gt;&lt;li&gt;Review medication dosages&lt;/li&gt;&lt;li&gt;Evaluate comorbid conditions&lt;ol&gt;&lt;li&gt;Evaluate weight or BMI&lt;/li&gt;&lt;li&gt;Check &lt;a href="../../CV/Exam/BldPrsr.htm" class="LinkPage"&gt;Blood Pressure&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Clean and check &lt;a href="../../Endo/Pharm/Glcmtr.htm" class="LinkPage"&gt;Glucometer&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Education&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Prevent/NtrtnInDbtsMlts.htm" class="LinkPage"&gt;Nutrition in Diabetes Mellitus&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Sports/ExrcsInDbtsMlts.htm" class="LinkPage"&gt;Exercise in Diabetes Mellitus&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Ortho/Anatomy/FtAntmy.htm" class="LinkPage"&gt;Foot&lt;/a&gt; Care (examine feet at every visit)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Examination&lt;ol&gt;&lt;li&gt;Annual Health Maintenance Exam&lt;/li&gt;&lt;li&gt;Annual Eye examination with &lt;a href="../../Eye/Exam/Mydrs.htm" class="LinkPage"&gt;Pupil Dilation&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Annual Dental Exam&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Labs&lt;ol&gt;&lt;li&gt;Daily&lt;ol&gt;&lt;li&gt;Home &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; monitoring before meals and bedtime&lt;/li&gt;&lt;li&gt;Postprandial &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; (2 hours after meal)&lt;ol&gt;&lt;li&gt;May be better marker for control&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Every 3 months&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/HmglbnAc.htm" class="LinkPage"&gt;Hemoglobin A1C&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Annual&lt;ol&gt;&lt;li&gt;Fasting &lt;a href="../../CV/Lab/Lpd.htm" class="LinkPage"&gt;Lipid&lt;/a&gt; Profile&lt;/li&gt;&lt;li&gt;&lt;a href="../../Renal/Lab/RnlFnctn.htm" class="LinkPage"&gt;Renal Function&lt;/a&gt; tests (BUN and &lt;a href="../../Renal/Lab/SrmCrtn.htm" class="LinkPage"&gt;Creatinine&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Uro/Lab/Urnlys.htm" class="LinkPage"&gt;Urinalysis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Uro/Lab/UrnMcrlbmn.htm" class="LinkPage"&gt;Urine Microalbumin&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Mayfield%20%20%5BAU%5D%20AND%202004%20%5BDP%5D%20AND%20%20Am%20Fam%20Physician%20%20%5BTA%5D" class="LinkRef"&gt;Mayfield (2004) Am Fam Physician 70:489-512&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Yki-Jarvinen%20%20%5BAU%5D%20AND%202001%20%5BDP%5D%20AND%20%20%20%5BTA%5D" class="LinkRef"&gt;Yki-Jarvinen (2001) 24:758-67&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0011860</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/DM/TypDbtsMlts1.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Type 2 Diabetes Mellitus, Type II Diabetes Mellitus, Non-Insulin Dependent Diabetes Mellitus, NIDDM, Type II Diabetes</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/DM/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Insulin Resistance  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0021655"&gt;&lt;i&gt;C0021655&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Pathologic Function (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0021655&amp;amp;tui=T046"&gt;&lt;i&gt;T046&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D007333&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;48606007&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Resistance, Insulin, Insulin resistance syndrome, Insulin Resistance [Disease/Finding], insulin resistance syndrome, Drug resistance to insulin, Insulin resistance, Drug resistance to insulin (disorder), Insulin Resistance, insulin resistance&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Insulino-resistenza, Sindrome da resistenza insulinica, Resistenza all'insulina&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;インスリン抵抗性, インスリン抵抗性症候群, ｲﾝｽﾘﾝﾃｲｺｳｾｲｼｮｳｺｳｸﾞﾝ, ｲﾝｽﾘﾝﾃｲｺｳｾｲ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Insulinresistens&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;insulin - rezistence, Syndrom inzulinové rezistence, Inzulinová rezistence&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Insuliiniresistenssi&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;INSULINOREZISTENTNOST', ИНСУЛИНОРЕЗИСТЕНТНОСТЬ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;resistencia a la insulina, resistencia a la insulina (trastorno), resistencia a la insulina de causa farmacológica, resistencia a la insulina de causa farmacológica (trastorno), Resistencia a la insulina, Síndrome de resistencia a la insulina, Resistencia a la Insulina&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Croatian&lt;/td&gt;
                &lt;td&gt;INZULINSKA REZISTENCIJA&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Oporność na insulinę, Insulinooporność&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;Insulin resistentia, Insulin resistentia syndroma&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Insulinorresistência, Síndrome de insulinorresistência, Resistência à Insulina&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;insulineresistentiesyndroom, insulineresistentie, Insulineresistentie, Resistentie, insuline-&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Syndrome d'insulino-résistance, Insulinorésistance, Insulino-résistance, Résistance à l'insuline&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Insulinresistenzsyndrom, Insulinresistenz&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Microvascular Angina  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0206064"&gt;&lt;i&gt;C0206064&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;ANGINA PECTORIS or angina-like chest pain with a normal coronary arteriogram and positive EXERCISE TEST. The cause of the syndrome is unknown. While its recognition is of clinical importance, its prognosis is excellent. (Braunwald, Heart Disease, 4th ed, p1346; Jablonski Dictionary of Syndromes &amp;amp; Eponymic Diseases, 2d ed). It is different from METABOLIC SYNDROME X, a syndrome characterized by INSULIN RESISTANCE and HYPERINSULINEMIA, that has increased risk for cardiovascular disease.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Disease or Syndrome (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0206064&amp;amp;tui=T047"&gt;&lt;i&gt;T047&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D017566&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;194869009, 233845001&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Angina Pectoris with Normal Coronary Arteriogram, Angina, Microvascular, Chest pain norm cor angio, Cardiac syndrome X (disorder), Syndrome X (Cardiac), Microvascular Angina [Disease/Finding], cardiac syndrome x, syndrome x, microvascular angina, Cardiac Syndrome X, Cardiac syndrome X, Chest pain with normal coronary angiography, Cardiac syndrome X (finding), Microvascular Angina, Syndrome X, Cardiac, Angina Syndrome Xs, Angina Syndrome X, Angina X Syndromes, Angina X Syndrome, Syndrome X, Angina, Syndrome Xs, Angina, Syndrome, Angina X, X Syndrome, Angina, Syndrome X, syndrome X, Microvascular angina&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;microvasculaire angina, cardiaal syndroom X, Angina pectoris met normaal coronair arteriogram, Angina, microvasculaire, Syndroom X, Cardiaal syndroom X, Microvasculaire angina, Syndroom X, angineus, Syndroom X, cardiaal&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;mikrovaskulaere Angina pectoris, Herzsyndrom X, Angina pectoris mit normalem Koronararteriogramm, Syndrom X, X-Syndrom, Angina, mikrovaskuläre&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Angina microvascular, Síndrome X cardíaca, Síndrome X Anginosa, Angina Microvascular, Angina Pectoris com Coronariografia Normal, Síndrome Cardíaca X, Síndrome X Cardíaca&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;Angina microvascular, Síndrome cardiaco X, Cardiac syndrome X, Sindrome X Anginoso, Síndrome X Anginoso, síndrome cardíaco X (hallazgo), síndrome cardíaco X, Angina Microvascular, Angina Pectoris con Arteriograma Coronario Normal, Síndrome Cardíaco X, Síndrome X Cardíaco, Sindrome Cardiaco X, Sindrome X Cardiaco&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Syndrome cardiaque X, Angor microvasculaire, Angine de poitrine à coronarographie normale, Angor à coronaires saines, Angine microvasculaire, Angor avec coronaires normales, Angine de poitrine à coronaires saines, Angor à coronarographie normale, Syndrome X cardiaque&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Sindrome X cardiaca, Angina pectoris con arteriogramma coronarico normale, Sindrome da angina, Angina microvascolare, Sindrome cardiaca X, Sindrome X&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;心Ｘ症候群, ｼﾝXｼｮｳｺｳｸﾞﾝ, ﾋﾞｼｮｳｹｯｶﾝｾｲｷｮｳｼﾝｼｮｳ, X症候群-心臓性, シンドロームX-心臓性, 微小血管性狭心症, 心臓性X症候群, 心臓性シンドロームX, 正常冠動脈造影図型狭心症, 狭心症-微小血管性, 狭心症-正常冠動脈造影図型&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Mikrovaskulär angina&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;srdce - syndrom X, mikrovaskulární angina pectoris, angina pectoris s normálním koronarografickým nálezem, Mikrovaskulární angína, Kardiální syndrom X&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Mikrovaskulaarinen angina&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;MIKROVASKULIARNAIA STENOKARDIIA, STENOKARDIIA S NORMAL'NOI KORONAROGRAFIEI, STENOKARDIIA MIKROVASKULIARNAIA, SINDROM X, X SINDROM, X СИНДРОМ, СИНДРОМ X, СТЕНОКАРДИЯ МИКРОВАСКУЛЯРНАЯ, СТЕНОКАРДИЯ С НОРМАЛЬНОЙ КОРОНАРОГРАФИЕЙ, МИКРОВАСКУЛЯРНАЯ СТЕНОКАРДИЯ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Zespół X kardiologiczny, Sercowy zespół X, Dusznica mikronaczyniowa, Dławica mikronaczyniowa&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;Microvascularis angina, Cardialis x syndroma&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Metabolic syndrome  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0948265"&gt;&lt;i&gt;C0948265&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MEDLINEPLUS)&lt;/td&gt;
                &lt;td&gt;
                  &lt;span&gt;
                    &lt;p&gt;Metabolic syndrome is a group of conditions that put you at risk for &lt;a href="http://www.nlm.nih.gov/medlineplus/heartdiseases.html"&gt;heart disease&lt;/a&gt; and &lt;a href="http://www.nlm.nih.gov/medlineplus/diabetes.html"&gt;diabetes&lt;/a&gt;. These conditions are  &lt;/p&gt;
                    &lt;ul&gt;&lt;li&gt;
                        &lt;a href="http://www.nlm.nih.gov/medlineplus/highbloodpressure.html"&gt;High blood pressure&lt;/a&gt;
                      &lt;/li&gt;
                      &lt;li&gt;	High blood sugar levels&lt;/li&gt;
                      &lt;li&gt;	High levels of &lt;a href="http://www.nlm.nih.gov/medlineplus/triglycerides.html"&gt;triglycerides&lt;/a&gt;, a type of fat, in your blood &lt;/li&gt;
                      &lt;li&gt;	Low levels of HDL, the good &lt;a href="http://www.nlm.nih.gov/medlineplus/cholesterol.html"&gt;cholesterol&lt;/a&gt;, in your blood&lt;/li&gt;
                      &lt;li&gt;	Too much fat around your waist&lt;/li&gt;
                    &lt;/ul&gt;&lt;p&gt;Not all doctors agree on the definition or cause of metabolic syndrome. The cause might be insulin resistance. Insulin is a hormone your body produces to help you turn sugar from food into energy for your body. If you are insulin resistant, too much sugar builds up in your blood, setting the stage for disease.&lt;/p&gt;
                    &lt;p style="font-weight:bold;font-style:italic;"&gt;NIH: National Institute of Diabetes and Digestive and Kidney Diseases&lt;/p&gt;
                  &lt;/span&gt;
                &lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CSP)&lt;/td&gt;
                &lt;td&gt;a multifaceted syndrome characterized by clustering of insulin resistance and hyperinsulinemia, associated with dyslipidemia, essential hypertension, abdominal obesity, glucose intolerance or noninsulin dependent diabetes mellitus, and an increased risk of cardiovascular events.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Disease or Syndrome (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0948265&amp;amp;tui=T047"&gt;&lt;i&gt;T047&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD10&lt;/td&gt;
                &lt;td&gt;E88.81&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Sindrome metabolica&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;代謝症候群, ﾀｲｼｬｼｮｳｺｳｸﾞﾝ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Metabolic Syndrome, metabolic syndromes, syndrome metabolic, Metabolic syndrome, metabolic syndrome&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;Metabolický syndrom&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;Metabolikus syndroma&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Síndrome metabólico&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;Síndrome metabólico&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;metabolisch syndroom&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Syndrome métabolique&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;metabolisches Syndrom&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Impaired glucose tolerance  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0271650"&gt;&lt;i&gt;C0271650&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A condition referring to fasting plasma glucose levels being less than 140 mg per deciliter while the plasma glucose levels after a glucose tolerance test being more than 200 mg per deciliter at 30, 60, or 90 minutes. It is observed in patients with diabetes mellitus. Other causes include immune disorders, genetic syndromes, and cirrhosis.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A disorder characterized by an inability to properly metabolize glucose.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;A pathological state in which BLOOD GLUCOSE level is less than approximately 140 mg/100 ml of PLASMA at fasting, and above approximately 200 mg/100 ml plasma at 30-, 60-, or 90-minute during a GLUCOSE TOLERANCE TEST. This condition is seen frequently in DIABETES MELLITUS, but also occurs with other diseases and MALNUTRITION.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Disease or Syndrome (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0271650&amp;amp;tui=T047"&gt;&lt;i&gt;T047&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D018149&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD10&lt;/td&gt;
                &lt;td&gt;R73.09&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;154720005, 190752008, 9414007, 267426009&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Glucose Intolerance, Glucose Intolerances, Intolerances, Glucose, GLUCOSE INTOLERANCE, Intolerance, Glucose, Impaired glucose tolerance, NOS, IGT - Impair glucose tolerance, glucose intolerance (diagnosis), glucose intolerance, Glucose: [intolerance] or [malabsorption] (disorder), impaired glucose tolerance, impaired glucose tolerance (diagnosis), prediabetes, Glucose tolerance impaired, Impaired glucose tolerance, Glucose Intolerance [Disease/Finding], chemicals diabetes, chemical diabetes, glucose impaired tolerance, Intolerance;glucose, malabsorption of glucose, diabetes chemical, latent diabetes, glucose malabsorption, Chemical diabetes, Latent diabetes, Prediabetic nonclinical diabetes, Glucose intolerance, IGT - Impaired glucose tolerance, Malabsorption of glucose, Impaired glucose tolerance (disorder), Malabsorption of glucose (disorder), chemicals; diabetes, diabetes; chemical, diabetes; latent, glucose; intolerance, glucose; malabsorption, intolerance; glucose, latent; diabetes, malabsorption; glucose, Glucose: [intolerance] or [malabsorption], Impaired;glucose tolerance&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Tolleranza al glucosio alterata, Diabete chimico, Diabete latente, Intolleranza al glucosio&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;chemische diabetes, latente diabetes, glucose-intolerantie, chemisch; diabetes, diabetes; chemisch, diabetes; latent, glucose; intolerantie, glucose; malabsorptie, intolerantie; glucose, latent; diabetes, malabsorptie; glucose, glucosetolerantie aangetast, Glucose-intolerantie, Intolerantie, glucose-&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Diabète latent, Diabète chimique, Intolérance au glucose&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;chemischer Diabetes, latenter Diabetes, eingeschraenkte Glukosetoleranz, Glukoseintoleranz&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Intolerância à glucose, Diabetes química, Diabetes latente, Tolerância à glucose alterada, Intolerância à Glucose&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;Diabetes química, Intolerancia a la glucosa, Diabetes latente, Glucose: [intolerance] or [malabsorption], Glucose intolerance, Malabsorption of glucose, Impaired glucose tolerance, diabetes latente, diabetes química, mala absorción de glucosa (trastorno), mala absorción de glucosa, seudodiabetes, trastorno de la tolerancia a la glucosa (trastorno), trastorno de la tolerancia a la glucosa, Alteración de la tolerancia a la glucosa, Intolerancia a la Glucosa&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;化学的糖尿病, 耐糖能障害, 潜在性糖尿病, ブドウ糖不耐性, ﾀｲﾄｳﾉｳｼｮｳｶﾞｲ, ｾﾝｻﾞｲｾｲﾄｳﾆｮｳﾋﾞｮｳ, ﾌﾞﾄﾞｳﾄｳﾌﾀｲｾｲ, ｶｶﾞｸﾃｷﾄｳﾆｮｳﾋﾞｮｳ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Glukosintolerans&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;glukosa - tolerance porušená, Intolerance glukózy, Latentní diabetes, Porušená glukózová tolerance, Chemický diabetes&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Glukoosi-intoleranssi&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;GLIUKOZY NEPERENOSIMOST', ГЛЮКОЗЫ НЕПЕРЕНОСИМОСТЬ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Croatian&lt;/td&gt;
                &lt;td&gt;GLUKOZA, INTOLERANCIJA&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Nietolerancja glukozy&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;Glucose intolerantia, Latens diabetes, Kémiai diabetes, Csökkent glucose tolerancia&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Impaired fasting glycaemia  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C1272092"&gt;&lt;i&gt;C1272092&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Finding (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C1272092&amp;amp;tui=T033"&gt;&lt;i&gt;T033&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD9&lt;/td&gt;
                &lt;td&gt;790.21&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD10&lt;/td&gt;
                &lt;td&gt;R73.01&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;390937007, 389984002, 390731003, 390951007&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Glicemia a digiuno alterata&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;[D]Impaired fasting glycaemia (context-dependent category), impaired fasting glucose (diagnosis), impaired fasting glucose, [D]Impaired fasting glycaemia (situation), [D]Impaired fasting glucose, Impaired fasting glycaemia (disorder), Impaired fasting glycaemia, Impaired fasting glycaemia -RETIRED-, [D]Impaired fasting glycaemia, Impaired fasting glucose&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;空腹時血中ブドウ糖不良, ｸｳﾌｸｼﾞｹｯﾁｭｳﾌﾞﾄﾞｳﾄｳﾌﾘｮｳ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;[D]glucemia en ayunas alterada (categoría dependiente del contexto), [D]Impaired fasting glycaemia, Impaired fasting glycaemia -RETIRED-, Impaired fasting glycaemia, [D]glucemia en ayunas alterada (situación), [D]glucemia en ayunas alterada, glucemia en ayunas alterada (trastorno), glucemia en ayunas alterada, Alteración de glucosa en ayunas&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;Porušená glykemie na lačno&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;Kóros éhomi glucose&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Alteração da glucose em jejum&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;verminderde nuchtere glucose&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Diminution du glucose à jeun&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Nuechternglukose krankhaft&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Insulin Resistance  (</value><value>)
</value><value>Microvascular Angina  (</value><value>)
</value><value>Metabolic syndrome  (</value><value>)
</value><value>Impaired glucose tolerance  (</value><value>)
</value><value>Impaired fasting glycaemia  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Insulin Resistance Syndrome</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Diabetes Mellitus</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;See also&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/DM/TypDbtsMlts1.htm" class="LinkPage"&gt;Type II Diabetes Mellitus&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Epidemiology&lt;ol&gt;&lt;li&gt;&lt;a href="../../Prevent/Epi/DsPrvlncRt.htm" class="LinkPage"&gt;Prevalence&lt;/a&gt; in U.S.&lt;ol&gt;&lt;li&gt;Total estimated at 70-80 million&lt;/li&gt;&lt;li&gt;Affects 25% of adults and 4% of teens&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Pathophysiology&lt;ol&gt;&lt;li&gt;Diminished &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; response results in hyperinsulinemia&lt;ol&gt;&lt;li&gt;Fewer &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; receptors on cells&lt;/li&gt;&lt;li&gt;Less &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; transporter (Glut 4) in cells&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Hyperinsulinemia predisposes to cardiovascular disease&lt;/li&gt;&lt;li&gt;Precursor to &lt;a href="../../Endo/DM/TypDbtsMlts1.htm" class="LinkPage"&gt;Type II Diabetes Mellitus&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Risk Factors&lt;ol&gt;&lt;li&gt;Strong &lt;a href="../../Prevent/HME/FmlyHstry.htm" class="LinkPage"&gt;Family History&lt;/a&gt; of &lt;a href="../../Endo/DM/DbtsMlts.htm" class="LinkPage"&gt;Diabetes Mellitus&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Prior &lt;a href="../../Endo/OB/GstnlDbts.htm" class="LinkPage"&gt;Gestational Diabetes&lt;/a&gt; Mellitus or &lt;a href="../../OB/Fetus/FtlMcrsm.htm" class="LinkPage"&gt;Fetal Macrosomia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Obesity/Obsty.htm" class="LinkPage"&gt;Obesity&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Exam/BdyMsIndx.htm" class="LinkPage"&gt;Body Mass Index&lt;/a&gt; 30 kg/m2 or higher&lt;/li&gt;&lt;li&gt;Waist to hip ratio increased&lt;ol&gt;&lt;li&gt;Men: 1.0 or higher&lt;/li&gt;&lt;li&gt;Women: 0.8 or higher&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Diagnosis: Three or more conditions below&lt;ol&gt;&lt;li&gt;Insulin Resistance (see labs below)&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Htn/Hyprtnsn.htm" class="LinkPage"&gt;Hypertension&lt;/a&gt; (&lt;a href="../../CV/Exam/BldPrsr.htm" class="LinkPage"&gt;Blood Pressure&lt;/a&gt; 130/85 or higher)&lt;ol&gt;&lt;li&gt;Seen in up to 40% of Metabolic Syndrome patients&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Lipid/Hyprchlstrlm.htm" class="LinkPage"&gt;Hyperlipidemia&lt;/a&gt; (see labs below)&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/CAD/ActCrnrySyndrm.htm" class="LinkPage"&gt;Coronary Artery Disease&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Gyn/Endo/PlycystcOvryDs.htm" class="LinkPage"&gt;Polycystic Ovary Syndrome&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Derm/AcnthsNgrcns.htm" class="LinkPage"&gt;Acanthosis Nigricans&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Gyn/Endo/HrAnSyndrm.htm" class="LinkPage"&gt;HAIR-AN Syndrome&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Abdominal &lt;a href="../../Endo/Obesity/Obsty.htm" class="LinkPage"&gt;Obesity&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Men with &lt;a href="../../Endo/Exam/WstTHpRt.htm" class="LinkPage"&gt;Waist Circumference&lt;/a&gt; &amp;gt;40 inches or 102 cm&lt;/li&gt;&lt;li&gt;Women with &lt;a href="../../Endo/Exam/WstTHpRt.htm" class="LinkPage"&gt;Waist Circumference&lt;/a&gt; &amp;gt;35 inches or 88 cm&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Labs&lt;ol&gt;&lt;li&gt;Screening Indications&lt;ol&gt;&lt;li&gt;See Risk Factors above&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Exam/BdyMsIndx.htm" class="LinkPage"&gt;Body Mass Index&lt;/a&gt; &amp;gt;25 kg/m2&lt;/li&gt;&lt;li&gt;&lt;a href="../../Prevent/HME/FmlyHstry.htm" class="LinkPage"&gt;Family History&lt;/a&gt; of &lt;a href="../../Endo/DM/DbtsMlts.htm" class="LinkPage"&gt;Diabetes Mellitus&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Prior history of &lt;a href="../../Endo/OB/GstnlDbts.htm" class="LinkPage"&gt;Gestational Diabetes&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Age over 45 years&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Lab/HdlChlstrl.htm" class="LinkPage"&gt;HDL Cholesterol&lt;/a&gt; &amp;lt;35 mg/dl&lt;/li&gt;&lt;li&gt;Serum &lt;a href="../../CV/Lab/Trglycrd.htm" class="LinkPage"&gt;Triglyceride&lt;/a&gt;s &amp;gt;250 mg/dl&lt;/li&gt;&lt;li&gt;&lt;a href="../../Gyn/Endo/PlycystcOvryDs.htm" class="LinkPage"&gt;Polycystic Ovary Syndrome&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Htn/Hyprtnsn.htm" class="LinkPage"&gt;Hypertension&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Impaired &lt;a href="../../Endo/Exam/GlcsMtblsm.htm" class="LinkPage"&gt;Glucose Metabolism&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Fasting &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt;: 100 to 125 mg/dl&lt;ol&gt;&lt;li&gt;Known as Impaired Fasting Glucose&lt;/li&gt;&lt;li&gt;New guidelines suggest bottom cut-off of 100 mg/dl&lt;/li&gt;&lt;li&gt;Metabolic Syndrome defined as 110 mg/dl or higher&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/GlcsTlrncTstHr.htm" class="LinkPage"&gt;Two hour Glucose Tolerance Test&lt;/a&gt; (75 g): 140-199 mg/dl&lt;ol&gt;&lt;li&gt;Known as Impaired Glucose Tolerance&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Lab/Lpd.htm" class="LinkPage"&gt;Lipid&lt;/a&gt; Profile&lt;ol&gt;&lt;li&gt;Serum &lt;a href="../../CV/Lab/Trglycrd.htm" class="LinkPage"&gt;Triglyceride&lt;/a&gt;s &amp;gt;150 mg/dl&lt;/li&gt;&lt;li&gt;Serum very &lt;a href="../../CV/Lab/LdlChlstrl.htm" class="LinkPage"&gt;Low Density Lipoprotein&lt;/a&gt; (VLDL) increased&lt;/li&gt;&lt;li&gt;Serum &lt;a href="../../CV/Lab/HdlChlstrl.htm" class="LinkPage"&gt;HDL Cholesterol&lt;/a&gt; decreased&lt;ol&gt;&lt;li&gt;Men &amp;lt;40 mg/dl&lt;/li&gt;&lt;li&gt;Women &amp;lt;50 mg/dl&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Best lab markers for Insulin Resistance&lt;ol&gt;&lt;li&gt;Plasma &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; level (or &lt;a href="../../Endo/Lab/GlcsTInslnRt.htm" class="LinkPage"&gt;Glucose to Insulin Ratio&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;Plasma &lt;a href="../../CV/Lab/Trglycrd.htm" class="LinkPage"&gt;Triglyceride&lt;/a&gt; levels&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Lab/Trglycrd.htm" class="LinkPage"&gt;Triglyceride&lt;/a&gt; to HDL ratio&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=McLaughlin%20%20%5BAU%5D%20AND%202003%20%5BDP%5D%20AND%20%20Ann%20Intern%20Med%20%20%5BTA%5D" class="LinkRef"&gt;McLaughlin (2003) Ann Intern Med 139:802-9&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Management: Prevention of progression to Diabetes&lt;ol&gt;&lt;li&gt;Moderate aerobic &lt;a href="../../Sports/Exercise/Exrcs.htm" class="LinkPage"&gt;Exercise&lt;/a&gt; for 30 minutes every day&lt;ol&gt;&lt;li&gt;Example: Brisk walking for total of 150 min/week&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Decreased caloric intake&lt;ol&gt;&lt;li&gt;Keep fat intake &amp;lt;30% with saturated fat &amp;lt;10%&lt;/li&gt;&lt;li&gt;Salad, vegetables, fruits&lt;/li&gt;&lt;li&gt;Whole grains and legumes&lt;/li&gt;&lt;li&gt;Fish high in &lt;a href="../../Pharm/Nutrition/Omg3FtyAcd.htm" class="LinkPage"&gt;Omega-3 Fatty Acid&lt;/a&gt;s and lean meats&lt;/li&gt;&lt;li&gt;Reduce intake of simple sugars&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Foods associated with improved &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; sensitivity&lt;ol&gt;&lt;li&gt;Coffee&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Salazar-Martinez%20%20%5BAU%5D%20AND%202004%20%5BDP%5D%20AND%20%20Ann%20Intern%20Med%20%20%5BTA%5D" class="LinkRef"&gt;Salazar-Martinez (2004) Ann Intern Med 140:1-8&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Tuomilehto%20%20%5BAU%5D%20AND%202004%20%5BDP%5D%20AND%20%20JAMA%20%20%5BTA%5D" class="LinkRef"&gt;Tuomilehto (2004) JAMA 291:1213-9&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Cinammon (1/2 teaspoon per day)&lt;ol&gt;&lt;li&gt;Appears to have &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt;-like activity&lt;/li&gt;&lt;li&gt;May increase &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; sensitivity&lt;/li&gt;&lt;li&gt;Improves lipid profile&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Khan%20%20%5BAU%5D%20AND%202003%20%5BDP%5D%20AND%20%20Diabetes%20Care%20%20%5BTA%5D" class="LinkRef"&gt;Khan (2003) Diabetes Care 26(12):3215-8&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Moderate &lt;a href="../../Psych/Pharm/Alchl.htm" class="LinkPage"&gt;Alcohol&lt;/a&gt; consumption&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Howard%20%20%5BAU%5D%20AND%202004%20%5BDP%5D%20AND%20%20Ann%20Intern%20Med%20%20%5BTA%5D" class="LinkRef"&gt;Howard (2004) Ann Intern Med 140:211-9&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Obesity/ObstyMngmnt.htm" class="LinkPage"&gt;Weight Reduction&lt;/a&gt; (lose 7-15% of prior weight)&lt;/li&gt;&lt;li&gt;Increase &lt;a href="../../Pharm/Nutrition/Fbr.htm" class="LinkPage"&gt;Dietary Fiber&lt;/a&gt; to 15 gram per 1000 calories&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Prevent/CrdcRskMngmnt.htm" class="LinkPage"&gt;Cardiac Risk Management&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Same as &lt;a href="../../Endo/DM/DbtsMlts.htm" class="LinkPage"&gt;Diabetes Mellitus&lt;/a&gt; and &lt;a href="../../CV/CAD/ActCrnrySyndrm.htm" class="LinkPage"&gt;Coronary Artery Disease&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Pharm/Analgesic/Asprn.htm" class="LinkPage"&gt;Aspirin&lt;/a&gt; 81 mg PO qd&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Lipid/Hyprchlstrlm.htm" class="LinkPage"&gt;Hyperlipidemia&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../CV/Lab/LdlChlstrl.htm" class="LinkPage"&gt;LDL Cholesterol&lt;/a&gt; &amp;lt;100 mg/dl&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Lab/HdlChlstrl.htm" class="LinkPage"&gt;HDL Cholesterol&lt;/a&gt; &amp;gt;40 mg/dl (50 mg/dl in women)&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Lab/Trglycrd.htm" class="LinkPage"&gt;Triglyceride&lt;/a&gt;s &amp;lt;150 mg/dl&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Pharm/HmgCRdctsInhbtr.htm" class="LinkPage"&gt;Statin&lt;/a&gt;s are preferred agents&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Sowers%20%20%5BAU%5D%20AND%202003%20%5BDP%5D%20AND%20%20Am%20J%20Cardiol%20%20%5BTA%5D" class="LinkRef"&gt;Sowers (2003) Am J Cardiol 91:14B-22B&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Htn/Hyprtnsn.htm" class="LinkPage"&gt;Hypertension&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Goal &lt;a href="../../CV/Exam/BldPrsr.htm" class="LinkPage"&gt;Blood Pressure&lt;/a&gt; &amp;lt; 125/75 mmhg&lt;/li&gt;&lt;li&gt;Consider &lt;a href="../../CV/Pharm/AcInhbtr.htm" class="LinkPage"&gt;ACE Inhibitor&lt;/a&gt; or &lt;a href="../../CV/Pharm/AngtnsnRcptrBlckngAgnt.htm" class="LinkPage"&gt;Angiotensin Blocker&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Consider pharmacologic agents for &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; control&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Glcphg.htm" class="LinkPage"&gt;Glucophage&lt;/a&gt; (&lt;a href="../../Endo/Pharm/Glcphg.htm" class="LinkPage"&gt;Metformin&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/AlphGlcsdsInhbtr.htm" class="LinkPage"&gt;Acarbose&lt;/a&gt; (&lt;a href="../../Endo/Pharm/AlphGlcsdsInhbtr.htm" class="LinkPage"&gt;Precose&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Thzldndn.htm" class="LinkPage"&gt;Avandia&lt;/a&gt; or &lt;a href="../../Endo/Pharm/Thzldndn.htm" class="LinkPage"&gt;Actos&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;References&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=2002%20%5BDP%5D%20AND%20%20N%20Engl%20J%20Med%20%20%5BTA%5D%20AND%20346%20%5BVI%5D%20AND%20393%20%5BPG%5D" class="LinkRef"&gt;(2002) N Engl J Med 346:393-403&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Scott%20%20%5BAU%5D%20AND%202003%20%5BDP%5D%20AND%20%20Am%20J%20Cardiol%20%20%5BTA%5D" class="LinkRef"&gt;Scott (2003) Am J Cardiol 92(2 suppl):35i-42i&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=2006%20%5BDP%5D%20AND%20%20Lancet%20%20%5BTA%5D%20AND%20368%20%5BVI%5D%20AND%201096%20%5BPG%5D" class="LinkRef"&gt;(2006) Lancet 368:1096-105&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Course&lt;ol&gt;&lt;li&gt;High risk for &lt;a href="../../Endo/DM/TypDbtsMlts1.htm" class="LinkPage"&gt;Type II Diabetes Mellitus&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Diabetes Prevention Program (DPP)&lt;ol&gt;&lt;li&gt;Basic diet and &lt;a href="../../Sports/Exercise/Exrcs.htm" class="LinkPage"&gt;Exercise&lt;/a&gt;: 11% develop diabetes/year&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Glcphg.htm" class="LinkPage"&gt;Metformin&lt;/a&gt; 850 bid/diet/&lt;a href="../../Sports/Exercise/Exrcs.htm" class="LinkPage"&gt;Exercise&lt;/a&gt;: 7.8% develop DM/year&lt;/li&gt;&lt;li&gt;Intensive diet, &lt;a href="../../Sports/Exercise/Exrcs.htm" class="LinkPage"&gt;Exercise&lt;/a&gt;: 4.8% develop diabetes/year&lt;ol&gt;&lt;li&gt;Classes and coaches&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Obesity/ObstyMngmnt.htm" class="LinkPage"&gt;Weight Reduction&lt;/a&gt; of 7%&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Reference&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=1999%20%5BDP%5D%20AND%20%20Diabetes%20Care%20%20%5BTA%5D%20AND%2022%20%5BVI%5D%20AND%20623%20%5BPG%5D" class="LinkRef"&gt;(1999) Diabetes Care 22:623-34&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=1997%20%5BDP%5D%20AND%20%20Diabetes%20Care%20%20%5BTA%5D%20AND%2021%20%5BVI%5D%20AND%20310%20%5BPG%5D" class="LinkRef"&gt;(1997) Diabetes Care 21:310-4&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=2001%20%5BDP%5D%20AND%20%20JAMA%20%20%5BTA%5D%20AND%20285%20%5BVI%5D%20AND%202486%20%5BPG%5D" class="LinkRef"&gt;(2001) JAMA 285:2486-97&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Goutham%20%20%5BAU%5D%20AND%202001%20%5BDP%5D%20AND%20%20Am%20Fam%20Physician%20%20%5BTA%5D" class="LinkRef"&gt;Goutham (2001) Am Fam Physician 63(6): 1159-66&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0021655</value><value>C0206064</value><value>C0948265</value><value>C0271650</value><value>C1272092</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/DM/InslnRstncSyndrm.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Insulin Resistance Syndrome, Impaired Glucose Tolerance, Impaired Fasting Glucose, Insulin Resistance, Glucose Intolerance, Metabolic Syndrome, Syndrome X</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/DM/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees></FP_UMLS_Trees><FP_Condition_name_check></FP_Condition_name_check><FP_Condition_name><value>Familial Short Stature</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Growth Disorders</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Signs&lt;ol&gt;&lt;li&gt;Short parents&lt;/li&gt;&lt;li&gt;Normal birth history and gestational weight&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Growth/ShrtStr.htm" class="LinkPage"&gt;Short Stature&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Normal &lt;a href="../../Endo/Exam/LnrGrwthVlcty.htm" class="LinkPage"&gt;Linear Growth Velocity&lt;/a&gt; for age&lt;/li&gt;&lt;li&gt;Bone age consistent with chronological age&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Normal age for the onset of &lt;a href="../../Endo/Exam/SxlDvlpmnt.htm" class="LinkPage"&gt;Puberty&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Absence of organic or psychologic disease&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Growth/FmlShrtStr.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Familial Short Stature</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Growth/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Diabetes Mellitus  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0011849"&gt;&lt;i&gt;C0011849&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A metabolic disorder characterized by abnormally high blood sugar levels due to diminished production of insulin or insulin resistance/desensitization.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CHV)&lt;/td&gt;
                &lt;td&gt;diabetes mellitus&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CHV)&lt;/td&gt;
                &lt;td&gt;diabetes mellitus&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CHV)&lt;/td&gt;
                &lt;td&gt;diabetes mellitus&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CHV)&lt;/td&gt;
                &lt;td&gt;diabetes mellitus&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CHV)&lt;/td&gt;
                &lt;td&gt;diabetes mellitus&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CHV)&lt;/td&gt;
                &lt;td&gt;diabetes mellitus&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MEDLINEPLUS)&lt;/td&gt;
                &lt;td&gt;
                  &lt;span&gt;
                    &lt;p&gt;Diabetes is a disease in which your blood glucose, or sugar, levels are too high.  Glucose comes from the foods you eat. Insulin is a hormone that helps the glucose get into your cells to give them energy.  With &lt;a href="http://www.nlm.nih.gov/medlineplus/diabetestype1.html"&gt;Type 1 diabetes&lt;/a&gt;, your body does not make insulin.  With Type 2 diabetes, the more common type, your body does not make or use insulin well. Without enough insulin, the glucose stays in your blood.&lt;/p&gt;
                    &lt;p&gt;Over time, having too much glucose in your blood can cause &lt;a href="http://www.nlm.nih.gov/medlineplus/diabetescomplications.html"&gt;serious problems&lt;/a&gt;.    It can damage your &lt;a href="http://www.nlm.nih.gov/medlineplus/diabeticeyeproblems.html"&gt;eyes&lt;/a&gt;, &lt;a href="http://www.nlm.nih.gov/medlineplus/diabetickidneyproblems.html"&gt;kidneys&lt;/a&gt;, and &lt;a href="http://www.nlm.nih.gov/medlineplus/diabeticnerveproblems.html"&gt;nerves&lt;/a&gt;. Diabetes can also cause heart disease, stroke and even the need to remove a limb. Pregnant women can also get diabetes, called &lt;a href="http://www.nlm.nih.gov/medlineplus/diabetesandpregnancy.html"&gt;gestational diabetes&lt;/a&gt;.&lt;/p&gt;
                    &lt;p&gt;Symptoms of Type 2 diabetes may include fatigue, thirst, weight loss, blurred vision and frequent urination.  Some people have no symptoms. A blood test can show if you have diabetes.  Exercise, weight control and sticking to your meal plan can help control your diabetes. You should also monitor your glucose level and take &lt;a href="http://www.nlm.nih.gov/medlineplus/diabetesmedicines.html"&gt;medicine&lt;/a&gt; if prescribed. &lt;/p&gt;
                    &lt;p style="font-weight:bold;font-style:italic;"&gt;NIH: National Institute of Diabetes and Digestive and Kidney Diseases&lt;/p&gt;
                  &lt;/span&gt;
                &lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A disease in which the body does not control the amount of glucose (a type of sugar) in the blood and the kidneys make a large amount of urine. This disease occurs when the body does not make enough insulin or does not use it the way it should.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CSP)&lt;/td&gt;
                &lt;td&gt;heterogeneous group of disorders that share glucose intolerance in common.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Disease or Syndrome (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0011849&amp;amp;tui=T047"&gt;&lt;i&gt;T047&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D003920&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD9&lt;/td&gt;
                &lt;td&gt;250&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD10&lt;/td&gt;
                &lt;td&gt;E10-E14.9, E14, E11, E08-E13&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;191044006, 73211009, 154671004, 267467004&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Diabetes, Diabetes Mellitus, DIABETES MELLITUS, Diabetes mellitus, NOS, diabetes, Unspecified diabetes mellitus, dm, diabetes mellitus, diabetes mellitus (diagnosis), DM, Diabetes mellitus NOS, DIABETES MELLITUS NOS DIAGNOSED, DIABETES MELLITUS NOS, diabetes NOS, Diabetes Mellitus [Disease/Finding], diabete mellitus, disorder diabetes mellitus, diabetes (DM), diabetes mellitus (DM), Diabetes mellitus (E08-E13), Diabetes mellitus, DM - Diabetes mellitus, Diabetes mellitus (disorder), Diabetes NOS&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;DIABETE SUCRE, Diabète sucré SAI, Diabete sucre, Diabète, Diabète sucré&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;DIABETES MELLITUS, Diabetes, Diabetes mellitus NE, Diabetes mellitus, Diabete Melito, Diabetes Melito, Diabetes Mellitus&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;DIABETES MELLITUS, Diabetes, Diabetes mellitus NEOM, Diabetes mellitus, diabetes mellitus (trastorno), diabetes mellitus, diabetes sacarina, Diabetes Mellitus&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;DIABETES MELLITUS, Diabetes, Diabetes mellitus NNB, Nicht naeher bezeichneter Diabetes mellitus, Diabetes mellitus&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;diabetes mellitus NAO, diabetes, diabetes mellitus, Niet gespecificeerde diabetes mellitus, Diabetes mellitus, Mellitus, diabetes, Suikerziekte&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Diabete, Diabete mellito NAS, Diabete mellito&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;糖尿病, 糖尿病ＮＯＳ, ﾄｳﾆｮｳﾋﾞｮｳ, ﾄｳﾆｮｳﾋﾞｮｳNOS&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Diabetes, DIABETES MELLITUS/SOCKERSJUKA&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;diabetes mellitus, Diabetes, Diabetes mellitus, Diabetes mellitus NOS&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Diabetes, SOKERITAUTI&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;SAKHARNYI DIABET, SAKHARNAIA BOLEZN', OZHIRENIE PRI DIABETE, DIABET SAKHARNYI, ДИАБЕТ САХАРНЫЙ, ОЖИРЕНИЕ ПРИ ДИАБЕТЕ, САХАРНАЯ БОЛЕЗНЬ, САХАРНЫЙ ДИАБЕТ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Danish&lt;/td&gt;
                &lt;td&gt;Diabetes mellitus&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Norwegian&lt;/td&gt;
                &lt;td&gt;SUKKERSYKE/DIABETES MELLITUS&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;diabetes mellitus, Diabetes, Diabetes mellitus, Diabetes mellitus k.m.n.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Korean&lt;/td&gt;
                &lt;td&gt;상세불명의 당뇨병&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Croatian&lt;/td&gt;
                &lt;td&gt;DIJABETES MELITUS&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Basque&lt;/td&gt;
                &lt;td&gt;DIABETES MELITUSA&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hebrew&lt;/td&gt;
                &lt;td&gt;sukeret&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Cukrzyca&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Diabetes Mellitus  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Diabetes Mellitus</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Diabetes Mellitus</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;See Also&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/DM/DbtsMltsGlcsMngmnt.htm" class="LinkPage"&gt;Diabetes Mellitus Glucose Management&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/DM/TypDbtsMlts.htm" class="LinkPage"&gt;Type I Diabetes Mellitus&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/DM/TypDbtsMlts1.htm" class="LinkPage"&gt;Type II Diabetes Mellitus&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/DM/InslnRstncSyndrm.htm" class="LinkPage"&gt;Insulin Resistance Syndrome&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/DM/DbtcEdctn.htm" class="LinkPage"&gt;Diabetes Mellitus Education&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Definition&lt;ol&gt;&lt;li&gt;Metabolic disorder of carbohydrate economy&lt;/li&gt;&lt;li&gt;Deficiency of pancreatic beta cell &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; secretion&lt;/li&gt;&lt;li&gt;Resistance to &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; effect peripherally&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Epidemiology (U.S. statistics for 2004 per ADA)&lt;ol&gt;&lt;li&gt;&lt;a href="../../Prevent/Epi/DsPrvlncRt.htm" class="LinkPage"&gt;Prevalence&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/DM/TypDbtsMlts.htm" class="LinkPage"&gt;Type I Diabetes Mellitus&lt;/a&gt;: 750,000&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/DM/TypDbtsMlts1.htm" class="LinkPage"&gt;Type II Diabetes Mellitus&lt;/a&gt;: 13 million&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/OB/GstnlDbts.htm" class="LinkPage"&gt;Gestational Diabetes&lt;/a&gt;: 135,000&lt;/li&gt;&lt;li&gt;Undiagnosed with diabetes: 5.2 million&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Prevent/Epi/DsIncdncRt.htm" class="LinkPage"&gt;Incidence&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Type 1: 30,000 new cases per year&lt;/li&gt;&lt;li&gt;Type 2: 850,000 new cases per year&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/OB/GstnlDbts.htm" class="LinkPage"&gt;Gestational Diabetes&lt;/a&gt; Mellitus: 4% of all pregnancies&lt;/li&gt;&lt;li&gt;Fastest growing groups&lt;ol&gt;&lt;li&gt;Ages 30 to 39 years&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/DM/TypDbtsMlts1.htm" class="LinkPage"&gt;Type II Diabetes&lt;/a&gt; in children&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Types&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/DM/TypDbtsMlts.htm" class="LinkPage"&gt;Type I Diabetes Mellitus&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Juvenile Diabetes Mellitus&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/DM/TypDbtsMlts.htm" class="LinkPage"&gt;Insulin Dependent Diabetes Mellitus&lt;/a&gt; (&lt;a href="../../Endo/DM/TypDbtsMlts.htm" class="LinkPage"&gt;IDDM&lt;/a&gt;)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/DM/TypDbtsMlts1.htm" class="LinkPage"&gt;Type II Diabetes Mellitus&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Adult onset Diabetes Mellitus&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/DM/TypDbtsMlts1.htm" class="LinkPage"&gt;Non-Insulin Dependent Diabetes Mellitus&lt;/a&gt; (&lt;a href="../../Endo/DM/TypDbtsMlts1.htm" class="LinkPage"&gt;NIDDM&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;Pediatric &lt;a href="../../Endo/DM/TypDbtsMlts1.htm" class="LinkPage"&gt;Type II Diabetes Mellitus&lt;/a&gt; (Pediatric &lt;a href="../../Endo/DM/TypDbtsMlts1.htm" class="LinkPage"&gt;NIDDM&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;Maturity onset Diabetes of youth (MODY)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Symptoms&lt;ol&gt;&lt;li&gt;Classic (75% of cases of &lt;a href="../../Endo/DM/TypDbtsMlts.htm" class="LinkPage"&gt;Type I Diabetes Mellitus&lt;/a&gt;)&lt;ol&gt;&lt;li&gt;Polyuria or nocturia&lt;/li&gt;&lt;li&gt;Polydipsia&lt;/li&gt;&lt;li&gt;Unexplained Weight Loss&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Other symptoms&lt;ol&gt;&lt;li&gt;Increased appetite&lt;/li&gt;&lt;li&gt;Blurred vision&lt;/li&gt;&lt;li&gt;Frequent &lt;a href="../../Uro/ID/UrnryTrctInfctn.htm" class="LinkPage"&gt;Urinary Tract Infection&lt;/a&gt;s&lt;/li&gt;&lt;li&gt;Frequent yeast infections&lt;/li&gt;&lt;li&gt;&lt;a href="../../Rheum/Sx/Ftg.htm" class="LinkPage"&gt;Fatigue&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Dry or pruritic skin&lt;/li&gt;&lt;li&gt;Numbness or tingling in the extremities&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Diagnosis: Two of the following&lt;ol&gt;&lt;li&gt;Random &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Serum Glucose&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Serum Glucose&lt;/a&gt; over 200 mg/dl with symptoms&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Fasting &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Serum Glucose&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Serum Glucose&lt;/a&gt; exceeds 126 mg/dl on 2 different days&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Postprandial &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; (2 hours post meal)&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Serum Glucose&lt;/a&gt; over 200 mg/dl&lt;/li&gt;&lt;li&gt;Precedes fasting &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; increase&lt;/li&gt;&lt;li&gt;More predictive of &lt;a href="../../Endo/DM/DbtsMltsCmplctns.htm" class="LinkPage"&gt;Diabetes Mellitus Complications&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Casual Plasma &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; (random &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt;)&lt;ol&gt;&lt;li&gt;Same criteria as postprandial &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Oral &lt;a href="../../Endo/Lab/GlcsTlrncTst3Hr.htm" class="LinkPage"&gt;Glucose Tolerance Test&lt;/a&gt; (OGGT)&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/GlcsTlrncTstHr.htm" class="LinkPage"&gt;Two hour Glucose Tolerance Test&lt;/a&gt; (75 gram) &amp;gt;200 mg/dl&lt;/li&gt;&lt;li&gt;Consider in patients with &lt;a href="../../Endo/DM/InslnRstncSyndrm.htm" class="LinkPage"&gt;Insulin Resistance&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Patients with pre-diabetes to qualify for education&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/HmglbnAc.htm" class="LinkPage"&gt;Hemoglobin A1C&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/HmglbnAc.htm" class="LinkPage"&gt;Hemoglobin A1C&lt;/a&gt; &amp;gt;6.5%&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Differential Diagnosis: &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Hyperglycemia&lt;/a&gt;&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Hyperglycemia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Stress response&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Glucose&lt;/a&gt; typically &amp;lt;200 mg/dl&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Non-diabetic patient following a large meal&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Glucose&lt;/a&gt; typically &amp;lt;160 mg/dl&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Labs: Other monitoring&lt;ol&gt;&lt;li&gt;Home &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Serum Glucose&lt;/a&gt; monitoring&lt;ol&gt;&lt;li&gt;Over 50% of values should fall in target range&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Management: Severe &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Hyperglycemia&lt;/a&gt; at diagnosis&lt;ol&gt;&lt;li&gt;Strongly consider &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; at onset if severe &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Hyperglycemia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Criteria&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Glucose&lt;/a&gt; &amp;gt;300 mg/dl&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/HmglbnAc.htm" class="LinkPage"&gt;Hemoglobin A1C&lt;/a&gt; &amp;gt;9.0&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Protocol based on &lt;a href="../../Uro/Lab/UrnKtn.htm" class="LinkPage"&gt;Urine Ketone&lt;/a&gt;s&lt;ol&gt;&lt;li&gt;&lt;a href="../../Uro/Lab/UrnKtn.htm" class="LinkPage"&gt;Urine Ketone&lt;/a&gt;s positive&lt;ol&gt;&lt;li&gt;Evaluate for &lt;a href="../../Endo/DM/DbtcKtcds.htm" class="LinkPage"&gt;Diabetic Ketoacidosis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Serum beta hydroxybutyrate (&lt;a href="../../Renal/Lab/SrmPtsm.htm" class="LinkPage"&gt;Serum K&lt;/a&gt;etones)  positive in &lt;a href="../../Endo/DM/DbtcKtcds.htm" class="LinkPage"&gt;Diabetic Ketoacidosis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Basic metabolic panel findings suggestive of &lt;a href="../../Endo/DM/DbtcKtcds.htm" class="LinkPage"&gt;Diabetic Ketoacidosis&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Decreased serum bicarbonate&lt;/li&gt;&lt;li&gt;Increased &lt;a href="../../Renal/Lab/AnGp.htm" class="LinkPage"&gt;Anion Gap&lt;/a&gt; suggests&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Uro/Lab/UrnKtn.htm" class="LinkPage"&gt;Urine Ketone&lt;/a&gt;s negative&lt;ol&gt;&lt;li&gt;Confirm adequate hydration&lt;ol&gt;&lt;li&gt;Consider intravenous fluids&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Type I vs Type II is not critical initially&lt;ol&gt;&lt;li&gt;Both are given &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; at this &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Hyperglycemia&lt;/a&gt; level&lt;/li&gt;&lt;li&gt;Type II suspected&lt;ol&gt;&lt;li&gt;Consider adding &lt;a href="../../Endo/Pharm/Glcphg.htm" class="LinkPage"&gt;Metformin&lt;/a&gt; if normal &lt;a href="../../Renal/Lab/RnlFnctn.htm" class="LinkPage"&gt;Renal Function&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Start &lt;a href="../../Endo/Pharm/Glcphg.htm" class="LinkPage"&gt;Metformin&lt;/a&gt; 500 mg orally daily to twice daily&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; can likely be weaned later&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; toxicity causes low &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; level&lt;/li&gt;&lt;li&gt;Endogenous &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; will later normalize&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Start &lt;a href="../../Endo/Pharm/AnlgBslInsln.htm" class="LinkPage"&gt;Lantus&lt;/a&gt;&lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; at 10 to 14 units SQ today&lt;ol&gt;&lt;li&gt;Low risk of &lt;a href="../../Endo/Hypoglycemia/Hypglycm.htm" class="LinkPage"&gt;Hypoglycemia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Alternative for a stable, asymptomatic patient with suspected &lt;a href="../../Endo/DM/TypDbtsMlts1.htm" class="LinkPage"&gt;Type II Diabetes&lt;/a&gt; (e.g. Emergency Department)&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Glcphg.htm" class="LinkPage"&gt;Metformin&lt;/a&gt; might be started without &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Close interval follow-up, as persistent severe &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Hyperglycemia&lt;/a&gt; may be poorly responsive to oral agents initially&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Teach &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; testing, &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; injection today&lt;ol&gt;&lt;li&gt;Formal &lt;a href="../../Endo/DM/DbtcEdctn.htm" class="LinkPage"&gt;Diabetic Education&lt;/a&gt; within 1 week&lt;/li&gt;&lt;li&gt;Consider endocrinology consultation later&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Give prescriptions today&lt;ol&gt;&lt;li&gt;Meter, strips, lancets, &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt;, syringes&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Management: Initial Education&lt;ol&gt;&lt;li&gt;Key Topics&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Endo/DM/DbtsMltsGlcsMngmnt.htm" class="LinkPage"&gt;Diabetes Mellitus Glucose Management&lt;/a&gt;&lt;/li&gt;&lt;li&gt;See &lt;a href="../../Endo/DM/DbtcEdctn.htm" class="LinkPage"&gt;Diabetes Mellitus Education&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Type specific Diabetes Information&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Endo/DM/TypDbtsMlts.htm" class="LinkPage"&gt;Type I Diabetes Mellitus&lt;/a&gt;&lt;/li&gt;&lt;li&gt;See &lt;a href="../../Endo/DM/TypDbtsMlts1.htm" class="LinkPage"&gt;Type II Diabetes Mellitus&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Adjunctive Management&lt;ol&gt;&lt;li&gt;See &lt;a href="../../CV/Endo/HyprtnsnInDbtsMlts.htm" class="LinkPage"&gt;Hypertension in Diabetes Mellitus&lt;/a&gt;&lt;/li&gt;&lt;li&gt;See &lt;a href="../../CV/Endo/CrnryArtryDsPrvntnInDbts.htm" class="LinkPage"&gt;Coronary Artery Disease Prevention in Diabetes&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Psych/CD/TbcCstn.htm" class="LinkPage"&gt;Tobacco Cessation&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Weight loss&lt;/li&gt;&lt;li&gt;&lt;a href="../../Pharm/Analgesic/Asprn.htm" class="LinkPage"&gt;Aspirin&lt;/a&gt; (Guidelines as of 2012)&lt;ol&gt;&lt;li&gt;Has historically been considered in all diabetic patients or starting at age 45 years in men and age 55 years in women&lt;/li&gt;&lt;li&gt;&lt;a href="../../Pharm/Analgesic/Asprn.htm" class="LinkPage"&gt;Aspirin&lt;/a&gt; does not increase risk of &lt;a href="../../Eye/Anatomy/RtnlAntmy.htm" class="LinkPage"&gt;Retina&lt;/a&gt;l &lt;a href="../../ER/FEN/HmrhgcShck.htm" class="LinkPage"&gt;Hemorrhage&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Indications for low dose &lt;a href="../../Pharm/Analgesic/Asprn.htm" class="LinkPage"&gt;Aspirin&lt;/a&gt; 81 mg daily (Framingham risk &amp;gt;10%, no vascular disease, and no &lt;a href="../../HemeOnc/Sx/BldngDsrdr.htm" class="LinkPage"&gt;Bleeding Diathesis&lt;/a&gt;)&lt;ol&gt;&lt;li&gt;Males over age 50 years or females over age 60 years and&lt;/li&gt;&lt;li&gt;One additional &lt;a href="../../CV/Prevent/CrdcRsk.htm" class="LinkPage"&gt;Cardiovascular Risk Factor&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../Psych/CD/Cgrt.htm" class="LinkPage"&gt;Tobacco&lt;/a&gt; abuse&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Htn/Hyprtnsn.htm" class="LinkPage"&gt;Hypertension&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Dyslipidemia&lt;/li&gt;&lt;li&gt;Albuminuria&lt;/li&gt;&lt;li&gt;&lt;a href="../../Prevent/HME/FmlyHstry.htm" class="LinkPage"&gt;Family History&lt;/a&gt; of premature cardiovascular death&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Indications for &lt;a href="../../HemeOnc/Pharm/AntpltltThrpy.htm" class="LinkPage"&gt;Clopidogrel&lt;/a&gt; (&lt;a href="../../HemeOnc/Pharm/AntpltltThrpy.htm" class="LinkPage"&gt;Plavix&lt;/a&gt;) 75 mg daily&lt;ol&gt;&lt;li&gt;Known cardiovascular disease&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Consider &lt;a href="../../CV/Pharm/AcInhbtr.htm" class="LinkPage"&gt;ACE Inhibitor&lt;/a&gt; in all diabetic patients&lt;ol&gt;&lt;li&gt;Use low dose (2.5 to 5 mg) in normotensive patient&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Lab/Lpd.htm" class="LinkPage"&gt;Lipid&lt;/a&gt; disorders&lt;ol&gt;&lt;li&gt;See &lt;a href="../../CV/Endo/CrnryArtryDsPrvntnInDbts.htm" class="LinkPage"&gt;Coronary Artery Disease Prevention in Diabetes&lt;/a&gt;&lt;/li&gt;&lt;li&gt;See &lt;a href="../../CV/Prevent/LwFtDt.htm" class="LinkPage"&gt;Low Fat Diet&lt;/a&gt;&lt;/li&gt;&lt;li&gt;See &lt;a href="../../CV/Lipid/Anthyprlpdmc.htm" class="LinkPage"&gt;AntiHyperlipidemic&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0011849</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/DM/DbtsMlts.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Diabetes Mellitus</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/DM/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Cachexia  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0006625"&gt;&lt;i&gt;C0006625&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;General ill health, malnutrition, and weight loss, usually associated with chronic disease.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CSP)&lt;/td&gt;
                &lt;td&gt;state of general ill health characterized by malnutrition, weakness, and emaciation; occurs during the course of a chronic disease.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;The loss of body weight and muscle mass frequently seen in patients with cancer, AIDS, or other diseases.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Sign or Symptom (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0006625&amp;amp;tui=T184"&gt;&lt;i&gt;T184&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D002100&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD9&lt;/td&gt;
                &lt;td&gt;799.4&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD10&lt;/td&gt;
                &lt;td&gt;R64&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;207558009, 207560006, 28928000, 158737005, 238108007, 285384003&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;CACHEXIE, Cachexie&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;CACHECTIC, CACHEXIA, Cachexia, NOS, Cachexia NOS, [D]Cachexia, [D]Cachexia NOS, Cachexia, [D]Cachexia (context-dependent category), [D]Cachexia NOS (context-dependent category), cachectic (physical finding), cachectic, cachexia, Cachexia (disorder), [D]Cachexia (situation), [D]Cachexia NOS (situation), Cachexia [Disease/Finding], General body deterioration, Cachectic, Cachexia (finding), Cachexia (disorder) [Ambiguous]&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;CAQUEXIA, [D]caquexia, SAI (categoría dependiente del contexto), [D]caquexia (categoría dependiente del contexto), [D]Cachexia, Consunción, Consuncion, [D]caquexia, SAI (situación), [D]caquexia, SAI, [D]caquexia (situación), [D]caquexia, caquexia (concepto no activo), caquexia (hallazgo), caquexia (trastorno), caquexia, deterioro corporal general, Caquexia&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;KACHEXIE, Auszehrung, Kachexie&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;悪液質, ｱｸｴｷｼﾂ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Utmärgling&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;kachexie, Kachexie&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Consunção, CAQUEQUEXIA, Caquexia&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Kakeksia&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;KAKHEKSIIA, КАХЕКСИЯ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Korean&lt;/td&gt;
                &lt;td&gt;악액질&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Charłactwo, Kacheksja&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;Cachexia&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;cachexie, Cachexie&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Cachessia&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Wasting Syndrome  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0043046"&gt;&lt;i&gt;C0043046&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;A condition of involuntary weight loss of greater then 10% of baseline body weight. It is characterized by atrophy of muscles and depletion of lean body mass. Wasting is a sign of MALNUTRITION as a result of inadequate dietary intake, malabsorption, or hypermetabolism.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Disease or Syndrome (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0043046&amp;amp;tui=T047"&gt;&lt;i&gt;T047&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D019282&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD10&lt;/td&gt;
                &lt;td&gt;R64&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;207559001, 271878009, 288517002, 28928000&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Wasting syndrome, Wasting disease, NOS, Wasting Disease, Wasting Diseases, Wasting Syndrome, Wasting Syndromes, [D]Wasting disease, [D]Wasting disease (context-dependent category), WASTING GENERALIZED, WASTING DIS, wasting syndrome, Wasting disease (finding), Wasting generalized, WASTING SYNDROME, [D]Wasting disease (situation), Wasting Syndrome [Disease/Finding], wasting diseases, wasting disease, Wasting disease, Wasting disease (disorder), disease (or disorder); wasting, disease; wasting, syndrome; wasting, wasting; disease, wasting; syndrome&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;algehele vermagering, aandoening; slopend, slopend; aandoening, syndroom; uittering, uittering; syndroom, ziekte; uittering, Syndroom, Wasting-, Wasting-syndroom&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Atrophie généralisée, Syndrome de dépérissement, Syndrome cachectique, Syndrome de cachexie progressive, Syndrome de cachexie&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Verfall generalisiert, Auszehrungssyndrom, Wasting-Syndrom, Auszehrungskrankheit&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Deperimento generalizzato, Wasting sindrome&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Comsumpção generalizada, Doença Consumptiva, Doença de Emaciação, Doença do Definhamento, Doença do Emagrecimento, Síndrome de Emaciação, Síndrome do Definhamento&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;Consunción generalizada, [D]enfermedad emaciante (categoría dependiente del contexto), Wasting disease, [D]enfermedad emaciante, [D]enfermedad emaciante (situación), enfermedad consuntiva (trastorno), enfermedad consuntiva, enfermedad emaciante, Enfermedad Debilitante, Síndrome Debilitante, Sindrome de Consuncion, Síndrome de Consunción, Sindrome Debilitante&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;全身性消耗, ｾﾞﾝｼﾝｾｲｼｮｳﾓｳ, 消耗疾患, 消耗性症候群, 消耗症候群, 消耗性疾患, 消耗病&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Tärande syndrom&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;syndrom chřadnutí, Generalizované chřadnutí&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Näivetysoireyhtymä&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;ISTOSHCHENIIA SINDROM, ИСТОЩЕНИЯ СИНДРОМ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Choroba wyniszczająca, Zespół wyniszczenia&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;Általános lesoványodás&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Cachexia  (</value><value>)
</value><value>Wasting Syndrome  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Unintentional Weight Loss</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Geriatric Medicine</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;See Also&lt;ol&gt;&lt;li&gt;&lt;a href="../../HemeOnc/Endo/CchxInCncr.htm" class="LinkPage"&gt;Cachexia in Cancer&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Peds/FlrTThrv.htm" class="LinkPage"&gt;Failure to Thrive&lt;/a&gt; (Children)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Epidemiology: &lt;a href="../../Prevent/Epi/DsIncdncRt.htm" class="LinkPage"&gt;Incidence&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../Geri/Exam/NrsngHmCr.htm" class="LinkPage"&gt;Nursing Home&lt;/a&gt; residents: 25-40%&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Silver%20%20%5BAU%5D%20AND%201988%20%5BDP%5D%20AND%20%20J%20Am%20Geriatr%20Soc%20%20%5BTA%5D" class="LinkRef"&gt;Silver (1988) J Am Geriatr Soc 36:487-91&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Overall over age 64 years: 13%&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Murden%20%20%5BAU%5D%20AND%201994%20%5BDP%5D%20AND%20%20J%20Gen%20Intern%20Med%20%20%5BTA%5D" class="LinkRef"&gt;Murden (1994) J Gen Intern Med 9:648-50&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Causes&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Endo/Geri/UntntnlWghtLsCs.htm" class="LinkPage"&gt;Unintentional Weight Loss Causes&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/MdctnsAsctdWthUntntnlWghtLs.htm" class="LinkPage"&gt;Unintentional Weight Loss due to Medications&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;History&lt;ol&gt;&lt;li&gt;How much weight loss over how much time?&lt;ol&gt;&lt;li&gt;Patients down play weight changes&lt;/li&gt;&lt;li&gt;Clothing or belt size changes&lt;/li&gt;&lt;li&gt;Impressions of friends and family on weight change&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Associated Gastrointestinal Symptoms&lt;ol&gt;&lt;li&gt;&lt;a href="../../GI/Sx/Vmtng.htm" class="LinkPage"&gt;Nausea&lt;/a&gt; or &lt;a href="../../GI/Sx/Vmtng.htm" class="LinkPage"&gt;Vomiting&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../GI/Diarrhea/ChrncDrh.htm" class="LinkPage"&gt;Chronic Diarrhea&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../GI/Diarrhea/InfctsDrh.htm" class="LinkPage"&gt;Infectious Diarrhea&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../GI/IBD/InflmtryBwlDs.htm" class="LinkPage"&gt;Inflammatory Bowel Disease&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Malabsorption (e.g. &lt;a href="../../GI/Malabsorption/GltnEntrpthy.htm" class="LinkPage"&gt;Celiac Sprue&lt;/a&gt;)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Surgery/GI/ActAbdmnlPn.htm" class="LinkPage"&gt;Abdominal Pain&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../GI/PUD/PptcUlcrDs.htm" class="LinkPage"&gt;Peptic Ulcer Disease&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Surgery/GI/BlryClc.htm" class="LinkPage"&gt;Biliary Colic&lt;/a&gt;, &lt;a href="../../Surgery/GI/ActChlcysts.htm" class="LinkPage"&gt;Cholecystitis&lt;/a&gt; or &lt;a href="../../Surgery/GI/Glstn.htm" class="LinkPage"&gt;Cholelithiasis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Surgery/GI/MsntrcIschm.htm" class="LinkPage"&gt;Mesenteric Ischemia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Surgery/GI/SmlBwlObstrctn.htm" class="LinkPage"&gt;Small Bowel Obstruction&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../GI/IBD/InflmtryBwlDs.htm" class="LinkPage"&gt;Inflammatory Bowel Disease&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Associated Symptoms&lt;ol&gt;&lt;li&gt;Lethargy or weakness&lt;ol&gt;&lt;li&gt;Underlying neuromuscular condition&lt;/li&gt;&lt;li&gt;&lt;a href="../../Psych/Pharm/Alchl.htm" class="LinkPage"&gt;Alcohol&lt;/a&gt; or &lt;a href="../../Psych/CD/ChmclDpndncy.htm" class="LinkPage"&gt;Drug Abuse&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Preoccupation with thinness&lt;ol&gt;&lt;li&gt;&lt;a href="../../Psych/Eating/AnrxNrvs.htm" class="LinkPage"&gt;Anorexia Nervosa&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Dietary history&lt;ol&gt;&lt;li&gt;General Questions&lt;ol&gt;&lt;li&gt;Are meals skipped?&lt;/li&gt;&lt;li&gt;Does the patient need help preparing meals?&lt;/li&gt;&lt;li&gt;Are meals well balanced (&lt;a href="../../Pharm/Nutrition/NtrtnGdlns.htm" class="LinkPage"&gt;Food Pyramid&lt;/a&gt;)?&lt;/li&gt;&lt;li&gt;Are any &lt;a href="../../Pharm/Nutrition/EntrlNtrtn.htm" class="LinkPage"&gt;Nutritional Supplement&lt;/a&gt;s used?&lt;/li&gt;&lt;li&gt;Is patient following any dietary restrictions?&lt;/li&gt;&lt;li&gt;Is there concurrent drug or &lt;a href="../../Psych/Pharm/Alchl.htm" class="LinkPage"&gt;Alcohol&lt;/a&gt; use?&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/MdctnsAsctdWthUntntnlWghtLs.htm" class="LinkPage"&gt;Unintentional Weight Loss due to Medications&lt;/a&gt;?&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Food is not appealing&lt;ol&gt;&lt;li&gt;Malignancy&lt;/li&gt;&lt;li&gt;Medication adverse effects&lt;/li&gt;&lt;li&gt;&lt;a href="../../Psych/Depress/MjrDprsn.htm" class="LinkPage"&gt;Major Depression&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Altered &lt;a href="../../ENT/Sx/TstSnstn.htm" class="LinkPage"&gt;Taste Sensation&lt;/a&gt; (&lt;a href="../../ENT/Sx/TstSnstn.htm" class="LinkPage"&gt;Dysgeusia&lt;/a&gt;)&lt;ol&gt;&lt;li&gt;Medication adverse effects&lt;/li&gt;&lt;li&gt;Acute Hepatitis or &lt;a href="../../GI/Prevent/PrvntnOfLvrDsPrgrsn.htm" class="LinkPage"&gt;Chronic Liver Disease&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../ENT/Sinus/Rhnsnsts.htm" class="LinkPage"&gt;Sinusitis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Vitamin B Deficiency&lt;/li&gt;&lt;li&gt;&lt;a href="../../Pharm/Minerals/ZncDfcncy.htm" class="LinkPage"&gt;Zinc Deficiency&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Mental health concerns&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Mechanical problems (affects chewing and swallowing)&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Neuro/Exam/Dysphg.htm" class="LinkPage"&gt;Dysphagia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;See &lt;a href="../../Lung/Sx/ActDyspn.htm" class="LinkPage"&gt;Dyspnea&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Poorly fitting Dentures&lt;/li&gt;&lt;li&gt;Painful &lt;a href="../../Dental/Exam/OrlLsn.htm" class="LinkPage"&gt;Oral Lesion&lt;/a&gt;s (e.g. &lt;a href="../../ID/Fungus/Cnds.htm" class="LinkPage"&gt;Candidiasis&lt;/a&gt;, &lt;a href="../../Dental/Gingiva/Gngvts.htm" class="LinkPage"&gt;Gingivitis&lt;/a&gt;)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Weight loss despite increased appetite&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/Hyprthyrdsm1.htm" class="LinkPage"&gt;Hyperthyroidism&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/DM/DbtsMlts.htm" class="LinkPage"&gt;Diabetes Mellitus&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../GI/Malabsorption/GltnEntrpthy.htm" class="LinkPage"&gt;Celiac Sprue&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Pancreatic Insufficiency&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Exam&lt;ol&gt;&lt;li&gt;Record accurate weights on same scale at every visit&lt;ol&gt;&lt;li&gt;Unexplained weight loss &amp;gt;5% should be investigated&lt;/li&gt;&lt;li&gt;Anticipated time for 15% weight loss&lt;ol&gt;&lt;li&gt;Complete starvation: 15% of weight lost in 3 weeks&lt;/li&gt;&lt;li&gt;Half of normal food intake: 3 months&lt;/li&gt;&lt;li&gt;Half food intake and comorbid conditions: 3 weeks&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Vital sign clues&lt;ol&gt;&lt;li&gt;&lt;a href="../../ID/Exam/Fvr.htm" class="LinkPage"&gt;Fever&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/EKG/Tchycrd.htm" class="LinkPage"&gt;Tachycardia&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Exam/BdyMsIndx.htm" class="LinkPage"&gt;Body Mass Index&lt;/a&gt; (BMI) predicts mortality in elderly&lt;ol&gt;&lt;li&gt;Women: BMI &amp;lt;22 kg/m2 predicts increased mortality&lt;/li&gt;&lt;li&gt;Men: BMI &amp;lt;23.5 kg/m2 predicts increased mortality&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Calle%20%20%5BAU%5D%20AND%201999%20%5BDP%5D%20AND%20%20N%20Engl%20J%20Med%20%20%5BTA%5D" class="LinkRef"&gt;Calle (1999) N Engl J Med 341:1097-105&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Head and neck changes&lt;ol&gt;&lt;li&gt;&lt;a href="../../Dental/Exam/Dntn.htm" class="LinkPage"&gt;Dentition&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../ENT/Sx/TngPn.htm" class="LinkPage"&gt;Glossitis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Thyromegaly&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Cognition&lt;ol&gt;&lt;li&gt;&lt;a href="../../Neuro/Exam/MnMntlStExm.htm" class="LinkPage"&gt;Mini-Mental State Exam&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Function: &lt;a href="../../Geri/Prevent/ActvtsOfDlyLvng.htm" class="LinkPage"&gt;Activities of Daily Living&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../Geri/Exam/ActvtsOfDlyLvngScl.htm" class="LinkPage"&gt;Katz ADL Scale&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Geri/Exam/InstrmntlActvtsOfDlyLvng.htm" class="LinkPage"&gt;Lawton IADL Scale&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Geri/Exam/SxMntWlkTst.htm" class="LinkPage"&gt;Six-Minute Walk Test&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Psych/Geri/DprsnInOldrAdlts.htm" class="LinkPage"&gt;Geriatric Depression&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../Psych/Exam/GrtrcDprsnScl.htm" class="LinkPage"&gt;Geriatric Depression Scale&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Malnutrition&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Pharm/Lab/LbMrkrsOfMlntrtn.htm" class="LinkPage"&gt;Lab Markers of Malnutrition&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Mini-Nutritional Assessment (Nestle Nutrition)&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.mna-elderly.com/clinical-practice.htm" class="LinkWebExt"&gt;http://www.mna-elderly.com/clinical-practice.htm&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Other examination focus areas&lt;ol&gt;&lt;li&gt;Loss of soft tissue mass in face and extremities&lt;/li&gt;&lt;li&gt;Abdominal masses&lt;/li&gt;&lt;li&gt;&lt;a href="../../HemeOnc/Lymph/Lymphdnpthy.htm" class="LinkPage"&gt;Lymphadenopathy&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Neuro/Sx/PrphrlNrpthy.htm" class="LinkPage"&gt;Peripheral Neuropathy&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Labs: Initial (Directed by history and physical)&lt;ol&gt;&lt;li&gt;&lt;a href="../../GI/Exam/Dfctn.htm" class="LinkPage"&gt;Stool&lt;/a&gt; studies&lt;ol&gt;&lt;li&gt;&lt;a href="../../GI/Lab/FclOcltBld.htm" class="LinkPage"&gt;Fecal Occult Blood&lt;/a&gt; (3 samples)&lt;/li&gt;&lt;li&gt;&lt;a href="../../GI/Exam/Dfctn.htm" class="LinkPage"&gt;Stool&lt;/a&gt; for &lt;a href="../../GI/Lab/PrstExmntnOfThStl.htm" class="LinkPage"&gt;Ova and Parasite&lt;/a&gt;s&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../HemeOnc/Lab/CmpltBldCnt.htm" class="LinkPage"&gt;Complete Blood Count&lt;/a&gt; with differential&lt;/li&gt;&lt;li&gt;&lt;a href="../../Uro/Lab/Urnlys.htm" class="LinkPage"&gt;Urinalysis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/ThyrdStmltngHrmn.htm" class="LinkPage"&gt;Thyroid Stimulating Hormone&lt;/a&gt; (TSH)&lt;/li&gt;&lt;li&gt;&lt;a href="../../HIV/Lab/HvTst.htm" class="LinkPage"&gt;HIV Test&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../ID/Lab/RpdPlsmRgn.htm" class="LinkPage"&gt;Rapid Plasma Reagin&lt;/a&gt; (RPR)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Lung/Lab/TbrclnSknTst.htm" class="LinkPage"&gt;Tuberculin Skin Test&lt;/a&gt; (PPD)&lt;/li&gt;&lt;li&gt;Chemistry Panel (&lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt;, electrolytes, &lt;a href="../../Renal/Lab/RnlFnctn.htm" class="LinkPage"&gt;Renal Function&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;Acute phase reactants&lt;ol&gt;&lt;li&gt;&lt;a href="../../HemeOnc/Lab/ErythrcytSdmntnRt.htm" class="LinkPage"&gt;Erythrocyte Sedimentation Rate&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../HemeOnc/Lab/CRctvPrtn.htm" class="LinkPage"&gt;C-Reactive Protein&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;See &lt;a href="../../Pharm/Lab/LbMrkrsOfMlntrtn.htm" class="LinkPage"&gt;Lab Markers of Malnutrition&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Labs: Diagnostic testing to consider&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/HmnGrwthHrmn.htm" class="LinkPage"&gt;Growth Hormone&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Uro/Lab/TtlTststrn.htm" class="LinkPage"&gt;Serum Testosterone&lt;/a&gt; in men&lt;/li&gt;&lt;li&gt;&lt;a href="../../ID/Lab/BldCltr.htm" class="LinkPage"&gt;Blood Culture&lt;/a&gt; (if febrile)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Lung/Rad/ChstXry.htm" class="LinkPage"&gt;Chest XRay&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Upper gastrointestinal series or Upper Endoscopy&lt;/li&gt;&lt;li&gt;&lt;a href="../../GI/Procedure/FlxblSgmdscpy.htm" class="LinkPage"&gt;Flexible Sigmoidoscopy&lt;/a&gt; or &lt;a href="../../GI/Procedure/ClnCncrScrngWthClnscpy.htm" class="LinkPage"&gt;Colonoscopy&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Gyn/Rad/Mmgrm.htm" class="LinkPage"&gt;Mammogram&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Screening with CT Scan not recommended (low yield)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Labs: Malabsorption (when indicated)&lt;ol&gt;&lt;li&gt;Fecal fat (sudan stain)&lt;/li&gt;&lt;li&gt;Serum carotene&lt;/li&gt;&lt;li&gt;Serum &lt;a href="../../Pharm/Vitamins/FlcAcd.htm" class="LinkPage"&gt;Folic Acid&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Evaluation Resources&lt;ol&gt;&lt;li&gt;Mini-Nutritional Assessment (Nestle Nutrition)&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.mna-elderly.com/clinical-practice.htm" class="LinkWebExt"&gt;http://www.mna-elderly.com/clinical-practice.htm&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Cognition&lt;ol&gt;&lt;li&gt;&lt;a href="../../Neuro/Exam/MnMntlStExm.htm" class="LinkPage"&gt;Mini-Mental State Exam&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Function: &lt;a href="../../Geri/Prevent/ActvtsOfDlyLvng.htm" class="LinkPage"&gt;Activities of Daily Living&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../Geri/Exam/ActvtsOfDlyLvngScl.htm" class="LinkPage"&gt;Katz ADL Scale&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Geri/Exam/InstrmntlActvtsOfDlyLvng.htm" class="LinkPage"&gt;Lawton IADL Scale&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Geri/Exam/SxMntWlkTst.htm" class="LinkPage"&gt;Six-Minute Walk Test&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Psych/Geri/DprsnInOldrAdlts.htm" class="LinkPage"&gt;Geriatric Depression&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../Psych/Exam/GrtrcDprsnScl.htm" class="LinkPage"&gt;Geriatric Depression Scale&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Management: Empiric&lt;ol&gt;&lt;li&gt;Identify underlying cause&lt;/li&gt;&lt;li&gt;Referrals&lt;ol&gt;&lt;li&gt;Dietician&lt;/li&gt;&lt;li&gt;Speech Therapy (swallowing evaluation)&lt;/li&gt;&lt;li&gt;Social services&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;General Measures&lt;ol&gt;&lt;li&gt;Increase meal frequency with manageable servings&lt;/li&gt;&lt;li&gt;Consider flavor enhancers (indicated in &lt;a href="../../ENT/Sx/LsOfSml.htm" class="LinkPage"&gt;Hyposmia&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;Eliminate or reduce dietary restrictions&lt;/li&gt;&lt;li&gt;Consider Meals on Wheels or senior dining facility&lt;/li&gt;&lt;li&gt;Choose foods with high calorie density&lt;ol&gt;&lt;li&gt;Consider dietary supplements (e.g. Ensure)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Correct ill fitting dentures&lt;/li&gt;&lt;li&gt;Encourage &lt;a href="../../Sports/Exercise/Exrcs.htm" class="LinkPage"&gt;Physical Activity&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Medications&lt;ol&gt;&lt;li&gt;Treat &lt;a href="../../Psych/Depress/MjrDprsn.htm" class="LinkPage"&gt;Major Depression&lt;/a&gt;: &lt;a href="../../Psych/Pharm/SlctvSrtnRptkInhbtr.htm" class="LinkPage"&gt;SSRI&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../Psych/Pharm/Mrtzpn.htm" class="LinkPage"&gt;Mirtazapine&lt;/a&gt; (&lt;a href="../../Psych/Pharm/Mrtzpn.htm" class="LinkPage"&gt;Remeron&lt;/a&gt;)&lt;ol&gt;&lt;li&gt;May be preferred &lt;a href="../../Psych/Pharm/SlctvSrtnRptkInhbtr.htm" class="LinkPage"&gt;SSRI&lt;/a&gt; in &lt;a href="../../Endo/Peds/FlrTThrv.htm" class="LinkPage"&gt;Failure to Thrive&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Raji%20%20%5BAU%5D%20AND%202001%20%5BDP%5D%20AND%20%20Ann%20Pharmacother%20%20%5BTA%5D" class="LinkRef"&gt;Raji (2001) Ann Pharmacother 35:1024-7&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Psych/Pharm/Flxtn.htm" class="LinkPage"&gt;Fluoxetine&lt;/a&gt; (&lt;a href="../../Psych/Pharm/Flxtn.htm" class="LinkPage"&gt;Prozac&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Psych/Pharm/Srtrln.htm" class="LinkPage"&gt;Sertraline&lt;/a&gt; (&lt;a href="../../Psych/Pharm/Srtrln.htm" class="LinkPage"&gt;Zoloft&lt;/a&gt;)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Cannabinoid: Dronabinol (Marinol)&lt;ol&gt;&lt;li&gt;Adverse effects: &lt;a href="../../Surgery/Anesthesia/PrcdrlSdtnAndAnlgs.htm" class="LinkPage"&gt;Sedation&lt;/a&gt; and confusion&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Medications that are no longer recommended due to lower efficacy and higher risk&lt;ol&gt;&lt;li&gt;Megestrol (Megace)&lt;ol&gt;&lt;li&gt;Typical dose: 320 mg to 800 mg PO qd&lt;/li&gt;&lt;li&gt;Adverse effects: edema, &lt;a href="../../GI/Constipation/CnstptnInAdlts.htm" class="LinkPage"&gt;Constipation&lt;/a&gt; and &lt;a href="../../Neuro/Cognitive/Dlrm.htm" class="LinkPage"&gt;Delirium&lt;/a&gt;; thrombosis risk&lt;/li&gt;&lt;li&gt;Low efficacy in appetite stimulation&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Complications of weight loss below 10-20% normal weight&lt;ol&gt;&lt;li&gt;Increased mortality approaches 16%&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Sullivan%20%20%5BAU%5D%20AND%201991%20%5BDP%5D%20AND%20%20Am%20J%20Clin%20Nutr%20%20%5BTA%5D" class="LinkRef"&gt;Sullivan (1991) Am J Clin Nutr 53:599-605&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Overall increase in morbidity&lt;ol&gt;&lt;li&gt;Weakness or &lt;a href="../../Rheum/Sx/Ftg.htm" class="LinkPage"&gt;Fatigue&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Muscle wasting&lt;/li&gt;&lt;li&gt;Immunosuppression&lt;/li&gt;&lt;li&gt;Skin breakdown&lt;/li&gt;&lt;li&gt;Mood changes (Apathy, Irritability)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;Heizer in Dornbrand (1992) Ambulatory Care, p. 15-18&lt;/li&gt;&lt;li&gt;Karsh in Friedman (1991) Medical Diagnosis, p. 13-16&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Dwyer%20%20%5BAU%5D%20AND%201993%20%5BDP%5D%20AND%20%20Am%20Fam%20Physician%20%20%5BTA%5D" class="LinkRef"&gt;Dwyer (1993) Am Fam Physician 47(3):613-20&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Grazewood%20%20%5BAU%5D%20AND%201998%20%5BDP%5D%20AND%20%20J%20Fam%20Pract%20%20%5BTA%5D" class="LinkRef"&gt;Grazewood (1998) J Fam Pract 47(1): 19-25&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Huffman%20%20%5BAU%5D%20AND%202002%20%5BDP%5D%20AND%20%20Am%20Fam%20Physician%20%20%5BTA%5D" class="LinkRef"&gt;Huffman (2002) Am Fam Physician 65(4):640-50&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Morley%20%20%5BAU%5D%20AND%201995%20%5BDP%5D%20AND%20%20Ann%20Intern%20Med%20%20%5BTA%5D" class="LinkRef"&gt;Morley (1995) Ann Intern Med 123:850-9&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Robertson%20%20%5BAU%5D%20AND%202004%20%5BDP%5D%20AND%20%20Am%20Fam%20Physician%20%20%5BTA%5D" class="LinkRef"&gt;Robertson (2004) Am Fam Physician 70:343-50&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=White%20%20%5BAU%5D%20AND%201991%20%5BDP%5D%20AND%20%20Am%20Fam%20Physician%20%20%5BTA%5D" class="LinkRef"&gt;White (1991) Am Fam Physician 44(6): 2087-97&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Zawada%20%20%5BAU%5D%20AND%201996%20%5BDP%5D%20AND%20%20Postgrad%20Med%20%20%5BTA%5D" class="LinkRef"&gt;Zawada (1996) Postgrad Med 100(1):207-25&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0006625</value><value>C0043046</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Geri/UntntnlWghtLs.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Unintentional Weight Loss, Geriatric Failure to Thrive, Cachexia, Wasting Syndrome</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Geri/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Tall stature  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0241240"&gt;&lt;i&gt;C0241240&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Finding (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0241240&amp;amp;tui=T033"&gt;&lt;i&gt;T033&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;248328003&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;STATURE TALL, stature tall, Stature tall, Large stature, Tall stature, Tall stature (finding), stature; tall, tall; stature, tall stature&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;grote gestalte, gestalte; groot, groot; gestalte&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Grande taille&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Statur grossgeachsen&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Statura alta&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Estatura alta&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;Estatura alta, alta estatura (hallazgo), alta estatura, talla alta&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;高身長, ｺｳｼﾝﾁｮｳ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;Vysoký vzrůst&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;Termet magas&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Tall stature  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Tall Stature</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Growth Disorders</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Causes&lt;ol&gt;&lt;li&gt;Constitutional Tall Stature&lt;/li&gt;&lt;li&gt;Familial Tall Stature&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/HmnGrwthHrmn.htm" class="LinkPage"&gt;Growth Hormone&lt;/a&gt; secreting tumors (&lt;a href="../../Endo/Pituitary/Ggntsm.htm" class="LinkPage"&gt;Gigantism&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/Hyprthyrdsm1.htm" class="LinkPage"&gt;Thyrotoxicosis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Growth/MrfnsSyndrm.htm" class="LinkPage"&gt;Marfan Syndrome&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Metabolism/Hmcystnr.htm" class="LinkPage"&gt;Homocystinuria&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Growth/CrbrlGgntsm.htm" class="LinkPage"&gt;Cerebral Gigantism&lt;/a&gt; (&lt;a href="../../Endo/Growth/CrbrlGgntsm.htm" class="LinkPage"&gt;Soto Syndrome&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;Beckwith-Wiedemann Syndrome&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Adrenal/CngntlAdrnlHyprpls.htm" class="LinkPage"&gt;Congenital Adrenal Hyperplasia&lt;/a&gt; (Untreated, pubertal)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Sex/KlnfltrSyndrm.htm" class="LinkPage"&gt;Klinefelter Syndrome&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Obesity/Obsty.htm" class="LinkPage"&gt;Obesity&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Sex/PrcsPbrty.htm" class="LinkPage"&gt;Precocious Puberty&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Evaluation&lt;ol&gt;&lt;li&gt;Assess parental heights!&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Endo/Exam/MdprntlHght.htm" class="LinkPage"&gt;Midparental Height&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Exam/WghtMsrmntInChldrn.htm" class="LinkPage"&gt;Weight Measurement in Children&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Exam/HghtMsrmntInChldrn.htm" class="LinkPage"&gt;Height Measurement in Children&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Exam/BdyMsIndx.htm" class="LinkPage"&gt;Body Mass Index&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Exam/WghtFrHghtAg.htm" class="LinkPage"&gt;Weight for Height Age&lt;/a&gt;&lt;/li&gt;&lt;li&gt;See &lt;a href="../../Endo/Exam/DysmrphcFtrsInCngntlDysrdrs.htm" class="LinkPage"&gt;Dysmorphic features in Congenital Dysorders&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Exam/UprTLwrSgmntRt.htm" class="LinkPage"&gt;Upper to Lower Segment Ratio&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Labs: Specific&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/HmnGrwthHrmn.htm" class="LinkPage"&gt;Growth Hormone&lt;/a&gt; Level (&lt;a href="../../Endo/Pituitary/Ggntsm.htm" class="LinkPage"&gt;Gigantism&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/ThyrdStmltngHrmn.htm" class="LinkPage"&gt;Thyroid Stimulating Hormone&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Amino acid screen (&lt;a href="../../Endo/Metabolism/Hmcystnr.htm" class="LinkPage"&gt;Homocystinuria&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;Chromosome Karyotype (&lt;a href="../../Endo/Sex/KlnfltrSyndrm.htm" class="LinkPage"&gt;Klinefelter Syndrome&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;17-Hydroxyprogesterone (&lt;a href="../../Endo/Adrenal/CngntlAdrnlHyprpls.htm" class="LinkPage"&gt;Congenital Adrenal Hyperplasia&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; (Beckwith-Wiedemann)&lt;/li&gt;&lt;li&gt;Androgen and &lt;a href="../../Gyn/Pharm/Estrgn.htm" class="LinkPage"&gt;Estrogen&lt;/a&gt; levels (&lt;a href="../../Endo/Sex/PrcsPbrty.htm" class="LinkPage"&gt;Precocious Puberty&lt;/a&gt;)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Imaging&lt;ol&gt;&lt;li&gt;Bone age XRay&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Evaluation&lt;ol&gt;&lt;li&gt;Normal exam, bone age and no dysmorphic features&lt;ol&gt;&lt;li&gt;Constitutional Tall Stature&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Normal exam without dysmorphic features, but with accelerated bone age&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Obesity/Obsty.htm" class="LinkPage"&gt;Obesity&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Sex/PrcsPbrty.htm" class="LinkPage"&gt;Precocious Puberty&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/HmnGrwthHrmn.htm" class="LinkPage"&gt;Growth Hormone&lt;/a&gt; excess&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Dysmorphic features and proportionate growth&lt;ol&gt;&lt;li&gt;Beckwith-Wiedemann Syndrome&lt;/li&gt;&lt;li&gt;Weaver Syndrome&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Dysmorphic features and dysproportionate growth&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Sex/KlnfltrSyndrm.htm" class="LinkPage"&gt;Klinefelter Syndrome&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Sotos Syndrome&lt;/li&gt;&lt;li&gt;&lt;a href="../../Gyn/Pharm/Estrgn.htm" class="LinkPage"&gt;Estrogen&lt;/a&gt; deficiency&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Alpert%20%20%5BAU%5D%20AND%201998%20%5BDP%5D%20AND%20%20Pediatr%20Rev%20%20%5BTA%5D" class="LinkRef"&gt;Alpert (1998) Pediatr Rev 19(9):303-5&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Cuttler%20%20%5BAU%5D%20AND%201987%20%5BDP%5D%20AND%20%20Pediatrician%20%20%5BTA%5D" class="LinkRef"&gt;Cuttler (1987) Pediatrician 14(3):109-20&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Leung%20%20%5BAU%5D%20AND%201995%20%5BDP%5D%20AND%20%20Can%20Fam%20Physician%20%20%5BTA%5D" class="LinkRef"&gt;Leung (1995) Can Fam Physician 41:457-68&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Nwosu%20%20%5BAU%5D%20AND%202008%20%5BDP%5D%20AND%20%20Am%20Fam%20Physician%20%20%5BTA%5D" class="LinkRef"&gt;Nwosu (2008) Am Fam Physician 78(5): 597-4&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Rosenfield%20%20%5BAU%5D%20AND%201996%20%5BDP%5D%20AND%20%20Endocrinol%20Metab%20Clin%20North%20Am%20%20%5BTA%5D" class="LinkRef"&gt;Rosenfield (1996) Endocrinol Metab Clin North Am 25:743&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0241240</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Growth/TlStr.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Tall Stature</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Growth/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Achondroplasia  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0001080"&gt;&lt;i&gt;C0001080&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;An autosomal dominant disorder that is the most frequent form of short-limb dwarfism. Affected individuals exhibit short stature caused by rhizomelic shortening of the limbs, characteristic facies with frontal bossing and mid-face hypoplasia, exaggerated lumbar lordosis, limitation of elbow extension, GENU VARUM, and trident hand. (Online Mendelian Inheritance in Man, http://www.ncbi.nlm.nih.gov/Omim, MIM#100800, April 20, 2001)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CSP)&lt;/td&gt;
                &lt;td&gt;autosomal dominant disorder that is the most frequent form of short-limb dwarfism; a disturbance of epiphyseal chondroblastic growth, causing inadequate enchondral bone formation.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;An autosomal dominant disorder that is the most frequent form of short-limb dwarfism. Affected individuals exhibit short stature caused by rhizomelic shortening of the limbs, characteristic facies with frontal bossing and mid-face hypoplasia, exaggerated lumbar lordosis, limitation of elbow extension, genu varum, and trident hand. (MeSH)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Congenital Abnormality (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0001080&amp;amp;tui=T019"&gt;&lt;i&gt;T019&lt;/i&gt;&lt;/a&gt;)
, Disease or Syndrome (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0001080&amp;amp;tui=T047"&gt;&lt;i&gt;T047&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D000130&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD10&lt;/td&gt;
                &lt;td&gt;Q77.4&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;190584003, 268273004, 86268005, 205467007, 268350005, 248299001&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Achondroplasias, CHONDRODYSTROPHIA FETALIS, DWARFISM, ACHONDROPLASTIC, Dwarf, achondroplastic, Achondroplastic physique, Chondrodystrophia foetalis, Physiologic dwarfism, Achondroplasia, Achondroplasia syndrome, Chondrodystrophy syndrome, ACHONDROPLASIA, ACH, achondroplasia, achondroplasia (diagnosis), DWARFISM ACHONDROPLASTIC, Achondroplasia [Disease/Finding], Achondroplastic Dwarf, chondrodystrophia, achondroplastic dwarfism, Chondrodystrophia fetalis, Congenital osteosclerosis, Achondroplastic dwarf, Achondroplastic dwarfism, Achondroplasia (disorder), Osteosclerosis congenita, chondrodysplasia; fetalis, dwarfism; achondroplastic, fetal; chondrodysplasia, achondroplastic; dwarfism, Achondroplastic physique (finding), osteosclerosis congenita, Chondrodystrophia, achondroplastic dwarf&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;achondroplastische dwerg, achondroplasie, achondroplastisch; dwerggroei, chondrodysplasie; foetalis, dwerggroei; achondroplastisch, foetaal; chondrodysplasie, Achondroplasia, Achondroplasie, Chondroplasie, a-&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Nain achondroplastique, Achondroplasie&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;achondroplastischer Zwerg, Achondroplasie&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Nanismo acondroplasico, Acondroplasia&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Nanismo acondroplásico, Acondroplasia&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;Enanismo acondroplásico, Achondroplasia, Achondroplastic dwarf, Achondroplastic dwarfism, acondroplasia (trastorno), acondroplasia, condrodistrofia fetal, enano acondroplásico, complexión física de tipo acondroplásico, constitución física acondroplásica (hallazgo), constitución física acondroplásica, enanismo constitucional, enanismo psicológico, físico acondroplásico, Acondroplasia&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;軟骨無形成症, ﾅﾝｺﾂﾑｹｲｾｲｼｮｳ, ﾅﾝｺﾂｹｲｾｲﾌｾﾞﾝｾｲﾃｲｼﾝﾁｮｳｼｮｳ, 軟骨形成不全性低身長症&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Akondroplasi&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;achondroplazie, Achondroplazie, Achondroplastický trpaslík&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Akondroplasia&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;APLAZIIA DIAFIZARNAIA, KHONDRODISTROFIIA GIPOPLASTICHESKAIA, AKHONDROPLAZIIA, KHONDRODISTROFIIA, KHONDRODISTROFIIA VROZHDENNAIA, PARRO-MARI BOLEZN', АПЛАЗИЯ ДИАФИЗАРНАЯ, АХОНДРОПЛАЗИЯ, ПАРРО-МАРИ БОЛЕЗНЬ, ХОНДРОДИСТРОФИЯ, ХОНДРОДИСТРОФИЯ ВРОЖДЕННАЯ, ХОНДРОДИСТРОФИЯ ГИПОПЛАСТИЧЕСКАЯ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Korean&lt;/td&gt;
                &lt;td&gt;연골무형성증&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Croatian&lt;/td&gt;
                &lt;td&gt;AHONDROPLAZIJA&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Achondroplazja&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;Achondroplasiás törpe, Achondroplasia&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Achondroplasia  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Achondroplasia</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Growth Disorders</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Epidemiology&lt;ol&gt;&lt;li&gt;&lt;a href="../../Prevent/Epi/DsIncdncRt.htm" class="LinkPage"&gt;Incidence&lt;/a&gt;: 1 in 40,000 births&lt;/li&gt;&lt;li&gt;Most common etiology for short-limb syndrome&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Pathophysiology&lt;ol&gt;&lt;li&gt;Hereditary (autosomal dominant)&lt;/li&gt;&lt;li&gt;Disease of cartilage and endochondral bone growth&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Signs&lt;ol&gt;&lt;li&gt;Facial features&lt;ol&gt;&lt;li&gt;Recessed nasal bridge&lt;/li&gt;&lt;li&gt;Large brachiocephalic head (prominent forehead)&lt;/li&gt;&lt;li&gt;Prominent jaw&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Trunk and spine features&lt;ol&gt;&lt;li&gt;Normal trunk&lt;/li&gt;&lt;li&gt;Dorsal kyphosis&lt;/li&gt;&lt;li&gt;Backward-tilting &lt;a href="../../Ortho/Anatomy/ScrlAntmy.htm" class="LinkPage"&gt;Sacrum&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Slight Abdominal distention&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Limb features&lt;ol&gt;&lt;li&gt;Rhizomelic limb shortening&lt;/li&gt;&lt;li&gt;Short muscular limbs&lt;/li&gt;&lt;li&gt;Stubby hands with thick fingers&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Associated conditions&lt;ol&gt;&lt;li&gt;Eustachian tube dysfunction&lt;/li&gt;&lt;li&gt;&lt;a href="../../Lung/Apnea/SlpApn.htm" class="LinkPage"&gt;Sleep Apnea&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Neuro/CSF/Hydrcphls.htm" class="LinkPage"&gt;Hydrocephalus&lt;/a&gt; (infants)&lt;/li&gt;&lt;li&gt;Lumbosacral spinal stenosis&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Radiology: Skeletal XRay&lt;ol&gt;&lt;li&gt;Short bowed wide bones with expanded ends&lt;/li&gt;&lt;li&gt;Increased bone density&lt;/li&gt;&lt;li&gt;Characteristic cupping of metaphases&lt;/li&gt;&lt;li&gt;Incomplete glenoid fossa and acetabulum&lt;/li&gt;&lt;li&gt;Wide joint spaces&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Course&lt;ol&gt;&lt;li&gt;Adult height: 4 feet&lt;/li&gt;&lt;li&gt;Normal intelligence development&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Hall%20%20%5BAU%5D%20AND%201995%20%5BDP%5D%20AND%20%20Pediatrics%20%20%5BTA%5D" class="LinkRef"&gt;Hall (1995) Pediatrics 95:443-451&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0001080</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Growth/Achndrpls.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Achondroplasia, Congenital Dwarfism</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Growth/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Dwarfism  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0013336"&gt;&lt;i&gt;C0013336&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MEDLINEPLUS)&lt;/td&gt;
                &lt;td&gt;
                  &lt;span&gt;
                    &lt;p&gt;A dwarf is a person of short stature - under 4â 10â as an adult. More than 200 different conditions can cause dwarfism. A single type, called achondroplasia, causes about 70 percent of all dwarfism. Achondroplasia is a genetic condition that affects about 1 in 25,000 people. It makes your arms and legs short in comparison to your head and trunk. Other genetic conditions, kidney disease and problems with metabolism or hormones can also cause short stature.&lt;/p&gt;
                    &lt;p&gt;Dwarfism itself is not a disease. However, there is a greater risk of some health problems With proper medical care, most people with dwarfism have active lives and live as long as other people.&lt;/p&gt;
                  &lt;/span&gt;
                &lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CSP)&lt;/td&gt;
                &lt;td&gt;condition of being undersized as a result of premature arrest of skeletal growth.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;A genetic or pathological condition that is characterized by short stature and undersize. Abnormal skeletal growth usually results in an adult who is significantly below the average height.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Congenital Abnormality (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0013336&amp;amp;tui=T019"&gt;&lt;i&gt;T019&lt;/i&gt;&lt;/a&gt;)
, Disease or Syndrome (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0013336&amp;amp;tui=T047"&gt;&lt;i&gt;T047&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D004392&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD10&lt;/td&gt;
                &lt;td&gt;E34.3&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;190584003, 422065006, 206931003, 237837007, 185797004, 90482002, 237836003, 205467007, 248299001, 190585002&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Nanism, DWARF, DWARFISM, Dwarf, NANISM, Nanasoma, Physiologic dwarf, Dwarf, NOS, Dwarfism, NOS, RUNTING, Short stature, constitution, Short stature, constitutional, Short stature, hereditary, Constitutional dwarfism, Physiologic dwarfism, Constitutional short stature, Constitutional short stature (disorder), [D]Short stature, constitutional (context-dependent category), [D]Short stature, constitution, [D]Short stature, constitutional, [D]Short stature, hereditary, dwarfism (diagnosis), dwarfism, Normal dwarfism, True dwarf, Pure dwarfism, constitutional dwarfism, constitutional dwarfism (diagnosis), Little person, Dwarfism NOS, Runting, [D]Short stature, constitutional (situation), Short stature disorder, Dwarfism [Disease/Finding], dwarf, primordial dwarf, dwarfs, short stature, constitutional short stature, runts, runt, hereditary short stature, Normal dwarf, Primordial dwarf, Pure dwarf, Nanosoma, Nanosomia, True dwarfism, Primordial dwarfism, Dwarfism (disorder), Primordial dwarfism (disorder), Short stature disorder (disorder), Dwarfism, nanism, constitutional; dwarfism, dwarfism; constitutional, short; stature, constitutional, stature; short, constitutional, Dwarfism (disorder) [Ambiguous]&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;NANISME, Nanisme SAI, Maladie des rabougris, Nain, Nanisme&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;NANISMO, Anão, Nanismo NE, De baixa estatura, Nanismo&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;ENANISMO, estatura baja constitucional (trastorno), estatura baja constitucional, Enanismo NEOM, Enano, enanismo, baja estatura constitucional, [D]baja estatura constitucional (categoría dependiente del contexto), baja estatura constitucional (trastorno), Dwarfism, Primordial dwarfism, [D]talla baja constitucional, [D]baja estatura constitucional (situación), [D]baja estatura constitucional, enanismo (concepto no activo), enanismo (trastorno), enanismo constitucional, enanismo fisiológico, enanismo primordial (trastorno), enanismo primordial, enanismo verdadero (trastorno), enanismo verdadero, nanosomía, pigmeo normal, pigmeo primordial, pigmeo puro, Enanismo&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;ZWERGWUCHS, Zwerg, Minderwuchs, Zwergwuchs NNB, Nanismus, Zwergwuchs&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;dwerggroei NAO, dwergachtig, dwerg, constitutioneel; dwerggroei, dwerggroei; constitutioneel, gestalte; kort, constitutioneel, kort; gestalte, constitutioneel, dwerggroei, Dwerggroei, Groei, dwerg-, Nanisme&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Nanismo NAS, Nano, Nanismo&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Dvärgväxt&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;nanismus, Nanismus, Trpaslík, Zakrslost NOS, Zakrslost&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;ﾃｲｼﾝﾁｮｳｼｮｳNOS, 低身長症ＮＯＳ, ﾃｲｼﾝﾁｮｳｼｮｳ, 矮小者, 小体症, こびと症, 侏儒, 小人症, 低身長症, 小人&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Lyhytkasvuisuus&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;KARLIKOVOST', MIKROSOMIIA, NANIZM, NANOSOMIIA, КАРЛИКОВОСТЬ, МИКРОСОМИЯ, НАНИЗМ, НАНОСОМИЯ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Croatian&lt;/td&gt;
                &lt;td&gt;PATULJASTI RAST&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Niskorosłość, Karłowatość&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;Törpeség, Törpe, Nanismus, Törpenövés k.m.n., Törpenövés&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Dwarfism  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Constitutional Short Stature</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Growth Disorders</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Signs&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Growth/ShrtStr.htm" class="LinkPage"&gt;Delayed Growth&lt;/a&gt; and development in either parent (50%)&lt;/li&gt;&lt;li&gt;Normal birth history&lt;/li&gt;&lt;li&gt;Normal growth for the first several months&lt;/li&gt;&lt;li&gt;Absence of organic or psychologic disease&lt;/li&gt;&lt;li&gt;Discrete interval of severe growth deceleration&lt;ol&gt;&lt;li&gt;Duration: 1-3 years&lt;/li&gt;&lt;li&gt;Onset: under age 2 years&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Onset &lt;a href="../../Endo/Exam/SxlDvlpmnt.htm" class="LinkPage"&gt;Puberty&lt;/a&gt; delayed&lt;/li&gt;&lt;li&gt;Final height appropriate for genetic height potential&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Imaging: &lt;a href="../../Endo/Rad/BnAgFlm.htm" class="LinkPage"&gt;Bone Age Film&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Bone age lags chronological age&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0013336</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Growth/CnsttnlShrtStr.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Constitutional Short Stature</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Growth/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Arachnodactyly  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0003706"&gt;&lt;i&gt;C0003706&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;An abnormal bone development that is characterized by extra long and slender hands and fingers, such that the clenched thumb extends beyond the ulnar side of the hand. Arachnodactyly can include feet and toes. Arachnodactyly has been associated with several gene mutations and syndromes.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Congenital Abnormality (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0003706&amp;amp;tui=T019"&gt;&lt;i&gt;T019&lt;/i&gt;&lt;/a&gt;)
, Disease or Syndrome (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0003706&amp;amp;tui=T047"&gt;&lt;i&gt;T047&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D054119, D008382&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;205816001, 271434006, 62250003&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;ARACHNODACTYLY, DOLICHOSTENOMELIA, HAND SPIDERLIKE, Arachnodactylies, Arachnodactyly, Arachnodactyly (&amp;amp; [congenital]) (disorder), Congenital arachnodactyly (disorder), Arachnodactyly [Disease/Finding], fingers spider, Dolichostenomelia, Spider finger, Congenital arachnodactyly, Arachnodactyly (disorder), arachnodactyly, dolichostenomelia, fingers; spider, spider; fingers, Arachnodactyly (&amp;amp; [congenital])&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;arachnodactylie, fingers; spider, spider; fingers, Arachnodactylie&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;くも指症, ｸﾓﾕﾋﾞｼｮｳ, ｸﾓｼｼｮｳ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Aracnodactilia&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;Arachnodactyly, Congenital arachnodactyly, Arachnodactyly (&amp;amp; [congenital]), Aracnodactilia, aracnodactilia (trastorno), aracnodactilia, dedos de araña, dolicoestenomelia&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Araknodaktylia&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Arachnodactylie&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Arachnodaktylie&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Aracnodattilia&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;АРАХНОДАКТИЛИЯ, ARAKHNODAKTILIIA&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;Arachnodaktylie, arachnodaktýlie&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Araknodaktyli&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Arachnodaktylia, Długopalczastość, Palce pajęcze, Pająkowatość palców&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;Arachnodactylia&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Marfan Syndrome  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0024796"&gt;&lt;i&gt;C0024796&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A genetic syndrome inherited as an autosomal dominant trait. It is caused by mutations in the FBN1 gene. It is characterized by tall stature, elongated extremities, mitral valve prolapse, aortic dilatation, aortic dissection, and sublaxation of the lens.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;An autosomal dominant disorder of CONNECTIVE TISSUE with abnormal features in the heart, the eye, and the skeleton. Cardiovascular manifestations include MITRAL VALVE PROLAPSE, dilation of the AORTA, and aortic dissection. Other features include lens displacement (ectopia lentis), disproportioned long limbs and enlarged DURA MATER (dural ectasia). Marfan syndrome is associated with mutations in the gene encoding fibrillin, a major element of extracellular microfibrils of connective tissue.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CHV)&lt;/td&gt;
                &lt;td&gt;A hereditary disorder of connective tissue characterized by tall stature, elongated extremities, dilatation of the ascending aorta, and pigeon breast.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CHV)&lt;/td&gt;
                &lt;td&gt;A hereditary disorder of connective tissue characterized by tall stature, elongated extremities, dilatation of the ascending aorta, and pigeon breast.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CHV)&lt;/td&gt;
                &lt;td&gt;A hereditary disorder of connective tissue characterized by tall stature, elongated extremities, dilatation of the ascending aorta, and pigeon breast.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CHV)&lt;/td&gt;
                &lt;td&gt;A hereditary disorder of connective tissue characterized by tall stature, elongated extremities, dilatation of the ascending aorta, and pigeon breast.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MEDLINEPLUS)&lt;/td&gt;
                &lt;td&gt;
                  &lt;span&gt;
                    &lt;p&gt;Marfan syndrome is a disorder that affects connective tissue. Connective tissues are proteins that support skin, bones, blood vessels and other organs. One of these proteins is fibrillin. A problem with the fibrillin gene causes Marfan syndrome. &lt;/p&gt;
                    &lt;p&gt;Marfan syndrome can be mild to severe, and the symptoms can vary. People with Marfan syndrome are often very tall, thin and loose jointed. Most people with Marfan syndrome have heart and blood vessel problems, such as a weakness in the aorta or heart valves that leak. They may also have problems with their bones, eyes, skin, nervous system and lungs.&lt;/p&gt;
                    &lt;p style="font-weight:bold;font-style:italic;"&gt;NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases&lt;/p&gt;
                  &lt;/span&gt;
                &lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CSP)&lt;/td&gt;
                &lt;td&gt;disorder of connective tissue characterized by tall stature, elongated extremities, subluxation of the lens, dilatation of the ascending aorta, and "pigeon breast"; inherited as an autosomal dominant trait.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Disease or Syndrome (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0024796&amp;amp;tui=T047"&gt;&lt;i&gt;T047&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D008382&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD9&lt;/td&gt;
                &lt;td&gt;759.82&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD10&lt;/td&gt;
                &lt;td&gt;Q87.4, Q87.40&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;157024004, 19346006, 157033002, 268359006&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Marfan's Syndrome, Marfans Syndrome, Syndrome, Marfan, Syndrome, Marfan's, MARFAN'S SYNDROME, MARFAN SYNDROME, MFS, MFS1, MARFAN SYNDROME, TYPE I, Marfan's syndrome (diagnosis), Marfan Syndrome, Marfan syndrome, Marfan's syndrome, unspecified, Marfan Syndrome [Disease/Finding], marfan syndrome, marfan's syndrome, marfan's disease, Marfans syndrome, Marfan's syndrome, Marfan's disease, Marfan's syndrome (disorder), Marfan, marfans syndrome&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Marfans syndrom&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;ﾏﾙﾌｧﾝｼｮｳｺｳｸﾞﾝ, マルファン症候群, Marfan症候群&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;Marfanův syndrom&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;Marfan's syndrome, enfermedad de Marfan, síndrome de Marfan (trastorno), síndrome de Marfan, Sindrome de Marfan, Síndrome de Marfan&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Marfanin oireyhtymä&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;MARFANA SINDROM, МАРФАНА СИНДРОМ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Korean&lt;/td&gt;
                &lt;td&gt;마르팡 증후군&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Zespół Marfana&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;Marfan-syndroma&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;syndroom van Marfan, Marfan-syndroom, Syndroom van Marfan, Syndroom, Marfan-&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Marfan Syndrom, Marfan-Syndrom&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Syndrome de Marfan, Maladie de Marfan&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Sindrome di Marfan&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Síndrome de Marfan&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Arachnodactyly  (</value><value>)
</value><value>Marfan Syndrome  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Marfan's Syndrome</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Growth Disorders</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Epidemiology&lt;ol&gt;&lt;li&gt;Autosomal Dominant with variable expression&lt;/li&gt;&lt;li&gt;Sporadic (non-hereditary) account for 15-33% of cases&lt;/li&gt;&lt;li&gt;&lt;a href="../../Prevent/Epi/DsPrvlncRt.htm" class="LinkPage"&gt;Prevalence&lt;/a&gt;: 1 in 10,000 (in United States)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Etiology&lt;ol&gt;&lt;li&gt;Defect in gene coding for fibrillin structure&lt;/li&gt;&lt;li&gt;Connective tissue defect affecting multiple systems&lt;ol&gt;&lt;li&gt;Musculoskeletal disease&lt;/li&gt;&lt;li&gt;Ocular disease&lt;/li&gt;&lt;li&gt;Cardiac disease&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Signs&lt;ol&gt;&lt;li&gt;Body habitus&lt;ol&gt;&lt;li&gt;Tall (Height exceeds 95th percentile for age)&lt;/li&gt;&lt;li&gt;Extremely slender build&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Cardiovascular signs and conditions&lt;ol&gt;&lt;li&gt;&lt;a href="../../CV/Valve/MtrlVlvPrlps.htm" class="LinkPage"&gt;Mitral Valve Prolapse&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Aortic root dilatation&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/CAD/ActCrnrySyndrm.htm" class="LinkPage"&gt;Myocardial Infarction&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Valve/ArtcRgrgtn.htm" class="LinkPage"&gt;Aortic Insufficiency&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/CHF/CngstvHrtFlr.htm" class="LinkPage"&gt;Congestive Heart Failure&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/ID/BctrlEndcrdts.htm" class="LinkPage"&gt;Subacute Bacterial Endocarditis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Vessel/ArtcDsctn.htm" class="LinkPage"&gt;Aortic Dissection&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Musculoskeletal signs and conditions&lt;ol&gt;&lt;li&gt;Arachnodactyly (Spider fingers)&lt;/li&gt;&lt;li&gt;Pectus deformity (&lt;a href="../../Lung/Exam/PctsCrntm.htm" class="LinkPage"&gt;Pigeon Breast&lt;/a&gt; or &lt;a href="../../Lung/Exam/PctsExcvtm.htm" class="LinkPage"&gt;Funnel Breast&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;High narrow &lt;a href="../../Dental/Anatomy/PltAntmy.htm" class="LinkPage"&gt;Palate&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Exam/ArmSpn.htm" class="LinkPage"&gt;Arm Span&lt;/a&gt; exceeds height&lt;/li&gt;&lt;li&gt;Leg length exceeds trunk length&lt;/li&gt;&lt;li&gt;Hyperextensible joints and ligaments&lt;/li&gt;&lt;li&gt;Pes planus&lt;/li&gt;&lt;li&gt;&lt;a href="../../Ortho/Foot/HmrT.htm" class="LinkPage"&gt;Hammer toe&lt;/a&gt;s&lt;/li&gt;&lt;li&gt;&lt;a href="../../Ortho/Anatomy/SpnAntmy.htm" class="LinkPage"&gt;Vertebral Column&lt;/a&gt; deformities (e.g. Kyphoscoliosis)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Surgery/GI/IngnlHrn.htm" class="LinkPage"&gt;Inguinal Hernia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Striae Distensae&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Ocular signs and conditions&lt;ol&gt;&lt;li&gt;Upward ectopia lentis&lt;/li&gt;&lt;li&gt;&lt;a href="../../Eye/Vision/Myp.htm" class="LinkPage"&gt;Myopia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Iridodonesis&lt;/li&gt;&lt;li&gt;&lt;a href="../../Eye/Glaucoma/Glcm.htm" class="LinkPage"&gt;Glaucoma&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Eye/Retina/RtnlDtchmnt.htm" class="LinkPage"&gt;Retinal Detachment&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Labs&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Metabolism/Hmcystnr.htm" class="LinkPage"&gt;Homocystinuria&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Radiology&lt;ol&gt;&lt;li&gt;&lt;a href="../../CV/Rad/TrnsthrcEchcrdgrm.htm" class="LinkPage"&gt;Echocardiogram&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Enlarged aortic root&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Lung/Rad/ChstXry.htm" class="LinkPage"&gt;Chest XRay&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Deformed aorta and pulmonary artery&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0003706</value><value>C0024796</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Growth/MrfnsSyndrm.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Marfan's Syndrome, Marfan Syndrome, Arachnodactyly</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Growth/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Congenital adrenal hyperplasia  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0001627"&gt;&lt;i&gt;C0001627&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A genetic disorder characterized by defects in the synthesis of cortisol and/or aldosterone, resulting in hyperplasia of the adrenal cortical cells.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;A group of inherited disorders of the ADRENAL GLANDS, caused by enzyme defects in the synthesis of cortisol (HYDROCORTISONE) and/or ALDOSTERONE leading to accumulation of precursors for ANDROGENS. Depending on the hormone imbalance, congenital adrenal hyperplasia can be classified as salt-wasting, hypertensive, virilizing, or feminizing. Defects in STEROID 21-HYDROXYLASE; STEROID 11-BETA-HYDROXYLASE; STEROID 17-ALPHA-HYDROXYLASE; 3-beta-hydroxysteroid dehydrogenase (3-HYDROXYSTEROID DEHYDROGENASES); TESTOSTERONE 5-ALPHA-REDUCTASE; or steroidogenic acute regulatory protein; among others, underlie these disorders.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CSP)&lt;/td&gt;
                &lt;td&gt;group of syndromes caused by inherited defects in cortisol and/or aldosterone biosynthesis; ACTH elevation is caused by low levels of cortisol, whose production is impaired by absence or deficiency of one of the five enzymes necessary for its synthesis from cholesterol.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Congenital Abnormality (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0001627&amp;amp;tui=T019"&gt;&lt;i&gt;T019&lt;/i&gt;&lt;/a&gt;)
, Disease or Syndrome (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0001627&amp;amp;tui=T047"&gt;&lt;i&gt;T047&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D000312&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD10&lt;/td&gt;
                &lt;td&gt;E25.0&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;237751000, 27037004&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Adrenal Hyperplasia, Congenital, Adrenal Hyperplasias, Congenital, Congenital Adrenal Hyperplasia, Congenital Adrenal Hyperplasias, Hyperplasia, Congenital Adrenal, Hyperplasias, Congenital Adrenal, ADRENAL HYPERPLASIA, CONGENITAL, Adrenal hyperplasia syndrome, congenital, CONGENITAL ADRENAL HYPERPLASIA, Congenital adrenal hyperplasia, NOS, CAH-Congenit adren hyperplasia, Congenital Adrenal Gland Hyperplasia, HYPERPLASIA CONGEN ADRENAL, ADRENAL HYPERPLASIA CONGEN, CONGEN ADRENAL HYPERPLASIA, congenital adrenal hyperplasia (diagnosis), congenital adrenal hyperplasia, ADRENAL HYPERPLASIA CONGENITAL, Adrenal Hyperplasia, Adrenal Hyperplasia, Congenital [Disease/Finding], hyperplasia congenital adrenal, adrenal congenital hyperplasia, hyperplasia adrenal congenital, CAH - Congenital adrenal hyperplasia, Congenital adrenal hyperplasia (disorder), Congenital adrenal hyperplasia, hyperplasia; adrenal, congenital, adrenal; hyperplasia, congenital&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;congenitale bijnierhyperplasie, bijnier; hyperplasie, congenitaal, hyperplasie; bijnier, congenitaal, Bijnierhyperplasie, congenitale, Congenitale bijnierhyperplasie, Hyperplasie, congenitale bijnier-&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Hyperplasie surrénalienne congénitale, Hyperplasie surrénale congénitale, Hyperplasie congénitale des surrénales&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;kongenitale adrenale Hyperplasie, Adrenale Hyperplasie, kongenitale, Kongenitale adrenale Hyperplasie, kongenitale Nebennierenrindenhyperplasie, Nebennierenrindenhyperplasie, kongenitale&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Hiperplasia supra-renal congénita, Hiperplasia Supra-Renal Congênita&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;Hiperplasia congénita de las glándulas suprarrenales, hiperplasia adrenal congénita, hiperplasia suprarrenal congénita (trastorno), hiperplasia suprarrenal congénita, Hiperplasia Suprarrenal Congénita, Hiperplasia Suprarrenal Congenita&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Binjurebarkshyperplasi, medfödd&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;ｾﾝﾃﾝｾｲﾌｸｼﾞﾝｶｹｲｾｲ, 先天副腎過形成, 副腎皮質過形成-先天性, 副腎皮質過形成, 先天性副腎皮質過形成, 先天性副腎過形成症, 先天性副腎過形成, 副腎過形成-先天性&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;kongenitální adrenální hyperplazie, nadledviny - hyperplazie kongenitální, Vrozená adrenální hyperplazie&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Synnynnäinen lisämunuaisten liikakasvu&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;NADPOCHECHNIKOV GIPERPLAZIIA VROZHDENNAIA, НАДПОЧЕЧНИКОВ ГИПЕРПЛАЗИЯ ВРОЖДЕННАЯ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Croatian&lt;/td&gt;
                &lt;td&gt;NADBUBREŽNA ŽLIJEZDA, HIPERPLAZIJA, PRIROĐENA, NADBUBREŽNA ŽLIJEZDA, HIPERPLAZIJA, KONGENITALNA&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Przerost nadnerczy wrodzony&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;Veleszületett adrenalis hyperplasia&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Iperplasia surrenale congenita&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Congenital adrenal hyperplasia  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Congenital Adrenal Hyperplasia</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Adrenal Disease</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;See Also&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Adrenal/AdsnsDs.htm" class="LinkPage"&gt;Adrenal Insufficiency&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Exam/StrdHrmnPthwy.htm" class="LinkPage"&gt;Steroid Hormone Pathway&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Definition&lt;ol&gt;&lt;li&gt;Inherited &lt;a href="../../Endo/Adrenal/AdsnsDs.htm" class="LinkPage"&gt;Adrenal Insufficiency&lt;/a&gt; onset at birth&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Pathophysiology&lt;ol&gt;&lt;li&gt;Autosomal recessive inheritance&lt;/li&gt;&lt;li&gt;Group of defective enzymes in &lt;a href="../../Endo/Exam/StrdHrmnPthwy.htm" class="LinkPage"&gt;Cortisol Synthesis&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Six different enzyme deficiencies possible&lt;/li&gt;&lt;li&gt;See &lt;a href="../../Endo/Exam/StrdHrmnPthwy.htm" class="LinkPage"&gt;Steroid Hormone Pathway&lt;/a&gt;&lt;/li&gt;&lt;li&gt;21-Hydroxylase deficiency is most common (90%)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Types&lt;ol&gt;&lt;li&gt;Complete Enzyme Deficiency (Classic, Salt-losing)&lt;ol&gt;&lt;li&gt;Onset as newborn with adrenal crisis by 2 weeks old&lt;/li&gt;&lt;li&gt;Most common cause of &lt;a href="../../Endo/Sex/AmbgsGntl.htm" class="LinkPage"&gt;Ambiguous Genitalia&lt;/a&gt; in females&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Partial Enzyme Deficiency (Simple virilizing)&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Adrenal/AdsnsDs.htm" class="LinkPage"&gt;Adrenal Insufficiency&lt;/a&gt; occurs only as stress reaction&lt;/li&gt;&lt;li&gt;Causes &lt;a href="../../Gyn/Endo/Hyprndrgnsm.htm" class="LinkPage"&gt;Androgen Excess&lt;/a&gt; in later childhood&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Sex/PrcsPbrty.htm" class="LinkPage"&gt;Precocious Puberty&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Derm/Hair/Hrstsm.htm" class="LinkPage"&gt;Hirsutism&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Derm/Acne/AcnVlgrs.htm" class="LinkPage"&gt;Acne Vulgaris&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Signs and Symptoms&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Endo/Adrenal/AdsnsDs.htm" class="LinkPage"&gt;Adrenal Insufficiency&lt;/a&gt;&lt;/li&gt;&lt;li&gt;See &lt;a href="../../Endo/Sex/AmbgsGntl.htm" class="LinkPage"&gt;Ambiguous Genitalia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;See &lt;a href="../../Endo/Sex/PrcsPbrty.htm" class="LinkPage"&gt;Precocious Puberty&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Diagnosis&lt;ol&gt;&lt;li&gt;Classic (complete deficiency) type in newborns&lt;ol&gt;&lt;li&gt;17-Hydroxyprogesterone increased&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Non-classic (Partial deficiency) type in children&lt;ol&gt;&lt;li&gt;17-Hydroxyprogesterone increased 1 hour post-ACTH&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Labs&lt;ol&gt;&lt;li&gt;Serum electrolytes&lt;ol&gt;&lt;li&gt;&lt;a href="../../Renal/Sodium/Hypntrm.htm" class="LinkPage"&gt;Hyponatremia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Renal/Chloride/Hypchlrm.htm" class="LinkPage"&gt;Hypochloremia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Renal/Potassium/Hyprklm.htm" class="LinkPage"&gt;Hyperkalemia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Hypoglycemia/Hypglycm.htm" class="LinkPage"&gt;Hypoglycemia&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Adrenal labs&lt;ol&gt;&lt;li&gt;Low cortisol&lt;/li&gt;&lt;li&gt;High renin&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Sex hormone abnormalities depend on enzyme deficiency&lt;ol&gt;&lt;li&gt;Virilizing if 21-Hydroxylase or 11-Hydroxylase&lt;/li&gt;&lt;li&gt;Testosterone increased in girls&lt;/li&gt;&lt;li&gt;&lt;a href="../../Sports/Pharm/Andrstndn.htm" class="LinkPage"&gt;Androstenedione&lt;/a&gt; increased in girls and boys&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0001627</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Adrenal/CngntlAdrnlHyprpls.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Congenital Adrenal Hyperplasia</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Adrenal/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Sotos' syndrome  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0175695"&gt;&lt;i&gt;C0175695&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A rare genetic syndrome caused by mutations in the NSD1 gene. It is characterized by excessive physical growth early in life, mild mental retardation, and delayed cognitive and social development. Children affected by this syndrome are tall with larger than normal heads.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;Congenital or postnatal overgrowth syndrome most often in height and occipitofrontal circumference with variable delayed motor and cognitive development. Other associated features include advanced bone age, seizures, NEONATAL JAUNDICE; HYPOTONIA; and SCOLIOSIS. It is also associated with increased risk of developing neoplasms in adulthood. Mutations in the NSD1 protein and its HAPLOINSUFFICIENCY are associated with the syndrome.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (JABL)&lt;/td&gt;
                &lt;td&gt;Increased birth weight with excessive growth during the first four years of life, macrocephaly, characteristic facial features, nonprogressive cerebral disorder and mental retardation.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Congenital Abnormality (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0175695&amp;amp;tui=T019"&gt;&lt;i&gt;T019&lt;/i&gt;&lt;/a&gt;)
, Disease or Syndrome (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0175695&amp;amp;tui=T047"&gt;&lt;i&gt;T047&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D058495&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD10&lt;/td&gt;
                &lt;td&gt;Q87.3&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;75968004&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Giant, cerebral, CEREBRAL GIGANTISM, SOTOS SYNDROME, Soto syndrome, Sotos' syndrome (diagnosis), Sotos' syndrome, cerebral gigantism, macrosomia-mental retardation syndrome, mental retardation-overgrowth sequence, Nevo syndrome, Sotos sequence, Gigantisms, Cerebral, Cerebral Gigantisms, Gigantism, Cerebral, Syndrome, Sotos, Cerebral Gigantism, Sotos Syndrome, soto syndrome, sotos' syndrome, syndrome cerebral gigantism, sotos syndrome, Sotos Syndrome [Disease/Finding], Cerebral gigantism syndrome, Cerebral giant, Cerebral gigantism, Sotos syndrome, Sotos' syndrome (disorder), Sotos&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;Sotos-syndroom, cerebraal gigantisme&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Syndrome de Soto, Gigantisme cérébral, Syndrome de Sotos&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Síndrome de Soto, Gigantismo cerebral, Gigantismo Cerebral, Síndrome de Sotos&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;zerebraler Gigantismus, Sotos-Syndrom, Zerebraler Gigantismus, Cerebraler Gigantismus&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;Gigantismo cerebral, Síndrome de Sotos, Sindrome de Sotos, gigante cerebral, síndrome de Sotos (trastorno), síndrome de Sotos, síndrome de gigantismo cerebral&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;ソトス症候群, 脳性巨人症, ｿﾄｽｼｮｳｺｳｸﾞﾝ, ﾉｳｾｲｷｮｼﾞﾝｼｮｳ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;Gigantismus mozku, cerebrální gigantismus, Sotosův syndrom&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Gigantismo cerebrale, Sindrome di Sotos&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;SOTOSA SINDROM, СОТОСА СИНДРОМ, ЦЕРЕБРАЛЬНЫЙ ГИГАНТИЗМ, MAKROSOMIIA TSEREBRAL'NAIA, TSEREBRAL'NYI GIGANTIZM, МАКРОСОМИЯ ЦЕРЕБРАЛЬНАЯ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;Sotos-syndroma, Cerebralis gigantismus&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Sotos' syndrome  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Cerebral Gigantism</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Growth Disorders</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Signs&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Growth/TlStr.htm" class="LinkPage"&gt;Tall Stature&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Prominent forehead&lt;/li&gt;&lt;li&gt;Hypertelorism&lt;/li&gt;&lt;li&gt;High arched &lt;a href="../../Dental/Anatomy/PltAntmy.htm" class="LinkPage"&gt;Palate&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Large irregular head&lt;/li&gt;&lt;li&gt;Antimongoloid slant of palpebral fissures&lt;/li&gt;&lt;li&gt;&lt;a href="../../Prevent/HME/HlthCrFrAdltsWthDvlpmntlDly.htm" class="LinkPage"&gt;Mental Retardation&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Advanced bone age&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Labs&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Endo/Growth/TlStr.htm" class="LinkPage"&gt;Tall Stature&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Lab results are normal in this condition&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0175695</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Growth/CrbrlGgntsm.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Cerebral Gigantism, Soto Syndrome</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Growth/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Hypoglycemia management  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0150254"&gt;&lt;i&gt;C0150254&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NIC)&lt;/td&gt;
                &lt;td&gt;Preventing and treating low blood glucose levels&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Therapeutic or Preventive Procedure (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0150254&amp;amp;tui=T061"&gt;&lt;i&gt;T061&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;386328006&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Hypoglycemia Management, hypoglycaemia management, hypoglycemia management, Hypoglycaemia management, Hypoglycemia management (procedure), Hypoglycemia management&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;manejo de la hipoglucemia (procedimiento), manejo de la hipoglucemia&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Hypoglycemia management  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Hypoglycemia Management</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Hypoglycemic Disorders</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Indications&lt;ol&gt;&lt;li&gt;Diabetes Management&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;See Also&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Hypoglycemia/Hypglycm.htm" class="LinkPage"&gt;Hypoglycemia&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Preparations&lt;ol&gt;&lt;li&gt;Oral: Equivalents of 15 grams &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; (1 carbohydrate)&lt;ol&gt;&lt;li&gt;Three &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; tablets (or 15 grams of &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; gel)&lt;/li&gt;&lt;li&gt;Fruit juice 1/2 cup (4 ounces)&lt;/li&gt;&lt;li&gt;Regular soda 3/4 cup (6 ounces)&lt;/li&gt;&lt;li&gt;Milk 1 cup (8 ounces)&lt;/li&gt;&lt;li&gt;Honey or corn syrup 3 teaspoons&lt;/li&gt;&lt;li&gt;Crackers (6 saltine crackers)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Glcgn.htm" class="LinkPage"&gt;Glucagon&lt;/a&gt; Intramuscular or Subcutaneous&lt;ol&gt;&lt;li&gt;Precautions&lt;ol&gt;&lt;li&gt;Transient effects only&lt;/li&gt;&lt;li&gt;Ineffective when &lt;a href="../../GI/Anatomy/LvrAntmy.htm" class="LinkPage"&gt;Liver&lt;/a&gt; Glycogen depleted&lt;/li&gt;&lt;li&gt;&lt;a href="../../GI/Sx/Vmtng.htm" class="LinkPage"&gt;Vomiting&lt;/a&gt; and aspiration risk&lt;ol&gt;&lt;li&gt;Roll patient onto their side when used&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Dose&lt;ol&gt;&lt;li&gt;Teens and adult: 1 mg&lt;/li&gt;&lt;li&gt;Children: 0.5 mg (0.5 ml) or 15 mcg/kg&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Administer &lt;a href="../../Endo/Pharm/IntrvnsDxtrs.htm" class="LinkPage"&gt;Intravenous Dextrose&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Bolus: 10-20 ml of D50W IV&lt;/li&gt;&lt;li&gt;Maintenance: D10W IV at 100 cc/hour until stable&lt;/li&gt;&lt;li&gt;Keep plasma &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; over 100 mg/dl&lt;/li&gt;&lt;li&gt;May require 10 grams/hour IV&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Protocol&lt;ol&gt;&lt;li&gt;Mild &lt;a href="../../Endo/Hypoglycemia/Hypglycm.htm" class="LinkPage"&gt;Hypoglycemia&lt;/a&gt; (BG 60-70 mg/dl): Give 15 carb grams&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; oral gel 40% 15 grams orally or&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; 3 tablets orally or&lt;/li&gt;&lt;li&gt;Juice 4 ounces orally&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Moderate &lt;a href="../../Endo/Hypoglycemia/Hypglycm.htm" class="LinkPage"&gt;Hypoglycemia&lt;/a&gt; (BG 45-59): Give 20 carb grams&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; oral gel 40% 20 grams orally or&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; 4 tablets orally or&lt;/li&gt;&lt;li&gt;Juice 6 ounces orally or&lt;/li&gt;&lt;li&gt;Dextrose 50% 25 ml IV&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Severe &lt;a href="../../Endo/Hypoglycemia/Hypglycm.htm" class="LinkPage"&gt;Hypoglycemia&lt;/a&gt; (BG &amp;lt;45): Give 30 carb grams&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; oral gel 40% 30 grams orally or&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; 6 tablets orally or&lt;/li&gt;&lt;li&gt;Juice 8 ounces orally or&lt;/li&gt;&lt;li&gt;Dextrose 50% 25 ml IV&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Unconscious with severe &lt;a href="../../Endo/Hypoglycemia/Hypglycm.htm" class="LinkPage"&gt;Hypoglycemia&lt;/a&gt; (BG&amp;lt;45)&lt;ol&gt;&lt;li&gt;Dextrose 50% 25 ml IV or&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Glcgn.htm" class="LinkPage"&gt;Glucagon&lt;/a&gt; 1 mg SQ or IM (0.5 mg for child)&lt;ol&gt;&lt;li&gt;&lt;a href="../../GI/Sx/Vmtng.htm" class="LinkPage"&gt;Vomiting&lt;/a&gt; and aspiration risk&lt;/li&gt;&lt;li&gt;Roll patient onto their side when used&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Protocol: &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; monitoring&lt;ol&gt;&lt;li&gt;Monitor &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Glucose&lt;/a&gt; every 15 minutes until &amp;gt;100 mg/dl&lt;/li&gt;&lt;li&gt;Redose &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; replacement per above every 15 min prn&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0150254</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Hypoglycemia/HypglycmMngmnt.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Hypoglycemia Management</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Hypoglycemia/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Cushing Syndrome  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0010481"&gt;&lt;i&gt;C0010481&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A syndrome caused by high levels of cortisol in the blood either due to excessive production and secretion of corticosteroids secondary to pituitary or adrenocortical neoplasms, or intake of glucocorticoid drugs. Signs and symptoms include a round face, upper body obesity, fragile and thin skin, purple stretch marks in the skin, fatigue, muscle weakness, hypertension, diabetes mellitus, hypertrichosis and amenorrhea in women, impotence in men, and osteoporosis.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CHV)&lt;/td&gt;
                &lt;td&gt;a rare hormonal disease that occurs when the body produces too much of the hormone cortisol&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CHV)&lt;/td&gt;
                &lt;td&gt;a rare hormonal disease that occurs when the body produces too much of the hormone cortisol&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MEDLINEPLUS)&lt;/td&gt;
                &lt;td&gt;
                  &lt;span&gt;
                    &lt;p&gt;Cushings syndrome is caused by long-term exposure to too much cortisol, a hormone that your adrenal gland makes. Sometimes, taking synthetic hormone medicine to treat an inflammatory disease leads to Cushing's. Some kinds of tumors secrete a hormone that can cause your body to make too much cortisol. &lt;/p&gt;
                    &lt;p&gt;Cushing's syndrome is rare. Some symptoms are &lt;/p&gt;
                    &lt;ul&gt;&lt;li&gt;Upper body obesity &lt;/li&gt;
                      &lt;li&gt;Thin arms and legs&lt;/li&gt;
                      &lt;li&gt;Severe fatigue and muscle weakness&lt;/li&gt;
                      &lt;li&gt;High blood pressure&lt;/li&gt;
                      &lt;li&gt;High blood sugar&lt;/li&gt;
                      &lt;li&gt;Easy bruising&lt;/li&gt;
                    &lt;/ul&gt;&lt;p&gt;Your treatment will depend on why you have too much cortisol. If it is because you have been taking synthetic hormones, a lower dose may control your symptoms. If a tumor caused it, surgery and other therapies may be needed.  Most of the time, Cushing's syndrome can be cured. &lt;/p&gt;
                    &lt;p style="font-weight:bold;font-style:italic;"&gt;NIH: National Institute of Neurological Disorders and Stroke&lt;/p&gt;
                  &lt;/span&gt;
                &lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A condition in which there is too much cortisol (a hormone made by the outer layer of the adrenal gland) in the body. Cushing syndrome may be caused by taking too many steroid drugs or by certain types of tumors. Tumors that make adrenocorticotropic hormone (ACTH) cause the adrenal gland to make too much cortisol. Symptoms of Cushing syndrome include a round face, thin arms and legs, severe fatigue and muscle weakness, high blood pressure, high blood sugar, purple or pink stretch marks on the skin, and weight gain, especially in the abdomen.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A condition in which there is too much cortisol (a hormone made by the outer layer of the adrenal gland) in the body. In Cushing disease, this happens when an adenoma (benign tumor) in the pituitary gland makes too much adrenocorticotropic hormone (ACTH). This causes the adrenal gland to make too much cortisol. Symptoms include a round face, thin arms and legs, severe fatigue and muscle weakness, high blood pressure and high blood sugar, purple or pink stretch marks on the skin, and weight gain, especially in the abdomen.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;A condition caused by prolonged exposure to excess levels of cortisol (HYDROCORTISONE) or other GLUCOCORTICOIDS from endogenous or exogenous sources. It is characterized by upper body OBESITY; OSTEOPOROSIS; HYPERTENSION; DIABETES MELLITUS; HIRSUTISM; AMENORRHEA; and excess body fluid. Endogenous Cushing syndrome or spontaneous hypercortisolism is divided into two groups, those due to an excess of ADRENOCORTICOTROPIN and those that are ACTH-independent.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CSP)&lt;/td&gt;
                &lt;td&gt;condition, more commonly seen in females, due to hyperadrenocorticism resulting from neoplasms of the adrenal cortex or the anterior lobe of the pituitary, or to prolonged excessive intake of glucocorticoids for therapeutic purposes; symptoms and signs may include rapidly developing adiposity of the face, neck, and trunk, kyphosis caused by osteoporosis of the spine, hypertension, diabetes mellitus, amenorrhea, hypertrichosis in females, impotence in males, dusky complexion with purple markings, polycythemia, pain in the abdomen and back, and muscular wasting and weakness.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Disease or Syndrome (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0010481&amp;amp;tui=T047"&gt;&lt;i&gt;T047&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D003480&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD9&lt;/td&gt;
                &lt;td&gt;255.0&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD10&lt;/td&gt;
                &lt;td&gt;E24, E24.9&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;154705004, 190505004, 47270006&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Cushing Syndrome, Cushing's Syndrome, Syndrome, Cushing's, CUSHINGS SYNDROME, CUSHING SYNDROME, CUSHING'S SYNDROME, SYNDROME CUSHING'S, Cushing's syndrome NOS, Cushing's syndrome, unspecified, Cushing syndrome, Cushing's basophilism, pituitary basophilism, Syndrome, Cushing, Cushing's syndrome (diagnosis), Cushing's syndrome (disorder), Cushings syndrome, Syndrome Cushing's, CUSHING, Cushing's syndrome NOS (disorder), Cushing Syndrome [Disease/Finding], cushing's syndrome, cushing syndrome, Cushing disease, Cushing's syndrome, Cushing's syndrome III, Itsenko disease, Itsenko-Cushing syndrome, Suprarenogenic syndrome, Hypercortisolism, Cushings Syndrome, cushings syndrome&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;SINDROME DE CUSHING, Síndrome de Cushing&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;SINDROME DE CUSHING, Cushing's syndrome, síndrome de Cushing, SAI (trastorno), síndrome de Cushing, SAI, síndrome de Cushing, síndrome de Itsenko - Cushing, Sindrome de Cushing, Síndrome de Cushing&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;syndroom van Cushing, Syndroom van Cushing, niet gespecificeerd, Cushing-syndroom, Syndroom van Cushing, Syndroom, Cushing-&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Syndrom, Cushing, CUSHING SYNDROM, Cushing-Syndrom, nicht naeher bezeichnet, Cushing Syndrom, Cushing-Syndrom&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Cushings syndrom&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;ｸｯｼﾝｸﾞｼｮｳｺｳｸﾞﾝ, Cushing症候群, クッシング症候群, 下垂体好塩基細胞腺腫, 脳下垂体好塩基細胞腺腫&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;Cushingův syndrom&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Cushingin oireyhtymä&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;ITSENKO-KUSHINGA BOLEZN', ITSENKO-KUSHINGA SINDROM, KUSHINGA SINDROM, ИЦЕНКО-КУШИНГА БОЛЕЗНЬ, ИЦЕНКО-КУШИНГА СИНДРОМ, КУШИНГА СИНДРОМ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;SYNDROME DE CUSHING, Syndrome de Cushing, Hypercortisolisme&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Ipercortisolismo, Sindrome di Cushing&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Korean&lt;/td&gt;
                &lt;td&gt;쿠싱 증후군, 상세불명의 쿠싱 증후군&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Croatian&lt;/td&gt;
                &lt;td&gt;CUSHINGOV SINDROM&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Zespół Cushinga&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;Cushing syndroma, Cushing-syndroma, Cushing-tünetegyüttes&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Cushing Syndrome  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Cushing's Disease</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Adrenal Disease</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Etiologies&lt;ol&gt;&lt;li&gt;Iatrogenic&lt;ol&gt;&lt;li&gt;Steroid therapy (most common cause)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Central Cause&lt;ol&gt;&lt;li&gt;Pituitary adenoma&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Adrenal Cause&lt;ol&gt;&lt;li&gt;Adrenal Adenoma&lt;/li&gt;&lt;li&gt;Adrenal Hyperplasia&lt;/li&gt;&lt;li&gt;Adrenal Malignancy (15%)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Ectopic Source&lt;ol&gt;&lt;li&gt;Malignancy (Small Cell Carcinoma of the lung: 15%)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Symptoms&lt;ol&gt;&lt;li&gt;Mood changes (depression and euphoria)&lt;/li&gt;&lt;li&gt;Easy bruising&lt;/li&gt;&lt;li&gt;Weakness&lt;/li&gt;&lt;li&gt;Weight gain&lt;/li&gt;&lt;li&gt;&lt;a href="../../Gyn/Sx/Amnrh.htm" class="LinkPage"&gt;Amenorrhea&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Back pain&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Signs&lt;ol&gt;&lt;li&gt;Truncal &lt;a href="../../Endo/Obesity/Obsty.htm" class="LinkPage"&gt;Obesity&lt;/a&gt; (90%)&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Htn/Hyprtnsn.htm" class="LinkPage"&gt;Hypertension&lt;/a&gt; (85%)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/DM/InslnRstncSyndrm.htm" class="LinkPage"&gt;Glucose Intolerance&lt;/a&gt; (80%)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Derm/Hair/Hrstsm.htm" class="LinkPage"&gt;Hirsutism&lt;/a&gt; (70%)&lt;/li&gt;&lt;li&gt;Wide, purple abdominal and thigh striae (65%)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Rheum/Bone/Ostprs.htm" class="LinkPage"&gt;Osteoporosis&lt;/a&gt; (55%)&lt;/li&gt;&lt;li&gt;Moon facies&lt;/li&gt;&lt;li&gt;Buffalo hump (Thoracic kyphosis)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Neuro/Motor/Mypthy.htm" class="LinkPage"&gt;Myopathy&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Plethoric face&lt;/li&gt;&lt;li&gt;Supraclavicular fat pad development&lt;/li&gt;&lt;li&gt;&lt;a href="../../Derm/Hair/Hyprtrchs.htm" class="LinkPage"&gt;Hypertrichosis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Peripheral &lt;a href="../../Renal/Edema/Edm.htm" class="LinkPage"&gt;Edema&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Htn/Hyprtnsn.htm" class="LinkPage"&gt;Hypertension&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Labs&lt;ol&gt;&lt;li&gt;&lt;a href="../../Prevent/Epi/ScrngTst.htm" class="LinkPage"&gt;Screening Test&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/FrUrnCrtsl.htm" class="LinkPage"&gt;24-hour Urinary free cortisol level&lt;/a&gt; (preferred)&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/FrUrnCrtsl.htm" class="LinkPage"&gt;Urine 17-Ketosteroid excretion&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/FrUrnCrtsl.htm" class="LinkPage"&gt;Urine 17-Hydroxysteroid excretion&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/SrmCrtsl.htm" class="LinkPage"&gt;Serum Cortisol&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Low dose &lt;a href="../../Endo/Lab/DxmthsnSprsnTst.htm" class="LinkPage"&gt;Dexamethasone Suppression Test&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/SystmcCrtcstrd.htm" class="LinkPage"&gt;Dexamethasone&lt;/a&gt; 1 mg at 11pm&lt;/li&gt;&lt;li&gt;Plasma Cortisol in following 8 AM&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Night-time &lt;a href="../../ENT/Anatomy/SlvryGlndAntmy.htm" class="LinkPage"&gt;Saliva&lt;/a&gt;ry cortisol testing&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Distinguish between pituitary, adrenal or ectopic cause&lt;ol&gt;&lt;li&gt;Plasma ACTH&lt;/li&gt;&lt;li&gt;High dose &lt;a href="../../Endo/Lab/DxmthsnSprsnTst.htm" class="LinkPage"&gt;Dexamethasone Suppression Test&lt;/a&gt; (8 mg)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Radiology&lt;ol&gt;&lt;li&gt;CT or MRI Cone down Sella Turcica&lt;ol&gt;&lt;li&gt;Pituitary adenoma&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;CT &lt;a href="../../GI/Anatomy/AbdmnlAntmy.htm" class="LinkPage"&gt;Abdomen&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Adrenal tumor&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Management&lt;ol&gt;&lt;li&gt;Exogenous Cushing's&lt;ol&gt;&lt;li&gt;Stop steroids or decrease dose&lt;/li&gt;&lt;li&gt;Change steroid dosing to qod with drug holiday&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Endogenous Cushing's&lt;ol&gt;&lt;li&gt;Surgically excise adenoma (in pituitary or adrenal)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Resources&lt;ol&gt;&lt;li&gt;Addison and Cushing International Federation (ACIF)&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.nvacp.nl/page.php?main=5" class="LinkWebExt"&gt;http://www.nvacp.nl/page.php?main=5&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Orth%20%20%5BAU%5D%20AND%201995%20%5BDP%5D%20AND%20%20N%20Engl%20J%20Med%20%20%5BTA%5D" class="LinkRef"&gt;Orth (1995) N Engl J Med 332:791-803&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0010481</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Adrenal/CshngsDs.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Cushing's Disease, Cushing's Syndrome</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Adrenal/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Addison Disease  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0001403"&gt;&lt;i&gt;C0001403&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A hormonal disorder that occurs when the adrenal glands fail to release adequate amounts of glucocorticoids (cortisol), mineralocorticoids (aldosterone, 11-deoxycorticosterone), and androgens (dehydroepiandrosterone) to meet physiologic needs, despite release of ACTH from the pituitary.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MEDLINEPLUS)&lt;/td&gt;
                &lt;td&gt;
                  &lt;span&gt;
                    &lt;p&gt;Your adrenal glands are just above your kidneys. The outside layer of these glands makes hormones that help your body respond to stress and regulate your blood pressure and water and salt balance.  Addison's disease occurs if the adrenal glands don't make enough of these hormones.&lt;/p&gt;
                    &lt;p&gt;A problem with your immune system usually causes Addison's disease. The immune system mistakenly attacks your own tissues, damaging your adrenal glands.&lt;/p&gt;
                    &lt;p&gt;Symptoms include&lt;/p&gt;
                    &lt;ul&gt;&lt;li&gt;Weight loss	&lt;/li&gt;
                      &lt;li&gt;Muscle weakness	&lt;/li&gt;
                      &lt;li&gt;Fatigue that gets worse over time	&lt;/li&gt;
                      &lt;li&gt;Low blood pressure	&lt;/li&gt;
                      &lt;li&gt;Patchy or dark skin &lt;/li&gt;
                    &lt;/ul&gt;&lt;p&gt;Lab tests can confirm that you have Addison's disease.  If you don't treat it, it can be fatal. You will need to take hormone pills for the rest of your life.  If you have Addison's disease, you should carry an emergency ID. It should say that you have the disease, list your medicines and say how much you need in an emergency.&lt;/p&gt;
                  &lt;/span&gt;
                &lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;An adrenal disease characterized by the progressive destruction of the ADRENAL CORTEX, resulting in insufficient production of ALDOSTERONE and HYDROCORTISONE. Clinical symptoms include ANOREXIA; NAUSEA; WEIGHT LOSS; MUSCLE WEAKNESS; and HYPERPIGMENTATION of the SKIN due to increase in circulating levels of ACTH precursor hormone which stimulates MELANOCYTES.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CSP)&lt;/td&gt;
                &lt;td&gt;disease characterized by hypotension, weight loss, anorexia, weakness, and sometimes a bronze-like melanotic hyperpigmentation of the skin; due to tuberculosis or autoimmune induced disease (hypofunction) of the adrenal glands that results in deficiency of aldosterone and cortisol.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Disease or Syndrome (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0001403&amp;amp;tui=T047"&gt;&lt;i&gt;T047&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D000224&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD10&lt;/td&gt;
                &lt;td&gt;E27.1&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;111562000, 367376006, 363732003, 373662000, 154707007, 267483004, 68588005&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Disease, Addison, ADDISON DISEASE, ADDISON'S DISEASE, ADRENAL INSUFFICIENCY (ADDISON'S DISEASE), ADRENOCORTICAL INSUFFICIENCY, PRIMARY FAILURE, DISEASE ADDISON'S, Addison's disease, NOS, Primary adrenal deficiency, Primary adrenocortical insuff, Disease Addison's, Adrenal insufficiency (Addison disease), ADDISONS DIS, ADDISON DIS, Chronic Adrenal Insufficiency, Hypocortisolism, Addison's disease NOS, primary adrenal insufficiency, primary adrenal insufficiency (diagnosis), Addison's disease, NOS (disorder), Addison Disease, Addison disease, Addison Disease [Disease/Finding], Disease;Addisons, addison disease, addison's disease, Primary adrenal insufficiency, Addison's disease, Primary adrenocortical insufficiency, Primary hypoadrenalism, Addison's disease (disorder), Primary adrenocortical insufficiency (disorder), corticoadrenal; deficiency, primary, deficiency; adrenocortical, primary, deficiency; corticoadrenal, primary, disease (or disorder); bronzed skin (Addison) (bronze disease), hypoadrenocorticism; primary, insufficiency; adrenal, primary, insufficiency; suprarenal, primary, adrenal cortex; deficiency, primary, adrenal cortex; hypofunction, primary, adrenal; insufficiency, primary, primary; hypoadrenocorticism, Addison; disease or syndrome, suprarenal; insufficiency, primary, syndrome; Addison, Addison's disease [Ambiguous], Addison's Disease, Hypoadrenalism, Primary, Hypoadrenalisms, Primary, Insufficiencies, Primary Adrenocortical, Insufficiency, Primary Adrenocortical, Primary Adrenal Insufficiency, Primary Adrenocortical Insufficiencies, Primary Adrenocortical Insufficiency, Primary Hypoadrenalism, Adrenal Insufficiency, Primary, Adrenocortical Insufficiencies, Primary, Adrenocortical Insufficiency, Primary, Addisons Disease, Addisons disease&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;DOENCA DE ADDISON, Hipadrenalismo primário, Insuficiência suprarrenal primária, Doença de Addison&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Insufficienza surrenale primitiva, Malattia di Addison, Iposurrenalismo primitivo, Insufficienza corticosurrenale cronica, Insufficienza adrenocorticale primaria, Ipoadrenalismo primario, Morbo di Addison&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;primair hypoadrenalisme, ziekte van Addison, Addison; ziekte of syndroom, aandoening; bronzed skin (Addison) (bronsziekte), bijnier; insufficiëntie, primair, bijnierschors; deficiëntie, primair, bijnierschors; hypofunctie, primair, cortico-adrenaal; deficiëntie, primair, deficiëntie; bijnierschors, primair, deficiëntie; cortico-adrenaal, primair, hypoadrenocorticisme; primair, insufficiëntie; bijnier, primair, insufficiëntie; suprarenaal, primair, primair; hypoadrenocorticisme, suprarenaal; insufficiëntie, primair, syndroom; Addison, primaire bijnierinsufficiëntie, Addison, syndroom van, Addison, ziekte van, Ziekte van Addison, Primaire bijnierschorsinsufficiëntie&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Hyposurrénalisme, MALADIE D'ADDISON, Insuffisance surrénalienne primaire, Insuffisance corticosurrénalienne primitive, Insuffisance surrénalienne primitive, Maladie d'Addison, Insuffisance surrénale lente, Insuffisance surrénale primitive&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Krankheit Addisonsche, Addisonsche Krankheit, primaerer Hypoadrenalismus, MORBUS ADDISON, Primaere Nebennierenrindeninsuffizienz, primaere Nebenniereninsuffizienz, Addison-Krankheit, Bronzehautkrankheit, Nebenniereninsuffizienz, primär chronische&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;Hipoadrenalismo primario, Addison's disease, Addison's disease, NOS, ADDISON, ENFERMEDAD, enfermedad de Addison (concepto no activo), enfermedad de Addison (trastorno), enfermedad de Addison, insuficiencia adrenal crónica, insuficiencia adrenal primaria, insuficiencia adrenocortical primaria, insuficiencia corticosuprarrenal primaria (trastorno), insuficiencia corticosuprarrenal primaria, insuficiencia suprarrenal crónica, insuficiencia suprarrenal primaria, Insuficiencia suprarrenal primaria, Enfermedad de Addison&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;原発性副腎機能不全, 原発性副腎機能低下症, ｹﾞﾝﾊﾟﾂｾｲﾌｸｼﾞﾝｷﾉｳﾌｾﾞﾝ, ｱｼﾞｿﾝﾋﾞｮｳ, ｹﾞﾝﾊﾟﾂｾｲﾌｸｼﾞﾝｷﾉｳﾃｲｶｼｮｳ, Addison病, アジソン病, 副腎性黒皮症, 副腎機能不全症-原発性, 原発性副腎機能不全症, 原発性副腎皮質機能低下症, 慢性副腎皮質不全症, アディソン病, 副腎皮質機能低下症-原発性&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Addisons sjukdom&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;Addisonova nemoc, Primární hypoadrenalismus, Primární nadledvinová nedostatečnost, Addisonova choroba&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Addisonin tauti&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;ADDISONOVA BOLEZN', BRONZOVAIA BOLEZN', АДДИСОНОВА БОЛЕЗНЬ, БРОНЗОВАЯ БОЛЕЗНЬ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Korean&lt;/td&gt;
                &lt;td&gt;원발성 부신피질 기능부전&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Croatian&lt;/td&gt;
                &lt;td&gt;ADDISONOVA BOLEST&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Choroba Addisona, Pierwotna przewlekła niedoczynność kory nadnerczy, Cisawica&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;Addison-kór, Addison-betegség, Primaer mellékvese elégtelenség, Primaer hypadrenia&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Adrenal gland hypofunction  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0001623"&gt;&lt;i&gt;C0001623&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;An endocrine or hormonal disorder that occurs when the adrenal cortex does not produce enough of the hormone cortisol and in some cases, the hormone aldosterone. It may be due to a disorder of the adrenal cortex (Addison's disease or primary adrenal insufficiency) or to inadequate secretion of ACTH by the pituitary gland (secondary adrenal insufficiency).&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A disorder that occurs when the adrenal cortex does not produce enough of the hormone cortisol and in some cases, the hormone aldosterone. It may be due to a disorder of the adrenal cortex as in Addison's disease or primary adrenal insufficiency.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;Conditions in which the production of adrenal CORTICOSTEROIDS falls below the requirement of the body. Adrenal insufficiency can be caused by defects in the ADRENAL GLANDS, the PITUITARY GLAND, or the HYPOTHALAMUS.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CSP)&lt;/td&gt;
                &lt;td&gt;abnormally diminished activity of the adrenal gland.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Disease or Syndrome (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0001623&amp;amp;tui=T047"&gt;&lt;i&gt;T047&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D000309&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;237785004, 111563005, 386584007, 68588005, 190527008&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;ADRENAL INSUFFICIENCY, HYPOADRENALISM, ADRENAL HYPOFUNCTION, HYPOFUNCTION ADRENAL, Hypofunction, Adrenal Gland, hypoadrenalism, Adrenal insufficiency, NOS, INSUFFICIENCY ADRENAL, adrenal insufficiency, adrenal insufficiency (diagnosis), Adrenal gland hypofunction, Hypofunction adrenal, Adrenal insufficiency NOS, Insufficiency adrenal, Adrenal Cortical Insufficiency, Adrenal Insufficiency [Disease/Finding], Insufficiency;adrenal, adrenal failure, adrenal hypofunctions, adrenal insufficiencies, insufficiency adrenal, adrenal hypofunction, Adrenal failure, Adrenal hypofunction, Adrenal insufficiency, Adrenal hypofunction (disorder), Hypoadrenalism (disorder), Adrenal Gland Hypofunction, Hypoadrenalism, Adrenal Insufficiencies, Adrenal Insufficiency, Adrenal Gland Insufficiency&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;INSUFFISANCE SURRENALE, Hypofonction surrénalienne, Hypofonction surrénale, Insuffisance surrénalienne SAI, HYPOFONCTIONNEMENT SURRENAL, HYPOSURRENALISME, Insuffisance surrénale, Hypofonctionnement de la glande surrénale, Hypofonctionnement surrénalien, Insuffisance surrénalienne&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;NEBENNIERENUNTERFUNKTION, Nebenniereninsuffizenz NNB, Insuffizienz Nebenniere, Hypoadrenalismus, Unterfunktion Nebenniere, HYPOADRENALISMUS, NEBENNIERENINSUFFIZIENZ, Nebenniereninsuffizienz, Hypokortizismus, Nebennierenunterfunktion&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Insufficienza surrenale, Ipofunzione surrenale, Insufficienza surrenale NAS, Iposurrenalismo, Ipoadrenalismo, Ipofunzione della ghiandola surrenale&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;hypofunctie bijnier, bijnierinsufficiëntie NAO, insufficiëntie bijnier, hypoadrenalisme, bijnierhypofunctie, bijnierinsufficiëntie, Bijnierhypofunctie, Hypocorticisme, Hypofunctie, bijnier-, Bijniermerginsufficiëntie, Bijnierschorsinsufficiëntie, Bijnierinsufficiëntie, Insufficiëntie, bijnier-&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Insuficiência supra-renal NE, Hipofunção supra-renal, Hipoadrenalismo, HIPOADRENALISMO, HIPOFUNCAO SUPRA-RENAL, INSUFICIENCIA SUPRA-RENAL, Insuficiência supra-renal, Hipofunção das Glândulas Supra-Renais, Insuficiência Adrenal, Insuficiência Supra-Renal&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;Insuficiencia suprarrenal NEOM, Insuficiencia adrenal, Hipofunción suprarrenal, Hipoadrenalismo, Adrenal hypofunction, HIPOADRENALISMO, INSUFICIENCIA SUPRARRENAL, SUPRARRENAL HIPOFUNCION, hipoadrenalismo (trastorno), hipoadrenalismo, hipofunción adrenal, hipofunción suprarrenal (trastorno), hipofunción suprarrenal, Insuficiencia suprarrenal, Hipofunción de las Glándulas Suprarrenales, Insuficiencia Suprarrenal, Hipofuncion de las Glandulas Suprarrenales&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;副腎機能不全ＮＯＳ, 副腎機能不全, ﾌｸｼﾞﾝｷﾉｳﾃｲｶ, ﾌｸｼﾞﾝｷﾉｳﾌｾﾞﾝNOS, ﾌｸｼﾞﾝｷﾉｳﾃｲｶｼｮｳ, ﾌｸｼﾞﾝｷﾉｳﾌｾﾞﾝ, 副腎皮質機能低下症, 副腎機能低下, 副腎機能低下症, 副腎皮質機能低下&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Binjurehypofunktion&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;nadledviny - hypofunkce, Nedostatečnost nadledvin NOS, Nedostatečnost nadledvin, Adrenální hypofunkce, Adrenální nedostatečnost, Hypoadrenalismus, nadledviny - insuficience, insuficience nadledvin&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Lisämunuaisen vajaatoiminta&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;NADPOCHECHNIKOV NEDOSTATOCHNOST', NADPOCHECHNIKOV GIPOFUNKTSIIA, НАДПОЧЕЧНИКОВ ГИПОФУНКЦИЯ, НАДПОЧЕЧНИКОВ НЕДОСТАТОЧНОСТЬ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Croatian&lt;/td&gt;
                &lt;td&gt;Not Translated[Adrenal Insufficiency]&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Niewydolność kory nadnerczy, Niedoczynność kory nadnerczy&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;Mellékvese-elégtelenség, Adrenalis hypofunctio, Hypadrenia, Mellékvese elégtelenség, Mellékvese hypofunctio, Mellékvese-elégtelenség k.m.n.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Adrenal cortical hypofunction  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0405580"&gt;&lt;i&gt;C0405580&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Disease or Syndrome (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0405580&amp;amp;tui=T047"&gt;&lt;i&gt;T047&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD9&lt;/td&gt;
                &lt;td&gt;255.4&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;267398003, 386584007, 154707007, 267483004, 68588005, 190527008&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;ADRENAL CORTEX INSUFFIENCY, ADRENAL CORTEX HYPOFUNCTION, ADRENAL CORTICAL INSUFFICIENCY, INSUFFICIENCY ADRENAL CORTEX, Adrenal cortical hypofunction, NOS, Adrenocortical hypofunction, NOS, Corticoadrenal insufficiency, NOS, Hypoadrenocorticism, NOS, Corticoadrenal insuffic. NOS, Corticoadrenal insufficiency NOS, Adrenocortical insufficiency syndrome, Adrenal insufficiency NOS, Adrenal cortex hypofunction, Adrenal cortex insuffiency, Adrenal cortical insufficiency, Insufficiency adrenal cortex, Adrenal cortex insufficiency, corticoadrenal insufficiency (diagnosis), corticoadrenal insufficiency, adrenal cortical hypofunction, adrenal cortical insufficiency, Adrenal cortical hypofunction, Adrenal insufficiency, ADRENAL INSUFFICIENCY CORTICAL, Corticoadrenal insufficiency NOS (disorder), adrenal insufficiency, adrenal insufficiencies, adrenal cortex insufficiency, adrenocortical hypofunction, Adrenal Insufficiency, Adrenal cortical hypofunctions, Corticoadrenal insufficiency, Hypoadrenocorticism, Adrenal cortical hypofunction (disorder), Adrenocortical hypofunction, corticoadrenal; deficiency, corticoadrenal; hypofunction, deficiency; corticoadrenal, hypoadrenocorticism, hypofunction; adrenocortical, insufficiency; adrenal, adrenal cortex; deficiency, adrenal; insufficiency&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Ipofunzioni corticosurrenali, Ipocorticosurrenalismo, Insufficienza corticosurrenale, Insufficienza della corteccia surrenale, Ipofunzione corticosurrenale&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;副腎皮質機能低下, ﾌｸｼﾞﾝﾋｼﾂｷﾉｳﾃｲｶ, 副腎皮質機能不全, ﾌｸｼﾞﾝﾋｼﾂｷﾉｳﾌｾﾞﾝ, 副腎皮質機能低下症, ﾌｸｼﾞﾝﾋｼﾂｷﾉｳﾃｲｶｼｮｳ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;Corticoadrenal insufficiency, Corticoadrenal insufficiency NOS, Hipoadrenocorticismo, Hipofunción corticosuprarrenal, Insuficiencia de la corteza suprarrenal, Hipofunción cortical suprarrenal, Insuficiencia córticosuprarrenal, Insuficiencia corticoadrenal, CORTEZA SUPRARRENAL, HIPOFUNCION, CORTICOSUPRARRENAL, INSUFICIENCIA, hipoadrenocorticismo, hipofunción adrenocortical, hipofunción de corteza adrenal (trastorno), hipofunción de corteza adrenal, insuficiencia corticoadrenal, SAI (trastorno), insuficiencia corticoadrenal, SAI, insuficiencia corticoadrenal, insuficiencia corticosuprarrenal, insuficiencia suprarrenal (trastorno), insuficiencia suprarrenal, Hipofunción de la corteza suprarrenal&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Insuffisance corticosurrénale, Insuffisance cortico-surrénalienne, Hypofonction cortico-surrénale, Insuffisance corticale surrénalienne, Hypoadrénocorticisme, Insuffisance corticosurrénalienne, Hypofonction de la corticosurrénale, Insuffisance cortico-surrénale, HYPOFONCTIONN CORTICO-SURRENAL, INSUFFISANCE CORTICO-SURRENALE, Hypofonctions adréno-corticales&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;bijnierschorshypofunctie, hypoadrenocorticisme, insufficiëntie bijnierschors, bijnierschorsinsufficiëntie, bijnier; insufficiëntie, bijnierschors; deficiëntie, bijnierschors; hypofunctie, cortico-adrenaal; deficiëntie, deficiëntie; cortico-adrenaal, hypofunctie; bijnierschors, insufficiëntie; bijnier, bijnierschorshypofuncties&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Insuficiência córtico-supra-renal, Insuficiência cortical suprarrenal, Hipoadrenocorticismo, Hipofunção córtico-supra-renal, Insuficiência adrenocortical, HIPOFUNCAO DO CORTEX SUPRA-RENAL, INSUFICIENCIA CORTICO-SUPRA-RENAL, Hipofuncionamento cortical suprarenal&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Nebennierenrindenunterfunktion, Hypoadrenokortizismus, Insuffizienz der Nebennierenrinde, kortikoadrenale Insuffizienz, Nebennierenrindeninsuffizienz, NNR INSUFFIZIENZ, NNR UNTERFUNKTION, Unterfunktionen der Nebennierenrinde&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;Hypofunkce nadledvinové kůry, Adrenokortikální nedostatečnost, Hypofunkce kůry nadledvin, Adrenokortikální hypofunkce, Nedostatečnost kůry nadledvin, Hypoadrenokorticismus, Insuficience kůry nadledvin, Insuficience adrenálního kortexu, Kortikoadrenální nedostatečnost&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;adrenocorticalis elégtelenség, Mellékvesekéreg insufficientia, Mellékvesekéreg insufficiencia, Corticoadrenalis elégtelenség, Adrenocorticalis hypofunkciók, Mellékvese kéreg hypofunctio, Mellékvesekéreg hypofunctio, Mellékvesekéreg elégtelensége, adrenocorticalis hypofunctio&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Addisonian crisis  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0151467"&gt;&lt;i&gt;C0151467&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Disease or Syndrome (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0151467&amp;amp;tui=T047"&gt;&lt;i&gt;T047&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD10&lt;/td&gt;
                &lt;td&gt;E27.2&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;190522002, 190526004, 237757001, 24867002, 154707007, 267483004&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;ADDISONIAN CRISIS, ADRENAL APOPLEXY, ADRENAL CRISIS, ADRENAL STORM, ADRENOCORTICAL INSUFFICIENCY, ACUTE, CRISIS ADDISONIAN, CRISIS ADRENAL, Addisonian crisis, Adrenal Apoplexy, Adrenocortical insufficiency syndrome, acute, Adrenal crisis syndrome, adrenal crisis (diagnosis), adrenal crisis, Adrenal storm, Acute adrenal insufficiency (&amp;amp; [Addisonian crisis] or [adrenal crisis]) (disorder), Addisonian crisis (disorder), Addisonian crisis (diagnosis), Adrenocortical insufficiency acute, Crisis addisonian, Crisis adrenal, acute adrenal insufficiency, addisonian crisis, adrenal storm, severe adrenal insufficiency, Adrenal crisis, Severe adrenal insufficiency, Acute adrenal insufficiency, Adrenocortical crisis, Severe adrenal insufficiency (disorder), collapse; adrenal, crisis; Addison, crisis; adrenal, adrenal; collapse, adrenal; crisis, adrenal; shock, Addison; crisis, shock; adrenal, Acute adrenal insufficiency (&amp;amp; [Addisonian crisis] or [adrenal crisis])&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Insufficienza corticosurrenale acuta, Crisi surrenale, Crisi Addisoniana, Crisi addisoniana, Tempesta surrenale&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;adrenale crisis, Addison-crisis, crisis bijnier, adrenale storm, Addison; crisis, adrenaal; crisis, bijnier; collaps, bijnier; shock, collaps; bijnier, crisis; Addison, crisis; adrenaal, shock; bijnier, acute bijnierschorsinsufficiëntie&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Crise d'Addison, Crise surrénale, Crise d'insuffisance surrénale, Crise surrénalienne, CATACLYSME SURRENAL, CRISE SURRENALE, Insuffisance surrénalienne aiguë&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Nebennierenkrise, Krise Nebenniere, Krise Addison, Addison-Krise, ADDISONKRISE, akute Nebennierenrindenueberfunktion, NEBENNIERENKRISE, Nebennierenrindeninsuffizienz akut&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Crise de Addison, Crise addisoniana, Crise supra-renal, Perturbação supra-renal, CRISE SUPRA-RENAL, Insuficiência adrenocortical aguda&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;Crisis adrenal, Crisis addisoniana, Addisonian crisis, Acute adrenal insufficiency (&amp;amp; [Addisonian crisis] or [adrenal crisis]), Acute adrenal insufficiency, Adrenal crisis, Tormenta adrenal, CRISIS SUPRARRENAL, SUPRARRENAL, CRISIS, crisis addisoniana, crisis suprarrenal, insuficiencia adrenal severa, insuficiencia suprarrenal aguda (trastorno), insuficiencia suprarrenal aguda, insuficiencia suprarrenal severa, Insuficiencia córticosuprarrenal aguda&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;アジソン病クリーゼ, 急性副腎皮質機能不全, 副腎クリーゼ, ｷｭｳｾｲﾌｸｼﾞﾝﾋｼﾂｷﾉｳﾌｾﾞﾝ, ｱｼﾞｿﾝﾋﾞｮｳｸﾘｰｾﾞ, ﾌｸｼﾞﾝｸﾘｰｾﾞ, ﾌｸｼﾞﾝｽﾄｰﾑ, 副腎ストーム&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;Addisonská krize, Adrenální krize, Adrenal storm (Akutní vyplavení hormonů kůry nadledvin), Akutní nedostatečnost kůry nadledvin&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Korean&lt;/td&gt;
                &lt;td&gt;아디슨 발증&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;Addison-crisis, Adrenalis crisis, Mellékvese izgalom, Acut mellékvesekéreg elégtelenség, Addisonos crisis&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Addison Disease  (</value><value>)
</value><value>Adrenal gland hypofunction  (</value><value>)
</value><value>Adrenal cortical hypofunction  (</value><value>)
</value><value>Addisonian crisis  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Addison's Disease</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Adrenal Disease</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;See Also&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Adrenal/AtmnPlyglndlrSyndrmTypI.htm" class="LinkPage"&gt;Autoimmune Polyglandular Syndrome&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Pathophysiology&lt;ol&gt;&lt;li&gt;Hypothalamic-Pituitary-Adrenal Axis (HPA) Dysfunction&lt;ol&gt;&lt;li&gt;Lab features: Cortisol low, ACTH Low&lt;/li&gt;&lt;li&gt;Causes&lt;ol&gt;&lt;li&gt;Severe illness&lt;/li&gt;&lt;li&gt;Exogenous &lt;a href="../../Endo/Pharm/SystmcCrtcstrd.htm" class="LinkPage"&gt;Corticosteroid&lt;/a&gt; (suppression lasts months)&lt;ol&gt;&lt;li&gt;Prednisone &amp;gt;7.5 mg/day for &amp;gt;3 weeks&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/SystmcCrtcstrd.htm" class="LinkPage"&gt;Dexamethasone&lt;/a&gt; &amp;gt;0.75 mg/day for &amp;gt;3 weeks&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Pituitary Infarction&lt;/li&gt;&lt;li&gt;&lt;a href="../../Neuro/ID/CnsInfctn.htm" class="LinkPage"&gt;CNS Infection&lt;/a&gt; or tumor invasion&lt;/li&gt;&lt;li&gt;&lt;a href="../../ER/Neuro/HdInjry.htm" class="LinkPage"&gt;Head Injury&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../HIV/Exam/HmnImndfcncyVrs.htm" class="LinkPage"&gt;HIV Infection&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Adrenal Insufficiency&lt;ol&gt;&lt;li&gt;Lab features: Cortisol low, ACTH high&lt;/li&gt;&lt;li&gt;Causes&lt;ol&gt;&lt;li&gt;Addison's Disease&lt;ol&gt;&lt;li&gt;Primary adrenal failure of &lt;a href="../../Endo/Anatomy/AdrnlAntmy.htm" class="LinkPage"&gt;Adrenal Gland&lt;/a&gt;s&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Idiopathic adrenal hypoplasia or destruction&lt;ol&gt;&lt;li&gt;Granulomatous disease (e.g. &lt;a href="../../Lung/Tb/Tbrcls.htm" class="LinkPage"&gt;Tuberculosis&lt;/a&gt;, Fungus)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Rheum/Diffuse/Amylds.htm" class="LinkPage"&gt;Amyloidosis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../GI/HemeOnc/Hmchrmts.htm" class="LinkPage"&gt;Hemochromatosis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Tumor&lt;/li&gt;&lt;li&gt;Autoimmune process&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Drug mediated cortisol inhibition&lt;ol&gt;&lt;li&gt;&lt;a href="../../Surgery/Pharm/Etmdt.htm" class="LinkPage"&gt;Etomidate&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../ID/Pharm/Ktcnzl.htm" class="LinkPage"&gt;Ketoconazole&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Symptoms&lt;ol&gt;&lt;li&gt;Weakness&lt;/li&gt;&lt;li&gt;&lt;a href="../../Rheum/Sx/Ftg.htm" class="LinkPage"&gt;Fatigue&lt;/a&gt; or Lethargy&lt;/li&gt;&lt;li&gt;&lt;a href="../../GI/Sx/Vmtng.htm" class="LinkPage"&gt;Nausea&lt;/a&gt; or &lt;a href="../../GI/Sx/Vmtng.htm" class="LinkPage"&gt;Vomiting&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../GI/Diarrhea/ActDrh.htm" class="LinkPage"&gt;Diarrhea&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Surgery/GI/ActAbdmnlPn.htm" class="LinkPage"&gt;Abdominal Pain&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Weight loss&lt;/li&gt;&lt;li&gt;Salt craving&lt;/li&gt;&lt;li&gt;&lt;a href="../../Neuro/LOC/AltrdLvlOfCnscsns.htm" class="LinkPage"&gt;Altered Level of Consciousness&lt;/a&gt; (e.g. &lt;a href="../../Neuro/Cognitive/Dlrm.htm" class="LinkPage"&gt;Delirium&lt;/a&gt;)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Signs&lt;ol&gt;&lt;li&gt;&lt;a href="../../ID/Exam/Fvr.htm" class="LinkPage"&gt;Fever&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Derm/Pigment/Hyprpgmntn.htm" class="LinkPage"&gt;Hyperpigmentation&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Skin with mottled areas of increased pigmentation&lt;/li&gt;&lt;li&gt;Pigment at &lt;a href="../../Dental/Exam/LblMcs.htm" class="LinkPage"&gt;Buccal mucosa&lt;/a&gt; (Caucasian)&lt;/li&gt;&lt;li&gt;Increased pigment in lips, vagina, rectum&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Reduced &lt;a href="../../Derm/Anatomy/Hr.htm" class="LinkPage"&gt;Hair Growth&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Exam/OrthstcHyptnsn.htm" class="LinkPage"&gt;Postural Hypotension&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Signs of dehydration&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Labs&lt;ol&gt;&lt;li&gt;&lt;a href="../../HemeOnc/Lab/CmpltBldCnt.htm" class="LinkPage"&gt;Complete Blood Count&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Normochromic &lt;a href="../../HemeOnc/Anemia/NrmcytcAnm.htm" class="LinkPage"&gt;Normocytic Anemia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../HemeOnc/Lab/EsnphlCnt.htm" class="LinkPage"&gt;Eosinophilia&lt;/a&gt; (helps differentiate from other causes)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Chemistry Panel&lt;ol&gt;&lt;li&gt;&lt;a href="../../Renal/Sodium/Hypntrm.htm" class="LinkPage"&gt;Hyponatremia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Renal/Chloride/Hypchlrm.htm" class="LinkPage"&gt;Hypochloremia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Renal/Potassium/Hyprklm.htm" class="LinkPage"&gt;Hyperkalemia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Hypoglycemia/Hypglycm.htm" class="LinkPage"&gt;Hypoglycemia&lt;/a&gt; (helps differentiate from other causes)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Urine 17-ketosteroids low&lt;/li&gt;&lt;li&gt;Urine 17-Hydroxysteroids low&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Diagnosis&lt;ol&gt;&lt;li&gt;Corticotropin Stimulation Test&lt;ol&gt;&lt;li&gt;Failed adrenal response&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Management&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Endo/Surgery/PrprtvCrtcstrd.htm" class="LinkPage"&gt;Stress Dose Steroid&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Acute&lt;ol&gt;&lt;li&gt;IV Cortisol&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Chronic Replacement&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/SystmcCrtcstrd.htm" class="LinkPage"&gt;Hydrocortisone&lt;/a&gt; (glucocorticoid) AND&lt;/li&gt;&lt;li&gt;Mineralocorticoid (9-alpha-fluorocortisol)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Resources&lt;ol&gt;&lt;li&gt;Addison and Cushing International Federation (ACIF)&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.nvacp.nl/page.php?main=5" class="LinkWebExt"&gt;http://www.nvacp.nl/page.php?main=5&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Cooper%20%20%5BAU%5D%20AND%202003%20%5BDP%5D%20AND%20%20N%20Engl%20J%20Med%20%20%5BTA%5D" class="LinkRef"&gt;Cooper (2003) N Engl J Med 348:727-34&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0001403</value><value>C0001623</value><value>C0405580</value><value>C0151467</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Adrenal/AdsnsDs.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Addison's Disease, Addisonian Crisis, Adrenal Cortical Insufficiency, Adrenal Insufficiency, Adrenal Hypofunction, Illness Induced Adrenal Insufficiency</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Adrenal/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Blood glucose decreased  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0595883"&gt;&lt;i&gt;C0595883&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Finding (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0595883&amp;amp;tui=T033"&gt;&lt;i&gt;T033&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;BLOOD SUGAR DECREASED, SUGAR BLOOD DECREASED, GLUCOSE BLOOD DECREASED, Glucose blood decreased, Blood sugar decreased, Decreased blood sugar, Sugar blood decreased, blood decreasing sugar, blood glucose decreased, Blood glucose decreased&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;glucose bloed verlaagd, suiker bloed verlaagd, bloed suiker verlaagd, verlaagd bloed suiker, bloed glucose verlaagd&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Glucose sanguin diminué, DIMINUTION DE LA GLYCEMIE, Glycémie diminuée&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Blutzucker erniedrigt, Blutzucker erniedigt, erniedrigter Blutzucker, BLUTZUCKER ERNIEDRIGT, Glukose im Blut erniedrigt&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Açúcar no sangue diminuído, BAIXA DA GLICEMIA, Glicemia diminuída&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;Azúcar disminuida en sangre, Azucar disminuida en sangre, AZUCAR EN SANGRE, DISMINUIDO, Glucosa disminuida en sangre&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;血中ブドウ糖減少, 血糖減少, ｹｯﾁｭｳﾌﾞﾄﾞｳﾄｳｹﾞﾝｼｮｳ, ｹｯﾄｳｹﾞﾝｼｮｳ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;Glykemie snížená, Hladina cukru v krvi snížená, Snížená hladina krevního cukru, Hodnoty glykemie snížené, Hladina krevního cukru snížená&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Zuccheri ematici diminuiti, Glucosio ematico diminuito&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;Glükóz vérszint csökkent, Vércukor csökkent, Vércukorszint csökkent&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Blood glucose decreased  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Hypoglycemia</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Hypoglycemic Disorders</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Causes&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/DM/DbtsMlts.htm" class="LinkPage"&gt;Diabetes Mellitus&lt;/a&gt; on &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; or &lt;a href="../../Endo/Pharm/Slfnylr.htm" class="LinkPage"&gt;Insulin Secretagogue&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Hypoglycemia/PstprndlHypglycm.htm" class="LinkPage"&gt;Postprandial Hypoglycemia&lt;/a&gt; (&lt;a href="../../Endo/Hypoglycemia/PstprndlHypglycm.htm" class="LinkPage"&gt;Reactive Hypoglycemia&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Hypoglycemia/FstngHypglycm.htm" class="LinkPage"&gt;Fasting Hypoglycemia&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Symptoms&lt;ol&gt;&lt;li&gt;Sympathetic response&lt;ol&gt;&lt;li&gt;Sweating&lt;/li&gt;&lt;li&gt;&lt;a href="../../Neuro/Tremor/Trmr.htm" class="LinkPage"&gt;Tremor&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/EKG/Tchycrd.htm" class="LinkPage"&gt;Tachycardia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Anxiety&lt;/li&gt;&lt;li&gt;Hunger&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;CNS symptoms&lt;ol&gt;&lt;li&gt;&lt;a href="../../CV/Sx/Dzns.htm" class="LinkPage"&gt;Dizziness&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Visual disturbance&lt;/li&gt;&lt;li&gt;Confusion&lt;/li&gt;&lt;li&gt;&lt;a href="../../Neuro/Seizure/Szr.htm" class="LinkPage"&gt;Convulsion&lt;/a&gt;s&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Sx/Syncp.htm" class="LinkPage"&gt;Syncope&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Diagnosis: Whipple's Triad&lt;ol&gt;&lt;li&gt;Low Plasma &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Men &amp;lt; 2.8 mmol/L (50 mg/dl)&lt;/li&gt;&lt;li&gt;Women &amp;lt; 2.2 mmol/L (40 mg/dl)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Hypoglycemic Symptoms&lt;ol&gt;&lt;li&gt;May be masked by certain conditions or medications&lt;ol&gt;&lt;li&gt;&lt;a href="../../Neuro/Autonomic/AtnmcDysfnctn.htm" class="LinkPage"&gt;Autonomic Neuropathy&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Pharm/BtBlckr.htm" class="LinkPage"&gt;Beta Blocker&lt;/a&gt;s&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Symptoms improve with plasma &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; correction&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Management&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Endo/Hypoglycemia/HypglycmMngmnt.htm" class="LinkPage"&gt;Hypoglycemia Management&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;General Dietary Measures&lt;ol&gt;&lt;li&gt;Avoid fasting&lt;/li&gt;&lt;li&gt;Small, frequent meals&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0595883</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Hypoglycemia/Hypglycm.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Hypoglycemia</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Hypoglycemia/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees></FP_UMLS_Trees><FP_Condition_name_check></FP_Condition_name_check><FP_Condition_name><value>Growth Assessment</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Growth Disorders</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;See Also&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Exam/GrwthPhyslgy.htm" class="LinkPage"&gt;Growth Physiology&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Evaluation: Linear Growth&lt;ol&gt;&lt;li&gt;Measurements&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Exam/HghtMsrmntInChldrn.htm" class="LinkPage"&gt;Height Measurement in Children&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Exam/MdprntlHght.htm" class="LinkPage"&gt;Calculation of Growth Delay&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Exam/LnrGrwthVlcty.htm" class="LinkPage"&gt;Linear Growth Velocity&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Exam/ArmSpn.htm" class="LinkPage"&gt;Arm Span&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Exam/StngHght.htm" class="LinkPage"&gt;Sitting Height&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Exam/UprTLwrSgmntRt.htm" class="LinkPage"&gt;Upper to Lower Segment Ratio&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Abnormalities&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Growth/ShrtStr.htm" class="LinkPage"&gt;Short Stature&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Growth/TlStr.htm" class="LinkPage"&gt;Tall Stature&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Evaluation: Weight&lt;ol&gt;&lt;li&gt;Measurements&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Exam/WghtMsrmntInChldrn.htm" class="LinkPage"&gt;Weight Measurement in Children&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Exam/WghtFrHghtAg.htm" class="LinkPage"&gt;Weight for Height Age&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Exam/WghtFrLngth.htm" class="LinkPage"&gt;Weight for Length&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Exam/BdyMsIndx.htm" class="LinkPage"&gt;Body Mass Index&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Exam/EnrgyDfctClcltn.htm" class="LinkPage"&gt;Resting Energy Expenditure&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Abnormalities&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Peds/FlrTThrv.htm" class="LinkPage"&gt;Failure to Thrive&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Peds/ObstyInChldrn.htm" class="LinkPage"&gt;Obesity in Children&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Growth/GrwthAssmnt.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Growth Assessment</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Growth/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees></FP_UMLS_Trees><FP_Condition_name_check></FP_Condition_name_check><FP_Condition_name><value>Fasting Hypoglycemia</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Hypoglycemic Disorders</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;See Also&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Hypoglycemia/Hypglycm.htm" class="LinkPage"&gt;Hypoglycemia&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Causes: Underproduction of &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Hormone Deficiency&lt;ol&gt;&lt;li&gt;Hypopituitarism&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Adrenal/AdsnsDs.htm" class="LinkPage"&gt;Adrenal Insufficiency&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Neuro/Pharm/AdrnrgcRcptr.htm" class="LinkPage"&gt;Catecholamine&lt;/a&gt; deficiency&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Glcgn.htm" class="LinkPage"&gt;Glucagon&lt;/a&gt; deficiency&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Enzyme Defect&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; 6 Phosphate dehydrogenase deficiency (&lt;a href="../../HemeOnc/Hemolysis/G6pdDfcncy.htm" class="LinkPage"&gt;G6PD&lt;/a&gt;)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Substrate deficiency&lt;ol&gt;&lt;li&gt;Ketotic &lt;a href="../../Endo/Hypoglycemia/Hypglycm.htm" class="LinkPage"&gt;Hypoglycemia&lt;/a&gt; of infancy&lt;/li&gt;&lt;li&gt;Severe malnutrition or wasting&lt;/li&gt;&lt;li&gt;Late pregnancy&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Acquired &lt;a href="../../GI/Anatomy/LvrAntmy.htm" class="LinkPage"&gt;Liver&lt;/a&gt; disease&lt;ol&gt;&lt;li&gt;Hepatic congestion&lt;/li&gt;&lt;li&gt;Severe hepatitis&lt;/li&gt;&lt;li&gt;&lt;a href="../../GI/Lvr/Crhs.htm" class="LinkPage"&gt;Cirrhosis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Renal/Failure/ActRnlFlr.htm" class="LinkPage"&gt;Uremia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../ER/Environ/Hypthrm.htm" class="LinkPage"&gt;Hypothermia&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Drugs&lt;ol&gt;&lt;li&gt;&lt;a href="../../Psych/Pharm/Alchl.htm" class="LinkPage"&gt;Alcohol&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Pharm/Prprnl.htm" class="LinkPage"&gt;Propranolol&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Pharm/Analgesic/Slcylt.htm" class="LinkPage"&gt;Salicylate&lt;/a&gt;s&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Causes: Overutilization of &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Hyperinsulinism&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/HemeOnc/Inslnm.htm" class="LinkPage"&gt;Insulinoma&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt;&lt;a href="../../ENT/Allergy/Atmnty.htm" class="LinkPage"&gt;Autoimmunity&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Medications&lt;ol&gt;&lt;li&gt;Exogenous &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Slfnylr.htm" class="LinkPage"&gt;Sulfonylurea&lt;/a&gt;s&lt;/li&gt;&lt;li&gt;Quinine&lt;/li&gt;&lt;li&gt;Disopyramide&lt;/li&gt;&lt;li&gt;&lt;a href="../../ID/Pharm/Pntmdn.htm" class="LinkPage"&gt;Pentamidine&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Endotoxic shock&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Appropriate &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; Level&lt;ol&gt;&lt;li&gt;Extrapancreatic tumor&lt;/li&gt;&lt;li&gt;Systemic carnitine deficiency&lt;/li&gt;&lt;li&gt;Deficiency in enzymes of fat oxidation&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Geri/UntntnlWghtLs.htm" class="LinkPage"&gt;Cachexia&lt;/a&gt; with fat depletion&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Symptoms and Signs&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Endo/Hypoglycemia/Hypglycm.htm" class="LinkPage"&gt;Hypoglycemia&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Labs&lt;ol&gt;&lt;li&gt;Plasma &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Plasma &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; &amp;gt;7175 pmol/L&lt;ol&gt;&lt;li&gt;Exogenous &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; injection&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Plasma &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; &amp;lt;1435 pmol/L&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/HemeOnc/Inslnm.htm" class="LinkPage"&gt;Insulinoma&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Slfnylr.htm" class="LinkPage"&gt;Sulfonylurea&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Proinsulin&lt;ol&gt;&lt;li&gt;Increased in &lt;a href="../../Endo/HemeOnc/Inslnm.htm" class="LinkPage"&gt;Insulinoma&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;C-Peptide&lt;ol&gt;&lt;li&gt;Increased in &lt;a href="../../Endo/HemeOnc/Inslnm.htm" class="LinkPage"&gt;Insulinoma&lt;/a&gt; and &lt;a href="../../Endo/Pharm/Slfnylr.htm" class="LinkPage"&gt;Sulfonylurea&lt;/a&gt; use&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Slfnylr.htm" class="LinkPage"&gt;Sulfonylurea&lt;/a&gt; assay&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Management&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Endo/Hypoglycemia/Hypglycm.htm" class="LinkPage"&gt;Hypoglycemia&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Hypoglycemia/FstngHypglycm.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Fasting Hypoglycemia</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Hypoglycemia/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Polyendocrinopathies, Autoimmune  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0085409"&gt;&lt;i&gt;C0085409&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A rare genetic syndrome characterized by autoantibodies production against more than one endocrine organ. The range of endocrinopathies includes hypoparathyroidism, adrenal insufficiency, hypogonadism, type 1 diabetes mellitus and hypothyroidism.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CHV)&lt;/td&gt;
                &lt;td&gt;an autoimmune diseases affecting multiple endocrine organs&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CHV)&lt;/td&gt;
                &lt;td&gt;an autoimmune diseases affecting multiple endocrine organs&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CHV)&lt;/td&gt;
                &lt;td&gt;an autoimmune diseases affecting multiple endocrine organs&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CHV)&lt;/td&gt;
                &lt;td&gt;an autoimmune diseases affecting multiple endocrine organs&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;Autoimmune diseases affecting multiple endocrine organs. Type I is characterized by childhood onset and chronic mucocutaneous candidiasis (CANDIDIASIS, CHRONIC MUCOCUTANEOUS), while type II exhibits any combination of adrenal insufficiency (ADDISON'S DISEASE), lymphocytic thyroiditis (THYROIDITIS, AUTOIMMUNE;), HYPOPARATHYROIDISM; and gonadal failure. In both types organ-specific ANTIBODIES against a variety of ENDOCRINE GLANDS have been detected. The type II syndrome differs from type I in that it is associated with HLA-A1 and B8 haplotypes, onset is usually in adulthood, and candidiasis is not present.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Disease or Syndrome (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0085409&amp;amp;tui=T047"&gt;&lt;i&gt;T047&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D016884&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD10&lt;/td&gt;
                &lt;td&gt;E31.0&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;18947001, 190568004, 41864002, 190567009&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Autoimmune Polyendocrinopathies, Polyendocrinopathy, Autoimmune, Autoimmune polyendocrinopathy, NOS, Autoimmune polyglandular syndrome, NOS, Polyglandular autoimmune syndrome, NOS, Autoimm polyglandular failure, Polyendocrine autoimmunity syn, Lloyd's syndrome (diagnosis), polyendocrine failure syndrome (diagnosis), endocrine Lloyd's syndrome, polyendocrine failure syndrome, Lloyd's syndrome (disorder), Autoimmune polyglandular failure (disorder), Autoimmune Polyendocrinopathy, Autoimmune Polyendocrinopathy Syndrome, Polyendocrinopathies, Autoimmune [Disease/Finding], lloyd's syndrome, autoimmune polyendocrinopathy, pga, aps, PGA, APS, Lloyd's syndrome, Autoimmune polyglandular failure, Polyendocrine autoimmunity syndrome, Polyglandular autoimmune syndrome, Autoimmune polyendocrinopathy (disorder), Autoimmune polyendocrinopathy, Autoimmune polyglandular syndrome, autoimmune; polyglandular syndrome, deficiency; polyglandular, autoimmune, polyglandular; deficiency, autoimmune, polyglandular; syndrome, autoimmune, syndrome; autoimmune polyglandular, syndrome; polyglandular, autoimmune, Polyendocrinopathies, Autoimmune&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Polyendokrinopatier, autoimmuna&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;polyendokrinopatie autoimunitní&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;Autoimmune polyglandular failure, Lloyd's syndrome, poliendocrinopatía autoinmunitaria (trastorno), poliendocrinopatía autoinmune (trastorno), poliendocrinopatía autoinmune, poliendocrinopatía autoinmunitaria, síndrome autoinmune poliglandular, síndrome poliglandular autoinmune, síndrome APS, síndrome PGA, síndrome de Lloyd (concepto no activo), síndrome de Lloyd, Poliendocrinopatías Autoinmunes, Poliendocrinopatias Autoinmunes&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Autoimmuunipolyendokrinopatiat&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;SHMIDTA SINDROM, POLIENDOKRINOPATII AUTOIMMUNNYE, AUTOIMMUNNYI SINDROM I TIPA POLIGLANDULIARNYI, AUTOIMMUNNYI SINDROM II TIPA POLIGLANDULIARNYI, POLIGLANDULIARNYI I TIPA AUTOIMMUNNYI SINDROM, AUTOIMMUNNAIA POLIENDOKRINOPATIIA-KANDIDOZ-EKTODERMAL'NAIA DISTROFIIA, POLIGLANDULIARNYI II TIPA AUTOIMMUNNYI SINDROM, ENDOKRINNYE BOLEZNI MNOZHESTVENNYE AUTOIMMUNNYE, АУТОИММУННАЯ ПОЛИЭНДОКРИНОПАТИЯ-КАНДИДОЗ-ЭКТОДЕРМАЛЬНАЯ ДИСТРОФИЯ, АУТОИММУННЫЙ СИНДРОМ II ТИПА ПОЛИГЛАНДУЛЯРНЫЙ, АУТОИММУННЫЙ СИНДРОМ I ТИПА ПОЛИГЛАНДУЛЯРНЫЙ, ПОЛИГЛАНДУЛЯРНЫЙ II ТИПА АУТОИММУННЫЙ СИНДРОМ, ПОЛИГЛАНДУЛЯРНЫЙ I ТИПА АУТОИММУННЫЙ СИНДРОМ, ПОЛИЭНДОКРИНОПАТИИ АУТОИММУННЫЕ, ШМИДТА СИНДРОМ, ЭНДОКРИННЫЕ БОЛЕЗНИ МНОЖЕСТВЕННЫЕ АУТОИММУННЫЕ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Autoimmune polyglandulaere Insuffizienz, Polyendokrinopathien, Autoimmun-&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;シュミット症候群, 自己免疫性多発性内分泌症, 多腺性自己免疫症候群, 自己免疫性多発性内分泌症-カンジダ症-外胚葉ジストロフィー, 多腺性自己免疫症候群1型, 多腺性2型自己免疫症候群, 自己免疫症候群2型-多腺性, 自己免疫症候群1型-多腺性, 多腺性自己免疫症候群2型, 多腺性1型自己免疫症候群, Schmidt症候群, 多発性内分泌症-自己免疫性&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Korean&lt;/td&gt;
                &lt;td&gt;자가면역성 뭇샘성 기능상실&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Choroby gruczołów dokrewnych autoimmunologiczne, Zespół wielogruczołowy autoimmunologiczny typ II, Zespół Schmidta, Zespół Carpentera, Autoimmunologiczne zaburzenia wielogruczołowe, Zespół wielogruczołowy autoimmunologiczny typ I, Poliendokrynopatie autoimmunologiczne, Zespół Blizzarda&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;auto-immuun; polyglandulair syndroom, deficiëntie; polyglandulair, auto-immuun, polyglandulair; deficiëntie, auto-immuun, polyglandulair; syndroom, auto-immuun, syndroom; auto-immuun polyglandulair, syndroom; polyglandulair, auto-immuun, Auto-immune polyglandulaire insufficiëntie, Auto-immune poly-endocrinopathie, Endocrinopathie auto-immune poly-, Poly-endocrinopathie, auto-immune&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Sindromi polighiandolari autoimmmuni&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Poliendocrinopatias Auto-Imunes&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Polyendocrinopathies auto-immunes, Polyendocrinopathies autoimmunes&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Autoimmune Syndrome Type II, Polyglandular  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0085860"&gt;&lt;i&gt;C0085860&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Disease or Syndrome (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0085860&amp;amp;tui=T047"&gt;&lt;i&gt;T047&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D016884&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD10&lt;/td&gt;
                &lt;td&gt;E31.0&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;63805001, 83728000, 190567009&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Autoimmune Syndrome Type II, Polyglandular, Schmidt Syndrome, Schmidt's Syndrome, Schmidts Syndrome, Syndrome, Schmidt's, Addison's disease, toxic diffuse goiter and insulin-dependent diabetes mellitus, Primary hypothyroidism and adrenocortical insufficiency, Diab mell,Add dis,myxoed, Polygland autoimm syn-typeII, Type 2 polyendoc autoimmun syn, Addison's disease, toxic diffuse goitre and insulin-dependent diabetes mellitus, POLYGLANDULAR AUTOIMMUNE SYNDROME, TYPE II, APS II, PGA II, DIABETES MELLITUS, ADDISON DISEASE, MYXEDEMA, POLYENDOCRINE AUTOIMMUNE SYNDROME, TYPE II, APS2, SCHMIDT SYNDROME, AUTOIMMUNE POLYENDOCRINE SYNDROME, TYPE II, Schmidt's syndrome (disorder), Schmidt's syndrome (diagnosis), Carpenter syndrome, schmidt syndrome, schmidt's syndrome, schmidts syndrome, syndrome schmidt, Diabetes Mellitus, Addison's Disease, Myxedema, Polyglandular Deficiency Syndrome, Type 2, Autoimmune Polyendocrine Syndrome, Type 2, Multiple Endocrine Deficiency Syndrome, Type 2, Polyglandular Autoimmune Syndrome, Type 2, Schmidt's syndrome, APS type 2, Addison's disease with struma lymphomatosa, Polyglandular autoimmune syndrome, type 2, Diabetes mellitus, Addison's disease and myxedema, Diabetes mellitus, Addison's disease and myxoedema, PGA - Polyglandular autoimmune syndrome - type II, Polyglandular autoimmune syndrome - type II, Schmidt syndrome, Type 2 polyendocrine autoimmunity syndrome, Addison's disease, toxic diffuse goiter AND insulin-dependent diabetes mellitus, Addison's disease, toxic diffuse goitre AND insulin-dependent diabetes mellitus, Polyglandular autoimmune syndrome, type 2 (disorder), Primary hypothyroidism AND adrenocortical insufficiency, Schmidt, Polyglandular Type II Autoimmune Syndrome, Polyglandular autoimmune syndrome type II, Autoimmune Polyglandular Syndrome Type II&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Sindrome autoimmune plurighiandolare tipo II&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;多腺性自己免疫性症候群２型, ﾀｾﾝｾｲｼﾞｺﾒﾝｴｷｾｲｼｮｳｺｳｸﾞﾝ2ｶﾞﾀ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;Schmidtův syndrom (endokrinní), autoimunitní syndrom polyglandulární typ II, Polyglandulární autoimunitní syndrom typu II&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;Schmidt's syndrome, síndrome autoinmune poliglandular, tipo 2 (trastorno), síndrome autoinmunitario poliglandular, tipo 2 (trastorno), enfermedad de Addison, bocio difuso tóxico Y diabetes mellitus insulino - dependiente, enfermedad de Addison, bocio difuso tóxico Y diabetes mellitus insulinodependiente, síndrome autoinmune poliglandular, tipo 2, síndrome autoinmunitario poliglandular, tipo 2, APS tipo 2, enfermedad de Addison con estruma linfomatoso, enfermedad de Addison, bocio difuso tóxico y diabetes mellitus insulino - dependiente, hipotiroidismo primario Y enfermedad de Addison, hipotiroidismo primario e insuficiencia adrenocortical, síndrome de Schmidt (concepto no activo), síndrome de Schmidt, Síndrome autoinmume poliglandular de tipo II, Síndrome de Schmidt, Síndrome Poliglandular Autoinmune Tipo II, Sindrome Poliglandular Autoinmune Tipo II, Sindrome de Schmidt&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Polyendocrinopathie auto-immune de type 2, Polyendocrinopathie auto-immune de type II, Polyendocrinopathie autoimmune de type 2, Polyendocrinopathie autoimmune de type II, Syndrome de Schmidt&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Autoimmunsyndrom Typ II, polyglanduläres, polyglandulaeres Autoimmunsyndrom Typ II, Schmidt-Syndrom, Polyglanduläres Typ-II-Autoimmunsyndrom&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;Polyglandularis autoimmun syndroma II. típus&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Síndrome auto-imune poliglandular tipo II, Síndrome de Schmidt, Síndrome Poliglandular Auto-Imune Tipo II&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;polyglandulair auto-immuun syndroom type II, Auto-immuun endocrien syndroom type II, poly-glandulair, Poly-glandulair endocrien syndroom type II, auto-immuun, Schmidt syndroom&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Polyendocrinopathies, Autoimmune  (</value><value>)
</value><value>Autoimmune Syndrome Type II, Polyglandular  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Autoimmune Polyglandular Syndrome, Type II</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Adrenal Disease</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Epidemiology&lt;ol&gt;&lt;li&gt;&lt;a href="../../Prevent/Epi/DsPrvlncRt.htm" class="LinkPage"&gt;Prevalence&lt;/a&gt;: 2 per 100,000&lt;/li&gt;&lt;li&gt;Age of Onset: 30-40 years&lt;/li&gt;&lt;li&gt;Gender: Women affected 3 times more than men&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Risk Factors&lt;ol&gt;&lt;li&gt;HLA haplotype DR3 (DQB*0201)&lt;/li&gt;&lt;li&gt;HLA haplotype DR4 (DQB1*0302)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Diagnosis&lt;ol&gt;&lt;li&gt;Required Conditions for diagnosis&lt;ol&gt;&lt;li&gt;Autoimmune &lt;a href="../../Endo/Adrenal/AdsnsDs.htm" class="LinkPage"&gt;Adrenal Insufficiency&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Presenting diagnosis in 50% of cases&lt;/li&gt;&lt;li&gt;Associated with second autoimmune condition in 50%&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Autoimmune &lt;a href="../../Endo/Anatomy/ThyrdAntmy.htm" class="LinkPage"&gt;Thyroid&lt;/a&gt; disease&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/DM/TypDbtsMlts.htm" class="LinkPage"&gt;Type I Diabetes Mellitus&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Commonly Associated Conditions (4-10%)&lt;ol&gt;&lt;li&gt;&lt;a href="../../Derm/Pigment/Vtlg.htm" class="LinkPage"&gt;Vitiligo&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Chronic atrophic &lt;a href="../../GI/Sx/Dysps.htm" class="LinkPage"&gt;Gastritis&lt;/a&gt; (and &lt;a href="../../HemeOnc/Anemia/VtmnBDfcncy.htm" class="LinkPage"&gt;Pernicious Anemia&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Sex/HyprgndtrpcHypgndsm.htm" class="LinkPage"&gt;Hypergonadotropic Hypogonadism&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Chronic &lt;a href="../../GI/Lvr/AtmnHpts.htm" class="LinkPage"&gt;Autoimmune Hepatitis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Derm/Hair/Alpc.htm" class="LinkPage"&gt;Alopecia&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Other Associated Conditions (&amp;lt;1%)&lt;ol&gt;&lt;li&gt;&lt;a href="../../Neuro/Motor/MysthnGrvs.htm" class="LinkPage"&gt;Myasthenia Gravis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Rheum/R_2/RhmtdArthrts.htm" class="LinkPage"&gt;Rheumatoid Arthritis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Rheum/Diffuse/SjgrnsSyndrm.htm" class="LinkPage"&gt;Sjogren's Syndrome&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Presentation&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Endo/Adrenal/AdsnsDs.htm" class="LinkPage"&gt;Adrenal Insufficiency&lt;/a&gt;&lt;/li&gt;&lt;li&gt;See other associated conditions listed above&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Diagnosis&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Endo/Adrenal/AdsnsDs.htm" class="LinkPage"&gt;Adrenal Insufficiency&lt;/a&gt;&lt;/li&gt;&lt;li&gt;See other associated conditions listed above&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Management&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Endo/Adrenal/AdsnsDs.htm" class="LinkPage"&gt;Adrenal Insufficiency&lt;/a&gt;&lt;/li&gt;&lt;li&gt;See other associated conditions listed above&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Betterie%20%20%5BAU%5D%20AND%202002%20%5BDP%5D%20AND%20%20Endocr%20Rev%20%20%5BTA%5D" class="LinkRef"&gt;Betterie (2002) Endocr Rev 23:327-64&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Majeroni%20%20%5BAU%5D%20AND%202007%20%5BDP%5D%20AND%20%20Am%20Fam%20Physician%20%20%5BTA%5D" class="LinkRef"&gt;Majeroni (2007) Am Fam Physician 75(5):667-70&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0085409</value><value>C0085860</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Adrenal/AtmnPlyglndlrSyndrmTypI.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Autoimmune Polyglandular Syndrome, Type II, Autoimmune Polyglandular Syndrome, APS II</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Adrenal/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Hyperaldosteronism  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0020428"&gt;&lt;i&gt;C0020428&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;A condition caused by the overproduction of ALDOSTERONE. It is characterized by sodium retention and potassium excretion with resultant HYPERTENSION and HYPOKALEMIA.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CSP)&lt;/td&gt;
                &lt;td&gt;abnormality of electrolyte function caused by excessive secretion of aldosterone by the adrenal cortex.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Disease or Syndrome (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0020428&amp;amp;tui=T047"&gt;&lt;i&gt;T047&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D006929&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD9&lt;/td&gt;
                &lt;td&gt;255.10, 255.1&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD10&lt;/td&gt;
                &lt;td&gt;E26, E26.9&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;190509005, 88213004, 190506003, 154709005, 267484005&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Aldosteronism, Hyperaldosteronism, ALDOSTERONISM, HYPERALDOSTERONISM, Aldosteronism, NOS, Hyperaldosteronism, NOS, Hyperaldosteronism NOS, Hyperaldosteronism, unspecified, aldosteronism, aldosteronism (diagnosis), hyperaldosteronism, Aldosteronism NOS, Hyperaldosteronism NOS (disorder), Hyperaldosteronism [Disease/Finding], Aldosteronism (disorder)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;aldosteronisme NAO, aldosteronisme, Hyperaldosteronisme, niet gespecificeerd, hyperaldosteronisme, Aldosteronisme, Aldosteronisme, hyper-, Hyperaldosteronisme&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Aldostéronisme SAI, Aldostéronisme, Hyperaldostéronisme, Hyperaldostéronisme primitif&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Aldosteronismus NNB, Hyperaldosteronismus, nicht naeher bezeichnet, Aldosteronismus, Hyperaldosteronismus&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Aldosteronismo NAS, Aldosteronismo, Iperaldosteronismo&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Aldosteronismo NE, Hiperaldosteronismo, Aldosteronismo&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;Aldosteronismo NEOM, Hyperaldosteronism, Aldosteronism, aldosteronismo con hiperplasia de la corteza suprarrenal, hiperaldosteronismo (trastorno), hiperaldosteronismo, SAI (trastorno), hiperaldosteronismo, SAI, hiperaldosteronismo, Hiperaldosteronismo, Aldosteronismo&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;アルドステロン症ＮＯＳ, ｱﾙﾄﾞｽﾃﾛﾝｼｮｳ, ｱﾙﾄﾞｽﾃﾛﾝｼｮｳNOS, ｺｳｱﾙﾄﾞｽﾃﾛﾝｼｮｳ, コン症候群, アルドステロン過剰症, アルドステロン過剰, アルドステロン症, 高アルドステロン症, Conn症候群&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Hyperaldosteronism&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;aldosteronismus, hyperaldosteronismus, Aldosteronismus, Aldosteronismus NOS, Hyperaldosteronismus&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Hyperaldosteronismi&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;KONNA SINDROM, GIPERAL'DOSTERONIZM PERVICHNYI, GIPERAL'DOSTERONIZM, AL'DOSTERONIZM, АЛЬДОСТЕРОНИЗМ, ГИПЕРАЛЬДОСТЕРОНИЗМ, ГИПЕРАЛЬДОСТЕРОНИЗМ ПЕРВИЧНЫЙ, КОННА СИНДРОМ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Korean&lt;/td&gt;
                &lt;td&gt;고알도스테론증, 상세불명의 고알도스테론증&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Croatian&lt;/td&gt;
                &lt;td&gt;HIPERALDOSTERONIZAM&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Aldosteronizm, Zespół Conna, Hiperaldosteronizm pierwotny, Hiperaldosteronizm&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;Hyperaldosteronismus k.m.n., Hyperaldosteronismus, Hyperaldosteronizmus&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Conn Syndrome  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C1384514"&gt;&lt;i&gt;C1384514&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;Primary hyperaldosteronism caused by the excess production of ALDOSTERONE by an ADENOMA of the ZONA GLOMERULOSA or CONN ADENOMA.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CSP)&lt;/td&gt;
                &lt;td&gt;overproduction of aldosterone by an adrenal cortical adenoma, characterized typically by low potassium levels, underacidity of the body, muscular weakness, excess urination, excess thirst, and high blood pressure.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Disease or Syndrome (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C1384514&amp;amp;tui=T047"&gt;&lt;i&gt;T047&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D006929&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD9&lt;/td&gt;
                &lt;td&gt;255.12&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD10&lt;/td&gt;
                &lt;td&gt;E26.0, E26.01&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;13536004, 258117004, 190507007, 154709005, 190506003, 267484005&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;ALDOSTERONISM, PRIMARY, CONN SYNDROME, HYPERALDOSTERONISM, PRIMARY, Hyperaldosteronism, primary, PRIMARY HYPERALDOSTERONISM, Aldosteronism Primary, Conn Syndrome, primary hyperaldosteronism, primary aldosteronism (diagnosis), primary aldosteronism, Primary aldosteronism (disorder), Conn's syndrome (diagnosis), Idiopathic aldosteronism, Idiopathic hyperaldosteronism, Conns Syndrome, Conn's Syndrome, Syndrome, Conn's, conn syndrome, conn's syndrome, conns syndrome, Conn's syndrome, Conn syndrome, Primary aldosteronism, Primary hyperaldosteronism, Idiopathic aldosteronism (disorder), Primary hyperaldosteronism (disorder), hyperaldosteronism; primary, primary; hyperaldosteronism, Conn, Primary aldosteronism (disorder) [Ambiguous], Syndrome, Conn, Primary Hyperaldosteronism, Hyperaldosteronism, Primary&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Iperaldosteronismo primitivo, Sindrome di Conn&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;Conn-syndroom, hyperaldosteronisme; primair, primair; hyperaldosteronisme, Primair hyperaldosteronisme, primair hyperaldosteronisme&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Syndrome de conn, Syndrome de Conn, Hyperaldostéronisme primaire, Hyperaldostéronisme primaire à rénine basse&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Conn-Syndrom, Primaerer Hyperaldosteronismus, primaerer Hyperaldosteronismus&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Síndrome de Conn, Hiperaldesteronismo primário&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;Síndrome de Conn, Conn's syndrome, aldosteronismo idiopático, aldosteronismo primario, hiperaldosteronismo idiopático (trastorno), hiperaldosteronismo idiopático, hiperaldosteronismo primario (concepto no activo), hiperaldosteronismo primario (trastorno), hiperaldosteronismo primario, síndrome de Conn, Hiperaldosteronismo primario&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;原発性アルドステロン症, コーン症候群, ｺｰﾝｼｮｳｺｳｸﾞﾝ, ｹﾞﾝﾊﾟﾂｾｲｱﾙﾄﾞｽﾃﾛﾝｼｮｳ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;Primární hyperaldosteronismus, Connův syndrom&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Korean&lt;/td&gt;
                &lt;td&gt;원발성 고알도스테론증&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Croatian&lt;/td&gt;
                &lt;td&gt;CONNOV SINDROM, PRIMARNI HIPERALDOSTERONIZAM&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;Conn-syndroma, Primaer hyperaldosteronismus&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Hyperaldosteronism  (</value><value>)
</value><value>Conn Syndrome  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Hyperaldosteronism</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Adrenal Disease</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Epidemiology&lt;ol&gt;&lt;li&gt;Represents under 1% of &lt;a href="../../CV/Htn/HyprtnsnCs.htm" class="LinkPage"&gt;Hypertension Causes&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Peak age 30-50 years&lt;/li&gt;&lt;li&gt;Most patients are women&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Pathophysiology&lt;ol&gt;&lt;li&gt;Inappropriate Aldosterone Hypersecretion&lt;ol&gt;&lt;li&gt;Primary Hyperaldosteronism (See Causes below)&lt;ol&gt;&lt;li&gt;Increased aldosterone is initiating event&lt;/li&gt;&lt;li&gt;Results in sodium retention and volume increase&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Exam/RnAngtnsnSystm.htm" class="LinkPage"&gt;Renin&lt;/a&gt; decreases&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Secondary Hyperaldosteronism (See Causes below)&lt;ol&gt;&lt;li&gt;Decreased circulating volume is initiating event&lt;/li&gt;&lt;li&gt;Results in increased renin and aldosterone&lt;/li&gt;&lt;li&gt;Results in sodium retention&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Physiologic response to Aldosterone Excess&lt;ol&gt;&lt;li&gt;Increased renal distal tubular sodium reabsorption&lt;ol&gt;&lt;li&gt;Increased total body sodium content&lt;/li&gt;&lt;li&gt;Increased water retention&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Escape phenomenon&lt;ol&gt;&lt;li&gt;Compensatory increased ANF secretion&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Htn/Hyprtnsn.htm" class="LinkPage"&gt;Hypertension&lt;/a&gt; may not be solely volume expansion&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Increased peripheral vascular resistance&lt;ol&gt;&lt;li&gt;&lt;a href="../../Renal/Potassium/Hypklm.htm" class="LinkPage"&gt;Hypokalemia&lt;/a&gt;: Potassium lost in distal renal tubule&lt;/li&gt;&lt;li&gt;Alkalosis: Ammoniagenesis&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Hydrogen ion loss (avid sodium retention)&lt;/li&gt;&lt;li&gt;Polyuria: Decreased renal concentrating ability&lt;/li&gt;&lt;li&gt;Plasma renin suppressed&lt;ol&gt;&lt;li&gt;Unresponsive to intravascular volume depletion&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Causes&lt;ol&gt;&lt;li&gt;Primary Hyperaldosteronism (Conn's Disease)&lt;ol&gt;&lt;li&gt;Solitary adrenal adenomas (80-90%)&lt;/li&gt;&lt;li&gt;Bilateral adrenal hyperplasia (10-20%)&lt;ol&gt;&lt;li&gt;Idiopathic Hyperaldosteronism&lt;/li&gt;&lt;li&gt;Accounts for 50% of cases at some referral centers&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Adrenal Carcinoma (rare)&lt;/li&gt;&lt;li&gt;Unilateral Adrenal Hyperplasia (very rare)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Secondary Hyperaldosteronism&lt;ol&gt;&lt;li&gt;Hypertensive States&lt;ol&gt;&lt;li&gt;Primary &lt;a href="../../CV/Exam/RnAngtnsnSystm.htm" class="LinkPage"&gt;Renin&lt;/a&gt;ism (rare renin producing tumor)&lt;/li&gt;&lt;li&gt;Secondary reninism due to decreased renal perfusion&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Renal/Edema/Edm.htm" class="LinkPage"&gt;Edema&lt;/a&gt;tous States&lt;ol&gt;&lt;li&gt;&lt;a href="../../GI/Lvr/Crhs.htm" class="LinkPage"&gt;Cirrhosis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Renal/Glomerulus/NphrtcSyndrm.htm" class="LinkPage"&gt;Nephrotic Syndrome&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Symptoms&lt;ol&gt;&lt;li&gt;Often Asymptomatic&lt;/li&gt;&lt;li&gt;Frontal &lt;a href="../../Neuro/Sx/Hdch.htm" class="LinkPage"&gt;Headache&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Rheum/Sx/MsclWkns.htm" class="LinkPage"&gt;Muscle Weakness&lt;/a&gt; to flaccid paralysis (&lt;a href="../../Renal/Potassium/Hypklm.htm" class="LinkPage"&gt;Hypokalemia&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;Polyuria and Polydipsia (carbohydrate intolerance)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Signs&lt;ol&gt;&lt;li&gt;&lt;a href="../../CV/Htn/Hyprtnsn.htm" class="LinkPage"&gt;Hypertension&lt;/a&gt;&lt;ol&gt;&lt;li&gt;May be severe&lt;/li&gt;&lt;li&gt;Rarely malignant&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Neuro/Exam/MtrExm.htm" class="LinkPage"&gt;Motor Exam&lt;/a&gt; with decreased &lt;a href="../../Neuro/Exam/MtrExm.htm" class="LinkPage"&gt;Muscle Strength&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Labs&lt;ol&gt;&lt;li&gt;Serum Electrolytes&lt;ol&gt;&lt;li&gt;&lt;a href="../../Renal/Lab/SrmPtsm.htm" class="LinkPage"&gt;Serum Potassium&lt;/a&gt; decreased (&lt;a href="../../Renal/Potassium/Hypklm.htm" class="LinkPage"&gt;Hypokalemia&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Renal/Lab/SrmSdm.htm" class="LinkPage"&gt;Serum Sodium&lt;/a&gt; increased (Mild)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Renal/AcidBase/MtblcAlkls.htm" class="LinkPage"&gt;Metabolic Alkalosis&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Morning Aldosterone to PRA ratio&lt;ol&gt;&lt;li&gt;Ratio over 20-25 (esp if &amp;gt;100) suggests Hyperaldosteronism&lt;/li&gt;&lt;li&gt;Aldosterone &amp;gt;15 ng/dl and plasma renin low&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Saline suppression&lt;ol&gt;&lt;li&gt;IVF: 300-500 cc/hour for 4 hours&lt;/li&gt;&lt;li&gt;Normal response&lt;ol&gt;&lt;li&gt;Aldosterone usually under 0.28&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Exam/RnAngtnsnSystm.htm" class="LinkPage"&gt;Renin&lt;/a&gt; usually suppressed&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Differential Diagnosis: &lt;a href="../../CV/Htn/Hyprtnsn.htm" class="LinkPage"&gt;Hypertension&lt;/a&gt; with &lt;a href="../../Renal/Potassium/Hypklm.htm" class="LinkPage"&gt;Hypokalemia&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Adrenal/CshngsDs.htm" class="LinkPage"&gt;Cushing's Disease&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Low Aldosterone and Low Plasma &lt;a href="../../CV/Exam/RnAngtnsnSystm.htm" class="LinkPage"&gt;Renin&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Renal/CV/RnlArtryStns.htm" class="LinkPage"&gt;Renal Artery Stenosis&lt;/a&gt; or other renal cause&lt;ol&gt;&lt;li&gt;High Aldosterone and High Plasma &lt;a href="../../CV/Exam/RnAngtnsnSystm.htm" class="LinkPage"&gt;Renin&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Management&lt;ol&gt;&lt;li&gt;Adrenal Adenoma&lt;ol&gt;&lt;li&gt;Surgical excision&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Adrenal Hyperplasia&lt;ol&gt;&lt;li&gt;First-Line Agents&lt;ol&gt;&lt;li&gt;&lt;a href="../../CV/Pharm/Sprnlctn.htm" class="LinkPage"&gt;Spironolactone&lt;/a&gt; (&lt;a href="../../CV/Pharm/Sprnlctn.htm" class="LinkPage"&gt;Aldactone&lt;/a&gt;)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Alternative agents if &lt;a href="../../Endo/Sx/Gyncmst.htm" class="LinkPage"&gt;Gynecomastia&lt;/a&gt; develops on &lt;a href="../../CV/Pharm/Sprnlctn.htm" class="LinkPage"&gt;Spironolactone&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../CV/Pharm/SlctvAldstrnRcptrAntgnst.htm" class="LinkPage"&gt;Eplerenone&lt;/a&gt; (&lt;a href="../../CV/Pharm/SlctvAldstrnRcptrAntgnst.htm" class="LinkPage"&gt;Inspra&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Pharm/PtsmSprngDrtc.htm" class="LinkPage"&gt;Amiloride&lt;/a&gt; (&lt;a href="../../CV/Pharm/PtsmSprngDrtc.htm" class="LinkPage"&gt;Midamor&lt;/a&gt;)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Precautions&lt;ol&gt;&lt;li&gt;Follow &lt;a href="../../Renal/Lab/SrmPtsm.htm" class="LinkPage"&gt;Serum Potassium&lt;/a&gt; and &lt;a href="../../Renal/Lab/SrmCrtn.htm" class="LinkPage"&gt;Serum Creatinine&lt;/a&gt; every 6 months with these agents&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0020428</value><value>C1384514</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Adrenal/Hyprldstrnsm.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Hyperaldosteronism, Aldosteronism, Conn's Disease, Conn's Syndrome</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Adrenal/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Male Pseudohermaphroditism  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0238395"&gt;&lt;i&gt;C0238395&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Disease or Syndrome (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0238395&amp;amp;tui=T047"&gt;&lt;i&gt;T047&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D058490&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD10&lt;/td&gt;
                &lt;td&gt;Q56.1&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;111332007&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;PSEUDOHERMAPHRODITISM, MALE, Pseudohermaphroditism syndrome, male, Pseudohermaphroditism male, Male pseudohermaphroditism NOS, Male Pseudohermaphroditism, Pseudohermaphroditism, Male, Male Pseudohermaphroditisms, Pseudohermaphroditisms, Male, merm, male pseudohermaphroditism, Male pseudohermaphroditism, Merms, Male pseudohermaphroditism (disorder), pseudohermaphroditism; male&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;mannelijk pseudohermafroditisme, pseudohermafroditisme; bij man, pseudohermafroditisme mannelijk&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;maennlicher Pseudohermaphroditismus, Pseudohermaphroditismus masculinus, Männlicher Pseudohermaphroditismus, Pseudohermaphroditismus des Mannes&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;男性仮性半陰陽, ﾀﾞﾝｾｲｶｾｲﾊﾝｲﾝﾖｳ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;Mužský pseudohermafroditismus, mužský pseudohermafroditismus&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Pseudohermaphrodisme masculin, Pseudo-hermaphrodisme masculin, Pseudo-hermaphrodisme mâle&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Pseudoermafroditismo maschile, Maschio XY con ridotta mascolinizzazione&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;Férfi pseudohermaphroditismus, Férfi álkétneműség&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;merms, pseudohermafroditismo masculino (trastorno), pseudohermafroditismo masculino, Pseudohermafroditismo masculino&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Pseudo-hermafroditismo masculino&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Male Pseudohermaphroditism  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Male Pseudohermaphroditism</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Sexual Development</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Pathophysiology&lt;ol&gt;&lt;li&gt;Karyotype is 46XY&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Causes&lt;ol&gt;&lt;li&gt;Testicular Dysgenesis&lt;ol&gt;&lt;li&gt;Associated with degenerative renal disease&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Disorders of androgen synthesis&lt;ol&gt;&lt;li&gt;Leydig cell hypoplasia&lt;/li&gt;&lt;li&gt;Abnormal &lt;a href="../../CV/Lab/Lpd.htm" class="LinkPage"&gt;Cholesterol&lt;/a&gt; transport&lt;/li&gt;&lt;li&gt;Deficiencies of steroidogenic enzyme activity&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Abnormal androgen receptor&lt;/li&gt;&lt;li&gt;Maternal &lt;a href="../../Gyn/Pharm/Estrgn.htm" class="LinkPage"&gt;Estrogen&lt;/a&gt;s or &lt;a href="../../Gyn/Pharm/Prgstrn.htm" class="LinkPage"&gt;Progestin&lt;/a&gt;s&lt;/li&gt;&lt;li&gt;Eponymic syndromes&lt;/li&gt;&lt;li&gt;Persistent Mullerian Duct syndromes&lt;/li&gt;&lt;li&gt;Vanishing &lt;a href="../../Uro/Anatomy/Tstcl.htm" class="LinkPage"&gt;Testes&lt;/a&gt; Syndromes&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Signs&lt;ol&gt;&lt;li&gt;External and internal genitalia are ambiguous&lt;ol&gt;&lt;li&gt;Incompletely masculinized&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Gonads recognizable as &lt;a href="../../Uro/Anatomy/Tstcl.htm" class="LinkPage"&gt;Testes&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0238395</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Sex/MlPsdhrmphrdtsm.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Male Pseudohermaphroditism</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Sex/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Female Pseudohermaphroditism  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0238394"&gt;&lt;i&gt;C0238394&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Congenital Abnormality (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0238394&amp;amp;tui=T019"&gt;&lt;i&gt;T019&lt;/i&gt;&lt;/a&gt;)
, Disease or Syndrome (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0238394&amp;amp;tui=T047"&gt;&lt;i&gt;T047&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D058489&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD10&lt;/td&gt;
                &lt;td&gt;Q56.2&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;8800006&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;PSEUDOHERMAPHRODITISM, FEMALE, Female Pseudohermaphroditism, Pseudohermaphroditism syndrome, female, female pseudohermaphroditism, female pseudohermaphroditism (diagnosis), Pseudohermaphroditism female, Female pseudohermaphroditism NOS, Pseudohermaphroditisms, Female, Female Pseudohermaphroditisms, Pseudohermaphroditism, Female, ferm, Female pseudohermaphroditism, Ferms, Female pseudohermaphroditism (disorder), pseudohermaphroditism; female&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;vrouwelijk pseudohermafroditisme, pseudohermafroditisme; bij vrouw, pseudohermafroditisme vrouwelijk&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;weiblicher Pseudohermaphroditismus, Pseudohermaphroditismus femininus, Weiblicher Pseudohermaphroditismus, Pseudohermaphroditismus der Frau&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;女性仮性半陰陽, ｼﾞｮｾｲｶｾｲﾊﾝｲﾝﾖｳ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;Ženský pseudohermafroditismus, ženský pseudohermafroditismus&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Pseudohermaphrodisme féminin, Pseudo-hermaphrodisme féminin, Pseudo-hermaphrodisme femelle&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Femmina XX con virilizzazione o mascolinizzazione, Pseudoermafroditismo femminile&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;Női pseudohermaphroditismus, Női álkétneműség&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;ferms, pseudohermafroditismo femenino (trastorno), pseudohermafroditismo femenino, Pseudohermafroditismo femenino&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Pseudo-hermafroditismo feminino&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Female Pseudohermaphroditism  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Female Pseudohermaphroditism</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Sexual Development</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Causes&lt;ol&gt;&lt;li&gt;Deficiencies of enzyme activity&lt;ol&gt;&lt;li&gt;3B Hydroxysteroid dehydrogenase - Type 2&lt;ol&gt;&lt;li&gt;Chromosome: 1p13.1&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;21-Hydroxylase&lt;ol&gt;&lt;li&gt;Chromosome: 6p21.3&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;11B-Hydroxylase - Type 1&lt;ol&gt;&lt;li&gt;Chromosome 8q21&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Deficiencies of placental or germ-line aromatase&lt;/li&gt;&lt;li&gt;Maternal &lt;a href="../../Gyn/Endo/Hyprndrgnsm.htm" class="LinkPage"&gt;Androgen Excess&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Virilizing luteoma&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Adrenal/CngntlAdrnlHyprpls.htm" class="LinkPage"&gt;Congenital Adrenal Hyperplasia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Ingestion of androgens, synthetic &lt;a href="../../Gyn/Pharm/Estrgn.htm" class="LinkPage"&gt;Estrogen&lt;/a&gt;s&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Eponymic Syndromes&lt;ol&gt;&lt;li&gt;Fraser syndrome&lt;/li&gt;&lt;li&gt;VACTERL association&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Signs&lt;ol&gt;&lt;li&gt;Internal genitalia are female&lt;/li&gt;&lt;li&gt;External genitalia are masculinized&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0238394</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Sex/FmlPsdhrmphrdtsm.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Female Pseudohermaphroditism</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Sex/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees></FP_UMLS_Trees><FP_Condition_name_check></FP_Condition_name_check><FP_Condition_name><value>Radioactive Iodine Uptake Scan</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Radiology</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Indications&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/Hyprthyrdsm1.htm" class="LinkPage"&gt;Hyperthyroidism&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Diffusely Low radioidoine uptake with hyperthyrodism&lt;ol&gt;&lt;li&gt;Medications and other intakes&lt;ol&gt;&lt;li&gt;Exogenous &lt;a href="../../Endo/Anatomy/ThyrdAntmy.htm" class="LinkPage"&gt;Thyroid&lt;/a&gt; intake&lt;/li&gt;&lt;li&gt;Excessive exogenous iodine&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Pharm/Amdrn.htm" class="LinkPage"&gt;Amiodarone&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Transient &lt;a href="../../Endo/Thyroid/Thyrdts.htm" class="LinkPage"&gt;Thyroiditis&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/ID/SbctGrnlmtsThyrdts.htm" class="LinkPage"&gt;Subacute Thyroiditis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/OB/PstprtmThyrdts.htm" class="LinkPage"&gt;Postpartum Thyroiditis&lt;/a&gt; (5-8% &lt;a href="../../Prevent/Epi/DsIncdncRt.htm" class="LinkPage"&gt;Incidence&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;Painless lymphocytic &lt;a href="../../Endo/Thyroid/Thyrdts.htm" class="LinkPage"&gt;Thyroiditis&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Focal low RAIU (cold &lt;a href="../../Derm/Exam/Ndl1.htm" class="LinkPage"&gt;Nodule&lt;/a&gt;) with &lt;a href="../../Endo/Thyroid/Hypthyrdsm.htm" class="LinkPage"&gt;Hypothyroidism&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Requires biopsy for &lt;a href="../../Endo/HemeOnc/ThyrdCrcnm.htm" class="LinkPage"&gt;Thyroid Cancer&lt;/a&gt; evaluation&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;High Radioiodine Uptake with &lt;a href="../../Endo/Thyroid/Hyprthyrdsm1.htm" class="LinkPage"&gt;Hyperthyroidism&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Diffusely increased uptake&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/Hyprthyrdsm1.htm" class="LinkPage"&gt;Thyrotoxicosis&lt;/a&gt; (e.g. &lt;a href="../../Endo/Thyroid/GrvsDs.htm" class="LinkPage"&gt;Grave's Disease&lt;/a&gt;)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Localized increased uptake (Hot &lt;a href="../../Derm/Exam/Ndl1.htm" class="LinkPage"&gt;Nodule&lt;/a&gt;)&lt;ol&gt;&lt;li&gt;Hyperfuntioning &lt;a href="../../Endo/HemeOnc/ThyrdAdnm.htm" class="LinkPage"&gt;Thyroid Nodule&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Rad/RdctvIdnUptkScn.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Radioactive Iodine Uptake Scan, Radioiodine Uptake, Thyroid Iodine Uptake, RAIU</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Rad/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Delayed Puberty  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0034012"&gt;&lt;i&gt;C0034012&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A disorder characterized by unusually late sexual maturity.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;The lack of development of SEXUAL MATURATION in boys and girls at a chronological age that is 2.5 standard deviations above the mean age at onset of PUBERTY in a population. Delayed puberty can be classified by defects in the hypothalamic LHRH pulse generator, the PITUITARY GLAND, or the GONADS. These patients will undergo spontaneous but delayed puberty whereas patients with SEXUAL INFANTILISM will not.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;Unusually late sexual maturity.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Pathologic Function (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0034012&amp;amp;tui=T046"&gt;&lt;i&gt;T046&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D011628&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD10&lt;/td&gt;
                &lt;td&gt;E30.0&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;154715005, 267487003, 400003000, 123526007, 39760001&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Puberty, Delayed, DELAYED PUBERTY, Puberty, delayed, SEXUAL DEVELOPMENT RETARDATION, delayed puberty (diagnosis), delayed puberty, Delayed Puberty, Delayed puberty (&amp;amp; [NOS]) (disorder), PUBERTY DELAYED, Puberty, Delayed [Disease/Finding], puberty delayed, Delayed;puberty, delay puberty, Delayed puberty, Delayed sexual development, Delay in sexual development AND/OR puberty (disorder), Delay in sexual development AND/OR puberty, Delayed puberty (disorder), delayed; development, sexual, delayed; puberty, development; delayed, sexual, puberty; delayed, puberty; delay, sexual; development delayed, Delay in sexual development AND/OR puberty (finding), Delayed puberty (&amp;amp; [NOS]), Delayed puberty NOS, Puberty - delayed&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Pubertà ritardata, Ritardo puberale&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;ｼｼｭﾝｷﾁﾊﾂｼｮｳ, 思春期遅発症, 性発育不全, 性発育遅延, 性的晩熟, 性的遅熟, 晩発思春期, 遅発思春期, 遅発症-思春期&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;puberta opožděná, Opožděná puberta&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;Delayed puberty NOS, Delayed puberty (&amp;amp; [NOS]), Delayed puberty, Puberty - delayed, pubertad tardía (hallazgo), pubertad tardía (trastorno), pubertad tardía, retraso del desarrollo sexual Y/O puberal (trastorno), retraso del desarrollo sexual Y/O puberal, Pubertad retardada, Pubertad Tardía, Pubertad Tardia&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Viivästynyt murrosikä&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;POLOVOGO RAZVITIIA ZADERZHKA, ПОЛОВОГО РАЗВИТИЯ ЗАДЕРЖКА&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Verzoegerte Pubertaet [Pubertas tarda], verzoegerte Pubertaet, Pubertas tarda, Pubertät, verspätete&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Korean&lt;/td&gt;
                &lt;td&gt;사춘기 지연&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Croatian&lt;/td&gt;
                &lt;td&gt;PUBERTET, ZAKAŠNJELI&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Pubertet, fördröjd&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Dojrzewanie opóźnione&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;Késői pubertas&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;ontwikkeling; vertraagd, seksueel, puberteit; vertraagd, puberteit; vertraging, seksueel; ontwikkeling vertraagd, vertraagd; ontwikkeling, seksueel, vertraagd; puberteit, vertraagde puberteit, Puberteit (ontwikkelingstoestand); vertraagd, Vertraagde puberteit&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Puberdade atrasada, Puberdade Tardia&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Puberté tardive, Retard pubertaire, Puberté retardée, Retard de la puberté&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Delayed Puberty  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Pubertal Delay</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Sexual Development</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Definition&lt;ol&gt;&lt;li&gt;Delayed Adolescence in Phenotypic Male or Female&lt;/li&gt;&lt;li&gt;Girls:&lt;ol&gt;&lt;li&gt;Delayed &lt;a href="../../Gyn/Anatomy/BrstAntmy.htm" class="LinkPage"&gt;Breast&lt;/a&gt; development&lt;ol&gt;&lt;li&gt;No &lt;a href="../../Gyn/Anatomy/BrstAntmy.htm" class="LinkPage"&gt;Breast&lt;/a&gt; development by age 14 years&lt;/li&gt;&lt;li&gt;No &lt;a href="../../Gyn/Anatomy/BrstAntmy.htm" class="LinkPage"&gt;Breast&lt;/a&gt; development 5 years after &lt;a href="../../Gyn/Exam/MnstrlBldng.htm" class="LinkPage"&gt;Menarche&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;No &lt;a href="../../Gyn/Exam/MnstrlBldng.htm" class="LinkPage"&gt;Menses&lt;/a&gt; by age 16 years (&lt;a href="../../Gyn/Menses/PrmryAmnrh.htm" class="LinkPage"&gt;Primary Amenorrhea&lt;/a&gt;)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Boys:&lt;ol&gt;&lt;li&gt;Testicular length under 2.5 cm by age 14 years&lt;/li&gt;&lt;li&gt;Genital growth not complete five years from start&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Differential Diagnosis&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Sex/HypgndtrpcHypgndsm.htm" class="LinkPage"&gt;Hypogonadotropic Causes of Delayed Puberty&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Sex/HyprgndtrpcHypgndsm.htm" class="LinkPage"&gt;Hypergonadotropic Causes of Delayed Puberty&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Sex/NrmgndtrpcHypgndsm.htm" class="LinkPage"&gt;Eugonadotropic Causes of Delayed Puberty&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Labs (See Evaluation below)&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/FlclStmltngHrmn.htm" class="LinkPage"&gt;Follicle Stimulating Hormone&lt;/a&gt; (FSH)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/LtnzngHrmn.htm" class="LinkPage"&gt;Luteinizing hormone&lt;/a&gt; (LH)&lt;/li&gt;&lt;li&gt;Estradiol Level (in girls)&lt;/li&gt;&lt;li&gt;Testosterone Level (in boys)&lt;/li&gt;&lt;li&gt;Consider &lt;a href="../../Endo/Lab/GnrhStmltnTst.htm" class="LinkPage"&gt;GnRH Stimulation Test&lt;/a&gt; (Step 2a below)&lt;/li&gt;&lt;li&gt;Consider Chromosome Analysis (Step 2b below)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Radiology (See Evaluation below)&lt;ol&gt;&lt;li&gt;Left wrist radiograph for bone age&lt;/li&gt;&lt;li&gt;Consider &lt;a href="../../Neuro/Rad/HdMgntcRsncImgng.htm" class="LinkPage"&gt;Head MRI&lt;/a&gt; (step 2a below)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Evaluation Step 1: Initial Evaluation&lt;ol&gt;&lt;li&gt;Clinical history and physical&lt;/li&gt;&lt;li&gt;Evaluate &lt;a href="../../Endo/Exam/SxlDvlpmnt.htm" class="LinkPage"&gt;Pubertal Milestone&lt;/a&gt;s (See &lt;a href="../../Endo/Exam/SxlDvlpmnt.htm" class="LinkPage"&gt;Tanner Staging&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;Evaluate growth chart&lt;/li&gt;&lt;li&gt;Obtain Left &lt;a href="../../Ortho/Rad/WrstXry.htm" class="LinkPage"&gt;Wrist XRay&lt;/a&gt; for bone age&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Evaluation Step 2a: Unremarkable Evaluation in Step 1&lt;ol&gt;&lt;li&gt;Findings&lt;ol&gt;&lt;li&gt;Unremarkable exam except Delayed Puberty&lt;/li&gt;&lt;li&gt;Patient has not yet experienced growth spurt&lt;/li&gt;&lt;li&gt;Bone age less than chronological age&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Differential Diagnosis&lt;ol&gt;&lt;li&gt;Constitutional delay&lt;/li&gt;&lt;li&gt;See &lt;a href="../../Endo/Sex/HypgndtrpcHypgndsm.htm" class="LinkPage"&gt;Hypogonadotropic Causes of Delayed Puberty&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Primary gonadal failure&lt;/li&gt;&lt;li&gt;Serious athletic training&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Further evaluation&lt;ol&gt;&lt;li&gt;Observation&lt;/li&gt;&lt;li&gt;Laboratory testing as above&lt;/li&gt;&lt;li&gt;Radiology evaluation as above&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Management&lt;ol&gt;&lt;li&gt;Counseling and reassurance&lt;/li&gt;&lt;li&gt;Consider sex &lt;a href="../../Gyn/Pharm/EstrgnRplcmnt.htm" class="LinkPage"&gt;Hormone Replacement&lt;/a&gt; for some patients&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Evaluation Step 2b: Suspect Chromosomal Abnormality&lt;ol&gt;&lt;li&gt;Findings&lt;ol&gt;&lt;li&gt;Abnormal exam suggests chromosomal abnormality&lt;/li&gt;&lt;li&gt;Bone age may be less than chronological age&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Diagnosis&lt;ol&gt;&lt;li&gt;Girls: &lt;a href="../../Endo/Sex/TrnrsSyndrm.htm" class="LinkPage"&gt;Turner's Syndrome&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Boys: Klinefelter's Syndrome&lt;/li&gt;&lt;li&gt;Noonan's Syndrome&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Further evaluation&lt;ol&gt;&lt;li&gt;Chromosome analysis&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Management&lt;ol&gt;&lt;li&gt;Counseling&lt;/li&gt;&lt;li&gt;Sex &lt;a href="../../Gyn/Pharm/EstrgnRplcmnt.htm" class="LinkPage"&gt;Hormone Replacement&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Oophorectomy in &lt;a href="../../Endo/Sex/TrnrsSyndrm.htm" class="LinkPage"&gt;Turner's Syndrome&lt;/a&gt; (malignancy risk)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Evaluation Step 2c: Suspect Chronic Disease in Step 1&lt;ol&gt;&lt;li&gt;Findings suggestive of chronic disease&lt;ol&gt;&lt;li&gt;Overt chronic illness signs or symptoms&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Growth/ShrtStr.htm" class="LinkPage"&gt;Short Stature&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Slow growth rate&lt;/li&gt;&lt;li&gt;Bone age less than chronological age&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Differential Diagnosis&lt;ol&gt;&lt;li&gt;&lt;a href="../../Psych/Eating/AnrxNrvs.htm" class="LinkPage"&gt;Anorexia Nervosa&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Malnutrition&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Sex/KlmnsSyndrm.htm" class="LinkPage"&gt;Kallmann's Syndrome&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Hypopituitarism&lt;/li&gt;&lt;li&gt;&lt;a href="../../ENT/Sx/LsOfSml.htm" class="LinkPage"&gt;Anosmia&lt;/a&gt; or &lt;a href="../../ENT/Sx/LsOfSml.htm" class="LinkPage"&gt;Hyposmia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Sex/HypgndtrpcHypgndsm.htm" class="LinkPage"&gt;Hypogonadotropic Hypogonadism&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Iatrogenic&lt;/li&gt;&lt;li&gt;Hypopituitarism&lt;ol&gt;&lt;li&gt;Findings&lt;ol&gt;&lt;li&gt;Growth failure&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/Hypthyrdsm.htm" class="LinkPage"&gt;Hypothyroidism&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Adrenal/AdsnsDs.htm" class="LinkPage"&gt;Adrenal Insufficiency&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Renal/Endo/DbtsInspds.htm" class="LinkPage"&gt;Diabetes Insipidus&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Delayed Puberty&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Causes&lt;ol&gt;&lt;li&gt;Intracranial lesion (esp. involving pituitary)&lt;/li&gt;&lt;li&gt;Infection of &lt;a href="../../Neuro/Anatomy/PtryAntmy.htm" class="LinkPage"&gt;Pituitary Gland&lt;/a&gt; (e.g. &lt;a href="../../Lung/Tb/Tbrcls.htm" class="LinkPage"&gt;Tuberculosis&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;&lt;a href="../../ER/Neuro/HdInjry.htm" class="LinkPage"&gt;Head Injury&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Chronic Systemic Illness&lt;ol&gt;&lt;li&gt;Malignancy&lt;/li&gt;&lt;li&gt;Chronic infection&lt;/li&gt;&lt;li&gt;Chronic metabolic disease&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Further evaluation&lt;ol&gt;&lt;li&gt;Work-up suspected underlying chronic disease&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Blondell%20%20%5BAU%5D%20AND%201999%20%5BDP%5D%20AND%20%20Am%20Fam%20Physician%20%20%5BTA%5D" class="LinkRef"&gt;Blondell (1999) Am Fam Physician 60:209-24&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Foster%20%20%5BAU%5D%20AND%201992%20%5BDP%5D%20AND%20%20Obstet%20Gynecol%20Clin%20North%20Am%20%20%5BTA%5D" class="LinkRef"&gt;Foster (1992) Obstet Gynecol Clin North Am 19:59-70&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Styne%20%20%5BAU%5D%20AND%201997%20%5BDP%5D%20AND%20%20Pediatr%20Clin%20North%20Am%20%20%5BTA%5D" class="LinkRef"&gt;Styne (1997) Pediatr Clin North Am 44(2):505-29&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0034012</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Sex/PbrtlDly.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Pubertal Delay, Delayed Puberty</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Sex/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees></FP_UMLS_Trees><FP_Condition_name_check></FP_Condition_name_check><FP_Condition_name><value>Risser Sign</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Radiology</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;See Also&lt;ol&gt;&lt;li&gt;Tanner Stage&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Indications&lt;ol&gt;&lt;li&gt;Skeletal Maturity estimation in &lt;a href="../../Ortho/T-Spine/Scls.htm" class="LinkPage"&gt;Scoliosis&lt;/a&gt; evaluation&lt;/li&gt;&lt;li&gt;&lt;a href="../../Ortho/T-Spine/Scls.htm" class="LinkPage"&gt;Scoliosis&lt;/a&gt; progression risk related to skeletal maturity&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Physiology&lt;ol&gt;&lt;li&gt;Iliac apophysis calcification begins at &lt;a href="../../Endo/Exam/SxlDvlpmnt.htm" class="LinkPage"&gt;Puberty&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Calcification completed over 2 year period&lt;/li&gt;&lt;li&gt;Completed with apophysis fusion to iliac crest&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Calcification (or ossification) begins anterolaterally&lt;ol&gt;&lt;li&gt;Anterior superior iliac spine is first to calcify&lt;/li&gt;&lt;li&gt;Calcification progresses posteromedially&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Grading (based on iliac crest divided into 4 quadrants)&lt;ol&gt;&lt;li&gt;Risser 1: 25% Iliac Apophysis Ossification&lt;ol&gt;&lt;li&gt;Anterior Superior iliac spine (anterolateral)&lt;/li&gt;&lt;li&gt;Seen in prepuberty or early &lt;a href="../../Endo/Exam/SxlDvlpmnt.htm" class="LinkPage"&gt;Puberty&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Risser 2: 50% Iliac Apophysis Ossification&lt;ol&gt;&lt;li&gt;Ossification extends halfway across iliac wing&lt;/li&gt;&lt;li&gt;Seen immediately before or during growth spurt&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Risser 3: 75% Iliac Apophysis Ossification&lt;/li&gt;&lt;li&gt;Risser 4: 100% Iliac Apophysis Ossification&lt;ol&gt;&lt;li&gt;Adjacent to sacroiliac joint (posteromedial)&lt;/li&gt;&lt;li&gt;Indicates slowing of growth&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Risser 5: Iliac apophysis fuses to iliac crest&lt;ol&gt;&lt;li&gt;Indicates cessation of growth&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;Lonstein (July 1989) J Musculoskeletal Med, p. 37-54&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Greiner%20%20%5BAU%5D%20AND%202002%20%5BDP%5D%20AND%20%20Am%20Fam%20Physician%20%20%5BTA%5D" class="LinkRef"&gt;Greiner (2002) Am Fam Physician 65(9):1817-22&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Haasbeek%20%20%5BAU%5D%20AND%201997%20%5BDP%5D%20AND%20%20Postgrad%20Med%20%20%5BTA%5D" class="LinkRef"&gt;Haasbeek (1997) Postgrad Med 101(6):207-16&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Rad/RsrSgn.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Risser Sign, Risser's Sign, Risser Grade, Risser Grading, Iliac Apophysis Ossification</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Rad/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Precocious Puberty  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0034013"&gt;&lt;i&gt;C0034013&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;Unusually early sexual maturity.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A disorder characterized by unusually early development of secondary sexual features; the onset of sexual maturation begins usually before age 8 for girls and before age 9 for boys.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;Unusually early sexual development or maturity; premature puberty.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CSP)&lt;/td&gt;
                &lt;td&gt;unusually early sexual maturity.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;Development of SEXUAL MATURATION in boys and girls at a chronological age that is 2.5 standard deviations below the mean age at onset of PUBERTY in the population. This early maturation of the hypothalamic-pituitary-gonadal axis results in sexual precocity, elevated serum levels of GONADOTROPINS and GONADAL STEROID HORMONES such as ESTRADIOL and TESTOSTERONE.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Disease or Syndrome (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0034013&amp;amp;tui=T047"&gt;&lt;i&gt;T047&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D011629&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD10&lt;/td&gt;
                &lt;td&gt;E30.1&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;154716006, 267488008, 400179000, 123527003, 190575003, 190576002, 70387004&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Pubertas praecox, Puberty, Precocious, ACCELERATED SEXUAL MATURITY, PRECOCIOUS PUBERTY, PUBERTY PRECOCIOUS, SEXUAL PRECOCITY, Precocious true puberty, Sexual precocity, NOS, Premature puberty, Sexual Precocity, MATURATION SEX ACCELERATED, Precocious Puberty, precocious puberty (diagnosis), precocious puberty, (Sexual precocity NOS) or (puberty - precocious) (disorder), Maturation sex accelerated, Accelerated sexual maturation, Accelerated sexual maturity, Early puberty, Precocious puberty NOS, Puberty precocious, True precocious puberty, Puberty, Precocious [Disease/Finding], premature puberty, early puberty, precocious sexual development, puberty precocious, Puberty;precocious, sexual precocity, true precocious puberty, puberty early, Precocious puberty, Sexual precocity, Precocious sexual development, Precocious puberty (disorder), Precocious sexual development (disorder), precocious; puberty, premature; puberty, pubertas praecox, puberty; precocious, puberty; premature, (Sexual precocity NOS) or (puberty - precocious), Puberty - precocious, Sexual precocity NOS&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;PUBERTE PRECOCE, Puberté précoce SAI, Maturation sexuelle accélérée, Maturité sexuelle accélérée, Puberté précoce vraie, Puberté précoce&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;PUBERDADE PRECOCE, Maturação sexual acelerada, Maturidade sexual acelerada, Puberdade precoce NE, Puberdade precoce, Puberdade precoce verdadeira, Puberdade Precoce&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;PUBERTAD PRECOZ, Pubertad temprana, Maduración sexual acelerada, Pubertad precoz NEOM, Madurez sexual acelerada, pubertad precoz verdadera, Sexual precocity NOS, Premature puberty, Precocious puberty, Puberty - precocious, (Sexual precocity NOS) or (puberty - precocious), Sexual precocity NEC, desarrollo sexual Y/O puberal precoz, desarrollo sexual precoz (trastorno), desarrollo sexual precoz, precocidad sexual, pubertad precoz (trastorno), pubertad precoz verdadera (trastorno), pubertad precoz, pubertas praecox, Pubertad precoz, Pubertad precoz verdadera, Pubertad Precoz&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Pubertà precoce vera, Pubertà precoce NAS, Pubertà anticipata, Maturità sessuale accelerata, Sviluppo sessuale precoce, Precocità puberale, Maturazione sessuale accelerata, Pubertà precoce&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;versnelde seksuele ontwikkeling, versnelde seksuele rijpheid, vroege puberteit, pubertas praecox NAO, seksuele ontwikkeling versneld, prematuur; puberteit, puberteit; prematuur, puberteit; vroegtijdigheid, vroegtijdigheid; puberteit, Pubertas praecox, echte pubertas praecox, pubertas praecox, Puberteit (ontwikkelingstoestand); vroegtijdig, Vroegtijdige puberteit&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;beschleunigte sexuelle Reife, fruehe Pubertaet, Geschlechtsreife beschleunigt, Pubertas praecox NNB, PUBERTAS PRAECOX, Vorzeitige Pubertaet [Pubertas praecox], Pubertas praecox vera, Pubertas praecox, Pubertät, verfrühte&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;思春期早発, 性成熟亢進, 思春期早発症ＮＯＳ, ｾｲｾｲｼﾞｭｸｺｳｼﾝ, ｼｼｭﾝｷｿｳﾊﾂ, ｼｼｭﾝｷｿｳﾊﾂｼｮｳNOS, ｼｼｭﾝｷｿｳﾊﾂｼｮｳ, ｼﾝｾｲｼｼｭﾝｷｿｳﾊﾂｼｮｳ, ｾｲﾃｷｿｳｼﾞｭｸ, 思春期早発症, 中枢性思春期早発症, 中枢性早熟症, 性早熟症, 性的早熟, 早期破瓜, 早熟, 早熟症, 早発思春期, 早発性大性器症, 早発青春期, 真性思春期早発症, 真性性早熟症, 性的早熟症, 早発症-思春期&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Pubertet, för tidig&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;puberta předčasná, Urychlená pohlavní zralost, Urychlené pohlavní dospívání, Pubertas praecox, Předčasná puberta, Pravá předčasná puberta, Pubertas praecox NOS&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Ennenaikainen murrosikä&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;POLOVOE RAZVITIE PREZHDEVREMENNOE, ПОЛОВОЕ РАЗВИТИЕ ПРЕЖДЕВРЕМЕННОЕ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Korean&lt;/td&gt;
                &lt;td&gt;사춘기 조숙&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Croatian&lt;/td&gt;
                &lt;td&gt;PUBERTET, PRIJEVREMENI&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Dojrzewanie przedwczesne, Dojrzewanie płciowe przedwczesne&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;Accelerált sexualis érettség, Pubertas praecox, Gyorsult nemi érés, Accelerált sexualis érés, Korai pubertas, Praecox pubertas k.m.n., Praecox pubertas, Valódi pubertas praecox&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Precocious Puberty  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Precocious Puberty Causes</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Sexual Development</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;GnRH dependent (True or Central): Complete Isosexual&lt;ol&gt;&lt;li&gt;Idiopathic&lt;/li&gt;&lt;li&gt;CNS lesion (e.g. pituitary tumor)&lt;/li&gt;&lt;li&gt;Secondary to GnRH independent &lt;a href="../../Endo/Sex/PrcsPbrty.htm" class="LinkPage"&gt;Precocious Puberty&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/Hypthyrdsm.htm" class="LinkPage"&gt;Hypothyroidism&lt;/a&gt; (unclear cause)&lt;/li&gt;&lt;li&gt;Chronic &lt;a href="../../Endo/Adrenal/AdsnsDs.htm" class="LinkPage"&gt;Adrenal Insufficiency&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;GnRH independent (Peripheral - always abnormal)&lt;ol&gt;&lt;li&gt;Adrenal Causes&lt;ol&gt;&lt;li&gt;21-OH deficiency&lt;/li&gt;&lt;li&gt;11-OH deficiency&lt;/li&gt;&lt;li&gt;Results&lt;ol&gt;&lt;li&gt;Girls: contrasexual&lt;/li&gt;&lt;li&gt;Boys: isosexual&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Tumor: Contrasexual OR Isosexual&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Gonadal Cause&lt;ol&gt;&lt;li&gt;McCune-Albright Syndrome (Isosexual)&lt;ol&gt;&lt;li&gt;Polyostotic fibrous dysplasia&lt;/li&gt;&lt;li&gt;&lt;a href="../../Neuro/Derm/CfALtMcl.htm" class="LinkPage"&gt;Cafe Au Lait&lt;/a&gt; spots&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Sex/PrcsPbrty.htm" class="LinkPage"&gt;Precocious Puberty&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Associated with &lt;a href="../../Endo/Thyroid/Hyprthyrdsm1.htm" class="LinkPage"&gt;Hyperthyroidism&lt;/a&gt;, &lt;a href="../../Endo/Adrenal/CshngsDs.htm" class="LinkPage"&gt;Cushing's Syndrome&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Familial Male (Testotoxicosis, Isosexual)&lt;/li&gt;&lt;li&gt;Tumor (Isosexual or Contrasexual)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Miscellaneous Cause&lt;ol&gt;&lt;li&gt;Ectopic hCG secreting tumor (Isosexual in boys)&lt;/li&gt;&lt;li&gt;Extraglandular aromatization (Contrasexual in boys)&lt;/li&gt;&lt;li&gt;Factitious (Isosexual or Contrasexual)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Partial &lt;a href="../../Endo/Exam/SxlDvlpmnt.htm" class="LinkPage"&gt;Sexual Development&lt;/a&gt; Causes&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Sex/BngnPrmtrThlrch.htm" class="LinkPage"&gt;Benign Premature Thelarche&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Isolated &lt;a href="../../Gyn/Anatomy/BrstAntmy.htm" class="LinkPage"&gt;Breast&lt;/a&gt; development as early as&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Sex/BngnPrmtrAdrnrch.htm" class="LinkPage"&gt;Benign Premature Adrenarche&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Isolated pubic hair develops under age 6 years&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Contrasexual Development Causes&lt;ol&gt;&lt;li&gt;Boys&lt;ol&gt;&lt;li&gt;&lt;a href="../../Gyn/Pharm/Estrgn.htm" class="LinkPage"&gt;Estrogen&lt;/a&gt;-secreting adrenal tumor&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Girls&lt;ol&gt;&lt;li&gt;Excessive pubic hair&lt;ol&gt;&lt;li&gt;Adrenal hyperplasia&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Sex/BngnPrmtrAdrnrch.htm" class="LinkPage"&gt;Benign Premature Adrenarche&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Gyn/Endo/PlycystcOvryDs.htm" class="LinkPage"&gt;Polycystic Ovary Disease&lt;/a&gt; (older girls)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Virilization (clitoromegaly and increased muscle)&lt;ol&gt;&lt;li&gt;Ovarian tumor&lt;/li&gt;&lt;li&gt;Adrenal tumor&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Adrenal/CshngsDs.htm" class="LinkPage"&gt;Cushing's Syndrome&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pituitary/Hyprprlctnm.htm" class="LinkPage"&gt;Hyperprolactinemia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pituitary/Acrmgly.htm" class="LinkPage"&gt;Acromegaly&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Exogenous androgens&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Blondell%20%20%5BAU%5D%20AND%201999%20%5BDP%5D%20AND%20%20Am%20Fam%20Physician%20%20%5BTA%5D" class="LinkRef"&gt;Blondell (1999) Am Fam Physician 60:209-24&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0034013</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Sex/PrcsPbrtyCs.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Precocious Puberty Causes</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Sex/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Gynecomastia  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0018418"&gt;&lt;i&gt;C0018418&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A disorder characterized by excessive development of the breasts in males.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CSP)&lt;/td&gt;
                &lt;td&gt;female mammary morphology in a XY genotype.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;Enlargement of the BREAST in the males, caused by an excess of ESTROGENS. Physiological gynecomastia is normally observed in NEWBORNS; ADOLESCENT; and AGING males.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;Excessive development of the breasts in males; usually the result of hormonal imbalance or treatment with certain drugs.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Disease or Syndrome (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0018418&amp;amp;tui=T047"&gt;&lt;i&gt;T047&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D006177&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD10&lt;/td&gt;
                &lt;td&gt;N62&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;4754008, 155963008, 198112004, 266646002&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;GYNECOMASTIE, Augmentation du volume mammaire chez l'homme, AUGM VOLUME SEIN CHEZ L'HOMME, Gynécomastie&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;BREAST ENLARGEMENT MALE, ENLARGEMENT BREAST MALE, GYNAECOMASTIA, GYNECOMASTIA, Gynecomastia, Breast enlargement male, Enlargement breast male, Gynecomastia [Disease/Finding], male breast enlargement, Gynaecomastia, Hypertrophy of male breast, Gynaecomazia, Gynecomazia, Gynecomastia (disorder), gynecomastia, Breast Enlargement, Male, Enlargement, Male Breast, Male Breast Enlargement, gynaecomastia&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;GINECOMASTIA, Aumento de volume da mama no homem, Aumento de volume mamário no homem, AUMENTO DO VOLUME MAMARIO NO HOME, Ginecomastia&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;GINECOMASTIA, Aumento de tamaño de la mama masculina, Gynecomastia, Gynaecomastia, MAMA MASCULINA AUMENTADA, ginecomastia (trastorno), ginecomastia, hipertrofia de la mama masculina, Ginecomastia&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;GYNAEKOMASTIE, Brustvergroesserung, maennlich, Vergroesserung der Brust, maennlich, BRUSTDRUESENVERGROESSERUNG MAENNL, Gynaekomastie, Gynäkomastie&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;borstvergroting bij man, gynaecomastie, Gynaecomastie&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Aumento di volume della mammella dell'uomo, Aumento di volume della mammella, maschile, Espansione della mammella maschile, Ginecomastia&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;男性乳房腫大, ﾀﾞﾝｾｲﾆｭｳﾎﾞｳｼｭﾀﾞｲ, ｼﾞｮｾｲｶﾆｭｳﾎﾞｳ, 女性化乳房, 女性型乳房&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Gynekomasti&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;gynekomastie, Gynekomastie, Zvětšení prsu u muže&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Gynekomastia&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;GINEKOMASTIIA, ГИНЕКОМАСТИЯ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Ginekomastia, Przerost sutka&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;Gynaecomastia, Gynecomastia, Férfi emlő megnagyobbodása, emlőmegnagyobbodás, férfi&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;GYNECOMASTIA, FAMILIAL  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C1844375"&gt;&lt;i&gt;C1844375&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Disease or Syndrome (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C1844375&amp;amp;tui=T047"&gt;&lt;i&gt;T047&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;GYNECOMASTIA, FAMILIAL&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Gynecomastia  (</value><value>)
</value><value>GYNECOMASTIA, FAMILIAL  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Gynecomastia</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Symptoms</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;See Also&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Sex/PrcsPbrty.htm" class="LinkPage"&gt;Precocious Puberty&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/MdctnCsOfGyncmst.htm" class="LinkPage"&gt;Medication Causes of Gynecomastia&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Causes: Physiologic in Newborn, &lt;a href="../../Endo/Exam/SxlDvlpmnt.htm" class="LinkPage"&gt;Puberty&lt;/a&gt;, Older men&lt;ol&gt;&lt;li&gt;Physiologic Mechanisms&lt;ol&gt;&lt;li&gt;&lt;a href="../../Gyn/Pharm/Estrgn.htm" class="LinkPage"&gt;Estrogen&lt;/a&gt; excess&lt;/li&gt;&lt;li&gt;Decreased androgen to &lt;a href="../../Gyn/Pharm/Estrgn.htm" class="LinkPage"&gt;Estrogen&lt;/a&gt; ratio&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Physiologic syndromes (25% of cases)&lt;ol&gt;&lt;li&gt;Gynecomastia in the newborn&lt;ol&gt;&lt;li&gt;Common response to maternal &lt;a href="../../Gyn/Pharm/Estrgn.htm" class="LinkPage"&gt;Estrogen&lt;/a&gt;s&lt;/li&gt;&lt;li&gt;&lt;a href="../../Gyn/Anatomy/BrstAntmy.htm" class="LinkPage"&gt;Breast&lt;/a&gt; enlargement usually resolves in weeks&lt;/li&gt;&lt;li&gt;May be accompanied by milk discharge (witch's milk)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Benign Gynecomastia of Adolescence&lt;ol&gt;&lt;li&gt;Frequently occurs in boys at mid to late &lt;a href="../../Endo/Exam/SxlDvlpmnt.htm" class="LinkPage"&gt;Puberty&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Asymmetric &lt;a href="../../Gyn/Anatomy/BrstAntmy.htm" class="LinkPage"&gt;Breast&lt;/a&gt; involvement and tenderness&lt;/li&gt;&lt;li&gt;Resolves spontaneously within 1-2 years&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Familial Gynecomastia&lt;ol&gt;&lt;li&gt;Common X-Linked recessive or dominant trait&lt;/li&gt;&lt;li&gt;Limited &lt;a href="../../Gyn/Anatomy/BrstAntmy.htm" class="LinkPage"&gt;Breast&lt;/a&gt; development during &lt;a href="../../Endo/Exam/SxlDvlpmnt.htm" class="LinkPage"&gt;Puberty&lt;/a&gt;&lt;/li&gt;&lt;li&gt;No further evaluation unless &lt;a href="../../Endo/Sex/Hypgndsm.htm" class="LinkPage"&gt;Hypogonadism&lt;/a&gt; present&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Gynecomastia of aging&lt;ol&gt;&lt;li&gt;Common in men over age 65 years (40-72%)&lt;/li&gt;&lt;li&gt;Decreased androgen to &lt;a href="../../Gyn/Pharm/Estrgn.htm" class="LinkPage"&gt;Estrogen&lt;/a&gt; ratio&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Causes: Secondary (75% of cases)&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Endo/Pharm/MdctnCsOfGyncmst.htm" class="LinkPage"&gt;Medication Causes of Gynecomastia&lt;/a&gt; (10-25% of cases)&lt;/li&gt;&lt;li&gt;Idiopathic (25% of cases)&lt;/li&gt;&lt;li&gt;&lt;a href="../../GI/Lvr/Crhs.htm" class="LinkPage"&gt;Cirrhosis&lt;/a&gt; (8% of causes)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Sex/Hypgndsm.htm" class="LinkPage"&gt;Hypogonadism&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Klinefelter's Syndrome&lt;/li&gt;&lt;li&gt;Kallman Syndrome&lt;/li&gt;&lt;li&gt;Congenital anorchia&lt;/li&gt;&lt;li&gt;5a-reductase deficiency&lt;/li&gt;&lt;li&gt;Androgen insensitivity&lt;/li&gt;&lt;li&gt;&lt;a href="../../GI/HemeOnc/Hmchrmts.htm" class="LinkPage"&gt;Hemochromatosis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Testicular trauma (e.g. &lt;a href="../../Uro/Testes/TstclrTrsn.htm" class="LinkPage"&gt;Testicular Torsion&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Uro/Testes/ActOrchts.htm" class="LinkPage"&gt;Orchitis&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Renal/Failure/ChrncRnlFlr.htm" class="LinkPage"&gt;Chronic Renal Failure&lt;/a&gt; (1% of cases)&lt;ol&gt;&lt;li&gt;Gynecomastia resolves with renal transplant (improves partially with &lt;a href="../../Renal/Pharm/Hmdlys.htm" class="LinkPage"&gt;Dialysis&lt;/a&gt;)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/Hyprthyrdsm1.htm" class="LinkPage"&gt;Hyperthyroidism&lt;/a&gt; (2% of cases)&lt;ol&gt;&lt;li&gt;Gynecomastia resolves within 2 months of treatment&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Obesity/Obsty.htm" class="LinkPage"&gt;Obesity&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Causes both pseudogynecomastia and Gynecomastia&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Primary tumor&lt;ol&gt;&lt;li&gt;Adrenal tumor&lt;/li&gt;&lt;li&gt;Testicular tumor (e.g. Leydig, Sertoli cell tumor)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/Prlctn.htm" class="LinkPage"&gt;Prolactin&lt;/a&gt;-secreting adenomas&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Ectopic hormone production (hcg secreting tumors)&lt;ol&gt;&lt;li&gt;&lt;a href="../../Lung/HemeOnc/LngCncr.htm" class="LinkPage"&gt;Lung Cancer&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../GI/HemeOnc/GstrcCncr.htm" class="LinkPage"&gt;Stomach Cancer&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../GI/Anatomy/LvrAntmy.htm" class="LinkPage"&gt;Liver&lt;/a&gt; cancer&lt;/li&gt;&lt;li&gt;Renal cell cancer&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Miscellaneous causes&lt;ol&gt;&lt;li&gt;Familial Gynecomastia&lt;/li&gt;&lt;li&gt;&lt;a href="../../HIV/Exam/HmnImndfcncyVrs.htm" class="LinkPage"&gt;Human Immunodeficiency Virus&lt;/a&gt; (HIV)&lt;/li&gt;&lt;li&gt;&lt;a href="../../GI/IBD/UlcrtvClts.htm" class="LinkPage"&gt;Ulcerative Colitis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Lung/Peds/CystcFbrs.htm" class="LinkPage"&gt;Cystic Fibrosis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../ER/Toxin/LdPsng.htm" class="LinkPage"&gt;Lead Toxicity&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Phthalate Toxicity&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;History: Red flags suggestive of non-physiologic Gynecomastia&lt;ol&gt;&lt;li&gt;Persistent Gynecomastia for &amp;gt;2 years&lt;/li&gt;&lt;li&gt;&lt;a href="../../Gyn/Sx/NplDschrg.htm" class="LinkPage"&gt;Nipple Discharge&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Gyn/Derm/BrstSknChngs.htm" class="LinkPage"&gt;Breast Skin Changes&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Rapid &lt;a href="../../Gyn/Anatomy/BrstAntmy.htm" class="LinkPage"&gt;Breast&lt;/a&gt; enlargement&lt;/li&gt;&lt;li&gt;Firm &lt;a href="../../Gyn/Breast/BrstLmp.htm" class="LinkPage"&gt;Breast Mass&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Testicular mass&lt;/li&gt;&lt;li&gt;Weight loss&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Signs&lt;ol&gt;&lt;li&gt;Firm &lt;a href="../../Gyn/Anatomy/BrstAntmy.htm" class="LinkPage"&gt;Breast&lt;/a&gt; swelling that is concentric centered under nipple and areola&lt;/li&gt;&lt;li&gt;Bilateral involvement is most common (typically left sided when unilateral)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Labs&lt;ol&gt;&lt;li&gt;All patients&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/ThyrdStmltngHrmn.htm" class="LinkPage"&gt;Thyroid Stimulating Hormone&lt;/a&gt; (TSH)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Renal/Lab/SrmCrtn.htm" class="LinkPage"&gt;Serum Creatinine&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../GI/Lab/AsprtAmntrnsfrs.htm" class="LinkPage"&gt;Serum AST&lt;/a&gt; and ALT&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Hormonally active tumor suspected&lt;ol&gt;&lt;li&gt;Serum &lt;a href="../../OB/Lab/PrgncyTst.htm" class="LinkPage"&gt;Beta hCG&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/SrmDhydrpndrstrn.htm" class="LinkPage"&gt;Serum Dehydroepiandrosterone&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Urinary 17-ketosteroid&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Sex/Hypgndsm.htm" class="LinkPage"&gt;Hypogonadism&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../Uro/Lab/TtlTststrn.htm" class="LinkPage"&gt;Serum Testosterone&lt;/a&gt; (total and free)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Gyn/Lab/SrmEstrdl.htm" class="LinkPage"&gt;Serum Estradiol&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/FlclStmltngHrmn.htm" class="LinkPage"&gt;Follicle Stimulating Hormone&lt;/a&gt; (FSH)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/LtnzngHrmn.htm" class="LinkPage"&gt;Luteinizing hormone&lt;/a&gt; (LH)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Other labs to consider&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/Prlctn.htm" class="LinkPage"&gt;Serum Prolactin&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Differential Diagnosis&lt;ol&gt;&lt;li&gt;Pseudogynecomastia (fatty tissue predominance)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Gyn/HemeOnc/BrstCncr.htm" class="LinkPage"&gt;Breast Cancer&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Derm/Hyperplasia/Lpm.htm" class="LinkPage"&gt;Lipoma&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Derm/Sebaceous/EpdrmlCyst.htm" class="LinkPage"&gt;Sebaceous Cyst&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Gyn/ID/Msts.htm" class="LinkPage"&gt;Mastitis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Dermoid &lt;a href="../../Derm/Exam/Cyst.htm" class="LinkPage"&gt;Cyst&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Trauma-related swelling (fat necrosis or hematoma)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Imaging&lt;ol&gt;&lt;li&gt;&lt;a href="../../Uro/Rad/TstclrUltrsnd.htm" class="LinkPage"&gt;Testicular Ultrasound&lt;/a&gt; indications&lt;ol&gt;&lt;li&gt;Palpable testicular mass&lt;/li&gt;&lt;li&gt;Gynecomastia size &amp;gt;5 cm&lt;/li&gt;&lt;li&gt;Persistent Gynecomastia without obvious cause&lt;/li&gt;&lt;li&gt;Serum HCG increased&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Gyn/Anatomy/BrstAntmy.htm" class="LinkPage"&gt;Breast&lt;/a&gt;&lt;a href="../../Rad/Ultrasound/Ultrsnd.htm" class="LinkPage"&gt;Ultrasound&lt;/a&gt; (and possibly FNA) indications&lt;ol&gt;&lt;li&gt;&lt;a href="../../Gyn/Breast/BrstLmp.htm" class="LinkPage"&gt;Breast Mass&lt;/a&gt; suspected&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;MRI brain&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pituitary/Prlctnm.htm" class="LinkPage"&gt;Prolactinoma&lt;/a&gt; suspected (increased &lt;a href="../../Endo/Lab/Prlctn.htm" class="LinkPage"&gt;Serum Prolactin&lt;/a&gt;)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Management&lt;ol&gt;&lt;li&gt;Evaluate for underlying cause&lt;ol&gt;&lt;li&gt;Physiologic cause is a diagnosis of exclusion&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Observation&lt;ol&gt;&lt;li&gt;Indicated in most cases&lt;/li&gt;&lt;li&gt;Routine follow-up on an every 6 month basis&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Medical management&lt;ol&gt;&lt;li&gt;Indicated in symptomatic or distressing Gynecomastia&lt;/li&gt;&lt;li&gt;&lt;a href="../../Gyn/Pharm/Tmxfn.htm" class="LinkPage"&gt;Tamoxifen&lt;/a&gt; 10 mg daily for 3 months&lt;/li&gt;&lt;li&gt;&lt;a href="../../Gyn/Pharm/Evst.htm" class="LinkPage"&gt;Raloxifene&lt;/a&gt; (&lt;a href="../../Gyn/Pharm/Evst.htm" class="LinkPage"&gt;Evista&lt;/a&gt;) 60 mg daily for 3-9 months&lt;/li&gt;&lt;li&gt;Dihydrotestosterone&lt;/li&gt;&lt;li&gt;&lt;a href="../../Gyn/Pharm/Dnzl.htm" class="LinkPage"&gt;Danazol&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Clomiphene (&lt;a href="../../Gyn/Pharm/Clmd.htm" class="LinkPage"&gt;Clomid&lt;/a&gt;)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Surgical management&lt;ol&gt;&lt;li&gt;Indicated in prolonged, severe, refractory to medication cases&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;Wilson (1998) Williams Endocrinology, Saunders, 885-92&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Braunstein%20%20%5BAU%5D%20AND%201993%20%5BDP%5D%20AND%20%20N%20Engl%20J%20Med%20%20%5BTA%5D" class="LinkRef"&gt;Braunstein (1993) N Engl J Med 328:490-5&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Braunstein%20%20%5BAU%5D%20AND%202007%20%5BDP%5D%20AND%20%20N%20Engl%20J%20Med%20%20%5BTA%5D" class="LinkRef"&gt;Braunstein (2007) N Engl J Med 357(12): 1229-37&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Dickson%20%20%5BAU%5D%20AND%202012%20%5BDP%5D%20AND%20%20Am%20Fam%20Physician%20%20%5BTA%5D" class="LinkRef"&gt;Dickson (2012) Am Fam Physician 85(7):716-22&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Sher%20%20%5BAU%5D%20AND%201998%20%5BDP%5D%20AND%20%20Clin%20Pediatr%20%20%5BTA%5D" class="LinkRef"&gt;Sher (1998) Clin Pediatr 37(6):367-71&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0018418</value><value>C1844375</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Sx/Gyncmst.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Gynecomastia, Male Breast Enlargement, Benign Gynecomastia of Adolescence, Familial Gynecomastia</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Sx/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees></FP_UMLS_Trees><FP_Condition_name_check></FP_Condition_name_check><FP_Condition_name><value>Exercise in Obesity</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Sports Medicine</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;See Also&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Obesity/ObstyMngmnt.htm" class="LinkPage"&gt;Obesity Management&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Sports/Exercise/Exrcs.htm" class="LinkPage"&gt;Exercise&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;General&lt;ol&gt;&lt;li&gt;Choose activities that use large muscle groups&lt;/li&gt;&lt;li&gt;Maximize total energy expenditure&lt;/li&gt;&lt;li&gt;Goal: &lt;a href="../../Sports/Exercise/Exrcs.htm" class="LinkPage"&gt;Exercise&lt;/a&gt; at least 30-45 minutes/day,5-7 days/week&lt;ol&gt;&lt;li&gt;Start slowly by committing to 5 minutes per day&lt;/li&gt;&lt;li&gt;Increase in 5 minute increments every 1-2 weeks&lt;/li&gt;&lt;li&gt;May split activity into 10 minute increments&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Aerobic intensity&lt;ol&gt;&lt;li&gt;Identify maximum &lt;a href="../../CV/Exam/HrtRt.htm" class="LinkPage"&gt;Heart Rate&lt;/a&gt; (220-age)&lt;/li&gt;&lt;li&gt;Maintain &lt;a href="../../CV/Exam/HrtRt.htm" class="LinkPage"&gt;Heart Rate&lt;/a&gt; in goal range during &lt;a href="../../Sports/Exercise/Exrcs.htm" class="LinkPage"&gt;Exercise&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Initial &lt;a href="../../CV/Exam/HrtRt.htm" class="LinkPage"&gt;Heart Rate&lt;/a&gt; goal: 40-60% of maximum&lt;/li&gt;&lt;li&gt;Long-term &lt;a href="../../CV/Exam/HrtRt.htm" class="LinkPage"&gt;Heart Rate&lt;/a&gt; goal: 50-75% of maximum&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;As fitness improves, &lt;a href="../../Sports/Exercise/Exrcs.htm" class="LinkPage"&gt;Exercise&lt;/a&gt; efficiency improves&lt;ol&gt;&lt;li&gt;Greater &lt;a href="../../Sports/Exercise/Exrcs.htm" class="LinkPage"&gt;Exercise&lt;/a&gt; performed at same &lt;a href="../../CV/Exam/HrtRt.htm" class="LinkPage"&gt;Heart Rate&lt;/a&gt;&lt;/li&gt;&lt;li&gt;May result in weight loss plateau&lt;/li&gt;&lt;li&gt;Respond with increased duration or intensity&lt;/li&gt;&lt;li&gt;Weight maintenance requires &lt;a href="../../Sports/Exercise/Exrcs.htm" class="LinkPage"&gt;Exercise&lt;/a&gt;&lt;ol&gt;&lt;li&gt;60 minutes of moderate &lt;a href="../../Sports/Exercise/Exrcs.htm" class="LinkPage"&gt;Exercise&lt;/a&gt; daily&lt;/li&gt;&lt;li&gt;20-30 minutes of vigorous &lt;a href="../../Sports/Exercise/Exrcs.htm" class="LinkPage"&gt;Exercise&lt;/a&gt; daily&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Example&lt;ol&gt;&lt;li&gt;Forty year old calculated maximum &lt;a href="../../CV/Exam/HrtRt.htm" class="LinkPage"&gt;Heart Rate&lt;/a&gt;: 180&lt;/li&gt;&lt;li&gt;Starts with &lt;a href="../../CV/Exam/HrtRt.htm" class="LinkPage"&gt;Heart Rate&lt;/a&gt; goal up to 110 (60%)&lt;/li&gt;&lt;li&gt;Work up to &lt;a href="../../CV/Exam/HrtRt.htm" class="LinkPage"&gt;Heart Rate&lt;/a&gt; goal of 135 (75%)&lt;/li&gt;&lt;li&gt;Initially might walk at normal pace to reach target&lt;/li&gt;&lt;li&gt;As fitness improves, brisk walk needed for target&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Precautions&lt;ol&gt;&lt;li&gt;Prevent hyperthermia&lt;ol&gt;&lt;li&gt;Stay hydrated for &lt;a href="../../Sports/Exercise/Exrcs.htm" class="LinkPage"&gt;Exercise&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Do not over-dress&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Avoid overuse and repetitive motion injury&lt;ol&gt;&lt;li&gt;Cross-train with variety of activites&lt;/li&gt;&lt;li&gt;Avoid high-impact activities (e.g. &lt;a href="../../Sports/Running/Rnng.htm" class="LinkPage"&gt;Running&lt;/a&gt;)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;Whaley (2006) ACSM's Guidelines for &lt;a href="../../Sports/Exercise/Exrcs.htm" class="LinkPage"&gt;Exercise&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Sports/ExrcsInObsty.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Exercise in Obesity, Obesity Management with Exercise</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Sports/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Prolactinoma  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0033375"&gt;&lt;i&gt;C0033375&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;A pituitary adenoma which secretes PROLACTIN, leading to HYPERPROLACTINEMIA. Clinical manifestations include AMENORRHEA; GALACTORRHEA; IMPOTENCE; HEADACHE; visual disturbances; and CEREBROSPINAL FLUID RHINORRHEA.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;An adenoma of the anterior lobe of the pituitary gland that produces prolactin. It is the most common type of pituitary gland adenomas and it is associated with hyperprolactinemia. Clinical manifestations include amenorrhea, galactorrhea, impotence, headache, and visual disturbances.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Neoplastic Process (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0033375&amp;amp;tui=T191"&gt;&lt;i&gt;T191&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D015175&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD10&lt;/td&gt;
                &lt;td&gt;M8271/0&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;367098005, 34337008, 134209002&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Adenoma, Prolactin-Secreting, Pituitary, Pituitary Adenoma, PRL-Secreting, Pituitary Adenoma, Prolactin-Producing, Pituitary Adenoma, Prolactin-Secreting, Pituitary Adenomas, PRL-Secreting, Pituitary Adenomas, Prolactin-Producing, Pituitary Adenomas, Prolactin-Secreting, PRL Secreting Pituitary Adenoma, PRL-Secreting Pituitary Adenoma, PRL-Secreting Pituitary Adenomas, Prolactin-Producing Pituitary Adenoma, Prolactin-Producing Pituitary Adenomas, Prolactin-Secreting Pituitary Adenomas, Prolactinomas, PITUITARY ADENOMA, PROLACTIN SECRETING, PROLACTINOMA, Pituitary Adenoma, Prolactin Secreting, PITUITARY NEOPLASM (PROLACTINOMA), Prolactin Producing Pituitary Gland Adenoma, Prolactin Secreting Pituitary Gland Adenoma, PRL Producing Pituitary Gland Adenoma, prolactinoma, prolactinoma of pituitary gland (diagnosis), prolactinoma of pituitary gland, pituitary prolactinoma, Prolactin-secret pit adenoma, PITUITARY PROLACTINOMA, PROLACTINOMA, FAMILIAL, PITUITARY ADENOMA, PROLACTIN-SECRETING, Prolactinoma, Prolactinoma [Disease/Finding], prolactinomas, adenoma prolactin secreting, pituitary prolactinomas, [M] Prolactinoma, Prolactinoma (morphologic abnormality), [M]Prolactinoma, Prolactin-secreting pituitary adenoma, Prolactinoma (disorder), prolactin secreting adenoma, adenoma, prolactin secreting, prolactinoma; unspecified site, Prolactin Producing Pituitary Adenoma, Prolactin Secreting Pituitary Adenoma, Pituitary Gland Prolactinoma, Pituitary Prolactinoma, Prolactin Producing Adenoma of Pituitary Gland, Prolactin Producing Adenoma of Pituitary, Prolactin Producing Adenoma of the Pituitary Gland, Prolactin Producing Adenoma of the Pituitary, Prolactin Secreting Adenoma of Pituitary Gland, Prolactin Secreting Adenoma of Pituitary, Prolactin Secreting Adenoma of the Pituitary Gland, Prolactin Secreting Adenoma of the Pituitary, Prolactin Secreting Adenoma, Prolactinoma of Pituitary Gland, Prolactinoma of Pituitary, Prolactinoma of the Pituitary Gland, Prolactinoma of the Pituitary, Prolactin-Secreting Pituitary Adenoma, Lactotroph Adenomas, Lactotroph Adenoma, Adenoma, Lactotroph, Adenomas, Lactotroph&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Prolaktinom&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;ﾌﾟﾛﾗｸﾁﾝｻﾝｾｲｼｭﾖｳ, PRL産生下垂体腺腫, プロラクチノーマ, PRL分泌下垂体腺腫(PRLブンピツカスイタイセンシュ), プロラクチン分泌下垂体腺腫(プロラクチンブンピツカスイタイセンシュ), プロラクチン産生下垂体腫瘍, プロラクチン産生下垂体腺腫, PRL分泌下垂体腺腫, PRL産生腺腫, Prolactin分泌腫瘍, Prolactin産生腫瘍, プロラクチン分泌下垂体腺腫, プロラクチン分泌腫瘍, プロラクチン産生腫瘍, プロラクチン産生腺腫, 下垂体腺腫-プロラクチン分泌, 下垂体腺腫-プロラクチン産生, 腺腫-プロラクチン分泌-下垂体&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;prolaktinom, Prolaktinom&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;Prolactinoma, (M)prolactinoma, prolactinoma (anomalía morfológica), prolactinoma, prolactinoma (trastorno), Adenoma Pituitario Secretor de PRL, Adenoma Pituitario Secretor de Prolactina, Adenoma Pituitario Secretorio de Prl, Adenoma Pituitario Secretorio de Prolactina&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Prolaktinooma&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;PROLAKTINOMA, ADENOMA PROLAKTINSEKRETIRUIUSHCHAIA GIPOFIZARNAIA, GIPOFIZARNAIA ADENOMA PROLAKTINSEKRETIRUIUSHCHAIA, PROLAKTINPRODUTSIRUIUSHCHAIA ADENOMA GIPOFIZA, PROLAKTINSEKRETIRUIUSHCHAIA ADENOMA GIPOFIZA, АДЕНОМА ПРОЛАКТИНСЕКРЕТИРУЮЩАЯ ГИПОФИЗАРНАЯ, ГИПОФИЗАРНАЯ АДЕНОМА ПРОЛАКТИНСЕКРЕТИРУЮЩАЯ, ПРОЛАКТИНОМА, ПРОЛАКТИНПРОДУЦИРУЮЩАЯ АДЕНОМА ГИПОФИЗА, ПРОЛАКТИНСЕКРЕТИРУЮЩАЯ АДЕНОМА ГИПОФИЗА&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Adenoma ipofisario prolattina-secernente, Adenoma lattotropo, Adenoma ipofisario PRL-secernente, Adenomi ipofisari che producono prolattina, Prolattinoma&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Croatian&lt;/td&gt;
                &lt;td&gt;PROLAKTINOM&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Prolaktynoma, Gruczolak przysadki wydzielający prolaktynę&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;Prolactinoma&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;prolactinoom; niet gespecificeerde lokalisatie, prolactinoom, Adenoom, prolactinesecernerend hypofysair, Hypofyseadenoom, prolactinesecernerend, Prolactinoom&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Prolactinome, Adénome lactotrope, Adénome à prolactine, Adénome hypophysaire sécrétant la PRL, Adénome hypophysaire sécrétant la prolactine&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Adenom, prolaktinsezernierendes, Hypophysen-, Hypophysenadenom, prolaktinsezernierendes, PRL-sezernierendes Hypophysenadenom, Prolaktinom, Prolaktinproduzierendes Hypophysenadenom&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Prolactinoma, Adenoma Pituitário Secretor de PRL, Adenoma Pituitário Secretor de Prolactina, Adenoma Pituitário Secretório de Prl, Adenoma Pituitário Secretório de Prolactina&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Prolactinoma  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Prolactinoma</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Pituitary Disease</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;See Also&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pituitary/Hyprprlctnm.htm" class="LinkPage"&gt;Hyperprolactinemia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Gyn/Sx/Glctrh.htm" class="LinkPage"&gt;Galactorrhea&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Epidemiology&lt;ol&gt;&lt;li&gt;Most common pituitary tumor&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Symptoms&lt;ol&gt;&lt;li&gt;&lt;a href="../../Gyn/Sx/Glctrh.htm" class="LinkPage"&gt;Galactorrhea&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Gyn/Sx/Amnrh.htm" class="LinkPage"&gt;Amenorrhea&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Gyn/Endo/FmlInfrtlty.htm" class="LinkPage"&gt;Infertility&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Decreased libido&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Labs&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/Prlctn.htm" class="LinkPage"&gt;Serum Prolactin&lt;/a&gt; &amp;gt; 100 to 200 ng/ml&lt;ol&gt;&lt;li&gt;Microadenoma: &lt;a href="../../Endo/Lab/Prlctn.htm" class="LinkPage"&gt;Prolactin&lt;/a&gt; &amp;lt;200 ng/ml in most cases&lt;/li&gt;&lt;li&gt;Macroadenoma: &lt;a href="../../Endo/Lab/Prlctn.htm" class="LinkPage"&gt;Prolactin&lt;/a&gt; &amp;gt;200 ng/ml in most cases&lt;ol&gt;&lt;li&gt;Very large macroadenomas (&amp;gt;3 cm) may give false negative &lt;a href="../../Endo/Lab/Prlctn.htm" class="LinkPage"&gt;Serum Prolactin&lt;/a&gt; (Hook effect)&lt;/li&gt;&lt;li&gt;False negatives (Hook effect) result if &lt;a href="../../Endo/Lab/Prlctn.htm" class="LinkPage"&gt;Prolactin&lt;/a&gt; detecting &lt;a href="../../ID/Exam/Imnglbln.htm" class="LinkPage"&gt;Antibody&lt;/a&gt; is saturated by very high &lt;a href="../../Endo/Lab/Prlctn.htm" class="LinkPage"&gt;Prolactin&lt;/a&gt; levels&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Imaging&lt;ol&gt;&lt;li&gt;&lt;a href="../../Neuro/Rad/HdMgntcRsncImgng.htm" class="LinkPage"&gt;MRI Head&lt;/a&gt; with cone-down view of sella turcica&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Differential Diagnosis&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Endo/Pituitary/Hyprprlctnm.htm" class="LinkPage"&gt;Hyperprolactinemia&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Management&lt;ol&gt;&lt;li&gt;Macroadenoma (&amp;gt;1 cm in diameter)&lt;ol&gt;&lt;li&gt;Suprasellar (may compress optic chiasm)&lt;ol&gt;&lt;li&gt;&lt;a href="../../Gyn/Endo/FmlInfrtlty.htm" class="LinkPage"&gt;Infertility&lt;/a&gt;: &lt;a href="../../Endo/Pharm/DpmnAgnst.htm" class="LinkPage"&gt;Bromocriptine&lt;/a&gt; or Surgery&lt;/li&gt;&lt;li&gt;&lt;a href="../../Gyn/Sx/Amnrh.htm" class="LinkPage"&gt;Amenorrhea&lt;/a&gt;: &lt;a href="../../Endo/Pharm/DpmnAgnst.htm" class="LinkPage"&gt;Bromocriptine&lt;/a&gt; or &lt;a href="../../Endo/Pharm/DpmnAgnst.htm" class="LinkPage"&gt;Cabergoline&lt;/a&gt; or Surgery&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Intrasellar&lt;ol&gt;&lt;li&gt;&lt;a href="../../Gyn/Endo/FmlInfrtlty.htm" class="LinkPage"&gt;Infertility&lt;/a&gt;: &lt;a href="../../Endo/Pharm/DpmnAgnst.htm" class="LinkPage"&gt;Bromocriptine&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Gyn/Sx/Amnrh.htm" class="LinkPage"&gt;Amenorrhea&lt;/a&gt;: &lt;a href="../../Endo/Pharm/DpmnAgnst.htm" class="LinkPage"&gt;Bromocriptine&lt;/a&gt; or &lt;a href="../../Endo/Pharm/DpmnAgnst.htm" class="LinkPage"&gt;Cabergoline&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Microadenoma (&amp;lt;1 cm in diameter)&lt;ol&gt;&lt;li&gt;No treatment needed if &lt;a href="../../Gyn/Exam/MnstrlBldng.htm" class="LinkPage"&gt;Menses&lt;/a&gt; regular&lt;/li&gt;&lt;li&gt;&lt;a href="../../Gyn/Endo/FmlInfrtlty.htm" class="LinkPage"&gt;Infertility&lt;/a&gt;: &lt;a href="../../Endo/Pharm/DpmnAgnst.htm" class="LinkPage"&gt;Bromocriptine&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Gyn/Sx/Amnrh.htm" class="LinkPage"&gt;Amenorrhea&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/DpmnAgnst.htm" class="LinkPage"&gt;Bromocriptine&lt;/a&gt; (&lt;a href="../../Endo/Pharm/DpmnAgnst.htm" class="LinkPage"&gt;Parlodel&lt;/a&gt;) or&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/DpmnAgnst.htm" class="LinkPage"&gt;Cabergoline&lt;/a&gt; (&lt;a href="../../Endo/Pharm/DpmnAgnst.htm" class="LinkPage"&gt;Dostinex&lt;/a&gt;) or&lt;/li&gt;&lt;li&gt;&lt;a href="../../Gyn/Pharm/OrlCntrcptv.htm" class="LinkPage"&gt;Oral Contraceptive&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Molitch%20%20%5BAU%5D%20AND%202001%20%5BDP%5D%20AND%20%20Endocrinol%20Metab%20Clin%20North%20Am%20%20%5BTA%5D" class="LinkRef"&gt;Molitch (2001) Endocrinol Metab Clin North Am 30:585&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Schlechte%20%20%5BAU%5D%20AND%202003%20%5BDP%5D%20AND%20%20N%20Engl%20J%20Med%20%20%5BTA%5D" class="LinkRef"&gt;Schlechte (2003) N Engl J Med 349:2035-41&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0033375</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Pituitary/Prlctnm.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Prolactinoma</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Pituitary/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Prader-Willi Syndrome  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0032897"&gt;&lt;i&gt;C0032897&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A genetic syndrome caused by deletions or disruptions of chromosome 15. It is characterized by reduced fetal activity, mental retardation, hypotonia, short stature, and hypogonadism.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MEDLINEPLUS)&lt;/td&gt;
                &lt;td&gt;
                  &lt;span&gt;
                    &lt;p&gt;Prader-Willi Syndrome (PWS) is an uncommon genetic disorder. It causes poor muscle tone, low levels of sex hormones and a constant feeling of hunger. The part of the brain that controls feelings of fullness or hunger does not work properly in people with PWS. They overeat, leading to obesity.&lt;/p&gt;
                    &lt;p&gt;Babies with PWS are usually floppy, with poor muscle tone, and have trouble sucking. Boys may have undescended testicles. Later, other signs appear. These include&lt;/p&gt;
                    &lt;ul&gt;&lt;li&gt;	Short stature&lt;/li&gt;
                      &lt;li&gt;	Poor motor skills&lt;/li&gt;
                      &lt;li&gt;	Weight gain &lt;/li&gt;
                      &lt;li&gt;Underdeveloped sex organs&lt;/li&gt;
                      &lt;li&gt;	Mild mental retardation and learning disabilities&lt;/li&gt;
                    &lt;/ul&gt;&lt;p&gt;There is no cure for PWS. Growth hormone and exercise can help build muscle mass and control weight. &lt;/p&gt;
                    &lt;p style="font-weight:bold;font-style:italic;"&gt;NIH: National Institute of Child Health and Human Development&lt;/p&gt;
                  &lt;/span&gt;
                &lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (JABL)&lt;/td&gt;
                &lt;td&gt;A syndrome characterized at birth by the lack of spontaneous movements and protective reflexes, thus giving an appearance of severe brain damage. Profound hypotonia may cause asphyxia. Sucking and swallowing reflexes are absent or decreased. Deficient thermoregulation, amyotonia, and hypogonadism are usually associated. After a few weeks or months, the affected infants become more responsive and more alert. Areflexia disappears gradually but hypotonia may persist longer. This phase is marked mainly by mental subnormality, delayed growth and motor development, speech defect, lack of emotional control, voracious appetite leading to obesity, hypotonia, hyperlaxity, delayed bone maturation, and multiple orofacial and other disoders. There is a tendency to develop diabetes mellitus and cardiac failure in some patients. Pain insensitivity is common. Prader-Willi habitus associated with osteopenia and camptodactyly is known as the Urban-Rogers-Meyer syndrome.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;An autosomal dominant disorder caused by deletion of the proximal long arm of the paternal chromosome 15 (15q11-q13) or by inheritance of both of the pair of chromosomes 15 from the mother (UNIPARENTAL DISOMY) which are imprinted (GENETIC IMPRINTING) and hence silenced. Clinical manifestations include MENTAL RETARDATION; MUSCULAR HYPOTONIA; HYPERPHAGIA; OBESITY; short stature; HYPOGONADISM; STRABISMUS; and HYPERSOMNOLENCE. (Menkes, Textbook of Child Neurology, 5th ed, p229)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CSP)&lt;/td&gt;
                &lt;td&gt;congenital neurobehavioral disorder characterized by rounded face, low forehead, almond shaped eyes, squinting, hypogonadism, hypotonia, insatiable appetite leading to obesity, and mental retardation; chromosomal disorder usually associated with a deletion of the proximal portion of the long arm of chromosome 15.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Congenital Abnormality (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0032897&amp;amp;tui=T019"&gt;&lt;i&gt;T019&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D011218&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD9&lt;/td&gt;
                &lt;td&gt;759.81&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD10&lt;/td&gt;
                &lt;td&gt;Q87.1&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;89392001, 205794007&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Prader-Willi Syndrome, Syndrome, Prader-Willi, OBESITY-CRYPTORCHIDISM-DWARFISM-SUBNORMAL MENTALITY SYNDROME, Prader Willi syndrome, PWS, PRADER-WILLI SYNDROME, PRADER-LABHART-WILLI SYNDROME, Prader-Willi syndrome (diagnosis), PRADER WILLI SYNDROME, Labhart Willi Prader Fanconi Syndrome, Labhart-Willi-Prader-Fanconi Syndrome, Syndrome, Labhart-Willi-Prader-Fanconi, Labhart Willi Syndrome, Labhart-Willi Syndrome, Syndrome, Labhart-Willi, Prader-willi syndrome, Syndrome, Willi-Prader, Willi Prader Syndrome, Willi-Prader Syndrome, Prader Labhart Willi Syndrome, cardiorespiratory syndrome of obesity in child, hypogenital dystrophy with diabetic tendency syndrome, Prader-Labhart-Willi-Fanconi syndrome, H2O syndrome, hypotonia-hypopigmentia-hypogonadism-obesity (HHHO) syndrome, hypotonia-hypopigmentia-hypogonadism-obesity syndrome, hypotonia-obesity-hypogonadism-mental retardation syndrome, hypotonia-hypogonadism-obesity syndrome, Prader-Labhart-Willi (PLW) syndrome (PLWS), Prader-Labhart-Willi syndrome, Prader-Willi syndrome (PWS), Prader-Willi Syndrome [Disease/Finding], syndrome prader-willi, prader syndrome willy, prader willis syndrome, prader willi syndrome, prader syndrome willis, prader willi syndromes, syndrome willi prader, prader syndrome willi, prader willies syndrome, prader syndrome willies, prader willy syndrome, prader-willi syndrome, willi prader syndrome, Prader-Willi syndrome, Prader-Willi syndrome (disorder), Prader-Willi, Prader - Willi syndrome, Prader Willi Syndrome&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;プラダーウィリ症候群, ﾌﾟﾗﾀﾞｰｳｨﾘｼｮｳｺｳｸﾞﾝ, プラダー･ウィリ症候群, プラーダー-ヴィリ症候群, プラーダー･ウィリ症候群, プラーダー･ウィリー症候群, プラーダー･ヴィリ症候群, Prader-Willi症候群&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Prader-Willis syndrom&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;Praderové-Williho syndrom, Prader-Williho syndrom&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;Prader-Willi Syndrome, Prader - Willi syndrome, Prader-Willi syndrome, síndrome de Prader - Willi (trastorno), síndrome de Prader - Willi, Sindrome de Prader-Willi, Síndrome de Labhart-Willi, Síndrome de Prader-Willi, Sindrome de Labhart-Willi&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Prader-Willin oireyhtymä&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;PRADERA-VILLI SINDROM, ПРАДЕРА-ВИЛЛИ СИНДРОМ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Sindrome di Labhart-Willi, Sindrome di Prader-Labhart-Willi-Fanconi, Sindrome di Prader-Willi&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Croatian&lt;/td&gt;
                &lt;td&gt;PRADER-WILLIJEV SINDROM&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;SPW (Syndrome de Prader-Willi), Syndrome de Prader-Willi, Syndrome de Prader-Labhart-Willi&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Zespół Pradera-Williego&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;Prader-Willi-syndroma&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;syndroom van Prader-Willi, Prader-Willi-syndroom, Syndroom, Prader-Willi-&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Prader-Willi Syndrom, Prader-Labhart-Willi-Fanconi-Syndrom, Prader-Willi-Syndrom, Labhart-Willi-Syndrom&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Síndrome de Labhart-Willi, Síndrome de Prader-Willi&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Prader-Willi Syndrome  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Prader-Willi Syndrome</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Pediatrics</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Epidemiology&lt;ol&gt;&lt;li&gt;&lt;a href="../../Prevent/Epi/DsIncdncRt.htm" class="LinkPage"&gt;Incidence&lt;/a&gt;: 1 in 16,000 births&lt;/li&gt;&lt;li&gt;Most common form of genetic syndrome related &lt;a href="../../Endo/Obesity/Obsty.htm" class="LinkPage"&gt;Obesity&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Pathophysiology&lt;ol&gt;&lt;li&gt;Associated with defect on long arm of chromosome 15&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Signs&lt;ol&gt;&lt;li&gt;Newborn&lt;ol&gt;&lt;li&gt;Hypotonia&lt;/li&gt;&lt;li&gt;Poor sucking reflex&lt;/li&gt;&lt;li&gt;Diminished cry&lt;/li&gt;&lt;li&gt;Somnolence&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Infant&lt;ol&gt;&lt;li&gt;Feeding difficulties and &lt;a href="../../Endo/Peds/FlrTThrv.htm" class="LinkPage"&gt;Failure to Thrive&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Increased eating starts after 1 year&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Early childhood (ages 1 to 6)&lt;ol&gt;&lt;li&gt;Hyperphagia&lt;/li&gt;&lt;li&gt;Rapid weight gain&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Classic dysmorphic facial features&lt;ol&gt;&lt;li&gt;Narrow face at temples&lt;/li&gt;&lt;li&gt;Almond shaped eyes&lt;/li&gt;&lt;li&gt;Mouth corners turn downward&lt;/li&gt;&lt;li&gt;Narrow nasal bridge&lt;/li&gt;&lt;li&gt;&lt;a href="../../Eye/Peds/Strbsms.htm" class="LinkPage"&gt;Strabismus&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Thin upper lip&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Other features&lt;ol&gt;&lt;li&gt;Morbid &lt;a href="../../Endo/Obesity/Obsty.htm" class="LinkPage"&gt;Obesity&lt;/a&gt; (onset after 12 months)&lt;/li&gt;&lt;li&gt;Developmental delay and learning disabilities&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Growth/ShrtStr.htm" class="LinkPage"&gt;Short Stature&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Sex/Hypgndsm.htm" class="LinkPage"&gt;Hypogonadism&lt;/a&gt; (e.g. &lt;a href="../../Uro/Peds/UndscndTstcl.htm" class="LinkPage"&gt;Cryptorchidism&lt;/a&gt;, small &lt;a href="../../Uro/Anatomy/Tstcl.htm" class="LinkPage"&gt;Testes&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;Skin &lt;a href="../../Derm/Exam/SknLsnSldWht.htm" class="LinkPage"&gt;Hypopigmentation&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Labs: Genetic testing&lt;ol&gt;&lt;li&gt;Indications: All suspected cases of Prader-Willi&lt;/li&gt;&lt;li&gt;&lt;a href="../../Prevent/Epi/TstSnstvty.htm" class="LinkPage"&gt;Test Sensitivity&lt;/a&gt;: 100%&lt;/li&gt;&lt;li&gt;Tests (both are done)&lt;ol&gt;&lt;li&gt;High resolution karyotype&lt;/li&gt;&lt;li&gt;Methylation analysis (specific for PWS)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Associated conditions&lt;ol&gt;&lt;li&gt;&lt;a href="../../Lung/Apnea/SlpApn.htm" class="LinkPage"&gt;Sleep Apnea&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Management&lt;ol&gt;&lt;li&gt;Consultations&lt;ol&gt;&lt;li&gt;Ophthalmology for &lt;a href="../../Eye/Peds/Strbsms.htm" class="LinkPage"&gt;Strabismus&lt;/a&gt; and &lt;a href="../../Eye/Vision/Myp.htm" class="LinkPage"&gt;Myopia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Pediatric endocrinology for possible &lt;a href="../../Endo/Pharm/HmnGrwthHrmn.htm" class="LinkPage"&gt;Growth Hormone&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Developmental pediatrician&lt;/li&gt;&lt;li&gt;Speech therapy&lt;/li&gt;&lt;li&gt;Physical therapy and occupational therapy&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Conditions to observe for and manage&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Peds/FlrTThrv.htm" class="LinkPage"&gt;Failure to Thrive&lt;/a&gt; as infant&lt;/li&gt;&lt;li&gt;Hypoventilation&lt;/li&gt;&lt;li&gt;Respiratory infections&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Preventive strategies&lt;ol&gt;&lt;li&gt;Closely supervise dietary intake&lt;/li&gt;&lt;li&gt;Daily &lt;a href="../../Sports/Exercise/Exrcs.htm" class="LinkPage"&gt;Physical Activity&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Resources&lt;ol&gt;&lt;li&gt;Prader-Willi Syndrome Association&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.pwsausa.org" class="LinkWebExt"&gt;http://www.pwsausa.org&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Wattendorf%20%20%5BAU%5D%20AND%202005%20%5BDP%5D%20AND%20%20Am%20Fam%20Physician%20%20%5BTA%5D" class="LinkRef"&gt;Wattendorf (2005) Am Fam Physician 72(5):827-30&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Wigren%20%20%5BAU%5D%20AND%202003%20%5BDP%5D%20AND%20%20Child%20Care%20Health%20Dev%20%20%5BTA%5D" class="LinkRef"&gt;Wigren (2003) Child Care Health Dev 29:449-56&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0032897</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Peds/PrdrWlSyndrm.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Prader-Willi Syndrome</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Peds/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees></FP_UMLS_Trees><FP_Condition_name_check></FP_Condition_name_check><FP_Condition_name><value>True Hermaphroditism</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Sexual Development</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Pathophysiology&lt;ol&gt;&lt;li&gt;Karyotype most often 46XX&lt;/li&gt;&lt;li&gt;Y DNA translocated to X&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Signs&lt;ol&gt;&lt;li&gt;Ambiguous internal and external genitalia&lt;/li&gt;&lt;li&gt;Microscopic evidence of ovaries and &lt;a href="../../Uro/Anatomy/Tstcl.htm" class="LinkPage"&gt;Testes&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Sex/TrHrmphrdtsm.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: True Hermaphroditism</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Sex/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Congenital Hypothyroidism  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0010308"&gt;&lt;i&gt;C0010308&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A deficiency of thyroid hormone present at birth. The etiology can be genetic or environmental, or a combination of both; treatment is based on severity and causality.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CSP)&lt;/td&gt;
                &lt;td&gt;condition due to congenital lack of thyroid hormone, marked by arrested physical and mental development, dystrophy of the bones and soft parts, and lowered basal metabolism; it is the congenital form of thyroid deficiency, while myxedema is the acquired form.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;A condition in infancy or early childhood due to an in-utero deficiency of THYROID HORMONES that can be caused by genetic or environmental factors, such as thyroid dysgenesis or HYPOTHYROIDISM in infants of mothers treated with THIOURACIL during pregnancy. Endemic cretinism is the result of iodine deficiency. Clinical symptoms include severe MENTAL RETARDATION, impaired skeletal development, short stature, and MYXEDEMA.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Congenital Abnormality (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0010308&amp;amp;tui=T019"&gt;&lt;i&gt;T019&lt;/i&gt;&lt;/a&gt;)
, Disease or Syndrome (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0010308&amp;amp;tui=T047"&gt;&lt;i&gt;T047&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D003409&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD9&lt;/td&gt;
                &lt;td&gt;243&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD10&lt;/td&gt;
                &lt;td&gt;E03.1&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;3614006, 190273009, 154661001, 75065003, 267376007, 190268003, 217710005, 154660000, 267465007&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;CRETINISM, CRETINISM, INFANTILE, HYPOTHYROIDISM CONGENITAL, HYPOTHYROIDISM, CONGENITAL, HYPOTHYROIDISM, INFANTILE, Cretinism, NOS, Congen hypothy not iodine def, Congenital hypothyroidism NOS, CONGEN HYPOTHYROIDISM, CHT - Congenit hypothyroidism, Hypothyroidism, congenital, congenital hypothyroidism (diagnosis), congenital hypothyroidism, Cretinism (disorder), Congenital hypothyroidism: [cretinism] or [NOS] (disorder), Hypothyroidism congenital, Congenital hypothyroidsm, Congenital hypothyroidism NOS (disorder), Congenital Hypothyroidism [Disease/Finding], infantile hypothyroidism, Hypothyroidism;congenital, hypothyroidism congenital, Congenital Hypothyroidism, Congenital hypothyroidism, Infantile hypothyroidism, Congenital hypothyroidism not due to iodine deficiency, Congenital goiter, Congenital goitre, CHT - Congenital hypothyroidism, Congenital hypothyroidism (disorder), congenital; hypothyroidism, cretin; type hypothyroid, cretin, hypothyroid; cretin (type), hypothyroidism; congenital, insufficiency; thyroid, congenital, thyroid; insufficiency, congenital, Congenital hypothyroidism: [cretinism] or [NOS], Cretinism (disorder) [Ambiguous], Congenital thyroid insufficiency, Goitrous cretinism, Cretinism, Hypothyroidism, Congenital, cretinism&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;cretinisme, congenitale hypothyroïdie, congenitaal; hypothyroïdie, cretin; type hypothyreotisch, hypothyreotisch; cretin (type), hypothyroïdie; congenitaal, insufficiëntie; schildklier, congenitaal, schildklier; insufficiëntie, congenitaal, hypothyreoïdie, congenitaal, Cretinisme, Myxoedeem, congenitaal&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Hypothyroïdisme congénital, HYPOTHYROIDIE CONGENITALE, Crétinisme, Hypothyroïdie congénitale&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Kretinismuns, Hypothyreose kongenital, HYPOTHYREOSE KONGENITAL, kongenitale Hypothyreose, Kretinismus, Angeborene Hypothyreose, Kongenitale Hypothyreose&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Medfödd hypotyreos&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;ｸﾚﾁﾝﾋﾞｮｳ, ｾﾝﾃﾝｾｲｺｳｼﾞｮｳｾﾝｷﾉｳﾃｲｶｼｮｳ, 地方病性クレチン症, 粘液水腫-先天性, クレチン症, クレチニスム, 甲状腺機能低下症-先天性, 粘液水腫-乳児, 先天性甲状腺機能低下症, クレチン病, 乳児粘液水腫, 先天性粘液水腫&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;kretenismus, kongenitální hypotyreoidismus, Vrozená hypotyreóza, Hypotyreóza vrozená, Kretinismus&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;Cretinism, Congenital hypothyroidism: [cretinism] or [NOS], Congenital hypothyroidism, Congenital hypothyroidism NOS, Congenital thyroid insufficiency, HIPOTIROIDISMO CONGENITO, cretinismo (concepto no activo), cretinismo (trastorno), cretinismo, hipotiroidismo congénito (trastorno), hipotiroidismo congénito no debido a la deficiencia de yodo, hipotiroidismo congénito, SAI (trastorno), hipotiroidismo congénito, SAI, hipotiroidismo congénito, hipotiroidismo infantil, Hipotiroidismo congénito, Cretinismo, Hipotiroidismo Congenito, Hipotiroidismo Congénito&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Kretinismi&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;VROZHDENNYI GIPOTIREOZ, FAGGE BOLEZN', MIKSEDEMA VROZHDENNAIA, KRETINIZM, GIPOTIREOZ VROZHDENNYI, МИКСЕДЕМА ВРОЖДЕННАЯ, ФАГГЕ БОЛЕЗНЬ, ГИПОТИРЕОЗ ВРОЖДЕННЫЙ, КРЕТИНИЗМ, ВРОЖДЕННЫЙ ГИПОТИРЕОЗ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;HIPOTIROIDISMO CONGENITO, Hipotiroidismo congénito, Cretinismo Endêmico Tipo Mixedematoso, Cretinismo, Hipotireoidismo Congênito&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Obrzęk śluzowaty wrodzony, Niedoczynność tarczycy wrodzona, Kretynizm&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;Veleszületett hypothyreosis, Cretinizmus&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Cretinismo, Ipotiroidismo congenito&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Congenital Hypothyroidism  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Infantile Hypothyroidism</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Neonatology</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;See Also&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/Hypthyrdsm.htm" class="LinkPage"&gt;Hypothyroidism&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../NICU/Lab/NwbrnScrn.htm" class="LinkPage"&gt;Newborn Screening&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Pathophysiology&lt;ol&gt;&lt;li&gt;Congenital &lt;a href="../../Endo/Thyroid/Hypthyrdsm.htm" class="LinkPage"&gt;Hypothyroidism&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Causes&lt;ol&gt;&lt;li&gt;Enzymatic defect&lt;/li&gt;&lt;li&gt;Idodine deficiency&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Signs&lt;ol&gt;&lt;li&gt;Dwarfism&lt;/li&gt;&lt;li&gt;Yellow dry thick skin&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Obesity/Obsty.htm" class="LinkPage"&gt;Overweight&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Thick lips and &lt;a href="../../ENT/Anatomy/Tng.htm" class="LinkPage"&gt;Tongue&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Short hands with thick fingers&lt;/li&gt;&lt;li&gt;Delayed deciduous &lt;a href="../../Dental/Exam/Dntn.htm" class="LinkPage"&gt;Dentition&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Prevent/HME/HlthCrFrAdltsWthDvlpmntlDly.htm" class="LinkPage"&gt;Mental Retardation&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Delayed &lt;a href="../../Endo/Exam/SxlDvlpmnt.htm" class="LinkPage"&gt;Sexual Development&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Slow Movement&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Labs&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Endo/Thyroid/Hypthyrdsm.htm" class="LinkPage"&gt;Hypothyroidism&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0010308</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/NICU/InfntlHypthyrdsm.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Infantile Hypothyroidism, Neonatal Hypothyroidism, Hypothyroidism in Infants, Cretinism</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/NICU/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Diabetic Nephropathy  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0011881"&gt;&lt;i&gt;C0011881&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;Progressive kidney disorder caused by vascular damage to the glomerular capillaries, in patients with diabetes mellitus. It is usually manifested with nephritic syndrome and glomerulosclerosis.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MEDLINEPLUS)&lt;/td&gt;
                &lt;td&gt;
                  &lt;span&gt;
                    &lt;p&gt;If you have &lt;a href="http://www.nlm.nih.gov/medlineplus/diabetes.html"&gt;diabetes&lt;/a&gt;, your blood sugar levels are too high.  Over time, this can damage your kidneys. Your kidneys are filters that clean your blood. If they are damaged, waste and fluids build up in your blood instead of leaving your body.&lt;/p&gt;
                    &lt;p&gt;Kidney damage from diabetes is called diabetic nephropathy.  It begins long before you have symptoms. An early sign of it is small amounts of protein in your urine. A urine test can detect it. A blood test can also help determine how well your kidneys are working.&lt;/p&gt;
                    &lt;p&gt;If the damage continues, your kidneys could fail. In fact, diabetes is the most common cause of &lt;a href="http://www.nlm.nih.gov/medlineplus/kidneyfailure.html"&gt;kidney failure&lt;/a&gt; in the United States. People with kidney failure need either &lt;a href="http://www.nlm.nih.gov/medlineplus/dialysis.html"&gt;dialysis&lt;/a&gt; or a &lt;a href="http://www.nlm.nih.gov/medlineplus/kidneytransplantation.html"&gt;kidney transplant&lt;/a&gt;.&lt;/p&gt;
                    &lt;p&gt;You can slow down kidney damage or keep it from getting worse. Controlling your blood sugar and blood pressure, taking your medicines and not eating too much &lt;a href="http://www.nlm.nih.gov/medlineplus/dietaryproteins.html"&gt;protein&lt;/a&gt; can help.&lt;/p&gt;
                    &lt;p style="font-weight:bold;font-style:italic;"&gt;NIH:  National Institute of Diabetes and Digestive and Kidney Diseases&lt;/p&gt;
                  &lt;/span&gt;
                &lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;KIDNEY injuries associated with diabetes mellitus and affecting KIDNEY GLOMERULUS; ARTERIOLES; KIDNEY TUBULES; and the interstitium. Clinical signs include persistent PROTEINURIA, from microalbuminuria progressing to ALBUMINURIA of greater than 300 mg/24 h, leading to reduced GLOMERULAR FILTRATION RATE and END-STAGE RENAL DISEASE.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CSP)&lt;/td&gt;
                &lt;td&gt;kidney disease and resultant kidney function impairment due to the long standing effects of diabetes on the microvasculature (glomerulus) of the kidney; features include increased urine protein and declining kidney function.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Disease or Syndrome (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0011881&amp;amp;tui=T047"&gt;&lt;i&gt;T047&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D003928&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD9&lt;/td&gt;
                &lt;td&gt;250.4&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;21858001, 127013003, 54181000, 197605007, 190338009, 267470000, 60009009&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Diabetic Nephropathies, Nephropathies, Diabetic, Diabetes with renal manifestations, DIABETIC NEPHROPATHY, Diabetic nephropathies, Nephropathy, Diabetic, Diabetic nephropathy syndrome, Nephrotic syndrome+diabetes M., Diabetes with renal manifestations (disorder), Renal disorder associated with diabetes mellitus, diabetic nephropathy, diabetic nephropathy (diagnosis), Diabetic Kidney Problems, Diabetic nephropathy NOS, DIABETIC RENAL MANIFESTATION, NEPHROPATHY DIABETIC, Diabetic Nephropathies [Disease/Finding], diabetic nephropathi, Nephropathy;diabetic, diabetic nephropathies, nephropathy diabetic, diabetic renal disease, diabetes with renal manifestations (diagnosis), diabetes with renal manifestations, Diabetes-nephrosis syndrome, Diabetic nephropathy, Nephrotic syndrome in diabetes mellitus, Diabetic renal disease, Diabetes-nephrosis syndrome (disorder), Diabetic renal disease (disorder), Nephrotic syndrome in diabetes mellitus (disorder), diabetes; nephropathy (manifestation), diabetes; nephrosis (manifestation), nephropathy; diabetes (manifestation), nephrosis; diabetes (manifestation), Diabetes + nephropathy, Nephropathy - diabetic, Diabetic Nephropathy, Diabetic Kidney Diseases, Diabetic Kidney Disease, Kidney Disease, Diabetic, Kidney Diseases, Diabetic&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;trastorno renal asociado con diabetes mellitus, Nefropatía diabética NEOM, Enfermedad renal diabética, Diabetes con manifestaciones renales, diabetes con manifestaciones renales (trastorno), diabetes con manifestaciones renales, Diabetic nephropathy, Diabetes + nephropathy, Nephropathy - diabetic, enfermedad renal diabética, nefropatía diabética (trastorno), nefropatía diabética, síndrome de diabetes - nefrosis (trastorno), síndrome de diabetes - nefrosis, síndrome nefrótico en diabetes mellitus (trastorno), síndrome nefrótico en diabetes mellitus, Nefropatía diabética, Nefropatías Diabéticas, Nefropatias Diabeticas&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;diabetische nierziekte, diabetische nefropathie NAO, diabetes met renale manifestaties, diabetes; nefropathie, diabetes; nefrose, nefropathie; diabetes, nefrose; diabetes, diabetische nefropathie, Diabetische nefropathie, Nefropathie, diabetische, Diabetische nefropathieën, Nefropathieën, diabetische&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Diabète avec manifestations rénales, Néphropathie diabétique SAI, Néphropathie diabétique, Néphropathies diabétiques, Maladie rénale diabétique&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;diabetische Nierenerkrankung, Diabetes mit renalen Manifestationen, diabetische Nephropathie NNB, diabetische Nephropathie, Diabetische Nephropathien&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Nefropatia diabetica NAS, Diabete con manifestazioni renali, Nefropatia diabetica, Nefropatie diabetiche&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Nefropatia diabética NE, Doença renal diabética, Diabetes com manifestações renais, Glomeruloesclerose Diabética, Nefropatia diabética, Nefropatias Diabéticas&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;糖尿病性腎症ＮＯＳ, 腎症状をともなう糖尿病, ﾄｳﾆｮｳﾋﾞｮｳｾｲｼﾞﾝｼｮｳNOS, ｼﾞﾝｼｮｳｼﾞｮｳｦﾄﾓﾅｳﾄｳﾆｮｳﾋﾞｮｳ, ﾄｳﾆｮｳﾋﾞｮｳｾｲｼﾞﾝｼｮｳ, 糖尿病性ネフロパシー, 糖尿病性腎障害, 糖尿病ネフロパシー, 糖尿病腎症, 糖尿病性腎症&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Diabetiska njursjukdomar&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;diabetické nefropatie, Diabetická nefropatie, Diabetes mellitus s postižením ledvin, Diabetická nefropatie NOS, diabetické onemocnění ledvin&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Diabeettiset nefropatiat&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;GLOMERULOSKLEROZ DIABETICHESKII, GLOMERULOSKLEROZ INTERKAPILLIARNYI, DIABETICHESKIE NEFROPATII, ГЛОМЕРУЛОСКЛЕРОЗ ДИАБЕТИЧЕСКИЙ, ГЛОМЕРУЛОСКЛЕРОЗ ИНТЕРКАПИЛЛЯРНЫЙ, ДИАБЕТИЧЕСКИЕ НЕФРОПАТИИ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Croatian&lt;/td&gt;
                &lt;td&gt;DIJABETIČNE NEFROPATIJE&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Nefropatie cukrzycowe&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;diabeteses vesebetegség, Diabetes veseérintettséggel, diabeteses nephropathia k.m.n., diabeteses nephropathia&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Diabetic Nephropathy  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Diabetic Nephropathy</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Nephrology</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Epidemiology&lt;ol&gt;&lt;li&gt;&lt;a href="../../Uro/Lab/UrnMcrlbmn.htm" class="LinkPage"&gt;Urine Microalbumin&lt;/a&gt;uria and &lt;a href="../../Uro/Lab/UrnMcrlbmn.htm" class="LinkPage"&gt;Macroalbuminuria&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../Prevent/Epi/DsPrvlncRt.htm" class="LinkPage"&gt;Prevalence&lt;/a&gt; in &lt;a href="../../Endo/DM/DbtsMlts.htm" class="LinkPage"&gt;Diabetes Mellitus&lt;/a&gt;: 35%&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Stage 2-3 &lt;a href="../../Renal/Failure/ChrncRnlFlr.htm" class="LinkPage"&gt;Chronic Kidney Disease&lt;/a&gt; in &lt;a href="../../Endo/DM/DbtsMlts.htm" class="LinkPage"&gt;Diabetes Mellitus&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Stage 2-3 CKD &lt;a href="../../Prevent/Epi/DsPrvlncRt.htm" class="LinkPage"&gt;Prevalence&lt;/a&gt;: 29% of those with Diabetes (2010)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Stage 4-5 &lt;a href="../../Renal/Failure/ChrncRnlFlr.htm" class="LinkPage"&gt;Chronic Kidney Disease&lt;/a&gt; (&lt;a href="../../Renal/Failure/ChrncRnlFlr.htm" class="LinkPage"&gt;ESRD&lt;/a&gt;) in &lt;a href="../../Endo/DM/DbtsMlts.htm" class="LinkPage"&gt;Diabetes Mellitus&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/DM/DbtsMlts.htm" class="LinkPage"&gt;Diabetes Mellitus&lt;/a&gt; accounts for 44% of all new cases of &lt;a href="../../Renal/Failure/ChrncRnlFlr.htm" class="LinkPage"&gt;ESRD&lt;/a&gt; in United States (2008)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Prevent/Epi/DsPrvlncRt.htm" class="LinkPage"&gt;Prevalence&lt;/a&gt;: Over 200,000 cases of &lt;a href="../../Renal/Failure/ChrncRnlFlr.htm" class="LinkPage"&gt;ESRD&lt;/a&gt; in &lt;a href="../../Endo/DM/DbtsMlts.htm" class="LinkPage"&gt;Diabetes Mellitus&lt;/a&gt; in United States (2008)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Prevent/Epi/DsIncdncRt.htm" class="LinkPage"&gt;Incidence&lt;/a&gt;: Approximately 48,000 new cases of Diabetes related &lt;a href="../../Renal/Failure/ChrncRnlFlr.htm" class="LinkPage"&gt;ESRD&lt;/a&gt; annually in United States (2008)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Risk Factors: Microlbuminuria&lt;ol&gt;&lt;li&gt;&lt;a href="../../CV/Htn/Hyprtnsn.htm" class="LinkPage"&gt;Hypertension&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Higher average &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Serum Glucose&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Lipid/Hyprchlstrlm.htm" class="LinkPage"&gt;Hyperlipidemia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Psych/CD/Cgrt.htm" class="LinkPage"&gt;Tobacco&lt;/a&gt; abuse&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/DM/TypDbtsMlts1.htm" class="LinkPage"&gt;Type II Diabetes Mellitus&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Even more than &lt;a href="../../Endo/DM/TypDbtsMlts.htm" class="LinkPage"&gt;Type I Diabetes Mellitus&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Ethnic groups with higher risk of developing &lt;a href="../../Uro/Lab/UrnMcrlbmn.htm" class="LinkPage"&gt;Microalbuminuria&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Native american&lt;/li&gt;&lt;li&gt;Asian&lt;/li&gt;&lt;li&gt;Hispanic&lt;/li&gt;&lt;li&gt;Black&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Precaution&lt;ol&gt;&lt;li&gt;Worsening &lt;a href="../../Renal/Lab/RnlFnctn.htm" class="LinkPage"&gt;Renal Function&lt;/a&gt; may present with sudden improvement in glycemic control or &lt;a href="../../Endo/Hypoglycemia/Hypglycm.htm" class="LinkPage"&gt;Hypoglycemia&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Pathophysiology: Nephropathy progression&lt;ol&gt;&lt;li&gt;Step 1: Incipient Nephropathy phase&lt;ol&gt;&lt;li&gt;&lt;a href="../../Uro/Lab/UrnMcrlbmn.htm" class="LinkPage"&gt;Microalbuminuria&lt;/a&gt; (low levels of albumin) present&lt;/li&gt;&lt;li&gt;&lt;a href="../../Uro/Lab/UrnPrtn.htm" class="LinkPage"&gt;Urine Albumin&lt;/a&gt; levels gradually rise during this phase&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Step 2: Overt Nephropathy phase&lt;ol&gt;&lt;li&gt;&lt;a href="../../Uro/Lab/UrnPrtn.htm" class="LinkPage"&gt;Urine Albumin&lt;/a&gt; &amp;gt;300 mg/24 hours&lt;/li&gt;&lt;li&gt;Hyperfiltration transiently occurs&lt;ol&gt;&lt;li&gt;Glomerular filtration (&lt;a href="../../Renal/Lab/CrtnClrnc.htm" class="LinkPage"&gt;Creatinine Clearance&lt;/a&gt;) rises&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Step 3: Renal Insufficiency&lt;ol&gt;&lt;li&gt;Glomerular filtration (&lt;a href="../../Renal/Lab/CrtnClrnc.htm" class="LinkPage"&gt;Creatinine Clearance&lt;/a&gt;) falls&lt;/li&gt;&lt;li&gt;Ultimately &lt;a href="../../Renal/Failure/ActRnlFlr.htm" class="LinkPage"&gt;Renal Failure&lt;/a&gt; ensues&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Protocol: Monitoring&lt;ol&gt;&lt;li&gt;Initiating monitoring&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/DM/TypDbtsMlts.htm" class="LinkPage"&gt;Type I Diabetes Mellitus&lt;/a&gt;: 5 years after diagnosis&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/DM/TypDbtsMlts1.htm" class="LinkPage"&gt;Type II Diabetes Mellitus&lt;/a&gt;: Start at time of diagnosis&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Labs&lt;ol&gt;&lt;li&gt;Spot &lt;a href="../../Uro/Lab/UrnPrtnTCrtnRt.htm" class="LinkPage"&gt;Urine Albumin to Creatinine Ratio&lt;/a&gt; (random &lt;a href="../../Uro/Lab/UrnMcrlbmn.htm" class="LinkPage"&gt;Urine Microalbumin&lt;/a&gt;)&lt;ol&gt;&lt;li&gt;Obtain every 6-12 months&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Renal/Lab/SrmCrtn.htm" class="LinkPage"&gt;Serum Creatinine&lt;/a&gt; with estimated GFR&lt;ol&gt;&lt;li&gt;Obtain every 6-12 months&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Labs: &lt;a href="../../Uro/Lab/UrnMcrlbmn.htm" class="LinkPage"&gt;Urine Microalbumin&lt;/a&gt;&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Uro/Lab/UrnMcrlbmn.htm" class="LinkPage"&gt;Urine Microalbumin&lt;/a&gt; (&lt;a href="../../Uro/Lab/UrnPrtnTCrtnRt.htm" class="LinkPage"&gt;Urine Albumin to Creatinine Ratio&lt;/a&gt;) for diagnostic criteria&lt;/li&gt;&lt;li&gt;Nephropathy diagnosis needs 2 of 3 samples positive&lt;/li&gt;&lt;li&gt;Spot &lt;a href="../../Uro/Lab/UrnPrtnTCrtnRt.htm" class="LinkPage"&gt;Urine Albumin to Creatinine Ratio&lt;/a&gt; (first morning void preferred)&lt;ol&gt;&lt;li&gt;&lt;a href="../../Uro/Lab/UrnMcrlbmn.htm" class="LinkPage"&gt;Microalbuminuria&lt;/a&gt;: 30-300 mcg/mg &lt;a href="../../Renal/Lab/SrmCrtn.htm" class="LinkPage"&gt;Creatinine&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Uro/Lab/UrnMcrlbmn.htm" class="LinkPage"&gt;Macroalbuminuria&lt;/a&gt;: &amp;gt;300 mcg/mg &lt;a href="../../Renal/Lab/SrmCrtn.htm" class="LinkPage"&gt;Creatinine&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Imaging: Renal &lt;a href="../../Rad/Ultrasound/Ultrsnd.htm" class="LinkPage"&gt;Ultrasound&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Evaluation for reversible causes of &lt;a href="../../Renal/Anatomy/RnlAntmy.htm" class="LinkPage"&gt;Kidney&lt;/a&gt; disease&lt;/li&gt;&lt;li&gt;Indications&lt;ol&gt;&lt;li&gt;New onset &lt;a href="../../Renal/Failure/ChrncRnlFlr.htm" class="LinkPage"&gt;Chronic Kidney Disease&lt;/a&gt;&lt;/li&gt;&lt;li&gt;New onset &lt;a href="../../Uro/Lab/UrnMcrlbmn.htm" class="LinkPage"&gt;Microalbuminuria&lt;/a&gt; or &lt;a href="../../Uro/Lab/UrnMcrlbmn.htm" class="LinkPage"&gt;Macroalbuminuria&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Diagnostics: Biopsy&lt;ol&gt;&lt;li&gt;Indications: Unclear diagnosis (see precautions below)&lt;/li&gt;&lt;li&gt;Findings suggestive of classic Diabetic Nephropathy&lt;ol&gt;&lt;li&gt;Light microscopy&lt;ol&gt;&lt;li&gt;Glomerular sclerosis&lt;/li&gt;&lt;li&gt;Nodular mesangial expansion and proliferation (Kimmelstiel-Wilson &lt;a href="../../Derm/Exam/Ndl1.htm" class="LinkPage"&gt;Nodule&lt;/a&gt;s)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Electron microscopy&lt;ol&gt;&lt;li&gt;Glomerular basement membrane thickening&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Management: General&lt;ol&gt;&lt;li&gt;Avoid Nephrotoxins (e.g. &lt;a href="../../Pharm/Analgesic/NnstrdlAntInflmtry.htm" class="LinkPage"&gt;NSAID&lt;/a&gt;s)&lt;/li&gt;&lt;li&gt;Most important modifiable factors (see below)&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/DM/DbtsMlts.htm" class="LinkPage"&gt;Diabetes Mellitus&lt;/a&gt; glycemic control&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Htn/Hyprtnsn.htm" class="LinkPage"&gt;Hypertension&lt;/a&gt; Control&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Other modifiable factors&lt;ol&gt;&lt;li&gt;&lt;a href="../../CV/Lipid/Hyprchlstrlm.htm" class="LinkPage"&gt;Hyperlipidemia&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Management: &lt;a href="../../Endo/DM/DbtsMlts.htm" class="LinkPage"&gt;Diabetes Mellitus&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Tight glycemic control is critical&lt;ol&gt;&lt;li&gt;Keep &lt;a href="../../Endo/Lab/HmglbnAc.htm" class="LinkPage"&gt;Hemoglobin A1C&lt;/a&gt; &amp;lt;7%&lt;/li&gt;&lt;li&gt;Better glycemic control reduces nephropathy risk&lt;/li&gt;&lt;li&gt;&lt;a href="../../Uro/Lab/UrnMcrlbmn.htm" class="LinkPage"&gt;Microalbuminuria&lt;/a&gt; risk with &lt;a href="../../Endo/Lab/HmglbnAc.htm" class="LinkPage"&gt;Hemoglobin A1C&lt;/a&gt; &amp;gt; 8.1%&lt;/li&gt;&lt;li&gt;Precaution: ACCORD Study found higher overall mortality with intensive glycemic control in &lt;a href="../../Endo/DM/TypDbtsMlts1.htm" class="LinkPage"&gt;Type II Diabetes&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Gerstein%20%20%5BAU%5D%20AND%202008%20%5BDP%5D%20AND%20%20N%20Engl%20J%20Med%20%20%5BTA%5D" class="LinkRef"&gt;Gerstein (2008) N Engl J Med 358(24): 2545-59&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;References&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Krolewski%20%20%5BAU%5D%20AND%201995%20%5BDP%5D%20AND%20%20N%20Engl%20J%20Med%20%20%5BTA%5D" class="LinkRef"&gt;Krolewski (1995) N Engl J Med 332(19):1251-5&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=2011%20%5BDP%5D%20AND%20%20Diabetes%20Care%20%20%5BTA%5D%20AND%2034%20%5BVI%5D%20AND%20%20S4%20%5BPG%5D" class="LinkRef"&gt;(2011) Diabetes Care 34(Suppl 1): S4-S10&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Management: &lt;a href="../../CV/Htn/Hyprtnsn.htm" class="LinkPage"&gt;Hypertension&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../CV/Htn/Hyprtnsn.htm" class="LinkPage"&gt;Hypertension&lt;/a&gt; goals&lt;ol&gt;&lt;li&gt;Keep &lt;a href="../../CV/Exam/BldPrsr.htm" class="LinkPage"&gt;Blood Pressure&lt;/a&gt; under 130/80&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Htn/IsltdSystlcHyprtnsn.htm" class="LinkPage"&gt;Isolated Systolic Hypertension&lt;/a&gt; goals&lt;ol&gt;&lt;li&gt;Keep Systolic &lt;a href="../../CV/Exam/BldPrsr.htm" class="LinkPage"&gt;Blood Pressure&lt;/a&gt; under 140&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Avoid overaggressive &lt;a href="../../CV/Exam/BldPrsr.htm" class="LinkPage"&gt;Blood Pressure&lt;/a&gt; lowering to systolic &lt;a href="../../CV/Exam/BldPrsr.htm" class="LinkPage"&gt;Blood Pressure&lt;/a&gt; below 120 mmHg&lt;ol&gt;&lt;li&gt;Associated with more adverse events (e.g. &lt;a href="../../CV/Exam/Hyptnsn.htm" class="LinkPage"&gt;Hypotension&lt;/a&gt;, &lt;a href="../../CV/EKG/Brdycrd.htm" class="LinkPage"&gt;Bradycardia&lt;/a&gt;, &lt;a href="../../Renal/Failure/ActRnlFlr.htm" class="LinkPage"&gt;Azotemia&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Cushman%20%20%5BAU%5D%20AND%202010%20%5BDP%5D%20AND%20%20N%20Engl%20J%20Med%20%20%5BTA%5D" class="LinkRef"&gt;Cushman (2010) N Engl J Med 362(17): 1575-85&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;First-line Antihypertensives: &lt;a href="../../CV/Pharm/AcInhbtr.htm" class="LinkPage"&gt;ACE Inhibitor&lt;/a&gt;s and ARBs&lt;ol&gt;&lt;li&gt;&lt;a href="../../CV/Pharm/AcInhbtr.htm" class="LinkPage"&gt;ACE Inhibitor&lt;/a&gt;s and ARBs are preferred first-line agents for &lt;a href="../../CV/Htn/Hyprtnsn.htm" class="LinkPage"&gt;Hypertension&lt;/a&gt; and &lt;a href="../../Uro/Urine/PrtnrInAdlts.htm" class="LinkPage"&gt;Proteinuria&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Best evidence is for &lt;a href="../../Uro/Lab/UrnMcrlbmn.htm" class="LinkPage"&gt;Macroalbuminuria&lt;/a&gt;, in which case these agents are indicated even without &lt;a href="../../CV/Htn/Hyprtnsn.htm" class="LinkPage"&gt;Hypertension&lt;/a&gt;&lt;/li&gt;&lt;li&gt;However evidence does not support &lt;a href="../../CV/Pharm/AcInhbtr.htm" class="LinkPage"&gt;ACE Inhibitor&lt;/a&gt; use for &lt;a href="../../Uro/Lab/UrnMcrlbmn.htm" class="LinkPage"&gt;Microalbuminuria&lt;/a&gt; without &lt;a href="../../CV/Htn/Hyprtnsn.htm" class="LinkPage"&gt;Hypertension&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../Uro/Lab/UrnMcrlbmn.htm" class="LinkPage"&gt;Microalbuminuria&lt;/a&gt; alone is not a good marker for renal disease&lt;/li&gt;&lt;li&gt;(2012) Prescr Lett 19(4): 24&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Do not use &lt;a href="../../CV/Pharm/AcInhbtr.htm" class="LinkPage"&gt;ACE Inhibitor&lt;/a&gt;s in combination with &lt;a href="../../CV/Pharm/AngtnsnRcptrBlckngAgnt.htm" class="LinkPage"&gt;Angiotensin Receptor Blocker&lt;/a&gt;s&lt;ol&gt;&lt;li&gt;Higher rate of progression to &lt;a href="../../Renal/Failure/ChrncRnlFlr.htm" class="LinkPage"&gt;ESRD&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Mann%20(2008)%20Lancet%20372%20%5BAU%5D%20AND%209638%20%5BDP%5D%20AND%20:%20%20%5BTA%5D" class="LinkRef"&gt;Mann (2008) Lancet 372(9638): 547-53&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Recent trials suggest &lt;a href="../../CV/Pharm/AcInhbtr.htm" class="LinkPage"&gt;ACE Inhibitor&lt;/a&gt;s and ARBs are equivalent in renal outcomes&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Mann%20(2008)%20Lancet%20372%20%5BAU%5D%20AND%209638%20%5BDP%5D%20AND%20:%20%20%5BTA%5D" class="LinkRef"&gt;Mann (2008) Lancet 372(9638): 547-53&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Lewis%20%20%5BAU%5D%20AND%202001%20%5BDP%5D%20AND%20%20N%20Engl%20J%20Med%20%20%5BTA%5D" class="LinkRef"&gt;Lewis (2001) N Engl J Med 345:851-60&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;All-cause mortality is reduced with &lt;a href="../../CV/Pharm/AcInhbtr.htm" class="LinkPage"&gt;ACE Inhibitor&lt;/a&gt;s, but not with &lt;a href="../../CV/Pharm/AngtnsnRcptrBlckngAgnt.htm" class="LinkPage"&gt;Angiotensin Receptor Blocker&lt;/a&gt;s&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Strippoli%20(2004)%20BMJ%20329%20%5BAU%5D%20AND%207470%20%5BDP%5D%20AND%20:%20%20%5BTA%5D" class="LinkRef"&gt;Strippoli (2004) BMJ 329(7470): 828&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Indications to stop &lt;a href="../../CV/Pharm/AcInhbtr.htm" class="LinkPage"&gt;ACE Inhibitor&lt;/a&gt;s or &lt;a href="../../CV/Pharm/AngtnsnRcptrBlckngAgnt.htm" class="LinkPage"&gt;Angiotensin Receptor Blocker&lt;/a&gt;s&lt;ol&gt;&lt;li&gt;&lt;a href="../../Renal/Lab/SrmCrtn.htm" class="LinkPage"&gt;Serum Creatinine&lt;/a&gt; rises 30% or more above baseline in first 2 months of starting medication or&lt;/li&gt;&lt;li&gt;&lt;a href="../../Renal/Potassium/Hyprklm.htm" class="LinkPage"&gt;Hyperkalemia&lt;/a&gt; persists with &lt;a href="../../Renal/Lab/SrmPtsm.htm" class="LinkPage"&gt;Serum Potassium&lt;/a&gt; &amp;gt;5.6 mEq/L&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Agents&lt;ol&gt;&lt;li&gt;&lt;a href="../../CV/Pharm/AcInhbtr.htm" class="LinkPage"&gt;ACE Inhibitor&lt;/a&gt;s (preferred - see above)&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Pharm/AngtnsnRcptrBlckngAgnt.htm" class="LinkPage"&gt;Angiotensin Receptor Blocker&lt;/a&gt;s (ARB)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Second-line Antihypertensives&lt;ol&gt;&lt;li&gt;&lt;a href="../../CV/Pharm/ThzdDrtc.htm" class="LinkPage"&gt;Thiazide Diuretic&lt;/a&gt;s (especially in combination with &lt;a href="../../CV/Pharm/AcInhbtr.htm" class="LinkPage"&gt;ACE Inhibitor&lt;/a&gt;s or ARB agents above)&lt;ol&gt;&lt;li&gt;&lt;a href="../../CV/Pharm/ThzdDrtc.htm" class="LinkPage"&gt;Hydrochlorothiazide&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Pharm/ThzdDrtc.htm" class="LinkPage"&gt;Chlorthalidone&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Bakris%20%20%5BAU%5D%20AND%202008%20%5BDP%5D%20AND%20%20Kidney%20Int%20%20%5BTA%5D" class="LinkRef"&gt;Bakris (2008) Kidney Int 73(11); 1303-9&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Pharm/NnDhydrpyrdnClcmChnlBlckr.htm" class="LinkPage"&gt;Non-Dihydropyridine Calcium Channel Blocker&lt;/a&gt;s&lt;ol&gt;&lt;li&gt;Example: &lt;a href="../../CV/Pharm/Dltzm.htm" class="LinkPage"&gt;Diltiazem&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Reduces &lt;a href="../../Uro/Urine/PrtnrInAdlts.htm" class="LinkPage"&gt;Proteinuria&lt;/a&gt; (less than &lt;a href="../../CV/Pharm/AcInhbtr.htm" class="LinkPage"&gt;ACE Inhibitor&lt;/a&gt;)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Avoid &lt;a href="../../CV/Pharm/DhydrpyrdnClcmChnlBlckr.htm" class="LinkPage"&gt;Dihydropyridine Calcium Channel Blocker&lt;/a&gt;s&lt;ol&gt;&lt;li&gt;&lt;a href="../../CV/Pharm/Nfdpn.htm" class="LinkPage"&gt;Nifedipine&lt;/a&gt; may increase &lt;a href="../../Uro/Urine/PrtnrInAdlts.htm" class="LinkPage"&gt;Proteinuria&lt;/a&gt;&lt;/li&gt;&lt;li&gt;However, &lt;a href="../../CV/Pharm/DhydrpyrdnClcmChnlBlckr.htm" class="LinkPage"&gt;Amlodipine&lt;/a&gt; appears to also reduce &lt;a href="../../Uro/Lab/UrnMcrlbmn.htm" class="LinkPage"&gt;Microalbuminuria&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Bakris%20%20%5BAU%5D%20AND%202008%20%5BDP%5D%20AND%20%20Kidney%20Int%20%20%5BTA%5D" class="LinkRef"&gt;Bakris (2008) Kidney Int 73(11); 1303-9&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Management: Dietary changes (incomplete evidence)&lt;ol&gt;&lt;li&gt;Dietary modification: CR-LIPE&lt;ol&gt;&lt;li&gt;Better than protein restriction in retarding CRI&lt;/li&gt;&lt;li&gt;Components&lt;ol&gt;&lt;li&gt;50% carbohydrate restricted (CR)&lt;/li&gt;&lt;li&gt;Low &lt;a href="../../HemeOnc/Exam/RdBldClPhyslgy.htm" class="LinkPage"&gt;Iron&lt;/a&gt; available (LI)&lt;/li&gt;&lt;li&gt;Polyphenol enriched (PE)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;References&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Facchini%20%20%5BAU%5D%20AND%202003%20%5BDP%5D%20AND%20%20Diabetes%20%20%5BTA%5D" class="LinkRef"&gt;Facchini (2003) Diabetes 52:1204-9&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Protein restriction&lt;ol&gt;&lt;li&gt;Efficacy&lt;ol&gt;&lt;li&gt;Decreases &lt;a href="../../Uro/Lab/UrnMcrlbmn.htm" class="LinkPage"&gt;Microalbuminuria&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Decreases progression to &lt;a href="../../Uro/Lab/UrnMcrlbmn.htm" class="LinkPage"&gt;Macroalbuminuria&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Protocol&lt;ol&gt;&lt;li&gt;Near Normal GFR: &amp;lt;0.8g/kg/day Protein&lt;/li&gt;&lt;li&gt;Falling GFR: &amp;lt;0.6g/kg/day Protein&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Management: Referral to Nephrology Indications&lt;ol&gt;&lt;li&gt;&lt;a href="../../Renal/Lab/SrmCrtn.htm" class="LinkPage"&gt;Serum Creatinine&lt;/a&gt; over 2.0 mg/dl&lt;/li&gt;&lt;li&gt;&lt;a href="../../Renal/Lab/CrtnClrnc.htm" class="LinkPage"&gt;Glomerular Filtration Rate&lt;/a&gt; (GFR) less than 70 ml/min&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Precautions: Findings that suggest cause other than typical Diabetic Nephropathy&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Uro/Urine/PrtnrCs.htm" class="LinkPage"&gt;Proteinuria Causes&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Albuminuria absent despite stage 3-5 CKD&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Eye/DbtcRtnpthy.htm" class="LinkPage"&gt;Diabetic Retinopathy&lt;/a&gt; absent despite Diabetic Nephropathy&lt;/li&gt;&lt;li&gt;Active urinary sediment (red cells or casts accompany &lt;a href="../../Uro/Urine/PrtnrInAdlts.htm" class="LinkPage"&gt;Proteinuria&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;Low GFR estimated at the time of initial diagnosis&lt;/li&gt;&lt;li&gt;GFR reduced &amp;gt;30% within 3 months of starting &lt;a href="../../CV/Pharm/AcInhbtr.htm" class="LinkPage"&gt;ACE Inhibitor&lt;/a&gt; or &lt;a href="../../CV/Pharm/AngtnsnRcptrBlckngAgnt.htm" class="LinkPage"&gt;Angiotensin Receptor Blocker&lt;/a&gt; (ARB)&lt;/li&gt;&lt;li&gt;GFR decreases rapidly (4 ml/min/year)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Uro/Urine/PrtnrInAdlts.htm" class="LinkPage"&gt;Proteinuria&lt;/a&gt; increases rapidly (or &lt;a href="../../Renal/Glomerulus/NphrtcSyndrm.htm" class="LinkPage"&gt;Nephrotic Syndrome&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Htn/RstntHyprtnsn.htm" class="LinkPage"&gt;Refractory Hypertension&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=2007%20%5BDP%5D%20AND%20%20Am%20J%20Kidney%20Dis%20%20%5BTA%5D%20AND%2049%20%5BVI%5D%20AND%20%20S12%20%5BPG%5D" class="LinkRef"&gt;(2007) Am J Kidney Dis 49(suppl 2): S12-S154&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Prognosis&lt;ol&gt;&lt;li&gt;&lt;a href="../../Renal/Pharm/Hmdlys.htm" class="LinkPage"&gt;Dialysis&lt;/a&gt; usually needed when GFR reaches 10 ml/min&lt;/li&gt;&lt;li&gt;Onset of &lt;a href="../../Uro/Urine/PrtnrInAdlts.htm" class="LinkPage"&gt;Proteinuria&lt;/a&gt; after diagnosis of &lt;a href="../../Endo/DM/DbtsMlts.htm" class="LinkPage"&gt;Diabetes Mellitus&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../Uro/Lab/UrnMcrlbmn.htm" class="LinkPage"&gt;Microalbuminuria&lt;/a&gt; develops in 2.0% of patients with diabetes per year&lt;/li&gt;&lt;li&gt;&lt;a href="../../Uro/Lab/UrnMcrlbmn.htm" class="LinkPage"&gt;Macroalbuminuria&lt;/a&gt; develops in 2.8% of diabetic patients with &lt;a href="../../Uro/Lab/UrnMcrlbmn.htm" class="LinkPage"&gt;Microalbuminuria&lt;/a&gt; per year&lt;/li&gt;&lt;li&gt;Increased &lt;a href="../../Renal/Lab/SrmCrtn.htm" class="LinkPage"&gt;Serum Creatinine&lt;/a&gt; develops in 2.3% of diabetic patients with &lt;a href="../../Uro/Lab/UrnMcrlbmn.htm" class="LinkPage"&gt;Macroalbuminuria&lt;/a&gt; per year&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Adler%20%20%5BAU%5D%20AND%202003%20%5BDP%5D%20AND%20%20Kidney%20Int%20%20%5BTA%5D" class="LinkRef"&gt;Adler (2003) Kidney Int 63(1): 225-32&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;GFR decline after onset &lt;a href="../../Uro/Lab/UrnMcrlbmn.htm" class="LinkPage"&gt;Microalbuminuria&lt;/a&gt;&lt;ol&gt;&lt;li&gt;No &lt;a href="../../CV/Pharm/AcInhbtr.htm" class="LinkPage"&gt;ACE Inhibitor&lt;/a&gt;: 10 ml/min/year&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Pharm/AcInhbtr.htm" class="LinkPage"&gt;ACE Inhibitor&lt;/a&gt;: 4-6 ml/min/year&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Exam/BldPrsr.htm" class="LinkPage"&gt;Blood Pressure&lt;/a&gt; &amp;lt;130/80: 1-4 ml/min/year&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Complications&lt;ol&gt;&lt;li&gt;&lt;a href="../../Uro/Lab/UrnMcrlbmn.htm" class="LinkPage"&gt;Microalbuminuria&lt;/a&gt; (and &lt;a href="../../Uro/Lab/UrnMcrlbmn.htm" class="LinkPage"&gt;Macroalbuminuria&lt;/a&gt;) are associated with an increased cardiovascular mortality and overall mortality&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Molitch%20%20%5BAU%5D%20AND%201997%20%5BDP%5D%20AND%20%20Am%20J%20Med%20%20%5BTA%5D" class="LinkRef"&gt;Molitch (1997) Am J Med 102:392-8&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Cooper%20%20%5BAU%5D%20AND%201998%20%5BDP%5D%20AND%20%20Lancet%20%20%5BTA%5D" class="LinkRef"&gt;Cooper (1998) Lancet 352:213-9&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Thorp%20%20%5BAU%5D%20AND%202005%20%5BDP%5D%20AND%20%20Am%20Fam%20Physician%20%20%5BTA%5D" class="LinkRef"&gt;Thorp (2005) Am Fam Physician 72:96-99&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Roett%20%20%5BAU%5D%20AND%202012%20%5BDP%5D%20AND%20%20Am%20Fam%20Physician%20%20%5BTA%5D" class="LinkRef"&gt;Roett (2012) Am Fam Physician 85(9): 883-9&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0011881</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Renal/DbtcNphrpthy.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Diabetic Nephropathy, Nephropathy of Diabetes Mellitus, Diabetic Kidney Disease</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Renal/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees></FP_UMLS_Trees><FP_Condition_name_check></FP_Condition_name_check><FP_Condition_name><value>Nutrition in Diabetes Mellitus Type 2</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Prevention</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;See Also&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Prevent/NtrtnInDbtsMlts.htm" class="LinkPage"&gt;Nutrition in Diabetes Mellitus&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Goals&lt;ol&gt;&lt;li&gt;First priority: &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Glucose&lt;/a&gt; control&lt;/li&gt;&lt;li&gt;Second priority: Weight loss&lt;ol&gt;&lt;li&gt;Do not overemphasize weight loss&lt;/li&gt;&lt;li&gt;Maximal weight loss: 10-20 pounds&lt;/li&gt;&lt;li&gt;Better &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Sugar&lt;/a&gt; control results in weight gain&lt;/li&gt;&lt;li&gt;DCC Trial found &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Sugar&lt;/a&gt; control more important&lt;/li&gt;&lt;li&gt;Reference&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Watts%20%20%5BAU%5D%20AND%201990%20%5BDP%5D%20AND%20%20Arch%20Intern%20Med%20%20%5BTA%5D" class="LinkRef"&gt;Watts (1990) Arch Intern Med 150(4):803-6&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Management: Moderately restrict calories&lt;ol&gt;&lt;li&gt;Improves &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Sugar&lt;/a&gt; control&lt;/li&gt;&lt;li&gt;Hypocaloric diet more important than weight loss&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Wing%20%20%5BAU%5D%20AND%201987%20%5BDP%5D" class="LinkRef"&gt;Wing (1987)&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Management: Adjust Meal Schedule&lt;ol&gt;&lt;li&gt;Break up caloric intake&lt;ol&gt;&lt;li&gt;Breakfast: 20%&lt;/li&gt;&lt;li&gt;Lunch: 40%&lt;/li&gt;&lt;li&gt;Dinner: 40%&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Intersperse small snacks between meals&lt;ol&gt;&lt;li&gt;Crackers or juice in afternoon and at bedtime&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Jenkins%20%20%5BAU%5D%20AND%201992%20%5BDP%5D%20AND%20%20Am%20J%20Clin%20Nutr%20%20%5BTA%5D" class="LinkRef"&gt;Jenkins (1992) Am J Clin Nutr 55(2): 461-7&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Management: Modify fat intake&lt;ol&gt;&lt;li&gt;Decrease overall fat intake&lt;/li&gt;&lt;li&gt;Avoid saturated fats&lt;/li&gt;&lt;li&gt;Switch to monounsaturated or polyunsaturated fats&lt;ol&gt;&lt;li&gt;Eating nuts and peanut butter reduces &lt;a href="../../Endo/DM/TypDbtsMlts1.htm" class="LinkPage"&gt;NIDDM&lt;/a&gt; risk&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Jiang%20%20%5BAU%5D%20AND%202002%20%5BDP%5D%20AND%20%20JAMA%20%20%5BTA%5D" class="LinkRef"&gt;Jiang (2002) JAMA 288:2554-60&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Management: Increase &lt;a href="../../Sports/Exercise/Exrcs.htm" class="LinkPage"&gt;Physical Activity&lt;/a&gt;&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Endo/Sports/ExrcsInDbtsMlts.htm" class="LinkPage"&gt;Exercise in Diabetes Mellitus&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Prevent/NtrtnInDbtsMltsTyp1.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Nutrition in Diabetes Mellitus Type 2, Nutrition in Diabetes Mellitus Type II</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Prevent/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Thyroiditis, Suppurative  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0040150"&gt;&lt;i&gt;C0040150&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;Acute inflammatory disease of the THYROID GLAND due to infections by BACTERIA; FUNGI; or other microorganisms. Symptoms include tender swelling, FEVER, and often with LEUKOCYTOSIS.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Disease or Syndrome (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0040150&amp;amp;tui=T047"&gt;&lt;i&gt;T047&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D013969&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD10&lt;/td&gt;
                &lt;td&gt;E06.0&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;25476006, 3511005&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Infectious Thyroiditides, Infectious Thyroiditis, Suppurative Thyroiditides, Suppurative Thyroiditis, Thyroiditides, Infectious, Thyroiditides, Suppurative, Thyroiditis, Infectious, THYROIDITIS, ACUTE SUPPURATIVE, Infectious thyroiditis, NOS, THYROIDITIS ACUTE PYOGENIC, INFECT THYROIDITIS, THYROIDITIS INFECT, Suppurative thyroiditis, Thyroiditis, Suppurative [Disease/Finding], acute suppurative thyroiditis, Thyroiditis, Suppurative, Acute suppurative thyroiditis, Acute suppurative thyroiditis (disorder), Infectious thyroiditis (disorder), Infectious thyroiditis, suppurative; thyroiditis, thyroiditis; suppurative, Infectious Thyroiditides, Acute, Infectious Thyroiditis, Acute, Suppurative Thyroiditides, Acute, Suppurative Thyroiditis, Acute, Thyroiditides, Acute Infectious, Thyroiditides, Acute Suppurative, Thyroiditis, Acute Infectious, Thyroiditis, Acute Suppurative, Acute Infectious Thyroiditides, Acute Infectious Thyroiditis, Acute Suppurative Thyroiditides, Acute Suppurative Thyroiditis&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Thyroïdite aigüe infectieuse, Thyroïdite aiguë infectieuse, Thyroïdite aigüe d'origine infectieuse, Thyroïdite suppurée, Thyroïdite infectieuse, Thyroïdite aiguë d'origine infectieuse&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Tyreoidit, varbildande&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;tyreoiditida hnisavá&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Märkivä kilpirauhastulehdus&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;TIREOIDIT INFEKTSIONNYI, TIREOIDIT GNOINYI, ТИРЕОИДИТ ГНОЙНЫЙ, ТИРЕОИДИТ ИНФЕКЦИОННЫЙ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Tiroidite infettiva, Tiroidite acuta infettiva, Tiroidite suppurativa acuta, Tiroidite suppurativa&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Zapalenie tarczycy ropne&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;化膿性甲状腺炎, 甲状腺炎-化膿性, 感染性甲状腺炎, 甲状腺炎-感染性&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;etterig; thyroïditis, thyroïditis; etterig, Suppuratieve thyreoiditis, Thyreoiditis, infectieuze, Thyreoiditis, suppuratieve&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;tiroiditis infecciosa (trastorno), tiroiditis infecciosa, tiroiditis supurativa aguda (trastorno), tiroiditis supurativa aguda, Tiroiditis Infecciosa, Tiroiditis Supurativa&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Thyreoiditis, eitrige, Thyreoiditis, infektiöse&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Tireoidite Infecciosa, Tireoidite Supurativa&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Thyroiditis, Suppurative  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Suppurative Thyroiditis</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Infectious Disease</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Definition&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/Thyrdts.htm" class="LinkPage"&gt;Painful Thyroiditis&lt;/a&gt; associated with Non-Viral Infection&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Epidemiology&lt;ol&gt;&lt;li&gt;Rare form of &lt;a href="../../Endo/Thyroid/Thyrdts.htm" class="LinkPage"&gt;Painful Thyroiditis&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Causes&lt;ol&gt;&lt;li&gt;Bacterial infection&lt;ol&gt;&lt;li&gt;&lt;a href="../../Lung/Bacteria/PnmcclPnmn.htm" class="LinkPage"&gt;Streptococcus Pneumoniae&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../ID/Bacteria/GrpABtHmlytcStrptccs.htm" class="LinkPage"&gt;Streptococcus Pyogenes&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../ID/Bacteria/Stphylccs.htm" class="LinkPage"&gt;Staphylococcus&lt;/a&gt; auerus&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Non-bacterial, non-viral infections&lt;ol&gt;&lt;li&gt;Parasitic Infections&lt;/li&gt;&lt;li&gt;Fungal infections&lt;/li&gt;&lt;li&gt;&lt;a href="../../ID/Bacteria/Mycbctr.htm" class="LinkPage"&gt;Mycobacteria&lt;/a&gt;l infections&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Risk Factors&lt;ol&gt;&lt;li&gt;Immunocompromised patients&lt;/li&gt;&lt;li&gt;Elderly&lt;/li&gt;&lt;li&gt;Pre-existing &lt;a href="../../Endo/Anatomy/ThyrdAntmy.htm" class="LinkPage"&gt;Thyroid&lt;/a&gt; disease in up to 50%&lt;/li&gt;&lt;li&gt;Congenital defect&lt;ol&gt;&lt;li&gt;Persistent thyroglossal duct&lt;/li&gt;&lt;li&gt;Piriform sinus fistula&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Symptoms&lt;ol&gt;&lt;li&gt;Acute unilateral &lt;a href="../../Ortho/Sx/ChrncNckPn.htm" class="LinkPage"&gt;Neck Pain&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Neuro/Exam/Dysphg.htm" class="LinkPage"&gt;Dysphagia&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Signs&lt;ol&gt;&lt;li&gt;&lt;a href="../../ID/Exam/Fvr.htm" class="LinkPage"&gt;Fever&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Erythematous skin overlying &lt;a href="../../Endo/Anatomy/ThyrdAntmy.htm" class="LinkPage"&gt;Thyroid&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Anatomy/ThyrdAntmy.htm" class="LinkPage"&gt;Thyroid&lt;/a&gt; tender to palpation&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Labs&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/ThyrdFnctnTst.htm" class="LinkPage"&gt;Thyroid Function Test&lt;/a&gt;s (TSH, &lt;a href="../../Endo/Lab/Thyrxn.htm" class="LinkPage"&gt;Free T4&lt;/a&gt;)&lt;ol&gt;&lt;li&gt;Variable abnormalities or may be euthyroid&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../HemeOnc/Lab/ErythrcytSdmntnRt.htm" class="LinkPage"&gt;Erythrocyte Sedimentation Rate&lt;/a&gt; increased&lt;/li&gt;&lt;li&gt;&lt;a href="../../HemeOnc/Lab/Lkcyts.htm" class="LinkPage"&gt;Leukocytosis&lt;/a&gt; with band forms&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Diagnosis&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Anatomy/ThyrdAntmy.htm" class="LinkPage"&gt;Thyroid&lt;/a&gt; FNA&lt;ol&gt;&lt;li&gt;Send for &lt;a href="../../ID/Lab/GrmStn.htm" class="LinkPage"&gt;Gram Stain&lt;/a&gt; and culture&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Management&lt;ol&gt;&lt;li&gt;Intravenous antibiotics to cover suspected organisms&lt;/li&gt;&lt;li&gt;Surgery consultation if abscess drainage required&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Bindra%20%20%5BAU%5D%20AND%202006%20%5BDP%5D%20AND%20%20Am%20Fam%20Physician%20%20%5BTA%5D" class="LinkRef"&gt;Bindra (2006) Am Fam Physician 73:1769-76&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Fukata%20%20%5BAU%5D%20AND%202002%20%5BDP%5D%20AND%20%20Thyroid%20%20%5BTA%5D" class="LinkRef"&gt;Fukata (2002) Thyroid 12:175-8&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0040150</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/ID/SprtvThyrdts.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Suppurative Thyroiditis</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/ID/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees></FP_UMLS_Trees><FP_Condition_name_check></FP_Condition_name_check><FP_Condition_name><value>Radioiodine</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Pharmacology</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Indications&lt;ol&gt;&lt;li&gt;Management of choice for &lt;a href="../../Endo/Thyroid/GrvsDs.htm" class="LinkPage"&gt;Grave's Disease&lt;/a&gt; of all ages&lt;/li&gt;&lt;li&gt;Recurrent &lt;a href="../../Endo/Thyroid/Hyprthyrdsm1.htm" class="LinkPage"&gt;Hyperthyroidism&lt;/a&gt; after &lt;a href="../../Endo/Pharm/AnthyrdDrg.htm" class="LinkPage"&gt;Antithyroid Drug&lt;/a&gt;s&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/MltndlrGtr.htm" class="LinkPage"&gt;Toxic Multinodular Goiter&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Toxic &lt;a href="../../Derm/Exam/Ndl1.htm" class="LinkPage"&gt;Nodule&lt;/a&gt; in patient over age 40 years&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Contraindications&lt;ol&gt;&lt;li&gt;Pregnancy&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Pharmacokinetics&lt;ol&gt;&lt;li&gt;Half-life of I-131: 9 days&lt;/li&gt;&lt;li&gt;Effects nos seen for over 3-4 weeks&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Mechanism&lt;ol&gt;&lt;li&gt;Concentrates in and destroys &lt;a href="../../Endo/Anatomy/ThyrdAntmy.htm" class="LinkPage"&gt;Thyroid&lt;/a&gt; tissue&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Precautions&lt;ol&gt;&lt;li&gt;Background&lt;ol&gt;&lt;li&gt;Radio-iodine excreted in urine, &lt;a href="../../ENT/Anatomy/SlvryGlndAntmy.htm" class="LinkPage"&gt;Saliva&lt;/a&gt;, feces&lt;/li&gt;&lt;li&gt;Most is eliminated in first 48 hours&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;For first 3 days&lt;ol&gt;&lt;li&gt;Avoid contact with children and pregnant women&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;For first few weeks&lt;ol&gt;&lt;li&gt;Double flush toilet&lt;/li&gt;&lt;li&gt;Wash hands carefully&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Adverse Effects&lt;ol&gt;&lt;li&gt;No increased risk of Cancer Death&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/RdtnIndcdThyrdts.htm" class="LinkPage"&gt;Radiation-Induced Thyroiditis&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/Thyrdts.htm" class="LinkPage"&gt;Acute Thyroiditis&lt;/a&gt; in first 1-2 weeks post-I131&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Slight increased risk of &lt;a href="../../Endo/HemeOnc/ThyrdCrcnm.htm" class="LinkPage"&gt;Thyroid Cancer&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Graves Disease predisposes to &lt;a href="../../Endo/HemeOnc/ThyrdCrcnm.htm" class="LinkPage"&gt;Thyroid Cancer&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Cancers may have been present before I-131&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Graves Ophthalmopathy may worsen on I-131&lt;ol&gt;&lt;li&gt;Occurs more commonly in &lt;a href="../../Psych/CD/Cgrt.htm" class="LinkPage"&gt;Tobacco&lt;/a&gt; abuse&lt;/li&gt;&lt;li&gt;Prednisone used to minimize this effect&lt;ol&gt;&lt;li&gt;Dose: 40-80 mg daily&lt;/li&gt;&lt;li&gt;Taper dose over 3 months&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Efficacy: Euthyroid or Hypothyroid after symptoms&lt;ol&gt;&lt;li&gt;Euthyroid at 6-8 weeks after I-131: 50 to 75%&lt;/li&gt;&lt;li&gt;Euthyroid after one dose I-131: 80 to 90%&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Follow-up&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/ThyrdStmltngHrmn.htm" class="LinkPage"&gt;Thyroid Stimulating Hormone&lt;/a&gt; every 6 weeks until stable&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Protocols&lt;ol&gt;&lt;li&gt;&lt;a href="../../CV/Pharm/BtBlckr.htm" class="LinkPage"&gt;Beta Blocker&lt;/a&gt;s control symptoms around radio-iodine&lt;/li&gt;&lt;li&gt;Stop all meds containing iodine 2-3 weeks before iodine&lt;/li&gt;&lt;li&gt;Concurrent use with &lt;a href="../../Endo/Pharm/AnthyrdDrg.htm" class="LinkPage"&gt;Antithyroid Drug&lt;/a&gt;s (e.g. PTU)&lt;ol&gt;&lt;li&gt;Indications&lt;ol&gt;&lt;li&gt;Not indicated in most cases&lt;/li&gt;&lt;li&gt;May be helpful in severe &lt;a href="../../Endo/Thyroid/Hyprthyrdsm1.htm" class="LinkPage"&gt;Hyperthyroidism&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Protocol near time of radio-iodine treatement&lt;ol&gt;&lt;li&gt;Stop &lt;a href="../../Endo/Pharm/AnthyrdDrg.htm" class="LinkPage"&gt;Antithyroid Drug&lt;/a&gt;s 3 days before radio-iodine&lt;/li&gt;&lt;li&gt;Restart &lt;a href="../../Endo/Pharm/AnthyrdDrg.htm" class="LinkPage"&gt;Antithyroid Drug&lt;/a&gt;s 3 days after radio-iodine&lt;/li&gt;&lt;li&gt;Continue &lt;a href="../../Endo/Pharm/AnthyrdDrg.htm" class="LinkPage"&gt;Antithyroid Drug&lt;/a&gt;s for 3 months then taper&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Pharm/Rdn.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Radioiodine, Radioactive Iodine, I-131</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Pharm/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Amaurotic Familial Idiocy  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0282220"&gt;&lt;i&gt;C0282220&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;An outdated term for Tay-Sachs disease.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Disease or Syndrome (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0282220&amp;amp;tui=T047"&gt;&lt;i&gt;T047&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D013661&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;111385000, 192786008&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;INFANTILE AMAUROTIC FAMILIAL IDIOCY, Amaurotic Idiocy, Familial, Familial Amaurotic Idiocy, Idiocies, Familial Amaurotic, amaurotic familial idiocy, familial amaurotic idiocy (diagnosis), familial amaurotic idiocy, Amaurotic familial idiocy, Infantile amaurotic familial disease, Amaurotic Familial Idiocy, Familial Idiocy (Amaurotic)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Idiozia familiare amaurotica&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;家族性黒内障白痴, ｶｿﾞｸｾｲｺｸﾅｲｼｮｳﾊｸﾁ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;Amaurotic familial idiocy, enfermedad familiar amaurótica infantil, enfermedad familiar amaurótica, idiotez familiar amaurótica, Idiocia familiar amaurótica&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Idiotie amaurotique familiale, Idiotie familiale amaurotique&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Amaurotische familiäre Idiotie, amaurotische familiaere Idiotie&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;Familiární amaurotická idiocie&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;Amaurotikus familiaris idiotizmus&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Idiotia anaurótica familiar juvenil&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;amaurotische familiale idiotie&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Tay-Sachs Disease  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0039373"&gt;&lt;i&gt;C0039373&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A rare, fatal, autosomal recessive lipid storage disorder caused by mutations in the HEXA gene. It is characterized by deficiency of beta-hexosaminidase A, resulting in accumulation of gangliosides in the neurons of the brain and spinal cord. Signs and symptoms include progressive deterioration of the mental and physical abilities early in life, accompanied by blindness, deafness, muscle atrophy, and paralysis.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MEDLINEPLUS)&lt;/td&gt;
                &lt;td&gt;
                  &lt;span&gt;
                    &lt;p&gt;Tay-Sachs disease is a rare, inherited disorder. It causes too much of a fatty substance to build up in tissues and nerve cells of the brain. This buildup destroys the nerve cells, causing mental and physical problems. &lt;/p&gt;
                    &lt;p&gt;Infants with Tay-Sachs disease appear to develop normally for the first few months of life. Then, as nerve cells become distended with fatty material, mental and physical abilities deteriorate. The child becomes blind, deaf, and unable to swallow. Muscles begin to atrophy and paralysis sets in. Even with the best of care, children with Tay-Sachs disease usually die by age 4.&lt;/p&gt;
                    &lt;p&gt;Tay-Sachs is most common in Eastern European Ashkenazi Jews. A blood test can determine if you carry or have the disease. There is no cure. Medicines and good nutrition can help some symptoms. Some children need feeding tubes.&lt;/p&gt;
                    &lt;p style="font-weight:bold;font-style:italic;"&gt;NIH: National Institute of Neurological Disorders and Stroke&lt;/p&gt;
                  &lt;/span&gt;
                &lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CSP)&lt;/td&gt;
                &lt;td&gt;autosomal recessive inherited gangliosidosis characterized by the onset in the first 6 months of life of an exaggerated startle response, delay in psychomotor development, hypotonia (followed by spasticity), visual loss, and a macular cherry red spot; hexosaminidase A is deficient, leading to the accumulation of GM2 ganglioside in neurons of the central nervous system and retina; this condition is strongly associated with Ashkenazic Jewish ancestry.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;An autosomal recessive neurodegenerative disorder characterized by the onset in infancy of an exaggerated startle response, followed by paralysis, dementia, and blindness. It is caused by mutation in the alpha subunit of the HEXOSAMINIDASE A resulting in lipid-laden ganglion cells. It is also known as the B variant (with increased HEXOSAMINIDASE B but absence of hexosaminidase A) and is strongly associated with Ashkenazic Jewish ancestry.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Disease or Syndrome (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0039373&amp;amp;tui=T047"&gt;&lt;i&gt;T047&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D013661&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD10&lt;/td&gt;
                &lt;td&gt;E75.02&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;111385000&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;GM2 gangliosidosis, type I, G(M2) Gangliosidosis, Type I, Gangliosidosis G(M2), Type I, GANGLIOSIDOSIS GM2 TYPE 1, INFANTILE GANGLIOSIDE LIPIDOSIS, LIPIDOSIS, GANGLIOSIDE, INFANTILE, TAY SACHS DISEASE, Tay Sachs disease, TAY SACH'S DISEASE, GM2 gangliosidosis, type 1, GM&amp;lt;sub&amp;gt;2&amp;lt;/sub&amp;gt; gangliosidosis, type 1, Gangliosidosis GM2, Type I, GM2 Gangliosidosis, Type I, GM2 Gangliosidosis, B Variant, Gangliosidosis GM2, B Variant, Tay Sachs Disease, B Variant, Tay-Sachs Disease, B Variant, TAY-SACHS DISEASE, HEXA DEFICIENCY, GM2-GANGLIOSIDOSIS, TYPE I, HEXOSAMINIDASE A DEFICIENCY, GANGLIOSIDOSIS GM 02 B VARIANT, TAY SACHS DIS, GM2 GANGLIOSIDOSIS TYPE I, GM GANGLIOSIDOSIS 02 TYPE I, GANGLIOSIDOSIS GM 02 TYPE I, GANGLIOSIDOSIS GM2 TYPE I, DEFIC DIS HEXOSAMINIDASE A, HEXOSAMINIDASE A DEFIC DIS, hexosaminidase A deficiency, gangliosidosis GM2 type I, B VARIANT GM2-GANGLIOSIDOSIS, Tay-Sachs disease (diagnosis), GM2 gangliosidosis, Deficiency Disease Hexosaminidase A, Hexosaminidase A Deficiency Disease, B Variant GM2 Gangliosidosis, Gangliosidosis GM2 , Type 1, Sphingolipidosis, Tay-Sachs, GM2 Gangliosidosis, Type 1, Sphingolipidosis, Tay Sachs, Tay-Sachs Sphingolipidosis, Tay-Sachs Disease [Disease/Finding], tsd, deficiency hexosaminidase, disease sach tay, disease tay sachs, disease sachs tay, tay sach's disease, diseases sachs tay, diseases tay sachs, disease sach's tay, disease tay sach, tay sachs disease, diseases sachs tays, tay-sachs disease, disease tay-sachs, Tay-Sachs disease, Severe hexosaminidase A deficiency, TSD, Hexosaminidase A deficiency, GM&amp;gt;2&amp;lt; gangliosidosis, type 1, Tay-Sachs disease (disorder), Sachs-Tay, Sachs, Tay-Sachs, Tay-Sachs Disease, Tay Sachs Disease, Disease, Tay-Sachs&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Gangliosidose GM2 Variante B, Doença de Tay-Sachs Variante B, Doença da Deficiência da Hexosaminidase A, Doença de Tay-Sachs, Gangliosidose G(M2) Tipo I&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;Gangliosidosis GM2 Variante B, Enfermedad de Tay-Sachs Variante B, gangliosidosis GM2, tipo 1, gangliosidosis GM&amp;lt;sub&amp;gt;2&amp;lt;/sub&amp;gt;, tipo 1, deficiencia severa de hexosaminidasa A, enfermedad de Tay - Sachs (trastorno), enfermedad de Tay - Sachs, gangliosidosis GM&amp;gt;2&amp;lt;, tipo 1, Enfermedad de Tay-Sachs, Enfermedad por Deficiencia de Hexosaminidasa A, Gangliosidosis G(M2) Tipo I&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Hexaminidase-A-Mangel, Morbus Tay-Sachs, GANGLIOSIDOSE GM 02 TYP I, GM GANGLIOSIDOSE 02 TYP I, GM Gangliosidose 02 Typ HI, Gangliosidose GM 02 Typ HI, Tay-Sachs-Syndrom, Tay-Sachs-Krankheit, G(M2)-Gangliosidose, Typ I, GM2-Gangliosidose, Typ I, Gangliosidose-G(M2), Typ I, Gangliosidose-GM2, Typ I, Hexosaminidase-A-Mangelkrankheit&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;ティサックス病, ﾃｨｻｯｸｽﾋﾞｮｳ, 黒内障性家族性認知症, ガングリオシドーシスGM2-1型, 家族性黒内障性白痴, 黒内障性家族性白痴, G(M2)ガングリオシド蓄積症1型, Tay-Sachs病, GM2-ガングリオシドーシス1型, テイ-サックス病, 黒内障性家族性痴呆, 黒内障性白痴, 1型G(M2)ガングリオシド症, 1型ガングリオシド症G(M2), GM2ガングリオシドーシス1型, GM2ガングリオシドーシスI型, ガングリオシドーシスGM2-I型, ガングリオシド蓄積症G(M2)1型&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Tay-Sachs sjukdom&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;Tayova-Sachsova nemoc, Tay-Sachsova nemoc&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Tay-Sachsin tauti&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;TEIA-SAKSA BOLEZN', IDIOTIIA AMAVROTICHESKAIA DETSKAIA RANNIAIA, GANGLIOZIDOZ G(M2), TIP I, ГАНГЛИОЗИДОЗ G(M2), ТИП I, ИДИОТИЯ АМАВРОТИЧЕСКАЯ ДЕТСКАЯ РАННЯЯ, ТЕЯ-САКСА БОЛЕЗНЬ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Choroba Taya-Sachsa&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;Tay-Sachs-betegség&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;ziekte van Tay-Sachs, GM2-gangliosidose type I, Gangliosidose GM2 type I, Gangliosidose GM2, type I, Tay-Sachs, ziekte van, Ziekte van Tay-Sachs, Hexosaminidase-A-deficiëntieziekte&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Maladie de Tay-Sachs, Déficit en hexosaminidase A, Gangliosidose à GM2 de type 1, Gangliosidose à GM2 de type I, Gangliosidose à GM2 variante B&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Malattia di Tay-Sachs&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Amaurotic Familial Idiocy  (</value><value>)
</value><value>Tay-Sachs Disease  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Tay-Sachs Disease</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Metabolic Disorders</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;See Also&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Metabolism/LysmlStrgDs.htm" class="LinkPage"&gt;Lysosomal Storage Disease&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Metabolism/InbrnErrsOfMtblsm.htm" class="LinkPage"&gt;Inborn Errors of Metabolism&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Epidemiology&lt;ol&gt;&lt;li&gt;Hereditary recessive trait&lt;/li&gt;&lt;li&gt;Jews of eastern European origin&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Pathophysiology&lt;ol&gt;&lt;li&gt;Inborn error of metabolism&lt;/li&gt;&lt;li&gt;Abnormal metabolism of neuronal lipids&lt;/li&gt;&lt;li&gt;Results in cerebral atrophy&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Symptoms&lt;ol&gt;&lt;li&gt;Insidious onset at about 6 months of age&lt;/li&gt;&lt;li&gt;Healthy infants develop progressive developmental delay&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Signs&lt;ol&gt;&lt;li&gt;Initial Stages&lt;ol&gt;&lt;li&gt;Decreased motor activity&lt;/li&gt;&lt;li&gt;Flaccidity&lt;/li&gt;&lt;li&gt;Apathy&lt;/li&gt;&lt;li&gt;Inattentiveness&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Later Stages&lt;ol&gt;&lt;li&gt;Spasticity&lt;/li&gt;&lt;li&gt;&lt;a href="../../Neuro/Motor/MvmntDsrdr.htm" class="LinkPage"&gt;Clonus&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Babinski with upgoing toes&lt;/li&gt;&lt;li&gt;&lt;a href="../../Neuro/Seizure/Szr.htm" class="LinkPage"&gt;Convulsion&lt;/a&gt;s&lt;/li&gt;&lt;li&gt;Increasing &lt;a href="../../Neuro/Cognitive/Dmnt.htm" class="LinkPage"&gt;Dementia&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Final Stages&lt;ol&gt;&lt;li&gt;Blindness&lt;/li&gt;&lt;li&gt;Idiocy&lt;/li&gt;&lt;li&gt;&lt;a href="../../Eye/Anatomy/RtnlAntmy.htm" class="LinkPage"&gt;Retina&lt;/a&gt;l cherry red spot of &lt;a href="../../Eye/Retina/AgRltdMclrDgnrtn.htm" class="LinkPage"&gt;Macular Degeneration&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Course&lt;ol&gt;&lt;li&gt;Death occurs in first 3-4 years&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0282220</value><value>C0039373</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Metabolism/TySchsDs.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Tay-Sachs Disease, Amaurotic Familial Idiocy</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Metabolism/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees></FP_UMLS_Trees><FP_Condition_name_check></FP_Condition_name_check><FP_Condition_name><value>Radiation-Induced Thyroiditis</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Pharmacology</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Definition&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/Thyrdts.htm" class="LinkPage"&gt;Acute Thyroiditis&lt;/a&gt; due to neck radiation&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Epidemiology: &lt;a href="../../Prevent/Epi/DsIncdncRt.htm" class="LinkPage"&gt;Incidence&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Occurs in 1% of patients on &lt;a href="../../Endo/Pharm/Rdn.htm" class="LinkPage"&gt;I-131&lt;/a&gt; for &lt;a href="../../Endo/Thyroid/Hyprthyrdsm1.htm" class="LinkPage"&gt;Hyperthyroidism&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Causes&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Rdn.htm" class="LinkPage"&gt;Radioiodine&lt;/a&gt; therapy (&lt;a href="../../Endo/Pharm/Rdn.htm" class="LinkPage"&gt;I-131&lt;/a&gt;) for &lt;a href="../../Endo/Thyroid/Hyprthyrdsm1.htm" class="LinkPage"&gt;Hyperthyroidism&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Head and neck radiation for &lt;a href="../../HemeOnc/Lymph/Lymphm.htm" class="LinkPage"&gt;Lymphoma&lt;/a&gt;&lt;ol&gt;&lt;li&gt;High dose irradiation&lt;/li&gt;&lt;li&gt;Pre-existing &lt;a href="../../Endo/Thyroid/Hypthyrdsm.htm" class="LinkPage"&gt;Hypothyroidism&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Younger women&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Symptoms&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Anatomy/ThyrdAntmy.htm" class="LinkPage"&gt;Thyroid&lt;/a&gt; pain onset in first 1-2 weeks after &lt;a href="../../Endo/Pharm/Rdn.htm" class="LinkPage"&gt;I-131&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Signs&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Anatomy/ThyrdAntmy.htm" class="LinkPage"&gt;Thyroid&lt;/a&gt; tenderness to palpation&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Labs&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/ThyrdFnctnTst.htm" class="LinkPage"&gt;Thyroid Function Test&lt;/a&gt;s (TSH, T4 Free)&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/Hyprthyrdsm1.htm" class="LinkPage"&gt;Hyperthyroidism&lt;/a&gt; surges temporarily&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Management&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Anatomy/ThyrdAntmy.htm" class="LinkPage"&gt;Thyroid&lt;/a&gt; Pain&lt;ol&gt;&lt;li&gt;&lt;a href="../../Pharm/Analgesic/NnstrdlAntInflmtry.htm" class="LinkPage"&gt;NSAID&lt;/a&gt;s&lt;/li&gt;&lt;li&gt;Prednisone if refractory to &lt;a href="../../Pharm/Analgesic/NnstrdlAntInflmtry.htm" class="LinkPage"&gt;NSAID&lt;/a&gt;s&lt;ol&gt;&lt;li&gt;Short course at 40-60 mg orally daily with taper&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/Hyprthyrdsm1.htm" class="LinkPage"&gt;Hyperthyroidism&lt;/a&gt; symptoms&lt;ol&gt;&lt;li&gt;&lt;a href="../../CV/Pharm/BtBlckr.htm" class="LinkPage"&gt;Beta Blocker&lt;/a&gt; (e.g. &lt;a href="../../CV/Pharm/Prprnl.htm" class="LinkPage"&gt;Propranolol&lt;/a&gt;)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Course&lt;ol&gt;&lt;li&gt;Resolves in 6-18 weeks as &lt;a href="../../Endo/Anatomy/ThyrdAntmy.htm" class="LinkPage"&gt;Thyroid&lt;/a&gt; fibrosis occurs&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Bindra%20%20%5BAU%5D%20AND%202006%20%5BDP%5D%20AND%20%20Am%20Fam%20Physician%20%20%5BTA%5D" class="LinkRef"&gt;Bindra (2006) Am Fam Physician 73:1769-76&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Jereczek%20%20%5BAU%5D%20AND%202004%20%5BDP%5D%20AND%20%20Cancer%20Treat%20Rev%20%20%5BTA%5D" class="LinkRef"&gt;Jereczek (2004) Cancer Treat Rev 30:369-84&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Pharm/RdtnIndcdThyrdts.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Radiation-Induced Thyroiditis</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Pharm/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Bariatric Surgery  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C1456587"&gt;&lt;i&gt;C1456587&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;Surgery performed in morbidly obese patients to help promote weight loss. The procedure aims at the reduction of the stomach size and it is usually achieved either with the implantation of a medical device or the removal of part of the stomach.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MEDLINEPLUS)&lt;/td&gt;
                &lt;td&gt;
                  &lt;span&gt;
                    &lt;p&gt;If you're &lt;a href="http://www.nlm.nih.gov/medlineplus/obesity.html"&gt;very overweight&lt;/a&gt; and can't lose pounds with a healthy diet and exercise, surgery might be an option for you. The surgery is usually for men who are at least 100 pounds overweight and women who are at least 80 pounds overweight. If you are somewhat less overweight, surgery still might be an option if you also have diabetes, heart disease or sleep apnea. &lt;/p&gt;
                    &lt;p&gt;Weight loss surgery limits the amount of food you can take in. Some operations also restrict the amount of food you can digest.  Many people who have the surgery lose weight quickly. If you follow diet and exercise recommendations, you can keep most of the weight off. The surgery has risks and complications, however, including infections, hernias and blood clots.&lt;/p&gt;
                    &lt;p style="font-weight:bold;font-style:italic;"&gt;NIH: National Institute of Diabetes and Digestive and Kidney Diseases&lt;/p&gt;
                  &lt;/span&gt;
                &lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;Surgical procedures aimed at producing major WEIGHT REDUCTION in patients with MORBID OBESITY.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CSP)&lt;/td&gt;
                &lt;td&gt;surgical treatment of obesity.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Therapeutic or Preventive Procedure (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C1456587&amp;amp;tui=T061"&gt;&lt;i&gt;T061&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D050110&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Överviktsoperationer&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;bariatrická chirurgie, Bariatrická operace&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Lihavuuden kirurginen hoito&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Chirurgie bariatriche, Intervento bariatrico, Chirurgia bariatrica&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;BARIATRICHESKAIA KHIRURGIIA, БАРИАТРИЧЕСКАЯ ХИРУРГИЯ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Bariatric surgery, Weight Loss Surgery, Gastrointestinal Bariatric Surgery, Bariatric Surgery, Bariatric Surgeries, Surgeries, Bariatric, Surgery, Bariatric, weight loss surgery, bariatric surgery&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;Cirugía bariátrica, Cirugia Bariatrica, Cirugía Bariátrica&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Cirurgia bariátrica, Cirurgia Bariátrica&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;bariatrische chirurgie&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Chirurgie bariatrique, Chirurgie baryatrique, Chirurgie de l'obésité&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;bariatrische Chirurgie, Bariatrisch-chirurgische Eingriffe, Bariatrische Chirurgie, Bariatrische Operation&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;ｹﾞﾝﾘｮｳｼｭｼﾞｭﾂ, 減量手術, 肥満症治療手術, 肥満手術, 肥満治療手術, 肥満外科手術&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Croatian&lt;/td&gt;
                &lt;td&gt;Not Translated[Bariatric Surgery]&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Zabiegi bariatryczne, Operacje bariatryczne, Chirurgiczne leczenie otyłości&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;Kóros elhízás elleni műtét&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Gastroplasty  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0017193"&gt;&lt;i&gt;C0017193&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;Surgical procedures involving the STOMACH and sometimes the lower ESOPHAGUS to correct anatomical defects, or to treat MORBID OBESITY by reducing the size of the stomach. There are several subtypes of bariatric gastroplasty, such as vertical banded gastroplasty, silicone ring vertical gastroplasty, and horizontal banded gastroplasty.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Therapeutic or Preventive Procedure (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0017193&amp;amp;tui=T061"&gt;&lt;i&gt;T061&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D015391&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;9429009, 149361001, 149355004, 265867007&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Gastroplasties, Gastroplasty, Gastroplasty, NOS, gastroplasty, Plastic repair with reconstruction of stomach, Gastroplasty (procedure), GP - Gastroplasty, Plastic repair with reconstruction of stomach (procedure)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;cirugía plástica con reconstrucción del estómago, Gastroplasty, cirugía plástica con reconstrucción del estómago (procedimiento), gastroplastia, Gastroplastia&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Gastroplastik&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;gastroplastika, Gastroplastika&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Gastroplastia&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;GASTROPLASTIKA, ГАСТРОПЛАСТИКА&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Plastyka żołądka&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;gastroplastiek, Gastroplastiek&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;ｲｹｲｾｲ, 胃形成, 胃形成術, 胃成形術, 胃再建術&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;Gastroplastica&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Gastroplastie&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Gastroplastie, Magenplastik&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Gastroplastica&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Gastroplastia&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Biliopancreatic Diversion  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0005435"&gt;&lt;i&gt;C0005435&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;A surgical procedure which diverts pancreatobiliary secretions via the duodenum and the jejunum into the colon, the remaining small intestine being anastomosed to the stomach after antrectomy. The procedure produces less diarrhea than does jejunoileal bypass.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Therapeutic or Preventive Procedure (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0005435&amp;amp;tui=T061"&gt;&lt;i&gt;T061&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D015904&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Bilio Pancreatic Bypass, Bilio Pancreatic Bypasses, Bilio Pancreatic Diversion, Bilio Pancreatic Diversions, Bilio-Pancreatic Bypass, Bilio-Pancreatic Bypasses, Bilio-Pancreatic Diversion, Bilio-Pancreatic Diversions, Biliopancreatic Bypass, Biliopancreatic Bypasses, Biliopancreatic Diversion, Biliopancreatic Diversions, Bypass, Bilio-Pancreatic, Bypass, Biliopancreatic, Bypasses, Bilio Pancreatic, Bypasses, Bilio-Pancreatic, Bypasses, Biliopancreatic, Diversion, Bilio Pancreatic, Diversion, Bilio-Pancreatic, Diversions, Bilio Pancreatic, Diversions, Bilio-Pancreatic, Diversions, Biliopancreatic, Pancreatic Bypasses, Bilio, Pancreatic Diversion, Bilio, Pancreatic Diversions, Bilio, biliopancreatic bypass, biliopancreatic diversion, Biliopancreatic bypass&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;biliopancreatische bypass, Biliopancreatische bypass, Bypass, biliopancreatische&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Court-circuit biliopancréatique, Bypass biliopancréatique, Bypass bilio-pancréatique, Dérivation bilio-pancréatique, DBP (Dérivation BilioPancréatique), Dérivation biliopancréatique&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;biliopankreatischer Bypass, Biliopankreatischer Bypass, Pankreatobiläre Umleitung&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Bypass biliopancreático, Derivação Biliopancreática, Desvio Biliopancreático&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;Derivación biliopancreática, Derivacion Biliopancreatica, Desviacion Biliopancreatica, Derivación Biliopancreática, Desviación Biliopancreática&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;胆膵路バイパス, ﾀﾝｽｲﾛﾊﾞｲﾊﾟｽ, 胆膵路転換手術, 胆膵バイパス術, 胆膵消化回避術, バイパス術-胆膵, 胆膵バイパス&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Biliopankreasavledning&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;biliopankreatická diverze, Biliopancreatický bypass&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Biliopankreaattinen diversio&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;ZHELCH' I PANKREATICHESKII SOK, OTVEDENIE, BILIOPANKREATICHESKOE SHUNTIROVANIE, BAIPASS BILIOPANKREATICHESKII, BILIOPANKREATICHESKOE OTVEDENIE, ZHELCHI I PODZHELUDOCHNOI ZHELEZY SOKA OTVEDENIE, БАЙПАСС БИЛИОПАНКРЕАТИЧЕСКИЙ, БИЛИОПАНКРЕАТИЧЕСКОЕ ОТВЕДЕНИЕ, БИЛИОПАНКРЕАТИЧЕСКОЕ ШУНТИРОВАНИЕ, ЖЕЛЧИ И ПОДЖЕЛУДОЧНОЙ ЖЕЛЕЗЫ СОКА ОТВЕДЕНИЕ, ЖЕЛЧЬ И ПАНКРЕАТИЧЕСКИЙ СОК, ОТВЕДЕНИЕ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Deviazione bilio-pancreatica, Deviazioni bilio pancreatiche, Bypass bilio-pancreatico, Bypass biliopancreatico, Bypass bilio pancreatici, Deviazione biliopancreatica&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Odprowadzenie żółciowo-trzustkowe, Bypass żółciowo-trzustkowy, Wyłączenie żółciowo-trzustkowe&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;Biliopancreaticus bypass&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Bariatric Surgery  (</value><value>)
</value><value>Gastroplasty  (</value><value>)
</value><value>Biliopancreatic Diversion  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Obesity Surgery</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Surgery</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Indication: &lt;a href="../../Endo/Obesity/Obsty.htm" class="LinkPage"&gt;Obesity&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Exam/BdyMsIndx.htm" class="LinkPage"&gt;Body Mass Index&lt;/a&gt; (BMI) &amp;gt;= 40 kg/m2&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Exam/BdyMsIndx.htm" class="LinkPage"&gt;Body Mass Index&lt;/a&gt; (BMI) &amp;gt;= 35 kg/m2 with comorbidity (e.g. Diabetes, &lt;a href="../../CV/Myocardium/Crdmypthy.htm" class="LinkPage"&gt;Cardiomyopathy&lt;/a&gt;)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Contraindications&lt;ol&gt;&lt;li&gt;High risk cardiopulmonary disease&lt;/li&gt;&lt;li&gt;Ongoing &lt;a href="../../Psych/CD/ChmclDpndncy.htm" class="LinkPage"&gt;Drug Abuse&lt;/a&gt;, &lt;a href="../../Psych/CD/AlchlAbs.htm" class="LinkPage"&gt;Alcohol Abuse&lt;/a&gt; or other uncontrolled mental health disorder&lt;/li&gt;&lt;li&gt;Reversible pathologic causes of &lt;a href="../../Endo/Obesity/Obsty.htm" class="LinkPage"&gt;Obesity&lt;/a&gt; (e.g. endocrine disorder)&lt;/li&gt;&lt;li&gt;Poor insight into the risks, benefits, lifestyle investment, alternative options, or expected outcomes&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Procedures: Common&lt;ol&gt;&lt;li&gt;Roux-en-Y gastric bypass (RYGB)&lt;ol&gt;&lt;li&gt;Gold standard method today&lt;/li&gt;&lt;li&gt;Description&lt;ol&gt;&lt;li&gt;&lt;a href="../../GI/Anatomy/StmchAntmy.htm" class="LinkPage"&gt;Stomach&lt;/a&gt; partitioned into 20 ml pouch&lt;/li&gt;&lt;li&gt;Pouch anastomosed to jejunum&lt;/li&gt;&lt;li&gt;Remainder of &lt;a href="../../GI/Anatomy/StmchAntmy.htm" class="LinkPage"&gt;Stomach&lt;/a&gt; and duodenum bypassed&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Efficacy:  Weight loss 30-40% at 1 year and 25% at 10 years&lt;/li&gt;&lt;li&gt;Perioperative mortality: &amp;lt;0.3%&lt;/li&gt;&lt;li&gt;Disadvantages&lt;ol&gt;&lt;li&gt;Malabsorption of iron, B12 and calcium&lt;/li&gt;&lt;li&gt;Technically difficult with higher morbidity&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Laparoscopic Adjustable Gastric Banding (introduced in 2006)&lt;ol&gt;&lt;li&gt;Reversible and tension can be adjusted via port&lt;/li&gt;&lt;li&gt;Replaces Vertical Banded Gastroplasty&lt;/li&gt;&lt;li&gt;Weight loss 21% at 1 year and 13% at 10 years&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Procedures: Other newer procedures&lt;ol&gt;&lt;li&gt;Biliopancreatic Diversion (introduced in 2004)&lt;ol&gt;&lt;li&gt;Very effective in super-obese patients (BMI&amp;gt;50 kg/m)&lt;/li&gt;&lt;li&gt;Weight loss 40% at 1 year and 30-40% at 10 years&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Gastric Sleeve (introduced in 2008)&lt;ol&gt;&lt;li&gt;Lateral &lt;a href="../../GI/Anatomy/StmchAntmy.htm" class="LinkPage"&gt;Stomach&lt;/a&gt; excised leaving a smaller residual &lt;a href="../../GI/Anatomy/StmchAntmy.htm" class="LinkPage"&gt;Stomach&lt;/a&gt; pouch&lt;/li&gt;&lt;li&gt;Promising new procedure with high efficacy and lower adverse effects (e.g. no dumping)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Procedures: Not recommended&lt;ol&gt;&lt;li&gt;Jejunoileal Bypass (Distal Gastric Bypass)&lt;ol&gt;&lt;li&gt;Less commonly performed since 1985 (with a few exceptions)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Vertical Banded Gastroplasty (VBG or &lt;a href="../../GI/Anatomy/StmchAntmy.htm" class="LinkPage"&gt;Stomach&lt;/a&gt; stapling)&lt;ol&gt;&lt;li&gt;Less commonly performed since 1989 due to low long-term efficacy&lt;ol&gt;&lt;li&gt;Replaced by Adjustable Gastric Banding&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Efficacy&lt;ol&gt;&lt;li&gt;At 3 years: 40-63% excess &lt;a href="../../Endo/Obesity/ObstyMngmnt.htm" class="LinkPage"&gt;Weight Reduction&lt;/a&gt;&lt;/li&gt;&lt;li&gt;At 10 years: 20% excess &lt;a href="../../Endo/Obesity/ObstyMngmnt.htm" class="LinkPage"&gt;Weight Reduction&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Disadvantages&lt;ol&gt;&lt;li&gt;Less effective than Roux-en-Y Procedure&lt;/li&gt;&lt;li&gt;High surgical revision rate (41-45%)&lt;ol&gt;&lt;li&gt;Due to high rate of staple dehiscence&lt;/li&gt;&lt;li&gt;Once staple line opens, weight gain returns&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Higher risk of stricture or &lt;a href="../../GI/Esophagus/GstrsphglRflx.htm" class="LinkPage"&gt;GERD&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Perioperative mortality: 0-1.0%&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;These procedures not recommended by NIH panel&lt;ol&gt;&lt;li&gt;Significantly higher risk of complications&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Complications: Acute serious complications&lt;ol&gt;&lt;li&gt;Perioperative Mortality&lt;ol&gt;&lt;li&gt;Procedure Type&lt;ol&gt;&lt;li&gt;Roux-en-Y gastric bypass (RYGB): &amp;lt;0.3% mortality&lt;/li&gt;&lt;li&gt;Biliopancreatic Diversion (BPD-DS): &amp;lt;0.3% mortality&lt;/li&gt;&lt;li&gt;Laparoscopic Adjustable Gastric Banding (LAGB): &amp;lt;0.1% mortality&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Patient factors: Highest risk&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Exam/BdyMsIndx.htm" class="LinkPage"&gt;Body Mass Index&lt;/a&gt; (BMI) over 60 kg/m2: 3% mortality&lt;/li&gt;&lt;li&gt;Age over 60 years: 1% mortality&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Patient factors: Additive risks (Mortality increases from 0.2% up to 2.4% if at least 4 criteria are present)&lt;ol&gt;&lt;li&gt;Age over 45 years old&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Htn/Hyprtnsn.htm" class="LinkPage"&gt;Hypertension&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Male gender&lt;/li&gt;&lt;li&gt;&lt;a href="../../Lung/CV/PlmnryEmblsm.htm" class="LinkPage"&gt;Pulmonary Embolism&lt;/a&gt; risk (DVT history, &lt;a href="../../CV/Lung/PlmnryHyprtnsn.htm" class="LinkPage"&gt;Pulmonary Hypertension&lt;/a&gt;, &lt;a href="../../Endo/Obesity/Obsty.htm" class="LinkPage"&gt;Obesity&lt;/a&gt;-related hypoventilation)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Exam/BdyMsIndx.htm" class="LinkPage"&gt;Body Mass Index&lt;/a&gt; &amp;gt;50&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Thromboembolic complications&lt;ol&gt;&lt;li&gt;See peri-operative thromboembolism prophylaxis below&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Anastomotic Leak (and secondary &lt;a href="../../ID/Fever/Sps1.htm" class="LinkPage"&gt;Sepsis&lt;/a&gt;)&lt;ol&gt;&lt;li&gt;Leak at anastomosis or banding site&lt;/li&gt;&lt;li&gt;Requires emergency evaluation&lt;/li&gt;&lt;li&gt;Presentation&lt;ol&gt;&lt;li&gt;Severe &lt;a href="../../Surgery/GI/ActAbdmnlPn.htm" class="LinkPage"&gt;Abdominal Pain&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../ID/Exam/Fvr.htm" class="LinkPage"&gt;Fever&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Hypotensive shock&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Exam/HrtRt.htm" class="LinkPage"&gt;Heart Rate&lt;/a&gt; over 120 associated with &lt;a href="../../Surgery/GI/ActAbdmnlPn.htm" class="LinkPage"&gt;Abdominal Pain&lt;/a&gt; increases &lt;a href="../../Prevent/Epi/TstSpcfcty.htm" class="LinkPage"&gt;Specificity&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Evaluation&lt;ol&gt;&lt;li&gt;CT &lt;a href="../../GI/Anatomy/AbdmnlAntmy.htm" class="LinkPage"&gt;Abdomen&lt;/a&gt; with contrast (only 60% sensitive)&lt;/li&gt;&lt;li&gt;Urgent surgical consultation&lt;ol&gt;&lt;li&gt;May require exploration despite negative CT &lt;a href="../../GI/Anatomy/AbdmnlAntmy.htm" class="LinkPage"&gt;Abdomen&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Surgery/IntrnlHrn.htm" class="LinkPage"&gt;Internal Hernia&lt;/a&gt; (occurs in up to 3% of retrocolic bypass procedures)&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Endo/Surgery/IntrnlHrn.htm" class="LinkPage"&gt;Internal Hernia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Requires immediate surgical consultation&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Complications: Short-term&lt;ol&gt;&lt;li&gt;&lt;a href="../../Surgery/Derm/Wnd.htm" class="LinkPage"&gt;Wound&lt;/a&gt; infection&lt;ol&gt;&lt;li&gt;Occurs up to 3 weeks after surgery&lt;/li&gt;&lt;li&gt;Risk of developing &lt;a href="../../Surgery/GI/IncsnlHrn.htm" class="LinkPage"&gt;Incisional Hernia&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Stomal stenosis&lt;ol&gt;&lt;li&gt;Results in &lt;a href="../../GI/Sx/Vmtng.htm" class="LinkPage"&gt;Vomiting&lt;/a&gt; even with liquid meals&lt;/li&gt;&lt;li&gt;Evaluate Upper gastrointestinal series&lt;/li&gt;&lt;li&gt;Treat with dilatation via upper endoscopy&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Peptic ulcer at surgical anastomosis (marginal ulcer)&lt;ol&gt;&lt;li&gt;Evaluate with upper endoscopy&lt;/li&gt;&lt;li&gt;Avoid &lt;a href="../../Pharm/Analgesic/NnstrdlAntInflmtry.htm" class="LinkPage"&gt;NSAID&lt;/a&gt;s&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../GI/Constipation/CnstptnInAdlts.htm" class="LinkPage"&gt;Constipation&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Maximize hydration (96 ounces clear fluid daily)&lt;/li&gt;&lt;li&gt;Minimize &lt;a href="../../Pharm/Analgesic/NrctcAnlgsc.htm" class="LinkPage"&gt;Narcotic Analgesic&lt;/a&gt;s post-operatively&lt;/li&gt;&lt;li&gt;Avoid &lt;a href="../../Pharm/Nutrition/Fbr.htm" class="LinkPage"&gt;Bulk Laxative&lt;/a&gt;s after gastric banding&lt;ol&gt;&lt;li&gt;Risk of obstruction&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Complications: Long-term&lt;ol&gt;&lt;li&gt;&lt;a href="../../Surgery/GI/Glstn.htm" class="LinkPage"&gt;Cholelithiasis&lt;/a&gt; or &lt;a href="../../Surgery/GI/ActChlcysts.htm" class="LinkPage"&gt;Cholecystitis&lt;/a&gt; (30% of patients)&lt;ol&gt;&lt;li&gt;Consider &lt;a href="../../Surgery/Procedure/Chlcystctmy.htm" class="LinkPage"&gt;Cholecystectomy&lt;/a&gt; at time of Bariatric Surgery&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Uro/Renal/Nphrlths.htm" class="LinkPage"&gt;Nephrolithiasis&lt;/a&gt; related to &lt;a href="../../Uro/Renal/ClcmNphrlths.htm" class="LinkPage"&gt;Calcium Oxalate Stone&lt;/a&gt; formation&lt;/li&gt;&lt;li&gt;Secondary &lt;a href="../../Endo/Parathyroid/Hyprprthyrdsm.htm" class="LinkPage"&gt;Hyperparathyroidism&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Malabsorption&lt;ol&gt;&lt;li&gt;See lab monitoring below&lt;/li&gt;&lt;li&gt;See post-operative diet below&lt;/li&gt;&lt;li&gt;Dumping Syndrome (60% of patients)&lt;/li&gt;&lt;li&gt;Protein-calorie malnutrition&lt;/li&gt;&lt;li&gt;Fat malabsorption&lt;/li&gt;&lt;li&gt;&lt;a href="../../GI/Malabsorption/LctsDfcncy.htm" class="LinkPage"&gt;Lactose Intolerance&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Beef intolerance (due to heightened sense of taste and smell)&lt;/li&gt;&lt;li&gt;Calcium malabsorption&lt;/li&gt;&lt;li&gt;Micronutrient deficiency (Copper deficiency, &lt;a href="../../Pharm/Minerals/ZncDfcncy.htm" class="LinkPage"&gt;Zinc Deficiency&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Pharm/Vitamins/VtmnA.htm" class="LinkPage"&gt;Vitamin A&lt;/a&gt; deficiency&lt;/li&gt;&lt;li&gt;&lt;a href="../../HemeOnc/Anemia/Anm.htm" class="LinkPage"&gt;Anemia&lt;/a&gt; due to &lt;a href="../../Pharm/Vitamins/VtmnDfcncy.htm" class="LinkPage"&gt;Vitamin Deficiency&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../HemeOnc/Anemia/IrnDfcncyAnm.htm" class="LinkPage"&gt;Iron Deficiency Anemia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../HemeOnc/Anemia/FltDfcncy.htm" class="LinkPage"&gt;Folate Deficiency&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../HemeOnc/Anemia/VtmnBDfcncy.htm" class="LinkPage"&gt;Vitamin B12 Deficiency&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Overall body changes&lt;ol&gt;&lt;li&gt;&lt;a href="../../Derm/Anatomy/Hr.htm" class="LinkPage"&gt;Hair&lt;/a&gt; thinning (due to rapid weight loss)&lt;ol&gt;&lt;li&gt;Supplement with more dietary protein&lt;/li&gt;&lt;li&gt;Consider Biotin&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Gyn/Menses/AnvltryBldng.htm" class="LinkPage"&gt;Metrorrhagia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Fertility increases&lt;ol&gt;&lt;li&gt;Use reliable &lt;a href="../../Gyn/Contraception/Cntrcptn.htm" class="LinkPage"&gt;Contraception&lt;/a&gt; to avoid pregnancy within first 2 years after surgery&lt;/li&gt;&lt;li&gt;Food intolerance&lt;ol&gt;&lt;li&gt;&lt;a href="../../GI/Malabsorption/LctsDfcncy.htm" class="LinkPage"&gt;Lactose Intolerance&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Beef intolerance (due to hypersensitivity to taste and smell)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Altered medication absorption&lt;ol&gt;&lt;li&gt;Gastric banding (gastric restriction)&lt;ol&gt;&lt;li&gt;Consider switch from XR to immediate release agents&lt;/li&gt;&lt;li&gt;Take one medication at a time&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Gastric Bypass&lt;ol&gt;&lt;li&gt;Monitor &lt;a href="../../CV/Pharm/Dgxn.htm" class="LinkPage"&gt;Digoxin&lt;/a&gt; and &lt;a href="../../Endo/Pharm/ThyrdHrmnRplcmnt.htm" class="LinkPage"&gt;Levothyroxine&lt;/a&gt; dosing closely&lt;/li&gt;&lt;li&gt;&lt;a href="../../Sports/Exercise/Exrcs.htm" class="LinkPage"&gt;Exercise&lt;/a&gt; caution when using &lt;a href="../../Derm/Pharm/ImdzlAntfngl.htm" class="LinkPage"&gt;Azole Antifungal&lt;/a&gt;s&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Bacterial overgrowth&lt;ol&gt;&lt;li&gt;Presents with abdominal distention, &lt;a href="../../GI/Rectum/Prcts.htm" class="LinkPage"&gt;Proctitis&lt;/a&gt;, nighttime &lt;a href="../../GI/Diarrhea/ActDrh.htm" class="LinkPage"&gt;Diarrhea&lt;/a&gt;, and arthralgias&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Panus: 	Paniculectomy indications&lt;ol&gt;&lt;li&gt;Refractory skin irritation&lt;/li&gt;&lt;li&gt;Panus severe enough to cover genitalia&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Efficacy&lt;ol&gt;&lt;li&gt;Bariatric Surgery may cure diabetes in morbid &lt;a href="../../Endo/Obesity/Obsty.htm" class="LinkPage"&gt;Obesity&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Rubino%20%20%5BAU%5D%20AND%202002%20%5BDP%5D%20AND%20%20Ann%20Surg%20%20%5BTA%5D" class="LinkRef"&gt;Rubino (2002) Ann Surg 236:554-9&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Significantly reduces morbidity and mortality&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/DM/DbtsMlts.htm" class="LinkPage"&gt;Diabetes Mellitus&lt;/a&gt; 76% resolved or improved&lt;/li&gt;&lt;li&gt;Total and &lt;a href="../../CV/Lab/LdlChlstrl.htm" class="LinkPage"&gt;LDL Cholesterol&lt;/a&gt; was significantly reduced&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Htn/Hyprtnsn.htm" class="LinkPage"&gt;Hypertension&lt;/a&gt; resolved in 61% (improved in 78%)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Lung/Apnea/SlpApn.htm" class="LinkPage"&gt;Sleep Apnea&lt;/a&gt; resolved or improved in 83%&lt;/li&gt;&lt;li&gt;Mortality over 9 years reduced from 28% to 9%&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Buchwald%20%20%5BAU%5D%20AND%202004%20%5BDP%5D%20AND%20%20JAMA%20%20%5BTA%5D" class="LinkRef"&gt;Buchwald (2004) JAMA 292:1724-37&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Labs: Preoperative evaluation&lt;ol&gt;&lt;li&gt;Comprehensive metabolic panel (renal and hepatic panel)&lt;/li&gt;&lt;li&gt;&lt;a href="../../HemeOnc/Lab/CmpltBldCnt.htm" class="LinkPage"&gt;Complete Blood Count&lt;/a&gt; with platelets&lt;/li&gt;&lt;li&gt;Coagulation studies (INR and PTT)&lt;/li&gt;&lt;li&gt;Fasting lipid panel&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/ThyrdStmltngHrmn.htm" class="LinkPage"&gt;Thyroid Stimulating Hormone&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Pharm/Vitamins/VtmnD.htm" class="LinkPage"&gt;Vitamin D&lt;/a&gt; (25-hydroxyvitamin D)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Pharm/Vitamins/VtmnB.htm" class="LinkPage"&gt;Vitamin B12&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Pharm/Vitamins/VtmnB6.htm" class="LinkPage"&gt;Vitamin B6&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Pharm/Vitamins/Thmn.htm" class="LinkPage"&gt;Vitamin B1&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Uro/Lab/Urnlys.htm" class="LinkPage"&gt;Urinalysis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Lung/Rad/ChstXry.htm" class="LinkPage"&gt;Chest XRay&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Exam/Elctrcrdgrm.htm" class="LinkPage"&gt;Electrocardiogram&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Labs: Monitoring schedule post-procedure&lt;ol&gt;&lt;li&gt;Three months after surgery&lt;ol&gt;&lt;li&gt;&lt;a href="../../HemeOnc/Lab/CmpltBldCnt.htm" class="LinkPage"&gt;Complete Blood Count&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Glucose&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Renal/Lab/SrmCrtn.htm" class="LinkPage"&gt;Serum Creatinine&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Six months after surgery&lt;ol&gt;&lt;li&gt;&lt;a href="../../HemeOnc/Lab/CmpltBldCnt.htm" class="LinkPage"&gt;Complete Blood Count&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Glucose&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Renal/Lab/SrmCrtn.htm" class="LinkPage"&gt;Serum Creatinine&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Renal/Lab/SrmClcm.htm" class="LinkPage"&gt;Serum Calcium&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../GI/Lab/LvrFnctnTst.htm" class="LinkPage"&gt;Liver Function Test&lt;/a&gt;s&lt;/li&gt;&lt;li&gt;&lt;a href="../../GI/Lab/SrmPrtn.htm" class="LinkPage"&gt;Serum Protein&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../GI/Lab/SrmAlbmn.htm" class="LinkPage"&gt;Serum Albumin&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../HemeOnc/Lab/SrmFrtn.htm" class="LinkPage"&gt;Serum Ferritin&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Serum &lt;a href="../../Pharm/Vitamins/VtmnB.htm" class="LinkPage"&gt;Vitamin B12&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Serum &lt;a href="../../Pharm/Vitamins/FlcAcd.htm" class="LinkPage"&gt;Folic Acid&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Nine months after surgery&lt;ol&gt;&lt;li&gt;&lt;a href="../../HemeOnc/Lab/CmpltBldCnt.htm" class="LinkPage"&gt;Complete Blood Count&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Glucose&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Renal/Lab/SrmCrtn.htm" class="LinkPage"&gt;Serum Creatinine&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;One year after surgery and then every year therafter&lt;ol&gt;&lt;li&gt;&lt;a href="../../HemeOnc/Lab/CmpltBldCnt.htm" class="LinkPage"&gt;Complete Blood Count&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Glucose&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Renal/Lab/SrmCrtn.htm" class="LinkPage"&gt;Serum Creatinine&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../HemeOnc/Lab/SrmFrtn.htm" class="LinkPage"&gt;Serum Ferritin&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Serum &lt;a href="../../Pharm/Vitamins/VtmnB.htm" class="LinkPage"&gt;Vitamin B12&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Serum &lt;a href="../../Pharm/Vitamins/VtmnD.htm" class="LinkPage"&gt;Vitamin D&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Serum &lt;a href="../../Pharm/Vitamins/VtmnA.htm" class="LinkPage"&gt;Vitamin A&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Other labs to consider&lt;ol&gt;&lt;li&gt;Serum &lt;a href="../../Pharm/Vitamins/Thmn.htm" class="LinkPage"&gt;Thiamine&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Serum Copper&lt;/li&gt;&lt;li&gt;Serum &lt;a href="../../Pharm/Minerals/Znc.htm" class="LinkPage"&gt;Zinc&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Renal/Lab/SrmMgnsm.htm" class="LinkPage"&gt;Serum Magnesium&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Serum &lt;a href="../../Pharm/Vitamins/VtmnB6.htm" class="LinkPage"&gt;Vitamin B6&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Management: Pre-operative Evaluation&lt;ol&gt;&lt;li&gt;Preoperative bariatric evaluation is identical to that in non-obese, non-Bariatric Surgery patients&lt;ol&gt;&lt;li&gt;Exceptions: &lt;a href="../../Lung/Apnea/ObstrctvSlpApn.htm" class="LinkPage"&gt;Obstructive Sleep Apnea&lt;/a&gt; and &lt;a href="../../HemeOnc/CV/DpVnThrmbs.htm" class="LinkPage"&gt;Venous Thromboembolism&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Lung/Apnea/ObstrctvSlpApn.htm" class="LinkPage"&gt;Obstructive Sleep Apnea&lt;/a&gt; (not yet evaluated)&lt;ol&gt;&lt;li&gt;Uncontrolled &lt;a href="../../Lung/Apnea/SlpApn.htm" class="LinkPage"&gt;Sleep Apnea&lt;/a&gt; is a significant risk factor for anastomotic leak&lt;/li&gt;&lt;li&gt;&lt;a href="../../Lung/Apnea/ObstrctvSlpApn.htm" class="LinkPage"&gt;Obstructive Sleep Apnea&lt;/a&gt;&lt;a href="../../Prevent/Epi/DsPrvlncRt.htm" class="LinkPage"&gt;Prevalence&lt;/a&gt; approaches 75% of patients pursuing Bariatric Surgery&lt;/li&gt;&lt;li&gt;Delay procedure for &lt;a href="../../Lung/Apnea/SlpApn.htm" class="LinkPage"&gt;Sleep Apnea&lt;/a&gt; evaluation with formal polysomonography&lt;ol&gt;&lt;li&gt;If positive for &lt;a href="../../Lung/Apnea/SlpApn.htm" class="LinkPage"&gt;Sleep Apnea&lt;/a&gt;, start &lt;a href="../../Lung/Procedure/CntnsPstvArwysPrsr.htm" class="LinkPage"&gt;CPAP&lt;/a&gt; and delay surgery for 4 weeks&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../HemeOnc/CV/DpVnThrmbs.htm" class="LinkPage"&gt;Venous Thromboembolism&lt;/a&gt; prophylaxis&lt;ol&gt;&lt;li&gt;Common (1-3%) and a leading cause of mortality following Bariatric Surgery&lt;/li&gt;&lt;li&gt;Risk Factors&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Exam/BdyMsIndx.htm" class="LinkPage"&gt;Body Mass Index&lt;/a&gt; &amp;gt;60 kg/m2&lt;/li&gt;&lt;li&gt;Chronic &lt;a href="../../Renal/Edema/LgEdm.htm" class="LinkPage"&gt;Leg Edema&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Lung/Apnea/ObstrctvSlpApn.htm" class="LinkPage"&gt;Obstructive Sleep Apnea&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Prior thromboembolism&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Best prophylactic strategy is unclear&lt;ol&gt;&lt;li&gt;Removable IVC Filters are commonly used in high risk patients (but inadequate evidence)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Reasonable strategy&lt;ol&gt;&lt;li&gt;Well-fitted &lt;a href="../../Surgery/Pharm/CmprsnStckngs.htm" class="LinkPage"&gt;Compression stockings&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Early ambulation&lt;/li&gt;&lt;li&gt;&lt;a href="../../HemeOnc/Pharm/LwMlclrWghtHprn.htm" class="LinkPage"&gt;Enoxaparin&lt;/a&gt; 30 mg bid (40 mg bid if BMI&amp;gt;50)&lt;/li&gt;&lt;li&gt;Consider removable IVC Filter for high risk patients&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Management: Diet post-operative&lt;ol&gt;&lt;li&gt;Dietary changes to avoid over-distention and &lt;a href="../../GI/Sx/Vmtng.htm" class="LinkPage"&gt;Vomiting&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Immediately after Gastric Bypass&lt;ol&gt;&lt;li&gt;Start with clear liquids and gradually progress to regular foods over first 3 months&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Longterm&lt;ol&gt;&lt;li&gt;Start meal with protein portion to ensure adequate protein intake&lt;/li&gt;&lt;li&gt;Cut food into small bite size amounts (as if using toddler utensils)&lt;/li&gt;&lt;li&gt;Chew well (to applesauce consistency) before swallowing&lt;/li&gt;&lt;li&gt;Eat slowly and without distraction (finish a meal within 30 minutes)&lt;/li&gt;&lt;li&gt;Avoid drinking fluids 30 minutes before and 30-60 minutes after each meal&lt;/li&gt;&lt;li&gt;Identify fullness sensation and stop eating immediately when you feel this&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Other dietary changes&lt;ol&gt;&lt;li&gt;Limits foods with substantial simple carbohydrates or high fats (avoids dumping)&lt;/li&gt;&lt;li&gt;Stay hydrated by taking 64 ounces non-caffeinated fluid and avoiding &lt;a href="../../Psych/Pharm/Alchl.htm" class="LinkPage"&gt;Alcohol&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Vitamin supplementation&lt;ol&gt;&lt;li&gt;Multivitamin chewable once to twice daily (twice if status-post roux-en-y)&lt;/li&gt;&lt;li&gt;&lt;a href="../../HemeOnc/Pharm/VtmnBSplmntn.htm" class="LinkPage"&gt;Vitamin B12 Supplementation&lt;/a&gt; (1000 mcg IM monthly or 350 mcg orally daily)&lt;/li&gt;&lt;li&gt;Calcium 1200 to 1500 mg daily&lt;/li&gt;&lt;li&gt;&lt;a href="../../Pharm/Vitamins/VtmnD.htm" class="LinkPage"&gt;Vitamin D&lt;/a&gt; 800 IU daily (2000 IU daily if status-post roux-en-y)&lt;/li&gt;&lt;li&gt;&lt;a href="../../HemeOnc/Pharm/IrnSplmntn.htm" class="LinkPage"&gt;Iron Supplementation&lt;/a&gt; 18-27 mg/day (higher in menstruating women)&lt;/li&gt;&lt;li&gt;Maintain adequate dietary protein intake (see above)&lt;/li&gt;&lt;li&gt;Additional supplements if deficiency identified (recheck monthly until normal)&lt;ol&gt;&lt;li&gt;&lt;a href="../../Pharm/Vitamins/Thmn.htm" class="LinkPage"&gt;Thiamine&lt;/a&gt; 50 mg orally daily for 6 months&lt;/li&gt;&lt;li&gt;&lt;a href="../../Pharm/Vitamins/VtmnB6.htm" class="LinkPage"&gt;Vitamin B6&lt;/a&gt; 50 mg orally daily&lt;/li&gt;&lt;li&gt;Folate 1 mg orally daily&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Follow-up: Post-operative&lt;ol&gt;&lt;li&gt;Imperative that patients continue life-long care&lt;ol&gt;&lt;li&gt;Compliance with diet above&lt;/li&gt;&lt;li&gt;Maintenance of regular physical &lt;a href="../../Sports/Exercise/Exrcs.htm" class="LinkPage"&gt;Exercise&lt;/a&gt; program&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Monitoring of labs (see above)&lt;/li&gt;&lt;li&gt;Pregnancy&lt;ol&gt;&lt;li&gt;Delay pregnancy for &amp;gt;18-24 months post-procedure&lt;/li&gt;&lt;li&gt;Supplement&lt;ol&gt;&lt;li&gt;Protein: Additional extra 10 grams per day&lt;/li&gt;&lt;li&gt;&lt;a href="../../Pharm/Vitamins/VtmnB.htm" class="LinkPage"&gt;Vitamin B12&lt;/a&gt;: 1000 mcg sublingual weekly&lt;/li&gt;&lt;li&gt;&lt;a href="../../Pharm/Vitamins/FlcAcd.htm" class="LinkPage"&gt;Folic Acid&lt;/a&gt; 800 mg orally daily&lt;/li&gt;&lt;li&gt;&lt;a href="../../HemeOnc/Exam/RdBldClPhyslgy.htm" class="LinkPage"&gt;Iron&lt;/a&gt; 325 mg orally daily&lt;/li&gt;&lt;li&gt;&lt;a href="../../Pharm/Vitamins/VtmnC.htm" class="LinkPage"&gt;Vitamin C&lt;/a&gt; 500 mg orally daily&lt;/li&gt;&lt;li&gt;Calcium 1200 mg orally daily&lt;/li&gt;&lt;li&gt;Prevent additional weight loss and expect weight gain during pregnancy&lt;/li&gt;&lt;li&gt;Consider adjustment of band pressure&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Continued education and reevaluation&lt;ol&gt;&lt;li&gt;Dieticians&lt;/li&gt;&lt;li&gt;Nurses&lt;/li&gt;&lt;li&gt;Surgical follow-up&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Balsiger%20%20%5BAU%5D%20AND%202000%20%5BDP%5D%20AND%20%20Mayo%20Clin%20Proc%20%20%5BTA%5D" class="LinkRef"&gt;Balsiger (2000) Mayo Clin Proc 75:673-80&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Buchwald%20%20%5BAU%5D%20AND%202004%20%5BDP%5D%20AND%20%20JAMA%20%20%5BTA%5D" class="LinkRef"&gt;Buchwald (2004) JAMA 292:1724-37&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Choban%20%20%5BAU%5D%20AND%201997%20%5BDP%5D%20AND%20%20J%20Am%20Coll%20Surg%20%20%5BTA%5D" class="LinkRef"&gt;Choban (1997) J Am Coll Surg 185:593-603&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Virji%20%20%5BAU%5D%20AND%202006%20%5BDP%5D%20AND%20%20Am%20Fam%20Physician%20%20%5BTA%5D" class="LinkRef"&gt;Virji (2006) Am Fam Physician 73:1403-8&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Schroeder%20%20%5BAU%5D%20AND%202011%20%5BDP%5D%20AND%20%20Am%20Fam%20Physician%20%20%5BTA%5D" class="LinkRef"&gt;Schroeder (2011) Am Fam Physician 84(7): 805-14&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C1456587</value><value>C0017193</value><value>C0005435</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Surgery/ObstySrgry.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Obesity Surgery, Roux-en-Y gastric bypass, Vertical Banded Gastroplasty, Distal Gastric Bypass, Biliopancreatic Diversion, Gastric Bypass, Gastroplasty, Bariatric Surgery</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Surgery/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees></FP_UMLS_Trees><FP_Condition_name_check></FP_Condition_name_check><FP_Condition_name><value>Perioperative Diabetes Management</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Surgery</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;See Also&lt;ol&gt;&lt;li&gt;&lt;a href="../../Surgery/Exam/PrprtvExmntn.htm" class="LinkPage"&gt;Preoperative Examination&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../HemeOnc/Prevent/DpVnThrmbsPrvntn.htm" class="LinkPage"&gt;Deep Vein Thrombosis Prevention&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../HemeOnc/Surgery/PrprtvAntcgltn.htm" class="LinkPage"&gt;Perioperative Anticoagulation&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/ID/SbPrphylxs.htm" class="LinkPage"&gt;Endocarditis Prophylaxis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../GI/Surgery/PstprtvNsAndVmtng.htm" class="LinkPage"&gt;Postoperative Nausea and Vomiting Prevention&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Preoperative Evaluation&lt;ol&gt;&lt;li&gt;Cardiovascular risk&lt;ol&gt;&lt;li&gt;See &lt;a href="../../CV/Surgery/PrprtvCrdvsclrEvltn.htm" class="LinkPage"&gt;Preoperative Cardiovascular Evaluation&lt;/a&gt;&lt;/li&gt;&lt;li&gt;See &lt;a href="../../CV/Surgery/PrprtvCrdvsclrEvltn.htm" class="LinkPage"&gt;Perioperative Cardiovascular Risk&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Preoperative stress testing is often indicated&lt;/li&gt;&lt;li&gt;Assess for cardiac &lt;a href="../../Neuro/Autonomic/AtnmcDysfnctn.htm" class="LinkPage"&gt;Autonomic Dysfunction&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Risk of perioperative &lt;a href="../../CV/Exam/Hyptnsn.htm" class="LinkPage"&gt;Hypotension&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Features&lt;ol&gt;&lt;li&gt;Resting &lt;a href="../../CV/EKG/Tchycrd.htm" class="LinkPage"&gt;Tachycardia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Exam/OrthstcHyptnsn.htm" class="LinkPage"&gt;Orthostatic Hypotension&lt;/a&gt;&lt;/li&gt;&lt;li&gt;No variation in &lt;a href="../../CV/Exam/HrtRt.htm" class="LinkPage"&gt;Heart Rate&lt;/a&gt; with respirations&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;References&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Burgos%20%20%5BAU%5D%20AND%201989%20%5BDP%5D%20AND%20%20Anesthesiology%20%20%5BTA%5D" class="LinkRef"&gt;Burgos (1989) Anesthesiology 70:591-7&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Renal insufficiency (&lt;a href="../../Endo/Renal/DbtcNphrpthy.htm" class="LinkPage"&gt;Diabetic Nephropathy&lt;/a&gt;)&lt;ol&gt;&lt;li&gt;&lt;a href="../../Renal/Lab/RnlFnctn.htm" class="LinkPage"&gt;Renal Function&lt;/a&gt; tests&lt;/li&gt;&lt;li&gt;Consider &lt;a href="../../Uro/Lab/4HrUrnPrtn.htm" class="LinkPage"&gt;24 Hour Urine Protein&lt;/a&gt; and &lt;a href="../../Renal/Lab/SrmCrtn.htm" class="LinkPage"&gt;Creatinine&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Sugar&lt;/a&gt; control&lt;ol&gt;&lt;li&gt;Optimize &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Sugar&lt;/a&gt; control prior to surgery&lt;/li&gt;&lt;li&gt;Perioperative basal &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/AnlgBslInsln.htm" class="LinkPage"&gt;Lantus&lt;/a&gt;: Give full dose of &lt;a href="../../Endo/Pharm/AnlgBslInsln.htm" class="LinkPage"&gt;Lantus&lt;/a&gt; even if NPO&lt;/li&gt;&lt;li&gt;NPH: Give 60% of AM NPH and 100% of PM NPH&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Stop long-acting &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; 1-2 days before surgery&lt;ol&gt;&lt;li&gt;Replace with NPH and short-acting &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Stop &lt;a href="../../Endo/Pharm/OrlHypglycmc.htm" class="LinkPage"&gt;Oral Hypoglycemic&lt;/a&gt; agents before surgery&lt;ol&gt;&lt;li&gt;Hold long-acting &lt;a href="../../Endo/Pharm/Slfnylr.htm" class="LinkPage"&gt;Sulfonylurea&lt;/a&gt;s 2-3 days before&lt;/li&gt;&lt;li&gt;Hold short-acting &lt;a href="../../Endo/Pharm/Slfnylr.htm" class="LinkPage"&gt;Sulfonylurea&lt;/a&gt;s night before&lt;/li&gt;&lt;li&gt;Hold &lt;a href="../../Endo/Pharm/Glcphg.htm" class="LinkPage"&gt;Metformin&lt;/a&gt; on day before surgery&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Thzldndn.htm" class="LinkPage"&gt;Thiazolidinedione&lt;/a&gt;s may be continued&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Perioperative and Postoperative Glycemic Control&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/VrblRtInslnInfsn.htm" class="LinkPage"&gt;Variable Rate Insulin Infusion&lt;/a&gt; (&lt;a href="../../Endo/Pharm/VrblRtInslnInfsn.htm" class="LinkPage"&gt;Insulin Drip&lt;/a&gt;)&lt;ol&gt;&lt;li&gt;Preferred over use of Sliding Scale &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Marks%20%20%5BAU%5D%20AND%202003%20%5BDP%5D%20AND%20%20Am%20Fam%20Physician%20%20%5BTA%5D" class="LinkRef"&gt;Marks (2003) Am Fam Physician 67:93-100&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Surgery/PrprtvDbtsMngmnt.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Perioperative Diabetes Management</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Surgery/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Subacute thyroiditis  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0040149"&gt;&lt;i&gt;C0040149&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;Spontaneously remitting inflammatory condition of the THYROID GLAND, characterized by FEVER; MUSCLE WEAKNESS; SORE THROAT; severe thyroid PAIN; and an enlarged damaged gland containing GIANT CELLS. The disease frequently follows a viral infection.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Disease or Syndrome (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0040149&amp;amp;tui=T047"&gt;&lt;i&gt;T047&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D013968&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD9&lt;/td&gt;
                &lt;td&gt;245.1&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD10&lt;/td&gt;
                &lt;td&gt;E06.1&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;38727009, 237533003, 428041004, 237530000, 237531001, 237532008, 154666006, 190296009&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Subacute Thyroiditides, Thyroiditis, Subacute, SUBACUTE THYROIDITIS, THYROIDITIS, DE QUERVAIN, THYROIDITIS, GIANT CELL, THYROIDITIS, PSEUDOTUBERCULOUS, THYROIDITIS, SUBACUTE, de Quervain's thyroiditis, Giant-cell thyroiditis, Non-supp subacute thyroiditis, THYROIDITIS SUBACUTE, Non-suppurative subacute thyroiditis (disorder), Granulomatous thyroiditis, De Quervain's thyroiditis, Non-suppurative subacute thyroiditis, Subacute granulomatous thyroiditis (disorder), Subacute granulomatous thyroiditis, Giant cell thyroiditis, subacute thyroiditis, subacute thyroiditis (diagnosis), De Quervain's thyroiditis (disorder), Giant-cell thyroiditis (disorder), Granulomatous thyroiditis (disorder), deQuervain's thyroiditis, Thyroiditis subacute, de Quervain thyroiditis, Thyroiditis, Subacute [Disease/Finding], subacute thyroidities, de quervains thyroiditis, de quervain thyroiditis, granulomatous thyroiditis, thyroiditis de quervain, thyroiditis subacute, dequervain's thyroiditis, de quervain's thyroiditis, Pseudogranulomatous thyroiditis, Subacute thyroiditis (disorder), Subacute thyroiditis, de Quervain; thyroiditis, giant cell; thyroiditis, granulomatous; thyroiditis, pseudotuberculous; thyroiditis, subacute; thyroiditis, thyroiditis; de Quervain, thyroiditis; giant cell, thyroiditis; granulomatous, thyroiditis; pseudotuberculous, thyroiditis; subacute, Subacute Thyroiditis, De Quervain's Thyroiditis, Subacute Granulomatous Thyroiditis, Giant cell thyroiditis,, De Quervain Thyroiditis, Thyroiditis, De Quervain, Cell Thyroiditides, Giant, Cell Thyroiditis, Giant, Giant Cell Thyroiditides, Giant Cell Thyroiditis, Granulomatous Thyroiditides, Granulomatous Thyroiditis, Nonsuppurative Thyroiditides, Subacute, Nonsuppurative Thyroiditis, Subacute, Painful Thyroiditides, Subacute, Painful Thyroiditis, Subacute, Subacute Nonsuppurative Thyroiditides, Subacute Nonsuppurative Thyroiditis, Subacute Painful Thyroiditides, Subacute Painful Thyroiditis, Thyroiditides, Giant Cell, Thyroiditides, Subacute Nonsuppurative, Thyroiditides, Subacute Painful, Thyroiditides, Subacute, Thyroiditis, Giant Cell, Thyroiditis, Granulomatous, Thyroiditis, Subacute Nonsuppurative, Thyroiditis, Subacute Painful, Thyroiditides, Granulomatous&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;subacute thyreoïditis, De Quervain-thyreoïditis, granulomateuze thyreoïditis, de Quervain; thyroïditis, granulomateus; thyroïditis, pseudotuberculeus; thyroïditis, reuscel; thyroïditis, subacuut; thyroïditis, thyroïditis; de Quervain, thyroïditis; granulomateus, thyroïditis; pseudotuberculeus, thyroïditis; reuscel, thyroïditis; subacuut, Subacute thyroïditis, thyreoïditis subacuut, De Quervain thyreoiditis, Subacute thyreoiditis, Thyreoiditis, De Quervain, Thyreoiditis, subacute, Thyroïditis, De Quervain&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Thyroïdite de Quervain, Thyroïdite sous-aiguë, Thyroïdite granulomateuse à cellules géantes, Thyroïdite subaigüe de De Quervain, Thyroïdite subaiguë granulomateuse, Thyroïdite subaigüe granulomateuse, Thyroïdite subaigüe, Thyroïdite de De Quervain, Thyroïdite granulomateuse, Thyroïdite subaiguë&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;deQuervain-Thyroiditis, granulomatoese Thyroiditis, subakute Thyroiditis, Thyreoiditis de Quervain, Subakute nichteitrige Thyreoiditis, Riesenzellthyreoiditis, De-Quervain-Thyreoiditis, Granulomatöse Thyreoiditis, Subakute Thyreoiditis, Thyreoiditis subakut, Thyreoiditis, subakute&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Tiroidite di de Quervain, Tiroidite subacuta non suppurativa, Tiroidite a cellule giganti, Tiroidite subacuta dolorosa, Tiroidite di De Quervain, Tiroidite granulomatosa, Tiroidite subacuta&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Tiroidite de De Quervain, Tiroidite granulomatosa, Tiroidite subaguda, Tireoidite de de Quervain, Tireoidite de Quervain, Tireoidite Subaguda&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;Tiroiditis granulomatosa, Tiroiditis de Quervain, De Quervain's thyroiditis, Giant-cell thyroiditis, Subacute thyroiditis, Granulomatous thyroiditis, tiroiditis granulomatosa subaguda (trastorno), tiroiditis granulomatosa, tiroiditis de células gigantes, tiroiditis subaguda no supurante, tiroiditis seudogranulomatosa, tiroiditis subaguda no supurante (trastorno), tiroiditis no supurativa subaguda, tiroiditis de De Quervain, tiroiditis granulomatosa de células gigantes, tiroiditis de de Quervain, tiroiditis granulomatosa subaguda, tiroiditis pseudogranulomatosa, tiroiditis subaguda (trastorno), tiroiditis subaguda, Tiroiditis subaguda, Tiroiditis de De Quervain, Tiroiditis Subaguda&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;ド・ケルバン甲状腺炎, ﾄﾞｹﾙﾊﾞﾝｺｳｼﾞｮｳｾﾝｴﾝ, ﾆｸｹﾞｼｭｾｲｺｳｼﾞｮｳｾﾝｴﾝ, ﾆｸｶﾞｼｭｾｲｺｳｼﾞｮｳｾﾝｴﾝ, ｱｷｭｳｾｲｺｳｼﾞｮｳｾﾝｴﾝ, 肉芽腫性甲状腺炎, 亜急性甲状腺炎, ドケルバン甲状腺炎, ド･ケルヴァン甲状腺炎, 甲状腺炎-亜急性, De Quervain甲状腺炎&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Tyreoidit, subakut&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;tyreoiditida subakutní, deQuervainova tyreoiditida, Subakutní tyreoiditida, Granulomatózní tyreoiditida, Subakutní zánět štítné žlázy&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Subakuutti kilpirauhastulehdus&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;DE KERVENA TIREOIDIT, TIREOIDIT PODOSTRYI, ДЕ КЕРВЕНА ТИРЕОИДИТ, ТИРЕОИДИТ ПОДОСТРЫЙ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Korean&lt;/td&gt;
                &lt;td&gt;아급성 갑상샘염&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Croatian&lt;/td&gt;
                &lt;td&gt;TIREOIDITIS, SUBAKUTNI&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Zapalenie tarczycy podostre&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;DeQuervain-thyreoiditis, Subacut pajzsmirigy-gyulladás, Subacut thyreoiditis, Granulomás thyreoiditis&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Subacute thyroiditis  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Subacute Granulomatous Thyroiditis</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Infectious Disease</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Definition&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/Thyrdts.htm" class="LinkPage"&gt;Painful Thyroiditis&lt;/a&gt; associated with Viral Infection&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Epidemiology&lt;ol&gt;&lt;li&gt;&lt;a href="../../Prevent/Epi/DsIncdncRt.htm" class="LinkPage"&gt;Incidence&lt;/a&gt;: 5 per 100,000 persons&lt;ol&gt;&lt;li&gt;Most common cause of &lt;a href="../../Endo/Thyroid/Thyrdts.htm" class="LinkPage"&gt;Painful Thyroiditis&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Most common at age 40 to 50 years&lt;/li&gt;&lt;li&gt;More common in women by 4 fold&lt;/li&gt;&lt;li&gt;Peak onset in summer months&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Pathophysiology&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/Thyrdts.htm" class="LinkPage"&gt;Thyroiditis&lt;/a&gt; associated with viral infection&lt;ol&gt;&lt;li&gt;Coxsackievirus&lt;/li&gt;&lt;li&gt;Echovirus&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Activated &lt;a href="../../HemeOnc/Lab/LymphcytCnt.htm" class="LinkPage"&gt;T-Lymphocyte&lt;/a&gt;s injure &lt;a href="../../Endo/Anatomy/ThyrdAntmy.htm" class="LinkPage"&gt;Thyroid&lt;/a&gt; follicular cells&lt;ol&gt;&lt;li&gt;Results in the initial T4 and T3 unbridled increase&lt;/li&gt;&lt;li&gt;Ultimately T4 and T3 falls when stores are exhausted&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Symptoms&lt;ol&gt;&lt;li&gt;Prodrome&lt;ol&gt;&lt;li&gt;Myalgias&lt;/li&gt;&lt;li&gt;Low-grade fever&lt;/li&gt;&lt;li&gt;&lt;a href="../../ENT/Mouth/Phryngts.htm" class="LinkPage"&gt;Pharyngitis&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Ortho/Sx/ChrncNckPn.htm" class="LinkPage"&gt;Neck Pain&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Tender, swollen &lt;a href="../../Endo/Anatomy/ThyrdAntmy.htm" class="LinkPage"&gt;Thyroid Gland&lt;/a&gt; and adjacent neck&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Signs&lt;ol&gt;&lt;li&gt;No &lt;a href="../../Eye/Sx/Prpts.htm" class="LinkPage"&gt;Proptosis&lt;/a&gt; (contrast with &lt;a href="../../Endo/Thyroid/GrvsDs.htm" class="LinkPage"&gt;Grave's Disease&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;No pretibial &lt;a href="../../Endo/Thyroid/Hypthyrdsm.htm" class="LinkPage"&gt;Myxedema&lt;/a&gt; (contrast with &lt;a href="../../Endo/Thyroid/GrvsDs.htm" class="LinkPage"&gt;Grave's Disease&lt;/a&gt;)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Stages of &lt;a href="../../Endo/Thyroid/Thyrdts.htm" class="LinkPage"&gt;Thyroiditis&lt;/a&gt;: Triphasic&lt;ol&gt;&lt;li&gt;Phase 1: &lt;a href="../../Endo/Thyroid/Hyprthyrdsm1.htm" class="LinkPage"&gt;Hyperthyroidism&lt;/a&gt; (initial)&lt;/li&gt;&lt;li&gt;Phase 2: &lt;a href="../../Endo/Thyroid/Hypthyrdsm.htm" class="LinkPage"&gt;Hypothyroidism&lt;/a&gt; (weeks to months)&lt;ol&gt;&lt;li&gt;May persist indefinately&lt;/li&gt;&lt;li&gt;May require longterm &lt;a href="../../Endo/Pharm/ThyrdHrmnRplcmnt.htm" class="LinkPage"&gt;Thyroid Replacement&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Phase 3: Euthyroid (normalizes by 6-12 months)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Labs&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/ThyrdFnctnTst.htm" class="LinkPage"&gt;Thyroid Function Test&lt;/a&gt;s (variable depending on phase)&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/ThyrdStmltngHrmn.htm" class="LinkPage"&gt;Thyroid Stimulating Hormone&lt;/a&gt; (TSH)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/Thyrxn.htm" class="LinkPage"&gt;Free T4&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Acute phase reactants&lt;ol&gt;&lt;li&gt;&lt;a href="../../HemeOnc/Lab/ErythrcytSdmntnRt.htm" class="LinkPage"&gt;Erythrocyte Sedimentation Rate&lt;/a&gt; (ESR) &amp;gt;50 mm/hour&lt;/li&gt;&lt;li&gt;&lt;a href="../../HemeOnc/Lab/CRctvPrtn.htm" class="LinkPage"&gt;C-Reactive Protein&lt;/a&gt; (CRP)&lt;/li&gt;&lt;li&gt;&lt;a href="../../HemeOnc/Lab/CmpltBldCnt.htm" class="LinkPage"&gt;Complete Blood Count&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Mild &lt;a href="../../HemeOnc/Lab/Lkcyts.htm" class="LinkPage"&gt;Leukocytosis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Mild &lt;a href="../../HemeOnc/Anemia/Anm.htm" class="LinkPage"&gt;Anemia&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Anatomy/ThyrdAntmy.htm" class="LinkPage"&gt;Thyroid&lt;/a&gt; antibodies&lt;ol&gt;&lt;li&gt;Negative (contrast with &lt;a href="../../Endo/Thyroid/GrvsDs.htm" class="LinkPage"&gt;Grave's Disease&lt;/a&gt;, Hashimoto's)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Imaging&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Rad/RdctvIdnUptkScn.htm" class="LinkPage"&gt;Radioiodine Uptake&lt;/a&gt; decreased (unlike &lt;a href="../../Endo/Thyroid/GrvsDs.htm" class="LinkPage"&gt;Grave's Disease&lt;/a&gt;)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Management&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Anatomy/ThyrdAntmy.htm" class="LinkPage"&gt;Thyroid&lt;/a&gt; pain (may persist for 5 weeks from onset)&lt;ol&gt;&lt;li&gt;&lt;a href="../../Pharm/Analgesic/NnstrdlAntInflmtry.htm" class="LinkPage"&gt;NSAID&lt;/a&gt;s (inital medication)&lt;/li&gt;&lt;li&gt;Prednisone 40-60 mg orally daily, taper over 6 weeks&lt;ol&gt;&lt;li&gt;Indicated if pain refractory to &lt;a href="../../Pharm/Analgesic/NnstrdlAntInflmtry.htm" class="LinkPage"&gt;NSAID&lt;/a&gt;s after week 1&lt;/li&gt;&lt;li&gt;Pain relieved in most cases by 48 hours&lt;/li&gt;&lt;li&gt;Not preventive of &lt;a href="../../Endo/Anatomy/ThyrdAntmy.htm" class="LinkPage"&gt;Thyroid&lt;/a&gt; dysfunction&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/Hyprthyrdsm1.htm" class="LinkPage"&gt;Hyperthyroidism&lt;/a&gt; symptoms&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Endo/Thyroid/Hyprthyrdsm1.htm" class="LinkPage"&gt;Hyperthyroidism&lt;/a&gt; for symptomatic treatment&lt;/li&gt;&lt;li&gt;Example of management: &lt;a href="../../CV/Pharm/BtBlckr.htm" class="LinkPage"&gt;Beta Blocker&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Course&lt;ol&gt;&lt;li&gt;Spontaneous resolution in most cases&lt;/li&gt;&lt;li&gt;Persistent &lt;a href="../../Endo/Thyroid/Hypthyrdsm.htm" class="LinkPage"&gt;Hypothyroidism&lt;/a&gt; can occur&lt;ol&gt;&lt;li&gt;Requires longterm &lt;a href="../../Endo/Anatomy/ThyrdAntmy.htm" class="LinkPage"&gt;Thyroid&lt;/a&gt; replacment&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Recurrence in 2% of cases&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Bindra%20%20%5BAU%5D%20AND%202006%20%5BDP%5D%20AND%20%20Am%20Fam%20Physician%20%20%5BTA%5D" class="LinkRef"&gt;Bindra (2006) Am Fam Physician 73(10):1769-76&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0040149</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/ID/SbctGrnlmtsThyrdts.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Subacute Granulomatous Thyroiditis, Granulomatous Thyroiditis, Giant Cell Thyroiditis, Subacute Thyroiditis, de Quervain's Thyroiditis</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/ID/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Cytomel  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0010826"&gt;&lt;i&gt;C0010826&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Amino Acid, Peptide, or Protein (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0010826&amp;amp;tui=T116"&gt;&lt;i&gt;T116&lt;/i&gt;&lt;/a&gt;)
, Pharmacologic Substance (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0010826&amp;amp;tui=T121"&gt;&lt;i&gt;T121&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D014284&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Cytomel&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;cytomel, Cytomel&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Triiodothyronine  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0041014"&gt;&lt;i&gt;C0041014&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A thyroid hormone.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;A T3 thyroid hormone normally synthesized and secreted by the thyroid gland in much smaller quantities than thyroxine (T4). Most T3 is derived from peripheral monodeiodination of T4 at the 5' position of the outer ring of the iodothyronine nucleus. The hormone finally delivered and used by the tissues is mainly T3.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CSP)&lt;/td&gt;
                &lt;td&gt;one of the thyroid hormones; an organic iodine containing compound secreted in small amounts by the thyroid gland; most circulating triiodothyroinine is produced by the deiodination of thyroxine in the peripheral tissues.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A thyroid hormone containing 3 iodine atoms generally synthesized from levothyroxine, and has greater biological activity.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A thyroid hormone. Also called triiodothyronine or liothyronine sodium.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (PDQ)&lt;/td&gt;
                &lt;td&gt;A therapeutic formulation of the primary physiologically active form of endogenous thyroid hormone. In vivo, triiodothyronine enters the nucleus and binds to nuclear thyroid hormone receptors that subsequently bind to thyroid response elements (TREs) located in target genes. Receptor binding by triiodothyronine in combination with recruited coactivators results in maximal transcriptional activation after binding to TREs; in general, binding of thyroid hormone receptor alone to TREs leads to repression of gene transcription. Check for "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=470233&amp;amp;idtype=1" active clinical trials or "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=470233&amp;amp;idtype=1&amp;amp;closed=1" closed clinical trials using this agent. ("http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;amp;code=C907" NCI Thesaurus)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A therapeutic formulation of the primary physiologically active form of endogenous thyroid hormone. In vivo, triiodothyronine enters the nucleus and binds to nuclear thyroid hormone receptors that subsequently bind to thyroid response elements (TREs) located in target genes. Receptor binding by triiodothyronine in combination with recruited coactivators results in maximal transcriptional activation after binding to TREs; in general, binding of thyroid hormone receptor alone to TREs leads to repression of gene transcription (NCI04)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Amino Acid, Peptide, or Protein (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0041014&amp;amp;tui=T116"&gt;&lt;i&gt;T116&lt;/i&gt;&lt;/a&gt;)
, Pharmacologic Substance (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0041014&amp;amp;tui=T121"&gt;&lt;i&gt;T121&lt;/i&gt;&lt;/a&gt;)
, Hormone (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0041014&amp;amp;tui=T125"&gt;&lt;i&gt;T125&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D014284&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;61275002, 350358003, 74495008, 36437009&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Liothyronine, Triiodothyronine, L-Tyrosine, O-(4-hydroxy-3-iodophenyl)-3,5-diiodo-, liothyronine, Triiodothyronine preparation, triiodothyronine, T-3, 3,3',5-triiodo-L-thyronine, T3, T&amp;lt;sub&amp;gt;3&amp;lt;/sub&amp;gt;, Triiodothyronine (T3), L-triiodothyronine preparation, T&amp;gt;3&amp;lt; preparation, T&amp;lt;sub&amp;gt;3&amp;lt;/sub&amp;gt; preparation, T3 preparation, Triiodothyronine preparation (product), therapeutic triiodothyronine, L-Triiodothyronine, T AAA THYROID HORMONE 003, Triiodothyronine [Chemical/Ingredient], t3 thyroid hormone, t3, LIOTHYRONINE, T3 Thyroid Hormone, Thyroid Hormone, T3, 3,5,3' Triiodothyronine, T3 - Liothyronine, Tri-iodothyronine product, T3 - Triiodothyronine, Total triiodothyronine, T&amp;gt;3&amp;lt;, Liothyronine (product), Triiodothyronine (substance), Liothyronine (substance), Triiodothyronine preparation (substance), Therapeutic T3&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Trijodtyronin&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;preparado con triyodotironina (producto), liotironina, preparado con T&amp;gt;3&amp;lt;, liotironina (producto), preparado de L-triyodotironina, preparado con triyodotironina, tri-iodotironina, producto (producto), tri-iodotironina, producto, preparado de T3, preparado con T3, preparado de T&amp;lt;sub&amp;gt;3&amp;lt;/sub&amp;gt;, preparado con T&amp;lt;sub&amp;gt;3&amp;lt;/sub&amp;gt;, T3, 3, 5, 3' triyodotironina, preparado de T&amp;gt;3&amp;lt;, preparado de triyodotironina (producto), preparado de triyodotironina (sustancia), preparado de triyodotironina, tri-iodotironina, producto (sustancia), triyodotironina (sustancia), triyodotironina, Triyodotironina, Hormona Tiroidea T3, Liotironina&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;hormon T3, trijodthyronin&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Trijodotyroniini&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;T3 (Hormone thyroïdienne), Tri-iodothyronine, Hormone thyroïdienne T3, Triiodothyronine, 3,5,3'-triiodothyronine, Liothyronine&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;TRIIODTIRONIN, LIOTIRONIN, ЛИОТИРОНИН, ТРИИОДТИРОНИН&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;リオチロニン, フリーT3, リオサイロニン, トリヨードチロニン, トリヨードサイロニン, L-トリヨードチロニン&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;T AAA SCHILDDRÜSENHORMON 003, Liothyronin, Triiodthyronin, T3-Schilddrüsenhormon&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Croatian&lt;/td&gt;
                &lt;td&gt;TRIJODTIRONIN&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;T3, Hormônio T3 da Tireóide, Hormônio Tireóideo T3, Liotironina, Triiodotironina&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Trójjodotyronina, T3, Trijodotyronina&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Triiodotironina&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Cytomel  (</value><value>)
</value><value>Triiodothyronine  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Liothyronine</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Pharmacology</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Indications&lt;ol&gt;&lt;li&gt;Adjunct to &lt;a href="../../Endo/Pharm/ThyrdHrmnRplcmnt.htm" class="LinkPage"&gt;Levothyroxine&lt;/a&gt; in &lt;a href="../../Endo/Thyroid/Hypthyrdsm.htm" class="LinkPage"&gt;Hypothyroidism&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Lethargy or memory deficits despite normal TSH&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Efficacy&lt;ol&gt;&lt;li&gt;May improve neuropsychiatric symptoms&lt;/li&gt;&lt;li&gt;Changes after replacing T3 and T4&lt;ol&gt;&lt;li&gt;Improved mood and energy&lt;/li&gt;&lt;li&gt;Decreased confusion, fear, and irritability&lt;/li&gt;&lt;li&gt;No difference in TSH normalization&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Recent study suggests no benefit&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Clyde%20%20%5BAU%5D%20AND%202003%20%5BDP%5D%20AND%20%20JAMA%20%20%5BTA%5D" class="LinkRef"&gt;Clyde (2003) JAMA 290:2952-8&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Dosing (with &lt;a href="../../Endo/Lab/Thyrxn.htm" class="LinkPage"&gt;Thyroxine&lt;/a&gt; dosing)&lt;ol&gt;&lt;li&gt;Start: 12.5 to 25 ug PO qd&lt;/li&gt;&lt;li&gt;Maximum: 100 ug PO qd&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Bunevicius%20%20%5BAU%5D%20AND%201999%20%5BDP%5D%20AND%20%20N%20Engl%20J%20Med%20%20%5BTA%5D" class="LinkRef"&gt;Bunevicius (1999) N Engl J Med 340:424&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0010826</value><value>C0041014</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Pharm/Lthyrn.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Liothyronine, Cytomel, Triiodothyronine Replacement, T3 Replacement</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Pharm/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Synthroid  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0728762"&gt;&lt;i&gt;C0728762&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CHV)&lt;/td&gt;
                &lt;td&gt;thyroid hormone in a drug form&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Amino Acid, Peptide, or Protein (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0728762&amp;amp;tui=T116"&gt;&lt;i&gt;T116&lt;/i&gt;&lt;/a&gt;)
, Pharmacologic Substance (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0728762&amp;amp;tui=T121"&gt;&lt;i&gt;T121&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D013974&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Synthroid&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;synthroid, Abbot Brand of Levothyroxine Sodium, Synthroid&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Synthroid  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Thyroid Hormone Replacement</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Pharmacology</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Indications&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/Hypthyrdsm.htm" class="LinkPage"&gt;Hypothyroidism&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Preparations&lt;ol&gt;&lt;li&gt;Generic Levothyroxine are of similar quality to brand drugs&lt;ol&gt;&lt;li&gt;However agents from different manufacturers are not bioequivalent&lt;/li&gt;&lt;li&gt;When manufacturer changes, recheck TSH level in 6 weeks after change&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;See oral and intravenous dosing below&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Drug Interactions (Take 4 hours apart)&lt;ol&gt;&lt;li&gt;&lt;a href="../../Pharm/Nutrition/Grpfrt.htm" class="LinkPage"&gt;Grapefruit&lt;/a&gt; should be avoided regardless of time taken&lt;/li&gt;&lt;li&gt;Interfere with GI absorption (lower levels)&lt;ol&gt;&lt;li&gt;&lt;a href="../../CV/Pharm/BlBndngRsn.htm" class="LinkPage"&gt;Cholestyramine&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Pharm/BlBndngRsn.htm" class="LinkPage"&gt;Colestipol&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../HemeOnc/Pharm/IrnSplmntn.htm" class="LinkPage"&gt;Ferrous Sulfate&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Orlst.htm" class="LinkPage"&gt;Orlistat&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Sucralfate&lt;/li&gt;&lt;li&gt;Aluminum hydroxide antacids&lt;/li&gt;&lt;li&gt;&lt;a href="../../Renal/Pharm/OrlClcm.htm" class="LinkPage"&gt;Calcium Supplementation&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Soy products&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Increase metabolism of &lt;a href="../../Endo/Lab/Thyrxn.htm" class="LinkPage"&gt;Thyroxine&lt;/a&gt; (lowers levels)&lt;ol&gt;&lt;li&gt;&lt;a href="../../Neuro/Pharm/Phnytn.htm" class="LinkPage"&gt;Phenytoin&lt;/a&gt; (&lt;a href="../../Neuro/Pharm/Phnytn.htm" class="LinkPage"&gt;Dilantin&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Neuro/Pharm/Crbmzpn.htm" class="LinkPage"&gt;Carbamazepine&lt;/a&gt; (&lt;a href="../../Neuro/Pharm/Crbmzpn.htm" class="LinkPage"&gt;Tegretol&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Lung/Pharm/Rfmpn.htm" class="LinkPage"&gt;Rifampin&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Phenobarbital&lt;/li&gt;&lt;li&gt;&lt;a href="../../HemeOnc/Pharm/Wrfrn.htm" class="LinkPage"&gt;Warfarin&lt;/a&gt; (&lt;a href="../../HemeOnc/Pharm/Wrfrn.htm" class="LinkPage"&gt;Coumadin&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/OrlHypglycmc.htm" class="LinkPage"&gt;Oral Hypoglycemic&lt;/a&gt; agents&lt;/li&gt;&lt;li&gt;&lt;a href="../../Psych/Pharm/SlctvSrtnRptkInhbtr.htm" class="LinkPage"&gt;Selective Serotonin Reuptake Inhibitor&lt;/a&gt;s or &lt;a href="../../Psych/Pharm/TrcyclcAntdprsnt.htm" class="LinkPage"&gt;Tricyclic Antidepressant&lt;/a&gt;s&lt;ol&gt;&lt;li&gt;Most common with &lt;a href="../../Psych/Pharm/Srtrln.htm" class="LinkPage"&gt;Sertraline&lt;/a&gt; (&lt;a href="../../Psych/Pharm/Srtrln.htm" class="LinkPage"&gt;Zoloft&lt;/a&gt;)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Medications interfere with T4 production (lower levels)&lt;ol&gt;&lt;li&gt;&lt;a href="../../Psych/Pharm/LthmCrbnt.htm" class="LinkPage"&gt;Lithium&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Pharm/Amdrn.htm" class="LinkPage"&gt;Amiodarone&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Medications containing iodine&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Medications increasing protein binding (lowers levels)&lt;ol&gt;&lt;li&gt;Pregnancy (high &lt;a href="../../Gyn/Pharm/Estrgn.htm" class="LinkPage"&gt;Estrogen&lt;/a&gt;ic state)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Gyn/Pharm/OrlCntrcptv.htm" class="LinkPage"&gt;Oral Contraceptive&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Gyn/Pharm/EstrgnRplcmnt.htm" class="LinkPage"&gt;Estrogen Replacement&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Medications decreasing protein binding (raises levels)&lt;ol&gt;&lt;li&gt;&lt;a href="../../CV/Pharm/LpDrtc.htm" class="LinkPage"&gt;Furosemide&lt;/a&gt; (&lt;a href="../../CV/Pharm/LpDrtc.htm" class="LinkPage"&gt;Lasix&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;Mefenamic acid (&lt;a href="../../Neuro/Anatomy/Pns.htm" class="LinkPage"&gt;Pons&lt;/a&gt;tel)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Pharm/Analgesic/Slcylt.htm" class="LinkPage"&gt;Salicylate&lt;/a&gt;s&lt;/li&gt;&lt;li&gt;Androgens&lt;/li&gt;&lt;li&gt;Decreased &lt;a href="../../GI/Lab/SrmPrtn.htm" class="LinkPage"&gt;Serum Protein&lt;/a&gt;s with aging&lt;/li&gt;&lt;li&gt;&lt;a href="../../Renal/Glomerulus/NphrtcSyndrm.htm" class="LinkPage"&gt;Nephrotic Syndrome&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../GI/Lvr/Crhs.htm" class="LinkPage"&gt;Cirrhosis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Protein-losing &lt;a href="../../GI/IBD/IntstnlEntrpthy.htm" class="LinkPage"&gt;Enteropathy&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Dosing (lower dosing in &lt;a href="../../Endo/Thyroid/SbclnclHypthyrdsm.htm" class="LinkPage"&gt;Subclinical Hypothyroidism&lt;/a&gt;)&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Endo/Thyroid/SbclnclHypthyrdsm.htm" class="LinkPage"&gt;Subclinical Hypothyroidism&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Dosing precautions&lt;ol&gt;&lt;li&gt;Doses should be taken 30 minutes before meals&lt;/li&gt;&lt;li&gt;Avoid within 4 hours of products that decrease Levothyroxine absorption&lt;ol&gt;&lt;li&gt;See drug interactions above&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Anticipated total dose (50 to 200 mcg/day)&lt;ol&gt;&lt;li&gt;Children: up to 4 mcg/kg/day (full replacement)&lt;/li&gt;&lt;li&gt;Adults: 1.6 mcg/kg/day&lt;/li&gt;&lt;li&gt;Elderly: 1 mcg/kg/day&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Younger persons (no comorbid conditions)&lt;ol&gt;&lt;li&gt;Usual starting dose: 75 to 100 mcg daily&lt;/li&gt;&lt;li&gt;Options for initiating dosing&lt;ol&gt;&lt;li&gt;Option 1&lt;ol&gt;&lt;li&gt;Start at 75 to 100 mcg qd&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Option 2&lt;ol&gt;&lt;li&gt;Start at 0.8 mcg/kg/day (50% of anticipated dose)&lt;/li&gt;&lt;li&gt;Increase to 1.6 mcg/kg/day at 2 weeks&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Age over 50 years or history of heart disease&lt;ol&gt;&lt;li&gt;Start at 25-50 mcg daily&lt;/li&gt;&lt;li&gt;Increase by 25 mcg increments every 4 weeks until full replacement dose reached&lt;/li&gt;&lt;li&gt;Follow &lt;a href="../../Endo/Lab/ThyrdStmltngHrmn.htm" class="LinkPage"&gt;Thyroid Stimulating Hormone&lt;/a&gt; (TSH) closely&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Dosing: Pregnancy&lt;ol&gt;&lt;li&gt;Endocrinology consult&lt;/li&gt;&lt;li&gt;Increase Levothyroxine dose at earliest knowledge of pregnancy&lt;ol&gt;&lt;li&gt;Pregnancy requires an increased Levothyroxine dose&lt;ol&gt;&lt;li&gt;Increased dose by 30-47% over baseline required in most pregnant patients&lt;/li&gt;&lt;li&gt;Increased dose required for remainder of pregnancy (with frequent monitoring of TSH)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Add 2 additional doses per week (9 total doses)&lt;/li&gt;&lt;li&gt;Example&lt;ol&gt;&lt;li&gt;Patient on 100 mcg daily before pregnancy&lt;/li&gt;&lt;li&gt;When pregnancy diagnosed, start taking an extra dose (total 200 mcg) on Tuesday and Saturday&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Recheck &lt;a href="../../Endo/Lab/ThyrdStmltngHrmn.htm" class="LinkPage"&gt;Thyroid Stimulating Hormone&lt;/a&gt; (TSH) at 5 weeks after dose change&lt;/li&gt;&lt;li&gt;Decrease dose to baseline immediately after delivery, and recheck TSH in 6-8 weeks&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;TSH Monitoring&lt;ol&gt;&lt;li&gt;TSH at earliest pregnancy diagnosis (Levothyroxine increased at this time)&lt;/li&gt;&lt;li&gt;TSH 5 weeks after initial Levothyroxine increase and every 4-5 weeks after dose change&lt;/li&gt;&lt;li&gt;TSH a minimum of every trimester&lt;/li&gt;&lt;li&gt;TSH at 6-8 weeks after delivery (levoothyroxine dose decreased to baseline at delivery)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Management: Intravenous dosing&lt;ol&gt;&lt;li&gt;Indicated if unable to take oral dose for &amp;gt;7 days&lt;/li&gt;&lt;li&gt;Parenteral dose is 70-80% of usual oral dose&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Adverse Effects: Excessive Thyroid Replacement&lt;ol&gt;&lt;li&gt;&lt;a href="../../Rheum/Bone/Ostprs.htm" class="LinkPage"&gt;Osteoporosis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/EKG/AtrlFbrltn.htm" class="LinkPage"&gt;Atrial Fibrillation&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Cardiac hypertrophy&lt;ol&gt;&lt;li&gt;Increased Intraventricular septum thickness&lt;/li&gt;&lt;li&gt;Increased Left Ventricular posterior wall thickness&lt;/li&gt;&lt;li&gt;Increased End Diastolic Dimension&lt;/li&gt;&lt;li&gt;Increased Left Ventricular Mass Index&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Decreased &lt;a href="../../Sports/Exercise/Exrcs.htm" class="LinkPage"&gt;Exercise&lt;/a&gt; Tolerance&lt;ol&gt;&lt;li&gt;Decreased VO2 Max&lt;/li&gt;&lt;li&gt;Decreased Anaerobic threshold&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Monitoring&lt;ol&gt;&lt;li&gt;Protocols for monitoring&lt;ol&gt;&lt;li&gt;Monitoring every 6 to 8 weeks&lt;ol&gt;&lt;li&gt;TSH not yet stabilized after initiation&lt;/li&gt;&lt;li&gt;Recent change in Thyroid Replacement dosing&lt;/li&gt;&lt;li&gt;Recent change in manufacturer&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Consider monitoring less frequently than annually (usually done annually in this group)&lt;ol&gt;&lt;li&gt;Requires dose stable&lt;/li&gt;&lt;li&gt;Age under 50 years with weight stable&lt;/li&gt;&lt;li&gt;No comorbid condition&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Monitoring at least annually (when on stable dose)&lt;ol&gt;&lt;li&gt;Age over 50 years&lt;/li&gt;&lt;li&gt;Weight change&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Specific Testing&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/ThyrdStmltngHrmn.htm" class="LinkPage"&gt;Thyroid Stimulating Hormone&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Lags Levothyroxine dose change by 6 weeks&lt;/li&gt;&lt;li&gt;Target adjusting TSH to the normal mid-range (&amp;lt;3 mg/dl)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/Thyrxn.htm" class="LinkPage"&gt;Thyroxine&lt;/a&gt; (T4)&lt;ol&gt;&lt;li&gt;Lags Levothyroxine dose change by 1-2 weeks&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;Svec (2001) CMEA Medicine Lecture, San Diego&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Dong%20%20%5BAU%5D%20AND%201997%20%5BDP%5D%20AND%20%20JAMA,%20%20%5BTA%5D" class="LinkRef"&gt;Dong (1997) JAMA, 277:1205-13&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Hueston%20%20%5BAU%5D%20AND%202001%20%5BDP%5D%20AND%20%20Am%20Fam%20Physician%20%20%5BTA%5D" class="LinkRef"&gt;Hueston (2001) Am Fam Physician 64:1717-24&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Mercuro%20%20%5BAU%5D%20AND%202000%20%5BDP%5D%20AND%20%20J%20Clin%20Endocrinol%20Metab%20%20%5BTA%5D" class="LinkRef"&gt;Mercuro (2000) J Clin Endocrinol Metab 85:159&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Singer%20%20%5BAU%5D%20AND%201995%20%5BDP%5D%20AND%20%20JAMA%20%20%5BTA%5D" class="LinkRef"&gt;Singer (1995) JAMA 273:808-12&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Surks%20%20%5BAU%5D%20AND%201995%20%5BDP%5D%20AND%20%20N%20Engl%20J%20Med%20%20%5BTA%5D" class="LinkRef"&gt;Surks (1995) N Engl J Med 333:1688-94&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0728762</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Pharm/ThyrdHrmnRplcmnt.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Thyroid Hormone Replacement, Thyroid Replacement, Levothyroxine, Synthroid, Thyroxine Replacement, T4 Replacement</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Pharm/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Drug-induced thyroiditis  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0342179"&gt;&lt;i&gt;C0342179&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Pathologic Function (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0342179&amp;amp;tui=T046"&gt;&lt;i&gt;T046&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD10&lt;/td&gt;
                &lt;td&gt;E06.4&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;237539004&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Arzneimittelinduzierte Thyreoiditis&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Korean&lt;/td&gt;
                &lt;td&gt;약물 유발성 갑상샘염&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Drug-induced thyroiditis, Drug-induced thyroiditis (disorder), drug; thyroiditis, thyroiditis; drug-induced&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;geneesmiddel; thyroïditis, thyroïditis; door geneesmiddel, Door geneesmiddel veroorzaakte thyroïditis&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;tiroiditis farmacógena (trastorno), tiroiditis farmacógena, tiroiditis medicamentosa (trastorno), tiroiditis medicamentosa&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Drug-induced thyroiditis  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Medications Affecting Thyroid Function</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Pharmacology</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;See Also&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/Hypthyrdsm.htm" class="LinkPage"&gt;Hypothyroidism&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/Hyprthyrdsm1.htm" class="LinkPage"&gt;Hyperthyroidism&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Causes: Medications associated with &lt;a href="../../Endo/Thyroid/Hypthyrdsm.htm" class="LinkPage"&gt;Hypothyroidism&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Inorganic iodine&lt;/li&gt;&lt;li&gt;Iodide&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Pharm/Amdrn.htm" class="LinkPage"&gt;Amiodarone&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Cyanates&lt;/li&gt;&lt;li&gt;&lt;a href="../../Psych/Pharm/LthmCrbnt.htm" class="LinkPage"&gt;Lithium&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Causes: Medications associated with &lt;a href="../../Endo/Thyroid/Hyprthyrdsm1.htm" class="LinkPage"&gt;Hyperthyroidism&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Excess &lt;a href="../../Endo/Anatomy/ThyrdAntmy.htm" class="LinkPage"&gt;Thyroid&lt;/a&gt; hormone intake&lt;/li&gt;&lt;li&gt;Excess Iodine exposure&lt;ol&gt;&lt;li&gt;Dietary Iodine&lt;/li&gt;&lt;li&gt;&lt;a href="../../Rad/Pharm/RdgrphcCntrstMd.htm" class="LinkPage"&gt;Radiocontrast Material&lt;/a&gt; (contains iodine)&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Pharm/Amdrn.htm" class="LinkPage"&gt;Amiodarone&lt;/a&gt; (contains 37% iodine)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Causes: Medications causing &lt;a href="../../Endo/Thyroid/Thyrdts.htm" class="LinkPage"&gt;Thyroiditis&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../CV/Pharm/Amdrn.htm" class="LinkPage"&gt;Amiodarone&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../GI/Pharm/IntrfrnAlf.htm" class="LinkPage"&gt;Interferon-alfa&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Interleukin-2&lt;/li&gt;&lt;li&gt;&lt;a href="../../Psych/Pharm/LthmCrbnt.htm" class="LinkPage"&gt;Lithium&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../HemeOnc/Exam/TyrsnKns.htm" class="LinkPage"&gt;Tyrosine Kinase&lt;/a&gt; inhibitors&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Barbesino%20%20%5BAU%5D%20AND%202010%20%5BDP%5D%20AND%20%20Thyroid%20%20%5BTA%5D" class="LinkRef"&gt;Barbesino (2010) Thyroid 20(7): 763-70&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Perez%20Lopez%20%20%5BAU%5D%20AND%202011%20%5BDP%5D%20AND%20%20Endocrinol%20Nutr%20%20%5BTA%5D" class="LinkRef"&gt;Perez Lopez (2011) Endocrinol Nutr 58(2): 94-6&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0342179</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Pharm/MdctnsAfctngThyrdFnctn.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Medications Affecting Thyroid Function, Drug-Induced Thyroiditis</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Pharm/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees></FP_UMLS_Trees><FP_Condition_name_check></FP_Condition_name_check><FP_Condition_name><value>Medications Associated with Unintentional Weight Loss</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Pharmacology</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;See Also&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Geri/UntntnlWghtLs.htm" class="LinkPage"&gt;Unintentional Weight Loss&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Cardiopulmonary Agents&lt;ol&gt;&lt;li&gt;&lt;a href="../../CV/Pharm/BtBlckr.htm" class="LinkPage"&gt;Beta Blocker&lt;/a&gt;s (common)&lt;/li&gt;&lt;li&gt;Central alpha antagonists (common)&lt;/li&gt;&lt;li&gt;Highly potent &lt;a href="../../CV/Pharm/Drtc.htm" class="LinkPage"&gt;Diuretic&lt;/a&gt;s (common)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Lung/Pharm/InhldBtAdrnrgcAgnst.htm" class="LinkPage"&gt;Albuterol&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Pharm/AcInhbtr.htm" class="LinkPage"&gt;ACE Inhibitor&lt;/a&gt;s&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Pharm/ClcmChnlBlckr.htm" class="LinkPage"&gt;Calcium Channel Blocker&lt;/a&gt;s&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Pharm/Dgxn.htm" class="LinkPage"&gt;Digoxin&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Lipid/Anthyprlpdmc.htm" class="LinkPage"&gt;AntiHyperlipidemic&lt;/a&gt; medications&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Pharm/LngActngNtrglycrn.htm" class="LinkPage"&gt;Transdermal Nitroglycerin&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Neuropsychiatric Preparations&lt;ol&gt;&lt;li&gt;&lt;a href="../../Neuro/Pharm/AntchlnrgcMdctn.htm" class="LinkPage"&gt;Anticholinergic Medication&lt;/a&gt;s (common)&lt;/li&gt;&lt;li&gt;Anticonvulsants, e.g. &lt;a href="../../Neuro/Pharm/Phnytn.htm" class="LinkPage"&gt;Phenytoin&lt;/a&gt; (common)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Psych/Pharm/Bnzdzpn.htm" class="LinkPage"&gt;Benzodiazepine&lt;/a&gt;s (common)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Psych/Pharm/Antpsychtc.htm" class="LinkPage"&gt;Neuroleptic&lt;/a&gt; agents (common)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Psych/Pharm/SlctvSrtnRptkInhbtr.htm" class="LinkPage"&gt;Selective Serotonin Reuptake Inhibitor&lt;/a&gt;s, &lt;a href="../../Psych/Pharm/SlctvSrtnRptkInhbtr.htm" class="LinkPage"&gt;SSRI&lt;/a&gt; (common)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Psych/Pharm/TrcyclcAntdprsnt.htm" class="LinkPage"&gt;Tricyclic Antidepressant&lt;/a&gt;s (common)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/DpmnAgnst.htm" class="LinkPage"&gt;Dopamine Agonist&lt;/a&gt;s (e.g. Levodopa)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Endocrine Preparations&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/SystmcCrtcstrd.htm" class="LinkPage"&gt;Corticosteroid&lt;/a&gt;s (common)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Rheum/Pharm/Bsphsphnts.htm" class="LinkPage"&gt;Alendronate&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Hormonal Medications&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Glcphg.htm" class="LinkPage"&gt;Metformin&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Rheumatologic Preparations&lt;ol&gt;&lt;li&gt;&lt;a href="../../Rheum/Pharm/Alprnl.htm" class="LinkPage"&gt;Allopurinol&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Pharm/Analgesic/NnstrdlAntInflmtry.htm" class="LinkPage"&gt;NSAID&lt;/a&gt;s&lt;/li&gt;&lt;li&gt;&lt;a href="../../Pharm/Analgesic/NrctcAnlgsc.htm" class="LinkPage"&gt;Narcotic Analgesic&lt;/a&gt;s&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Infectious Disease Preparations&lt;ol&gt;&lt;li&gt;Antibiotics&lt;/li&gt;&lt;li&gt;&lt;a href="../../ID/Pharm/Admntn.htm" class="LinkPage"&gt;Amantadine&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../ID/Pharm/Mtrndzl.htm" class="LinkPage"&gt;Metronidazole&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Miscellaneous Preparations&lt;ol&gt;&lt;li&gt;&lt;a href="../../ENT/Pharm/SdtngAnthstmn.htm" class="LinkPage"&gt;Antihistamine&lt;/a&gt;s&lt;/li&gt;&lt;li&gt;&lt;a href="../../ENT/Pharm/Dcngstnt.htm" class="LinkPage"&gt;Decongestant&lt;/a&gt;s&lt;/li&gt;&lt;li&gt;&lt;a href="../../HemeOnc/Exam/RdBldClPhyslgy.htm" class="LinkPage"&gt;Iron&lt;/a&gt; Supplements&lt;/li&gt;&lt;li&gt;Potassium&lt;/li&gt;&lt;li&gt;Xanthines&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Huffman%20%20%5BAU%5D%20AND%202002%20%5BDP%5D%20AND%20%20Am%20Fam%20Physician%20%20%5BTA%5D" class="LinkRef"&gt;Huffman (2002) Am Fam Physician 65(4):640-50&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Verdery%20%20%5BAU%5D%20AND%201997%20%5BDP%5D%20AND%20%20Clin%20Geriatr%20Med%20%20%5BTA%5D" class="LinkRef"&gt;Verdery (1997) Clin Geriatr Med 13:769-78&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Pharm/MdctnsAsctdWthUntntnlWghtLs.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Medications Associated with Unintentional Weight Loss, Unintentional Weight Loss due to Medications</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Pharm/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Growth Hormone  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0037663"&gt;&lt;i&gt;C0037663&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A protein made by the pituitary gland that helps control body growth and the use of glucose and fat in the body.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;A polypeptide that is secreted by the adenohypophysis (PITUITARY GLAND, ANTERIOR). Growth hormone, also known as somatotropin, stimulates mitosis, cell differentiation and cell growth. Species-specific growth hormones have been synthesized.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CSP)&lt;/td&gt;
                &lt;td&gt;polypeptide that is secreted by the anterior pituitary gland; affects protein, carbohydrate and lipid metabolism; stimulates mitosis, cell differentiation and cell growth.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A peptide hormone secreted by the anterior lobe of the pituitary gland and regulates several physiologic processes, including growth and metabolism.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Amino Acid, Peptide, or Protein (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0037663&amp;amp;tui=T116"&gt;&lt;i&gt;T116&lt;/i&gt;&lt;/a&gt;)
, Pharmacologic Substance (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0037663&amp;amp;tui=T121"&gt;&lt;i&gt;T121&lt;/i&gt;&lt;/a&gt;)
, Hormone (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0037663&amp;amp;tui=T125"&gt;&lt;i&gt;T125&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D013006&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;76765004, 350365006, 56234005&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Somatotropic hormone (STH), Growth Hormone, Pituitary, Pituitary Growth Hormone, Somatotropin, GH - Growth hormone, Growth hormone, STH, Somatotrophin, Somatotropic hormone, Somatrophic hormone, somatotropin, Growth Hormone, STH (somatotropic hormone), Somatrophic hormone (product), Growth Hormone [Chemical/Ingredient], growth hormones, somatotrophin, pituitary growth hormone, somatotropic hormone, growth hormone, Growth hormone preparation, Growth hormone product, Somatotropin preparation, Somatotropin preparation (product), Somatotropin preparation (substance), Somatrophic hormone (substance), GH, GHN, Growth Hormone 1, Somatotropic Hormone, hGHN, SOMATOTROPIN&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Tillväxthormon&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;růstový hormon, somatotropin&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Kasvuhormoni&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Somatotrophine, Hormone de croissance, Hormone somatotrope, Somatotropine, GH (Growth hormone), STH (Somatotrophic hormone), Somathormone&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;ROSTA GORMON GIPOFIZARNYI, SOMATOTROPIN, ROSTA GORMON, GORMONY ROSTA GIPOFIZARNYE REKOMBINANTNYE, ROSTA GORMONY GIPOFIZARNYE REKOMBINANTNYE, GIPOFIZARNYE GORMONY ROSTA REKOMBINANTNYE, GORMON ROSTA GIPOFIZARNYI, SOMATOTROPINY REKOMBINANTNYE, ГИПОФИЗАРНЫЕ ГОРМОНЫ РОСТА РЕКОМБИНАНТНЫЕ, ГОРМОН РОСТА ГИПОФИЗАРНЫЙ, ГОРМОНЫ РОСТА ГИПОФИЗАРНЫЕ РЕКОМБИНАНТНЫЕ, РОСТА ГОРМОН, РОСТА ГОРМОН ГИПОФИЗАРНЫЙ, РОСТА ГОРМОНЫ ГИПОФИЗАРНЫЕ РЕКОМБИНАНТНЫЕ, СОМАТОТРОПИН, СОМАТОТРОПИНЫ РЕКОМБИНАНТНЫЕ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;下垂体成長ホルモン, 下垂体成長ホルモン-組換え, 組換え下垂体成長ホルモン, 組換え成長ホルモン, 組換え成長ホルモン下垂体, 脳下垂体成長ホルモン-組換え, 成長ホルモン-脳下垂体性, 組換え脳下垂体成長ホルモン, 成長ホルモン下垂体-組換え, ソマトトロピン, 下垂体組替え成長ホルモン, 組換成長ホルモン, 組替えソマトトロピン, ソマトトロピン-組換え, 脳下垂体成長ホルモン, 成長ホルモン-組換え, 組換えソマトトロピン, 遺伝子組換え成長ホルモン, 成長ホルモン&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;preparado de somatotrofina (producto), hormona somatotrófica, somatotrofina (producto), hormona somatotrófica (producto), somatotrofina, preparado de somatotrofina, hormona somatrófica (sustancia), preparado de STH, preparado de hormona del crecimiento, preparado de somatotrofina (sustancia), preparado de somatotropina, hormona somatrófica (producto), hormona somatrófica, Hormona del Crecimiento, Somatotrofina, Somatotropina, Hormona Hipofisaria del Crecimiento&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Ormone della crescita, Ormone pituitario della crescita, Ormone somatotropo, GH, Somatotropina&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Croatian&lt;/td&gt;
                &lt;td&gt;SOMATOTROPIN, HORMON RASTA&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Ludzki rekombinowany hormon wzrostu, Somatotropiny rekombinowane, rhGH, Hormon wzrostu, Rekombinowane przysadkowe hormony wzrostu, Rekombinowany hormon wzrostu&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Hypophysen-Wachstumshormon, STH, Somatotropin, Wachstumshormon, Hypophysen-, Wachstumshormon&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Somatotrofina, Somatotropina, Hormônio do Crescimento, Hormônio Hipofisário do Crescimento&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Somatropin  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0169964"&gt;&lt;i&gt;C0169964&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;A 191-amino acid polypeptide hormone secreted by the human adenohypophysis (PITUITARY GLAND, ANTERIOR), also known as GH or somatotropin. Synthetic growth hormone, termed somatropin, has replaced the natural form in therapeutic usage such as treatment of dwarfism in children with growth hormone deficiency.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Amino Acid, Peptide, or Protein (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0169964&amp;amp;tui=T116"&gt;&lt;i&gt;T116&lt;/i&gt;&lt;/a&gt;)
, Pharmacologic Substance (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0169964&amp;amp;tui=T121"&gt;&lt;i&gt;T121&lt;/i&gt;&lt;/a&gt;)
, Hormone (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0169964&amp;amp;tui=T125"&gt;&lt;i&gt;T125&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D019382&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;395883003, 76765004, 325892008, 325831003, 129495007&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Human growth hormone (HGH), Somatotropin (human), Biosynthetic human growth horm, Growth Hormone, Human, HGH, HGH - Growth hormone, Human Growth Hormone, Somatotropin (Human), Somatropin, somatropin, Somatotrophin, Human growth hormone, Human growth hormone (substance), GH - Growth hormone, Somatropin [2] (product), Somatropin [2], Somatotropic hormone, Growth hormone, hGH (human growth hormone), SOMATROPIN, growth hormones, growth hormones (medication), Human Growth Hormone [Chemical/Ingredient], hgh growth hormone, hgh human hormone growth, human growth hormone hgh, hgh human growth hormone, growth hormone hgh, human growth hormone (HGH), human growth hormone, hGH, Somatropin (Human), hGH (Human Growth Hormone), Biosynthetic human growth hormone, Somatropin (product), Somatropin (substance), Somatropin [2] (substance)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Humant tillväxthormon&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;hormona del crecimiento, hormona del crecimiento humano, hormona de crecimiento, somatotrofina, somatropina (2), somatropina (2) (producto), hormona del crecimiento humano (sustancia), hormona somatotrófica, somatotropina, Somatropin, Biosynthetic human growth hormone, somatropina (producto), somatropina (sustancia), somatropina, Hormona de Crecimiento Humana, Somatotropina (Humana), Somatropina (Humana)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;somatropin (lidský), lidský růstový hormon, somatotropin (lidský)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Ihmisen kasvuhormoni&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Somatotropine humaine, Somatropine humaine, Hormone de croissance humaine, hGH (Human Growth Hormone)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Somatotropina (umana), Somatropina (umana), Somatropina, Ormone della crescita umano, hGH (ormone della crescita umano)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;GORMON ROSTA CHELOVEKA, ROSTA GORMON METIONILOVYI CHELOVEKA, SOMATOTROPIN CHELOVEKA, SOMATROPIN, ROSTA GORMON CHELOVEKA, METIONILOVYI GORMON ROSTA CHELOVEKA, SOMATREM, ГОРМОН РОСТА ЧЕЛОВЕКА, МЕТИОНИЛОВЫЙ ГОРМОН РОСТА ЧЕЛОВЕКА, РОСТА ГОРМОН МЕТИОНИЛОВЫЙ ЧЕЛОВЕКА, РОСТА ГОРМОН ЧЕЛОВЕКА, СОМАТОТРОПИН ЧЕЛОВЕКА, СОМАТРЕМ, СОМАТРОПИН&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;ソマトトロピン(ヒト), ソマトトロピン-ヒト, ヒト成長ホルモン, ソマトロピン, 成長ホルモン-ヒト&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Croatian&lt;/td&gt;
                &lt;td&gt;HORMON RASTA, HUMANI, HUMANI HORMON RASTA&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Ludzki hormon wzrostu, Hormon wzrostu ludzki, Somatropina, HGH, Somatotropina (ludzka)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Humanes Wachstumshormon, Somatotropin (humanes), Somatropin, HGH (Humanes Wachstumshormon), Somatropin (humanes)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Somatotropina (Humana), Somatropina (Humana), Hormônio do Crescimento Humano&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Growth Hormone  (</value><value>)
</value><value>Somatropin  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Human Growth Hormone</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Pharmacology</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Indications&lt;ol&gt;&lt;li&gt;Medical Uses&lt;ol&gt;&lt;li&gt;Used to enhance growth in &lt;a href="../../Endo/Growth/ShrtStr.htm" class="LinkPage"&gt;Short Stature&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Illicit uses&lt;ol&gt;&lt;li&gt;&lt;a href="../../Sports/Pharm/SprtsPrfrmncSplmnt.htm" class="LinkPage"&gt;Ergogenic Aid&lt;/a&gt; used by athletes&lt;/li&gt;&lt;li&gt;Similar effect as with &lt;a href="../../Sports/Pharm/AnblcStrd.htm" class="LinkPage"&gt;Anabolic Steroid&lt;/a&gt;s&lt;ol&gt;&lt;li&gt;Difficult to detect&lt;/li&gt;&lt;li&gt;Expensive (&amp;gt;$1000/month)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Mechanism&lt;ol&gt;&lt;li&gt;&lt;a href="../../GI/Anatomy/LvrAntmy.htm" class="LinkPage"&gt;Liver&lt;/a&gt; converts GH to &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt;-like growth factor (IGF-1)&lt;/li&gt;&lt;li&gt;Precursor to testosterone&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Source&lt;ol&gt;&lt;li&gt;Initially derived from cadavers in 1950's&lt;ol&gt;&lt;li&gt;Transmitted &lt;a href="../../ID/Prion/CrtzfldtJkbDs.htm" class="LinkPage"&gt;Creutzfeldt-Jakob Disease&lt;/a&gt; to patients&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Now produced by recombinant genetics&lt;ol&gt;&lt;li&gt;Genentech developed &lt;a href="../../Rheum/Pharm/SkltlMsclRlxnt.htm" class="LinkPage"&gt;Soma&lt;/a&gt;trem (Protropin) in 1990s&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Dosing&lt;ol&gt;&lt;li&gt;Available only via injection&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Adverse Effects&lt;ol&gt;&lt;li&gt;Growth-hormone induced &lt;a href="../../Neuro/Motor/Mypthy.htm" class="LinkPage"&gt;Myopathy&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Muscles hypertrophy, but are weaker than before&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pituitary/Acrmgly.htm" class="LinkPage"&gt;Acromegaly&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/DM/DbtsMlts.htm" class="LinkPage"&gt;Diabetes Mellitus&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Myocardium/Crdmypthy.htm" class="LinkPage"&gt;Cardiomyopathy&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/CHF/CngstvHrtFlr.htm" class="LinkPage"&gt;Congestive Heart Failure&lt;/a&gt;&lt;/li&gt;&lt;li&gt;May be related to &lt;a href="../../HemeOnc/Leukemia/Lkm.htm" class="LinkPage"&gt;Leukemia&lt;/a&gt; development&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0037663</value><value>C0169964</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Pharm/HmnGrwthHrmn.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Human Growth Hormone, Growth Hormone, hGH</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Pharm/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees></FP_UMLS_Trees><FP_Condition_name_check></FP_Condition_name_check><FP_Condition_name><value>Intravenous Dextrose</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Pharmacology</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Indications&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Hypoglycemia/Hypglycm.htm" class="LinkPage"&gt;Hypoglycemia&lt;/a&gt; by rapid bedside &lt;a href="../../Endo/Pharm/Glcmtr.htm" class="LinkPage"&gt;Glucometer&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Child who fails to respond to &lt;a href="../../ER/Exam/CrdplmnryRsctn.htm" class="LinkPage"&gt;Resuscitation&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Physiology&lt;ol&gt;&lt;li&gt;Ill children deplete glycogen stores rapidly&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Hypoglycemia/Hypglycm.htm" class="LinkPage"&gt;Hypoglycemia&lt;/a&gt; depresses neonatal myocardial function&lt;/li&gt;&lt;li&gt;Effects of &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; on brain&lt;ol&gt;&lt;li&gt;Ischemic Neonatal brain&lt;ol&gt;&lt;li&gt;May benefit from &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Mature Child brain&lt;ol&gt;&lt;li&gt;Poor neurologic outcome with &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Dosing&lt;ol&gt;&lt;li&gt;See dosing by the rule of 50 below&lt;/li&gt;&lt;li&gt;Dextrose 12.5% (D12.5W): 1:3 dilution of D50W in water&lt;ol&gt;&lt;li&gt;Newborn: 0.5-1.0 g/kg (4-8 ml/kg) D12.5W IV or IO&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Dextrose 25% (D25W): 1:1 dilution of D50W in water&lt;ol&gt;&lt;li&gt;Children: 0.5-1.0 g/kg (2-4 ml/kg) D25W IV or IO&lt;/li&gt;&lt;li&gt;Do not use in newborns!&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Dextrose 50% (D50)&lt;ol&gt;&lt;li&gt;Use exclusively in adults at 1 ml/kg&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Dosing: Rule of 50&lt;ol&gt;&lt;li&gt;Divide 50 by the type of dextrose solution to arrive at rate in ml/kg&lt;ol&gt;&lt;li&gt;Adult (D50): 50/50 = 1 ml/kg&lt;/li&gt;&lt;li&gt;Child (D25): 50/25 = 2 ml/kg&lt;/li&gt;&lt;li&gt;Infant (D10): 50/10 = 5 ml/kg&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Dosing&lt;ol&gt;&lt;li&gt;Adult: D50 at 1 ml/kg&lt;/li&gt;&lt;li&gt;Child:  D25 at 2 ml/kg&lt;/li&gt;&lt;li&gt;Infant: D10 at 5 ml/kg&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Precautions&lt;ol&gt;&lt;li&gt;Peripheral vein sclerosis&lt;ol&gt;&lt;li&gt;Occurs with concentrated Dextrose (D25)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Poor outcomes related to repeated &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; bolus in:&lt;ol&gt;&lt;li&gt;Severe &lt;a href="../../ER/Neuro/HdInjry.htm" class="LinkPage"&gt;Head Injury&lt;/a&gt; (poor neurologic outcome)&lt;/li&gt;&lt;li&gt;Submersion&lt;/li&gt;&lt;li&gt;Hypovolemic &lt;a href="../../CV/Exam/Hyptnsn.htm" class="LinkPage"&gt;Shock&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Pharm/IntrvnsDxtrs.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Intravenous Dextrose</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Pharm/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Glucagon  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0017687"&gt;&lt;i&gt;C0017687&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A hormone produced by the pancreas that increases the level of glucose (sugar) in the blood.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A hormone produced by the pancreas that increases the level of glucose (sugar) in the blood.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A pancreatic hormone consisting of 29 amino acids that causes increases in blood sugar levels by stimulating hepatic glycogenolysis and gluconeogenesis.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CSP)&lt;/td&gt;
                &lt;td&gt;pancreatic hormone secreted by the alpha cells of the pancreatic islets; a 29-amino acid straight chain polypeptide that plays an important role in regulation of blood glucose concentration, ketone metabolism, and several other biochemical and physiological processes.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;A 29-amino acid pancreatic peptide derived from proglucagon which is also the precursor of intestinal GLUCAGON-LIKE PEPTIDES. Glucagon is secreted by PANCREATIC ALPHA CELLS and plays an important role in regulation of BLOOD GLUCOSE concentration, ketone metabolism, and several other biochemical and physiological processes. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1511)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Amino Acid, Peptide, or Protein (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0017687&amp;amp;tui=T116"&gt;&lt;i&gt;T116&lt;/i&gt;&lt;/a&gt;)
, Pharmacologic Substance (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0017687&amp;amp;tui=T121"&gt;&lt;i&gt;T121&lt;/i&gt;&lt;/a&gt;)
, Neuroreactive Substance or Biogenic Amine (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0017687&amp;amp;tui=T124"&gt;&lt;i&gt;T124&lt;/i&gt;&lt;/a&gt;)
, Hormone (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0017687&amp;amp;tui=T125"&gt;&lt;i&gt;T125&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D005934&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;10712001, 66603002&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Glucagon, Glucagon (1-29), Glucagon preparation, Glucagon, NOS, Hyperglycemic-glycogenolytic factor preparation, Hyperglycaemic-glycogenolytic factor preparation, Proglucagon (33-61), glucagon, Hyperglycemic-Glycogenolytic Factor, HG Factor, HG-Factor, Glukagon, antidiabetic hormone, glucagon (medication), GLUCAGON, Glucagon [Chemical/Ingredient], glucagons, Glucagon product, Glucagon (substance), Glucagon product (product), Hyperglycaemic-glycogenolytic factor product, Hyperglycemic-glycogenolytic factor product, Glucagon preparation (substance), Hyperglycemic Glycogenolytic Factor, GCG, Antidiabetic Hormone&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Glucagon, Glukagon (1-29), Glukagon, Glucagon (1-29), Hyperglykämisch-glykogenolytischer Faktor, HG-Faktor&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Glukagon&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;glukagon&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Glukagoni&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Fattore glicogenolitico iperglicemico, Pro-glucagone, Fattore HG, Glucagone&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;GLIUKAGON, ГЛЮКАГОН&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;preparado con glucagón (producto), preparado con glucagón, preparado con factor hiperglucemiante-glucogenolítico, producto con glucagón (producto), glucagón (producto), producto con factor hiperglucemiante-glucogenolítico, producto con glucagón, glucagón (sustancia), glucagón, preparado de factor hiperglucemiante-glucogenolítico, preparado de glucagón (producto), preparado de glucagón (sustancia), preparado de glucagón, Glucagon, Glucagón&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;グルカゴン&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Croatian&lt;/td&gt;
                &lt;td&gt;GLUKAGON&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Glukagon&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Glucagon, Facteur glycogénolytique hyperglycémique, Glucagon (1-29)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Glucagon&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;GlucaGen  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0591569"&gt;&lt;i&gt;C0591569&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Organic Chemical (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0591569&amp;amp;tui=T109"&gt;&lt;i&gt;T109&lt;/i&gt;&lt;/a&gt;)
, Pharmacologic Substance (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0591569&amp;amp;tui=T121"&gt;&lt;i&gt;T121&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;GlucaGen, glucagen&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Glucagon  (</value><value>)
</value><value>GlucaGen  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Glucagon</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Pharmacology</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Indications&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Hypoglycemia/Hypglycm.htm" class="LinkPage"&gt;Hypoglycemia&lt;/a&gt; with difficult &lt;a href="../../ER/Procedure/IvAcs.htm" class="LinkPage"&gt;Intravenous Access&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/NICU/NntlHypglycm.htm" class="LinkPage"&gt;Neonatal Hypoglycemia&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Pharmacokinetics&lt;ol&gt;&lt;li&gt;Onset of action: 5 to 20 minutes&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Dosing&lt;ol&gt;&lt;li&gt;Adult: 1 mg IV, IM or SC&lt;/li&gt;&lt;li&gt;Pediatric&lt;ol&gt;&lt;li&gt;Standard dose: 30 ug/kg IM&lt;/li&gt;&lt;li&gt;Newborn of diabetic mother: 300 ug/kg IM&lt;/li&gt;&lt;li&gt;Maximum dose: 1 mg&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0017687</value><value>C0591569</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Pharm/Glcgn.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Glucagon, GlucaGen</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Pharm/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Antithyroid Agents  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0040125"&gt;&lt;i&gt;C0040125&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;Agents that are used to treat hyperthyroidism by reducing the excessive production of thyroid hormones.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CSP)&lt;/td&gt;
                &lt;td&gt;any agent or substance which suppresses, prevents or opposes the biosynthesis of thyroid hormones.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Pharmacologic Substance (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0040125&amp;amp;tui=T121"&gt;&lt;i&gt;T121&lt;/i&gt;&lt;/a&gt;)
, Hormone (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0040125&amp;amp;tui=T125"&gt;&lt;i&gt;T125&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D013956&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;5067008, 418416001&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Antagonists, Thyroid, Antithyroid Drugs, Drugs, Antithyroid, Thyroid Antagonists, thyroid inhibitor, Thyroid antagonists, Agents, Antithyroid, Antithyroid Agents, Antithyroid preparation, NOS, Thyroid inhibitor preparation, NOS, Thyroid inhibitor, THYROID ANTAG, ANTITHYROID AGENTS, anti-thyroid agents, anti-thyroid agents (medication), thyroid antagonists, [HS852] ANTITHYROID AGENTS, antithyroid drug, inhibitors thyroid, antithyroid agents, antithyroid preparations, antithyroid drugs, Antithyroid drugs, Antithyroid agent (product), Antithyroid agent, Thyroid inhibitor preparation, antithyroid agent, Antithyroid Agent, Antithyroid agent (substance)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;agente antitiroideo (sustancia), agente antitiroideo, preparado antitiroideo (producto), preparado antitiroideo (sustancia), preparado antitiroideo, preparado inhibidor tiroideo, Agentes Antitiroideos, Antagonistas Tiroideos&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Anti-thyroïdiens, Agents antithyroïdiens, Thyréostatiques, Médicaments antithyroïdiens, Agents anti-thyroïdiens, Médicaments anti-thyroïdiens, Antithyroïdiens&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Tyreostatika&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;thyreostatika, tyreostatika, antithyreoidní látky&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Tyreostaatit&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Sostanze antitiroidee, Antagonisti tiroidei, Farmaci antitiroidei&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;TIREOIDNYKH GORMONOV ANTAGONISTY, STRUMOGENNYE FAKTORY, ANTITIREOIDNYE VESHCHESTVA, АНТИТИРЕОИДНЫЕ ВЕЩЕСТВА, СТРУМОГЕННЫЕ ФАКТОРЫ, ТИРЕОИДНЫХ ГОРМОНОВ АНТАГОНИСТЫ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;甲状腺拮抗物質, 抗甲状腺薬, 甲状腺腫誘発物質, 抗甲状腺剤, 甲状腺きっ抗剤&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Croatian&lt;/td&gt;
                &lt;td&gt;ANTITIREOIDNE TVARI&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Tyreostatyki, Goitrogeny, Środki przeciwtarczycowe, Strumigeny&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Antithyreodika, Thyreostatika&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Antagonistas Tireóideos, Antitiróideos&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Thioamides  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0039875"&gt;&lt;i&gt;C0039875&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CSP)&lt;/td&gt;
                &lt;td&gt;compounds of the type R-(C=S)-N=.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;Organic compounds containing the radical -CSNH2.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Organic Chemical (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0039875&amp;amp;tui=T109"&gt;&lt;i&gt;T109&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D013854&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;406762005&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Thioamides, thioamide, Thioamides [Chemical/Ingredient], thioamides, Thioamide (substance), Thioamide&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Tioamider&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;thioamidy&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Tioamidit&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;TIOAMIDY, ТИОАМИДЫ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Tioamidy&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;tioamida (sustancia), tioamida, Tioamidas&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Thioamides&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Thioamide&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Tioamidi&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Tioamidas&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Tapazole  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0728778"&gt;&lt;i&gt;C0728778&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Organic Chemical (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0728778&amp;amp;tui=T109"&gt;&lt;i&gt;T109&lt;/i&gt;&lt;/a&gt;)
, Pharmacologic Substance (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0728778&amp;amp;tui=T121"&gt;&lt;i&gt;T121&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D008713&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;tapazole, Tapazole, Eli Lilly Brand of Methimazole, Jones Brand of Methimazole&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Methimazole  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0025644"&gt;&lt;i&gt;C0025644&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;A thioureylene antithyroid agent that inhibits the formation of thyroid hormones by interfering with the incorporation of iodine into tyrosyl residues of thyroglobulin. This is done by interfering with the oxidation of iodide ion and iodotyrosyl groups through inhibition of the peroxidase enzyme.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Organic Chemical (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0025644&amp;amp;tui=T109"&gt;&lt;i&gt;T109&lt;/i&gt;&lt;/a&gt;)
, Pharmacologic Substance (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0025644&amp;amp;tui=T121"&gt;&lt;i&gt;T121&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D008713&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;37656002, 404864000&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;1 Methyl 2 mercaptoimidazole, 1-Methyl-2-mercaptoimidazole, Mercasolyl, Mercazolyl, Merkazolil, Methimazole, Methylmercaptoimidazole, Methymazol, Thiamazole, Thimazol, Tiamazol, 2H-Imidazole-2-thione, 1,3-dihydro-1-methyl-, Methimazole preparation, Thiamazole preparation, methimazole, METHIMAZOLE, methimazole (medication), Methimazole [Chemical/Ingredient], tiamazol, thiamazole, Methimazole (substance), Methimazole (product)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Metimazol&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;preparado de metimazol, metimazol (sustancia), metimazol, preparado de metimazol (sustancia), preparado de tiamazol, metimazol (producto), Metimazol, Tiamazol&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;methimazol&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Metimatsoli&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;METIMAZOL, MERKAZOLIL, TIMAZOL, МЕРКАЗОЛИЛ, МЕТИМАЗОЛ, ТИМАЗОЛ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;チアマゾール, メルカプトメチルイミダゾール, メルカゾール, チマゾール, メチマゾール&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Croatian&lt;/td&gt;
                &lt;td&gt;METIMAZOL&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Metizol&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Thiamazole&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Methimazol, Methymazol, Thiamazol&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Metimazolo&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Metimazol, Tiamazol&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Propylthiouracil  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0033511"&gt;&lt;i&gt;C0033511&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;A thiourea antithyroid agent. Propythiouracil inhibits the synthesis of thyroxine and inhibits the peripheral conversion of throxine to tri-iodothyronine. It is used in the treatment of hyperthyroidism. (From Martindale, The Extra Pharmacopeoia, 30th ed, p534)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A thiourea derivative with antithyroid property. Propylthiouracil (PTU) interferes with the oxidation of iodine possibly by interaction with peroxidase or a peroxidase-mediated complex reaction, thereby inhibiting synthesis of thyroid hormones tri-iodothyronine (T3) and thyroxine (T4). In addition, this agent inhibits the Type I 5'-deiodinase (D1), an enzyme involved in the peripheral conversion of thyroxine to tri-iodothyronine. This results in decreased plasma triodothyronine concentrations and decreased entrance of thyroxine into cells thereby reducing thyroid hormone activity.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (PDQ)&lt;/td&gt;
                &lt;td&gt;A thiourea derivative with antithyroid property. Propylthiouracil (PTU) interferes with the oxidation of iodine possibly by interaction with peroxidase or a peroxidase-mediated complex reaction, thereby inhibiting synthesis of thyroid hormones tri-iodothyronine (T3) and thyroxine (T4). In addition, this agent inhibits the Type I 5'-deiodinase (D1), an enzyme involved in the peripheral conversion of thyroxine to tri-iodothyronine. This results in decreased plasma triodothyronine concentrations and decreased entrance of thyroxine into cells thereby reducing thyroid hormone activity. Check for "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39288&amp;amp;idtype=1" active clinical trials or "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39288&amp;amp;idtype=1&amp;amp;closed=1" closed clinical trials using this agent. ("http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;amp;code=C781" NCI Thesaurus)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Nucleic Acid, Nucleoside, or Nucleotide (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0033511&amp;amp;tui=T114"&gt;&lt;i&gt;T114&lt;/i&gt;&lt;/a&gt;)
, Pharmacologic Substance (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0033511&amp;amp;tui=T121"&gt;&lt;i&gt;T121&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D011441&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;3814009, 387203007&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;6-Propyl-2-Thiouracil, Propylthiouracil, 4(1H)-Pyrimidinone, 2,3-dihydro-6-propyl-2-thioxo-, 6 Propyl 2 Thiouracil, propylthiouracil, Propylthiouracil preparation, 6-Propyl-2-thiouracil, anti-thyroid agents propylthiouracil (propylthiouracil), propylthiouracil (medication), PTU (propylthiouracil), PROPYLTHIOURACIL, Propylthiouracil [Chemical/Ingredient], PTU preparation, Propylthiouracil product, Propylthiouracil (product), Propylthiouracil (substance)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Propyltiouracil&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;preparado de propiltiouracilo, preparado de PTU, preparado de propiltiouracilo (producto), preparado de propiltiouracilo (sustancia), propiltiouracilo (producto), propiltiouracilo (sustancia), propiltiouracilo, Propiltiouracilo&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;propylthiouracil&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Propyylitiourasiili&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;PROPILTIOURATSIL, ПРОПИЛТИОУРАЦИЛ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Propylotiouracyl&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;チウラジール, プロピルチオウラシル, プロパジール&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Propylthiouracile&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Propylthiouracil&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Propiltiouracile&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Propiltiouracila&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Antithyroid Agents  (</value><value>)
</value><value>Thioamides  (</value><value>)
</value><value>Tapazole  (</value><value>)
</value><value>Methimazole  (</value><value>)
</value><value>Propylthiouracil  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Antithyroid Drug</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Pharmacology</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;See Also&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/Hyprthyrdsm1.htm" class="LinkPage"&gt;Hyperthyroidism&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/HyprthyrdsmMngmnt.htm" class="LinkPage"&gt;Hyperthyroidism Management&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Indications&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/Hyprthyrdsm1.htm" class="LinkPage"&gt;Hyperthyroidism&lt;/a&gt; in children and adolescents&lt;/li&gt;&lt;li&gt;Pregnancy (PTU)&lt;/li&gt;&lt;li&gt;Severe &lt;a href="../../Endo/Thyroid/GrvsDs.htm" class="LinkPage"&gt;Grave's Disease&lt;/a&gt; (e.g. &lt;a href="../../Endo/Thyroid/ThyrdStrm.htm" class="LinkPage"&gt;Thyroid Storm&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/SbclnclHyprthyrdsm.htm" class="LinkPage"&gt;Subclinical Hyperthyroidism&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Dose: &lt;a href="../../Endo/Thyroid/GrvsDs.htm" class="LinkPage"&gt;Grave's Disease&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Target dose to &lt;a href="../../Endo/Lab/Thyrxn.htm" class="LinkPage"&gt;Free T4&lt;/a&gt; high end of normal range&lt;/li&gt;&lt;li&gt;Methimazole (Tapazole)&lt;ol&gt;&lt;li&gt;Preferred first-line agent&lt;/li&gt;&lt;li&gt;Advantages over Propylthiouracil (PTU)&lt;ol&gt;&lt;li&gt;Once daily dosing&lt;/li&gt;&lt;li&gt;Decreases T4 and T3 levels more rapidly&lt;/li&gt;&lt;li&gt;Much safer than PTU&lt;ol&gt;&lt;li&gt;Lower risk of &lt;a href="../../HemeOnc/Lab/Ntrpn.htm" class="LinkPage"&gt;Agranulocytosis&lt;/a&gt; at moderate doses&lt;/li&gt;&lt;li&gt;Does not carry the same liver toxicity risk as PTU&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Dosing: &lt;a href="../../Endo/Thyroid/Hyprthyrdsm1.htm" class="LinkPage"&gt;Hyperthyroidism&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Start: 10-30 mg PO qd&lt;/li&gt;&lt;li&gt;Titrate Methimazole dose down after 4-6 weeks&lt;ol&gt;&lt;li&gt;Goal: maintain normal &lt;a href="../../Endo/Anatomy/ThyrdAntmy.htm" class="LinkPage"&gt;Thyroid&lt;/a&gt; function&lt;/li&gt;&lt;li&gt;Dose: reduce to 5-10 mg per day&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Dosing: Other&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/SbclnclHyprthyrdsm.htm" class="LinkPage"&gt;Subclinical Hyperthyroidism&lt;/a&gt;: 5 mg PO qd&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Propylthiouracil (PTU)&lt;ol&gt;&lt;li&gt;Indications (reasons to use PTU instead of Methimazole)&lt;ol&gt;&lt;li&gt;&lt;a href="../../OB/Lactation/BrstFdng.htm" class="LinkPage"&gt;Lactation&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Pregnancy (both PTU and Methimazole are Category D)&lt;ol&gt;&lt;li&gt;Use PTU in first trimester&lt;/li&gt;&lt;li&gt;Use Methimazole in second and third trimester&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Dosing: &lt;a href="../../Endo/Thyroid/Hyprthyrdsm1.htm" class="LinkPage"&gt;Hyperthyroidism&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Start: 100 mg po tid&lt;/li&gt;&lt;li&gt;Maximum: 150 mg every 6-8 hours&lt;/li&gt;&lt;li&gt;Titrate PTU dose down after 4-6 weeks&lt;ol&gt;&lt;li&gt;Goal: maintain normal &lt;a href="../../Endo/Anatomy/ThyrdAntmy.htm" class="LinkPage"&gt;Thyroid&lt;/a&gt; function&lt;/li&gt;&lt;li&gt;Dose: reduce to 50-100 mg per day&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Dosing: Other&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/ThyrdStrm.htm" class="LinkPage"&gt;Thyroid Storm&lt;/a&gt;: 1 gram load, then 300 mg PO q6 hours&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/SbclnclHyprthyrdsm.htm" class="LinkPage"&gt;Subclinical Hyperthyroidism&lt;/a&gt;: 50-100 mg PO qd&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Adverse effects (3 per 1000 patients)&lt;ol&gt;&lt;li&gt;&lt;a href="../../HemeOnc/Pharm/MdctnCsOfNtrpn.htm" class="LinkPage"&gt;Drug-Induced Agranulocytosis&lt;/a&gt; (more common with PTU)&lt;ol&gt;&lt;li&gt;Risk: over age 40 years&lt;/li&gt;&lt;li&gt;Presentation: Infection (e.g. &lt;a href="../../ENT/Mouth/Phryngts.htm" class="LinkPage"&gt;Pharyngitis&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;Course&lt;ol&gt;&lt;li&gt;Resolves within 2-3 weeks after drug stopped&lt;/li&gt;&lt;li&gt;Severe, refractory course may occur&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Contraindication to further Antithyroid Drugs&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../GI/Derm/Jndc.htm" class="LinkPage"&gt;Jaundice&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Cholestatic &lt;a href="../../GI/Derm/Jndc.htm" class="LinkPage"&gt;Jaundice&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Occurs more commonly with Methimazole&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Hepatitis&lt;ol&gt;&lt;li&gt;Occurs with both Methimazole and Propylthiouracil (PTU)&lt;/li&gt;&lt;li&gt;Propylthiouracil (PTU) is associated with severe liver injury&lt;ol&gt;&lt;li&gt;Adults: 1 in 10,000&lt;/li&gt;&lt;li&gt;Children: 1 in 2,000&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Rheum/CV/Vsclts.htm" class="LinkPage"&gt;Vasculitis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Rheum/Diffuse/SystmcLpsErythmts.htm" class="LinkPage"&gt;Lupus&lt;/a&gt;-like syndrome&lt;/li&gt;&lt;li&gt;&lt;a href="../../HemeOnc/Marrow/AplstcAnm.htm" class="LinkPage"&gt;Aplastic Anemia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Rash or &lt;a href="../../Derm/Sx/PrtcCndtn.htm" class="LinkPage"&gt;Pruritus&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Switch from PTU to Methimazole if severe&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Arthralgia or &lt;a href="../../Rheum/joint/PlyrtclrArthrts.htm" class="LinkPage"&gt;Polyarthritis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../ID/Exam/Fvr.htm" class="LinkPage"&gt;Fever&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Congenital abnormalities possible with Methimazole&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Monitoring&lt;ol&gt;&lt;li&gt;Repeat examination every 3 months&lt;/li&gt;&lt;li&gt;&lt;a href="../../OB/Lab/PrgncyTst.htm" class="LinkPage"&gt;Pregnancy Test&lt;/a&gt; before starting therapy&lt;/li&gt;&lt;li&gt;Lab Testing monthly for 6 to 12 months&lt;ol&gt;&lt;li&gt;&lt;a href="../../HemeOnc/Lab/CmpltBldCnt.htm" class="LinkPage"&gt;Complete Blood Count&lt;/a&gt; (CBC)&lt;/li&gt;&lt;li&gt;&lt;a href="../../GI/Lab/LvrFnctnTst.htm" class="LinkPage"&gt;Liver Function Test&lt;/a&gt;s&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/ThyrdStmltngHrmn.htm" class="LinkPage"&gt;Thyroid Stimulating Hormone&lt;/a&gt; (TSH)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/Thyrxn.htm" class="LinkPage"&gt;Free T4&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/Trdthyrn.htm" class="LinkPage"&gt;Free T3&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Indications to discontinue medication&lt;ol&gt;&lt;li&gt;TSH normalized for 6-12 months&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Indications to consider &lt;a href="../../Endo/Anatomy/ThyrdAntmy.htm" class="LinkPage"&gt;Thyroid&lt;/a&gt; ablation&lt;ol&gt;&lt;li&gt;Inadequate suppression at 12 months from initiation&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Efficacy: Predictors of Relapse (occurs in 50% of cases)&lt;ol&gt;&lt;li&gt;&lt;a href="../../Psych/CD/Cgrt.htm" class="LinkPage"&gt;Tobacco&lt;/a&gt; abuse&lt;/li&gt;&lt;li&gt;Large &lt;a href="../../Endo/Thyroid/Gtr.htm" class="LinkPage"&gt;Goiter&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Anatomy/ThyrdAntmy.htm" class="LinkPage"&gt;Thyroid&lt;/a&gt; Stmulating &lt;a href="../../ID/Exam/Imnglbln.htm" class="LinkPage"&gt;Antibody&lt;/a&gt; high at end of treatment&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0040125</value><value>C0039875</value><value>C0728778</value><value>C0025644</value><value>C0033511</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Pharm/AnthyrdDrg.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Antithyroid Drug, Thioamide, Propylthiouracil, PTU, Methimazole, Tapazole</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Pharm/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Fludrocortisone  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0016280"&gt;&lt;i&gt;C0016280&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A synthetic corticosteroid. It is used to replace steroid hormones normally produced by the adrenal gland.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A synthetic corticosteroid with antiinflammatory and antiallergic properties. Fludrocortisone is a mineralocorticoid receptor and glucocorticoid receptor agonist that binds to cytoplasmic receptors, translocates to the nucleus and subsequently initiates the transcription of glucocorticoid-responsive genes such as lipocortins to inhibit phospholipase A2. This prevents the release of arachidonic acid, a precursor to prostaglandins and leukotrienes, both important mediators in the pro-inflammatory response mechanism. In addition, this agent exerts its mineralocorticoid effect on the distal tubules and collecting ducts of the kidney by inducing permease, an enzyme that regulates Na+ permeability in cells, thereby enhancing Na+ reabsorption and water retention as well as increasing K+, H+ excretion.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;A synthetic mineralocorticoid with anti-inflammatory activity.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Steroid (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0016280&amp;amp;tui=T110"&gt;&lt;i&gt;T110&lt;/i&gt;&lt;/a&gt;)
, Pharmacologic Substance (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0016280&amp;amp;tui=T121"&gt;&lt;i&gt;T121&lt;/i&gt;&lt;/a&gt;)
, Hormone (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0016280&amp;amp;tui=T125"&gt;&lt;i&gt;T125&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D005438&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;116586002, 89192008&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;9 alpha-Fluorohydrocortisone, 9-Fluorocortisol, 9-Fluorohydrocortisone, Fludrocortisone, 9 Fluorocortisol, 9 Fluorohydrocortisone, 9 alpha Fluorohydrocortisone, fludrocortisone, Pregn-4-ene-3,20-dione, 9-fluoro-11,17,21-trihydroxy-, (11beta)-, 9 Fluoro 17 Hydroxycortisone, 9 alpha Fludrohydrocortisone, 9 alpha Fluoro 17 Hydroxycorticosterone, 9 alpha-Fluoro-17-Hydroxycorticosterone, 9-Fluoro-17-Hydroxycortisone, FLUOROCORTISOL 09, Fludrocortisone [Chemical/Ingredient], 9-fluorohydrocortisone, Fludrocortisone preparation, Fludrocortisone (substance), Fludrocortisone preparation (product), Fludrocortisone preparation (substance), FLUDROCORTISONE&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Fludrokortison&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;fludrokortison&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Fludrokortisoni&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;FLUDROKORTIZON, 9-FLUOROKORTIZOL, 9-FTORKORTIZOL, 9-ФЛУОРОКОРТИЗОЛ, 9-ФТОРКОРТИЗОЛ, ФЛУДРОКОРТИЗОН&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;fludrocortisona (producto), preparado con fludrocortisona (producto), preparado con fludrocortisona, fludrocortisona (sustancia), fludrocortisona, preparado de fludrocortisona (producto), preparado de fludrocortisona (sustancia), preparado de fludrocortisona, 9-Fluorocortisol, Fludrocortisona&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;9 alfa-Fluoro-17-idrossicortisone, 9-Fludro-idrocortisone, 9 alfa Fludro-idrocortisone, 9-Fluoro-17-idrossicortisone, 9-Fluorocortisolo, 9-Fluoro-17-idrocortisone, Fludrocortisone&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;FLUORCORTISOL 09, 9-Fluorcortisol, Fludrocortison&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Fludrokortyzon&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;酢酸フルドロコルチゾン, フルドロコルチゾン, 9-フルオロコーチゾル, フロリネフ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Fludrocortisone&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Fludrocortisona, 9-Fluorcortisol&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Florinef  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0060486"&gt;&lt;i&gt;C0060486&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Steroid (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0060486&amp;amp;tui=T110"&gt;&lt;i&gt;T110&lt;/i&gt;&lt;/a&gt;)
, Pharmacologic Substance (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0060486&amp;amp;tui=T121"&gt;&lt;i&gt;T121&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;C034635&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Florinef Acetate, Florinef, Florinef acetate, florinef, florinef acetate, acetate florinef, Bristol-Myers Squibb brand of fludrocortisone 21-acetate, Monarch brand of fludrocortisone 21-acetate, Shire brand of fludrocortisone 21-acetate&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Fludrocortisone  (</value><value>)
</value><value>Florinef  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Fludrocortisone</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Pharmacology</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Mechanism&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/SystmcCrtcstrd.htm" class="LinkPage"&gt;Systemic Corticosteroid&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Expands intravascular volume&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Indications&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Adrenal/AdsnsDs.htm" class="LinkPage"&gt;Adrenal Insufficiency&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Exam/OrthstcHyptnsn.htm" class="LinkPage"&gt;Orthostatic Hypotension&lt;/a&gt; (some forms)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Adverse Effects&lt;ol&gt;&lt;li&gt;Volume overload&lt;/li&gt;&lt;li&gt;&lt;a href="../../Renal/Potassium/Hypklm.htm" class="LinkPage"&gt;Hypokalemia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Renal/Magnesium/Hypmgnsm.htm" class="LinkPage"&gt;Hypomagnesemia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Neuro/Sx/Hdch.htm" class="LinkPage"&gt;Headache&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Renal/Edema/Edm.htm" class="LinkPage"&gt;Edema&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Weight gain&lt;/li&gt;&lt;li&gt;Supine &lt;a href="../../CV/Htn/Hyprtnsn.htm" class="LinkPage"&gt;Hypertension&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;(2003) Lexi-comp Drug Database&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0016280</value><value>C0060486</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Pharm/Fldrcrtsn.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Fludrocortisone, Florinef</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Pharm/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees></FP_UMLS_Trees><FP_Condition_name_check></FP_Condition_name_check><FP_Condition_name><value>Corticosteroid Associated Osteoporosis</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Pharmacology</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;See Also&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/SystmcCrtcstrd.htm" class="LinkPage"&gt;Systemic Corticosteroid&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Rheum/Bone/Ostprs.htm" class="LinkPage"&gt;Osteoporosis&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Risk of &lt;a href="../../Rheum/Bone/Ostprs.htm" class="LinkPage"&gt;Osteoporosis&lt;/a&gt; on long-term &lt;a href="../../Endo/Pharm/SystmcCrtcstrd.htm" class="LinkPage"&gt;Corticosteroid&lt;/a&gt;s&lt;ol&gt;&lt;li&gt;Prednisone 1-5 mg: Relative risk 1.9x&lt;/li&gt;&lt;li&gt;Prednisone 5-10 mg: Relative risk 4.5x&lt;/li&gt;&lt;li&gt;Prednisone &amp;gt;10 mg: Relative risk 32x&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Evaluation: Obtain &lt;a href="../../Rheum/Rad/BnMnrlDnsty.htm" class="LinkPage"&gt;Bone Mineral Density&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Check BMD at baseline prior to therapy&lt;/li&gt;&lt;li&gt;Check BMD every 6-12 months during first 2 years&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Prevention of &lt;a href="../../Rheum/Bone/Ostprs.htm" class="LinkPage"&gt;Osteoporosis&lt;/a&gt; from long-term steroids&lt;ol&gt;&lt;li&gt;Use lowest dose of a short-acting glucocorticoid&lt;/li&gt;&lt;li&gt;Maintain a well-balanced, low sodium diet (2-3 gram)&lt;/li&gt;&lt;li&gt;Weight bearing &lt;a href="../../Sports/Exercise/Exrcs.htm" class="LinkPage"&gt;Exercise&lt;/a&gt; and &lt;a href="../../Sports/Exercise/StrngthTrng.htm" class="LinkPage"&gt;Isometric Exercise&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Renal/Pharm/OrlClcm.htm" class="LinkPage"&gt;Calcium Supplementation&lt;/a&gt; 1500 mg/day&lt;/li&gt;&lt;li&gt;&lt;a href="../../Pharm/Vitamins/VtmnD.htm" class="LinkPage"&gt;Vitamin D&lt;/a&gt; Supplementation 400-800 IU/day&lt;/li&gt;&lt;li&gt;Control &lt;a href="../../Renal/Lab/UrnClcm.htm" class="LinkPage"&gt;Hypercalciuria&lt;/a&gt; with &lt;a href="../../CV/Pharm/ThzdDrtc.htm" class="LinkPage"&gt;Thiazide Diuretic&lt;/a&gt;s&lt;/li&gt;&lt;li&gt;Treat &lt;a href="../../Endo/Sex/Hypgndsm.htm" class="LinkPage"&gt;Hypogonadism&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../Gyn/Endo/Mnps.htm" class="LinkPage"&gt;Menopause&lt;/a&gt;: &lt;a href="../../Gyn/Pharm/EstrgnRplcmnt.htm" class="LinkPage"&gt;Hormone Replacement Therapy&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Men with low testosterone: &lt;a href="../../Uro/Pharm/TststrnSplmntn.htm" class="LinkPage"&gt;Testosterone Replacement&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Treat bone loss if it occurs with &lt;a href="../../Endo/Pharm/SystmcCrtcstrd.htm" class="LinkPage"&gt;Corticosteroid&lt;/a&gt; use&lt;ol&gt;&lt;li&gt;&lt;a href="../../Gyn/Pharm/EstrgnRplcmnt.htm" class="LinkPage"&gt;Hormone Replacement Therapy&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Rheum/Pharm/Bsphsphnts.htm" class="LinkPage"&gt;Bisphosphonates&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Rheum/Pharm/Clctn.htm" class="LinkPage"&gt;Calcitonin&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Dubois%20%20%5BAU%5D%20AND%202002%20%5BDP%5D%20AND%20%20Chest%20%20%5BTA%5D" class="LinkRef"&gt;Dubois (2002) Chest 121:1456-63&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Lane%20%20%5BAU%5D%20AND%201998%20%5BDP%5D%20AND%20%20Endocrinol%20Metab%20Clin%20North%20Am%20%20%5BTA%5D" class="LinkRef"&gt;Lane (1998) Endocrinol Metab Clin North Am 27:465-83&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Pharm/CrtcstrdAsctdOstprs.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Corticosteroid Associated Osteoporosis, Osteoporosis Secondary to Corticosteroid Use</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Pharm/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Dostinex  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0526034"&gt;&lt;i&gt;C0526034&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Organic Chemical (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0526034&amp;amp;tui=T109"&gt;&lt;i&gt;T109&lt;/i&gt;&lt;/a&gt;)
, Pharmacologic Substance (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0526034&amp;amp;tui=T121"&gt;&lt;i&gt;T121&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;C047047&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Dostinex, Cabaser, Cabaseril, Pfizer brand of cabergoline, cabaser, dostinex&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;cabergoline  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0107994"&gt;&lt;i&gt;C0107994&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A synthetic ergoline derivative and a long-acting dopamine receptor agonist with high affinity for the dopamine D2 receptor. Cabergoline exerts an inhibitory effect on prolactin secretion by acting on dopamine receptors present in pituitary lactotrophs. This drug also binds to dopamine D2 receptors in the corpus striatum, thereby mimicking the actions of dopamine on motor control. Cabergoline also possesses antioxidant and neuroprotective properties due to its free radical scavenging activity. Cabergoline is used in the treatment of Parkinson's disease and in the treatment of hyperprolactinemia.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Organic Chemical (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0107994&amp;amp;tui=T109"&gt;&lt;i&gt;T109&lt;/i&gt;&lt;/a&gt;)
, Pharmacologic Substance (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0107994&amp;amp;tui=T121"&gt;&lt;i&gt;T121&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;C047047&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;323191001, 109139002, 386979007&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;cabergoline, 1-((6-Allylergolin-8beta-yl)carbonyl)-1-(3-(dimethylamino)propyl)-3-ethylurea, Cabergoline [parkinsons], Cabergoline [parkinsons] (product), cabergoline (medication), dopamine agonists cabergoline, 1-((6-allylergolin-8beta-yl)carbonyl)-1-(3-(dimethylamino)propyl)-3-ethylurea, CABERGOLINE, cabergoline [Chemical/Ingredient], cabergoline parkinsons, Cabergoline, Cabergoline (product), Cabergoline (substance), Cabergoline [parkinsons] (substance)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;cabergolina [antiparkinsonianos], cabergolina [antiparkinsonianos] (producto), cabergolina (producto), cabergolina (sustancia), cabergolina&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Dopamine Agonists  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0178601"&gt;&lt;i&gt;C0178601&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;Any agent that binds to and activates dopamine receptors.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;Drugs that bind to and activate dopamine receptors.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CSP)&lt;/td&gt;
                &lt;td&gt;class of drugs and natural products which enhance dopaminergic function by increasing dopamine biosynthesis, decreasing dopamine degradation or reuptake, or interacting positively with dopamine receptors.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Pharmacologic Substance (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0178601&amp;amp;tui=T121"&gt;&lt;i&gt;T121&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D018491&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;384952006, 108808007, 395987003, 418222008&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Agonists, Dopamine, Agonists, Dopamine Receptor, Dopamine Receptor Agonists, Receptor Agonists, Dopamine, dopamine agonist, Agonist, Dopamine, Agonist, Dopamine Receptor, Agonist, Dopaminergic, Agonists, Dopaminergic, Dopamine Agonist, Dopamine Receptor Agonist, Dopaminergic Agonist, Dopaminergic Agonists, Receptor Agonist, Dopamine, Dopaminergic drugs used in parkinsonism, Dopaminergics in parkinsons, RECEPT AGON DOPAMINE, DOPAMINE AG, DOPAMINERGIC AG, DOPAMINERGIC AGON, AGON DOPAMINERGIC, DOPAMINE RECEPT AG, AGON DOPAMINE RECEPT, DOPAMINE AGON, DOPAMINE RECEPT AGON, Dopaminergics, dopamine receptor agonist, dopamine agonists (medication), dopamine agonists, Dopamine Agonists, Dopaminergic Agonist [EPC], dopaminergic agonists, agonist dopamine receptor, agonists dopamine receptor, Dopamine agonist product (product), Dopamine agonist product, Dopamine agonist (substance), Dopamine agonist (product), Dopamine agonist, Dopamine receptor agonist (substance), Dopamine receptor agonist, Dopamine agonist agent (substance), Dopamine agonist agent&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;agonista de dopamina, agonista dopamínico (sustancia), agonista dopamínico, agonista dopaminérgico (producto), agonista del receptor de dopamina, agonista del receptor de dopamina (sustancia), agonista dopaminérgico, agonista de la dopamina (producto), agonista de la dopamina, agonista dopaminérgico (sustancia), Agonistas de Dopamina, Agonistas de Receptores de Dopamina, Agonistas Dopaminergicos, Agonistas Dopaminérgicos&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Agonistes de la dopamine, Agonistes du récepteur de la dopamine, Agonistes des récepteurs dopaminergiques, Agonistes dopaminergiques&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Dopaminstimulerare&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;dopamin agonisté&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Dopamiiniagonistit&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Agonista del recettore della dopamina, Agonista della dopamina, Agonisti del recettore della dopamina, Agonista dopaminergico, Agonisti dopaminergici, Agonisti della dopamina&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;DOFAMINA RETSEPTOROV AGONISTY, DOFAMINERGICHESKIE AGONISTY, DOFAMINA AGONISTY, ДОФАМИНА АГОНИСТЫ, ДОФАМИНА РЕЦЕПТОРОВ АГОНИСТЫ, ДОФАМИНЕРГИЧЕСКИЕ АГОНИСТЫ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Croatian&lt;/td&gt;
                &lt;td&gt;DOPAMINSKI AGONISTI&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Agoniści dopaminy, Agoniści dopaminergiczni, Agoniści receptora dopaminowego&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;ドーパミン作動剤, ドーパミンアゴニスト, ドーパミン作用薬, ドーパミン受容体作用薬, ドーパミン作用剤, ドーパミン受容体作用物質&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Dopaminagonisten, Dopaminerge Agonisten, Dopaminrezeptoragonisten&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Agonistas de Dopamina, Agonistas Dopaminérgicos, Agonistas dos Receptores de Dopamina&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Parlodel  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0000266"&gt;&lt;i&gt;C0000266&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Organic Chemical (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0000266&amp;amp;tui=T109"&gt;&lt;i&gt;T109&lt;/i&gt;&lt;/a&gt;)
, Pharmacologic Substance (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0000266&amp;amp;tui=T121"&gt;&lt;i&gt;T121&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D001971&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;parlodel, Parlodel&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Bromocriptine  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0006230"&gt;&lt;i&gt;C0006230&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A semisynthetic, ergot alkaloid with antiparkinson and lactation inhibitory activities. Bromocriptine selectively binds to and activates the postsynaptic dopamine D2-like receptors in the corpus striatum of the central nervous system (CNS). D2-like receptors are coupled to inhibitory G-proteins, which inhibit adenylyl cyclase, thereby preventing signal transduction mediated via cAMP and leading to an inhibitory effect on neurotransmission. This improves Parkinson symptoms, such as dyskinesia. Bromocriptine also has an inhibitory effect on the anterior pituitary gland, which results in blockage of prolactin secretion, thereby suppressing lactation.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CSP)&lt;/td&gt;
                &lt;td&gt;D2 dopamine agonist used as a prolactin inhibitor.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;A semisynthetic ergotamine alkaloid that is a dopamine D2 agonist. It suppresses prolactin secretion.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Organic Chemical (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0006230&amp;amp;tui=T109"&gt;&lt;i&gt;T109&lt;/i&gt;&lt;/a&gt;)
, Pharmacologic Substance (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0006230&amp;amp;tui=T121"&gt;&lt;i&gt;T121&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D001971&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;325985002, 323134006, 325986001, 116656002, 387039007, 46293006&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;2 Bromoergocryptine, 2-Bromoergocryptine, 2-Bromoergokryptine, Bromocriptin, Bromocriptine, Bromocryptin, 2 Bromoergokryptine, bromocriptine, 2 Bromo alpha ergocryptine, 2 Bromo alpha ergokryptine, 2-Bromo-alpha-ergocryptine, 2-Bromo-alpha-ergokryptine, Bromocriptine [endocrine], BROMOERGOCRYPTINE 02, Bromocriptine [endocrine use], Bromocriptine [parkinsons], Bromocriptine [endocrine use] (product), Bromocriptine [parkinsons] (product), Bromocriptine [endocrine] (product), Ergotaman-3',6',18-trione, 2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-, (5'alpha)-, BROMOCRIPTINE, Bromocriptine [Chemical/Ingredient], bromocriptin, bromocryptin, bromocryptine, Ergotaman-3',6',18-trione, 2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'alpha-(2-methylpropyl)-, 2-Br-alpha-ergocryptine, Brom-ergocryptine, Bromocryptine, Bromocriptine (product), Bromocriptine (substance), BRCR, Bromocriptine [endocrine use] (substance), Bromocriptine [endocrine] (substance), Bromocriptine [parkinsons] (substance)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Bromokriptin&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;bromokriptin&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;bromocriptina [endocrina] (producto), bromocriptina [uso endocrino] (producto), bromocriptina [antiparkinsoniano], bromocriptina [antiparkinsoniano] (producto), bromocriptina [uso endocrino], bromocriptina [endocrina], 2-br-alfa-ergocriptina, 2-bromoergocriptina, brom-ergocriptina, bromocriptina (producto), bromocriptina (sustancia), bromocriptina, 2-Bromoergocriptina, Bromocriptina&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Bromokryptiini&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;2-Bromoergocriptina, 2-Bromo-alfa-ergocriptina, Bromocriptina&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;2-BROMOERGOKRIPTIN, BROMOKRIPTIN, PARLODEL, 2-БРОМОЭРГОКРИПТИН, БРОМОКРИПТИН, ПАРЛОДЕЛ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;BROMERGOCRYPTIN 02, 2-Bromergocryptin, Bromocriptin, Bromocryptin&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Croatian&lt;/td&gt;
                &lt;td&gt;BROMOKRIPTIN&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Bromokryptyna&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;ブロモクリプチン, 2-ブロモエルゴクリプチン&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Bromocriptine&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;2-Bromoergocriptina, Bromocriptina&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Dostinex  (</value><value>)
</value><value>cabergoline  (</value><value>)
</value><value>Dopamine Agonists  (</value><value>)
</value><value>Parlodel  (</value><value>)
</value><value>Bromocriptine  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Dopamine Agonist</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Pharmacology</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;See Also&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pituitary/Hyprprlctnm.htm" class="LinkPage"&gt;Hyperprolactinemia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Gyn/Sx/Glctrh.htm" class="LinkPage"&gt;Galactorrhea&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Indications&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pituitary/Hyprprlctnm.htm" class="LinkPage"&gt;Hyperprolactinemia&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Dosing&lt;ol&gt;&lt;li&gt;Bromocriptine (Parlodel)&lt;ol&gt;&lt;li&gt;Larger safety database than Cabergoline (preferred in women trying to conceive)&lt;/li&gt;&lt;li&gt;Start: 1.25 to 2.5 mg at bedtime&lt;/li&gt;&lt;li&gt;Titrate: Increase by 2.5 mg every 3-7 days up to 15 mg daily&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Cabergoline (Dostinex)&lt;ol&gt;&lt;li&gt;Fewer side effects than Bromocriptine&lt;/li&gt;&lt;li&gt;Start: 0.25 orally  twice weekly&lt;/li&gt;&lt;li&gt;Titrate: Increase by 0.25 mg every month up to 1 mg twice daily&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Adverse Effects&lt;ol&gt;&lt;li&gt;&lt;a href="../../GI/Sx/Vmtng.htm" class="LinkPage"&gt;Nausea&lt;/a&gt; or &lt;a href="../../GI/Sx/Vmtng.htm" class="LinkPage"&gt;Vomiting&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Exam/OrthstcHyptnsn.htm" class="LinkPage"&gt;Postural Hypotension&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Sx/Dzns.htm" class="LinkPage"&gt;Dizziness&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Neuro/Sx/Hdch.htm" class="LinkPage"&gt;Headache&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Surgery/Anesthesia/PrcdrlSdtnAndAnlgs.htm" class="LinkPage"&gt;Sedation&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Valvular disorders&lt;ol&gt;&lt;li&gt;Reported with high dose Cabergoline (&amp;gt;4 mg daily)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Huang%20%20%5BAU%5D%20AND%202012%20%5BDP%5D%20AND%20%20Am%20Fam%20Physician%20%20%5BTA%5D" class="LinkRef"&gt;Huang (2012) Am Fam Physician 85(11): 1073-80&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0526034</value><value>C0107994</value><value>C0178601</value><value>C0000266</value><value>C0006230</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Pharm/DpmnAgnst.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Dopamine Agonist, Bromocriptine, Parlodel, Cabergoline, Dostinex</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Pharm/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Phentermine  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0031447"&gt;&lt;i&gt;C0031447&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A natural monoamine alkaloid derivative and a sympathomimetic stimulant with appetite suppressant property. Phentermine, which was part of the Fen-Phen anti-obesity medication, stimulates hypothalamic release of norepinephrine, a neurotransmitter involved in stress responses (fight-or-flight reactions), and reduces hunger sensation. Phentermine also causes the release of epinephrine or adrenaline outside of the brain, resulting in breakdown of stored fat.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;A central nervous system stimulant and sympathomimetic with actions and uses similar to those of DEXTROAMPHETAMINE. It has been used most frequently in the treatment of obesity.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CSP)&lt;/td&gt;
                &lt;td&gt;central nervous system stimulant and sympathomimetic with actions and uses similar to dextroamphetamine; used in the treatment of obesity.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Organic Chemical (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0031447&amp;amp;tui=T109"&gt;&lt;i&gt;T109&lt;/i&gt;&lt;/a&gt;)
, Pharmacologic Substance (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0031447&amp;amp;tui=T121"&gt;&lt;i&gt;T121&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D010645&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;373343009, 53480001&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Phentermine, Benzeneethanamine, alpha,alpha-dimethyl-, phentermine, Phentermine [Chemical/Ingredient], 1,1-Dimethyl-2-phenylethylamine, 2-Phenyl-tert-butylamine, 2-Amino-2-methyl-1-phenylpropane, PHENTERMINE, Phenyl-tertiary-butylamine, Phentermine (product), Phentermine (substance)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Fentermin&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;fentermin&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Fentermiini&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;FENTERMIN, ФЕНТЕРМИН&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;フェンテルミン, フェンテルミン塩酸塩, デュロミン, 塩酸フェンテルミン, イオナミン&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Fentermina&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;fentermina (producto), fentermina (sustancia), fentermina, Fentermina&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Phentermine&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Phentermin&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Fentermina&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Fentermina&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Phentermine  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Phentermine</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Pharmacology</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Trade Name&lt;ol&gt;&lt;li&gt;Fastin&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Mechanism&lt;ol&gt;&lt;li&gt;Stimulates CNS adrenergic system&lt;/li&gt;&lt;li&gt;Reduces food seeking behavior&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Indication&lt;ol&gt;&lt;li&gt;Short term (12 weeks per year) &lt;a href="../../Endo/Obesity/ObstyMngmnt.htm" class="LinkPage"&gt;Obesity Management&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Physician discretion for indication to continue&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;
              &lt;a href="../../Pharm/Manage/DCntrldSbstnc.htm" class="LinkPage"&gt;DEA Controlled Substance&lt;/a&gt;
              &lt;ol&gt;&lt;li&gt;Class IV (Limited dependence liability)&lt;/li&gt;
              &lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Dosing&lt;ol&gt;&lt;li&gt;Start: 8 mg PO tid&lt;/li&gt;&lt;li&gt;Alternative: 15 to 37.5 mg PO qd 10 hours before sleep&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0031447</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Pharm/Phntrmn.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Phentermine, Ionamin</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Pharm/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;orlistat  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0076275"&gt;&lt;i&gt;C0076275&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A reversible active-site inhibitor of gastrointestinal lipases. Orlistat forms a covalent bond with the active serine site in gastric and pancreatic lipases, thereby inhibiting their activity and preventing dietary fat from being hydrolyzed and absorbed. (NCI04)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Organic Chemical (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0076275&amp;amp;tui=T109"&gt;&lt;i&gt;T109&lt;/i&gt;&lt;/a&gt;)
, Pharmacologic Substance (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0076275&amp;amp;tui=T121"&gt;&lt;i&gt;T121&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;C055122&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;116093009, 387007000&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;1-((3-hexyl-4-oxo-2-oxetanyl)methyl)dodecyl-2-formamido-4-methylvalerate, L-Leucine, N-formyl-, 1-((3-hexyl-4-oxo-2-oxetanyl)methyl)dodecyl ester, (2S-(2alpha(R*),3beta))-, tetrahydrolipstatin, THLP, orlistat, orlistat (medication), ORLISTAT, orlistat [Chemical/Ingredient], Orlistat, Orlistat (product), Orlistat (substance)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;orlistat (producto), orlistat (sustancia), orlistat&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Xenical  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0732649"&gt;&lt;i&gt;C0732649&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Organic Chemical (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0732649&amp;amp;tui=T109"&gt;&lt;i&gt;T109&lt;/i&gt;&lt;/a&gt;)
, Pharmacologic Substance (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0732649&amp;amp;tui=T121"&gt;&lt;i&gt;T121&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;C055122&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;xenical, Hoffmann-La Roche brand of orlistat, Roche brand of orlistat, Xenical&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>orlistat  (</value><value>)
</value><value>Xenical  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Orlistat</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Pharmacology</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Indication for &lt;a href="../../Endo/Obesity/ObstyMngmnt.htm" class="LinkPage"&gt;Obesity Management&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Exam/BdyMsIndx.htm" class="LinkPage"&gt;Body Mass Index&lt;/a&gt; over 30 kg/m2&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Exam/BdyMsIndx.htm" class="LinkPage"&gt;Body Mass Index&lt;/a&gt; over 27 kg/m2 with comorbidity&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/DM/DbtsMlts.htm" class="LinkPage"&gt;Diabetes Mellitus&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Htn/Hyprtnsn.htm" class="LinkPage"&gt;Hypertension&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Dyslipidemia&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Mechanism&lt;ol&gt;&lt;li&gt;Pentanoic acid ester binds gastric, pancreatic &lt;a href="../../GI/Lab/Lps.htm" class="LinkPage"&gt;Lipase&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../GI/Lab/Lps.htm" class="LinkPage"&gt;Lipase&lt;/a&gt; Inhibitor (Blocks Fat absorption)&lt;ol&gt;&lt;li&gt;Decreased &lt;a href="../../CV/Lab/Trglycrd.htm" class="LinkPage"&gt;Triglyceride&lt;/a&gt; absorption&lt;/li&gt;&lt;li&gt;Decreased &lt;a href="../../CV/Lab/Lpd.htm" class="LinkPage"&gt;Cholesterol&lt;/a&gt; absorption&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Pharmacokinetics&lt;ol&gt;&lt;li&gt;Minimal systemic absorption&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Efficacy&lt;ol&gt;&lt;li&gt;Combined results of two large &lt;a href="../../Pharm/Psych/PlcbEfct.htm" class="LinkPage"&gt;Placebo&lt;/a&gt; controlled trials&lt;ol&gt;&lt;li&gt;Year one&lt;ol&gt;&lt;li&gt;Orlistat: 9-10 kg loss (10% of baseline weight)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Pharm/Psych/PlcbEfct.htm" class="LinkPage"&gt;Placebo&lt;/a&gt;: 6 kg (6% of baseline weight)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Year two&lt;ol&gt;&lt;li&gt;Orlistat: 1.5-3 kg regained weight&lt;/li&gt;&lt;li&gt;&lt;a href="../../Pharm/Psych/PlcbEfct.htm" class="LinkPage"&gt;Placebo&lt;/a&gt;: 4-6 kg regained weight&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;References&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Sjostrom%20%20%5BAU%5D%20AND%201998%20%5BDP%5D%20AND%20%20Lancet%20%20%5BTA%5D" class="LinkRef"&gt;Sjostrom (1998) Lancet 352:167&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Davidson%20%20%5BAU%5D%20AND%201999%20%5BDP%5D%20AND%20%20JAMA%20%20%5BTA%5D" class="LinkRef"&gt;Davidson (1999) JAMA 281:235&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Adverse effects&lt;ol&gt;&lt;li&gt;Gastrointestinal side effects (40%)&lt;ol&gt;&lt;li&gt;Flatus with discharge&lt;/li&gt;&lt;li&gt;Oily stool with spotting&lt;/li&gt;&lt;li&gt;Fecal urgency&lt;/li&gt;&lt;li&gt;&lt;a href="../../GI/Rectum/FclIncntnc.htm" class="LinkPage"&gt;Fecal Incontinence&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Surgery/GI/ActAbdmnlPn.htm" class="LinkPage"&gt;Abdominal Pain&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Fat soluble &lt;a href="../../Pharm/Vitamins/BtCrtn.htm" class="LinkPage"&gt;Carotenoid&lt;/a&gt; (fruit, vegetable) malabsorption&lt;/li&gt;&lt;li&gt;Fat soluble vitamin malabsorption: No supplement needed&lt;ol&gt;&lt;li&gt;&lt;a href="../../Pharm/Vitamins/VtmnA.htm" class="LinkPage"&gt;Vitamin A&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Pharm/Vitamins/VtmnD.htm" class="LinkPage"&gt;Vitamin D&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Pharm/Vitamins/VtmnE.htm" class="LinkPage"&gt;Vitamin E&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Pharm/Vitamins/VtmnK.htm" class="LinkPage"&gt;Vitamin K&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Drug Interactions&lt;ol&gt;&lt;li&gt;Does not interfere with absorption of other medications&lt;ol&gt;&lt;li&gt;&lt;a href="../../HemeOnc/Pharm/Wrfrn.htm" class="LinkPage"&gt;Coumadin&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Gyn/Pharm/OrlCntrcptv.htm" class="LinkPage"&gt;Oral Contraceptive&lt;/a&gt;s&lt;/li&gt;&lt;li&gt;Antihypertensives&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Dosing&lt;ol&gt;&lt;li&gt;Take three times daily with each meal containing fat&lt;/li&gt;&lt;li&gt;Prescription dose: 120 mg orally three times daily&lt;/li&gt;&lt;li&gt;OTC dose: 60 mg orally three time daily&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Precautions&lt;ol&gt;&lt;li&gt;Avoid fat-soluble vitamins within 2 hours of Orlistat&lt;/li&gt;&lt;li&gt;Maintain &lt;a href="../../Pharm/Nutrition/FtyAcd.htm" class="LinkPage"&gt;Dietary Fat&lt;/a&gt; intake &amp;lt;30% of calories&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=(1999)%20Med%20Lett%20Drugs%20Ther%2041%20%5BAU%5D%20AND%201055%20%5BDP%5D%20AND%20:%20%5BTA%5D" class="LinkRef"&gt;(1999) Med Lett Drugs Ther 41(1055):55-6&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0076275</value><value>C0732649</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Pharm/Orlst.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Orlistat, Xenical</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Pharm/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees></FP_UMLS_Trees><FP_Condition_name_check></FP_Condition_name_check><FP_Condition_name><value>Medication Causes of Hyperprolactinemia</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Pharmacology</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;See Also&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pituitary/Hyprprlctnm.htm" class="LinkPage"&gt;Hyperprolactinemia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pituitary/HyprprlctnmCs.htm" class="LinkPage"&gt;Hyperprolactinemia Causes&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pituitary/Prlctnm.htm" class="LinkPage"&gt;Prolactinoma&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Gyn/Sx/Glctrh.htm" class="LinkPage"&gt;Galactorrhea&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Causes: Psychotropic Medications&lt;ol&gt;&lt;li&gt;&lt;a href="../../Psych/Pharm/Bnzdzpn.htm" class="LinkPage"&gt;Benzodiazepine&lt;/a&gt;s (e.g. &lt;a href="../../Psych/Pharm/Alprzlm.htm" class="LinkPage"&gt;Alprazolam&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Psych/Pharm/Bspr.htm" class="LinkPage"&gt;Buspirone&lt;/a&gt; (&lt;a href="../../Psych/Pharm/Bspr.htm" class="LinkPage"&gt;Buspar&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Psych/Pharm/MnmnOxdsInhbtr.htm" class="LinkPage"&gt;Monoamine Oxidase Inhibitor&lt;/a&gt;s (e.g. Moclobemide)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Psych/Pharm/SlctvSrtnRptkInhbtr.htm" class="LinkPage"&gt;Selective Serotonin Reuptake Inhibitor&lt;/a&gt;s&lt;/li&gt;&lt;li&gt;&lt;a href="../../Psych/Pharm/TrcyclcAntdprsnt.htm" class="LinkPage"&gt;Tricyclic Antidepressant&lt;/a&gt;s (e.g. &lt;a href="../../Psych/Pharm/Amtrptyln.htm" class="LinkPage"&gt;Amitriptyline&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;Butyrophenones (e.g. &lt;a href="../../Psych/Pharm/Hlprdl.htm" class="LinkPage"&gt;Haloperidol&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;Phenothiazines (e.g. Thorazine or &lt;a href="../../GI/Pharm/Prchlrprzn.htm" class="LinkPage"&gt;Compazine&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;Thioxanthenes (e.g. Thiothixene)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Psych/Pharm/Antpsychtc.htm" class="LinkPage"&gt;Antipsychotic&lt;/a&gt;s - Second generation (Atypical &lt;a href="../../Psych/Pharm/Antpsychtc.htm" class="LinkPage"&gt;Antipsychotic&lt;/a&gt;s)&lt;ol&gt;&lt;li&gt;&lt;a href="../../Psych/Pharm/Rsprdn.htm" class="LinkPage"&gt;Risperidone&lt;/a&gt; (&lt;a href="../../Psych/Pharm/Rsprdn.htm" class="LinkPage"&gt;Risperdal&lt;/a&gt;)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Psych/Pharm/Antpsychtc.htm" class="LinkPage"&gt;Antipsychotic&lt;/a&gt;s - First generation&lt;ol&gt;&lt;li&gt;&lt;a href="../../Psych/Pharm/Hlprdl.htm" class="LinkPage"&gt;Haloperidol&lt;/a&gt; (&lt;a href="../../Psych/Pharm/Hlprdl.htm" class="LinkPage"&gt;Haldol&lt;/a&gt;) or &lt;a href="../../Psych/Pharm/Hlprdl.htm" class="LinkPage"&gt;Haloperidol decanoate&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Perphenazine (Trilafon)&lt;/li&gt;&lt;li&gt;Thiothixene HCl (Navane)&lt;/li&gt;&lt;li&gt;Fluphenazine HCl (Prolixin)&lt;/li&gt;&lt;li&gt;Trifluoperazine (Stelazine)&lt;/li&gt;&lt;li&gt;Loxapine (Loxitane)&lt;/li&gt;&lt;li&gt;Molindone (Moban)&lt;/li&gt;&lt;li&gt;Chlorpromazine HCl (Thorazine) - not available in U.S.&lt;/li&gt;&lt;li&gt;Thioridazine HCl (Mellaril) - not available in U.S.&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Causes: Neurologic Medications&lt;ol&gt;&lt;li&gt;&lt;a href="../../Neuro/Pharm/Trptn.htm" class="LinkPage"&gt;Sumatriptan&lt;/a&gt; (&lt;a href="../../Neuro/Pharm/Trptn.htm" class="LinkPage"&gt;Imitrex&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Neuro/Pharm/Vlprt.htm" class="LinkPage"&gt;Valproic Acid&lt;/a&gt; (&lt;a href="../../Neuro/Pharm/Vlprt.htm" class="LinkPage"&gt;Depakene&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Neuro/Pharm/Dhydrgtmn.htm" class="LinkPage"&gt;Dihydroergotamine&lt;/a&gt; (DHE 45)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Causes: Antihypertensives&lt;ol&gt;&lt;li&gt;&lt;a href="../../CV/Pharm/AlphAdrnrgcCntrlAgnst.htm" class="LinkPage"&gt;Methyldopa&lt;/a&gt; (&lt;a href="../../CV/Pharm/AlphAdrnrgcCntrlAgnst.htm" class="LinkPage"&gt;Aldomet&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Pharm/PrphrlActngAdrnrgcAntgnst.htm" class="LinkPage"&gt;Reserpine&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Pharm/Vrpml.htm" class="LinkPage"&gt;Verapamil&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Pharm/BtBlckr.htm" class="LinkPage"&gt;Atenolol&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Causes: Hormonal preparations&lt;ol&gt;&lt;li&gt;&lt;a href="../../Gyn/Pharm/Dnzl.htm" class="LinkPage"&gt;Danazol&lt;/a&gt; (Danocrine)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Gyn/Pharm/Estrgn.htm" class="LinkPage"&gt;Estrogen&lt;/a&gt; (e.g. Premarin)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Gyn/Pharm/Prvr.htm" class="LinkPage"&gt;Medroxyprogesterone&lt;/a&gt; acetate (e.g. &lt;a href="../../Gyn/Pharm/DpPrvr.htm" class="LinkPage"&gt;Depo Provera&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Gyn/Pharm/OrlCntrcptv.htm" class="LinkPage"&gt;Oral Contraceptive&lt;/a&gt;s&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Causes: Gastrointestinal agents&lt;ol&gt;&lt;li&gt;Metoclopramide (Reglan)&lt;/li&gt;&lt;li&gt;&lt;a href="../../GI/Pharm/HRcptrAntgnst.htm" class="LinkPage"&gt;H2 Blocker&lt;/a&gt;s&lt;ol&gt;&lt;li&gt;&lt;a href="../../GI/Pharm/HRcptrAntgnst.htm" class="LinkPage"&gt;Cimetidine&lt;/a&gt; (&lt;a href="../../GI/Pharm/HRcptrAntgnst.htm" class="LinkPage"&gt;Tagamet&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;&lt;a href="../../GI/Pharm/HRcptrAntgnst.htm" class="LinkPage"&gt;Famotidine&lt;/a&gt; (&lt;a href="../../GI/Pharm/HRcptrAntgnst.htm" class="LinkPage"&gt;Pepcid&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;&lt;a href="../../GI/Pharm/HRcptrAntgnst.htm" class="LinkPage"&gt;Ranitidine&lt;/a&gt; (&lt;a href="../../GI/Pharm/HRcptrAntgnst.htm" class="LinkPage"&gt;Zantac&lt;/a&gt;)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Causes: Other medication causes&lt;ol&gt;&lt;li&gt;&lt;a href="../../Lung/Pharm/Isnzd.htm" class="LinkPage"&gt;Isoniazid&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Arginine&lt;/li&gt;&lt;li&gt;Octreotide (Sandostatin)&lt;/li&gt;&lt;li&gt;&lt;a href="../../ID/Pharm/Admntn.htm" class="LinkPage"&gt;Rimantadine&lt;/a&gt; (&lt;a href="../../ID/Pharm/Admntn.htm" class="LinkPage"&gt;Flumadine&lt;/a&gt;)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Causes: Controlled substances and &lt;a href="../../Psych/CD/SbstncAbsEvltn.htm" class="LinkPage"&gt;Illicit Drug&lt;/a&gt;s&lt;ol&gt;&lt;li&gt;&lt;a href="../../Psych/CD/Amphtmn.htm" class="LinkPage"&gt;Amphetamine&lt;/a&gt;s&lt;/li&gt;&lt;li&gt;&lt;a href="../../Psych/CD/Mrjn.htm" class="LinkPage"&gt;Cannabis&lt;/a&gt; (&lt;a href="../../Psych/CD/Mrjn.htm" class="LinkPage"&gt;Marijuana&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;Opiates (e.g. Codeine, Morphine)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Psych/CD/Ccn.htm" class="LinkPage"&gt;Cocaine&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Causes: Anesthetic or &lt;a href="../../Pharm/Analgesic/Anlgsc.htm" class="LinkPage"&gt;Analgesic&lt;/a&gt; Medications&lt;ol&gt;&lt;li&gt;&lt;a href="../../Pharm/Analgesic/NrctcAnlgsc.htm" class="LinkPage"&gt;Narcotic&lt;/a&gt;s&lt;/li&gt;&lt;li&gt;General anesthesia&lt;/li&gt;&lt;li&gt;&lt;a href="../../Rheum/Pharm/Cyclbnzprn.htm" class="LinkPage"&gt;Cyclobenzaprine&lt;/a&gt; (&lt;a href="../../Rheum/Pharm/Cyclbnzprn.htm" class="LinkPage"&gt;Flexeril&lt;/a&gt;)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Causes: Herbal and Food Preparations&lt;ol&gt;&lt;li&gt;Anise&lt;/li&gt;&lt;li&gt;Blessed Thistle&lt;/li&gt;&lt;li&gt;Fennel&lt;/li&gt;&lt;li&gt;Fenugreek Seed&lt;/li&gt;&lt;li&gt;Marshmallow&lt;/li&gt;&lt;li&gt;Nettle&lt;/li&gt;&lt;li&gt;Red Clover&lt;/li&gt;&lt;li&gt;Red Raspberry&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Pharm/MdctnCsOfHyprprlctnm.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Medication Causes of Hyperprolactinemia, Medication Causes of Galactorrhea</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Pharm/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees></FP_UMLS_Trees><FP_Condition_name_check></FP_Condition_name_check><FP_Condition_name><value>Medication Causes of Gynecomastia</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Pharmacology</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;See Also&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Sx/Gyncmst.htm" class="LinkPage"&gt;Gynecomastia&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Causes: Recreational and &lt;a href="../../Psych/CD/SbstncAbsEvltn.htm" class="LinkPage"&gt;Illicit Drug&lt;/a&gt; use&lt;ol&gt;&lt;li&gt;Anti-androgen&lt;ol&gt;&lt;li&gt;&lt;a href="../../Psych/CD/Mrjn.htm" class="LinkPage"&gt;Marijuana&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Psych/Pharm/Alchl.htm" class="LinkPage"&gt;Alcohol&lt;/a&gt; (also contains &lt;a href="../../Pharm/Nutrition/SyPrtn.htm" class="LinkPage"&gt;Phytoestrogen&lt;/a&gt;s)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Miscellaneous&lt;ol&gt;&lt;li&gt;&lt;a href="../../Psych/CD/Amphtmn.htm" class="LinkPage"&gt;Amphetamine&lt;/a&gt;s&lt;/li&gt;&lt;li&gt;&lt;a href="../../Psych/CD/OpdAbs.htm" class="LinkPage"&gt;Heroin&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Pharm/Analgesic/MthdnInChrncPn.htm" class="LinkPage"&gt;Methadone&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Sports/Pharm/AnblcStrd.htm" class="LinkPage"&gt;Anabolic Steroid&lt;/a&gt;s (see below under hormonal agents)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Causes: &lt;a href="../../HemeOnc/Pharm/Chmthrpy.htm" class="LinkPage"&gt;Chemotherapy&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Anti-androgens&lt;ol&gt;&lt;li&gt;&lt;a href="../../HemeOnc/Pharm/AlkyltngAgnt.htm" class="LinkPage"&gt;Alkylating Agent&lt;/a&gt;s&lt;/li&gt;&lt;li&gt;&lt;a href="../../Rheum/Pharm/Mthtrxt.htm" class="LinkPage"&gt;Methotrexate&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Rheum/Pharm/DPnclmn.htm" class="LinkPage"&gt;Penicillamine&lt;/a&gt; (Cuprimine)&lt;/li&gt;&lt;li&gt;Cisplatin&lt;/li&gt;&lt;li&gt;Vinca alkaloids&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Causes: Antimicrobial&lt;ol&gt;&lt;li&gt;Anti-androgens&lt;ol&gt;&lt;li&gt;&lt;a href="../../Lung/Pharm/Isnzd.htm" class="LinkPage"&gt;Isoniazid&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../ID/Pharm/Ktcnzl.htm" class="LinkPage"&gt;Ketoconazole&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../ID/Pharm/Mtrndzl.htm" class="LinkPage"&gt;Metronidazole&lt;/a&gt; (&lt;a href="../../ID/Pharm/Mtrndzl.htm" class="LinkPage"&gt;Flagyl&lt;/a&gt;)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Miscellaneous&lt;ol&gt;&lt;li&gt;&lt;a href="../../HIV/Pharm/AntRtrvrlThrpy.htm" class="LinkPage"&gt;Antiretroviral&lt;/a&gt; agents&lt;/li&gt;&lt;li&gt;&lt;a href="../../HIV/Pharm/Ddnsn.htm" class="LinkPage"&gt;Didanosine&lt;/a&gt; (&lt;a href="../../HIV/Pharm/Ddnsn.htm" class="LinkPage"&gt;Videx&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;&lt;a href="../../ID/Pharm/Ttrcycln.htm" class="LinkPage"&gt;Minocycline&lt;/a&gt; (Minocin)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Causes: Gastrointestinal&lt;ol&gt;&lt;li&gt;Anti-androgens&lt;ol&gt;&lt;li&gt;&lt;a href="../../GI/Pharm/HRcptrAntgnst.htm" class="LinkPage"&gt;Cimetidine&lt;/a&gt; (&lt;a href="../../GI/Pharm/HRcptrAntgnst.htm" class="LinkPage"&gt;Tagamet&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;&lt;a href="../../GI/Pharm/HRcptrAntgnst.htm" class="LinkPage"&gt;Ranitidine&lt;/a&gt; (&lt;a href="../../GI/Pharm/HRcptrAntgnst.htm" class="LinkPage"&gt;Zantac&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;&lt;a href="../../GI/Pharm/PrtnPmpInhbtr.htm" class="LinkPage"&gt;Omeprazole&lt;/a&gt; (&lt;a href="../../GI/Pharm/PrtnPmpInhbtr.htm" class="LinkPage"&gt;Prilosec&lt;/a&gt;)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pituitary/Hyprprlctnm.htm" class="LinkPage"&gt;Hyperprolactinemia&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Metoclopramide (Reglan)&lt;/li&gt;&lt;li&gt;Phenothiazines&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Causes: Hormonal agents&lt;ol&gt;&lt;li&gt;Anti-androgens&lt;ol&gt;&lt;li&gt;Bicalutamide (Casodex)&lt;/li&gt;&lt;li&gt;Flutamide (Eulexin)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Gyn/Pharm/Estrgn.htm" class="LinkPage"&gt;Estrogen&lt;/a&gt;ic agents&lt;ol&gt;&lt;li&gt;&lt;a href="../../Gyn/Pharm/Estrgn.htm" class="LinkPage"&gt;Estrogen&lt;/a&gt;s (including &lt;a href="../../Gyn/Pharm/VgnlEstrgn.htm" class="LinkPage"&gt;Topical Estrogen&lt;/a&gt; exposure from sexual partner)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Gyn/Pharm/GndtrpnRlsngHrmnAgnst.htm" class="LinkPage"&gt;Gonadotropin-releasing Hormone Agonist&lt;/a&gt;s&lt;/li&gt;&lt;li&gt;Human chorionic gonadotropins&lt;/li&gt;&lt;li&gt;&lt;a href="../../Pharm/Nutrition/SyPrtn.htm" class="LinkPage"&gt;Phytoestrogen&lt;/a&gt;s&lt;/li&gt;&lt;li&gt;&lt;a href="../../Gyn/Pharm/Tmxfn.htm" class="LinkPage"&gt;Tamoxifen&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Sports/Pharm/AnblcStrd.htm" class="LinkPage"&gt;Anabolic Steroid&lt;/a&gt;s&lt;ol&gt;&lt;li&gt;Suppress endogenous testosterone production&lt;/li&gt;&lt;li&gt;Allows for &lt;a href="../../Gyn/Pharm/Estrgn.htm" class="LinkPage"&gt;Estrogen&lt;/a&gt; predominance between &lt;a href="../../Sports/Pharm/AnblcStrd.htm" class="LinkPage"&gt;Anabolic Steroid&lt;/a&gt; injections&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Causes: Cardiovascular agents&lt;ol&gt;&lt;li&gt;Anti-androgens&lt;ol&gt;&lt;li&gt;&lt;a href="../../CV/Pharm/Sprnlctn.htm" class="LinkPage"&gt;Spironolactone&lt;/a&gt; (&lt;a href="../../CV/Pharm/Sprnlctn.htm" class="LinkPage"&gt;Aldactone&lt;/a&gt;)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Gyn/Pharm/Estrgn.htm" class="LinkPage"&gt;Estrogen&lt;/a&gt;ic agents&lt;ol&gt;&lt;li&gt;&lt;a href="../../CV/Pharm/Dgxn.htm" class="LinkPage"&gt;Digoxin&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Miscellaneous&lt;ol&gt;&lt;li&gt;&lt;a href="../../CV/Pharm/Amdrn.htm" class="LinkPage"&gt;Amiodarone&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Pharm/DhydrpyrdnClcmChnlBlckr.htm" class="LinkPage"&gt;Amlodipine&lt;/a&gt; (&lt;a href="../../CV/Pharm/DhydrpyrdnClcmChnlBlckr.htm" class="LinkPage"&gt;Norvasc&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Exam/RnAngtnsnSystm.htm" class="LinkPage"&gt;Angiotensin&lt;/a&gt;-converting enzyme inhibitors&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Pharm/HmgCRdctsInhbtr.htm" class="LinkPage"&gt;Atorvastatin&lt;/a&gt; (&lt;a href="../../CV/Pharm/HmgCRdctsInhbtr.htm" class="LinkPage"&gt;Lipitor&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Pharm/Dltzm.htm" class="LinkPage"&gt;Diltiazem&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Pharm/FbrcAcd.htm" class="LinkPage"&gt;Fenofibrate&lt;/a&gt; (&lt;a href="../../CV/Pharm/FbrcAcd.htm" class="LinkPage"&gt;Tricor&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Pharm/Nfdpn.htm" class="LinkPage"&gt;Nifedipine&lt;/a&gt; (&lt;a href="../../CV/Pharm/Nfdpn.htm" class="LinkPage"&gt;Procardia&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Pharm/AlphAdrnrgcCntrlAgnst.htm" class="LinkPage"&gt;Methyldopa&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Pharm/PrphrlActngAdrnrgcAntgnst.htm" class="LinkPage"&gt;Reserpine&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Pharm/HmgCRdctsInhbtr.htm" class="LinkPage"&gt;Rosuvastatin&lt;/a&gt; (&lt;a href="../../CV/Pharm/HmgCRdctsInhbtr.htm" class="LinkPage"&gt;Crestor&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Pharm/Vrpml.htm" class="LinkPage"&gt;Verapamil&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Derm/Pharm/Mnxdl.htm" class="LinkPage"&gt;Minoxidil&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Causes: Neuropsychiatric agents&lt;ol&gt;&lt;li&gt;&lt;a href="../../Gyn/Pharm/Estrgn.htm" class="LinkPage"&gt;Estrogen&lt;/a&gt;ic agents&lt;ol&gt;&lt;li&gt;&lt;a href="../../Psych/Pharm/Dzpm.htm" class="LinkPage"&gt;Diazepam&lt;/a&gt; (&lt;a href="../../Psych/Pharm/Dzpm.htm" class="LinkPage"&gt;Valium&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Neuro/Pharm/Phnytn.htm" class="LinkPage"&gt;Phenytoin&lt;/a&gt; (&lt;a href="../../Neuro/Pharm/Phnytn.htm" class="LinkPage"&gt;Dilantin&lt;/a&gt;)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pituitary/Hyprprlctnm.htm" class="LinkPage"&gt;Hyperprolactinemia&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../Psych/Pharm/Hlprdl.htm" class="LinkPage"&gt;Haloperidol&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Miscellaneous&lt;ol&gt;&lt;li&gt;&lt;a href="../../Psych/Pharm/Flxtn.htm" class="LinkPage"&gt;Fluoxetine&lt;/a&gt; (&lt;a href="../../Psych/Pharm/Flxtn.htm" class="LinkPage"&gt;Prozac&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Psych/Pharm/Mrtzpn.htm" class="LinkPage"&gt;Mirtazapine&lt;/a&gt; (&lt;a href="../../Psych/Pharm/Mrtzpn.htm" class="LinkPage"&gt;Remeron&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Psych/Pharm/Prxtn.htm" class="LinkPage"&gt;Paroxetine&lt;/a&gt; (&lt;a href="../../Psych/Pharm/Prxtn.htm" class="LinkPage"&gt;Paxil&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Psych/Pharm/TrcyclcAntdprsnt.htm" class="LinkPage"&gt;Tricyclic Antidepressant&lt;/a&gt;s&lt;/li&gt;&lt;li&gt;&lt;a href="../../Psych/Pharm/Vnlfxn.htm" class="LinkPage"&gt;Venlafaxine&lt;/a&gt; (&lt;a href="../../Psych/Pharm/Vnlfxn.htm" class="LinkPage"&gt;Effexor&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Psych/Pharm/Rsprdn.htm" class="LinkPage"&gt;Risperidone&lt;/a&gt; (&lt;a href="../../Psych/Pharm/Rsprdn.htm" class="LinkPage"&gt;Risperdal&lt;/a&gt;)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Causes: Herbals&lt;ol&gt;&lt;li&gt;Lavender&lt;/li&gt;&lt;li&gt;Tea tree oil&lt;/li&gt;&lt;li&gt;&lt;a href="../../Pharm/Alternative/DnQ.htm" class="LinkPage"&gt;Dong Quai&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Tribulus terrestris&lt;/li&gt;&lt;li&gt;&lt;a href="../../Pharm/Nutrition/SyPrtn.htm" class="LinkPage"&gt;Soy Protein&lt;/a&gt; (&amp;gt;300 mg/day)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Causes: Miscellaneous agents&lt;ol&gt;&lt;li&gt;&lt;a href="../../Uro/Pharm/5RdctsInhbtr.htm" class="LinkPage"&gt;Finasteride&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Theophylline&lt;/li&gt;&lt;li&gt;Sulindac (Clinoril)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Surgery/Pharm/Etmdt.htm" class="LinkPage"&gt;Etomidate&lt;/a&gt; (&lt;a href="../../Surgery/Pharm/Etmdt.htm" class="LinkPage"&gt;Amidate&lt;/a&gt;)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=" class="LinkRef"&gt;Braunstein N Engl J Med 357(12): 1229-37&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Dickson%20%20%5BAU%5D%20AND%202012%20%5BDP%5D%20AND%20%20Am%20Fam%20Physician%20%20%5BTA%5D" class="LinkRef"&gt;Dickson (2012) Am Fam Physician 85(7):716-22&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Eckman%20%20%5BAU%5D%20AND%202008%20%5BDP%5D%20AND%20%20Expert%20Opin%20Drug%20Saf%20%20%5BTA%5D" class="LinkRef"&gt;Eckman (2008) Expert Opin Drug Saf 7(6):691-702&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Pharm/MdctnCsOfGyncmst.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Medication Causes of Gynecomastia, Drug-Induced Gynecomastia, Gynecomastia Secondary to Medication</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Pharm/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;sibutramine  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0074493"&gt;&lt;i&gt;C0074493&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Organic Chemical (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0074493&amp;amp;tui=T109"&gt;&lt;i&gt;T109&lt;/i&gt;&lt;/a&gt;)
, Pharmacologic Substance (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0074493&amp;amp;tui=T121"&gt;&lt;i&gt;T121&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;C058254&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;108373009, 386838007, 371164009&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;sibutramine, SIBUTRAMINE, sibutramine [Chemical/Ingredient], Sibutramine (product), Sibutramine (substance), Sibutramine, Sibutramine product (product), Sibutramine product&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;sibutramina (producto), sibutramina (sustancia), sibutramina, producto (producto), sibutramina, producto, sibutramina&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Meridia  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0635898"&gt;&lt;i&gt;C0635898&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Organic Chemical (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0635898&amp;amp;tui=T109"&gt;&lt;i&gt;T109&lt;/i&gt;&lt;/a&gt;)
, Pharmacologic Substance (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0635898&amp;amp;tui=T121"&gt;&lt;i&gt;T121&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;C058254&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Meridia, sibutramine hydrochloride (Meridia), meridia&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>sibutramine  (</value><value>)
</value><value>Meridia  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Sibutramine</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Pharmacology</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Background&lt;ol&gt;&lt;li&gt;Sibutramine taken off the market October 2010 in United States due to risk of serious cardiovascular events&lt;/li&gt;&lt;li&gt;Listed for historical purposes only&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Contraindications&lt;ol&gt;&lt;li&gt;Severe renal insufficiency&lt;/li&gt;&lt;li&gt;Hepatic insufficiency&lt;/li&gt;&lt;li&gt;&lt;a href="../../Neuro/CV/IschmcStrk.htm" class="LinkPage"&gt;Cerebrovascular Accident&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Htn/Hyprtnsn.htm" class="LinkPage"&gt;Hypertension&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Advanced cardiovascular disease&lt;ol&gt;&lt;li&gt;&lt;a href="../../CV/CAD/ActCrnrySyndrm.htm" class="LinkPage"&gt;Coronary Artery Disease&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/CHF/CngstvHrtFlr.htm" class="LinkPage"&gt;Congestive Heart Failure&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Arrhythmias&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/Hyprthyrdsm1.htm" class="LinkPage"&gt;Hyperthyroidism&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Narrow-Angle &lt;a href="../../Eye/Glaucoma/Glcm.htm" class="LinkPage"&gt;Glaucoma&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Psych/CD/ChmclDpndncy.htm" class="LinkPage"&gt;Substance Abuse&lt;/a&gt; history&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Dosing&lt;ol&gt;&lt;li&gt;Continuous: Sibutramine 15 mg qd&lt;/li&gt;&lt;li&gt;Intermittent (similar weight loss, less side effects)&lt;ol&gt;&lt;li&gt;Weeks 1-12: Sibutramine 15 mg qd&lt;/li&gt;&lt;li&gt;Weeks 19-30: Sibutamine 15 mg qd&lt;/li&gt;&lt;li&gt;Weeks 37-48: Sibutramine 15 mg qd&lt;/li&gt;&lt;li&gt;No medication taken in other weeks&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Wirth%20%20%5BAU%5D%20AND%202001%20%5BDP%5D%20AND%20%20JAMA%20%20%5BTA%5D" class="LinkRef"&gt;Wirth (2001) JAMA 286:1331-9&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Efficacy: One year study&lt;ol&gt;&lt;li&gt;&lt;a href="../../Pharm/Psych/PlcbEfct.htm" class="LinkPage"&gt;Placebo&lt;/a&gt; group weight loss: 3.8 kg in 48 weeks&lt;/li&gt;&lt;li&gt;Continuous Sibutramine: 7.9 kg in 48 weeks&lt;/li&gt;&lt;li&gt;Intermittent Sibutramine: 7.8 kg in 48 weeks&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Wirth%20%20%5BAU%5D%20AND%202001%20%5BDP%5D%20AND%20%20JAMA%20%20%5BTA%5D" class="LinkRef"&gt;Wirth (2001) JAMA 286:1331-9&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Mechanism&lt;ol&gt;&lt;li&gt;Monoamine reuptake inhibitor &lt;a href="../../Psych/Pharm/Antdprsnt.htm" class="LinkPage"&gt;Antidepressant&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../Psych/Neuro/Srtn.htm" class="LinkPage"&gt;Serotonin&lt;/a&gt; and &lt;a href="../../CV/Pharm/Nrpnphrn.htm" class="LinkPage"&gt;Norepinephrine&lt;/a&gt; reuptake inhibitor&lt;/li&gt;&lt;li&gt;Similar to &lt;a href="../../Psych/Pharm/Vnlfxn.htm" class="LinkPage"&gt;Effexor&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Effects (dose dependent)&lt;ol&gt;&lt;li&gt;Enhances satiety&lt;/li&gt;&lt;li&gt;Increases energy expenditure (metabolic rate)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Adverse effects (Very similar to &lt;a href="../../Psych/Pharm/Vnlfxn.htm" class="LinkPage"&gt;Effexor&lt;/a&gt;)&lt;ol&gt;&lt;li&gt;Reduced adverse effects with intermittent treatment&lt;/li&gt;&lt;li&gt;Common&lt;ol&gt;&lt;li&gt;Diastolic &lt;a href="../../CV/Htn/Hyprtnsn.htm" class="LinkPage"&gt;Hypertension&lt;/a&gt; (2-10 mmHg increase)&lt;ol&gt;&lt;li&gt;Optimize &lt;a href="../../CV/Exam/BldPrsr.htm" class="LinkPage"&gt;Blood Pressure&lt;/a&gt; control before use&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/EKG/Tchycrd.htm" class="LinkPage"&gt;Tachycardia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Psych/Sleep/Insmn.htm" class="LinkPage"&gt;Insomnia&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Less common&lt;ol&gt;&lt;li&gt;&lt;a href="../../Neuro/Sx/Hdch.htm" class="LinkPage"&gt;Headache&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Irritability&lt;/li&gt;&lt;li&gt;&lt;a href="../../ENT/Sx/DryMth.htm" class="LinkPage"&gt;Dry Mouth&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Derm/Dry/DrySkn.htm" class="LinkPage"&gt;Dry Skin&lt;/a&gt; or rash&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Drug Interactions: Mixed Noradrenergic-Serotonergic Agent&lt;ol&gt;&lt;li&gt;&lt;a href="../../Psych/Pharm/SlctvSrtnRptkInhbtr.htm" class="LinkPage"&gt;SSRI&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Neuro/Pharm/Trptn.htm" class="LinkPage"&gt;Triptan&lt;/a&gt;s (for &lt;a href="../../Neuro/Headache/MgrnHdchMngmnt.htm" class="LinkPage"&gt;Migraine Headache Management&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Neuro/Pharm/Dhydrgtmn.htm" class="LinkPage"&gt;Dihydroergotamine&lt;/a&gt; (DHE)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Lung/Pharm/Dxtrmthrphn.htm" class="LinkPage"&gt;Dextromethorphan&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Pharm/Analgesic/Mprdn.htm" class="LinkPage"&gt;Meperidine&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Pentazocine&lt;/li&gt;&lt;li&gt;&lt;a href="../../Pharm/Analgesic/Fntnyl.htm" class="LinkPage"&gt;Fentanyl&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Psych/Pharm/LthmCrbnt.htm" class="LinkPage"&gt;Lithium&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Psych/Pharm/MnmnOxdsInhbtr.htm" class="LinkPage"&gt;MAO inhibitor&lt;/a&gt;s&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Pharm/PrphrlActngAdrnrgcAntgnst.htm" class="LinkPage"&gt;Guanethidine&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Psych/Pharm/TrcyclcAntdprsnt.htm" class="LinkPage"&gt;Tricyclic Antidepressant&lt;/a&gt;s&lt;/li&gt;&lt;li&gt;&lt;a href="../../Psych/Pharm/Alchl.htm" class="LinkPage"&gt;Alcohol&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Centrally acting stimulants or anorexiants&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0074493</value><value>C0635898</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Pharm/Sbtrmn.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Sibutramine, Meridia</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Pharm/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees></FP_UMLS_Trees><FP_Condition_name_check></FP_Condition_name_check><FP_Condition_name><value>Sulfonylurea Overdose</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Pharmacology</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Signs and Symptoms&lt;ol&gt;&lt;li&gt;&lt;a href="../../Neuro/LOC/Cm2.htm" class="LinkPage"&gt;Coma&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Decreased Appetite&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Sx/Dzns.htm" class="LinkPage"&gt;Dizziness&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Hypoglycemia/Hypglycm.htm" class="LinkPage"&gt;Hypoglycemia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Lethargy&lt;/li&gt;&lt;li&gt;&lt;a href="../../Neuro/Seizure/Szr.htm" class="LinkPage"&gt;Seizure&lt;/a&gt;s&lt;/li&gt;&lt;li&gt;Weakness&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Management: Adults&lt;ol&gt;&lt;li&gt;Dextrose bolus followed by continuous infusion (dose based on degree of &lt;a href="../../Endo/Hypoglycemia/Hypglycm.htm" class="LinkPage"&gt;Hypoglycemia&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;Octreotide (Sandostatin) 50-100 mcg/dose SQ twice to three times daily&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Glcgn.htm" class="LinkPage"&gt;Glucagon&lt;/a&gt; 1 mg per dose and may repeat every 20 minutes&lt;ol&gt;&lt;li&gt;Only transient elevation in &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; to temporize until definitive other management&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Management: Children&lt;ol&gt;&lt;li&gt;Dextrose bolus followed by continuous infusion&lt;ol&gt;&lt;li&gt;Age 1 to 24 months: Dextrose 25% IV 2-4 ml/kg&lt;/li&gt;&lt;li&gt;Age &amp;gt;24 months: Dextrose 50% IV 1-2 ml/kg&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Octreotide (Sandostatin) 4-5 mcg/kg/day  SQ  divided every 6 hours to maximum of 50 mcg/dose&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Glcgn.htm" class="LinkPage"&gt;Glucagon&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Infants: 0.025 mg/kg/dose every 20 minutes&lt;/li&gt;&lt;li&gt;Children: 0.5 mg/dose every 20 minutes&lt;/li&gt;&lt;li&gt;Only transient elevation in &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; to temporize until definitive other management&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Harrigan%20%20%5BAU%5D%20AND%202001%20%5BDP%5D%20AND%20%20Ann%20Emerg%20Med%20%20%5BTA%5D" class="LinkRef"&gt;Harrigan (2001) Ann Emerg Med 38(1): 68-78&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Rath%20%20%5BAU%5D%20AND%202008%20%5BDP%5D%20AND%20%20J%20Paeditr%20Child%20Health%20%20%5BTA%5D" class="LinkRef"&gt;Rath (2008) J Paeditr Child Health 44(6): 383-4&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Pharm/SlfnylrOvrds.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Sulfonylurea Overdose, Sulfonylurea Toxicity</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Pharm/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees></FP_UMLS_Trees><FP_Condition_name_check></FP_Condition_name_check><FP_Condition_name><value>Medications Associated with Weight Gain</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Pharmacology</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Preparations: Endocrine Agents&lt;ol&gt;&lt;li&gt;Diabetes medications&lt;ol&gt;&lt;li&gt;Most weight gain:  &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt;, &lt;a href="../../Endo/Pharm/Slfnylr.htm" class="LinkPage"&gt;Sulfonylurea&lt;/a&gt;s (&lt;a href="../../Endo/Pharm/ScndGnrtnSlfnylr.htm" class="LinkPage"&gt;Glyburide&lt;/a&gt;, &lt;a href="../../Endo/Pharm/ScndGnrtnSlfnylr.htm" class="LinkPage"&gt;Glipizide&lt;/a&gt;), &lt;a href="../../Endo/Pharm/NnSlfnylrInslnScrtgs.htm" class="LinkPage"&gt;Meglitinide&lt;/a&gt;s, &lt;a href="../../Endo/Pharm/Thzldndn.htm" class="LinkPage"&gt;Thiazolidinedione&lt;/a&gt;s&lt;/li&gt;&lt;li&gt;Least weight gain: &lt;a href="../../Endo/Pharm/AlphGlcsdsInhbtr.htm" class="LinkPage"&gt;Acarbose&lt;/a&gt;, &lt;a href="../../Endo/Pharm/IncrtnMmtc.htm" class="LinkPage"&gt;Exenatide&lt;/a&gt;, glimepiride, &lt;a href="../../Endo/Pharm/Glcphg.htm" class="LinkPage"&gt;Glucophage&lt;/a&gt;, &lt;a href="../../Endo/Pharm/AlphGlcsdsInhbtr.htm" class="LinkPage"&gt;Miglitol&lt;/a&gt;, &lt;a href="../../Endo/Pharm/Symln.htm" class="LinkPage"&gt;Pramlintide&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Gyn/Pharm/Tmxfn.htm" class="LinkPage"&gt;Tamoxifen&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Steroid hormones&lt;/li&gt;&lt;li&gt;Glucocorticoids and &lt;a href="../../Endo/Pharm/SystmcCrtcstrd.htm" class="LinkPage"&gt;Corticosteroid&lt;/a&gt;s&lt;/li&gt;&lt;li&gt;Progestational steroids&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Medications: Psychotropics&lt;ol&gt;&lt;li&gt;&lt;a href="../../Psych/Pharm/SlctvSrtnRptkInhbtr.htm" class="LinkPage"&gt;Selective Serotonin Reuptake Inhibitor&lt;/a&gt;s (&lt;a href="../../Psych/Pharm/SlctvSrtnRptkInhbtr.htm" class="LinkPage"&gt;SSRI&lt;/a&gt;), &lt;a href="../../Psych/Pharm/TrcyclcAntdprsnt.htm" class="LinkPage"&gt;Tricyclic Antidepressant&lt;/a&gt;s and atypicals&lt;ol&gt;&lt;li&gt;Weight gain is associated with Histamine H1 receptor blockade&lt;/li&gt;&lt;li&gt;Most weight gain: &lt;a href="../../Psych/Pharm/TrcyclcAntdprsnt.htm" class="LinkPage"&gt;Tricyclic Antidepressant&lt;/a&gt;s, &lt;a href="../../Psych/Pharm/Mrtzpn.htm" class="LinkPage"&gt;Remeron&lt;/a&gt;, &lt;a href="../../Psych/Pharm/Prxtn.htm" class="LinkPage"&gt;Paxil&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Least weight gain: &lt;a href="../../Psych/Pharm/Bprpn.htm" class="LinkPage"&gt;Bupropion&lt;/a&gt;, &lt;a href="../../Psych/Pharm/Flxtn.htm" class="LinkPage"&gt;Prozac&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Psych/Pharm/MnmnOxdsInhbtr.htm" class="LinkPage"&gt;Monoamine Oxidase Inhibitor&lt;/a&gt;s (&lt;a href="../../Psych/Pharm/MnmnOxdsInhbtr.htm" class="LinkPage"&gt;Phenelzine&lt;/a&gt;)&lt;ol&gt;&lt;li&gt;Consider &lt;a href="../../Psych/Pharm/MnmnOxdsInhbtr.htm" class="LinkPage"&gt;Tranylcypromine&lt;/a&gt; instead&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Phenothiazines&lt;/li&gt;&lt;li&gt;&lt;a href="../../Psych/Pharm/TrcyclcAntdprsnt.htm" class="LinkPage"&gt;Tricyclic Antidepressant&lt;/a&gt;s (&lt;a href="../../Psych/Pharm/Amtrptyln.htm" class="LinkPage"&gt;Amitriptyline&lt;/a&gt;, &lt;a href="../../Psych/Pharm/Imprmn.htm" class="LinkPage"&gt;Imipramine&lt;/a&gt;, &lt;a href="../../Psych/Pharm/Nrtrptyln.htm" class="LinkPage"&gt;Nortriptyline&lt;/a&gt;)&lt;ol&gt;&lt;li&gt;Consider &lt;a href="../../Psych/Pharm/Nrprmn.htm" class="LinkPage"&gt;Desipramine&lt;/a&gt; or protriptyline instead&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Atypical &lt;a href="../../Psych/Pharm/Antpsychtc.htm" class="LinkPage"&gt;Antipsychotic&lt;/a&gt;s (&lt;a href="../../Psych/Pharm/Clzpn.htm" class="LinkPage"&gt;Clozapine&lt;/a&gt;, &lt;a href="../../Psych/Pharm/Olnzpn.htm" class="LinkPage"&gt;Olanzapine&lt;/a&gt;, &lt;a href="../../Psych/Pharm/Rsprdn.htm" class="LinkPage"&gt;Risperidone&lt;/a&gt;)&lt;ol&gt;&lt;li&gt;Consider &lt;a href="../../Psych/Pharm/Arprzl.htm" class="LinkPage"&gt;Aripiprazole&lt;/a&gt; (&lt;a href="../../Psych/Pharm/Arprzl.htm" class="LinkPage"&gt;Abilify&lt;/a&gt;) or &lt;a href="../../Psych/Pharm/Zprsdn.htm" class="LinkPage"&gt;Ziprasidone&lt;/a&gt; (&lt;a href="../../Psych/Pharm/Zprsdn.htm" class="LinkPage"&gt;Geodon&lt;/a&gt;) instead&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Psych/Pharm/LthmCrbnt.htm" class="LinkPage"&gt;Lithium&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Medications: Neurologic Agents&lt;ol&gt;&lt;li&gt;Anticonvulsants&lt;ol&gt;&lt;li&gt;Most weight gain: &lt;a href="../../Neuro/Pharm/Vlprt.htm" class="LinkPage"&gt;Valproic Acid&lt;/a&gt;, &lt;a href="../../Neuro/Pharm/Gbpntn.htm" class="LinkPage"&gt;Gabapentin&lt;/a&gt;, &lt;a href="../../Neuro/Pharm/Crbmzpn.htm" class="LinkPage"&gt;Carbamazepine&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Least weight gain: &lt;a href="../../Neuro/Pharm/Lmtrgn.htm" class="LinkPage"&gt;Lamotrigine&lt;/a&gt;, &lt;a href="../../Neuro/Pharm/Tprmt.htm" class="LinkPage"&gt;Topiramate&lt;/a&gt;, &lt;a href="../../Neuro/Pharm/Znsmd.htm" class="LinkPage"&gt;Zonisamide&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Medications: Cardiovascular Agents&lt;ol&gt;&lt;li&gt;Alpha adrenergic blockers&lt;ol&gt;&lt;li&gt;Consider &lt;a href="../../CV/Pharm/AlphAdrnrgcAntgnst.htm" class="LinkPage"&gt;Doxazosin&lt;/a&gt; instead&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Beta adrenergic blockers (esp. &lt;a href="../../CV/Pharm/Prprnl.htm" class="LinkPage"&gt;Propranolol&lt;/a&gt;)&lt;ol&gt;&lt;li&gt;Consider &lt;a href="../../CV/Pharm/AcInhbtr.htm" class="LinkPage"&gt;ACE Inhibitor&lt;/a&gt;s, &lt;a href="../../CV/Pharm/AngtnsnRcptrBlckngAgnt.htm" class="LinkPage"&gt;Angiotensin Receptor Blocker&lt;/a&gt;s, &lt;a href="../../CV/Pharm/ClcmChnlBlckr.htm" class="LinkPage"&gt;Calcium Channel Blocker&lt;/a&gt;s, selective &lt;a href="../../CV/Pharm/BtBlckr.htm" class="LinkPage"&gt;Beta Blocker&lt;/a&gt;s instead&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Preparations: Miscellaneous&lt;ol&gt;&lt;li&gt;Highly active &lt;a href="../../HIV/Pharm/AntRtrvrlThrpy.htm" class="LinkPage"&gt;Antiretroviral&lt;/a&gt; therapy&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Malone%20%20%5BAU%5D%20AND%202005%20%5BDP%5D%20AND%20%20Ann%20Pharmacother%20%20%5BTA%5D" class="LinkRef"&gt;Malone (2005) Ann Pharmacother 39(12): 2046-55&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Pharm/MdctnsAsctdWthWghtGn.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Medications Associated with Weight Gain, Medications that exacerbate Obesity</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Pharm/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Pramlintide  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0537551"&gt;&lt;i&gt;C0537551&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A synthetic analogue of the hormone amylin with antidiabetic activities. Upon administration, pramlintide mimics the actions of the naturally occurring amylin (islet amyloid polypeptide), a hormone that is produced by the beta cells of the pancreas and helps regulate blood glucose levels by 1) Inhibiting glucagon secretion; 2) Decreasing the rate of gastric emptying and 3) Suppressing appetite. Production of amylin is absent or decreased in patients with diabetes type I or II, respectively.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Amino Acid, Peptide, or Protein (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0537551&amp;amp;tui=T116"&gt;&lt;i&gt;T116&lt;/i&gt;&lt;/a&gt;)
, Pharmacologic Substance (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0537551&amp;amp;tui=T121"&gt;&lt;i&gt;T121&lt;/i&gt;&lt;/a&gt;)
, Hormone (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0537551&amp;amp;tui=T125"&gt;&lt;i&gt;T125&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;C105254&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;416392006, 416425000&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;pramlintide, PRAMLINTIDE, Pramlintide, pramlintide [Chemical/Ingredient], Pramlintide (product), Pramlintide (substance)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;pramlintida (producto), pramlintida (sustancia), pramlintida&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Symlin  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C1174780"&gt;&lt;i&gt;C1174780&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Amino Acid, Peptide, or Protein (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C1174780&amp;amp;tui=T116"&gt;&lt;i&gt;T116&lt;/i&gt;&lt;/a&gt;)
, Pharmacologic Substance (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C1174780&amp;amp;tui=T121"&gt;&lt;i&gt;T121&lt;/i&gt;&lt;/a&gt;)
, Hormone (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C1174780&amp;amp;tui=T125"&gt;&lt;i&gt;T125&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;C105254&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Symlin, Amylin Pharmaceuticals brand of pramlintide acetate&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Pramlintide  (</value><value>)
</value><value>Symlin  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Symlin</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Pharmacology</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Indications&lt;ol&gt;&lt;li&gt;Type I and II &lt;a href="../../Endo/DM/DbtsMlts.htm" class="LinkPage"&gt;Diabetes Mellitus&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Adjunct to &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; therapy&lt;/li&gt;&lt;li&gt;Third-line measure due to &lt;a href="../../Endo/Hypoglycemia/Hypglycm.htm" class="LinkPage"&gt;Hypoglycemia&lt;/a&gt; risk and cost&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Mechanism&lt;ol&gt;&lt;li&gt;Pramlintide is a synthetic analogue of human Amylin&lt;/li&gt;&lt;li&gt;Amylin is secreted with &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; from &lt;a href="../../GI/Anatomy/PncrsAntmy.htm" class="LinkPage"&gt;Pancreas&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Amylin lowers post-prandial &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Sugar&lt;/a&gt;s&lt;ol&gt;&lt;li&gt;Delays gastric emptying&lt;/li&gt;&lt;li&gt;Inhibits glucago release&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Dosing&lt;ol&gt;&lt;li&gt;Protocol&lt;ol&gt;&lt;li&gt;Reduce short and mixed-acting &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; dose by 50%&lt;/li&gt;&lt;li&gt;Use 100 unit 0.3 ml syringe&lt;/li&gt;&lt;li&gt;Take with at least 250 calories (&amp;gt;30 g Carbohydrate)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/DM/TypDbtsMlts.htm" class="LinkPage"&gt;Type I Diabetes Mellitus&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Start: 15 mcg (2.5 U) SQ tid immediately before meals&lt;/li&gt;&lt;li&gt;Titrated in 15 mcg increments q3-7 days&lt;/li&gt;&lt;li&gt;Target: 30-60 mcg (5-10 units) SQ tid before meals&lt;/li&gt;&lt;li&gt;Discontinue if significant &lt;a href="../../GI/Sx/Vmtng.htm" class="LinkPage"&gt;Nausea&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/DM/TypDbtsMlts1.htm" class="LinkPage"&gt;Type II Diabetes Mellitus&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Start:  60 mcg (10 U) SQ tid immediately before meals&lt;/li&gt;&lt;li&gt;Target: 60-120 mcg (10-20 units) SQ tid before meals&lt;/li&gt;&lt;li&gt;Discontinue if significant &lt;a href="../../GI/Sx/Vmtng.htm" class="LinkPage"&gt;Nausea&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Precautions&lt;ol&gt;&lt;li&gt;Switch to new pen device which replaces the vials and prevents dosing errors&lt;ol&gt;&lt;li&gt;Warning: Pen concentration is different than vial concentration&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Dosing errors are common with the vials&lt;ol&gt;&lt;li&gt;Dosing is typically listed in mcg, but is drawn up in &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; syringes marked with units&lt;/li&gt;&lt;li&gt;A patient who mistakes their 30 mcg dose for 30 units is accidentally taking 180 mcg&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Adverse effects&lt;ol&gt;&lt;li&gt;&lt;a href="../../GI/Sx/Vmtng.htm" class="LinkPage"&gt;Nausea&lt;/a&gt; (28%) or &lt;a href="../../GI/Sx/Vmtng.htm" class="LinkPage"&gt;Vomiting&lt;/a&gt; (8%): Especically Type I DM&lt;/li&gt;&lt;li&gt;&lt;a href="../../Neuro/Sx/Hdch.htm" class="LinkPage"&gt;Headache&lt;/a&gt; (13%)&lt;/li&gt;&lt;li&gt;Anorexia (9%)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Surgery/GI/ActAbdmnlPn.htm" class="LinkPage"&gt;Abdominal Pain&lt;/a&gt; (8%)&lt;/li&gt;&lt;li&gt;Severe &lt;a href="../../Endo/Hypoglycemia/Hypglycm.htm" class="LinkPage"&gt;Hypoglycemia&lt;/a&gt; (4.7%)&lt;ol&gt;&lt;li&gt;Occurs 3 hours after &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; and Pramlintide dose&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Advantages&lt;ol&gt;&lt;li&gt;Lowers weight 3 lb or 1.4 kg (&lt;a href="../../Pharm/Psych/PlcbEfct.htm" class="LinkPage"&gt;Placebo&lt;/a&gt;: 0.6 kg gained)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Disadvantages&lt;ol&gt;&lt;li&gt;&lt;a href="../../GI/Sx/Vmtng.htm" class="LinkPage"&gt;Nausea&lt;/a&gt; and Severe &lt;a href="../../Endo/Hypoglycemia/Hypglycm.htm" class="LinkPage"&gt;Hypoglycemia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Expensive (Almost $400 for 1 month at 120 mcg tid)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Efficacy&lt;ol&gt;&lt;li&gt;Drops A1C 0.5 to 0.6% (contrast with &lt;a href="../../Pharm/Psych/PlcbEfct.htm" class="LinkPage"&gt;Placebo&lt;/a&gt;: 0.25% )&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Jones%20%20%5BAU%5D%20AND%202007%20%5BDP%5D%20AND%20%20Am%20Fam%20Physician%20%20%5BTA%5D" class="LinkRef"&gt;Jones (2007) Am Fam Physician 75:1831-5&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Kruger%20%20%5BAU%5D%20AND%202004%20%5BDP%5D%20AND%20%20Drugs%20%20%5BTA%5D" class="LinkRef"&gt;Kruger (2004) Drugs 64: 1419-32&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Kleppinger%20%20%5BAU%5D%20AND%202003%20%5BDP%5D%20AND%20%20Ann%20Pharmacother%20%20%5BTA%5D" class="LinkRef"&gt;Kleppinger (2003) Ann Pharmacother 37:1082-9&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Ryan%20%20%5BAU%5D%20AND%202005%20%5BDP%5D%20AND%20%20Clin%20Ther%20%20%5BTA%5D" class="LinkRef"&gt;Ryan (2005) Clin Ther 27:1500-12&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0537551</value><value>C1174780</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Pharm/Symln.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Symlin, Pramlintide, Amylinomimetic</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Pharm/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Insulin  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0021641"&gt;&lt;i&gt;C0021641&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CSP)&lt;/td&gt;
                &lt;td&gt;protein hormone secreted by beta cells of the pancreas; insulin plays a major role in the regulation of glucose metabolism, generally promoting the cellular utilization of glucose and is also an important regulator of protein and lipid metabolism; insulin is used as a drug to control insulin-dependent diabetes mellitus.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A short-acting form of insulin. Regular insulin is obtained from animal or recombinant sources. The onset of action of regular insulin occurs at 30-90 minutes after injection; its effect lasts for 6 to 8 hours. Endogenous human insulin, a pancreatic hormone composed of two polypeptide chains, is important for the normal metabolism of carbohydrates, proteins and fats; it has anabolic effects on many types of tissues. (NCI04)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;Human insulin protein (110 aa, 12 kDa) is encoded by the human insulin (INS) gene. This cytosolic protein, a heterodimer of disulfide-linked alpha and beta chains, is produced in pancreatic islet beta cells. Binding of insulin to its receptor stimulates glucose uptake, accelerates both glycolysis and the pentose phosphate cycle and increases glycogen synthesis in the liver. Insulin regulates protein and lipid metabolism. It also decreases blood glucose concentration by shuttling molecules into cells to be used for energy. Decreased expression of insulin protein causes familial hyperproinsulinemia.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1).&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Amino Acid, Peptide, or Protein (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0021641&amp;amp;tui=T116"&gt;&lt;i&gt;T116&lt;/i&gt;&lt;/a&gt;)
, Pharmacologic Substance (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0021641&amp;amp;tui=T121"&gt;&lt;i&gt;T121&lt;/i&gt;&lt;/a&gt;)
, Hormone (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0021641&amp;amp;tui=T125"&gt;&lt;i&gt;T125&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D007328&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;67866001, 39487003, 412222002&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Insulin, insulin, INSULIN PREPARATIONS, Insulin preparation, NOS, Regular Insulin, Regular insulin preparation, Unmodified insulin preparation, Insulin Regular, INSULIN, insulin preparations, insulin preparations (medication), A22 INSULIN PREPARATIONS, insulin regular, Insulin (ox), 8A-L-threonine-10A-L-isoleucine-30B-L-threonine-, Insulin [Chemical/Ingredient], [HS501] INSULIN, Insulin regular, insulin products, insulin preparation, insulin product, regular insulin, insulins, Insulin, Soluble, Soluble Insulin, Insulin, Regular, Insulin product, Insulin (substance), Insulin preparation, Insulin product (product), Regular insulin product, Unmodified insulin product, Insulin preparation (substance), Regular insulin (substance), Regular insulin&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Insulin&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;insulin, inzulin&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Insuliini&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Insuline ordinaire, Insuline&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;INSULIN, ИНСУЛИН&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;producto con insulina (producto), preparado insulínico, insulina (producto), producto con insulina, insulina (sustancia), insulina, preparado de insulina (producto), preparado de insulina (sustancia), preparado de insulina cristalina de cinc, preparado de insulina cristalina de zinc, preparado de insulina no modificada, preparado de insulina, insulina regular (sustancia), insulina regular, Insulina&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Insulina regolare, Insulina&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Croatian&lt;/td&gt;
                &lt;td&gt;INZULIN&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Insulina&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;インスリン, インスリン亜鉛水性懸濁液, インシュリン&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Insulin&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Insulina&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Insulin  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Variable Rate Insulin Infusion</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Pharmacology</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;See Also&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/HrlySbctnsInsln.htm" class="LinkPage"&gt;Hourly Subcutaneous Insulin Lispro&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Indications&lt;ol&gt;&lt;li&gt;Patient not eating (e.g. post-operative)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Preparation&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Regular Insulin&lt;/a&gt; 100 units in 100 cc NS (1 u per 1 ml)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Protocol: Insulin Infusion&lt;ol&gt;&lt;li&gt;Starting dose of Insulin Infusion&lt;ol&gt;&lt;li&gt;Type I Diabetic: 0.5 to 1 unit per hour&lt;/li&gt;&lt;li&gt;Type II Diabetic or poor control: 2-3 units per hour&lt;/li&gt;&lt;li&gt;Weight-based (use true weight, not &lt;a href="../../Endo/Exam/IdlWghtInAdlts.htm" class="LinkPage"&gt;Ideal Weight&lt;/a&gt;)&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/DM/DbtcKtcds.htm" class="LinkPage"&gt;Diabetic Ketoacidosis&lt;/a&gt;: 0.1 Units/kg/h&lt;/li&gt;&lt;li&gt;Non-ketotic: 0.05 Units/kg/h&lt;ol&gt;&lt;li&gt;Consider starting with this dose in very large patients with high calculated doses&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; bolus prior to starting Insulin Drip is controversial&lt;ol&gt;&lt;li&gt;Not recommended in pediatric patients&lt;/li&gt;&lt;li&gt;Use in adult &lt;a href="../../Endo/DM/DbtcKtcds.htm" class="LinkPage"&gt;Diabetic Ketoacidosis&lt;/a&gt; does not offer additional benefit over Insulin Infusion alone&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Goval%20%20%5BAU%5D%20AND%202010%20%5BDP%5D%20AND%20%20J%20Emerg%20Med%20%20%5BTA%5D" class="LinkRef"&gt;Goval (2010) J Emerg Med 38(4): 422-7&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; bolus dosing in &lt;a href="../../Endo/DM/DbtcKtcds.htm" class="LinkPage"&gt;Diabetic Ketoacidosis&lt;/a&gt; if used (adults only)&lt;ol&gt;&lt;li&gt;Bolus &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; dose: 10 units&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Coadminister D5W at 100 to 125 cc per hour&lt;/li&gt;&lt;li&gt;Check &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Glucose&lt;/a&gt; every 30 minutes to 1 hour&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; &amp;lt;70 Then&lt;ol&gt;&lt;li&gt;Turn off Insulin Drip for 30 minutes&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Glucose&lt;/a&gt; on recheck still &amp;lt;70&lt;ol&gt;&lt;li&gt;Give 25 ml of D50 IV (or 10-12 grams &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt;)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Recheck &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Glucose&lt;/a&gt; every 30 minutes&lt;ol&gt;&lt;li&gt;Restart infusion when &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; &amp;gt;100 mg/dl&lt;/li&gt;&lt;li&gt;Decrease Insulin Drip rate by 1.0 u/h&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; 71-120 Then&lt;ol&gt;&lt;li&gt;Decrease Insulin Drip by 1.0 u/hour&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; 121-180 Then&lt;ol&gt;&lt;li&gt;No change&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; 181-250 Then&lt;ol&gt;&lt;li&gt;Increase Insulin Drip by 2 units/hour&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; 251-300 Then&lt;ol&gt;&lt;li&gt;Increase Insulin Drip by 3 units/hour&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; 301-350 Then&lt;ol&gt;&lt;li&gt;Increase Insulin Drip by 4 units/hour&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; 351-400 Then&lt;ol&gt;&lt;li&gt;Increase Insulin Drip by 5 units/hour&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; &amp;gt;400 Then&lt;ol&gt;&lt;li&gt;Increase Insulin Drip by 6 units/hour&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;IF Insulin Drip drops to 0 units/hour&lt;ol&gt;&lt;li&gt;Continue q2 hour &lt;a href="../../Endo/DM/DbtsMltsGlcsMngmnt.htm" class="LinkPage"&gt;Blood Glucose Monitoring&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Restart Insulin Drip when &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Glucose&lt;/a&gt; &amp;gt;150&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Discontinuation (e.g. Postoperatively)&lt;ol&gt;&lt;li&gt;Administer patient's usual &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; dose pre-meal&lt;/li&gt;&lt;li&gt;Patient eats meal&lt;/li&gt;&lt;li&gt;Discontinue Insulin Infusion two hours after meal&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Marks%20%20%5BAU%5D%20AND%202003%20%5BDP%5D%20AND%20%20Am%20Fam%20Physician%20%20%5BTA%5D" class="LinkRef"&gt;Marks (2003) Am Fam Physician 67(1):93-100&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0021641</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Pharm/VrblRtInslnInfsn.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Variable Rate Insulin Infusion, Insulin Infusion, Insulin Drip</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Pharm/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Methylprednisolone  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0025815"&gt;&lt;i&gt;C0025815&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CHV)&lt;/td&gt;
                &lt;td&gt;a kind of steroidal anti-inflammatory drugs&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;A PREDNISOLONE derivative with similar anti-inflammatory action.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CSP)&lt;/td&gt;
                &lt;td&gt;synthetic glucocorticoid derived from progesterone, used in replacement therapy for adrenal insufficiency and as an anti-inflammatory and immunosuppressant.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A corticosteroid hormone replacement.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A synthetic corticosteroid with anti-inflammatory and immunomodulating properties. Methylprednisolone binds to and activates specific nuclear receptors, resulting in altered gene expression and inhibition of proinflammatory cytokine production. This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (PDQ)&lt;/td&gt;
                &lt;td&gt;A synthetic corticosteroid with anti-inflammatory and immunomodulating properties. Methylprednisolone binds to and activates specific nuclear receptors, resulting in altered gene expression and inhibition of proinflammatory cytokine production. This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations. Check for "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41528&amp;amp;idtype=1" active clinical trials or "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41528&amp;amp;idtype=1&amp;amp;closed=1" closed clinical trials using this agent. ("http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;amp;code=C647" NCI Thesaurus)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Steroid (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0025815&amp;amp;tui=T110"&gt;&lt;i&gt;T110&lt;/i&gt;&lt;/a&gt;)
, Pharmacologic Substance (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0025815&amp;amp;tui=T121"&gt;&lt;i&gt;T121&lt;/i&gt;&lt;/a&gt;)
, Hormone (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0025815&amp;amp;tui=T125"&gt;&lt;i&gt;T125&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D008775&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;325387001, 116593003, 27242001&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;6 Methylprednisolone, 6-Methylprednisolone, Methylprednisolone, Metipred, Pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-6-methyl-, (6alpha,11beta)-, Methylprednisolone [endoc], 6Alpha-Methylprednisolone, (6alpha,11beta)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione, methylprednisolone, Methylprednisolonum, Methylprednisolone [endocrine use], Methylprednisolone [endocrine use] (product), methylprednisolone (medication), METHYLPREDNISOLONE, Methylprednisolone [Chemical/Ingredient], methylPREDNISolone, 6-alpha-Methylprednisolone preparation, Methylprednisolone preparation, Methylprednisolone (substance), Methylprednisolone preparation (product), MePRDL, Methylprednisolone [endocrine use] (substance), Methylprednisolone preparation (substance), MethylPREDNISolone&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Metylprednisolon&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;methylprednisolon&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Metyyliprednisoloni&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;METILPREDNIZOLON, METIPRED, URBAZON, МЕТИЛПРЕДНИЗОЛОН, МЕТИПРЕД, УРБАЗОН&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;metilprednisolona (uso endocrino) (producto), metilprednisolona (uso endocrino), preparado con 6-alfa-metilprednisolona, preparado con metilprednisolona (producto), metilprednisolona (producto), preparado con metilprednisolona, metilprednisolona (sustancia), metilprednisolona, preparado de 6-alfa-metilprednisolona, preparado de metilprednisolona (producto), preparado de metilprednisolona (sustancia), preparado de metilprednisolona, Metilprednisolona&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;メドロール, メチルプレドニゾロン, メチルプレドニソロン, ウルバソン&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;6-Méthylprednisolone, Méthylprednisolone&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Croatian&lt;/td&gt;
                &lt;td&gt;METILPREDNISOLON&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Metyloprednizolon&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Methylprednisolon&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Metilprednisolone&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Metilprednisolona&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Cortisone  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0010137"&gt;&lt;i&gt;C0010137&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A corticosteroid with potent glucocorticoid activity. Therapeutic cortisone is the inactive precursor molecule of the active hormone cortisol, which is the hydroxylation product of cortisone by 11-beta-steroid dehydrogenase. Cortisol increases blood pressure and blood sugar levels, and suppresses the immune system, therefore cortisone is used to treat allergies or inflammation.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;A naturally occurring glucocorticoid. It has been used in replacement therapy for adrenal insufficiency and as an anti-inflammatory agent. Cortisone itself is inactive. It is converted in the liver to the active metabolite HYDROCORTISONE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p726)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CSP)&lt;/td&gt;
                &lt;td&gt;naturally occurring glucocorticoid used in replacement therapy for adrenal insufficiency and as an anti-inflammatory agent; cortisone itself is inactive and is converted in the liver to the active metabolite cortisol.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A natural steroid hormone produced in the adrenal gland. It can also be made in the laboratory. Cortisone reduces swelling and can suppress immune responses.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A steroid hormone synthesized and secreted by the adrenal gland and necessary for life. It is involved with maintaining cardiovascular function, blood glucose balance, regulating the inflammatory response and metabolism of proteins, carbohydrates, and fat.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Steroid (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0010137&amp;amp;tui=T110"&gt;&lt;i&gt;T110&lt;/i&gt;&lt;/a&gt;)
, Pharmacologic Substance (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0010137&amp;amp;tui=T121"&gt;&lt;i&gt;T121&lt;/i&gt;&lt;/a&gt;)
, Hormone (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0010137&amp;amp;tui=T125"&gt;&lt;i&gt;T125&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D003348&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;32498003, 111150008&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;cortisone, Pregn-4-ene-3,11,20-trione, 17,21-dihydroxy-, 17,21-Dihydroxypregn-4-ene-3,11,20-trione, Cortisone, Cortisone [Chemical/Ingredient], cortisones, Compound E, Cortisone preparation, Cortisone (substance), Cortisone preparation (product), Cortisone product, CORT, Cortisone preparation (substance), Therapeutic Cortisone, CORTISONE&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Kortison&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;kortison&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Kortisoni&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;KORTIZON, КОРТИЗОН&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;コルチゾン, 11-デヒドロ-17-ヒドロキシコルチコステロン&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;preparado con cortisona (producto), cortisona (producto), preparado con cortisona, cortisona (sustancia), cortisona, preparado de cortisona (producto), preparado de cortisona (sustancia), preparado de cortisona, Cortisona&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Croatian&lt;/td&gt;
                &lt;td&gt;KORTIZON&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Kortyzon&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Cortisone&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Cortison&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Cortisone&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Cortisona&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Betamethasone  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0005308"&gt;&lt;i&gt;C0005308&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;A glucocorticoid given orally, parenterally, by local injection, by inhalation, or applied topically in the management of various disorders in which corticosteroids are indicated. Its lack of mineralocorticoid properties makes betamethasone particularly suitable for treating cerebral edema and congenital adrenal hyperplasia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p724)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A synthetic glucocorticoid with metabolic, immunosuppressive and anti-inflammatory activities. Betamethasone binds to specific intracellular glucocorticoid receptors and subsequently binds to DNA to modify gene expression. The synthesis of certain anti-inflammatory proteins is induced while the synthesis of certain inflammatory mediators is inhibited. As a result, there is an overall reduction in chronic inflammation and autoimmune reactions.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (PDQ)&lt;/td&gt;
                &lt;td&gt;A synthetic glucocorticoid with metabolic, immunosuppressive and anti-inflammatory activities. Betamethasone binds to specific intracellular glucocorticoid receptors and subsequently binds to DNA to modify gene expression. The synthesis of certain anti-inflammatory proteins is induced while the synthesis of certain inflammatory mediators is inhibited. As a result, there is an overall reduction in chronic inflammation and autoimmune reactions. Check for "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39273&amp;amp;idtype=1" active clinical trials or "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39273&amp;amp;idtype=1&amp;amp;closed=1" closed clinical trials using this agent. ("http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;amp;code=C303" NCI Thesaurus)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Steroid (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0005308&amp;amp;tui=T110"&gt;&lt;i&gt;T110&lt;/i&gt;&lt;/a&gt;)
, Pharmacologic Substance (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0005308&amp;amp;tui=T121"&gt;&lt;i&gt;T121&lt;/i&gt;&lt;/a&gt;)
, Hormone (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0005308&amp;amp;tui=T125"&gt;&lt;i&gt;T125&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D001623&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;116571008, 29896003&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Betadexamethasone, Betamethasone, Flubenisolone, Pregna-1,4-diene-3,20-dione, 9-fluoro-11,17,21-trihydroxy-16-methyl-, (11beta,16beta)-, betamethasone, betamethasone (medication), Betamethasone [Chemical/Ingredient], Betamethasone preparation, Flubenisolone preparation, Betamethasone (substance), Betamethasone preparation (product), Betamethasone preparation (substance), BETAMETHASONE&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Betametason&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;betamethason&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Beetametasoni&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Betadesametasone, Flubenisolone, Betametasone&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;BETADEKSAMETAZON, BETAMETAZON, FLUBENIZOLON, БЕТАДЕКСАМЕТАЗОН, БЕТАМЕТАЗОН, ФЛУБЕНИЗОЛОН&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;preparado de betametasona (producto), betametasona (producto), preparado de flubenisolona, preparado de betametasona, betametasona (sustancia), betametasona, preparado de betametasona (sustancia), Betadexametasona, Betametasona, Flubenisolona&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Flubenisolonum, Betametazon&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;フルベニソロン, ベタメタゾン, ベタデキサメタゾン&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Bétaméthasone&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Betadexamethason, Betamethason, Flubenisolon&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Betadexametasona, Betametasona, Flubenisolona&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Dexamethasone  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0011777"&gt;&lt;i&gt;C0011777&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CHV)&lt;/td&gt;
                &lt;td&gt;a kind of steroid drug&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CHV)&lt;/td&gt;
                &lt;td&gt;a kind of steroid drug&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CSP)&lt;/td&gt;
                &lt;td&gt;anti-inflammatory 9-fluoro-glucocorticoid.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;An anti-inflammatory 9-fluoro-glucocorticoid.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (PSY)&lt;/td&gt;
                &lt;td&gt;A synthetic analogue of cortisol.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A synthetic adrenal corticosteroid with potent anti-inflammatory properties. In addition to binding to specific nuclear steroid receptors, dexamethasone also interferes with NF-kB activation and apoptotic pathways. This agent lacks the salt-retaining properties of other related adrenal hormones. (NCI04)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A synthetic steroid (similar to steroid hormones produced naturally in the adrenal gland). Dexamethasone is used to treat leukemia and lymphoma and may be used to treat some of the problems caused by other cancers and their treatment.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (PDQ)&lt;/td&gt;
                &lt;td&gt;A synthetic adrenal corticosteroid with potent anti-inflammatory properties. In addition to binding to specific nuclear steroid receptors, dexamethasone also interferes with NF-kB activation and apoptotic pathways. This agent lacks the salt-retaining properties of other related adrenal hormones. Check for "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39789&amp;amp;idtype=1" active clinical trials or "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39789&amp;amp;idtype=1&amp;amp;closed=1" closed clinical trials using this agent. ("http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;amp;code=C422" NCI Thesaurus)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Steroid (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0011777&amp;amp;tui=T110"&gt;&lt;i&gt;T110&lt;/i&gt;&lt;/a&gt;)
, Pharmacologic Substance (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0011777&amp;amp;tui=T121"&gt;&lt;i&gt;T121&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D003907&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;325354000, 372584003, 7561000, 116568000&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Dexamethasone, Hexadecadrol, Methylfluorprednisolone, Pregna-1,4-diene-3,20-dione, 9-fluoro-11,17,21-trihydroxy-16-methyl-, (11beta,16alpha)-, 1-Dehydro-16alpha-methyl-9alpha-fluorohydrocortisone, 9Alpha-fluoro-11beta,17alpha,21-trihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione, 9Alpha-fluoro-16alpha-methylprednisolone, 9alpha-Fluoro-16alpha- methylprednisolone, Fluoro-9alpha Methyl-16alpha Prednisolone, (11Beta,16alpha)-9-fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione, 16Alpha-methyl-9alpha-fluoro-1,4-pregnadiene-11beta,17alpha,21-triol-3,20-dione, 16Alpha-methyl-9alpha-fluoro-delta1-hydrocortisone, 16Alpha-methyl-9alpha-fluoroprednisolone, dexamethasone, Dexamethasonum, Desamethasone, Dexamethasone [endocrine use], DEXAMETHASONE, Dexamethasone [endocrine use] (product), dexamethasone (medication), Dexamethasone [Chemical/Ingredient], dexamethasone (DMX), Dexamethasone preparation, Dexamethasone (substance), Dexamethasone preparation (product), DXM, DM, Dexamethasone (product), Dexamethasone [endocrine use] (substance), Dexamethasone preparation (substance)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Dexametason&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;dexamethason&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Deksametasoni&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;DEKSAMETAZON, GEKSADEKADROL, ГЕКСАДЕКАДРОЛ, ДЕКСАМЕТАЗОН&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;dexametasona (uso endocrino) (producto), dexametasona (uso endocrino), preparado con dexametasona (producto), dexametasona (producto), preparado con dexametasona, dexametasona (sustancia), dexametasona, preparado de dexametasona (producto), preparado de dexametasona (sustancia), preparado de dexametasona, Dexametasona, Hexadecadrol&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;コルソン, デキサA, デキサメサゾン, ダブM, デカドロン, ビスオDS, ミタゾーン, オイラゾンD, デカドロンN, デキサ･チョーセイ, デキサ･ママレット, デキサメ, ヘキサデカドロール, デルゾン, サンテゾーン, デキサルチン, フルメプレドニゾロン, マキシデックス, デキサメタゾン, エースミン&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Metil-fluoro-prednisolone, Esadecadrol, Desametasone&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Croatian&lt;/td&gt;
                &lt;td&gt;DEKSAMETAZON&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Deksametazon&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Dexaméthasone&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Dexamethason, Hexadecadrol&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Dexametasona, Hexadecadrol&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;prednisolone  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0032950"&gt;&lt;i&gt;C0032950&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A drug that lessens inflammation and suppresses the body's immune response. It may also kill cancer cells. Prednisolone is used to treat disorders in many organ systems and to treat the symptoms of several types of leukemia and lymphoma. It is also being studied in the treatment of other types of cancer. Prednisolone is a type of therapeutic glucocorticoid.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CSP)&lt;/td&gt;
                &lt;td&gt;synthetic glucocorticoid with the general properties of the corticosteroids.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. After cell surface receptor attachment and cell entry, prednisolone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production. This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cells populations. (NCI04)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (PDQ)&lt;/td&gt;
                &lt;td&gt;A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. After cell surface receptor attachment and cell entry, prednisolone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production. This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cells populations. Check for "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43296&amp;amp;idtype=1" active clinical trials or "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43296&amp;amp;idtype=1&amp;amp;closed=1" closed clinical trials using this agent. ("http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;amp;code=C769" NCI Thesaurus)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Steroid (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0032950&amp;amp;tui=T110"&gt;&lt;i&gt;T110&lt;/i&gt;&lt;/a&gt;)
, Pharmacologic Substance (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0032950&amp;amp;tui=T121"&gt;&lt;i&gt;T121&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D011239&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;325425005, 317418003, 116601002, 52388000&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Prednisolone, Pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-, (11beta)-, Prednisolone [for preparations see rectal prednisolone], Prednisolone [see rectal pred], .delta.1-Hydrocortisone, 1,2-Dehydrohydrocortisone, (11beta)-11,17,21-Trihydroxypregna-1,4-diene-3,20-dione, Metacortandralone, Delta(1)Hydrocortisone, Delta-F, Delta1-dehydro-hydrocortisone, Prednisolonum, Prednisolone [endocrine use], Prednisolone [for preparations see rectal prednisolone] (product), Prednisolone [endocrine use] (product), prednisolone (medication), PREDNISOLONE, Prednisolone [Chemical/Ingredient], prednisoLONE, Deltahydrocortisone, Deltahydrocortisone preparation, Metacortandralone preparation, Prednisolone preparation, Prednisolone product, Prednisolone (substance), Prednisolone preparation (product), PRDL, Prednisolone [endocrine use] (substance), Prednisolone [for preparations see rectal prednisolone] (substance), Prednisolone preparation (substance), prednisolone, PrednisoLONE&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Prednisolon&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;prednisolon, depersolon&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Prednisoloni&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;DEPERZOLON, PREDNIZOLON, ДЕПЕРЗОЛОН, ПРЕДНИЗОЛОН&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;prednisolona (para preparaciones ver prednisolona rectal) (producto), prednisolona (uso endocrino) (producto), prednisolona (para preparaciones ver prednisolona rectal), prednisolona (uso endocrino), preparado con metacortandralona, preparado con prednisolona (producto), prednisolona (producto), preparado con deltahidrocortisona, preparado con prednisolona, prednisolona (sustancia), prednisolona, preparado de deltahidrocortisona, preparado de metacortandralona, preparado de prednisolona (producto), preparado de prednisolona (sustancia), preparado de prednisolona, Prednisolona&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;プレドニソロン, デルポPD, ドニソロン, プレドニン, シエリゾロン, プレドニゾロン&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Croatian&lt;/td&gt;
                &lt;td&gt;PREDNIZOLON&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Encortolon, Prednizolon&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Prednisolone&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Prednisolon&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Prednisolone&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Prednisolona&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Adrenal Cortex Hormones  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0001617"&gt;&lt;i&gt;C0001617&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;Any steroid hormone made in the adrenal cortex (the outer part of the adrenal gland). They are also made in the laboratory. Corticosteroids have many different effects in the body, and are used to treat many different conditions. They may be used as hormone replacement, to suppress the immune system, and to treat some side effects of cancer and its treatment. Corticosteroids are also used to treat certain lymphomas and lymphoid leukemias.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CSP)&lt;/td&gt;
                &lt;td&gt;any of the 21-carbon steroids elaborated by the adrenal cortex (excluding the sex hormones of adrenal origin) in response to adrenocorticotropic hormone (ACTH) released by the pituitary gland or to angiotensin II; called also adrenocorticoid, corticoid, adrenal cortical or adrenocortical steroid, and adrenocortical or cortical hormone.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;Hormones synthesized in the cortex of the adrenal gland and consist of two subclasses, glucocorticoids (carbohydrate regulation) and mineralocorticoids (electrolyte regulation).&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Steroid (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0001617&amp;amp;tui=T110"&gt;&lt;i&gt;T110&lt;/i&gt;&lt;/a&gt;)
, Pharmacologic Substance (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0001617&amp;amp;tui=T121"&gt;&lt;i&gt;T121&lt;/i&gt;&lt;/a&gt;)
, Hormone (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0001617&amp;amp;tui=T125"&gt;&lt;i&gt;T125&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D000305&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;332333008, 320476006, 79440004, 21568003&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Corticoid, Adrenal Cortex Hormones, Corticoids, Corticosteroids, Hormones, Adrenal Cortex, Adrenal cortical hormone, NOS, Corticoid preparation, NOS, Corticosteroids [resp], Corticosteroids [skin], Corticosteroids [skin] (product), Corticosteroids [respiratory use] (product), Corticosteroids [respiratory use], adrenal cortex hormone, corticosteroids, adrenal cortex hormones, corticoids, Corticosteroid [EPC], Adrenal Cortex Hormones [Chemical/Ingredient], Corticosteroid, Adrenal cortex hormones, adrenal corticosteroids, adrenal cortical hormone, adrenal corticosteroid, adrenocorticosteroids, corticoid, Adrenal cortical hormone, Adrenocorticosteroids, Corticoid preparation (product), Corticoid preparation, Adrenal cortical hormone (substance), corticosteroid, Corticoid preparation (substance), Corticosteroids [respiratory use] (substance), Corticosteroids [skin] (substance), Adrenal Cortex Steroids, Therapeutic Corticosteroid&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Binjurebarkshormoner&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;corticosteroide (uso dermatológico), corticosteroide (uso dermatológico) (producto), corticosteroide [uso respiratorio] (producto), corticosteroide [uso respiratorio], corticoides (producto), preparado con corticoides (producto), corticoides, preparado con corticoides, Corticoesteroides, Corticosteroides, adrenocorticoesteroide, corticosteroides (piel) (producto), corticosteroides (piel), corticosteroides [uso respiratorio] (producto), corticosteroides [uso respiratorio], hormona de la corteza suprarrenal, hormona suprarrenal cortical (sustancia), hormona suprarrenal cortical, preparado de corticoides (producto), preparado de corticoides (sustancia), preparado de corticoides, Corticoides, Hormonas de la Corteza Suprarrenal&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;hormony kůry nadledvin, kortikosteroidy, kortikoidy&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Lisämunuaiskuoren hormonit&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Hormones cortico-surrénaliennes, Corticoïdes, Corticostéroïdes, Hormones corticosurrénaliennes&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Corticoidi, Corticosteroidi, Ormoni corticosurrenali&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;NADPOCHECHNIKOV KORY GORMONY, KORTIKOSTEROIDY, KORTIKOIDY, КОРТИКОИДЫ, КОРТИКОСТЕРОИДЫ, НАДПОЧЕЧНИКОВ КОРЫ ГОРМОНЫ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Croatian&lt;/td&gt;
                &lt;td&gt;KORTIKOSTEROIDI&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Corticoesteróides, Corticóides, Corticosteróides, Hormônios do Córtex Supra-Renal&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Hormony kory nadnerczy, Kortykoidy, Kortykosteroidy&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;コルチコイド, 副腎皮質ホルモン, コルチコステロイド, ステロイドホルモン-副腎皮質, 副腎皮質ステロイド&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Corticoide, Corticosteroide, Nebennierenrindenhormone&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Hydrocortisone  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0020268"&gt;&lt;i&gt;C0020268&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A hormone made by the adrenal cortex (the outer layer of the adrenal gland). It helps the body use glucose (a sugar), protein, and fats. Cortisol made in the laboratory is called hydrocortisone. It is used to treat many conditions, including inflammation, allergies, and some cancers. Cortisol is a type of glucocorticoid hormone.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;The main glucocorticoid secreted by the ADRENAL CORTEX. Its synthetic counterpart is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CSP)&lt;/td&gt;
                &lt;td&gt;main glucocorticoid secreted by the adrenal cortex; its synthetic counterpart is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A synthetic or semisynthetic analog of natural hydrocortisone hormone produced by the adrenal glands with primary glucocorticoid and minor mineralocorticoid effects. As a glucocorticoid receptor agonist, hydrocortisone promotes protein catabolism, gluconeogenesis, capillary wall stability, renal excretion of calcium, and suppresses immune and inflammatory responses. (NCI04)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A drug used to relieve the symptoms of certain hormone shortages and to suppress an immune response.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (PDQ)&lt;/td&gt;
                &lt;td&gt;A synthetic or semisynthetic analog of natural hydrocortisone hormone produced by the adrenal glands with primary glucocorticoid and minor mineralocorticoid effects. As a glucocorticoid receptor agonist, hydrocortisone promotes protein catabolism, gluconeogenesis, capillary wall stability, renal excretion of calcium, and suppresses immune and inflammatory responses. Check for "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39274&amp;amp;idtype=1" active clinical trials or "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39274&amp;amp;idtype=1&amp;amp;closed=1" closed clinical trials using this agent. ("http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;amp;code=C555" NCI Thesaurus)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Steroid (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0020268&amp;amp;tui=T110"&gt;&lt;i&gt;T110&lt;/i&gt;&lt;/a&gt;)
, Pharmacologic Substance (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0020268&amp;amp;tui=T121"&gt;&lt;i&gt;T121&lt;/i&gt;&lt;/a&gt;)
, Hormone (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0020268&amp;amp;tui=T125"&gt;&lt;i&gt;T125&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D006854&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;396458002, 56423005, 16602005&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Compound F, Cortisol, Hydrocortisone, Pregn-4-ene-3,20-dione, 11,17,21-trihydroxy-, (11beta)-, Dihydrocortisone, (11beta)-11,17,21-Trihydroxypregn-4-ene-3,20-dione, hydrocortisone, Cortisol (substance), Domolene, Therapeutic Hydrocortisone, hydrocortisone (medication), 17-hydroxycorticosterone, HYDROCORTISONE, Hydrocortisone [Chemical/Ingredient], cortisols, hydrocortisones, Compound F preparation, Cortisol preparation, Cortisol product, HC - Hydrocortisone, Hydrocortisone preparation, Hydrocortisone product, Hydrocortisone (substance), Hydrocortisone preparation (product), cortisol, HC, Hydrocortisone preparation (substance)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Hydrokortison&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;cortisol, cortisol (sustancia), preparado con hidrocortisona (producto), hidrocortisona (producto), preparado con hidrocortisona, hidrocortisona (sustancia), hidrocortisona, preparado de hidrocortisona (producto), preparado de hidrocortisona (sustancia), preparado de hidrocortisona, Cortisol, Hidrocortisona&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;hydrokortison, kortisol, kortizol, hydrokortizon&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Kortisoli&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;KORTIZOL, GIDROKORTIZON, ГИДРОКОРТИЗОН, КОРТИЗОЛ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;コルチソール, ヒドロコルチゾン, コルチソル, 17-ヒドロキシコルチコステロン, ハイドロコルチゾン, コートリル, コルチゾール&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Cortisolo, Idrocortisone&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Croatian&lt;/td&gt;
                &lt;td&gt;HIDROKORTIZON&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Hydrokortyzon, Kortyzol&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Cortisol, Hydrocortisone&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Cortisol, Hydrocortison, Kortisol&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Cortisol, Hidrocortisona&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Methylprednisolone  (</value><value>)
</value><value>Cortisone  (</value><value>)
</value><value>Betamethasone  (</value><value>)
</value><value>Dexamethasone  (</value><value>)
</value><value>prednisolone  (</value><value>)
</value><value>Adrenal Cortex Hormones  (</value><value>)
</value><value>Hydrocortisone  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Systemic Corticosteroid</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Pharmacology</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;See Also&lt;ol&gt;&lt;li&gt;&lt;a href="../../Derm/Pharm/TpclCrtcstrd.htm" class="LinkPage"&gt;Topical Corticosteroid&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Lung/Pharm/InhldCrtcstrd.htm" class="LinkPage"&gt;Inhaled Corticosteroid&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../ENT/Pharm/IntrnslStrd.htm" class="LinkPage"&gt;Intranasal Steroid&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Rheum/Pharm/InjctblCrtcstrd.htm" class="LinkPage"&gt;Intra-articular Corticosteroid&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/CrtcstrdAsctdOstprs.htm" class="LinkPage"&gt;Corticosteroid Associated Osteoporosis&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Dosing: Adult&lt;ol&gt;&lt;li&gt;Betamethasone (Celestone) 0.5 to 0.9 mg IM/PO qd&lt;/li&gt;&lt;li&gt;Cortisone (Cortone) 25-300 mg PO qd&lt;/li&gt;&lt;li&gt;Dexamethasone (Decadron) 0.75-9 mg PO/IM/IV divided q6h&lt;/li&gt;&lt;li&gt;Hydrocortisone (Cortef)&lt;ol&gt;&lt;li&gt;Parenteral: 100 to 150 mg IV/IM q2-6 hours prn&lt;/li&gt;&lt;li&gt;Oral: 20 to 240 mg/day PO in divided dosing&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Methylprednisolone&lt;ol&gt;&lt;li&gt;Parenteral (Solu-Medrol) 10 to 125 mg IV/IM&lt;/li&gt;&lt;li&gt;Oral (Medrol) 4 to 48 mg PO qd&lt;/li&gt;&lt;li&gt;Medrol Dose pack: tapers from 24 to 0 PO over 7 days&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Prednisolone (Prelone) 5-60 mg PO/IV/IM qd&lt;/li&gt;&lt;li&gt;Prednisone (Deltasone) 5-60 mg PO qd&lt;/li&gt;&lt;li&gt;Triamcinolone (Aristocort, &lt;a href="../../Derm/Pharm/TpclCrtcstrd.htm" class="LinkPage"&gt;Kenalog&lt;/a&gt;) 4 to 48 mg PO/IM qd&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Dosing: Child&lt;ol&gt;&lt;li&gt;Methylprednisolone (Solu-Medrol)&lt;ol&gt;&lt;li&gt;Dose: 1-2 mg/kg/dose PO/IV/IM q6h up to 125 mg/dose&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Prednisolone (Prelone)&lt;ol&gt;&lt;li&gt;Dose: 1-2 mg/kg/dose PO qd to bid up to 60 mg/day&lt;/li&gt;&lt;li&gt;Maximum: 60 mg per day&lt;/li&gt;&lt;li&gt;Preparations&lt;ol&gt;&lt;li&gt;Syrup: 15 mg/5 ml&lt;/li&gt;&lt;li&gt;Liquid: 5 mg/5 ml&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Agents: Overall potency (equivalent dosages)&lt;ol&gt;&lt;li&gt;High potency&lt;ol&gt;&lt;li&gt;Betamethasone 0.6 to 0.75 mg&lt;/li&gt;&lt;li&gt;Dexamethasone 0.75 mg&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Medium potency&lt;ol&gt;&lt;li&gt;Methylprednisolone 4 mg&lt;/li&gt;&lt;li&gt;Triamcinolone 4 mg&lt;/li&gt;&lt;li&gt;Prednisolone 5 mg&lt;/li&gt;&lt;li&gt;Prednisone 5 mg&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Low potency&lt;ol&gt;&lt;li&gt;Hydrocortisone 20 mg&lt;/li&gt;&lt;li&gt;Cortisone 25 mg&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Agents: Relative anti-inflammatory potency&lt;ol&gt;&lt;li&gt;High anti-inflammatory potency&lt;ol&gt;&lt;li&gt;Betamethasone 20-30&lt;/li&gt;&lt;li&gt;Dexamethasone 20-30&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Medium anti-inflammatory potency&lt;ol&gt;&lt;li&gt;Methylprednisolone 5&lt;/li&gt;&lt;li&gt;Triamcinolone 5&lt;/li&gt;&lt;li&gt;Prednisolone 4&lt;/li&gt;&lt;li&gt;Prednisone 4&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Low anti-inflammatory potency&lt;ol&gt;&lt;li&gt;Hydrocortisone 1&lt;/li&gt;&lt;li&gt;Cortisone 0.8&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Agents: Relative Mineralocorticoid Potency&lt;ol&gt;&lt;li&gt;Mineralocorticoid Activity&lt;ol&gt;&lt;li&gt;Cortisone 2&lt;/li&gt;&lt;li&gt;Hydrocortisone 2&lt;/li&gt;&lt;li&gt;Prednisolone 1&lt;/li&gt;&lt;li&gt;Prednisone 1&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;No Mineralocorticoid Activity&lt;ol&gt;&lt;li&gt;Betamethasone&lt;/li&gt;&lt;li&gt;Dexamethasone&lt;/li&gt;&lt;li&gt;Methylprednisolone&lt;/li&gt;&lt;li&gt;Triamcinolone&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Agents: Half Life&lt;ol&gt;&lt;li&gt;Long half-life (36-54 hours)&lt;ol&gt;&lt;li&gt;Betamethasone&lt;/li&gt;&lt;li&gt;Dexamethasone&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Medium half-life (18-36 hours)&lt;ol&gt;&lt;li&gt;Methylprednisolone&lt;/li&gt;&lt;li&gt;Prednisolone&lt;/li&gt;&lt;li&gt;Prednisone&lt;/li&gt;&lt;li&gt;Triamcinolone&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Short half-life (8-12 hours)&lt;ol&gt;&lt;li&gt;Cortisone&lt;/li&gt;&lt;li&gt;Hydrocortisone&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Adverse Effects: Long-term Corticosteroids&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/CrtcstrdAsctdOstprs.htm" class="LinkPage"&gt;Corticosteroid Associated Osteoporosis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Corticosteroid &lt;a href="../../Neuro/Motor/Mypthy.htm" class="LinkPage"&gt;Myopathy&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Emotional lability (depression or &lt;a href="../../Psych/Bipolar/BplrDsrdr.htm" class="LinkPage"&gt;Hypomania&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;Motor restlessness&lt;/li&gt;&lt;li&gt;&lt;a href="../../Psych/Sleep/Insmn.htm" class="LinkPage"&gt;Insomnia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Htn/Hyprtnsn.htm" class="LinkPage"&gt;Hypertension&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Iatrogenic &lt;a href="../../Endo/DM/DbtsMlts.htm" class="LinkPage"&gt;Diabetes Mellitus&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Lipid/Hyprchlstrlm.htm" class="LinkPage"&gt;Hyperlipidemia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Fluid retention&lt;/li&gt;&lt;li&gt;Osteonecrosis of the hip&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Prevention of Corticosteroid complications&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Endo/Pharm/CrtcstrdAsctdOstprs.htm" class="LinkPage"&gt;Corticosteroid Associated Osteoporosis&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Lane%20%20%5BAU%5D%20AND%201998%20%5BDP%5D%20AND%20%20Endocrinol%20Metab%20Clin%20North%20Am%20%20%5BTA%5D" class="LinkRef"&gt;Lane (1998) Endocrinol Metab Clin North Am 27:465-83&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0025815</value><value>C0010137</value><value>C0005308</value><value>C0011777</value><value>C0032950</value><value>C0001617</value><value>C0020268</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Pharm/SystmcCrtcstrd.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Systemic Corticosteroid, Corticosteroid, Betamethasone, Dexamethasone, Cortisone, Hydrocortisone, Methylprednisolone, Prednisolone</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Pharm/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Dexfenfluramine  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0011786"&gt;&lt;i&gt;C0011786&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;The S-isomer of FENFLURAMINE. It is a serotonin agonist and is used as an anorectic. Unlike fenfluramine, it does not possess any catecholamine agonist activity.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Organic Chemical (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0011786&amp;amp;tui=T109"&gt;&lt;i&gt;T109&lt;/i&gt;&lt;/a&gt;)
, Pharmacologic Substance (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0011786&amp;amp;tui=T121"&gt;&lt;i&gt;T121&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D020372&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;322047008, 412366002&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Dexfenfluramine, DEXFENFLURAMINE, Benzeneethanamine, N-ethyl-alpha-methyl-3-(trifluoromethyl)-, (S)-, dexfenfluramine, Dexfenfluramine [Chemical/Ingredient], Dexfenfluramine (product), Dexfenfluramine (substance)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Dexfenfluramin&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;dexfenfluramin&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Deksfenfluramiini&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;DEKSFENFLURAMIN, ДЕКСФЕНФЛУРАМИН&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;デキスフェンフルラミン, デクストロフェンフルラミン, 塩酸デクスフェンフルラミン, デクスフェンフルラミン&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Deksfenfluramina&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;dexfenfluramina (producto), dexfenfluramina, dexfenfluramina (sustancia), Dexfenfluramina&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Dexfenfluramine&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Dexfenfluramin&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Desfenfluramina&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Dexfenfluramina&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Redux  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0728749"&gt;&lt;i&gt;C0728749&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Organic Chemical (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0728749&amp;amp;tui=T109"&gt;&lt;i&gt;T109&lt;/i&gt;&lt;/a&gt;)
, Pharmacologic Substance (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0728749&amp;amp;tui=T121"&gt;&lt;i&gt;T121&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D020372&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;redux, Redux, Wyeth Brand of Dexfenfluramine Hydrochloride&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Dexfenfluramine  (</value><value>)
</value><value>Redux  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Dexfenfluramine</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Pharmacology</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Note&lt;ol&gt;&lt;li&gt;No longer available in United States&lt;ol&gt;&lt;li&gt;Due to significant adverse effects (See below)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Included for historical information only&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Evaluating for adverse cardiac effects&lt;ol&gt;&lt;li&gt;Careful history and exam&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Rad/TrnsthrcEchcrdgrm.htm" class="LinkPage"&gt;Echocardiogram&lt;/a&gt; indications&lt;ol&gt;&lt;li&gt;Symptoms suggestive of cardiopulmonary disease&lt;/li&gt;&lt;li&gt;New onset murmur&lt;/li&gt;&lt;li&gt;Consider for high patient anxiety&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Dosage&lt;ol&gt;&lt;li&gt;Dosing: 15 mg bid (Historical reference only)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Mechanism&lt;ol&gt;&lt;li&gt;D-Isomer of d,I-fenfluramine (Pondimin)&lt;/li&gt;&lt;li&gt;Was used in combination with &lt;a href="../../Endo/Pharm/Phntrmn.htm" class="LinkPage"&gt;Phentermine&lt;/a&gt; (&lt;a href="../../Endo/Pharm/Phntrmn.htm" class="LinkPage"&gt;Ionamin&lt;/a&gt;)&lt;ol&gt;&lt;li&gt;Combination was known as "Phen-Fen"&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Efficacy&lt;ol&gt;&lt;li&gt;Obese patient over 6 months (n=822)&lt;ol&gt;&lt;li&gt;Diet alone: 4.9 kg &lt;a href="../../Endo/Obesity/ObstyMngmnt.htm" class="LinkPage"&gt;Weight Reduction&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Redux and Diet: 9.7 kg &lt;a href="../../Endo/Obesity/ObstyMngmnt.htm" class="LinkPage"&gt;Weight Reduction&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Obese patients over 1 year (n=60)&lt;ol&gt;&lt;li&gt;Diet alone: 7.2 kg &lt;a href="../../Endo/Obesity/ObstyMngmnt.htm" class="LinkPage"&gt;Weight Reduction&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Redux and Diet: 9.8 kg &lt;a href="../../Endo/Obesity/ObstyMngmnt.htm" class="LinkPage"&gt;Weight Reduction&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;No difference from diet alone 5 months after treatment&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Adverse Effects&lt;ol&gt;&lt;li&gt;Drowsiness&lt;/li&gt;&lt;li&gt;&lt;a href="../../GI/Diarrhea/ActDrh.htm" class="LinkPage"&gt;Diarrhea&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../ENT/Sx/DryMth.htm" class="LinkPage"&gt;Dry Mouth&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Primary &lt;a href="../../CV/Lung/PlmnryHyprtnsn.htm" class="LinkPage"&gt;Pulmonary Hypertension&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Associated with use beyond 3 months&lt;/li&gt;&lt;li&gt;Risk increased from 1 per Million to 18 per Million&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Obesity/Obsty.htm" class="LinkPage"&gt;Obesity&lt;/a&gt; increases &lt;a href="../../CV/Lung/PlmnryHyprtnsn.htm" class="LinkPage"&gt;Pulmonary Hypertension&lt;/a&gt; risk 2 fold&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Valvular Heart Disease association&lt;ol&gt;&lt;li&gt;New &lt;a href="../../CV/Exam/HrtMrmr.htm" class="LinkPage"&gt;Heart Murmur&lt;/a&gt;s developed in 24 Phen-Fen Patients&lt;ol&gt;&lt;li&gt;&lt;a href="../../CV/Valve/MtrlRgrgtn.htm" class="LinkPage"&gt;Mitral Regurgitation&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Valve/ArtcRgrgtn.htm" class="LinkPage"&gt;Aortic Insufficiency&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Tricuspid Regurgitation&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Occurred in women with over 1 year of Phen-Fen use&lt;/li&gt;&lt;li&gt;References&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Connolly%20%20%5BAU%5D%20AND%201997%20%5BDP%5D%20AND%20%20N%20Engl%20J%20Med,%20%20%5BTA%5D" class="LinkRef"&gt;Connolly (1997) N Engl J Med, 337(9): 581-8&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0011786</value><value>C0728749</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Pharm/Dxfnflrmn.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Dexfenfluramine, Redux</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Pharm/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees></FP_UMLS_Trees><FP_Condition_name_check></FP_Condition_name_check><FP_Condition_name><value>Somogyi Phenomena</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Pharmacology</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Pathophysiology&lt;ol&gt;&lt;li&gt;Rebound Hyperglycemia in &lt;a href="../../Endo/DM/DbtsMlts.htm" class="LinkPage"&gt;Diabetes Mellitus&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Follows a hypoglycemic reaction during the night&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Diagnosis&lt;ol&gt;&lt;li&gt;Check 3 am &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Sugar&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Management&lt;ol&gt;&lt;li&gt;Decrease evening long-acting &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; (NPH) dose&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Pharm/SmgyPhnmn.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Somogyi Phenomena, Rebound Hyperglycemia</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Pharm/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Sulfonylurea Compounds  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0038766"&gt;&lt;i&gt;C0038766&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CSP)&lt;/td&gt;
                &lt;td&gt;compounds of the type R-SO2-NHCONH-; when R=Ph, these are a group of hypoglycemic agents which enhance insulin secretion by beta cells and insulin sensitivity in target tissue, and so are effective in type II (noninsulin-dependent) diabetes mellitus.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Organic Chemical (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0038766&amp;amp;tui=T109"&gt;&lt;i&gt;T109&lt;/i&gt;&lt;/a&gt;)
, Pharmacologic Substance (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0038766&amp;amp;tui=T121"&gt;&lt;i&gt;T121&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D013453&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;273950002, 34012005, 372711004, 259552008&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Compounds, Sulfonylurea, SULFONYLUREAS, Sulfonylurea, NOS, SULFONYLUREA CPDS, Sulfonylurea and its derivs, Sulphonylurea and its derivs, sulfonylureas (medication), sulfonylureas, sulfonylurea compounds, oral hypoglycemics sulfonylureas, A24 SULFONYLUREAS, Sulfonylurea Compounds, Sulfonylurea Compounds [Chemical/Ingredient], Sulfonylurea [EPC], Sulfonylurea-class Agent, sulphonylureas, sulphonylurea, Sulfonylurea, Sulfonylurea compounds, Sulfonylurea product, Sulphonylurea, Sulphonylurea compounds, Sulphonylurea product, Sulfonylurea and its derivatives, Sulphonylurea and its derivatives, Sulfonylurea (product), Sulfonylurea (substance), Sulfonylurea and its derivatives (substance), sulfonylurea, Sulfonylurea [dup] (substance), Sulfonylureas&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Sulfonylureaföreningar&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;sulfonylmočovinové sloučeniny, glibornurid&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;Sulphonylurea, Sulfonylurea [dup] (substance), Sulfonylurea, sulfonilurea (producto), sulfonilurea (sustancia), sulfonilurea y derivados (sustancia), sulfonilurea y derivados, sulfonilurea, Compuestos de Sulfonilurea&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Sulfonyyliurea&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;SUL'FONILMOCHEVINY SOEDINENIIA, GLIBORNURID, ГЛИБОРНУРИД, СУЛЬФОНИЛМОЧЕВИНЫ СОЕДИНЕНИЯ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Croatian&lt;/td&gt;
                &lt;td&gt;SULFONILUREJA, SPOJEVI&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Sulfonylomocznika związki&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Sulfonylurées&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Sulfonylharnstoffverbindungen&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Derivati della solfonilurea&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Compostos de Sulfoniluréia&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Sulfonylurea Compounds  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Sulfonylurea</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Pharmacology</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;See Also&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/OrlHypglycmc.htm" class="LinkPage"&gt;Oral Hypoglycemic&lt;/a&gt; Agents&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Background&lt;ol&gt;&lt;li&gt;Discovered in 1940's when investigating antibiotics&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Mechanism&lt;ol&gt;&lt;li&gt;Stimulates potassium channel closure on pancreatic beta cell surface&lt;/li&gt;&lt;li&gt;Results in &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; release&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Types&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/FrstGnrtnSlfnylr.htm" class="LinkPage"&gt;First Generation Sulfonylurea&lt;/a&gt; (Listed for historical purposes only)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/ScndGnrtnSlfnylr.htm" class="LinkPage"&gt;Second Generation Sulfonylurea&lt;/a&gt; (e.g. &lt;a href="../../Endo/Pharm/ScndGnrtnSlfnylr.htm" class="LinkPage"&gt;Glipizide&lt;/a&gt;, &lt;a href="../../Endo/Pharm/ScndGnrtnSlfnylr.htm" class="LinkPage"&gt;Glyburide&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/NnSlfnylrInslnScrtgs.htm" class="LinkPage"&gt;Non-Sulfonylurea Insulin Secretagogues&lt;/a&gt; (e.g. &lt;a href="../../Endo/Pharm/NnSlfnylrInslnScrtgs.htm" class="LinkPage"&gt;Meglitinide&lt;/a&gt;, &lt;a href="../../Endo/Pharm/NnSlfnylrInslnScrtgs.htm" class="LinkPage"&gt;Repaglinide&lt;/a&gt;)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0038766</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Pharm/Slfnylr.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Sulfonylurea, Insulin Secretagogue</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Pharm/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Avandia  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0875967"&gt;&lt;i&gt;C0875967&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Organic Chemical (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0875967&amp;amp;tui=T109"&gt;&lt;i&gt;T109&lt;/i&gt;&lt;/a&gt;)
, Pharmacologic Substance (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0875967&amp;amp;tui=T121"&gt;&lt;i&gt;T121&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;C089730&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Avandia, rosiglitazone maleate (Avandia), avandia, Glaxo Wellcome brand of rosiglitazone maleate, GlaxoSmithKline brand of rosiglitazone maleate, SmithKline Beecham brand of rosiglitazone maleate&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Thiazolidinediones  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C1257987"&gt;&lt;i&gt;C1257987&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;THIAZOLES with two keto oxygens. Members are insulin-sensitizing agents which overcome INSULIN RESISTANCE by activation of the peroxisome proliferator activated receptor gamma (PPAR-gamma).&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Organic Chemical (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C1257987&amp;amp;tui=T109"&gt;&lt;i&gt;T109&lt;/i&gt;&lt;/a&gt;)
, Pharmacologic Substance (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C1257987&amp;amp;tui=T121"&gt;&lt;i&gt;T121&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D045162&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;109086001, 372568004&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Tiazolidinedioner&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;thiazolidinediony&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Tiatsolidiinidionit&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;TIAZOLIDINEDIONY, ТИАЗОЛИДИНЕДИОНЫ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;thiazolidinediones, thiazolidinediones (medication), Thiazolidinediones [Chemical/Ingredient], Thiazolidinedione-class Agent, Thiazolidinedione [EPC], glitazone, glitazones, thiazolidinedione, Glitazones, Thiazolidinedione (product), Thiazolidinedione (substance), Thiazolidinedione, Thiazolidinediones&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;チアゾリジンジオン類, チアゾリジンジオン&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Glitazoni, Tiazolidinedioni&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;tiazolidinadiona (producto), tiazolidinediona (producto), tiazolidinediona, tiazolidinadiona (sustancia), tiazolidinadiona, tiazolidinediona (sustancia), Tiazolidindionas, Tiazolidinedionas&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Tiazolidinedionu pochodne, Tiazolidinediony&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Glitazones, Thiazolidine-diones, Thiazolidinediones&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Thiazolidindione&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Tiazolidinedionas&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;troglitazone  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0245514"&gt;&lt;i&gt;C0245514&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;An orally-active thiazolidinedione with antidiabetic and hepatotoxic properties and potential antineoplastic activity. Troglitazone activates peroxisome proliferator-activated receptor gamma (PPAR-gamma), a ligand-activated transcription factor, thereby inducing cell differentiation and inhibiting cell growth and angiogenesis. This agent also modulates the transcription of insulin-responsive genes, inhibits macrophage and monocyte activation, and stimulates adipocyte differentiation. (NCI04)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (PDQ)&lt;/td&gt;
                &lt;td&gt;An orally-active thiazolidinedione with antidiabetic and hepatotoxic properties and potential antineoplastic activity. Troglitazone activates peroxisome proliferator-activated receptor gamma (PPAR-gamma), a ligand-activated transcription factor, thereby inducing cell differentiation and inhibiting cell growth and angiogenesis. This agent also modulates the transcription of insulin-responsive genes, inhibits macrophage and monocyte activation, and stimulates adipocyte differentiation. Check for "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42706&amp;amp;idtype=1" active clinical trials or "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42706&amp;amp;idtype=1&amp;amp;closed=1" closed clinical trials using this agent. ("http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;amp;code=C1522" NCI Thesaurus)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Organic Chemical (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0245514&amp;amp;tui=T109"&gt;&lt;i&gt;T109&lt;/i&gt;&lt;/a&gt;)
, Pharmacologic Substance (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0245514&amp;amp;tui=T121"&gt;&lt;i&gt;T121&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;C057693&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;109085002, 386967007&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;2,4-Thiazolidinedione, 5-((4-((3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy)phenyl)methyl)-, 5-(4-((6-hydroxy-2,5,7,8-tetramethylchroman-2-yl-methoxy)benzyl)-2,4-thiazolidinedione), troglitazone, 5-[4-[(6-Hydroxy-2,5,7,8-tetramethylchroman-2-yl)methoxy]benzyl]-2,4-thiazolidinedione, 5-[[4-[4(3,4-Dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy]phenyl]methyl\-2,4-thiazolidinedione, 5-[[4-[4(3,4-Dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy]phenyl]methyl-2,4-thiazolidinedione, troglitazone [Chemical/Ingredient], Troglitazone, Troglitazone (product), Troglitazone (substance), TROGLITAZONE&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;troglitazona (producto), troglitazona (sustancia), troglitazona&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;pioglitazone  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0071097"&gt;&lt;i&gt;C0071097&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;An orally-active thiazolidinedione with antidiabetic properties and potential antineoplastic activity. Pioglitazone activates peroxisome proliferator-activated receptor gamma (PPAR-gamma), a ligand-activated transcription factor, thereby inducing cell differentiation and inhibiting cell growth and angiogenesis. This agent also modulates the transcription of insulin-responsive genes, inhibits macrophage and monocyte activation, and stimulates adipocyte differentiation.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A drug that is used to treat type 2 diabetes and is being studied in the prevention of head and neck cancer. It may be able to stop leukoplakia (a condition affecting the mouth ) from developing into cancer. It is a type of thiazolidinedione.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Organic Chemical (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0071097&amp;amp;tui=T109"&gt;&lt;i&gt;T109&lt;/i&gt;&lt;/a&gt;)
, Pharmacologic Substance (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0071097&amp;amp;tui=T121"&gt;&lt;i&gt;T121&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;C060836&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;326058001, 395828009&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;5-(4-(2-(5-ethyl-2-pyridyl)ethoxy)benzyl)-2,4-thiazolidinedione, pioglitazone, pioglitazone [Chemical/Ingredient], Pioglitazone (product), Pioglitazone (substance), Pioglitazone, PIOGLITAZONE&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;pioglitazona (producto), pioglitazona (sustancia), pioglitazona&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;rosiglitazone  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0289313"&gt;&lt;i&gt;C0289313&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;The active ingredient in a drug that helps control the amount of glucose (sugar) in the blood and is being studied in the prevention and treatment of some types of cancer. Rosiglitazone stops cells from growing and may prevent the growth of new blood vessels that tumors need to grow. It is a type of thiazolidinedione and a type of antiangiogenesis agent.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CSP)&lt;/td&gt;
                &lt;td&gt;peroxisome proliferator activated receptor agonist; reduces lipid availability; improves insulin action and glucoregulation.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (PDQ)&lt;/td&gt;
                &lt;td&gt;An orally-active thiazolidinedione with antidiabetic properties and potential antineoplastic activity. Rosiglitazone activates peroxisome proliferator-activated receptor gamma (PPAR-gamma), a ligand-activated transcription factor, thereby inducing cell differentiation and inhibiting cell growth and angiogenesis. This agent also modulates the transcription of insulin-responsive genes, inhibits macrophage and monocyte activation, and stimulates adipocyte differentiation. Check for "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=37793&amp;amp;idtype=1" active clinical trials or "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=37793&amp;amp;idtype=1&amp;amp;closed=1" closed clinical trials using this agent. ("http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;amp;code=C2583" NCI Thesaurus)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;An orally-active thiazolidinedione with antidiabetic properties and potential antineoplastic activity. Rosiglitazone activates peroxisome proliferator-activated receptor gamma (PPAR-gamma), a ligand-activated transcription factor, thereby inducing cell differentiation and inhibiting cell growth and angiogenesis. This agent also modulates the transcription of insulin-responsive genes, inhibits macrophage and monocyte activation, and stimulates adipocyte differentiation. (NCI04)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Organic Chemical (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0289313&amp;amp;tui=T109"&gt;&lt;i&gt;T109&lt;/i&gt;&lt;/a&gt;)
, Pharmacologic Substance (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0289313&amp;amp;tui=T121"&gt;&lt;i&gt;T121&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;C089730&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;326053005, 395869000&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;5-((4-(2-methyl-2-(pyridinylamino)ethoxy)phenyl)methyl)-2,4-thiazolidinedione-2-butenedioate, rosiglitazone, rosiglitazone [Chemical/Ingredient], rosiglitazones, 2,4-Thiazolidinedione, 5-004-02-((((methyl-2-pyridinylamino)ethoxy)phenyl)methyl)-, Rosiglitazone (product), Rosiglitazone (substance), Rosiglitazone, ROS, ROSIGLITAZONE&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;rosiglitazona (producto), rosiglitazona (sustancia), rosiglitazona&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Rezulin  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0701265"&gt;&lt;i&gt;C0701265&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Organic Chemical (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0701265&amp;amp;tui=T109"&gt;&lt;i&gt;T109&lt;/i&gt;&lt;/a&gt;)
, Pharmacologic Substance (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0701265&amp;amp;tui=T121"&gt;&lt;i&gt;T121&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;C057693&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Rezulin, rezulin, Parke Davis brand of troglitazone, Warner-Lambert brand of troglitazone&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Actos  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0875954"&gt;&lt;i&gt;C0875954&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A drug that is used to treat type 2 diabetes and is being studied in the prevention of head and neck cancer. It may be able to stop leukoplakia (a condition affecting the mouth ) from developing into cancer. It is a type of thiazolidinedione.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Organic Chemical (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0875954&amp;amp;tui=T109"&gt;&lt;i&gt;T109&lt;/i&gt;&lt;/a&gt;)
, Pharmacologic Substance (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0875954&amp;amp;tui=T121"&gt;&lt;i&gt;T121&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;C060836&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Actos, pioglitazone (Actos), actos, acto, Eli Lilly brand of pioglitazone hydrochloride, Takeda brand of pioglitazone hydrochloride&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Avandia  (</value><value>)
</value><value>Thiazolidinediones  (</value><value>)
</value><value>troglitazone  (</value><value>)
</value><value>pioglitazone  (</value><value>)
</value><value>rosiglitazone  (</value><value>)
</value><value>Rezulin  (</value><value>)
</value><value>Actos  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Thiazolidinedione</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Pharmacology</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Indications&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/OrlHypglycmc.htm" class="LinkPage"&gt;Oral Hypoglycemic&lt;/a&gt; for &lt;a href="../../Endo/DM/TypDbtsMlts1.htm" class="LinkPage"&gt;Type II Diabetes Mellitus&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Second line agent&lt;/li&gt;&lt;li&gt;Add to other &lt;a href="../../Endo/Pharm/OrlHypglycmc.htm" class="LinkPage"&gt;Oral Hypoglycemic&lt;/a&gt; agents&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Diabetes with coronary &lt;a href="../../CV/CAD/AngnPctrs.htm" class="LinkPage"&gt;Vasospastic Angina&lt;/a&gt; pectoris&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Murakami%20%20%5BAU%5D%20AND%201999%20%5BDP%5D%20AND%20%20Am%20J%20Cardiol%20%20%5BTA%5D" class="LinkRef"&gt;Murakami (1999) Am J Cardiol 84:92-4&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/DM/InslnRstncSyndrm.htm" class="LinkPage"&gt;Insulin Resistance Syndrome&lt;/a&gt;s (experimental)&lt;ol&gt;&lt;li&gt;&lt;a href="../../Gyn/Endo/PlycystcOvryDs.htm" class="LinkPage"&gt;Polycystic Ovary Syndrome&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Derm/Hyperplasia/Psrs.htm" class="LinkPage"&gt;Psoriasis&lt;/a&gt; (experimental)&lt;ol&gt;&lt;li&gt;Thiazolidinediones activate PPARs&lt;ol&gt;&lt;li&gt;Peroxisome proliferator-activated receptors (PPARs)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;PPARs have antiinflammatory activity in &lt;a href="../../Derm/Hyperplasia/Psrs.htm" class="LinkPage"&gt;Psoriasis&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Ellis%20%20%5BAU%5D%20AND%202000%20%5BDP%5D%20AND%20%20Arch%20Dermatol%20%20%5BTA%5D" class="LinkRef"&gt;Ellis (2000) Arch Dermatol 136(5):609-16&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Contraindications&lt;ol&gt;&lt;li&gt;&lt;a href="../../GI/Anatomy/LvrAntmy.htm" class="LinkPage"&gt;Liver&lt;/a&gt; disease (ALT &amp;gt; 2.5x upper limit of normal)&lt;/li&gt;&lt;li&gt;CHF NYA Class III or Class IV &lt;a href="../../CV/CHF/CngstvHrtFlr.htm" class="LinkPage"&gt;Heart Failure&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Precautions&lt;ol&gt;&lt;li&gt;CHF exacerbation risk (and contraindicated for &lt;a href="../../CV/CHF/NyhHrtFlrClsfctn.htm" class="LinkPage"&gt;NYHA Class&lt;/a&gt; III or IV) for ALL Glitazones (FDA Black Box warning)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Mechanism&lt;ol&gt;&lt;li&gt;Thiazolidinedione derivative&lt;/li&gt;&lt;li&gt;Primary mechanism: Increases peripheral tissue &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; sensitivity&lt;/li&gt;&lt;li&gt;Secondary mechanism: Decreases hepatic &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; production&lt;/li&gt;&lt;li&gt;Acts at liver, skeletal muscle and fat cells&lt;/li&gt;&lt;li&gt;Activates peroxisome proliferator activated receptors&lt;ol&gt;&lt;li&gt;Receptors known as PPARS&lt;/li&gt;&lt;li&gt;Reduces &lt;a href="../../Endo/DM/InslnRstncSyndrm.htm" class="LinkPage"&gt;Insulin Resistance&lt;/a&gt;&lt;/li&gt;&lt;li&gt;May independently reduce cardiovascular risk&lt;/li&gt;&lt;li&gt;Increases &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; uptake&lt;/li&gt;&lt;li&gt;Decreases hepatic &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; output&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Shifts fat deposition from visceral to subcutaneous&lt;/li&gt;&lt;li&gt;Decreases free &lt;a href="../../Pharm/Nutrition/FtyAcd.htm" class="LinkPage"&gt;Fatty Acid&lt;/a&gt; levels&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Adverse Effects&lt;ol&gt;&lt;li&gt;Hepatotoxicity and &lt;a href="../../GI/Anatomy/LvrAntmy.htm" class="LinkPage"&gt;Liver&lt;/a&gt; Failure&lt;ol&gt;&lt;li&gt;Associated with Troglitazone use&lt;/li&gt;&lt;li&gt;Troglitazone removed from U.S. market in March 2000&lt;/li&gt;&lt;li&gt;Rosiglitazone and Pioglitazone may also cause&lt;/li&gt;&lt;li&gt;Follow &lt;a href="../../GI/Lab/LvrFnctnTst.htm" class="LinkPage"&gt;Liver Function Test&lt;/a&gt;s closely&lt;ol&gt;&lt;li&gt;Especially follow in first year&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;References&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=May%20%20%5BAU%5D%20AND%202002%20%5BDP%5D%20AND%20%20Ann%20Intern%20Med%20%20%5BTA%5D" class="LinkRef"&gt;May (2002) Ann Intern Med 136:449-52&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Fluid retention&lt;ol&gt;&lt;li&gt;&lt;a href="../../CV/CHF/CngstvHrtFlr.htm" class="LinkPage"&gt;Congestive Heart Failure&lt;/a&gt; risk (see below)&lt;/li&gt;&lt;li&gt;Peripheral edema (in 3-5% of patients)&lt;/li&gt;&lt;li&gt;Moderate weight gain (1-3 kg)&lt;/li&gt;&lt;li&gt;Mild &lt;a href="../../HemeOnc/Anemia/Anm.htm" class="LinkPage"&gt;Anemia&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Variable lipid effects&lt;ol&gt;&lt;li&gt;Pioglitazone (Actos)&lt;ol&gt;&lt;li&gt;Lowers &lt;a href="../../CV/Lab/Trglycrd.htm" class="LinkPage"&gt;Triglyceride&lt;/a&gt;s by 9-12%&lt;/li&gt;&lt;li&gt;Raises &lt;a href="../../CV/Lab/HdlChlstrl.htm" class="LinkPage"&gt;HDL Cholesterol&lt;/a&gt; by 12-19%&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Rosiglitazone (Avandia):&lt;ol&gt;&lt;li&gt;RAISES &lt;a href="../../CV/Lab/Trglycrd.htm" class="LinkPage"&gt;Triglyceride&lt;/a&gt;s by 15%&lt;/li&gt;&lt;li&gt;Raises &lt;a href="../../CV/Lab/HdlChlstrl.htm" class="LinkPage"&gt;HDL Cholesterol&lt;/a&gt; by 8-19%&lt;/li&gt;&lt;li&gt;Raises &lt;a href="../../CV/Lab/LdlChlstrl.htm" class="LinkPage"&gt;LDL Cholesterol&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;References&lt;ol&gt;&lt;li&gt;(2005) Prescriber's Letter 12(8):43&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Risks of adverse effects compounded with &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Weight gain (3-4 kg)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Renal/Edema/Edm.htm" class="LinkPage"&gt;Edema&lt;/a&gt; (8-10% of cases)&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/CHF/CngstvHrtFlr.htm" class="LinkPage"&gt;Congestive Heart Failure&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Observe patients with CHF risk closely&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Hypoglycemia/Hypglycm.htm" class="LinkPage"&gt;Hypoglycemia&lt;/a&gt; risk&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Decrease Bone Density (&lt;a href="../../Rheum/Bone/Ostprs.htm" class="LinkPage"&gt;Osteoporosis&lt;/a&gt; risk)&lt;ol&gt;&lt;li&gt;Class effect&lt;/li&gt;&lt;li&gt;Odds Ratio approaches 2.5 for Glitazone use &amp;gt;8 months&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=2008%20%5BDP%5D%20AND%20%20Arch%20Intern%20Med%20%20%5BTA%5D%20AND%20168%20%5BVI%5D%20AND%20820%20%5BPG%5D" class="LinkRef"&gt;(2008) Arch Intern Med 168:820-5&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Cardiovascular risk&lt;ol&gt;&lt;li&gt;Rosiglitazone (Avandia) appears to increase CAD risk&lt;ol&gt;&lt;li&gt;No longer recommended as a first-line agent&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Pioglitazone (Actos) may slightly decrease CAD risk&lt;ol&gt;&lt;li&gt;Atherosclerosis may be slowed by Actos&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Nissen%20%20%5BAU%5D%20AND%202008%20%5BDP%5D%20AND%20%20JAMA%20%20%5BTA%5D" class="LinkRef"&gt;Nissen (2008) JAMA 299(13):1561-73&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Preparations: Pioglitazone&lt;ol&gt;&lt;li&gt;Preferred of the Glitazones due to vascular disease risk increase with Rosiglitazone&lt;/li&gt;&lt;li&gt;Protocol&lt;ol&gt;&lt;li&gt;Discontinue if no improvement in 8-12 weeks&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Dosing&lt;ol&gt;&lt;li&gt;Initial: 15 to 30 mg orally daily&lt;/li&gt;&lt;li&gt;Maximum: 45 mg per day&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Preparations: Rosiglitazone (use only with caution)&lt;ol&gt;&lt;li&gt;Precautions&lt;ol&gt;&lt;li&gt;Limited use now due to increased cardiovascular risk&lt;/li&gt;&lt;li&gt;FDA has restricted further Rosiglitazone use to those with refractory &lt;a href="../../Endo/DM/TypDbtsMlts1.htm" class="LinkPage"&gt;Type II Diabetes&lt;/a&gt; on other agents&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Conversion to Pioglitazone&lt;ol&gt;&lt;li&gt;Rosiglitazone 2 mg is equivalent to Pioglitazone 15 mg&lt;/li&gt;&lt;li&gt;Rosiglitazone 4 mg is equivalent to Pioglitazone 30 mg&lt;/li&gt;&lt;li&gt;Rosiglitazone 8 mg is equivalent to Pioglitazone 45 mg&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Rosiglitazone (Avandia)&lt;ol&gt;&lt;li&gt;Initial: 4 mg PO qd (or 2 mg PO bid)&lt;/li&gt;&lt;li&gt;Maximum: 8 mg per day (4 mg if on &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt;)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Pharmacokinetics&lt;ol&gt;&lt;li&gt;Hepatic metabolism by Cytochrome P450: CYP2C8&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Monitoring&lt;ol&gt;&lt;li&gt;&lt;a href="../../GI/Lab/LvrFnctnTst.htm" class="LinkPage"&gt;Liver Function Test&lt;/a&gt;s&lt;ol&gt;&lt;li&gt;Initial: Baseline and in 6-12 weeks&lt;/li&gt;&lt;li&gt;Later: Every 6 months&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Do not start medication if LFTs &amp;gt; 2.5x normal&lt;/li&gt;&lt;li&gt;Stop medication if LFTs &amp;gt;3x normal&lt;/li&gt;&lt;li&gt;Follow weight for weight gain (esp. if CHF risk)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Efficacy&lt;ol&gt;&lt;li&gt;Add to &lt;a href="../../Endo/Pharm/Glcphg.htm" class="LinkPage"&gt;Metformin&lt;/a&gt;, &lt;a href="../../Endo/Pharm/Slfnylr.htm" class="LinkPage"&gt;Sulfonylurea&lt;/a&gt; - delays &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; need&lt;/li&gt;&lt;li&gt;References&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Aljabri%20%20%5BAU%5D%20AND%202004%20%5BDP%5D%20AND%20%20Am%20J%20Med%20%20%5BTA%5D" class="LinkRef"&gt;Aljabri (2004) Am J Med 116:230-5&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Dailey%20%20%5BAU%5D%20AND%202004%20%5BDP%5D%20AND%20%20Am%20J%20Med%20%20%5BTA%5D" class="LinkRef"&gt;Dailey (2004) Am J Med 116:223-9&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Cost&lt;ol&gt;&lt;li&gt;Expensive! (Up to $175 to $192 per month)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=(1999)%20Med%20Lett%20Drugs%20Ther%2041%20%5BAU%5D%20AND%201059%20%5BDP%5D%20AND%20:%20%5BTA%5D" class="LinkRef"&gt;(1999) Med Lett Drugs Ther 41(1059):71-3&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Krische%20%20%5BAU%5D%20AND%202000%20%5BDP%5D%20AND%20%20West%20J%20Med%20%20%5BTA%5D" class="LinkRef"&gt;Krische (2000) West J Med 173:54-7&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Schwartz%20%20%5BAU%5D%20AND%201998%20%5BDP%5D%20AND%20%20N%20Engl%20J%20Med%20%20%5BTA%5D" class="LinkRef"&gt;Schwartz (1998) N Engl J Med 338:861-6&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Saltiel%20%20%5BAU%5D%20AND%201996%20%5BDP%5D%20AND%20%20Diabetes%20%20%5BTA%5D" class="LinkRef"&gt;Saltiel (1996) Diabetes 45:1661-9&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0875967</value><value>C1257987</value><value>C0245514</value><value>C0071097</value><value>C0289313</value><value>C0701265</value><value>C0875954</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Pharm/Thzldndn.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Thiazolidinedione, Glitazone, Rosiglitazone, Avandia, Pioglitazone, Actos, Troglitazone, Rezulin</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Pharm/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Hypoglycemic Agents  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0020616"&gt;&lt;i&gt;C0020616&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MEDLINEPLUS)&lt;/td&gt;
                &lt;td&gt;
                  &lt;span&gt;
                    &lt;p&gt;
                      &lt;a href="http://www.nlm.nih.gov/medlineplus/diabetes.html"&gt;Diabetes&lt;/a&gt; means your blood glucose, or blood sugar, is too high. If you can't control your diabetes with wise food choices and physical activity, you may need diabetes medicines. The kind of medicine you take depends on your type of diabetes, your schedule, and your other health conditions. &lt;/p&gt;
                    &lt;p&gt;With &lt;a href="http://www.nlm.nih.gov/medlineplus/diabetestype1.html"&gt;Type 1 diabetes&lt;/a&gt;, your pancreas does not make insulin. Insulin is a hormone that helps glucose get into your cells to give them energy. Without insulin, too much glucose stays in your blood. If you have type 1 diabetes, you will need to take insulin. &lt;/p&gt;
                    &lt;p&gt;Type 2 diabetes, the most common type, can start when the body doesn't use insulin as it should. If your body can't keep up with the need for insulin, you may need to take pills.  Some people need both insulin and pills. Along with meal planning and physical activity, diabetes pills help people with type 2 diabetes or gestational diabetes keep their blood glucose levels on target. Several kinds of pills are available. Each works in a different way. Many people take two or three kinds of pills. Some people take combination pills. Combination pills contain two kinds of diabetes medicine in one tablet. Some people take pills and insulin.&lt;/p&gt;
                    &lt;p style="font-weight:bold;font-style:italic;"&gt;NIH: National Institute of Diabetes and Digestive and Kidney Diseases&lt;/p&gt;
                  &lt;/span&gt;
                &lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;Substances which lower blood glucose levels.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CSP)&lt;/td&gt;
                &lt;td&gt;class of agents which lower blood glucose levels.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Pharmacologic Substance (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0020616&amp;amp;tui=T121"&gt;&lt;i&gt;T121&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D007004&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;325290009, 373299009, 9356005, 312064005&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Agents, Hypoglycemic, Hypoglycemic Agents, hypoglycemic agent, Hypoglycemic agents, Drugs, Hypoglycemic, Hypoglycemic Drugs, Hypoglycemic drug, Hypoglycemics, Drugs for hypoglycaemia, Drugs for hypoglycemia, Hypoglycemic drug, NOS, Hypoglycaemic drug, NOS, Drugs for hypoglycemia (product), antihyperglycemic, Hypoglycaemic drug, Anti-hyperglycemics, hypoglycemic drugs, hypoglycemic agents, hypoglycaemic, hypoglycemic, hypoglycemic drug, Diabetes Medicines, Hypoglycemic Medicines, Agents, Antihyperglycemic, Antihyperglycemic Agents, Antihyperglycemics, Hypoglycaemic, Hypoglycemic agent (substance), Hypoglycemic, Hypoglycaemic agent, Hypoglycemic agent, Hypoglycaemic product, Hypoglycemic agent (product), Hypoglycemic product, Drugs for hypoglycemia (substance), Hypoglycemic drug (substance), Hypoglycemic product (product)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Agents hypoglycémiques, Agents hypoglycémiants, Médicaments hypoglycémiants, Médicaments hypoglycémiques, Hypoglycémiants&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Hypoglykemiska medel&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;fármacos para el tratamiento de la hipoglucemia, fármacos para el tratamiento de la hipoglucemia (producto), agente hipoglucemiante (sustancia), agente hipoglucemiante, droga hipoglucemiante (producto), droga hipoglucemiante (sustancia), droga hipoglucemiante, fármaco hipoglucemiante (producto), fármaco hipoglucemiante, hipoglucemiante (producto), hipoglucemiante, Agentes Hipoglucemicos, Agentes Hipoglucémicos&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;hypoglykemika&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Verensokeria alentavat aineet&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Ipoglicemici, Farmaci ipoglicemici, Sostanze ipoglicemiche&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;PROTIVODIABETICHESKIE SREDSTVA, ANTIDIABETICHESKIE SREDSTVA, GIPOGLIKEMICHESKIE SREDSTVA, АНТИДИАБЕТИЧЕСКИЕ СРЕДСТВА, ГИПОГЛИКЕМИЧЕСКИЕ СРЕДСТВА, ПРОТИВОДИАБЕТИЧЕСКИЕ СРЕДСТВА&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;血糖降下薬, 経口抗糖尿病薬, 抗糖尿病薬, 糖尿病薬, 糖尿病治療剤, 抗糖尿病剤, 血糖降下剤, 経口血糖降下薬&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Croatian&lt;/td&gt;
                &lt;td&gt;ANTIDIJABETICI&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Leki hipoglikemizujące, Czynniki hipoglikemizujące, Środki przeciwcukrzycowe, Środki hipoglikemiczne&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Blutzuckersenkende Mittel&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Hipoglicêmicos&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Hypoglycemic Agents  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Oral Hypoglycemic</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Pharmacology</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Preparations&lt;ol&gt;&lt;li&gt;General&lt;ol&gt;&lt;li&gt;Lifestyle changes can lower A1C by 1-2%&lt;/li&gt;&lt;li&gt;Efficacy Example: Weight loss, diet and &lt;a href="../../Sports/Exercise/Exrcs.htm" class="LinkPage"&gt;Exercise&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Pre-intervention: &lt;a href="../../Endo/Lab/HmglbnAc.htm" class="LinkPage"&gt;HBA1C&lt;/a&gt; is 10%&lt;/li&gt;&lt;li&gt;Post-intervention: &lt;a href="../../Endo/Lab/HmglbnAc.htm" class="LinkPage"&gt;HBA1C&lt;/a&gt; might drop to 8-9%&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; is very cost effective (consider early especially if  &lt;a href="../../Endo/Lab/HmglbnAc.htm" class="LinkPage"&gt;Hemoglobin A1C&lt;/a&gt;&amp;gt;9%)&lt;ol&gt;&lt;li&gt;Lowers &lt;a href="../../Endo/Lab/HmglbnAc.htm" class="LinkPage"&gt;HBA1C&lt;/a&gt; an unlimited amount&lt;/li&gt;&lt;li&gt;Can be used with &lt;a href="../../Endo/DM/InslnRstncSyndrm.htm" class="LinkPage"&gt;Insulin Resistance&lt;/a&gt; agents&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Thzldndn.htm" class="LinkPage"&gt;Thiazolidinedione&lt;/a&gt;s (e.g. &lt;a href="../../Endo/Pharm/Thzldndn.htm" class="LinkPage"&gt;Rosiglitazone&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Glcphg.htm" class="LinkPage"&gt;Metformin&lt;/a&gt; (&lt;a href="../../Endo/Pharm/Glcphg.htm" class="LinkPage"&gt;Glucophage&lt;/a&gt;)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Start with basal &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; (e.g. &lt;a href="../../Endo/Pharm/AnlgBslInsln.htm" class="LinkPage"&gt;Insulin Glargine&lt;/a&gt; or &lt;a href="../../Endo/Pharm/AnlgBslInsln.htm" class="LinkPage"&gt;Lantus&lt;/a&gt;)&lt;ol&gt;&lt;li&gt;Basal &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; can be used with Oral Hypoglycemics&lt;ol&gt;&lt;li&gt;Includes &lt;a href="../../Endo/Pharm/Slfnylr.htm" class="LinkPage"&gt;Sulfonylurea&lt;/a&gt;s (cautiously)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Add bolus &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; (e.g. &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt;&lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Lispro&lt;/a&gt;) if &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Hyperglycemia&lt;/a&gt; persists (especially if post-prandial)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Slfnylr.htm" class="LinkPage"&gt;Insulin Secretagogue&lt;/a&gt;s (early &lt;a href="../../Endo/DM/TypDbtsMlts1.htm" class="LinkPage"&gt;Type II Diabetes&lt;/a&gt;)&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/ScndGnrtnSlfnylr.htm" class="LinkPage"&gt;Second Generation Sulfonylurea&lt;/a&gt; (e.g. &lt;a href="../../Endo/Pharm/ScndGnrtnSlfnylr.htm" class="LinkPage"&gt;Glipizide&lt;/a&gt;, Glimepiride; avoid &lt;a href="../../Endo/Pharm/ScndGnrtnSlfnylr.htm" class="LinkPage"&gt;Glyburide&lt;/a&gt;)&lt;ol&gt;&lt;li&gt;Lowers &lt;a href="../../Endo/Lab/HmglbnAc.htm" class="LinkPage"&gt;HBA1C&lt;/a&gt; by 1.5%&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/NnSlfnylrInslnScrtgs.htm" class="LinkPage"&gt;Meglitinide&lt;/a&gt;s (e.g. &lt;a href="../../Endo/Pharm/NnSlfnylrInslnScrtgs.htm" class="LinkPage"&gt;Nateglinide&lt;/a&gt;, &lt;a href="../../Endo/Pharm/NnSlfnylrInslnScrtgs.htm" class="LinkPage"&gt;Repaglinide&lt;/a&gt;)&lt;ol&gt;&lt;li&gt;More expensive alternative to &lt;a href="../../Endo/Pharm/Slfnylr.htm" class="LinkPage"&gt;Sulfonylurea&lt;/a&gt;s&lt;/li&gt;&lt;li&gt;Lowers &lt;a href="../../Endo/Lab/HmglbnAc.htm" class="LinkPage"&gt;HBA1C&lt;/a&gt; by 0.5 to 1%&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Incretin Agents&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Stglptn.htm" class="LinkPage"&gt;DPP-4 Inhibitor&lt;/a&gt;s (e.g. &lt;a href="../../Endo/Pharm/Stglptn.htm" class="LinkPage"&gt;Sitagliptin&lt;/a&gt;, Saxagliptin, Linagliptin)&lt;ol&gt;&lt;li&gt;Inhibits incretin degradation resulting in &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; secretion&lt;/li&gt;&lt;li&gt;Lowers &lt;a href="../../Endo/Lab/HmglbnAc.htm" class="LinkPage"&gt;HBA1C&lt;/a&gt; by 0.5 to 1%&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/IncrtnMmtc.htm" class="LinkPage"&gt;GLP-1&lt;/a&gt; Agonists (e.g. &lt;a href="../../Endo/Pharm/IncrtnMmtc.htm" class="LinkPage"&gt;Exenatide&lt;/a&gt;)&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/IncrtnMmtc.htm" class="LinkPage"&gt;Incretin Mimetic&lt;/a&gt; that binds &lt;a href="../../Endo/Pharm/IncrtnMmtc.htm" class="LinkPage"&gt;GLP-1&lt;/a&gt; receptors and stimulates &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; release&lt;/li&gt;&lt;li&gt;Facilitates weight loss&lt;/li&gt;&lt;li&gt;Lowers &lt;a href="../../Endo/Lab/HmglbnAc.htm" class="LinkPage"&gt;HBA1C&lt;/a&gt; by 1 to 1.5%&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/DM/InslnRstncSyndrm.htm" class="LinkPage"&gt;Insulin Resistance&lt;/a&gt; Agents&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Glcphg.htm" class="LinkPage"&gt;Biguanide&lt;/a&gt;s (e.g. &lt;a href="../../Endo/Pharm/Glcphg.htm" class="LinkPage"&gt;Metformin&lt;/a&gt; or &lt;a href="../../Endo/Pharm/Glcphg.htm" class="LinkPage"&gt;Glucophage&lt;/a&gt;)&lt;ol&gt;&lt;li&gt;Decreases hepatic &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; release&lt;/li&gt;&lt;li&gt;Lowers &lt;a href="../../Endo/Lab/HmglbnAc.htm" class="LinkPage"&gt;HBA1C&lt;/a&gt; by 1.5%&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Thzldndn.htm" class="LinkPage"&gt;Thiazolidinedione&lt;/a&gt;s (e.g. &lt;a href="../../Endo/Pharm/Thzldndn.htm" class="LinkPage"&gt;Pioglitazone&lt;/a&gt;)&lt;ol&gt;&lt;li&gt;Increases muscle and fat &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; sensitivity&lt;/li&gt;&lt;li&gt;May also independently reduce cardiovascular risk (especially &lt;a href="../../Endo/Pharm/Thzldndn.htm" class="LinkPage"&gt;Rosiglitazone&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;Lowers &lt;a href="../../Endo/Lab/HmglbnAc.htm" class="LinkPage"&gt;HBA1C&lt;/a&gt; by up to 1 to 1.5%&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; Absorption Agents&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/AlphGlcsdsInhbtr.htm" class="LinkPage"&gt;Alpha-glucosidase Inhibitor&lt;/a&gt;s (e.g. &lt;a href="../../Endo/Pharm/AlphGlcsdsInhbtr.htm" class="LinkPage"&gt;Acarbose&lt;/a&gt;)&lt;ol&gt;&lt;li&gt;Decreases gastrointestinal carbohydrate absorption&lt;/li&gt;&lt;li&gt;Lowers &lt;a href="../../Endo/Lab/HmglbnAc.htm" class="LinkPage"&gt;HBA1C&lt;/a&gt; by 0.5 to 1%&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Combination agents&lt;ol&gt;&lt;li&gt;Actoplus Met: &lt;a href="../../Endo/Pharm/Thzldndn.htm" class="LinkPage"&gt;Pioglitazone&lt;/a&gt; and &lt;a href="../../Endo/Pharm/Glcphg.htm" class="LinkPage"&gt;Metformin&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Duetact: &lt;a href="../../Endo/Pharm/Thzldndn.htm" class="LinkPage"&gt;Pioglitazone&lt;/a&gt; and Glimepiride&lt;/li&gt;&lt;li&gt;Janumet: &lt;a href="../../Endo/Pharm/Stglptn.htm" class="LinkPage"&gt;Sitagliptin&lt;/a&gt; and &lt;a href="../../Endo/Pharm/Glcphg.htm" class="LinkPage"&gt;Metformin&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Metaglip: &lt;a href="../../Endo/Pharm/ScndGnrtnSlfnylr.htm" class="LinkPage"&gt;Glipizide&lt;/a&gt; and &lt;a href="../../Endo/Pharm/Glcphg.htm" class="LinkPage"&gt;Metformin&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Avoid agents with increased risk&lt;ol&gt;&lt;li&gt;Glucovance contains &lt;a href="../../Endo/Pharm/ScndGnrtnSlfnylr.htm" class="LinkPage"&gt;Glyburide&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Avandamet and Avandaryl contain &lt;a href="../../Endo/Pharm/Thzldndn.htm" class="LinkPage"&gt;Rosiglitazone&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Protocol: Sample Template for Prescribing Combination Oral Agents&lt;ol&gt;&lt;li&gt;General&lt;ol&gt;&lt;li&gt;Use a combination of agents (consider from onset)&lt;/li&gt;&lt;li&gt;Treat &lt;a href="../../Endo/DM/InslnRstncSyndrm.htm" class="LinkPage"&gt;Insulin Resistance&lt;/a&gt; and &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; shortage&lt;/li&gt;&lt;li&gt;Lifestyle changes form the base of treatment&lt;ol&gt;&lt;li&gt;Weight loss with calorie restriction and daily activity&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Prevent/CrbhydrtCnt.htm" class="LinkPage"&gt;Carbohydrate Counting&lt;/a&gt; and awareness of its impact on &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; control&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Step 1: &lt;a href="../../Endo/Pharm/Glcphg.htm" class="LinkPage"&gt;Metformin&lt;/a&gt; (&lt;a href="../../Endo/Pharm/Glcphg.htm" class="LinkPage"&gt;Glucophage&lt;/a&gt;)&lt;ol&gt;&lt;li&gt;Most effective single agent in all patients&lt;/li&gt;&lt;li&gt;Previously a &lt;a href="../../Endo/Pharm/Slfnylr.htm" class="LinkPage"&gt;Sulfonylurea&lt;/a&gt; was considered first-line in lean patients (no longer the case)&lt;/li&gt;&lt;li&gt;Contraindicated in GFR &amp;lt;60 due to &lt;a href="../../Derm/Pharm/AlphHydrxyAcd.htm" class="LinkPage"&gt;Lactic Acid&lt;/a&gt;osis risk&lt;ol&gt;&lt;li&gt;However, there is some controversy as to what GFR level should contraindicate &lt;a href="../../Endo/Pharm/Glcphg.htm" class="LinkPage"&gt;Metformin&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Consider starting with a combination agent that includes &lt;a href="../../Endo/Pharm/Glcphg.htm" class="LinkPage"&gt;Metformin&lt;/a&gt; (e.g. Metaglip - &lt;a href="../../Endo/Pharm/Glcphg.htm" class="LinkPage"&gt;Metformin&lt;/a&gt; with &lt;a href="../../Endo/Pharm/ScndGnrtnSlfnylr.htm" class="LinkPage"&gt;Glipizide&lt;/a&gt;)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Step 2: Add second agent to &lt;a href="../../Endo/Pharm/Glcphg.htm" class="LinkPage"&gt;Metformin&lt;/a&gt;&lt;ol&gt;&lt;li&gt;See Step 3 for other agents to consider instead of &lt;a href="../../Endo/Pharm/Slfnylr.htm" class="LinkPage"&gt;Sulfonylurea&lt;/a&gt;s&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Slfnylr.htm" class="LinkPage"&gt;Sulfonylurea&lt;/a&gt; (e.g. &lt;a href="../../Endo/Pharm/ScndGnrtnSlfnylr.htm" class="LinkPage"&gt;Glipizide&lt;/a&gt;, Glimepiride)&lt;ol&gt;&lt;li&gt;Most cost effective second agent&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/NnSlfnylrInslnScrtgs.htm" class="LinkPage"&gt;Meglitinide&lt;/a&gt;s (e.g. &lt;a href="../../Endo/Pharm/NnSlfnylrInslnScrtgs.htm" class="LinkPage"&gt;Repaglinide&lt;/a&gt;) may be used as alternative (but more expensive)&lt;ol&gt;&lt;li&gt;Consider for as needed pre-meal dosing in post-prandial &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Hyperglycemia&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Step 3: Add third agent&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Thzldndn.htm" class="LinkPage"&gt;Thiazolidinedione&lt;/a&gt;s (e.g. &lt;a href="../../Endo/Pharm/Thzldndn.htm" class="LinkPage"&gt;Pioglitazone&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;Incretin agent (choose one)&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Stglptn.htm" class="LinkPage"&gt;Sitagliptin&lt;/a&gt; (&lt;a href="../../Endo/Pharm/Stglptn.htm" class="LinkPage"&gt;Januvia&lt;/a&gt;): Oral&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/IncrtnMmtc.htm" class="LinkPage"&gt;Exenatide&lt;/a&gt; (&lt;a href="../../Endo/Pharm/IncrtnMmtc.htm" class="LinkPage"&gt;Byetta&lt;/a&gt;): Twice daily injection, but more effective and facilitates weight loss&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Basal &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; (e.g. &lt;a href="../../Endo/Pharm/AnlgBslInsln.htm" class="LinkPage"&gt;Insulin Glargine&lt;/a&gt; or &lt;a href="../../Endo/Pharm/AnlgBslInsln.htm" class="LinkPage"&gt;Lantus&lt;/a&gt;)&lt;ol&gt;&lt;li&gt;Consider for longer history of &lt;a href="../../Endo/DM/TypDbtsMlts1.htm" class="LinkPage"&gt;Type II Diabetes&lt;/a&gt; or if persistent &lt;a href="../../Endo/Lab/HmglbnAc.htm" class="LinkPage"&gt;HBA1C&lt;/a&gt; &amp;gt;9%&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Step 4: &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; for refractory &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Hyperglycemia&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Basal &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; (e.g. &lt;a href="../../Endo/Pharm/AnlgBslInsln.htm" class="LinkPage"&gt;Insulin Glargine&lt;/a&gt; or &lt;a href="../../Endo/Pharm/AnlgBslInsln.htm" class="LinkPage"&gt;Lantus&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;Bolus &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; or pre-meal &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; (e.g. &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Lispro&lt;/a&gt;)&lt;ol&gt;&lt;li&gt;Stop &lt;a href="../../Endo/Pharm/Slfnylr.htm" class="LinkPage"&gt;Sulfonylurea&lt;/a&gt; or &lt;a href="../../Endo/Pharm/NnSlfnylrInslnScrtgs.htm" class="LinkPage"&gt;Meglitinide&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Agents with greatest effect based on timing of &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Hyperglycemia&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Pre-meal fasting &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Hyperglycemia&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Slfnylr.htm" class="LinkPage"&gt;Sulfonylurea&lt;/a&gt; (most of effect is on pre-meal &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/DM/InslnRstncSyndrm.htm" class="LinkPage"&gt;Insulin Resistance&lt;/a&gt; agents&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Glcphg.htm" class="LinkPage"&gt;Glucophage&lt;/a&gt; (&lt;a href="../../Endo/Pharm/Glcphg.htm" class="LinkPage"&gt;Metformin&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Thzldndn.htm" class="LinkPage"&gt;Thiazolidinedione&lt;/a&gt;s (e.g. &lt;a href="../../Endo/Pharm/Thzldndn.htm" class="LinkPage"&gt;Rosiglitazone&lt;/a&gt;)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Postprandial &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Hyperglycemia&lt;/a&gt; (&lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; deficiency)&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/NnSlfnylrInslnScrtgs.htm" class="LinkPage"&gt;Meglitinide&lt;/a&gt;s (e.g. &lt;a href="../../Endo/Pharm/NnSlfnylrInslnScrtgs.htm" class="LinkPage"&gt;Repaglinide&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/AlphGlcsdsInhbtr.htm" class="LinkPage"&gt;Alpha-glucosidase Inhibitor&lt;/a&gt;s&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Agents with greatest effect based on body habitus&lt;ol&gt;&lt;li&gt;Obese patients&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Glcphg.htm" class="LinkPage"&gt;Metformin&lt;/a&gt; (&lt;a href="../../Endo/Pharm/Glcphg.htm" class="LinkPage"&gt;Glucophage&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Thzldndn.htm" class="LinkPage"&gt;Thiazolidinedione&lt;/a&gt;s (e.g. &lt;a href="../../Endo/Pharm/Thzldndn.htm" class="LinkPage"&gt;Rosiglitazone&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/IncrtnMmtc.htm" class="LinkPage"&gt;Exenatide&lt;/a&gt; (&lt;a href="../../Endo/Pharm/IncrtnMmtc.htm" class="LinkPage"&gt;Byetta&lt;/a&gt;)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Lean patients&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Slfnylr.htm" class="LinkPage"&gt;Sulfonylurea&lt;/a&gt; (e.g. &lt;a href="../../Endo/Pharm/ScndGnrtnSlfnylr.htm" class="LinkPage"&gt;Glipizide&lt;/a&gt;) or &lt;a href="../../Endo/Pharm/NnSlfnylrInslnScrtgs.htm" class="LinkPage"&gt;Meglitinide&lt;/a&gt; (e.g. &lt;a href="../../Endo/Pharm/NnSlfnylrInslnScrtgs.htm" class="LinkPage"&gt;Repaglinide&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Stglptn.htm" class="LinkPage"&gt;Sitagliptin&lt;/a&gt; (&lt;a href="../../Endo/Pharm/Stglptn.htm" class="LinkPage"&gt;Januvia&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Adverse Effects: Oral Agents&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Hypoglycemia/Hypglycm.htm" class="LinkPage"&gt;Hypoglycemia&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Higher risk with &lt;a href="../../Endo/Pharm/Slfnylr.htm" class="LinkPage"&gt;Sulfonylurea&lt;/a&gt;s (especially &lt;a href="../../Endo/Pharm/ScndGnrtnSlfnylr.htm" class="LinkPage"&gt;Glyburide&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;Associated with Diabetics on &lt;a href="../../CV/Pharm/AcInhbtr.htm" class="LinkPage"&gt;ACE Inhibitor&lt;/a&gt;s&lt;/li&gt;&lt;li&gt;Higher risk with &lt;a href="../../CV/Pharm/AcInhbtr.htm" class="LinkPage"&gt;Captopril&lt;/a&gt; than &lt;a href="../../CV/Pharm/AcInhbtr.htm" class="LinkPage"&gt;Enalapril&lt;/a&gt;&lt;/li&gt;&lt;li&gt;May account for 14% DM admissions for &lt;a href="../../Endo/Hypoglycemia/Hypglycm.htm" class="LinkPage"&gt;Hypoglycemia&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Weight gain&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Slfnylr.htm" class="LinkPage"&gt;Sulfonylurea&lt;/a&gt;s&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Gastrointestinal side effects&lt;ol&gt;&lt;li&gt;Metfiormin (&lt;a href="../../Endo/Pharm/Glcphg.htm" class="LinkPage"&gt;Glucophage&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/AlphGlcsdsInhbtr.htm" class="LinkPage"&gt;Alpha-glucosidase Inhibitor&lt;/a&gt;s (&lt;a href="../../Endo/Pharm/AlphGlcsdsInhbtr.htm" class="LinkPage"&gt;Acarbose&lt;/a&gt;, &lt;a href="../../Endo/Pharm/AlphGlcsdsInhbtr.htm" class="LinkPage"&gt;Miglitol&lt;/a&gt;)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Derm/Pharm/AlphHydrxyAcd.htm" class="LinkPage"&gt;Lactic Acid&lt;/a&gt;osis&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Glcphg.htm" class="LinkPage"&gt;Metformin&lt;/a&gt; (&lt;a href="../../Endo/Pharm/Glcphg.htm" class="LinkPage"&gt;Glucophage&lt;/a&gt;)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../GI/Anatomy/LvrAntmy.htm" class="LinkPage"&gt;Liver&lt;/a&gt; toxicity&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Thzldndn.htm" class="LinkPage"&gt;Thiazolidinedione&lt;/a&gt;s (e.g. &lt;a href="../../Endo/Pharm/Thzldndn.htm" class="LinkPage"&gt;Actos&lt;/a&gt; or &lt;a href="../../Endo/Pharm/Thzldndn.htm" class="LinkPage"&gt;Avandia&lt;/a&gt;)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Renal/Edema/Edm.htm" class="LinkPage"&gt;Edema&lt;/a&gt; (avoid in &lt;a href="../../CV/CHF/CngstvHrtFlr.htm" class="LinkPage"&gt;Congestive Heart Failure&lt;/a&gt;)&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Thzldndn.htm" class="LinkPage"&gt;Thiazolidinedione&lt;/a&gt;s (e.g. &lt;a href="../../Endo/Pharm/Thzldndn.htm" class="LinkPage"&gt;Actos&lt;/a&gt; or &lt;a href="../../Endo/Pharm/Thzldndn.htm" class="LinkPage"&gt;Avandia&lt;/a&gt;)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;(2012) Diabetes Care 35(suppl 1): s11-63&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Luna%20%20%5BAU%5D%20AND%202001%20%5BDP%5D%20AND%20%20Am%20Fam%20Physician%20%20%5BTA%5D" class="LinkRef"&gt;Luna (2001) Am Fam Physician 63(9):1747-56ces&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Yki-Jarvinen%20%20%5BAU%5D%20AND%202001%20%5BDP%5D%20AND%20%20%20%5BTA%5D" class="LinkRef"&gt;Yki-Jarvinen (2001) 24:758-67&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Resources&lt;ol&gt;&lt;li&gt;&lt;a href="http://care.diabetesjournals.org/content/35/Supplement_1" class="LinkWebExt"&gt;http://care.diabetesjournals.org/content/35/Supplement_1&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0020616</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Pharm/OrlHypglycmc.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Oral Hypoglycemic, Oral Medications for Type 2 Diabetes</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Pharm/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Januvia  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C1702177"&gt;&lt;i&gt;C1702177&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Organic Chemical (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C1702177&amp;amp;tui=T109"&gt;&lt;i&gt;T109&lt;/i&gt;&lt;/a&gt;)
, Pharmacologic Substance (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C1702177&amp;amp;tui=T121"&gt;&lt;i&gt;T121&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;C496398&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Januvia&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;sitagliptin  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C1565750"&gt;&lt;i&gt;C1565750&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Organic Chemical (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C1565750&amp;amp;tui=T109"&gt;&lt;i&gt;T109&lt;/i&gt;&lt;/a&gt;)
, Pharmacologic Substance (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C1565750&amp;amp;tui=T121"&gt;&lt;i&gt;T121&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;C496398&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;424106006, 423307000&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;4-oxo-4-(3-(trifluoromethyl)-5,6-dihydro(1,2,4)triazolo(4,3-a)pyrazin-7(8H)-yl)-1-(2,4,5-trifluorophenyl)butan-2-amine, sitagliptin, Sitagliptin (product), Sitagliptin, Sitagliptin (substance), SITAGLIPTIN, sitagliptin [Chemical/Ingredient], sitaGLIPtin&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;sitagliptina (producto), sitagliptina, sitagliptina (sustancia)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Januvia  (</value><value>)
</value><value>sitagliptin  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Sitagliptin</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Pharmacology</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;See Also&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/IncrtnMmtc.htm" class="LinkPage"&gt;Incretin Mimetic&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/IncrtnMmtc.htm" class="LinkPage"&gt;Byetta&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Indications&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/DM/TypDbtsMlts1.htm" class="LinkPage"&gt;Type II Diabetes Mellitus&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; deficiency and &lt;a href="../../Endo/DM/InslnRstncSyndrm.htm" class="LinkPage"&gt;Insulin Resistance&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Adjunct to &lt;a href="../../Endo/Pharm/Glcphg.htm" class="LinkPage"&gt;Glucophage&lt;/a&gt;, &lt;a href="../../Endo/Pharm/Slfnylr.htm" class="LinkPage"&gt;Sulfonylurea&lt;/a&gt;s, &lt;a href="../../Endo/Pharm/Thzldndn.htm" class="LinkPage"&gt;Glitazone&lt;/a&gt;s&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Contraindications&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/DM/TypDbtsMlts.htm" class="LinkPage"&gt;Type I Diabetes Mellitus&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Concurrent &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; use&lt;/li&gt;&lt;li&gt;Prior history of malignancy&lt;ol&gt;&lt;li&gt;Due to increased risk of cancer invasion and metastases&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Women of child bearing age (relative contraindication)&lt;ol&gt;&lt;li&gt;&lt;a href="../../OB/Fetus/TrtgnExpsr.htm" class="LinkPage"&gt;Teratogen&lt;/a&gt;icity risk&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Adverse Effects&lt;ol&gt;&lt;li&gt;&lt;a href="../../GI/Pancreas/ActPncrts.htm" class="LinkPage"&gt;Acute Pancreatitis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Serious &lt;a href="../../ENT/Allergy/Anphylxs.htm" class="LinkPage"&gt;Allergic Reaction&lt;/a&gt; (Sitagliptin)&lt;ol&gt;&lt;li&gt;&lt;a href="../../ENT/Allergy/Anphylxs.htm" class="LinkPage"&gt;Anaphylaxis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../ENT/Derm/Angdm.htm" class="LinkPage"&gt;Angioedema&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Hepatotoxicity (Vildagliptin)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Mechanism&lt;ol&gt;&lt;li&gt;Blocks Dipeptidyl Peptidase-4 Inhibitor (DPP-4) allowing 2-3x accumulation of &lt;a href="../../Endo/Pharm/IncrtnMmtc.htm" class="LinkPage"&gt;GLP-1&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Differs from &lt;a href="../../Endo/Pharm/IncrtnMmtc.htm" class="LinkPage"&gt;Byetta&lt;/a&gt;: Weight neutral, no &lt;a href="../../GI/Sx/Vmtng.htm" class="LinkPage"&gt;Nausea&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Dosing: Sitagliptin&lt;ol&gt;&lt;li&gt;May be dosed with or without food&lt;/li&gt;&lt;li&gt;&lt;a href="../../Renal/Lab/CrtnClrnc.htm" class="LinkPage"&gt;Creatinine Clearance&lt;/a&gt; &amp;gt;50 ml/min: 100 mg once daily&lt;/li&gt;&lt;li&gt;&lt;a href="../../Renal/Lab/CrtnClrnc.htm" class="LinkPage"&gt;Creatinine Clearance&lt;/a&gt; 30-49 ml/min: 50 mg once daily&lt;/li&gt;&lt;li&gt;&lt;a href="../../Renal/Lab/CrtnClrnc.htm" class="LinkPage"&gt;Creatinine Clearance&lt;/a&gt; &amp;lt;30 ml/min: 25 mg once daily&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Efficacy&lt;ol&gt;&lt;li&gt;Lowers &lt;a href="../../Endo/Lab/HmglbnAc.htm" class="LinkPage"&gt;HBA1C&lt;/a&gt; 0.6%&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Jones%20%20%5BAU%5D%20AND%202007%20%5BDP%5D%20AND%20%20Am%20Fam%20Physician%20%20%5BTA%5D" class="LinkRef"&gt;Jones (2007) Am Fam Physician 75:1831-5&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C1702177</value><value>C1565750</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Pharm/Stglptn.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Sitagliptin, Januvia, DPP-4 Inhibitor, Dipeptidyl Peptidase-4 Inhibitor, DPP-4</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Pharm/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees></FP_UMLS_Trees><FP_Condition_name_check></FP_Condition_name_check><FP_Condition_name><value>Medication Causes of Hyperglycemia</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Pharmacology</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;See Also&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Hyperglycemia&lt;/a&gt; Causes&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Causes: Medications antagonizing action of &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Glucocorticoid&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Causes: Medications suppressing secretion of &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Potassium-wasting &lt;a href="../../CV/Pharm/Drtc.htm" class="LinkPage"&gt;Diuretic&lt;/a&gt;s&lt;ol&gt;&lt;li&gt;&lt;a href="../../CV/Pharm/ThzdDrtc.htm" class="LinkPage"&gt;Thiazide&lt;/a&gt; (&lt;a href="../../CV/Pharm/ThzdDrtc.htm" class="LinkPage"&gt;Hydrochlorothiazide&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Pharm/LpDrtc.htm" class="LinkPage"&gt;Loop Diuretic&lt;/a&gt;s (e.g. &lt;a href="../../CV/Pharm/LpDrtc.htm" class="LinkPage"&gt;Furosemide&lt;/a&gt; or &lt;a href="../../CV/Pharm/LpDrtc.htm" class="LinkPage"&gt;Lasix&lt;/a&gt;)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Neuro/Pharm/Phnytn.htm" class="LinkPage"&gt;Phenytoin&lt;/a&gt; (&lt;a href="../../Neuro/Pharm/Phnytn.htm" class="LinkPage"&gt;Dilantin&lt;/a&gt;)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Causes: Medications with miscellaneous activity&lt;ol&gt;&lt;li&gt;&lt;a href="../../HemeOnc/Pharm/Azthprn.htm" class="LinkPage"&gt;Azathioprine&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Pharm/ClcmChnlBlckr.htm" class="LinkPage"&gt;Calcium Channel Blocker&lt;/a&gt;s&lt;/li&gt;&lt;li&gt;Chemotherapeutic medications&lt;/li&gt;&lt;li&gt;Chlorpromazine&lt;/li&gt;&lt;li&gt;&lt;a href="../../GI/Pharm/HRcptrAntgnst.htm" class="LinkPage"&gt;Cimetidine&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Pharm/DrctActngVsdltr.htm" class="LinkPage"&gt;Diazoxide&lt;/a&gt; (&lt;a href="../../CV/Pharm/DrctActngVsdltr.htm" class="LinkPage"&gt;Hyperstat&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Psych/Pharm/Olnzpn.htm" class="LinkPage"&gt;Olanzapine&lt;/a&gt; (&lt;a href="../../Psych/Pharm/Olnzpn.htm" class="LinkPage"&gt;Zyprexa&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Pharm/Prprnl.htm" class="LinkPage"&gt;Propranolol&lt;/a&gt;&lt;/li&gt;&lt;li&gt;ACTH&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/Thyrxn.htm" class="LinkPage"&gt;Thyroxine&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Pharm/Epnphrn.htm" class="LinkPage"&gt;Epinephrine&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Morphine&lt;/li&gt;&lt;li&gt;Anesthetics&lt;/li&gt;&lt;li&gt;&lt;a href="../../Psych/CD/BnzdzpnAbs.htm" class="LinkPage"&gt;Tranquilizer&lt;/a&gt;s&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Pharm/MdctnCsOfHyprglycm.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Medication Causes of Hyperglycemia, Medications Affecting Glucose Control</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Pharm/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Insulin  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0021641"&gt;&lt;i&gt;C0021641&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CSP)&lt;/td&gt;
                &lt;td&gt;protein hormone secreted by beta cells of the pancreas; insulin plays a major role in the regulation of glucose metabolism, generally promoting the cellular utilization of glucose and is also an important regulator of protein and lipid metabolism; insulin is used as a drug to control insulin-dependent diabetes mellitus.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A short-acting form of insulin. Regular insulin is obtained from animal or recombinant sources. The onset of action of regular insulin occurs at 30-90 minutes after injection; its effect lasts for 6 to 8 hours. Endogenous human insulin, a pancreatic hormone composed of two polypeptide chains, is important for the normal metabolism of carbohydrates, proteins and fats; it has anabolic effects on many types of tissues. (NCI04)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;Human insulin protein (110 aa, 12 kDa) is encoded by the human insulin (INS) gene. This cytosolic protein, a heterodimer of disulfide-linked alpha and beta chains, is produced in pancreatic islet beta cells. Binding of insulin to its receptor stimulates glucose uptake, accelerates both glycolysis and the pentose phosphate cycle and increases glycogen synthesis in the liver. Insulin regulates protein and lipid metabolism. It also decreases blood glucose concentration by shuttling molecules into cells to be used for energy. Decreased expression of insulin protein causes familial hyperproinsulinemia.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1).&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Amino Acid, Peptide, or Protein (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0021641&amp;amp;tui=T116"&gt;&lt;i&gt;T116&lt;/i&gt;&lt;/a&gt;)
, Pharmacologic Substance (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0021641&amp;amp;tui=T121"&gt;&lt;i&gt;T121&lt;/i&gt;&lt;/a&gt;)
, Hormone (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0021641&amp;amp;tui=T125"&gt;&lt;i&gt;T125&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D007328&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;67866001, 39487003, 412222002&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Insulin, insulin, INSULIN PREPARATIONS, Insulin preparation, NOS, Regular Insulin, Regular insulin preparation, Unmodified insulin preparation, Insulin Regular, INSULIN, insulin preparations, insulin preparations (medication), A22 INSULIN PREPARATIONS, insulin regular, Insulin (ox), 8A-L-threonine-10A-L-isoleucine-30B-L-threonine-, Insulin [Chemical/Ingredient], [HS501] INSULIN, Insulin regular, insulin products, insulin preparation, insulin product, regular insulin, insulins, Insulin, Soluble, Soluble Insulin, Insulin, Regular, Insulin product, Insulin (substance), Insulin preparation, Insulin product (product), Regular insulin product, Unmodified insulin product, Insulin preparation (substance), Regular insulin (substance), Regular insulin&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Insulin&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;insulin, inzulin&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Insuliini&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Insuline ordinaire, Insuline&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;INSULIN, ИНСУЛИН&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;producto con insulina (producto), preparado insulínico, insulina (producto), producto con insulina, insulina (sustancia), insulina, preparado de insulina (producto), preparado de insulina (sustancia), preparado de insulina cristalina de cinc, preparado de insulina cristalina de zinc, preparado de insulina no modificada, preparado de insulina, insulina regular (sustancia), insulina regular, Insulina&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Insulina regolare, Insulina&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Croatian&lt;/td&gt;
                &lt;td&gt;INZULIN&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Insulina&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;インスリン, インスリン亜鉛水性懸濁液, インシュリン&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Insulin&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Insulina&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Insulin  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Insulin Simulation</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Pharmacology</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;See Also&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/InslnDsng.htm" class="LinkPage"&gt;Insulin Dosing&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Insulin Simulations from AIDA On-Line&lt;ol&gt;&lt;li&gt;AIDA Online Main Page&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.2aida.org/online" class="LinkWebExt"&gt;http://www.2aida.org/online&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Short-acting (Regular) &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; Example&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.2aida.org/aida/fast-track.htm" class="LinkWebExt"&gt;http://www.2aida.org/aida/fast-track.htm&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Long-acting &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; Example&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.2aida.org/aida/fast-track2.htm" class="LinkWebExt"&gt;http://www.2aida.org/aida/fast-track2.htm&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Pre-mixed (biphasic) 30/70 &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; Example&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.2aida.org/aida/fast-track3.htm" class="LinkWebExt"&gt;http://www.2aida.org/aida/fast-track3.htm&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Alternative Pre-mixed (biphasic) 30/70 &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; Example&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.2aida.org/aida/fast-track4.htm" class="LinkWebExt"&gt;http://www.2aida.org/aida/fast-track4.htm&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Pre-mixed (biphasic) 50/50 &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; Example&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.2aida.org/aida/fast-track5.htm" class="LinkWebExt"&gt;http://www.2aida.org/aida/fast-track5.htm&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Intermediate acting &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; Example&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.2aida.org/aida/fast-track6.htm" class="LinkWebExt"&gt;http://www.2aida.org/aida/fast-track6.htm&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Short-acting &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; Example&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.2aida.org/aida/fast-track7.htm" class="LinkWebExt"&gt;http://www.2aida.org/aida/fast-track7.htm&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Long-acting (Pump) &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; Example&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.2aida.org/aida/fast-track8.htm" class="LinkWebExt"&gt;http://www.2aida.org/aida/fast-track8.htm&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0021641</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Pharm/InslnSmltn.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Insulin Simulation</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Pharm/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Glyburide  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0017628"&gt;&lt;i&gt;C0017628&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;An antidiabetic sulfonylurea derivative with actions similar to those of chlorpropamide.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CSP)&lt;/td&gt;
                &lt;td&gt;N-4-beta-(2-methoxy-5-chlorobenzamido) -ethylbenzosulfonyl-N'- cyclohexylurea; hypoglycemic used against non-insulin dependent diabetes mellitus; thought to act by increasing insulin receptor expression in target tissues.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A member of the second generation of the sulfonylurea hypoglycemic agents. Glyburide inhibits the ATP-sensitive potassium channels on the beta-cell membrane, thereby preventing potassium efflux leading to membrane depolarization and subsequent calcium influx. The increased intracellular levels of calcium induce insulin secretion from functioning beta-cells of the pancreatic islet tissue and leads to a lowering in blood glucose levels.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Organic Chemical (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0017628&amp;amp;tui=T109"&gt;&lt;i&gt;T109&lt;/i&gt;&lt;/a&gt;)
, Pharmacologic Substance (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0017628&amp;amp;tui=T121"&gt;&lt;i&gt;T121&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D005905&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;387466004, 384978002, 80870001&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Glibenclamide, Glybenclamide, Benzamide, 5-chloro-N-(2-(4-((((cyclohexylamino)carbonyl)amino)sulfonyl)phenyl)ethyl)-2-methoxy-, glyburide, Glyburide, Gyburide, Glyburide (substance), glyburide (medication), GLYBURIDE, Glyburide [Chemical/Ingredient], glibenclamide, glybenclamide, glyBURIDE, Glybenzcyclamide, Glyburide (product), Glibenclamide (substance), GlyBURIDE&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Glyburid&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;gliburida, gliburida (sustancia), glibenclamida (producto), glibenclamida (sustancia), glibenclamida, glibenzciclamida, Glibenclamida, Gliburida&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;glibenklamid&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Glyburidi&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Glyburid, Glibenclamid, Glybencylamid&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;GLIBURID, GLIBENKLAMID, ГЛИБЕНКЛАМИД, ГЛИБУРИД&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Croatian&lt;/td&gt;
                &lt;td&gt;GLIBURID&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Euclamin, Glyburide, Glibenklamid&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;グリベンクラミド, グリブリド&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Glibenclamide&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Gliburide&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Glibenclamida, Glibureto&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Glipizide  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0017642"&gt;&lt;i&gt;C0017642&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;An oral hypoglycemic agent which is rapidly absorbed and completely metabolized.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CSP)&lt;/td&gt;
                &lt;td&gt;1-cyclohexyl-3-(p-(2-(5-methyl pyrazinecarboxamido) ethyl) phenyl) sulfonylurea; a typical member of the sulfonylurea family of type II (NIDDM) antidiabetic drugs.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A member of the second generation of the sulfonylurea hypoglycemic agents. Glipizide inhibits the ATP-sensitive potassium channels on the beta-cell membrane, thereby preventing potassium efflux leading to membrane depolarization and subsequent calcium influx. The increased intracellular calcium levels induce insulin secretion from functioning beta-cells of the pancreatic islet tissue and reduces blood glucose levels.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Organic Chemical (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0017642&amp;amp;tui=T109"&gt;&lt;i&gt;T109&lt;/i&gt;&lt;/a&gt;)
, Pharmacologic Substance (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0017642&amp;amp;tui=T121"&gt;&lt;i&gt;T121&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D005913&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;26124005, 387143009&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Glidiazinamide, Glipizide, Glydiazinamide, Glypidizine, Pyrazinecarboxamide, N-(2-(4-((((cyclohexylamino)carbonyl)amino)sulfonyl)phenyl)ethyl)-5-methyl-, glipizide, GLIPIZIDE, glipizide (medication), Glipizide [Chemical/Ingredient], glipiZIDE, Glipizide product, Glipizide (product), Glipizide (substance), GlipiZIDE&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Glipizid&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;glipizid&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Glipitsidi&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;GLIPIZID, ГЛИПИЗИД&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;グリピジジン, グリジアジンアミド, グリピジド&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Glipizyd&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;glidiacinamida, glidiazinamida, glipicida (sustancia), glipicida, glipizida (producto), glipizida (sustancia), glipizida, Glidiacinamida, Glipidicina, Glipizida&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Glipizide&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Glidiazinamid, Glipizidum, Glipizid, Glydiazinamid, Glypidizin&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Glipizide&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Glidiazinamida, Glipidizina, Glipizida&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Glyburide  (</value><value>)
</value><value>Glipizide  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Second Generation Sulfonylurea</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Pharmacology</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;See Also&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/FrstGnrtnSlfnylr.htm" class="LinkPage"&gt;First Generation Sulfonylurea&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/OrlHypglycmc.htm" class="LinkPage"&gt;Oral Hypoglycemic&lt;/a&gt; Agents&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Indications: &lt;a href="../../Endo/DM/TypDbtsMlts1.htm" class="LinkPage"&gt;Type II Diabetes Mellitus&lt;/a&gt; (early, phase 1-2)&lt;ol&gt;&lt;li&gt;Better effect in lean patients&lt;/li&gt;&lt;li&gt;Consider when &lt;a href="../../Endo/Lab/HmglbnAc.htm" class="LinkPage"&gt;Hemoglobin A1C&lt;/a&gt; &amp;lt;9%&lt;/li&gt;&lt;li&gt;Second-line to &lt;a href="../../Endo/Pharm/Glcphg.htm" class="LinkPage"&gt;Metformin&lt;/a&gt; in most patients&lt;/li&gt;&lt;li&gt;Consider as first-line in specific cohorts&lt;ol&gt;&lt;li&gt;Consider when post-prandial &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; 200 to 300 mg/dl&lt;/li&gt;&lt;li&gt;Consider when Type II with polyuria, polydipsia&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Contraindication&lt;ol&gt;&lt;li&gt;Sulfa allergy (applies to sulonylureas)&lt;/li&gt;&lt;li&gt;Renal and liver dysfunction&lt;ol&gt;&lt;li&gt;Use caution with &lt;a href="../../Endo/Pharm/Slfnylr.htm" class="LinkPage"&gt;Sulfonylurea&lt;/a&gt;s (especially Glyburide)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/NnSlfnylrInslnScrtgs.htm" class="LinkPage"&gt;Repaglinide&lt;/a&gt; or &lt;a href="../../Endo/Pharm/NnSlfnylrInslnScrtgs.htm" class="LinkPage"&gt;Nateglinide&lt;/a&gt; may be preferred here&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Avoid Glyburide in cardiovascular disease&lt;ol&gt;&lt;li&gt;Glimepiride and Glipizide do not appear to increase risk&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Mechanism&lt;ol&gt;&lt;li&gt;Pancreatic beta cell stimulation for &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; release&lt;/li&gt;&lt;li&gt;Secretagogues do not burn out the beta cells sooner&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Dosing Pearls&lt;ol&gt;&lt;li&gt;Use Long acting agents&lt;/li&gt;&lt;li&gt;Increase dose every 1-2 weeks until adequate response&lt;/li&gt;&lt;li&gt;No response in 25-30% of Type II Diabetics&lt;/li&gt;&lt;li&gt;Never combine secretagogues&lt;ol&gt;&lt;li&gt;They all have same site of activity&lt;/li&gt;&lt;li&gt;If one does not work, then all will not work&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Preparations: Glimepiride&lt;ol&gt;&lt;li&gt;Glimepiride (Amaryl)&lt;ol&gt;&lt;li&gt;Start: 1-2 mg PO qd&lt;/li&gt;&lt;li&gt;Usual: 4 mg PO qd&lt;/li&gt;&lt;li&gt;Maximum: 8 mg PO qd&lt;/li&gt;&lt;li&gt;Advantages&lt;ol&gt;&lt;li&gt;More rapid onset with longer duration&lt;/li&gt;&lt;li&gt;Lower &lt;a href="../../Prevent/Epi/DsIncdncRt.htm" class="LinkPage"&gt;Incidence&lt;/a&gt; of &lt;a href="../../Endo/Hypoglycemia/Hypglycm.htm" class="LinkPage"&gt;Hypoglycemia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Preferred of class for &lt;a href="../../CV/CAD/ActCrnrySyndrm.htm" class="LinkPage"&gt;Coronary Artery Disease&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Preparations: Glipizide&lt;ol&gt;&lt;li&gt;Glipizide (Glucotrol)&lt;ol&gt;&lt;li&gt;Start: 5 mg PO qd&lt;/li&gt;&lt;li&gt;Usual: 10-20 mg PO qd&lt;/li&gt;&lt;li&gt;Maximum: 20 mg PO bid&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Glipizide Extended Release (Glucotrol XL)&lt;ol&gt;&lt;li&gt;Start: 5 mg PO qd&lt;/li&gt;&lt;li&gt;Usual: 5-10 mg PO qd&lt;/li&gt;&lt;li&gt;Maximum: 20 mg PO qd&lt;/li&gt;&lt;li&gt;Advantages: Least expensive &lt;a href="../../Endo/Pharm/Slfnylr.htm" class="LinkPage"&gt;Sulfonylurea&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Preparations: Glyburide&lt;ol&gt;&lt;li&gt;Precautions&lt;ol&gt;&lt;li&gt;Glipizide and Glimepiride may be preferred instead due to increased risks associated with Glyburide&lt;ol&gt;&lt;li&gt;Other agents are generic (no cost advantage to Glyburide)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Glyburide has been associated with worse cardiovascular outcomes in patients presenting for emergent PCI&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=J%C3%B8rgensen%20%20%5BAU%5D%20AND%202011%20%5BDP%5D%20AND%20%20Int%20J%20Cardiol%20%20%5BTA%5D" class="LinkRef"&gt;Jørgensen (2011) Int J Cardiol 152:327-331&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Glyburide appears to predispose to more severe &lt;a href="../../Endo/Hypoglycemia/Hypglycm.htm" class="LinkPage"&gt;Hypoglycemia&lt;/a&gt; than the other Second Generation Sulfonylureas&lt;ol&gt;&lt;li&gt;Glyburide should be avoided in renal dysfunction where GFR &amp;lt;50 mL/min (increases hypglycemia risk)&lt;/li&gt;&lt;li&gt;Glyburide should be avoided in severe hepatic dysfunction (increases &lt;a href="../../Endo/Hypoglycemia/Hypglycm.htm" class="LinkPage"&gt;Hypoglycemia&lt;/a&gt; risk)&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Gangji%20%20%5BAU%5D%20AND%202007%20%5BDP%5D%20AND%20%20Diabetes%20Care%20%20%5BTA%5D" class="LinkRef"&gt;Gangji (2007) Diabetes Care 30:389-94&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Glyburide (DiaBeta, Micronase)&lt;ol&gt;&lt;li&gt;Start: 2.5 to 5 mg PO qd&lt;/li&gt;&lt;li&gt;Usual: 5-20 mg PO qd&lt;/li&gt;&lt;li&gt;Maximum: 20 mg PO qd&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Glyburide Micronized (Glynase, PresTab)&lt;ol&gt;&lt;li&gt;Start: 1.5 to 3 mg PO qd&lt;/li&gt;&lt;li&gt;Usual: 3-12 mg PO qd&lt;/li&gt;&lt;li&gt;Maximum: 12 mg PO qd&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Adverse Effects&lt;ol&gt;&lt;li&gt;Weight gain&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Hypoglycemia/Hypglycm.htm" class="LinkPage"&gt;Hypoglycemia&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Higher risk of severe &lt;a href="../../Endo/Hypoglycemia/Hypglycm.htm" class="LinkPage"&gt;Hypoglycemia&lt;/a&gt; with Glyburide&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Defronzo%20%20%5BAU%5D%20AND%201999%20%5BDP%5D%20AND%20%20Ann%20Intern%20Med%20%20%5BTA%5D" class="LinkRef"&gt;Defronzo (1999) Ann Intern Med 131:281-303&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Gangji%20%20%5BAU%5D%20AND%202007%20%5BDP%5D%20AND%20%20Diabetes%20Care%20%20%5BTA%5D" class="LinkRef"&gt;Gangji (2007) Diabetes Care 30:389-94&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Luna%20%20%5BAU%5D%20AND%201999%20%5BDP%5D%20AND%20%20Prim%20Care%20%20%5BTA%5D" class="LinkRef"&gt;Luna (1999) Prim Care 26:895-915&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0017628</value><value>C0017642</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Pharm/ScndGnrtnSlfnylr.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Second Generation Sulfonylurea, Glipizide, Glyburide</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Pharm/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Insulin pump  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C1140609"&gt;&lt;i&gt;C1140609&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (SPN)&lt;/td&gt;
                &lt;td&gt;An infusion pump is a device used in a health care facility to pump fluids into a patient in a controlled manner. The device may use a piston pump, a roller pump, or a peristaltic pump and may be powered electrically or mechanically. The device may also operate using a constant force to propel the fluid through a narrow tube which determines the flow rate. The device may include means to detect a fault condition, such as air in, or blockage of, the infusion line and to activate an alarm.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Medical Device (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C1140609&amp;amp;tui=T074"&gt;&lt;i&gt;T074&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;69805005&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Insulin pump, NOS, PUMP, INFUSION, INSULIN, Pumps, Insulin, Insulin Pumps, Insulin pump, device, insulin pumps, insulin infusion pump, Insulin Infusion Pump - Device, Insulin pump, device (physical object), Insulin pump, insulin pump&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;bomba de insulina (objeto físico), bomba de insulina&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Insulin pump  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Insulin Pump</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Pharmacology</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Background&lt;ol&gt;&lt;li&gt;Device that delivers &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; subcutaneously&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Components&lt;ol&gt;&lt;li&gt;Insulin Pump&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; reservoir (disposable)&lt;/li&gt;&lt;li&gt;Control pad&lt;ol&gt;&lt;li&gt;Enter &lt;a href="../../Endo/Pharm/VrblRtInslnInfsn.htm" class="LinkPage"&gt;Insulin Infusion&lt;/a&gt; maintenance rate&lt;/li&gt;&lt;li&gt;Enter bolus dose directly or calculated based on carbohydrate intake&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Infusion set (disposable)&lt;ol&gt;&lt;li&gt;Tubing&lt;/li&gt;&lt;li&gt;Cannula to insert subcutaneously&lt;ol&gt;&lt;li&gt;Introduced in similar fashion to IV start (except subcutaneous)&lt;/li&gt;&lt;li&gt;Needle is used to introduce the catheter subcutaneously&lt;/li&gt;&lt;li&gt;Needle is removed after insertion and catheter is left in place&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Insertion site&lt;ol&gt;&lt;li&gt;Subcutaneous cannula with adhesive to hold it in place&lt;/li&gt;&lt;li&gt;Changed every 3-5 days&lt;/li&gt;&lt;li&gt;In rare cases, site may become infected&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Protocol: Persistent &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Hyperglycemia&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Subcutaneous &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; injections can still be given in addition to pump for persistently high &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Glucose&lt;/a&gt; values&lt;/li&gt;&lt;li&gt;Detach the pump in severe &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Hyperglycemia&lt;/a&gt; or &lt;a href="../../Endo/DM/DbtcKtcds.htm" class="LinkPage"&gt;Diabetic Ketoacidosis&lt;/a&gt; and manage per &lt;a href="../../Endo/Pharm/VrblRtInslnInfsn.htm" class="LinkPage"&gt;Insulin Drip&lt;/a&gt; or &lt;a href="../../Endo/Pharm/HrlySbctnsInsln.htm" class="LinkPage"&gt;Hourly Subcutaneous Insulin&lt;/a&gt; protocols&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Protocol: &lt;a href="../../Endo/Hypoglycemia/Hypglycm.htm" class="LinkPage"&gt;Hypoglycemia&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Immediately detach pump in severe hypoglycemic episode&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Procotol: Hospitalization&lt;ol&gt;&lt;li&gt;Detach the Insulin Pump during hospitalizations where &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; will be managed by nursing and provider orders&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Resources&lt;ol&gt;&lt;li&gt;American Diabetes Association&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.diabetes.org/living-with-diabetes/treatment-and-care/medication/insulin/insulin-pumps.html" class="LinkWebExt"&gt;http://www.diabetes.org/living-with-diabetes/treatment-and-care/medication/insulin/insulin-pumps.html&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Wikipedia&lt;ol&gt;&lt;li&gt;&lt;a href="http://en.wikipedia.org/wiki/Insulin_pump" class="LinkWebExt"&gt;http://en.wikipedia.org/wiki/Insulin_pump&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C1140609</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Pharm/InslnPmp.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Insulin Pump</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Pharm/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Sliding scale insulin regime  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0557977"&gt;&lt;i&gt;C0557977&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Therapeutic or Preventive Procedure (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0557977&amp;amp;tui=T061"&gt;&lt;i&gt;T061&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;225301004&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;esquema de insulina con escala variable (régimen/tratamiento), esquema de insulina con escala variable (régimen/terapia), esquema de insulina con escala variable&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Sliding scale insulin regime, Sliding scale insulin regime (regime/therapy), Sliding scale insulin regime (procedure)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Sliding scale insulin regime  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Insulin Sliding Scale</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Pharmacology</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;General&lt;ol&gt;&lt;li&gt;Use this sliding scale as an example only&lt;/li&gt;&lt;li&gt;Adjust per patient weight and activity or &lt;a href="../../Sports/Disability/Dsblty.htm" class="LinkPage"&gt;Disability&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/DM/TypDbtsMlts.htm" class="LinkPage"&gt;Type I Diabetes Mellitus&lt;/a&gt; = 0.6 - 0.7 u/kg/d&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/DM/TypDbtsMlts1.htm" class="LinkPage"&gt;Type II Diabetes Mellitus&lt;/a&gt; = 0.3 u/Kg/d&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Disadvantages: Sliding Scale &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Reactive approach to &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Sugar&lt;/a&gt; control&lt;ol&gt;&lt;li&gt;Delays &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; until &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Hyperglycemia&lt;/a&gt; appears&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Does not meet basal &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; requirements&lt;/li&gt;&lt;li&gt;Promotes large swings in &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; control&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Protocol: Summary&lt;ol&gt;&lt;li&gt;Cover as units per &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; 50 mg/dl over 150 mg/dl&lt;/li&gt;&lt;li&gt;Adjust per condition&lt;ol&gt;&lt;li&gt;Lower doses&lt;ol&gt;&lt;li&gt;Low weight patient with &lt;a href="../../Endo/DM/TypDbtsMlts.htm" class="LinkPage"&gt;Type I Diabetes Mellitus&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Renal/Failure/ActRnlFlr.htm" class="LinkPage"&gt;Renal Failure&lt;/a&gt; (&lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; 50% renal excreted)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Higher dose&lt;ol&gt;&lt;li&gt;Large patient with &lt;a href="../../Endo/DM/TypDbtsMlts1.htm" class="LinkPage"&gt;Type II Diabetes Mellitus&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/SystmcCrtcstrd.htm" class="LinkPage"&gt;Corticosteroid&lt;/a&gt; use&lt;/li&gt;&lt;li&gt;&lt;a href="../../ID/Fever/Sps1.htm" class="LinkPage"&gt;Sepsis&lt;/a&gt; or severe illness&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Protocol 1: Based on &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; sensitivity&lt;ol&gt;&lt;li&gt;Basal &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; should not be eliminated&lt;ol&gt;&lt;li&gt;Applies even to those not eating&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/AnlgBslInsln.htm" class="LinkPage"&gt;Lantus&lt;/a&gt; should be continued at usual dose&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;NPH Insulin&lt;/a&gt;&lt;ol&gt;&lt;li&gt;AM dose: 50% of usual dose&lt;/li&gt;&lt;li&gt;PM dose: 100% of usual dose&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Estimate sensitivity using "rule of 1800"&lt;ol&gt;&lt;li&gt;BG change per unit &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; = 1800/total &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; daily&lt;/li&gt;&lt;li&gt;Example of 60 units/day: 1 unit drops BG 30 mg/dl&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Protocol (uses rapid acting &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt;, e.g. &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Lispro&lt;/a&gt;)&lt;ol&gt;&lt;li&gt;Goal &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Glucose&lt;/a&gt; is &amp;lt;150&lt;/li&gt;&lt;li&gt;Using sensitivity, how many units to drop 50 mg/dl&lt;ol&gt;&lt;li&gt;For example above, ~1 unit to drop BG 50 mg/dl&lt;ol&gt;&lt;li&gt;BG 150-199: 1 unit bolus &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; (regular or RA)&lt;/li&gt;&lt;li&gt;BG 200-249: 2 units bolus &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt;&lt;/li&gt;&lt;li&gt;BG 250-299: 3 units bolus &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt;&lt;/li&gt;&lt;li&gt;BG 300-349: 4 units bolus &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt;&lt;/li&gt;&lt;li&gt;BG Over 350: 5 units bolus &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Add in coverage for meal intake&lt;ol&gt;&lt;li&gt;Based on per carbohydrate when &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; &amp;gt;60 mg/dl&lt;/li&gt;&lt;li&gt;Use for &lt;a href="../../Endo/DM/TypDbtsMlts.htm" class="LinkPage"&gt;Type I Diabetes&lt;/a&gt;, consider for Type II&lt;/li&gt;&lt;li&gt;Add to sliding scale coverage above&lt;/li&gt;&lt;li&gt;Add 1 unit &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; per carbohydrate&lt;/li&gt;&lt;li&gt;Example: For 3 carbohydrate meal, add 3 units&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Protocols: Sliding Scales (contact provider if maximum &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; is exceeded)&lt;ol&gt;&lt;li&gt;Very low schedule (&lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt;-sensitive)&lt;ol&gt;&lt;li&gt;BG 150-199: 0.5 unit bolus &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; (regular or rapid-acting)&lt;/li&gt;&lt;li&gt;BG 200-249: 1 units bolus &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt;&lt;/li&gt;&lt;li&gt;BG 250-299: 1.5 units bolus &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt;&lt;/li&gt;&lt;li&gt;BG 300-349: 2 units bolus &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt;&lt;/li&gt;&lt;li&gt;BG Over 350: 2.5 units bolus &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Low schedule&lt;ol&gt;&lt;li&gt;BG 150-199: 1 unit bolus &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; (regular or rapid-acting)&lt;/li&gt;&lt;li&gt;BG 200-249: 2 units bolus &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt;&lt;/li&gt;&lt;li&gt;BG 250-299: 3 units bolus &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt;&lt;/li&gt;&lt;li&gt;BG 300-349: 4 units bolus &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt;&lt;/li&gt;&lt;li&gt;BG Over 350: 5 units bolus &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Medium schedule&lt;ol&gt;&lt;li&gt;BG 150-199: 1 unit bolus &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; (regular or rapid-acting)&lt;/li&gt;&lt;li&gt;BG 200-249: 3 units bolus &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt;&lt;/li&gt;&lt;li&gt;BG 250-299: 5 units bolus &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt;&lt;/li&gt;&lt;li&gt;BG 300-349: 7 units bolus &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt;&lt;/li&gt;&lt;li&gt;BG Over 350: 8 units bolus &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;High schedule (&lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt;-resistant)&lt;ol&gt;&lt;li&gt;BG 150-199: 2 unit bolus &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; (regular or rapid-acting)&lt;/li&gt;&lt;li&gt;BG 200-249: 4 units bolus &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt;&lt;/li&gt;&lt;li&gt;BG 250-299: 7 units bolus &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt;&lt;/li&gt;&lt;li&gt;BG 300-349: 10 units bolus &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt;&lt;/li&gt;&lt;li&gt;BG Over 350: 12 units bolus &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Schnipper%20%20%5BAU%5D%20AND%202009%20%5BDP%5D%20AND%20%20J%20Hosp%20Med%20%20%5BTA%5D" class="LinkRef"&gt;Schnipper (2009) J Hosp Med 4(1): 16-27&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0557977</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Pharm/InslnSldngScl.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Insulin Sliding Scale, Correctional Insulin Dosing</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Pharm/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Meglitinide  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0065880"&gt;&lt;i&gt;C0065880&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Organic Chemical (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0065880&amp;amp;tui=T109"&gt;&lt;i&gt;T109&lt;/i&gt;&lt;/a&gt;)
, Pharmacologic Substance (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0065880&amp;amp;tui=T121"&gt;&lt;i&gt;T121&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;C030516&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;109075003, 372566000&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;4-(2-(5-chloro-2-methoxybenzamido)ethyl)benzoic acid, meglitinide, MEGLITINIDE, meglitinide [Chemical/Ingredient], meglitinides, Meglitinide, Meglitinide (product), Meglitinide (substance)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;meglitinida (producto), meglitinida (sustancia), meglitinida&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;repaglinide  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0246689"&gt;&lt;i&gt;C0246689&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A benzoic acid derivative belonging to the meglitinide class of antidiabetic agents. Repaglinide blocks ATP-dependent potassium channels in pancreatic beta cells, thereby causing depolarization of the cell membrane and subsequent opening of calcium channels. The increased calcium influx into the pancreatic beta cells induces insulin secretion, thereby lowering blood glucose levels.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Organic Chemical (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0246689&amp;amp;tui=T109"&gt;&lt;i&gt;T109&lt;/i&gt;&lt;/a&gt;)
, Pharmacologic Substance (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0246689&amp;amp;tui=T121"&gt;&lt;i&gt;T121&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;C072379&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;109074004, 386964000&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;repaglinide, (+)-2-Ethoxy-alpha-(((S)-alpha-isobutyl-o-piperidinobenzyl)carbamoyl)-p-toluic Acid, Benzoic Acid, 2-ethoxy-4-(2-((3-methyl-1-(2-(1-piperidinyl)phenyl)butyl)amino)-2-oxoethyl)-,(S)-, repa-glinide, repaglinide (medication), REPAGLINIDE, repaglinide [Chemical/Ingredient], (S)-2-ethoxy-4-(2-((3-methyl-1-(2-(1-piperidinyl)-phenyl)butyl)amino)-2-oxoethyl)-benzoic acid, Repaglinide, Repaglinide (product), Repaglinide (substance)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;レパグリニド&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;repaglinida (producto), repaglinida (sustancia), repaglinida&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Prandin  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0722725"&gt;&lt;i&gt;C0722725&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Organic Chemical (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0722725&amp;amp;tui=T109"&gt;&lt;i&gt;T109&lt;/i&gt;&lt;/a&gt;)
, Pharmacologic Substance (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0722725&amp;amp;tui=T121"&gt;&lt;i&gt;T121&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;C072379&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Prandin, repaglinide (Prandin), prandin, Novo Nordisk brand 2 of repaglinide&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;nateglinide  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0903898"&gt;&lt;i&gt;C0903898&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Amino Acid, Peptide, or Protein (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0903898&amp;amp;tui=T116"&gt;&lt;i&gt;T116&lt;/i&gt;&lt;/a&gt;)
, Pharmacologic Substance (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0903898&amp;amp;tui=T121"&gt;&lt;i&gt;T121&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;C060142&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;129496008, 134604002, 387070004&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;IPCCPA, N-((4-isopropylcyclohexyl)carbonyl)phenylalanine, nate-glinide, nateglinide (medication), NATEGLINIDE, nateglinide [Chemical/Ingredient], nateglinide, D-phenylalanine, N-((trans-4-(1-methylethyl)cyclohexyl)carbonyl)-, senaglinide, Nateglinide (product), Nateglinide (substance), Nateglinide&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;nateglinida (concepto no activo), nateglinida (producto), nateglinida (sustancia), nateglinida&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Starlix  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C1323198"&gt;&lt;i&gt;C1323198&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Organic Chemical (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C1323198&amp;amp;tui=T109"&gt;&lt;i&gt;T109&lt;/i&gt;&lt;/a&gt;)
, Pharmacologic Substance (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C1323198&amp;amp;tui=T121"&gt;&lt;i&gt;T121&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;C060142&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;starlix, Starlix, Novartis brand of nateglinide&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Meglitinide  (</value><value>)
</value><value>repaglinide  (</value><value>)
</value><value>Prandin  (</value><value>)
</value><value>nateglinide  (</value><value>)
</value><value>Starlix  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Non-Sulfonylurea Insulin Secretagogues</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Pharmacology</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;See Also&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/ScndGnrtnSlfnylr.htm" class="LinkPage"&gt;Second Generation Sulfonylurea&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Mechanism&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; secretogogue&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Indication&lt;ol&gt;&lt;li&gt;Early &lt;a href="../../Endo/DM/TypDbtsMlts1.htm" class="LinkPage"&gt;Type II Diabetes Mellitus&lt;/a&gt; Oral Agent&lt;/li&gt;&lt;li&gt;Elevated postprandial &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Consider if only used intermittently pre-meal&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Contraindications&lt;ol&gt;&lt;li&gt;&lt;a href="../../ENT/Exam/HyprsnstvtyRctn.htm" class="LinkPage"&gt;Hypersensitivity Reaction&lt;/a&gt; to sulfa&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Category&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Slfnylr.htm" class="LinkPage"&gt;Insulin Secretagogue&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Mechanism&lt;ol&gt;&lt;li&gt;Benzoic acid derivative&lt;/li&gt;&lt;li&gt;Similar to &lt;a href="../../Endo/Pharm/Slfnylr.htm" class="LinkPage"&gt;Sulfonylurea&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Binds different sites from &lt;a href="../../Endo/Pharm/Slfnylr.htm" class="LinkPage"&gt;Sulfonylurea&lt;/a&gt;s&lt;/li&gt;&lt;li&gt;Closes ATP sensitive K+ channels&lt;/li&gt;&lt;li&gt;Results in &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; secretion&lt;/li&gt;&lt;li&gt;Shorter duration of binding and shorter effect&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Predominately effects postprandial &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Advantages&lt;ol&gt;&lt;li&gt;Low risk of &lt;a href="../../Endo/Hypoglycemia/Hypglycm.htm" class="LinkPage"&gt;Hypoglycemia&lt;/a&gt; (2.4%)&lt;/li&gt;&lt;li&gt;Effect depends on &lt;a href="../../Psych/Pharm/Zlpdm.htm" class="LinkPage"&gt;Ambien&lt;/a&gt;t &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Glucose&lt;/a&gt; levels&lt;/li&gt;&lt;li&gt;No significant gastrointestinal side effects&lt;/li&gt;&lt;li&gt;Minimal weight gain&lt;/li&gt;&lt;li&gt;No lab monitoring required&lt;/li&gt;&lt;li&gt;No significant drug interactions&lt;/li&gt;&lt;li&gt;No &lt;a href="../../Derm/Pharm/AlphHydrxyAcd.htm" class="LinkPage"&gt;Lactic Acid&lt;/a&gt;osis&lt;/li&gt;&lt;li&gt;No adjustments needed (other than per meal)&lt;ol&gt;&lt;li&gt;No adjustment in &lt;a href="../../CV/CHF/CngstvHrtFlr.htm" class="LinkPage"&gt;Congestive Heart Failure&lt;/a&gt;&lt;/li&gt;&lt;li&gt;No adjustment for age&lt;/li&gt;&lt;li&gt;No adjustment in renal insufficiency&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Adverse Effects&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Hypoglycemia/Hypglycm.htm" class="LinkPage"&gt;Hypoglycemia&lt;/a&gt; (lower risk of &lt;a href="../../Endo/Pharm/Slfnylr.htm" class="LinkPage"&gt;Sulfonylurea&lt;/a&gt;s)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Disadvantages&lt;ol&gt;&lt;li&gt;Two to three times as expensive as &lt;a href="../../Endo/Pharm/Slfnylr.htm" class="LinkPage"&gt;Sulfonylurea&lt;/a&gt;s&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Agents&lt;ol&gt;&lt;li&gt;Repaglinide (Prandin)&lt;/li&gt;&lt;li&gt;Nateglinide (Starlix)&lt;ol&gt;&lt;li&gt;Significantly weaker activity compared with Prandin&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Luna%20%20%5BAU%5D%20AND%202001%20%5BDP%5D%20AND%20%20Am%20Fam%20Physician%20%20%5BTA%5D" class="LinkRef"&gt;Luna (2001) Am Fam Physician 63(9):1747-56&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Luna%20%20%5BAU%5D%20AND%201999%20%5BDP%5D%20AND%20%20Prim%20Care%20%20%5BTA%5D" class="LinkRef"&gt;Luna (1999) Prim Care 26:895-915&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0065880</value><value>C0246689</value><value>C0722725</value><value>C0903898</value><value>C1323198</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Pharm/NnSlfnylrInslnScrtgs.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Non-Sulfonylurea Insulin Secretagogues, Meglitinide, Repaglinide, Prandin, Nateglinide, Starlix</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Pharm/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Insulin  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0021641"&gt;&lt;i&gt;C0021641&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CSP)&lt;/td&gt;
                &lt;td&gt;protein hormone secreted by beta cells of the pancreas; insulin plays a major role in the regulation of glucose metabolism, generally promoting the cellular utilization of glucose and is also an important regulator of protein and lipid metabolism; insulin is used as a drug to control insulin-dependent diabetes mellitus.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A short-acting form of insulin. Regular insulin is obtained from animal or recombinant sources. The onset of action of regular insulin occurs at 30-90 minutes after injection; its effect lasts for 6 to 8 hours. Endogenous human insulin, a pancreatic hormone composed of two polypeptide chains, is important for the normal metabolism of carbohydrates, proteins and fats; it has anabolic effects on many types of tissues. (NCI04)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;Human insulin protein (110 aa, 12 kDa) is encoded by the human insulin (INS) gene. This cytosolic protein, a heterodimer of disulfide-linked alpha and beta chains, is produced in pancreatic islet beta cells. Binding of insulin to its receptor stimulates glucose uptake, accelerates both glycolysis and the pentose phosphate cycle and increases glycogen synthesis in the liver. Insulin regulates protein and lipid metabolism. It also decreases blood glucose concentration by shuttling molecules into cells to be used for energy. Decreased expression of insulin protein causes familial hyperproinsulinemia.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1).&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Amino Acid, Peptide, or Protein (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0021641&amp;amp;tui=T116"&gt;&lt;i&gt;T116&lt;/i&gt;&lt;/a&gt;)
, Pharmacologic Substance (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0021641&amp;amp;tui=T121"&gt;&lt;i&gt;T121&lt;/i&gt;&lt;/a&gt;)
, Hormone (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0021641&amp;amp;tui=T125"&gt;&lt;i&gt;T125&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D007328&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;67866001, 39487003, 412222002&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Insulin, insulin, INSULIN PREPARATIONS, Insulin preparation, NOS, Regular Insulin, Regular insulin preparation, Unmodified insulin preparation, Insulin Regular, INSULIN, insulin preparations, insulin preparations (medication), A22 INSULIN PREPARATIONS, insulin regular, Insulin (ox), 8A-L-threonine-10A-L-isoleucine-30B-L-threonine-, Insulin [Chemical/Ingredient], [HS501] INSULIN, Insulin regular, insulin products, insulin preparation, insulin product, regular insulin, insulins, Insulin, Soluble, Soluble Insulin, Insulin, Regular, Insulin product, Insulin (substance), Insulin preparation, Insulin product (product), Regular insulin product, Unmodified insulin product, Insulin preparation (substance), Regular insulin (substance), Regular insulin&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Insulin&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;insulin, inzulin&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Insuliini&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Insuline ordinaire, Insuline&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;INSULIN, ИНСУЛИН&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;producto con insulina (producto), preparado insulínico, insulina (producto), producto con insulina, insulina (sustancia), insulina, preparado de insulina (producto), preparado de insulina (sustancia), preparado de insulina cristalina de cinc, preparado de insulina cristalina de zinc, preparado de insulina no modificada, preparado de insulina, insulina regular (sustancia), insulina regular, Insulina&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Insulina regolare, Insulina&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Croatian&lt;/td&gt;
                &lt;td&gt;INZULIN&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Insulina&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;インスリン, インスリン亜鉛水性懸濁液, インシュリン&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Insulin&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Insulina&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Insulin  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Hourly Subcutaneous Insulin</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Pharmacology</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;See Also&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/VrblRtInslnInfsn.htm" class="LinkPage"&gt;Insulin Infusion&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/DM/DbtcKtcds.htm" class="LinkPage"&gt;Diabetic Ketoacidosis&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Indications&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/DM/DbtcKtcds.htm" class="LinkPage"&gt;Diabetic Ketoacidosis&lt;/a&gt; in adults&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Protocol: Subcutaneous &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt;&lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Lispro&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Initial dose: 0.3 units/kg&lt;/li&gt;&lt;li&gt;Next: 0.1 units/kg/hour until &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Hyperglycemia&lt;/a&gt; corrects&lt;/li&gt;&lt;li&gt;Next: 0.05 units/kg/hour until DKA resolves&lt;/li&gt;&lt;li&gt;Coadminister fluids as per &lt;a href="../../Endo/DM/DbtcKtcds.htm" class="LinkPage"&gt;Diabetic Ketoacidosis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Discontinue hourly dosing when &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; 150-200&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Precautions&lt;ol&gt;&lt;li&gt;Correct &lt;a href="../../Renal/Potassium/Hypklm.htm" class="LinkPage"&gt;Hypokalemia&lt;/a&gt; prior to &lt;a href="../../Endo/Pharm/InslnDsng.htm" class="LinkPage"&gt;Insulin Dosing&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Fluid administration is central to DKA treatment&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Monitoring&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Glucose&lt;/a&gt; every 30 minutes to 1 hour&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Advantage over &lt;a href="../../Endo/Pharm/VrblRtInslnInfsn.htm" class="LinkPage"&gt;Insulin Infusion&lt;/a&gt;&lt;ol&gt;&lt;li&gt;May be monitored on regular medical ward (non-ICU)&lt;/li&gt;&lt;li&gt;Reduced cost by 39% compared with infusion&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Safety and efficacy&lt;ol&gt;&lt;li&gt;As effective and safe as &lt;a href="../../Endo/Pharm/VrblRtInslnInfsn.htm" class="LinkPage"&gt;Insulin Infusion&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Umpierrez%20%20%5BAU%5D%20AND%202004%20%5BDP%5D%20AND%20%20Am%20J%20Med%20%20%5BTA%5D" class="LinkRef"&gt;Umpierrez (2004) Am J Med 117:291-6&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Karoli%20%20%5BAU%5D%20AND%202011%20%5BDP%5D%20AND%20%20Indian%20J%20Pharmacol%20%20%5BTA%5D" class="LinkRef"&gt;Karoli (2011) Indian J Pharmacol 43(4): 398-401&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0021641</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Pharm/HrlySbctnsInsln.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Hourly Subcutaneous Insulin, Hourly Subcutaneous Insulin Aspart, Hourly Subcutaneous Insulin Lispro</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Pharm/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Insulin  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0021641"&gt;&lt;i&gt;C0021641&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CSP)&lt;/td&gt;
                &lt;td&gt;protein hormone secreted by beta cells of the pancreas; insulin plays a major role in the regulation of glucose metabolism, generally promoting the cellular utilization of glucose and is also an important regulator of protein and lipid metabolism; insulin is used as a drug to control insulin-dependent diabetes mellitus.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A short-acting form of insulin. Regular insulin is obtained from animal or recombinant sources. The onset of action of regular insulin occurs at 30-90 minutes after injection; its effect lasts for 6 to 8 hours. Endogenous human insulin, a pancreatic hormone composed of two polypeptide chains, is important for the normal metabolism of carbohydrates, proteins and fats; it has anabolic effects on many types of tissues. (NCI04)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;Human insulin protein (110 aa, 12 kDa) is encoded by the human insulin (INS) gene. This cytosolic protein, a heterodimer of disulfide-linked alpha and beta chains, is produced in pancreatic islet beta cells. Binding of insulin to its receptor stimulates glucose uptake, accelerates both glycolysis and the pentose phosphate cycle and increases glycogen synthesis in the liver. Insulin regulates protein and lipid metabolism. It also decreases blood glucose concentration by shuttling molecules into cells to be used for energy. Decreased expression of insulin protein causes familial hyperproinsulinemia.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1).&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Amino Acid, Peptide, or Protein (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0021641&amp;amp;tui=T116"&gt;&lt;i&gt;T116&lt;/i&gt;&lt;/a&gt;)
, Pharmacologic Substance (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0021641&amp;amp;tui=T121"&gt;&lt;i&gt;T121&lt;/i&gt;&lt;/a&gt;)
, Hormone (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0021641&amp;amp;tui=T125"&gt;&lt;i&gt;T125&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D007328&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;67866001, 39487003, 412222002&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Insulin, insulin, INSULIN PREPARATIONS, Insulin preparation, NOS, Regular Insulin, Regular insulin preparation, Unmodified insulin preparation, Insulin Regular, INSULIN, insulin preparations, insulin preparations (medication), A22 INSULIN PREPARATIONS, insulin regular, Insulin (ox), 8A-L-threonine-10A-L-isoleucine-30B-L-threonine-, Insulin [Chemical/Ingredient], [HS501] INSULIN, Insulin regular, insulin products, insulin preparation, insulin product, regular insulin, insulins, Insulin, Soluble, Soluble Insulin, Insulin, Regular, Insulin product, Insulin (substance), Insulin preparation, Insulin product (product), Regular insulin product, Unmodified insulin product, Insulin preparation (substance), Regular insulin (substance), Regular insulin&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Insulin&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;insulin, inzulin&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Insuliini&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Insuline ordinaire, Insuline&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;INSULIN, ИНСУЛИН&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;producto con insulina (producto), preparado insulínico, insulina (producto), producto con insulina, insulina (sustancia), insulina, preparado de insulina (producto), preparado de insulina (sustancia), preparado de insulina cristalina de cinc, preparado de insulina cristalina de zinc, preparado de insulina no modificada, preparado de insulina, insulina regular (sustancia), insulina regular, Insulina&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Insulina regolare, Insulina&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Croatian&lt;/td&gt;
                &lt;td&gt;INZULIN&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Insulina&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;インスリン, インスリン亜鉛水性懸濁液, インシュリン&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Insulin&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Insulina&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Insulin  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Insulin Dosing in Type 2 Diabetes</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Pharmacology</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;See Also&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/InslnSmltn.htm" class="LinkPage"&gt;Insulin Simulation&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/InslnDsng.htm" class="LinkPage"&gt;Insulin Dosing&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/InslnDsngInTypDbts.htm" class="LinkPage"&gt;Insulin Dosing in Type I Diabetes&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Prevent/CrbhydrtCnt.htm" class="LinkPage"&gt;Carbohydrate Counting&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/CrbhydrtCntInInslnDsng.htm" class="LinkPage"&gt;Insulin Adjustment with Carbohydrate Counting&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Indications&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Endo/DM/TypDbtsMlts1.htm" class="LinkPage"&gt;Type II Diabetes Mellitus&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Protocol: Identify &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Glucose&lt;/a&gt; goals&lt;ol&gt;&lt;li&gt;No predisposition to &lt;a href="../../Endo/Hypoglycemia/Hypglycm.htm" class="LinkPage"&gt;Hypoglycemia&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Pre-meal or fasting: 70-120&lt;/li&gt;&lt;li&gt;Bedtime: 100-140&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/HmglbnAc.htm" class="LinkPage"&gt;Hemoglobin A1C&lt;/a&gt;: &amp;lt;7% (Normal 4.0 - 6.0%)&lt;/li&gt;&lt;li&gt;Two hour post-prandial &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; &amp;lt;160 mg/dl&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Glucose&lt;/a&gt; 20-40 mg/dl above pre-meal &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Predisposition for &lt;a href="../../Endo/Hypoglycemia/Hypglycm.htm" class="LinkPage"&gt;Hypoglycemia&lt;/a&gt; (Comorbid conditions)&lt;ol&gt;&lt;li&gt;Pre-meal/fasting:  100-150&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/HmglbnAc.htm" class="LinkPage"&gt;Hemoglobin A1C&lt;/a&gt;: 7-8&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Protocol: Starting Basal &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; (e.g. &lt;a href="../../Endo/Pharm/AnlgBslInsln.htm" class="LinkPage"&gt;Lantus&lt;/a&gt;) and Bolus &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; (e.g. &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Lispro&lt;/a&gt;)&lt;ol&gt;&lt;li&gt;Step 0: Adjust oral medications&lt;ol&gt;&lt;li&gt;Stop &lt;a href="../../Endo/Pharm/Slfnylr.htm" class="LinkPage"&gt;Insulin Secretagogue&lt;/a&gt; (&lt;a href="../../Endo/Pharm/Slfnylr.htm" class="LinkPage"&gt;Sulfonylurea&lt;/a&gt;, &lt;a href="../../Endo/Pharm/NnSlfnylrInslnScrtgs.htm" class="LinkPage"&gt;Meglitinide&lt;/a&gt;) when on twice daily bolus &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Continue &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; sensitizers (&lt;a href="../../Endo/Pharm/Glcphg.htm" class="LinkPage"&gt;Metformin&lt;/a&gt;, &lt;a href="../../Endo/Pharm/Thzldndn.htm" class="LinkPage"&gt;Glitazone&lt;/a&gt;)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Step 1: Choose a 24 hour basal &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; (once daily):&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/AnlgBslInsln.htm" class="LinkPage"&gt;Detemir&lt;/a&gt; (&lt;a href="../../Endo/Pharm/AnlgBslInsln.htm" class="LinkPage"&gt;Levemir&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/AnlgBslInsln.htm" class="LinkPage"&gt;Glargine&lt;/a&gt; (&lt;a href="../../Endo/Pharm/AnlgBslInsln.htm" class="LinkPage"&gt;Lantus&lt;/a&gt;)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Step 2: Choose a bolus &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; (pre-meal &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt;):&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Regular Insulin&lt;/a&gt; (&lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Novolin&lt;/a&gt; R, &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Humulin&lt;/a&gt; R)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Glulisine&lt;/a&gt; (&lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Apidra&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Lispro&lt;/a&gt; (&lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Humalog&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Aspart&lt;/a&gt; (&lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Novolog&lt;/a&gt;)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Step 3: Starting dose&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/HmglbnAc.htm" class="LinkPage"&gt;Hemoglobin A1C&lt;/a&gt; &amp;lt;8&lt;ol&gt;&lt;li&gt;Basal &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; 0.1 units/kg once daily AND&lt;/li&gt;&lt;li&gt;Bolus &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; 0.1 units/kg divided equally before meals (start before breakfast and dinner)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/HmglbnAc.htm" class="LinkPage"&gt;Hemoglobin A1C&lt;/a&gt; 8-10&lt;ol&gt;&lt;li&gt;Basal &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; 0.2 units/kg once daily AND&lt;/li&gt;&lt;li&gt;Bolus &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; 0.2 units/kg divided equally before meals (start before breakfast and dinner)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/HmglbnAc.htm" class="LinkPage"&gt;Hemoglobin A1C&lt;/a&gt; &amp;gt;10&lt;ol&gt;&lt;li&gt;Basal &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; 0.3 units/kg once daily AND&lt;/li&gt;&lt;li&gt;Bolus &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; 0.3 units/kg divided equally before meals (start before breakfast and dinner)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Protocol: Starting &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; using Premixed &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Step 0: Adjust oral medications&lt;ol&gt;&lt;li&gt;Stop &lt;a href="../../Endo/Pharm/Slfnylr.htm" class="LinkPage"&gt;Insulin Secretagogue&lt;/a&gt; (&lt;a href="../../Endo/Pharm/Slfnylr.htm" class="LinkPage"&gt;Sulfonylurea&lt;/a&gt;, &lt;a href="../../Endo/Pharm/NnSlfnylrInslnScrtgs.htm" class="LinkPage"&gt;Meglitinide&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;Continue &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; sensitizers (&lt;a href="../../Endo/Pharm/Glcphg.htm" class="LinkPage"&gt;Metformin&lt;/a&gt;, &lt;a href="../../Endo/Pharm/Thzldndn.htm" class="LinkPage"&gt;Glitazone&lt;/a&gt;)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; preparations (for twice daily dosing)&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Lispro&lt;/a&gt; Mix 75/25 or&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Aspart&lt;/a&gt; Premix 70/30&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Starting dose&lt;ol&gt;&lt;li&gt;A1C &amp;lt;8: 0.1 units/kg in AM and 0.1 units/kg in PM&lt;/li&gt;&lt;li&gt;A1C 8-10: 0.2 units/kg in AM and 0.2 units/kg in PM&lt;/li&gt;&lt;li&gt;A1C &amp;gt;10: 0.3 units/kg in AM and 0.3 units/kg in PM&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Protocol: Converting from Mixed &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; to Basal Bolus &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Calculate total &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; units/kg&lt;ol&gt;&lt;li&gt;Total &amp;gt;1.5 units/kg: Lower total to 1.0 unit/kg&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/HmglbnAc.htm" class="LinkPage"&gt;Hemoglobin A1C&lt;/a&gt; &amp;lt;9: Decrease total &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; by 10%&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Divide total &lt;a href="../../Endo/Pharm/InslnDsng.htm" class="LinkPage"&gt;Insulin Dosing&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/AnlgBslInsln.htm" class="LinkPage"&gt;Insulin Glargine&lt;/a&gt;: 50% of total &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Rapid acting: 50% of total divided across meals&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Protocol: Advancing Basal/Bolus Dosing in &lt;a href="../../Endo/DM/TypDbtsMlts1.htm" class="LinkPage"&gt;Type II Diabetes&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Starting point&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/AnlgBslInsln.htm" class="LinkPage"&gt;Insulin Glargine&lt;/a&gt; (G) once daily and&lt;/li&gt;&lt;li&gt;Oral &lt;a href="../../Endo/Pharm/Slfnylr.htm" class="LinkPage"&gt;Insulin Secretagogue&lt;/a&gt; and&lt;/li&gt;&lt;li&gt;Oral &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; sensitizer&lt;/li&gt;&lt;li&gt;Protocol below, adds rapid acting &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; (RA)&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt;&lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Lispro&lt;/a&gt; or &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Aspart&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Step 1: 0-0-RA-G&lt;ol&gt;&lt;li&gt;Add 0.1 units/kg &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Lispro&lt;/a&gt; (RA) before largest meal&lt;/li&gt;&lt;li&gt;Decrease &lt;a href="../../Endo/Pharm/AnlgBslInsln.htm" class="LinkPage"&gt;Insulin Glargine&lt;/a&gt; by 0.1 units/kg&lt;/li&gt;&lt;li&gt;Continue &lt;a href="../../Endo/Pharm/Slfnylr.htm" class="LinkPage"&gt;Insulin Secretagogue&lt;/a&gt; and sensitizer&lt;/li&gt;&lt;li&gt;Check &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Glucose&lt;/a&gt; fasting, before RA dose, bedtime&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Step 2: RA-0-RA-G&lt;ol&gt;&lt;li&gt;Add 0.1 units/kg &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Lispro&lt;/a&gt; (RA) before 2nd largest meal&lt;/li&gt;&lt;li&gt;Decrease &lt;a href="../../Endo/Pharm/AnlgBslInsln.htm" class="LinkPage"&gt;Insulin Glargine&lt;/a&gt; by 0.1 units/kg&lt;/li&gt;&lt;li&gt;Stop &lt;a href="../../Endo/Pharm/Slfnylr.htm" class="LinkPage"&gt;Insulin Secretagogue&lt;/a&gt;, continue sensitizer&lt;/li&gt;&lt;li&gt;Check &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Glucose&lt;/a&gt; fasting, before RA dose, bedtime&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Step 3: RA-RA-RA-G&lt;ol&gt;&lt;li&gt;Add 0.1 units/kg &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Lispro&lt;/a&gt; (RA) before 3rd largest meal&lt;/li&gt;&lt;li&gt;Decrease &lt;a href="../../Endo/Pharm/AnlgBslInsln.htm" class="LinkPage"&gt;Insulin Glargine&lt;/a&gt; by 0.1 units/kg&lt;/li&gt;&lt;li&gt;Check &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Glucose&lt;/a&gt; fasting, before RA dose, bedtime&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Precautions&lt;ol&gt;&lt;li&gt;Keep &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; split into 50% basal and 50% bolus&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Protocol: Starting &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; using NPH&lt;ol&gt;&lt;li&gt;Background&lt;ol&gt;&lt;li&gt;Other regimens less complicated and therefore preferred&lt;/li&gt;&lt;li&gt;However, NPH and &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Regular Insulin&lt;/a&gt; are least expensive &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; options&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Step 0: Adjust oral medications&lt;ol&gt;&lt;li&gt;Stop &lt;a href="../../Endo/Pharm/Slfnylr.htm" class="LinkPage"&gt;Insulin Secretagogue&lt;/a&gt; (&lt;a href="../../Endo/Pharm/Slfnylr.htm" class="LinkPage"&gt;Sulfonylurea&lt;/a&gt;, &lt;a href="../../Endo/Pharm/NnSlfnylrInslnScrtgs.htm" class="LinkPage"&gt;Meglitinide&lt;/a&gt;) when on twice daily bolus &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Continue &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; sensitizers (&lt;a href="../../Endo/Pharm/Glcphg.htm" class="LinkPage"&gt;Metformin&lt;/a&gt;, &lt;a href="../../Endo/Pharm/Thzldndn.htm" class="LinkPage"&gt;Glitazone&lt;/a&gt;)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Step 1: Starting dose&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/HmglbnAc.htm" class="LinkPage"&gt;Hemoglobin A1C&lt;/a&gt; &amp;lt;8: Total &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt;: 0.1 units/kg in AM and 0.1 units/kg in PM&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/HmglbnAc.htm" class="LinkPage"&gt;Hemoglobin A1C&lt;/a&gt; 8-10: Total &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt;: 0.2 units/kg in AM and 0.2 units/kg in PM&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/HmglbnAc.htm" class="LinkPage"&gt;Hemoglobin A1C&lt;/a&gt; &amp;gt;10: Total &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt;: 0.3 units/kg in AM and 0.3 units/kg in PM&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Step 2: Divide each &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; dose into 1/3 bolus (e.g. &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Regular Insulin&lt;/a&gt;) and 2/3 &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;NPH Insulin&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Step 3: Schedule 2 doses of bolus &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; (e.g. regular) and 2 doses of NPH daily&lt;ol&gt;&lt;li&gt;Breakfast (50%): &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;NPH Insulin&lt;/a&gt; (2/3) and &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Regular Insulin&lt;/a&gt; (1/3)&lt;/li&gt;&lt;li&gt;Dinner (50%): &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;NPH Insulin&lt;/a&gt; (2/3) and &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Regular Insulin&lt;/a&gt; (1/3)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Protocol: &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; Adjustments&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Endo/Pharm/InslnDsng.htm" class="LinkPage"&gt;Insulin Dosing&lt;/a&gt;&lt;/li&gt;&lt;li&gt;See &lt;a href="../../Endo/Pharm/CrbhydrtCntInInslnDsng.htm" class="LinkPage"&gt;Insulin Adjustment with Carbohydrate Counting&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0021641</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Pharm/InslnDsngInTypDbts1.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Insulin Dosing in Type 2 Diabetes, Insulin Dosing in Type II Diabetes</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Pharm/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Exubera  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C1176237"&gt;&lt;i&gt;C1176237&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Amino Acid, Peptide, or Protein (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C1176237&amp;amp;tui=T116"&gt;&lt;i&gt;T116&lt;/i&gt;&lt;/a&gt;)
, Pharmacologic Substance (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C1176237&amp;amp;tui=T121"&gt;&lt;i&gt;T121&lt;/i&gt;&lt;/a&gt;)
, Hormone (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C1176237&amp;amp;tui=T125"&gt;&lt;i&gt;T125&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;C473734&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;EXUBERA, Exubera&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Exubera  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Inhaled Insulin</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Pharmacology</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Background&lt;ol&gt;&lt;li&gt;Off U.S. Market as of October 2007 (based on business decisions, not on recall)&lt;/li&gt;&lt;li&gt;Listed for historical reasons&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Indications&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/DM/DbtsMlts.htm" class="LinkPage"&gt;Diabetes Mellitus&lt;/a&gt; when intollerant to SQ injection&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Mechanism&lt;ol&gt;&lt;li&gt;Dry powder form of rapid acting &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Delivery by oral inhalation&lt;/li&gt;&lt;li&gt;Large doses needed due to inefficient absorption&lt;ol&gt;&lt;li&gt;Most &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; remains in lung and is inactive&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Dosing&lt;ol&gt;&lt;li&gt;Powder 1 mg (in &lt;a href="../../Derm/Exam/Blstr.htm" class="LinkPage"&gt;Blister&lt;/a&gt; pack) = &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; 3 units&lt;/li&gt;&lt;li&gt;Powder 3 mg (in &lt;a href="../../Derm/Exam/Blstr.htm" class="LinkPage"&gt;Blister&lt;/a&gt; pack) = &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; 8 units&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Preparations&lt;ol&gt;&lt;li&gt;Starter: Inhaler/parts, 180 packs 1 mg, 90 packs 3 mg&lt;/li&gt;&lt;li&gt;Refill 12: 90 packs 1 mg, 90 packs 3 mg (990 units)&lt;/li&gt;&lt;li&gt;Refill 15: 180 packs 1 mg, 90 packs 3 mg (1260 units)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Cost: Expensive (twice the cost of SQ &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt;)&lt;ol&gt;&lt;li&gt;Starter: $190&lt;/li&gt;&lt;li&gt;Refills: $140-180&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Efficacy&lt;ol&gt;&lt;li&gt;Similar to SC &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Adverse Effects&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Hypoglycemia/Hypglycm.htm" class="LinkPage"&gt;Hypoglycemia&lt;/a&gt; (esp. when used with &lt;a href="../../Endo/Pharm/OrlHypglycmc.htm" class="LinkPage"&gt;Oral Hypoglycemic&lt;/a&gt;s)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Lung/Sx/Cgh.htm" class="LinkPage"&gt;Cough&lt;/a&gt; (&amp;lt;5%)&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Sx/ChstPn.htm" class="LinkPage"&gt;Chest Pain&lt;/a&gt; (&amp;lt;5%)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Lung/Sx/ActDyspn.htm" class="LinkPage"&gt;Dyspnea&lt;/a&gt; (&amp;lt;5%)&lt;/li&gt;&lt;li&gt;&lt;a href="../../ENT/Sx/DryMth.htm" class="LinkPage"&gt;Dry Mouth&lt;/a&gt; (&amp;lt;5%)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Monitoring: &lt;a href="../../Lung/Lab/Sprmtry.htm" class="LinkPage"&gt;Pulmonary Function Test&lt;/a&gt;s&lt;ol&gt;&lt;li&gt;Schedule: Baseline, 6 months and annually&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Borja%20%20%5BAU%5D%20AND%202007%20%5BDP%5D%20AND%20%20Am%20Fam%20Physician%20%20%5BTA%5D" class="LinkRef"&gt;Borja (2007) Am Fam Physician 75: 1546-7&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Cefalu%20%20%5BAU%5D%20AND%202001%20%5BDP%5D%20AND%20%20Ann%20Intern%20Med%20%20%5BTA%5D" class="LinkRef"&gt;Cefalu (2001) Ann Intern Med 134:203-7&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Quattrin%20%20%5BAU%5D%20AND%202004%20%5BDP%5D%20AND%20%20Diabetes%20Care%20%20%5BTA%5D" class="LinkRef"&gt;Quattrin (2004) Diabetes Care 27:2622-7&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C1176237</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Pharm/InhldInsln.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Inhaled Insulin, Insulin Inhalation Powder, Exubera</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Pharm/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Byetta  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C1636686"&gt;&lt;i&gt;C1636686&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Amino Acid, Peptide, or Protein (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C1636686&amp;amp;tui=T116"&gt;&lt;i&gt;T116&lt;/i&gt;&lt;/a&gt;)
, Pharmacologic Substance (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C1636686&amp;amp;tui=T121"&gt;&lt;i&gt;T121&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;C074031&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Byetta&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;exenatide  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0167117"&gt;&lt;i&gt;C0167117&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Amino Acid, Peptide, or Protein (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0167117&amp;amp;tui=T116"&gt;&lt;i&gt;T116&lt;/i&gt;&lt;/a&gt;)
, Pharmacologic Substance (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0167117&amp;amp;tui=T121"&gt;&lt;i&gt;T121&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;C074031&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;416859008, 417734003&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;exendin-4, EXENATIDE, exenatide (medication), exenatide [Chemical/Ingredient], Ex4 peptide, exendin 4, exenatide, Exendin 4, Exenatide (product), Exenatide (substance), Exenatide&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;exenatida (producto), exenatida (sustancia), exenatida&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Byetta  (</value><value>)
</value><value>exenatide  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Incretin Mimetic</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Pharmacology</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;See Also&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Stglptn.htm" class="LinkPage"&gt;Sitagliptin&lt;/a&gt; (&lt;a href="../../Endo/Pharm/Stglptn.htm" class="LinkPage"&gt;Januvia&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Stglptn.htm" class="LinkPage"&gt;Dipeptidyl Peptidase-4 Inhibitor&lt;/a&gt; (&lt;a href="../../Endo/Pharm/Stglptn.htm" class="LinkPage"&gt;DPP-4 Inhibitor&lt;/a&gt;)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Indications&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/DM/TypDbtsMlts1.htm" class="LinkPage"&gt;Type II Diabetes Mellitus&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Especially in &lt;a href="../../Endo/Obesity/Obsty.htm" class="LinkPage"&gt;Obesity&lt;/a&gt;&lt;/li&gt;&lt;li&gt;May be used in combination with basal &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; (e.g. &lt;a href="../../Endo/Pharm/AnlgBslInsln.htm" class="LinkPage"&gt;Lantus&lt;/a&gt;)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; deficiency and &lt;a href="../../Endo/DM/InslnRstncSyndrm.htm" class="LinkPage"&gt;Insulin Resistance&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Adjunct to &lt;a href="../../Endo/Pharm/Glcphg.htm" class="LinkPage"&gt;Glucophage&lt;/a&gt;, &lt;a href="../../Endo/Pharm/Slfnylr.htm" class="LinkPage"&gt;Sulfonylurea&lt;/a&gt;s, &lt;a href="../../Endo/Pharm/Thzldndn.htm" class="LinkPage"&gt;Glitazone&lt;/a&gt;s&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Contraindications&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/DM/TypDbtsMlts.htm" class="LinkPage"&gt;Type I Diabetes Mellitus&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Concurrent prandial &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; (bolus &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt;)&lt;ol&gt;&lt;li&gt;Basal &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; (e.g. &lt;a href="../../Endo/Pharm/AnlgBslInsln.htm" class="LinkPage"&gt;Lantus&lt;/a&gt;) may be used with Byetta&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Renal/Failure/ActRnlFlr.htm" class="LinkPage"&gt;Renal Failure&lt;/a&gt;: &lt;a href="../../Renal/Lab/CrtnClrnc.htm" class="LinkPage"&gt;Creatinine Clearance&lt;/a&gt; &amp;lt;30 ml/min&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Mechanism&lt;ol&gt;&lt;li&gt;Synthetic form of exendin-4&lt;ol&gt;&lt;li&gt;Originally identified in Gila Monster &lt;a href="../../ENT/Anatomy/SlvryGlndAntmy.htm" class="LinkPage"&gt;Saliva&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Peptide with 39 amino acids&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Incretin Mimetic&lt;ol&gt;&lt;li&gt;Incretin analogue that mimics endogenous hormone&lt;/li&gt;&lt;li&gt;Incretin released from GI tract following meals&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Incretin effects&lt;ol&gt;&lt;li&gt;Increases &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; dependent &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; secretion&lt;/li&gt;&lt;li&gt;Delays gastric emptying&lt;/li&gt;&lt;li&gt;Decreases food intake (improves satiety)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Preparations&lt;ol&gt;&lt;li&gt;Exenatide (Byetta)&lt;ol&gt;&lt;li&gt;Glucagon-Like Peptide 1 (GLP-1) agonist derived from Gila monster &lt;a href="../../ENT/Anatomy/SlvryGlndAntmy.htm" class="LinkPage"&gt;Saliva&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Associated with weight loss and &lt;a href="../../GI/Sx/Vmtng.htm" class="LinkPage"&gt;Nausea&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Exenatide Weekly (Bydureon)&lt;ol&gt;&lt;li&gt;Injected once weekly&lt;/li&gt;&lt;li&gt;More effective than Byetta and as effectiev as Victoza&lt;/li&gt;&lt;li&gt;Less &lt;a href="../../GI/Sx/Vmtng.htm" class="LinkPage"&gt;Nausea&lt;/a&gt; than Byetta or Victoza&lt;/li&gt;&lt;li&gt;Requires reconstitution from powder before dose&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Liraglutide (Victoza)&lt;ol&gt;&lt;li&gt;Single daily injection (as contrasted with twice daily Byetta)&lt;/li&gt;&lt;li&gt;More potent than Byetta in lowering &lt;a href="../../Endo/Lab/HmglbnAc.htm" class="LinkPage"&gt;Hemoglobin A1C&lt;/a&gt; and similar efficacy to&lt;/li&gt;&lt;li&gt;Adverse effects include &lt;a href="../../GI/Sx/Vmtng.htm" class="LinkPage"&gt;Nausea&lt;/a&gt; (transient) and &lt;a href="../../Neuro/Sx/Hdch.htm" class="LinkPage"&gt;Headache&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Dosing: Byetta&lt;ol&gt;&lt;li&gt;Initial&lt;ol&gt;&lt;li&gt;Byetta 5 mcg SQ twice daily&lt;/li&gt;&lt;li&gt;Give within 60 minutes of morning and evening meals&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Later, if &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Sugar&lt;/a&gt;s not optimized&lt;ol&gt;&lt;li&gt;May increase to 10 mcg bid after 1 month&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Preparations: Prefilled pen holds 30 day supply&lt;ol&gt;&lt;li&gt;5 mcg/dose pen holds 1.2 ml of 250 mcg/ml&lt;/li&gt;&lt;li&gt;10 mcg/dose pen holds 2.4 ml of 250 mcg/ml&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Efficacy&lt;ol&gt;&lt;li&gt;Lowers &lt;a href="../../Endo/Lab/HmglbnAc.htm" class="LinkPage"&gt;HBA1C&lt;/a&gt; 0.4 to 0.8% (at 5 and 10 mcg doses)&lt;/li&gt;&lt;li&gt;Lowers weight by up to 4-10 pounds&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Cost&lt;ol&gt;&lt;li&gt;Monthly: $340 per month&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Adverse effects: Byetta&lt;ol&gt;&lt;li&gt;&lt;a href="../../GI/Sx/Vmtng.htm" class="LinkPage"&gt;Nausea&lt;/a&gt; (44%) or &lt;a href="../../GI/Sx/Vmtng.htm" class="LinkPage"&gt;Vomiting&lt;/a&gt; (13%)&lt;ol&gt;&lt;li&gt;Less frequent with Bydureon&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../GI/Diarrhea/ActDrh.htm" class="LinkPage"&gt;Diarrhea&lt;/a&gt; (13%)&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Sx/Dzns.htm" class="LinkPage"&gt;Dizziness&lt;/a&gt; (9%)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Neuro/Sx/Hdch.htm" class="LinkPage"&gt;Headache&lt;/a&gt; (9%)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Hypoglycemia/Hypglycm.htm" class="LinkPage"&gt;Hypoglycemia&lt;/a&gt;&lt;ol&gt;&lt;li&gt;With &lt;a href="../../Endo/Pharm/Slfnylr.htm" class="LinkPage"&gt;Sulfonylurea&lt;/a&gt;: 14.4% at 5 mcg, 35.7% at 10 mcg&lt;/li&gt;&lt;li&gt;With &lt;a href="../../Endo/Pharm/Glcphg.htm" class="LinkPage"&gt;Glucophage&lt;/a&gt;: 4.5% at 5 mcg, 5.3% at 10 mcg&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../GI/Pancreas/ActPncrts.htm" class="LinkPage"&gt;Pancreatitis&lt;/a&gt; (rare)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Precautions&lt;ol&gt;&lt;li&gt;Avoid using 2 Incretins (e.g. Byetta with &lt;a href="../../Endo/Pharm/Stglptn.htm" class="LinkPage"&gt;Januvia&lt;/a&gt;) in combination (raises cost, risk of &lt;a href="../../GI/Pancreas/ActPncrts.htm" class="LinkPage"&gt;Pancreatitis&lt;/a&gt; without significant benefit)&lt;/li&gt;&lt;li&gt;(2012) Presc Lett 19(8): 45&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=2012%20%5BDP%5D%20AND%20%20Presc%20Lett%20%20%5BTA%5D%20AND%2019%20%5BVI%5D%20AND%20%2015%20%5BPG%5D" class="LinkRef"&gt;(2012) Presc Lett 19(3): 15&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Dungan%20%20%5BAU%5D%20AND%202005%20%5BDP%5D%20AND%20%20Clin%20Diabetes%20%20%5BTA%5D" class="LinkRef"&gt;Dungan (2005) Clin Diabetes 23: 56-62&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Ezzo%20%20%5BAU%5D%20AND%202006%20%5BDP%5D%20AND%20%20Am%20Fam%20Physician%20%20%5BTA%5D" class="LinkRef"&gt;Ezzo (2006) Am Fam Physician 73&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Fineman%20%20%5BAU%5D%20AND%202003%20%5BDP%5D%20AND%20%20Diabetes%20Care%20%20%5BTA%5D" class="LinkRef"&gt;Fineman (2003) Diabetes Care 26:2370-7&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Jones%20%20%5BAU%5D%20AND%202007%20%5BDP%5D%20AND%20%20Am%20Fam%20Physician%20%20%5BTA%5D" class="LinkRef"&gt;Jones (2007) Am Fam Physician 75:1831-5&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Joy%20%20%5BAU%5D%20AND%202005%20%5BDP%5D%20AND%20%20Ann%20Pharmacol%20%20%5BTA%5D" class="LinkRef"&gt;Joy (2005) Ann Pharmacol 39:110-8&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C1636686</value><value>C0167117</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Pharm/IncrtnMmtc.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Incretin Mimetic, Byetta, Exenatide, Bydureon, Liraglutide, Victoza, GLP-1 Analog, Glucagon-Like Peptide 1, GLP-1</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Pharm/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Insulin  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0021641"&gt;&lt;i&gt;C0021641&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CSP)&lt;/td&gt;
                &lt;td&gt;protein hormone secreted by beta cells of the pancreas; insulin plays a major role in the regulation of glucose metabolism, generally promoting the cellular utilization of glucose and is also an important regulator of protein and lipid metabolism; insulin is used as a drug to control insulin-dependent diabetes mellitus.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A short-acting form of insulin. Regular insulin is obtained from animal or recombinant sources. The onset of action of regular insulin occurs at 30-90 minutes after injection; its effect lasts for 6 to 8 hours. Endogenous human insulin, a pancreatic hormone composed of two polypeptide chains, is important for the normal metabolism of carbohydrates, proteins and fats; it has anabolic effects on many types of tissues. (NCI04)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;Human insulin protein (110 aa, 12 kDa) is encoded by the human insulin (INS) gene. This cytosolic protein, a heterodimer of disulfide-linked alpha and beta chains, is produced in pancreatic islet beta cells. Binding of insulin to its receptor stimulates glucose uptake, accelerates both glycolysis and the pentose phosphate cycle and increases glycogen synthesis in the liver. Insulin regulates protein and lipid metabolism. It also decreases blood glucose concentration by shuttling molecules into cells to be used for energy. Decreased expression of insulin protein causes familial hyperproinsulinemia.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1).&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Amino Acid, Peptide, or Protein (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0021641&amp;amp;tui=T116"&gt;&lt;i&gt;T116&lt;/i&gt;&lt;/a&gt;)
, Pharmacologic Substance (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0021641&amp;amp;tui=T121"&gt;&lt;i&gt;T121&lt;/i&gt;&lt;/a&gt;)
, Hormone (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0021641&amp;amp;tui=T125"&gt;&lt;i&gt;T125&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D007328&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;67866001, 39487003, 412222002&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Insulin, insulin, INSULIN PREPARATIONS, Insulin preparation, NOS, Regular Insulin, Regular insulin preparation, Unmodified insulin preparation, Insulin Regular, INSULIN, insulin preparations, insulin preparations (medication), A22 INSULIN PREPARATIONS, insulin regular, Insulin (ox), 8A-L-threonine-10A-L-isoleucine-30B-L-threonine-, Insulin [Chemical/Ingredient], [HS501] INSULIN, Insulin regular, insulin products, insulin preparation, insulin product, regular insulin, insulins, Insulin, Soluble, Soluble Insulin, Insulin, Regular, Insulin product, Insulin (substance), Insulin preparation, Insulin product (product), Regular insulin product, Unmodified insulin product, Insulin preparation (substance), Regular insulin (substance), Regular insulin&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Insulin&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;insulin, inzulin&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Insuliini&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Insuline ordinaire, Insuline&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;INSULIN, ИНСУЛИН&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;producto con insulina (producto), preparado insulínico, insulina (producto), producto con insulina, insulina (sustancia), insulina, preparado de insulina (producto), preparado de insulina (sustancia), preparado de insulina cristalina de cinc, preparado de insulina cristalina de zinc, preparado de insulina no modificada, preparado de insulina, insulina regular (sustancia), insulina regular, Insulina&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Insulina regolare, Insulina&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Croatian&lt;/td&gt;
                &lt;td&gt;INZULIN&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Insulina&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;インスリン, インスリン亜鉛水性懸濁液, インシュリン&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Insulin&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Insulina&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Insulin  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Insulin Dosing</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Pharmacology</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Protocols&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Endo/Pharm/InslnDsngInTypDbts.htm" class="LinkPage"&gt;Insulin Dosing in Type I Diabetes&lt;/a&gt;&lt;/li&gt;&lt;li&gt;See &lt;a href="../../Endo/Pharm/InslnDsngInTypDbts1.htm" class="LinkPage"&gt;Insulin Dosing in Type II Diabetes&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/CrbhydrtCntInInslnDsng.htm" class="LinkPage"&gt;Insulin Adjustment with Carbohydrate Counting&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Protocol: Goal &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Glucose&lt;/a&gt; for Type I and &lt;a href="../../Endo/DM/TypDbtsMlts1.htm" class="LinkPage"&gt;Type II Diabetes&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/HmglbnAc.htm" class="LinkPage"&gt;Hemoglobin A1C&lt;/a&gt; &amp;lt;7%&lt;/li&gt;&lt;li&gt;Goal: &amp;gt;50% of &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Sugar&lt;/a&gt;s in range&lt;ol&gt;&lt;li&gt;Pre-meal &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Glucose&lt;/a&gt; 70-120 mg/dl&lt;/li&gt;&lt;li&gt;Two hour post-prandial &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Glucose&lt;/a&gt; &amp;lt;160 mg/dl&lt;/li&gt;&lt;li&gt;Bed-time &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Glucose&lt;/a&gt; 100-140 mg/dl&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Evaluation: &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Sugar&lt;/a&gt;s&lt;ol&gt;&lt;li&gt;Monitoring pointers&lt;ol&gt;&lt;li&gt;Be consistent in monitoring&lt;/li&gt;&lt;li&gt;Aim for 50% of &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Glucose&lt;/a&gt;s in target range&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Look for consistent pattern in &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Sugar&lt;/a&gt;s for &amp;gt;3 days&lt;ol&gt;&lt;li&gt;Compare &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Sugar&lt;/a&gt; for same time each day&lt;/li&gt;&lt;li&gt;For each time of day:&lt;ol&gt;&lt;li&gt;Calculate &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Glucose&lt;/a&gt; range&lt;/li&gt;&lt;li&gt;Calculate median &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Glucose&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Consider eating and activity patterns during day&lt;/li&gt;&lt;li&gt;Ignore spurious values&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Adjust only one &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; dose at a time&lt;ol&gt;&lt;li&gt;Correct &lt;a href="../../Endo/Hypoglycemia/Hypglycm.htm" class="LinkPage"&gt;Hypoglycemia&lt;/a&gt; first&lt;/li&gt;&lt;li&gt;Correct highest &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Sugar&lt;/a&gt;s next&lt;/li&gt;&lt;li&gt;Maintain a 50:50 mix of Basal to bolus &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Evaluation: Adjustment of &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Adjustment factors (for lows and highs)&lt;ol&gt;&lt;li&gt;Adjust &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; in small steps at a time&lt;/li&gt;&lt;li&gt;Adjustment steps based on &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; amount&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; dose &amp;lt;10 units: Adjust by 1 unit&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; dose 10-20 units: Adjust by 2 units&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; dose &amp;gt;20 units: Adjust by 10% &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; dose&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Adjustment steps based on diabetes type&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/DM/TypDbtsMlts.htm" class="LinkPage"&gt;Type I Diabetes Mellitus&lt;/a&gt;: 1-2 units change&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/DM/TypDbtsMlts1.htm" class="LinkPage"&gt;Type II Diabetes Mellitus&lt;/a&gt;: 2-4 units change&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Correction protocol for &lt;a href="../../Endo/Hypoglycemia/Hypglycm.htm" class="LinkPage"&gt;Hypoglycemia&lt;/a&gt;&lt;ol&gt;&lt;li&gt;General measures to consider&lt;ol&gt;&lt;li&gt;Increase carbohydrate preceeding low&lt;ol&gt;&lt;li&gt;Carbohydrate at prior meal or&lt;/li&gt;&lt;li&gt;Snack or&lt;/li&gt;&lt;li&gt;Pre-&lt;a href="../../Sports/Exercise/Exrcs.htm" class="LinkPage"&gt;Exercise&lt;/a&gt; carbohydrate&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Adjust &lt;a href="../../Sports/Exercise/Exrcs.htm" class="LinkPage"&gt;Exercise&lt;/a&gt; timing during the day&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Basal &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; (e.g. &lt;a href="../../Endo/Pharm/AnlgBslInsln.htm" class="LinkPage"&gt;Lantus&lt;/a&gt;) adjustment&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Glucose&lt;/a&gt; low in AM&lt;ol&gt;&lt;li&gt;Decrease basal &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; (&lt;a href="../../Endo/Pharm/AnlgBslInsln.htm" class="LinkPage"&gt;Lantus&lt;/a&gt;)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Rapid acting &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; (e.g. &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Lispro&lt;/a&gt;) adjustment&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Glucose&lt;/a&gt; low before lunch&lt;ol&gt;&lt;li&gt;Decrease rapid &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; (&lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Lispro&lt;/a&gt;) at breakfast&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Glucose&lt;/a&gt; low before dinner&lt;ol&gt;&lt;li&gt;Decrease rapid &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; (&lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Lispro&lt;/a&gt;) at lunch&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Glucose&lt;/a&gt; low before bedtime&lt;ol&gt;&lt;li&gt;Decrease rapid &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; (&lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Lispro&lt;/a&gt;) at dinner&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Correction protocol for &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Hyperglycemia&lt;/a&gt;&lt;ol&gt;&lt;li&gt;General measures to consider&lt;ol&gt;&lt;li&gt;Decrease carbohydrate preceeding high&lt;ol&gt;&lt;li&gt;Carbohydrate at prior meal or&lt;/li&gt;&lt;li&gt;Stop or decrease snack&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Increase &lt;a href="../../Sports/Exercise/Exrcs.htm" class="LinkPage"&gt;Exercise&lt;/a&gt; prior to meal&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Adjust &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; based on &lt;a href="../../Endo/Prevent/CrbhydrtCnt.htm" class="LinkPage"&gt;Carbohydrate Count&lt;/a&gt;&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Endo/Pharm/CrbhydrtCntInInslnDsng.htm" class="LinkPage"&gt;Insulin Adjustment with Carbohydrate Counting&lt;/a&gt;&lt;/li&gt;&lt;li&gt;One Unit covers each 10-15 grams carbohydrate&lt;/li&gt;&lt;li&gt;Add 1-2 units for every 50 mg/dl &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; &amp;gt;150&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Indications to adjust basal &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; (e.g. &lt;a href="../../Endo/Pharm/AnlgBslInsln.htm" class="LinkPage"&gt;Glargine&lt;/a&gt;)&lt;ol&gt;&lt;li&gt;All &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Glucose&lt;/a&gt;s &amp;gt;200 mg/dl&lt;ol&gt;&lt;li&gt;Increase basal &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; by 0.1 units/kg&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;All &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Glucose&lt;/a&gt;s high (within 50 mg/dl)&lt;ol&gt;&lt;li&gt;Increase basal &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; per adjustment above&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Pre-supper &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Glucose&lt;/a&gt; high&lt;ol&gt;&lt;li&gt;Adjust basal &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; per adjustment above&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Fasting (AM) &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Glucose&lt;/a&gt; high&lt;ol&gt;&lt;li&gt;Perform 3 am &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Sugar&lt;/a&gt; checks&lt;/li&gt;&lt;li&gt;Critical to distinguish 3 AM low BG from high BG&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/DwnPhnmn.htm" class="LinkPage"&gt;Dawn Phenomena&lt;/a&gt; (relative &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; deficiency)&lt;ol&gt;&lt;li&gt;Increase basal &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; by adjustment above&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/SmgyPhnmn.htm" class="LinkPage"&gt;Somogyi Phenomena&lt;/a&gt; (&lt;a href="../../Endo/Pharm/SmgyPhnmn.htm" class="LinkPage"&gt;Rebound Hyperglycemia&lt;/a&gt;)&lt;ol&gt;&lt;li&gt;Decrease basal &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; by adjustment above&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Indications to adjust bolus &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; (e.g. &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Lispro&lt;/a&gt;)&lt;ol&gt;&lt;li&gt;Two hour post-prandial &amp;gt;40-60 mg/dl over premeal&lt;ol&gt;&lt;li&gt;Increase rapid acting &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; before meal&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Glucose&lt;/a&gt; low before meal&lt;ol&gt;&lt;li&gt;Decrease rapid &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; before prior meal&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Average &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; doses after titrating from start&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/DM/TypDbtsMlts.htm" class="LinkPage"&gt;Type I Diabetes Mellitus&lt;/a&gt;: 0.7 units/kg&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/DM/TypDbtsMlts1.htm" class="LinkPage"&gt;Type II Diabetes Mellitus&lt;/a&gt;: 1.2 units/kg&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Resources&lt;ol&gt;&lt;li&gt;AIDA Diabetes &lt;a href="../../Endo/Pharm/InslnSmltn.htm" class="LinkPage"&gt;Insulin Simulation&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.2aida.org/online" class="LinkWebExt"&gt;http://www.2aida.org/online&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0021641</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Pharm/InslnDsng.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Insulin Dosing</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Pharm/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Blood glucose meters (medical device)  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0472226"&gt;&lt;i&gt;C0472226&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Medical Device (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0472226&amp;amp;tui=T074"&gt;&lt;i&gt;T074&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;337414009&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Blood-Glucose Meter, BLOOD-GLUCOSE MEASURING EQUIP. MISC. EACH, BLOOD-GLUCOSE METER @ @ EACH, BLOOD-GLUCOSE METER EACH, Glucometers, Glucose Analyzers, Blood glucose meters (medical device), Glucose Blood Test, BLOOD-GLUCOSE METER MISCELL EACH, BLOOD-GLUCOSE METER@@MISCELL@EACH, glucose analyzer, blood glucose meter, glucometers, glucometer, blood glucose meters, Blood glucose meters, Blood glucose meters (physical object), Glucometer&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;glucosímetros (objeto físico), glucosímetros&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Blood glucose meters (medical device)  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Glucometer</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Pharmacology</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Costs&lt;ol&gt;&lt;li&gt;Glucometers cost $10 to over $100 (Voicemate is $395)&lt;ol&gt;&lt;li&gt;Manufacturers give meters away (via DM educators)&lt;/li&gt;&lt;li&gt;The meters cost far less than years of test strips&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Test Strips cost 36 to 85 cents per strip&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Preparations: Glucometers (13) by Quality per Consumer Reports&lt;ol&gt;&lt;li&gt;Consumer reports recommended devices&lt;ol&gt;&lt;li&gt;Lifescan: One Touch Ultrasmart and Ultra&lt;/li&gt;&lt;li&gt;The Ultra was also their top choice in 2001&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Most consistent and accurate&lt;ol&gt;&lt;li&gt;Abbott: FreeStyle Flash, Freestyle&lt;/li&gt;&lt;li&gt;Bayer: Ascensia Complete&lt;/li&gt;&lt;li&gt;Becton: BD Logic&lt;/li&gt;&lt;li&gt;Lifescan: One Touch Ultrasmart and Ultra&lt;/li&gt;&lt;li&gt;Roche: Accu-check Complete&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Least consistent and least accurate (avoid these)&lt;ol&gt;&lt;li&gt;Hypoguard: Advance Micro-Draw&lt;/li&gt;&lt;li&gt;Solartek: NewTek ReliOn (also most difficult to use)&lt;/li&gt;&lt;li&gt;Home: TrueTrack SmartSystem&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Anecdotal Quality reports (not from Consumer Reports)&lt;ol&gt;&lt;li&gt;BD meters may be more "touchy"; require repeat tests&lt;/li&gt;&lt;li&gt;Hypoguard QuickTek appears to be lower quality&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;References&lt;ol&gt;&lt;li&gt;(August 2005) Consumer Reports, p. 9&lt;/li&gt;&lt;li&gt;(October 2001) Consumer Reports, p. 38&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Preparations: Glucometers by key features (best marked with *)&lt;ol&gt;&lt;li&gt;Smallest sample needed (1 microliter or less, *=0.3)&lt;ol&gt;&lt;li&gt;Abbott: FreeStyle Flash*, Freestyle*&lt;/li&gt;&lt;li&gt;Bayer: Ascensia contour&lt;/li&gt;&lt;li&gt;Becton: BD Logic*&lt;/li&gt;&lt;li&gt;Home: TrueTrack SmartSystem&lt;/li&gt;&lt;li&gt;Lifescan: One Touch Ultrasmart and Ultra, Induo&lt;/li&gt;&lt;li&gt;Roche: Accu-check Active&lt;/li&gt;&lt;li&gt;Solartek: ReliOn&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Largest sample needed (4-10 microliters)&lt;ol&gt;&lt;li&gt;Lifescan: One Touch Basic, SureStep (10 ul)&lt;/li&gt;&lt;li&gt;Roche: Accu-check Advantage, Complete, Voicemate&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Shortest reaction time (10 seconds or less, *=5)&lt;ol&gt;&lt;li&gt;Abbott: FreeStyle Flash, Freestyle, Precision Xtra&lt;/li&gt;&lt;li&gt;Becton: BD Logic*&lt;/li&gt;&lt;li&gt;TruTrack SmartSystem&lt;/li&gt;&lt;li&gt;Hypoguard: Advance Intuition, Assure3&lt;/li&gt;&lt;li&gt;Infopia: EasyGluco&lt;/li&gt;&lt;li&gt;Lifescan: One Touch &lt;a href="../../Pharm/Analgesic/Trmdl.htm" class="LinkPage"&gt;Ultram&lt;/a&gt;art* and Ultra*, Induo*&lt;/li&gt;&lt;li&gt;Roche: Accu-Chek Active and Compact&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Computer Download available&lt;ol&gt;&lt;li&gt;Abbott: FreeStyle Flash, Freestyle, Precision Xtra&lt;/li&gt;&lt;li&gt;Bayer: All 5 Ascensia models&lt;/li&gt;&lt;li&gt;Becton: BD Logic&lt;/li&gt;&lt;li&gt;Home: Prestige IQ&lt;/li&gt;&lt;li&gt;Hypoguard: Advance Micro-Draw, Assure, QuickTec&lt;/li&gt;&lt;li&gt;Lifescan: All 5 One Touch/indio models&lt;/li&gt;&lt;li&gt;Roche: All 5 Accu-Chek models&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Most internal memory for storing sugars (450 or more)&lt;ol&gt;&lt;li&gt;Abbott: Precision Xtra&lt;/li&gt;&lt;li&gt;Lifescan: One Touch Ultrasmart* (stores 3000 values)&lt;/li&gt;&lt;li&gt;Roche: Accu-Chek Advantage, Accu-Chek Complete&lt;/li&gt;&lt;li&gt;Solartek: ReliOn&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Lightest weight meters (2 oz or less)&lt;ol&gt;&lt;li&gt;Abbott: FreeStyle Flash, Precision Xtra&lt;/li&gt;&lt;li&gt;Bayer: Ascencia contour, Elite&lt;/li&gt;&lt;li&gt;Home: TrueTrack Smart System&lt;/li&gt;&lt;li&gt;Hypoguard: Advance Micro-Draw&lt;/li&gt;&lt;li&gt;Infopia: EasyGluco&lt;/li&gt;&lt;li&gt;Lifescan: OneTouch Ultra&lt;/li&gt;&lt;li&gt;Roche: Accu-Chek Advantage&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Test Strip expense&lt;ol&gt;&lt;li&gt;Annual cost for test strips (testing 4 times daily)&lt;ol&gt;&lt;li&gt;Low cost strips (36-50 cents): $520 to $730/year&lt;/li&gt;&lt;li&gt;Most expensive strips (70-85 cents): $1020 to $1240&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Least expensive test strips (60 cents or less, *=36)&lt;ol&gt;&lt;li&gt;Home: Prestige IQ, TrueTrack Smart (52 cents)&lt;/li&gt;&lt;li&gt;Hypoguard: QuickTec*, Intuition, Micro, Assure 2-3&lt;/li&gt;&lt;li&gt;Infopia: EasyGluco&lt;/li&gt;&lt;li&gt;Solartek: ReliOn (43 cents)&lt;/li&gt;&lt;li&gt;Roche: Accu-Chek Active (60 cents)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Most expensive test strips (70 cents or more, *=85)&lt;ol&gt;&lt;li&gt;Abbott: FreeStyle Flash, Freestyle, Precision Xtra&lt;/li&gt;&lt;li&gt;Bayer: All 5 Ascensia models&lt;/li&gt;&lt;li&gt;Becton: BD Logic&lt;/li&gt;&lt;li&gt;Lifescan: All 5 one touch/indio models (SureStep*)&lt;/li&gt;&lt;li&gt;Roche: All Accu-Chek models except Accu-Chek Active&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Glucometer cost&lt;ol&gt;&lt;li&gt;Least expensive meters ($20 or less, ReliOn is &amp;lt;$10)&lt;ol&gt;&lt;li&gt;Home: Prestige IQ, TrueTrack Smart (rebranded)&lt;/li&gt;&lt;li&gt;Hypoguard: QuickTec*, Intuition, Micro, Assure 2-3&lt;/li&gt;&lt;li&gt;Infopia: EasyGluco&lt;/li&gt;&lt;li&gt;Solartek: ReliOn*&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Most expensive meter ($90 or more, *=$395)&lt;ol&gt;&lt;li&gt;Roche: Accu-Chek Complete, Accu-Chek VoiceMate*&lt;/li&gt;&lt;li&gt;Lifescan: OneTouch Ultrasmart, Induo&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Coldest tolerance (&amp;lt;45 degrees F, *=40)&lt;ol&gt;&lt;li&gt;Abbott: FreeStyle Flash*, Freestyle*&lt;/li&gt;&lt;li&gt;Lifescan: OneTouch Ultrasmart, Induo, Ultra&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Warmest tolerance (&amp;gt;110 degrees F)&lt;ol&gt;&lt;li&gt;Lifescan: OneTouch Ultrasmart, Induo, Ultra&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0472226</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Pharm/Glcmtr.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Glucometer, Blood-Glucose Monitor</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Pharm/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Biguanides  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0005382"&gt;&lt;i&gt;C0005382&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Organic Chemical (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0005382&amp;amp;tui=T109"&gt;&lt;i&gt;T109&lt;/i&gt;&lt;/a&gt;)
, Pharmacologic Substance (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0005382&amp;amp;tui=T121"&gt;&lt;i&gt;T121&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D001645&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;109082004, 373306007&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Biguanides, Biguanides [Chemical/Ingredient], Biguanide-class Agent, Biguanide [EPC], biguanide, biguanides, Biguanide, Biguanide (product), Biguanide (substance)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Biguanider&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;biguanidy&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Biguanidit&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;BIGUANIDY, БИГУАНИДЫ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Croatian&lt;/td&gt;
                &lt;td&gt;BIGVANIDI, BIGUANIDI&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Biguanidu pochodne&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;biguanida (producto), biguanida (sustancia), biguanida, Biguanidas&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Biguanides&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Biguanide&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Biguanidi&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Biguanidas&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Metformin  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0025598"&gt;&lt;i&gt;C0025598&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A biguanide with antihyperglycemic activity. Metformin exerts its action by improving hepatic sensitivity to insulin, thereby suppressing hepatic glucose production and increasing hepatic glycogen stores. In addition, metformin increases the number and/or affinity of insulin receptors on cell surface membranes in muscle and adipose tissue, thereby increasing the sensitivity to insulin at receptor and post-receptor binding sites and increasing glucose uptake peripherally.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CHV)&lt;/td&gt;
                &lt;td&gt;a kind of diabetes treatment drug&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;The active ingredient in a drug used to treat diabetes mellitus (a condition in which the body cannot control the level of sugar in the blood). It is also being studied in the treatment of cancer. It decreases the amount of glucose (a type of sugar) released into the bloodstream from the liver and increases the body's use of the glucose. Metformin is a type of antidiabetic agent.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CSP)&lt;/td&gt;
                &lt;td&gt;N,N-dimethylimidodicarbonimidic diamide; an oral hypogylcemic agent.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Organic Chemical (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0025598&amp;amp;tui=T109"&gt;&lt;i&gt;T109&lt;/i&gt;&lt;/a&gt;)
, Pharmacologic Substance (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0025598&amp;amp;tui=T121"&gt;&lt;i&gt;T121&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D008687&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;109081006, 372567009&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Dimethylbiguanidine, Dimethylguanylguanidine, Metformin, Imidodicarbonimidic diamide, N,N-dimethyl-, METFORMIN, 1,1-Dimethylbiguanide, N,N-Dimethylimidodicarbonimidic Diamide, metformin, Metformin [Chemical/Ingredient], metFORMIN, Metformin (product), Metformin (substance)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Metformin&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;metformin&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Metformiini&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;METFORMIN, DIMETILGUANILGUANIDIN, ДИМЕТИЛГУАНИЛГУАНИДИН, МЕТФОРМИН&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;ジメチルグアニルグアニジン, 1,1-ジメチルビグアニド, メトホルミン塩酸塩, ネルビス, 塩酸メトホルミン, グリコラン, メデット, メトホルミン, メルビン, メトフォルミン&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Dimetilbiguanide, Dimetil guanil guanidina, Metoformina&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Croatian&lt;/td&gt;
                &lt;td&gt;METFORMIN&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Metformina&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;metformina (producto), metformina (sustancia), metformina, Dimetilguanilguanidina, Metformina&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Diméthylbiguanide, Metformine&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Dimethylguanylguanidin, Metformin&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Dimetil Guanil Guanidina, Metformina&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Glucophage  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0591573"&gt;&lt;i&gt;C0591573&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CHV)&lt;/td&gt;
                &lt;td&gt;brand name of metformin an anti-diabetic drug&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CHV)&lt;/td&gt;
                &lt;td&gt;brand name of metformin an anti-diabetic drug&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Organic Chemical (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0591573&amp;amp;tui=T109"&gt;&lt;i&gt;T109&lt;/i&gt;&lt;/a&gt;)
, Pharmacologic Substance (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0591573&amp;amp;tui=T121"&gt;&lt;i&gt;T121&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D008687&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;glucophage, Glucophage [brand name], Glucophage&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Biguanides  (</value><value>)
</value><value>Metformin  (</value><value>)
</value><value>Glucophage  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Glucophage</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Pharmacology</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;See Also&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/OrlHypglycmc.htm" class="LinkPage"&gt;Oral Hypoglycemic&lt;/a&gt; Agents&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Mechanism&lt;ol&gt;&lt;li&gt;Primary mechanism: Inhibits hepatic gluconeogenesis&lt;/li&gt;&lt;li&gt;Secondary mechanism: Sensitize peripheral tissue to &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;History&lt;ol&gt;&lt;li&gt;Other Biguanides removed from U.S. market in 1960's&lt;ol&gt;&lt;li&gt;Toxicity limited prior use&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Oldest &lt;a href="../../Endo/DM/DbtsMlts.htm" class="LinkPage"&gt;Diabetes Mellitus&lt;/a&gt; agent&lt;ol&gt;&lt;li&gt;Derivative of Goat's Rue (French Lily)&lt;/li&gt;&lt;li&gt;Used in medieval Europe for &lt;a href="../../Endo/DM/DbtsMlts.htm" class="LinkPage"&gt;Diabetes Mellitus&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Pathophysiology&lt;ol&gt;&lt;li&gt;Decreases hepatic &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; production&lt;/li&gt;&lt;li&gt;Increases peripheral &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; uptake&lt;/li&gt;&lt;li&gt;Slows intestinal &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; absorption&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Indications&lt;ol&gt;&lt;li&gt;First line agent in &lt;a href="../../Endo/DM/TypDbtsMlts1.htm" class="LinkPage"&gt;Type II Diabetes Mellitus&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Obese patients&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Lipid/Hyprchlstrlm.htm" class="LinkPage"&gt;Hyperlipidemia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Children over age 10 with &lt;a href="../../Endo/DM/TypDbtsMlts1.htm" class="LinkPage"&gt;Type II Diabetes&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/DM/InslnRstncSyndrm.htm" class="LinkPage"&gt;Metabolic Syndrome&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Gyn/Endo/PlycystcOvryDs.htm" class="LinkPage"&gt;Polycystic Ovary Syndrome&lt;/a&gt; (&lt;a href="../../Gyn/Endo/PlycystcOvryDs.htm" class="LinkPage"&gt;PCOS&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;Induces &lt;a href="../../Gyn/Exam/Ovltn.htm" class="LinkPage"&gt;Ovulation&lt;/a&gt; (with or without &lt;a href="../../Gyn/Endo/Hyprndrgnsm.htm" class="LinkPage"&gt;Hyperandrogenism&lt;/a&gt;)&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Carmina%20%20%5BAU%5D%20AND%202004%20%5BDP%5D%20AND%20%20Am%20J%20Obstet%20Gynecol%20%20%5BTA%5D" class="LinkRef"&gt;Carmina (2004) Am J Obstet Gynecol 191:1580-4&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Other indicators&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/HmglbnAc.htm" class="LinkPage"&gt;Hemoglobin A1C&lt;/a&gt; &amp;lt;9%&lt;/li&gt;&lt;li&gt;High fasting &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Glucose&lt;/a&gt; 160-250 mg/dl&lt;/li&gt;&lt;li&gt;Dyslipidemia&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Contraindications&lt;ol&gt;&lt;li&gt;Risk of &lt;a href="../../Derm/Pharm/AlphHydrxyAcd.htm" class="LinkPage"&gt;Lactic Acid&lt;/a&gt;osis (theoretical based on older Biguanides)&lt;ol&gt;&lt;li&gt;Avoid in Renal Insufficiency (GFR &amp;lt;60 ml/min)&lt;ol&gt;&lt;li&gt;&lt;a href="../../Renal/Lab/SrmCrtn.htm" class="LinkPage"&gt;Serum Creatinine&lt;/a&gt; &amp;gt;1.5 mg/dl in men and &amp;gt;1.4 mg/dl in women&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Avoid with &lt;a href="../../Psych/CD/AlchlAbs.htm" class="LinkPage"&gt;Alcohol Abuse&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Avoid concurrent IV iodinated contrast dye use&lt;ol&gt;&lt;li&gt;Allow 48 hour wash-out of dye or&lt;/li&gt;&lt;li&gt;Confirm normal &lt;a href="../../Renal/Lab/RnlFnctn.htm" class="LinkPage"&gt;Renal Function&lt;/a&gt; tests after dye&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Large review found no associated increased risk of &lt;a href="../../Derm/Pharm/AlphHydrxyAcd.htm" class="LinkPage"&gt;Lactic Acid&lt;/a&gt;osis&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Salpeter%20%20%5BAU%5D%20AND%202003%20%5BDP%5D%20AND%20%20Arch%20Intern%20Med%20%20%5BTA%5D" class="LinkRef"&gt;Salpeter (2003) Arch Intern Med 163(21): 2594-602&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Avoid in hepatic insufficiency&lt;ol&gt;&lt;li&gt;Also avoid if excessive &lt;a href="../../Psych/Pharm/Alchl.htm" class="LinkPage"&gt;Alcohol&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Hold prior to iodinated contrast dye or surgery&lt;/li&gt;&lt;li&gt;Avoid in &lt;a href="../../Uro/Urine/PrtnrInAdlts.htm" class="LinkPage"&gt;Proteinuria&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Avoid in &lt;a href="../../Surgery/CV/PrphrlArtrlOclsvDs.htm" class="LinkPage"&gt;Peripheral Vascular Disease&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Avoid in &lt;a href="../../CV/CAD/ActCrnrySyndrm.htm" class="LinkPage"&gt;Coronary Artery Disease&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Not contraindicated in stable &lt;a href="../../CV/CHF/CngstvHrtFlr.htm" class="LinkPage"&gt;Congestive Heart Failure&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Eurich%20(2007)%20BMJ%20335%20%5BAU%5D%20AND%207618%20%5BDP%5D%20AND%20:%20%5BTA%5D" class="LinkRef"&gt;Eurich (2007) BMJ 335(7618):497&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Dosing: General&lt;ol&gt;&lt;li&gt;Maximum daily dose of Metformin  is 2500 mg (for either regular or XR)&lt;/li&gt;&lt;li&gt;Effective maximum dose is 2000 mg daily&lt;ol&gt;&lt;li&gt;Effect drops off above 2000 mg&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Dose related drop in fasting &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Glucose&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Metformin 500 mg decreases fasting &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Glucose&lt;/a&gt; by 19 mg/dl&lt;/li&gt;&lt;li&gt;Metformin 1000 mg decreases fasting &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Glucose&lt;/a&gt; by 31 mg/dl&lt;/li&gt;&lt;li&gt;Metformin 1500 mg decreases fasting &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Glucose&lt;/a&gt; by 41 mg/dl&lt;/li&gt;&lt;li&gt;Metformin 2000 mg decreases fasting &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Glucose&lt;/a&gt; by 78 mg/dl&lt;/li&gt;&lt;li&gt;Metformin 2500 mg decreases fasting &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Glucose&lt;/a&gt; by 62 mg/dl&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;References&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Garber%20%20%5BAU%5D%20AND%201997%20%5BDP%5D%20AND%20%20Am%20J%20Med%20%5BTA%5D" class="LinkRef"&gt;Garber (1997) Am J Med&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Dosing: Short acting&lt;ol&gt;&lt;li&gt;Week 1: 500 mg PO bid&lt;/li&gt;&lt;li&gt;Week 2&lt;ol&gt;&lt;li&gt;Example 1: 1000 mg PO qAM and 500 mg PO qPM&lt;/li&gt;&lt;li&gt;Example 2: 850 mg PO bid&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Week 3: 1000 mg PO bid&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Dosing: Long Acting&lt;ol&gt;&lt;li&gt;Start: Metformin XR 500 mg daily&lt;/li&gt;&lt;li&gt;Increase by 500 mg weekly until at 2000 mg or at goal &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Sugar&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Cost&lt;ol&gt;&lt;li&gt;More expensive than &lt;a href="../../Endo/Pharm/Slfnylr.htm" class="LinkPage"&gt;Sulfonylurea&lt;/a&gt;s (except generic Metformin)&lt;/li&gt;&lt;li&gt;Less expensive than &lt;a href="../../Endo/Pharm/Thzldndn.htm" class="LinkPage"&gt;Thiazolidinedione&lt;/a&gt;s&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Adverse effects&lt;ol&gt;&lt;li&gt;Abdominal discomfort&lt;/li&gt;&lt;li&gt;&lt;a href="../../GI/Diarrhea/ActDrh.htm" class="LinkPage"&gt;Diarrhea&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../ENT/Sx/MtlcTst.htm" class="LinkPage"&gt;Metallic Taste&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../GI/Sx/Vmtng.htm" class="LinkPage"&gt;Nausea&lt;/a&gt; or &lt;a href="../../GI/Sx/Vmtng.htm" class="LinkPage"&gt;Vomiting&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Anorexia&lt;/li&gt;&lt;li&gt;Decreased absorption of &lt;a href="../../Pharm/Vitamins/FlcAcd.htm" class="LinkPage"&gt;Folic Acid&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../HemeOnc/Anemia/VtmnBDfcncy.htm" class="LinkPage"&gt;Vitamin B12 Deficiency&lt;/a&gt; (due to decreased absorption)&lt;ol&gt;&lt;li&gt;Consider periodic screening&lt;/li&gt;&lt;li&gt;Check serum B12 when &lt;a href="../../Neuro/Sx/PrphrlNrpthy.htm" class="LinkPage"&gt;Peripheral Neuropathy&lt;/a&gt; occurs (do not assume &lt;a href="../../Endo/Renal/DbtcNphrpthy.htm" class="LinkPage"&gt;Diabetic Nephropathy&lt;/a&gt; only)&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Ting%20%20%5BAU%5D%20AND%202007%20%5BDP%5D%20AND%20%20Arch%20Intern%20Med%20%20%5BTA%5D" class="LinkRef"&gt;Ting (2007) Arch Intern Med 166:1975-9&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Derm/Pharm/AlphHydrxyAcd.htm" class="LinkPage"&gt;Lactic Acid&lt;/a&gt;osis Risk&lt;ol&gt;&lt;li&gt;See contraindications above&lt;/li&gt;&lt;li&gt;Despite theoretical risk, no evidence that &lt;a href="../../Derm/Pharm/AlphHydrxyAcd.htm" class="LinkPage"&gt;Lactic Acid&lt;/a&gt;osis occurs with Metformin&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Salpeter%20%20%5BAU%5D%20AND%202003%20%5BDP%5D%20AND%20%20Arch%20Intern%20Med%20%20%5BTA%5D" class="LinkRef"&gt;Salpeter (2003) Arch Intern Med 163:2594-602&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Bailey%20%20%5BAU%5D%20AND%201996%20%5BDP%5D%20AND%20%20N%20Engl%20J%20Med%20%20%5BTA%5D" class="LinkRef"&gt;Bailey (1996) N Engl J Med 334:574-9&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Defronzo%20%20%5BAU%5D%20AND%201995%20%5BDP%5D%20AND%20%20N%20Engl%20J%20Med%20%20%5BTA%5D" class="LinkRef"&gt;Defronzo (1995) N Engl J Med 333:541-9, 550-4&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Hermann%20%20%5BAU%5D%20AND%201994%20%5BDP%5D%20AND%20%20Diabetes%20Care%20%20%5BTA%5D" class="LinkRef"&gt;Hermann (1994) Diabetes Care 17:1100-9&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Stumvoll%20%20%5BAU%5D%20AND%201995%20%5BDP%5D%20AND%20%20N%20Engl%20J%20Med%20%20%5BTA%5D" class="LinkRef"&gt;Stumvoll (1995) N Engl J Med 333:550-4&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Luna%20%20%5BAU%5D%20AND%202001%20%5BDP%5D%20AND%20%20Am%20Fam%20Physician%20%20%5BTA%5D" class="LinkRef"&gt;Luna (2001) Am Fam Physician 63(9):1747-56&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0005382</value><value>C0025598</value><value>C0591573</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Pharm/Glcphg.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Glucophage, Metformin, Biguanide</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Pharm/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Insulin  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0021641"&gt;&lt;i&gt;C0021641&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CSP)&lt;/td&gt;
                &lt;td&gt;protein hormone secreted by beta cells of the pancreas; insulin plays a major role in the regulation of glucose metabolism, generally promoting the cellular utilization of glucose and is also an important regulator of protein and lipid metabolism; insulin is used as a drug to control insulin-dependent diabetes mellitus.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A short-acting form of insulin. Regular insulin is obtained from animal or recombinant sources. The onset of action of regular insulin occurs at 30-90 minutes after injection; its effect lasts for 6 to 8 hours. Endogenous human insulin, a pancreatic hormone composed of two polypeptide chains, is important for the normal metabolism of carbohydrates, proteins and fats; it has anabolic effects on many types of tissues. (NCI04)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;Human insulin protein (110 aa, 12 kDa) is encoded by the human insulin (INS) gene. This cytosolic protein, a heterodimer of disulfide-linked alpha and beta chains, is produced in pancreatic islet beta cells. Binding of insulin to its receptor stimulates glucose uptake, accelerates both glycolysis and the pentose phosphate cycle and increases glycogen synthesis in the liver. Insulin regulates protein and lipid metabolism. It also decreases blood glucose concentration by shuttling molecules into cells to be used for energy. Decreased expression of insulin protein causes familial hyperproinsulinemia.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1).&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Amino Acid, Peptide, or Protein (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0021641&amp;amp;tui=T116"&gt;&lt;i&gt;T116&lt;/i&gt;&lt;/a&gt;)
, Pharmacologic Substance (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0021641&amp;amp;tui=T121"&gt;&lt;i&gt;T121&lt;/i&gt;&lt;/a&gt;)
, Hormone (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0021641&amp;amp;tui=T125"&gt;&lt;i&gt;T125&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D007328&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;67866001, 39487003, 412222002&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Insulin, insulin, INSULIN PREPARATIONS, Insulin preparation, NOS, Regular Insulin, Regular insulin preparation, Unmodified insulin preparation, Insulin Regular, INSULIN, insulin preparations, insulin preparations (medication), A22 INSULIN PREPARATIONS, insulin regular, Insulin (ox), 8A-L-threonine-10A-L-isoleucine-30B-L-threonine-, Insulin [Chemical/Ingredient], [HS501] INSULIN, Insulin regular, insulin products, insulin preparation, insulin product, regular insulin, insulins, Insulin, Soluble, Soluble Insulin, Insulin, Regular, Insulin product, Insulin (substance), Insulin preparation, Insulin product (product), Regular insulin product, Unmodified insulin product, Insulin preparation (substance), Regular insulin (substance), Regular insulin&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Insulin&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;insulin, inzulin&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Insuliini&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Insuline ordinaire, Insuline&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;INSULIN, ИНСУЛИН&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;producto con insulina (producto), preparado insulínico, insulina (producto), producto con insulina, insulina (sustancia), insulina, preparado de insulina (producto), preparado de insulina (sustancia), preparado de insulina cristalina de cinc, preparado de insulina cristalina de zinc, preparado de insulina no modificada, preparado de insulina, insulina regular (sustancia), insulina regular, Insulina&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Insulina regolare, Insulina&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Croatian&lt;/td&gt;
                &lt;td&gt;INZULIN&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Insulina&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;インスリン, インスリン亜鉛水性懸濁液, インシュリン&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Insulin&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Insulina&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Insulin  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Insulin Dosing in Type 1 Diabetes</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Pharmacology</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;See Also&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Prevent/CrbhydrtCnt.htm" class="LinkPage"&gt;Carbohydrate Counting&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/InslnDsng.htm" class="LinkPage"&gt;Insulin Dosing&lt;/a&gt;&lt;/li&gt;&lt;li&gt;See &lt;a href="../../Endo/Pharm/InslnDsngInTypDbts1.htm" class="LinkPage"&gt;Insulin Dosing in Type II Diabetes&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/CrbhydrtCntInInslnDsng.htm" class="LinkPage"&gt;Insulin Adjustment with Carbohydrate Counting&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Dose: Initial Dosing with basal/bolus &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Calculate total daily &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; (TDI) dose&lt;ol&gt;&lt;li&gt;Ketones moderate or less: 0.5 units/kg/day&lt;/li&gt;&lt;li&gt;Ketones large: 0.7 units/kg/day&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Divide total &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; into basal and bolus dosing&lt;ol&gt;&lt;li&gt;Basal &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; (long-acting): 50% of total &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/AnlgBslInsln.htm" class="LinkPage"&gt;Insulin Glargine&lt;/a&gt; (&lt;a href="../../Endo/Pharm/AnlgBslInsln.htm" class="LinkPage"&gt;Lantus&lt;/a&gt;) once daily (any time) or&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;NPH Insulin&lt;/a&gt; twice daily&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Bolus &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; (rapid acting): 50% of total &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Rapid acting &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt;s: &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Lispro&lt;/a&gt;, &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Aspart&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Regular Insulin&lt;/a&gt; may be used instead due to cost&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Divide out equally before meals&lt;/li&gt;&lt;li&gt;Adjust later for carb count variations at meals&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Example: 60 kg adult with moderate ketones&lt;ol&gt;&lt;li&gt;Total &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; dose: 30 units&lt;/li&gt;&lt;li&gt;Divide &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/AnlgBslInsln.htm" class="LinkPage"&gt;Insulin Glargine&lt;/a&gt; (&lt;a href="../../Endo/Pharm/AnlgBslInsln.htm" class="LinkPage"&gt;Lantus&lt;/a&gt;): 15 units at bedtime&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt;&lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Lispro&lt;/a&gt;: 15 units total divided over meals&lt;ol&gt;&lt;li&gt;Before breakfast: 5 units&lt;/li&gt;&lt;li&gt;Before lunch: 5 units&lt;/li&gt;&lt;li&gt;Before dinner: 5 units&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Dose: Conversion from mixed &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; (70/30 or 75/25)&lt;ol&gt;&lt;li&gt;Calculate total &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; units&lt;/li&gt;&lt;li&gt;Reduce total &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; depending of &lt;a href="../../Endo/Lab/HmglbnAc.htm" class="LinkPage"&gt;Hemoglobin A1C&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/HmglbnAc.htm" class="LinkPage"&gt;Hemoglobin A1C&lt;/a&gt; &amp;gt;9%: Decrease total &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; by 10%&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/HmglbnAc.htm" class="LinkPage"&gt;Hemoglobin A1C&lt;/a&gt; &amp;lt;9%: Decrease total &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; by 20%&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Divide total &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; into basal and bolus dosing&lt;ol&gt;&lt;li&gt;Basal &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; (long-acting): 50% of total &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/AnlgBslInsln.htm" class="LinkPage"&gt;Insulin Glargine&lt;/a&gt; (&lt;a href="../../Endo/Pharm/AnlgBslInsln.htm" class="LinkPage"&gt;Lantus&lt;/a&gt;) once daily or&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;NPH Insulin&lt;/a&gt; twice daily&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Bolus &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; (rapid acting): 50% of total &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Rapid acting &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt;s: &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Lispro&lt;/a&gt;, &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Aspart&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Divide out equally before meals&lt;/li&gt;&lt;li&gt;Adjust later for carb count variations at meals&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Management: Adjustments&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Endo/Pharm/InslnDsng.htm" class="LinkPage"&gt;Insulin Dosing&lt;/a&gt; for adjustment regimen&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0021641</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Pharm/InslnDsngInTypDbts.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Insulin Dosing in Type 1 Diabetes, Insulin Dosing in Type I Diabetes</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Pharm/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees></FP_UMLS_Trees><FP_Condition_name_check></FP_Condition_name_check><FP_Condition_name><value>Dawn Phenomena</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Pharmacology</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Pathophysiology&lt;ol&gt;&lt;li&gt;Waning-off of &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; action in AM hours&lt;/li&gt;&lt;li&gt;Secondary to increased nocturnal GH output&lt;/li&gt;&lt;li&gt;Results in high AM &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Sugar&lt;/a&gt;s&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Diagnosis&lt;ol&gt;&lt;li&gt;Checking 3 am &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Sugar&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Management&lt;ol&gt;&lt;li&gt;Increase evening long-acting &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; (NPH) dose&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Pharm/DwnPhnmn.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Dawn Phenomena</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Pharm/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees></FP_UMLS_Trees><FP_Condition_name_check></FP_Condition_name_check><FP_Condition_name><value>GlucoWatch Biographer</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Pharmacology</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;See also&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Glucose&lt;/a&gt; Meter (&lt;a href="../../Endo/Pharm/Glcmtr.htm" class="LinkPage"&gt;Glucometer&lt;/a&gt;)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Indications&lt;ol&gt;&lt;li&gt;Adjunct to &lt;a href="../../Endo/Pharm/Glcmtr.htm" class="LinkPage"&gt;Glucometer&lt;/a&gt; in &lt;a href="../../Endo/DM/DbtsMlts.htm" class="LinkPage"&gt;Diabetes Mellitus&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Medical Letter does not recommend for routine use yet&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Mechanism&lt;ol&gt;&lt;li&gt;Meter ($300) worn as wristwatch&lt;/li&gt;&lt;li&gt;Samples &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; levels through intact skin&lt;/li&gt;&lt;li&gt;Disposable auto-sensor snaps onto back of device&lt;ol&gt;&lt;li&gt;Auto-sensor ($4) provides 12 hours of readings&lt;/li&gt;&lt;li&gt;Contains &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; oxidase gel discs and electrodes&lt;/li&gt;&lt;li&gt;Samples &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; via reverse &lt;a href="../../Sports/Pharm/Intphrs.htm" class="LinkPage"&gt;Iontophoresis&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Low electric current assists &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; collection&lt;/li&gt;&lt;li&gt;Discs convert &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; to hydrogen peroxide&lt;/li&gt;&lt;li&gt;Sensor detects electrons released&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Technique&lt;ol&gt;&lt;li&gt;Attach auto-sensor to watch&lt;/li&gt;&lt;li&gt;Allow 3-hour warm-up period&lt;/li&gt;&lt;li&gt;Calibrate device with &lt;a href="../../Endo/Pharm/Glcmtr.htm" class="LinkPage"&gt;Glucometer&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Set high and low alert values&lt;/li&gt;&lt;li&gt;Device displays new reading every 20 minutes&lt;ol&gt;&lt;li&gt;Readings are averages of two ten-minute measurements&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Alarm sounds for &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; values in alert range&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Efficacy&lt;ol&gt;&lt;li&gt;Accurate for &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Sugar&lt;/a&gt;s over 80 mg/dl&lt;/li&gt;&lt;li&gt;Less accurate for &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Sugar&lt;/a&gt;s below 80 mg/dl&lt;/li&gt;&lt;li&gt;Accuracy and device function altered by&lt;ol&gt;&lt;li&gt;Perspiration&lt;/li&gt;&lt;li&gt;Device jarring&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Adverse Effects&lt;ol&gt;&lt;li&gt;Skin irritation occurs with short-term use&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=(2001)%20Med%20Lett%20Drugs%20Ther%2043%20%5BAU%5D%20AND%201104%20%5BDP%5D%20AND%20:%20%5BTA%5D" class="LinkRef"&gt;(2001) Med Lett Drugs Ther 43(1104):42&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Garg%20%20%5BAU%5D%20AND%201999%20%5BDP%5D%20AND%20%20Diabetes%20Care%20%20%5BTA%5D" class="LinkRef"&gt;Garg (1999) Diabetes Care 22:1708&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Tamada%20%20%5BAU%5D%20AND%201999%20%5BDP%5D%20AND%20%20JAMA%20%20%5BTA%5D" class="LinkRef"&gt;Tamada (1999) JAMA 282:1839&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Tierney%20%20%5BAU%5D%20AND%202000%20%5BDP%5D%20AND%20%20Ann%20Med%20%20%5BTA%5D" class="LinkRef"&gt;Tierney (2000) Ann Med 32:632&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Pharm/GlcwtchBgrphr.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: GlucoWatch Biographer</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Pharm/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Lantus  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0876064"&gt;&lt;i&gt;C0876064&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Amino Acid, Peptide, or Protein (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0876064&amp;amp;tui=T116"&gt;&lt;i&gt;T116&lt;/i&gt;&lt;/a&gt;)
, Pharmacologic Substance (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0876064&amp;amp;tui=T121"&gt;&lt;i&gt;T121&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;C106526&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Lantus, lantu, lantus&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Basal insulin  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0650607"&gt;&lt;i&gt;C0650607&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Amino Acid, Peptide, or Protein (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0650607&amp;amp;tui=T116"&gt;&lt;i&gt;T116&lt;/i&gt;&lt;/a&gt;)
, Pharmacologic Substance (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0650607&amp;amp;tui=T121"&gt;&lt;i&gt;T121&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;416303005&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Basal insulin (product), Basal insulin&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;insulina basal (producto), insulina basal&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Levemir  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C1314782"&gt;&lt;i&gt;C1314782&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Amino Acid, Peptide, or Protein (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C1314782&amp;amp;tui=T116"&gt;&lt;i&gt;T116&lt;/i&gt;&lt;/a&gt;)
, Pharmacologic Substance (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C1314782&amp;amp;tui=T121"&gt;&lt;i&gt;T121&lt;/i&gt;&lt;/a&gt;)
, Hormone (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C1314782&amp;amp;tui=T125"&gt;&lt;i&gt;T125&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;C105111&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Levemir, levemir&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;insulin detemir  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0537270"&gt;&lt;i&gt;C0537270&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Amino Acid, Peptide, or Protein (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0537270&amp;amp;tui=T116"&gt;&lt;i&gt;T116&lt;/i&gt;&lt;/a&gt;)
, Pharmacologic Substance (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0537270&amp;amp;tui=T121"&gt;&lt;i&gt;T121&lt;/i&gt;&lt;/a&gt;)
, Hormone (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0537270&amp;amp;tui=T125"&gt;&lt;i&gt;T125&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;C105111&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;414518007, 414515005&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;12C-Lys(B29)-DB30I, B29-tetradecanoyl-Lys-B30-des-Ala-insulin, Insulin Detemir, des-(B30)-insulin, Lys(B29)-tetradecanoyl-, insulin, tetradecanoyllysyl(B29)-desalanyl(B30)-, INSULIN DETEMIR, basal insulin detemir, insulin detemir (medication), Insulin detemir (substance), Insulin detemir product (product), Insulin detemir product, Insulin detemir, insulin detemir, insulin, tetradecanoyl-Lys(B29)-des-Ala(B30)-&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;insulina detemir (producto), producto con insulina detemir (producto), producto con insulina detemir, insulina detemir (sustancia), insulina detemir&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Insulin Glargine  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0907402"&gt;&lt;i&gt;C0907402&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A recombinant human insulin analog with long-acting, blood glucose-lowering activity. Insulin glargine, like regular types of human insulin, regulates glucose metabolism by binding to insulin receptors on muscle and fat cells, thereby facilitating the cellular uptake of glucose. This lowers blood glucose levels. At the same time, insulin glargine inhibits the liver's conversion of stored glycogen into glucose, which also contributes to lower blood glucose levels. Insulin glargine also inhibits lipolysis in adipose tissue, inhibits proteolysis, and enhances protein synthesis. (NCI05)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A drug used to control the amount of sugar in the blood of patients with diabetes. It is a form of the hormone insulin that is made in the laboratory. Insulin glargine controls blood sugar longer than insulin does. It is a type of therapeutic insulin.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Amino Acid, Peptide, or Protein (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0907402&amp;amp;tui=T116"&gt;&lt;i&gt;T116&lt;/i&gt;&lt;/a&gt;)
, Pharmacologic Substance (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0907402&amp;amp;tui=T121"&gt;&lt;i&gt;T121&lt;/i&gt;&lt;/a&gt;)
, Hormone (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0907402&amp;amp;tui=T125"&gt;&lt;i&gt;T125&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;C106526&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;126212009, 126207008, 411529005&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;A21-Gly-B31-Arg-B32-Arg-insulin, Insulin Glargine,Hum.Rec.Anlog, insulin, Gly(A21)-Arg(B31,B32)-, insulin, glycyl(A21)-arginyl(B31,B32)-, insulin glargine, Insulin Glargine, Insulin glargine preparation, Insulin Glargine Recombinant, INSULIN GLARGINE, glargine [Chemical/Ingredient], glargine insulin, insulin glargine human, insulin glargine recombinant, glargine, Insulin glargine product (product), Insulin glargine product, Insulin glargine (product), Insulin glargine preparation (substance), Insulin glargine, Insulin glargine (substance), INSULIN,GLARGINE,HUMAN/rDNA&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;insulina glargina (producto), preparado de glargina insulínica (producto), preparado de glargina insulínica, glargina insulínica (producto), glargina insulínica (sustancia), glargina insulínica, preparado de glargina insulínica (sustancia), insulina glargina (sustancia), insulina glargina&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Lantus  (</value><value>)
</value><value>Basal insulin  (</value><value>)
</value><value>Levemir  (</value><value>)
</value><value>insulin detemir  (</value><value>)
</value><value>Insulin Glargine  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Anologue Basal Insulin</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Pharmacology</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;See Also&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Preparations&lt;ol&gt;&lt;li&gt;Insulin Glargine (Lantus)&lt;ol&gt;&lt;li&gt;Information below is based on Lantus&lt;/li&gt;&lt;li&gt;Most closely matches 24 hour coverage&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Detemir (Levemir)&lt;ol&gt;&lt;li&gt;Similar pharmacokinetics as Lantus&lt;/li&gt;&lt;li&gt;Less burning on injection compared with Lantus&lt;/li&gt;&lt;li&gt;Binds and released from circulating albumin&lt;/li&gt;&lt;li&gt;Most consistent basal &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; day to day&lt;/li&gt;&lt;li&gt;Duration varies by dose (bid may be preferred)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Precautions&lt;ol&gt;&lt;li&gt;Basal &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; does not cover meal times&lt;/li&gt;&lt;li&gt;Use in combination with agents to cover meals&lt;ol&gt;&lt;li&gt;Rapid acting &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; (e.g. &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Lispro&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;Oral agents (&lt;a href="../../Endo/Pharm/Slfnylr.htm" class="LinkPage"&gt;Sulfonylurea&lt;/a&gt;s, &lt;a href="../../Endo/Pharm/Glcphg.htm" class="LinkPage"&gt;Metformin&lt;/a&gt;, &lt;a href="../../Endo/Pharm/Thzldndn.htm" class="LinkPage"&gt;Glitazone&lt;/a&gt;) or&lt;ol&gt;&lt;li&gt;Switch to basal/bolus when Glargine &amp;gt;0.5 units/kg&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Pharmacokinetics&lt;ol&gt;&lt;li&gt;Onset: 1 hour&lt;/li&gt;&lt;li&gt;Duration: 21 to 24 hours&lt;ol&gt;&lt;li&gt;May require divided dosing bid to maintain basal rate&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Peak: No peak&lt;ol&gt;&lt;li&gt;Flat action profile throughout duration&lt;/li&gt;&lt;li&gt;Mimics continuous &lt;a href="../../Endo/Pharm/VrblRtInslnInfsn.htm" class="LinkPage"&gt;Insulin Infusion&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Adverse effects&lt;ol&gt;&lt;li&gt;Less nocturnal &lt;a href="../../Endo/Hypoglycemia/Hypglycm.htm" class="LinkPage"&gt;Hypoglycemia&lt;/a&gt; than other &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt;s&lt;/li&gt;&lt;li&gt;Lower post-prandial &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Dosing&lt;ol&gt;&lt;li&gt;Starting dose (no prior &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt;)&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/HmglbnAc.htm" class="LinkPage"&gt;Hemoglobin A1C&lt;/a&gt; &amp;lt;8%: 0.1 units/kg&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/HmglbnAc.htm" class="LinkPage"&gt;Hemoglobin A1C&lt;/a&gt; &amp;gt;8-10%: 0.2 units/kg&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/HmglbnAc.htm" class="LinkPage"&gt;Hemoglobin A1C&lt;/a&gt; &amp;gt;10%: 0.3 units/kg&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Old regimen for starting dose (use units/kg as above instead)&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/DM/TypDbtsMlts.htm" class="LinkPage"&gt;Type I Diabetes&lt;/a&gt;: 10 Units qhs&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/DM/TypDbtsMlts1.htm" class="LinkPage"&gt;Type II Diabetes&lt;/a&gt;: 10-14 Units qhs&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Conversion from other long-acting &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt;&lt;ol&gt;&lt;li&gt;NPH/&lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Ultralente&lt;/a&gt; qhs: start Lantus at same dose&lt;ol&gt;&lt;li&gt;Consider starting Lantus at 80% of prior NPH dose&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;NPH bid: Start Lantus at 80% of total daily NPH dose&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Adjustment based on fasting plasma &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; (FPG)&lt;ol&gt;&lt;li&gt;Protocol 1&lt;ol&gt;&lt;li&gt;FPG &amp;lt;70 mg/dl for 3 days: Decrease Lantus 1-2 units&lt;/li&gt;&lt;li&gt;FPG 140-250 for 3 days: Increase Lantus 2-4 units&lt;/li&gt;&lt;li&gt;FPG &amp;gt;250 for 3 days: Increase Lantus 4-8 units&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Protocol 2&lt;ol&gt;&lt;li&gt;FPG &amp;lt;80 for 3 days: Decrease Lantus by 2 units&lt;/li&gt;&lt;li&gt;FPG 100-120 for 3 days: Increase Lantus by 2 units&lt;/li&gt;&lt;li&gt;FPG 120-140 for 3 days: Increase Lantus by 4 units&lt;/li&gt;&lt;li&gt;FPG 140-180 for 3 days: Increase Lantus by 6 units&lt;/li&gt;&lt;li&gt;FPG &amp;gt;180 for 3 days: Increase Lantus by 8 units&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Timing of dose for Lantus&lt;ol&gt;&lt;li&gt;Studies gave Lantus at bedtime to avoid confusion&lt;/li&gt;&lt;li&gt;Lantus is most effective if given in the morning&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Delivery Devices: OptiClik Pen&lt;ol&gt;&lt;li&gt;Pens are free from Aventis&lt;ol&gt;&lt;li&gt;Phone: 800-207-8049&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Pens ease &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; delivery&lt;/li&gt;&lt;li&gt;Lantus in cartridges costs 2 cents/unit more than vial&lt;/li&gt;&lt;li&gt;(2005) Prescriber's Letter 12:32&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=(2001)%20Med%20Lett%20Drugs%20Ther%2043%20%5BAU%5D%20AND%201110%20%5BDP%5D%20AND%20:%20%5BTA%5D" class="LinkRef"&gt;(2001) Med Lett Drugs Ther 43(1110):65-6&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Riddle%20%20%5BAU%5D%20AND%202003%20%5BDP%5D%20AND%20%20Diabetes%20Care%20%20%5BTA%5D" class="LinkRef"&gt;Riddle (2003) Diabetes Care 26:3080-6&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0876064</value><value>C0650607</value><value>C1314782</value><value>C0537270</value><value>C0907402</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Pharm/AnlgBslInsln.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Anologue Basal Insulin, Insulin Glargine, Glargine, Lantus, Levemir, Detemir</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Pharm/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Humulin insulin  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0020171"&gt;&lt;i&gt;C0020171&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Amino Acid, Peptide, or Protein (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0020171&amp;amp;tui=T116"&gt;&lt;i&gt;T116&lt;/i&gt;&lt;/a&gt;)
, Pharmacologic Substance (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0020171&amp;amp;tui=T121"&gt;&lt;i&gt;T121&lt;/i&gt;&lt;/a&gt;)
, Hormone (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0020171&amp;amp;tui=T125"&gt;&lt;i&gt;T125&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D007328&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;350348002&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Humulin insulin, insulin, human (Humulin), insulin humulin, humulin, humulin insulin, Humulin insulin (substance)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;Humulin insulin (substance), Humulin insulin&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Humulin&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;Humulin&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Insulin  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0021641"&gt;&lt;i&gt;C0021641&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CSP)&lt;/td&gt;
                &lt;td&gt;protein hormone secreted by beta cells of the pancreas; insulin plays a major role in the regulation of glucose metabolism, generally promoting the cellular utilization of glucose and is also an important regulator of protein and lipid metabolism; insulin is used as a drug to control insulin-dependent diabetes mellitus.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A short-acting form of insulin. Regular insulin is obtained from animal or recombinant sources. The onset of action of regular insulin occurs at 30-90 minutes after injection; its effect lasts for 6 to 8 hours. Endogenous human insulin, a pancreatic hormone composed of two polypeptide chains, is important for the normal metabolism of carbohydrates, proteins and fats; it has anabolic effects on many types of tissues. (NCI04)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;Human insulin protein (110 aa, 12 kDa) is encoded by the human insulin (INS) gene. This cytosolic protein, a heterodimer of disulfide-linked alpha and beta chains, is produced in pancreatic islet beta cells. Binding of insulin to its receptor stimulates glucose uptake, accelerates both glycolysis and the pentose phosphate cycle and increases glycogen synthesis in the liver. Insulin regulates protein and lipid metabolism. It also decreases blood glucose concentration by shuttling molecules into cells to be used for energy. Decreased expression of insulin protein causes familial hyperproinsulinemia.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1).&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Amino Acid, Peptide, or Protein (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0021641&amp;amp;tui=T116"&gt;&lt;i&gt;T116&lt;/i&gt;&lt;/a&gt;)
, Pharmacologic Substance (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0021641&amp;amp;tui=T121"&gt;&lt;i&gt;T121&lt;/i&gt;&lt;/a&gt;)
, Hormone (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0021641&amp;amp;tui=T125"&gt;&lt;i&gt;T125&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D007328&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;67866001, 39487003, 412222002&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Insulin, insulin, INSULIN PREPARATIONS, Insulin preparation, NOS, Regular Insulin, Regular insulin preparation, Unmodified insulin preparation, Insulin Regular, INSULIN, insulin preparations, insulin preparations (medication), A22 INSULIN PREPARATIONS, insulin regular, Insulin (ox), 8A-L-threonine-10A-L-isoleucine-30B-L-threonine-, Insulin [Chemical/Ingredient], [HS501] INSULIN, Insulin regular, insulin products, insulin preparation, insulin product, regular insulin, insulins, Insulin, Soluble, Soluble Insulin, Insulin, Regular, Insulin product, Insulin (substance), Insulin preparation, Insulin product (product), Regular insulin product, Unmodified insulin product, Insulin preparation (substance), Regular insulin (substance), Regular insulin&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Insulin&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;insulin, inzulin&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Insuliini&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Insuline ordinaire, Insuline&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;INSULIN, ИНСУЛИН&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;producto con insulina (producto), preparado insulínico, insulina (producto), producto con insulina, insulina (sustancia), insulina, preparado de insulina (producto), preparado de insulina (sustancia), preparado de insulina cristalina de cinc, preparado de insulina cristalina de zinc, preparado de insulina no modificada, preparado de insulina, insulina regular (sustancia), insulina regular, Insulina&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Insulina regolare, Insulina&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Croatian&lt;/td&gt;
                &lt;td&gt;INZULIN&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Insulina&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;インスリン, インスリン亜鉛水性懸濁液, インシュリン&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Insulin&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Insulina&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;NovoLog  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0939412"&gt;&lt;i&gt;C0939412&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Amino Acid, Peptide, or Protein (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0939412&amp;amp;tui=T116"&gt;&lt;i&gt;T116&lt;/i&gt;&lt;/a&gt;)
, Pharmacologic Substance (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0939412&amp;amp;tui=T121"&gt;&lt;i&gt;T121&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D061267&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Novolog, novolog, novorapid, NovoLOG, NovoRapid, Novo Nordisk Brand of Insulin Aspart, NovoLog&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Novolin  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0028467"&gt;&lt;i&gt;C0028467&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Amino Acid, Peptide, or Protein (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0028467&amp;amp;tui=T116"&gt;&lt;i&gt;T116&lt;/i&gt;&lt;/a&gt;)
, Pharmacologic Substance (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0028467&amp;amp;tui=T121"&gt;&lt;i&gt;T121&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D007328&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Novolin&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;novolin, Novolin&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Humalog  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0528249"&gt;&lt;i&gt;C0528249&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Amino Acid, Peptide, or Protein (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0528249&amp;amp;tui=T116"&gt;&lt;i&gt;T116&lt;/i&gt;&lt;/a&gt;)
, Pharmacologic Substance (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0528249&amp;amp;tui=T121"&gt;&lt;i&gt;T121&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D061268&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;humalog, HumaLOG, Humalog, Eli Lilly brand of Insulin Lispro&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Insulin Lispro  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0293359"&gt;&lt;i&gt;C0293359&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A recombinant therapeutic agent which is chemically identical to or similar to endogenous human insulin. In lispro insulin, the amino acid proline at B-28 and the amino acid lysine at B-29 are reversed, resulting in the rapid dissolution of this insulin to a monomer that is absorbed rapidly after subcutaneous administration. Lispro insulin is equipotent to human insulin on a molar basis but its effects are faster and of shorter duration. Endogenous insulin, a pancreatic hormone composed of two polypeptide chains, is important in the normal metabolism of carbohydrates, proteins and fats, promoting glucose utilization and protein synthesis; it has anabolic effects on many types of tissues. (NCI04)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;Insulin that has been modified so that the B-chain contains a LYSINE at position 28 instead of a PROLINE and a PROLINE at position 29 instead of a LYSINE.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Amino Acid, Peptide, or Protein (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0293359&amp;amp;tui=T116"&gt;&lt;i&gt;T116&lt;/i&gt;&lt;/a&gt;)
, Pharmacologic Substance (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0293359&amp;amp;tui=T121"&gt;&lt;i&gt;T121&lt;/i&gt;&lt;/a&gt;)
, Hormone (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0293359&amp;amp;tui=T125"&gt;&lt;i&gt;T125&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D061268&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;388454007, 412210000, 125703000&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Insulin Lispro, Insulin lispro, insulin lispro, insulin LISPRO, lispro, 28(B)-Lys-29(B)-Pro-insulin, insulin LISPRO [Chemical/Ingredient], insulin, lysine(B28)-proline(B29), 28(B)-lysine-29(B)-prolineinsulin, insulin, lysyl(28B)-prolyl(28B)-, insulin, Lys(B28)-Pro(B29), B28-Lys-B29-Pro-insulin, insulin, Lys(28B)-Pro(29B)-, insulin human lispro, lispro human insulin, lispro insulin, INSULIN LISPRO, Lispro, 28(B)-Lys-29(B)-Pro-Insulin, LYSPRO, Lispro, Insulin, 28(B)-Lysine-29(B)-Prolineinsulin, Insulin, Lysyl(28B)-Prolyl(28B)-, Insulin, Lys(28B)-Pro(29B)-, Lispro insulin (product), Lispro insulin, Lispro insulin (substance), INSULIN,LISPRO,HUMAN/rDNA&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;insulina lispro (producto), insulina lispro, insulina lispro (sustancia)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Humulin insulin  (</value><value>)
</value><value>Insulin  (</value><value>)
</value><value>NovoLog  (</value><value>)
</value><value>Novolin  (</value><value>)
</value><value>Humalog  (</value><value>)
</value><value>Insulin Lispro  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Insulin</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Pharmacology</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;See Also&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/InslnDsng.htm" class="LinkPage"&gt;Insulin Dosing&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/InslnSmltn.htm" class="LinkPage"&gt;Insulin Simulation&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Exam/GlcsMtblsm.htm" class="LinkPage"&gt;Glucose Metabolism&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Technique&lt;ol&gt;&lt;li&gt;Injection sites: &lt;a href="../../GI/Anatomy/AbdmnlAntmy.htm" class="LinkPage"&gt;Abdomen&lt;/a&gt;, outer thigh, back of arm, flank and buttocks&lt;/li&gt;&lt;li&gt;Insert needle at 90 degree angle into skin&lt;/li&gt;&lt;li&gt;Hold needle in place for 5-10 seconds after injection to prevent leakage of Insulin&lt;/li&gt;&lt;li&gt;Rotate injection sites to prevent lipohypertrophy (see adverse effects below)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Preparations: Insulin Selection&lt;ol&gt;&lt;li&gt;New Insulin anologues are preferred&lt;ol&gt;&lt;li&gt;More consistent absorption than traditional Insulin&lt;/li&gt;&lt;li&gt;Bolus analogues have more rapid onset&lt;/li&gt;&lt;li&gt;Basal agents release at more constant rate&lt;/li&gt;&lt;li&gt;Only disadvantage is anologues double price&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Combination agents are discouraged unless noncompliant&lt;ol&gt;&lt;li&gt;Reduces flexibility in meal and activity timing&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Drug Interactions: Diabetes Agents&lt;ol&gt;&lt;li&gt;Agents safe to use with Insulin&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Glcphg.htm" class="LinkPage"&gt;Metformin&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Thzldndn.htm" class="LinkPage"&gt;Thiazolidinedione&lt;/a&gt;s&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/AlphGlcsdsInhbtr.htm" class="LinkPage"&gt;Alpha-glucosidase Inhibitor&lt;/a&gt;s&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Stglptn.htm" class="LinkPage"&gt;Sitagliptin&lt;/a&gt; (&lt;a href="../../Endo/Pharm/Stglptn.htm" class="LinkPage"&gt;Januvia&lt;/a&gt;)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Agents safe to use with basal Insulin (&lt;a href="../../Endo/Pharm/AnlgBslInsln.htm" class="LinkPage"&gt;Lantus&lt;/a&gt;, &lt;a href="../../Endo/Pharm/AnlgBslInsln.htm" class="LinkPage"&gt;Levemir&lt;/a&gt;); avoid or use caution if used with bolus Insulin (Lispro, Aspart)&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Slfnylr.htm" class="LinkPage"&gt;Sulfonylurea&lt;/a&gt;s&lt;/li&gt;&lt;li&gt;Glitinides&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Agents: Intravenous Regular Insulin&lt;ol&gt;&lt;li&gt;Note that all other Insulins listed on this page are subcutaneous&lt;/li&gt;&lt;li&gt;See &lt;a href="../../Endo/Pharm/VrblRtInslnInfsn.htm" class="LinkPage"&gt;Insulin Drip&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Onset: Immediate&lt;/li&gt;&lt;li&gt;Half-life: 5-10 minutes&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Agents: Bolus Insulins (Meal-time Insulin)&lt;ol&gt;&lt;li&gt;Traditional Insulins&lt;ol&gt;&lt;li&gt;Regular Insulin (Novolin R, Humulin R)&lt;ol&gt;&lt;li&gt;Onset: 15 to 30 minutes&lt;/li&gt;&lt;li&gt;Peak: 2.5 to 5 hours&lt;/li&gt;&lt;li&gt;Duration: 6 to 8 hours&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Analogue Insulins (Rapid, consistent absorption)&lt;ol&gt;&lt;li&gt;Glulisine (Apidra)&lt;ol&gt;&lt;li&gt;Onset: 5 to 15 minutes&lt;/li&gt;&lt;li&gt;Peak: 1 to 2 hours&lt;/li&gt;&lt;li&gt;Duration: 3 to 5 hours&lt;/li&gt;&lt;li&gt;Similar to other bolus analogues&lt;/li&gt;&lt;li&gt;FDA approved to take after meal&lt;ol&gt;&lt;li&gt;Other analogues expected with same effect&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Lispro (Humalog)&lt;ol&gt;&lt;li&gt;Onset: 5 to 15  minutes&lt;/li&gt;&lt;li&gt;Peak: 1 to 2 hours&lt;/li&gt;&lt;li&gt;Duration: 3 to 5 hours&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Aspart (Novolog)&lt;ol&gt;&lt;li&gt;Onset: 5 to 15 minutes&lt;/li&gt;&lt;li&gt;Peak: 1 to 2 hours&lt;/li&gt;&lt;li&gt;Duration: 3 to 5 hours&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Agents: Basal Insulins&lt;ol&gt;&lt;li&gt;Traditional Insulins&lt;ol&gt;&lt;li&gt;NPH Insulin, Novolin N, Humulin N, Humulin L (Lente)&lt;ol&gt;&lt;li&gt;Onset: 1 to 2 hours&lt;/li&gt;&lt;li&gt;Peak: 6 to 8 hours&lt;ol&gt;&lt;li&gt;Peak time is higher risk of hypoglcemia&lt;/li&gt;&lt;li&gt;Consider snack at 6 hours after dose&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Duration: 10 to 16 hours (Lente slightly longer)&lt;/li&gt;&lt;li&gt;Humulin L (Lente) discontinued in U.S. in 2006&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Ultralente Insulin (extended Insulin zinc suspension)&lt;ol&gt;&lt;li&gt;Discontinued in U.S. in 2006&lt;/li&gt;&lt;li&gt;Significant inconsistent effect even in same person&lt;/li&gt;&lt;li&gt;Onset: 6-10 hours&lt;/li&gt;&lt;li&gt;Peak: No peak&lt;/li&gt;&lt;li&gt;Duration: 18 to 24 hours&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Analogue Insulins&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/AnlgBslInsln.htm" class="LinkPage"&gt;Detemir&lt;/a&gt; (&lt;a href="../../Endo/Pharm/AnlgBslInsln.htm" class="LinkPage"&gt;Levemir&lt;/a&gt;)&lt;ol&gt;&lt;li&gt;Onset: 2-4 hours&lt;/li&gt;&lt;li&gt;Peak: 6-8 hours&lt;/li&gt;&lt;li&gt;Duration: 12 to 20 hours (varies by dosage)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/AnlgBslInsln.htm" class="LinkPage"&gt;Glargine&lt;/a&gt; (&lt;a href="../../Endo/Pharm/AnlgBslInsln.htm" class="LinkPage"&gt;Lantus&lt;/a&gt;)&lt;ol&gt;&lt;li&gt;Onset: 1-2 hours&lt;/li&gt;&lt;li&gt;Duration: 21 to 24 hours&lt;/li&gt;&lt;li&gt;Peak: No peak (flat action curve mimics continuous &lt;a href="../../Endo/Pharm/VrblRtInslnInfsn.htm" class="LinkPage"&gt;Insulin Infusion&lt;/a&gt;)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Combination Agents (&lt;a href="../../Endo/DM/TypDbtsMlts1.htm" class="LinkPage"&gt;Type II Diabetes&lt;/a&gt; if poor compliance)&lt;ol&gt;&lt;li&gt;NPH 50/Regular 50&lt;/li&gt;&lt;li&gt;NPH 70/Regular 30 (Humulin 70/30 or Novolin 70/30)&lt;/li&gt;&lt;li&gt;NPL 75/Lispro 25 (Humalog Mix 75/25)&lt;/li&gt;&lt;li&gt;NPH 70/Aspart 30 (Novolog Mix 70/30)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Adverse Effects&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Hypoglycemia/Hypglycm.htm" class="LinkPage"&gt;Hypoglycemia&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Increased risk when &lt;a href="../../Endo/Lab/HmglbnAc.htm" class="LinkPage"&gt;Hemoglobin A1C&lt;/a&gt; &amp;lt;7.4%&lt;/li&gt;&lt;li&gt;Decreased risk with analogue Insulins&lt;/li&gt;&lt;li&gt;Higher risk with severe renal insufficiency&lt;ol&gt;&lt;li&gt;Insulin is excreted by the &lt;a href="../../Renal/Anatomy/RnlAntmy.htm" class="LinkPage"&gt;Kidney&lt;/a&gt; (30% of total)&lt;/li&gt;&lt;li&gt;Gluconeogenesis occurs in the &lt;a href="../../Renal/Anatomy/RnlAntmy.htm" class="LinkPage"&gt;Kidney&lt;/a&gt; (30% of total)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Weight gain (Excess of 4 kg over 10 years)&lt;ol&gt;&lt;li&gt;Countered with &lt;a href="../../Endo/Pharm/Glcphg.htm" class="LinkPage"&gt;Metformin&lt;/a&gt; in type 2 diabetics&lt;/li&gt;&lt;li&gt;Countered with diet and &lt;a href="../../Sports/Exercise/Exrcs.htm" class="LinkPage"&gt;Exercise&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Benefits of &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; control outweigh weight risks&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Lipohypertrophy&lt;ol&gt;&lt;li&gt;Localized fat hypertrophy and scar tissue from repeated injections in the same area&lt;/li&gt;&lt;li&gt;Results in variable Insulin absorption as below&lt;/li&gt;&lt;li&gt;Prevent by rotating injection sites (see below)&lt;/li&gt;&lt;li&gt;Medical providers should examine injection sites&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Variable Insulin absorption&lt;ol&gt;&lt;li&gt;Insulin absorption varies by body site&lt;ol&gt;&lt;li&gt;&lt;a href="../../GI/Anatomy/AbdmnlAntmy.htm" class="LinkPage"&gt;Abdomen&lt;/a&gt; (best absorption)&lt;/li&gt;&lt;li&gt;Arms&lt;/li&gt;&lt;li&gt;&lt;a href="../../Ortho/Anatomy/ThghAntmy.htm" class="LinkPage"&gt;Thigh&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Buttocks (least absorption)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Variable absorption at lipohypertrophy sites&lt;ol&gt;&lt;li&gt;Poor absorption causes early postprandial &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Hyperglycemia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Depot formation causes delayed &lt;a href="../../Endo/Hypoglycemia/Hypglycm.htm" class="LinkPage"&gt;Hypoglycemia&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Site rotation (prevents lipohypertrophy - see above)&lt;ol&gt;&lt;li&gt;Rotate injections within same body region&lt;ol&gt;&lt;li&gt;Avoids Insulin absorption variability&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Rotate to widely different sites within region&lt;ol&gt;&lt;li&gt;Example: &lt;a href="../../GI/Anatomy/AbdmnlAntmy.htm" class="LinkPage"&gt;Abdomen&lt;/a&gt; rotate to LUQ, RUQ, LLQ, RLQ&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Lepore%20%20%5BAU%5D%20AND%202000%20%5BDP%5D%20AND%20%20Diabetes%20%20%5BTA%5D" class="LinkRef"&gt;Lepore (2000) Diabetes 49:2142-8&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Mayfield%20%20%5BAU%5D%20AND%202004%20%5BDP%5D%20AND%20%20Am%20Fam%20Physician%20%20%5BTA%5D" class="LinkRef"&gt;Mayfield (2004) Am Fam Physician 70(3):489-512&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0020171</value><value>C0021641</value><value>C0939412</value><value>C0028467</value><value>C0528249</value><value>C0293359</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Pharm/Insln.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Insulin, Regular Insulin, NPH Insulin, Lispro, Lente, Ultralente, Novolin, Humulin, Novolog, Humalog, Aspart, Apidra, Glulisine</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Pharm/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Preoperative hormone treatment  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C1535921"&gt;&lt;i&gt;C1535921&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Therapeutic or Preventive Procedure (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C1535921&amp;amp;tui=T061"&gt;&lt;i&gt;T061&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;preoperatieve hormoonbehandeling&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Traitement hormonal préopératoire&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Trattamento ormonale preoperatorio&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Tratamento hormonal pré-operatório&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;Tratamiento hormonal prequirúrgico&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;術前ホルモン療法, ｼﾞｭﾂｾﾞﾝﾎﾙﾓﾝﾘｮｳﾎｳ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;Hormonální léčba před operací&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;Preoperativ hormonkezelés&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Preoperative hormone treatment&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;praeoperative Hormonbehandlung&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Preoperative hormone treatment  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Perioperative Corticosteroid</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Surgery</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;See Also&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Adrenal/AdsnsDs.htm" class="LinkPage"&gt;Adrenal Insufficiency&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Protocol: Stress Dose Steroid&lt;ol&gt;&lt;li&gt;Indication: Acute severe illness&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/SrmCrtsl.htm" class="LinkPage"&gt;Serum Cortisol&lt;/a&gt; &amp;lt;15 to 34 mcg/dl&lt;/li&gt;&lt;li&gt;Cortisol &amp;lt;9 after Corticotropin Stimulation Test&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Management&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/SystmcCrtcstrd.htm" class="LinkPage"&gt;Hydrocortisone&lt;/a&gt; 50 mg IV or IM q6 hours&lt;/li&gt;&lt;li&gt;Consider adding fludricortisone 50 mcg qd&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Protocol: Perioperative Corticosteroids&lt;ol&gt;&lt;li&gt;Indications: Primary or secondary &lt;a href="../../Endo/Adrenal/AdsnsDs.htm" class="LinkPage"&gt;Adrenal Insufficiency&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Hypothalamic pituitary axis suppression&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Surgery/SrgclRskFrCrdcEvnt.htm" class="LinkPage"&gt;Low Risk Surgery&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Initial: &lt;a href="../../Endo/Pharm/SystmcCrtcstrd.htm" class="LinkPage"&gt;Hydrocortisone&lt;/a&gt; 50 mg IV&lt;/li&gt;&lt;li&gt;Next: &lt;a href="../../Endo/Pharm/SystmcCrtcstrd.htm" class="LinkPage"&gt;Hydrocortisone&lt;/a&gt; 25 mg IV every 8 hours for 24 to 48 hours&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Surgery/SrgclRskFrCrdcEvnt.htm" class="LinkPage"&gt;High Risk Surgery&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Initial: &lt;a href="../../Endo/Pharm/SystmcCrtcstrd.htm" class="LinkPage"&gt;Hydrocortisone&lt;/a&gt; 100 mg IV&lt;/li&gt;&lt;li&gt;Next: &lt;a href="../../Endo/Pharm/SystmcCrtcstrd.htm" class="LinkPage"&gt;Hydrocortisone&lt;/a&gt; 50 mg IV every 8 hours for 24 to 48 hours&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;Fraboni (2012) Board Review Express, San Jose&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C1535921</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Surgery/PrprtvCrtcstrd.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Perioperative Corticosteroid, Stress Dose Steroid</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Surgery/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Acetohexamide  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0000992"&gt;&lt;i&gt;C0000992&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;A sulfonylurea hypoglycemic agent that is metabolized in the liver to 1-hydrohexamide.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A sulfonylurea with oral hypoglycemic properties that is used in the treatment of Type II diabetes mellitus. Acetohexamide lowers blood sugar by stimulating insulin release from the pancreas and increases the sensitivity of beta cells to glucose stimulus. This drug also increases the sensitivity of insulin receptors in muscle, liver, and adipose tissue thereby promoting glucose transport across cell membranes. This results in better controlled blood glucose levels. (NCI05)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Organic Chemical (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0000992&amp;amp;tui=T109"&gt;&lt;i&gt;T109&lt;/i&gt;&lt;/a&gt;)
, Pharmacologic Substance (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0000992&amp;amp;tui=T121"&gt;&lt;i&gt;T121&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D000092&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;391708007, 391707002, 387210001, 39064002&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Benzenesulfonamide, 4-acetyl-N-((cyclohexylamino)carbonyl)-, 3-Cyclohexyl-1-(p-acetylphenylsulfonyl)urea, Cyclamide, 4-Acetyl-N-((cyclohexylamino)carbonyl)benzenesulfonamide, 1-(p-Acetylbenzenesulfonyl)-3-Cyclohexylurea, N-(p-Acetylbenzenesulfonyl)-N'-cyclohexylurea, N-(p-Acetylphenylsulfonyl)-N'-cyclohexylurea, Acetohexamide, acetohexamide (medication), Acetylcholine chloride - chemical (substance), Acetohexamide - chemical (substance), acetohexamide, Acetohexamide [Chemical/Ingredient], acetoHEXAMIDE, Acetohexamide (product), Acetohexamide (substance), Acetohexamide - chemical, Acetylcholine chloride - chemical, ACETOHEXAMIDE, AcetoHEXAMIDE&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Acetohexamid&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;acetohexamid&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;Acetylcholine chloride - chemical, Acetohexamide - chemical, acetohexamida (producto), acetohexamida (sustancia), acetohexamida, Acetohexamida&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Asetoheksamidi&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;ATSETOGEKSAMID, АЦЕТОГЕКСАМИД&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;アセトヘキサミド&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Acetoheksamid, Dymelor&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Acétohexamide&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Acetohexamid&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Acetoesamide&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Acetoexamida&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Chlorpropamide  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0008287"&gt;&lt;i&gt;C0008287&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;A sulfonylurea hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. (From Martindale, The Extra Pharmacopoeia, 30th ed, p277)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A sulfonylurea with oral hypoglycemic properties that is used in the treatment of Type II diabetes mellitus. Chlorpropamide stimulates pancreatic secretion of insulin and improves insulin release by increasing sensitivity of beta cells to glucose stimuli. This drug also increases the sensitivity of insulin receptors in muscle, liver, and adipose tissue thereby promoting glucose transport across cell membranes. This results in better controlled blood glucose levels. Chlorpropamide has the longest duration of action of the sulfonylurea class but could cause more severe and frequent side effects, including hypoglycemia and hyponatremia.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Organic Chemical (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0008287&amp;amp;tui=T109"&gt;&lt;i&gt;T109&lt;/i&gt;&lt;/a&gt;)
, Pharmacologic Substance (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0008287&amp;amp;tui=T121"&gt;&lt;i&gt;T121&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D002747&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;111154004, 386991003&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Chlorpropamide, Clorpropamid, chlorpropamide, Benzenesulfonamide, 4-chloro-N-((propylamino)carbonyl)-, Urea, 1-((p-chlorophenyl)sulfonyl)-3-propyl-, CHLORPROPAMIDE, 4-Chloro-4-((propylamino)carbonyl)benzenesulfonamide, Chlorpropamide [Chemical/Ingredient], chlorproPAMIDE, Chlorpropamide (product), Chlorpropamide (substance), ChlorproPAMIDE&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Klorpropamid&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;chlorpropamid&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Klooripropamidi&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;KHLORPROPAMID, ХЛОРПРОПАМИД&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Croatian&lt;/td&gt;
                &lt;td&gt;KLORPROPAMID&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Chlorpropamid&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;クロルプロパミド, クロルプロパマイド&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;clorpropamida (producto), clorpropamida (sustancia), clorpropamida, Clorpropamida&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Chlorpropamide&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Chlorpropamid, Clorpropamid&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Clorpropamide&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Clorpropamida&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Tolazamide  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0040372"&gt;&lt;i&gt;C0040372&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;A sulphonylurea hypoglycemic agent with actions and uses similar to those of CHLORPROPAMIDE.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A sulfonylurea derivative and an antidiabetic agent with hypoglycemic property. Tolazamide binds to the ATP-dependent potassium channels on the plasma membrane of pancreatic beta-cells, which results in an inhibition of potassium efflux and membrane depolarization. Membrane depolarization stimulates calcium influx through voltage-gated calcium channels and subsequently induces the release of insulin from viable beta-cells thereby leading to a decrease in blood glucose levels. In addition, this agent potentiates the anti-diuretic effect of antidiuretic hormone (ADH).&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Organic Chemical (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0040372&amp;amp;tui=T109"&gt;&lt;i&gt;T109&lt;/i&gt;&lt;/a&gt;)
, Pharmacologic Substance (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0040372&amp;amp;tui=T121"&gt;&lt;i&gt;T121&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D014042&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;34393009, 387186009&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Tolazamide, Benzenesulfonamide, N-(((hexahydro-1H-azepin-1-yl)amino)carbonyl)-4-methyl-, tolazamide, tolazamide (medication), TOLAZAMIDE, Tolazamide [Chemical/Ingredient], TOLAZamide, Tolazamide (product), Tolazamide (substance)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Tolazamid&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;tolazamid&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Tolatsamidi&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;TOLAZAMID, ТОЛАЗАМИД&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;トラザミド&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Tolazamid&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;tolazamida (producto), tolazamida (sustancia), tolazamida, Tolazamida&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Tolazamide&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Tolazamid&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Tolazamide&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Tolazamida&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Tolbutamide  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0040374"&gt;&lt;i&gt;C0040374&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A first-generation sulfonylurea with hypoglycemic activity. Tolbutamide binds to and blocks adenosine triphosphate (ATP)-sensitive potassium channels on the beta cell membrane of the pancreatic islet tissues. This leads to potassium efflux, which results in depolarization, calcium influx, calcium-calmodulin binding, kinase activation, and release of insulin-containing granules by exocytosis. In addition, tolbutamide may increase the number and affinity of cell surface insulin receptors, thereby enhancing the peripheral response to insulin. Tolbutamide is a CYP2C9 substrate.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;A sulphonylurea hypoglycemic agent with actions and uses similar to those of CHLORPROPAMIDE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p290)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CSP)&lt;/td&gt;
                &lt;td&gt;sulfonylurea compound used as a hypoglycemic in the treatment of noninsulin dependent diabetes mellitus.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Organic Chemical (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0040374&amp;amp;tui=T109"&gt;&lt;i&gt;T109&lt;/i&gt;&lt;/a&gt;)
, Pharmacologic Substance (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0040374&amp;amp;tui=T121"&gt;&lt;i&gt;T121&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D014044&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;33124007, 373481003&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Tolbutamide, tolbutamide, Benzenesulfonamide, N-((butylamino)carbonyl)-4-methyl-, tolbutamide (medication), Tolbutamide [Chemical/Ingredient], TOLBUTamide, TOLBUTAMIDE, Tolbutamide (product), Tolbutamide (substance)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Tolbutamid&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;tolbutamid&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Tolbutamidi&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;BUTAMID, TOLBUTAMID, БУТАМИД, ТОЛБУТАМИД&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;トルブタミド, 1-ブチル-p-トリルスルホニル尿素&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Tolbutamid, Diabetol&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;tolbutamida (producto), tolbutamida (sustancia), tolbutamida, Tolbutamida&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Tolbutamide&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Tolbutamid&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Tolbutamide&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Tolbutamida&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;First generation sulfonylurea  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C1300197"&gt;&lt;i&gt;C1300197&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Organic Chemical (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C1300197&amp;amp;tui=T109"&gt;&lt;i&gt;T109&lt;/i&gt;&lt;/a&gt;)
, Pharmacologic Substance (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C1300197&amp;amp;tui=T121"&gt;&lt;i&gt;T121&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;386049002&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;First generation sulfonylurea (product), First generation sulfonylurea, First generation sulphonylurea&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;sulfonilurea de primera generación (producto), sulfonilurea de primera generación&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Acetohexamide  (</value><value>)
</value><value>Chlorpropamide  (</value><value>)
</value><value>Tolazamide  (</value><value>)
</value><value>Tolbutamide  (</value><value>)
</value><value>First generation sulfonylurea  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>First Generation Sulfonylurea</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Pharmacology</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;See Also&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/ScndGnrtnSlfnylr.htm" class="LinkPage"&gt;Second Generation Sulfonylurea&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/OrlHypglycmc.htm" class="LinkPage"&gt;Oral Hypoglycemic&lt;/a&gt; Agents&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Indications&lt;ol&gt;&lt;li&gt;Replaced by &lt;a href="../../Endo/Pharm/ScndGnrtnSlfnylr.htm" class="LinkPage"&gt;Second Generation Sulfonylurea&lt;/a&gt; agents for the management of &lt;a href="../../Endo/DM/TypDbtsMlts1.htm" class="LinkPage"&gt;Type II Diabetes Mellitus&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Preparations&lt;ol&gt;&lt;li&gt;Acetohexamide (Dymelor)&lt;ol&gt;&lt;li&gt;Dose: 500-750 mg qd or divided ($14)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Chlorpropamide (Diabinese)&lt;ol&gt;&lt;li&gt;Dose: 100-250 up to 750 mg qd/bid&lt;/li&gt;&lt;li&gt;Antidiuretic effect (used in &lt;a href="../../Renal/Endo/DbtsInspds.htm" class="LinkPage"&gt;Diabetes Insipidus&lt;/a&gt;)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Tolazamide (Tolinase)&lt;ol&gt;&lt;li&gt;Dose: 250-500 mg PO qd or divided ($2.81)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Tolbutamide (Orinase)&lt;ol&gt;&lt;li&gt;Dose: 1000-2000mg qd or divided bid ($2.75)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0000992</value><value>C0008287</value><value>C0040372</value><value>C0040374</value><value>C1300197</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Pharm/FrstGnrtnSlfnylr.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: First Generation Sulfonylurea, Tolbutamide, Tolazamide, Chlorpropamide, Acetohexamide</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Pharm/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;CHROMIUM PICOLINATE  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0163657"&gt;&lt;i&gt;C0163657&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;Chromium Piccolinate is a salt of the trace metallic element chromium (Cr), essential in glucose metabolism. Found in vitamins and mineral supplements, Chromium may be necessary for utilization of dietary sugars and carbohydrates by optimizing the effects of insulin. Animal studies suggest that chromium picolinate may be carcinogenic, it enters cells directly and can causes mutations. (NCI04)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Organic Chemical (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0163657&amp;amp;tui=T109"&gt;&lt;i&gt;T109&lt;/i&gt;&lt;/a&gt;)
, Pharmacologic Substance (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0163657&amp;amp;tui=T121"&gt;&lt;i&gt;T121&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;C030614&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;442428005&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;CHROMIUM PICOLINATE, mineral supplements chromium picolinate, chromium picolinate (medication), Chromium Picolinate, Chromium picolinate (substance), Chromium picolinate, chromium picolinate&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;picolinato de cromo (sustancia), picolinato de cromo&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>CHROMIUM PICOLINATE  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Chromium Picolinate</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Pharmacology</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;See Also&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/OrlHypglycmc.htm" class="LinkPage"&gt;Oral Hypoglycemic&lt;/a&gt; Agents&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Dosing&lt;ol&gt;&lt;li&gt;Chromium Picolinate 200-500 ug/day&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Advantages&lt;ol&gt;&lt;li&gt;Inexpensive: 4 cents per day&lt;/li&gt;&lt;li&gt;Improves &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; sensitivity&lt;/li&gt;&lt;li&gt;Improves &lt;a href="../../CV/Lab/Lpd.htm" class="LinkPage"&gt;Lipid&lt;/a&gt; metabolism&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Disadvantages&lt;ol&gt;&lt;li&gt;Toxicity&lt;/li&gt;&lt;li&gt;Weak agent compared with newer hypoglycemics&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Indication&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/DM/TypDbtsMlts1.htm" class="LinkPage"&gt;Type II Diabetes Mellitus&lt;/a&gt; with other agents&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0163657</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Pharm/ChrmPclnt.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Chromium Picolinate</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Pharm/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Hernia of abdominal cavity  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0178282"&gt;&lt;i&gt;C0178282&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;A protrusion of abdominal structures through the retaining ABDOMINAL WALL. It involves two parts: an opening in the abdominal wall, and a hernia sac consisting of PERITONEUM and abdominal contents. Abdominal hernias include groin hernia (HERNIA, FEMORAL; HERNIA, INGUINAL) and VENTRAL HERNIA.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Disease or Syndrome (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0178282&amp;amp;tui=T047"&gt;&lt;i&gt;T047&lt;/i&gt;&lt;/a&gt;)
, Anatomical Abnormality (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0178282&amp;amp;tui=T190"&gt;&lt;i&gt;T190&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D046449&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD9&lt;/td&gt;
                &lt;td&gt;550-553.99&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD10&lt;/td&gt;
                &lt;td&gt;K46, K46.9&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;155758000, 155737006, 196799009, 196968002, 196973008, 52515009, 30477007, 359801000, 6515007&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Abdominal Hernia, Hernia of abdominal cavity, HERNIA, INTERNAL, Hernia, abdominal, HERNIAS OF THE ABDOMINAL CAVITY, Hernia of abdominal cavity, NOS, Intra-abdominal hernia, NOS, Abdominal cavity hernia NOS, Unsp.abd.cavity hernia NOS, Unspecified abdominal cavity hernia NOS, abdominal hernia, hernia of abdominal cavity, abdominal hernia (physical finding), abdomen hernia, SECTION 5-6 HERNIAS OF THE ABDOMINAL CAVITY, intra-abdominal hernia, intra-abdominal hernia (diagnosis), Abdominal cavity hernia NOS (disorder), Abdominal hernia NOS, Abdominal herniation, Unspecified abdominal cavity hernia NOS (disorder), Unspecified abdominal hernia, Hernia, Abdominal [Disease/Finding], hernia abdominal, internal hernia, intraperitoneal hernia, abdominal hernias, abdominal herniation, Abdominal hernia, Internal hernia, Hernia of abdominal cavity (disorder), Intra-abdominal hernia (disorder), Intra-abdominal hernia, Intraperitoneal hernia, hernia; abdominal, Hernia of abdominal cavity [Ambiguous], Abdominal Hernias, Hernia, Abdominal, Hernias, Abdominal, HERNIA OF ABDOMINAL CAVITY&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Ernia interna, Erniazione addominale, Ernia addominale NAS, Ernia addominale&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;abdominale hernia NAO, abdominale uitstulping, hernia; abdominalis, abdominale hernia, inwendige hernia, Niet gespecificeerde buikbreuk, Buikwandbreuk, Buikhernia, Hernia, buik-&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Hernie abdominale SAI, Hernie interne, Hernie abdominale, Hernie de la paroi abdominale, Laparocèle&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Hernia abdominalis NNB, abdominale Herniation, Nicht naeher bezeichnete abdominale Hernie, interne Hernie, Abdominalhernie, Hernia abdominalis&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Herniação abdominal, Hérnia abdominal NE, Hérnia abdominal, Hérnia interna, Hérnia Abdominal&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;Hernia abdominal NEOM, Hernia of abdominal cavity, Hernia of abdominal cavity [Ambiguous], Abdominal cavity hernia NOS, hernia abdominal, hernia de la cavidad abdominal (trastorno), hernia de la cavidad abdominal no especificada, SAI (trastorno), hernia de la cavidad abdominal no especificada, SAI, hernia de la cavidad abdominal, SAI (trastorno), hernia de la cavidad abdominal, SAI, hernia de la cavidad abdominal, hernia intrabdominal (trastorno), hernia intrabdominal, Hernia abdominal, Hernia interna, Hernia Abdominal&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;腹部ヘルニア形成, 腹部ヘルニアＮＯＳ, 内ヘルニア, 腹部ヘルニア, ﾌｸﾌﾞﾍﾙﾆｱ, ﾌｸﾌﾞﾍﾙﾆｱNOS, ﾅｲﾍﾙﾆｱ, ﾌｸﾌﾞﾍﾙﾆｱｹｲｾｲ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Bukbråck&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;břišní kýla, hernie abdominální, Břišní výhřez, Břišní kýla NOS, Bišní kýla, Vnitřní kýla&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Vatsatyrä&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;GRYZHA BRIUSHNOI STENKI, GRYZHA BRIUSHNAIA, ГРЫЖА БРЮШНАЯ, ГРЫЖА БРЮШНОЙ СТЕНКИ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Korean&lt;/td&gt;
                &lt;td&gt;상세불명의 복부헤르니아&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Croatian&lt;/td&gt;
                &lt;td&gt;Not Translated[Hernia, Abdominal]&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Przepuklina brzuszna&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;Abdominalis hernia, Abdominalis sérv k.m.n., Abdominalis herniatio, Belső hernia&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Hernia of abdominal cavity  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Internal Hernia</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Surgery</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Causes&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Surgery/ObstySrgry.htm" class="LinkPage"&gt;Roux-en-Y gastric bypass&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Intraabdominal hernia near &lt;a href="../../Endo/Surgery/ObstySrgry.htm" class="LinkPage"&gt;Gastric Bypass&lt;/a&gt; site with secondary ischemia and infarction of bowel&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Epidemiology&lt;ol&gt;&lt;li&gt;Occurs in up to 3% of retrocolic bypass procedures&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Risk Factors&lt;ol&gt;&lt;li&gt;Greatest post-surgical weight loss (exaggerates defects)&lt;/li&gt;&lt;li&gt;Laparoscopic surgery (less adhesions)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Types&lt;ol&gt;&lt;li&gt;Peterson Defect (approximately 66% of cases)&lt;ol&gt;&lt;li&gt;Occurs in the space between the mesentary and the overlying roux limb as it approaches the pouch&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../GI/Anatomy/SmlBwlAntmy.htm" class="LinkPage"&gt;Small Bowel&lt;/a&gt; anastomosis defect (approximately 33% of cases)&lt;ol&gt;&lt;li&gt;Occurs in the space between the mesentary and the overlying jejunostomy&lt;/li&gt;&lt;li&gt;Higher risk of &lt;a href="../../GI/Anatomy/SmlBwlAntmy.htm" class="LinkPage"&gt;Small Bowel&lt;/a&gt; ischemia or infarction&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Signs: Presentation&lt;ol&gt;&lt;li&gt;Most common in first 6-18 months post-operatively&lt;/li&gt;&lt;li&gt;Presents with colicky &lt;a href="../../Surgery/GI/EpgstrcPn.htm" class="LinkPage"&gt;Epigastric Pain&lt;/a&gt; that worsens with eating&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Evaluation&lt;ol&gt;&lt;li&gt;Requires urgent surgical consultation&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Imaging: Abdominal CT with oral and IV contrast&lt;ol&gt;&lt;li&gt;Positive findings are subtle&lt;ol&gt;&lt;li&gt;Mesenteric edema&lt;/li&gt;&lt;li&gt;Swirling mesenteric vessels&lt;ol&gt;&lt;li&gt;Pathognomonic for Internal Hernia&lt;/li&gt;&lt;li&gt;Represent bowel loops around the Internal Hernia site&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;CT is only helpful if positive (often normal initially)&lt;ol&gt;&lt;li&gt;Emergent surgery is indicated for a positive CT&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Negative result should not be considered reassuring&lt;ol&gt;&lt;li&gt;Does not replace urgent consultation with bariatric surgeon if Internal Hernia is suspected&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Complications&lt;ol&gt;&lt;li&gt;Death&lt;/li&gt;&lt;li&gt;Short bowel syndrome&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;Weinstock in Majoewsky (2012) EM:RAP 12(3): 3&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0178282</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Surgery/IntrnlHrn.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Internal Hernia, Abdominal Cavity Hernia</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Surgery/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Carbohydrate counting  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C1562940"&gt;&lt;i&gt;C1562940&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Health Care Activity (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C1562940&amp;amp;tui=T058"&gt;&lt;i&gt;T058&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;416576000&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Carbohydrate counting (regime/therapy), Carbohydrate counting&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;recuento de carbohidratos (régimen/tratamiento), recuento de carbohidratos, recuento de hidratos de carbono&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Carbohydrate counting  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Carbohydrate Count in Insulin Dosing</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Pharmacology</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;See Also&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Prevent/CrbhydrtCnt.htm" class="LinkPage"&gt;Carbohydrate Counting&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/InslnDsng.htm" class="LinkPage"&gt;Insulin Dosing&lt;/a&gt;&lt;/li&gt;&lt;li&gt;See &lt;a href="../../Endo/Pharm/InslnDsngInTypDbts.htm" class="LinkPage"&gt;Insulin Dosing in Type I Diabetes&lt;/a&gt;&lt;/li&gt;&lt;li&gt;See &lt;a href="../../Endo/Pharm/InslnDsngInTypDbts1.htm" class="LinkPage"&gt;Insulin Dosing in Type II Diabetes&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Step 1a: Determine Carbohydrate to &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; ratio&lt;ol&gt;&lt;li&gt;Determine total &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; used per day&lt;ol&gt;&lt;li&gt;Option 1: Known dose from multiple daily doses or &lt;a href="../../Endo/Pharm/InslnPmp.htm" class="LinkPage"&gt;Insulin Pump&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Option 2: Calculate based on patient weight&lt;ol&gt;&lt;li&gt;Type I: Total daily &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; (TDI)&lt;ol&gt;&lt;li&gt;WtKg x 0.1 to 0.3 units/kg (start low)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Type II: Total daily &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; (TDI)&lt;ol&gt;&lt;li&gt;WtKg x 0.3 units/kg: Underweight, advance age, &lt;a href="../../Renal/Pharm/Hmdlys.htm" class="LinkPage"&gt;Dialysis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;WtKg x 0.4 units/kg: Normal weight&lt;/li&gt;&lt;li&gt;WtKg x 0.5 units/kg: &lt;a href="../../Endo/Obesity/Obsty.htm" class="LinkPage"&gt;Overweight&lt;/a&gt;&lt;/li&gt;&lt;li&gt;WtKg x 0.6 units/kg: Obese, steroid use, high &lt;a href="../../Endo/DM/InslnRstncSyndrm.htm" class="LinkPage"&gt;Insulin Resistance&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Option 3: Simple carbohydrate based-method (below in Step Ib)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Plan to split the basal &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; and bolus &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; evenly (50% to each)&lt;/li&gt;&lt;li&gt;Calculate carbohydrate to &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; ratio&lt;ol&gt;&lt;li&gt;Short-acting rapid &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt;: &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Humalog&lt;/a&gt; (&lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Lispro&lt;/a&gt;)&lt;ol&gt;&lt;li&gt;Ratio = 500 / (total daily &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; dose)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Short-acting &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt;: Regular&lt;ol&gt;&lt;li&gt;Ratio = 450 / (total daily &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; dose)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Interpretation&lt;ol&gt;&lt;li&gt;Ratio is carbohydrate grams covered by 1 unit &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/DM/TypDbtsMlts.htm" class="LinkPage"&gt;Type I Diabetes&lt;/a&gt;&lt;ol&gt;&lt;li&gt;One unit per carbohydrate (15 grams) is typical&lt;/li&gt;&lt;li&gt;Effect of one unit &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; on &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; lowering&lt;ol&gt;&lt;li&gt;Typically 1 Unit bolus &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; lowers &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; 20-60 mg/dl&lt;/li&gt;&lt;li&gt;Estimate: 1800/(daily &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; dose)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Example&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/DM/TypDbtsMlts.htm" class="LinkPage"&gt;Type I Diabetes&lt;/a&gt; patient weighs 110 kg and uses ~35 total units of &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; per day (0.3 units/kg)&lt;/li&gt;&lt;li&gt;One unit &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; covers 500/35 or 14 g carbohydrates&lt;/li&gt;&lt;li&gt;One unit &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; would be expected to lower &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt;  1800/35 or 50 mg/dl (in &lt;a href="../../Endo/DM/TypDbtsMlts.htm" class="LinkPage"&gt;Type I Diabetes Mellitus&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/AnlgBslInsln.htm" class="LinkPage"&gt;Lantus&lt;/a&gt;: Takes 18 units of &lt;a href="../../Endo/Pharm/AnlgBslInsln.htm" class="LinkPage"&gt;Lantus&lt;/a&gt; per day&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Lispro&lt;/a&gt;: Takes 16 units total  (4 units for each of 3 meals and 2 units for each of 2 snacks)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Step 1b: Alternative to Step 1a (Simple Method)&lt;ol&gt;&lt;li&gt;Dietician directs grams of carbohydrate per meal&lt;ol&gt;&lt;li&gt;Estimate &lt;a href="../../Endo/Exam/DlyEnrgyAlwnc.htm" class="LinkPage"&gt;Daily Energy Allowance&lt;/a&gt; (calories)&lt;/li&gt;&lt;li&gt;Estimate percentage of calories in diet (50-60%)&lt;/li&gt;&lt;li&gt;Calories per gram of carbohydrate = 4&lt;/li&gt;&lt;li&gt;Calculate total daily carbohydrate grams&lt;ol&gt;&lt;li&gt;Daily Carbs (grams) = (Total Calories x 0.5) / 4&lt;/li&gt;&lt;li&gt;Example = (1800 x 0.5)/4 = 225 carbohydrate grams&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Spread out carbohydrate grams across meals&lt;ol&gt;&lt;li&gt;Example: 70 grams per meal, and two 20 gram snacks&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Choose carbohydrate servings to meet needs&lt;ol&gt;&lt;li&gt;Each serving contains 12-15 grams carbohydrate&lt;/li&gt;&lt;li&gt;Choose servings from 3 groups&lt;ol&gt;&lt;li&gt;Breads and starches&lt;/li&gt;&lt;li&gt;Fruit&lt;/li&gt;&lt;li&gt;Milk&lt;/li&gt;&lt;li&gt;Vegetables are not counted&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Step 2: Predict carbohydrate effect on &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Serum Glucose&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; rises at constant rate per gram carbohydrate&lt;ol&gt;&lt;li&gt;Weight 100 lbs: 1g carb raises &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; 5 points&lt;/li&gt;&lt;li&gt;Weight 150 lbs: 1g carb raises &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; 4 points&lt;/li&gt;&lt;li&gt;Weight 200 lbs: 1g carb raises &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; 3 points&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Other modifiers of carbohydrate effect on &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Serum Glucose&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../Pharm/Nutrition/GlycmcIndx.htm" class="LinkPage"&gt;Glycemic Index&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Percentage of food from protein and fat&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Step 3: Count Carbohydrates&lt;ol&gt;&lt;li&gt;Indications&lt;ol&gt;&lt;li&gt;Estimate &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; needs per meal&lt;/li&gt;&lt;li&gt;Plan meal to raise &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; to certain level&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Techniques&lt;ol&gt;&lt;li&gt;Food labels (use grams of carbohydrate per serving)&lt;/li&gt;&lt;li&gt;Food tables (e.g. cookbooks, references)&lt;/li&gt;&lt;li&gt;Food weight&lt;ol&gt;&lt;li&gt;Determine Carb Factor for particular food&lt;ol&gt;&lt;li&gt;Percentage of given food from carbohydrate&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Weigh food on gram scale&lt;/li&gt;&lt;li&gt;Carbohydrate grams = (food weight) x (carb factor)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Step 5: Summary: Combining &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; protocols&lt;ol&gt;&lt;li&gt;Basal &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; (Maintenance, covers between meals and ovenight)&lt;ol&gt;&lt;li&gt;Once daily: &lt;a href="../../Endo/Pharm/AnlgBslInsln.htm" class="LinkPage"&gt;Lantus&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Twice daily: &lt;a href="../../Endo/Pharm/AnlgBslInsln.htm" class="LinkPage"&gt;Levemir&lt;/a&gt;, &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;NPH Insulin&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Bolus &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; (pre-meal &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt;, covers post-meal &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Sugar&lt;/a&gt;s)&lt;ol&gt;&lt;li&gt;Units per carbohydrate of planned meal AND&lt;/li&gt;&lt;li&gt;Units of &lt;a href="../../Endo/Pharm/InslnSldngScl.htm" class="LinkPage"&gt;Correctional Insulin Dosing&lt;/a&gt; based on &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Sugar&lt;/a&gt;s over 149 before the meal&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Example&lt;ol&gt;&lt;li&gt;A 70 kg man with &lt;a href="../../Endo/DM/TypDbtsMlts1.htm" class="LinkPage"&gt;Type II Diabetes Mellitus&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/AnlgBslInsln.htm" class="LinkPage"&gt;Insulin Glargine&lt;/a&gt; (&lt;a href="../../Endo/Pharm/AnlgBslInsln.htm" class="LinkPage"&gt;Lantus&lt;/a&gt;)&lt;ol&gt;&lt;li&gt;Uses 14 units per day at dinner&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt;&lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Humalog&lt;/a&gt; (&lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Lispro&lt;/a&gt;) with coverage&lt;ol&gt;&lt;li&gt;Uses 1 unit per carbohydrate PLUS 1 unit per 50 over 150&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Sugar&lt;/a&gt; of 200 at lunch and having prepared a 4 carbohydrate meal&lt;/li&gt;&lt;li&gt;Takes a total of 6 units: 4 units (4 carbs) plus an additional 2 units (for &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Sugar&lt;/a&gt; of 200)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C1562940</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Pharm/CrbhydrtCntInInslnDsng.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Carbohydrate Count in Insulin Dosing, Insulin Adjustment with Carbohydrate Counting</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Pharm/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Phenylketonurias  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0031485"&gt;&lt;i&gt;C0031485&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A disorder characterized by the body's inability to break down and utilize the essential amino acid phenylalanine.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CHV)&lt;/td&gt;
                &lt;td&gt;A genetic disorder in which the body lacks the enzyme necessary to metabolize phenylalanine&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CHV)&lt;/td&gt;
                &lt;td&gt;A genetic disorder in which the body lacks the enzyme necessary to metabolize phenylalanine&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CHV)&lt;/td&gt;
                &lt;td&gt;A genetic disorder in which the body lacks the enzyme necessary to metabolize phenylalanine&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CHV)&lt;/td&gt;
                &lt;td&gt;A genetic disorder in which the body lacks the enzyme necessary to metabolize phenylalanine&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CHV)&lt;/td&gt;
                &lt;td&gt;A genetic disorder in which the body lacks the enzyme necessary to metabolize phenylalanine&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CHV)&lt;/td&gt;
                &lt;td&gt;A genetic disorder in which the body lacks the enzyme necessary to metabolize phenylalanine&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CHV)&lt;/td&gt;
                &lt;td&gt;A genetic disorder in which the body lacks the enzyme necessary to metabolize phenylalanine&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MEDLINEPLUS)&lt;/td&gt;
                &lt;td&gt;
                  &lt;span&gt;
                    &lt;p&gt;Phenylketonuria (PKU) is a genetic disorder in which the body can't process part of a protein called phenylalanine (Phe). Phe is in almost all foods. If the Phe level gets too high, it can damage the brain and cause severe mental retardation. All babies born in U.S. hospitals must now have a &lt;a href="http://www.nlm.nih.gov/medlineplus/newbornscreening.html"&gt;screening&lt;/a&gt; test for PKU. This makes it easier to diagnose and treat the problem early. &lt;/p&gt;
                    &lt;p&gt;The best treatment for PKU is a diet of low-protein foods. There are special formulas for newborns.  For older children and adults, the diet includes many fruits and vegetables. It also includes some low-protein breads, pastas and cereals. Nutritional formulas provide the vitamins and minerals they can't get from their food.&lt;/p&gt;
                    &lt;p&gt;Babies who get on this special diet soon after they are born develop normally. Many have no symptoms of PKU. It is important that they stay on the diet for the rest of their lives.&lt;/p&gt;
                    &lt;p style="font-weight:bold;font-style:italic;"&gt;NIH: National Institute of Child Health and Human Development&lt;/p&gt;
                  &lt;/span&gt;
                &lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;An inherited disorder that causes a build-up of phenylalanine (an amino acid) in the blood. This can cause mental retardation, behavioral and movement problems, seizures, and delayed development. Using a blood test, PKU can easily be found in newborns, and treatment is a diet low in phenylalanine.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;A group of autosomal recessive disorders marked by a deficiency of the hepatic enzyme PHENYLALANINE HYDROXYLASE or less frequently by reduced activity of DIHYDROPTERIDINE REDUCTASE (i.e., atypical phenylketonuria). Classical phenylketonuria is caused by a severe deficiency of phenylalanine hydroxylase and presents in infancy with developmental delay; SEIZURES; skin HYPOPIGMENTATION; ECZEMA; and demyelination in the central nervous system. (From Adams et al., Principles of Neurology, 6th ed, p952).&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CSP)&lt;/td&gt;
                &lt;td&gt;group of autosomal recessive disorders marked by a deficiency of the hepatic enzyme phenylaline hydroxylase or less frequently by reduced activity of dihydropteridine reductase.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Disease or Syndrome (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0031485&amp;amp;tui=T047"&gt;&lt;i&gt;T047&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D010661&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD9&lt;/td&gt;
                &lt;td&gt;270.1&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;190687004, 154735006&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Phenylketonuria, Phenylketonuria (PKU), PHENYLKETONURIA, PKU, PHENYLKETOURIA, PKU - Phenylketonuria, Phenylketonuria, NOS, phenylalaninemia, phenylketonuria (diagnosis), phenylketonuria, Phenylketonuria (disorder), Phenylalaninemia, Phenylketouria, Phenylketonuria - pku, Phenylketonurias [Disease/Finding], phenylketonurias, phenylketonuria (PKU), phenylketouria, pku phenylketonuria, Phenylalaninaemia, Phenylketonurias, PKU (Hereditary Disorder), Phenylketonuria [PKU]&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;PHENYLCETONURIE, Phénylalaninémie, Phénylkétonurie (PKU), PKU, Phénylcétonuries, Phénylcétonurie&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;FENILCETONURIA, Fenilalaninemia, Fenilcetonúria, Fenilcetonúrias&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;FENILCETONURIA, Fenilalaninemia, PKU, Fenilcetonuria (FCU), Phenylketonuria, Fenilcetonuria, Fenilcetonurias&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;PHENYLKETONURIE, Phenylketonurie (PKU), Phenylalaninaemie, PKU, Phenylketonurie&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Fenilchetonuria, Fenilalaninemia, Fenilchetonuria (PKU), PKU, Fenilchetonurie&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;FKU, fenylalaninemie, fenylketonurie (FKU), fenylketonurie, Fenylketonurie, Ketonurie, fenyl-, Fenylketonurieën, Ketonurieën, fenyl-&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;フェニルアラニン血症, ﾌｪﾆﾙｱﾗﾆﾝｹﾂｼｮｳ, ﾌｪﾆﾙｱﾗﾆﾝｹｯｼｮｳ, ﾌｪﾆﾙｹﾄﾝﾆｮｳｼｮｳ, フェーリング病, フェニル焦性ブドウ酸性白痴, フォリング症候群, フォリング病, Folling病, フェニルアラニンヒドロキシラーゼ欠損症, フェニルケトン尿, フェニルピルビン酸性白痴, フェニルケトン尿症, Folling症候群&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Fenylketonuri&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;fenylketonurie, Fenylalaninemie, PKU, Fenylketonurie (PKU), Fenylketonurie&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Klassinen fenylketonuria&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;FENILKETONURII, ФЕНИЛКЕТОНУРИИ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Croatian&lt;/td&gt;
                &lt;td&gt;FENILKETONURIJE&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Fenyloketonuria&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;Phenylalaninaemia, Phenylketonuria (phenylketonuria), Phenylalaninemia, Phenylketonuria, Phenylketouria&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Phenylketonurias  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Phenylketonuria</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Metabolic Disorders</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;See Also&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Metabolism/InbrnErrsOfMtblsm.htm" class="LinkPage"&gt;Inborn Errors of Metabolism&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Epidemiology&lt;ol&gt;&lt;li&gt;&lt;a href="../../Prevent/Epi/DsIncdncRt.htm" class="LinkPage"&gt;Incidence&lt;/a&gt;: 1:15000&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Pathophysiology&lt;ol&gt;&lt;li&gt;Autosomal-recessive disorder&lt;/li&gt;&lt;li&gt;Phenylalanine hydroxylase gene mutation&lt;ol&gt;&lt;li&gt;Enzyme converts phenylalanine to tyrosine&lt;/li&gt;&lt;li&gt;Phenylalanine concentrations rise with mutation&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Phenylalanine threshold for adverse effects &amp;gt;20 mg/dl&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Symptoms&lt;ol&gt;&lt;li&gt;Irritability&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Signs: Complications on unrestricted diet&lt;ol&gt;&lt;li&gt;&lt;a href="../../NICU/Exam/HdCrcmfrnc.htm" class="LinkPage"&gt;Head Circumference&lt;/a&gt; small for age (&lt;a href="../../NICU/Exam/HdCrcmfrnc.htm" class="LinkPage"&gt;Microcephaly&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;Cognitive delay&lt;/li&gt;&lt;li&gt;Light skin pigmention&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Labs&lt;ol&gt;&lt;li&gt;Identified on &lt;a href="../../NICU/Lab/NwbrnScrn.htm" class="LinkPage"&gt;Newborn Screen&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Management&lt;ol&gt;&lt;li&gt;Strict low phenylalanine diet for life&lt;ol&gt;&lt;li&gt;Infant: Low Phenylalanine formula&lt;/li&gt;&lt;li&gt;Pregnancy: Monitor phenylalanine concentrations&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Supplementation&lt;ol&gt;&lt;li&gt;Tyrosine 25 mg/kg/day&lt;/li&gt;&lt;li&gt;Amino acid dosing&lt;ol&gt;&lt;li&gt;Infant: 3 g/kg/day&lt;/li&gt;&lt;li&gt;Child: 2 g/kg/day&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Raghuveer%20%20%5BAU%5D%20AND%202006%20%5BDP%5D%20AND%20%20Am%20Fam%20Physician%20%20%5BTA%5D" class="LinkRef"&gt;Raghuveer (2006) Am Fam Physician 73:1981-90&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0031485</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Metabolism/Phnylktnr.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Phenylketonuria, PKU</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Metabolism/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Medium-chain acyl-coenzyme A dehydrogenase deficiency  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0220710"&gt;&lt;i&gt;C0220710&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A genetic disorder characterized by deficiency of the enzyme medium-chain acyl-coenzyme A dehydrogenase that metabolizes medium-chain fatty acids. Signs and symptoms appear in infancy or childhood and may be triggered during fasting or illness. They include vomiting, hypoglycemia and lethargy.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Disease or Syndrome (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0220710&amp;amp;tui=T047"&gt;&lt;i&gt;T047&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;C536038&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD10&lt;/td&gt;
                &lt;td&gt;E71.311&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;393571006, 394513008, 128596003, 74351001&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Deficiency of medium-chain acyl-CoA dehydrogenase, MCAD DEFICIENCY, MCADH DEFICIENCY, CARNITINE DEFICIENCY SECONDARY TO MEDIUM-CHAIN ACYL-CoA DEHYDROGENASE DEFICIENCY, ACADM DEFICIENCY, ACYL-CoA DEHYDROGENASE, MEDIUM-CHAIN, DEFICIENCY OF, Medium-chain acyl-coenzyme A dehydrogenase deficiency, medium-chain acyl-CoA dehydrogenase deficiency, medium-chain acyl-CoA dehydrogenase deficiency (diagnosis), Medium chain acyl-CoA dehydrogenase deficiency (disorder), MCAD-Med ch acyl-CoA dehyd def, Med ch acyl-CoA dehydrog defic, MCAD, Acyl-CoA Dehydrogenase, Medium-Chain Deficiency, Medium-Chain Acyl-Coenzyme A Dehydrogenase Deficiency (MCAD), Medium-Chain Acyl-CoA Dehydrogenase Deficiency (MCAD), Medium-chain Acyl-CoA dehydrogenase deficiency, Medium chain acyl CoA dehydrogenase deficiency, Acyl-CoA dehydrogenase, medium chain, deficiency of, mcad deficiency, ACADMD, MCAD deficiency, MCAD - Medium chain acyl-CoA dehydrogenase deficiency, Medium chain acyl-CoA dehydrogenase deficiency, Medium-chain acyl-coenzyme A dehydrogenase deficiency (disorder), Medium chain acyl CoA dehydrogenase deficiency (MCAD)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;Medium chain acyl-CoA dehydrogenase deficiency, insuficiencia de acilcoenzima A deshidrogenasa de cadena media (trastorno), insuficiencia de acilcoenzima A deshidrogenasa de cadena media&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Medium-chain acyl-coenzyme A dehydrogenase deficiency  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>MCAD Deficiency</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Metabolic Disorders</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;See Also&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Metabolism/InbrnErrsOfMtblsm.htm" class="LinkPage"&gt;Inborn Errors of Metabolism&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Epidemiology&lt;ol&gt;&lt;li&gt;&lt;a href="../../Prevent/Epi/DsIncdncRt.htm" class="LinkPage"&gt;Incidence&lt;/a&gt;: 1:15,000&lt;/li&gt;&lt;li&gt;Autosomal recessive inheritance&lt;/li&gt;&lt;li&gt;Most common in northwestern european descendents&lt;ol&gt;&lt;li&gt;Due to homozygous A985G missense mutation (see below)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Pathophysiology&lt;ol&gt;&lt;li&gt;Defect in &lt;a href="../../Pharm/Nutrition/FtyAcd.htm" class="LinkPage"&gt;Fatty Acid&lt;/a&gt; oxidation&lt;/li&gt;&lt;li&gt;A985G Missense mutation is most common cause&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Signs&lt;ol&gt;&lt;li&gt;Progressive nonketotic &lt;a href="../../Endo/Hypoglycemia/Hypglycm.htm" class="LinkPage"&gt;Hypoglycemia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Lethargy to coma&lt;/li&gt;&lt;li&gt;&lt;a href="../../Neuro/Seizure/Szr.htm" class="LinkPage"&gt;Seizure&lt;/a&gt;s&lt;/li&gt;&lt;li&gt;Encephalopathy&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Labs&lt;ol&gt;&lt;li&gt;Urine organic acids&lt;/li&gt;&lt;li&gt;Acylcarnitine&lt;/li&gt;&lt;li&gt;Genetic testing&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Management&lt;ol&gt;&lt;li&gt;Frequent meals (cornstarch) to avoid &lt;a href="../../Endo/Hypoglycemia/Hypglycm.htm" class="LinkPage"&gt;Hypoglycemia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Careful management when ill, &lt;a href="../../GI/Sx/Vmtng.htm" class="LinkPage"&gt;Vomiting&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Medic alert tag to notify responders in emergency&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Complications&lt;ol&gt;&lt;li&gt;&lt;a href="../../Peds/Prevent/SdnInfntDthSyndrm.htm" class="LinkPage"&gt;Sudden Infant Death Syndrome&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0220710</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Metabolism/McdDfcncy.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: MCAD Deficiency, Medium-Chain-Acyl-CoA-Dehydrogenase Deficiency</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Metabolism/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees></FP_UMLS_Trees><FP_Condition_name_check></FP_Condition_name_check><FP_Condition_name><value>Type 2 Gaucher's Disease</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Metabolic Disorders</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;See Also&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Metabolism/TypGchrsDs.htm" class="LinkPage"&gt;Type 1 Gaucher's Disease&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Signs&lt;ol&gt;&lt;li&gt;&lt;a href="../../Eye/Peds/Strbsms.htm" class="LinkPage"&gt;Strabismus&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Bulbar signs&lt;/li&gt;&lt;li&gt;Cognitive deterioration&lt;/li&gt;&lt;li&gt;Myoclonic &lt;a href="../../Neuro/Seizure/Szr.htm" class="LinkPage"&gt;Seizure&lt;/a&gt;s&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Metabolism/TypGchrsDs1.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Type 2 Gaucher's Disease, Type 3 Gaucher's Disease</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Metabolism/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees></FP_UMLS_Trees><FP_Condition_name_check></FP_Condition_name_check><FP_Condition_name><value>Neonatal Hypoglycemia</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Neonatology</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Causes&lt;ol&gt;&lt;li&gt;Decreased &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; stores&lt;ol&gt;&lt;li&gt;Prematurity&lt;/li&gt;&lt;li&gt;&lt;a href="../../OB/Fetus/IntrtrnGrwthRtrdtn.htm" class="LinkPage"&gt;Intrauterine Growth Retardation&lt;/a&gt; (&lt;a href="../../OB/Fetus/IntrtrnGrwthRtrdtn.htm" class="LinkPage"&gt;IUGR&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Renal/Lab/Hypx.htm" class="LinkPage"&gt;Hypoxia&lt;/a&gt; or asphyxia&lt;/li&gt;&lt;li&gt;&lt;a href="../../ID/Fever/Sps1.htm" class="LinkPage"&gt;Sepsis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../ER/Environ/Hypthrm.htm" class="LinkPage"&gt;Hypothermia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Peds/CngntlHrtDs.htm" class="LinkPage"&gt;Congenital Heart Disease&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Metabolism/DsrdrsOfEnrgyMtblsm.htm" class="LinkPage"&gt;Glycogen Storage Disease&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Glcgn.htm" class="LinkPage"&gt;Glucagon&lt;/a&gt; deficiency&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Adrenal/AdsnsDs.htm" class="LinkPage"&gt;Adrenal Insufficiency&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Metabolism/Glctsm.htm" class="LinkPage"&gt;Galactosemia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Fructose intollerance&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Hyperinsulinism&lt;ol&gt;&lt;li&gt;Mother with &lt;a href="../../Endo/DM/DbtsMlts.htm" class="LinkPage"&gt;Diabetes Mellitus&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../NICU/HemeOnc/HmlytcDsOfThNwbrn.htm" class="LinkPage"&gt;Erythroblastosis Fetalis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../NICU/GI/ExchngTrnsfsn.htm" class="LinkPage"&gt;Exchange Transfusion&lt;/a&gt;s&lt;/li&gt;&lt;li&gt;Beckwith-Wiedemann Syndrome&lt;/li&gt;&lt;li&gt;Nesidioblastosis&lt;/li&gt;&lt;li&gt;Islet Cell adenoma&lt;/li&gt;&lt;li&gt;Leucine sensitivity&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Maternal Medications&lt;ol&gt;&lt;li&gt;&lt;a href="../../Pharm/Analgesic/Slcylt.htm" class="LinkPage"&gt;Salicylate&lt;/a&gt;s&lt;/li&gt;&lt;li&gt;Beta-&lt;a href="../../Neuro/Pharm/AdrnrgcRcptr.htm" class="LinkPage"&gt;Sympathomimetic&lt;/a&gt;s&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/FrstGnrtnSlfnylr.htm" class="LinkPage"&gt;Chlorpropamide&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Benzothiadiazide&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Associated Conditions in children of diabetic mothers&lt;ol&gt;&lt;li&gt;Perinatal asphyxia&lt;/li&gt;&lt;li&gt;&lt;a href="../../NICU/Birth/NwbrnInjry.htm" class="LinkPage"&gt;Birth Trauma&lt;/a&gt; (&lt;a href="../../Ortho/Anatomy/ShldrAntmy.htm" class="LinkPage"&gt;Shoulder&lt;/a&gt; dystochia)&lt;/li&gt;&lt;li&gt;Congenital anomalies&lt;/li&gt;&lt;li&gt;&lt;a href="../../Renal/Calcium/Hypclcm.htm" class="LinkPage"&gt;Hypocalcemia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../GI/Lab/Blrbn.htm" class="LinkPage"&gt;Hyperbilirubinemia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Respiratory distress syndrome&lt;/li&gt;&lt;li&gt;Polycythemia&lt;/li&gt;&lt;li&gt;Feeding problems&lt;/li&gt;&lt;li&gt;Renal vein thrombosis&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Symptoms&lt;ol&gt;&lt;li&gt;Jittery or &lt;a href="../../Neuro/Tremor/Trmr.htm" class="LinkPage"&gt;Tremor&lt;/a&gt;s&lt;/li&gt;&lt;li&gt;Lethargic&lt;/li&gt;&lt;li&gt;Hypotonia&lt;/li&gt;&lt;li&gt;Apnea&lt;/li&gt;&lt;li&gt;&lt;a href="../../ER/Environ/Hypthrm.htm" class="LinkPage"&gt;Hypothermia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Cyanosis&lt;/li&gt;&lt;li&gt;&lt;a href="../../Neuro/Seizure/Szr.htm" class="LinkPage"&gt;Seizure&lt;/a&gt;s&lt;/li&gt;&lt;li&gt;Weak or high pitched cry&lt;/li&gt;&lt;li&gt;Poor feeding&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Labs&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/DM/DbtsMltsGlcsMngmnt.htm" class="LinkPage"&gt;Blood Glucose Monitoring&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Hours of life: 1, 2, 3, 6, 12, 24, and 48 hours&lt;/li&gt;&lt;li&gt;Increase frequency of checks for symptoms&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Renal/Lab/SrmClcm.htm" class="LinkPage"&gt;Serum Calcium&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Check if lethargic or jittery despite normal &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../HemeOnc/Lab/Hmtcrt.htm" class="LinkPage"&gt;Hematocrit&lt;/a&gt;&lt;ol&gt;&lt;li&gt;For signs of Polycythemia&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../GI/Lab/NntlBlrbn.htm" class="LinkPage"&gt;Neonatal Bilirubin&lt;/a&gt; (as indicated)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Renal/Lab/ArtrlBldGs.htm" class="LinkPage"&gt;Arterial Blood Gas&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Indicated for signs of respiratory distress&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Radiology&lt;ol&gt;&lt;li&gt;&lt;a href="../../Lung/Rad/ChstXry.htm" class="LinkPage"&gt;Chest XRay&lt;/a&gt; indicated for respiratory distress&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Management: General Approach&lt;ol&gt;&lt;li&gt;Monitor &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Sugar&lt;/a&gt; closely at above intervals&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; 35 to 45 mg/dl&lt;ol&gt;&lt;li&gt;Oral &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; replacement (see below)&lt;/li&gt;&lt;li&gt;Parenteral &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; replacement if symptomatic&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; 25-34 mg/dl&lt;ol&gt;&lt;li&gt;Attempt oral &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; replacement (see below)&lt;/li&gt;&lt;li&gt;Parenteral &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; replacement usually indicated&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; &amp;lt;25 mg/dl&lt;ol&gt;&lt;li&gt;Parenteral &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; Replacement (initially with bolus)&lt;/li&gt;&lt;li&gt;Strongly consider NICU Admission&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Glcgn.htm" class="LinkPage"&gt;Glucagon&lt;/a&gt; if &lt;a href="../../ER/Procedure/IvAcs.htm" class="LinkPage"&gt;Intravenous Access&lt;/a&gt; delayed&lt;ol&gt;&lt;li&gt;Dose: 0.1 mg/kg/dose to 1 mg max IM or SQ q30 min&lt;/li&gt;&lt;li&gt;Not effective in SGA infants&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Oral &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; Replacement&lt;ol&gt;&lt;li&gt;Gavage or oral feedings hourly until &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; normal&lt;/li&gt;&lt;li&gt;Use 5% Dextrose in Water (D5W) or Infant Formula&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Parenteral &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; Replacement&lt;ol&gt;&lt;li&gt;Preparation of &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; Solutions&lt;ol&gt;&lt;li&gt;D10W = 1:4 Dilution of D50W in sterile water&lt;/li&gt;&lt;li&gt;Do NOT use &amp;gt;12.5% &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; solutions in newborns&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Intravenous &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; Maintenance&lt;ol&gt;&lt;li&gt;Load: 2 ml/kg D10W at 2 ml/min&lt;/li&gt;&lt;li&gt;Maintenance: 80 ml/kg/day D10W&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Emergent &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; replacement&lt;ol&gt;&lt;li&gt;Dose: 0.5-1.0 g/kg (5-10 ml/kg D10W) IV over 20 min&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/NICU/NntlHypglycm.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Neonatal Hypoglycemia, Hypoglycemia in Infants</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/NICU/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Alpha-glucoside inhibitor  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C1299007"&gt;&lt;i&gt;C1299007&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Pharmacologic Substance (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C1299007&amp;amp;tui=T121"&gt;&lt;i&gt;T121&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;109072000, 372565001&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Alpha-glucoside inhibitor, alpha glucosidase inhibitor, alpha glucosidase inhibitors, alpha glucoside inhibitors, alpha-glucosidase inhibitor, alpha glucosides inhibitors, Alpha-glucosidase inhibitor, Alpha-glucoside inhibitor (product), Alpha-glucoside inhibitor (substance), Alpha Glucosidase Inhibitors&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;inhibidor de alfa glucósido (sustancia), inhibidor de alfa glucósido, inhibidor de alfaglucosidasa (producto), inhibidor de alfaglucosidasa, inhibidor de alfaglucósido (producto), inhibidor de alfaglucósido (sustancia), inhibidor de alfaglucósido&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Precose  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0591572"&gt;&lt;i&gt;C0591572&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Carbohydrate (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0591572&amp;amp;tui=T118"&gt;&lt;i&gt;T118&lt;/i&gt;&lt;/a&gt;)
, Pharmacologic Substance (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0591572&amp;amp;tui=T121"&gt;&lt;i&gt;T121&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D020909&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;glucobay, precose, Glucobay, Bayer Brand of Acarbose, Glucor, Prandase, Precose&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;miglitol  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0066535"&gt;&lt;i&gt;C0066535&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Organic Chemical (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0066535&amp;amp;tui=T109"&gt;&lt;i&gt;T109&lt;/i&gt;&lt;/a&gt;)
, Pharmacologic Substance (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0066535&amp;amp;tui=T121"&gt;&lt;i&gt;T121&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;C045621&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;386046009, 109071007&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;miglitol, N-hydroxyethyl-1-desoxynojirimycin, N-hydroxyethyl-1-desoxy-nojirimycin, miglitol (medication), miglitol [Chemical/Ingredient], Miglitol (product), Miglitol (substance), Miglitol, MIGLITOL&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;miglitol (producto), miglitol (sustancia), miglitol&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Glyset  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0720692"&gt;&lt;i&gt;C0720692&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Organic Chemical (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0720692&amp;amp;tui=T109"&gt;&lt;i&gt;T109&lt;/i&gt;&lt;/a&gt;)
, Pharmacologic Substance (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0720692&amp;amp;tui=T121"&gt;&lt;i&gt;T121&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;C045621&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Glyset, glyset&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Acarbose  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0050393"&gt;&lt;i&gt;C0050393&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;An inhibitor of alpha glucosidase that retards the digestion and absorption of carbohydrates in the small intestine and hence reduces the increase in blood-glucose concentrations after a carbohydrate load. It is given orally to non-insulin dependent diabetes mellitus patients where diet modification or oral hypoglycemic agents do not control their condition. (From Martindale The Extra Pharmacopoeia, 31st ed)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (PDQ)&lt;/td&gt;
                &lt;td&gt;A complex oligosaccharide used as a hypoglycemic agent in diabetes management. Acarbose inhibits enzymes required in catabolism of carbohydrates, specifically pancreatic alpha-amylase, which hydrolyzes complex starches to oligosaccharides in the lumen of the small intestine, and the membrane-bound intestinal alpha-glucosidases, which hydrolyze oligosaccharides, trisaccharides, and disaccharides to glucose and other monosaccharides in the small intestine. When acarbose is orally administered, less digestion of complex carbohydrates occur and less glucose is absorbed in the small intestine, thereby producing a smaller rise in postprandial blood glucose levels after a carbohydrate load. Check for "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42140&amp;amp;idtype=1" active clinical trials or "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42140&amp;amp;idtype=1&amp;amp;closed=1" closed clinical trials using this agent. ("http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&amp;amp;code=C983" NCI Thesaurus)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A complex oligosaccharide used as a hypoglycemic agent in diabetes management. Acarbose inhibits enzymes required in catabolism of carbohydrates, specifically pancreatic alpha-amylase, which hydrolyzes complex starches to oligosaccharides in the lumen of the small intestine, and the membrane-bound intestinal alpha-glucosidases, which hydrolyze oligosaccharides, trisaccharides, and disaccharides to glucose and other monosaccharides in the small intestine. When acarbose is orally administered, less digestion of complex carbohydrates occur and less glucose is absorbed in the small intestine, thereby producing a smaller rise in postprandial blood glucose levels after a carbohydrate load.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Carbohydrate (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0050393&amp;amp;tui=T118"&gt;&lt;i&gt;T118&lt;/i&gt;&lt;/a&gt;)
, Pharmacologic Substance (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0050393&amp;amp;tui=T121"&gt;&lt;i&gt;T121&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D020909&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;391700000, 109077006, 386965004&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Acarbose, O-4,6-Dideoxy-4-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-2-cyclohexen-1-yl]amino]-alpha-D-glucopyranosyl-(1-4)-O-alpha-D-glucopyranosyl-(1-4)-D-glucose, acarbose, acarbose (medication), oral hypoglycemics acarbose, Acarbose - chemical (substance), ACARBOSE, Acarbose [Chemical/Ingredient], D-glucose, O-4,6-dideoxy-4-(((1S-(1 alpha,4 alpha,5 beta,6 alpha))-4,5,6-trihydroxy-3-(hydroxymethyl)-2-cyclohexen-1-yl)amino)-alpha-D-glucopyranosyl-(1-4)-O-alpha-D-glucopyr anosyl-(1-4)-, Acarbose (product), Acarbose (substance), Acarbose - chemical&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Akarbos&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;akarbosa&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;Acarbose - chemical, acarbosa (producto), acarbosa (sustancia), acarbosa, Acarbosa&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Akarboosi&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;AKARBOZA, АКАРБОЗА&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;アカルボース&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Akarboza&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Acarbose&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Acarbose&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Acarbosio&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Acarbose&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Alpha-glucoside inhibitor  (</value><value>)
</value><value>Precose  (</value><value>)
</value><value>miglitol  (</value><value>)
</value><value>Glyset  (</value><value>)
</value><value>Acarbose  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Alpha-glucosidase Inhibitor</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Pharmacology</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;See Also&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/OrlHypglycmc.htm" class="LinkPage"&gt;Oral Hypoglycemic&lt;/a&gt; Agents&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Indications&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/DM/TypDbtsMlts1.htm" class="LinkPage"&gt;Type II Diabetes Mellitus&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Close to target (&lt;a href="../../Endo/Lab/HmglbnAc.htm" class="LinkPage"&gt;Hemoglobin A1C&lt;/a&gt; &amp;lt;8% as monotherapy)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Contraindications&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/DM/DbtcKtcds.htm" class="LinkPage"&gt;Diabetic Ketoacidosis&lt;/a&gt; (DKA)&lt;/li&gt;&lt;li&gt;Intestinal disorder&lt;ol&gt;&lt;li&gt;&lt;a href="../../GI/IBD/InflmtryBwlDs.htm" class="LinkPage"&gt;Inflammatory Bowel Disease&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Colonic &lt;a href="../../Derm/Exam/SknErsn.htm" class="LinkPage"&gt;Ulceration&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Partial &lt;a href="../../Surgery/GI/IntstnlObstrctn.htm" class="LinkPage"&gt;Intestinal Obstruction&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Mechanism&lt;ol&gt;&lt;li&gt;Structurally similar to &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Reversible inhibitor of alpha glucosidase&lt;ol&gt;&lt;li&gt;Present in brush border of &lt;a href="../../GI/Anatomy/SmlBwlAntmy.htm" class="LinkPage"&gt;Small Intestine&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Interferes with hydrolysis of carbohydrates&lt;ol&gt;&lt;li&gt;Complex carbohydrates&lt;/li&gt;&lt;li&gt;Dietary disaccharides&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Delays absorption of &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; and other monosaccharides&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Pharmacokinetics&lt;ol&gt;&lt;li&gt;Acarbose is not absorbed from gastrointestinal tract&lt;/li&gt;&lt;li&gt;Miglitol is absorbed from gastrointestinal tract&lt;ol&gt;&lt;li&gt;Not metabolized&lt;/li&gt;&lt;li&gt;Excreted in urine&lt;/li&gt;&lt;li&gt;Elimination half-life: 2 hours&lt;/li&gt;&lt;li&gt;Excreted in &lt;a href="../../Gyn/Anatomy/BrstAntmy.htm" class="LinkPage"&gt;Breast&lt;/a&gt; milk in small amounts&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Adverse Effects&lt;ol&gt;&lt;li&gt;Poorly tolerated&lt;/li&gt;&lt;li&gt;Gastrointestinal side effects (unabsorbed carbohydrate)&lt;ol&gt;&lt;li&gt;&lt;a href="../../Surgery/GI/ActAbdmnlPn.htm" class="LinkPage"&gt;Abdominal Pain&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../GI/Diarrhea/ActDrh.htm" class="LinkPage"&gt;Diarrhea&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../GI/Sx/Fltlnc.htm" class="LinkPage"&gt;Flatulence&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Hypoglycemia/Hypglycm.htm" class="LinkPage"&gt;Hypoglycemia&lt;/a&gt;&lt;ol&gt;&lt;li&gt;If used with other &lt;a href="../../Endo/Pharm/OrlHypglycmc.htm" class="LinkPage"&gt;Oral Hypoglycemic&lt;/a&gt; agent or &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Use oral &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; (not sucrose) to treat &lt;a href="../../Endo/Hypoglycemia/Hypglycm.htm" class="LinkPage"&gt;Hypoglycemia&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Efficacy&lt;ol&gt;&lt;li&gt;Acarbose associated with cardiovascular benefits&lt;ol&gt;&lt;li&gt;Reduced cardiovascular events&lt;/li&gt;&lt;li&gt;Reduced &lt;a href="../../CV/Htn/Hyprtnsn.htm" class="LinkPage"&gt;Hypertension&lt;/a&gt; risk&lt;/li&gt;&lt;li&gt;Significant weight loss&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Chiasson%20%20%5BAU%5D%20AND%202003%20%5BDP%5D%20AND%20%20JAMA%20%20%5BTA%5D" class="LinkRef"&gt;Chiasson (2003) JAMA 290:486-94&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Dosages&lt;ol&gt;&lt;li&gt;Acarbose (Precose)&lt;ol&gt;&lt;li&gt;Start dose: 25 mg PO tid at start of meal&lt;/li&gt;&lt;li&gt;Maintenance: 50-100 mg PO tid ($45/month)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Miglitol (Glyset)&lt;ol&gt;&lt;li&gt;Start dose: 25 mg PO tid at start of meal&lt;/li&gt;&lt;li&gt;Maintenance: 50-100 mg PO tid ($52/month)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=(1999)%20Med%20Lett%20Drugs%20Ther,%2041%20%5BAU%5D%20AND%201053%20%5BDP%5D%20AND%20:%20%5BTA%5D" class="LinkRef"&gt;(1999) Med Lett Drugs Ther, 41(1053):49-50&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Chiasson%20%20%5BAU%5D%20AND%201994%20%5BDP%5D%20AND%20%20Ann%20Intern%20Med%20%20%5BTA%5D" class="LinkRef"&gt;Chiasson (1994) Ann Intern Med 121:928-35&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C1299007</value><value>C0591572</value><value>C0066535</value><value>C0720692</value><value>C0050393</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Pharm/AlphGlcsdsInhbtr.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Alpha-glucosidase Inhibitor, Acarbose, Precose, Miglitol, Glyset</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Pharm/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees></FP_UMLS_Trees><FP_Condition_name_check></FP_Condition_name_check><FP_Condition_name><value>Type 1 Gaucher's Disease</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Metabolic Disorders</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;See Also&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Metabolism/TypGchrsDs1.htm" class="LinkPage"&gt;Type 2 Gaucher's Disease&lt;/a&gt; or &lt;a href="../../Endo/Metabolism/TypGchrsDs1.htm" class="LinkPage"&gt;Type 3 Gaucher's Disease&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Metabolism/LysmlStrgDs.htm" class="LinkPage"&gt;Lysosomal Storage Disease&lt;/a&gt; (&lt;a href="../../Endo/Metabolism/LysmlStrgDs.htm" class="LinkPage"&gt;Gangliosidosis&lt;/a&gt;)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Epidemiology: &lt;a href="../../Prevent/Epi/DsIncdncRt.htm" class="LinkPage"&gt;Incidence&lt;/a&gt;&lt;ol&gt;&lt;li&gt;General population: 1:60,000&lt;/li&gt;&lt;li&gt;Ashkenazi Jews: 1:900&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Pathophysiology&lt;ol&gt;&lt;li&gt;Inherited Inborn error of metabolism&lt;/li&gt;&lt;li&gt;Disturbed Cerebroside metabolism&lt;/li&gt;&lt;li&gt;Autosomal recessive inheritance&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Types&lt;ol&gt;&lt;li&gt;Type 1 Gaucher's: Most common&lt;ol&gt;&lt;li&gt;Gastrointestinal presentation (Described below)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Metabolism/TypGchrsDs1.htm" class="LinkPage"&gt;Type 2 Gaucher's Disease&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Neurologic presentation&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Metabolism/TypGchrsDs1.htm" class="LinkPage"&gt;Type 3 Gaucher's Disease&lt;/a&gt; (Similar to Type 2)&lt;ol&gt;&lt;li&gt;Neurologic presentation&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Symptoms&lt;ol&gt;&lt;li&gt;Abdominal heavy feeling&lt;/li&gt;&lt;li&gt;Bone pain (at lesion sites)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Signs&lt;ol&gt;&lt;li&gt;Progressive Abdominal distention&lt;/li&gt;&lt;li&gt;&lt;a href="../../GI/Exam/Splnmgly.htm" class="LinkPage"&gt;Splenomegaly&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../GI/Exam/Hptmgly.htm" class="LinkPage"&gt;Hepatomegaly&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Eye/Anatomy/EyAntmy.htm" class="LinkPage"&gt;Conjunctiva&lt;/a&gt; with brown pigmentation&lt;/li&gt;&lt;li&gt;Skin with brown to yellow discoloration&lt;/li&gt;&lt;li&gt;Coarse facial features&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Labs&lt;ol&gt;&lt;li&gt;&lt;a href="../../HemeOnc/Lab/CmpltBldCnt.htm" class="LinkPage"&gt;Complete Blood Count&lt;/a&gt; (CBC): &lt;a href="../../HemeOnc/Lab/Pncytpn.htm" class="LinkPage"&gt;Pancytopenia&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../HemeOnc/Anemia/Anm.htm" class="LinkPage"&gt;Anemia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../HemeOnc/Lab/WhtBldCl.htm" class="LinkPage"&gt;Leukopenia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../HemeOnc/Platelet/Thrmbcytpn.htm" class="LinkPage"&gt;Thrombocytopenia&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Diagnosis&lt;ol&gt;&lt;li&gt;&lt;a href="../../HemeOnc/Lab/WhtBldCl.htm" class="LinkPage"&gt;Leukocyte&lt;/a&gt; B-glucocere-brosidase assay&lt;/li&gt;&lt;li&gt;&lt;a href="../../HemeOnc/Procedure/BnMrwAsprtn.htm" class="LinkPage"&gt;Bone Marrow Biopsy&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Gaucher Cells&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Radiology: Long bone XRay&lt;ol&gt;&lt;li&gt;Localized thinning of bony cortex&lt;/li&gt;&lt;li&gt;Femoral head &lt;a href="../../Derm/Exam/SknErsn.htm" class="LinkPage"&gt;Erosion&lt;/a&gt; and compression&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Metabolism/TypGchrsDs.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Type 1 Gaucher's Disease, Gaucher's Disease</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Metabolism/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Methylmalonic acidemia  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0268583"&gt;&lt;i&gt;C0268583&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CSP)&lt;/td&gt;
                &lt;td&gt;autosomal recessive aminoacidopathy characterized by an excess of methylmalonic acid in the blood and urine, with metabolic ketoacidosis, hyperglycinemia, hyperglycinuria and hyperammonemia; results from defects that cause deficiencies of methylmalonyl-CoA mutase.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Disease or Syndrome (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0268583&amp;amp;tui=T047"&gt;&lt;i&gt;T047&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;C537358&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD10&lt;/td&gt;
                &lt;td&gt;E71.120&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;42393006, 190727006&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Methylmalonic acidemia, NOS, Methylmalonic aciduria, methylmalonic aciduria, methylmalonic acidemia (diagnosis), methylmalonic aciduria (diagnosis), methylmalonic acidemia, Methylmalonic acidemias, Acidemia, methylmalonic, Methylmalonic acidemia, methylmalonic acidaemia, acidemias methylmalonic, MMA - Methylmalonic aciduria, Methylmalonic acidaemia, Methylmalonic acidemia (disorder), disorder; methylmalonic acidemia, acidemia; methylmalonic, methylmalonic acidemia; disorder, methylmalonic; acidemia&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Aciduria metilmalonica&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;メチルマロン酸尿症, ﾒﾁﾙﾏﾛﾝｻﾝﾆｮｳｼｮｳ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;Methylmalonic acidemia, Methylmalonic acidaemia, acidemia metilmalónica (trastorno), acidemia metilmalónica, Aciduria metilmalónica&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;Methylmalonová acidurie&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;Methylmalonil aciduria&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;acidemie; methylmalon, methylmalon; acidemie, methylmalonacidemie; stoornis, stoornis; methylmalonacidemie, methylmalonzuur acidurie&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Acidúria metilmalónica&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Acidurie méthylmalonique&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Methylmalonazidurie&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Methylmalonic acidemia  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Methylmalonic acidemia</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Metabolic Disorders</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;See Also&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Metabolism/InbrnErrsOfMtblsm.htm" class="LinkPage"&gt;Inborn Errors of Metabolism&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Epidemiology&lt;ol&gt;&lt;li&gt;&lt;a href="../../Prevent/Epi/DsIncdncRt.htm" class="LinkPage"&gt;Incidence&lt;/a&gt;: 1:20,000&lt;/li&gt;&lt;li&gt;Autosomal recessive inheritance&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Pathophysiology&lt;ol&gt;&lt;li&gt;Organic Aciduria&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Causes&lt;ol&gt;&lt;li&gt;Most common genetic causes&lt;ol&gt;&lt;li&gt;Methyl-malonyl-CoA mutase defect&lt;/li&gt;&lt;li&gt;&lt;a href="../../Pharm/Vitamins/VtmnB.htm" class="LinkPage"&gt;Cobalamin&lt;/a&gt; synthesis defect&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Acquired causes&lt;ol&gt;&lt;li&gt;&lt;a href="../../HemeOnc/Anemia/VtmnBDfcncy.htm" class="LinkPage"&gt;Pernicious Anemia&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Signs&lt;ol&gt;&lt;li&gt;Metabolic ketoacidosis&lt;/li&gt;&lt;li&gt;Encephalopathy&lt;/li&gt;&lt;li&gt;hyperammonemia&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Labs&lt;ol&gt;&lt;li&gt;Urine organic acids&lt;/li&gt;&lt;li&gt;Enzyme assay of skin fibroblasts&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Management&lt;ol&gt;&lt;li&gt;Acute&lt;ol&gt;&lt;li&gt;&lt;a href="../../Renal/Pharm/SdmBcrbnt.htm" class="LinkPage"&gt;Sodium Bicarbonate&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Carnitine&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Chronic maintenance&lt;ol&gt;&lt;li&gt;Protein restriction&lt;/li&gt;&lt;li&gt;Methylmalonate precursor restriction&lt;/li&gt;&lt;li&gt;&lt;a href="../../HemeOnc/Pharm/VtmnBSplmntn.htm" class="LinkPage"&gt;Vitamin B12 Supplementation&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Raghuveer%20%20%5BAU%5D%20AND%202006%20%5BDP%5D%20AND%20%20Am%20Fam%20Physician%20%20%5BTA%5D" class="LinkRef"&gt;Raghuveer (2006) Am Fam Physician 73:1981-90&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0268583</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Metabolism/MthylmlncAcdm.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Methylmalonic acidemia, Methylmalonicaciduria</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Metabolism/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Homocystinuria  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0019880"&gt;&lt;i&gt;C0019880&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;Autosomal recessive inborn error of methionine metabolism usually caused by a deficiency of CYSTATHIONINE BETA-SYNTHASE and associated with elevations of homocysteine in plasma and urine. Clinical features include a tall slender habitus, SCOLIOSIS, arachnodactyly, MUSCLE WEAKNESS, genu varus, thin blond hair, malar flush, lens dislocations, an increased incidence of MENTAL RETARDATION, and a tendency to develop fibrosis of arteries, frequently complicated by CEREBROVASCULAR ACCIDENTS and MYOCARDIAL INFARCTION. (From Adams et al., Principles of Neurology, 6th ed, p979)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;An autosomal recessive inherited metabolic disorder caused by mutations in the CBS, MTHFR, MTR, and MTRR genes. It is characterized by abnormalities in the methionine metabolism and is associated with deficiency of cystathionine synthase. It results in the accumulation of homocysteine in the serum. It may affect the cardiovascular, musculoskeletal and the central nervous systems.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CSP)&lt;/td&gt;
                &lt;td&gt;autosomal recessive inborn error of methionine metabolism usually caused by a deficiency of cystathionine beta-synthase and associated with elevations of homocysteine in plasma and urine; clinical features include a tall, slender habitus, scoliosis, arachnodactyly, muscle weakness, genu varis, thin blond hair, malar flush, lens dislocations, an increased incidence of mental retardation, and a tendency to develop fibrosis of arteries, frequently complicated by cerebrovascular accidents and myocardial infarction.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Disease or Syndrome (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0019880&amp;amp;tui=T047"&gt;&lt;i&gt;T047&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D006712&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD10&lt;/td&gt;
                &lt;td&gt;E72.11&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;190709008, 11282001&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;HOMOCYSTINURIA, Homocystinuria, NOS, Homocystinuria, cystathionine synthase deficiency, homocystinuria, homocystinuria (diagnosis), Cystathionine synthase deficiency, Homocystinuria [Disease/Finding], homocystinurias, Homocystinuria (disorder), Homocystinuria [Ambiguous]&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;ホモシスチン尿, ﾎﾓｼｽﾁﾝﾆｮｳ, ホモシスチン血症, シスタチオニン合成酵素欠損, シスタチオニン合成酵素欠損症, ホモシスチン尿症, 高ホモシスチン血症&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Homocystinuri&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;homocystinurie, Homocystinurie&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;Homocystinuria [Ambiguous], Homocystinuria, homocistinuria (trastorno), homocistinuria, Homocistinuria&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Homokystinuria&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;GOMOTSISTINURIIA, ГОМОЦИСТИНУРИЯ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Homocystynuria&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;Homocystinuria&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;homocystinurie, Cystinurie, homo-, Homocystinurie&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Homocystinurie, Homozystinurie&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Homocystinurie&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Omocistinuria&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Homocistinúria&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Homocystinuria  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Homocystinuria</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Metabolic Disorders</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;See Also&lt;ol&gt;&lt;li&gt;&lt;a href="../../CV/Prevent/Hmcystn.htm" class="LinkPage"&gt;Homocysteine&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Metabolism/InbrnErrOfSmlMlclMtblsm.htm" class="LinkPage"&gt;Inborn Error of Small Molecule Metabolism&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Metabolism/InbrnErrsOfMtblsm.htm" class="LinkPage"&gt;Inborn Errors of Metabolism&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Pathophysiology&lt;ol&gt;&lt;li&gt;Inherited enzyme deficiency&lt;/li&gt;&lt;li&gt;Effects&lt;ol&gt;&lt;li&gt;Intimal fibrosis and &lt;a href="../../Pharm/Nutrition/Fbr.htm" class="LinkPage"&gt;Fiber&lt;/a&gt; destruction&lt;ol&gt;&lt;li&gt;Destroys arterial elastic fibers&lt;/li&gt;&lt;li&gt;Destroys Zonular fibers of the lens&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../GI/Lvr/NnlchlcFtyLvr.htm" class="LinkPage"&gt;Fatty Liver&lt;/a&gt; infiltration&lt;/li&gt;&lt;li&gt;Gliosis and focal necrosis of the &lt;a href="../../Neuro/Anatomy/Mdbrn.htm" class="LinkPage"&gt;Midbrain&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Etiology&lt;ol&gt;&lt;li&gt;&lt;a href="../../Derm/Exam/Cyst.htm" class="LinkPage"&gt;Cyst&lt;/a&gt;athionine B-synthase deficiency&lt;/li&gt;&lt;li&gt;Methylene tetrahydrofolate reductase deficiency&lt;/li&gt;&lt;li&gt;Methionine synthase defect&lt;/li&gt;&lt;li&gt;&lt;a href="../../Pharm/Vitamins/VtmnB.htm" class="LinkPage"&gt;Vitamin B12&lt;/a&gt; transport or coenzyme defect&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Signs&lt;ol&gt;&lt;li&gt;&lt;a href="../../Prevent/HME/HlthCrFrAdltsWthDvlpmntlDly.htm" class="LinkPage"&gt;Mental Retardation&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Neuro/Seizure/Szr.htm" class="LinkPage"&gt;Seizure&lt;/a&gt;s&lt;/li&gt;&lt;li&gt;&lt;a href="../../Eye/Lens/Ctrct.htm" class="LinkPage"&gt;Cataract&lt;/a&gt;s&lt;/li&gt;&lt;li&gt;Lenticular subluxation&lt;/li&gt;&lt;li&gt;Sparse hair&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Growth/MrfnsSyndrm.htm" class="LinkPage"&gt;Arachnodactyly&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Lung/Exam/PctsExcvtm.htm" class="LinkPage"&gt;Pectus Excavatum&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Long and thin trunk, arms and legs&lt;/li&gt;&lt;li&gt;Thromboembolic phenomenon&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Labs&lt;ol&gt;&lt;li&gt;Increased levels &lt;a href="../../CV/Prevent/Hmcystn.htm" class="LinkPage"&gt;Homocysteine&lt;/a&gt; and methionine&lt;ol&gt;&lt;li&gt;Present in CSF, Plasma and Urine&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0019880</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Metabolism/Hmcystnr.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Homocystinuria</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Metabolism/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Ornithine carbamoyltransferase deficiency  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0268542"&gt;&lt;i&gt;C0268542&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;An inherited urea cycle disorder associated with deficiency of the enzyme ORNITHINE CARBAMOYLTRANSFERASE, transmitted as an X-linked trait and featuring elevations of amino acids and ammonia in the serum. Clinical features, which are more prominent in males, include seizures, behavioral alterations, episodic vomiting, lethargy, and coma. (Menkes, Textbook of Child Neurology, 5th ed, pp49-50)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;An X-linked urea cycle metabolic disorder characterized by deficiency of ornithine transcarbamylase, resulting in the accumulation of ammonia in the serum. Symptoms include vomiting, lethargy, and coma.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;An X-linked urea cycle metabolic disorder characterized by deficiency of ornithine carbamoyltransferase, resulting in the accumulation of amino acids and ammonia in the serum. Signs and symptoms include seizures, delayed growth, behavioral changes, ataxia, lethargy, and coma.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (JABL)&lt;/td&gt;
                &lt;td&gt;Inborn error of metabolism of the urea cycle due to ornithine carbomoyltransferase (E.C. 2.1.3.3) deficiency associated with hyperammonemia and accumulation of ammonia in the brain and liver. In most cases the early symptoms appear within the first three days of life and include respiratory distress, feeding difficulty, hypotonia, lethargy, and death in untreated cases. Neonatal hyperammonemic coma lasting longer than 48 hours usually results in cortical atrophy and mental retardation. In late-onset OTC deficiency the symptoms appear from 2 months to 44 years with normal appearance at birth, followed by irritability, vomiting, lethargy, seizures, delayed development, ataxia, and seizures. Accumulation of ammonium in the brain and blood usually follows a protein load or intermittent infection. OTC deficient patients are particularly sensitive to toxic effects of valproate.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Disease or Syndrome (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0268542&amp;amp;tui=T047"&gt;&lt;i&gt;T047&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D020163&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD10&lt;/td&gt;
                &lt;td&gt;E72.4&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;124249000, 80908008&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Ornithine carbamoyltransferase deficiency, OCT-Ornith carbamoyltransf def, OTC-Ornith transcarbamyl defic, Ornith carbamoyltransferas def, Ornithin transcarbamoylase def, ORNITHINE TRANSCARBAMYLASE DEFICIENCY, HYPERAMMONEMIA DUE TO, ORNITHINE CARBAMOYLTRANSFERASE DEFICIENCY, OTC DEFICIENCY, ORNITHINE CARBAMOYLTRANSFERASE DEFIC DIS, ORNITHINE TRANSCARBAMYLASE DEFIC DIS, DEFIC DIS ORNITHINE CARBAMOYLTRANSFERASE, DEFIC DIS ORNITHINE TRANSCARBAMYLASE, ornithine carbamoyltransferase deficiency, ornithine transcarbamylase deficiency, ornithine transcarbamylase deficiency (diagnosis), Deficiency of ornithine carbamoyltransferase (disorder), Deficiency Disease, Ornithine Carbamoyltransferase, Ornithine Carbamoyltransferase Deficiency Disease, Deficiency Disease, Ornithine Transcarbamylase, Ornithine Transcarbamylase Deficiency Disease, Ornithine Transcarbamylase Deficiency, Deficiency, Ornithine Transcarbamylase, Deficiencies, OTC, OTC Deficiencies, Deficiencies, Ornithine Transcarbamylase, Deficiency, OTC, Ornithine Transcarbamylase Deficiencies, OTC Deficiency, ornithine carbomoyltransferase (OCT) deficiency, ornithine carbomoyltransferase deficiency, hyperammonemia due to ornithine transcarbamylase deficiency, ornithine transcarbamylase (OTC) deficiency (OTCD), hyperammonemic syndrome, Ornithine Carbamoyltransferase Deficiency Disease [Disease/Finding], octd, ornithine carbamoyltransferase deficiency (OCTD), OCT deficiency, OCTD, Ornithine transcarbamylase deficiency, OCT - Ornithine carbamoyltransferase deficiency, OTC - Ornithine transcarbamylase deficiency, Ornithine transcarbamoylase deficiency, Deficiency of citrulline phosphorylase, Deficiency of ornithine carbamoyltransferase, Deficiency of ornithine transcarbamylase, Ornithine carbamoyltransferase deficiency (disorder), deficiency; ornithine transcarbamylase, ornithine transcarbamylase; deficiency&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Deficit di ornitina transcarbamilasi, Deficit di ornitina carbamil-transferasi, Malattia da carenza di ornitine carbamiltransferasi&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;ornitinecarbamoyltransferasedeficiëntie, ornithine-transcarbamylasedeficiëntie, deficiëntie; ornithinetranscarbamylase, ornithinetranscarbamylase; deficiëntie, ornitinetranscarbamoylasedeficiëntie, Deficiëntie, ornithinecarbamoyltransferase-, Ornithinecarbamoyltransferasedeficiëntie, Ornithinetranscarbamylasedeficiëntie&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Carence en ornithine carbamoyltransférase, Déficit en ornithine transcarbamylase, Carence en ornithine transcarbamylase, Déficience en ornithine-transcarbamylase, Déficit en OTC, Déficit en ornithine carbamyl transférase, Déficit en ornithine carbamyltransférase&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Carência de ornitina carbamoiltransferase, Doença por Deficiência de Ornitina Carbomoiltransferase, Doença por Deficiência de Ornitina Transcarbamilase, Deficiência de Ornitina Transcarbamilase, Deficiência da Ornitina Transcarbamilase, Deficiência de OTC, Deficiência em ornitonina transcarmabilase, Deficiência de ornitina transcarbamoilase, Doença da Deficiência de Ornitina Carbomoiltransferase, Doença da Deficiência de Ornitina Transcarbamilase&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Ornitinkarbamoyltransferasbristsjukdom&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;ｵﾙﾆﾁﾝﾄﾗﾝｽｶﾙﾊﾞﾐﾗｰｾﾞｹｯｿﾝｼｮｳ, ｵﾙﾆﾁﾝｶﾙﾊﾞﾓｲﾙﾄﾗﾝｽﾌｪﾗｰｾﾞｹｯｿﾝｼｮｳ, OCT欠損症, オルニチンカルバモイルトランスフェラーゼ欠損症, OTC欠損症, オルニチントランスカルバミラーゼ欠損症&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;ornithinkarbamoyltransferasa - nedostatek, ornithintranskarbamylasa - nedostatek, Deficit ornitinkarbamoyltransferázy, Deficit ornitintranskarbamoylázy&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Ornitiinitranskarbamylaasin puutos&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;ORNITIN-TRANSKARBAMILAZY NEDOSTATOCHNOSTI BOLEZN', ORNITIN-KARBAMOILTRANSFERAZY NEDOSTATOCHNOSTI BOLEZN', ОРНИТИН-КАРБАМОИЛТРАНСФЕРАЗЫ НЕДОСТАТОЧНОСТИ БОЛЕЗНЬ, ОРНИТИН-ТРАНСКАРБАМИЛАЗЫ НЕДОСТАТОЧНОСТИ БОЛЕЗНЬ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;Deficiencia de OTC, Deficiencia de Ornitina Transcarbamilasa, Deficiencia de ornitina transcarbamilasa, deficiencia de ornitina carbamoiltransferasa, deficiencia de citrulina fosforilasa, deficiencia de ornitina carbamoiltransferasa (concepto no activo), deficiencia de ornitina carbamoiltransferasa (trastorno), deficiencia de ornitina transcarbamilasa, Enfermedad por Deficiencia de Ornitina Carbamoiltransferasa, Enfermedad por Deficiencia de Ornitina Transcarbamilasa&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Choroba niedoboru karbamylotransferazy ornitynowej&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Ornithintranscarbamylase-Mangel, Ornithintranscarbamoylase-Mangel, Ornithincarbamoyltransferase-Mangelkrankheit, Ornithintranscarbamylase-Mangelkrankheit&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;Ornithin transcarbamylase hiány, Ornithin transcarbamoylase hiány, Ornithin carbamoyltransferase hiány&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Hyperornithinemia  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0599035"&gt;&lt;i&gt;C0599035&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CSP)&lt;/td&gt;
                &lt;td&gt;excess of ornithine in the plasma, such as occurs in the genetic disorders gyrate atrophy of choroid and retina and hyperornithinemia-hyperamonemia-homocitrullinuria syndrome.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Disease or Syndrome (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0599035&amp;amp;tui=T047"&gt;&lt;i&gt;T047&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;C537132&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;276426004, 190716009, 193471005, 33985005, 87126009, 124292005&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Hyperornithinemia, NOS, Ornithinemia, OAT-Ornth ox-acd amno trns def, Ornith ketoacid transamin def, Ornith oxo-acid aminotrans def, Ornith oxoacidaminotrans def, Ornithine oxoacidaminotransferase deficiency, Hyperornithinaemia, NOS, Hyperornithinemia, Ornithine oxo-acid aminotransferase deficiency, ornithine aminotransferase deficiency, hyperornithinemia (diagnosis), hyperornithinemia, Hyperornithinemia with gyrate atrophy of choroid and retina, Ornithine ketoacid aminotransferase deficiency, Ornithine aminotransferase deficiency, Gyrate atrophy of choroid and retina, OAT deficiency, OKT deficiency, Ornithine ketoacid transaminase deficiency, Ornithine-delta-aminotransferase deficiency, Ornithine-oxo-acid amino acid transferase deficiency, Hyperornithinaemia, OAT - Ornithine oxo-acid aminotransferase deficiency, Hyperornithinemia (disorder), Ornithine oxo-acid aminotransferase deficiency (disorder), ornithinemia, Ornithine oxo-acid aminotransferase deficiency [Ambiguous], Deficiency of ornithine-oxo-acid aminotransferase (disorder), Deficiency of ornithine-oxo-acid aminotransferase&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;deficiencia de ornitina - oxo - ácido aminotransferasa (trastorno), deficiencia de ornitina - oxo - ácido aminotransferasa, Ornithine oxo-acid aminotransferase deficiency, Ornithine oxo-acid aminotransferase deficiency [Ambiguous], deficiencia de ornitina - delta - aminotransferasa, deficiencia de ornitina - oxo - ácido - aminoácido transferasa, deficiencia de ornitina aminotransferasa (trastorno), deficiencia de ornitina aminotransferasa, deficiencia de ornitina cetoácido transaminasa, deficiencia de ornitina oxo-ácido aminotransferasa, deficiencia de transaminasa cetoácida de ornitina, hiperornitinemia (trastorno), hiperornitinemia&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Ornithine carbamoyltransferase deficiency  (</value><value>)
</value><value>Hyperornithinemia  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Ornithine Transcarbamylase Deficiency</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Metabolic Disorders</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;See Also&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Metabolism/InbrnErrsOfMtblsm.htm" class="LinkPage"&gt;Inborn Errors of Metabolism&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Epidemiology&lt;ol&gt;&lt;li&gt;Most common urea cycle disorder&lt;/li&gt;&lt;li&gt;&lt;a href="../../Prevent/Epi/DsIncdncRt.htm" class="LinkPage"&gt;Incidence&lt;/a&gt;: 1:70,000&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Pathophysiology&lt;ol&gt;&lt;li&gt;X-Linked disorder&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Signs: Boys (severe signs due to single X-chromosome)&lt;ol&gt;&lt;li&gt;Refractory &lt;a href="../../GI/Sx/Vmtng.htm" class="LinkPage"&gt;Emesis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Hyperammonemia&lt;/li&gt;&lt;li&gt;Progressive encephalopathy&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Signs: Girl (mild signs due to heterozygous)&lt;ol&gt;&lt;li&gt;Mild hyperammonemia&lt;/li&gt;&lt;li&gt;May present with patient avoiding protein in general&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Management&lt;ol&gt;&lt;li&gt;Acute&lt;ol&gt;&lt;li&gt;Sodium benzoate&lt;/li&gt;&lt;li&gt;Sodium phenylacetate&lt;/li&gt;&lt;li&gt;Arginine&lt;/li&gt;&lt;li&gt;&lt;a href="../../Renal/Pharm/Hmdlys.htm" class="LinkPage"&gt;Dialysis&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Chronic: Maintenance&lt;ol&gt;&lt;li&gt;Low protein diet with essential &lt;a href="../../Sports/Pharm/AmnAcdSplmnt.htm" class="LinkPage"&gt;Amino Acid Supplement&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Complications&lt;ol&gt;&lt;li&gt;Hepatic failure&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Raghuveer%20%20%5BAU%5D%20AND%202006%20%5BDP%5D%20AND%20%20Am%20Fam%20Physician%20%20%5BTA%5D" class="LinkRef"&gt;Raghuveer (2006) Am Fam Physician 73:1981-90&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0268542</value><value>C0599035</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Metabolism/OrnthnTrnscrbmylsDfcncy.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Ornithine Transcarbamylase Deficiency, Hyperornithinemia</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Metabolism/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Galactosemias  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0016952"&gt;&lt;i&gt;C0016952&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;An autosomal recessive inherited metabolic disorder caused by mutations in the GALE, GALK1, and GALT genes. It is characterized by deficiency of the enzymes responsible for the metabolism of galactose. Signs and symptoms include intellectual disability, hepatomegaly, hepatic failure, and renal failure.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;A group of inherited enzyme deficiencies which feature elevations of GALACTOSE in the blood. This condition may be associated with deficiencies of GALACTOKINASE; UDPGLUCOSE-HEXOSE-1-PHOSPHATE URIDYLYLTRANSFERASE; or UDPGLUCOSE 4-EPIMERASE. The classic form is caused by UDPglucose-Hexose-1-Phosphate Uridylyltransferase deficiency, and presents in infancy with FAILURE TO THRIVE; VOMITING; and INTRACRANIAL HYPERTENSION. Affected individuals also may develop MENTAL RETARDATION; JAUNDICE; hepatosplenomegaly; ovarian failure (PRIMARY OVARIAN INSUFFICIENCY); and cataracts. (From Menkes, Textbook of Child Neurology, 5th ed, pp61-3)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CSP)&lt;/td&gt;
                &lt;td&gt;group of inherited enzyme deficiencies which feature elevations of galactose in the blood; this condition may be associated with deficiencies of galactokinase, UDP glucose-hexose-1-phosphate uridylyltransferase (classic form), or UDP glucose 4-epimerase; the classic form presents in infancy with failure to thrive, vomiting, and intracranial hypertension; affected individuals also may develop mental retardation, jaundice, hepatosplenomegaly, ovarian failure and cataracts.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Disease or Syndrome (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0016952&amp;amp;tui=T047"&gt;&lt;i&gt;T047&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D005693&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD9&lt;/td&gt;
                &lt;td&gt;271.1&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD10&lt;/td&gt;
                &lt;td&gt;E74.21&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;38177000, 190747003, 190745006, 190749000, 154738008, 267498002&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;GALACTOSE INTOLERANCE, GALACTOSEMIA, Galactosemia, NOS, Galactosaemia NOS, Galactosemia NOS, Galactosaemia, NOS, Galactose intolerance, NOS, Galactosemias, galactosemia (diagnosis), galactosemia, Galactosemia NOS (disorder), Galactosemias [Disease/Finding], disorder galactosemia, galactosemias, galactosaemia, galactose intolerance, Galactosemia, Galactosaemia, Galactose intolerance, Galactosemia (disorder), Galactosemia (disorder) [Ambiguous]&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Galattosemia, Intolleranza al galattosio, Disturbi del metabolismo del galattosio, Galactosemie&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;ガラクトース不耐症, ｶﾞﾗｸﾄｰｽｹﾂｼｮｳ, ｶﾞﾗｸﾄｰｽﾌﾀｲｼｮｳ, ｶﾞﾗｸﾄｰｽｹｯｼｮｳ, ガラクトキナーゼ欠損症, ガラクトキナーゼ-1-リン酸ウリジルトランスフェラーゼ欠損症, UDPグルコースヘキソース-1-リン酸ウリジリルトランスフェラーゼ欠損症, ガラクトース血, UDPグルコース-4-エピメラーゼ欠損症, ガラクトース血症&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Galaktosemier&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;galaktosémie, Galaktosemie, Intolerance galaktózy&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;Galactosemia, Galactosaemia, Deficiencia de UDPglucosa-Hexosa-1-Fosfato Uridililtransferasa, galactosemia (concepto no activo), galactosemia (trastorno), galactosemia, SAI (trastorno), galactosemia, SAI, galactosemia, intolerancia a la galactosa, Intolerancia a la galactosa, Enfermedad por Deficiencia de Galactocinasa, Galactosemias&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Galaktosemiat&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;GALAKTOZEMII, ГАЛАКТОЗЕМИИ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Deficiência de UDPglucose-Hexose-1-Fosfato Uridililtransferase, Galactosemia, Intolerância à galactose, Galactosemias&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Galaktozemia, Choroby z niedoboru galaktokinazy&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;Galactose intolerantia, Galactosaemia&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;galactose-intolerantie, galactosemie, Galactosemie&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Galactosémie, Intolérance au galactose, Galactosémies&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Galaktosaemie, Galaktoseunvertraeglichkeit, Galaktosämie&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Galactosemias  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Galactosemia</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Metabolic Disorders</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;See Also&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Metabolism/InbrnErrsOfMtblsm.htm" class="LinkPage"&gt;Inborn Errors of Metabolism&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Metabolism/InbrnErrOfSmlMlclMtblsm.htm" class="LinkPage"&gt;Inborn Error of Small Molecule Metabolism&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Epidemiology&lt;ol&gt;&lt;li&gt;Identified in newborn period&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Pathophysiology&lt;ol&gt;&lt;li&gt;Autosomal recessive trait&lt;/li&gt;&lt;li&gt;Galactose-1-Phosphate Uridyl Transferase Deficiency&lt;ol&gt;&lt;li&gt;Most common of 3 genetic defects causing Galactosemia&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Failure to convert galactose to &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Results in fatty &lt;a href="../../GI/Lvr/Crhs.htm" class="LinkPage"&gt;Cirrhosis&lt;/a&gt; of the liver&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Symptoms&lt;ol&gt;&lt;li&gt;Presentation follows milk ingestion after days to weeks&lt;/li&gt;&lt;li&gt;&lt;a href="../../GI/Sx/Vmtng.htm" class="LinkPage"&gt;Vomiting&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../GI/Diarrhea/ActDrh.htm" class="LinkPage"&gt;Diarrhea&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Dehydration&lt;/li&gt;&lt;li&gt;Lethargy&lt;/li&gt;&lt;li&gt;Weight loss&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Signs&lt;ol&gt;&lt;li&gt;Growth Failure or &lt;a href="../../Endo/Peds/FlrTThrv.htm" class="LinkPage"&gt;Failure to Thrive&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../GI/Derm/Jndc.htm" class="LinkPage"&gt;Jaundice&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../GI/Exam/Hptmgly.htm" class="LinkPage"&gt;Hepatomegaly&lt;/a&gt; (see &lt;a href="../../NICU/Surgery/HptmglyInNwbrns.htm" class="LinkPage"&gt;Hepatomegaly in Newborns&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;&lt;a href="../../GI/Exam/Splnmgly.htm" class="LinkPage"&gt;Splenomegaly&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Eye/Lens/Ctrct.htm" class="LinkPage"&gt;Cataract&lt;/a&gt;s&lt;/li&gt;&lt;li&gt;&lt;a href="../../Prevent/HME/HlthCrFrAdltsWthDvlpmntlDly.htm" class="LinkPage"&gt;Mental Retardation&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Hypotonia&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Labs&lt;ol&gt;&lt;li&gt;Galactosemia&lt;/li&gt;&lt;li&gt;Erythrocyte Galactose-1-Phosphate uridyl transferase&lt;ol&gt;&lt;li&gt;Activity diminished&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../GI/Lab/LvrFnctnTst.htm" class="LinkPage"&gt;Liver Function Test&lt;/a&gt;s increased&lt;/li&gt;&lt;li&gt;&lt;a href="../../HemeOnc/Lab/PrthrmbnTm.htm" class="LinkPage"&gt;ProTime&lt;/a&gt; (INR) may be elevated&lt;/li&gt;&lt;li&gt;Urine exam&lt;ol&gt;&lt;li&gt;General Findings&lt;ol&gt;&lt;li&gt;Galactosuria&lt;/li&gt;&lt;li&gt;Aminoaciduria&lt;/li&gt;&lt;li&gt;Albuminuria&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Following milk ingestion&lt;ol&gt;&lt;li&gt;Urine reducing substances positive&lt;/li&gt;&lt;li&gt;&lt;a href="../../Uro/Lab/UrnGlcs.htm" class="LinkPage"&gt;Urine Glucose&lt;/a&gt; negative&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Diagnosis: Identify false positives on &lt;a href="../../NICU/Lab/NwbrnScrn.htm" class="LinkPage"&gt;Newborn Screen&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Distinguish homozygous deficiency from heterozygotes&lt;/li&gt;&lt;li&gt;Heterozygotes need no management and are asymptomatic&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Management&lt;ol&gt;&lt;li&gt;Eliminate lactose from the diet&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0016952</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Metabolism/Glctsm.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Galactosemia, GALT Deficiency</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Metabolism/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Hereditary fructose intolerance syndrome  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0016751"&gt;&lt;i&gt;C0016751&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A genetic disorder characterized by the absence of the enzyme aldolase-B from the liver. This enzyme is essential for the metabolism of fructose. Signs and symptoms from fructose ingestion are evident in infancy and include vomiting, abdominal pain and hypoglycemia. Long term complications include hepatic and renal failure.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;An autosomal recessive fructose metabolism disorder due to deficient fructose-1-phosphate aldolase (EC 2.1.2.13) activity, resulting in accumulation of fructose-1-phosphate. The accumulated fructose-1-phosphate inhibits glycogenolysis and gluconeogenesis, causing severe hypoglycemia following ingestion of fructose. Prolonged fructose ingestion in infants leads ultimately to hepatic failure and death. Patients develop a strong distaste for sweet food, and avoid a chronic course of the disease by remaining on a fructose- and sucrose-free diet.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CSP)&lt;/td&gt;
                &lt;td&gt;autosomal recessive fructose metabolism disorder due to deficient fructose-1-phosphate aldolase (EC 2.1.2.13) activity, resulting in accumulation of fructose-1-phosphate; accumulated fructose-1-phosphate inhibits glycogenolysis and gluconeogenesis, causing severe hypoglycemia following ingestion of fructose; prolonged fructose ingestion in infants leads ultimately to hepatic failure and death; patients develop a strong distaste for sweet food, and avoid a chronic course of the disease by remaining on a fructose- and sucrose-free diet.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Disease or Syndrome (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0016751&amp;amp;tui=T047"&gt;&lt;i&gt;T047&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D005633&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD9&lt;/td&gt;
                &lt;td&gt;271.2&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD10&lt;/td&gt;
                &lt;td&gt;E74.12&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;20052008, 20290005, 237962008&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Fructose Intolerance, Fructose Intolerances, Intolerances, Fructose, FRUCTOSE INTOLERANCE, Intolerance, Fructose, hereditary fructose intolerance, Fructose intolerance, NOS, Hereditary fructose intolerance syndrome, ALDB - aldolose B deficiency, Fructo-16-bisphosph aldolB def, Hereditary fructose intoleran., ALDB - aldolase B deficiency, FRUCTOSEMIA, FRUCTOSE-1,6-BISPHOSPHATE ALDOLASE B DEFICIENCY, ALDOLASE B DEFICIENCY, FRUCTOSE INTOLERANCE, HEREDITARY, FRUCTOSE-1-PHOSPHATE ALDOLASE DEFICIENCY, fructose 1 phosphate aldolase deficiency, fructose intolerance (diagnosis), fructose intolerance, Fructosemia (disorder), Fructose intolerance hereditary, ALDOB DEFICIENCY, Hered fructose intoleran, Hereditary Fructose Intolerance, Intolerance, Hereditary Fructose, Hereditary Fructose Intolerances, Aldolase Deficiency, Fructose-1-Phosphate, Fructose 1 Phosphate Aldolase Deficiency, Deficiencies, Fructose-1-Phosphate Aldolase, Fructose-1,6-Biphosphate Aldolase Deficiency, Aldolase Deficiencies, Fructose-1,6-Biphosphate, Intolerances, Hereditary Fructose, Fructose-1-Phosphate Aldolase Deficiency, Aldolase Deficiencies, Fructose-1-Phosphate, Fructose-1,6-Biphosphate Aldolase Deficiencies, Fructose Aldolase B Deficiency, Aldolase Deficiency, Fructose-1,6-Biphosphate, Fructose-1-Phosphate Aldolase Deficiencies, Fructose 1,6 Biphosphate Aldolase Deficiency, Fructose Intolerance, Hereditary, Fructose Intolerances, Hereditary, Deficiency, Fructose-1-Phosphate Aldolase, Deficiencies, Fructose-1,6-Biphosphate Aldolase, Deficiency, Fructose-1,6-Biphosphate Aldolase, Fructose Intolerance [Disease/Finding], fructose hereditary intolerance, fructose intolerance hereditary, Hereditary fructose intolerance, Fructosemia, ALDB deficiency, Aldolase B deficiency, Fructose-1-phosphate aldolase deficiency, Fructose-biphosphate aldolase B deficiency, Hereditary fructosuria, Fructosaemia, Fructose-1,6-bisphosphate aldolase B deficiency, Fructose intolerance, Fructose-1,6-bisphosphate aldolase B deficiency (disorder), fructose; intolerance, fructosemia, intolerance; fructose, Hereditary fructosuria (disorder)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Intolleranza ereditaria al fruttosio, Intolleranza al fruttosio&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;erfelijke fructose-intolerantie, fructose; intolerantie, intolerantie; fructose, fructose-intolerantie, erfelijk, Fructose-intolerantie, Intolerantie, fructose-&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Intolérance au fructose héréditaire, Intolérance héréditaire au fructose, Déficit héréditaire en fructose-1-phosphate aldolase, Fructosémie congénitale, Intolérance au fructose&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Fructoseunvertraeglichkeit, hereditaer, hereditaere Fructoseunvertraeglichkeit, Fruktoseintoleranz&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;Intolerancia hereditaria a la glucosa, fructosuria hereditaria (trastorno), deficiencia de fructosa-1,6-bifosfato aldolasa B (trastorno), deficiencia de fructosa-1,6-bifosfato aldolasa B, Fructose-1,6-bisphosphate aldolase B deficiency, deficiencia de ALDB, deficiencia de aldolasa B, deficiencia de fructosa - 1 - fosfato aldolasa, deficiencia de fructosa bifosfato aldolasa B, fructosemia (concepto no activo), fructosemia, fructosuria hereditaria, intolerancia hereditaria a la fructosa, Intolerancia hereditaria a la fructosa, Intolerancia a la Fructosa&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Fruktosintolerans&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;ｲﾃﾞﾝｾｲﾌﾙｸﾄｰｽﾌﾀｲｼｮｳ, フルクトース不耐性, 1-Phosphofructaldolase欠損症, フルクトース不耐症, 果糖不耐性, 果糖不耐症, 遺伝性フルクトース不耐症, 遺伝性果糖不耐容性, 遺伝性果糖不耐症, 1-ホスホフルクトアルドラーゼ欠損症, フルクトース-1-リン酸アルドラーゼ欠損症&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;fruktosa - nesnášenlivost, Hereditární intolerance fruktózy&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Fruktoosi-intoleranssi&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;FRUKTOZA, INTOLERANTNOST' K FRUKTOZE, FRUKTOZY NEPERENOSIMOST', ФРУКТОЗА, ИНТОЛЕРАНТНОСТЬ К ФРУКТОЗЕ, ФРУКТОЗЫ НЕПЕРЕНОСИМОСТЬ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Nietolerancja fruktozy&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;Fructose intolerantia öröklött, Öröklött fructose intolerantia&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Intolerância hereditária à frutose, Intolerância à Frutose&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Hereditary fructose intolerance syndrome  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Hereditary Fructose Intolerance</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Metabolic Disorders</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;See Also&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Metabolism/InbrnErrsOfMtblsm.htm" class="LinkPage"&gt;Inborn Errors of Metabolism&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Metabolism/InbrnErrOfSmlMlclMtblsm.htm" class="LinkPage"&gt;Inborn Error of Small Molecule Metabolism&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Pathophysiology&lt;ol&gt;&lt;li&gt;Intolerance to fructose or sucrose&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Symptoms (follows sucrose or fructose exposure)&lt;ol&gt;&lt;li&gt;&lt;a href="../../GI/Sx/Vmtng.htm" class="LinkPage"&gt;Vomiting&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Hypoglycemia/Hypglycm.htm" class="LinkPage"&gt;Hypoglycemia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Neuro/Seizure/Szr.htm" class="LinkPage"&gt;Seizure&lt;/a&gt;s&lt;/li&gt;&lt;li&gt;&lt;a href="../../Neuro/LOC/Cm2.htm" class="LinkPage"&gt;Coma&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../GI/Exam/Hptmgly.htm" class="LinkPage"&gt;Hepatomegaly&lt;/a&gt; (see &lt;a href="../../NICU/Surgery/HptmglyInNwbrns.htm" class="LinkPage"&gt;Hepatomegaly in Newborns&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;&lt;a href="../../GI/Derm/Jndc.htm" class="LinkPage"&gt;Jaundice&lt;/a&gt; (Direct &lt;a href="../../GI/Lab/Blrbn.htm" class="LinkPage"&gt;Hyperbilirubinemia&lt;/a&gt;)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Labs&lt;ol&gt;&lt;li&gt;Hepatic fructose-1-phosphatase aldolase activity&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Management&lt;ol&gt;&lt;li&gt;Fructose and sucrose eliminated from diet&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0016751</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Metabolism/HrdtryFrctsIntlrnc.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Hereditary Fructose Intolerance</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Metabolism/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees></FP_UMLS_Trees><FP_Condition_name_check></FP_Condition_name_check><FP_Condition_name><value>Inborn Error of Small Molecule Metabolism</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Metabolic Disorders</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;See Also&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Metabolism/InbrnErrsOfMtblsm.htm" class="LinkPage"&gt;Inborn Errors of Metabolism&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Types&lt;ol&gt;&lt;li&gt;Organic acid disorders&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Metabolism/MthylmlncAcdm.htm" class="LinkPage"&gt;Methylmalonic acidemia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Propionic acidemia&lt;/li&gt;&lt;li&gt;Isovaleric acidemia&lt;/li&gt;&lt;li&gt;Glutaric Acidemia Type I&lt;/li&gt;&lt;li&gt;Beta-Ketothiolase deficiency&lt;/li&gt;&lt;li&gt;3-Methylcrotonyl-CoA Carboxylase Deficiency&lt;/li&gt;&lt;li&gt;3-Hydroxy-3-Methylglutaryl CoA Lyase Deficiency&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Carbohydrate metabolism defects&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Metabolism/Glctsm.htm" class="LinkPage"&gt;Galactosemia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Metabolism/HrdtryFrctsIntlrnc.htm" class="LinkPage"&gt;Hereditary Fructose Intolerance&lt;/a&gt;&lt;/li&gt;&lt;li&gt;See &lt;a href="../../Endo/Metabolism/DsrdrsOfEnrgyMtblsm.htm" class="LinkPage"&gt;Glycogen Storage Disease&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Amino acid metabolism and Urea Cycle defects&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Metabolism/Phnylktnr.htm" class="LinkPage"&gt;Phenylketonuria&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Maple syrup urine disease&lt;/li&gt;&lt;li&gt;Tyrosinemia&lt;/li&gt;&lt;li&gt;Tryptophanuria&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Metabolism/OrnthnTrnscrbmylsDfcncy.htm" class="LinkPage"&gt;Hyperornithinemia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Beta-alaninemia&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Metabolism/Hmcystnr.htm" class="LinkPage"&gt;Homocystinuria&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Methionine malabsorption&lt;/li&gt;&lt;li&gt;Citrullinemia&lt;/li&gt;&lt;li&gt;Arginase Deficiency&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Metabolism/InbrnErrOfSmlMlclMtblsm.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Inborn Error of Small Molecule Metabolism</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Metabolism/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Inborn Errors of Metabolism  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0025521"&gt;&lt;i&gt;C0025521&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A group of disorders present at birth that involve genetic defects leading to disturbances in carbohydrate, lipid, lysosomal storage or amino acid metabolism in the body.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;Errors in metabolic processes resulting from inborn genetic mutations that are inherited or acquired in utero.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CSP)&lt;/td&gt;
                &lt;td&gt;errors in metabolic processes resulting from inborn genetic mutations that are inherited or acquired in utero.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Congenital Abnormality (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0025521&amp;amp;tui=T019"&gt;&lt;i&gt;T019&lt;/i&gt;&lt;/a&gt;)
, Disease or Syndrome (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0025521&amp;amp;tui=T047"&gt;&lt;i&gt;T047&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D008661&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;86095007, 363205007&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Metabolism, Inborn errors of, Error, Inborn Metabolism, Errors Metabolism, Inborn, Errors Metabolisms, Inborn, Errors, Inborn Metabolism, Inborn Errors Metabolism, Inborn Errors Metabolisms, Inborn Metabolism Error, Inborn Metabolism Errors, Metabolism Error, Inborn, Metabolism Errors, Inborn, Metabolism Inborn Error, Metabolism Inborn Errors, Metabolism, Inborn Errors, Metabolisms, Inborn Errors, inborn metabolism disorder, Inborn error of metabolism, NOS, METAB ERR INBORN, INBORN ERR METAB, METAB INBORN ERR, IBEM - Inborn error of metabol, IEM - Inborn error metabolism, Congenital Metabolic Disorder, Inborn Errors of Metabolism, Inborn error of metabolism NOS, Metabolism, Inborn Errors [Disease/Finding], inborn error of metabolism, inborn error metabolism, errors inborn metabolism, inborn errors metabolism, inborn errors of metabolism, Inborn errors of metabolism, Inborn error of metabolism, IBEM - Inborn error of metabolism, IEM - Inborn error of metabolism, Inborn error of metabolism (disorder), Metabolic hereditary disorder (disorder), Metabolic hereditary disorder&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Errore congenito del metabolismo, Errore congenito del metabolismo NAS, Errori congeniti del metabolismo&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;metabolisme aangeboren afwijking NAO, aangeboren metabolismestoornissen, metabolisme aangeboren afwijking, Aangeboren afwijking van de stofwisseling, Afwijking, aangeboren, stofwisseling, Stofwisseling, aangeboren afwijking van de&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Erreur innée du métabolisme SAI, Erreur innée du métabolisme, Erreurs innées du métabolisme, Maladies métaboliques congénitales&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;angeborene Stoffwechselstoerung NNB, Angeborene Stoffwechselstoerungen, angeborene Stoffwechselstoerung, Angeborene Stoffwechseldefekte, Angeborene Stoffwechselerkrankungen, Angeborene Stoffwechselstörungen, Stoffwechsel, angeborene Störungen&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Erro congénito do metabolismo NE, Erro congénito do metabolismo, Erros congénitos de metabolismo, Erros Inatos do Metabolismo&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;Error innato del metabolismo NEOM, metabolopatía congénita (trastorno), metabolopatía congénita, metabolopatía hereditaria, trastorno hereditario del metabolismo (trastorno), trastorno hereditario del metabolismo, trastorno metabólico hereditario, Errores innatos del metabolismo, Error innato del metabolismo, enzimopatía congénita, Errores Innatos del Metabolismo&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;先天性代謝異常症ＮＯＳ, 先天性代謝障害, 先天性代謝異常症, ｾﾝﾃﾝｾｲﾀｲｼｬｲｼﾞｮｳｼｮｳ, ｾﾝﾃﾝｾｲﾀｲｼｬｼｮｳｶﾞｲ, ｾﾝﾃﾝｾｲﾀｲｼｬｲｼﾞｮｳｼｮｳNOS, 代謝異常-先天性, 先天性代謝異常, 先天代謝異常, 代謝-先天性異常&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Ämnesomsättningsrubbningar, medfödda&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;metabolismus - vrozené poruchy, Vrozené poruchy metabolismu, Vrozená vada metabolismu, Vrozená vada metabolismu NOS&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Synnynnäiset aineenvaihduntahäiriöt&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;OBMENA VESHCHESTV VROZHDENNYE NARUSHENIIA, OBMENA VESHCHESTV NARUSHENIIA VROZHDENNYE, VROZHDENNYE OTKLONENIIA METABOLIZMA, ВРОЖДЕННЫЕ ОТКЛОНЕНИЯ МЕТАБОЛИЗМА, ОБМЕНА ВЕЩЕСТВ ВРОЖДЕННЫЕ НАРУШЕНИЯ, ОБМЕНА ВЕЩЕСТВ НАРУШЕНИЯ ВРОЖДЕННЫЕ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Croatian&lt;/td&gt;
                &lt;td&gt;METABOLIZAM, PRIROĐENE GREŠKE&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Choroby metaboliczne wrodzone&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;Veleszületett anyagcserezavar k.m.n., Veleszületett anyagcserezavar, Metabolizmus veleszületett hibái&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Inborn Errors of Metabolism  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Inborn Errors of Metabolism</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Metabolic Disorders</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;See Also&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Metabolism/DsrdrsOfEnrgyMtblsm.htm" class="LinkPage"&gt;Disorders of Energy Metabolism&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Metabolism/LysmlStrgDs.htm" class="LinkPage"&gt;Lysosomal Storage Disease&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Metabolism/InbrnErrOfSmlMlclMtblsm.htm" class="LinkPage"&gt;Inborn Error of Small Molecule Metabolism&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Labs: Metabolic disorders tested on &lt;a href="../../NICU/Lab/NwbrnScrn.htm" class="LinkPage"&gt;Newborn Screen&lt;/a&gt;&lt;ol&gt;&lt;li&gt;See &lt;a href="../../NICU/Lab/NwbrnScrn.htm" class="LinkPage"&gt;Newborn Screen&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Classification&lt;ol&gt;&lt;li&gt;Inborn Errors of Small &lt;a href="../../Derm/HemeOnc/Ml.htm" class="LinkPage"&gt;Mole&lt;/a&gt;cule Metabolism&lt;ol&gt;&lt;li&gt;Example: &lt;a href="../../Endo/Metabolism/Glctsm.htm" class="LinkPage"&gt;Galactosemia&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Metabolism/LysmlStrgDs.htm" class="LinkPage"&gt;Lysosomal Storage Disease&lt;/a&gt;s&lt;ol&gt;&lt;li&gt;Example: &lt;a href="../../Endo/Metabolism/TypGchrsDs.htm" class="LinkPage"&gt;Gaucher's Disease&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Metabolism/DsrdrsOfEnrgyMtblsm.htm" class="LinkPage"&gt;Disorders of Energy Metabolism&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Example: &lt;a href="../../Endo/Metabolism/DsrdrsOfEnrgyMtblsm.htm" class="LinkPage"&gt;Glycogen Storage Disease&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Other more rare classes of metabolism error&lt;ol&gt;&lt;li&gt;Paroxysmal disorders&lt;/li&gt;&lt;li&gt;Transport disorders&lt;/li&gt;&lt;li&gt;Defects in purine and pyrimidine metabolism&lt;/li&gt;&lt;li&gt;Receptor Defects&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Symptoms: Presentations of Inborn Errors of Metabolism&lt;ol&gt;&lt;li&gt;Cardiopulmonary changes&lt;ol&gt;&lt;li&gt;&lt;a href="../../Sports/Exercise/Exrcs.htm" class="LinkPage"&gt;Exercise&lt;/a&gt; intolerance&lt;/li&gt;&lt;li&gt;Familal vascular disease&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Gastrointestinal changes&lt;ol&gt;&lt;li&gt;&lt;a href="../../GI/Diarrhea/ActDrh.htm" class="LinkPage"&gt;Diarrhea&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Recurrent &lt;a href="../../GI/Sx/Vmtng.htm" class="LinkPage"&gt;Emesis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../GI/Pancreas/ActPncrts.htm" class="LinkPage"&gt;Pancreatitis&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Neurologic changes&lt;ol&gt;&lt;li&gt;Muscle cramping or spasticity&lt;/li&gt;&lt;li&gt;&lt;a href="../../Neuro/Sx/PrphrlNrpthy.htm" class="LinkPage"&gt;Peripheral Neuropathy&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Upward gaze paralysis&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Signs: Presentations of Inborn Errors of Metabolism&lt;ol&gt;&lt;li&gt;Cardiopulmonary changes&lt;ol&gt;&lt;li&gt;&lt;a href="../../CV/Myocardium/Crdmypthy.htm" class="LinkPage"&gt;Cardiomyopathy&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Neurologic changes&lt;ol&gt;&lt;li&gt;&lt;a href="../../Neuro/CV/IschmcStrk.htm" class="LinkPage"&gt;Cerebrovascular Accident&lt;/a&gt; or stroke-like events&lt;/li&gt;&lt;li&gt;Encephalopathy&lt;/li&gt;&lt;li&gt;Cerebral calcifications&lt;/li&gt;&lt;li&gt;Agenesis of corpus callosum&lt;/li&gt;&lt;li&gt;&lt;a href="../../NICU/Exam/HdCrcmfrnc.htm" class="LinkPage"&gt;Macrocephaly&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Eye changes&lt;ol&gt;&lt;li&gt;Lenticular &lt;a href="../../Eye/Lens/Ctrct.htm" class="LinkPage"&gt;Cataract&lt;/a&gt;s&lt;/li&gt;&lt;li&gt;&lt;a href="../../Eye/Cornea/CrnlOpcfctn.htm" class="LinkPage"&gt;Corneal Opacity&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Cherry red &lt;a href="../../Derm/Exam/Mcl.htm" class="LinkPage"&gt;Macule&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Lens discoloration&lt;/li&gt;&lt;li&gt;Optic atrophy&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Skin changes&lt;ol&gt;&lt;li&gt;&lt;a href="../../Uro/Derm/Angkrtm.htm" class="LinkPage"&gt;Angiokeratoma&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Non-specific dermatitis or hair changes&lt;/li&gt;&lt;li&gt;&lt;a href="../../Derm/Dry/Ichthys.htm" class="LinkPage"&gt;Ichthyosis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Inverted nipples&lt;/li&gt;&lt;li&gt;Xanthomas&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Musculoskeletal changes&lt;ol&gt;&lt;li&gt;Arthrosis&lt;/li&gt;&lt;li&gt;Dystosis multiplex&lt;/li&gt;&lt;li&gt;&lt;a href="../../Rheum/Bone/Ostprs.htm" class="LinkPage"&gt;Osteoporosis&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Renal Changes&lt;ol&gt;&lt;li&gt;&lt;a href="../../Uro/Renal/Nphrlths.htm" class="LinkPage"&gt;Renal Calculi&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Renal &lt;a href="../../Renal/Tubule/FncnsSyndrm.htm" class="LinkPage"&gt;Fanconi Syndrome&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Raghuveer%20%20%5BAU%5D%20AND%202006%20%5BDP%5D%20AND%20%20Am%20Fam%20Physician%20%20%5BTA%5D" class="LinkRef"&gt;Raghuveer (2006) Am Fam Physician 73(11):1981-90&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0025521</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Metabolism/InbrnErrsOfMtblsm.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Inborn Errors of Metabolism</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Metabolism/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Sphingolipidoses  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0037899"&gt;&lt;i&gt;C0037899&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CSP)&lt;/td&gt;
                &lt;td&gt;lysosomal storage diseases characterized by abnormal storage of spingolipids.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;A group of inherited metabolic disorders characterized by the intralysosomal accumulation of SPHINGOLIPIDS primarily in the CENTRAL NERVOUS SYSTEM and to a variable degree in the visceral organs. They are classified by the enzyme defect in the degradation pathway and the substrate accumulation (or storage). Clinical features vary in subtypes but neurodegeneration is a common sign.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Disease or Syndrome (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0037899&amp;amp;tui=T047"&gt;&lt;i&gt;T047&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D013106&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD10&lt;/td&gt;
                &lt;td&gt;E75.3&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;238028008, 58459009&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Sphingolipidoses, Sphingolipidosis, Sphingolipidosis, NOS, Sphingolipidosis, unspecified, SPHINGOLIPID STORAGE DIS, sphingolipidosis (diagnosis), sphingolipidosis, Sphingolipid Storage Disease, Sphingolipid Storage Diseases, Storage Disease, Sphingolipid, Storage Diseases, Sphingolipid, Sphingolipidoses [Disease/Finding], sphingolipidose, sphingolipidoses, Sphingolipidosis (disorder)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Sphingolipidspeicherkrankheiten, Sphingolipid-Speicherkrankheiten, Sphingolipidose, Sphingolipidose, nicht naeher bezeichnet, Sphingolipidosen&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Sfingolipidoser&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;sfingolipidózy&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Sfingolipidoosit&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Malattie da accumulo di sfingolipidi, Sfingolipidosi&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;SFINGOLIPIDOZY, СФИНГОЛИПИДОЗЫ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;スフィンゴリピド症, スフィンゴ脂質症, スフィンゴリピドーシス&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Korean&lt;/td&gt;
                &lt;td&gt;상세불명의 스핑고지질증&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Sfingolipidozy&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;Sfingolipidose, niet gespecificeerd, Lipidose, sfingo-, Sfingolipidose, Sfingolipidosen&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;esfingolipidosis, esfingolipoidosis (trastorno), esfingolipoidosis, Esfingolipidosis&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Sphingolipidoses, Maladies de surcharge en sphingolipides&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Esfingolipidoses&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Glycoprotein storage disorder  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0268220"&gt;&lt;i&gt;C0268220&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Disease or Syndrome (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0268220&amp;amp;tui=T047"&gt;&lt;i&gt;T047&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;7810004&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Glycoprotein storage disorder, NOS, Glycoprotein storage disorder (disorder), Glycoprotein storage disorder&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;trastorno por almacenamiento de glicoproteínas, trastorno por almacenamiento de glucoproteínas (trastorno), trastorno por almacenamiento de glucoproteínas&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Lysosomal Storage Diseases  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0085078"&gt;&lt;i&gt;C0085078&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A group of autosomal recessive or X-linked inherited metabolic disorders caused by defects in the function of the lysosomes. Signs and symptoms include hepatomegaly, splenomegaly, nervous system manifestations, skeletal abnormalities, and mental deterioration. Representative examples include Gaucher disease, Niemann-Pick disease, Wolman disease, and Fabry disease.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;Inborn errors of metabolism characterized by defects in specific lysosomal hydrolases and resulting in intracellular accumulation of unmetabolized substrates.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CSP)&lt;/td&gt;
                &lt;td&gt;inborn errors of metabolism characterized by defects in specific lysosomal hydrolases and resulting in intracellular accumulation of unmetabolized substrates.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Disease or Syndrome (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0085078&amp;amp;tui=T047"&gt;&lt;i&gt;T047&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D016464&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;23585005&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Disease, Lysosomal Storage, Diseases, Lysosomal Storage, Disorder, Lysosomal Enzyme, Disorders, Lysosomal Enzyme, Enzyme Disorder, Lysosomal, Enzyme Disorders, Lysosomal, Lysosomal Enzyme Disorder, Lysosomal Enzyme Disorders, Lysosomal Storage Diseases, inborn lysosomal enzyme disorder, DISORDERS OF LYSOSOMAL ENZYMES, Disorder of lysosomal enzyme, NOS, lysosomal storage disease, LYSOSOMAL STORAGE DIS, LYSOSOMAL ENZYME DIS, Lysosomal Storage Disease, SECTION 6-7 DISORDERS OF LYSOSOMAL ENZYMES, Lysosomal Storage Diseases [Disease/Finding], lysosomal storage disorders, lysosomal storage diseases, lysosomal storage disorder, Lysosomal storage disorders, Disorder of lysosomal enzyme (disorder), Disorder of lysosomal enzyme, defect; lysosomal enzyme, lysosomal enzyme; defect&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Patologie da accumulo lisosomiale, Difetti dell'enzima lisosomiale, Malattie da accumulo lisosomiale&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Lysosomala upplagringssjukdomar&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;ﾘｿｿｰﾑﾁｸｾｷｼｮｳ, リソソーム蓄積症, 先天性リソソーム病, ハリソン病, ライソゾーム性蓄積症, リソソーム性蓄積症, リソソーム病, リソソーム酵素障害, 網内系脂肪蓄積症, ライソソーム病, ライソソーム蓄積病, ライソソーム酵素障害, ライソゾーム病, ライソゾーム蓄積病, ライソゾーム酵素障害, リソソーム蓄積病&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;lyzozomální nemoci z ukládání, Poruchy střádání v lysozomech&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Lysosomaaliset kertymäsairaudet&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;LIZOSOMAL'NYKH ENZIMOV OBMENA NARUSHENIIA, LIZOSOMAL'NOGO NAKOPLENIIA BOLEZNI, ЛИЗОСОМАЛЬНОГО НАКОПЛЕНИЯ БОЛЕЗНИ, ЛИЗОСОМАЛЬНЫХ ЭНЗИМОВ ОБМЕНА НАРУШЕНИЯ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;trastorno de enzimas lisosomales, trastorno de enzimas lisosómicas, trastorno de enzimas lisosómicas (trastorno), trastorno de enzimas lisosomales (trastorno), Alteraciones lisosómicas de almacenamiento, Enfermedades por Almacenamiento Lisosomal, Trastornos de la Enzima Lisosomal&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Choroby spichrzeniowe lizosomalne, Zaburzenia enzymów lizosomalnych&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;Lysosomalis tárolási betegségek&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;defect; lysosomaal enzym, lysosomaal enzym; defect, lysosomale stapelingsstoornissen, Lysosomale enzymafwijkingen, Lysosomale stapelingsziekte, Lysosomale stapelingsziekten, Lysosomale ziekte, Stapelingsziekte, lysosomale, Ziekte, lysosomale stapelings-&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Alterações do armazenamento lisossómico, Doenças por Armazenamento dos Lisossomos, Transtornos da Enzima Lisossômica&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Troubles lysosomaux, Maladies lysosomiales, Maladies lysosomales&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Stoerungen der Lysosomenspeicherung, Lysosomale Speicherkrankheiten, Lysosomale Enzymstörungen&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Mucolipidoses  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0026697"&gt;&lt;i&gt;C0026697&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A group of inherited lysosomal storage diseases characterized by accumulation of lipids and carbohydrates in the tissues, resulting in mental disabilities and skeletal malformations.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;A group of inherited metabolic diseases characterized by the accumulation of excessive amounts of acid mucopolysaccharides, sphingolipids, and/or glycolipids in visceral and mesenchymal cells. Abnormal amounts of sphingolipids or glycolipids are present in neural tissue. INTELLECTUAL DISABILITY and skeletal changes, most notably dysostosis multiplex, occur frequently. (From Joynt, Clinical Neurology, 1992, Ch56, pp36-7)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Disease or Syndrome (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0026697&amp;amp;tui=T047"&gt;&lt;i&gt;T047&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D009081&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;70528007&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Mucolipidoses, Mucolipidosis, Mucolipidosis, NOS, mucolipidosis (diagnosis), mucolipidosis, Mucolipidoses [Disease/Finding], mucolipidoses, Mucolipidosis (disorder)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Mukolipidoser&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;mukolipidózy&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Mukolipidoosit&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;I-KLETOK BOLEZN', MUKOLIPIDOZ, MUKOLIPIDOZY, I-КЛЕТОК БОЛЕЗНЬ, МУКОЛИПИДОЗ, МУКОЛИПИДОЗЫ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;シアリドーシス, I細胞病, Iセル病, ガングリオシドシアリダーゼ欠損症, I-Cell病, サクランボ赤色斑ミオクローヌス症候群, ノイラミニダーゼ欠損症, ムコ脂質症, リポムコ多糖代謝異常症, ムコリピド症, リポムコ多糖沈着症, リポムコ多糖症, 偽ハーラー多発性ジストロフィ, ノイラミニダーゼ欠損病, Hurler病様ポリジストロフィー, ムコリピドーシス&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Choroba pseudo-Hurlera, Mukolipidozy&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;mucolipidosis (trastorno), mucolipidosis, Mucolipidosis&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Mucolipidoses&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Mukolipidose, Mukolipidosen&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Mucolipidosi&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;Lipidose, muco-, Mucolipidose, Mucolipidosis&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Mucolipidose, Mucolipidoses&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Gangliosidoses  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0017083"&gt;&lt;i&gt;C0017083&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CSP)&lt;/td&gt;
                &lt;td&gt;group of often fatal inherited diseases marked by the accumulation of gangliosides in lysosomes secondary to enzymatic deficiency states; gangliosidoses include Tay-Sachs disease, gangliosidosis GM1, gangliosidoses GM2, and Sandhoff disease; which share the infantile or childhood onset of central nervous system deterioration.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;A group of autosomal recessive lysosomal storage disorders marked by the accumulation of GANGLIOSIDES. They are caused by impaired enzymes or defective cofactors required for normal ganglioside degradation in the LYSOSOMES. Gangliosidoses are classified by the specific ganglioside accumulated in the defective degradation pathway.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Disease or Syndrome (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0017083&amp;amp;tui=T047"&gt;&lt;i&gt;T047&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D005733&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD10&lt;/td&gt;
                &lt;td&gt;E75.10&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;50967008&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Gangliosidoses, Gangliosidosis, Ganglioside storage disease, NOS, Gangliosidosis, NOS, GANGLIOSIDE STORAGE DIS, Ganglioside Storage Disease, Ganglioside Storage Diseases, Storage Disease, Ganglioside, Storage Diseases, Ganglioside, Ganglioside Storage Disorder, Ganglioside Storage Disorders, Storage Disorder, Ganglioside, Storage Disorders, Ganglioside, Gangliosidosis NOS, Unspecified gangliosidosis, Gangliosidoses [Disease/Finding], ganglioside storage diseases, ganglioside storage disease, gangliosidoses, Ganglioside accumulation in nervous tissue lysosomes, Ganglioside storage disease, Gangliosidosis (disorder), gangliosidosis, Disease, Gangliosidosis&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Gangliosidoser&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;gangliosidóza&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Gangliosidoosit&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;GANGLIOZIDOZY, ГАНГЛИОЗИДОЗЫ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;ガングリオシドーシス, ガングリオシド蓄積症&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Disordini da accumulo di gangliosidi, Malattie da accumulo di gangliosidi, Gangliosidosi&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Gangliozydozy&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;acumulación de gangliósidos en lisosomas del tejido nervioso, enfermedad por almacenamiento de gangliósidos, gangliosidosis (trastorno), gangliosidosis, Gangliosidosis&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Gangliosidoses&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Gangliosidosen&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;Ganglioside&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Gangliosidoses&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Mucopolysaccharidoses  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0026703"&gt;&lt;i&gt;C0026703&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A group of autosomal recessive or X-linked inherited lysosomal storage disorders affecting the metabolism of mucopolysaccharides, resulting in the accumulation of mucopolysaccharides in the body. Signs and symptoms include organomegaly, mental retardation, abnormal skeletal development, heart disorders, hearing loss, and central nervous system deficiencies.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;Group of lysosomal storage diseases each caused by an inherited deficiency of an enzyme involved in the degradation of glycosaminoglycans (mucopolysaccharides). The diseases are progressive and often display a wide spectrum of clinical severity within one enzyme deficiency.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CSP)&lt;/td&gt;
                &lt;td&gt;any of a group of lysosomal storage diseases resulting from defects in degradation of glycosaminoglycans, which are excreted in urine and accumulate in tissue.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Disease or Syndrome (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0026703&amp;amp;tui=T047"&gt;&lt;i&gt;T047&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D009083&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD9&lt;/td&gt;
                &lt;td&gt;277.5&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD10&lt;/td&gt;
                &lt;td&gt;E76.3&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;267452003, 190942001, 11380006, 190936000&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Mucopolysaccharidoses, Mucopolysaccharidosis, Mucopolysaccharidosis, NOS, Mucopolysaccharidosis NOS, Mucopolysaccharidosis, unspecified, mucopolysaccharidosis, mucopolysaccharidosis (diagnosis), Mucopolysaccharidosis NOS (disorder), Mucopolysaccharidoses [Disease/Finding], mucopolysaccharidose, mucopolysaccharidoses, MPS - Mucopolysaccharidosis, Mucopolysaccharidosis (disorder), Mucopolysaccharidosis [Ambiguous]&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;mucopolysacharidose NAO, Mucopolysaccharidose, niet gespecificeerd, mucopolysacharidose, Mucopolysaccharidose, Stapelingsziekte&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Mucopolysaccharidose SAI, Mucopolysaccharidose, Mucopolysaccharidoses&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Mukopolysaccharidose NNB, Mukopolysaccharidose, nicht naeher bezeichnet, Mukopolysaccharidose, Mukopolysaccharidosen&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Mucopolisaccaridosi NAS, Mucopolisaccaridosi&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Mucopolissacaridose NE, Mucopolisacaridose, Mucopolissacaridoses&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;Mucopolisacaridosis NEOM, Mucopolysaccharidosis [Ambiguous], Mucopolysaccharidosis, mucopolisacaridosis (trastorno), mucopolisacaridosis, SAI (trastorno), mucopolisacaridosis, SAI, mucopolisacaridosis, Mucopolisacaridosis&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;ムコ多糖症ＮＯＳ, ﾑｺﾀﾄｳｼｮｳNOS, ﾑｺﾀﾄｳｼｮｳ, グリコサミノグリカン蓄積症, ムコ多糖症, ムコポリサッカリドーシス, ムコ多糖体沈着, ムコ多糖体沈着症, ムコ多糖体症, ムコ多糖沈着, ムコ多糖沈着症, 酸性ムコ多糖体症&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Mukopolysackaridoser&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;mukopolysacharidózy, Mukopolysacharidóza NOS, Mukopolysacharidóza&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Mukopolysakkaridoosit&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;MUKOPOLISAKHARIDOZY, МУКОПОЛИСАХАРИДОЗЫ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Korean&lt;/td&gt;
                &lt;td&gt;상세불명의 점액다당질증&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Mukopolisacharydozy&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;Mucopolysaccharidosis k.m.n., Mucopolysaccharidosis&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Sphingolipidoses  (</value><value>)
</value><value>Glycoprotein storage disorder  (</value><value>)
</value><value>Lysosomal Storage Diseases  (</value><value>)
</value><value>Mucolipidoses  (</value><value>)
</value><value>Gangliosidoses  (</value><value>)
</value><value>Mucopolysaccharidoses  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Lysosomal Storage Disease</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Metabolic Disorders</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;See Also&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Metabolism/InbrnErrsOfMtblsm.htm" class="LinkPage"&gt;Inborn Errors of Metabolism&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Mucopolysaccharidosis&lt;ol&gt;&lt;li&gt;Hurler's Syndrome&lt;/li&gt;&lt;li&gt;Scheie's Syndrome&lt;/li&gt;&lt;li&gt;Hunter's Syndrome&lt;/li&gt;&lt;li&gt;Sanfilippo's Syndrome (Types A-D)&lt;/li&gt;&lt;li&gt;Morquio A-B&lt;/li&gt;&lt;li&gt;Maroteaux-Lamy Syndrome&lt;/li&gt;&lt;li&gt;Beta-glucuronidase deficiency&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Mucolipidosis&lt;ol&gt;&lt;li&gt;Type 2: CNS, Bone and connective tissue involvement&lt;/li&gt;&lt;li&gt;Type 3: Joint and connective tissue involvement&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Glycoprotein disorders&lt;ol&gt;&lt;li&gt;Fucosidosis&lt;/li&gt;&lt;li&gt;Mannosidosis&lt;/li&gt;&lt;li&gt;Sialidosis&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Metabolism/DsrdrsOfEnrgyMtblsm.htm" class="LinkPage"&gt;Glycogen Storage Disease&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Aspart&lt;/a&gt;ylglycosaminuria&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Gangliosidosis (Sphingolipidosis)&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Metabolism/TypGchrsDs.htm" class="LinkPage"&gt;Gaucher's Disease&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Niemann-&lt;a href="../../Neuro/Cognitive/FrntmprlDmnt.htm" class="LinkPage"&gt;Pick Disease&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Krabbe's Disease (Globoid leukodystrophy)&lt;/li&gt;&lt;li&gt;Metachromatic leukodystrophy&lt;/li&gt;&lt;li&gt;Ceramide lactoside lipidosis&lt;/li&gt;&lt;li&gt;Fabry's Disease&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Metabolism/TySchsDs.htm" class="LinkPage"&gt;Tay-Sachs Disease&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Sandhoff's Disease&lt;/li&gt;&lt;li&gt;Landing's Disease&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0037899</value><value>C0268220</value><value>C0085078</value><value>C0026697</value><value>C0017083</value><value>C0026703</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Metabolism/LysmlStrgDs.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Lysosomal Storage Disease, Mucopolysaccharidoses, Mucolipidosis, Glycoprotein Metabolism Disorder, Gangliosidosis, Sphingolipidosis</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Metabolism/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees></FP_UMLS_Trees><FP_Condition_name_check></FP_Condition_name_check><FP_Condition_name><value>Nutrition in Diabetes Mellitus Type 1</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Prevention</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;
              &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt;: Conventional &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; therapy&lt;ol&gt;&lt;li&gt;Long-acting &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; (&lt;a href="../../Endo/Pharm/AnlgBslInsln.htm" class="LinkPage"&gt;Lantus&lt;/a&gt;) provides basal needs&lt;/li&gt;&lt;li&gt;Short acting &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; (&lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Lispro&lt;/a&gt;) covers mealtimes&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Diet&lt;ol&gt;&lt;li&gt;Synchronize food with &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Eat consistently and adjust &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Better nutrition behaviors (per DCC Trial)&lt;ol&gt;&lt;li&gt;Adhere to meal plan&lt;/li&gt;&lt;li&gt;Appropriately treat &lt;a href="../../Endo/Hypoglycemia/Hypglycm.htm" class="LinkPage"&gt;Hypoglycemia&lt;/a&gt; (do not over-treat)&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; tablet raises &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Sugar&lt;/a&gt; in &amp;lt;10 minutes&lt;/li&gt;&lt;li&gt;Orange Juice raises &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Sugar&lt;/a&gt; in 10-20 minutes&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Respond promptly to &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Hyperglycemia&lt;/a&gt; with &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Snack consistently&lt;ol&gt;&lt;li&gt;Take afternoon snack if taking NPH in morning&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Prevent/NtrtnInDbtsMltsTyp.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Nutrition in Diabetes Mellitus Type 1, Nutrition in Diabetes Mellitus Type I</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Prevent/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees></FP_UMLS_Trees><FP_Condition_name_check></FP_Condition_name_check><FP_Condition_name><value>Diabetes Screening</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Prevention</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Indications: Diabetes Screening in children (every 2 years starting at age 10 years or &lt;a href="../../Endo/Exam/SxlDvlpmnt.htm" class="LinkPage"&gt;Puberty&lt;/a&gt;)&lt;ol&gt;&lt;li&gt;BMI or weight over 85% or more than 120% over &lt;a href="../../Endo/Exam/IdlWghtInAdlts.htm" class="LinkPage"&gt;Ideal Weight&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Two of the following risk factors&lt;ol&gt;&lt;li&gt;&lt;a href="../../Prevent/HME/FmlyHstry.htm" class="LinkPage"&gt;Family History&lt;/a&gt; of diabetes in first or second degree relative&lt;/li&gt;&lt;li&gt;High risk ethnic group&lt;/li&gt;&lt;li&gt;Signs or symptoms of &lt;a href="../../Endo/DM/InslnRstncSyndrm.htm" class="LinkPage"&gt;Insulin Resistance&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Derm/AcnthsNgrcns.htm" class="LinkPage"&gt;Acanthosis Nigricans&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Htn/Hyprtnsn.htm" class="LinkPage"&gt;Hypertension&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Dyslipidemia (especially elevated &lt;a href="../../CV/Lab/Trglycrd.htm" class="LinkPage"&gt;Triglyceride&lt;/a&gt;s, &lt;a href="../../CV/Lab/HdlChlstrl.htm" class="LinkPage"&gt;HDL Cholesterol&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;Polycystic ovarian disease&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Indications: Diabetes Screening in adults (every 3 years starting at age 45 years)&lt;ol&gt;&lt;li&gt;Screen if &lt;a href="../../Endo/Exam/BdyMsIndx.htm" class="LinkPage"&gt;Body Mass Index&lt;/a&gt; (BMI) &amp;gt;25 and one additional risk factor below&lt;/li&gt;&lt;li&gt;Physical inactivity&lt;/li&gt;&lt;li&gt;&lt;a href="../../Prevent/HME/FmlyHstry.htm" class="LinkPage"&gt;Family History&lt;/a&gt; of diabetes (especially first degree relative)&lt;/li&gt;&lt;li&gt;High risk of ethnic group&lt;/li&gt;&lt;li&gt;Prior &lt;a href="../../Endo/OB/GstnlDbts.htm" class="LinkPage"&gt;Gestational Diabetes&lt;/a&gt; mellitus (or newborn &amp;gt;9 pounds)&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Htn/Hyprtnsn.htm" class="LinkPage"&gt;Hypertension&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Cardiovascular disease history&lt;/li&gt;&lt;li&gt;Dyslipidemia&lt;ol&gt;&lt;li&gt;&lt;a href="../../CV/Lab/HdlChlstrl.htm" class="LinkPage"&gt;HDL Cholesterol&lt;/a&gt; &amp;lt;35 and&lt;/li&gt;&lt;li&gt;Serum &lt;a href="../../CV/Lab/Trglycrd.htm" class="LinkPage"&gt;Triglyceride&lt;/a&gt;s &amp;gt;250 mg/dl&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;History of &lt;a href="../../Endo/DM/InslnRstncSyndrm.htm" class="LinkPage"&gt;Impaired Glucose Tolerance&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Polycystic ovarian syndrome (&lt;a href="../../Gyn/Endo/PlycystcOvryDs.htm" class="LinkPage"&gt;PCOS&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;Clinical findings suggestive of &lt;a href="../../Endo/DM/DbtsMlts.htm" class="LinkPage"&gt;Diabetes Mellitus&lt;/a&gt; (e.g. &lt;a href="../../Endo/Derm/AcnthsNgrcns.htm" class="LinkPage"&gt;Acanthosis Nigricans&lt;/a&gt;)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;Vail (2012) AAFP Board Review Express, San Jose&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Prevent/DbtsScrng.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Diabetes Screening</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Prevent/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Carbohydrate counting  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C1562940"&gt;&lt;i&gt;C1562940&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Health Care Activity (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C1562940&amp;amp;tui=T058"&gt;&lt;i&gt;T058&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;416576000&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Carbohydrate counting (regime/therapy), Carbohydrate counting&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;recuento de carbohidratos (régimen/tratamiento), recuento de carbohidratos, recuento de hidratos de carbono&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Carbohydrate counting  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Carbohydrate Count</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Prevention</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;See Also&lt;ol&gt;&lt;li&gt;&lt;a href="../../Pharm/Nutrition/GlycmcIndx.htm" class="LinkPage"&gt;Glycemic Index&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/CrbhydrtCntInInslnDsng.htm" class="LinkPage"&gt;Carbohydrate Count in Insulin Dosing&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;General&lt;ol&gt;&lt;li&gt;Total carbohydrate is most important&lt;ol&gt;&lt;li&gt;Source is not critical (sugar is no longer taboo)&lt;/li&gt;&lt;li&gt;All carbohydrates raise &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Sugar&lt;/a&gt; equally&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Balance and good nutrition is still needed&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Endo/Prevent/NtrtnInDbtsMlts.htm" class="LinkPage"&gt;Nutrition in Diabetes Mellitus&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Protocol: Basic Carbohydrate Counting&lt;ol&gt;&lt;li&gt;Each 15 gram serving of carbohydrate raises BG 50 mg/dl&lt;/li&gt;&lt;li&gt;Each meal has 3-4 carbohydrate servings (45-60 grams)&lt;ol&gt;&lt;li&gt;Weight loss needed&lt;ol&gt;&lt;li&gt;Women: 2-3 carbs/meal&lt;/li&gt;&lt;li&gt;Men: 3-4 carbs/meal&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Weight maintenance (1500-2000 cals)&lt;ol&gt;&lt;li&gt;Women: 3-4 carbs/meal&lt;/li&gt;&lt;li&gt;Men: 4-5 carbs/meal&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Very active&lt;ol&gt;&lt;li&gt;Women: 4-5 carbs/meal&lt;/li&gt;&lt;li&gt;Men: 4-6 carbs/meal&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Examples of 15 gram carbohydrate servings&lt;ol&gt;&lt;li&gt;One slice bread (1 oz)&lt;/li&gt;&lt;li&gt;One half cup peas&lt;/li&gt;&lt;li&gt;One cup squash&lt;/li&gt;&lt;li&gt;One half-cup potato&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Examples of foods with high carbohydrates counts&lt;ol&gt;&lt;li&gt;One 4 oz bagel is worth 4 carbohydrates (60 grams)&lt;/li&gt;&lt;li&gt;Low fat yogurt (8 oz), sweetened, fruit: 2-3 carbs&lt;/li&gt;&lt;li&gt;Bean burrito is worth 3 carbohydrates (45 grams)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Plate method (9 inch plate)&lt;ol&gt;&lt;li&gt;50% of plate can be carbohydrates&lt;ol&gt;&lt;li&gt;Grains, beans and starches&lt;/li&gt;&lt;li&gt;Milk and yogurt&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;25% of plate is composed of vegetables&lt;/li&gt;&lt;li&gt;25% of plate is composed of meat, fish, eggs, cheese&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Protocol: Carbohydrate Counting special topics&lt;ol&gt;&lt;li&gt;&lt;a href="../../Pharm/Nutrition/Fbr.htm" class="LinkPage"&gt;Fiber&lt;/a&gt; content&lt;ol&gt;&lt;li&gt;Subtract fiber carbohydrate grams if &amp;gt; 5 grams&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Pharm/Nutrition/GlycmcIndx.htm" class="LinkPage"&gt;Glycemic Index&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Some value, but all carbohydrates raise &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Sugar&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Low &lt;a href="../../Pharm/Nutrition/GlycmcIndx.htm" class="LinkPage"&gt;Glycemic Index&lt;/a&gt; diets lower &lt;a href="../../Endo/Lab/HmglbnAc.htm" class="LinkPage"&gt;Hemoglobin A1C&lt;/a&gt; by 0.4%&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Sugar &lt;a href="../../Psych/Pharm/Alchl.htm" class="LinkPage"&gt;Alcohol&lt;/a&gt;s (poor absorption)&lt;ol&gt;&lt;li&gt;Fewer calories than sugar (2 calories per gram)&lt;/li&gt;&lt;li&gt;GI upset if more than 10 grams in food item&lt;/li&gt;&lt;li&gt;Subtract 1/2 sugar &lt;a href="../../Psych/Pharm/Alchl.htm" class="LinkPage"&gt;Alcohol&lt;/a&gt; grams&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Psych/Pharm/Alchl.htm" class="LinkPage"&gt;Alcohol&lt;/a&gt; lowers &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Glucose&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Drink with food to prevent &lt;a href="../../Endo/Hypoglycemia/Hypglycm.htm" class="LinkPage"&gt;Hypoglycemia&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Links&lt;ol&gt;&lt;li&gt;Carbohydrate Counter&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.carbohydrate-counter.org" class="LinkWebExt"&gt;http://www.carbohydrate-counter.org&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Nutrition Facts and Calorie Counter&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.nutritiondata.com" class="LinkWebExt"&gt;http://www.nutritiondata.com&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Resources&lt;ol&gt;&lt;li&gt;Netzer (2000) Complete Book of Food Counts&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.amazon.com/exec/obidos/ASIN/%200440225639/familypracticeno" class="LinkBookStore"&gt;Paid link to Amazon.com (ISBN  0440225639)&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Borushek (2001) Doctors Pocket .. Carbohydrate Counter&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.amazon.com/exec/obidos/ASIN/%201930044804X/familypracticeno" class="LinkBookStore"&gt;Paid link to Amazon.com (ISBN  1930044804X)&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Holzmeister (2000) Diabetes Carbohydrate .. Gram Guide&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.amazon.com/exec/obidos/ASIN/%201580400507/familypracticeno" class="LinkBookStore"&gt;Paid link to Amazon.com (ISBN  1580400507)&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C1562940</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Prevent/CrbhydrtCnt.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Carbohydrate Count, Carbohydrate Counting</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Prevent/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees></FP_UMLS_Trees><FP_Condition_name_check></FP_Condition_name_check><FP_Condition_name><value>Nutrition in Diabetes Mellitus</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Prevention</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;See Also&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Prevent/CrbhydrtCnt.htm" class="LinkPage"&gt;Carbohydrate Count&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Prevent/NtrtnInDbtsMltsTyp.htm" class="LinkPage"&gt;Nutrition in Diabetes Mellitus Type I&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Prevent/NtrtnInDbtsMltsTyp1.htm" class="LinkPage"&gt;Nutrition in Diabetes Mellitus Type II&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Pearls&lt;ol&gt;&lt;li&gt;Omit sugar beverages (soda, energy drinks) and juices&lt;ol&gt;&lt;li&gt;Improves &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; control immediately&lt;/li&gt;&lt;li&gt;Use &lt;a href="../../Pharm/Nutrition/NnNtrtvSwtnr.htm" class="LinkPage"&gt;Non-nutritive Sweetener&lt;/a&gt;s in drinks or water&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Avoid skipping meals (3) and planned snacks (2)&lt;ol&gt;&lt;li&gt;Increases &lt;a href="../../Endo/Hypoglycemia/Hypglycm.htm" class="LinkPage"&gt;Hypoglycemia&lt;/a&gt; risk&lt;/li&gt;&lt;li&gt;Increases baseline hepatic &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; output&lt;/li&gt;&lt;li&gt;Appetite becomes dysregulated&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Additional points&lt;ol&gt;&lt;li&gt;No set ADA diet&lt;/li&gt;&lt;li&gt;No set caloric restriction&lt;/li&gt;&lt;li&gt;Modify on an individual basis&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Protein&lt;ol&gt;&lt;li&gt;No Nephropathy&lt;ol&gt;&lt;li&gt;Same intake as general population&lt;/li&gt;&lt;li&gt;Percent of calories per day: 10-20%&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Nephropathy&lt;ol&gt;&lt;li&gt;Normal GFR: &amp;lt;0.8 grams/kg/day Protein&lt;/li&gt;&lt;li&gt;Falling GFR: &amp;lt;0.6g/kg/day Protein&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Carbohydrates&lt;ol&gt;&lt;li&gt;Complex carbohydrates are generally preferred&lt;/li&gt;&lt;li&gt;Simple carbohydrates (fruit juice, sucrose)&lt;ol&gt;&lt;li&gt;Limit to occasional treats&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Nutritive sweeteners (Fructose)&lt;ol&gt;&lt;li&gt;No benefit&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Pharm/Nutrition/NnNtrtvSwtnr.htm" class="LinkPage"&gt;Non-nutritive Sweetener&lt;/a&gt;s (&lt;a href="../../Pharm/Nutrition/NnNtrtvSwtnr.htm" class="LinkPage"&gt;Aspartame&lt;/a&gt;, &lt;a href="../../Pharm/Nutrition/NnNtrtvSwtnr.htm" class="LinkPage"&gt;Acesulfame-K&lt;/a&gt;)&lt;ol&gt;&lt;li&gt;Safety confirmed&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;
              &lt;a href="../../Pharm/Nutrition/Fbr.htm" class="LinkPage"&gt;Fiber&lt;/a&gt;
              &lt;ol&gt;&lt;li&gt;Same recommendations as general population&lt;/li&gt;
              &lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Fat&lt;ol&gt;&lt;li&gt;First Priority: &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Sugar&lt;/a&gt; control&lt;/li&gt;&lt;li&gt;Second Priority: Weight control&lt;/li&gt;&lt;li&gt;Third Priority: Dietary changes&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;
              &lt;a href="../../Psych/Pharm/Alchl.htm" class="LinkPage"&gt;Alcohol&lt;/a&gt;
              &lt;ol&gt;&lt;li&gt;Limit to 2 drinks per day&lt;/li&gt;
                &lt;li&gt;Risk of &lt;a href="../../Endo/Hypoglycemia/Hypglycm.htm" class="LinkPage"&gt;Hypoglycemia&lt;/a&gt; if &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; taken and fasting&lt;/li&gt;
              &lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Prevent/NtrtnInDbtsMlts.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Nutrition in Diabetes Mellitus</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Prevent/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees></FP_UMLS_Trees><FP_Condition_name_check></FP_Condition_name_check><FP_Condition_name><value>Diabetic Foot Care</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Prevention</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;See Also&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/DM/DbtsMlts.htm" class="LinkPage"&gt;Diabetes Mellitus&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Surgery/Derm/FtWnd.htm" class="LinkPage"&gt;Foot Wound&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Complications: &lt;a href="../../Endo/DM/DbtsMlts.htm" class="LinkPage"&gt;Diabetes Mellitus&lt;/a&gt;&lt;a href="../../Ortho/Anatomy/FtAntmy.htm" class="LinkPage"&gt;Foot&lt;/a&gt; conditions&lt;ol&gt;&lt;li&gt;&lt;a href="../../Surgery/Derm/FtWnd.htm" class="LinkPage"&gt;Foot Wound&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Rheum/Neuro/ChrctFt.htm" class="LinkPage"&gt;Charcot Foot&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Neuro/DbtcNrpthy.htm" class="LinkPage"&gt;Diabetic Neuropathy&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;General &lt;a href="../../Ortho/Anatomy/FtAntmy.htm" class="LinkPage"&gt;Foot&lt;/a&gt; Care&lt;ol&gt;&lt;li&gt;Self foot exam daily&lt;/li&gt;&lt;li&gt;&lt;a href="../../Ortho/Anatomy/FtAntmy.htm" class="LinkPage"&gt;Foot&lt;/a&gt; examined regularly at physician visits&lt;ol&gt;&lt;li&gt;Perform &lt;a href="../../Neuro/Exam/DbtcNrpthyTstng.htm" class="LinkPage"&gt;Peripheral Neuropathy Testing&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Check for pedal pulses&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Evaluate and aggressively treat new &lt;a href="../../Surgery/Derm/FtWnd.htm" class="LinkPage"&gt;Foot Wound&lt;/a&gt;s&lt;/li&gt;&lt;li&gt;Avoid foot trauma&lt;ol&gt;&lt;li&gt;Do not walk barefoot&lt;/li&gt;&lt;li&gt;Cut nails carefully&lt;/li&gt;&lt;li&gt;Avoid excessive heat or chemicals&lt;ol&gt;&lt;li&gt;Avoid hydrogen peroxide&lt;/li&gt;&lt;li&gt;Avoid iodine&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Shoe selection and modifications&lt;ol&gt;&lt;li&gt;Obtain well-cushioned walking shoes&lt;/li&gt;&lt;li&gt;Shoes should have adequate room in toe box&lt;/li&gt;&lt;li&gt;Consider custom molded shoes&lt;/li&gt;&lt;li&gt;Break in a new shoe gradually&lt;/li&gt;&lt;li&gt;Reduce pressure points&lt;ol&gt;&lt;li&gt;Cushioned insole&lt;/li&gt;&lt;li&gt;Custom &lt;a href="../../Ortho/Procedure/Orthtc.htm" class="LinkPage"&gt;Orthotic&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Consider corrective foot surgery for deformities&lt;ol&gt;&lt;li&gt;&lt;a href="../../Ortho/Foot/HmrT.htm" class="LinkPage"&gt;Hammertoe&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Ortho/Anatomy/Mtrsl.htm" class="LinkPage"&gt;Metatarsal&lt;/a&gt; head resection&lt;/li&gt;&lt;li&gt;Achilles tendon lengthening&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Frykberg%20%20%5BAU%5D%20AND%202002%20%5BDP%5D%20AND%20%20Am%20Fam%20Physician%20%20%5BTA%5D" class="LinkRef"&gt;Frykberg (2002) Am Fam Physician 66(9):1655-62&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Frykberg%20%20%5BAU%5D%20AND%202000%20%5BDP%5D%20AND%20%20J%20Foot%20Ankle%20Surg%20%20%5BTA%5D" class="LinkRef"&gt;Frykberg (2000) J Foot Ankle Surg 39:S46&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Prevent/DbtcFtCr.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Diabetic Foot Care, Amputation Prevention in Diabetes Mellitus, Foot Wound Prevention</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Prevent/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees></FP_UMLS_Trees><FP_Condition_name_check></FP_Condition_name_check><FP_Condition_name><value>Failure to Thrive Evaluation</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Pediatrics</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;See Also&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Growth/ShrtStr.htm" class="LinkPage"&gt;Delayed Growth&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Peds/FlrTThrv.htm" class="LinkPage"&gt;Failure to Thrive&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Peds/FlrTThrvCs.htm" class="LinkPage"&gt;Failure to Thrive Causes&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Peds/FlrTThrvDgns.htm" class="LinkPage"&gt;Failure to Thrive Diagnosis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Peds/FlrTThrvRdFlgs.htm" class="LinkPage"&gt;Failure to Thrive Red Flags&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Peds/FlrTThrvMngmnt.htm" class="LinkPage"&gt;Failure to Thrive Management&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Evaluation: Step 1 - Review Growth Patterns&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Endo/Growth/GrwthAssmnt.htm" class="LinkPage"&gt;Growth Assessment&lt;/a&gt;&lt;/li&gt;&lt;li&gt;See &lt;a href="../../Endo/Exam/HghtMsrmntInChldrn.htm" class="LinkPage"&gt;Height Measurement in Children&lt;/a&gt;&lt;/li&gt;&lt;li&gt;See &lt;a href="../../Endo/Exam/WghtMsrmntInChldrn.htm" class="LinkPage"&gt;Weight Measurement in Children&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../NICU/Exam/HdCrcmfrnc.htm" class="LinkPage"&gt;Head Circumference&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Expected Weight gain (g/day)&lt;ol&gt;&lt;li&gt;Age 0 to 3 months: 26-31 grams weight gained per day&lt;/li&gt;&lt;li&gt;Age 3 to 9 months: 13-18 grams weight gained per day&lt;/li&gt;&lt;li&gt;Age 9 to 14 months: 10-11 grams weight per day&lt;/li&gt;&lt;li&gt;Age 15 to 24 months: 7-9 grams weight per day&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Plot weight, height and &lt;a href="../../NICU/Exam/HdCrcmfrnc.htm" class="LinkPage"&gt;Head Circumference&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Correct premature infant gestational age (&amp;lt;24 months)&lt;/li&gt;&lt;li&gt;35% of &lt;a href="../../OB/Fetus/IntrtrnGrwthRtrdtn.htm" class="LinkPage"&gt;Small for Gestational Age&lt;/a&gt; infants &amp;lt;5% at age 4&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Evaluation: Step 2- Determine if &lt;a href="../../Endo/Peds/FlrTThrv.htm" class="LinkPage"&gt;Failure to Thrive&lt;/a&gt; is present and to what degree&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Endo/Peds/FlrTThrvDgns.htm" class="LinkPage"&gt;Failure to Thrive Diagnosis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;See &lt;a href="../../Endo/Peds/FlrTThrvRdFlgs.htm" class="LinkPage"&gt;Failure to Thrive Red Flags&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Evaluation below is in light of distinguishing &lt;a href="../../Endo/Peds/FlrTThrvCs.htm" class="LinkPage"&gt;Failure to Thrive Causes&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;History: Nutrition&lt;ol&gt;&lt;li&gt;Dietary intake&lt;ol&gt;&lt;li&gt;Consider detailed 1-3 day diary of dietary intake&lt;/li&gt;&lt;li&gt;Quality and Quantity of food&lt;/li&gt;&lt;li&gt;Does the child feed themself (e.g. spoon, cup)&lt;/li&gt;&lt;li&gt;Psychosocial events around feeding time&lt;ol&gt;&lt;li&gt;Is the child distracted or not supervised?&lt;/li&gt;&lt;li&gt;Are there food battles or food refusal?&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Discuss food preparation (e.g. formula too dilute)&lt;/li&gt;&lt;li&gt;Beverages (e.g. Milk, juice, water, soda)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../GI/Exam/Dfctn.htm" class="LinkPage"&gt;Stool&lt;/a&gt; habits (e.g. frequency and consistency)&lt;/li&gt;&lt;li&gt;Consider dietary or nutrition consultation&lt;/li&gt;&lt;li&gt;&lt;a href="../../HemeOnc/Sx/Pc2.htm" class="LinkPage"&gt;Pica&lt;/a&gt; history&lt;/li&gt;&lt;li&gt;Nursing or &lt;a href="../../OB/Lactation/BrstFdng.htm" class="LinkPage"&gt;Breast Feeding&lt;/a&gt; history&lt;ol&gt;&lt;li&gt;Infequent brief feedings&lt;/li&gt;&lt;li&gt;Maternal ingestion of milk suppressant&lt;ol&gt;&lt;li&gt;&lt;a href="../../Psych/Pharm/Alchl.htm" class="LinkPage"&gt;Alcohol&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Pharm/Drtc.htm" class="LinkPage"&gt;Diuretic&lt;/a&gt;s&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Inadequate milk supply&lt;/li&gt;&lt;li&gt;Nipple problems&lt;/li&gt;&lt;li&gt;Inadequate milk let down&lt;/li&gt;&lt;li&gt;Poor suck&lt;/li&gt;&lt;li&gt;Maternal malnutrition&lt;/li&gt;&lt;li&gt;Maternal exhaustion or &lt;a href="../../Psych/Depress/MjrDprsn.htm" class="LinkPage"&gt;Major Depression&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;History: Social&lt;ol&gt;&lt;li&gt;Interference with adequate caretaking&lt;/li&gt;&lt;li&gt;Risk factors&lt;ol&gt;&lt;li&gt;Economic stress&lt;/li&gt;&lt;li&gt;Disorganized family&lt;/li&gt;&lt;li&gt;Social isolation&lt;/li&gt;&lt;li&gt;Parental depression&lt;/li&gt;&lt;li&gt;History of parent loss&lt;/li&gt;&lt;li&gt;Overworked parent&lt;/li&gt;&lt;li&gt;&lt;a href="../../Psych/CD/AlchlAbs.htm" class="LinkPage"&gt;Alcohol Abuse&lt;/a&gt; or &lt;a href="../../Psych/CD/ChmclDpndncy.htm" class="LinkPage"&gt;Drug Abuse&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Consider physical, psychological or marital problems&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;History: Past Medical&lt;ol&gt;&lt;li&gt;Birth: Gestational age, birth weight, complications&lt;/li&gt;&lt;li&gt;Chronic medical conditions (e.g. &lt;a href="../../HemeOnc/Anemia/Anm.htm" class="LinkPage"&gt;Anemia&lt;/a&gt;, &lt;a href="../../Lung/Asthma/Asthm.htm" class="LinkPage"&gt;Asthma&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;Acute illness (&lt;a href="../../ENT/Ear/OtsMd.htm" class="LinkPage"&gt;Otitis Media&lt;/a&gt;, &lt;a href="../../GI/Diarrhea/ActDrh.htm" class="LinkPage"&gt;Gastroenteritis&lt;/a&gt;)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;History: Family&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Growth/ShrtStr.htm" class="LinkPage"&gt;Short Stature&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Peds/FlrTThrv.htm" class="LinkPage"&gt;Failure to Thrive&lt;/a&gt; in siblings&lt;/li&gt;&lt;li&gt;Mental illness&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Exam: Observe interaction between parent and child&lt;ol&gt;&lt;li&gt;Feeding and non-feeding times&lt;/li&gt;&lt;li&gt;Decreased, inconsistent, or nonmutual interactions&lt;/li&gt;&lt;li&gt;Maladaptive parent-child feeding interactions&lt;/li&gt;&lt;li&gt;Consider 10-14 day observation in hospital&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Exam: Assess for developmental delay&lt;ol&gt;&lt;li&gt;Gross Motor function from neuromuscular weakness&lt;/li&gt;&lt;li&gt;Social skills and Expressive Language&lt;ol&gt;&lt;li&gt;Gaze avoidance&lt;/li&gt;&lt;li&gt;Minimal smiling&lt;/li&gt;&lt;li&gt;Non-responsive to people&lt;/li&gt;&lt;li&gt;Inappropriately friendly to strangers&lt;/li&gt;&lt;li&gt;Bizarre behavior&lt;/li&gt;&lt;li&gt;Apathy&lt;/li&gt;&lt;li&gt;Poor hygiene&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Exam: Complete Physical&lt;ol&gt;&lt;li&gt;Decrease in skin fold thickness and Subcutaneous fat&lt;ol&gt;&lt;li&gt;Suggests malnutrition&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Exam/DysmrphcFtrsInCngntlDysrdrs.htm" class="LinkPage"&gt;Dysmorphic features in Congenital Dysorders&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Focus on evaluation for &lt;a href="../../Endo/Peds/FlrTThrvRdFlgs.htm" class="LinkPage"&gt;Failure to Thrive Red Flags&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Identify findings suggestive of physical abuse or neglect&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Labs&lt;ol&gt;&lt;li&gt;Indications&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Peds/FlrTThrvRdFlgs.htm" class="LinkPage"&gt;Failure to Thrive Red Flags&lt;/a&gt; are present&lt;/li&gt;&lt;li&gt;Refractory course despite adequate caloric replacement&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Efficacy&lt;ol&gt;&lt;li&gt;Normal in 98% of &lt;a href="../../Endo/Peds/FlrTThrv.htm" class="LinkPage"&gt;Failure to Thrive&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Consider obtaining only if no improvement&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Sills%20%20%5BAU%5D%20AND%201978%20%5BDP%5D%20AND%20%20Am%20J%20Dis%20Child%20%20%5BTA%5D" class="LinkRef"&gt;Sills (1978) Am J Dis Child 132:967-9&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Initial labs&lt;ol&gt;&lt;li&gt;&lt;a href="../../Uro/Lab/Urnlys.htm" class="LinkPage"&gt;Urinalysis&lt;/a&gt; and &lt;a href="../../Uro/Lab/UrnCltr.htm" class="LinkPage"&gt;Urine Culture&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Serum Comprehensive Metabolic Panel (electrolytes, &lt;a href="../../Renal/Lab/RnlFnctn.htm" class="LinkPage"&gt;Renal Function&lt;/a&gt; tests, &lt;a href="../../GI/Lab/LvrFnctnTst.htm" class="LinkPage"&gt;Liver Function Test&lt;/a&gt;s)&lt;/li&gt;&lt;li&gt;&lt;a href="../../HemeOnc/Lab/CmpltBldCnt.htm" class="LinkPage"&gt;Complete Blood Count&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/ThyrdFnctnTst.htm" class="LinkPage"&gt;Thyroid Function Test&lt;/a&gt;s&lt;/li&gt;&lt;li&gt;&lt;a href="../../HemeOnc/Lab/ErythrcytSdmntnRt.htm" class="LinkPage"&gt;Erythrocyte Sedimentation Rate&lt;/a&gt; (ESR) or &lt;a href="../../HemeOnc/Lab/CRctvPrtn.htm" class="LinkPage"&gt;C-Reactive Protein&lt;/a&gt; (C-RP)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Specific Labs if indicated by history and physical&lt;ol&gt;&lt;li&gt;&lt;a href="../../GI/Exam/Dfctn.htm" class="LinkPage"&gt;Stool&lt;/a&gt; for fat content&lt;/li&gt;&lt;li&gt;&lt;a href="../../GI/Exam/Dfctn.htm" class="LinkPage"&gt;Stool&lt;/a&gt; for &lt;a href="../../GI/Lab/PrstExmntnOfThStl.htm" class="LinkPage"&gt;Ova and Parasite&lt;/a&gt;s&lt;/li&gt;&lt;li&gt;Serum complement levels&lt;/li&gt;&lt;li&gt;&lt;a href="../../ID/Exam/Imnglbln.htm" class="LinkPage"&gt;Immunoglobulin&lt;/a&gt; levels&lt;/li&gt;&lt;li&gt;&lt;a href="../../Renal/Lab/SrmClcm.htm" class="LinkPage"&gt;Serum Calcium&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Seum Phosphate&lt;/li&gt;&lt;li&gt;&lt;a href="../../GI/Lab/SrmAlbmn.htm" class="LinkPage"&gt;Serum Albumin&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Pharm/Vitamins/BtCrtn.htm" class="LinkPage"&gt;Beta Carotene&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Rad/TrnsthrcEchcrdgrm.htm" class="LinkPage"&gt;Echocardiogram&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../HIV/Lab/HvTst.htm" class="LinkPage"&gt;HIV Test&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../GI/Lab/HptsBSrlgy.htm" class="LinkPage"&gt;Hepatitis B Surface Antigen&lt;/a&gt;&lt;/li&gt;&lt;li&gt;PPD or Tb Quantiferon&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Imaging&lt;ol&gt;&lt;li&gt;Skeletal XRay of hands and wrist for bone age&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Peds/FlrTThrvEvltn.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Failure to Thrive Evaluation</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Peds/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Childhood obesity  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C2362324"&gt;&lt;i&gt;C2362324&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;Having a high amount of body fat during childhood.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (SNOMEDCT)&lt;/td&gt;
                &lt;td&gt;Body mass index at or above 95th percentile as compared to children of the same age and sex&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MEDLINEPLUS)&lt;/td&gt;
                &lt;td&gt;
                  &lt;span&gt;
                    &lt;p&gt;
                      &lt;a href="http://www.nlm.nih.gov/medlineplus/obesity.html"&gt;Obesity&lt;/a&gt; means having too much body fat. It is different from being overweight, which means weighing too much. Both terms mean that a person's weight is greater than what is considered healthy for his or her height.  Children grow at different rates, so it isn't always easy to know when a child is obese or overweight. Ask your doctor to measure your child's height and weight to determine if he or she is in a healthy range.&lt;/p&gt;
                    &lt;p&gt;If a weight loss program is necessary, involve the whole family in healthy habits so your child doesn't feel singled out. You can encourage healthy eating by serving more fruits and vegetables and buying fewer sodas and high-calorie, high-fat snack foods.  Physical activity can also help your child overcome obesity or being overweight. Kids need about 60 minutes each day. &lt;/p&gt;
                    &lt;p style="font-weight:bold;font-style:italic;"&gt;NIH: National Institute of Diabetes and Digestive and Kidney Diseases&lt;/p&gt;
                  &lt;/span&gt;
                &lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Disease or Syndrome (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C2362324&amp;amp;tui=T047"&gt;&lt;i&gt;T047&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;444862003&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Obesity in Children, Pediatric Obesity, Childhood obesity, Childhood obesity (disorder), Childhood Obesity&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;obesidad de la infancia (trastorno), obesidad infantil, obesidad de la infancia&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Childhood obesity  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Obesity in Children</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Pediatrics</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;See Also&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Obesity/Obsty.htm" class="LinkPage"&gt;Obesity&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Epidemiology&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Obesity/Obsty.htm" class="LinkPage"&gt;Overweight&lt;/a&gt; between age 2 to 19 in 2004: 17.1% (was 12% in 1994)&lt;/li&gt;&lt;li&gt;Number of obese children and adolescents in U.S. trippled between 1980 and 2000&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Causes: Secondary Causes of Childhood Obesity (&amp;lt;10% of cases)&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/Hypthyrdsm.htm" class="LinkPage"&gt;Hypothyroidism&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Adrenal/CshngsDs.htm" class="LinkPage"&gt;Cushing's Syndrome&lt;/a&gt; (Hypercortisolism)&lt;/li&gt;&lt;li&gt;Primary Hyperinsulinism&lt;/li&gt;&lt;li&gt;Pseudohypoparathyroidism&lt;/li&gt;&lt;li&gt;Hypothalamic abnormality&lt;/li&gt;&lt;li&gt;Genetic Syndromes with &lt;a href="../../Prevent/HME/HlthCrFrAdltsWthDvlpmntlDly.htm" class="LinkPage"&gt;Mental Retardation&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Peds/PrdrWlSyndrm.htm" class="LinkPage"&gt;Prader-Willi Syndrome&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Laurence-Moon or Bardet-Biedl Syndrome&lt;/li&gt;&lt;li&gt;Borjeson-Forssman-Lehmann Syndrome&lt;/li&gt;&lt;li&gt;Cohen Syndrome&lt;/li&gt;&lt;li&gt;Ruvalcaba Syndrome&lt;/li&gt;&lt;li&gt;Familial &lt;a href="../../HIV/Pharm/Lpdystrphy.htm" class="LinkPage"&gt;Lipodystrophy&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Genetic Syndromes without &lt;a href="../../Prevent/HME/HlthCrFrAdltsWthDvlpmntlDly.htm" class="LinkPage"&gt;Mental Retardation&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Alstrom Syndrome&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Sex/TrnrsSyndrm.htm" class="LinkPage"&gt;Turner's Syndrome&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Beckwith-Wiedemann Syndrome&lt;/li&gt;&lt;li&gt;Sotos' Syndrome (cognitive delay may be present)&lt;/li&gt;&lt;li&gt;Weaver Syndrome&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Risk Factors&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Obesity/ObstyRsk.htm" class="LinkPage"&gt;Obesity Risk&lt;/a&gt; increases with television viewing time&lt;ol&gt;&lt;li&gt;Lowest &lt;a href="../../Prevent/Epi/DsPrvlncRt.htm" class="LinkPage"&gt;Prevalence&lt;/a&gt; for &amp;lt;1 hour/day: 8% &lt;a href="../../Endo/Obesity/Obsty.htm" class="LinkPage"&gt;Obesity&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Highest &lt;a href="../../Prevent/Epi/DsPrvlncRt.htm" class="LinkPage"&gt;Prevalence&lt;/a&gt; for &amp;gt;4 hours/day: 17% &lt;a href="../../Endo/Obesity/Obsty.htm" class="LinkPage"&gt;Obesity&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Crespo%20%20%5BAU%5D%20AND%202001%20%5BDP%5D%20AND%20%20Arch%20Pediatr%20Adolesc%20Med%20%20%5BTA%5D" class="LinkRef"&gt;Crespo (2001) Arch Pediatr Adolesc Med 155:363&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Obesity/Obsty.htm" class="LinkPage"&gt;Obesity&lt;/a&gt; in child's parent&lt;/li&gt;&lt;li&gt;Decreased &lt;a href="../../Sports/Exercise/Exrcs.htm" class="LinkPage"&gt;Physical Activity&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../Sports/Exercise/Exrcs.htm" class="LinkPage"&gt;Physical Activity&lt;/a&gt; is inversely related to &lt;a href="../../Endo/Obesity/Obsty.htm" class="LinkPage"&gt;Obesity&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Evaluation&lt;ol&gt;&lt;li&gt;See &lt;a href="../../CV/Prevent/CrdcRsk.htm" class="LinkPage"&gt;Cardiac Risk Factor&lt;/a&gt;s&lt;/li&gt;&lt;li&gt;See &lt;a href="../../Endo/Exam/BdyMsIndx.htm" class="LinkPage"&gt;Body Mass Index&lt;/a&gt;&lt;/li&gt;&lt;li&gt;See &lt;a href="../../Endo/Exam/DlyEnrgyAlwnc.htm" class="LinkPage"&gt;Daily Energy Allowance&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Exam/BldPrsr.htm" class="LinkPage"&gt;Blood Pressure&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Labs&lt;ol&gt;&lt;li&gt;&lt;a href="../../CV/Lab/Lpd.htm" class="LinkPage"&gt;Lipid&lt;/a&gt; profile&lt;/li&gt;&lt;li&gt;Indications for suspected secondary cause evaluation&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Growth/ShrtStr.htm" class="LinkPage"&gt;Short Stature&lt;/a&gt; (&amp;lt;5th percentile)&lt;/li&gt;&lt;li&gt;Minimal to no &lt;a href="../../Prevent/HME/FmlyHstry.htm" class="LinkPage"&gt;Family History&lt;/a&gt; of &lt;a href="../../Endo/Obesity/Obsty.htm" class="LinkPage"&gt;Obesity&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Prevent/HME/HlthCrFrAdltsWthDvlpmntlDly.htm" class="LinkPage"&gt;Mental Retardation&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Delayed bone age&lt;/li&gt;&lt;li&gt;Physical findings suggest secondary cause&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Complications&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Endo/Obesity/ObstyRsk.htm" class="LinkPage"&gt;Obesity Risk&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Ortho/Peds/SlpdCptlFmrlEphys.htm" class="LinkPage"&gt;Slipped Capital Femoral Epiphysis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Tibia vara&lt;/li&gt;&lt;li&gt;Adult &lt;a href="../../Endo/Obesity/Obsty.htm" class="LinkPage"&gt;Obesity&lt;/a&gt; (high risk)&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Kvaavik%20%20%5BAU%5D%20AND%202003%20%5BDP%5D%20AND%20%20Arch%20Pediatr%20Adolesc%20Med%20%20%5BTA%5D" class="LinkRef"&gt;Kvaavik (2003) Arch Pediatr Adolesc Med 157:1212-18&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Associated Conditions&lt;ol&gt;&lt;li&gt;&lt;a href="../../CV/Htn/Hyprtnsn.htm" class="LinkPage"&gt;Hypertension&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/DM/DbtsMlts.htm" class="LinkPage"&gt;Diabetes Mellitus&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/DM/InslnRstncSyndrm.htm" class="LinkPage"&gt;Metabolic Syndrome&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Lipid/Hyprchlstrlm.htm" class="LinkPage"&gt;Hyperlipidemia&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Management&lt;ol&gt;&lt;li&gt;See Prevention measures below&lt;/li&gt;&lt;li&gt;Set reasonable weight loss goal&lt;ol&gt;&lt;li&gt;Monthly: 1 to 4 pound loss&lt;/li&gt;&lt;li&gt;Month 3 to 6: 5 to 10 pound loss&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Establish dietary guidelines&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Pharm/Nutrition/NtrtnGdlns.htm" class="LinkPage"&gt;Food Pyramid&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Calculate &lt;a href="../../Endo/Exam/DlyEnrgyAlwnc.htm" class="LinkPage"&gt;Daily Energy Allowance&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Approximate a 500 calorie deficit per day&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Establish regular &lt;a href="../../Sports/Exercise/Exrcs.htm" class="LinkPage"&gt;Exercise&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../Sports/Exercise/Exrcs.htm" class="LinkPage"&gt;Exercise&lt;/a&gt; in addition to school physical education&lt;/li&gt;&lt;li&gt;Home &lt;a href="../../Sports/Exercise/Exrcs.htm" class="LinkPage"&gt;Exercise&lt;/a&gt; for more than 30 minutes/day&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Psych/Exam/BhvrMdfctn.htm" class="LinkPage"&gt;Behavior Modification&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Stimulus control&lt;/li&gt;&lt;li&gt;Modify eating habits&lt;/li&gt;&lt;li&gt;Attitude change&lt;/li&gt;&lt;li&gt;Reward positive new behaviors&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Involve family in &lt;a href="../../Endo/Obesity/ObstyMngmnt.htm" class="LinkPage"&gt;Weight Reduction&lt;/a&gt; program&lt;ol&gt;&lt;li&gt;Parent nutritional counseling&lt;/li&gt;&lt;li&gt;Family activity&lt;/li&gt;&lt;li&gt;Family television viewing limited&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Prevention&lt;ol&gt;&lt;li&gt;Provide balanced diet (see &lt;a href="../../Pharm/Nutrition/NtrtnGdlns.htm" class="LinkPage"&gt;Food Pyramid&lt;/a&gt;)&lt;ol&gt;&lt;li&gt;Maximize child's &lt;a href="../../Pharm/Nutrition/Fbr.htm" class="LinkPage"&gt;Dietary Fiber&lt;/a&gt; intake&lt;/li&gt;&lt;li&gt;Eat 5 or more fruits and vegetables per day&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Eliminate excessive fat and sugars&lt;ol&gt;&lt;li&gt;Limit fat calories to &amp;lt;30% of total calories&lt;/li&gt;&lt;li&gt;Replace whole milk with skim milk at age 2 years&lt;/li&gt;&lt;li&gt;Avoid  fast-food and "junk-food" (e.g. potato-chips, twinkies)&lt;/li&gt;&lt;li&gt;Avoid sugar-sweetened drinks (e.g. Gatorade, soda, fruit drinks)&lt;/li&gt;&lt;li&gt;Limit high calorie foods in home&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Encourage healthy eating behaviors&lt;ol&gt;&lt;li&gt;Eat meals as a family at least 5 days per week&lt;/li&gt;&lt;li&gt;Limit eating out (esp. fast food restaurants)&lt;/li&gt;&lt;li&gt;Do not skip breakfast&lt;/li&gt;&lt;li&gt;Use appropriate food portions&lt;/li&gt;&lt;li&gt;Food should not be used to comfort or reward child&lt;/li&gt;&lt;li&gt;Treats should not be used to reward finishing a meal&lt;/li&gt;&lt;li&gt;Child does not need to "clean plate": stop with satiety&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Encourage activity&lt;ol&gt;&lt;li&gt;Limit television, computer and video games to 2 hour or less per day&lt;/li&gt;&lt;li&gt;Do not keep a television in the child's room&lt;/li&gt;&lt;li&gt;Foster active play and family &lt;a href="../../Sports/Exercise/Exrcs.htm" class="LinkPage"&gt;Exercise&lt;/a&gt; for &amp;gt;30-60 minutes per day&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Resources&lt;ol&gt;&lt;li&gt;Shapedown Pediatric &lt;a href="../../Endo/Obesity/Obsty.htm" class="LinkPage"&gt;Obesity&lt;/a&gt; Program (Ages 6 to 20)&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.shapedown.com" class="LinkWebExt"&gt;http://www.shapedown.com&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Phone: 415-453-8886&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Children's Hospital of Pittsburgh&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.chp.edu/clinical/03a_weightmanage.php" class="LinkWebExt"&gt;http://www.chp.edu/clinical/03a_weightmanage.php&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;Kreipe (1998) &lt;a href="../../Peds/Teen/AdlscntHlth.htm" class="LinkPage"&gt;Adolescent Health&lt;/a&gt; Update 10(2):1-8&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Moran%20%20%5BAU%5D%20AND%201999%20%5BDP%5D%20AND%20%20Am%20Fam%20Physician%20%20%5BTA%5D" class="LinkRef"&gt;Moran (1999) Am Fam Physician 59(4):861-8&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Rao%20%20%5BAU%5D%20AND%202008%20%5BDP%5D%20AND%20%20Am%20Fam%20Physician%20%20%5BTA%5D" class="LinkRef"&gt;Rao (2008) Am Fam Physician 78(1): 56-66&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Spiotta%20%20%5BAU%5D%20AND%202008%20%5BDP%5D%20AND%20%20Am%20Fam%20Physician%20%20%5BTA%5D" class="LinkRef"&gt;Spiotta (2008) Am Fam Physician 78(9): 1052-8&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Williams%20%20%5BAU%5D%20AND%201997%20%5BDP%5D%20AND%20%20Ann%20N%20Y%20Acad%20Sci%20%20%5BTA%5D" class="LinkRef"&gt;Williams (1997) Ann N Y Acad Sci 817:225-40&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C2362324</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Peds/ObstyInChldrn.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Obesity in Children, Childhood Obesity</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Peds/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees></FP_UMLS_Trees><FP_Condition_name_check></FP_Condition_name_check><FP_Condition_name><value>Failure to Thrive Diagnosis</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Pediatrics</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;See Also&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Growth/ShrtStr.htm" class="LinkPage"&gt;Delayed Growth&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Peds/FlrTThrv.htm" class="LinkPage"&gt;Failure to Thrive&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Peds/FlrTThrvCs.htm" class="LinkPage"&gt;Failure to Thrive Causes&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Peds/FlrTThrvRdFlgs.htm" class="LinkPage"&gt;Failure to Thrive Red Flags&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Peds/FlrTThrvEvltn.htm" class="LinkPage"&gt;Failure to Thrive Evaluation&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Peds/FlrTThrvMngmnt.htm" class="LinkPage"&gt;Failure to Thrive Management&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Precautions&lt;ol&gt;&lt;li&gt;Defining whether a child's growth is normal is difficult due to conflicting guidelines and growth curves&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Evaluation: Initial Criteria (expect false positives)&lt;ol&gt;&lt;li&gt;Weight for age &amp;lt;5th percentile (or BMI for age &amp;lt;5th percentile)&lt;/li&gt;&lt;li&gt;Weight deceleration that crosses 2 or more major percentile lines&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Evaluation: Re-evaluate growth in relation to normal modifiers of growth pattern&lt;ol&gt;&lt;li&gt;Growth may be adequate for genetic predisposition or &lt;a href="../../OB/Lactation/BrstFdng.htm" class="LinkPage"&gt;Breast Feeding&lt;/a&gt; versus &lt;a href="../../Pharm/NICU/FrmlFdng.htm" class="LinkPage"&gt;Bottle Feeding&lt;/a&gt;&lt;ol&gt;&lt;li&gt;See Resources under &lt;a href="../../Endo/Exam/WghtMsrmntInChldrn.htm" class="LinkPage"&gt;Weight Measurement in Children&lt;/a&gt; (particular attention to WHO growth curves)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Interpret trends (3rd percentile may be normal if always following 3rd percentile)&lt;/li&gt;&lt;li&gt;Consider using modified growth charts&lt;ol&gt;&lt;li&gt;Prematurity&lt;/li&gt;&lt;li&gt;Ethnicity&lt;/li&gt;&lt;li&gt;Down's Syndrome&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Evaluation: Further evaluate with most specific indicators of abnormal growth&lt;ol&gt;&lt;li&gt;Weight &amp;lt;75% of median &lt;a href="../../Endo/Exam/WghtFrLngth.htm" class="LinkPage"&gt;Weight for Length&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Exam/WghtVlcty.htm" class="LinkPage"&gt;Weight Velocity&lt;/a&gt; &amp;lt;5th percentile&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Olsen%20%20%5BAU%5D%20AND%202007%20%5BDP%5D%20AND%20%20Arch%20Dis%20Child%20%20%5BTA%5D" class="LinkRef"&gt;Olsen (2007) Arch Dis Child 92(2): 109-14&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Peds/FlrTThrvDgns.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Failure to Thrive Diagnosis</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Peds/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees></FP_UMLS_Trees><FP_Condition_name_check></FP_Condition_name_check><FP_Condition_name><value>Failure to Thrive Management</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Pediatrics</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;See Also&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Growth/ShrtStr.htm" class="LinkPage"&gt;Delayed Growth&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Peds/FlrTThrv.htm" class="LinkPage"&gt;Failure to Thrive&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Peds/FlrTThrvCs.htm" class="LinkPage"&gt;Failure to Thrive Causes&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Peds/FlrTThrvDgns.htm" class="LinkPage"&gt;Failure to Thrive Diagnosis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Peds/FlrTThrvRdFlgs.htm" class="LinkPage"&gt;Failure to Thrive Red Flags&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Peds/FlrTThrvEvltn.htm" class="LinkPage"&gt;Failure to Thrive Evaluation&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Management: Calories required for catch-up&lt;ol&gt;&lt;li&gt;Children with FTT require 150% of RDA of calories&lt;/li&gt;&lt;li&gt;Schedule: Replacement calories needed per day&lt;ol&gt;&lt;li&gt;Kg based on expected weight&lt;/li&gt;&lt;li&gt;Age 2-4 weeks: 120 KCal/kg/day&lt;/li&gt;&lt;li&gt;Age 1-2 months: 115 KCal/kg/day&lt;/li&gt;&lt;li&gt;Age 2-3 months: 105 KCal/kg/day&lt;/li&gt;&lt;li&gt;Age 3-6 months: 95 KCal/kg/day&lt;/li&gt;&lt;li&gt;Age 6 months to 5 years: 90 KCal/kg/day&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Formula: Replacement calories needed per day&lt;ol&gt;&lt;li&gt;KCals/kg = (120 kcal/kg x (Normal kg)) / (current kg)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Management: Dietary&lt;ol&gt;&lt;li&gt;Dietician consultation&lt;/li&gt;&lt;li&gt;General&lt;ol&gt;&lt;li&gt;Stop solids less in calories/ounce than formula, milk&lt;/li&gt;&lt;li&gt;Limit fruit juice to &amp;lt;8 ounces per day&lt;/li&gt;&lt;li&gt;Consider &lt;a href="../../Pharm/Nutrition/EntrlNtrtn.htm" class="LinkPage"&gt;Nutritional Supplement&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Take daily multivitamin&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Gyn/Anatomy/BrstAntmy.htm" class="LinkPage"&gt;Breast&lt;/a&gt;-fed infants&lt;ol&gt;&lt;li&gt;See &lt;a href="../../OB/Lactation/BrstFdngTchnq.htm" class="LinkPage"&gt;Breast Feeding Technique&lt;/a&gt;&lt;/li&gt;&lt;li&gt;See &lt;a href="../../OB/Lactation/BrstFdngPrblmsFrThInfnt.htm" class="LinkPage"&gt;Breast Feeding Problems for the Infant&lt;/a&gt;&lt;/li&gt;&lt;li&gt;See &lt;a href="../../OB/Lactation/BrstFdngPrblmsFrThMthr.htm" class="LinkPage"&gt;Breast Feeding Problems for the Mother&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Obtain &lt;a href="../../OB/Lactation/BrstFdng.htm" class="LinkPage"&gt;Lactation&lt;/a&gt; consultation&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Bottle fed infants&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Pharm/NICU/InfntFdng.htm" class="LinkPage"&gt;Infant Feeding&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Use 22 calorie per ounce formula (and prepare as energy dense formula with less water)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Toddlers and younger children&lt;ol&gt;&lt;li&gt;Add rice cereal, cheese, and peanut butter to foods to increase calorie intake&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Older children&lt;ol&gt;&lt;li&gt;Add gravies, sauces, butter to foods to increase calorie intake&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Management: Behavioral&lt;ol&gt;&lt;li&gt;Involve parents actively in evaluation and management&lt;ol&gt;&lt;li&gt;Helps with frustration and guilt of &lt;a href="../../Endo/Peds/FlrTThrv.htm" class="LinkPage"&gt;Failure to Thrive&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Surgery/Pharm/HydrcldDrsng.htm" class="LinkPage"&gt;Restore&lt;/a&gt; adequate caretaking&lt;/li&gt;&lt;li&gt;Modify maladaptive learned feeding responses&lt;ol&gt;&lt;li&gt;Behavioral and Family Treatment&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Address interactional difficulties with parents&lt;/li&gt;&lt;li&gt;Consider Psychiatric and  Social Services&lt;/li&gt;&lt;li&gt;Developmental Stimulation&lt;ol&gt;&lt;li&gt;Community infant-stimulation programs&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Monitoring&lt;ol&gt;&lt;li&gt;Close, weekly pediatric follow-up&lt;/li&gt;&lt;li&gt;Hospitalization indicated in severe or refractory cases&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;Bauchner in Behrman (2000) Nelson Pediatrics, p. 120-1&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Krugman%20%20%5BAU%5D%20AND%202003%20%5BDP%5D%20AND%20%20Am%20Fam%20Physician%20%20%5BTA%5D" class="LinkRef"&gt;Krugman (2003) Am Fam Physician 68(5)?879-886&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Maggioni%20%20%5BAU%5D%20AND%201995%20%5BDP%5D%20AND%20%20Pediatr%20Clin%20North%20Am%20%20%5BTA%5D" class="LinkRef"&gt;Maggioni (1995) Pediatr Clin North Am 42(4):791-810&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Peds/FlrTThrvMngmnt.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Failure to Thrive Management</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Peds/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Glycogen Storage Disease  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0017919"&gt;&lt;i&gt;C0017919&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;An inherited metabolic disorder characterized either by defects in glycogen synthesis or defects in the breaking down of glycogen. It results either in the creation of abnormal forms of glycogen or accumulation of glycogen in the tissues.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CSP)&lt;/td&gt;
                &lt;td&gt;any of a group of metabolic disorders characterized by excessive storage of glycogen.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;A group of inherited metabolic disorders involving the enzymes responsible for the synthesis and degradation of glycogen. In some patients, prominent liver involvement is presented. In others, more generalized storage of glycogen occurs, sometimes with prominent cardiac involvement.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Disease or Syndrome (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0017919&amp;amp;tui=T047"&gt;&lt;i&gt;T047&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D006008&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD9&lt;/td&gt;
                &lt;td&gt;271.0&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD10&lt;/td&gt;
                &lt;td&gt;E74.0, E74.00&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;190744005, 29633007, 154738008, 267498002&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Diseases, Glycogen Storage, Glycogen Storage Disease, Glycogen Storage Diseases, Glycogenoses, Glycogenosis, Storage Disease, Glycogen, Storage Diseases, Glycogen, Disease, Glycogen Storage, Glycogen storage disease, NOS, Glycogenosis, NOS, Glycogenosis NOS, GLYCOGEN STORAGE DIS, glycogen storage disease, glycogen storage disease (diagnosis), Glycogen storage disorder NOS, Glycogenosis NOS (disorder), Glycogen storage disease, unspecified, Glycogen Storage Disease [Disease/Finding], disorders glycogen storage, glycogen storage disorder, glycogen storage diseases, disease glycogen storage, diseases glycogen storage, glycogenoses, glycogenose, Glycogen storage disorder, Glycogen storage disease, GSD - Glycogen storage disease, Glycogen storage disease (disorder), glycogenosis, Gierke, glycogen storage; disease, liver; disease, glycogen storage (etiology), liver; disease, glycogen storage (manifestation), storage disease; glycogen, thesaurismosis; glycogen&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;glycogeenopslagstoornis NAO, glycogenosen, glycogenose, glycogeen; stapelingsziekte, lever; aandoening, glycogeenstapeling, stapelingsziekte; glycogeen, thesaurismose; glycogeen, glycogeenopslagstoornis, Glucogenose, Glycogeenstapelingsziekte, Ziekte, glycogeenstapelings-&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Glycogénoses, Glycogénose SAI, Glycogénose, Maladie glycogénique&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Glykogenosen, Glykogenspeicherstoerung NNB, Glykogenspeicherkrankheit [Glykogenose], Glykogenspeicherstoerung, Glykogenose, Glykogenspeicherkrankheit&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Glicogenosi NAS, Malattia da accumulo di glicogeno, Glicogenosi&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Glicogenoses, Glicogenose NE, Doença do Armazenamento de Glicogênio, Glicogenose, Doença de Depósito de Glicogênio&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;Trastorno del almacenamiento del glucógeno NEOM, Glicogenosis, Glycogen storage disease, enfermedad por almacenamiento de glucógeno, glucogenosis (trastorno), glucogenosis, SAI (trastorno), glucogenosis, SAI, glucogenosis, Trastorno del almacenamiento del glucógeno, Enfermedad del Almacenamiento de Glucógeno, Glucogenosis, Enfermedad del Almacenamiento de Glucogeno&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;糖原病ＮＯＳ, ﾄｳｹﾞﾝﾋﾞｮｳNOS, ﾄｳｹﾞﾝﾋﾞｮｳ, 糖原病, グリコーゲン蓄積症, 糖原症, 糖原貯蔵症, グリコゲン貯蔵病, グリコーゲン病&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Glykogenupplagringssjukdom&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;glykogen - nemoc z ukládání, Porucha ukládání glykogenu, Glykogenóza, Glykogenóza NOS, Glykogenózy&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Glykogenoosi&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;GLIKOGENA NAKOPLENIIA BOLEZN', GLIKOGENOZ, GLIKOGENOVAIA BOLEZN', GLIKOGENOZY, ГЛИКОГЕНА НАКОПЛЕНИЯ БОЛЕЗНЬ, ГЛИКОГЕНОВАЯ БОЛЕЗНЬ, ГЛИКОГЕНОЗ, ГЛИКОГЕНОЗЫ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Korean&lt;/td&gt;
                &lt;td&gt;당원 축적병&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Choroby spichrzania glikogenu, Glikogenozy&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;Glycogen tárolás betegség, Glycogenosis, Glycogen tárolás betegség k.m.n., ((glikogénraktározási betegségek))&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Lipid Metabolism Disorders  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0154251"&gt;&lt;i&gt;C0154251&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CSP)&lt;/td&gt;
                &lt;td&gt;condition in which there is a deviation or interruption in the processing of lipids in the body: synthesis, absorption, transport, storage, and utilization.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;Pathological conditions resulting from abnormal anabolism or catabolism of lipids in the body.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Disease or Syndrome (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0154251&amp;amp;tui=T047"&gt;&lt;i&gt;T047&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D052439&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD9&lt;/td&gt;
                &lt;td&gt;272.9, 272&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;190806008, 267431006, 190771005, 154739000, 267499005&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Unspecified disorder of lipoid metabolism, FAT DISORDER, LIPID METABOLISM DISORDER NOS, Disorder of Lipid Metabolism, Disorder of lipoid metabolism NOS, Lipoid metabolism disorder NOS, Lipid Metabolism Disorders, Lipid Metabolism Disorder, Metabolism Disorder, Lipid, Metabolism Disorders, Lipid, Disease of lipid metabolism, lipid disorder, Lipid Disorders, lipoid metabolism disorder (diagnosis), lipoid metabolism disorder, disorders of lipid metabolism, lipid metabolism disorder, Fat disorder, Disorders of lipid metabolism, Lipid metabolism disorder NOS, Unspecified disorders of lipoid metabolism, Lipoid metabol dis NOS, Disorder of lipoid metabolism NOS (disorder), Lipid Metabolism Disorders [Disease/Finding], disorders fat, lipid disorders, Disease;lipid metabolism, Disorder;lipid metabolism, fat disorder, lipid metabolism disorders, disorder lipid metabolism, disorders lipid, disorders fats, disorders lipids, Lipid metabolism disorders, Lipid metabolism disorder, Disorders of lipoid metabolism, Disorder of lipid metabolism, Disorder of lipid metabolism (disorder), Lipid disorder, disorder; lipid metabolism, lipid; metabolic disorder, metabolic disorder; lipid, Lipid metabol. disorder, disorder of lipid metabolism, lipid metabolism disease&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Disturbi del metabolismo lipidico, Disturbo del metabolismo lipidico, Disturbi del metabolismo lipoideo, Patologia adiposa, Disturbo del metabolismo lipidico NAS, Disturbi non specificati del metabolismo dei lipoidi, Disturbi del metabolismo dei lipidi&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;stoornissen van lipoïdmetabolisme, vetstoornis, niet-gespecificeerde stoornis van lipoïdmetabolisme, lipidemetabolismestoornis NAO, niet-gespecificeerde stoornissen van lipoïdmetabolisme, Vetstofwisselingsstoornissen, Vetstofwisselingsstoornis, lipide; metabole stoornis, stofwisselingsstoornis; lipide, stoornis; lipidenmetabolisme, lipidemetabolismestoornis, lipidenmetabolismestoornissen&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Troubles non précisés du métabolisme des lipoïdes, Trouble lipidique, Troubles du métabolisme des lipoïdes, Trouble du métabolisme lipidique SAI, Trouble du métabolisme des lipoïdes non précisé, Troubles du métabolisme des lipides, Troubles du métabolisme lipidique, ANOMALIE DU TISSU GRAISSEUX, Dyslipidemies, TROUBLE DU METABOL. LIPIDIQUE SAI, Trouble du métabolisme lipidique&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Stoerungen des Lipoidstoffwechsels, Fettstoffwechselerkrankungen, Fettstoffwechselstoerung NNB, unspezifische Stoerung des Lipoidstoffwechsels, unspezifische Stoerungen des Lipoidstoffwechsels, Lipidstoffwechselstörungen, FETT VERAENDERT, FETTSTOFFWECHSELSTOERUNG, Fettstoffwechselstoerungen, Lipidstoffwechselstoerung&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Alteração do metabolismo dos lípidos NE, Alterações NE do metabolismo lipóide, Alteração das gorduras, Alteração NE do metabolismo lipóide, Alterações do metabolismo lipóide, Transtornos do Metabolismo dos Lipídeos, Distúrbios Metabólicos dos Lipídeos, Distúrbios do Metabolismo dos Lipídeos, Transtornos Metabólicos dos Lipídeos, Transtornos do Metabolismo Lipídico, Distúrbios do Metabolismo dos Lipídios, Distúrbios do Metabolismo Lipídico, ALTERACAO DO METABOLISMO LIPIDICO, Alteracoes do metabolismo lipidico, DISTURB. DO METABOLISMO LIPIDICO, Alteração de metabolismo dos lípidos, Alteração do metabolismo dos lípidos&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;Trastornos no especificados del metabolismo lipoideo, Trastornos del metabolismo lipoideo, Trastorno de las grasas, Trastorno no especificado del metabolismo lipoideo, Trastorno del metabolismo de los lipidos NEOM, Desordenes Metabolicos de los Lipidos, Trastornos Metabólicos de los Lípidos, Trastornos del Metabolismo Lipídico, Trastornos Metabolicos de los Lipidos, Desórdenes Metabólicos de los Lípidos, Trastornos del Metabolismo de los Lipidos, Trastornos del Metabolismo Lipidico, Trastornos del Metabolismo de los Lípidos, trastorno de metabolismo de lípidico, Disorder of lipid metabolism, Disorders of lipid metabolism, Lipid metabol. disorder, Disorders of lipoid metabolism, Enf metabolismo lipidico, GRASA, TRASTORNO, LIPIDOS, TRASTORNOS DEL METABOLIS, trastorno del metabolismo lipídico, SAI (trastorno), trastorno del metabolismo lipídico, SAI, Trastorno del metabolismo de los lípidos, Trastornos del metabolismo de los lípidos, trastorno de metabolismo de lípidico (trastorno), trastorno del metabolismo lipídico, trastornos de metabolismo lipoideo, trastorno del metabolismo lípidico (trastorno), trastorno del metabolismo lípidico&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;ЛИПИДНОГО МЕТАБОЛИЗМА РАССТРОЙСТВА, РАССТРОЙСТВА ЛИПИДНОГО ОБМЕНА, LIPIDNOGO METABOLIZMA RASSTROISTVA, RASSTROISTVA LIPIDNOGO OBMENA&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;脂質代謝障害ＮＯＳ, 脂質代謝異常, 脂質代謝障害, 脂質代謝障害、詳細不明, ｼｼﾂﾀｲｼｬｼｮｳｶﾞｲ, ｼｼﾂﾀｲｼｬｼｮｳｶﾞｲNOS, ｼｼﾂﾀｲｼｬｲｼﾞｮｳ, ｼｼﾂﾀｲｼｬｼｮｳｶﾞｲｼｮｳｻｲﾌﾒｲ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Fettomsättningsrubbningar, RUBBNINGAR I LIPIDOMSATTNINGEN&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Lipidiaineenvaihdunnan häiriöt, RASVA-AINEENVAIHDUNNAN HAIRIO&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;metabolismus lipidů - poruchy, lipidy - poruchy metabolismu, Poruchy metabolismu tuků, Porucha lipidového metabolismu NOS, Blíže neurčená porucha lipidového metabolismu, Porucha lipidového metabolismu, Neurčené poruchy lipidového metabolismu, Poruchy lipidového metabolismu, Porucha metabolismu tuků&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Norwegian&lt;/td&gt;
                &lt;td&gt;FORSTYRR VED LIPID-STOFFSKIFTET&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Danish&lt;/td&gt;
                &lt;td&gt;Forstyrrelser i lipid-stofskiftet&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;zsiranyagcsere-zavar, Lipid metabolizmus betegségei, Lipid metabolizmus betegség k.m.n., Lipoid metabolizmus nem meghatározott betegsége, Lipid metabolizmus betegség, Lipoid metabolizmus betegségei, Zsír rendellenesség, Lipoid metabolizmus nem meghatározott betegségei&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Basque&lt;/td&gt;
                &lt;td&gt;LIPIDOETAKO METABOLISMO NAHASKETA&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hebrew&lt;/td&gt;
                &lt;td&gt;hiperlipidemia.hiperxolesterolemia&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Zaburzenia metabolizmu lipidów, Zaburzenia przemiany lipidów&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Croatian&lt;/td&gt;
                &lt;td&gt;METABOLIZAM LIPIDA, POREMEĆAJI&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Disorder of carbohydrate metabolism  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0149670"&gt;&lt;i&gt;C0149670&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Disease or Syndrome (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0149670&amp;amp;tui=T047"&gt;&lt;i&gt;T047&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD10&lt;/td&gt;
                &lt;td&gt;E74.9&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;20957000&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;DISORDER OF CARBOHYDRATE METABOLISM, DISORDERS OF CARBOHYDRATE METABOLISM, Disorder of carbohydrate metabolism, NOS, Disord of carbohydrate metabol, Disorder of carbohydrate metabolism, unspecified, Disease of carbohydrate metabolism, Diseases of Carbohydrate Metabolism, carbohydrate metabolism disorder, disorders of carbohydrate metabolism, 6-50 DISORDERS OF CARBOHYDRATE METABOLISM, carbohydrate disorders metabolism, Carbohydrate metabolism disorder, Disorder of carbohydrate metabolism, Disorder of carbohydrate metabolism (disorder), carbohydrate; metabolic disorder, disorder; carbohydrate metabolism, metabolic disorder; carbohydrate, Disorder;carbohydrate metabol, disorder of carbohydrate metabolism&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Disturbo del metabolismo dei carboidrati&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;炭水化物代謝障害, ﾀﾝｽｲｶﾌﾞﾂﾀｲｼｬｼｮｳｶﾞｲ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Stoerung des Kohlenhydratstoffwechsels, nicht naeher bezeichnet, Stoerung des Kohlehydratstoffwechsels&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;Porucha metabolismu sacharidů&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Korean&lt;/td&gt;
                &lt;td&gt;상세불명의 탄수화물 대사 장애&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;Szénhidrát metabolizmus betegség&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;koolhydraat; metabole stoornis, stofwisselingsstoornis; koolhydraat, stoornis; koolhydraatstofwisseling, Stofwisselingsstoornis van koolhydraten, niet gespecificeerd, koolhydraatmetabolismestoornis&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;trastorno del metabolismo de los carbohidratos (trastorno), trastorno del metabolismo de los carbohidratos, trastorno del metabolismo de los glúcidos, trastorno del metabolismo de los hidratos de carbono, Alteración del metabolismo de los hidratos de carbono&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Anomalia do metabolismos dos hidratos de carbono&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Trouble du métabolisme des hydrates de carbone&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Glycogen Storage Disease  (</value><value>)
</value><value>Lipid Metabolism Disorders  (</value><value>)
</value><value>Disorder of carbohydrate metabolism  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Disorders of Energy Metabolism</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Metabolic Disorders</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;See Also&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Metabolism/InbrnErrsOfMtblsm.htm" class="LinkPage"&gt;Inborn Errors of Metabolism&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Metabolism/LysmlStrgDs.htm" class="LinkPage"&gt;Lysosomal Storage Disease&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Metabolism/InbrnErrOfSmlMlclMtblsm.htm" class="LinkPage"&gt;Inborn Error of Small Molecule Metabolism&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Types&lt;ol&gt;&lt;li&gt;Oxidation defects&lt;/li&gt;&lt;li&gt;Disorders of &lt;a href="../../Pharm/Nutrition/FtyAcd.htm" class="LinkPage"&gt;Fatty Acid&lt;/a&gt; mobilization and metabolism&lt;ol&gt;&lt;li&gt;Medium-chain-acyl-CoA Dehydrogenase Deficiency&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Glycogen Storage Diseases&lt;ol&gt;&lt;li&gt;Type 1: von Gierke's Disease&lt;/li&gt;&lt;li&gt;Type 2: Pompe's Disease&lt;/li&gt;&lt;li&gt;Type 3: Forbes Disease&lt;/li&gt;&lt;li&gt;Type 4: Andersen's Disease&lt;/li&gt;&lt;li&gt;Type 5: McArdle's Disease&lt;/li&gt;&lt;li&gt;Type 6: Hers Disease&lt;/li&gt;&lt;li&gt;Type 7: Tarui's Disease&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0017919</value><value>C0154251</value><value>C0149670</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Metabolism/DsrdrsOfEnrgyMtblsm.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Disorders of Energy Metabolism, Glycogen Storage Disease, Disorder of Carbohydrate Metabolism, Lipid Metabolism Disorders</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Metabolism/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees></FP_UMLS_Trees><FP_Condition_name_check></FP_Condition_name_check><FP_Condition_name><value>Failure to Thrive Causes</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Pediatrics</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;See Also&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Growth/ShrtStr.htm" class="LinkPage"&gt;Delayed Growth&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Peds/FlrTThrv.htm" class="LinkPage"&gt;Failure to Thrive&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Peds/FlrTThrvDgns.htm" class="LinkPage"&gt;Failure to Thrive Diagnosis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Peds/FlrTThrvRdFlgs.htm" class="LinkPage"&gt;Failure to Thrive Red Flags&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Peds/FlrTThrvEvltn.htm" class="LinkPage"&gt;Failure to Thrive Evaluation&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Peds/FlrTThrvMngmnt.htm" class="LinkPage"&gt;Failure to Thrive Management&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Precautions&lt;ol&gt;&lt;li&gt;First define if growth is truly abnormal (See &lt;a href="../../Endo/Peds/FlrTThrvDgns.htm" class="LinkPage"&gt;Failure to Thrive Diagnosis&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Peds/FlrTThrvRdFlgs.htm" class="LinkPage"&gt;Failure to Thrive Red Flags&lt;/a&gt; suggest organic cause&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Causes: Normal Physiologic&lt;ol&gt;&lt;li&gt;Half of infants under age 2 shift weight, height by 25%&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Growth/FmlShrtStr.htm" class="LinkPage"&gt;Familial Short Stature&lt;/a&gt; (Short Parents)&lt;ol&gt;&lt;li&gt;Most common reason for &lt;a href="../../Endo/Growth/ShrtStr.htm" class="LinkPage"&gt;Short Stature&lt;/a&gt; in children&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Causes: Nonorganic (80% of cases, no &lt;a href="../../Endo/Peds/FlrTThrvRdFlgs.htm" class="LinkPage"&gt;Failure to Thrive Red Flags&lt;/a&gt;)&lt;ol&gt;&lt;li&gt;Accidental error in formula preparation or &lt;a href="../../OB/Lactation/BrstFdng.htm" class="LinkPage"&gt;Breast Feeding&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Improper feeding technique&lt;/li&gt;&lt;li&gt;Misconception about nutrition needs&lt;/li&gt;&lt;li&gt;&lt;a href="../../Gyn/Anatomy/BrstAntmy.htm" class="LinkPage"&gt;Breast&lt;/a&gt; fed infants without sufficient caloric intake&lt;/li&gt;&lt;li&gt;Formula too dilute&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Economic deprivation or limited access to food&lt;/li&gt;&lt;li&gt;Emotional deprivation&lt;/li&gt;&lt;li&gt;Child neglect&lt;/li&gt;&lt;li&gt;&lt;a href="../../Prevent/Abuse/ChldAbs.htm" class="LinkPage"&gt;Child Abuse&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Caregiver &lt;a href="../../Psych/Depress/MjrDprsn.htm" class="LinkPage"&gt;Major Depression&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Causes: Organic - Insufficient caloric intake&lt;ol&gt;&lt;li&gt;Infant or toddler&lt;ol&gt;&lt;li&gt;&lt;a href="../../NICU/ENT/ClftLp.htm" class="LinkPage"&gt;Cleft Palate&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../NICU/ENT/ChnlAtrs.htm" class="LinkPage"&gt;Choanal Atresia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Peds/GI/PdtrcRflx.htm" class="LinkPage"&gt;Pediatric Gastroesophageal Reflux&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Child or adolescent&lt;ol&gt;&lt;li&gt;&lt;a href="../../Peds/GI/PdtrcRflx.htm" class="LinkPage"&gt;Pediatric Gastroesophageal Reflux&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Eating Disorder&lt;/li&gt;&lt;li&gt;&lt;a href="../../Psych/Peds/ChldhdDprsn.htm" class="LinkPage"&gt;Major Depression in Children&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Causes: Organic - Defect in food assimilation or absorption&lt;ol&gt;&lt;li&gt;Infant or Toddler&lt;ol&gt;&lt;li&gt;&lt;a href="../../ENT/Allergy/FdAlrgy.htm" class="LinkPage"&gt;Food Allergy&lt;/a&gt; (e.g. 	Cow's milk protein allergy)&lt;/li&gt;&lt;li&gt;Inborn error of metabolism&lt;/li&gt;&lt;li&gt;&lt;a href="../../GI/ID/GrdLmbl.htm" class="LinkPage"&gt;Giardia&lt;/a&gt;sis&lt;/li&gt;&lt;li&gt;Protein losing &lt;a href="../../GI/IBD/IntstnlEntrpthy.htm" class="LinkPage"&gt;Enteropathy&lt;/a&gt; or other malabsorption&lt;/li&gt;&lt;li&gt;Gastrointestinal malformation&lt;ol&gt;&lt;li&gt;Pyloric stenosis&lt;/li&gt;&lt;li&gt;Biliary atresia&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Child or adolescent&lt;ol&gt;&lt;li&gt;&lt;a href="../../ENT/Allergy/FdAlrgy.htm" class="LinkPage"&gt;Food Allergy&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../GI/Malabsorption/GltnEntrpthy.htm" class="LinkPage"&gt;Celiac Disease&lt;/a&gt; or other malabsorption&lt;/li&gt;&lt;li&gt;&lt;a href="../../GI/IBD/InflmtryBwlDs.htm" class="LinkPage"&gt;Inflammatory Bowel Disease&lt;/a&gt; or other &lt;a href="../../GI/Diarrhea/ChrncDrh.htm" class="LinkPage"&gt;Chronic Diarrhea&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Inborn error of metabolism&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Causes: Organic - Increased energy requirements, expenditure&lt;ol&gt;&lt;li&gt;Malignancy&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Peds/CngntlHrtDs.htm" class="LinkPage"&gt;Congenital Heart Disease&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Chronic pulmonary disease (e.g. &lt;a href="../../Lung/Asthma/SvrPrstntAsthm.htm" class="LinkPage"&gt;Severe Persistent Asthma&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;Renal disease&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/Hyprthyrdsm1.htm" class="LinkPage"&gt;Hyperthyroidism&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../ID/Immune/PrmryImndfcncy.htm" class="LinkPage"&gt;Primary Immunodeficiency&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../HemeOnc/Lymph/GnrlzdLymphdnpthy.htm" class="LinkPage"&gt;Generalized Lymphadenopathy&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Hepatosplenomegaly&lt;/li&gt;&lt;li&gt;&lt;a href="../../ENT/Mouth/Thrsh.htm" class="LinkPage"&gt;Oral Candidiasis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../ENT/Ear/OtsMd.htm" class="LinkPage"&gt;Otitis Media&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Lung/ID/Pnmn.htm" class="LinkPage"&gt;Pneumonia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Recurrent or &lt;a href="../../GI/Diarrhea/ChrncDrh.htm" class="LinkPage"&gt;Chronic Diarrhea&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Causes: Organic - Prenatal&lt;ol&gt;&lt;li&gt;Intrauterine infection&lt;/li&gt;&lt;li&gt;Maternal malnutrition&lt;/li&gt;&lt;li&gt;Maternal smoking&lt;/li&gt;&lt;li&gt;&lt;a href="../../Neuro/Disability/FtlAlchlSyndrm.htm" class="LinkPage"&gt;Fetal Alcohol Syndrome&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../OB/Pharm/FtlHydntnSyndrm.htm" class="LinkPage"&gt;Fetal Hydantoin Syndrome&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Chromosomal disorders&lt;/li&gt;&lt;li&gt;Dysmorphic syndromes&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Levy%20%20%5BAU%5D%20AND%202009%20%5BDP%5D%20AND%20%20J%20Pediatr%20Gastroenterol%20Nutr%20%20%5BTA%5D" class="LinkRef"&gt;Levy (2009) J Pediatr Gastroenterol Nutr 48(3): 355-62&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Shah%20%20%5BAU%5D%20AND%202002%20%5BDP%5D%20AND%20%20J%20Clin%20Gastroenterol%20%20%5BTA%5D" class="LinkRef"&gt;Shah (2002) J Clin Gastroenterol 35(5): 371-4&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Peds/FlrTThrvCs.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Failure to Thrive Causes</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Peds/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees></FP_UMLS_Trees><FP_Condition_name_check></FP_Condition_name_check><FP_Condition_name><value>Exercise in Diabetes Mellitus</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Sports Medicine</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;See Also&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/DM/DbtsMlts.htm" class="LinkPage"&gt;Diabetes Mellitus&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Sports/Exercise/Exrcs.htm" class="LinkPage"&gt;Exercise&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Benefits of Exercise in Diabetes Mellitus&lt;ol&gt;&lt;li&gt;&lt;a href="../../Sports/Exercise/Exrcs.htm" class="LinkPage"&gt;Exercise&lt;/a&gt; lowers &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Serum Glucose&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Benefits &lt;a href="../../Endo/DM/TypDbtsMlts.htm" class="LinkPage"&gt;Type I Diabetes Mellitus&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Benefits &lt;a href="../../Endo/DM/TypDbtsMlts1.htm" class="LinkPage"&gt;Type II Diabetes&lt;/a&gt; most significantly&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Sports/Exercise/Exrcs.htm" class="LinkPage"&gt;Exercise&lt;/a&gt; augments &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; effect&lt;ol&gt;&lt;li&gt;Facilitates &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; transport across cell&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Sports/Exercise/Exrcs.htm" class="LinkPage"&gt;Exercise&lt;/a&gt; reduces heart disease and stroke risk&lt;ol&gt;&lt;li&gt;Increases HDL&lt;/li&gt;&lt;li&gt;Lowers LDL&lt;/li&gt;&lt;li&gt;Lowers &lt;a href="../../CV/Lab/Lpd.htm" class="LinkPage"&gt;Total Cholesterol&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Decreases SBP and DBP&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Sports/Exercise/Exrcs.htm" class="LinkPage"&gt;Exercise&lt;/a&gt; improves general wellness&lt;ol&gt;&lt;li&gt;Increases self esteem&lt;/li&gt;&lt;li&gt;Improves socialization&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Risks of Exercise in Diabetes Mellitus&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Hypoglycemia/Hypglycm.htm" class="LinkPage"&gt;Hypoglycemia&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Use caution in &lt;a href="../../Sports/Water/ScbDvng.htm" class="LinkPage"&gt;Scuba Diving&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Use caution in rock-climbing&lt;/li&gt;&lt;li&gt;Use caution in long-distance swimming&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Retinopathy&lt;ol&gt;&lt;li&gt;Avoid weight lifting&lt;/li&gt;&lt;li&gt;Avoid mountain climbing&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Neuro/Sx/PrphrlNrpthy.htm" class="LinkPage"&gt;Neuropathy&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Avoid weight bearing &lt;a href="../../Sports/Exercise/Exrcs.htm" class="LinkPage"&gt;Exercise&lt;/a&gt;s&lt;/li&gt;&lt;li&gt;Choose stationary bike or water sports&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Neuro/Autonomic/AtnmcDysfnctn.htm" class="LinkPage"&gt;Autonomic Dysfunction&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Abnormal hemodynamic response to &lt;a href="../../Sports/Exercise/Exrcs.htm" class="LinkPage"&gt;Exercise&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Inappropriate &lt;a href="../../CV/Exam/HrtRt.htm" class="LinkPage"&gt;Heart Rate&lt;/a&gt; response&lt;/li&gt;&lt;li&gt;Inappropriate &lt;a href="../../CV/Exam/BldPrsr.htm" class="LinkPage"&gt;Blood Pressure&lt;/a&gt; response&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;May not experience &lt;a href="../../CV/CAD/AngnPctrs.htm" class="LinkPage"&gt;Angina&lt;/a&gt;l symptoms with &lt;a href="../../Sports/Exercise/Exrcs.htm" class="LinkPage"&gt;Exercise&lt;/a&gt;&lt;/li&gt;&lt;li&gt;May not experience hypoglycemic symptoms&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Renal/DbtcNphrpthy.htm" class="LinkPage"&gt;Diabetic Nephropathy&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Avoid &lt;a href="../../Sports/Exercise/StrngthTrng.htm" class="LinkPage"&gt;Resistance Training&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Cardiovascular disease&lt;ol&gt;&lt;li&gt;Consider Stress Testing prior to &lt;a href="../../Sports/Exercise/Exrcs.htm" class="LinkPage"&gt;Exercise&lt;/a&gt; program&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Starting &lt;a href="../../Sports/Exercise/Exrcs.htm" class="LinkPage"&gt;Exercise&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Evaluate coronary, nephropathy, &lt;a href="../../Neuro/Sx/PrphrlNrpthy.htm" class="LinkPage"&gt;Neuropathy&lt;/a&gt;, retinopathy&lt;ol&gt;&lt;li&gt;Confirm no contraindications to starting &lt;a href="../../Sports/Exercise/Exrcs.htm" class="LinkPage"&gt;Exercise&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Goal energy expenditure (See &lt;a href="../../Sports/Exam/ExrcsEnrgyExpndtr.htm" class="LinkPage"&gt;METS&lt;/a&gt;)&lt;ol&gt;&lt;li&gt;No weight loss intended: 1000 KCal/week&lt;/li&gt;&lt;li&gt;Weight loss intended: 2000 KCal/week&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Sports/Exercise/StrngthTrng.htm" class="LinkPage"&gt;Progressive Resistance Training&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Low resistance (40-60% of 1 repetition maximum)&lt;/li&gt;&lt;li&gt;Low intensity&lt;/li&gt;&lt;li&gt;Gradually increase to 15-20 repetitions&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;General &lt;a href="../../Sports/Exercise/Exrcs.htm" class="LinkPage"&gt;Exercise&lt;/a&gt; Tips in &lt;a href="../../Endo/DM/DbtsMlts.htm" class="LinkPage"&gt;Diabetes Mellitus&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Preparation for regular &lt;a href="../../Sports/Exercise/Exrcs.htm" class="LinkPage"&gt;Exercise&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Check feet for lesions related to &lt;a href="../../Sports/Exercise/Exrcs.htm" class="LinkPage"&gt;Exercise&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Pre-&lt;a href="../../Sports/Exercise/Exrcs.htm" class="LinkPage"&gt;Exercise&lt;/a&gt; evaluation (consider Stress Test)&lt;/li&gt;&lt;li&gt;Medic-Alert tag&lt;/li&gt;&lt;li&gt;Exercising diabetics must use &lt;a href="../../Endo/Pharm/Glcmtr.htm" class="LinkPage"&gt;Glucometer&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Pre-planned strategy for &lt;a href="../../Endo/Hypoglycemia/Hypglycm.htm" class="LinkPage"&gt;Hypoglycemia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Evaluate &lt;a href="../../Sports/Exam/ExrcsEnrgyExpndtr.htm" class="LinkPage"&gt;Exercise Energy Expenditure&lt;/a&gt; (&lt;a href="../../Sports/Exam/ExrcsEnrgyExpndtr.htm" class="LinkPage"&gt;METS&lt;/a&gt;)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Time &lt;a href="../../Sports/Exercise/Exrcs.htm" class="LinkPage"&gt;Exercise&lt;/a&gt; appropriately&lt;ol&gt;&lt;li&gt;Avoid late-evening &lt;a href="../../Sports/Exercise/Exrcs.htm" class="LinkPage"&gt;Exercise&lt;/a&gt; in &lt;a href="../../Endo/DM/TypDbtsMlts.htm" class="LinkPage"&gt;Type I Diabetes&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Aerobic &lt;a href="../../Sports/Exercise/Exrcs.htm" class="LinkPage"&gt;Exercise&lt;/a&gt; recommended 6 to 7 days per week&lt;ol&gt;&lt;li&gt;Duration: 20 to 60 minutes&lt;/li&gt;&lt;li&gt;Level: 60-80% of maximum &lt;a href="../../CV/Exam/HrtRt.htm" class="LinkPage"&gt;Heart Rate&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Allow time for warm up and cool down&lt;ol&gt;&lt;li&gt;Reduces injury risk&lt;/li&gt;&lt;li&gt;Reduces post-&lt;a href="../../Sports/Exercise/Exrcs.htm" class="LinkPage"&gt;Exercise&lt;/a&gt; arrhythmia risk&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;
              &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Sugar&lt;/a&gt; Management&lt;ol&gt;&lt;li&gt;Check pre-&lt;a href="../../Sports/Exercise/Exrcs.htm" class="LinkPage"&gt;Exercise&lt;/a&gt;&lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Sugar&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Sugar&lt;/a&gt; &amp;lt;100 mg/dl&lt;ol&gt;&lt;li&gt;Snack 15-20 grams carbohydrate before &lt;a href="../../Sports/Exercise/Exrcs.htm" class="LinkPage"&gt;Exercise&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Sugar&lt;/a&gt; 100 to 250 mg/dl&lt;ol&gt;&lt;li&gt;No snack needed&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Sugar&lt;/a&gt; &amp;gt;250 with ketones (or &amp;gt;300 without)&lt;ol&gt;&lt;li&gt;Delay &lt;a href="../../Sports/Exercise/Exrcs.htm" class="LinkPage"&gt;Exercise&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Check &lt;a href="../../Renal/Lab/SrmPtsm.htm" class="LinkPage"&gt;Serum K&lt;/a&gt;etones&lt;/li&gt;&lt;li&gt;Treat &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Hyperglycemia&lt;/a&gt; and dehydration&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Pre-&lt;a href="../../Sports/Exercise/Exrcs.htm" class="LinkPage"&gt;Exercise&lt;/a&gt;&lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Take &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; more than 1 hour before &lt;a href="../../Sports/Exercise/Exrcs.htm" class="LinkPage"&gt;Exercise&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Inject &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; into a non-exercising site&lt;ol&gt;&lt;li&gt;Absorption at &lt;a href="../../GI/Anatomy/AbdmnlAntmy.htm" class="LinkPage"&gt;Abdomen&lt;/a&gt; is fastest and most reliable&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Decrease short-acting &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; before &lt;a href="../../Sports/Exercise/Exrcs.htm" class="LinkPage"&gt;Exercise&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Decrease 30% for &lt;a href="../../Sports/Exercise/Exrcs.htm" class="LinkPage"&gt;Exercise&lt;/a&gt; less than 1 hour&lt;/li&gt;&lt;li&gt;Decrease 40% for &lt;a href="../../Sports/Exercise/Exrcs.htm" class="LinkPage"&gt;Exercise&lt;/a&gt; 1-2 hours&lt;/li&gt;&lt;li&gt;Decrease 50% for &lt;a href="../../Sports/Exercise/Exrcs.htm" class="LinkPage"&gt;Exercise&lt;/a&gt; over 3 hours&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Decrease risk of &lt;a href="../../Endo/Hypoglycemia/Hypglycm.htm" class="LinkPage"&gt;Hypoglycemia&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Avoid &lt;a href="../../Sports/Exercise/Exrcs.htm" class="LinkPage"&gt;Exercise&lt;/a&gt; during times of peak &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; activity&lt;/li&gt;&lt;li&gt;Consider &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Humalog&lt;/a&gt;&lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; injection site may affect absorption rate&lt;/li&gt;&lt;li&gt;Avoid &lt;a href="../../Endo/Pharm/Slfnylr.htm" class="LinkPage"&gt;Sulfonylurea&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Be aware of your own &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Sugar&lt;/a&gt; response to &lt;a href="../../Sports/Exercise/Exrcs.htm" class="LinkPage"&gt;Exercise&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Pre-&lt;a href="../../Sports/Exercise/Exrcs.htm" class="LinkPage"&gt;Exercise&lt;/a&gt; Food&lt;ol&gt;&lt;li&gt;Meals should be ingested 1-2 hours before &lt;a href="../../Sports/Exercise/Exrcs.htm" class="LinkPage"&gt;Exercise&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Strenuous or prolonged &lt;a href="../../Sports/Exercise/Exrcs.htm" class="LinkPage"&gt;Exercise&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Start increasing calorie intake 24 hours before&lt;/li&gt;&lt;li&gt;Supplement carbohydrates every 30 minutes during&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Supplement during &lt;a href="../../Sports/Exercise/Exrcs.htm" class="LinkPage"&gt;Exercise&lt;/a&gt; with &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Glucose&lt;/a&gt; solutions&lt;ol&gt;&lt;li&gt;One bottle for each 30 minutes strenuous &lt;a href="../../Sports/Exercise/Exrcs.htm" class="LinkPage"&gt;Exercise&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Replenish glycogen stores after &lt;a href="../../Sports/Exercise/Exrcs.htm" class="LinkPage"&gt;Exercise&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Based on &lt;a href="../../Sports/Exercise/Exrcs.htm" class="LinkPage"&gt;Exercise&lt;/a&gt; duration and intensity&lt;/li&gt;&lt;li&gt;Be aware of delayed &lt;a href="../../Endo/Hypoglycemia/Hypglycm.htm" class="LinkPage"&gt;Hypoglycemia&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Carry an activity pack while exercising&lt;ol&gt;&lt;li&gt;Personal identification&lt;/li&gt;&lt;li&gt;Mobile phone&lt;/li&gt;&lt;li&gt;Adequate water and carbohydrate source&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Glucose&lt;/a&gt; monitor&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Complications: Post-&lt;a href="../../Sports/Exercise/Exrcs.htm" class="LinkPage"&gt;Exercise&lt;/a&gt;&lt;a href="../../Endo/Hypoglycemia/Hypglycm.htm" class="LinkPage"&gt;Hypoglycemia&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Delayed &lt;a href="../../Endo/Hypoglycemia/Hypglycm.htm" class="LinkPage"&gt;Hypoglycemia&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Occurs 6 to 28 hours after strenuous &lt;a href="../../Sports/Exercise/Exrcs.htm" class="LinkPage"&gt;Exercise&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Occurs despite normal &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Blood Sugar&lt;/a&gt;s during &lt;a href="../../Sports/Exercise/Exrcs.htm" class="LinkPage"&gt;Exercise&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Occurs regardless of age or illness severity&lt;/li&gt;&lt;li&gt;Often occurs at night&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Mechanism&lt;ol&gt;&lt;li&gt;Glycogen stores depleted and not replenished&lt;/li&gt;&lt;li&gt;Increased &lt;a href="../../Endo/Pharm/Insln.htm" class="LinkPage"&gt;Insulin&lt;/a&gt; sensitivity post-&lt;a href="../../Sports/Exercise/Exrcs.htm" class="LinkPage"&gt;Exercise&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Resources&lt;ol&gt;&lt;li&gt;Diabetes, &lt;a href="../../Sports/Exercise/Exrcs.htm" class="LinkPage"&gt;Exercise&lt;/a&gt; and Sports Association&lt;ol&gt;&lt;li&gt;&lt;p&gt;&lt;/p&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Mountains for Active Diabetics (extreme sports)&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.mountain-mad.org" class="LinkWebExt"&gt;http://www.mountain-mad.org&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;Whaley (2006) ACSM's Guidelines for &lt;a href="../../Sports/Exercise/Exrcs.htm" class="LinkPage"&gt;Exercise&lt;/a&gt;&lt;/li&gt;&lt;li&gt;White (1997) Lecture: AAFP Sports Medicine, Dallas&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Baraz%20%20%5BAU%5D%20AND%201994%20%5BDP%5D%20AND%20%20Clin%20Diab%20%20%5BTA%5D" class="LinkRef"&gt;Baraz (1994) Clin Diab 12(4):94-8&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Fahey%20%20%5BAU%5D%20AND%201996%20%5BDP%5D%20AND%20%20Am%20Fam%20Physician%20%20%5BTA%5D" class="LinkRef"&gt;Fahey (1996) Am Fam Physician 53:1611-7&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Landry%20%20%5BAU%5D%20AND%201992%20%5BDP%5D%20AND%20%20Clin%20Sports%20Med%20%20%5BTA%5D" class="LinkRef"&gt;Landry (1992) Clin Sports Med 11:403-18&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Sports/ExrcsInDbtsMlts.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Exercise in Diabetes Mellitus, Diabetes Mellitus and Exercise</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Sports/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees></FP_UMLS_Trees><FP_Condition_name_check></FP_Condition_name_check><FP_Condition_name><value>Failure to Thrive</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Pediatrics</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;See Also&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Growth/ShrtStr.htm" class="LinkPage"&gt;Delayed Growth&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Peds/FlrTThrvCs.htm" class="LinkPage"&gt;Failure to Thrive Causes&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Peds/FlrTThrvDgns.htm" class="LinkPage"&gt;Failure to Thrive Diagnosis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Peds/FlrTThrvRdFlgs.htm" class="LinkPage"&gt;Failure to Thrive Red Flags&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Peds/FlrTThrvEvltn.htm" class="LinkPage"&gt;Failure to Thrive Evaluation&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Peds/FlrTThrvMngmnt.htm" class="LinkPage"&gt;Failure to Thrive Management&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Definition&lt;ol&gt;&lt;li&gt;Malnutrition due to inadequate caloric intake or absorption or excessive caloric expendature&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Epidemiology&lt;ol&gt;&lt;li&gt;&lt;a href="../../Prevent/Epi/DsIncdncRt.htm" class="LinkPage"&gt;Incidence&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Hospitalized children &amp;lt;2 years: 1-5%&lt;/li&gt;&lt;li&gt;Families with Medical, Psychosocial problems: 10%&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Causes&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Peds/FlrTThrvCs.htm" class="LinkPage"&gt;Failure to Thrive Causes&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Signs: Associated Findings&lt;ol&gt;&lt;li&gt;Length and &lt;a href="../../NICU/Exam/HdCrcmfrnc.htm" class="LinkPage"&gt;Head Circumference&lt;/a&gt; affected in severe cases&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Diagnosis: Failure to Thrive&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Endo/Peds/FlrTThrvDgns.htm" class="LinkPage"&gt;Failure to Thrive Diagnosis&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Evaluation&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Endo/Peds/FlrTThrvEvltn.htm" class="LinkPage"&gt;Failure to Thrive Evaluation&lt;/a&gt;&lt;/li&gt;&lt;li&gt;See &lt;a href="../../Endo/Growth/GrwthAssmnt.htm" class="LinkPage"&gt;Growth Assessment&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Management&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Endo/Peds/FlrTThrvMngmnt.htm" class="LinkPage"&gt;Failure to Thrive Management&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Prognosis&lt;ol&gt;&lt;li&gt;Nonorganic Failure to Thrive risks poor outcomes&lt;ol&gt;&lt;li&gt;Risk of cognitive delay and school difficulty&lt;ol&gt;&lt;li&gt;Lower &lt;a href="../../Peds/Neuro/WchslrIntlgncScl.htm" class="LinkPage"&gt;Wechsler Intelligence Scale&lt;/a&gt; for Children&lt;/li&gt;&lt;li&gt;Poorer language development and reading skills&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Social immaturity&lt;ol&gt;&lt;li&gt;More frequent behavior problems&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;References&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Oates%20%20%5BAU%5D%20AND%201985%20%5BDP%5D%20AND%20%20Pediatrics%20%20%5BTA%5D" class="LinkRef"&gt;Oates (1985) Pediatrics 75:36&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Cole%20%20%5BAU%5D%20AND%202011%20%5BDP%5D%20AND%20%20Am%20fam%20Physician%20%20%5BTA%5D" class="LinkRef"&gt;Cole (2011) Am fam Physician 83(7): 829-34&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Gahagen%20%20%5BAU%5D%20AND%202006%20%5BDP%5D%20AND%20%20Pediatr%20Rev%20%20%5BTA%5D" class="LinkRef"&gt;Gahagen (2006) Pediatr Rev 27(1): e1-11&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Shah%20%20%5BAU%5D%20AND%202002%20%5BDP%5D%20AND%20%20J%20Clin%20Gastroenterol%20%20%5BTA%5D" class="LinkRef"&gt;Shah (2002) J Clin Gastroenterol 35(5):371-4&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Peds/FlrTThrv.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Failure to Thrive, FTT</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Peds/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Hyperprolactinemia  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0020514"&gt;&lt;i&gt;C0020514&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CSP)&lt;/td&gt;
                &lt;td&gt;increased levels of prolactin in the blood, which may be associated with amenorrhea and galactorrhea; relatively common etiologies include prolactinoma, medication effect, kidney failure, granulomatous diseases of the pituitary gland, and disorders which interfere with the hypothalamic inhibition of prolactin release; ectopic (non-pituitary) production of prolactin may also occur.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;Increased levels of PROLACTIN in the BLOOD, which may be associated with AMENORRHEA and GALACTORRHEA. Relatively common etiologies include PROLACTINOMA, medication effect, KIDNEY FAILURE, granulomatous diseases of the PITUITARY GLAND, and disorders which interfere with the hypothalamic inhibition of prolactin release. Ectopic (non-pituitary) production of prolactin may also occur. (From Joynt, Clinical Neurology, 1992, Ch36, pp77-8)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Disease or Syndrome (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0020514&amp;amp;tui=T047"&gt;&lt;i&gt;T047&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D006966&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD10&lt;/td&gt;
                &lt;td&gt;E22.1&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;367422005, 190468001, 237662005, 21170004&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Hyperprolactinemias, HYPERPROLACTINAEMIA, HYPERPROLACTINEMIA, Hyperprolactinaemia, NOS, Hyperprolactinemia, NOS, INAPPROPRIATE PROLACTIN SECRET SYNDROME, PROLACTIN HYPERSECRET SYNDROME, INAPPROPRIATE PROLACTIN SECRET, PROLACTIN INAPPROPRIATE SECRET, hyperprolactinemia (diagnosis), hyperprolactinemia, Idiopathic hyperprolactinemia (disorder), Idiopathic hyperprolactinemia [dup], Idiopathic hyperprolactinemia, Hyperprolactinaemia (disorder), Hyperprolactinemia, Hypersecretion Syndrome, Prolactin, Prolactin Hypersecretion Syndrome, Syndrome, Prolactin Hypersecretion, Inappropriate Prolactin Secretion, Inappropriate Secretion Prolactin, Prolactin Secretion, Inappropriate, Prolactin, Inappropriate Secretion, Secretion Prolactin, Inappropriate, Secretion, Inappropriate Prolactin, Inappropriate Prolactin Secretion Syndrome, Hyperprolactinemia [Disease/Finding], Hyperprolactinaemia, Hyperprolactinemia (disorder), hyperprolactinaemia&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;HYPERPROLACTINEMIE, Hyperprolactinémie, Syndrome de sécrétion inappropriée d'hormone lutéotrope, Syndrome de sécrétion inappropriée de LTH, Syndrome de sécrétion inappropriée de PRL, Syndrome de sécrétion inappropriée de prolactine&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;HIPERPROLACTINEMIA, Hiperprolactinemia, Secreção Inadequada de Prolactina, Síndrome da Hipersecrecão de Prolactina&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;HIPERPROLACTINEMIA, Hyperprolactinaemia, Hyperprolactinemia, hiperprolactinemia (concepto no activo), hiperprolactinemia (trastorno), hiperprolactinemia, hipersecreción de prolactina, Hiperprolactinemia, Secreción Inapropiada de Prolactina, Síndrome de Hipersecreción de Prolactina, Secrecion Inapropiada de Prolactina, Sindrome de Hipersecrecion de Prolactina&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;HYPERPROLAKTINAEMIE, Hyperprolactinaemie, Hyperprolaktinaemie, Prolaktin-Hypersekretionssyndrom, Hyperprolaktinämie, Prolaktinämie, Hyper-, Prolaktin, inadäquate Sekretion&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Hyperprolaktinemi&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;ｺｳﾌﾟﾛﾗｸﾁﾝｹﾂｼｮｳ, ｺｳﾌﾟﾛﾗｸﾁﾝｹｯｼｮｳ, 過プロラクチン血症, 高プロラクチン血症, 高プロラクチン血&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;hyperprolaktinémie, Hyperprolaktinemie&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Hyperprolaktinemia&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;GIPERPROLAKTINEMIIA, ГИПЕРПРОЛАКТИНЕМИЯ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Secrezione inappropriata di prolattina, Iperprolattinemia&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Korean&lt;/td&gt;
                &lt;td&gt;고프로락틴혈증&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Croatian&lt;/td&gt;
                &lt;td&gt;HIPERPROLAKTINEMIJA&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Hiperprolaktynemia, Nadmierne wydzielanie prolaktyny&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;Hyperprolactinaemia&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;hyperprolactinemie, Hyperprolactinemie, Prolactinehypersecretiesyndroom, Prolactinemie, hyper-, Prolactinesecretie, inadequate&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Galactorrhea associated with childbirth  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0269995"&gt;&lt;i&gt;C0269995&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Disease or Syndrome (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0269995&amp;amp;tui=T047"&gt;&lt;i&gt;T047&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD9&lt;/td&gt;
                &lt;td&gt;676.60, 676.6&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD10&lt;/td&gt;
                &lt;td&gt;O92.6&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;71639005, 65377004&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Galactorrhea, LACTATION PUERPERAL INCREASED, Galactorrhea associated with childbirth, Galactorrhoea, Lactation puerperal increased, Galactorrhea preg-unspec, galactorrhoea, Persistent secretion of milk associated with childbirth, Polygalactia, Increased postpartum lactation, Increased puerperal lactation, Galactorrhea associated with childbirth (disorder), Galactorrhoea associated with childbirth, Polygalactia (disorder), galactorrhea, Galactorrhea associated with childbirth, unspecified as to episode of care&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Lattazione puerperale aumentata, Galattorrea associata al parto, episodio di cura non specificato&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;galactorrhoea veroorzaakt door geboorte kind, niet-gespecificeerd naar behandelperiode, Galactorroe, borstvoeding toegenomen, puerperaal&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Galactorrhée associée à l'accouchement, épisode de soins non précisé, LACTATION PUERPERALE EXCESSIVE, Hypersécrétion lactée puerpérale&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Galaktorrhoe, assoziiert mit Geburt, ohne Angabe der Behandlungsepisode, Galaktorrhoe, LAKTATION GESTEIGERT, Laktation gesteigert&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Galactorreia associada a parto, episódio de cuidados NE, LACTACAO PUERPERAL AUMENTADA, Lactação puerperal aumentada&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;Galactorrea asociada al parto, sin especificación del episodio de asistencia, hipergalactia (trastorno), SECRECION LACTEA PUERPERAL AUMENT, galactorrea asociada con el parto (trastorno), galactorrea asociada con el parto, hipergalactia, lactancia posparto aumentada, lactancia postparto aumentada, secreción persistente de leche asociada con el parto, Lactación puerperal aumentada, poligalactia (trastorno), poligalactia&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;産褥期乳汁分泌増加, 分娩に伴う乳汁漏出症、治療経過詳細不明, ﾌﾞﾝﾍﾞﾝﾆﾄﾓﾅｳﾆｭｳｼﾞｭｳﾛｳｼｭﾂｼｮｳﾁﾘｮｳｹｲｶｼｮｳｻｲﾌﾒｲ, ｻﾝｼﾞｮｸｷﾆｭｳｼﾞｭｳﾌﾞﾝﾋﾟﾂｿﾞｳｶ, ｻﾝｼﾞｮｸｷﾆｭｳｼﾞｭｳﾌﾞﾝﾋﾟｿﾞｳｶ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;Zvýšená laktace v šestinedělí, Galaktorea související s porodem, bez určení vztahu k péči&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Korean&lt;/td&gt;
                &lt;td&gt;젖흐름증&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;Gondozás időpontjával nem összefüggő, szüléshez kapcsolódó galactorrhoea, Fokozott puerperalis tejelválasztás&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Hyperprolactinemia  (</value><value>)
</value><value>Galactorrhea associated with childbirth  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Hyperprolactinemia Causes</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Pituitary Disease</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;See Also&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pituitary/Hyprprlctnm.htm" class="LinkPage"&gt;Hyperprolactinemia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Gyn/Sx/Glctrh.htm" class="LinkPage"&gt;Galactorrhea&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pituitary/Prlctnm.htm" class="LinkPage"&gt;Prolactinoma&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Causes: Timing of increases&lt;ol&gt;&lt;li&gt;Very brief increases in &lt;a href="../../Endo/Lab/Prlctn.htm" class="LinkPage"&gt;Prolactin&lt;/a&gt; (hours)&lt;ol&gt;&lt;li&gt;Meals&lt;/li&gt;&lt;li&gt;&lt;a href="../../Psych/Pharm/Clzpn.htm" class="LinkPage"&gt;Clozapine&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Generalized Tonic-Clonic &lt;a href="../../Neuro/Seizure/Szr.htm" class="LinkPage"&gt;Seizure&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Sexual intercourse&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Transient increase in &lt;a href="../../Endo/Lab/Prlctn.htm" class="LinkPage"&gt;Prolactin&lt;/a&gt; levels (days to weeks)&lt;ol&gt;&lt;li&gt;First-generation &lt;a href="../../Psych/Pharm/Antpsychtc.htm" class="LinkPage"&gt;Antipsychotic&lt;/a&gt; medications (e.g. &lt;a href="../../Psych/Pharm/Hlprdl.htm" class="LinkPage"&gt;Haloperidol&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;Second-generation &lt;a href="../../Psych/Pharm/Antpsychtc.htm" class="LinkPage"&gt;Antipsychotic&lt;/a&gt; medications (except &lt;a href="../../Psych/Pharm/Clzpn.htm" class="LinkPage"&gt;Clozapine&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;Recent &lt;a href="../../Psych/Pharm/Alchl.htm" class="LinkPage"&gt;Alcohol&lt;/a&gt; or nicotine use&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Sustained increase in &lt;a href="../../Endo/Lab/Prlctn.htm" class="LinkPage"&gt;Prolactin&lt;/a&gt; levels (weeks to months)&lt;ol&gt;&lt;li&gt;Exogenous &lt;a href="../../Gyn/Pharm/Estrgn.htm" class="LinkPage"&gt;Estrogen&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Pregnancy&lt;/li&gt;&lt;li&gt;&lt;a href="../../OB/Lactation/BrstFdng.htm" class="LinkPage"&gt;Lactation&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Pharm/Analgesic/NrctcAnlgsc.htm" class="LinkPage"&gt;Narcotic&lt;/a&gt;s&lt;/li&gt;&lt;li&gt;&lt;a href="../../Renal/Failure/ChrncRnlFlr.htm" class="LinkPage"&gt;Chronic Renal Failure&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../GI/Lvr/Crhs.htm" class="LinkPage"&gt;Cirrhosis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pituitary/Prlctnm.htm" class="LinkPage"&gt;Prolactinoma&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;References&lt;ol&gt;&lt;li&gt;Naus (2009) Federal Practitioner p. 44-9&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Haddad%20%20%5BAU%5D%20AND%202001%20%5BDP%5D%20AND%20%20J%20Psychopharmacol%20%20%5BTA%5D" class="LinkRef"&gt;Haddad (2001) J Psychopharmacol 15(4):293-5&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Causes: Physiologic&lt;ol&gt;&lt;li&gt;&lt;a href="../../Gyn/Anatomy/BrstAntmy.htm" class="LinkPage"&gt;Breast&lt;/a&gt; stimulation&lt;/li&gt;&lt;li&gt;Sexual Intercourse&lt;/li&gt;&lt;li&gt;Eating or dehydration&lt;/li&gt;&lt;li&gt;&lt;a href="../../Sports/Exercise/Exrcs.htm" class="LinkPage"&gt;Exercise&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Psych/Exam/Slp.htm" class="LinkPage"&gt;Sleep&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Stress&lt;/li&gt;&lt;li&gt;&lt;a href="../../OB/Lactation/BrstFdng.htm" class="LinkPage"&gt;Lactation&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Pregnancy or Puerperium&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/Prlctn.htm" class="LinkPage"&gt;Prolactin&lt;/a&gt; levels may reach 200 mcg/L&lt;/li&gt;&lt;li&gt;Resolves within 6 months postpartum&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Neonatal &lt;a href="../../Gyn/Sx/Glctrh.htm" class="LinkPage"&gt;Galactorrhea&lt;/a&gt; (Witch's Milk)&lt;ol&gt;&lt;li&gt;Resolves in first 2 months of life&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Causes: Medications&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Endo/Pharm/MdctnCsOfHyprprlctnm.htm" class="LinkPage"&gt;Medication Causes of Hyperprolactinemia&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Causes: Non-Neoplastic&lt;ol&gt;&lt;li&gt;Afferent Neural Stimulation&lt;ol&gt;&lt;li&gt;Mechanism&lt;ol&gt;&lt;li&gt;&lt;a href="../../Lung/Anatomy/ChstAntmy.htm" class="LinkPage"&gt;Chest&lt;/a&gt; wall &lt;a href="../../Neuro/Exam/SnsryExm.htm" class="LinkPage"&gt;Sensory Nerve&lt;/a&gt; signal passed via spinal cord to hypothalamus&lt;/li&gt;&lt;li&gt;Signal reduces &lt;a href="../../CV/Pharm/Dpmn.htm" class="LinkPage"&gt;Dopamine&lt;/a&gt; levels, which in turn generate less inhibition of &lt;a href="../../Endo/Lab/Prlctn.htm" class="LinkPage"&gt;Prolactin&lt;/a&gt; secretion&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Gyn/Anatomy/BrstAntmy.htm" class="LinkPage"&gt;Breast&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Chronic &lt;a href="../../Gyn/ID/Msts.htm" class="LinkPage"&gt;Breast abscess&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Excessive nipple or &lt;a href="../../Gyn/Anatomy/BrstAntmy.htm" class="LinkPage"&gt;Breast&lt;/a&gt; manipulation&lt;ol&gt;&lt;li&gt;Irritating clothes&lt;/li&gt;&lt;li&gt;Ill-fitting brassieres&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Lung/Anatomy/ChstAntmy.htm" class="LinkPage"&gt;Chest&lt;/a&gt; Wall and Skin&lt;ol&gt;&lt;li&gt;&lt;a href="../../ID/Virus/HrpsZstr.htm" class="LinkPage"&gt;Herpes Zoster&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Gyn/Surgery/Mstctmy.htm" class="LinkPage"&gt;Mastectomy&lt;/a&gt; or other &lt;a href="../../Gyn/Anatomy/BrstAntmy.htm" class="LinkPage"&gt;Breast&lt;/a&gt; surgery&lt;/li&gt;&lt;li&gt;Thoracotomy&lt;/li&gt;&lt;li&gt;&lt;a href="../../ER/Environ/BrnInjry.htm" class="LinkPage"&gt;Burn Injury&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Spinal Cord tumor, injury or surgery&lt;ol&gt;&lt;li&gt;&lt;a href="../../Neuro/Cerebellum/Syrngmyl.htm" class="LinkPage"&gt;Syringomyelia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../ID/Neuro/Nrsyphls.htm" class="LinkPage"&gt;Tabes Dorsalis&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Endocrine&lt;ol&gt;&lt;li&gt;Adrenal adenoma or tumor&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/Hypthyrdsm.htm" class="LinkPage"&gt;Hypothyroidism&lt;/a&gt; (related to TRH increase)&lt;/li&gt;&lt;li&gt;Ovarian tumor&lt;/li&gt;&lt;li&gt;&lt;a href="../../Gyn/Endo/PlycystcOvryDs.htm" class="LinkPage"&gt;Polycystic Ovary Disease&lt;/a&gt;&lt;/li&gt;&lt;li&gt;FSH-Secreting Tumor (related to &lt;a href="../../Gyn/Pharm/Estrgn.htm" class="LinkPage"&gt;Estrogen&lt;/a&gt; increase)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/Prlctn.htm" class="LinkPage"&gt;Prolactin&lt;/a&gt; Inhibiting Factor (PIF) synthesis Inhibition&lt;ol&gt;&lt;li&gt;Hypothalamic cause&lt;/li&gt;&lt;li&gt;&lt;a href="../../Neuro/CV/IschmcStrk.htm" class="LinkPage"&gt;Cerebrovascular Accident&lt;/a&gt; (Infarction)&lt;/li&gt;&lt;li&gt;Infiltrative Disease&lt;ol&gt;&lt;li&gt;&lt;a href="../../Neuro/ID/VrlEncphlts.htm" class="LinkPage"&gt;Encephalitis&lt;/a&gt; or post-&lt;a href="../../Neuro/ID/VrlEncphlts.htm" class="LinkPage"&gt;Encephalitis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../GI/HemeOnc/Hmchrmts.htm" class="LinkPage"&gt;Hemochromatosis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Histiocytosis&lt;/li&gt;&lt;li&gt;&lt;a href="../../Lung/ILD/Srcds.htm" class="LinkPage"&gt;Sarcoidosis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Lung/Tb/Tbrcls.htm" class="LinkPage"&gt;Tuberculosis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../ID/Parasite/Schstsms.htm" class="LinkPage"&gt;Schistosomiasis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Schuller-Christian Disease&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Irradiation&lt;/li&gt;&lt;li&gt;Pseudocyesis&lt;/li&gt;&lt;li&gt;&lt;a href="../../Neuro/Tremor/PrknsnsDs.htm" class="LinkPage"&gt;Parkinson's Disease&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/Prlctn.htm" class="LinkPage"&gt;Prolactin&lt;/a&gt; Inhibiting Factor (PIF) transport interrupted&lt;ol&gt;&lt;li&gt;Pituitary stalk section interrupted&lt;/li&gt;&lt;li&gt;Pituitary Stalk compression&lt;ol&gt;&lt;li&gt;&lt;a href="../../Neuro/CV/CrbrlAnrysm.htm" class="LinkPage"&gt;Cerebral Aneurysm&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Cerebral cyst&lt;/li&gt;&lt;li&gt;Empty sella syndrome&lt;/li&gt;&lt;li&gt;&lt;a href="../../Neuro/CSF/PsdtmrCrbr.htm" class="LinkPage"&gt;Pseudotumor Cerebri&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Rathke's Cleft &lt;a href="../../Derm/Exam/Cyst.htm" class="LinkPage"&gt;Cyst&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Other non-neoplastic causes&lt;ol&gt;&lt;li&gt;Acute Intermittent porphyria&lt;/li&gt;&lt;li&gt;Hepatic &lt;a href="../../GI/Lvr/Crhs.htm" class="LinkPage"&gt;Cirrhosis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Neuro/Demyelinating/MltplSclrs.htm" class="LinkPage"&gt;Multiple Sclerosis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Renal/Failure/ChrncRnlFlr.htm" class="LinkPage"&gt;Chronic Kidney Disease&lt;/a&gt; (&lt;a href="../../Renal/Failure/ChrncRnlFlr.htm" class="LinkPage"&gt;Chronic Renal Failure&lt;/a&gt; or Renal Insufficiency)&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/Prlctn.htm" class="LinkPage"&gt;Prolactin&lt;/a&gt; levels may reach 1000 mcg/L&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Causes: Neoplastic&lt;ol&gt;&lt;li&gt;Hypothalamic &lt;a href="../../CV/Pharm/Dpmn.htm" class="LinkPage"&gt;Dopamine&lt;/a&gt; (&lt;a href="../../Endo/Lab/Prlctn.htm" class="LinkPage"&gt;Prolactin&lt;/a&gt; Inhibiting Factor or PIF) deficiency&lt;ol&gt;&lt;li&gt;Hypothalamic &lt;a href="../../CV/Pharm/Dpmn.htm" class="LinkPage"&gt;Dopamine&lt;/a&gt; synthesis inhibition&lt;ol&gt;&lt;li&gt;Hypothalamic Tumors&lt;ol&gt;&lt;li&gt;Craniopharyngioma&lt;/li&gt;&lt;li&gt;Germinoma&lt;/li&gt;&lt;li&gt;Meningioma&lt;/li&gt;&lt;li&gt;Metastases&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Pineal Tumors (Primary or metastatic)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Pituitary stalk compression (hypothalamic &lt;a href="../../CV/Pharm/Dpmn.htm" class="LinkPage"&gt;Dopamine&lt;/a&gt; transport interrupted)&lt;ol&gt;&lt;li&gt;Hypothalamic tumor&lt;/li&gt;&lt;li&gt;Pituitary tumor&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/Prlctn.htm" class="LinkPage"&gt;Prolactin&lt;/a&gt;-secreting tumors&lt;ol&gt;&lt;li&gt;Pituitary tumors&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pituitary/Acrmgly.htm" class="LinkPage"&gt;Acromegaly&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Pituitary adenomas secreting &lt;a href="../../Endo/Pharm/HmnGrwthHrmn.htm" class="LinkPage"&gt;Growth Hormone&lt;/a&gt; also secrete &lt;a href="../../Endo/Lab/Prlctn.htm" class="LinkPage"&gt;Prolactin&lt;/a&gt; in up to 50% of cases&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/HmnGrwthHrmn.htm" class="LinkPage"&gt;Growth Hormone&lt;/a&gt; also has an independent &lt;a href="../../OB/Lactation/BrstFdng.htm" class="LinkPage"&gt;Lactation&lt;/a&gt; effect&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Adrenal/CshngsDs.htm" class="LinkPage"&gt;Cushing's Disease&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Nelson Disease&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/Prlctn.htm" class="LinkPage"&gt;Prolactin&lt;/a&gt;-secreting pituitary tumor&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Ectopic tumor production&lt;ol&gt;&lt;li&gt;&lt;a href="../../Gyn/HemeOnc/BrstCncr.htm" class="LinkPage"&gt;Breast Cancer&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Lung/HemeOnc/LngCncr.htm" class="LinkPage"&gt;Bronchogenic Carcinoma&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Hypernephroma&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Other tumors&lt;ol&gt;&lt;li&gt;&lt;a href="../../OB/HemeOnc/HydtdfrmMl.htm" class="LinkPage"&gt;Hydatidiform Mole&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;Stenchever (2001) Comprehensive Gynecology, p. 1125-42&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Serri%20%20%5BAU%5D%20AND%202003%20%5BDP%5D%20AND%20%20CMAJ%20%20%5BTA%5D" class="LinkRef"&gt;Serri (2003) CMAJ 169:575-81&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0020514</value><value>C0269995</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Pituitary/HyprprlctnmCs.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Hyperprolactinemia Causes, Galactorrhea Causes</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Pituitary/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Gigantism  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0017547"&gt;&lt;i&gt;C0017547&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A clinical finding indicating abnormal and excessive body growth and height resulting from the overproduction of human growth hormone.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A condition in which the whole body or any of its parts grow much larger than normal.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CSP)&lt;/td&gt;
                &lt;td&gt;condition of abnormal overgrowth or excessive size of the whole body or any of its parts.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;The condition of accelerated and excessive GROWTH in children or adolescents who are exposed to excess HUMAN GROWTH HORMONE before the closure of EPIPHYSES. It is usually caused by somatotroph hyperplasia or a GROWTH HORMONE-SECRETING PITUITARY ADENOMA. These patients are of abnormally tall stature, more than 3 standard deviations above normal mean height for age.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Disease or Syndrome (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0017547&amp;amp;tui=T047"&gt;&lt;i&gt;T047&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D005877&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;123111004, 80849007, 86073008, 363094008, 154698000, 267480001&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Gigantism, GIGANTISM, GIGANTISM, PITUITARY, Giant, NOS, Giant, genetic, Giantism, NOS, Gigantism, NOS, Gigantosoma, gigantism (diagnosis), gigantism, gigantism (physical finding), Giant (disorder), gigantism was noted, Gigantism [Disease/Finding], giant, giantism, gigantism disorder, genetics giant, giants, Giant, Pituitary gigantism, Genetic giant, Normal giant, Primordial giant, Disorders with tall stature (disorder), Disorders with tall stature, Giantism, Gigantism (disorder), gigantism; pituitary, pituitary; gigantism, Giant -RETIRED-, Gigantism, Pituitary, Pituitary Gigantism&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;GIGANTISME, Gigantisme, Gigantisme hypophysaire&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;GIGANTISMO, Gigantismo&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;GIGANTISMO, trastornos relacionados con talla alta, Gigantism, gigante (concepto no activo), gigante genético, gigante normal, gigante primordial, gigante, gigantismo (trastorno), gigantismo, trastornos asociados con estatura elevada (trastorno), trastornos asociados con estatura elevada, trastornos relacionados con talla alta (trastorno), Gigantismo&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;GIGANTISMUS, Gigantismus&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Jätteväxt&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;ｷｮｼﾞﾝｼｮｳ, 巨人症&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;gigantismus, Gigantismus&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Jättikasvu&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;MAKROSOMIIA, GIGANTIZM, ГИГАНТИЗМ, МАКРОСОМИЯ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Gigantismo pituitario, Gigantismo&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Croatian&lt;/td&gt;
                &lt;td&gt;GIGANTIZAM, DIVOVSKI RAST, ORIJAŠKI RAST&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Gigantyzm&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;Gigantizmus&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;gigantisme; hypofyse, hypofyse; gigantisme, gigantisme, Gigantisme, Reuzengroei&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Gigantism  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Gigantism</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Pituitary Disease</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;See Also&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pituitary/Acrmgly.htm" class="LinkPage"&gt;Acromegaly&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Pathophysiology&lt;ol&gt;&lt;li&gt;&lt;a href="../../HemeOnc/Lab/EsnphlCnt.htm" class="LinkPage"&gt;Eosinophil&lt;/a&gt;ic pituitary adenoma&lt;/li&gt;&lt;li&gt;Results in hypersecretion of &lt;a href="../../Endo/Pharm/HmnGrwthHrmn.htm" class="LinkPage"&gt;Growth Hormone&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Occurs in children before epiphyseal closure&lt;ol&gt;&lt;li&gt;Results in excessive growth&lt;/li&gt;&lt;li&gt;Contrast with &lt;a href="../../Endo/Pituitary/Acrmgly.htm" class="LinkPage"&gt;Acromegaly&lt;/a&gt; in adults&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Symptoms&lt;ol&gt;&lt;li&gt;Rapid excessive growth&lt;/li&gt;&lt;li&gt;Weakness&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Signs&lt;ol&gt;&lt;li&gt;Excessive lengthening of bones&lt;/li&gt;&lt;li&gt;Normal body proportions&lt;/li&gt;&lt;li&gt;&lt;a href="../../Neuro/Exam/IncrsdIntrcrnlPrsrInTrm.htm" class="LinkPage"&gt;Increased Intracranial Pressure&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Diffuse organ hyperplasia&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Radiology&lt;ol&gt;&lt;li&gt;XRay Sinuses&lt;ol&gt;&lt;li&gt;&lt;a href="../../ENT/Anatomy/FrntlSns.htm" class="LinkPage"&gt;Frontal Sinus&lt;/a&gt;es enlarged&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;XRay Hand&lt;ol&gt;&lt;li&gt;Tufting of distal phalanges&lt;/li&gt;&lt;li&gt;&lt;a href="../../Ortho/Anatomy/MtcrplBn.htm" class="LinkPage"&gt;Metacarpal&lt;/a&gt; broadening&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;XRay Spine&lt;ol&gt;&lt;li&gt;&lt;a href="../../Ortho/Anatomy/SpnAntmy.htm" class="LinkPage"&gt;Vertebra&lt;/a&gt;l broadening&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;XRay &lt;a href="../../Dental/Anatomy/MndblAntmy.htm" class="LinkPage"&gt;Mandible&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Hyperplasia of the &lt;a href="../../Dental/Anatomy/MndblAntmy.htm" class="LinkPage"&gt;Mandible&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Neuro/Rad/CtHd.htm" class="LinkPage"&gt;CT Head&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Sella turcica widening&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0017547</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Pituitary/Ggntsm.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Gigantism</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Pituitary/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Hyperprolactinemia  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0020514"&gt;&lt;i&gt;C0020514&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CSP)&lt;/td&gt;
                &lt;td&gt;increased levels of prolactin in the blood, which may be associated with amenorrhea and galactorrhea; relatively common etiologies include prolactinoma, medication effect, kidney failure, granulomatous diseases of the pituitary gland, and disorders which interfere with the hypothalamic inhibition of prolactin release; ectopic (non-pituitary) production of prolactin may also occur.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;Increased levels of PROLACTIN in the BLOOD, which may be associated with AMENORRHEA and GALACTORRHEA. Relatively common etiologies include PROLACTINOMA, medication effect, KIDNEY FAILURE, granulomatous diseases of the PITUITARY GLAND, and disorders which interfere with the hypothalamic inhibition of prolactin release. Ectopic (non-pituitary) production of prolactin may also occur. (From Joynt, Clinical Neurology, 1992, Ch36, pp77-8)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Disease or Syndrome (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0020514&amp;amp;tui=T047"&gt;&lt;i&gt;T047&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D006966&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD10&lt;/td&gt;
                &lt;td&gt;E22.1&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;367422005, 190468001, 237662005, 21170004&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Hyperprolactinemias, HYPERPROLACTINAEMIA, HYPERPROLACTINEMIA, Hyperprolactinaemia, NOS, Hyperprolactinemia, NOS, INAPPROPRIATE PROLACTIN SECRET SYNDROME, PROLACTIN HYPERSECRET SYNDROME, INAPPROPRIATE PROLACTIN SECRET, PROLACTIN INAPPROPRIATE SECRET, hyperprolactinemia (diagnosis), hyperprolactinemia, Idiopathic hyperprolactinemia (disorder), Idiopathic hyperprolactinemia [dup], Idiopathic hyperprolactinemia, Hyperprolactinaemia (disorder), Hyperprolactinemia, Hypersecretion Syndrome, Prolactin, Prolactin Hypersecretion Syndrome, Syndrome, Prolactin Hypersecretion, Inappropriate Prolactin Secretion, Inappropriate Secretion Prolactin, Prolactin Secretion, Inappropriate, Prolactin, Inappropriate Secretion, Secretion Prolactin, Inappropriate, Secretion, Inappropriate Prolactin, Inappropriate Prolactin Secretion Syndrome, Hyperprolactinemia [Disease/Finding], Hyperprolactinaemia, Hyperprolactinemia (disorder), hyperprolactinaemia&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;HYPERPROLACTINEMIE, Hyperprolactinémie, Syndrome de sécrétion inappropriée d'hormone lutéotrope, Syndrome de sécrétion inappropriée de LTH, Syndrome de sécrétion inappropriée de PRL, Syndrome de sécrétion inappropriée de prolactine&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;HIPERPROLACTINEMIA, Hiperprolactinemia, Secreção Inadequada de Prolactina, Síndrome da Hipersecrecão de Prolactina&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;HIPERPROLACTINEMIA, Hyperprolactinaemia, Hyperprolactinemia, hiperprolactinemia (concepto no activo), hiperprolactinemia (trastorno), hiperprolactinemia, hipersecreción de prolactina, Hiperprolactinemia, Secreción Inapropiada de Prolactina, Síndrome de Hipersecreción de Prolactina, Secrecion Inapropiada de Prolactina, Sindrome de Hipersecrecion de Prolactina&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;HYPERPROLAKTINAEMIE, Hyperprolactinaemie, Hyperprolaktinaemie, Prolaktin-Hypersekretionssyndrom, Hyperprolaktinämie, Prolaktinämie, Hyper-, Prolaktin, inadäquate Sekretion&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Hyperprolaktinemi&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;ｺｳﾌﾟﾛﾗｸﾁﾝｹﾂｼｮｳ, ｺｳﾌﾟﾛﾗｸﾁﾝｹｯｼｮｳ, 過プロラクチン血症, 高プロラクチン血症, 高プロラクチン血&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;hyperprolaktinémie, Hyperprolaktinemie&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Hyperprolaktinemia&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;GIPERPROLAKTINEMIIA, ГИПЕРПРОЛАКТИНЕМИЯ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Secrezione inappropriata di prolattina, Iperprolattinemia&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Korean&lt;/td&gt;
                &lt;td&gt;고프로락틴혈증&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Croatian&lt;/td&gt;
                &lt;td&gt;HIPERPROLAKTINEMIJA&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Hiperprolaktynemia, Nadmierne wydzielanie prolaktyny&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;Hyperprolactinaemia&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;hyperprolactinemie, Hyperprolactinemie, Prolactinehypersecretiesyndroom, Prolactinemie, hyper-, Prolactinesecretie, inadequate&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Hyperprolactinemia  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Hyperprolactinemia</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Pituitary Disease</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;See Also&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pituitary/HyprprlctnmCs.htm" class="LinkPage"&gt;Hyperprolactinemia Causes&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Gyn/Sx/Glctrh.htm" class="LinkPage"&gt;Galactorrhea&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pituitary/Prlctnm.htm" class="LinkPage"&gt;Prolactinoma&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Causes&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Endo/Pituitary/HyprprlctnmCs.htm" class="LinkPage"&gt;Hyperprolactinemia Causes&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/MdctnCsOfHyprprlctnm.htm" class="LinkPage"&gt;Medication Causes of Hyperprolactinemia&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Symptoms&lt;ol&gt;&lt;li&gt;&lt;a href="../../Gyn/Sx/Glctrh.htm" class="LinkPage"&gt;Galactorrhea&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Occurs in 90% of women with Hyperprolactinemia&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Gyn/Sx/Amnrh.htm" class="LinkPage"&gt;Amenorrhea&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Gyn/Endo/FmlInfrtlty.htm" class="LinkPage"&gt;Infertility&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Diagnosis&lt;ol&gt;&lt;li&gt;&lt;a href="../../Gyn/Sx/Glctrh.htm" class="LinkPage"&gt;Galactorrhea&lt;/a&gt; with &lt;a href="../../Gyn/Sx/Amnrh.htm" class="LinkPage"&gt;Amenorrhea&lt;/a&gt; is pathognomonic for Hyperprolactinemia&lt;/li&gt;&lt;li&gt;&lt;a href="../../Gyn/Sx/Glctrh.htm" class="LinkPage"&gt;Galactorrhea&lt;/a&gt; without &lt;a href="../../Gyn/Sx/Amnrh.htm" class="LinkPage"&gt;Amenorrhea&lt;/a&gt; is associated with normal &lt;a href="../../Endo/Lab/Prlctn.htm" class="LinkPage"&gt;Serum Prolactin&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Imaging: Brain&lt;ol&gt;&lt;li&gt;MRI Brain with IV contrast&lt;ol&gt;&lt;li&gt;Thin cuts through the sella turcica, hypothalamus and optic chiasm&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Neuro/Rad/CtHd.htm" class="LinkPage"&gt;CT Head&lt;/a&gt; with cone down sella turcica&lt;ol&gt;&lt;li&gt;Lower &lt;a href="../../Prevent/Epi/TstSnstvty.htm" class="LinkPage"&gt;Test Sensitivity&lt;/a&gt; than MRI for pituitary adenoma and associated abnormalities&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Approach: Initial Evaluation&lt;ol&gt;&lt;li&gt;Confirm Hyperprolactinemia&lt;ol&gt;&lt;li&gt;Repeat &lt;a href="../../Endo/Lab/Prlctn.htm" class="LinkPage"&gt;Serum Prolactin&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Repeat in 6 months if repeat &lt;a href="../../Endo/Lab/Prlctn.htm" class="LinkPage"&gt;Prolactin&lt;/a&gt; normal&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Evaluate for Physiologic Cause&lt;ol&gt;&lt;li&gt;History&lt;ol&gt;&lt;li&gt;&lt;a href="../../Gyn/Anatomy/BrstAntmy.htm" class="LinkPage"&gt;Breast&lt;/a&gt; stimulation or &lt;a href="../../OB/Lactation/BrstFdng.htm" class="LinkPage"&gt;Lactation&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Sexual Intercourse temporally related to lab test&lt;/li&gt;&lt;li&gt;Excessive Eating, &lt;a href="../../Sports/Exercise/Exrcs.htm" class="LinkPage"&gt;Exercise&lt;/a&gt;, &lt;a href="../../Psych/Exam/Slp.htm" class="LinkPage"&gt;Sleep&lt;/a&gt; or Stress&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Labs&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/ThyrdStmltngHrmn.htm" class="LinkPage"&gt;Thyroid Stimulating Hormone&lt;/a&gt; (&lt;a href="../../Endo/Thyroid/Hypthyrdsm.htm" class="LinkPage"&gt;Hypothyroidism&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;Urine &lt;a href="../../OB/Lab/PrgncyTst.htm" class="LinkPage"&gt;Pregnancy Test&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Renal/Lab/SrmCrtn.htm" class="LinkPage"&gt;Serum Creatinine&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Consider reproductive hormone levels if &lt;a href="../../Endo/Sex/Hypgndsm.htm" class="LinkPage"&gt;Hypogonadism&lt;/a&gt; is present&lt;ol&gt;&lt;li&gt;Serum &lt;a href="../../Gyn/Pharm/Estrgn.htm" class="LinkPage"&gt;Estrogen&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Uro/Lab/TtlTststrn.htm" class="LinkPage"&gt;Serum Testosterone&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/FlclStmltngHrmn.htm" class="LinkPage"&gt;Follicle Stimulating Hormone&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/LtnzngHrmn.htm" class="LinkPage"&gt;Luteinizing hormone&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Approach: &lt;a href="../../Endo/Lab/Prlctn.htm" class="LinkPage"&gt;Prolactin&lt;/a&gt; 20 to 50 ng/ml&lt;ol&gt;&lt;li&gt;Identify medication related Hyperprolactinemia cause&lt;ol&gt;&lt;li&gt;Discontinue &lt;a href="../../Endo/Pharm/MdctnCsOfHyprprlctnm.htm" class="LinkPage"&gt;Medication Causes of Hyperprolactinemia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Repeat &lt;a href="../../Endo/Lab/Prlctn.htm" class="LinkPage"&gt;Prolactin&lt;/a&gt; in 1-2 months&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;No obvious medication cause&lt;ol&gt;&lt;li&gt;Recheck &lt;a href="../../Endo/Lab/Prlctn.htm" class="LinkPage"&gt;Serum Prolactin&lt;/a&gt; in 3 months&lt;/li&gt;&lt;li&gt;Consider lab testing as above (e.g. TSH, HCG)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Approach: &lt;a href="../../Endo/Lab/Prlctn.htm" class="LinkPage"&gt;Prolactin&lt;/a&gt; 50 to 100 ng/ml&lt;ol&gt;&lt;li&gt;Identify medication related Hyperprolactinemia cause&lt;ol&gt;&lt;li&gt;Discontinue offending medication&lt;/li&gt;&lt;li&gt;Repeat &lt;a href="../../Endo/Lab/Prlctn.htm" class="LinkPage"&gt;Prolactin&lt;/a&gt; in 1-2 months&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;No obvious medication cause&lt;ol&gt;&lt;li&gt;Obtain CT or &lt;a href="../../Neuro/Rad/HdMgntcRsncImgng.htm" class="LinkPage"&gt;MRI Head&lt;/a&gt; (cone-down sella turcica)&lt;/li&gt;&lt;li&gt;Imaging Abnormal&lt;ol&gt;&lt;li&gt;Evaluate Pituitary Tumor (see &lt;a href="../../Endo/Pituitary/Prlctnm.htm" class="LinkPage"&gt;Prolactinoma&lt;/a&gt;)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Imaging Normal&lt;ol&gt;&lt;li&gt;Consider &lt;a href="../../Endo/Pharm/DpmnAgnst.htm" class="LinkPage"&gt;Dopamine Agonist&lt;/a&gt; (e.g. &lt;a href="../../Endo/Pharm/DpmnAgnst.htm" class="LinkPage"&gt;Bromocriptine&lt;/a&gt;, &lt;a href="../../Endo/Pharm/DpmnAgnst.htm" class="LinkPage"&gt;Cabergoline&lt;/a&gt;)&lt;ol&gt;&lt;li&gt;Symptomatic Hyperprolactinemia (e.g. bothersome &lt;a href="../../Gyn/Sx/Glctrh.htm" class="LinkPage"&gt;Galactorrhea&lt;/a&gt; or &lt;a href="../../Gyn/Sx/Amnrh.htm" class="LinkPage"&gt;Amenorrhea&lt;/a&gt;)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Consider hormonal therapy (&lt;a href="../../Gyn/Pharm/Estrgn.htm" class="LinkPage"&gt;Estrogen&lt;/a&gt; or testosterone)&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Sex/Hypgndsm.htm" class="LinkPage"&gt;Hypogonadism&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Repeat evaluation and testing&lt;ol&gt;&lt;li&gt;Repeat &lt;a href="../../Endo/Lab/Prlctn.htm" class="LinkPage"&gt;Prolactin&lt;/a&gt; at 6 month intervals&lt;/li&gt;&lt;li&gt;Repeat CT or &lt;a href="../../Neuro/Rad/HdMgntcRsncImgng.htm" class="LinkPage"&gt;MRI Head&lt;/a&gt; (cone-down sella) in 1 year&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Approach: &lt;a href="../../Endo/Lab/Prlctn.htm" class="LinkPage"&gt;Prolactin&lt;/a&gt; &amp;gt;100 ng/ml&lt;ol&gt;&lt;li&gt;Causes&lt;ol&gt;&lt;li&gt;Empty sella syndrome&lt;/li&gt;&lt;li&gt;Pituitary adenoma (especially if &amp;gt;200 ng/ml)&lt;/li&gt;&lt;li&gt;Consider medication related Hyperprolactinemia&lt;ol&gt;&lt;li&gt;Less likely to raise the &lt;a href="../../Endo/Lab/Prlctn.htm" class="LinkPage"&gt;Serum Prolactin&lt;/a&gt; this high&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Obtain CT or &lt;a href="../../Neuro/Rad/HdMgntcRsncImgng.htm" class="LinkPage"&gt;MRI Head&lt;/a&gt; (cone-down sella turcica)&lt;ol&gt;&lt;li&gt;Imaging Abnormal&lt;ol&gt;&lt;li&gt;Evaluate Pituitary Tumor (see &lt;a href="../../Endo/Pituitary/Prlctnm.htm" class="LinkPage"&gt;Prolactinoma&lt;/a&gt;)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Imaging Normal&lt;ol&gt;&lt;li&gt;Treatment with &lt;a href="../../Endo/Pharm/DpmnAgnst.htm" class="LinkPage"&gt;Dopamine Agonist&lt;/a&gt; (e.g. &lt;a href="../../Endo/Pharm/DpmnAgnst.htm" class="LinkPage"&gt;Bromocriptine&lt;/a&gt;, &lt;a href="../../Endo/Pharm/DpmnAgnst.htm" class="LinkPage"&gt;Cabergoline&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;Repeat &lt;a href="../../Endo/Lab/Prlctn.htm" class="LinkPage"&gt;Serum Prolactin&lt;/a&gt; every 3 months&lt;/li&gt;&lt;li&gt;Repeat CT or &lt;a href="../../Neuro/Rad/HdMgntcRsncImgng.htm" class="LinkPage"&gt;MRI Head&lt;/a&gt; (cone-down sella) in 1 year&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Complications&lt;ol&gt;&lt;li&gt;&lt;a href="../../Rheum/Bone/Ostprs.htm" class="LinkPage"&gt;Osteoporosis&lt;/a&gt; (secondary to &lt;a href="../../Endo/Sex/Hypgndsm.htm" class="LinkPage"&gt;Hypogonadism&lt;/a&gt;)&lt;ol&gt;&lt;li&gt;Consider Bone density scan (&lt;a href="../../Rheum/Rad/DlEnrgyXryAbsrptmtry.htm" class="LinkPage"&gt;DEXA&lt;/a&gt;)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Huang%20%20%5BAU%5D%20AND%202012%20%5BDP%5D%20AND%20%20Am%20Fam%20Physician%20%20%5BTA%5D" class="LinkRef"&gt;Huang (2012) Am Fam Physician 85(11): 1073-80&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0020514</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Pituitary/Hyprprlctnm.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Hyperprolactinemia</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Pituitary/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Acromegaly  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0001206"&gt;&lt;i&gt;C0001206&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A syndrome characterized by enlargement of the hands, feet, ears, nose, lips, and tongue, skin thickening and swelling of internal organs. It is caused by overproduction of growth hormone in the pituitary gland, usually by a pituitary adenoma.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A condition in which the pituitary gland makes too much growth hormone after normal growth of the skeleton is finished. This causes the bones of the hands, feet, head, and face to grow larger than normal. Acromegaly can be caused by a pituitary gland tumor.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (AIR)&lt;/td&gt;
                &lt;td&gt;WHAT: Acromegaly:	Hypersecretion of growth hormone from a pituitary tumor resulting in insidious increase in the skeleton, soft tissues and organs.	WHY:	Acromegaly can result in an arthropathy with initial cartilage hypertrophy resulting in widening of the cartilage space on radiographs. The cartilage then undergoes premature osteoarthritis change with productive bony change characterized by broad distal tufts in the phalanges.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CSP)&lt;/td&gt;
                &lt;td&gt;disorder caused by excessive secretion of somatotropin, characterized by bony enlargement of face, hands, feet, head and thorax.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;A condition caused by prolonged exposure to excessive HUMAN GROWTH HORMONE in adults. It is characterized by bony enlargement of the FACE; lower jaw (PROGNATHISM); hands; FEET; HEAD; and THORAX. The most common etiology is a GROWTH HORMONE-SECRETING PITUITARY ADENOMA. (From Joynt, Clinical Neurology, 1992, Ch36, pp79-80)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Disease or Syndrome (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0001206&amp;amp;tui=T047"&gt;&lt;i&gt;T047&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D000172&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;74107003, 154698000, 267480001&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Eosinophilic adenoma syndrome, Marie's syndrome, ACROMEGALY, SOMATOTROPIN HYPERSECRET SYNDROME ACROMEGALY, INAPPROPRIATE GROWTH HORMONE SECRET SYNDROME ACROMEGALY, INAPPROPRIATE GH SECRET SYNDROME ACROMEGALY, acromegaly (diagnosis), acromegaly, Inappropriate GH Secretion Syndrome (Acromegaly), Inappropriate Growth Hormone Secretion Syndrome (Acromegaly), Somatotropin Hypersecretion Syndrome (Acromegaly), Acromegaly [Disease/Finding], acromegalia, acromegali, marie disease, Hypersecretion Syndrome, Somatotropin (Acromegaly), Hypersecretion Syndromes, Somatotropin (Acromegaly), Somatotropin Hypersecretion Syndromes (Acromegaly), Syndrome, Somatotropin Hypersecretion (Acromegaly), Syndromes, Somatotropin Hypersecretion (Acromegaly), Acromegalia, Anterior pituitary adenoma syndrome, Growth hormone hypersecretion syndrome, Marie disease, STH hypersecretion syndrome, Acromegaly (disorder), Acromegaly&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;ACROMEGALIE, Acromégalie, Syndrome d'hypersécrétion d'hormone somatotrope (Acromégalie), Syndrome de sécrétion inappropriée d'hormone de croissance (Acromégalie), Syndrome de sécrétion inappropriée de GH (Acromégalie)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;ACROMEGALIA, Acromegalia, Síndrome da Hipersecreção de Somatotropina (Acromegalia), Síndrome da Secreção Inadequada de Hormônio de Crescimento (Acromegalia)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;ACROMEGALIA, Acromegaly, acromegalia (trastorno), acromegalia, enfermedad de Marie, hipersecreción de STH, síndrome de adenoma hipofisario anterior, síndrome de hipersecreción de somatotrofina, síndrome de hipersecreción de somatotropina, Acromegalia, Síndrome de Hipersecreción de Somatotropina (Acromegalia), Síndrome de Secreción Inapropiada de Hormona del Crecimiento (Acromegalia), Sindrome de Hipersecrecion de Somatotropina (Acromegalia), Sindrome de Secrecion Inapropiada de Hormona del Crecimiento (Acromegalia)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;AKROMEGALIE, Akromegalie, Somatotropin-Hypersekretionssyndrom (Akromegalie), Syndrom der inadäquaten Wachstumshormonsekretion (Akromegalie)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Akromegali&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;akromegalie, Akromegalie&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Akromegalia&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Sindrome da inappropriata secrezione del GH (Acromegalia), Sindrome da ipersecrezione della somatotropina (Acromegalia), Sindrome da inappropriata secrezione dell'ormone della crescita (Acromegalia), Acromegalia&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;AKROMEGALIIA, АКРОМЕГАЛИЯ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;ｾﾝﾀﾝｷｮﾀﾞｲｼｮｳ, Marie症候群, 先端巨大症, 下垂体症候群, 先端巨大, 巨端症, 末端肥大症, 肢端巨大, 肢端巨大症, 肢端肥大症, アクロメガリー&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Croatian&lt;/td&gt;
                &lt;td&gt;AKROMEGALIJA&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Somatotropowa nadczynność przysadki, Akromegalia&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;Acromegalia&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;acromegalie, Acromegalie, Somatotrofine hypersecretie syndroom (acromegalie), Verstoorde groeihormoon-uitscheiding syndroom (acromegalie)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Acromegaly  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Acromegaly</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Pituitary Disease</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;See Also&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Pituitary/Ggntsm.htm" class="LinkPage"&gt;Gigantism&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Pathophysiology&lt;ol&gt;&lt;li&gt;Pituitary adenoma hypersecretion of &lt;a href="../../Endo/Pharm/HmnGrwthHrmn.htm" class="LinkPage"&gt;Growth Hormone&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Occurs after closure of epiphyses&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Causes&lt;ol&gt;&lt;li&gt;Hyperplastic pituitary adenoma&lt;/li&gt;&lt;li&gt;&lt;a href="../../HemeOnc/Lab/EsnphlCnt.htm" class="LinkPage"&gt;Eosinophil&lt;/a&gt;ic pituitary adenoma&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Symptoms&lt;ol&gt;&lt;li&gt;&lt;a href="../../Neuro/Sx/Hdch.htm" class="LinkPage"&gt;Headache&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Eye/Sx/DcrsdVslActy.htm" class="LinkPage"&gt;Vision Loss&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Muscular weakness&lt;/li&gt;&lt;li&gt;Back pain&lt;/li&gt;&lt;li&gt;Limb pain&lt;/li&gt;&lt;li&gt;Sweating&lt;/li&gt;&lt;li&gt;&lt;a href="../../Gyn/Sx/Amnrh.htm" class="LinkPage"&gt;Amenorrhea&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Polydipsia&lt;/li&gt;&lt;li&gt;Polyuria&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Signs&lt;ol&gt;&lt;li&gt;Exaggerated supraorbital ridges&lt;/li&gt;&lt;li&gt;&lt;a href="../../Eye/Sx/Prpts.htm" class="LinkPage"&gt;Exophthalmos&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Enlargement of:&lt;ol&gt;&lt;li&gt;Hands and Feet&lt;/li&gt;&lt;li&gt;&lt;a href="../../Dental/Anatomy/MndblAntmy.htm" class="LinkPage"&gt;Mandible&lt;/a&gt; (separation of teeth)&lt;/li&gt;&lt;li&gt;Nose, Lips and &lt;a href="../../ENT/Anatomy/Tng.htm" class="LinkPage"&gt;Tongue&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Bitemporal hemianopsia to blindness&lt;/li&gt;&lt;li&gt;Weight gain&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Htn/Hyprtnsn.htm" class="LinkPage"&gt;Hypertension&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Cardiomegaly&lt;/li&gt;&lt;li&gt;&lt;a href="../../GI/Exam/Hptmgly.htm" class="LinkPage"&gt;Hepatomegaly&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Derm/Hair/Hyprtrchs.htm" class="LinkPage"&gt;Hypertrichosis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/Hyprthyrdsm1.htm" class="LinkPage"&gt;Hyperthyroidism&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/Gtr.htm" class="LinkPage"&gt;Goiter&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/Hyprthyrdsm1.htm" class="LinkPage"&gt;Thyrotoxicosis&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Renal/Endo/DbtsInspds.htm" class="LinkPage"&gt;Diabetes Insipidus&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Radiology&lt;ol&gt;&lt;li&gt;Overgrowth of cancellous bone&lt;/li&gt;&lt;li&gt;&lt;a href="../../Rheum/Bone/Ostprs.htm" class="LinkPage"&gt;Osteoporosis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Tufted phalangeal tips&lt;/li&gt;&lt;li&gt;&lt;a href="../../Rheum/OA/Ostrthrts.htm" class="LinkPage"&gt;Osteoarthritis&lt;/a&gt; signs&lt;/li&gt;&lt;li&gt;Enlarged sella turcica&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Labs&lt;ol&gt;&lt;li&gt;Elevated plasma &lt;a href="../../Endo/Pharm/HmnGrwthHrmn.htm" class="LinkPage"&gt;Growth Hormone&lt;/a&gt; (in active stage)&lt;/li&gt;&lt;li&gt;Increased urinary 17-ketosteroids&lt;/li&gt;&lt;li&gt;High serum inorganic Phosphate&lt;/li&gt;&lt;li&gt;Elevated &lt;a href="../../GI/Lab/AlklnPhsphts.htm" class="LinkPage"&gt;Alkaline Phosphatase&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Hyperglycemia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Uro/Lab/UrnGlcs.htm" class="LinkPage"&gt;Glycosuria&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Management&lt;ol&gt;&lt;li&gt;Transphenoidal surgery&lt;/li&gt;&lt;li&gt;&lt;a href="../../HemeOnc/Rad/RdtnThrpy.htm" class="LinkPage"&gt;Radiation Therapy&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pharm/DpmnAgnst.htm" class="LinkPage"&gt;Bromocriptine&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0001206</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Pituitary/Acrmgly.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Acromegaly</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Pituitary/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees></FP_UMLS_Trees><FP_Condition_name_check></FP_Condition_name_check><FP_Condition_name><value>Bone Age Film</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Radiology</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Indications&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Growth/GrwthAssmnt.htm" class="LinkPage"&gt;Growth Assessment&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Peds/FlrTThrv.htm" class="LinkPage"&gt;Failure to Thrive&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Technique&lt;ol&gt;&lt;li&gt;Age under 2 years&lt;ol&gt;&lt;li&gt;&lt;a href="../../Ortho/Rad/KnXry.htm" class="LinkPage"&gt;Knee XRay&lt;/a&gt; (Anteroposterior and lateral)&lt;/li&gt;&lt;li&gt;Hand XRay (Anteroposterior and Lateral)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Age over 2 years&lt;ol&gt;&lt;li&gt;Left hand (anteroposterior)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Rad/BnAgFlm.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Bone Age Film</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Rad/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Adrenal mass  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0342500"&gt;&lt;i&gt;C0342500&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Disease or Syndrome (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0342500&amp;amp;tui=T047"&gt;&lt;i&gt;T047&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;237783006&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Massa surrenale&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;副腎腫瘤, ﾌｸｼﾞﾝｼｭﾘｭｳ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;Rezistence nadledviny&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;ADRENAL MASS, Mass of adrenal gland, adrenal masses, mass adrenal, Adrenal mass, Adrenal Mass, Mass;adrenal, adrenal mass, Mass of adrenal gland (finding), Adrenal mass (disorder)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;masa adrenal, masa suprarrenal, Masa suprarrenal, masa suprarrenal (hallazgo), masa suprarrenal (trastorno)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;Mellékvese térfoglaló folyamata&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Massa suprarrenal&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;bijnier gezwel&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Masse de la glande surrénale&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Raumforderung der Nebenniere&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Adrenal mass  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Adrenal Mass</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Radiology</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Epidemiology&lt;ol&gt;&lt;li&gt;Incidental Adrenal Mass found on up to 3-4% of Abdominal CTs or MRIs&lt;/li&gt;&lt;li&gt;Incidental Adrenal Masses found in 20% of autopsies&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Differential Diagnosis of Incidental Adrenal Mass&lt;ol&gt;&lt;li&gt;Adrenal Adenoma (51%)&lt;ol&gt;&lt;li&gt;Non-functioning adenoma&lt;/li&gt;&lt;li&gt;Functioning adenoma&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Adrenal/CshngsDs.htm" class="LinkPage"&gt;Cushing's Syndrome&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Adrenal/Phchrmcytm.htm" class="LinkPage"&gt;Pheochromocytoma&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Adrenal/Hyprldstrnsm.htm" class="LinkPage"&gt;Hyperaldosteronism&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Metastatic cancer (31%)&lt;ol&gt;&lt;li&gt;&lt;a href="../../Lung/HemeOnc/LngCncr.htm" class="LinkPage"&gt;Bronchogenic Carcinoma&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Renal cell carcinoma&lt;/li&gt;&lt;li&gt;&lt;a href="../../Derm/HemeOnc/Mlnm.htm" class="LinkPage"&gt;Melanoma&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Adrenal Carcinoma (1-4%)&lt;/li&gt;&lt;li&gt;Adrenal &lt;a href="../../Derm/Exam/Cyst.htm" class="LinkPage"&gt;Cyst&lt;/a&gt; (4%)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Adrenal/Phchrmcytm.htm" class="LinkPage"&gt;Pheochromocytoma&lt;/a&gt; (4%)&lt;/li&gt;&lt;li&gt;Adrenal Hyperplasia (2%)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Derm/Hyperplasia/Lpm.htm" class="LinkPage"&gt;Lipoma&lt;/a&gt; (2%)&lt;/li&gt;&lt;li&gt;Myelolipoma (2%)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Labs&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Adrenal/Phchrmcytm.htm" class="LinkPage"&gt;Pheochromocytoma&lt;/a&gt; Screening&lt;ol&gt;&lt;li&gt;Consider plasma free metanephrines (in all patients)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/UrnMtnphrn.htm" class="LinkPage"&gt;24-hour Urine Metanephrine&lt;/a&gt;s&lt;/li&gt;&lt;li&gt;24-hour &lt;a href="../../Endo/Lab/UrnVnlylmndlcAcd.htm" class="LinkPage"&gt;Urine Vanillylmandelic Acid&lt;/a&gt; (VMA)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Adrenal/CshngsDs.htm" class="LinkPage"&gt;Cushing's Syndrome&lt;/a&gt; Screening&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/DxmthsnSprsnTst.htm" class="LinkPage"&gt;Dexamethasone Suppression Test&lt;/a&gt; (in all patients)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/FrUrnCrtsl.htm" class="LinkPage"&gt;24-hour Urinary free cortisol level&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Adrenal/Hyprldstrnsm.htm" class="LinkPage"&gt;Hyperaldosteronism&lt;/a&gt; Screening (hypertensive patients)&lt;ol&gt;&lt;li&gt;&lt;a href="../../Renal/Lab/SrmPtsm.htm" class="LinkPage"&gt;Serum Potassium&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Plasma aldosterone to renin activity ratio&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Imaging&lt;ol&gt;&lt;li&gt;CT &lt;a href="../../GI/Anatomy/AbdmnlAntmy.htm" class="LinkPage"&gt;Abdomen&lt;/a&gt;&lt;ol&gt;&lt;li&gt;With IV contrast&lt;/li&gt;&lt;li&gt;With delayed-phase (to perform washout calculations)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;MRI &lt;a href="../../GI/Anatomy/AbdmnlAntmy.htm" class="LinkPage"&gt;Abdomen&lt;/a&gt;&lt;ol&gt;&lt;li&gt;With Chemical Shift&lt;/li&gt;&lt;li&gt;Indicated if CT with IV contrast contraindicated&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Fluorodeoxyglucose-positron emission testing (FDG-PET)&lt;ol&gt;&lt;li&gt;Indicated for lesions not definitively characterized on CT or MRI&lt;/li&gt;&lt;li&gt;High &lt;a href="../../Prevent/Epi/TstSnstvty.htm" class="LinkPage"&gt;Test Sensitivity&lt;/a&gt; for malignancy&lt;/li&gt;&lt;li&gt;Decreased &lt;a href="../../Prevent/Epi/TstSpcfcty.htm" class="LinkPage"&gt;Test Specificity&lt;/a&gt; for malignancy (false positives possible)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Evaluation: Reassuring findings suggestive of benign Adrenal Mass&lt;ol&gt;&lt;li&gt;No history of other malignancy (lowers risk to 0.3% chance of cancer)&lt;/li&gt;&lt;li&gt;Reassuring imaging findings suggestive of benign mass&lt;ol&gt;&lt;li&gt;Lesions smaller than 4 cm with smooth borders&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Lab/Lpd.htm" class="LinkPage"&gt;Lipid&lt;/a&gt;-containing lesions&lt;ol&gt;&lt;li&gt;CT with low attenuation (&amp;lt;10 &lt;a href="../../Rad/CT/HnsfldUnt.htm" class="LinkPage"&gt;Hounsfield Unit&lt;/a&gt;s) homogeneous mass&lt;/li&gt;&lt;li&gt;MRI with signal loss on out-of-phase imaging&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Rapid-washout of IV iodinated contrast&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Indications: Follow-up Imaging&lt;ol&gt;&lt;li&gt;Distinguish benign Lesions versus cancer&lt;/li&gt;&lt;li&gt;Distinguish functioning versus non-functioning&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Evaluation: Protocol&lt;ol&gt;&lt;li&gt;Adrenal Mass on CT Scan &amp;lt;1 cm in greatest diameter&lt;ol&gt;&lt;li&gt;No further evaluation needed&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Adrenal Mass on CT Scan &amp;gt;4 cm in greatest diameter&lt;ol&gt;&lt;li&gt;Evaluate endocrine labs above (especially to rule out &lt;a href="../../Endo/Adrenal/Phchrmcytm.htm" class="LinkPage"&gt;Pheochromocytoma&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;Refer to surgery for removal&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Adrenal Mass 1-4 cm and lipid containing lesion on initial imaging (see above)&lt;ol&gt;&lt;li&gt;Consider evaluating endocrine labs above (especially to rule out &lt;a href="../../Endo/Adrenal/Phchrmcytm.htm" class="LinkPage"&gt;Pheochromocytoma&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;Repeat unenhanced CT &lt;a href="../../GI/Anatomy/AbdmnlAntmy.htm" class="LinkPage"&gt;Abdomen&lt;/a&gt; in 12 months to confirm no change&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Adrenal Mass 1-4 cm and not a lipid containing lesion&lt;ol&gt;&lt;li&gt;Evaluate endocrine labs above (especially to rule out &lt;a href="../../Endo/Adrenal/Phchrmcytm.htm" class="LinkPage"&gt;Pheochromocytoma&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;Perform CT &lt;a href="../../GI/Anatomy/AbdmnlAntmy.htm" class="LinkPage"&gt;Abdomen&lt;/a&gt; with IV contrast and delayed phase (or MRI as alternative)&lt;/li&gt;&lt;li&gt;If CT or MRI non-diagnostic, consider FDG-PET&lt;/li&gt;&lt;li&gt;Referral&lt;ol&gt;&lt;li&gt;Endocrinology for functional adenomas&lt;/li&gt;&lt;li&gt;General surgery for suspicious or non-diagnostic imaging&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Cook%20%20%5BAU%5D%20AND%201996%20%5BDP%5D%20AND%20%20Am%20J%20Med%20%20%5BTA%5D" class="LinkRef"&gt;Cook (1996) Am J Med 101:88-94&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Grumbach%20%20%5BAU%5D%20AND%202003%20%5BDP%5D%20AND%20%20Ann%20Intern%20Med%20%20%5BTA%5D" class="LinkRef"&gt;Grumbach (2003) Ann Intern Med 138:424-9&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Higgins%20%20%5BAU%5D%20AND%202001%20%5BDP%5D%20AND%20%20Am%20Fam%20Physician%20%20%5BTA%5D" class="LinkRef"&gt;Higgins (2001) Am Fam Physician 63:288-99&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Yoh%20%20%5BAU%5D%20AND%202008%20%5BDP%5D%20AND%20%20Ann%20Nucl%20Med%20%20%5BTA%5D" class="LinkRef"&gt;Yoh (2008) Ann Nucl Med 22(6): 513-9&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Young%20%20%5BAU%5D%20AND%202007%20%5BDP%5D%20AND%20%20N%20Engl%20J%20Med%20%20%5BTA%5D" class="LinkRef"&gt;Young (2007) N Engl J Med 356(6): 601-10&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Willatt%20%20%5BAU%5D%20AND%202010%20%5BDP%5D%20AND%20%20Am%20Fam%20Physician%20%20%5BTA%5D" class="LinkRef"&gt;Willatt (2010) Am Fam Physician 81(11): 1361-6&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0342500</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Rad/AdrnlMs.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Adrenal Mass, Adrenal Incidentaloma</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Rad/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Premature development of the breasts  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0425772"&gt;&lt;i&gt;C0425772&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Finding (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0425772&amp;amp;tui=T033"&gt;&lt;i&gt;T033&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD10&lt;/td&gt;
                &lt;td&gt;E30.8&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;102889008, 190577006&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Premature thelarche, Premature developmnt of breast, precocious breast development (symptom), premature thelarche, premature thelarche (diagnosis), precocious breast development, Premature thelarche (disorder), precocious thelarche, premature breast development, Precocious breast development, Precocious thelarche, Premature development of the breasts, Premature breast development at puberty, Premature development of the breasts (finding), precocious; thelarche, premature; thelarche, thelarche; precocious, thelarche; premature&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;vroegtijdige thelarche, prematuur; thelarche, thelarche; prematuur, thelarche; vroegtijdigheid, vroegtijdigheid; thelarche&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Thélarche précoce&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;vorzeitige Thelarche&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Telarca prematuro&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Telarca prematura&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;Telarquia prematura, Precocious thelarche, Precocious breast development, Premature thelarche, desarrollo mamario de la pubertad precoz, desarrollo mamario de la pubertad prematuro, telarca precoz, telarca prematura (hallazgo), telarca prematura&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;早発乳房発育開始, ｿｳﾊﾂﾆｭｳﾎﾞｳﾊﾂｲｸｶｲｼ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;Předčasná telarché&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;Korai thelarche&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Premature development of the breasts  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Benign Premature Thelarche</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Sexual Development</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Pathophysiology&lt;ol&gt;&lt;li&gt;Benign self-limited cause of &lt;a href="../../Endo/Sex/PrcsPbrty.htm" class="LinkPage"&gt;Precocious Puberty&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Epidemiology&lt;ol&gt;&lt;li&gt;Onset as early as age 18 months&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Signs&lt;ol&gt;&lt;li&gt;Early &lt;a href="../../Gyn/Anatomy/BrstAntmy.htm" class="LinkPage"&gt;Breast&lt;/a&gt; development (not to mature &lt;a href="../../Gyn/Anatomy/BrstAntmy.htm" class="LinkPage"&gt;Breast&lt;/a&gt; contour)&lt;/li&gt;&lt;li&gt;No other signs of &lt;a href="../../Endo/Exam/SxlDvlpmnt.htm" class="LinkPage"&gt;Puberty&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Normal prepubertal growth rate&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Radiology&lt;ol&gt;&lt;li&gt;Bone age consistent chronological age&lt;/li&gt;&lt;li&gt;Ovarian &lt;a href="../../Rad/Ultrasound/Ultrsnd.htm" class="LinkPage"&gt;Ultrasound&lt;/a&gt; normal&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Labs&lt;ol&gt;&lt;li&gt;Serum Gonadotropin levels normal&lt;/li&gt;&lt;li&gt;&lt;a href="../../Gyn/Lab/SrmEstrdl.htm" class="LinkPage"&gt;Serum Estradiol&lt;/a&gt; normal&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Management&lt;ol&gt;&lt;li&gt;Reassurance&lt;/li&gt;&lt;li&gt;Do not biopsy &lt;a href="../../Gyn/Anatomy/BrstAntmy.htm" class="LinkPage"&gt;Breast&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Biopsy results in partial &lt;a href="../../Gyn/Surgery/Mstctmy.htm" class="LinkPage"&gt;Mastectomy&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Further &lt;a href="../../Gyn/Anatomy/BrstAntmy.htm" class="LinkPage"&gt;Breast&lt;/a&gt; development abnormal post-biopsy&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Course&lt;ol&gt;&lt;li&gt;Spontaneous resolution&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0425772</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Sex/BngnPrmtrThlrch.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Benign Premature Thelarche, Premature Thelarche</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Sex/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Night sweats  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0028081"&gt;&lt;i&gt;C0028081&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;Nocturnal periods of profuse diaphoresis.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Sign or Symptom (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0028081&amp;amp;tui=T184"&gt;&lt;i&gt;T184&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD10&lt;/td&gt;
                &lt;td&gt;R61&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;42984000, 139115006, 161859009&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;NIGHT SWEAT, NIGHT SWEATS, sweating heavily at night, night sweats, sweating heavily at night (symptom), Night Sweating, Night Sweats, Night sweat, night sweat, nights sweats, Nocturnal perspiration, Night sweats, Night sweats (finding), nocturnal; sweating, sweat; night sweats, sweating; night, Problem;sweating;night&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Sudorazione notturna&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;nachtelijke transpiratie, nachtelijk; zweten, zweet; nachtzweten, zweten; nacht, nachtzweet&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Transpiration nocturne, Sueurs nocturnes&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Nachtschweiss, naechtliche Perspiration, naechtliche Schweissausbrueche&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Transpiração nocturna, Suor nocturno, Suores nocturnos&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;Sudor nocturno, Transpiración nocturna, Night sweats, sudor nocturno, sudoración nocturna (hallazgo), sudoración nocturna, Sudores nocturnos&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;寝汗, 夜間発汗, ﾈｱｾ, ﾔｶﾝﾊｯｶﾝ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;Noční pot, Noční poty, Noční perspirace&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;Nocturnalis perspiratio, Éjszakai verejtékezés, Éjszakai izzadás&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Night sweats  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Night Sweats</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Symptoms</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;See Also&lt;ol&gt;&lt;li&gt;&lt;a href="../../Gyn/Sx/VsmtrSymptmsOfMnps.htm" class="LinkPage"&gt;Hot Flashes&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Derm/Sweat/Hyprhdrs.htm" class="LinkPage"&gt;Hyperhidrosis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../ID/Exam/Fvr.htm" class="LinkPage"&gt;Fever&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Causes&lt;ol&gt;&lt;li&gt;Malignancy (e.g. &lt;a href="../../HemeOnc/Lymph/Lymphm.htm" class="LinkPage"&gt;Lymphoma&lt;/a&gt; or &lt;a href="../../HemeOnc/Leukemia/Lkm.htm" class="LinkPage"&gt;Leukemia&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;Rheumatologic condition (&lt;a href="../../Neuro/Eye/GntClArtrts.htm" class="LinkPage"&gt;Temporal Arteritis&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;Infection&lt;ol&gt;&lt;li&gt;&lt;a href="../../HIV/Exam/HmnImndfcncyVrs.htm" class="LinkPage"&gt;HIV Infection&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Lung/Tb/Tbrcls.htm" class="LinkPage"&gt;Tuberculosis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Infectious &lt;a href="../../ID/Virus/Mncls.htm" class="LinkPage"&gt;Mononucleosis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Fungal infection (&lt;a href="../../Lung/Fungus/Hstplsms.htm" class="LinkPage"&gt;Histoplasmosis&lt;/a&gt;, &lt;a href="../../Lung/Fungus/Ccdmycs.htm" class="LinkPage"&gt;Coccidioidomycosis&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;Endocarditis&lt;/li&gt;&lt;li&gt;&lt;a href="../../Lung/ID/LngAbscs.htm" class="LinkPage"&gt;Lung Abscess&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Endocrinopathy&lt;ol&gt;&lt;li&gt;&lt;a href="../../Gyn/Endo/Mnps.htm" class="LinkPage"&gt;Menopause&lt;/a&gt; (See &lt;a href="../../Gyn/Sx/VsmtrSymptmsOfMnps.htm" class="LinkPage"&gt;Hot Flashes&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/Hyprthyrdsm1.htm" class="LinkPage"&gt;Hyperthyroidism&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/DM/DbtsMlts.htm" class="LinkPage"&gt;Diabetes Mellitus&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Renal/Endo/DbtsInspds.htm" class="LinkPage"&gt;Diabetes Insipidus&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../GI/HemeOnc/CrcndTmr.htm" class="LinkPage"&gt;Carcinoid&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Adrenal/Phchrmcytm.htm" class="LinkPage"&gt;Pheochromocytoma&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Medications&lt;ol&gt;&lt;li&gt;&lt;a href="../../Pharm/Analgesic/Actmnphn.htm" class="LinkPage"&gt;Acetaminophen&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Pharm/Analgesic/Asprn.htm" class="LinkPage"&gt;Aspirin&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Antihypertensives&lt;/li&gt;&lt;li&gt;Phenothiazines&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Pharm/Ncn.htm" class="LinkPage"&gt;Niacin&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Leuprolide (Lupron)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Gyn/Pharm/Tmxfn.htm" class="LinkPage"&gt;Tamoxifen&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../HIV/Pharm/PrtsInhbtr.htm" class="LinkPage"&gt;Protease Inhibitor&lt;/a&gt;s (&lt;a href="../../HIV/Pharm/Indnvr.htm" class="LinkPage"&gt;Indinavir&lt;/a&gt;, &lt;a href="../../HIV/Pharm/Sqnvr.htm" class="LinkPage"&gt;Saquinavir&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;&lt;a href="../../HemeOnc/Pharm/MnclnlAntbdyMdtdChmthrpy.htm" class="LinkPage"&gt;Monoclonal Antibody&lt;/a&gt; (Daclizumab, &lt;a href="../../Rheum/Pharm/Rtxmb.htm" class="LinkPage"&gt;Rituximab&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;Antineoplastics (&lt;a href="../../GI/Pharm/IntrfrnAlf.htm" class="LinkPage"&gt;Interferon alfa&lt;/a&gt;-2a, Pegaspargase)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Drugs of abuse&lt;ol&gt;&lt;li&gt;&lt;a href="../../Psych/CD/AlchlAbs.htm" class="LinkPage"&gt;Alcohol Abuse&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Psych/CD/OpdAbs.htm" class="LinkPage"&gt;Heroin&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Miscellaneous Causes&lt;ol&gt;&lt;li&gt;&lt;a href="../../Lung/Apnea/SlpApn.htm" class="LinkPage"&gt;Sleep Apnea&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../GI/Esophagus/GstrsphglRflx.htm" class="LinkPage"&gt;Gastroesophageal Reflux&lt;/a&gt; (&lt;a href="../../GI/Esophagus/GstrsphglRflx.htm" class="LinkPage"&gt;GERD&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;Anxiety&lt;/li&gt;&lt;li&gt;Pregnancy&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;History&lt;ol&gt;&lt;li&gt;Infectious disease exposure (HIV, &lt;a href="../../Lung/Tb/Tbrcls.htm" class="LinkPage"&gt;Tuberculosis&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;Travel (&lt;a href="../../Lung/Fungus/Ccdmycs.htm" class="LinkPage"&gt;Coccidioidomycosis&lt;/a&gt;, &lt;a href="../../ID/Parasite/Mlr1.htm" class="LinkPage"&gt;Malaria&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;Full Review of Systems for comorbid conditions&lt;ol&gt;&lt;li&gt;Evaluate for causes below&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Exam: Focused on suspected causes&lt;ol&gt;&lt;li&gt;Temperature&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Exam/BldPrsr.htm" class="LinkPage"&gt;Blood Pressure&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Thyromegaly&lt;/li&gt;&lt;li&gt;&lt;a href="../../HemeOnc/Lymph/Lymphdnpthy.htm" class="LinkPage"&gt;Lymphadenopathy&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../GI/Exam/Splnmgly.htm" class="LinkPage"&gt;Splenomegaly&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Evaluation&lt;ol&gt;&lt;li&gt;Step 1&lt;ol&gt;&lt;li&gt;Evaluate for causes suggested by history and exam&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Step 2&lt;ol&gt;&lt;li&gt;&lt;a href="../../HemeOnc/Lab/CmpltBldCnt.htm" class="LinkPage"&gt;Complete Blood Count&lt;/a&gt; (CBC)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Lung/Rad/ChstXry.htm" class="LinkPage"&gt;Chest XRay&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Lung/Lab/TbrclnSknTst.htm" class="LinkPage"&gt;Purified Protein Derivative&lt;/a&gt; (PPD)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Step 3&lt;ol&gt;&lt;li&gt;&lt;a href="../../HIV/Lab/HvTst.htm" class="LinkPage"&gt;HIV Test&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../HemeOnc/Lab/ErythrcytSdmntnRt.htm" class="LinkPage"&gt;Erythrocyte Sedimentation Rate&lt;/a&gt; (ESR)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Step 4: &lt;a href="../../GI/Esophagus/GstrsphglRflx.htm" class="LinkPage"&gt;Gastroesophageal Reflux&lt;/a&gt; Empiric Mangement&lt;ol&gt;&lt;li&gt;&lt;a href="../../GI/Pharm/PrtnPmpInhbtr.htm" class="LinkPage"&gt;Proton Pump Inhibitor&lt;/a&gt; trial&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Step 5: Chart for nocturnal fever spikes&lt;ol&gt;&lt;li&gt;Obtain &lt;a href="../../ID/Lab/BldCltr.htm" class="LinkPage"&gt;Blood Culture&lt;/a&gt;s if positive&lt;/li&gt;&lt;li&gt;Include atypical organisms&lt;ol&gt;&lt;li&gt;&lt;a href="../../ID/Bacteria/Pstrlc.htm" class="LinkPage"&gt;Haemophilus&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../ID/Bacteria/Pstrlc.htm" class="LinkPage"&gt;Actinobacillus&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Cardiobacterium&lt;/li&gt;&lt;li&gt;Eikenella&lt;/li&gt;&lt;li&gt;Kingella&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Step 6&lt;ol&gt;&lt;li&gt;&lt;a href="../../Lung/Anatomy/ChstAntmy.htm" class="LinkPage"&gt;Chest&lt;/a&gt; CT&lt;/li&gt;&lt;li&gt;Abdominal CT&lt;/li&gt;&lt;li&gt;&lt;a href="../../HemeOnc/Procedure/BnMrwAsprtn.htm" class="LinkPage"&gt;Bone Marrow Biopsy&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Other tests to consider&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/FlclStmltngHrmn.htm" class="LinkPage"&gt;Follicle Stimulating Hormone&lt;/a&gt; (FSH)&lt;ol&gt;&lt;li&gt;Early menopausal symptoms suspected&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;References&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Vera%20%20%5BAU%5D%20AND%202003%20%5BDP%5D%20AND%20%20Am%20Fam%20Physician%20%20%5BTA%5D" class="LinkRef"&gt;Vera (2003) Am Fam Physician 67(5):1019-24&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Smetana%20%20%5BAU%5D%20AND%201993%20%5BDP%5D%20AND%20%20JAMA%20%20%5BTA%5D" class="LinkRef"&gt;Smetana (1993) JAMA 270:2502-3&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Vera%20%20%5BAU%5D%20AND%202003%20%5BDP%5D%20AND%20%20Am%20Fam%20Physician%20%20%5BTA%5D" class="LinkRef"&gt;Vera (2003) Am Fam Physician 67(5):1019-24&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0028081</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Sx/NghtSwts.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Night Sweats</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Sx/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees></FP_UMLS_Trees><FP_Condition_name_check></FP_Condition_name_check><FP_Condition_name><value>Normogonadotropic Hypogonadism</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Sexual Development</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Definition: Normogonadotropic Hypogonadism&lt;ol&gt;&lt;li&gt;Delayed &lt;a href="../../Endo/Exam/SxlDvlpmnt.htm" class="LinkPage"&gt;Sexual Development&lt;/a&gt; and growth delay&lt;/li&gt;&lt;li&gt;Occurs despite normal pituitary gonadotropin secretion&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;See Also&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Sex/PbrtlDly.htm" class="LinkPage"&gt;Delayed Puberty&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Gyn/Menses/PrmryAmnrh.htm" class="LinkPage"&gt;Primary Amenorrhea&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Sex/Hypgndsm.htm" class="LinkPage"&gt;Hypogonadism&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Causes: &lt;a href="../../Gyn/Menses/PrmryAmnrh.htm" class="LinkPage"&gt;Delayed Menarche&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Gonadal dysgenesis variants&lt;ol&gt;&lt;li&gt;Residually functioning ovarian tissue&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Abnormalities Mullerian duct development&lt;ol&gt;&lt;li&gt;Absence of &lt;a href="../../Gyn/Anatomy/UtrnAntmy.htm" class="LinkPage"&gt;Uterus&lt;/a&gt; and possibly Vagina&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Polycystic Ovarian disease&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pituitary/Hyprprlctnm.htm" class="LinkPage"&gt;Hyperprolactinemia&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Sex/NrmgndtrpcHypgndsm.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Normogonadotropic Hypogonadism, Eugonadotropic Causes of Delayed Puberty, Normogonadropic Causes of Delayed Puberty</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Sex/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Precocious Puberty  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0034013"&gt;&lt;i&gt;C0034013&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;Unusually early sexual maturity.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A disorder characterized by unusually early development of secondary sexual features; the onset of sexual maturation begins usually before age 8 for girls and before age 9 for boys.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;Unusually early sexual development or maturity; premature puberty.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CSP)&lt;/td&gt;
                &lt;td&gt;unusually early sexual maturity.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;Development of SEXUAL MATURATION in boys and girls at a chronological age that is 2.5 standard deviations below the mean age at onset of PUBERTY in the population. This early maturation of the hypothalamic-pituitary-gonadal axis results in sexual precocity, elevated serum levels of GONADOTROPINS and GONADAL STEROID HORMONES such as ESTRADIOL and TESTOSTERONE.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Disease or Syndrome (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0034013&amp;amp;tui=T047"&gt;&lt;i&gt;T047&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D011629&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD10&lt;/td&gt;
                &lt;td&gt;E30.1&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;154716006, 267488008, 400179000, 123527003, 190575003, 190576002, 70387004&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Pubertas praecox, Puberty, Precocious, ACCELERATED SEXUAL MATURITY, PRECOCIOUS PUBERTY, PUBERTY PRECOCIOUS, SEXUAL PRECOCITY, Precocious true puberty, Sexual precocity, NOS, Premature puberty, Sexual Precocity, MATURATION SEX ACCELERATED, Precocious Puberty, precocious puberty (diagnosis), precocious puberty, (Sexual precocity NOS) or (puberty - precocious) (disorder), Maturation sex accelerated, Accelerated sexual maturation, Accelerated sexual maturity, Early puberty, Precocious puberty NOS, Puberty precocious, True precocious puberty, Puberty, Precocious [Disease/Finding], premature puberty, early puberty, precocious sexual development, puberty precocious, Puberty;precocious, sexual precocity, true precocious puberty, puberty early, Precocious puberty, Sexual precocity, Precocious sexual development, Precocious puberty (disorder), Precocious sexual development (disorder), precocious; puberty, premature; puberty, pubertas praecox, puberty; precocious, puberty; premature, (Sexual precocity NOS) or (puberty - precocious), Puberty - precocious, Sexual precocity NOS&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;PUBERTE PRECOCE, Puberté précoce SAI, Maturation sexuelle accélérée, Maturité sexuelle accélérée, Puberté précoce vraie, Puberté précoce&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;PUBERDADE PRECOCE, Maturação sexual acelerada, Maturidade sexual acelerada, Puberdade precoce NE, Puberdade precoce, Puberdade precoce verdadeira, Puberdade Precoce&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;PUBERTAD PRECOZ, Pubertad temprana, Maduración sexual acelerada, Pubertad precoz NEOM, Madurez sexual acelerada, pubertad precoz verdadera, Sexual precocity NOS, Premature puberty, Precocious puberty, Puberty - precocious, (Sexual precocity NOS) or (puberty - precocious), Sexual precocity NEC, desarrollo sexual Y/O puberal precoz, desarrollo sexual precoz (trastorno), desarrollo sexual precoz, precocidad sexual, pubertad precoz (trastorno), pubertad precoz verdadera (trastorno), pubertad precoz, pubertas praecox, Pubertad precoz, Pubertad precoz verdadera, Pubertad Precoz&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Pubertà precoce vera, Pubertà precoce NAS, Pubertà anticipata, Maturità sessuale accelerata, Sviluppo sessuale precoce, Precocità puberale, Maturazione sessuale accelerata, Pubertà precoce&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;versnelde seksuele ontwikkeling, versnelde seksuele rijpheid, vroege puberteit, pubertas praecox NAO, seksuele ontwikkeling versneld, prematuur; puberteit, puberteit; prematuur, puberteit; vroegtijdigheid, vroegtijdigheid; puberteit, Pubertas praecox, echte pubertas praecox, pubertas praecox, Puberteit (ontwikkelingstoestand); vroegtijdig, Vroegtijdige puberteit&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;beschleunigte sexuelle Reife, fruehe Pubertaet, Geschlechtsreife beschleunigt, Pubertas praecox NNB, PUBERTAS PRAECOX, Vorzeitige Pubertaet [Pubertas praecox], Pubertas praecox vera, Pubertas praecox, Pubertät, verfrühte&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;思春期早発, 性成熟亢進, 思春期早発症ＮＯＳ, ｾｲｾｲｼﾞｭｸｺｳｼﾝ, ｼｼｭﾝｷｿｳﾊﾂ, ｼｼｭﾝｷｿｳﾊﾂｼｮｳNOS, ｼｼｭﾝｷｿｳﾊﾂｼｮｳ, ｼﾝｾｲｼｼｭﾝｷｿｳﾊﾂｼｮｳ, ｾｲﾃｷｿｳｼﾞｭｸ, 思春期早発症, 中枢性思春期早発症, 中枢性早熟症, 性早熟症, 性的早熟, 早期破瓜, 早熟, 早熟症, 早発思春期, 早発性大性器症, 早発青春期, 真性思春期早発症, 真性性早熟症, 性的早熟症, 早発症-思春期&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Pubertet, för tidig&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;puberta předčasná, Urychlená pohlavní zralost, Urychlené pohlavní dospívání, Pubertas praecox, Předčasná puberta, Pravá předčasná puberta, Pubertas praecox NOS&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Ennenaikainen murrosikä&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;POLOVOE RAZVITIE PREZHDEVREMENNOE, ПОЛОВОЕ РАЗВИТИЕ ПРЕЖДЕВРЕМЕННОЕ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Korean&lt;/td&gt;
                &lt;td&gt;사춘기 조숙&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Croatian&lt;/td&gt;
                &lt;td&gt;PUBERTET, PRIJEVREMENI&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Dojrzewanie przedwczesne, Dojrzewanie płciowe przedwczesne&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;Accelerált sexualis érettség, Pubertas praecox, Gyorsult nemi érés, Accelerált sexualis érés, Korai pubertas, Praecox pubertas k.m.n., Praecox pubertas, Valódi pubertas praecox&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Precocious Puberty  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Precocious Puberty</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Sexual Development</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Epidemiology&lt;ol&gt;&lt;li&gt;Girls: Benign central cause in 50 to 90%&lt;/li&gt;&lt;li&gt;Boys: Pathologic peripheral cause in 50%&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Definition of Precocious Puberty&lt;ol&gt;&lt;li&gt;Girls&lt;ol&gt;&lt;li&gt;&lt;a href="../../Gyn/Anatomy/BrstAntmy.htm" class="LinkPage"&gt;Breast&lt;/a&gt; development (modified 1999)&lt;ol&gt;&lt;li&gt;White: Before age 7 years&lt;/li&gt;&lt;li&gt;Black: Before age 6 years&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Gyn/Exam/MnstrlBldng.htm" class="LinkPage"&gt;Menarche&lt;/a&gt; before age 10 years&lt;/li&gt;&lt;li&gt;Pubic &lt;a href="../../Derm/Anatomy/Hr.htm" class="LinkPage"&gt;Hair&lt;/a&gt; (modified 1999)&lt;ol&gt;&lt;li&gt;White: Before age 7 years&lt;/li&gt;&lt;li&gt;Black: Before age 6 years&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Referral recommended if 2 signs at age &amp;lt;8 years&lt;/li&gt;&lt;li&gt;References&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Kaplowitz%20%20%5BAU%5D%20AND%201999%20%5BDP%5D%20AND%20%20Pediatrics%20%20%5BTA%5D" class="LinkRef"&gt;Kaplowitz (1999) Pediatrics 104:936-41&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Midyett%20%20%5BAU%5D%20AND%202003%20%5BDP%5D%20AND%20%20Pediatrics%20%20%5BTA%5D" class="LinkRef"&gt;Midyett (2003) Pediatrics 111:47-51&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Boys&lt;ol&gt;&lt;li&gt;&lt;a href="../../Uro/Anatomy/Tstcl.htm" class="LinkPage"&gt;Testes&lt;/a&gt; &amp;gt; 2.5 cm (&amp;gt;3 ml vol) before age 9 years&lt;/li&gt;&lt;li&gt;Pubic hair before age 9 years&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Red Flags suggesting pathologic cause&lt;ol&gt;&lt;li&gt;Premature &lt;a href="../../Endo/Exam/SxlDvlpmnt.htm" class="LinkPage"&gt;Puberty&lt;/a&gt; in very young children&lt;/li&gt;&lt;li&gt;Contrasexual development&lt;ol&gt;&lt;li&gt;Feminization in boys&lt;/li&gt;&lt;li&gt;Virilization in girls&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Peripheral cause (often asynchronous development)&lt;ol&gt;&lt;li&gt;&lt;a href="../../Uro/Anatomy/AntmyOfThPns.htm" class="LinkPage"&gt;Penis&lt;/a&gt; enlarges without scrotal enlargement&lt;/li&gt;&lt;li&gt;Extensive pubic &lt;a href="../../Derm/Anatomy/Hr.htm" class="LinkPage"&gt;Hair Growth&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Gyn/Exam/MnstrlBldng.htm" class="LinkPage"&gt;Menarche&lt;/a&gt; without &lt;a href="../../Gyn/Anatomy/BrstAntmy.htm" class="LinkPage"&gt;Breast&lt;/a&gt; bud development in girls&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Precocious Puberty in boys (50% pathologic)&lt;/li&gt;&lt;li&gt;Visual field deficit suggests pituitary mass&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Causes&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Endo/Sex/PrcsPbrtyCs.htm" class="LinkPage"&gt;Precocious Puberty Causes&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Labs (See Evaluation below)&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/FlclStmltngHrmn.htm" class="LinkPage"&gt;Follicle Stimulating Hormone&lt;/a&gt; (FSH)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/LtnzngHrmn.htm" class="LinkPage"&gt;Luteinizing hormone&lt;/a&gt; (LH)&lt;/li&gt;&lt;li&gt;Estradiol Level (in girls)&lt;/li&gt;&lt;li&gt;Testosterone Level (in boys)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/ThyrdStmltngHrmn.htm" class="LinkPage"&gt;Thyroid Stimulating Hormone&lt;/a&gt; (TSH)&lt;/li&gt;&lt;li&gt;Serum Human chorionic gonadotropin (HCG)&lt;ol&gt;&lt;li&gt;Screen for gonadotropin secreting tumor&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Consider &lt;a href="../../Endo/Lab/GnrhStmltnTst.htm" class="LinkPage"&gt;GnRH Stimulation Test&lt;/a&gt;&lt;/li&gt;&lt;li&gt;See additional evaluation for Step 2c below&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Radiology (See Evaluation below)&lt;ol&gt;&lt;li&gt;Left wrist radiograph for bone age&lt;/li&gt;&lt;li&gt;Consider &lt;a href="../../Neuro/Rad/HdMgntcRsncImgng.htm" class="LinkPage"&gt;Head MRI&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Screen for pituitary or other CNS lesion&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;See additional evaluation for Step 2c below&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Evaluation Step 1: Initial Evaluation&lt;ol&gt;&lt;li&gt;Clinical history and physical&lt;/li&gt;&lt;li&gt;Exogenous Sex Hormone sources&lt;ol&gt;&lt;li&gt;Androgens and &lt;a href="../../Sports/Pharm/AnblcStrd.htm" class="LinkPage"&gt;Anabolic Steroid&lt;/a&gt;s in boys&lt;/li&gt;&lt;li&gt;&lt;a href="../../Gyn/Pharm/OrlCntrcptv.htm" class="LinkPage"&gt;Oral Contraceptive&lt;/a&gt; use in girls&lt;/li&gt;&lt;li&gt;&lt;a href="../../Gyn/Pharm/Estrgn.htm" class="LinkPage"&gt;Estrogen&lt;/a&gt; or placental containing hair products&lt;ol&gt;&lt;li&gt;Common use in African American girls&lt;/li&gt;&lt;li&gt;Associated with &lt;a href="../../Gyn/Anatomy/BrstAntmy.htm" class="LinkPage"&gt;Breast&lt;/a&gt; or pubic hair development&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Evaluate &lt;a href="../../Endo/Exam/SxlDvlpmnt.htm" class="LinkPage"&gt;Pubertal Milestone&lt;/a&gt;s (See &lt;a href="../../Endo/Exam/SxlDvlpmnt.htm" class="LinkPage"&gt;Tanner Staging&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;Evaluate growth chart&lt;/li&gt;&lt;li&gt;Obtain Left &lt;a href="../../Ortho/Rad/WrstXry.htm" class="LinkPage"&gt;Wrist XRay&lt;/a&gt; for bone age&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Evaluation Step 2a: Unremarkable Evaluation in Step 1&lt;ol&gt;&lt;li&gt;Findings&lt;ol&gt;&lt;li&gt;Early, but normal &lt;a href="../../Endo/Exam/SxlDvlpmnt.htm" class="LinkPage"&gt;Puberty&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Girls: &lt;a href="../../Gyn/Anatomy/BrstAntmy.htm" class="LinkPage"&gt;Breast&lt;/a&gt;s enlarge early&lt;/li&gt;&lt;li&gt;Boys: &lt;a href="../../Uro/Anatomy/Tstcl.htm" class="LinkPage"&gt;Testicle&lt;/a&gt;s enlarge early&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Bone age exceeds chronological age&lt;ol&gt;&lt;li&gt;Early growth spurt and initially taller than peers&lt;/li&gt;&lt;li&gt;Early epiphyseal closure and short in adulthood&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Diagnosis&lt;ol&gt;&lt;li&gt;Constitutional or Idiopathic Precocious Puberty&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Further evaluation&lt;ol&gt;&lt;li&gt;Observation&lt;/li&gt;&lt;li&gt;Consider further diagnostic testing (see above)&lt;ol&gt;&lt;li&gt;All labs at pubertal levels&lt;/li&gt;&lt;li&gt;All imaging studies normal&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Management&lt;ol&gt;&lt;li&gt;Counseling and reassurance&lt;/li&gt;&lt;li&gt;Consider GnRH analog to suppress FSH and LH&lt;ol&gt;&lt;li&gt;Leuprolide (Lupron) long acting injectable&lt;/li&gt;&lt;li&gt;Nafarelin (&lt;a href="../../Gyn/Pharm/GndtrpnRlsngHrmnAgnst.htm" class="LinkPage"&gt;Synarel&lt;/a&gt;) short acting intranasal&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Evaluation Step 2b: Normal Variation in Step 1&lt;ol&gt;&lt;li&gt;Findings&lt;ol&gt;&lt;li&gt;Early, but normal &lt;a href="../../Endo/Exam/SxlDvlpmnt.htm" class="LinkPage"&gt;Puberty&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Bone age consistent with chronological age&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Diagnosis: &lt;a href="../../Endo/Sex/BngnPrmtrAdrnrch.htm" class="LinkPage"&gt;Benign Premature Adrenarche&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Girls&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Sex/BngnPrmtrThlrch.htm" class="LinkPage"&gt;Benign Premature Thelarche&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Benign premature &lt;a href="../../Gyn/Exam/MnstrlBldng.htm" class="LinkPage"&gt;Menarche&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Boys&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Sx/Gyncmst.htm" class="LinkPage"&gt;Benign Gynecomastia of Adolescence&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Sx/Gyncmst.htm" class="LinkPage"&gt;Familial Gynecomastia&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Further evaluation&lt;ol&gt;&lt;li&gt;Observation&lt;/li&gt;&lt;li&gt;Consider further laboratory testing (see above)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Management&lt;ol&gt;&lt;li&gt;Counseling and reassurance&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Evaluation Step 2c: Abnormal Evaluation in Step 1&lt;ol&gt;&lt;li&gt;Findings&lt;ol&gt;&lt;li&gt;Abnormal &lt;a href="../../Endo/Exam/SxlDvlpmnt.htm" class="LinkPage"&gt;Pubertal Milestone&lt;/a&gt; sequence&lt;/li&gt;&lt;li&gt;Bone age variable&lt;ol&gt;&lt;li&gt;May be consistent with chronological age&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Differential Diagnosis (pathologic cause suspected)&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Endo/Sex/PrcsPbrtyCs.htm" class="LinkPage"&gt;Precocious Puberty Causes&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Further evaluation&lt;ol&gt;&lt;li&gt;Further laboratory testing (see above)&lt;/li&gt;&lt;li&gt;Additional lab testing (esp. virilization of girls)&lt;ol&gt;&lt;li&gt;17-Hydroxyprogesterone&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/SrmDhydrpndrstrn.htm" class="LinkPage"&gt;Serum Dehydroepiandrosterone&lt;/a&gt; (&lt;a href="../../Endo/Lab/SrmDhydrpndrstrn.htm" class="LinkPage"&gt;Serum DHEA&lt;/a&gt;)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Additional imaging (suspect peripheral cause)&lt;ol&gt;&lt;li&gt;Pelvic &lt;a href="../../Rad/Ultrasound/Ultrsnd.htm" class="LinkPage"&gt;Ultrasound&lt;/a&gt; of Ovaries&lt;/li&gt;&lt;li&gt;Adrenal CT&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Management&lt;ol&gt;&lt;li&gt;Assess for exogenous sex steroid exposure&lt;/li&gt;&lt;li&gt;Treat based on underlying cause&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Blondell%20%20%5BAU%5D%20AND%201999%20%5BDP%5D%20AND%20%20Am%20Fam%20Physician%20%20%5BTA%5D" class="LinkRef"&gt;Blondell (1999) Am Fam Physician 60:209-24&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Fahmy%20%20%5BAU%5D%20AND%202000%20%5BDP%5D%20AND%20%20Br%20J%20Radiol%20%20%5BTA%5D" class="LinkRef"&gt;Fahmy (2000) Br J Radiol 73(869):560-7&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Foster%20%20%5BAU%5D%20AND%201992%20%5BDP%5D%20AND%20%20Obstet%20Gynecol%20Clin%20North%20Am%20%20%5BTA%5D" class="LinkRef"&gt;Foster (1992) Obstet Gynecol Clin North Am 19:59-70&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Styne%20%20%5BAU%5D%20AND%201997%20%5BDP%5D%20AND%20%20Pediatr%20Clin%20North%20Am%20%20%5BTA%5D" class="LinkRef"&gt;Styne (1997) Pediatr Clin North Am 44(2):505-29&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Tiwary%20%20%5BAU%5D%20AND%201998%20%5BDP%5D%20AND%20%20Clin%20Pediatr%20%20%5BTA%5D" class="LinkRef"&gt;Tiwary (1998) Clin Pediatr 37(12):733-9&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Walvoord%20%20%5BAU%5D%20AND%201999%20%5BDP%5D%20AND%20%20Pediatrics%20%20%5BTA%5D" class="LinkRef"&gt;Walvoord (1999) Pediatrics 104(4):1010-4&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0034013</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Sex/PrcsPbrty.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Precocious Puberty, Premature Sexual Development</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Sex/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Isolated lutropin deficiency (disorder)  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0271582"&gt;&lt;i&gt;C0271582&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Disease or Syndrome (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0271582&amp;amp;tui=T047"&gt;&lt;i&gt;T047&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;C537919&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD10&lt;/td&gt;
                &lt;td&gt;E23.0&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;8829008&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;FERTILE EUNUCH SYNDROME, Isolated lutropin deficiency (disorder), Fertile eunuch syndrome, Fertile eunuch, Isolated lutropin deficiency, fertile eunuch syndrome, fertile eunuch; syndrome, syndrome; fertile eunuch&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;fertiel eunuchoïdisme; syndroom, syndroom; fertiel eunuchoïdisme&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;deficiencia aislada de LH, deficiencia aislada de lutropina (trastorno), deficiencia aislada de lutropina, síndrome del eunuco fértil&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Kallmann Syndrome  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0162809"&gt;&lt;i&gt;C0162809&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;An X-linked or autosomal dominant genetic syndrome characterized by hypogonadotropic hypogonadism and anosmia.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (JABL)&lt;/td&gt;
                &lt;td&gt;A syndrome, sometimes considered as three separate entities (Kalmann syndromes 1, 2, and 3), characterized mainly by reduced hypothalamic function and reduced pituitary gonadotropic activity and deficiency of gonadotropin-releasing hormone with resulting hypogonadism and absent or reduced sense of smell due to agenesis of the olfactory bulbs. Associated anomalies include cleft palate, neurosensory hearing loss, congenital heart defect, intestinal malrotation, renal agenesis, hypertension, mental retardation, color blindness, and other defects. Most abnormalities occur in types 1 and 2; type 3 is marked mainly by hypogonadotropic hypogonadism, anosmia, and craniofacial abnormalities.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CSP)&lt;/td&gt;
                &lt;td&gt;anosmia due to failure of the olfactory lobes to develop, with secondary hypogonadism due to gonadotropic hormone deficiency.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;A genetically heterogeneous disorder caused by hypothalamic GNRH deficiency and OLFACTORY NERVE defects. It is characterized by congenital HYPOGONADOTROPIC HYPOGONADISM and ANOSMIA, possibly with additional midline defects. It can be transmitted as an X-linked (GENETIC DISEASES, X-LINKED), an autosomal dominant, or an autosomal recessive trait.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Disease or Syndrome (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0162809&amp;amp;tui=T047"&gt;&lt;i&gt;T047&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D017436&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD10&lt;/td&gt;
                &lt;td&gt;E23.0&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;93559003, 190559001, 33927004&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Syndrome, Kallmann's, Kallmann's Syndrome, Kallmanns Syndrome, Syndrome, Kallmann, HYPOGONADISM, HYPOGONADOTROPIC, WITH ANOSMIA, KALLMANN SYNDROME, OLFACTOGENITAL DYSPLASIA, Gonadotrophin defic + anosmia, KALLMANN SYNDROME 3, KAL3, HYPOGONADOTROPIC HYPOGONADISM AND ANOSMIA, de Morsier's syndrome, Kallmann Syndrome, familial hypogonadism with anosmia, Kallmann's syndrome (diagnosis), Kallmann syndrome 3, congenital anosmia-hypogonadotropic hypogonadism syndrome, hypogonadotropic hypogonadism-anosmia (HHA) syndrome, hypogonadotropic hypogonadism-anosmia syndrome, hypogonadism-anosmia syndrome, Maestre de San Juan-Kallmann-de Morsier syndrome, de Morsier-Gauthier syndrome, Mastre de San Juan-Kallmann syndrome, Maestre-Kallmann-de Morsier syndrome, Kallmann-de Morsier syndrome, de Morsier syndrome, olfacto-ethmoidohypothalamic dysplasia, olfactogenital dysplasia, olfacto-ethmoidodypothalamic dysraphia, hyposmia-hypogonadotropic hypogonadism syndrome, idiopathic hypothalamic hypogonadism, idiopathic hypothalamic hypogonadism (IHH), olfactogenital syndrome, Kallmann Syndrome [Disease/Finding], kallmans syndrome, de morsier syndrome, kallman's syndrome, kallmann syndrome, kallman syndrome, de morsiers syndrome, kallmanns syndrome, Dysplasia olfactogenitalis of De Morsier, Anosmic Hypogonadism, Hypogonadism, Anosmic, Hypogonadisms, Anosmic, Dysplasia Olfactogenitalis of De Morsier, Anosmic Hypogonadisms, Olfacto genital dysplasia, de Morsier-Kallman's syndrome, Kallmann's syndrome, Anosmia eunuchoidism, Dysplasia olfactogenitalis of de Morsier, Kallman syndrome, Kallman's syndrome, Olfactogenital dysplasia, Gonadotrophin deficiency with anosmia, Hypogonadism with anosmia, Hypogonadism with anosmia (disorder), kallmann's syndrome&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Displasia olfatto-genitale, Sindrome di de Morsier-Kallman, Sindrome di Kallman, Sindrome di de Morsier, Sindrome di Kallmann&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;syndroom van Kallmann, de Morsier-Kallman-syndroom, de Morsier-syndroom, Kallmann-syndroom, Syndroom, Kallmann-&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Syndrome de De Morsier-Kallman, Syndrome de De Morsier, Dysplasie olfactogénitale, Dysplasie olfacto-génitale de De Morsier, Dysplasie olfacto-génitale de Kallmann-De Morsier, Dysplasie olfactogénitale de De Morsier, Dysplasie olfactogénitale de Kallmann-De Morsier, Syndrome de Kallmann, Syndrome de De Morsier-Kallmann, Syndrome de Kallman-De Morsier&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;De-Morsier-Kallmann-Syndrom, De-Morsier-Syndrom, Olfaktogenitale Dysplasie, Kallmann-Syndrom&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Síndrome de De Morsier-Kallman, Síndrome de Kallman, Síndrome de De Morsier, Displasia olfacto-genital, Síndrome de Kallmann&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;Síndrome de Kallman, Síndrome de Morsier-Kallman, Síndrome de Morsier, Kallman's syndrome, Kallmann's syndrome, anosmia eunicoide, displasia olfatogenital de Morsier, displasia olfatogenital, hipogonadismo con anosmia (trastorno), hipogonadismo con anosmia, síndrome de Kallman, Displasia olfato genital, Síndrome de Kallmann, Sindrome de Kallmann&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;嗅脳性器異形成, ド・モルシア・カルマン症候群, ﾄﾞﾓﾙｼｱｶﾙﾏﾝｼｮｳｺｳｸﾞﾝ, ﾄﾞﾓﾙｼｱｼｮｳｺｳｸﾞﾝ, ド・モルシア症候群, ｷｭｳﾉｳｾｲｷｲｹｲｾｲ, ｶﾙﾏﾝｼｮｳｺｳｸﾞﾝ, Kallmann症候群, カルマン症候群&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Kallmanns syndrom&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;Kallmannův syndrom, Olfaktogenitální dysplazie, de Morsier-Kallmanův syndrom, de Morsierův syndrom, Kallmanův syndrom&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Kallmannin oireyhtymä&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;KALLMENA SINDROM, КАЛЛМЕНА СИНДРОМ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Zespół węchowo-płciowy, Zespół Kallmanna&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;Kallman-syndroma, De morsier-kallman-syndroma, Olfactogenitalis dysplasia, Kallmann-syndroma, De morsier-syndroma&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Isolated lutropin deficiency (disorder)  (</value><value>)
</value><value>Kallmann Syndrome  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Kallmann's Syndrome</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Sexual Development</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Epidemiology: &lt;a href="../../Prevent/Epi/DsPrvlncRt.htm" class="LinkPage"&gt;Prevalence&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Males: 1 in 7500&lt;/li&gt;&lt;li&gt;Females: 1 in 50,000&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Pathophysiology&lt;ol&gt;&lt;li&gt;Secondary to LHRH deficiency (GnRH deficiency)&lt;/li&gt;&lt;li&gt;Results in isolated &lt;a href="../../Endo/Sex/HypgndtrpcHypgndsm.htm" class="LinkPage"&gt;Hypogonadotropic Hypogonadism&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Kallmann's Syndrome is most common cause&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Partial LHRH deficiency results in fertile eunuch&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Signs&lt;ol&gt;&lt;li&gt;&lt;a href="../../ENT/Sx/LsOfSml.htm" class="LinkPage"&gt;Anosmia&lt;/a&gt; or &lt;a href="../../ENT/Sx/LsOfSml.htm" class="LinkPage"&gt;Hyposmia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Sex/PbrtlDly.htm" class="LinkPage"&gt;Delayed Puberty&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Small &lt;a href="../../Uro/Anatomy/Tstcl.htm" class="LinkPage"&gt;Testes&lt;/a&gt; (size correlates with LHRH deficiency)&lt;/li&gt;&lt;li&gt;Micropenis (50% of cases)&lt;/li&gt;&lt;li&gt;Other findings seen in &lt;a href="../../Endo/Sex/HypgndtrpcHypgndsm.htm" class="LinkPage"&gt;Hypogonadotropic Hypogonadism&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Sx/Gyncmst.htm" class="LinkPage"&gt;Gynecomastia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Uro/Peds/UndscndTstcl.htm" class="LinkPage"&gt;Undescended Testes&lt;/a&gt; (&lt;a href="../../Uro/Peds/UndscndTstcl.htm" class="LinkPage"&gt;Cryptorchidism&lt;/a&gt;)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Associated Conditions (loosely correlated)&lt;ol&gt;&lt;li&gt;&lt;a href="../../NICU/ENT/ClftLp.htm" class="LinkPage"&gt;Cleft Lip&lt;/a&gt; and &lt;a href="../../Dental/Anatomy/PltAntmy.htm" class="LinkPage"&gt;Palate&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Neuro/Seizure/Szr.htm" class="LinkPage"&gt;Seizure&lt;/a&gt; disorder&lt;/li&gt;&lt;li&gt;Short &lt;a href="../../Ortho/Anatomy/MtcrplBn.htm" class="LinkPage"&gt;Metacarpal&lt;/a&gt;s&lt;/li&gt;&lt;li&gt;Pes cavus&lt;/li&gt;&lt;li&gt;&lt;a href="../../ENT/Hearing/SnsrnrlHrngLs.htm" class="LinkPage"&gt;Sensorineural Hearing Loss&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Cerebellar ataxia&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;Wilson (1998) Williams Endocrinology, p. 1555-6&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0271582</value><value>C0162809</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Sex/KlmnsSyndrm.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Kallmann's Syndrome, Fertile Eunuch Syndrome</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Sex/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Hypogonadotropic hypogonadism  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0271623"&gt;&lt;i&gt;C0271623&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Disease or Syndrome (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0271623&amp;amp;tui=T047"&gt;&lt;i&gt;T047&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D007006&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD10&lt;/td&gt;
                &lt;td&gt;E23.0&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;67718002, 33927004&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Hypogonadotropic hypogonadism, Secondary hypogonadism, NOS, Gonadotropin deficiency syndrome, male, HYPOGONADOTROPIC HYPOGONADISM, HYPOGONADISM, ISOLATED HYPOGONADOTROPIC, Gonadotropin deficiency, hypogonadotrophic hypogonadism (diagnosis), hypogonadotrophic hypogonadism, Secondary hypogonadism (disorder), secondary testicular failure (diagnosis), secondary testicular failure, Hypogonadotrophic hypogonadism, secondary hypogonadism, hypogonadotropic hypogonadism, Gonadotrophin deficiency, Secondary hypogonadism, Hypogonadotropic hypogonadism (disorder), deficiency; gonadotropin, gonadotropin; deficiency, Secondary hypogonadism -RETIRED-, Hypogonadotropic Hypogonadism, Hypogonadism, Hypogonadotropic&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Deficit di gonadotropina, Ipogonadismo secondario, Ipogonadismo ipogonadotropo&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;hypogonadotroop hypogonadisme, deficiëntie; gonadotropine, gonadotropine; deficiëntie, gonadotropinedeficiëntie, secundair hypogonadisme&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;hypogonadotropher Hypogonadismus, Gonadotropinmangel, sekundaerer Hypogonadismus&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Hipogonadismo hipogonadotrófico, Hipogonadismo secundário, Insuficiência de gonadotrofinas&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;Hipogonadismo hipogonadotrófico, hipognonadismo hipogonadotrófico, hipogonadismo hipogonadotrófico, hipognonadismo hipogonadotrófico (trastorno), hipogonadismo hipogonadotrófico (trastorno), hipogonadismo secundario - RETIRADO - (concepto no activo), hipogonadismo secundario - RETIRADO -, hipogonadismo secundario, Hipogonadismo secundario, Déficit de gonadotropinas&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;ゴナドトロピン欠乏症, 続発性性腺機能低下, 低性腺刺激ホルモン性性腺機能低下症, ｺﾞﾅﾄﾞﾄﾛﾋﾟﾝｹﾂﾎﾞｳｼｮｳ, ｿﾞｸﾊﾂｾｲｾｲｾﾝｷﾉｳﾃｲｶ, ﾃｲｾｲｾﾝｼｹﾞｷﾎﾙﾓﾝｾｲｾｲｾﾝｷﾉｳﾃｲｶｼｮｳ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Hypogonadisme hypogonadotrophique, Déficit gonadotrope, Hypogonadisme secondaire&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;Gonadotropinový deficit, Sekundární hypogonadismus, Hypogonadotropní hypogonadismus&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;Gonadotropin hiány, Másodlagos hypogonadismus, Hypogonadotrophiás hypogonadismus&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Hypogonadotropic hypogonadism  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Hypogonadotropic Hypogonadism</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Sexual Development</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;See Also&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Sex/PbrtlDly.htm" class="LinkPage"&gt;Delayed Puberty&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Sex/Hypgndsm.htm" class="LinkPage"&gt;Hypogonadism&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Gyn/Menses/PrmryAmnrh.htm" class="LinkPage"&gt;Primary Amenorrhea&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Definition: Hypogonadotropic Hypogonadism&lt;ol&gt;&lt;li&gt;Decreased functional activity of ovaries or &lt;a href="../../Uro/Anatomy/Tstcl.htm" class="LinkPage"&gt;Testes&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Results from pituitary failure to secrete gonadotropins&lt;/li&gt;&lt;li&gt;Results in delayed sexual vevelopment and growth delay&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Etiology&lt;ol&gt;&lt;li&gt;Central defect of Hypothalamic-Pituitary Axis&lt;/li&gt;&lt;li&gt;Low gonadotropin&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;General&lt;ol&gt;&lt;li&gt;Late eunuchoid body proportions&lt;/li&gt;&lt;li&gt;Grow normally during childhood&lt;ol&gt;&lt;li&gt;Fail to have pubertal growth spurt&lt;/li&gt;&lt;li&gt;Growth retardation is recent event&lt;/li&gt;&lt;li&gt;Plot growth velocity!!&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Causes: Endocrine&lt;ol&gt;&lt;li&gt;Multiple tropic hormone deficiency&lt;/li&gt;&lt;li&gt;Isolated &lt;a href="../../Endo/Pharm/HmnGrwthHrmn.htm" class="LinkPage"&gt;Growth Hormone&lt;/a&gt; (&lt;a href="../../Rheum/Pharm/SkltlMsclRlxnt.htm" class="LinkPage"&gt;Soma&lt;/a&gt;totropin) deficiency&lt;ol&gt;&lt;li&gt;Severe growth retardation (&amp;gt;3 SD from mean)&lt;/li&gt;&lt;li&gt;Long duration of growth retardation since childhood&lt;/li&gt;&lt;li&gt;Height Retardation exceeds Weight retardation&lt;/li&gt;&lt;li&gt;Proportionate dwarfism&lt;/li&gt;&lt;li&gt;Immature round face&lt;/li&gt;&lt;li&gt;Mild truncal fat distribution&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Isolated Gonadotropin deficiency&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Sex/KlmnsSyndrm.htm" class="LinkPage"&gt;Kallmann's Syndrome&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Congenital adrenal hypoplasia&lt;/li&gt;&lt;li&gt;Isolated LH or FSH deficiency&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Other endocrine disorders&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Thyroid/Hypthyrdsm.htm" class="LinkPage"&gt;Hypothyroidism&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/DM/DbtsMlts.htm" class="LinkPage"&gt;Diabetes Mellitus&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Glucocorticoid excess (Cushing Syndrome)&lt;ol&gt;&lt;li&gt;Growth delay  mild if adrenal sex steroid increased&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Pituitary/Hyprprlctnm.htm" class="LinkPage"&gt;Hyperprolactinemia&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Causes: CNS&lt;ol&gt;&lt;li&gt;CNS insult due to infection, radiation or trauma&lt;/li&gt;&lt;li&gt;&lt;a href="../../Neuro/HemeOnc/BrnTmr.htm" class="LinkPage"&gt;Brain Tumor&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Craniopharygioma&lt;/li&gt;&lt;li&gt;Astrocytoma&lt;/li&gt;&lt;li&gt;Hypothalamic glioma&lt;/li&gt;&lt;li&gt;Pituitary tumor (e.g. &lt;a href="../../Endo/Pituitary/Prlctnm.htm" class="LinkPage"&gt;Prolactinoma&lt;/a&gt;)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Causes: Miscellaneous&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Peds/PrdrWlSyndrm.htm" class="LinkPage"&gt;Prader-Willi Syndrome&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Obesity/Obsty.htm" class="LinkPage"&gt;Obesity&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Growth/ShrtStr.htm" class="LinkPage"&gt;Short Stature&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Mild &lt;a href="../../Prevent/HME/HlthCrFrAdltsWthDvlpmntlDly.htm" class="LinkPage"&gt;Mental Retardation&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Systemic Conditions&lt;ol&gt;&lt;li&gt;Chronic gastrointestinal conditions&lt;/li&gt;&lt;li&gt;&lt;a href="../../Renal/Failure/ChrncRnlFlr.htm" class="LinkPage"&gt;Chronic Kidney Disease&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Metabolism/TypGchrsDs.htm" class="LinkPage"&gt;Gaucher's Disease&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Lung/Peds/CystcFbrs.htm" class="LinkPage"&gt;Cystic Fibrosis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../HemeOnc/Hemoglobin/ScklClAnm.htm" class="LinkPage"&gt;Sickle Cell Anemia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../HIV/Exam/HmnImndfcncyVrs.htm" class="LinkPage"&gt;Human Immunodeficiency Virus&lt;/a&gt; infection&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Medications&lt;ol&gt;&lt;li&gt;&lt;a href="../../Rheum/Pain/ChrncNrctcGdln.htm" class="LinkPage"&gt;Chronic Opioid&lt;/a&gt; use (86% of users)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Nutritional deficiency OR extreme energy expenditure&lt;ol&gt;&lt;li&gt;&lt;a href="../../Sports/Gyn/FmlAthltTrd.htm" class="LinkPage"&gt;Female Athlete Triad&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Psychogenic&lt;ol&gt;&lt;li&gt;Weight Retardation exceeds Height Retardation&lt;/li&gt;&lt;li&gt;Anorexia&lt;/li&gt;&lt;li&gt;&lt;a href="../../Psych/Eating/BlmNrvs.htm" class="LinkPage"&gt;Bulimia&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Constitutional Delay in Growth and Development&lt;ol&gt;&lt;li&gt;Compare siblings and parental growth&lt;/li&gt;&lt;li&gt;Calculate target height from parental contribution&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0271623</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Sex/HypgndtrpcHypgndsm.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Hypogonadotropic Hypogonadism, Hypogonadotropic Causes of Delayed Puberty, Hypogonadotropic Causes of Primary Amenorrhea, Sexual Infantilism due to Gonadotropin Deficiency, Secondary Hypogonadism</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Sex/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Premature adrenarche  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0342546"&gt;&lt;i&gt;C0342546&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Disease or Syndrome (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0342546&amp;amp;tui=T047"&gt;&lt;i&gt;T047&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD10&lt;/td&gt;
                &lt;td&gt;E27.0&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;190521009, 103021001, 190516006&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;vroegtijdige adrenarche, adrenarche; prematuur, prematuur; adrenarche&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Adrénarche précoce&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;vorzeitige Adrenarche&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Adrenarca precoce&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Adrenarca prematura&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;Adrenarquia prematura, Premature adrenarche, adrenarca prematura (hallazgo), adrenarca prematura&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;早発性副腎皮質機能障害, ｿｳﾊﾂｾｲﾌｸｼﾞﾝﾋｼﾂｷﾉｳｼｮｳｶﾞｲ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;precocious adrenarche (diagnosis), precocious adrenarche, Premature adrenarche (disorder), premature adrenarche, Premature adrenarche, Premature adrenarche (finding), adrenarche; premature, premature; adrenarche&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;Předčasná adrenarché&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;Korai adrenarche&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Premature adrenarche  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Benign Premature Adrenarche</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Sexual Development</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Pathophysiology&lt;ol&gt;&lt;li&gt;Benign self-limited cause of &lt;a href="../../Endo/Sex/PrcsPbrty.htm" class="LinkPage"&gt;Precocious Puberty&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Epidemiology&lt;ol&gt;&lt;li&gt;Onset before age 6 years&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Signs&lt;ol&gt;&lt;li&gt;Early secondary sexual characteristics in children&lt;ol&gt;&lt;li&gt;Early pubic hair and axillary hair development&lt;/li&gt;&lt;li&gt;Increased sebaceous activity&lt;/li&gt;&lt;li&gt;Adult-type body odor&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;No &lt;a href="../../Endo/Exam/SxlDvlpmnt.htm" class="LinkPage"&gt;Sexual Development&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Normal growth pattern&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Radiology&lt;ol&gt;&lt;li&gt;Bone age consistent chronological age&lt;/li&gt;&lt;li&gt;Other imaging studies normal&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Labs&lt;ol&gt;&lt;li&gt;Slight increase in &lt;a href="../../Endo/Lab/SrmDhydrpndrstrn.htm" class="LinkPage"&gt;Serum DHEA&lt;/a&gt; level&lt;/li&gt;&lt;li&gt;Other adrenal steroid hormones normal&lt;/li&gt;&lt;li&gt;Sex hormone levels normal&lt;/li&gt;&lt;li&gt;ACTH stimulation test normal&lt;ol&gt;&lt;li&gt;No &lt;a href="../../Endo/Adrenal/CngntlAdrnlHyprpls.htm" class="LinkPage"&gt;Congenital Adrenal Hyperplasia&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/GnrhStmltnTst.htm" class="LinkPage"&gt;GnRH Stimulation Test&lt;/a&gt; normal&lt;ol&gt;&lt;li&gt;Consistent with prepubertal pattern&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Management&lt;ol&gt;&lt;li&gt;Reassurance&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0342546</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Sex/BngnPrmtrAdrnrch.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Benign Premature Adrenarche, Premature Adrenarche</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Sex/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees></FP_UMLS_Trees><FP_Condition_name_check></FP_Condition_name_check><FP_Condition_name><value>Failure to Thrive Red Flags</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Pediatrics</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;See Also&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Growth/ShrtStr.htm" class="LinkPage"&gt;Delayed Growth&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Peds/FlrTThrv.htm" class="LinkPage"&gt;Failure to Thrive&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Peds/FlrTThrvCs.htm" class="LinkPage"&gt;Failure to Thrive Causes&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Peds/FlrTThrvEvltn.htm" class="LinkPage"&gt;Failure to Thrive Evaluation&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Peds/FlrTThrvMngmnt.htm" class="LinkPage"&gt;Failure to Thrive Management&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Indications&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Peds/FlrTThrvEvltn.htm" class="LinkPage"&gt;Failure to Thrive Evaluation&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Red Flags&lt;ol&gt;&lt;li&gt;Cardiac findings (suggesting. &lt;a href="../../CV/Peds/CngntlHrtDs.htm" class="LinkPage"&gt;Congenital Heart Disease&lt;/a&gt;)&lt;ol&gt;&lt;li&gt;&lt;a href="../../CV/Exam/HrtMrmr.htm" class="LinkPage"&gt;Heart Murmur&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Extremity edema&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Exam/JglrVnsDstntn.htm" class="LinkPage"&gt;Jugular Venous Distention&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Developmental delay&lt;/li&gt;&lt;li&gt;See &lt;a href="../../Endo/Exam/DysmrphcFtrsInCngntlDysrdrs.htm" class="LinkPage"&gt;Dysmorphic features in Congenital Dysorders&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Peds/FlrTThrv.htm" class="LinkPage"&gt;Failure to Thrive&lt;/a&gt; refractory to adequate caloric replacement&lt;/li&gt;&lt;li&gt;&lt;a href="../../GI/Exam/Hptmgly.htm" class="LinkPage"&gt;Hepatomegaly&lt;/a&gt; or &lt;a href="../../GI/Exam/Splnmgly.htm" class="LinkPage"&gt;Splenomegaly&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Abnormal &lt;a href="../../HemeOnc/Lymph/Lymphdnpthy.htm" class="LinkPage"&gt;Lymphadenopathy&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Recurrent infections (e.g. recurrent respiratory infections, &lt;a href="../../Uro/ID/RcrntCysts.htm" class="LinkPage"&gt;Recurrent UTI&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;Recurrent &lt;a href="../../GI/Sx/Vmtng.htm" class="LinkPage"&gt;Vomiting&lt;/a&gt; or &lt;a href="../../GI/Diarrhea/ActDrh.htm" class="LinkPage"&gt;Diarrhea&lt;/a&gt; with dehydration&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Interpretation&lt;ol&gt;&lt;li&gt;Positive findings suggest organic cause of &lt;a href="../../Endo/Peds/FlrTThrv.htm" class="LinkPage"&gt;Failure to Thrive&lt;/a&gt; and warrant diagnostic evaluation&lt;/li&gt;&lt;li&gt;Negative findings (no red flags) are reassuring for non-organic cause and empiric caloric management can be instituted&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Ficicioglu%20%20%5BAU%5D%20AND%202009%20%5BDP%5D%20AND%20%20Pediatrics%20%20%5BTA%5D" class="LinkRef"&gt;Ficicioglu (2009) Pediatrics 124(3): 972-9&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Cole%20%20%5BAU%5D%20AND%202011%20%5BDP%5D%20AND%20%20Am%20Fam%20Physician%20%20%5BTA%5D" class="LinkRef"&gt;Cole (2011) Am Fam Physician 83(7): 829-34&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Peds/FlrTThrvRdFlgs.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Failure to Thrive Red Flags</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Peds/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Hypogonadism  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0020619"&gt;&lt;i&gt;C0020619&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CSP)&lt;/td&gt;
                &lt;td&gt;condition resulting from or characterized by abnormally decreased functional activity of the gonads, with retardation of growth and sexual development.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;Condition resulting from deficient gonadal functions, such as GAMETOGENESIS and the production of GONADAL STEROID HORMONES. It is characterized by delay in GROWTH, germ cell maturation, and development of secondary sex characteristics. Hypogonadism can be due to a deficiency of GONADOTROPINS (hypogonadotropic hypogonadism) or due to primary gonadal failure (hypergonadotropic hypogonadism).&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Disease or Syndrome (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0020619&amp;amp;tui=T047"&gt;&lt;i&gt;T047&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D007006&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;48130008&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Hypogonadism, HYPOGONADISM, Hypogonadism, NOS, Hypogonadotropism, hypogonadism (diagnosis), hypogonadism, Hypogonadism [Disease/Finding], hypogonadotropism, Hypogonadism (disorder)&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Hypogonadism&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;ｾｲｾﾝｷﾉｳﾃｲｶ, 性腺機能不全, 生殖腺機能低下症, 性機能不全, 性腺機能低下, 生殖腺機能不全症, 性機能不全症, 性腺機能低下症, 性腺機能不全症, 性機能低下症, 性機能低下&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;hypogonadismus, Hypogonadismus&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Hypogonadismi&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;INFANTILIZM POLOVOI, INFANTILIZM PSIKHOSEKSUAL'NYI, GIPOGONADIZM, INFANTILIZM GENITAL'NYI, ГИПОГОНАДИЗМ, ИНФАНТИЛИЗМ ГЕНИТАЛЬНЫЙ, ИНФАНТИЛИЗМ ПОЛОВОЙ, ИНФАНТИЛИЗМ ПСИХОСЕКСУАЛЬНЫЙ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Hipogonadyzm, Infantylizm, Niedoczynność gonad&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;Hypogonadismus&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;hipogonadismo (trastorno), hipogonadismo, Hipogonadismo&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;hypogonadisme, Gonadisme, hypo-, Hypogonadisme&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Hypogonadisme&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Hypogonadismus&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Ipogonadismo&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Hipogonadismo&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Hypogonadism  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Hypogonadism</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Sexual Development</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;See Also&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Sex/PbrtlDly.htm" class="LinkPage"&gt;Delayed Puberty&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Gyn/Menses/PrmryAmnrh.htm" class="LinkPage"&gt;Primary Amenorrhea&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Uro/Endo/AndrgnDclnInThAgngMl.htm" class="LinkPage"&gt;Androgen Decline in the Aging Male&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Uro/Endo/TstclrFlr.htm" class="LinkPage"&gt;Testicular Failure&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Gyn/Endo/Mnps.htm" class="LinkPage"&gt;Menopause&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Gyn/Endo/PrmtrOvrnFlr.htm" class="LinkPage"&gt;Premature Ovarian Failure&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Definitions: Hypogonadism&lt;ol&gt;&lt;li&gt;Decreased testicular or ovarian functional activity&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Hypogonadism in Children&lt;ol&gt;&lt;li&gt;See &lt;a href="../../Endo/Sex/PbrtlDly.htm" class="LinkPage"&gt;Delayed Puberty&lt;/a&gt;&lt;/li&gt;&lt;li&gt;See &lt;a href="../../Gyn/Menses/PrmryAmnrh.htm" class="LinkPage"&gt;Primary Amenorrhea&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Categories of &lt;a href="../../Endo/Sex/HyprgndtrpcHypgndsm.htm" class="LinkPage"&gt;Primary Hypogonadism&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Sex/HypgndtrpcHypgndsm.htm" class="LinkPage"&gt;Hypogonadotropic Hypogonadism&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Sex/NrmgndtrpcHypgndsm.htm" class="LinkPage"&gt;Normogonadotropic Hypogonadism&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Sex/HyprgndtrpcHypgndsm.htm" class="LinkPage"&gt;Hypergonadotropic Hypogonadism&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Hypogonadism in Adults&lt;ol&gt;&lt;li&gt;Hypogonadism in Men&lt;ol&gt;&lt;li&gt;&lt;a href="../../Uro/Endo/AndrgnDclnInThAgngMl.htm" class="LinkPage"&gt;Androgen Decline in the Aging Male&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Uro/Endo/TstclrFlr.htm" class="LinkPage"&gt;Testicular Failure&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Hypogonadism in Women&lt;ol&gt;&lt;li&gt;&lt;a href="../../Gyn/Endo/Mnps.htm" class="LinkPage"&gt;Menopause&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Gyn/Endo/PrmtrOvrnFlr.htm" class="LinkPage"&gt;Premature Ovarian Failure&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0020619</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Sex/Hypgndsm.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Hypogonadism</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Sex/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Primary hypogonadism  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0948896"&gt;&lt;i&gt;C0948896&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Disease or Syndrome (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0948896&amp;amp;tui=T047"&gt;&lt;i&gt;T047&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D007006&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;370999003&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;PRIMARY HYPOGONADISM, Primary hypogonadism, GONADAL FAILURE PRIMARY, HYPOGONADISM PRIMARY, hypergonadotropic hypogonadism, primary hypogonadism, Hypergonadotrophic hypogonadism, Hypergonadotropic hypogonadism, Primary hypogonadism (disorder), Hypergonadotropic Hypogonadism, Hypogonadism, Hypergonadotropic&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Ipogonadismo primitivo, Ipogonadismo ipergonadotropo&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;hypergonadotroop hypogonadisme, primair hypogonadisme&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;hypergonadotroper Hypogonadismus, primaerer Hypogonadismus&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;Hipogonadismo hipergonadotrópico, Hipogonadismo primário&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;Hipergonadismo hipergonadotrópico, hipogonadismo hipergonadotrófico, hipogonadismo primario (trastorno), hipogonadismo primario, Hipogonadismo primario&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;高性腺刺激ホルモン性性腺機能低下, 原発性性腺機能低下, ｺｳｾｲｾﾝｼｹﾞｷﾎﾙﾓﾝｾｲｾｲｾﾝｷﾉｳﾃｲｶ, ｹﾞﾝﾊﾟﾂｾｲｾｲｾﾝｷﾉｳﾃｲｶ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Hypogonadisme hypergonadotrophique, Hypogonadisme primaire&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;Hypergonadotropní hypogonadismus, Primární hypogonadismus&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;Primaer hypogonadismus, Hypergonadotrop hypogonadismus&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Primary hypogonadism  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Hypergonadotropic Hypogonadism</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Sexual Development</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;See Also&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Sex/PbrtlDly.htm" class="LinkPage"&gt;Delayed Puberty&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Sex/Hypgndsm.htm" class="LinkPage"&gt;Hypogonadism&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Gyn/Menses/PrmryAmnrh.htm" class="LinkPage"&gt;Primary Amenorrhea&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Definition: Hypergonadotropic Hypogonadism&lt;ol&gt;&lt;li&gt;Defective development of ovaries or &lt;a href="../../Uro/Anatomy/Tstcl.htm" class="LinkPage"&gt;Testes&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Associated with excess pituitary gonadotropin secretion&lt;/li&gt;&lt;li&gt;Results in delayed &lt;a href="../../Endo/Exam/SxlDvlpmnt.htm" class="LinkPage"&gt;Sexual Development&lt;/a&gt; and growth delay&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Etiology&lt;ol&gt;&lt;li&gt;Gonads deficient in sex hormone production&lt;ol&gt;&lt;li&gt;&lt;a href="../../Uro/Anatomy/Tstcl.htm" class="LinkPage"&gt;Testes&lt;/a&gt; produce less testosterone&lt;/li&gt;&lt;li&gt;Ovaries produce less estogen&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Hypothalamus and pituitary responds&lt;ol&gt;&lt;li&gt;Increased gonadotropin release (FSH, LH)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Causes&lt;ol&gt;&lt;li&gt;Variants of Ovarian and Testicular Dysgenesis&lt;ol&gt;&lt;li&gt;Male: &lt;a href="../../Endo/Sex/KlnfltrSyndrm.htm" class="LinkPage"&gt;Klinefelter Syndrome&lt;/a&gt; (XXY)&lt;/li&gt;&lt;li&gt;Female: &lt;a href="../../Endo/Sex/TrnrsSyndrm.htm" class="LinkPage"&gt;Turner's Syndrome&lt;/a&gt; (XO)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Gonadal Toxins (&lt;a href="../../HemeOnc/Pharm/Chmthrpy.htm" class="LinkPage"&gt;Chemotherapy&lt;/a&gt;/Radiation)&lt;ol&gt;&lt;li&gt;Cytotoxic drugs (e.g. &lt;a href="../../HemeOnc/Pharm/Chmthrpy.htm" class="LinkPage"&gt;Chemotherapy&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;Glucocorticoids&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Enzyme defects&lt;ol&gt;&lt;li&gt;Female: 17 alpha hydroxylase deficiency&lt;/li&gt;&lt;li&gt;Male: 17 ketosteroid reductase deficiency&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Androgen Insensitivity (Testicular feminization)&lt;/li&gt;&lt;li&gt;Miscellaneous&lt;ol&gt;&lt;li&gt;&lt;a href="../../ID/Virus/Mmps.htm" class="LinkPage"&gt;Mumps&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Pelvic radiation&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Gonadal failure (in adults)&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Sex/Hypgndsm.htm" class="LinkPage"&gt;Hypogonadism&lt;/a&gt; in Men&lt;ol&gt;&lt;li&gt;&lt;a href="../../Uro/Endo/AndrgnDclnInThAgngMl.htm" class="LinkPage"&gt;Androgen Decline in the Aging Male&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Uro/Endo/TstclrFlr.htm" class="LinkPage"&gt;Testicular Failure&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Sex/Hypgndsm.htm" class="LinkPage"&gt;Hypogonadism&lt;/a&gt; in Women&lt;ol&gt;&lt;li&gt;&lt;a href="../../Gyn/Endo/Mnps.htm" class="LinkPage"&gt;Menopause&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Gyn/Endo/PrmtrOvrnFlr.htm" class="LinkPage"&gt;Premature Ovarian Failure&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0948896</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Sex/HyprgndtrpcHypgndsm.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Hypergonadotropic Hypogonadism, Hypergonadotropic Causes of Delayed Puberty, Hypergonadotropic Causes of Primary Amenorrhea, Sexual Infantilism due to Gonadotropin Excess, Primary Hypogonadism</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Sex/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Klinefelter Syndrome  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0022735"&gt;&lt;i&gt;C0022735&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A sex chromosome disorder caused by the presence of an extra X chromosome in the male karyotype. Affected individuals are infertile and have a small penis and testes. They tend to have tall stature and long legs and may have difficulties with speech and language development. Gynecomastia may be present.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MEDLINEPLUS)&lt;/td&gt;
                &lt;td&gt;
                  &lt;span&gt;
                    &lt;p&gt;Klinefelter's syndrome is a condition that occurs in men who have an extra X chromosome in most of their cells. The syndrome can affect different stages of physical, language and social development.  The most common symptom is &lt;a href="http://www.nlm.nih.gov/medlineplus/maleinfertility.html"&gt;infertility&lt;/a&gt;. Because they often don't make as much of the male hormone testosterone as other boys, teenagers with Klinefelter's syndrome may have less facial and body hair and may be less muscular than other boys. They may have trouble using language to express themselves.  They may be shy and have trouble fitting in.&lt;/p&gt;
                    &lt;p&gt;It is important to start treatment as early as possible. With treatment, most boys grow up to have normal sex lives, successful careers and normal social relationships.Treatments include&lt;/p&gt;
                    &lt;ul&gt;&lt;li&gt;	Educational services&lt;/li&gt;
                      &lt;li&gt;	Physical, speech and occupational therapy &lt;/li&gt;
                      &lt;li&gt;	Medical treatments including testosterone replacement&lt;/li&gt;
                    &lt;/ul&gt;&lt;p style="font-weight:bold;font-style:italic;"&gt;NIH: National Institute of Child Health and Human Development&lt;/p&gt;
                  &lt;/span&gt;
                &lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A genetic disorder in males caused by having one or more extra X chromosomes. Males with this disorder may have larger than normal breasts, a lack of facial and body hair, a rounded body type, and small testicles. They may learn to speak much later than other children and may have difficulty learning to read and write. Klinefelter syndrome increases the risk of developing extragonadal germ cell tumors and breast cancer.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (JABL)&lt;/td&gt;
                &lt;td&gt;A common sex chromosomal anomaly in males characterized mainly by small testes with tubular hyalinization, azospermia with infertility, slight breast enlargement, elevated urinary gonadotropins, and decreased urinary 17-ketosteroids. Dull mentality has been noted. The affected individuals appear normal after birth, except for small testes. Most characteristic features become evident at adolescence as hypogonadism, gynecomastia, incomplete virilization with variable eunuchoidism, and dull mentality. Without testosterone therapy, most adult patients may become obese. Occasional abnormalities may include cryptorchidism, hypospadias, ataxia, scoliosis during adolescence, and diabetes mellitus in adulthood.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CSP)&lt;/td&gt;
                &lt;td&gt;genetic disease that produces sterile males with small testes lacking sperm due to XXY karyotype.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;A form of male HYPOGONADISM, characterized by the presence of an extra X CHROMOSOME, small TESTES, seminiferous tubule dysgenesis, elevated levels of GONADOTROPINS, low serum TESTOSTERONE, underdeveloped secondary sex characteristics, and male infertility (INFERTILITY, MALE). Patients tend to have long legs and a slim, tall stature. GYNECOMASTIA is present in many of the patients. The classic form has the karyotype 47,XXY. Several karyotype variants include 48,XXYY; 48,XXXY; 49,XXXXY, and mosaic patterns ( 46,XY/47,XXY; 47,XXY/48,XXXY, etc.).&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Congenital Abnormality (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0022735&amp;amp;tui=T019"&gt;&lt;i&gt;T019&lt;/i&gt;&lt;/a&gt;)
, Disease or Syndrome (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0022735&amp;amp;tui=T047"&gt;&lt;i&gt;T047&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D007713&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD9&lt;/td&gt;
                &lt;td&gt;758.7&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD10&lt;/td&gt;
                &lt;td&gt;Q98.0, Q98.4&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;205712007, 205696000, 205701007, 405769009, 22053006, 157021007, 268357008, 405770005&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Syndrome, Klinefelter's, KLINEFELTER SYNDROME, KLINEFELTER'S SYNDROME, XXY SYNDROME, Klinefelter's karyotype 47,XXY, Klinefelter's syndrome NOS, Klinefelter's syndrome karyotype 47,XXY, Klinefelter's syndrome, unspecified, Klinefelter's Syndrome, XXY trisomy, seminiferous tubule dysgenesis, seminiferous tubule dysgenesis (diagnosis), XXY Klinefelter's syndrome (disorder), XXY Klinefelter's syndrome (diagnosis), XXY male, KLINEFELTER DISEASE, Klinefelter Syndrome, Klinefelter-Reifenstein-Albright syndrome, chromosome XXY syndrome, hypogonadotropic hypogonadism, primary hypogonadism, Klinefelter syndrome (KS), Klinefelter-Reifenstein syndrome, Xq Klinefelter syndrome, 47,XXY complex intersex, 47,XXY complex intersex (diagnosis), intersex complex 47,XXY, Klinefelter's syndrome NOS (disorder), Klinefelter syndrome, XXY, XXY Syndrome (Klinefelter Syndrome), Klinefelter syndrome karyotype 47, XXY, Klinefelter syndrome, unspecified, Klinefelter Syndrome [Disease/Finding], klinefelter's syndrome, XXY, Syndrome, XX Male, XX Male Syndromes, XX Male Syndrome, Syndromes, XX Male, chromosome xxy syndrome, xxy syndrome, klinefelter's syndrome, klinefelter 's syndrome, klinefelter disease, klinefelters syndrome, klinefelter's syndromes, Syndrome, XXY, XXY Syndromes, XXY Syndrome, Syndromes, XXY, Klinefelter Syndromes, Syndrome, Klinefelter, Syndromes, Klinefelter, XXY syndrome, Klinefelter's syndrome, Klinefelter syndrome, Klinefelter's syndrome karyotype 47 XXY, XXY Klinefelter's syndrome, Klinefelter's syndrome, XXY (disorder), Klinefelter's syndrome, XXY, Klinefelter, chromosome; anomaly, sex, Klinefelter, XXY; syndrome, hypogonadism; hypogonadotropic, hypogonadotropic; hypogonadism, karyotype; 47,XXY, Klinefelter, syndrome; XXY, anomaly; chromosomes, chromosomal, sex, Klinefelter, Klinefelter syndrome (disorder), Klinefelter's syndrome (disorder), Klinefelters Syndrome, Hypogonadotropic Hypogonadism, klinefelter syndrome&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;SINDROME DE KLINEFELTER, Síndrome XXY, Síndrome de Klinefelter&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;SINDROME DE KLINEFELTER, Síndrome XXY, XXY Klinefelter's syndrome, Klinefelter's syndrome, síndrome de Klinefelter, SAI (trastorno), síndrome de Klinefelter, SAI, síndrome XXY, síndrome de Klinefelter (trastorno), síndrome de Klinefelter, síndrome de Klinefelter, XXY (trastorno), síndrome de Klinefelter, XXY, Sindrome de Klinefelter, Síndrome de Klinefelter&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;XXY syndroom, XXY; syndroom, anomalie; chromosomen, chromosomaal, geslacht, Klinefelter, chromosoom; anomalie, geslacht, Klinefelter, hypogonadisme; hypogonadotroop, hypogonadotroop; hypogonadisme, karyotype; 47,XXY, Klinefelter, syndroom; XXY, Syndroom van Klinefelter karyotype 47,XXY, Syndroom van Klinefelter, niet gespecificeerd, syndroom van Klinefelter, Klinefelter, syndroom van, Klinefeltersyndroom, Syndroom van Klinefelter&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Syndrome XXY, SYNDROME DE KLINEFELTER, Syndrome de Klinefelter&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;XXY Syndrom, KLINEFELTER SYNDROM, Klinefelter-Syndrom, Karyotyp 47,XXY, Klinefelter-Syndrom, nicht naeher bezeichnet, Klinefelter Syndrom, Klinefelter-Syndrom&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Sindrome XXY, Sindrome di Klinefelter&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;ＸＸＹ症候群, XXYｼｮｳｺｳｸﾞﾝ, ｸﾗｲﾝﾌｪﾙﾀｰｼｮｳｺｳｸﾞﾝ, Klinefelter症候群, クラインフェルター症候群&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Klinefelters syndrom&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;Klinefelterův syndrom, XXY syndrom&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Klinefelterin oireyhtymä&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;KLAINFELTERA SINDROM, КЛАЙНФЕЛТЕРА СИНДРОМ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Korean&lt;/td&gt;
                &lt;td&gt;클라인펠터 증후군, 핵형 47, XXY, 상세불명의 클라인펠터 증후군&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Zespół Klinefeltera, Zespół XXY&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;Klinefelter-syndroma, Xxy syndroma&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Klinefelter Syndrome  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Klinefelter Syndrome</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Sexual Development</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Epidemiology&lt;ol&gt;&lt;li&gt;Most common major sexual differentiation abnormality&lt;/li&gt;&lt;li&gt;&lt;a href="../../Prevent/Epi/DsIncdncRt.htm" class="LinkPage"&gt;Incidence&lt;/a&gt; of Klinefelter Syndrome in specific cohorts&lt;ol&gt;&lt;li&gt;Newborn males: 1 in 500 to 1000&lt;/li&gt;&lt;li&gt;Male &lt;a href="../../Gyn/HemeOnc/BrstCncr.htm" class="LinkPage"&gt;Breast Cancer&lt;/a&gt;: 7.5%&lt;/li&gt;&lt;li&gt;Infertile males: 3%&lt;/li&gt;&lt;li&gt;Mild &lt;a href="../../Prevent/HME/HlthCrFrAdltsWthDvlpmntlDly.htm" class="LinkPage"&gt;Mental Retardation&lt;/a&gt;: 1%&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Pathophysiology&lt;ol&gt;&lt;li&gt;Results in testicular dysgenesis&lt;/li&gt;&lt;li&gt;Chromosomal abnormality with 47,XXY karyotype&lt;ol&gt;&lt;li&gt;Abnormality of nondisjunction during meiosis&lt;/li&gt;&lt;li&gt;Maternal or paternal origin&lt;/li&gt;&lt;li&gt;Most of additional X Chromosome is inactivated&lt;ol&gt;&lt;li&gt;Functioning extra genes confer phenotype&lt;/li&gt;&lt;li&gt;More severe cases with XXXY, XXXXY or XXYY&lt;/li&gt;&lt;li&gt;Less severe cases with mosaicism (&amp;gt;1 cell line)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Signs&lt;ol&gt;&lt;li&gt;Late Eunuchoid body proportions&lt;ol&gt;&lt;li&gt;Tall, slim and underweight&lt;/li&gt;&lt;li&gt;Long legs and short torso&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Obesity/Obsty.htm" class="LinkPage"&gt;Obesity&lt;/a&gt; and varicosities may occur in 33% of patients&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Sex/HyprgndtrpcHypgndsm.htm" class="LinkPage"&gt;Hypergonadotropic Hypogonadism&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../Uro/Anatomy/Tstcl.htm" class="LinkPage"&gt;Testes&lt;/a&gt; small and firm (usually &amp;lt;2.0 cm or 2 ml)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Uro/Anatomy/AntmyOfThPns.htm" class="LinkPage"&gt;Penis&lt;/a&gt; small&lt;/li&gt;&lt;li&gt;Azoospermia or oligospermia (and &lt;a href="../../Gyn/Endo/FmlInfrtlty.htm" class="LinkPage"&gt;Infertility&lt;/a&gt;)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Other signs of &lt;a href="../../Gyn/Pharm/AndrgnRplcmntInWmn.htm" class="LinkPage"&gt;Hypoandrogenism&lt;/a&gt;&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Sx/Gyncmst.htm" class="LinkPage"&gt;Gynecomastia&lt;/a&gt; (bilateral and painless)&lt;/li&gt;&lt;li&gt;Decreased facial hair, but pubic hair abundant&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Labs&lt;ol&gt;&lt;li&gt;Karyotype: XXY&lt;/li&gt;&lt;li&gt;Post-&lt;a href="../../Endo/Exam/SxlDvlpmnt.htm" class="LinkPage"&gt;Puberty&lt;/a&gt; labs&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/FlclStmltngHrmn.htm" class="LinkPage"&gt;Follicle Stimulating Hormone&lt;/a&gt; (FSH) increased&lt;/li&gt;&lt;li&gt;Leutinizing Hormone (LH) increased&lt;/li&gt;&lt;li&gt;Inhibin B decreased&lt;/li&gt;&lt;li&gt;Increased estradiol to testosterone ratio&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Associated Conditions&lt;ol&gt;&lt;li&gt;Mild &lt;a href="../../Prevent/HME/HlthCrFrAdltsWthDvlpmntlDly.htm" class="LinkPage"&gt;Mental Retardation&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Motor function delay&lt;/li&gt;&lt;li&gt;Language comprehension problems&lt;/li&gt;&lt;li&gt;Speech may also be affected&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Peds/Neuro/LrngDsrdr.htm" class="LinkPage"&gt;Learning Disorder&lt;/a&gt;s&lt;ol&gt;&lt;li&gt;&lt;a href="../../Peds/Neuro/AtntnDfctDsrdr.htm" class="LinkPage"&gt;Attention Deficit Disorder&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Dyslexia&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Social maladjustment&lt;/li&gt;&lt;li&gt;Mental illness&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Anatomy/ThyrdAntmy.htm" class="LinkPage"&gt;Thyroid&lt;/a&gt; dysfunction&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/DM/DbtsMlts.htm" class="LinkPage"&gt;Diabetes Mellitus&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Lung/Anatomy/LngAntmy.htm" class="LinkPage"&gt;Lung&lt;/a&gt; disease&lt;/li&gt;&lt;li&gt;&lt;a href="../../Gyn/HemeOnc/BrstCncr.htm" class="LinkPage"&gt;Breast Cancer&lt;/a&gt; (20x risk of healthy men)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Rheum/Bone/Ostprs.htm" class="LinkPage"&gt;Osteoporosis&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Management: General&lt;ol&gt;&lt;li&gt;Complete neurodevelopment evaluation at diagnosis&lt;ol&gt;&lt;li&gt;Indicated if diagnosis in childhood&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Gyn/HemeOnc/BrstCncr.htm" class="LinkPage"&gt;Breast Cancer&lt;/a&gt; surveillance&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Management: &lt;a href="../../Uro/Pharm/TststrnSplmntn.htm" class="LinkPage"&gt;Testosterone Replacement&lt;/a&gt; after age 11&lt;ol&gt;&lt;li&gt;Start&lt;ol&gt;&lt;li&gt;Long acting Testosterone 25-50 mg IM q3-4 weeks&lt;/li&gt;&lt;li&gt;Increase Testosterone dose by 50 mg q6-9 months&lt;/li&gt;&lt;li&gt;Goal: 200 to 250 mg q3-4 weeks&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Maintenance&lt;ol&gt;&lt;li&gt;Convert to Testosterone patches when at 200-250 mg&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Resources&lt;ol&gt;&lt;li&gt;American Association for Klinefelter Syndrome&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.aaksis.org" class="LinkWebExt"&gt;http://www.aaksis.org&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Klinefelter Syndrome Support Group&lt;ol&gt;&lt;li&gt;&lt;a href="http://klinefeltersyndrome.org" class="LinkWebExt"&gt;http://klinefeltersyndrome.org&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Mendoki%20%20%5BAU%5D%20AND%201991%20%5BDP%5D%20AND%20%20J%20Am%20Acad%20Child%20Adolesc%20Psychiatry%20%20%5BTA%5D" class="LinkRef"&gt;Mendoki (1991) J Am Acad Child Adolesc Psychiatry 30&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Schwartz%20%20%5BAU%5D%20AND%201991%20%5BDP%5D%20AND%20%20Endocrinol%20Metab%20Clin%20North%20Am%20%20%5BTA%5D" class="LinkRef"&gt;Schwartz (1991) Endocrinol Metab Clin North Am 20:153&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Smyth%20%20%5BAU%5D%20AND%201998%20%5BDP%5D%20AND%20%20Arch%20Intern%20Med%20%20%5BTA%5D" class="LinkRef"&gt;Smyth (1998) Arch Intern Med 158(12):1309-14&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Behrman (2000) Nelson Pediatrics, Saunders, p. 1746-9&lt;/li&gt;&lt;li&gt;Wattendorf (2005) Am Fam Physician 72:2259-62&lt;/li&gt;&lt;li&gt;Wilson (1991) Harrison's Medicine, McGraw-Hill, p. 1800&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0022735</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Sex/KlnfltrSyndrm.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Klinefelter Syndrome</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Sex/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Turner Syndrome  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0041408"&gt;&lt;i&gt;C0041408&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A gonadal dysgenesis syndrome occurring in phenotypic females, characterized by the complete absence of one of the sex chromosomes. Signs and symptoms include short stature and hypogonadism.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (NCI)&lt;/td&gt;
                &lt;td&gt;A gonadal dysgenesis syndrome occurring in phenotypic females, characterized by the absence of a part or all of one of the sex chromosomes. Signs and symptoms include short stature, webbing of neck, low-set ears, hypogonadism, and sterility.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MSH)&lt;/td&gt;
                &lt;td&gt;A syndrome of defective gonadal development in phenotypic females associated with the karyotype 45,X (or 45,XO). Patients generally are of short stature with undifferentiated GONADS (streak gonads), SEXUAL INFANTILISM, HYPOGONADISM, webbing of the neck, cubitus valgus, elevated GONADOTROPINS, decreased ESTRADIOL level in blood, and CONGENITAL HEART DEFECTS. NOONAN SYNDROME (also called Pseudo-Turner Syndrome and Male Turner Syndrome) resembles this disorder; however, it occurs in males and females with a normal karyotype and is inherited as an autosomal dominant.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CHV)&lt;/td&gt;
                &lt;td&gt;genetic disease that produces sterile females due to the X chromosome defect&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CHV)&lt;/td&gt;
                &lt;td&gt;genetic disease that produces sterile females due to the X chromosome defect&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CHV)&lt;/td&gt;
                &lt;td&gt;genetic disease that produces sterile females due to the X chromosome defect&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CHV)&lt;/td&gt;
                &lt;td&gt;genetic disease that produces sterile females due to the X chromosome defect&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CHV)&lt;/td&gt;
                &lt;td&gt;genetic disease that produces sterile females due to the X chromosome defect&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (MEDLINEPLUS)&lt;/td&gt;
                &lt;td&gt;
                  &lt;span&gt;
                    &lt;p&gt;Turner syndrome is a genetic disorder that affects a girl's development. The cause is a missing or incomplete X chromosome. Girls who have it are short, and their ovaries don't work properly. Most are &lt;a href="http://www.nlm.nih.gov/medlineplus/infertility.html"&gt;infertile&lt;/a&gt;. They are at risk for health difficulties such as high blood pressure, kidney problems, diabetes, cataracts, osteoporosis and thyroid problems.&lt;/p&gt;
                    &lt;p&gt;Other physical features typical of Turner syndrome are&lt;/p&gt;
                    &lt;ul&gt;&lt;li&gt;	Short, "webbed" neck with folds of skin from tops of shoulders to sides of neck&lt;/li&gt;
                      &lt;li&gt;	Low hairline in the back&lt;/li&gt;
                      &lt;li&gt;	Low-set ears&lt;/li&gt;
                      &lt;li&gt;	Swollen hands and feet&lt;/li&gt;
                    &lt;/ul&gt;&lt;p&gt;There is no cure for Turner syndrome, but there are some treatments for the symptoms. Growth hormone often helps girls reach heights that are close to average. Hormone replacement can stimulate sexual development. Assisted reproduction techniques can help some women with Turner syndrome get pregnant. &lt;/p&gt;
                    &lt;p style="font-weight:bold;font-style:italic;"&gt;NIH: National Institute of Child Health and Human Development&lt;/p&gt;
                  &lt;/span&gt;
                &lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (JABL)&lt;/td&gt;
                &lt;td&gt;A syndrome in which the affected patients have only 45 chromosomes, the loss of one of the X chromosomes producing an XO chromosome constitution. The syndrome occurs in 1/2500 female births and nearly 99% of XO fetuses are aborted. Gonadal agenesis and short stature are the main features in the surviving infants. Associated anomalies may included webbed neck, cubitus valgus, shield chest, short stature, lymphedema, coarctation of the aorta, pigmented nevi, and various renal, skeletal, dermatologic, neoplastic, and autoimmune complications. Mental retardation is attributed to ring chromosome X. The phenotype varies and not all abnormalities occur in all patients.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Definition (CSP)&lt;/td&gt;
                &lt;td&gt;genetic disease that produces sterile females due to monosomy for X chromosome; the ovaries are rudimentary or missing; other abnormalities include short stature, webbed neck, and a broad chest with widely spaced nipples.&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Congenital Abnormality (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0041408&amp;amp;tui=T019"&gt;&lt;i&gt;T019&lt;/i&gt;&lt;/a&gt;)
, Disease or Syndrome (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0041408&amp;amp;tui=T047"&gt;&lt;i&gt;T047&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D014424&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD10&lt;/td&gt;
                &lt;td&gt;Q96, Q96.0, Q96.9&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;205685008, 268299006, 38804009, 157020008, 268356004, 205691005&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Turner's Syndrome, DWARFISM, OVARIAN, TURNER SYNDROME, TURNER'S SYNDROME, TURNER-VARNY SYNDROME, ULLRICH-TURNER SYNDROME, Ullrich-Turner syndrome, XO SYNDROME, Turner syndrome, NOS, Turner's syndrome NOS, Karyotype 45,X, Turner's syndrome, unspecified, monosomy X syndrome, Karyotype 45, X (disorder), Turner's syndrome (diagnosis), Primary ovarian insufficiency, XO genotype, Turner Syndrome, Morgagni-Turner-Albright syndrome, Turner-Albright syndrome, chromosome XO syndrome, genital dwarfism, ovarian dwarfism, pseudonuchal infantilism, primary ovarian insufficiency, Morgagni-Turner syndrome, ovarian short stature syndrome, Shereshevskii-Turner syndrome, Turner syndrome (TS), Ullrich-Turner syndrome (UTS), Turner's syndrome NOS (disorder), Turner Syndrome (XO Syndrome), XO Syndrome, Turner Syndrome [Disease/Finding], gonadal dysgenesis, xo syndrome, bonnevie-ullrich syndrome, turner's syndrome, gonadal dysgenesis syndrome, Syndrome, Ullrich-Turner, Ullrich Turner Syndrome, Ullrich-Turner Syndrome, Pterygolymphangiectasia syndrome, XO syndrome, Turner's syndrome, 45, X syndrome, Karyotype 45, X, TS - Turner's syndrome, X0 - Turner's syndrome, 45X0 - Turner's syndrome, Turner syndrome, Turner syndrome (disorder), chromosome; anomaly, sex, Turner, Morgagni-Turner, Turner-Ullrich, Turner; sex chromosome abnormality, Turner; syndrome, X; monosomy, karyotype; 45,X, monosomy; X, syndrome; Turner, anomaly; chromosomes, chromosomal, sex, Turner, Gonadal dysgenesis - Turner, Turners Syndrome, Monosomy X, turner syndrome&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Portuguese&lt;/td&gt;
                &lt;td&gt;SINDROME DE TURNER, Genótipo XO, Síndrome de Turner&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;SINDROME DE TURNER, Genotipo XO, Gonadal dysgenesis - Turner, Turner's syndrome, Turner's syndrome NOS, Karyotype 45, X, síndrome 45, X, síndrome de Turner (trastorno), síndrome de Turner, SAI (trastorno), síndrome de Turner, SAI, síndrome de Turner, síndrome de XO, síndrome de pterigolinfangiectasia, Sindrome de Turner, Síndrome de Turner&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;XO genotype, Turner; geslachtschromosoomafwijking, Turner; syndroom, X; monosomie, anomalie; chromosomen, chromosomaal, geslacht, Turner, chromosoom; anomalie, geslacht, Turner, karyotype; 45,X, monosomie; X, syndroom; Turner, Karyotype 45,X, Syndroom van Turner, niet gespecificeerd, syndroom van Turner, Syndroom van Turner, Turner, syndroom van&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Génotype XO, SYNDROME DE TURNER, Syndrome de Turner&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;XO-Genotyp, Karyotyp 45,X, TURNER SYNDROM, Turner-Syndrom, nicht naeher bezeichnet, Turner Syndrom, Albright-Turner-Syndrom, Infantilismus, pterygogonadaler, Turner-Syndrom, Ullrich-Turner-Syndrom, Zwergwuchs, ovarieller&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Italian&lt;/td&gt;
                &lt;td&gt;Genotipo XO, Sindrome di Turner&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Japanese&lt;/td&gt;
                &lt;td&gt;ＸＯ遺伝子型, ﾀｰﾅｰｼｮｳｺｳｸﾞﾝ, XOｲﾃﾞﾝｼｶﾞﾀ, 性器発育異常-45X, XO性器発育異常, 45X性器発育異常, 性器発育異常-XO, ターナー症候群, 女子性腺発育障害症候群, 性腺発育障害症候群, Bonnevie-Ullrich症候群, Turner症候群&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Swedish&lt;/td&gt;
                &lt;td&gt;Turners syndrom&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;Turnerův syndrom, XO genotyp&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Finnish&lt;/td&gt;
                &lt;td&gt;Turnerin oireyhtymä&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Russian&lt;/td&gt;
                &lt;td&gt;DISGENEZIIA GONAD, 45, X, TERNERA SINDROM, DISGENEZIIA GONAD, 45, XO, ДИСГЕНЕЗИЯ ГОНАД, 45, XO, ДИСГЕНЕЗИЯ ГОНАД, 45, X, ТЕРНЕРА СИНДРОМ&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Korean&lt;/td&gt;
                &lt;td&gt;상세불명의 터너 증후군, 터너 증후군, 핵형 45, X&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Croatian&lt;/td&gt;
                &lt;td&gt;TURNEROV SINDROM&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Polish&lt;/td&gt;
                &lt;td&gt;Zespół Turnera, Dyzgenezja gonad 45X, Dyzgenezja gonad X0&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Hungarian&lt;/td&gt;
                &lt;td&gt;Xo genotípus, Turner-syndroma&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Turner Syndrome  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Turner's Syndrome</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Sexual Development</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Epidemiology&lt;ol&gt;&lt;li&gt;&lt;a href="../../Prevent/Epi/DsIncdncRt.htm" class="LinkPage"&gt;Incidence&lt;/a&gt;: 1 in 3000 live female births&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Pathophysiology&lt;ol&gt;&lt;li&gt;Partial or complete absence of one X-Chromosome&lt;ol&gt;&lt;li&gt;Karyotype: 45,X&lt;/li&gt;&lt;li&gt;Results in X-chromosome genes that fail inactivation&lt;ol&gt;&lt;li&gt;Expression of these genes causes Turner Phenotype&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Ovarian sex hormone deficiency&lt;ol&gt;&lt;li&gt;Due to congenitally fibrotic ovaries&lt;/li&gt;&lt;li&gt;Results in lack of spontaneous pubertal development&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;High spontanous &lt;a href="../../OB/Bleed/FrstTrmstrBldng.htm" class="LinkPage"&gt;Miscarriage&lt;/a&gt; rate&lt;ol&gt;&lt;li&gt;Karyotype 45,X associated with 99% &lt;a href="../../OB/Bleed/FrstTrmstrBldng.htm" class="LinkPage"&gt;Miscarriage&lt;/a&gt; rate&lt;/li&gt;&lt;li&gt;Turner's causes 10% of first trimester abortions&lt;/li&gt;&lt;li&gt;No known risk factors and recurrence is rare&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Symptoms&lt;ol&gt;&lt;li&gt;&lt;a href="../../Gyn/Menses/PrmryAmnrh.htm" class="LinkPage"&gt;Primary Amenorrhea&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Gyn/Endo/FmlInfrtlty.htm" class="LinkPage"&gt;Infertility&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Signs: Fetus and infant&lt;ol&gt;&lt;li&gt;&lt;a href="../../NICU/HemeOnc/HydrpsFtls.htm" class="LinkPage"&gt;Fetal hydrops&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Increased &lt;a href="../../OB/Rad/NchlTrnslcncy.htm" class="LinkPage"&gt;Nuchal Translucency&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../ENT/HemeOnc/CystcHygrm.htm" class="LinkPage"&gt;Cystic Hygroma&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Surgery/CV/Lymphdm.htm" class="LinkPage"&gt;Lymphedema&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Signs: Teen and older&lt;ol&gt;&lt;li&gt;Majority of patients&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Growth/ShrtStr.htm" class="LinkPage"&gt;Short Stature&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Infantile female genitalia and &lt;a href="../../Gyn/Anatomy/BrstAntmy.htm" class="LinkPage"&gt;Breast&lt;/a&gt;s&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;More than 50% of patients have:&lt;ol&gt;&lt;li&gt;High arched, narrow &lt;a href="../../Dental/Anatomy/PltAntmy.htm" class="LinkPage"&gt;Palate&lt;/a&gt; with crowded teeth&lt;/li&gt;&lt;li&gt;&lt;a href="../../Eye/Anatomy/LdAntmy.htm" class="LinkPage"&gt;Eyelid&lt;/a&gt;&lt;a href="../../Eye/Lid/Pts.htm" class="LinkPage"&gt;Ptosis&lt;/a&gt; and infraorbital creases&lt;/li&gt;&lt;li&gt;Webbed neck&lt;/li&gt;&lt;li&gt;Shield (broad) chest with widely spaced nipples&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Growth/ShrtStr.htm" class="LinkPage"&gt;Delayed Growth&lt;/a&gt; of axillary and pubic hair&lt;/li&gt;&lt;li&gt;Hyperconvex nails&lt;/li&gt;&lt;li&gt;Deformed or rotated ears&lt;/li&gt;&lt;li&gt;Cubitus valgus&lt;/li&gt;&lt;li&gt;Short &lt;a href="../../Ortho/Anatomy/MtcrplBn.htm" class="LinkPage"&gt;Metacarpal&lt;/a&gt;s (especially fourth)&lt;/li&gt;&lt;li&gt;&lt;a href="../../Surgery/Peds/CngntlLymphdm.htm" class="LinkPage"&gt;Congenital Lymphedema&lt;/a&gt; involving arms and legs&lt;/li&gt;&lt;li&gt;Increased pigmented nevi&lt;/li&gt;&lt;li&gt;Low posterior hairline&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Associated Conditions&lt;ol&gt;&lt;li&gt;Cardiac malformation (33% of patients)&lt;ol&gt;&lt;li&gt;&lt;a href="../../CV/Peds/ArtcCrctn.htm" class="LinkPage"&gt;Aortic Coarctation&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Bicuspid aortic valve&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Htn/Hyprtnsn.htm" class="LinkPage"&gt;Hypertension&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Eye/Peds/Strbsms.htm" class="LinkPage"&gt;Strabismus&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../ENT/Hearing/SnsrnrlHrngLs.htm" class="LinkPage"&gt;Sensorineural Hearing Loss&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Recurrent &lt;a href="../../ENT/Ear/OtsMd.htm" class="LinkPage"&gt;Otitis Media&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Renal malformations (e.g. horseshoe &lt;a href="../../Renal/Anatomy/RnlAntmy.htm" class="LinkPage"&gt;Kidney&lt;/a&gt;)&lt;/li&gt;&lt;li&gt;Autoimmune &lt;a href="../../Endo/Thyroid/Thyrdts.htm" class="LinkPage"&gt;Thyroiditis&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../GI/Malabsorption/GltnEntrpthy.htm" class="LinkPage"&gt;Celiac Disease&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Ortho/Peds/CngntlHpDslctn.htm" class="LinkPage"&gt;Congenital Hip dysplasia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Ortho/T-Spine/Scls.htm" class="LinkPage"&gt;Scoliosis&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Labs&lt;ol&gt;&lt;li&gt;Initial&lt;ol&gt;&lt;li&gt;Karyotype&lt;ol&gt;&lt;li&gt;Missing X Chromosome (45,X) in 50% of cases&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/FlclStmltngHrmn.htm" class="LinkPage"&gt;Follicle Stimulating Hormone&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Abnormally increased by age 14 years&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Dental/Exam/LblMcs.htm" class="LinkPage"&gt;Buccal mucosa&lt;/a&gt; smear (historical interest only)&lt;ol&gt;&lt;li&gt;Negative sex chromatin (male pattern)&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Annual&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Lab/ThyrdStmltngHrmn.htm" class="LinkPage"&gt;Thyroid Stimulating Hormone&lt;/a&gt; (TSH)&lt;/li&gt;&lt;li&gt;&lt;a href="../../GI/Lab/LvrFnctnTst.htm" class="LinkPage"&gt;Liver Function Test&lt;/a&gt;s&lt;/li&gt;&lt;li&gt;Fasting lipid profile&lt;/li&gt;&lt;li&gt;Fasting &lt;a href="../../Endo/Lab/SrmGlcs.htm" class="LinkPage"&gt;Serum Glucose&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Other&lt;ol&gt;&lt;li&gt;Tissue transglutaminase IgA (celiac) q2-4 years&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Imaging&lt;ol&gt;&lt;li&gt;&lt;a href="../../Lung/Rad/ChstXry.htm" class="LinkPage"&gt;Chest XRay&lt;/a&gt; (initially)&lt;ol&gt;&lt;li&gt;&lt;a href="../../CV/Peds/ArtcCrctn.htm" class="LinkPage"&gt;Aortic Coarctation&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Rheum/Bone/Ostprs.htm" class="LinkPage"&gt;Osteoporosis&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Rad/TrnsthrcEchcrdgrm.htm" class="LinkPage"&gt;Echocardiogram&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Obtain initially at diagnosis&lt;/li&gt;&lt;li&gt;Repeat q5-10 years to evaluate aortic root dilatation&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Rheum/Rad/DlEnrgyXryAbsrptmtry.htm" class="LinkPage"&gt;DEXA Scan&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Obtain baseline in adulthood&lt;/li&gt;&lt;li&gt;Repeat periodically&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Management: Children and Teens&lt;ol&gt;&lt;li&gt;Genetic consultation&lt;/li&gt;&lt;li&gt;&lt;a href="../../CV/Peds/CngntlHrtDs.htm" class="LinkPage"&gt;Congenital Heart Disease&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Initial &lt;a href="../../CV/Rad/TrnsthrcEchcrdgrm.htm" class="LinkPage"&gt;Echocardiogram&lt;/a&gt; and &lt;a href="../../Lung/Rad/ChstXry.htm" class="LinkPage"&gt;Chest XRay&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Initial &lt;a href="../../CV/Exam/BldPrsr.htm" class="LinkPage"&gt;Blood Pressure&lt;/a&gt;s in all 4 extremities&lt;/li&gt;&lt;li&gt;Monitor and treat as needed&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Linear growth delay&lt;ol&gt;&lt;li&gt;Consider &lt;a href="../../Endo/Pharm/HmnGrwthHrmn.htm" class="LinkPage"&gt;Growth Hormone&lt;/a&gt; from age 1-2 to age 14&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Gyn/Pharm/Estrgn.htm" class="LinkPage"&gt;Estrogen&lt;/a&gt; therapy&lt;ol&gt;&lt;li&gt;Start in preteen years&lt;/li&gt;&lt;li&gt;Promotes &lt;a href="../../Endo/Exam/SxlDvlpmnt.htm" class="LinkPage"&gt;Sexual Development&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Prevents &lt;a href="../../Rheum/Bone/Ostprs.htm" class="LinkPage"&gt;Osteoporosis&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Hearing evaluation&lt;ol&gt;&lt;li&gt;Audiometry initially and monitoring periodically&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Vision evaluation&lt;ol&gt;&lt;li&gt;Refer to pediatric ophthalmology after age 1&lt;/li&gt;&lt;li&gt;Evaluate for &lt;a href="../../Eye/Peds/Strbsms.htm" class="LinkPage"&gt;Strabismus&lt;/a&gt; and &lt;a href="../../Eye/Vision/RfrctvErr.htm" class="LinkPage"&gt;Hyperopia&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Musculoskeletal evaluation&lt;ol&gt;&lt;li&gt;Barlow and &lt;a href="../../Ortho/Exam/OrtlnTst.htm" class="LinkPage"&gt;Ortolani Test&lt;/a&gt;ing for hip dysplasia&lt;/li&gt;&lt;li&gt;Evaluate for &lt;a href="../../Ortho/T-Spine/Scls.htm" class="LinkPage"&gt;Scoliosis&lt;/a&gt; and kyphosis in teens&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Genitourinary evaluation&lt;ol&gt;&lt;li&gt;Renal &lt;a href="../../Rad/Ultrasound/Ultrsnd.htm" class="LinkPage"&gt;Ultrasound&lt;/a&gt; to assess for anomalies&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Dental evaluation&lt;ol&gt;&lt;li&gt;Orthodontist evaluation for malocclusion&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Management: Women&lt;ol&gt;&lt;li&gt;Fertility and &lt;a href="../../Endo/Exam/SxlDvlpmnt.htm" class="LinkPage"&gt;Sexual Development&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Consult with gynecologic specialists&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Manage comorbid &lt;a href="../../CV/Prevent/CrdcRsk.htm" class="LinkPage"&gt;Coronary Risk Factor&lt;/a&gt;s&lt;/li&gt;&lt;li&gt;&lt;a href="../../Rheum/Bone/OstprsMngmnt.htm" class="LinkPage"&gt;Osteoporosis Prevention&lt;/a&gt;&lt;ol&gt;&lt;li&gt;Calcium and &lt;a href="../../Pharm/Vitamins/VtmnD.htm" class="LinkPage"&gt;Vitamin D&lt;/a&gt; supplementation&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;References&lt;ol&gt;&lt;li&gt;Behrman (2000) Nelson Pediatrics, Saunders, p. 1753-4&lt;/li&gt;&lt;li&gt;Wilson (1998) Williams Endocrinology, p. 1337-52&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Morgan%20%20%5BAU%5D%20AND%202007%20%5BDP%5D%20AND%20%20Am%20Fam%20Physician%20%20%5BTA%5D" class="LinkRef"&gt;Morgan (2007) Am Fam Physician 76:405-10&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;amp;amp;db=PubMed&amp;amp;amp;term=Saenger%20%20%5BAU%5D%20AND%202001%20%5BDP%5D%20AND%20%20J%20Clin%20Endocrinol%20Metab%20%20%5BTA%5D" class="LinkRef"&gt;Saenger (2001) J Clin Endocrinol Metab 86(7):3061-9&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0041408</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Sex/TrnrsSyndrm.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Turner's Syndrome, Ovarian Dysgenesis, Ovarian Agenesis</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Sex/index.htm</FP_SubChap_url></item><item><FP_UMLS_Trees><value>&lt;div class="umls"&gt;
            &lt;table&gt;&lt;colgroup&gt;&lt;col class="col1"&gt;&lt;col class="col2"&gt;&lt;/colgroup&gt;&lt;tr&gt;&lt;th colspan="2"&gt;
                  &lt;h3&gt;Ambiguous Genitalia  (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0266362"&gt;&lt;i&gt;C0266362&lt;/i&gt;&lt;/a&gt;)
&lt;/h3&gt;
                &lt;/th&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Concepts&lt;/td&gt;
                &lt;td&gt;Congenital Abnormality (&lt;a href="http://www.fpnotebook.com/asp3/myaccount/cui.aspx?q=C0266362&amp;amp;tui=T019"&gt;&lt;i&gt;T019&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;MSH&lt;/td&gt;
                &lt;td&gt;D012734&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ICD10&lt;/td&gt;
                &lt;td&gt;Q56.4&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;SnomedCT&lt;/td&gt;
                &lt;td&gt;21321009&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;English&lt;/td&gt;
                &lt;td&gt;Genital ambiguity, Ambiguous Genitalia, Ambiguity, Genital, Genitalia, Ambiguous, Genital Ambiguities, Genital Ambiguity, Ambiguities, Genital, genitalia ambiguous, Ambiguous genitalia, Ambiguous genitalia (disorder), genital organs; ambiguous, ambiguous genitalia&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;French&lt;/td&gt;
                &lt;td&gt;Ambiguïté de l'organe génital, Ambiguïté des organes génitaux, Ambiguïté génitale, Organes génitaux ambigüs, Ambigüité des organes génitaux, Ambigüité génitale, Organe génital ambigü, Ambigüité de l'organe génital&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;German&lt;/td&gt;
                &lt;td&gt;Nichteindeutige Genitale, Intersexuelle Genitale&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Czech&lt;/td&gt;
                &lt;td&gt;obojetné genitálie&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Dutch&lt;/td&gt;
                &lt;td&gt;geslachtsorganen; indifferent&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Spanish&lt;/td&gt;
                &lt;td&gt;genitales ambiguos (trastorno), genitales ambiguos&lt;/td&gt;
              &lt;/tr&gt;&lt;tr&gt;&lt;td&gt;
                  &lt;i&gt;Sources&lt;/i&gt;
                &lt;/td&gt;
                &lt;td align="center"&gt;
                  &lt;br&gt;&lt;i&gt;
                    &lt;small&gt;Derived from the NIH UMLS &lt;/small&gt;
                  &lt;/i&gt; (&lt;a href="http://www.nlm.nih.gov/research/umls/"&gt;&lt;i&gt;&lt;small&gt;Unified Medical Language System&lt;/small&gt;&lt;/i&gt;&lt;/a&gt;)
&lt;/td&gt;
              &lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</value></FP_UMLS_Trees><FP_Condition_name_check><value>Ambiguous Genitalia  (</value><value>)
</value></FP_Condition_name_check><FP_Condition_name><value>Ambiguous Genitalia</value></FP_Condition_name><FP_SubChap_name><value>Endocrinology: Sexual Development</value></FP_SubChap_name><FP_Condition_Tree><value>&lt;ol&gt;&lt;li&gt;Classification&lt;ol&gt;&lt;li&gt;&lt;a href="../../Endo/Sex/TrHrmphrdtsm.htm" class="LinkPage"&gt;True Hermaphroditism&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Sex/MlPsdhrmphrdtsm.htm" class="LinkPage"&gt;Male Pseudohermaphroditism&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Sex/FmlPsdhrmphrdtsm.htm" class="LinkPage"&gt;Female Pseudohermaphroditism&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Evaluation&lt;ol&gt;&lt;li&gt;History&lt;ol&gt;&lt;li&gt;&lt;a href="../../Prevent/HME/FmlyHstry.htm" class="LinkPage"&gt;Family History&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Maternal exposure to toxic agents&lt;/li&gt;&lt;li&gt;Endogenous androgen production&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Physical Examination&lt;ol&gt;&lt;li&gt;Ambiguous Genitalia&lt;/li&gt;&lt;li&gt;Associated congenital anomalies&lt;/li&gt;&lt;li&gt;Perineal orifice&lt;/li&gt;&lt;li&gt;Phallic size&lt;/li&gt;&lt;li&gt;Gonads palpable or not palpable&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Imaging&lt;ol&gt;&lt;li&gt;Pelvic and renal &lt;a href="../../Rad/Ultrasound/Ultrsnd.htm" class="LinkPage"&gt;Ultrasound&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Vaginography&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Labs&lt;ol&gt;&lt;li&gt;Karyotype&lt;/li&gt;&lt;li&gt;17-Hydroxyprogesterone&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Approach&lt;ol&gt;&lt;li&gt;Gonads not palpable, Mullerian structures present, 46XX&lt;ol&gt;&lt;li&gt;17 Hydroxyprogesterone Increased&lt;ol&gt;&lt;li&gt;21-hydoxylase Deficiency&lt;/li&gt;&lt;li&gt;&lt;a href="../../Endo/Adrenal/CngntlAdrnlHyprpls.htm" class="LinkPage"&gt;Congenital Adrenal Hyperplasia&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Measure:&lt;ol&gt;&lt;li&gt;&lt;a href="../../Renal/Lab/SrmSdm.htm" class="LinkPage"&gt;Serum Sodium&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href="../../Renal/Lab/SrmPtsm.htm" class="LinkPage"&gt;Serum Potassium&lt;/a&gt;&lt;/li&gt;&lt;li&gt;Plasma renin activity&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;17 Hydroxyprogesterone Normal or slightly increased&lt;ol&gt;&lt;li&gt;17-Hydroxypregnolone&lt;/li&gt;&lt;li&gt;11-Deoxycortisol&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Gonads palpable (46XY or variant)&lt;ol&gt;&lt;li&gt;Mullerian structure present&lt;ol&gt;&lt;li&gt;Measure MIH and intermediates of testosterone&lt;/li&gt;&lt;li&gt;Administer hcg and re-measure testosterone&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;Mullerian structure absent&lt;ol&gt;&lt;li&gt;Measure intermediates of testosterone&lt;/li&gt;&lt;li&gt;Administer hcg and re-measure testosterone&lt;/li&gt;&lt;li&gt;Assess Androgen receptor&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;li&gt;No diagnosis&lt;ol&gt;&lt;li&gt;Gonadal biopsy for &lt;a href="../../Endo/Sex/TrHrmphrdtsm.htm" class="LinkPage"&gt;True Hermaphroditism&lt;/a&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
            &lt;li&gt;Management&lt;ol&gt;&lt;li&gt;Medical and psychological emergency!&lt;/li&gt;&lt;li&gt;Evaluation must begin immediately after birth&lt;/li&gt;&lt;li&gt;Defer sex assignment until etiology identified&lt;ol&gt;&lt;li&gt;Much more difficult to change a sex assignment later&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;&lt;/ol&gt;&lt;/li&gt;
          &lt;/ol&gt;</value></FP_Condition_Tree><FP_Condition_ID><value>C0266362</value></FP_Condition_ID><FP_SubChap_LinkTo><value>http://www.fpnotebook.com/Endo/Sex/AmbgsGntl.htm</value></FP_SubChap_LinkTo><FP_Condition_aka><value>Aka: Ambiguous Genitalia</value></FP_Condition_aka><FP_SubChap_url>http://www.fpnotebook.com/Endo/Sex/index.htm</FP_SubChap_url></item></items>